<SEC-DOCUMENT>0000950170-24-023095.txt : 20240229
<SEC-HEADER>0000950170-24-023095.hdr.sgml : 20240229
<ACCEPTANCE-DATETIME>20240229161541
ACCESSION NUMBER:		0000950170-24-023095
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		107
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240229
DATE AS OF CHANGE:		20240229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptive Biotechnologies Corp
		CENTRAL INDEX KEY:			0001478320
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				270907024
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38957
		FILM NUMBER:		24703854

	BUSINESS ADDRESS:	
		STREET 1:		1165 EASTLAKE AVE E
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98109
		BUSINESS PHONE:		206-659-0067

	MAIL ADDRESS:	
		STREET 1:		1165 EASTLAKE AVE E
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98109

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptive TCR Corp
		DATE OF NAME CHANGE:	20091209
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>adpt-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:adpt="http://www.adaptivebiotech.com/20231231" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_cd95f3fb-1b6e-4c7c-beef-668725e2a1e4" name="dei:AmendmentFlag" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed">false</ix:nonNumeric><ix:nonNumeric id="F_85eafb05-c8b6-4d46-b7c4-7d981967cf39" name="dei:EntityCentralIndexKey" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed">0001478320</ix:nonNumeric><ix:nonNumeric id="F_ea9e46df-0042-4170-9204-7ef4ffd5aa19" name="dei:DocumentFiscalPeriodFocus" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed">FY</ix:nonNumeric><ix:nonFraction id="F_55f8f7d6-632f-412e-bc01-7554244a9f4d" name="us-gaap:CommitmentsAndContingencies" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_d6a13563-c650-4666-8b43-b3a899701ff8" name="us-gaap:CommitmentsAndContingencies" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_adfd113e-7a67-4aa1-b775-f1a7ae594c82" name="us-gaap:PreferredStockValue" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_a75961d9-fdf4-4b72-9a99-3b20df2adb39" name="us-gaap:PreferredStockValue" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_de9ea103-2ab7-4e3e-8c48-d7bbaf7c674a" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" contextRef="C_1e988e7e-5089-4aac-8a2c-022b8659ce3b">http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</ix:nonNumeric><ix:nonNumeric id="F_644ede94-23a3-4d5b-89f7-eb3175c3cb6c" name="us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed">http://www.adaptivebiotech.com/20231231#ImpairmentOfRightOfUseAndRelatedLongLivedAssets</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="adpt-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_204a4f00-21f5-4dcb-a003-2209a2b96734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ce95484-a0e7-43c5-830f-bb7a29b093db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1289e3d3-be6d-4b21-8182-0e0ea07d3d38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adpt:NonEmployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_546b97c7-d4df-492a-864d-7d19a8b5b897"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dddab8cd-a34a-45e6-93ef-3d378391ba43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee2c393f-edb6-49f1-8cc5-881b50f4a194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">adpt:MonteCarloValuationModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5aa06285-f2dc-4040-87ff-e52ba00117cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d8710412-3f02-4dca-a349-7c6431efb35f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80445f63-6e69-4b85-a4cc-f71cd5e32898"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_744c7609-f08e-4e56-a57b-92d4b5817a10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_83e9af4e-f8d0-4e18-894d-bef3e41d1fa4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_210fa5b6-4781-4834-bdb9-d0bc4fba918c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:RegulatoryMilestoneRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d31f8e3-6174-4d62-813b-9a04cfbac43b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:CommonStockWarrantOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e97676e6-a32f-4929-a773-40c1fd1dd414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_321cee55-58fd-4472-9917-05fb1e50572d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_508f5dbc-ed11-4aeb-8235-78423618619e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3ef0edc-d7e9-410c-9e8c-a9c962f71593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0865de4-d48f-44cc-8042-17b502c84d61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6df997e0-9e1b-4ab7-9d87-d11884be8e4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_974e34a3-8a7b-44ac-b595-2e251f3f2e9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncAndRocheGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6893910-acd0-4028-a16a-e72e33a1a487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb640244-c177-44b5-8d08-c43654ceed7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ec6bc83-92c5-47f4-97fb-4663a45fb872"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d207b5e8-b241-4c93-8d72-a110d70a2fa2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38611b62-cabf-4f6e-b0a1-2efc9958f5fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb89157d-97e5-40d0-828e-fcafd3b932a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17868eb1-c4c5-48c6-b75e-f00ebc3afa5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a17c4258-455e-423a-b8b4-bc69663eb694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:ImmuneMedicineServiceRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fbb4d461-a817-4980-9efc-c5c5e7bea481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f120f473-834e-48d7-9c3d-c58cb26bc159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c035e4ca-1c96-49e2-bf85-b7dc628cce3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fdc597b9-fce4-4adb-aca1-c9147dc51edc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04747ad8-13d5-4de0-966f-56ff96064b6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b24663a-22c4-43fd-8173-22c3ea3e4a68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a720e09d-5c96-4740-a504-9844af0c34ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e8a9a7fc-8e3b-4b0f-9703-17e3dba9a414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">adpt:MonteCarloValuationModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b70f1afc-db7d-4741-a566-077b3ae24fae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ca7acdb-a921-4bb3-90a1-1d13fd95b1fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b0f7c504-6f69-48ba-bdd7-d64ff949d238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e722b79-1338-44ce-bc10-fb18fa0cad8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ae500b5-b450-4303-939a-c1ade0ffffce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dfa7b2ec-aa90-4f5c-b852-1f27ae360214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:SequencingRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_743fa22e-b9d5-4339-a15c-2d857ef34156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2253a734-72b4-4815-b0fe-904db241abd5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c6f52ef-cda4-46f2-8c5e-0be3e165c699"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac72162c-f6d5-4828-ba60-f9c5be19f188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b01e241-462b-4cbe-9903-9e86be9bdd64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:RegulatoryMilestoneRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_866da907-3204-49a4-a785-caa968f66943"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_233dab25-77c1-4413-89c5-c93d77ebf3f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1d9df12-63b0-41e0-839c-848d1971a89b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_feb3a029-611b-49cd-afb7-35c3b0ac8813"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b2a261c-6d6a-470b-b858-a470f3e89fa6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa96d089-dfe6-4ac2-947d-35adf78b92c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncAndRocheGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39323104-bdda-4a5f-b4e0-aa2def94b95a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab0a4bc0-c687-4b75-97a5-8e7d11a1a0be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11c9cefe-d945-4687-baad-0cb3aed4a0b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4af3728-9703-4193-8445-5f99fb79c576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a866f0e-30b1-4ade-9e73-d9a9bba031bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c236b85-61c5-4e71-b6c3-ced8a4945424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13005d32-f646-429f-a0e2-4fd8c00bf69a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d77ee3a7-0648-4c68-ad86-6a36e26d4d2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9af75d46-039e-4da0-97be-856b25cedf1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:CommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd0b38a4-c17a-4584-ace9-9eb7a4dba7cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8432b103-20fe-4d39-a798-e24e82f7508a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f97d20b9-f753-4b1f-9310-f5374bf7a287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8afb5c3-07c8-4db4-ac88-9ca5562689cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3e3db77-5861-422c-a654-f78b40f8db36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">adpt:DigitalBiotechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ebe0fdc-225c-4155-afc8-97ad3dc284b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44860682-94f0-4904-9f2d-90b50cef0eaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDDevelopmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_241a14e0-c83c-46be-9595-a7086d9fdf64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c9aa062-7dde-4480-8d81-ee9c2d275da3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_11a7257f-ddc9-4e22-ad34-a161c6bbbc38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e840ef1f-0c35-4d10-9610-9d3bd41786d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e988e7e-5089-4aac-8a2c-022b8659ce3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9f3e4a6-a161-4edd-ae17-b5c6c4d1afc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2513f06-b4d4-4816-bbc2-a3007d07bc1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc38ff0f-2c7c-4c26-ba5a-4c9791880b39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b727e5f9-4a98-4fe3-92ea-13e9386f4879"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b34e135-b44f-41a1-b917-b0dc0f2c4bf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7306e5e5-de3a-49c5-8ca6-d62df03366ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_590e8b43-3f28-4c61-98e6-73136a10b460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a78ff4ac-0c2c-49b3-b6c9-440cbe865835"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aab74f81-a01f-4770-b79a-d5141418080d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_041a7632-3fc1-4163-8570-83d81957490c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_41662c43-8800-4ae7-bc2d-55dfc7db0bb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a716e596-2c29-46d5-9c2b-dba9981ab3f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_58ce94ff-2264-4ea2-a84c-edf34c96332a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d63aae94-5743-4e75-a64b-3a0caabf8bd7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96f09fd3-7634-4ea2-a021-1e8adb2f4bc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-29</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e47f789a-559d-43f2-a31d-acdeac94f7f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f24c325-cbc5-4f36-913f-12d35e35dc7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee1fde54-f065-4656-a66d-cb2acf02bfac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_adce8143-c708-4ab4-aad4-7932228c2737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2eb19fde-1742-44b2-a814-dd6adf82062d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d4928f6-2311-4267-a962-fb87a6ccc8c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b79125c-aadc-43ba-85de-4c5908f2bb4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89c81479-2ca4-45be-bc13-7804c0d2f507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedMarketBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d872d1b-6381-4a56-9eee-12e5744bc07e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0652792-ebc5-4eac-b642-e4d6670801ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af47b662-9bf3-44d8-8091-3006d4c6e691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d643066a-d834-4dbc-94f7-b192fb198f27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_225e2fb7-7901-40b4-90c2-b52ec6899530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_efab56ea-21ee-4b9f-a82c-12261558a450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_87dd786a-314b-49f8-baec-1edeb4120c74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7982225b-427f-4a1e-8cd0-412895f4f7f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef1ad520-2e19-4c3f-ad13-c493a883fa78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e26ca88-f723-4c17-a005-4eccedfed38e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2650e075-e451-49ad-955d-e9ad14d5bf33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0dca8ac-f948-40e9-872d-4956561f7f9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51e0ed6a-9fac-4c20-a4e8-435eb73af38d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f834ab3e-f5d2-4656-891f-53272cd08ed4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedMarketBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52090110-82a5-4e46-93f8-8226b4b52be6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02b5636a-5e74-4e33-b07e-81d5098e6ddd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_919788e3-23fd-4409-b58e-83649ea5febe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a66f191-30ec-42f3-b59c-6f6b27af199f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3bce53c7-facd-4e2e-ad21-6441c070f91f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01aa24c7-60e3-49ec-b493-ede3c4266545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82171477-fd8e-4a87-a38e-80b61f287043"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a81b7d4-7c86-4a5a-9662-9fa8a4acafae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e2c359c-7df3-4fd0-ade8-9c6156b3f9ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99d18c69-4d22-43ef-8389-5fdf986876eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_097b7e33-8328-4df1-98a7-2fb97904b263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff22cd37-5751-4b76-bb68-14093905829b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27e427e6-2646-46ca-93cd-c733bfaf29eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db4b7b1a-cb0e-4d01-8b52-9a8b1f192635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd98abbe-6241-4fc8-af88-d9979790e940"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_682d1e35-b24e-473d-a5dc-2e2a8f3b17fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_879ff3e9-d994-4359-a193-fdc194e1100d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4bbcd131-d371-4bbb-964c-f9710f39d70f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3bfaebb-d3c1-42af-942f-8e8d8be6dd92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e2b380b-13d2-47a9-a0f7-95998f87ee50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_698d77cb-703e-4d5b-acbd-9c92d097b8bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60b74489-28b2-4615-9786-6fdacef93898"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95bf0290-eef6-4156-a6ce-f1dc2af43daa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_497af0a4-b8d1-426d-b46e-bab07be8dadd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57eacb73-0b36-49e5-8d6b-de05bc131c61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">adpt:MonteCarloValuationModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e49e82a-95b6-4034-a713-b8f1ec42273a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5345840c-9735-4c5d-b8ec-b10aa2abbce6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_90b18a98-b831-4016-b24b-b23fdc203a9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46e84d5a-c9e4-4c07-ab2c-1b337f1e4935"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_905db261-8b17-447c-a833-556502ab34a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a8f8700-656c-4aa0-a7b1-18a1188de95d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_454dcbb2-775d-4dc6-8e99-ed83e128e3ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b549b79-66c4-4298-ba5f-b1b62fef2585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82f4bbd7-e097-4e32-bf62-da8405a3dbfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedRestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_623eef52-d53d-46c2-8e13-de37ddc266db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e77e6257-9358-42eb-8b65-6f87bb11fe8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef915afd-ec97-428b-a6f3-a6066e32a6a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a889da6-68e6-499f-9f09-345a151867c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b0c61c69-cbe1-4b8f-9a70-56d35c5b6efc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_67aee0e6-f162-469f-95d2-8cd5d55d1668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:DevelopmentMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87feba55-a051-420f-828e-ec84f440b3a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a75aed5b-f247-4baf-af25-a000ba7211d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b2a6703f-315a-4dab-97f7-15768deba909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_091e55d9-10c4-4aba-84c0-5a9e97322c47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedRestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3dfafff-e989-4644-9b5f-c4c61d62483b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26c20ab9-dfe4-46c3-b509-3bf6d6c00d37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ebf03ab-8700-457d-a330-2b6afbc9f9dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fab848dc-7a49-4318-bdad-9aa948d6f630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ea6d2a9-4933-428d-a214-8f22b0ee534e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3787167f-f9fe-4167-8297-ba5c7cf2cf41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f352b237-e382-41ae-acc7-96078de3a980"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a82a556c-1601-4580-ab77-910e118cd40c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f2870833-bf7c-4640-b2de-b1f3f45dc7ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1347ec09-38d8-439d-8a28-61beab707a2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71aa9e96-4108-4a98-82b6-96eb9ed09cbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a21c196f-6dfe-415c-b90a-3c3da2b36e46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a850bcd3-da63-46d2-b9d7-bfe3de139a9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18612828-7d58-4576-a6a2-b4505743ef18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46c823cf-5ea5-4b9b-b0ea-af9c60b6fd51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2fd988f0-f2ea-429d-b4f6-17267c9ddedc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff166e5f-74cd-481e-a4de-3d85ebc33d6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:ImmuneMedicineServiceRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b1f3710-0d39-453d-82f3-7b451fd927d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea6a3074-5c90-4942-a6a0-917ee25491db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b6979c8-1fdd-4825-99b4-52c44d8a83f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7984164c-34fb-49f5-8c89-ae672ec9ae5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0b012e9-1d72-456e-818b-e7c99403c318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7763f050-ced0-429d-9db0-76d18214c5c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">adpt:MonteCarloValuationModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae994e8c-99db-42b9-978b-de43f2096cd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79087f84-8200-4e59-be47-56564ec79f8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3b1db82-a429-41f4-a3a7-519573159ff1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1bea693b-1342-45f0-bcda-ded1c10280e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61d852e8-fe3d-43d3-9908-9744f1adec07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52139d7b-c2be-477b-8367-d18a6a83b6e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6dd27e3-1742-4ce3-b818-2cc2fe370e7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7318b790-ee25-41a4-acff-80a6c93d4e3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_060ee2a5-56eb-46bd-b35a-e98de401cab1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd3f7f0d-8716-4252-b061-74865b34ce51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aef81851-9d40-4e26-b3cc-121716608ec6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36aa5e03-ecb8-4303-b58a-1c55adb14e7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6428414-6c4a-46a9-aaa6-447acbd2d45a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:NonvestedMarketBasedRestrictedStockUnitsGrantedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f19237c-a155-4029-b45f-b9fb5332f737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b9b7218-2fe1-41c4-b97c-55fcf735df6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_461360c8-498f-4146-b38f-94ec6b8507ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac662e7b-0f00-4834-864f-bfae853d3fae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncAndRocheGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b1ddbb7-6337-4d2b-8237-82b13e821312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f60e9643-430c-4ac5-b6d2-f2549cc4ce16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a86b9bb-1277-4e79-955e-d1edb50cca23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-12</xbrli:startDate><xbrli:endDate>2022-09-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_155c8aa1-a117-426c-ae23-7248267399d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18d7a278-e320-4faa-bd10-c3406fe899df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f712f0be-9f2e-4186-a7b5-0091ce1762f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f7590b76-24a6-4b4b-aa70-3aa848e7a0e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10ea6fb1-7d69-445d-8fcf-bcaaaf8ea019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:CommonStockExerciseOfOutstandingStockOptionsGrantedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91cb6778-e1d1-4172-888b-784d43882ecc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04434413-9490-4c62-8db8-4065a648f009"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_216614d0-45a0-4666-935c-4122d8cd59aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e1886f0-fb32-4498-bc32-5c4175f816eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4963ee4-2b06-4690-ba19-b7f24dff5cc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c035c769-db33-4f4f-a68d-722fe5a08f44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adpt:SeriesFOneConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MicrosoftCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8026f205-9131-4390-94dd-4a04d3c584e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bff5bd4a-2423-48c0-a5ec-9acfc6922d16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43621f8b-6a5f-47d0-a30e-6bf513d24ad8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be4b3886-95a1-499a-bdda-548e8b19d654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:NonvestedMarketBasedRestrictedStockUnitsGrantedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4c37a096-1a6a-45aa-8fc2-563181d9f721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d0727108-4458-4e50-b34a-e52b89840f12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dfe2e57d-4fb2-4493-8bac-7c38728d7cb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MicrosoftCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2bf1a599-2304-4abc-8e54-646171f11931"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b809ccc7-b28c-4fe5-bb88-66507dc666e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_026378ef-7341-4384-9043-f55629b2679d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c8126e1-b6cc-428b-b0c0-8e108d6c872f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ba2e40d-74e7-4c45-8c1b-863af5547a3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0cf4be7f-ab3d-44bd-8576-4b5ab607235c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d2cc705-f6fa-4bf8-a55b-b2a0844f2132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_701c755f-589d-411b-a770-4fbc3fc69793"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c608cb9-e9d3-4e98-b40b-a50be54d13e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d18ea8b5-6b95-48a5-8cf4-dca1eb7587d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb59ede3-9e6b-4249-8eda-53f2caa6aa96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8a04fa6-b5e0-4214-92b3-ab7f17428e2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f45bf03e-7ed0-4ba6-8ffc-ba5f9e654d96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fdeb24a7-efd0-43c6-90cc-7c4a9389752a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55a33622-5845-472e-a76b-82768e6681b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1b230a8-3c3c-45c2-a49f-2549b9086405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1bac84b6-f743-48d7-8309-6858a505babc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f90dae10-b7ce-472b-bbb0-33e4307f7344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97bc012b-5315-4313-9c87-2f9e1fa58826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ea1b178-9b53-435d-bea7-af3f35409ca9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_Segment"><xbrli:measure>adpt:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Employee"><xbrli:measure>adpt:Employee</xbrli:measure></xbrli:unit><xbrli:unit id="U_Performance_Obligation"><xbrli:measure>adpt:Performance_Obligation</xbrli:measure></xbrli:unit><xbrli:unit id="U_Vote"><xbrli:measure>adpt:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="min-height:0.4in;"></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, DC 20549</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37655dc6-7d30-4ccc-b20e-4cdc534576c4" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5%;"/>
    <td style="width:95%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_700e129e-8e7b-47e2-915f-4f2c79342377" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5f79e630-4fb5-498b-b23c-ad50683a7615" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cf555f04-7046-4a9b-b336-2227057a8a4d" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_81134731-31df-47f0-aecd-db584d83e5ac" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OR</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5%;"/>
    <td style="width:95%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_e080add7-d7ba-491b-877e-08991480ff6b" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from _____to _____</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee57939e-66db-4c99-b7b1-f290d0f7084b" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-38957</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7b498bb8-d218-4c9c-9807-c531c87339b3" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;min-width:fit-content;">ADAPTIVE BIOTECHNOLOGIES CORPORATION</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact Name of Registrant as Specified in its Charter)</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:1.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_62f46534-2118-40c4-874b-7aac3bcddb06" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Washington</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e1b86055-5b45-473d-adcf-535d692a6cf0" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">27-0907024</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_0ced6460-ccdf-4752-8799-ebe364936e5c" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1165 Eastlake Avenue East</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_87a4ab9e-f2f6-43b1-81aa-8ef9785ad088" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Seattle</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_9ca7f2b9-beb7-4aa2-b3a4-e8e241f1998c" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Washington</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_191c32d5-79c8-435b-baa5-bfed2d1bddfd" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">98109</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed95b0ec-4887-4e59-9ad5-b818bcfbacf4" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(206)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_737f52ad-1e2a-48d1-a390-17258dc45a18" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">659-0067</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:42.2%;"/>
    <td style="width:3%;"/>
    <td style="width:9.64%;"/>
    <td style="width:2.96%;"/>
    <td style="width:42.2%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_121dd42b-d033-4609-9b10-f0893ea46c75" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_9aecc1aa-1031-4d4c-9de1-7b879dae6b69" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ADPT</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_ca684741-df6d-4fb0-9ac9-d5015a4aa7bf" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The NASDAQ Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">None</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2079a94-993f-49ff-acda-dad2e5696497" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:EntityWellKnownSeasonedIssuer"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_93aecf34-1176-4535-8712-467c32f34416" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:EntityVoluntaryFilers"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79184b76-e536-4857-b3e2-7c9adb4e9a49" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:EntityCurrentReportingStatus"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04aef337-c285-42d2-8bc2-cca0af009ba2" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:EntityInteractiveDataCurrent"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.88%;"/>
    <td style="width:1%;"/>
    <td style="width:55.86%;"/>
    <td style="width:1.06%;"/>
    <td style="width:20.1%;"/>
    <td style="width:1%;"/>
    <td style="width:2.1%;"/>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_c4bae6aa-0a71-4990-9233-efa14c11b8cf" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:3.6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_5ecbda32-7484-4af6-9277-f37152d6db30" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_f2e131f5-34e3-4510-96fb-9f26a31a72e9" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_b4e9990f-d472-4230-89d4-234d5ed7a906" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5da85698-6a4a-44c2-80bc-fd5a10f9f60f" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">    No  </span><span style="font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_5ad394a2-984d-4dc1-846d-0dd64f994a0c" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The NASDAQ Global Select Market on June 30, 2023 (the last business day of the Registrant&#8217;s most recently completed second fiscal quarter), was approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2895f85-ef4a-4737-ade0-85565d2df610" contextRef="C_026378ef-7341-4384-9043-f55629b2679d" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">756,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">As of February 23, 2024, the Registrant had </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a85bd9c9-f883-4c2d-a08b-f410f05d6b8f" contextRef="C_9b1f3710-0d39-453d-82f3-7b451fd927d2" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">145,092,271</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, $0.0001 par value per share, outstanding.</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div><ix:nonNumeric id="F_3dff39db-a7b5-4787-9c8f-abacc75e58a5" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">The information required by Part III of this Annual Report on Form 10-K, to the extent not set forth herein, is incorporated herein by reference from the Registrant&#8217;s definitive proxy statement relating to the Annual Meeting of Shareholders to be held in 2024.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;min-height:0.4in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.4in;"></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.4in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.1%;"/>
    <td style="width:82.82%;"/>
    <td style="width:7.08%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART I</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART II</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_quantitative_qualitative_disclosu"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_and_suppleme"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART III</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">SIGNATURES</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements that are based on management&#8217;s beliefs and assumptions and on information available to management. Some of the statements in the &#8220;Business,&#8221; &#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections and elsewhere in this Annual Report on Form 10-K contain forward-looking statements. In some cases, you can identify forward-looking statements by the following words: &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe we have a reasonable basis for each forward-looking statement contained in this Annual Report on Form 10-K, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements expressed or implied in this Annual Report on Form 10-K include, but are not limited to, statements about:</span></p>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of our significant investments in our continued research and development of new products;</span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of developing, commercializing and achieving commercial market acceptance of clonoSEQ, Adaptive Immunosequencing, T cell receptor (&#8220;TCR&#8221;)-based cellular therapies, antibody-based therapeutics products and additional products beyond our portfolio;</span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential for our identified research priorities to advance our proprietary immune medicine ("IM") platform or our future products;</span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success, cost and timing of our research and development activities, preclinical and clinical studies and, in certain instances, clinical trials and clinical validations;</span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential benefits of collaborations, our ability to enter into collaborations or arrangements and our ability to attract collaborators with development, manufacturing, regulatory and commercialization expertise; </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability and willingness of our collaborators to continue development, manufacturing, distribution and commercialization activities relating to our jointly developed products;</span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to identify research priorities and apply a risk-mitigated strategy to efficiently discover and develop products and services, including new targets in autoimmunity and neurodegenerative disorders;</span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain regulatory approval of our products;</span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the pricing and reimbursement of our products following approval where required;</span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain equipment and materials (including reagents or other materials that may also require additional internal validation) from our suppliers, and in some cases single suppliers;</span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to generate revenue and obtain funding for our operations, including funding necessary to complete further development of our current and future products, and if successful, commercialization;</span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to manage operating expenses;</span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size and growth potential of the markets for our products, and our ability to serve those markets, either alone or in combination with others;</span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the rate and degree of market acceptance of our products;</span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our financial performance;</span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding our ability to obtain and maintain intellectual property protection for our immune medicine platform, products, and related technologies and the direction of such protection;</span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory developments in the United States (&#8220;U.S.&#8221;) and foreign countries;</span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of competing products or services that are or may become available;</span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments relating to our competitors and our industry;</span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to attract and retain key scientific or management personnel;</span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of laws and regulations; and</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, you should refer to the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K for a discussion of other important factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report on Form 10-K will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements herein represent our views as of the date of this Annual Report on Form 10-K. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In this Annual Report on Form 10-K, unless the context requires otherwise, all references to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Adaptive&#8221; and the &#8220;Company&#8221; refer to Adaptive Biotechnologies Corporation.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART I</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Throughout our history, we have advanced the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature&#8217;s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient&#8217;s immune system and understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database and related antigen annotations, which are underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that can be tailored to the needs of individual patients.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2023, we continued to pursue our business around two main areas: clinical assessment of minimal residual disease (&#8220;MRD&#8221;) in lymphoid malignancies and immune medicine (&#8220;IM&#8221;)-driven drug discovery and development. We believe the total addressable market for the MRD business is $5.1 billion, $4.4 billion of which is derivable from clinical testing. The IM business focuses its research and development investments on catalysts that achieve strategic priorities, including continued support of our partner, Genentech, Inc. (&#8220;Genentech&#8221;), in its development of TCR-based cell therapies in oncology as well as the discovery of novel druggable targets in autoimmunity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The MRD business focuses on the use of our highly sensitive, next-generation sequencing (&#8220;NGS&#8221;) assay to measure MRD in patients with hematologic malignancies. It is comprised of our clonoSEQ clinical diagnostic test, offered to clinicians, and our clonoSEQ assay, offered to biopharmaceutical partners, to advance drug development efforts (&#8220;MRD Pharma&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clonoSEQ is the first test authorized by the Food and Drug Administration (&#8220;FDA&#8221;) for the detection and monitoring of MRD in patients with multiple myeloma (&#8220;MM&#8221;), B cell acute lymphoblastic leukemia (&#8220;ALL&#8221;) and chronic lymphocytic leukemia (&#8220;CLL&#8221;) and is also available as a CLIA-validated laboratory developed test (&#8220;LDT&#8221;) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (&#8220;DLBCL&#8221;). We believe clonoSEQ is the test of choice in MRD testing for hematologic malignancies with industry leading sensitivity. With the use of clonoSEQ, we are transforming how lymphoid cancers are treated by working with providers, pharmaceutical partners and payors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The IM business leverages our proprietary ability to sequence, map, pair and characterize TCRs and B cell receptors (&#8220;BCRs&#8221;) at scale. We have created a powerful data engine to drive the development of novel therapies. These datasets, which we own, include over 100,000 signatures of cancer and autoimmune disease and approximately 500,000 matches of TCRs to disease-related antigens.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our sizable data and differentiated capabilities uniquely positions our IM business to discover novel targets and develop therapeutic candidates, such as TCR-based therapies and antibodies, against these targets. Our goal is to better understand and treat challenging conditions such as autoimmune disease and cancer. The tremendous potential of IM in drug discovery is demonstrated by our worldwide collaboration and license agreement with Genentech (the &#8220;Genentech Agreement&#8221;). Under the Genentech Agreement, we will continue development of TCR-based cell therapies in cancer. In 2023, a first FDA-cleared investigational new drug (&#8220;IND&#8221;) for a shared antigen cell therapy product candidate was secured by Genentech. This milestone also established an important proof of concept for our first discovered TCR to be used in a cell therapy product candidate and supports our work towards a TCR-based fully personalized approach. The IM business also applies the potential of our immune medicine platform in the treatment of autoimmune diseases, such as multiple sclerosis (&#8220;MS&#8221;), Crohn&#8217;s disease, type 1 diabetes and rheumatoid arthritis.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selected 2023 Results</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2023, our revenue was $170.3 million compared to $185.3 million in 2022, with the reduction primarily reflecting a decline in the amortization of the upfront payment from Genentech, a slowdown in pharma services largely due to broader macroeconomic factors impacting the biopharmaceutical industry and no MRD milestones. At the same time, our operating expenses were significantly leveraged as a result of continued streamlining of our operations during the year. Operating expenses were $397.3 million during 2023, of which $25.4 million represented non-cash impairment charges, as compared to $385.5 million during 2022. As of December 31, 2023, cash, cash equivalents and marketable securities was $346.4 million.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">MRD Highlights</span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We grew clonoSEQ test volume by 53% year over year. Clinical test revenue increased by 53% over 2022. Payor coverage for the test has grown to 300 million lives in ALL and MM, 200 million lives in CLL and 70 million lives in DLBCL.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We integrated the clonoSEQ&#8239;clinical diagnostic test via the Epic System Corporation's (&#8220;Epic&#8221;) comprehensive electronic medical record (&#8220;EMR&#8221;) system into the records systems of four accounts in 2023 to enable easier test ordering, with a fifth account nearing launch. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our MRD Pharma revenue, excluding milestones, increased by 1% from 2022, attributable primarily to the slowdown in pharma services due to broader macroeconomic factors impacting the biopharmaceutical industry. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our clonoSEQ assay was being used in 143 active trials being conducted by 43 biopharmaceutical partners, including 75 trials in which it represented a clinical endpoint (primary endpoint in 10 trials).</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">IM Highlights</span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In Drug Discovery, we made significant progress under the Genentech Agreement with respect to both the Shared Products and Personalized Product. For the Shared Products, we completed an assessment of efficacy and safety data which enabled selection of a TCR candidate to advance as a potential therapeutic product candidate. The first FDA IND clearance under our Genentech Agreement was obtained for this candidate in 2023. In addition, fully characterized TCR data packages against validated neoantigen targets have also been provided to Genentech for further evaluation.</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For our fully personalized approach, blood samples from 165 cancer patients have been screened. A Personalized Product proof of concept was completed by identifying and characterizing patient specific TCRs to unique tumor mutations. In 2023, we successfully built our personalized process workflow under regulated conditions in our South San Francisco lab. This foundation enables us to initiate end-to-end testing in preparation for future clinical readiness of our fully personalized process.</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In autoimmune diseases, we continued our drug discovery efforts in MS, Crohn&#8217;s disease, type 1 diabetes and rheumatoid arthritis, and discovered a novel therapeutic target in MS. Validation of this novel MS self-antigen as a therapeutic target and assessment of potential therapeutic modalities against this target are planned to occur over the next few years. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Immunosequencing Platform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The adaptive immune system is comprised of specific immune cells, called T cells and B cells, that hold the instructions for diagnosing and treating most diseases. These instructions enable specialized receptors that sit on the surface of TCRs and BCRs to identify, bind and destroy pathogens or human cells presenting foreign signals of disease (&#8220;antigens&#8221;). Unlike all other genes in the human genome, the genetic sequences of TCRs and BCRs rearrange over time creating massive genetic diversity. In contrast to the static human genome that is made up of approximately 30,000 genes, the adaptive immune repertoire of a healthy adult consists of more than 100 million different genes. This massive genetic diversity gives the immune system the ability to detect and respond to millions of different antigens associated with human disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our immunosequencing platform combines a suite of proprietary chemistry, computational biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. It extracts and interprets insights from the adaptive immune system with the scale, precision and speed required to enable the design of clinical products tailored to the specific genetics of each patient&#8217;s immune system.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">A Primer: The Adaptive Immune System</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Over millions of years, the adaptive immune system has evolved an elegant solution to keeping people healthy. It recognizes and responds to most antigens, whether they come from outside the body, such as a virus, or inside the body, such as mutations that drive cancer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The innate and adaptive immune systems both play a role in human immunity. However, the adaptive immune system alone provides a specific response to signals of disease, or antigens. These disease specific antigens are primarily fragments of proteins that are recognized as foreign, such as proteins from a virus. However, antigens can be recognized as foreign even if they are not from a virus or pathogen. In cancer cells, tumor associated antigens (&#8220;TAAs&#8221;) are normal proteins that are aberrantly expressed in a tumor; neoantigens are mutated versions of normal proteins that are specific to the cancer and not found in healthy normal cells. Both TAAs and neoantigens are recognized by the immune system as foreign. For autoimmune disorders, the immune system loses the ability to distinguish between 'self' and 'non-self' and mistakenly recognizes normal protein fragments (&#8220;self-antigens&#8221;) as foreign, which results in attacking otherwise healthy tissue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Adaptive Immune Response</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The key cells of the adaptive immune system that enable our bodies to mount responses against antigens are called T cells and B cells. T cells can destroy target cells directly, and B cells secrete antibodies, activating other parts of the immune system to destroy targets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each T cell and B cell has a unique Y-shaped receptor, which can recognize one or a small number of the millions of antigens to which our bodies are continuously exposed. When an adaptive immune response is initiated against a particular disease, the T cells and B cells encoding the disease-specific targeting receptors rapidly multiply through clonal expansion, allowing for a powerful immune response. Some of these expanded cells directly attack the disease, and others form long-term memory to allow rapid recognition of the same antigens in the future and protect against reinfection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unlike all other genes in the human genome, the genetic sequences of TCRs and BCRs rearrange over time through a complex biological process resulting in massive diversity. The diversity of these receptors is made possible by a unique reshuffling of their genetic code known as V(D)J recombination (V=Variable, D=Diversity, J=Joining). This recombination process only occurs in T cells and B cells, and it results in each cell clone having a unique receptor-associated deoxyribonucleic acid (&#8220;DNA&#8221;) sequence. This unique DNA sequence acts like a barcode that can be used to identify and track an individual receptor over time, as shown in the figure below:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img63237988_0.jpg" alt="img63237988_0.jpg" style="width:691px;height:389px;"/>&#160;</p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The adaptive immune response requires millions of these unique receptors to be widely distributed and present in the blood in order to have the ability to rapidly respond to many different diseases simultaneously. Even after a specific TCR binds to an antigen and clonally expands, the frequency of these expanded T-cell clones containing the TCR remains relatively low in relation to the estimated trillions of other T cells that are circulating. We now know that disease-specific TCRs that are clonally expanded in a patient&#8217;s blood are present, on average, at less than 1 cell out of 100,000 cells. Despite their relatively low abundance, disease-specific TCRs can mount a systemic, persistent response to most perturbations because of the highly specialized properties of the immune response, as summarized in the table below:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img63237988_1.jpg" alt="img63237988_1.jpg" style="width:691px;height:389px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to fully leverage the natural properties of the immune system to develop clinical products, the enormous diversity and scale of the adaptive immune system must be taken into consideration, including the ability to accurately and reliably measure the relative frequency of each disease-specific T (or B) cell in the blood. For example, cancer-specific TCRs circulating in the blood of a cancer patient are only present at 1 out of 100,000 cells. Auto-reactive T cells specific to any given autoimmune disorder circulating in the blood are only present at 1 out of 1,000,000 cells. Accordingly, the ability to detect disease-specific T cells requires a technology that can quantitatively probe a minimum of hundreds of thousands to millions of blood cells from each sample. Our technology was built and validated to address this need.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our immune medicine platform combines proprietary chemistry, computational biology and machine learning to generate clinical immunomics data that we use to decode the adaptive immune system. It extracts and interprets insights from the adaptive immune system with the scale, precision and speed required to enable the design of clinical products tailored to the specific genetics of each patient&#8217;s immune system. To that end, we developed a combination of technologies to perform the following key functions that broaden our understanding of immune-mediated biology:</span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sequencing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our proprietary NGS-based immunosequencing methods provide sequences for single chains of &#8220;Y-shaped&#8221; TCRs or BCRs, which enables understanding of the quantity and diversity of T cells and B cells in a biological sample. Together with our massive clinical immunomics database of immune receptor sequences, our sequencing capabilities provide deep insights into individual and collective immune responses at a scale that is thousands of times greater than was previously possible.</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Antigen Identification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We have developed powerful approaches to identify disease-related antigens which trigger a T-cell response, even at levels of one T-cell in a million (as may occur in autoimmune disorders).</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:13.602%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6262181994953586%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human leukocyte antigen (&#8220;HLA&#8221;)-presented disease specific antigens. By applying proprietary screening methods, we can identify TCRs which cluster around a presumably identical HLA-presented antigen and identify that antigen by a process we call &#8220;de-orphanization&#8221;. Our massive database of TCRs and healthy control samples enables us to rapidly confirm whether such antigens are disease-specific, even if the antigen or its relationship to the disease was previously unknown.</span></div></div>
  <div style="margin-left:13.602%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.6262181994953586%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Antigen-TCR mapping. MIRA (Multiplexed Identification of TCR Antigen Specificity) maps millions of TCRs to thousands of clinically relevant Class I and Class II antigens. MIRA is another proprietary method which enables us to elucidate </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in silico</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> what potential diseases a patient&#8217;s immune system has been exposed to or is actively fighting.</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pair.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> pairSEQ provides a combinatorial strategy to accurately pair both chains of Y-shaped immune cell receptors at high-throughput, which is challenging to do at scale using other methods because the two chains of the Y-shaped receptors are located on different chromosomes. The ability to accurately pair both chains of the receptors in a sample enables us to reconstruct receptors for therapeutic purposes.</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Characterize.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our platform characterizes binding, functionality and safety properties of antigen-specific, paired TCRs or BCRs. Our high-throughput sequencing and antibody discovery process allows us to select from a diversity of potent, naturally occurring, full length human receptors. We identify and focus on a subset of therapeutic-grade candidates to designate and further develop as TCR or antibody based therapeutic products. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Products and Pipeline (MRD)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The MRD business area focuses on the use of our highly sensitive, FDA-authorized NGS assay to measure MRD in patients with hematologic malignancies. It is comprised of our clonoSEQ clinical diagnostic test, offered to clinicians, and our clonoSEQ assay offered to biopharmaceutical partners to advance drug development efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe clonoSEQ is the test of choice in MRD testing for hematological malignancies with industry leading sensitivity of 1 out of 1,000,000 cells, given sufficient sample input. By taking a baseline measurement prior to starting therapy and then tracking the number of cells at several time points following therapy initiation, hematologists can improve their ability to assess treatment response, predict long-term patient outcomes, monitor disease burden over time and detect potential relapse.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With the use of clonoSEQ, we are transforming how lymphoid cancers are treated by working with biopharmaceutical partners, providers and payors. For instance, with the use of clonoSEQ we have the potential to accelerate the development of drugs in lymphoid cancers, assist physicians with critical clinical decisions and enable treatment decisions which may lower payor cost through the discontinuation of costly drugs that are no longer needed.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Technology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clonoSEQ is our FDA-authorized, NGS MRD technology that is designed to sequence all rearranged receptor sequences in a tumor in parallel to ensure accurate, sensitive and robust MRD monitoring.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the steps we perform in clonoSEQ is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">gDNA is extracted from bone marrow. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Extracted DNA quality is assessed, and rearranged immune receptors are amplified using a multiplex polymerase chain reaction (&#8220;PCR&#8221;). </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reaction-specific index barcode sequences for sample identification are added to the amplified receptor sequences by PCR. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sequencing libraries are prepared from barcoded amplified DNA which are then sequenced by synthesis using NGS. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Raw sequence data are uploaded from the sequencing instrument to our analysis pipeline. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sequence data is analyzed in a multi-step process, where a sample&#8217;s sequence data is first identified using the sample index sequences and the data is then processed using a proprietary algorithm with in-line controls to remove amplification bias. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following completion of these data processing steps, a report is issued. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">clonoSEQ</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our clonoSEQ diagnostic test detects and monitors the remaining number of cancer cells that are present in a patient&#8217;s body during and after treatment, known as MRD. We believe clonoSEQ has broad applicability across all lymphoid malignancies, including ALL, CLL, MM, and Non-Hodgkins Lymphoma (&#8220;NHL&#8221;) conditions (DLCBL, mantle cell lymphoma (&#8220;MCL&#8221;), and cutaneous T-cell lymphoma (&#8220;CTCL&#8221;).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2018, clonoSEQ was granted marketing authorization from the FDA, under the de novo process, for patients with MM and ALL to monitor their MRD from bone marrow samples. In August 2020, the clonoSEQ label was expanded to include patients with CLL from bone marrow and blood samples.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2022, the assay was launched as a CLIA-validated LDT to detect MRD in blood for patients with DLBCL by measuring circulating tumor DNA (&#8220;ctDNA&#8221;), which provides patients and clinicians with a powerful blood-based prognostic tool. We are pursuing FDA clearance of our DLBCL test to support clinical adoption and increase its usage by our biopharmaceutical partners.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical penetration with clonoSEQ has grown significantly</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as illustrated below.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img63237988_2.jpg" alt="img63237988_2.jpg" style="width:537px;height:446px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img63237988_3.jpg" alt="img63237988_3.jpg" style="width:239px;height:22px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2019, clonoSEQ received Medicare coverage aligned with the FDA label and National Comprehensive Cancer Network (&#8220;NCCN&#8221;) guidelines for longitudinal monitoring in MM and ALL. clonoSEQ is now incorporated in NCCN guidelines and used by all 33 NCCN cancer centers. Over the years since, we have secured additional payor coverage for clonoSEQ aligned with our FDA label with Medicare, national private payors and large regional plans, expanding coverage to 300 million covered lives for ALL and MM, 200 million covered lives for CLL and 70 million covered lives for DLBCL.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, MolDX published its local coverage decision (&#8220;LCD&#8221;) for MRD testing. This LCD not only affirmed the importance of MRD and clonoSEQ coverage in ALL, MM and CLL in bone marrow and blood, but it also provided a clear and efficient pathway for seeking expanded clonoSEQ coverage through technical assessments in NHL.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2022, coverage expansion continued as we secured Medicare coverage for DLBCL, the most common form of NHL. We secured clonoSEQ coverage with Medicare for DLBCL patients regardless of line of therapy, treatment regimen or testing timepoint. clonoSEQ is the first and only MRD test to receive Medicare coverage in DLBCL. We anticipate receiving Medicare coverage for another NHL condition, MCL, in early 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2022, we entered into a partnership with Epic to integrate clonoSEQ into Epic&#8217;s EMR system, which we believe will enable easier test ordering and results access for the clonoSEQ test. In 2023, clonoSEQ became integrated into the EMRs of five customers and we expect significant growth in customer integrations in 2024, including through an additional EMR collaboration with Flatiron Health, Inc. entered into in February 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a multi-pronged strategy to deepen penetration of clonoSEQ and improve our commercial and operational infrastructure:</span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Increase clinical testing in blood to facilitate adoption for clinicians in the community setting and increase frequency of testing across treatment settings.</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expand into new patient populations mainly within NHL subtypes, starting with DLBCL, MCL and CTCL.</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expand patient use bases by continuing to generate clinical evidence in clonoSEQ utility at multiple points along the patient continuum of care. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In parallel, we continue to enhance customer experience with EMR integration, optimize payor coverage and leverage our operating infrastructure to drive margin improvements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Through 2023, clonoSEQ is also being used by 43 biopharmaceutical companies in 143 active clinical trials, representing (depending on the disease) between 9% and 44% penetration (peak for MM) of active industry sponsored clinical trials in lymphoid cancers as of December 31, 2023. We continue to deepen our commercial investments to expand clinical adoption of clonoSEQ and have increased the strength of our specialized sales and customer support organization and supporting infrastructure in the U.S. We have also successfully transferred certain sequencing technology under non-exclusive licenses to multiple labs in other parts of the world.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Evolving Clinical Utility Data</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that the value of clonoSEQ as a decision-making tool may enable clinicians to select the best patient treatment options based on MRD status. Some examples of recent expanded clinical use cases and drug development advances include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PERSEUS is a phase 3 randomized study of Daratumumab + VRd (Velcade, Revlimid, and dexamethasone) versus VRd alone in patients with newly diagnosed MM who are eligible for ASCT. MRD was assessed by clonoSEQ in 355 patients in the D-RVd group and 354 patients in the VRd alone group. Deep and durable MRD negativity was achieved with D-VRd, and 64% of patients receiving maintenance in the D-VRd group discontinued Daratumumab after achieving sustained MRD negativity per the protocol. Not only has MRD been shown to be prognostic but it also informs clinical care in the sustained MRD negativity group. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In an MRD-adapted study from the University of Wisconsin, MRD status assessed by clonoSEQ in peripheral blood was used to determine the relationship between early response and outcomes, as well as to guide maintenance therapy in patients with previously untreated MCL. The data were presented in a poster presentation titled Minimal Residual Disease (MRD) Testing by Next Generation Sequencing (NGS) after Two Cycles (CY) of Non-Intensive Chemoimmunotherapy Is Predictive of Remission Duration and Need for Maintenance Therapy (MT) in Previously Untreated Mantle Cell Lymphoma (MCL): A Wisconsin Oncology Network Study (Abstract 4407). In this study of 21 patients, those with a complete response who were MRD negative by clonoSEQ after induction and consolidation therapy were not given maintenance therapy. In patients without a complete response or with persistent MRD positivity, obinutuzumab maintenance was given for 8 cycles. Patients were followed for greater than or equal to two years from therapy completion. In patients achieving MRD negative status after induction and consolidation, omission of obinutuzumab maintenance did not result in worsening progression free survival (&#8220;PFS&#8221;) compared to those that did receive maintenance. Additionally, MRD status post cycle two of induction was prognostic.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional prospective studies are underway, and many have shared interim data at industry conferences. As more studies read out, we expect there may be greater adoption of MRD in clinical decision making, which could result in more patients benefiting from clonoSEQ and greater frequency of testing for each patient helped.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Adaptive Assist: Patient support program</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Assist is our patient support program to facilitate access to clonoSEQ testing services for patients who could benefit from the clinical insights provided by NGS MRD testing. Patients can call to discuss their individual circumstances with one of our dedicated patient support representatives in order to better understand their coverage prior to clonoSEQ testing and to navigate the insurance process, including appeals for denied claims. We also offer financial assistance for qualified uninsured and under-insured patients who cannot afford their patient financial responsibility for clonoSEQ.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">MRD Pharma</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The MRD Pharma business area focuses on offering our clonoSEQ assay to biopharmaceutical partners to advance drug development efforts. Given the broad penetration of clonoSEQ, we believe there is a significant growth opportunity for our MRD Pharma business, as we aim to replicate clonoSEQ's success in other indications. For example, clonoSEQ is currently identified as an endpoint in approximately 30% of U.S.-based clinical trials being conducted by biopharmaceutical companies in MM.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Products and Pipeline (Immune Medicine)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The goal of our IM business is to scale our target discovery and drug discovery efforts to bring transformative therapies into the clinic either on our own or with a partner. The engine driving the IM platform is our immunosequencing technology that allows us to tap into the massive diversity of the immune repertoire at unparalleled scale and specificity. Our immunosequencing approach utilizes multiplex, bias-controlled PCR to accurately and quantitatively sequence, map, pair and characterize millions of TCRs and BCRs at scale. The proprietary datasets we have generated to date include over 100,000 signatures of disease (such as cancer and autoimmune conditions) and approximately 500,000 matches of paired TCRs to disease-related antigens.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Drug Discovery</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We are focusing our drug discovery programs to develop therapies on our own or in partnership. In these respects, our proprietary data and capabilities uniquely position IM to discover and develop therapeutic candidates such as TCR-based modalities, antibodies and potentially vaccines to better understand immune-mediate biology and treat challenging conditions such as cancer and autoimmune disorders.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img63237988_4.jpg" alt="img63237988_4.jpg" style="width:691px;height:388px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The tremendous potential of IM in drug discovery is demonstrated by the Genentech Agreement. Two product development pathways for T cell immunotherapies in cancer are being pursued under the Genentech Agreement in which Genentech intends to use TCRs discovered and characterized by our immune medicine platform to engineer and manufacture cellular medicines:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img63237988_5.jpg" alt="img63237988_5.jpg" style="width:691px;height:388px;"/>&#160;</p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shared Products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The shared products will use &#8220;off-the-shelf&#8221; TCRs identified against cancer antigens shared among many cancer patients (&#8220;Shared Products&#8221;). We have completed an assessment of efficacy and safety data which enabled selection of a TCR candidate to progress as a potential therapeutic product candidate for which FDA IND clearance was secured by Genentech in 2023. Fully characterized TCR data packages against additional validated antigen targets have also been provided to Genentech for further evaluation.</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Personalized Product. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The personalized product will use patient-specific TCRs identified by real-time screening of TCRs specific to each patient's unique cancer mutations (&#8220;Personalized Product&#8221;). Blood from 165 cancer patients has been screened. A Personalized Product proof of concept was completed by identifying and characterizing patient specific TCRs to unique tumor mutations. In 2023, we successfully built our personalized process workflow under regulated conditions. This foundation enables us to initiate end-to-end testing in preparation for future clinical readiness of our fully personalized process. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Genentech Agreement, IM supports Genentech in the development of two categories of TCR-based cancer cell therapies for the treatment of patients with solid tumors. The first neoantigen-directed cell therapy product candidate was recently FDA IND cleared with plans to enter the clinic.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The IM business is also advancing a pipeline of potential immune-based therapies to novel targets in autoimmune disorders such as MS, Crohn&#8217;s disease, type 1 diabetes and rheumatoid arthritis. In autoimmunity, the immune system attacks self-antigens, which are human proteins normally found in our body. Specifically, T cells lose their ability to distinguish &#8216;self&#8217; from &#8216;non-self&#8217; antigens which may cause disease. In MS, for example, we have discovered a novel self-antigen that we are validating as a potential therapeutic target. MS is a T-cell mediated disease involving mostly unknown self-antigens for which current treatments lack specificity to disease-causing targets, leading to suboptimal efficacy and risk of significant side effects. We have identified and validated specific TCRs that are shared and clustered in MS patients, which enabled the discovery of this particular self-antigen, which we believe is likely to play a causative role in MS. Validation of the self-antigen as a therapeutic target is ongoing and drug discovery to select the best therapeutic modality to drug this target and designate a therapeutic candidate is planned to occur over the next few years.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expanding on our capabilities in</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">finding HLA-presented, disease specific epitopes that T cells hit naturally, we are also identifying causative target antigens of interest for therapeutic development in inflammatory bowel disease conditions, which includes Crohn&#8217;s disease, as well as other autoimmune disorders such as rheumatoid arthritis and type 1 diabetes, where there is a high unmet need for more targeted and specific therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Competitive Strengths</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We harness the inherent biology of the adaptive immune system to develop clinical products and services that improve human health by leveraging our core competitive strengths.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our immune medicine platform is uniquely capable of supporting clinical products for us and our collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We have developed a platform that is capable of reading and translating the massive genetic diversity of the adaptive immune system and its selective response to disease. Specifically, our platform</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> sequences</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> immune receptors and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> maps </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">them to antigens for diagnostic applications,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> pairs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> receptor chains and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">characterizes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> antigen-specific, paired receptors to identify optimal clinical targets for therapeutic use. We believe that we have a differentiated ability to perform these functions at an unprecedented scale to develop novel clinical diagnostic and therapeutic products.</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our clinical immunomics database provides a robust product development engine.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Using the adaptive immune system as our product source-code, we are building a dynamic clinical immunomics database that is machine learning/AI-enabled. We translate the natural capabilities of the immune system into the clinic by capturing the millions of diverse unique receptors present in a patient&#8217;s blood. The combination of our large, quality data and our ability to generate additional insights creates a data foundation which we will continue to leverage to accelerate our target and drug discovery efforts. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are well capitalized and on a path to profitability for our MRD business area. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had $346.4 million in cash, cash equivalents and marketable securities. In 2023, we focused on reducing our operating expense growth rate. For the MRD business, we estimate positive adjusted EBITDA by the end of 2025 and expect to be cash flow breakeven by the end of 2026. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical applicability spans diagnostic and therapeutic product potential.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our ability to accumulate, synthesize and process billions of immunomic datapoints to generate multiple clinical applications across disease areas provides optionality to our commercial pipeline. Each of our products also has broad applicability, enabling robust product lifecycle extensions. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Transformational collaborations with industry leaders validate our platform.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our collaborations with industry-defining leaders such as Genentech and Microsoft Corporation (&#8220;Microsoft&#8221;) validate our unique approach to advancing the promise of immune medicine. We will continue to seek opportunities to optimize our ever-growing clinical immunomics database to drive product development and commercial success and facilitate efficient use of capital. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expanding regulatory and reimbursement expertise will help inform future clinical product development. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Having obtained FDA marketing authorization and expanded coverage to 300 million covered lives for multiple indications of clonoSEQ from Medicare, national private payors and large regional plans, we believe we have developed valuable core capabilities that will facilitate future product development through to regulatory approval and reimbursement. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Strong intellectual property protects our immune medicine platform and its applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> As of December 31, 2023, we had filed over 800 patent applications, more than 450 of which were issued and active as of that date, covering improvements in sequencing methods and new ways to leverage adaptive immune receptors for our MRD and IM business areas.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Strategy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our focus is to leverage our immune medicine platform and competitive strengths to develop transformative clinical solutions that are accessible to patients with a range of diseases.</span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Powering the age of immune medicine.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We contribute to the immune medicine field by generating a large quantity and quality of immunomics data that facilitates a deeper understanding of, and biological discovery from, the adaptive immune system. We leverage the unique capability of our platform to translate the genetics of a patient&#8217;s immune system with the scale, precision and speed that enables novel target discovery and the development of personalized and immune-based therapeutic products.</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Increase blood-based testing with clonoSEQ in ALL, MM, CLL, and DLBCL</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As noted, a study reported at the American Society of Hematology annual meeting in 2023 demonstrated that MRD negativity confirmed by clonoSEQ in the blood of MM patients in early treatment for MM correlated well with PFS. Testing with blood is less invasive for patients and less expensive as compared to MRD testing from bone marrow samples. Therefore, blood-based MRD testing may enable more frequent monitoring of patients over longer periods of time. We believe continued validation of clonoSEQ in blood will increase usage, particularly by clinicians in the community setting who perform fewer bone marrow aspirations. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expand clonoSEQ in NHL. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With the end goal of clonoSEQ becoming a universal MRD test for all lymphoid malignancies, we have developed a robust lifecycle development plan to generate sufficient clinical evidence to support increased adoption across lymphoid malignancies. We are already cleared in ALL and MM from bone marrow and CLL from bone marrow and blood. At the same time, we are increasing marketing support for clonoSEQ usage as a CLIA-validated lab-developed testing service, where samples for any lymphoid cancer indication and a range of sample types (including blood) are acceptable, and payor coverage is already in place for blood-based testing in ALL, MM, CLL and a form of NHL, DLBCL. NHL represents 50% of all newly diagnosed patients with lymphoid malignancies in the U.S., and DLBCL represents 30% of NHL patients. clonoSEQ has Medicare coverage for all DLBCL patients.</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improve our margins for clonoSEQ.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We continue to enhance our average selling price (&#8220;ASP&#8221;) for clonoSEQ while increasing the efficiencies of operations in our production laboratories and managing our overall operating expenses.</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Entrench our products in clinical drug development with biopharmaceutical collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Maintain our platform as the gold standard for the validation of potential immune-driven clinical discoveries in late-stage clinical trials, including designation of clonoSEQ as a basis for clinical endpoints. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leverage our foundational technology to address clinical therapeutic challenges in key disease states, such as cancer and autoimmune disorders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We believe that by leveraging our established capabilities, we can scale our target and drug discovery efforts and aim to successfully develop differentiated immune medicine-based therapies, including TCR-based therapies and prophylactic or therapeutic antibodies and potentially vaccines against novel druggable targets to treat patients with cancer or autoimmune disorders.</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Maintain an entrepreneurial, scientifically rigorous, data-driven and inclusive corporate culture. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fuel the promise and potential that our platform offers to help patients better manage their disease by translating insights from our world-class team with expertise in biology, chemistry, bioinformatics, software, drug discovery, development and commercialization, into clinical products.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Strategic Collaborations and Other Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Genentech Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2018, we entered into the Genentech Agreement to develop, manufacture and commercialize novel neoantigen directed T cell therapies for the treatment of a broad range of cancers. Pursuant to the Genentech Agreement, we are responsible for the screening and identification of TCRs that can most effectively recognize and directly target specific neoantigens, while Genentech is responsible for clinical, regulatory and commercialization efforts. During the term of the Genentech Agreement, we have agreed to certain defined exclusivity obligations or restrictions with respect to the development and commercialization of certain cell therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2019, we received a $300.0 million upfront payment from Genentech and, in 2023, we received a $10.0 million milestone payment for FDA IND acceptance of the first cell therapy product candidate under our Genentech Agreement. We also may be eligible to receive approximately $1.8 billion over time, including payments of up to $65.0 million upon the achievement of specified regulatory milestones, up to $300.0 million upon the achievement of specified development milestones, and up to $1.4 billion upon the achievement of specified commercial milestones. Genentech will also pay us tiered royalties at a rate ranging from the mid-single digits to the mid-teens on aggregate worldwide net sales of the Shared Products and the Personalized Product arising from the strategic collaboration, subject to certain reductions, with aggregate minimum floors. The Genentech Agreement accounted for 25%, 34% and 40% of our revenue for the year ended December 31, 2023, 2022 and 2021, respectively.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Genentech Agreement will continue until the expiration of all royalty payments, but may be terminated by mutual agreement, upon an uncured material breach by either party, upon insolvency of either party, or by Genentech for convenience upon prior written notice.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Microsoft Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2017, we entered into a strategic collaboration agreement with Microsoft (the &#8220;Microsoft Agreement&#8221;) to map TCR sequences to the antigens they bind with with the goal of developing diagnostic tests for early detection of many diseases from a single blood test.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Microsoft Agreement, Microsoft applies machine learning and computational statistics to our clinical immunomics data in order to produce predictive models that allow us to map TCR sequences to the antigens they bind with. Under the Microsoft Agreement, we retain all rights to these predictive models and the data underlying our TCR-Antigen Map, including the right to commercialize clinical products using our TCR-Antigen Map. We and Microsoft have granted each other certain licenses to one another&#8217;s intellectual property rights and have agreed to certain defined exclusivity obligations with respect to collaborations and projects that are substantially similar to the Microsoft Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the term of the Microsoft Agreement, we have agreed to exclusively use Microsoft&#8217;s Azure cloud services at standard volume pricing with a minimum Azure consumption requirement. We have also agreed to host each diagnostic product developed as a direct result of the Microsoft Agreement on Azure throughout the term of the Microsoft Agreement and for a period of five years thereafter. In addition, we have agreed to exclusively use Microsoft&#8217;s immunomics artificial intelligence services for TCR-antigen mapping in connection with all of our technology, products and services developed as a direct result of our collaboration with Microsoft throughout the term of the Microsoft Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Microsoft Agreement has a seven-year term and may be terminated by mutual agreement or by either party upon an uncured material breach. Concurrently with entry into the Microsoft Agreement, Microsoft purchased shares of our Series F-1 convertible preferred stock, which were converted into common stock upon the closing of our initial public offering in July 2019.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Interest Purchase Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2022, we entered into a Revenue Interest Purchase Agreement (the "Purchase Agreement") with OrbiMed Royalty &amp; Credit Opportunities IV, LP ("OrbiMed"), an affiliate of OrbiMed Advisors LLC, as collateral agent and administrative agent for the purchasers party thereto (the &#8220;Purchasers&#8221;). Pursuant to the Purchase Agreement, we received $124.4 million from the Purchasers (the "First Payment"), net of expenses. We will also be entitled to receive up to $125.0 million in subsequent installments as follows: (i) $75.0 million upon our request occurring no later than September 12, 2025 (the &#8220;Second Payment&#8221;) and (ii) $50.0 million upon our request in connection with certain permitted acquisitions occurring no later than September 12, 2025 (the &#8220;Third Payment&#8221;), in each case subject to certain funding conditions. To secure our obligations under the Purchase Agreement, we and our subsidiaries have granted OrbiMed a security interest in our core platform technology assets, subject to certain customary exclusions, as defined in the Purchase Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As consideration for such payments, the Purchasers will have a right to receive certain revenue interests (the &#8220;Revenue Interests&#8221;) from us based on a percentage (the &#8220;Applicable Payment Percentage&#8221;) of all GAAP revenue (the &#8220;Revenue Base&#8221;). If only the First Payment has been made, the Applicable Payment Percentage shall be five percent of the quarterly Revenue Base. If both the First Payment and Second Payment have been made, the Applicable Payment Percentage shall be eight percent of the quarterly Revenue Base. If each of the First Payment, Second Payment and Third Payment have been made, the applicable payment percentage applied to the Revenue Interest shall be ten percent of the quarterly Revenue Base. Payments in respect of the Revenue Interests shall be made quarterly within 45 days following the end of each fiscal quarter (each, a &#8220;Revenue Interest Payment&#8221;). If OrbiMed has not received Revenue Interest Payments in the aggregate equal to or greater than the sum of its invested capital (the &#8220;Cumulative Purchaser Payments&#8221;) on or prior to September 12, 2028, the revenue interest rate shall be increased to a rate which, if applied retroactively to our cumulative Revenue Base, would have resulted in Revenue Interest Payments equal to the sum of all Cumulative Purchaser Payments.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OrbiMed will be entitled to 100% of the Revenue Interest Payments until it has received a total cumulative value of 165% of the Cumulative Purchaser Payments (the &#8220;Return Cap&#8221;), unless full repayment of the amount of the Return Cap has not been made by September 12, 2032, in which case the Return Cap shall be increased to 175% of the Cumulative Purchaser Payments.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We incurred interest expense of $13.8 million and $4.2 million under the Purchase Agreement for the year ended December 31, 2023 and 2022, respectively.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Processing and Manufacturing</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We process both clinical and research use samples in our laboratory in Seattle, Washington. Our Seattle laboratory is CLIA-certified, College of American Pathologists (&#8220;CAP&#8221;)-accredited and International Organization for Standardization (&#8220;ISO&#8221;) 13485-certified. After we intake samples sent to us from healthcare providers or research and biopharmaceutical customers, we extract DNA from the sample if required, amplify it and otherwise prepare it for our sequencing and data analysis. Throughout our processes, we apply a rigorous quality management system, which is designed to comply with the Quality System Regulation (&#8220;QSR&#8221;) and the requirements of CLIA, CAP and other applicable state licensing and accreditation requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to process and sequence immune receptors in samples submitted to us, we utilize a combination of proprietary primer mixes and commercial materials, including a multiplex PCR master mix, enzymes, high throughput multi-cycle sequencing reagents and other materials, which we obtain and assemble as needed from various third-party vendors on customary terms. A number of our processing steps utilize automated equipment to help ensure consistency and efficiency. Sequencing is performed using the Illumina NextSeq System, which we have appropriately qualified for the intended uses of our products and services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For our TCR-Antigen Map and drug discovery initiatives, we conduct our operations at our laboratories in Seattle, Washington and South San Francisco, California. These laboratories have cell sorting, tissue culture and other processing equipment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use a limited number of suppliers, or in some cases, single suppliers, for our laboratory equipment and materials. We manage this concentration risk by targeting or building to levels of surplus stock that, we believe, would allow us to locate alternative suppliers if needed. However, if one of our suppliers fails to perform adequately or fulfill our needs, we may be required to incur significant costs and devote significant efforts to find new suppliers and may face delays in processing samples or developing and commercializing our products and services. For example, we have purchased the Illumina NextSeq System, and Illumina, Inc. (&#8220;Illumina&#8221;) also supplies us with reagents that have been designed for use solely with this sequencer. While we acquire these reagents from Illumina on customary terms, if we had to replace the reagents we use, we may also need to acquire and qualify a replacement sequencer, validate the reagents and potentially revalidate aspects of our existing assays.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Distribution</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We processed our first samples in 2011 and issued our first clonoSEQ report in 2013. Since then, we have focused on expanding our customer base. We sell our products primarily through our own internal sales force. Our sales and marketing efforts are targeted at department heads, laboratory directors, principal investigators, core facility directors, clinicians, payors and research scientists and pathologists at leading academic institutions, biopharmaceutical companies, research institutions and contract research organizations. We seek to increase awareness of our products and services among our target customers through direct sales calls, trade shows, seminars, academic conferences, web presence and other forms of internet marketing. Our drug discovery efforts are internally focused and may also be pursued in collaboration with one or more biopharmaceutical companies.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have an extensive global portfolio of intellectual property rights to protect our immune medicine platform, the products and services that draw on it and our reputation in the industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we owned or controlled more than 450 active issued patents and more than 55 patent applications whose claims are intended to cover what we do, what we plan to do and what others might do to compete with us. From our earliest patent filings in 2009, our portfolio has been tailored to reflect our efforts to harness the adaptive immune system for research, diagnostic and therapeutic applications. Our patent claims extend to not only adaptive immune receptor molecules, but also to uniquely powerful techniques for sequencing immune cell receptors, determining clonality and immune competency, diagnosing disease, predicting responses to immunotherapy and identifying new drug candidates. Our granted patent protection generally expires in years ranging from 2029 to 2040.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical know-how we develop is protected by a trade secrecy program to ensure against inappropriate disclosure or use. Encompassed in our know-how is our proprietary database of coding sequences, antigen reactivities and safety profiles for immune receptors, which is vast and growing. Even with collaborators, access to our immune medicine platform technology is limited and tightly controlled through contracts and careful communication. We own our immune medicine platform, including improvements we or collaborators make to it, and retain rights in data resulting from its use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also pursue trademark registration for our product and service names and promotional slogans in our existing and projected markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual Property Portfolio by the Numbers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our intellectual property portfolio consisted of the following:</span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">More than 800 patent applications filed worldwide directly or in conjunction with a co-owner or licensor since 2009; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">More than 55 pending patent applications;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">More than 450 issued patents across our immune medicine platform, including more than 145 patents related to diagnostic approaches in lymphoid malignancies; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24 patent families directed to methods and tools useful in our immune medicine platform for non-target specific immunosequencing and research; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17 patent families directed to methods and tools useful in diagnosis, prognosis and disease monitoring, including clonoSEQ, certain diagnostic methods and the TCR-Antigen Map; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12 patent families directed to methods and tools useful in drug discovery, including our drug discovery screening processes, MIRA and pairSEQ; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3 patent families directed to therapeutic antibodies and novel antigen targets; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1 patent family directed to SARS-CoV-2 vaccines;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3 patent families directed to gene sequencing technology; and </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28 trademarks registered and pending registration worldwide. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Portfolio</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have developed an expansive patent portfolio in commercially important markets with claims to critical aspects of our technology, beginning with our first patent applications exclusively licensed from Fred Hutchinson Cancer Research Center (&#8220;Fred Hutch&#8221;) in 2009. Our ongoing patent strategy is to generate a return on our patenting investments, which values substantive quality over volume to build a defensible moat around technology we use as well as what others might develop to design around our position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We prioritize pursuing patent claims with a reasonable likelihood of being granted. Where patentability for a particular invention is questionable, we often choose to protect it as a trade secret instead. In some instances, however, we may seek to push the patentability envelope when the state of the applicable patent laws are in flux, such as patent eligibility for naturally occurring molecules, including TCRs, in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Methods of Measuring Adaptive Immunity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2009, a U.S. provisional patent application was filed to pursue protection for immunosequencing by our co-founder, Dr. Harlan Robins. The invention broadly relates to methods for assessing the adaptive immune system status of individuals. Rearranged V and J segment genes of TCRs or BCRs are targeted as biomarkers for assessing the status of the immune system at one or more points in time. Granted claims extend to the use of particular sets of amplification primers, while pending claims are being pursued to capture additional assessment techniques. Licensed exclusively to us by Fred Hutch, the application has since spawned more than 31 additional patent applications, many of which have been granted as of December 31, 2023, including U.S. Patent No. 9,809,813.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Optimizing Nucleic Acid Amplification Reactions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amplification of nucleic acids can result in over- or under-representation of the amplified molecules, misrepresenting the number present in the source material, such as a blood sample. Dr. Robins invented a method to correct for such bias, thereby improving the precision of PCR-based quantification of TCR and BCR coding sequences in a sample. The claimed approach utilizes synthetic templates, reflecting nucleic acid sequences for rearranged V and J receptor segments in the sampled cells. More than 28 related patent applications have since been filed, many of which have been granted as of December 31, 2023, including U.S. Patent Nos. 9,371,558 and 10,214,770.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Diagnosing and Monitoring Disease</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with our acquisition (&#8220;Sequenta Acquisition&#8221;) of Sequenta, Inc. (&#8220;Sequenta&#8221;) in 2015, we purchased Sequenta&#8217;s extensive patent portfolio. The portfolio includes 124 patent applications which disclose and claim methods to identify and quantify T cell-based immune responses to antigen exposure using NGS. TCR and BCR DNA, ribonucleic acid or cell-free DNA from samples, including blood and bone marrow, are used to detect, prognose and monitor disease, including autoimmune disease, infection and cancer. More than 112 patents have been granted in the portfolio as of December 31, 2023, including U.S. Patent Nos. 8,628,927 and 8,236,503.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our diagnostic methods also apply to the detection of MRD (the target of our B cell-based clonoSEQ diagnostic test for assessing how disease burden changes in response to treatment or during remission) and T-Detect (our T cell-based diagnostic tests). Multiple patents have been granted from additional applications relating to MRD assessment, diagnostic methods and diagnostically significant TCRs filed by us, including U.S. Patent Nos. 9,824,179 and 11,047,008. Additional patent applications are pending to TCR-based diagnostic signals in specific indications, including COVID-19.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TCR-Antigen Map</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with our Microsoft collaboration, we are developing a diagnostic product to detect cancer and other diseases at their earliest stage by learning the signals and responses of the activated immune receptors in a patient&#8217;s blood. Pre-collaboration, we filed 10 related patent applications for methods to produce antigen-exposed enriched T cell populations and identify their antigen specificities by comparison to a pre-exposure population of cells or by use of an algorithm. We have filed additional patent applications relating to algorithmic-based methods to characterize antigen specificities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">MIRA</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We developed and are pursuing patent protection for bioinformatic-based methods to determine the antigen specificity of TCRs by exposing T cells to a panel of multiple antigens. Antigen exposure can be performed by incubation or presentation; for example, it can be performed via recombinant expression in another cell. These methods may also be used to pair the two TCR chains as well as to identify high avidity TCRs. Several patents have been granted as of December 31, 2023, including U.S. Patent No. 10,066,265.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">pairSEQ</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In nature, TCRs and BCRs exist as a heterodimer of paired chains, each of which is encoded on a different chromosome. Immunosequencing reveals the nucleotide structure of each individual chain, but not which chains match as cognate pairs. We developed and are pursuing patent protection for multiple bioinformatic-based approaches to pairing the two chains of TCRs and BCRs, including one deployed in our pairSEQ technique. Our methods also allow for identification of receptor chain pairs which are specific to particular antigen targets. Over fifty related patent applications have been filed, nearly half of which have matured into granted patents as of December 31, 2023, including U.S. Patent No. 10,077,478.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Assessing Responsiveness to Immunotherapy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leveraging our immunosequencing technologies, we developed methods for predicting responses to immunotherapy, vaccines and infection. To those ends, rearranged TCR or BCR sequences are quantified and their levels or frequencies compared at different points in time. More than 20 related patent applications have been filed, most of which have been granted as of December 31, 2023, including U.S. Patent No. 10,221,461.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Therapeutic Antibodies</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We developed a therapeutic antibody discovery process called TruAB from which neutralizing antibodies have been and are being produced against target antigens in conditions such as SARS-CoV-2, influenza, Respiratory Syncytial Virus, inflammatory bowel disease and MS. Patent applications to a number of these antibodies have been filed and are pending.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Vaccines</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Together with our partner Nykode Therapeutics, we filed a patent application which is pending and directed to COVID-19 vaccines, the development of which was informed by our immunosequencing-based drug discovery efforts.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Therapeutic TCRs</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a granted patent application to TCRs responsive to WT-1 antigens with potential utility in cell therapy against WT-1 related cancers. We are also pursuing a patent application to TCRs responsive to other cancer antigens which are of interest in our collaboration with Genentech.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In-Licensed and Acquired Intellectual Property Rights</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we have developed the majority of our immune medicine platform, products and services, we occasionally license or acquire third-party owned inventions to bolster the strength of our patent estate and ensure freedom to operate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Early work by Dr. Robins with Fred Hutch led to discoveries around immunosequencing methods and tools covered by 128 patents and patent applications in the U.S. and abroad which we exclusively licensed. Our rights are for all fields of use worldwide and are sublicensable. To the extent any licensed granted patent rights extend to products or services sold by us, we pay Fred Hutch a royalty rate of 0.75% of net sales on licensed products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Through our Sequenta Acquisition, we also obtained an exclusive paid-up license, with rights to sublicense, to patents filed in the U.S., Europe, Australia and China owned by iRepertoire, Inc. The license is for worldwide use in diagnosis, prognosis, treatment and monitoring of any proliferative disorder for which rearranged nucleic acids capable of encoding an immune receptor, whether productive or unproductive, or functional or nonfunctional, of a cell, excluding tumor infiltrating lymphocytes, of the proliferative disorder can be used as markers for the disorder, including, but not limited to, lymphoid and myeloid proliferative disorders, such as ALL, CLL, acute myeloid leukemia, chronic myelogenous leukemia, Hodgkin&#8217;s and NHL, plasma cell neoplasms, such as MM, monoclonal gammopathy of undetermined significance, monoclonal B cell lymphocytosis and myelodysplastic syndromes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the patent estate acquired from Sequenta, we also acquired ownership of immunosequencing-related patent portfolios from Imdaptive, Inc. and ImmunID S.A.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trademarks</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We own various trademarks, applications and unregistered trademarks in the U.S. and other commercially important markets, including our company name, product and service names and other trade or service marks. Our trademark portfolio is designed to protect the brands for our products and services, both current and in the pipeline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trade Secrecy Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a trade secrecy program to prevent disclosure of our trade secrets to others, except under stringent conditions of confidentiality when disclosure is critical to our business. Our trade secrets include the composition of certain reagents, assay protocols and immunosequencing-related data, such as immune receptor sequences. We protect trade secrets and know-how by establishing confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and collaborators. These agreements provide that all confidential information developed or made known during the course of an individual&#8217;s or entities&#8217; relationship with us must be kept confidential during and after the relationship. These agreements also provide that all inventions resulting from work performed for us or relating to our business and conceived or completed during the period of employment or assignment, as applicable, shall be our exclusive property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary information by third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Accordingly, we may not be able to meaningfully protect our trade secrets. For more information regarding the risks related to our intellectual property, see &#8220;Risk Factors&#8212;Risks Relating to our Intellectual Property.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biotechnology and pharmaceutical industries, including the fields of life sciences research, clinical diagnostics and drug discovery, are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property. Given the breadth and promise of immune medicine, we face substantial competition from many different sources, including life sciences tools, diagnostics, pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions across various components of our platform and product and service offerings. Due to the significant interest and growth in immune medicine more broadly, we expect the intensity of the competition to increase. However, we believe our scale, precision and speed, and the resulting clinical applicability, distinguish us from our competitors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In clinical diagnostics, clonoSEQ faces competition primarily from institutions performing flow cytometry in-house, particularly outside of the U.S. We may also face competition from companies developing early cancer detection testing products for indications that do not currently compete with clonoSEQ, such as methods for MRD assessment directed at solid tumors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In drug discovery, clinical trials in the field of immune medicine are being pursued by a number of industry and academic players.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immune medicine is being pursued by several biotechnology companies as well as by large-cap biopharmaceutical companies. Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, regulatory approval and compliance, and sales and distribution than we do. Mergers and acquisitions involving life sciences research, clinical diagnostics or drug discovery companies in the immune medicine space may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize research or diagnostic products or services that are more accurate, more convenient to use or more cost-effective than our products or services. Competitor therapeutic products could also prove safer, more effective, more convenient to administer or more cost-effective than any therapeutic products we may develop with our collaborators. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the relevant market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Life Sciences Research Use Only Technologies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our core research product, Adaptive Immunosequencing, is a research use only (&#8220;RUO&#8221;) tool in the U.S. that provides data to third parties such as biopharmaceutical companies that are themselves engaged in the research and development of potential diagnostic and therapeutic products and services for which they may later pursue investigation and clearance, authorization or approval from regulatory authorities, such as the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RUO products belong to a separate regulatory classification under a long-standing FDA regulation. From an FDA perspective, products that are intended for research use only and are labeled as RUO are exempt from most regulatory controls, and are therefore not subject to the regulatory requirements discussed below for clinical diagnostic products. Thus, RUO products may be used or distributed for research use without first obtaining FDA clearance, authorization or approval. The products must bear the statement: &#8220;For Research Use Only. Not for use in diagnostic procedures.&#8221; RUO products cannot make any claims related to safety, effectiveness or diagnostic utility, and they cannot be intended for human clinical diagnostic use. Accordingly, a product labeled RUO but intended or promoted for clinical diagnostic use may be viewed by the FDA as adulterated and misbranded under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and subject to FDA enforcement action. The FDA will consider the totality of the circumstances surrounding distribution and use of an RUO product, including how the product is marketed and to whom, when determining its intended use. If the FDA disagrees with a company&#8217;s RUO status for its product, the company may be subject to FDA enforcement activities, including, without limitation, requiring the company to seek clearance, authorization or approval for the products. If the FDA determines an RUO product is adulterated and misbranded, enforcement may also include a warning letter, seizure, an injunction and/or criminal fines for FDCA violations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Diagnostics in the U.S.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our first diagnostic product, clonoSEQ, was granted marketing authorization by the FDA for the detection and monitoring of MRD in bone marrow samples in patients with MM and ALL under the de novo process in September 2018, which classified clonoSEQ and future DNA-based tests to measure MRD in hematological malignancies as Class II devices, as explained further below. In August 2020, we received FDA clearance for clonoSEQ, following a 510(k) submission, for CLL in bone marrow as well as blood samples. We also received FDA clearance in 2021 for ALL from blood samples, launched a NHL (DLBCL) test under CLIA as a LDT and are actively advancing validation studies in certain other NHL sub-types.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., medical devices are subject to extensive regulation by the FDA under the FDCA and its implementing regulations, and other federal and state statutes and regulations. The FDA regulates the design, development, preclinical, analytical and clinical testing, manufacture, safety, effectiveness, clearance, authorization or approval, record-keeping, packaging, labeling, storage, adverse event reporting, advertising, promotion, marketing, sales, distribution and import and export of medical devices. In vitro diagnostic products (&#8220;IVDs&#8221;) are a type of medical device and include reagents and instruments used in the diagnosis or detection of diseases, conditions or infections, including, without limitation, the presence of certain chemicals, genetic information or other biomarkers. Predictive, prognostic and screening tests can also be IVDs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After a medical device is placed on the market, numerous regulatory requirements apply. These include:</span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with the FDA&#8217;s QSR, which requires manufacturers to follow stringent design, testing, control, documentation, record maintenance, including maintenance of complaint and related investigation files, and other quality assurance controls during the manufacturing process;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">labeling regulations, which prohibit the promotion of products for uncleared, or unapproved uses, or &#8220;off-label&#8221; uses, and impose other restrictions on labeling; and</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obligations to investigate and report to the FDA adverse events, including deaths, or serious injuries that may have been or were caused by a medical device and malfunctions in the device that would likely cause or contribute to a death or serious injury if it were to recur.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include sanctions, including but not limited to, warning letters; fines, injunctions, and civil penalties; recall or seizure of the device; operating restrictions, partial suspension or total shutdown of production; refusal to grant 510(k) clearance or premarket approvals (&#8220;PMAs&#8221;) of new devices; withdrawal of clearance or approval; and civil or criminal prosecution.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Position in the European Union</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the European Union (&#8220;EU&#8221;), IVDs can be placed on the market by obtaining a &#8220;CE mark,&#8221; which demonstrates conformity via a self-certification with the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> In vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diagnostic Medical Device Directive (&#8220;IVDD&#8221;). clonoSEQ obtained a CE mark in May 2019 for all B-cell malignancies with blood and bone marrow. The requirements under the IVDD include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Essential Requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The IVDD specifies &#8220;essential requirements&#8221; that all medical devices must meet to demonstrate the product is safe and effective under normal conditions of use. The requirements are similar to those adopted by the FDA relating to quality systems and product labeling. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Conformity Assessment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The requirements to obtain a CE mark are risk-based, and follow a similar classification system as in the U.S. However, unlike the U.S., which requires virtually all devices to undergo some level of premarket review by the FDA, the IVDD currently allows manufacturers to bring many devices to market using a process in which the manufacturer self-certifies that the device conforms to the applicable essential requirements. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Vigilance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The IVDD specifies requirements for post market reporting similar to those adopted by the FDA. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 26, 2017, the EU released a new regulatory framework, the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Diagnostic Medical Device Regulation (&#8220;IVDR&#8221;), which will replace the IVDD. Our products in the EU will have to comply with the IVDR requirements by May 2026, subject to the applicable transitional provisions before full compliance is required. To that end, we submitted an application for IVDR approval of clonoSEQ in 2023. The IVDR is considerably stricter in regulatory oversight than the IVDD and will require more IVD devices to be reviewed by a notified body before being placed on the market. Until that time, our products must continue to meet the requirements of IVDD for commercialization in the EU.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Federal and State Regulation of Laboratories</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given that aspects of our business at certain facilities involve acting as a clinical laboratory, we are required to hold certain federal and state licenses, certifications and permits to conduct our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As to federal certifications, CLIA establishes rigorous quality standards for all laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease, or the impairment of, or assessment of health. As a clinical laboratory, we must obtain a CLIA certificate based on the complexity of testing performed at the laboratory, such as a Certificate of Compliance for high-complexity testing. CLIA also mandates compliance with various operational, personnel, facilities administration, quality and proficiency requirements, intended to ensure that their clinical laboratory testing services are accurate, reliable and timely. CLIA compliance and certification is also a prerequisite to be eligible to bill for services provided to government payors and for many private payors. Furthermore, we are subject to survey and inspection every two years to assess compliance with program standards, and may be subject to additional unannounced inspections. Laboratories performing high-complexity testing are required to meet more stringent requirements than laboratories performing less complex tests.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to CLIA requirements, we elect to participate in the accreditation program of the CAP. The U.S. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), the agency that oversees CLIA, has deemed CAP standards to be equally or more stringent than CLIA regulations and has approved CAP as a recognized accrediting organization. Inspection by CAP is performed in lieu of CMS inspections for accredited laboratories. Therefore, because we are accredited by the CAP Laboratory Accreditation Program, we are deemed to also comply with CLIA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CLIA provides that a state may adopt laboratory regulations that are more stringent than those under federal law, and a number of states have implemented their own more stringent laboratory regulatory requirements. Select states, including Washington, have laboratory regulations that have been deemed by the federal government to be at least as stringent as CLIA, and thus laboratories licensed under those state regimes are exempt from CLIA and the state Department of Health is permitted to issue a CLIA number, along with a state Medical Test Site license, rather than a certificate being issued by CMS. Our laboratory holds the required Washington license. State laws may require that laboratory personnel meet certain qualifications, specify certain quality control procedures, facility requirements or prescribe record maintenance requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Several states additionally require the licensure of out-of-state laboratories that accept specimens from those states. For example, New York requires a laboratory to hold a permit which is issued after an on-site inspection and approval of each LDT offered by a laboratory, and has various, more stringent requirements than CLIA and CAP, including those for personnel qualifications, proficiency testing, physical facility and equipment and quality control standards. Our laboratory holds the required licenses for Maryland, Rhode Island, Pennsylvania, New York and California.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, other states may require out-of-state laboratories to obtain licensure in order to accept specimens from the state. If we identify any other state with such requirements, or if we are contacted by any other state advising us of such requirements, we intend to follow instructions from the state regulators as to how we should comply with such requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a clinical laboratory is found to be out of compliance with CLIA certification, CAP accreditation or a state license or permit, the applicable regulatory agency may, among other things, suspend, restrict or revoke the certification, accreditation, license or permit to operate the clinical laboratory, assess civil monetary penalties and impose specific corrective action plans, among other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">LDTs in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA has historically exercised enforcement discretion to not regulate most LDTs. As such, LDTs have not been subject to FDA&#8217;s marketing clearance and approval processes, or post-marketing controls, for medical devices. LDTs are generally considered to be tests that are designed, developed, validated and used within a single laboratory. Laboratories certified as &#8220;high complexity&#8221; under CLIA may develop, manufacture, validate and run LDTs. clonoSEQ is available as an LDT for use in assessing MRD for other lymphoid malignancies, including NHL and use in other specimen types, at our Seattle, Washington laboratory.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In that respect, Congress introduced legislation to establish a framework for the FDA to oversee marketing of in vitro clinical tests (&#8220;IVCTs&#8221;), such as test kits and LDTs (the Verifying Accurate Leading-edge IVCT Development Act, or &#8220;VALID Act&#8221;). Under the VALID Act, FDA would oversee IVCTs, requiring pre-market review for high-risk IVCTs which expose patients to serious or irreversible harm and novel IVCTs. As currently drafted, existing LDTs at the time of VALID Act passage would be grandfathered as approved. For new low risk IVCTs, developers would submit a representative IVCT to the FDA for review and issuance of a technology certification for the specific IVCT reviewed and later developed test within the scope of the certification. It is not certain whether or in what form the VALID Act bill will pass Congress, but passage could increase the stringency of regulatory review required for our LDT products. If the VALID Act does not pass, the FDA may decide to exercise enforcement discretion for LDTs, especially if it perceives an LDT as posing a risk to patients. Therefore, the regulatory path for marketing of LDTs is subject to uncertainty given the FDA&#8217;s latitude in interpreting and applying its laws and policies.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Federal and State Privacy, Security and Breach Notification Laws</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many state and federal laws govern the processing of personal information or individually identifiable health information. At the federal level, under the administrative simplification provisions of the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) and the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) issued regulations that establish standards for protecting the privacy and security of &#8220;protected health information&#8221; used or disclosed by certain healthcare providers and other &#8220;covered entities&#8221; and their &#8220;business associates.&#8221; Three principal data protection-related regulations with which we are required to comply have been issued in final form under HIPAA and HITECH: privacy regulations, security regulations and security breach notification regulations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The privacy regulations govern the use and disclosure of &#8220;protected&#8221; health information by covered healthcare providers, as well as health insurance plans. They also set forth certain rights that an individual has with respect to his or her protected health information maintained by a covered health care provider, including the right to access or amend certain records containing protected health information or to request restrictions on the use or disclosure of protected health information. The security regulations establish requirements for safeguarding the confidentiality, integrity and availability of protected health information that is electronically transmitted or electronically stored. HITECH, among other things, established certain health information security breach notification requirements. A covered entity must notify HHS and each affected individual of a breach of unsecured protected health information as well as the media if the breach involves more than 500 individuals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA violations are subject to civil and criminal penalties. Additionally, to the extent that we submit electronic healthcare claims and payment transactions that do not comply with the electronic data transmission standards established under HIPAA and HITECH, payments to us may be delayed or denied.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 5(a) of the Federal Trade Commission Act (&#8220;FTCA&#8221;) has also been used to regulate data privacy and security at the federal level. According to the U.S. Federal Trade Commission (&#8220;FTC&#8221;), failing to take appropriate steps to keep consumers&#8217; personal information secure or using or disclosing personal information in violation of a company&#8217;s privacy notice may constitute unfair or deceptive acts or practices in or affecting commerce in violation of the FTCA. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities. Although we have and maintain a system for compliance with privacy laws and regulations, failure to comply with them could expose us to potential FTC enforcement action and fines.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, certain state laws govern the privacy and security of health information and personal information. Some of the state laws governing health information privacy and security are more stringent than HIPAA (including providing for patient enforcement of these state laws) and often differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. There has also recently been an influx of state privacy and security laws that introduce similar compliance complexities, including the Washington state My Health My Data Act, the California Consumer Privacy Act in combination with the California Privacy Rights Act and associated regulations and the Colorado Privacy Act. In addition, there are state breach notification laws in every state, as well as in the District of Columbia, Guam and Puerto Rico. Failure to comply with these laws, where applicable, can result in the imposition of significant civil or criminal penalties and private litigation as further detailed in the &#8220;Risk Factors&#8221; section.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to laws that directly impose privacy and data protection obligations on companies, there is also a growing interest in laws and regulations that govern data areas that are related to, but not completely related to data privacy. One area of these laws relates to use and testing of genetic and genomic data. In addition to the federal Genetic Information Nondiscrimination Act, there are a number of state laws that have recently passed (e.g., the California Genetic Information Privacy Act) and that continue to make appearances on states&#8217; legislative schedules. There have been similar draft bills at the state level that would regulate machine learning, artificial intelligence, the Internet of Things, and human specimen use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General Data Protection Regulation in the EU and other International Privacy Laws</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The General Data Protection Regulation (&#8220;GDPR&#8221;) is a legal framework that sets requirements for the collection and processing of personal information of individuals within the European Economic Area (&#8220;EEA&#8221;). The GDPR sets out the principles for data management and the rights of the individual, while also imposing very significant fines that can be revenue-based. It applies to U.S. companies that process personal information of persons in the EEA in connection with the offer of products or services to those persons, or the monitoring of such persons&#8217; behavior. It may also apply when a U.S. company processes personal information in the context of the activities of an entity established in the EEA. The GDPR became enforceable on May 25, 2018. The regulation is a comprehensive privacy law, meaning that it applies to all types of personal information, including the human resources record of employees and even the Internet Protocol addresses of people using online services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many other countries and regions also have privacy and data protection laws, some of which are modeled after the European framework. This includes countries within Europe that are not part of the EEA, such as the United Kingdom and Switzerland, and therefore operate under different privacy and data protection frameworks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In response to the advancements in artificial intelligence and machine learning, there are also global efforts to regulate the use of these technologies. One prominent law that is pending finalization is the European Union's AI Act.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Federal, State and Foreign Fraud and Abuse Laws</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., there are various fraud and abuse laws with which we must comply and we are subject to regulation by various federal, state and local authorities, including CMS, other divisions of HHS, such as the Office of Inspector General (&#8220;OIG&#8221;), the U.S. Department of Justice (&#8220;DOJ&#8221;) and individual U.S. Attorney offices within the DOJ, and state and local governments. We also may be subject to foreign fraud and abuse laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., the Anti-Kickback Statute (&#8220;AKS&#8221;) prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for patient referrals for, or purchasing, leasing, ordering or arranging for the purchase, lease or order of, any healthcare item or service reimbursable under a governmental payor program. Courts have stated that a financial arrangement may violate the AKS if any one purpose of the arrangement is to encourage patient referrals or other federal healthcare program business, regardless of whether there are other legitimate purposes for the arrangement. The definition of &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including gifts, discounts, meals, travel, credit arrangements, payments of cash, consulting fees, waivers of co-payments, ownership interests and providing anything at less than its fair market value. Recognizing that the AKS is broad and may technically prohibit many innocuous or beneficial arrangements within the healthcare industry, the OIG issued a series of regulatory &#8220;safe harbors.&#8221; These safe harbor regulations set forth certain provisions, which, if met, will assure healthcare providers and other parties that they will not be prosecuted under the AKS. The failure of a transaction or arrangement to fit within a specific safe harbor does not necessarily mean that the transaction or arrangement is illegal or that prosecution under the AKS will be pursued. In those instances, arrangements will be evaluated on a case-by-case basis to determine whether enforcement will be pursued. Penalties for AKS violations are severe and can include imprisonment, criminal fines, civil monetary penalties and exclusion from participation in federal healthcare programs. The regulations establishing safe harbor protection are subject to change and could affect future operations. Many states also have anti-kickback statutes, some of which may apply to items or services reimbursed by any third-party payor, including commercial insurers as well as patient self-pay. A violation of the AKS may be grounds for the government or a whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The civil monetary penalties statute is another potential statute under which a clinical laboratory may be subject to enforcement. Among other things, the civil monetary penalties statute imposes fines against any person who is determined to have presented, or caused to be presented, claims to a federal healthcare program that the person knows, or should know, is for an item or service that was not provided as claimed or is false or fraudulent. The civil monetary penalties statute also prohibits a person from offering or providing remuneration to any Medicare or Medicaid beneficiary that is likely to influence the individual to order or receive its items or services from a particular provider or supplier.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The exclusion statute requires the exclusion of entities and individuals who have been convicted of federal-program related crimes or healthcare felony fraud or controlled substance charges. The statute also permits the exclusion of those that have been convicted of any form of fraud, the AKS, for obstructing an investigation or audit, certain controlled substance offenses, those whose healthcare license has been revoked or suspended and those who have filed claims for excessive charges or unnecessary services. If we were to be excluded, our products and services would be ineligible for reimbursement from any federal programs, including Medicare and Medicaid, and no other entity participating in those programs would be permitted to enter into contracts with us. In order to preserve access to beneficial healthcare items and services, the government may elect to exclude officers and key employees of manufacturers, rather than excluding the organization. Such enforcement actions would prohibit us from engaging those individuals, which could adversely affect operations and result in significant reputational harm.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Congress has also enacted statutes that impose criminal liability for healthcare fraud and abuse. The Health Care Fraud Statute prohibits knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private payors. A violation of this statute is a felony and may result in fines, imprisonment or exclusion from governmental payor programs such as the Medicare and Medicaid programs. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefit programs, items or services-public or private. A violation of this statute is a felony and may result in fines, imprisonment or exclusion from governmental payor programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal governmental payor program. The qui tam provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government alleging that the defendant has defrauded the federal government by submitting a false claim to the federal government and permit such individuals to share in any amounts paid by the entity to the government in fines or settlement. Qui tam complaints are filed under seal, and the cases may progress for a number of years before a complaint is unsealed and a healthcare provider or supplier becomes aware of its existence. When an entity is determined to have violated the False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each false claim. The False Claims Act is the federal government&#8217;s primary civil tool in healthcare fraud cases. False Claims Act liability is not limited to direct providers of health items or services. The government has asserted liability under the False Claims Act against manufacturers and other third parties who caused another party to file a false claim.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, various states have enacted false claim laws analogous to the federal False Claims Act, although many of these state laws apply where a claim is submitted to any third-party payor and not merely a governmental payor program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 25, 2018, the Substance Use-Disorder Prevention that Promoted Opioid Recovery and Treatment for Patients and Communities Act of 2018 (&#8220;SUPPORT Act&#8221;) was enacted. The SUPPORT Act included the Eliminating Kickbacks in Recovery Act of 2018 (&#8220;EKRA&#8221;), which establishes an all-payor anti-kickback prohibition that extends to arrangements with recovery homes, clinical laboratories and clinical treatment facilities. EKRA includes a number of statutory exceptions, and directs agencies to develop further exceptions. Current exceptions in some cases reference and in others differ from the AKS safe harbors. Significantly, the prohibitions apply with respect to the soliciting or receipt of remuneration for any referrals to recovery homes, clinical treatment facilities, or clinical laboratories, whether or not related to treating substance use disorders. Further, the prohibitions cover the payment or offer of remuneration to induce a referral to, or in exchange for, an individual using the services of, such providers. This law creates additional risk that relationships with referral sources could be problematic.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For anti-corruption legislation, the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) is the most widely enforced law. It is the first to introduce corporate liability, responsibility for third parties and extraterritoriality for corruption offences, meaning companies and persons can be held criminally and civilly responsible for corruption offences committed abroad. It was enacted for the purpose of making it unlawful for certain classes of persons and entities to make payments to foreign government officials to assist in obtaining or retaining business. With the enactment of certain amendments in 1998, the anti-bribery provisions of the FCPA now also apply to foreign firms and persons who cause, directly or through agents, an act in furtherance of such a corrupt payment to take place within the territory of the U.S. The FCPA also requires companies whose securities are listed in the U.S. to meet its accounting provisions, which were designed to operate in tandem with the anti-bribery provisions, and require corporations covered by the provisions to (a) make and keep books and records that accurately and fairly reflect the transactions of the corporation and (b) devise and maintain an adequate system of internal accounting controls.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In Europe, various countries have adopted anti-bribery laws providing for severe consequences, in the form of criminal penalties or significant fines, for individuals or companies committing a bribery offence. Violations of these anti-bribery laws, or allegations of such violations, could have a negative impact on our business, results of operations and reputation. For instance, in the United Kingdom, under the Bribery Act 2010, which came into effect in July 2011, a bribery offense occurs when a person offers, gives or promises to give a financial or other advantage to induce or reward another individual to improperly perform certain functions or activities, including any function of a public nature. Bribery of foreign public officials also falls within the scope of the Bribery Act 2010. Under this regime, an individual found in breach of the Bribery Act 2010 faces imprisonment of up to 10 years. In addition, the individual can be subject to an unlimited fine, if found to have committed an offense, as can commercial organizations that are found to have failed to prevent bribery. In 2016, France passed an anti-bribery and compliance law (&#8220;Sapin II&#8221;), and the French anti-corruption agency (&#8220;AFA&#8221;) was established. The Sapin II law makes it compulsory for companies within the scope of the law to implement internal procedures to fight corruption. One of the items that must be prepared is a corruption risk map, as well as an anti-corruption code of conduct. These documents are subject to investigation by the AFA and failure to comply with the requirements can lead to significant fines for companies and executives. If we were to have future growth in the European market, this law could potentially become applicable to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Physician Referral Prohibitions</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Physician Self-Referral Law (&#8220;Stark Law&#8221;) prohibits physicians from referring patients to entities with which the physician or an immediate family member has a financial relationship, such as ownership, investment or compensation, for designed health services (&#8220;DHS&#8221;) payable by Medicare and Medicaid, unless the financial arrangement meets an applicable exception. DHS includes clinical laboratory tests. Penalties for violating the Stark Law include the return of funds received for all prohibited referrals, fines, civil monetary penalties and possible exclusion from federal health care programs. In addition to the Stark Law, many states have their own self-referral bans, which may extend to all self-referrals, regardless of the payor. See &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors&#8212;Risks Relating to Government Regulation&#8212;We are subject to various laws and regulations, such as healthcare fraud and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">abuse laws, false claim laws and health information privacy and security laws, among others, and failure to comply with these laws and regulations may have an adverse effect on our business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Corporate Practice of Medicine in the U.S.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Numerous states have enacted laws prohibiting business corporations, such as us, from practicing medicine and employing or engaging physicians to practice medicine, generally referred to as the prohibition against the corporate practice of medicine. These laws are designed to prevent interference in the medical decision-making process by anyone who is not a licensed physician. For example, California&#8217;s Medical Board has indicated that determining what diagnostic tests are appropriate for a particular condition and taking responsibility for the ultimate overall care of the patient, including providing treatment options available to the patient, would constitute the unlicensed practice of medicine if performed by an unlicensed person. Violation of these corporate practice of medicine laws may result in civil or criminal fines, as well as sanctions imposed against us or the professional through licensure proceedings. Typically, such laws are only applicable to entities that have a physical presence in the state.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Regulatory Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our laboratory is subject to federal, state and local regulations relating to the handling and disposal of regulated medical waste, hazardous waste and biohazardous waste, including chemical, biological agents and compounds, blood and bone marrow samples and other human tissue. Typically, we use outside vendors who are contractually obligated to comply with applicable laws and regulations to dispose of such waste. These vendors are licensed or otherwise qualified to handle and dispose of such waste.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our partners in the development of therapeutic agents are responsible for developing and manufacturing those products. In so doing, they are subject to FDA and Medicare regulatory requirements related to, among other things, manufacture, promotion, price reporting and fraud and abuse laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our laboratories are subject to extensive requirements related to workplace safety established by the U.S. Occupational Safety and Health Administration. These include requirements to develop and implement programs to protect workers from exposure to blood-borne pathogens by preventing or minimizing any exposure through needle stick or similar penetrating injuries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Healthcare Reform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., a number of recent legislative and regulatory changes at the federal and state levels have sought to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Affordable Care Act (&#8220;ACA&#8221;) became law. This law substantially changed the way healthcare is financed by both commercial and government payors, and it has significantly impacted our industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate there will continue to be proposals by legislators at both the federal and state levels, regulators and commercial payors to reduce costs while trying to expand individual healthcare benefits. If enacted, some such proposals could expand or contract the insured population, increasing or decreasing demand for our products and services. On the other hand, some proposals could impose additional limitations on the prices we will be able to charge for our tests or on the coverage of or the amounts of reimbursement available for our tests from payors, including commercial payors and government payors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal physician payment transparency requirements (&#8220;Physician Payments Sunshine Act&#8221;) and its implementing regulations, which requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the State Children&#8217;s Health Insurance Program, with certain exceptions, to annually report to HHS information related to certain payments or other transfers of value made or distributed to covered recipients, defined to include doctors, dentists, optometrists, podiatrists, chiropractors, physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and anesthesiologist assistants, certified nurse-midwives, and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are also state transparency and gift ban laws that require manufacturers to provide reports to state governments on pricing and marketing information. Several states have enacted legislation requiring medical device manufacturers to, among other things, establish marketing compliance programs, file periodic reports with the state, and make periodic public disclosures on sales and marketing activities, and such laws may also prohibit or limit certain other sales and marketing practices. These laws may adversely affect our sales, marketing and other activities by imposing administrative and compliance burdens on us. Although we have a system for tracking and reporting &#8220;sunshine&#8221; law required information, if we fail to do so as required, we could be subject to government enforcement action and potential penalties.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Coverage and Reimbursement Generally</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reimbursement and billing requirements of applicable laws and payors for diagnostic services are highly complex. Laboratories must bill various payors, such as private third-party payors, including managed care organizations (&#8220;MCO&#8221;) and state and federal health care programs, such as Medicare and Medicaid, and each may have different billing requirements. Depending on the reimbursement arrangement and applicable law, the party that reimburses us for our services may be a third party who provides coverage to the patient, such as an insurance company or MCO, a state or federal healthcare program, or the patient. Additionally, the audit requirements we must meet to ensure compliance with applicable laws and regulations, as well as our internal compliance policies and procedures, add further complexity to the billing process. As such, we are at risk of being paid less or no part of our price for our products for reasons including:</span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">variability in coverage and information requirements among various payors;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patient financial assistance programs;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">missing, incomplete or inaccurate billing information provided by ordering physicians; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">billings to payors with whom we do not have contracts; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes with payors as to which party is responsible for payment; and </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes with payors as to the appropriate level of reimbursement.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may not be free to determine the price charged for our products. For instance, the No Surprises Act (&#8220;NSA&#8221;) was enacted on December 27, 2020 and took effect on January 1, 2022. One of the goals of the NSA is to protect patients from &#8220;surprise&#8221; medical bills resulting from gaps in coverage for services provided by out-of-network providers, such as laboratories, related to patient visits at in-network facilities. The NSA limits the amount out-of-network laboratories may charge a patient for laboratory services ordered during an in-network facility visit. In addition, the NSA establishes an independent dispute resolution process for determining the amount of reimbursement for the laboratory service in the event that the laboratory and insurer cannot agree on a rate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain countries, including a number of member states of the EU, set prices and make reimbursement decisions for diagnostics and pharmaceutical products. Additionally, some countries require approval of the maximum sale price of a product before it can be marketed, and this price may be reviewed during the product lifecycle, or mandatory discounts or profit caps may be applied. In many countries, the pricing review period begins after marketing or product licensing approval is granted or the CE mark is obtained. We may therefore be constrained in our pricing strategies in markets outside of the U.S.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For additional information on coverage and reimbursement in the U.S., see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors&#8212;Risks Relating to Government Regulation&#8212;Future Medicare payment rates are uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Compliance Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our compliance program is intended to prevent and detect violations of law or our policies. It was developed in view of both adopting the principles of the AdvaMed Code of Ethics and addressing the HHS OIG&#8217;s elements of a compliance program. We have designed our compliance program to fit the size, resources, market position and other unique aspects of our company. Our code of conduct is our statement of ethical and compliance principles that guide our daily operations. In addition, we have developed policies and procedures, and corresponding education and training, to effectively communicate our standards to employees as it relates to job functions and legal obligations under applicable state and federal healthcare program requirements, as well as those outside the U.S. We regularly perform live and process monitoring activities on a risk-based approach, and audit capabilities are built into our transparency procedures. We maintain a hotline available via multiple channels to report any known or suspected compliance violations, and we have a strict non-retaliation policy for all claims brought forward in good faith.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our People and Culture</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our employees, internally referred to as &#8220;Adapters,&#8221; are passionate about immune medicine, empowered by scientific discipline and fueled by our foresight and curiosity about the adaptive immune system.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had 709 full-time employees of which 132 hold medical or doctoral degrees. None of our employees are subject to a collective bargaining agreement and we have not experienced any work stoppages. We believe relations with our employees are good.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our talented employees drive our mission and share core values that both stem from and define our culture. This plays an invaluable role in our ability to execute at all levels in our organization. Our core values are used in candidate screening, rewards and recognition criteria and in employee evaluations to help reinforce their importance in our organization:</span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Make it happen. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Individual ownership and accountability keep us moving forward</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Innovate fearlessly. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Push against boundaries and think boldly to achieve world-changing results</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debate openly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Value discussions inspired by different points of view</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Work together. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Demonstrate you care about the success of others. The same goes for our partners and customers&#8212;together we can achieve more</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Follow True North. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Show up with integrity and do the right thing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Have fun.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Fun makes everything better</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe our employees are highly engaged, and we were recognized consecutively from 2018 to 2022 by the Puget Sound Business Journal as one of Washington State&#8217;s Best Places to Work. We were also nationally certified as a Great Place to Work in 2021 and 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We pride ourselves on inclusive team building, product design and gender diversity at all levels of management. We are committed to creating and maintaining a culture of belonging.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We strive to provide compensation and benefits that are competitive to market and create incentives to attract and retain employees. Our compensation package includes market-competitive base pay, performance-based short-term incentives, health care, retirement benefits, paid time off and family leave. In addition, we offer employees the benefit of equity ownership in the Company through restricted stock unit awards. We also provide access to a variety of health and wellness resources.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corporate Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were incorporated in the State of Washington on September 8, 2009 under the name Adaptive TCR Corporation. On December 21, 2011, we changed our name to Adaptive Biotechnologies Corporation. In January 2015, we acquired Sequenta, a San Francisco, California-based company that was also developing an NGS test for MRD. Our principal executive offices are located at 1165 Eastlake Avenue East, Seattle, Washington 98109, and our telephone number is (206) 659-0067.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain a website at www.adaptivebiotech.com. The contents of our website are not incorporated in, or otherwise to be regarded as part of, this Annual Report on Form 10-K. We make available, free of charge on our website, access to our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), as soon as reasonably practicable after we file or furnish them electronically with the Securities and Exchange Commission (&#8220;SEC&#8221;). Investors and others should note that we announce material financial information to our investors using our investor relations website (http://investors.adaptivebiotech.com), SEC filings, press releases, public conference calls and webcasts. We use these channels as well as social media to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on social media channels.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Risk </span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Factors</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing in our Company involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all other information in this Annual Report on Form 10-K, including our consolidated financial statements and related notes and the &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; section, before investing in our Company. Any of the risk factors we describe below could adversely affect our business, financial condition, results of operations, prospects or the trading price of our securities. The risks described below are not the only ones we face and additional risks that we currently do not know about or that we currently believe to be immaterial may also impair our business, financial condition, operating results, prospects and the trading price of our securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of Risk Factors</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Generally, the risks described below relate to the following:</span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our significant net losses since inception, expected net losses in the future and need for significant investments in products and services, as well as our ability to manage operating expenses in light of profitability goals;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our collaboration with Genentech and ability to develop and commercialize cellular therapeutics, including our ability to achieve milestones and realize the intended benefits of the collaboration;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our laboratory operations, including errors or defects in our products or services and our reliance on a limited number of suppliers, and in some cases single suppliers, for our equipment and materials, some of which include reagents or other materials that may also require additional internal validation prior to use;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our limited experience with the development and commercialization of therapeutic products, including cellular therapies and antibodies;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to leverage our immune medicine platform to discover, develop and commercialize target antigens and therapeutic products may not be successful;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expected and potential reliance on collaborators for development and clinical testing of therapeutic product candidates, which may fail at any time due to a number of possible unforeseen events;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market acceptance of our products and services;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to increase our capacity, manage the evolution of our products and services, stay current in our rapidly changing industry and otherwise manage our growth;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the loss of any member of our senior management team, or of the support of key opinion leaders;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extensive regulation of our industry, including reimbursement coverage decisions;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the validity of our patents, protection of our trade secrets and related intellectual property matters; and</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effects of health epidemics in regions where we or third parties on which we rely have significant laboratory operations, manufacturing facilities, concentrations of clinical trial sites or other business operations.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Relating to Our Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant losses since our inception. For the year ended December 31, 2023, 2022 and 2021, we incurred a net loss of $225.3 million, $200.4 million and $207.3 million, respectively. As of December 31, 2023, we had an accumulated deficit of $1.1 billion. We have funded our operations to date principally from the sale of convertible preferred stock and common stock, including the sale of common stock in our initial public offering, and, to a lesser extent, revenue as well as entry into the Purchase Agreement. We expect to continue to incur significant expenses and operating losses as we continue to invest in the development of products and services utilizing our immune medicine platform to support the validation of additional clinical diagnostic and therapeutic products and services. We will need to generate significant additional revenue to achieve and sustain profitability.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are not successful in leveraging our immune medicine platform to discover, develop and commercialize additional products and services, our ability to expand our business and achieve our strategic objectives would be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our strategy is to leverage our immune medicine platform to discover, develop and potentially commercialize additional diagnostic and therapeutic products and services for various disease states. In particular, for clonoSEQ we are attempting to generate sufficient clinical evidence to support the utility of MRD in additional lymphoid cancers beyond ALL, MM, CLL, and DLBCL while also demonstrating the clinical utility of blood as a sample type for all lymphoid cancers. If we are unable to generate compelling evidence supporting clonoSEQ use in other indications or sample types, we may not succeed in expanding our clonoSEQ product platform.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In our immune medicine business, our focus on target antigen discovery and development of therapeutic products, including antibodies and cellular therapies, faces significant challenges in the identification, validation, development, clinical testing and marketing approval of new products. If we or our collaborators are unable to discover novel targets and develop transformative immune-based therapies, we may not succeed in commercializing new therapeutic products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Identifying new products and services requires substantial technical, financial and human resources, whether or not any products or services are ultimately developed or commercialized. We may pursue what we believe is a promising opportunity to leverage our platform only to discover that certain of our risk or resource allocation decisions were incorrect or insufficient, or that individual products, services or our science in general has technology or biology risks that were previously unknown or underappreciated. Our strategy of pursuing the value of our immune medicine platform over a long time horizon and across a broad array of human diseases may not be effective. In the event material decisions in any of these areas turn out to be incorrect or sub-optimal, we may experience a material adverse impact on our business and ability to fund our operations and we may never realize what we believe is the potential of our immune medicine platform.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We expect to make significant investments in our continued research and development of new products and services, which may not be successful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are seeking to leverage our immune medicine platform to develop a pipeline of future disease-specific research, diagnostic and therapeutic products. For example, we continually expand our immunomics database and antigen-annotated TCR-Antigen Map with a view toward continually advancing target antigen discovery to leverage in developing therapies such as prophylactic or therapeutic antibodies. In addition, we are developing certain therapeutic product candidates under our collaboration agreement with Genentech by leveraging our platform to identify TCRs that can be engineered into personalized cellular therapeutic products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also attempting to leverage our immune medicine platform to discover and develop potential antibody therapies, which have been informed by our previous investment in producing, collecting and analyzing data related to COVID-19. Our efforts in this area are early and continue to evolve and mature as we augment our databases and pool of knowledge. As we continue to collect and analyze additional data, we may find that our initial hypotheses regarding any disease state which is a target for antibody discovery is not supported by a larger data set or further analysis. If our beliefs regarding the effectiveness of our antibody discovery and development capabilities are incorrect, that could have a material adverse effect on the market for our products.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Developing new products is a speculative and risky endeavor. Products or services that initially show promise may fail to achieve the desired results or may not achieve acceptable levels of analytical accuracy or clinical utility. We may need to alter our products in development and repeat clinical studies before we identify a potentially successful product or service. Therapeutic product development is expensive, may take years to complete and can have uncertain outcomes. Failure can occur at any stage of the development. If, after development, a product or service appears successful, we or our collaborators (if any) may, depending on the nature of the product or service, still need to obtain FDA and other regulatory clearances, authorizations or approvals before we can market it. The clearance, authorization or approval pathways at the FDA and other regulatory authorities are likely to involve significant time, as well as additional research, development and clinical study expenditures. The FDA or other regulatory authorities may not clear, authorize or approve any future product we develop. Even if we develop a product that receives regulatory clearance, authorization or approval, we or our collaborators would need to commit substantial resources to commercialize, sell and market it before it could be profitable, and the product may never be commercially successful. Additionally, development of any product may be disrupted or made less viable by the development of competing products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because new potential products may fail at any stage of development or commercialization and if we determine that any of our current or future products are unlikely to succeed, we may abandon them without any return on our investment. If we are unsuccessful in developing additional products, our potential for growth may be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our efforts to develop products leveraging our antigen-annotated TCR-Antigen Map may not be successful, and it may not yield the insights we expect at all or on a timetable that allows development or commercialization of new diagnostic and therapeutic products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are using our immunosequencing capabilities, proprietary computational modeling and machine learning to map TCR sequences to the antigens they bind. However, we may not be successful in developing a sufficiently comprehensive TCR-Antigen Map for development of new therapies for any number of reasons including difficulty accessing required sample sets to validate signals and complications in advancing algorithmic-based methods that accurately define TCR signatures to be validated.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, even with the aid of machine learning, we expect the TCR-Antigen Map to take us several years to fully develop as planned. The TCR-Antigen Map we are developing therefore may not yield clinically actionable insights on a timetable that is commercially viable for our products or our collaborators&#8217; products, or at all. Our goal is to leverage the TCR-Antigen Map in connection with drug discovery and development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have established proof of concept for identification of disease-specific signals from TCRs produced in patients with SARS-CoV-2, acute Lyme disease, Crohn&#8217;s disease, celiac disease and MS. We have also identified early signals in ulcerative colitis and rheumatoid arthritis and we will seek to confirm those signals in ongoing validation work.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In pursuit of discovering and developing new drugs, we will leverage our immunomics database and further develop our TCR-Antigen Map through the discovery of potential new drug targets (antigens). Once we have a validated target, we will use our immune medicine platform and our growing TCR-Antigen Map to support development of TCR-based, antigen-based, and antibody-based therapeutic modalities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have agreed to exclusively use Microsoft's immunomics artificial intelligence services for TCR-antigen mapping in connection with all of our technology, products and services developed as a direct result of our collaboration with Microsoft throughout the term of the Microsoft Agreement, which expires in 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our computational modeling and machine learning efforts do not accelerate the pace at which we can validate association of TCR sequences to the antigens they bind, the timetable for our business model may not be commercially viable. Even if we can accelerate this timeline, products derived from our novel technologies may have product level errors. If we are unable to make meaningful progress in our TCR-Antigen Map and successfully use it to develop and commercialize new therapeutic products or services, our business and results of operations will suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We utilize artificial intelligence in data and document generation, which may impact reliability of our data.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not use artificial intelligence as an element of any product or service but do use it to assist in generation of datasets and documentation as well as to assist in training computational models. As with many innovations, the use of artificial intelligence presents risks and challenges, including flawed, insufficient or biased datasets. Challenges inherent to the use of artificial intelligence could adversely impact the reliability of our data and subject us to delays and competitive harm, regulatory action, or legal liability, as well as brand or reputational harm.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are exposed to risks associated with our agreement with Genentech, and we may not realize the advantages we expect from it.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2018, we entered into the Genentech Agreement with the goal of accelerating the development and commercialization of novel cancer-specific antigen and neoantigen directed T cell therapies for the treatment of a broad range of tumor types. Under the terms of the Genentech Agreement, we received $300.0 million in an initial upfront payment in February 2019 and may be eligible to receive up to approximately $1.8 billion in additional payments over time upon achievement of specified development, regulatory and commercial milestones. In addition, Genentech will pay us royalties on sales of products commercialized under the agreement. We may not be successful in achieving these milestones, and products developed under the Genentech Agreement may not be commercialized in the timeframe we expect, achieve significant sales, or be commercialized at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to numerous risks associated with the Genentech Agreement, including sharing a measure of control over the operations of our research and development portions of the collaboration with Genentech and Genentech having sole control over the commercialization of any products developed via the collaboration. For instance, in 2021, Genentech suspended development of a drug against our first shared antigen target candidate in response to published data, followed by its selection of an alternative candidate. The Genentech Agreement also prevents us from, among other things, developing or commercializing TCR-based cellular therapies outside the scope of the collaboration in the field of oncology on our own or with any third party. Our collaboration involves risks that are different from the risks involved in independently conducting operations, including that Genentech may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">have or develop economic or business interests that are inconsistent with ours; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">take actions contrary to our instructions, requests, policies or objectives; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">take actions that reduce our return on investment for this collaboration; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fail to distinguish itself from biosimilar competition; or </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">take actions that harm our reputation or restrict our ability to run our business. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Genentech&#8217;s degree of control over collaboration development and commercialization efforts may impact the amounts we receive under the Genentech Agreement. For example, Genentech may suspend development of product candidates or decide not to pursue commercialization of product candidates at all, or it may agree to pay royalties to third parties or adopt a pricing model that reduces the amount of royalties we might otherwise expect. It is also possible that effective cell therapies will not be developed under the Genentech Agreement or, if developed, approved by the FDA or comparable regulatory authorities outside of the U.S. Genentech may also terminate the Genentech Agreement at its convenience, at any time and without cause.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to perform our product research, development and commercialization related obligations under the Genentech Agreement, including performing TCR screening activities for product candidates being developed and commercialized under that agreement. For example, in the event a product is commercialized under the Genentech Agreement, as the volume of product sales grows, we will likely need to continue to increase our workflow capacity for sample intake, customer service and general process improvements, and expand our internal quality assurance program to support TCR screening on a larger scale within expected turnaround times. We will likely need additional certified laboratory scientists and other scientific and technical personnel for the Personalized Product to identify and target therapeutically relevant, patient-specific neoantigens. We will likely also need to acquire additional laboratory space and equipment, which can take several months or more to procure, set up and validate. These process enhancements and increases in scale, expansion of personnel, laboratory space and equipment may not be successfully implemented, and we may not have adequate laboratory facilities or resources to accommodate all the requirements that we currently anticipate needing to be successful. If we cannot satisfy our obligations, Genentech is entitled to trigger a technology transfer of our TCR screening process (specific to the Personalized Product) or terminate the Genentech Agreement. In addition, due to our significant obligations under the Genentech Agreement, we may face challenges in meeting the needs of existing customers, collaborators and suppliers and securing new customers, including any biopharmaceutical customers that are actual or potential competitors with Genentech.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we support the commercialization of one or more products under the Genentech Agreement, we may need to incorporate new equipment, implement new technology systems and laboratory processes and hire new personnel with different qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher product costs, declining product quality, deteriorating customer service and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our products and could damage our reputation and the prospects for our business, both under the Genentech Agreement and otherwise. As a result, our relationship with Genentech may not result in the realization of its anticipated benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have limited experience with the development and commercialization of cellular therapeutics, and future TCR-based cellular therapies may never be successfully developed and commercialized as part of our Genentech collaboration.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have limited experience with the development of cellular therapeutics, and no experience with the commercialization, marketing and distribution of cellular therapeutics. Our therapeutic product candidates are at an early stage of discovery and development under our Genentech collaboration, and we are continuing to develop our process being used under that collaboration to develop TCR-based cellular therapies for the treatment of cancer. Under our Genentech collaboration, Genentech has invested significant financial resources to develop future TCR-based cellular therapies, including conducting preclinical studies and other early research and development activities, and providing general and administrative support for these operations. Our future success is dependent on our and Genentech&#8217;s ability to successfully develop therapeutic product candidates and advance those product candidates into the clinic, and Genentech&#8217;s ability, where applicable, to obtain regulatory and marketing approval for, and then successfully commercialize, cellular therapeutics. We and Genentech have not yet developed and commercialized any cellular therapeutics, and we may not be able to do so.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have limited experience with the development and commercialization of antibody-based therapeutics, and future such products may never be successfully developed and commercialized by us or our collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have limited experience with the development of clinically applicable antibodies, and no experience with the commercialization, marketing and distribution of antibody-based therapeutic products. Our antibody-based therapeutic product candidates are at an early stage of discovery and development. We and any of our collaborators we work with to develop and commercialize therapeutic antibody products may not be able to do so.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We currently use, and in the future expect to continue using, collaborators for several aspects of our operations as well as to commercially leverage our drug discovery platform, and if we cannot maintain current and enter new relationships with collaborators when necessary or desirable to do so, our business will suffer.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have limited resources to conduct our operations in both the MRD and IM business areas, and have not yet fully established infrastructure for sales, marketing or distribution in connection with all of our current or potential products. We have entered into collaboration agreements under which our collaborators have provided, and may in the future provide, funding and other resources for developing and potentially commercializing our products and services. For example, we have entered into the Genentech Agreement, with the goal of accelerating the development and commercialization of T cell therapies for the treatment of a broad range of tumor types, and the Microsoft Agreement, which has provided us with access to Microsoft&#8217;s research and machine learning technologies that we are using to develop our TCR-Antigen Map.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are pursuing several additional industry and academic collaborations to access patient cohorts that could accelerate our TCR-Antigen Map signal generation and validation for our immune-based diagnostics or drug discovery product or services pipeline. These collaborations may result in our incurring significant expenses in pursuit of potential products and services, and we may not be successful in identifying, developing or commercializing any potential products or services.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also pursuing, and may in the future pursue, drug discovery and development opportunities with our pharmaceutical services collaborators to develop and commercialize TCR-based, antigen-based, and antibody-based therapeutic modalities. Many of these collaborations provide us with upfront and milestone payments. We may not succeed in identifying therapeutic assets in these collaborations and our collaborators may not succeed in developing and commercializing such assets, which may cause us not to realize the expected monetary benefits of the collaborations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many factors may impact the success of such collaborations, including our ability to perform our obligations, our collaborators&#8217; satisfaction with our products and services, our collaborators&#8217; performance of their obligations to us, our collaborators&#8217; internal priorities, resource allocation decisions and competitive opportunities, the ability to obtain regulatory approvals, disagreements with collaborators, the costs required of either party to the collaboration and related financing needs, and operating, legal and other risks in any relevant jurisdiction. In addition to reducing our revenue or delaying the development of our future products and services, the loss of one or more of these relationships may reduce our exposure to research, data, clinical trials or computing technologies that facilitate the collection and incorporation of new information into our clinical immunomics database and TCR-Antigen Map. All of the risks relating to product development, regulatory clearance, authorization or approval and commercialization described herein apply to us derivatively through the activities of our collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We engage in conversations with companies regarding potential collaborations on an ongoing basis. These conversations may not result in a commercial agreement. Even if an agreement is reached, the resulting relationship may not be successful, and any products and services developed as part of the collaboration may not produce successful outcomes. Speculation in the industry about our existing or potential collaborations can be a catalyst for adverse speculation about us or our products, which can adversely affect our reputation and our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant additional research and development and, in certain instances, clinical trials or validation will be required before we or our collaborators can potentially seek regulatory clearance, authorization or approval for, or commercialize any of our products or services in development.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing a pipeline of immune-driven diagnostics and medicine therapeutics, including cellular therapies in oncology, but significant additional research and development activities, validations, and clinical trials could be required before we and, as pertinent, our collaborators will have a chance to achieve additional commercially viable products. Our research and development efforts remain subject to all of the risks associated with the development of new products based on pharmaceutical therapies. Development of the underlying technology may be affected by unanticipated technical or other problems, among other research and development issues, and the possible insufficiency of funds needed to complete development of these products. Safety, regulatory and efficacy issues, clinical hurdles or other challenges may result in delays and cause us to incur additional expenses that would increase our losses. If we and our collaborators cannot complete, or if we experience significant delays in developing, our clinical diagnostics or therapeutics, including T-cell based cellular therapies and antibodies, particularly after incurring significant expenditures, our business may fail and investors may lose the entirety of their investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to obtaining regulatory clearances, authorizations or approvals for the commercial sale of any new therapeutic products or services, we must demonstrate that our products are both safe and effective for use in each target disease indication. Clinical studies will be necessary to demonstrate that a product is safe and effective. Clinical testing and other validation efforts are expensive and can take many years to complete, the outcome of which is inherently uncertain. Failure can occur at any time. For therapeutics, the results of preclinical studies and early clinical trials of products and services in development may not be predictive of the results of later-stage clinical trials, and initial success in clinical trials may not be indicative of results obtained when clinical trials are completed. There is typically an extremely high rate of failure as therapeutic products in development proceed through clinical trials. Products in later stages of clinical trials or validation also may fail to show the desired safety and efficacy profile despite having progressed through non-clinical studies and initial clinical trials or validations. Any delays in the development of our products and services may harm our business, financial condition and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Errors or defects in our products or services could harm our reputation, decrease market acceptance of our products or services or expose us to product liability claims.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are creating new products, many of which are initially based on largely untested technologies. As all of our products and services progress, we or others may determine that we made product or service level scientific or technological mistakes or omissions. The testing processes utilize a number of complex and sophisticated biochemical, informatics, optical and mechanical processes, many of which are highly sensitive to external factors and variation between testing runs. Refinements to our processes may initially result in unanticipated issues that reduce the efficiency or increase variability. In particular, DNA sequencing, which is a key component of these processes, could be inefficient with higher than expected variability thereby increasing total sequencing costs and reducing the number of samples we can process in a given time period, which may negatively impact customer turnaround time. Therefore, inefficient or variable processes can cause variability in our operating results and damage our reputation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our development laboratory operations could result in any number of errors or defects. Our quality assurance system or product development processes may fail to prevent us from inadvertent problems with samples, sample quality, lab processes including sequencing, software, data upload or analysis, raw materials, reagent manufacturing, assay quality or design, or other components or processes. In addition, our assays may have quality or design errors, and we may have inadequate procedures or instrumentation to process samples, assemble our proprietary primer mixes and commercial materials, upload and analyze data, or otherwise conduct our development laboratory operations. If we provide products or services with undiscovered errors to our customers, our clinical diagnostics may falsely indicate a patient has a disease or fail to detect disease in a patient who requires treatment. We believe our customers are likely to be particularly sensitive to product and service defects, errors and delays, including if our products and services fail to indicate the presence of residual disease with high accuracy from clinical specimens or if we fail to list or inaccurately indicate the presence or absence of disease in our test report. In drug discovery, such errors may interfere with our collaborators&#8217; clinical studies or result in adverse safety or efficacy profiles for their products in development. This may harm our customers&#8217; businesses and may cause us to incur significant costs, divert the attention of key personnel, encourage regulatory enforcement action against us, create a significant customer relations problem for us and cause our reputation to suffer. We may also be subject to liability claims for damages related to errors or defects in our products. Any of these developments could harm our business and operating results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our current and future products and services may never achieve significant commercial market acceptance.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends on the market&#8217;s confidence that we can provide immune-driven research, diagnostic and therapeutic products and services that improve clinical outcomes, lower healthcare costs and enable better biopharmaceutical development. Failure of our products and services, or those jointly developed with our collaborators, to perform as expected could significantly impair our operating results and our reputation. We believe patients, clinicians, academic institutions and biopharmaceutical companies are likely to be particularly sensitive to defects, errors, inaccuracies, delays and toxicities in or associated with our products and services. Furthermore, inadequate performance of these products or services may result in lower confidence in our immune medicine platform in general.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and our collaborators may not succeed in achieving significant commercial market acceptance for our current or future products and services due to a number of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability, and that of our collaborators, to secure and maintain FDA and other regulatory clearance, authorization or approval for our products; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the agreement by third-party payors to reimburse our diagnostics, the scope and extent of which will affect patients&#8217; willingness or ability to pay for our diagnostics, even in markets that we expect to be primarily self-pay, and will likely heavily influence physicians&#8217; decisions to recommend our tests; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the rate of adoption of our immune medicine platform and related products and services by academic institutions, clinicians, key opinion leaders, advocacy groups and biopharmaceutical companies; and </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of our investments in product innovation and commercial growth. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, our customers and collaborators may decide to decrease or discontinue their use of our products and services due to changes in their research and development plans, failures in their clinical trials, financial constraints, the regulatory environment, negative publicity about our products and services, competing products or the reimbursement landscape, all of which are circumstances outside of our control. We may not be successful in addressing these or other factors that might affect the market acceptance of our products, services and technologies. Failure to achieve widespread market acceptance of our immune medicine platform and related products and services would materially harm our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on a limited number of suppliers or, in many cases, single suppliers, for laboratory equipment and materials and may not be able to find replacements or immediately transition to alternative suppliers.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on a limited number of suppliers, or in many cases single suppliers, to provide certain sequencers, reagents, equipment and other materials that we use in our laboratory operations and product development. An interruption in our laboratory operations, kit distribution, technology transfer, or development activities could occur if we encounter delays, quality issues or other difficulties in securing these sequencers, equipment, reagents or other materials, and if we cannot then obtain an acceptable substitute. In such an event, we would likely be required to incur significant costs and devote significant efforts to find new suppliers, acquire and qualify new equipment, validate new reagents and revalidate aspects of our existing assays, which may cause delays in our processing of samples or development and commercialization of products. Any such interruption could significantly affect our business, financial condition, results of operations and reputation. Internal changes in processes or compositions of our reagents or other materials may also require validation efforts by us and supply of new materials from our suppliers which could impact timing of production and levels of inventory while such changes are being implemented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, we have purchased and rely on the Illumina NextSeq System. Illumina supplies us with reagents that have been designed for use solely with this sequencer and Illumina is the sole provider of maintenance and repair services for the Illumina NextSeq System. We also license our laboratory information management software from Illumina and receive services from Illumina related to that software. In addition, Illumina is not obligated to meet all of our requirements for reagent supply. In the event Illumina ceases or slows its production of, or is otherwise unwilling or unable to continue to supply the sequencer reagents necessary for and currently used in our business at or near current pricing, we may be required to purchase different reagents from Illumina or to purchase from a different reagent vendor under terms and conditions which could be less favorable to us. Any disruption in Illumina&#8217;s operations or the suppliers of our reagents, materials or other equipment could impact our ability to do business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe there are only a few other equipment manufacturers that are currently capable of supplying the equipment necessary for our laboratory operations and product development, including sequencers and various associated reagents. The use of sequencers manufactured by a company other than Illumina would require us to alter our laboratory operations. Transitioning to and qualifying a new sequencer would be time-consuming and expensive, may result in interruptions in our laboratory operations, could affect the performance specifications of our laboratory operations or could require that we revalidate the reagents we use in immunosequencing, potentially including our clonoSEQ diagnostic testing services, and could require us to obtain additional clearance, authorization, approval, accreditation, or licensure for the changes. We may not be able to secure and implement alternative sequencers, associated reagents and other materials without experiencing interruptions in our workflow. In the case of an alternative supplier to Illumina, any replacement sequencers and various associated reagents may not be available or may not meet our quality control and performance requirements for our laboratory operations. If we should encounter delays or difficulties in securing, reconfiguring or revalidating the equipment and reagents we require for our products and services, our business, financial condition, results of operations and reputation could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have limited experience in marketing and selling certain products and services, and if we are unable to expand our direct sales and marketing force or partner with collaborators in certain product areas and markets to adequately address our customers&#8217; needs, our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have no experience marketing and selling therapeutic products. Accordingly, we or our drug discovery and development collaborators may not be able to market and sell our current or future products and services effectively enough to support our planned growth.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our sales and marketing efforts are targeted at a large and diverse market with highly specialized segments, including department heads, laboratory directors, principal investigators, core facility directors, clinicians, payors and research scientists and pathologists at leading academic institutions, biopharmaceutical companies, research institutions and contract research organizations. As a result, we believe it is necessary for our sales representatives to have relevant, specialized market experience. Competition for experienced sales and marketing personnel is intense, and new members of our sales organization may require intense training to apply their experience and expertise to our products and services. We may not be able to attract and retain personnel or be able to build or adequately train an efficient and effective sales organization, which could negatively impact sales and market acceptance of our clinical diagnostics and limit our revenue growth and potential profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Genentech Agreement, Genentech has the sole right and authority to commercialize products developed under that agreement. It will be Genentech&#8217;s responsibility to locate, qualify and engage distribution partners, clinicians and local hospitals with industry experience and knowledge to effectively market and sell products developed under that agreement. Genentech may not be able to engage distribution partners, clinicians or hospitals on favorable terms, or at all. If Genentech&#8217;s sales and marketing efforts with respect to products developed under the Genentech Agreement are not successful, we may not achieve significant market acceptance for our drug discovery services and platform, which would materially and adversely impact our business operations. We face similar risks in our pharmaceutical services collaborations where milestone payments to us are dependent on successful commercialization of drugs by our collaborators.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we or our collaborators experience any of a number of possible unforeseen events in connection with clinical trials, our or their ability to conduct further clinical trials of, obtain regulatory clearance, authorization or approval of or commercialize future products and services or improvements to current products, could be delayed or prevented.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or our collaborators may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our or their ability to conduct further clinical trials or obtain regulatory clearance, authorization or approval of or commercialize future products and services or improvements to current products and services, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Evolving Regulatory Requirements and Policies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the area of &#8220;precision medicine&#8221; or &#8220;personalized medicine&#8221; and its regulation may be subject to ongoing changes in terms of regulatory requirements and governmental policies, in ways we cannot predict; </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trial Design</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities or ethical review boards, including IRBs, may not authorize commencement of a clinical trial or conduct a clinical trial at a prospective trial site; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">there may be delays in reaching or failure to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or other regulatory authorities may disagree with a clinical trial design or a sponsor&#8217;s interpretation of data and may change the requirements for product clearance, authorization or approval even after they have reviewed and commented on the clinical trial design; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">differences in trial design between early stage clinical trials and later-stage clinical trials may make it difficult to extrapolate the results of earlier clinical trials to later clinical trials; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or other regulatory authorities may disagree about whether study endpoints are clinically meaningful; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of patients, or amount of data, required for clinical trials, or improvements to current products, may be larger than anticipated, patient enrollment in these clinical trials may be slower than anticipated or patients may drop out of clinical trials at a higher rate than anticipated; </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Testing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes may be made to product candidates after commencing clinical trials, which may require that previously completed stages of clinical testing be repeated or delay later stages of testing, for example, we, or our collaborators, may pursue one or more different product development pathways for our T cell therapeutic products; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trials may fail to satisfy the applicable regulatory requirements of the FDA or other regulatory authorities responsible for oversight of the conduct of clinical trials in other countries; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulators may elect to impose a clinical hold, or governing IRBs, data safety monitoring board or ethics committees may elect to suspend or terminate our clinical research or trials for various reasons, including non-compliance with regulatory requirements or a finding that the participants are being exposed to unacceptable risks to their health or the privacy of their health information being disclosed; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of clinical trials of future products, or improvements to current products, may be greater than we anticipate; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not have sufficient capacity in our laboratories to perform testing as requested or volumes requested or with the requested turnaround times necessary for clinical trials; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the supply or quality of materials or data necessary to conduct clinical trials of future products, or improvements to current products, may be insufficient or inadequate; </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trial Outcomes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the outcome of our collaborators&#8217; preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product candidates may be associated with negative or inconclusive results in clinical trials, and we or our collaborators may decide to deprioritize or abandon these product candidates, or regulatory authorities may require us to abandon them or impose onerous changes or requirements, which could lead to deprioritization or abandonment; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product candidates may have undesirable side effects which could lead to serious adverse events, or other unexpected characteristics. One or more of such effects or events could cause regulators to impose a clinical hold on the applicable trial, or cause us, our collaborators or their investigators, IRBs or ethics committees to suspend or terminate the trial of that product candidate; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trials may suggest or demonstrate that our products are not as efficacious or safe as other similar diagnostics or therapies; and </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preclinical and clinical data are often susceptible to varying interpretations and analyses, and our products may fail to obtain regulatory clearance, authorization or approval, even if they perform satisfactorily in preclinical studies and clinical trials. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delays of this nature could also allow competitors to bring products to market before we or our collaborators do, potentially impairing our ability to successfully commercialize products and harming our business and results of operations. Any delays in the development of our products or those jointly developed with our collaborators may significantly harm our business, financial condition and prospects. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory clearance, authorization or approval of products in development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may need to expand our workforce, commercial infrastructure and laboratory operations over time to support demand for our products. We may encounter difficulties in managing this and in meeting fluctuations in this demand.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may need to further expand our workforce, commercial infrastructure and laboratory operations to support demand for our products. If we are unable to support fluctuations in the demand for our products and services, including ensuring that we have adequate capacity to meet potential increased demand as well as other customer requirements (such as turnaround time and service level), our business could suffer. As of December 31, 2023, we had 709 full-time employees and we may be required to increase the number of employees, including potential contingent employees as needed to address demand fluctuations. As we and our collaborators commercialize additional products and services, we may need to incorporate new equipment, implement new technology systems and laboratory processes and hire new personnel with different qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher service costs, declining service quality, deteriorating customer service and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our products and services and could damage our reputation and the prospects for our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Due to the technical proficiency required from much of our workforce, we may not be able to effectively recruit, train, and retain additional qualified personnel. This may result in weaknesses in our infrastructure, operational mistakes, slower development of our products and services, missed or delayed milestone achievement, significant cost overruns, loss of business opportunities, loss of employees and contingent workers, inability to execute on hiring plans and reduced productivity among remaining employees and contingent workers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our financial condition and operating results have varied in the past and will continue to fluctuate from quarter-to-quarter and year-to-year in the future due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include the following, as well as other factors described elsewhere in this Annual Report on Form 10-K:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of upfront payments from our collaborators; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability and that of our collaborators to develop and successfully commercialize our products, including therapeutic products; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to achieve collaboration-based milestones on currently contemplated timelines, or at all; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">availability and extent of reimbursement by governmental and private payors for our products; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability of our clinical sales teams to continue converting physicians from using incumbent products in the market to clonoSEQ and new diagnostic products and services we may develop; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to continue driving repeat usage of the clonoSEQ diagnostic test by physicians and get reimbursed for that repeat usage by commercial and government payors for monitoring of MRD; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the outcomes of research initiatives, clinical trials or other product development or approval processes conducted by us or our collaborators; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the level of demand for our products; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our relationships, and any associated exclusivity terms, with collaborators; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to manage our growth and operating expenses; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our contractual or other obligations to provide resources to fund our products and services and to provide resources to our collaborations; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays or failures in advancement of future products in clinical trials by us or our collaborators; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">risks associated with any future international expansion of our business, including the potential to conduct clinical trials and commercialize our products and services in multiple international locations; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability and that of our collaborators to consistently manufacture our products; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our dependence on, and the need to attract and retain, key management and other personnel; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain, protect and enforce our intellectual property rights; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to prevent the theft or misappropriation of our intellectual property, know-how or technologies; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain additional capital that may be necessary to expand our business; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to accurately report our financial results in a timely manner; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business interruptions such as power outages, strikes, acts of terrorism or natural disasters; and </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to use our net operating loss (&#8220;NOL&#8221;) carryforwards to offset future taxable income. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The cumulative effects of factors discussed above could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. In any particular period, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While as a general matter we intend to periodically report on the status of our development initiatives, including anticipated next steps, we may not provide forward-looking guidance on the timing of those next steps. In addition, we do not control the timing of disclosure of any such milestones related to any of our products that are managed by our collaborators. Any disclosure by us or our collaborators of data that is perceived as negative may have a material adverse impact on our stock price or overall valuation. Our stock price may decline as a result of unexpected clinical trial results in one or more of our products, including adverse safety events reported for any of our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have estimated the sizes of the markets for our current and future products and services, and these markets may be smaller than we estimate.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our estimates of the annual addressable markets for our current products and services and those under development are based on a number of internal and third-party estimates, including, without limitation, the number of patients who have developed one or more of a broad range of cancers, the number of individuals who are at a higher risk for developing one or more of a broad range of cancers, and the number of individuals who have developed or are at a higher risk of developing certain autoimmune disorders, as well as the proportion of patients in each market whose needs can be addressed by our or our collaborators&#8217; products, and the assumed prices at which we can sell our current and future products and services for markets that have not been established. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual addressable market for our current or future products may prove to be incorrect. If the actual number of patients who would benefit from our products, the price at which we can sell future products and services or the annual addressable market for our products or services is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we do not compete effectively with our competitors, we may not be able to successfully commercialize our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biotechnology and pharmaceutical industries in the field of drug discovery are intense and highly competitive. These fields are characterized by rapidly advancing technologies and a strong emphasis on intellectual property. Given the breadth and promise of immune medicine, we face substantial competition from many different sources, including diagnostic, pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions across various components of our platform and current and potential product offerings. Due to the significant interest and growth in immune medicine more broadly, we expect the intensity of the competition to increase.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For instance, in clinical diagnostics, our clonoSEQ MRD test faces competition from both conventional and next-generation flow cytometry performed either in-house by our target customers or by reference labs, as well as from labs and institutions advancing research-use-only MRD technologies for clinical applications and commercial-stage oncology diagnostics companies extending the application of their solid tumor (ctDNA) MRD products into the hematology MRD space. In drug discovery, clinical trials of immune medicines are being undertaken by a number of industry and academic players.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our competitors may have or obtain the knowledge necessary to generate and characterize similar data to our known data for the purpose of identifying and developing products or services that could compete with any of our products or services. Further, immune medicine is being pursued by several biotechnology companies as well as by large-cap biopharmaceutical companies. Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, regulatory approval and compliance, and sales and distribution than we do.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We could be adversely affected if we do not develop our clinical diagnostic and drug discovery products, obtain required regulatory and other clearances, authorizations or approvals, obtain or enforce patents covering our discoveries and launch our products before our competitors. Moreover, our competitors may succeed in developing clinical diagnostics and therapies that circumvent our intellectual property rights. Our competitors may succeed in developing and commercializing therapies or diagnostic products that are more accurate, more convenient to use or more cost-effective than our products or could prove to be safer, more effective, more convenient to administer or more cost-effective than any therapeutic products we may develop with our collaborators or that would render our products less competitive or obsolete. We expect competition to intensify in the fields in which we are involved as technical advances in these fields occur and become more widely known. For additional information regarding our competition, see the &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business&#8212;Competition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; section of this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The life sciences industry is subject to rapid change, which could make our immune medicine platform and related products that we develop obsolete.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our industry is characterized by rapid changes, including technological and scientific breakthroughs, frequent new product and service introductions and enhancements and evolving industry standards, all of which could make our current and future products obsolete. For example, there have been numerous advances in technologies relating to life sciences research and the diagnosis and treatment of cancer, and autoimmune disorders. There have also been advances in technologies used to computationally analyze very large amounts of biologic information. Our future success will depend on our ability to keep pace with evolving needs of our customers on a timely and cost-effective basis and to pursue new market opportunities that develop as a result of scientific and technological advances. If we do not update our platform and products to reflect new scientific knowledge about DNA sequencing, immunology, computational biology, software development, new disease diagnostics and therapies or the diseases we seek to treat, our products and technology could become obsolete so products and services based on our immune medicine platform could decline or fail to grow as expected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The loss of any member of our senior management team or our inability to attract and retain highly skilled scientists, clinicians and salespeople could adversely affect our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends on the skills, experience and performance of key members of our senior management team, including our co-founders and executive officers. The individual and collective efforts of these employees will be important as we continue to develop products and services based on our immune medicine platform. The loss or incapacity of existing members of our executive management team could adversely affect our operations if we experience difficulties in hiring qualified successors. Our executive officers have signed employment agreements with us, but their service is at-will and may end at any point in time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our research and development initiatives and laboratory operations depend on our ability to attract and retain highly skilled scientists, technicians and software engineers. We may not be able to attract or retain qualified scientists, technicians or software engineers in the future due to the competition for qualified personnel among life sciences and technology businesses, particularly near our facilities located in Seattle, Washington and our laboratory facilities located in South San Francisco, California. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. We may have difficulties locating, recruiting or retaining qualified salespeople. Recruiting, training and retention difficulties can limit our ability to support our research and development and commercialization efforts. All of our employees are at-will, which means that either we or the employee may terminate their employment at any time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we rely on consultants, contractors and advisors, including scientific and clinical advisors, to assist us in formulating our research and development, regulatory and commercialization strategies. Our consultants and advisors may provide services to other organizations and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. The loss of the services of one or more of our current consultants or advisors might impede the achievement of our research, development, regulatory and commercialization objectives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we lose the support of key thought leaders, it may be difficult to establish products and services enabled by our immune medicine platform as industry standards, which may limit our revenue growth and ability to achieve profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have established relationships with leading oncology, hematology, immunology, autoimmunity or inflammatory disease, transplantation and solid tumor thought leaders at premier academic and research institutions. If these key thought leaders determine that our immune medicine platform or our current or future products or services are not clinically effective, determine that alternative technologies are more effective or elect to use internally developed services, we could encounter significant difficulty validating our products or services, driving adoption or establishing our immune medicine platform as an industry standard, which would limit our revenue growth and our ability to achieve profitability. In addition, negative publications or reviews by clinicians, industry groups or other important stakeholders may negatively impact our revenue growth and ability to achieve profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We depend on our information technology systems and any failure of these systems could harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We depend on information technology and telecommunications systems, including third-party cloud computing infrastructure, operating systems and artificial intelligence platforms, for significant elements of our operations, including our laboratory information management system, clinical immunomics database, TCR-Antigen Map, laboratory workflow tools, customer and collaborator reporting and related functions. We also depend on our proprietary workflow software to support new product launches and regulatory compliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use complex software processes and pipelines to manage samples and evaluate sequencing result data. These are subject to initial design or ongoing modifications which may result in unanticipated issues that could cause variability in patient results, leading to service disruptions or errors, resulting in liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have installed, and expect to expand, a number of enterprise software systems that affect a broad range of business processes and functional areas, including systems handling human resources, financial controls and reporting, contract management, regulatory compliance and other infrastructure operations. In addition to these business systems, we have installed, and intend to extend, the capabilities of both our preventative and detective security controls by augmenting the monitoring and alerting functions, the network design and the automatic countermeasure operations of our technical systems. These information technology and telecommunications systems support a variety of functions, including laboratory operations, test validation, sample tracking, quality control, customer service support, billing and reimbursement, research and development activities, scientific and medical curation and general administrative activities. In addition, our third-party billing and collections provider depends upon technology and telecommunications systems provided by outside vendors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the risks directly relevant to our vendors, systems, and information technology, there are risks associated with the outside vendors and third parties with whom they subcontract. For example, our third-party billing and collections provider depends upon technology and telecommunications systems provided by outside vendors. Subcontractors can be a vector of vulnerability, as any weaknesses in their organization&#8217;s technical and organizational controls could affect vendor operations as well as data management, in turn impacting our own operations and ability to safeguard critical data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information technology and telecommunications systems are vulnerable to attack in a variety of forms and from a variety of sources, including telecommunications or network failures, malicious human acts (such as ransomware) and natural disasters. Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. Despite the precautionary measures we have taken to prevent unanticipated problems that could affect our information technology and telecommunications systems, failures or significant downtime of these systems or those used by our collaborators or subcontractors could prevent us from conducting our business. Any disruption or loss of information technology or telecommunications systems on which critical aspects of our operations depend could have an adverse effect on our business and our reputation, and we may be unable to regain or repair our reputation in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our laboratory facilities become damaged or inoperable or we are required to vacate our existing facilities, our ability to conduct our laboratory processes and analysis and pursue our research and development efforts may be jeopardized.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We operate laboratory facilities located in Seattle, Washington and South San Francisco, California. Our facilities and equipment could be harmed or rendered inoperable by natural or man-made disasters, including war, fire, earthquake, power loss, communications failure or terrorism, which may render it difficult or impossible for us to operate our immune medicine platform for some period of time. The inability to perform our laboratory processes that could develop if our facilities are inoperable, for even a short period of time, or to replace or repair inventory such as reagents or customer samples may result in the loss of customers or harm to our reputation, and we may be unable to regain those customers or repair our reputation in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, our facilities and the equipment we use to perform our research and development work could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facilities, to locate and qualify new facilities or license or transfer our proprietary technologies to a third party, particularly in light of licensure and accreditation requirements. Even in the unlikely event we are able to find a third party with such qualifications to enable us to conduct our laboratory processes, we may be unable to negotiate commercially reasonable terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We carry insurance for damage to our property and the disruption of our business, but this insurance may not cover all of the risks associated with damage or disruption to our business, may not provide coverage in amounts sufficient to cover our potential losses and may not continue to be available to us on acceptable terms, if at all.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may need to raise additional capital to fund our existing operations, develop additional products and services, commercialize new products and services or expand our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on our current business plan, we believe our current cash, cash equivalents and marketable securities will be sufficient to meet our anticipated cash requirements over at least the next 12 months. If our available cash and investment balances and anticipated cash flow from operations are insufficient to satisfy our liquidity requirements, including because of lower demand for our products and services as a result of risks described herein, we may seek to sell common or preferred equity or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may consider raising additional capital in the future to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons, including to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increase our sales and marketing efforts to drive market adoption of our life sciences research, clinical diagnostics and therapeutics; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fund development efforts for our current and future products and services; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expand our products and services into other disease indications and clinical applications; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acquire, license or invest in technologies; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acquire or invest in complementary businesses or assets; and </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">finance capital expenditures, such as our corporate headquarters expansion, and general and administrative expenses. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our present and future funding requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to achieve revenue growth; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our rate of continued progress in establishing payor coverage and reimbursement arrangements with domestic and international commercial third-party payors and government payors for our clonoSEQ diagnostic test; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of expanding our laboratory operations and offerings, including our sales and marketing efforts; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our rate of progress in supporting the development of cellular therapies developed under the Genentech Agreement; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our rate of progress in, and research and development expenses associated with, products and services in research and early development; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effect of competing technological, product and market developments; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs related to international expansion; and </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential cost of and delays in product development as a result of any regulatory oversight applicable to our products and services. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity securities, dilution to our shareholders could result. Any preferred equity securities issued also could provide for rights, preferences or privileges senior to those of holders of our common stock. If we raise funds by issuing debt securities, those debt securities would have rights, preferences and privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or products and services or grant licenses on terms that are not favorable to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to use our NOL carryforwards and certain other tax attributes may be limited.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred net losses since our inception and we may never achieve or sustain profitability. Generally, losses incurred will carry forward until such losses expire (for losses generated prior to January 1, 2018) or are used to offset future taxable income, if any. Utilization of our NOL carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986 (&#8220;Section 382&#8221;) and similar state provisions. The annual limitation may result in the expiration of NOL carryforwards and credits before utilization. If there should be an ownership change, our ability to utilize our NOL carryforwards and credits could be limited. We have completed a Section 382 analysis for changes in ownership through June 30, 2023 and continue to monitor for changes that could trigger a limitation. Based on this analysis, we do not expect to have any permanent limitations on the utilization of our federal NOLs. Under the Tax Cuts and Jobs Act of 2017 (the &#8220;TCJA&#8221;), federal NOLs incurred in 2018 and future years may be carried forward indefinitely, but the deductibility of such federal NOLs is subject to an annual limitation. NOLs generated prior to 2018 are eligible to be carried forward up to 20 years. Based on the available objective evidence, management determined that it was more likely than not that the net deferred tax assets would not be realizable as of December 31, 2023. Accordingly, management applied a full valuation allowance against net deferred tax assets as of December 31, 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may experience ownership changes in the future as a result of shifts in our stock ownership, which may be outside of our control. As a result, if we earn net taxable income, our ability to use our pre-ownership change NOL carryforwards to offset such taxable income will be subject to limitations. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. As a result, even if we attain profitability, we may be unable to use a material portion of our NOL carryforwards and other tax attributes, which could adversely affect our future cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We could be adversely affected by violations of the FCPA and other worldwide anti-bribery laws.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we expand geographically, commercialize our products and services, and attempt to obtain required clearances, authorizations or approvals required to offer products and services for sale, we or our collaborators may be deemed to do business outside the U.S., including because international customers may be able to order our products and services. As a result, we or our collaborators would be subject to the FCPA, which prohibits companies and their intermediaries from making payments in violation of law to non-U.S. government officials for the purpose of obtaining or retaining business or securing any other improper advantage. In addition, our collaborators or any third-party distributors could be deemed to be our agents and we could be held responsible for their actions, including violations of the FCPA. Other U.S. companies in the life sciences industry have faced criminal penalties under the FCPA for allowing their agents to deviate from appropriate practices in doing business with non-U.S. government officials. We may also become subject to similar anti-bribery laws in the jurisdictions in which we may operate, including the United Kingdom&#8217;s Bribery Act of 2010, which also prohibits commercial bribery and makes it a crime for companies to fail to prevent bribery. These laws are complex and far-reaching in nature, and we may be required in the future to alter one or more of our practices to be in compliance with these laws. Accordingly, our expansion internationally will demand a high degree of vigilance, and any violations of these laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, involve significant costs and expenses, including legal fees, and could result in a material adverse effect on our business, prospects, financial condition or results of operations. We could also suffer severe penalties, including criminal and civil penalties, disgorgement and other remedial measures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may acquire other businesses or form joint ventures or make investments in other companies or technologies that could negatively affect our operating results, dilute our shareholders&#8217; ownership, increase our debt or cause us to incur significant expense.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may pursue acquisitions of businesses and assets. We also may pursue joint ventures or investments that leverage our immune medicine platform and industry experience to expand our offerings or distribution. We have no experience forming joint ventures and limited experience investing in or acquiring other companies. We may not be able to find suitable joint ventures, investment or acquisition candidates, and we may not be able to complete such transactions on favorable terms, if at all. If we make any acquisitions, we may not be able to integrate the acquired company successfully into our existing business, and we could assume unknown or contingent liabilities, including regulatory violations such as the FCPA or similar laws. Any future acquisitions also could result in the incurrence of debt, contingent liabilities or future write-offs of intangible assets or goodwill, any of which could have a material adverse effect on our financial condition, results of operations and cash flows. Integration of an acquired company also may disrupt ongoing operations and require management resources that we would otherwise focus on developing our existing business. We may experience losses related to investments in other companies, which could have a material negative effect on our results of operations and financial condition. We may not realize the anticipated benefits of any acquisition, technology license, collaboration or joint venture.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To finance any acquisitions or joint ventures, we may choose to issue shares of our common stock as consideration, which would dilute the ownership of our shareholders. Additional funds may not be available on terms that are favorable to us, or at all. If the price of our common stock is low or volatile, we may not be able to acquire other companies or fund a joint venture project using our stock as consideration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unfavorable U.S. or global economic conditions could adversely affect our business, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our results of operations could be adversely affected by general conditions in the global economy and financial markets. Changes in these economic conditions can arise suddenly, such as in the case of the recent rise in inflation. A severe or prolonged economic downturn, as result of a global pandemic or otherwise, could result in a variety of risks to our business, including weakened demand for our products and services and our ability to raise additional capital when needed on favorable terms, if at all. For instance, we have observed a slowdown in pharmaceutical services due to macroeconomic factors impacting the biopharmaceutical industry. A weak or declining economy could also strain our collaborators, possibly resulting in supply disruption, or cause delays in their payments to us. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We use biological and hazardous materials that require considerable expertise and expense for handling, storage and disposal and may result in claims against us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We work with materials, including chemicals, biological agents and compounds and samples that could be hazardous to human health and safety or the environment. Our operations also produce hazardous and biological waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental laws and regulations may restrict our operations. If we do not comply with applicable regulations, we may be subject to fines and penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes, which increase with the volume of material and sample transfers and could cause an interruption of our commercialization efforts, research and development programs, and business operations, as well as environmental damage resulting in costly cleanup and liabilities under applicable laws and regulations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. While our property insurance policy provides limited coverage in the event of contamination from hazardous and biological products and the resulting cleanup costs, we do not currently have any additional insurance coverage for legal liability for claims arising from the handling, storage or disposal of hazardous materials. Accordingly, in the event of contamination or injury, we could be liable for damages or penalized with fines in an amount exceeding our resources and our operations could be suspended or otherwise adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we were to be sued for product liability or professional liability, we could face substantial liabilities that exceed our resources.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The marketing, sale and use of our products and services could lead to the filing of product or professional liability claims were someone to allege that our products or services failed to perform as designed or intended. We could also be potentially exposed to claims relating to therapeutic failures of products commercialized under our collaborations, such as a cellular therapy marketed by Genentech that is manufactured based on TCR-related sequences and data we provide. We may also be subject to liability for errors in, a misunderstanding of or inappropriate reliance upon, the information we provide in the ordinary course of our business activities. A product liability or professional liability claim could result in substantial damages and be costly and time-consuming for us to defend. Regardless of merit or eventual outcome, product liability and professional liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decreased demand for any products, services or clinical solutions that we have developed or may develop; </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss of revenue; </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards to patients or their families; </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significant time and costs to defend related litigation; </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to commercialize any products, services or clinical solutions that we have developed or may develop; and </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injury to our reputation and significant negative media attention. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain product and professional liability insurance, but this insurance may not fully protect us from the financial impact of defending against product liability or professional liability claims. Any product liability or professional liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit could cause current collaborators to terminate existing agreements or potential collaborators to seek other companies, any of which could impact our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may never obtain approval in the EU or in any other foreign country for any of our products or services and, even if we do, we or our collaborators may never be able to commercialize them in any other jurisdiction, which would limit our ability to realize their full market potential.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to eventually market any of our current or future products and services in any particular foreign jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a jurisdiction-by-jurisdiction basis regarding quality, safety, performance and efficacy. In addition, clinical trials or clinical investigations conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory clearance, authorization or approval in one country does not guarantee regulatory clearance, authorization or approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Seeking foreign regulatory clearance, authorization or approval could result in difficulties and costs for us and our collaborators and require additional preclinical studies, clinical trials or clinical investigations which could be costly and time-consuming. Regulatory requirements and ethical approval obligations can vary widely from country to country and could delay or prevent the introduction of our products and services in those countries. The foreign regulatory clearance, authorization or approval process involves all of the risks and uncertainties associated with FDA clearance, authorization or approval. We have completed a technology transfer process for research use to international sites including France, Germany, Italy, the United Kingdom, Spain, and Australia, but have no experience in obtaining regulatory clearance, authorization or approval in international markets. If we or our collaborators fail to comply with regulatory requirements in international markets or to obtain and maintain required regulatory clearances, authorizations or approvals in international markets, or if those approvals are delayed, our target market will be reduced and our ability to realize the full market potential of our products and services will be unrealized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We or our collaborators may be adversely affected by natural or man-made disasters or other business interruptions, such as cybersecurity attacks, and our business continuity and disaster recovery plans, or those of our collaborators, may not adequately protect us from the effects of a serious disaster.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Natural and man-made disasters and other events beyond our control could severely disrupt our operations, or those of our collaborators, and have a material adverse impact on our business, results of operations, financial condition and prospects. If a natural disaster, power outage, cybersecurity attack or other event occurred that prevented us from using all or a significant portion of our headquarters, damaged critical infrastructure, such as our laboratory facilities or those of our collaborators, limited our or our collaborators&#8217; ability to access or use our respective digital information systems or that otherwise disrupted our respective operations, it may be difficult or, in certain cases, impossible for us or our collaborators to continue our respective businesses for a substantial period of time. The disaster recovery and business continuity plans we and our collaborators currently have in place are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. Our cybersecurity liability insurance may not cover any or all damages, depending on the severity and extent, we or our collaborators could sustain based on any breach of our respective computer security protocols or other cybersecurity attack, including potential liability arising out of third parties&#8217; negatively impacted data privacy rights. We may incur substantial expenses as a result of the limited nature of our respective disaster recovery and business continuity plans, which could have a material adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business could be adversely affected by the effects of health epidemics, such as the recent COVID&#8209;19 pandemic, in regions where we or third parties on which we rely have significant laboratory operations, manufacturing facilities, concentrations of clinical trial sites or other business operations. Such epidemics could materially affect our operations as well as the business or operations of our manufacturers, contract research organizations or other third parties with whom we do or will need to conduct business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business could be adversely affected by global pandemics or health epidemics in regions where we have concentrations of clinical trial sites or other business operations, and such pandemics or epidemics could cause significant disruption in the operations of third-party manufacturers, suppliers, general contractors and sub-contractors related to capital projects and CROs upon whom we do or will need to rely.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Quarantines, stay at home orders and similar government orders, or the perception that such orders, shutdowns or other restrictions on business operations could occur, whether related to COVID-19 or other infectious diseases, could impact personnel at third-party manufacturing or supplier facilities in the U.S. and other countries, or the availability or cost of materials, which would disrupt our supply chain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Relating to Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We conduct our business in a heavily regulated industry, and changes in regulations or violations of regulations may, directly or indirectly, reduce our revenue, adversely affect our results of operations and financial condition and harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The life sciences industry is highly regulated, and the regulatory environment in which we and our collaborators operate may change significantly and adversely to us in the future. Areas of the regulatory environment that may affect our ability to conduct business include, without limitation, federal and state laws relating to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">laboratory testing, including CLIA and state laboratory licensing laws; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the development, testing, use, distribution, promotion and advertising of research services, kits, clinical diagnostics and pharmaceutical therapies, including certain LDTs, and related services, which are regulated by the FDA under the FDCA and the FTC; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">test ordering, documentation of tests ordered, billing practices and claims payment under CMS and the HHS OIG enforcing those laws and regulations; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cellular therapies, medical device and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> diagnostic clearance, marketing authorization or approval; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">laboratory anti-mark-up laws; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the handling and disposal of medical and hazardous waste; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fraud and abuse laws such as the False Claims Act, the AKS, EKRA, and the Stark Law; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Occupational Safety and Health Administration rules and regulations; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA and other federal and state medical data privacy and security laws; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Genetic Information Nondiscrimination Act (&#8220;GINA&#8221;) and similar state laws; and </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">coverage and restrictions on coverage and reimbursement for clinical diagnostics and pharmaceutical therapies and Medicare, Medicaid, other governmental payors and private insurers reimbursement levels. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In particular, the laws, regulations and policies governing the marketing of RUO products, LDTs and clinical diagnostic tests and services are extremely complex and are subject to interpretation by the courts and governmental agencies. Our failure to comply could lead to civil or criminal penalties, exclusion from participation in state and federal health care programs, or prohibitions or restrictions on our laboratories&#8217; ability to provide or receive payment for our services. We believe that we are in material compliance with all statutory and regulatory requirements, but there is a risk that one or more government agencies could take a contrary position, or that a private party could file suit under the qui tam provisions of the federal False Claims Act or a similar state law. Such occurrences, regardless of their outcome, could damage our reputation and adversely affect important business relationships with third parties, including managed care organizations, and other private third-party payors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The insurance coverage and reimbursement status of newly approved products, in a new category of diagnostics and therapeutics, is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for current or future products could limit our ability, and that of our collaborators, to fully commercialize our products and decrease our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford the clinical diagnostic tests and therapeutics that we and our collaborators plan to develop and sell. In addition, because our clinical diagnostics and some of our potential therapeutic products will represent new approaches to the research, diagnosis, detection and treatment of diseases, we cannot accurately estimate how our products and services, and those jointly created with our collaborators, would be priced, whether reimbursement could be obtained or any potential revenue generated. Sales of our products will depend substantially, both domestically and internationally, on the extent to which the costs of our products and services are paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize some of our products or services. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment in any of our products or services. If we adopt a self-pay strategy with respect to any products or services, we may experience similar difficulties in the establishment or maintenance of sufficiently high pricing. Changes in the reimbursement landscape may occur, which are outside of our control, and may impact the commercial viability of our products and services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly cleared, authorized or approved products and services. In the U.S., many significant decisions about reimbursement for new diagnostics and medicines are typically made by CMS, an agency within the HHS, and its contractors. CMS and its contractors decide whether and to what extent a new diagnostic or medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS policies to a substantial degree. It is difficult to predict what CMS and its contractors will decide with respect to reimbursement for novel products and services such as ours. Additionally, reimbursement agencies in Europe may be more conservative than CMS. These inherent limitations could affect our ability to realize revenues from our clinical products, including new indications addressed for clonoSEQ.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside the U.S., the reimbursement process and timelines vary significantly. Certain countries, including a number of member states of the EU, set prices and make reimbursement decisions for diagnostics and pharmaceutical products, or medicinal products, as they are commonly referred to in the EU, with limited participation from the marketing authorization or Conformit&#233; Europ&#233;ene (&#8220;CE&#8221;) mark holders, or may take decisions that are unfavorable to the authorization or CE mark holder where they have participated in the process. We cannot be sure that such prices and reimbursement decisions will be acceptable to us or our collaborators. If the regulatory authorities in these foreign jurisdictions set prices or make reimbursement criteria that are not commercially attractive for us or our collaborators, our revenues and the potential profitability of our products and services in those countries would be negatively affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An increasing number of countries, including the U.S. and the EU, are pursuing initiatives to attempt to control the healthcare budget by focusing cost-cutting efforts on medicinal products, and to a lesser extent, medical devices, provided under their state-run healthcare systems. Additionally, some countries require approval of the sale price of a product before it can be marketed or mandatory discounts or profit caps may be applied. Further, after the sale price is approved, it remains subject to review during the product lifecycle. In many countries, the pricing review period begins after marketing or product licensing approval is granted or the CE mark is obtained. As a result, we or our collaborators might obtain marketing approval for a product or service in a particular country, but then may experience delays in the reimbursement approval or be subject to price regulations that would delay the commercial launch of our product or service, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the sale of that product or service in that particular country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payors, in the U.S. and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for newly cleared, authorized or approved devices and medicines and, as a result, they may not cover or provide adequate payment for our clinical diagnostics or the cellular therapies to be sold by us or our collaborators. For example, the U.S. government introduced the Lower Drug Costs Now Act of 2019 to reduce the cost of drugs. This blueprint contains certain measures that HHS is already working to implement. In addition, the No Surprises Act (&#8220;NSA&#8221;) took effect in January 2022. One of the goals of the NSA is to protect patients from &#8220;surprise&#8221; medical bills resulting from gaps in coverage for services provided by out-of-network providers, such as laboratories, related to patient visits at in-network facilities. The NSA limits the amount out-of-network laboratories may charge a patient for laboratory services ordered during an in-network facility visit and establishes an independent dispute resolution process for determining the amount of reimbursement for the laboratory service in the event that the laboratory and insurer cannot agree on a rate. To the extent the NSA limits the price charged for our diagnostic products or cellular therapeutics, the commercial viability of those products may be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological program pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, which are, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to experience pricing pressures on our clinical diagnostics and cellular therapies sold by us and our collaborators due to the trend toward value-based pricing and coverage, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business could be harmed by the loss, suspension or other restriction on a license, certification or accreditation, or by the imposition of a fine or penalties, under CLIA, its implementing regulations or other state, federal and foreign laws and regulations affecting licensure or certification, or by future changes in these laws or regulations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal law requires virtually all clinical laboratories to comply with CLIA, which generally involves becoming certified by the federal and state government for the testing that will be performed and complying with various operational, personnel, facilities administration, quality and proficiency testing requirements intended to ensure that testing services are accurate and reliable. CLIA certification is also a prerequisite to be eligible to bill state and federal healthcare programs, as well as many private third-party payors, for laboratory research and clinical diagnostic testing services. As a condition of our CLIA certification, our Seattle, Washington laboratory is subject to survey and inspection every other year, additional random inspections and surprise inspections based on complaints received by state or federal regulators. The biennial survey and inspection is conducted by CMS, a CMS agent or, if the laboratory holds a CLIA certificate of accreditation, a CMS-approved accreditation organization, such as CAP. Sanctions for failure to comply with CLIA requirements, including proficiency testing violations, may include suspension, revocation or limitation of a laboratory&#8217;s CLIA certificate, which is necessary to conduct business, as well as the imposition of significant civil, administrative or criminal sanctions against the lab, its owners and other individuals. In addition, we are subject to regulation under certain state laws and regulations governing laboratory licensure. Some states, including Washington, have enacted laboratory licensure and compliance laws that are more stringent than CLIA. Changes in state licensure laws that affect our ability to offer and provide research and diagnostic products and services across state or foreign country lines could materially and adversely affect our business. In addition, state and foreign requirements for laboratory certification may be costly or difficult to meet and could affect our ability to receive specimens from certain states or foreign countries.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any sanction imposed under CLIA, its implementing regulations or state or foreign laws or regulations governing licensure, or our failure to renew a CLIA certificate, a state or foreign license or accreditation, could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in law relating to health insurance coverage and payment may adversely affect our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the ACA was passed, which substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. clinical diagnostic and biopharmaceutical industries. The ACA, among other things, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs and medical devices, including laboratory kits, and promoted a new Medicare Part D coverage gap discount program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some of the provisions of the ACA have been subject to judicial and Congressional challenges. It is also unclear how regulatory provisions and sub-regulatory guidance, both of which fluctuate continually, may affect interpretation and implementation of the ACA and its practical effects on our business. In addition, changes in the number of patients that can look to third-party payment to help afford our products and services may affect the demand for these products and services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict what healthcare reform initiatives may be adopted in the future. Further federal, state and foreign legislative and regulatory developments are likely, and we expect ongoing initiatives to increase downward pressure on drug and device pricing. Such reforms could have an adverse effect on anticipated revenues from our products and services, including those that we jointly develop with our collaborators, and may affect our overall financial condition and ability to develop or obtain regulatory clearance, authorization or approval for our products and services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inadequate funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability of the FDA to review and clear, authorize or approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel, and statutory, regulatory and policy changes. In addition, government funding of agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and devices to be reviewed and cleared, authorized or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We must maintain compliance with marketing authorization requirements of the FDA and equivalent foreign and state regulatory authorities for our products and services whose sale is subject to their authority and failure to maintain compliance with FDA requirements may prevent or delay the marketing of our products and services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even after we have obtained marketing authorization (as we did for clonoSEQ) we must comply with the scope of that clearance, authorization or approval. Failure to comply with those limitations or the additional, extensive and ongoing post-marketing obligations imposed by the FDA or other regulatory requirements of other regulatory agencies, such as the Clinical Laboratory Evaluation Program for New York State, could result in unanticipated compliance expenditures, a range of administrative enforcement actions, injunctions and criminal prosecution. FDA post-market obligations include, among other things, compliance with the FDA QSR, establishing registration and device listings, labeling requirements, reporting of certain adverse events and malfunctions, and reporting of certain recalls. In addition, circumstances may arise that cause us to recall equipment used in connection with our products and services. Such recalls could have an adverse effect on our ability to provide those products and services, which in turn would adversely affect our financial condition. Our collaborators will also be required to maintain FDA clearance and possibly also other authorizations or approvals for the products and services that we jointly develop. Any failure by us or our collaborators to maintain such clearance, authorization or approval could impair or cause a delay in our ability to profit from these collaborations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Products and services offered RUO may be subject to regulatory scrutiny.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain of our products are currently provided on a RUO basis, not for use in the diagnosis or treatment of disease. Pursuant to FDA guidance on RUO products, a company may not make clinical or diagnostic claims about an RUO product or provide clinical directions or clinical support services to customers of RUO products. If the FDA were to disagree with our RUO classification or modify its approach to regulating RUO products, we could experience reduced revenue or increased compliance and other costs, which could adversely affect our business, prospects, results of operations and financial condition. In the event that the FDA requires marketing authorization of our RUO products in the future, the FDA may not ultimately grant any clearance, authorization or approval requested by us in a timely manner, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future changes in FDA enforcement discretion for LDTs could subject our operations to much more significant regulatory requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to offering the cleared version of clonoSEQ as a test for MRD in certain blood cancers, we also currently offer LDT versions of this test for other indications. The FDA has a policy of enforcement discretion with respect to LDTs whereby the FDA does not actively enforce its medical device regulatory requirements for such tests. However, in October 2014, the FDA issued two draft guidance documents stating that the FDA intended to modify its policy of enforcement discretion with respect to LDTs in a risk-based manner consistent with the existing classification of medical devices. Although the FDA halted finalization of the guidance in November 2016 to allow for further public discussion on an appropriate oversight approach to LDTs and to give Congressional authorizing committees the opportunity to develop a legislative solution, it is unclear if Congress or the FDA will modify the current approach to the regulation of LDTs in a way that would subject our current or future services marketed as LDTs to the enforcement of FDA regulatory requirements. The FDA Commissioner and the Director of the Center for Devices and Radiological Health (&#8220;CDRH&#8221;) have expressed significant concerns regarding disparities between some LDTs and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> diagnostics that have been reviewed, cleared, authorized or approved by the FDA. If the FDA were to determine that NGS MRD tests offered as LDTs are not within the policy for LDTs for any reason, including new rules, policies or guidance, or due to changes in statute, our tests may become subject to extensive FDA requirements or our business may otherwise be adversely affected. If the FDA were to disagree with our LDT status or modify its approach to regulating LDTs, we could experience reduced revenue or increased costs, which could adversely affect our business, prospects, results of operations and financial condition. If required, the regulatory marketing authorization process required to bring our current or future LDTs into compliance may involve, among other things, successfully completing additional clinical validations and submitting to and obtaining clearance from the FDA for a premarket clearance (510(k)) submission or authorization for a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> de novo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or approval of a PMA. Furthermore, recently introduced legislation, if passed, such as the VALID Act, could create new or different regulatory and compliance burdens on us and could have a negative effect on our ability to develop new products, which could have a material effect on our business. In the event that the FDA requires marketing authorization of our LDTs in the future, the FDA may not ultimately grant any clearance, authorization or approval requested by us in a timely manner, or at all. In addition, if the FDA inspects our laboratory in relation to the marketing of our FDA-cleared clonoSEQ test, any enforcement action the FDA takes might not be limited to the FDA-cleared clonoSEQ test and could encompass our LDT testing service.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">For each product we are developing that requires FDA premarket review or equivalent regulatory approval, the FDA or other regulatory authority may not grant clearance, authorization or premarket approval and failure to obtain necessary approvals for our future products and services would adversely affect our ability to grow our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before we begin to manufacture, label and market additional clinical diagnostic products for commercial diagnostic use in the U.S., we may be required to obtain either clearance, marketing authorization or approval from the FDA and state regulatory authorities with jurisdiction over such products, unless an exemption applies or, in the case of the FDA, it exercises its enforcement discretion and refrains from enforcing its requirements. For example, the FDA currently has a policy of refraining from enforcing its medical device requirements with respect to LDTs, which the FDA considers to be a type of in vitro diagnostic test that is designed, manufactured and used within a single properly licensed laboratory.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process of obtaining PMA from the FDA is much more rigorous, costly, lengthy and uncertain than the 510(k) clearance process. In the PMA approval process, the FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing and labeling data. Conversely, in the 510(k) clearance process, the FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to a legally marketed &#8220;predicate&#8221; device in order for the product to be cleared for marketing. To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics or if it has different technological characteristics as the predicate device, the proposed device must be as safe and effective as, and not raise different questions of safety or effectiveness than, the predicate device. Clinical data is sometimes required to support substantial equivalence. For lower-risk devices that would otherwise automatically be placed into Class III, which require a PMA because no predicate device is available and the devices do not fall within an existing 510(k)-exempt classification, an applicant may submit a de novo request to down classify the device into Class II or Class I, which would not require a PMA. In the de novo process, the FDA must determine that general and special controls are sufficient to provide reasonable assurance of the safety and effectiveness of a device, which is low to moderate risk and has no predicate. In other words, the applicant must justify the &#8220;down-classification&#8221; to Class I or II for a new product type that would otherwise automatically be placed into Class III, but is lower risk. Clinical data may be required. For laboratory tests for which FDA clearance, authorization or approval is required, the FDA may also require data to support analytical and clinical validity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 510(k), de novo and PMA processes can be expensive and lengthy and require the payment of significant fees, unless an exemption applies. The FDA&#8217;s 510(k) clearance pathway usually takes from three to nine months from submission, but it can take longer for a novel type of product. The FDA&#8217;s de novo classification pathway usually takes from six to 12 months, but for many applicants can take up to 18 months or more.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process of obtaining a PMA generally takes from one to three years, or even longer, from the time the PMA is submitted to the FDA until an approval is obtained. Any delay or failure to obtain necessary regulatory clearances, authorizations or approvals would have a material adverse effect on our business, financial condition and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA can delay, limit or deny clearance, authorization or approval of a device for many reasons, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to demonstrate to the satisfaction of the FDA that the products are safe or effective for their intended uses; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the disagreement of the FDA with the design, conduct or implementation of the clinical trials or the analysis or interpretation of data from preclinical studies, analytical studies or clinical trials; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">serious and unexpected adverse device effects experienced by participants in clinical trials; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the data from preclinical studies, analytical studies and clinical trials may be insufficient to support clearance, authorization or approval, where required; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to demonstrate that the clinical and other benefits of the device outweigh the risks; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an advisory committee, if convened by the FDA, may recommend against approval of a PMA or other application or may recommend that the FDA require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions, or even if an advisory committee makes a favorable recommendation, the FDA may still not approve the product; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA may identify deficiencies in our marketing application; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA may identify deficiencies in our or our collaborators&#8217; manufacturing processes, facilities or analytical methods; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential for policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering clinical data or regulatory filings insufficient for clearance, authorization or approval; and </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or foreign regulatory authorities may audit clinical trial data and conclude that the data is not sufficiently reliable to support a PMA. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are numerous FDA personnel assigned to review different aspects of marketing submissions, which can present uncertainties based on their ability to exercise judgment and discretion during the review process. During the course of review, the FDA may request or require additional data and information, and the development and provision of these data and information may be time-consuming and expensive. The process of obtaining regulatory clearances, authorizations or approvals to market a medical device can be costly and time-consuming, and we may not be able to obtain these clearances, authorizations or approvals on a timely basis, or at all for our products in development. If we are unable to obtain clearance, authorization or approval for any products for which we plan to seek clearance, authorization or approval, our business may be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Modifications to our products with FDA clearance may require new FDA clearances, authorizations or approvals, or may require us to cease marketing or recall the modified clinical diagnostic products or future clinical products until clearances are obtained.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any modification to a 510(k)-cleared device that significantly affects its safety or effectiveness, or that constitutes a major change in its intended use, could require a new 510(k) clearance, a new de novo authorization or approval of a PMA. The FDA requires every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer&#8217;s decision. The FDA may not agree with our decisions regarding whether new clearances, authorizations or approvals are necessary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For any product approved pursuant to a PMA, we would be required to seek supplemental approval for many types of modifications to the approved product. The FDA requires manufacturers in the first instance to determine whether a PMA supplement or other regulatory filing is needed or whether the change may be reported via the PMA Annual Report, but may disagree with a company&#8217;s assessment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA disagrees with our determination, which it may not review until we submit an annual report or the FDA conducts an inspection or other inquiry, and requires us to seek new clearances, authorizations or approvals for modifications to our previously cleared, authorized or approved clinical diagnostic products for which we have concluded new clearances, authorizations or approvals are unnecessary, we may be required to cease marketing or distribution of these clinical diagnostic products or to recall the modified products until we obtain clearance, authorization or approval. We may also be subject to enforcement action, including, among other things, significant regulatory fines or penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, principal investigators, consultants and collaborators may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, consultants and those of our collaborators. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the U.S. and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent improper marketing, fraud, misconduct, kickbacks, bribery, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and cause serious harm to our reputation. We currently have a code of conduct applicable to all of our employees and suppliers, but it is not always possible to identify and deter misconduct. In addition, our code of conduct and the other precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses, or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such investigations or actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant fines or other sanctions, which could have a significant impact on our business. We currently have a compliance program in accordance with the elements of an effective program outlined by the HHS OIG, which could help mitigate damages, but cannot prevent all misconduct. Whether or not we are successful in defending against such actions or investigations, we could incur substantial costs, including legal fees, suffer adverse publicity and reputational harm, and have the attention of management diverted in defending ourselves against any of these claims or investigations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If third-party payors, including private payors and government healthcare programs, do not provide coverage of, or adequate reimbursement for, our clinical diagnostic products, our commercial success will be negatively affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our diagnostic revenue depends in part on achieving broad coverage and reimbursement for our diagnostic tests from payors, including both private and government payors. Certain large private payors have issued policies that decline to cover testing methods that they regard as experimental or investigational. Other payors may issue similar non-coverage policies. If payors do not provide coverage of, or do not provide adequate reimbursement for, a substantial portion of the price of our diagnostic tests, we may need to seek payment from the patient where this is not precluded by law or contract, which may adversely affect demand for our tests. Coverage determinations by a payor may depend on a number of factors, including, but not limited to, a payor&#8217;s determination that a certain diagnostic test is appropriate, medically necessary or cost-effective. If we are unable to provide payors with sufficient evidence of the clinical utility and validity of our diagnostic tests, they may not provide coverage, or may provide limited coverage, which will adversely affect our revenues and our ability to succeed. To the extent that more competitors enter our markets, the availability of coverage and the reimbursement rate for our tests and new diagnostic products may decrease as we encounter pricing pressure from our competitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each payor makes its own decision regarding coverage of our tests and the applicable payment rates, and payors may not provide adequate coverage or reimbursement for our current or future products. Although we may contract with certain payors, working with payors through contract or otherwise to assure reimbursement is time-consuming and costly and outcomes are uncertain. In addition, the determinations by a payor whether to cover our clinical diagnostic product and the amount it will reimburse for them are often made on an indication-by-indication basis. In cases where there is no coverage policy or we do not have a contracted rate for reimbursement as a participating provider, the patient is typically responsible for a greater share of the cost of the test, which may result in further delay of our revenue, increase our collection costs or decrease the likelihood of collection. Through our Adaptive Assist patient support program, we provide clonoSEQ diagnostic tests for reduced rates or without charge to eligible low-income patients that may result in payors requiring us to provide evidence of eligibility of such patients to pay reduced out-of-pocket amounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our claims for reimbursement from payors may be denied upon submission, and we may need to take additional steps to receive payment, such as appealing the denials. Such appeals and other processes are time-consuming, expensive and may not result in payment. Payors may perform audits of historically paid claims and attempt to recoup funds years after the funds were initially distributed if the payors believe the funds were paid in error or determine that our clonoSEQ diagnostic tests or other clinical diagnostic products were medically unnecessary. In addition, similar to federal payors, state and federal laws permit commercial payors to seek civil and criminal penalties against a manufacturer if they feel they have been defrauded. If a payor audits our claims and issues a negative audit finding, and we are not able to overturn the audit findings through appeal, the recoupment may result in a material adverse effect on our revenue. Additionally, in some cases commercial payors for whom we are not a participating provider may elect at any time to review claims previously paid and determine the amount they paid was too much. In these situations, the payor will typically notify us of their decision and then offset whatever amount they determine they overpaid against amounts they owe us on current claims. We do not have a mechanism to dispute these retroactive adjustments and we cannot predict when, or how often, a payor might engage in these reviews.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future Medicare payment rates are uncertain.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2020, CMS revised the National Coverage Determination (&#8220;NCD&#8221;) for molecular diagnostic laboratory testing services utilizing a NGS methodology, which includes our clinical diagnostic products, for Medicare beneficiaries with advanced cancer. CMS revised the NCD to extend specific coverage for germline (inherited) testing. CMS stated that it is continuing to make other technical, clarifying and conforming changes in the NCD manual and they are also clarifying the existing policy related to diagnostic tests for Somatic (Acquired) Cancer. If CMS were to make material revisions to policy, this could potentially impact the scope of clonoSEQ coverage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under Medicare Part B, payment for most diagnostic laboratory tests is made under the Clinical Laboratory Fee Schedule (&#8220;CLFS&#8221;), which assigns payment amounts to tests based on billing codes. Under the Protecting Access to Medicare Act of 2014 (&#8220;PAMA&#8221;), certain laboratories that receive the majority of their Medicare revenue from payments made under the CLFS or Medicare&#8217;s Physician Fee Schedule are required to report to CMS every three years, or annually for &#8220;advanced diagnostic laboratory tests,&#8221; commercial payor payment rates and volumes for tests they perform and that are assigned specific billing codes. PAMA has special provisions relating to &#8220;advanced diagnostic laboratory tests,&#8221; as defined by the statute, and these provisions affect the rate-setting at the time of launch and the periodicity of rate reporting and revision. Laboratories that fail to report the required payment information may be subject to substantial civil monetary penalties. If, in the future, clonoSEQ or any of our tests are assigned a specific code we would be required to report commercial payor payment data on those tests. Payments for tests billed under miscellaneous codes are determined by the MACs, which also have discretion to change those payment rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CMS uses the data reported by laboratories to calculate a payment rate for each CLFS test, other than those coded with miscellaneous codes and certain others, based on the volume-weighted median of the private payor rates. These rates apply for three years, except that payment rates for advanced diagnostic laboratory tests apply for one year. If we offer tests with specific codes, this apparatus will apply. Under these circumstances, Medicare&#8217;s payment rates would be determined by the rates we and other laboratories, if any, with tests that share the specific codes we use, obtain from commercial payors. In that case, if we are unable to obtain and maintain adequate reimbursement rates from commercial payors, this may adversely affect our Medicare rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some circumstances, our tests may be furnished to hospital inpatients and paid by Medicare under different rules. For example, when a specimen is obtained from a patient who is at the time classified by Medicare as a hospital inpatient, Medicare would not make a separate payment for the test and we would have to look to the hospital for payment. We do not know how often this will occur or whether hospitals will resist paying us for our tests. In this situation, Medicare coverage would be determined by the MAC for the jurisdiction where the hospital is located, which may not cover our tests.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our products, and those jointly developed with our collaborators, may in the future be subject to product or service recalls. A recall of products or services, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our or our collaborators&#8217; products or services, could have a significant adverse impact on us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA has the authority to require the recall of commercialized products or services that are subject to FDA regulation. Manufacturers may, under their own initiative, recall a product or service if any deficiency is found. The FDA requires that certain corrections and removals, including recalls intended to reduce a health risk, be reported to the FDA within ten working days of initiating such correction or removal. For reportable corrections and removals, companies are required to make additional periodic submissions to the FDA after initiating the recall, and often engage with the FDA on their recall strategy prior to initiating the recall. A government-mandated or voluntary recall by us, one of our distributors or our collaborators could occur as a result of an unacceptable health risk, component failures, failures in laboratory processes, malfunctions, manufacturing errors, design or labeling defects, or other deficiencies and issues. Recalls of any of our commercialized products or services or those jointly developed with our collaborators would divert managerial and financial resources and adversely affect our reputation, results of operations and financial condition. We may also be subject to liability claims, be required to bear other costs or take other actions that may negatively impact our future sales and our ability to generate profits. Companies are also required to maintain certain records of corrections and removals, even if these do not require reporting to the FDA. We or our collaborators may initiate voluntary recalls involving our commercialized products or services in the future that we determine do not require FDA notification. If the FDA disagrees with our determinations, they may require us to report those actions as recalls. A future recall announcement by us or our collaborators could harm our reputation with customers and negatively affect our results of operations and financial condition. In addition, the FDA or other agency could take enforcement action for failing to report the recalls when they were conducted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or our collaborators initiate a recall, including a correction or removal, for one of our commercialized products or services, issue a safety alert, or undertake a field action or recall to reduce a health risk, this could lead to increased scrutiny by the FDA, other governmental and regulatory enforcement bodies, and our or our collaborators&#8217; customers regarding the quality and safety of our products and services, and to negative publicity, including FDA alerts, press releases, or administrative or judicial actions. Furthermore, the submission of these reports could be used against us by competitors and cause customers to delay purchase decisions or cancel orders, which would harm our reputation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any additional commercialized products or any future products that obtain regulatory clearance, authorization, approval, accreditation or licensure will remain subject to regulatory scrutiny and our failure to maintain our regulatory clearances, authorizations, approvals, accreditations or licensures could adversely affect our reputation, business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we or our collaborators obtain regulatory clearance, authorization, approval, accreditation or licensure in a jurisdiction for our products and services, the applicable regulatory authority may still impose significant restrictions on the indicated uses or marketing of our products and services, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance of our or our collaborators&#8217; manufacturing and distribution. Advertising for certain devices and labeling, including promotional labeling, for all devices must comply with FDA requirements. In addition, device advertising and promotion may also be subject to other federal and state laws. For example, the FDA shares jurisdiction over the regulation of device advertising with the FTC. Advertising for devices characterized as restricted by the FDA is subject to specified FDA requirements, while advertising for non-restricted devices is regulated by the FTC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or our collaborators fail to comply with applicable regulatory requirements following clearance, authorization, approval, accreditation or licensure of any of our products and services, a regulatory agency may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initiate an inspection of our or our collaborators&#8217; facilities; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issue an untitled or warning letter asserting that we or our collaborators are in violation of law; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek an injunction or impose civil or criminal penalties or monetary fines; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspend or withdraw regulatory clearance, authorization or approval, or revoke a license or accreditation; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspend any ongoing clinical studies; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay or refuse clearance, authorization or approval of a pending regulatory submission or supplement submitted by us or our collaborators; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impose restrictions on our or our collaborators&#8217; cleared, authorized, approved, accredited or licensed products or services; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seize or recall the product or service; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">partially suspend or entirely shut down our or our collaborators&#8217; manufacturing or laboratory operations; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issue advisories or other field actions; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impose operating restrictions; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refuse to allow us or our collaborators to enter into supply contracts, including government contracts; or </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refer matters to the DOJ or other enforcement or regulatory bodies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our and our collaborators&#8217; ability to commercialize any cleared, authorized or approved products and services and generate revenues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If any of our diagnostic products or services cause or contribute to a death or serious injury, or malfunction in certain ways, we will be required to report such death, serious injury or malfunction under applicable medical device reporting regulations, and such events can result in voluntary corrective actions or agency enforcement actions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under FDA medical device reporting regulations, medical device manufacturers are required to report to the FDA information that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction of the device or one of our similar devices were to recur. If such a death, serious injury or malfunction were to occur, and we or our collaborators are unable to demonstrate that the adverse events were caused by factors other than our or our collaborator&#8217;s products and services, regulatory authorities could order us to cease further development of, or deny clearance, authorization or approval of, any of our or our collaborators&#8217; products and services for any or all targeted indications. Even if we and our collaborators are able to demonstrate that any serious adverse events are not related to our products and services, such occurrences could affect patient recruitment or the ability of enrolled trial participants to complete the trial. Moreover, if we or our collaborators elect, or are required, to delay, suspend or terminate any clinical trial of any product in development, the commercial prospects of such product in development may be harmed and our ability to generate product revenues may be delayed or eliminated. Any of these occurrences may harm our and our collaborators&#8217; ability to identify and develop future products and services, and may significantly harm our business, financial condition, result of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to various laws and regulations, such as healthcare fraud and abuse laws, false claim laws and health information privacy and security laws, among others, and failure to comply with these laws and regulations may have an adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare providers, physicians, hospitals and third-party payors often play a primary role in the recommendation and prescription of any currently marketed products and services for which we may obtain clearance, authorization or approval. Our current and future arrangements with healthcare providers, physicians, hospitals and third-party payors, and our sales, marketing and educational activities related to our products and services, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations at the federal and state level that may constrain our business or financial arrangements, and the relationships through which we market, sell and distribute our products and services. In addition, our operations are also subject to various federal and state fraud and abuse, physician payment transparency, and privacy and security laws, including, without limitation:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The AKS, which prohibits, among other things, persons and entities, including clinical laboratories, from knowingly and willfully soliciting, receiving, offering or paying remuneration, whether directly or indirectly, overtly or covertly, in case or in kind, to induce or reward or in return for either the referral of an individual or the purchase, lease, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program such as Medicare or Medicaid. The AKS has been interpreted broadly to apply to, among other things, arrangements between clinical laboratories and prescribers and purchasers of our tests. The term &#8220;remuneration&#8221; expressly includes kickbacks, bribes or rebates and has been broadly interpreted to include anything of value, including gifts, discounts, waivers of payment, ownership interests and any goods or services provided at less than their fair market value. There are several statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, however, these exceptions and safe harbors are drawn narrowly, and practices that do not fit squarely within an exception or safe harbor may be subject to scrutiny. The failure to meet all of the requirements of a particular statutory exception or regulatory safe harbor does not make the conduct</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> per se</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of the facts and circumstances to determine whether one purpose of the remuneration in the arrangement was to induce referrals or generate business that is payable by a federal healthcare program. A violation of the AKS may be grounds for the government or a whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes of the False Claims Act. Moreover, certain AKS safe harbors currently protecting rebates paid by device manufacturers to third parties and other arrangements between device manufacturers and third parties may later be modified or repealed pursuant to a pending regulatory proposal, which could require us to revisit or modify our business practices. Our practices may not meet all of the criteria for safe harbor protection from AKS liability in all cases. A person or entity does not need to have actual knowledge of the AKS or specific intent to violate any AKS provisions to have committed a violation. In addition, renumeration may not be offered or provided to beneficiaries under the monetary penalty law provision prohibiting inducements to beneficiaries.</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 8122 of the SUPPORT Act, EKRA, which establishes an all-payor anti-kickback prohibition that extends to arrangements with recovery homes, clinical laboratories and clinical treatment facilities. EKRA includes a number of statutory exceptions, and directs agencies to develop further exceptions. Current EKRA exceptions in some cases reference, and in others differ from, the AKS safe harbors. Significantly, the EKRA prohibitions apply to the soliciting or receipt of remuneration for any referrals to recovery homes, clinical treatment facilities or clinical laboratories, whether or not related to the treatment of substance use disorders. Further, the EKRA prohibitions cover the payment or offer of remuneration to induce a referral to, or in exchange for, an individual using the services of such providers. EKRA creates additional risk that relationships with referral sources could be problematic. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, which prohibits individuals or entities from, among other things, knowingly presenting, or causing to be presented, claims for payment to, or approval by, the federal government that are false, fictitious or fraudulent, or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the federal government. The False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the False Claims Act and to share in any monetary recovery. In addition, AKS violations implicate the False Claims Act. Conduct that results in a False Claims Act violation may also implicate various federal criminal statutes. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Criminal Health Care Fraud Statute, which imposes criminal and civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the AKS, a person or entity does not need to have actual knowledge or specific intent to violate the Criminal Health Care Fraud Statute. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Stark Law, which is directed at &#8220;self-referral,&#8221; prohibits, with certain exceptions, referrals for certain DHS, including laboratory services, that are covered by Medicare and Medicaid by physicians who personally, or through a family member, have an investment or ownership interest in, or a compensation arrangement with, an entity performing the tests. The prohibition also extends to payment for any testing referred in violation of the Stark Law. Because the Stark Law is a strict liability statute, proof of specific intent to violate the law is not a required element of a violation. Any person who engages in a scheme to circumvent the Stark Law&#8217;s referral prohibition may be subject to significant fines for each such arrangement or scheme. In addition, any person who presents or causes to be presented a claim to Medicare or Medicaid in violation of the Stark Law is subject to civil monetary penalties applied to each bill submission, an assessment of up to three times the amount claimed and possible exclusion from participation in federal governmental payor programs, and those claims are considered false claims for which the parties to the arrangement may be liable under the False Claims Act. Bills submitted in violation of the Stark Law may not be paid by Medicare or Medicaid, and any person collecting any amounts with respect to any such prohibited bill is obligated to refund such amounts. Many states have comparable laws that are not limited to Medicare and Medicaid referrals. The Stark Law also places an annual cap on the amount of non-monetary compensation, which consists of meal spend and educational items, that a company can spend on a physician in the aggregate. We occasionally enter into financial relationships, usually compensation relationships, such as a consulting arrangement, with physicians who refer patients for testing. If these arrangements do not meet the Stark Law&#8217;s requirements, any claims submitted to Medicare or Medicaid could violate the law and put both the physician referral source and us at risk. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The administrative simplification provisions of HIPAA, as amended and supplemented by HITECH, impose, among other things, obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of protected health information (&#8220;PHI&#8221;) held by certain healthcare providers, health plans and healthcare clearinghouses, known as covered entities, and their respective business associates. Among other things, HITECH made certain aspects of HIPAA&#8217;s rules, notably the &#8220;HIPAA Security Rule,&#8221; directly applicable to business associates, independent contractors or agents of covered entities that create, receive, maintain or transmit PHI in connection with providing a function on behalf of, or a service to, a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal court to enforce the federal HIPAA regulation and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. The HHS Office for Civil Rights (&#8220;OCR&#8221;) has increased its focus on compliance and continues to train state attorneys general for enforcement purposes. The OCR has recently increased both its efforts to audit HIPAA compliance and its level of enforcement, with one recent penalty exceeding $16 million. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GINA, which restricts employers and health insurance companies from requiring or using the results of genetic tests in specific contexts and does not provide a private right of action. A number of states have also adopted laws regarding genetic tests, some aligned with GINA and some with broader applicability, including granting broader rights to individuals and imposing strict obligations on organizations to safeguard genetic data and the results of any such testing. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Physician Payments Sunshine Act created under the ACA, and its implementing regulations, which requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the State Children&#8217;s Health Insurance Program, with certain exceptions, to annually report to HHS information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. The Physician Payments Sunshine Act has been extended to payments and transfers of value to physician assistants, nurse practitioners and other mid-level healthcare providers for payments and other transfers of value made to these practitioners. In addition, certain state and local laws may impose additional transparency and healthcare compliance requirements on medical device manufacturers, as well as certain restrictions or limits on interactions with healthcare professionals. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FTCA, which the FTC interprets to require taking appropriate steps to secure consumers&#8217; personal information and considers the failures to do so to constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the FTCA. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Medical data is considered sensitive data that merits stronger safeguards, and the FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is consistent with what is required by the HIPAA Security Rule. Some states, most notably Massachusetts and Nevada, also have adopted laws requiring the implementation of security measures to protect personal information, and all 50 states and the District of Columbia, Puerto Rico and Guam, have adopted breach notification laws. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Analogous state laws and regulations, such as state anti-kickback, self-referral and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers, and in some cases even in self-pay scenarios. In addition, some state laws require life sciences companies to comply with the industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to impose transparency requirements or restrictions on marketing activities. </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Various state, federal and foreign laws and regulations govern our ability to communicate, prospect, advertise and market our products and services through email, phone, text messages, facsimile and online methods. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the exceptions and safe harbors available under them, it is possible that certain of our business activities could be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of the ongoing interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring that business arrangements with third parties comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert management&#8217;s attention from our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our operations are found to be in violation of any of the health regulatory laws described above or any other laws that apply to us, we may be subject to penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in government healthcare programs, injunctions, private</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> qui tam</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> actions brought by individual whistleblowers in the name of the government and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our collection, use and disclosure of personal information, including health and employee information, is subject to state, federal and foreign privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The privacy and security of personal information stored, maintained, received or transmitted, including electronically, is a major issue in the U.S. and abroad. While we strive to comply with all applicable privacy and security laws and regulations, including, in our case, our own posted privacy policies, legal standards for privacy, including but not limited to &#8220;unfairness&#8221; and &#8220;deception,&#8221; as enforced by the FTC and state attorneys general, these laws and regulations continue to evolve and any failure or perceived failure to comply may result in proceedings or actions against us by government entities or others, or could cause us to lose customers, which could have a material adverse effect on our business. Recently, there has been an increase in public awareness of privacy issues in the wake of revelations about the data-collection activities of various government agencies and in the number of private privacy-related lawsuits filed against companies (including a private right of action under the CCPA and other similar state laws, as described below). Concerns about our practices with regard to the collection, use, retention, disclosure or security of personal information or other privacy-related matters, even if unfounded and even if we are in compliance with applicable laws, could damage our reputation and harm our business. Additionally, we receive personal information, including PHI from third parties, and if such third parties breach their representations to us regarding their compliance with applicable privacy and security laws, we could be exposed to proceedings or actions by government agencies or others.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Numerous foreign, federal and state laws and regulations govern the collection, dissemination, use and confidentiality of personal information, including genetic, biometric and health information, including state privacy, data security and breach notification laws, federal and state consumer protection and employment laws, HIPAA, GINA, the GDPR and other foreign data protection laws. These laws and regulations are increasing in complexity and number, may change frequently and sometimes conflict.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The HIPAA privacy, security and breach notification regulations, including the expanded requirements under HITECH, establish comprehensive federal standards with respect to the uses and disclosures of PHI by health plans, healthcare providers, including laboratories, and healthcare clearinghouses, in addition to setting standards to protect the confidentiality, integrity and security of PHI. The regulations establish a complex regulatory framework on a variety of subjects, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the circumstances under which uses and disclosures of PHI are permitted or required without a specific authorization by the patient; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a patient&#8217;s rights to access, amend and receive an accounting of certain disclosures of PHI; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirements to notify individuals if there is a breach of their unsecured PHI; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the contents of notices that must be provided to patients regarding our privacy practices for PHI; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">administrative, technical and physical safeguards required of entities that use or receive PHI; and </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the safeguarding of PHI. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Penalties for violations of these laws vary. For instance, penalties for failure to comply with a requirement of HIPAA and HITECH vary significantly, and include substantial per violation civil monetary penalties for each provision of HIPAA that is violated up to a statutory cap and, in certain circumstances, significant criminal penalties with fines per violation and potential imprisonment. A single breach can result in findings of violations of multiple provisions, leading to possible penalties in excess of any applicable cap for violations in a calendar year. Any person who knowingly obtains or discloses PHI in violation of HIPAA may face a significant criminal penalty and up to one year of imprisonment. The criminal penalties increase if the wrongful conduct involves false pretenses or the intent to sell, transfer or use identifiable health information for commercial advantage, personal gain or malicious harm. In addition, responding to government investigations or related third-party private rights of action regarding alleged violations of these and other laws and regulations, even if they ultimately result in no findings of violations or no penalties imposed, can consume our resources and impact our business and, if public, harm our reputation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Computer networks are vulnerable to breach and unauthorized persons may in the future be able to exploit weaknesses in the security systems of our computer networks and gain access to PHI. Additionally, we share PHI with third-party contractors, and while they are contractually obligated under business associate agreements to safeguard and maintain the confidentiality of PHI, their indemnification of us would not insulate us from reputational harm. Unauthorized persons may be able to gain access to PHI stored in such third-party contractors&#8217; computer networks. Any wrongful use or disclosure of PHI by us or our third-party contractors, including disclosure due to data theft or unauthorized access to our or our third-party contractors&#8217; computer networks, could subject us to fines or penalties that could adversely affect our business and results of operations. Although HIPAA and the regulations promulgated thereunder do not provide for a private right of action, we could incur damages under state laws to private parties for the wrongful use or disclosure of confidential health information or other private personal information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, various states, such as California, New York and Massachusetts, have implemented similar privacy laws and regulations (such as the California Confidentiality of Medical Information Act, California Consumer Privacy Act and California Privacy Rights Act) that impose restrictive requirements regulating the use and disclosure of personal information, while other states are considering adoption of similar provisions. These laws and regulations are not necessarily preempted by HIPAA, but they have a wider scope and afford greater protection to individuals than HIPAA. Where state laws are more protective, we and our collaborators must comply with the stricter provisions where they apply. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. The interplay of federal and state laws may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and our customers and potentially exposing us to additional expense, adverse publicity and liability. Further, as regulatory focus on privacy, security and data use issues continues to increase and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to our immune medicine platform and related products and services could intensify. Changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as PHI, along with increased customer demand for enhanced data security infrastructure, could greatly increase the cost of providing our products and services, decrease demand for our products and services, reduce our revenue and subject us to additional liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently operate in some and may eventually operate in additional countries outside of the U.S. whose laws may in some cases be more stringent than the requirements in the U.S. For example, the EU has specific requirements relating to cross-border transfers of personal data to certain jurisdictions, including to the U.S. In addition, some countries have stricter consumer notice or consent requirements relating to personal data collection, use or sharing, have more stringent requirements relating to organizations&#8217; privacy programs and provide stronger individual rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, international privacy and data security regulations are becoming more complex and may result in greater penalties. For instance, the GDPR governs the collection and use of personal data of data subjects in the EU and the EEA. The GDPR applies extra-territorially under certain circumstances and imposes stringent requirements on controllers and processors of personal data, including, for example, requirements to obtain consent or other legal bases from individuals to process their personal data, provide robust disclosures to individuals, accommodate a set of individual data rights, provide data security breach notifications after becoming aware of the breach, limit retention of personal information and apply enhanced protections to health data and other special categories of personal data. The GDPR also applies to pseudonymized data, which is defined as &#8220;the processing of personal data in such a way that the data can no longer be attributed to a specific data subject without the use of additional information,&#8221; and imposes additional obligations when we contract with third-party processors in connection with the processing of any personal data. The GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit our ability to use and share personal data, could cause our costs to increase and could harm our financial condition. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EU member states may result in substantial fines in a lump sum or a percentage of our worldwide annual turnover of our preceding fiscal year, whichever is higher, and other administrative penalties. Compliance with the GDPR requires us to put in place and maintain additional policies, procedures and documentation as the law and updates to it require, which may result in other substantial expenditures. This may be onerous and adversely affect our business. Failure to comply with the GDPR and other countries&#8217; privacy or data security-related laws, rules or regulations could result in material penalties imposed by regulators, affect our compliance with contracts entered into with our collaborators and other third-party payors, and have an adverse effect on our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The GDPR also imposes strict rules on the transfer of personal data out of the EU to the U.S. These obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other requirements or our practices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the GDPR, we continue to expand our business into several countries that have or are developing data privacy laws. Compliance with such laws may be onerous and adversely impact expansion of our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the breadth of these data protection laws and the narrowness of their exceptions and safe harbors, it is possible that our business or data protection policies could be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of heightened regulatory focus on data privacy and security issues. If our operations are found to be in violation of any of the data protection laws described above or any other laws that apply to us, we may be subject to penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in government healthcare programs, injunctions, private</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> qui tam</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> actions brought by individual whistleblowers in the name of the government, class action litigation and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corrective action plan or other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, within the U.S., an increasing number of states and the federal government are considering or have proposed adoption of new data privacy laws. While not all of these bills become law, they add significant uncertainty about additional obligations or potential penalties which we may face in conducting our business. These uncertainties are confounded by parallel changes in laws adjacent to privacy, such as those impacting machine learning and artificial intelligence or data use, and we may incur substantial expense or experience disruption as related to compliance with these laws, which would adversely affect our ability to conduct our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Security and cybersecurity breaches, loss of data and other disruptions could compromise confidential, personal and sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of our business, we and our collaborators collect and store sensitive data, including PHI, personal information, financial information, intellectual property and proprietary business information owned or controlled by ourselves or our customers, third-party payors, our collaborators, government entities, insurance companies and other parties. We manage and maintain our applications and data through a combination of on-site systems and cloud-based data centers. We utilize external security and infrastructure vendors to manage components of our data centers. We also transmit sensitive data, including patient data, telephonically, through our website and pursuant to arrangements with multiple third-party vendors and their subcontractors. These applications and data encompass a wide variety of critical business information, including research and development information, patient data, commercial information and financial information. We face a number of risks related to protecting this critical information, including loss-of-access risk, unauthorized access, use, disclosure or modification, and the risk of our inability to adequately monitor, audit and modify our respective control over our critical information. This risk extends to the data we entrust to the third-party vendors and subcontractors that help us manage this sensitive data or otherwise process it on our behalf.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The secure processing, storage, maintenance and transmission of this critical information are vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take reasonable measures to protect sensitive and proprietary data from unauthorized access, use or disclosure, no security measures can be perfect and our respective information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to employee error, malfeasance or other malicious or inadvertent disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, breach or other loss of information could result in legal claims or proceedings, liability under federal or state laws that protect the privacy of personal information, such as HIPAA or HITECH, and regulatory penalties. Notice of breaches may be required to be provided to affected individuals, the Secretary of HHS or other federal, state and foreign regulators, the media or state attorneys general. Such a notice could harm our reputation and ability to compete. Although we have implemented security measures and formal, dedicated enterprise security programs to prevent unauthorized access to patient and other personal data, including policies and procedures to safeguard us from various types of cybersecurity threats, such data is currently accessible through multiple channels and we may experience one or more data or cybersecurity breaches. Unauthorized access, loss or dissemination could also disrupt our operations and damage our reputation, which could adversely affect our results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, a growing number of states are considering or have adopted cybersecurity requirements for cloud-based provision of services which we may be required to comply with as a condition of doing business with government-affiliated organizations, such as state universities. Implementation of the controls required by such laws can be onerous and may affect our ability to provide services to government-affiliated organizations in such states, adversely affecting our results of operations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No TCR-based cellular therapies have been approved in this new potential category of medicines and may never be approved as a result of efforts by others or us. TCR-based cellular therapy drug discovery has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of immune medicines.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a potential new category of medicines, no TCR-based cellular therapies have been approved to date by the FDA or other regulatory agency. Successful discovery and development of TCR-based cellular therapies by us and our collaborators is highly uncertain and depends on numerous factors, many of which are beyond our and their control. We and our collaborators have made and will continue to make a series of business decisions and take calculated risks to advance our development efforts and pipeline of immune-driven therapeutic product candidates, including those related to TCR-based cellular therapies, delivery technology and manufacturing processes, which may be shown to be incorrect based on further work by us, our collaborators or others. Our cellular therapeutics product candidates that appear promising in the early phases of development may fail to advance, experience delays in the clinic, experience clinical holds or fail to reach the market for many reasons, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">discovery efforts identifying potential TCR-based cellular therapies may not be successful; </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nonclinical or preclinical study results may show potential TCR-based cellular therapies to be less effective than desired or to have harmful or problematic side effects; </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trials may fail to meet one or more endpoints, or results may show the TCR-based cellular therapies to be less effective than expected or to have unacceptable side effects or toxicities; </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse effects relating to any one of our therapeutic product candidates or adverse effects relating to our therapeutics discovery process may lead to delays in or termination of one or more of our products or services; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability of our translational models to reduce risk or predict outcomes in humans, given that each component of our therapeutic product candidates may have a dependent or independent effect on safety, tolerability and efficacy, and that such effects may, among other things, be species-dependent; </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing failures or insufficient supply of current good manufacturing practices (&#8220;cGMP&#8221;) materials for future clinical trials, or higher than expected cost, could delay or set back clinical trials or make TCR-based cellular therapies commercially unattractive; </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our collaborators&#8217; improvements in the manufacturing processes for this new class of potential immune medicines may not be sufficient to satisfy the clinical or commercial demand of our jointly developed TCR-based cellular therapies or regulatory requirements for clinical trials; </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes that we or our collaborators make to optimize manufacturing, testing or formulating of cGMP materials could impact the safety, tolerability and efficacy of our therapeutic products in development; </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pricing or reimbursement issues or other factors that delay clinical trials or make any TCR-based cellular therapies uneconomical or noncompetitive with other therapeutic products; </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to timely advance our or our collaborators&#8217; therapeutic products or receive the necessary regulatory clearances, authorizations or approvals or a delay in receiving such clearances, authorizations or approvals due to, among other reasons, slow or failure to complete enrollment in clinical trials, withdrawal by trial participants from trials, failure to achieve trial endpoints, additional time requirements for data analysis, data integrity issues, Biologics License Application or the equivalent application, discussions with the FDA or the European Medicines Agency, a regulatory request for additional nonclinical or clinical data, or safety formulation or manufacturing issues may lead to our inability to obtain sufficient funding; and </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the proprietary rights of others and their competing products and services that may prevent our TCR-based cellular therapies from being commercialized or threaten future commercialization activities. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Relating to our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be successful in obtaining or maintaining sufficient intellectual property protection for our products, services and technologies and uses thereof, and the scope of the intellectual property protection obtained may not be sufficiently broad.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is the case with other companies engaged in the life sciences industry, our success depends in large part on our ability to obtain and maintain protection of the intellectual property we may own solely and jointly with others, or license from third parties, particularly patents, in the U.S. and other countries with respect to our products, services and technologies. We rely on patent protection in addition to trademark, copyright, trade secret and other intellectual property rights protection and contractual restrictions to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or enable us to gain or maintain any competitive advantage. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us. In addition, we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct competition. If our intellectual property does not provide adequate barriers to competition, our competitive position could be adversely affected, as could our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We apply for and have in-licensed patents covering our products and technologies and uses thereof, as we deem appropriate. However, obtaining and enforcing patents is costly, time-consuming and complex, and we may fail to apply for patents on important products, services and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions. We may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications or to maintain the rights to patents licensed from third parties. Consequently, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we own or have rights to more than 450 active patents and patent applications filed in the U.S., Europe and elsewhere. Of these, there are more than 55 pending patent applications. Our pending patent applications may not result in issued patents in a timely fashion or at all. Even if patents are granted, they may not provide a basis for intellectual property protection of commercially viable products or services, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties. It is also possible that others will design around our current or future patented technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some of our patents, licensed patents or patent applications may be challenged in the future, and we may not be successful in defending any such challenges. For example, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;), or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights. Any successful third-party challenge to our patents could result in patent claims being narrowed, or patents being invalidated or held unenforceable, in whole or in part, which could lead to increased competition to our business. Conversely, we may have to challenge the patents or patent applications of third parties. The outcome of patent litigation or other proceeding can be uncertain, and any attempt by us to enforce our patent rights against others or to challenge the patent rights of others may not be successful, or, if successful, may take substantial time and result in substantial cost, and may divert our efforts and attention from other aspects of our business. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products or services. The patent positions of biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. Inconsistent policies regarding the eligibility for patent protection and the breadth of patentable claims in such companies&#8217; patents has emerged to date in the U.S. or elsewhere. Courts frequently render opinions in the biotechnology field that may affect the patentability of certain inventions or discoveries, including opinions that may affect the patentability of diagnostic methods and biological molecules.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent position of companies engaged in the development and commercialization of clinical diagnostic tests (like our clonoSEQ diagnostic test) and of biologic material (such as TCRs) are particularly uncertain. Various courts, including the U.S. Supreme Court, have rendered decisions that affect the eligibility and scope of patentability of certain inventions or discoveries relating to certain diagnostic tests, naturally-occurring molecules and related technology. These decisions state, among other things, that a patent claim that recites an abstract idea, natural phenomenon or law of nature (for example, the relationship between particular immune receptors and cancer) may not be patentable. Precisely what constitutes a law of nature is uncertain, and it is possible that certain aspects of our clinical diagnostics would be considered natural laws. The evolving case law in the U.S. may adversely affect our ability to obtain patents or defend patents we have obtained or have licensed and may facilitate third-party challenges to any owned or licensed patents. The laws of some foreign countries do not protect intellectual property rights to the same extent or for the same subject matter as the laws of the U.S., and we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patents in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Filing, prosecuting and defending patents on our products and services in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S., and we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patents in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in patent law in the U.S. and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products and services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in either the patent laws or in interpretations of patent laws in the U.S. or other countries or regions may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. In addition, a third party that files a patent application before us could be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the U.S. and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either file any patent application related to our products or services or invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties may also submit prior art to the USPTO during patent prosecution to attack the validity of a patent and it is also possible in the U.S. and other countries for third parties to challenge granted patents through Patent Office proceedings such as, in the U.S., post-grant review, inter partes review and derivation proceedings. In the U.S., a lower evidentiary standard is imposed in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim. As such, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent U.S. Supreme Court rulings have also narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations, including with respect to naturally occurring biological molecules such as the immune cell receptors which are a focus of our immune medicine platform. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Issued patents covering our products and services could be found invalid or unenforceable if challenged.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and some of our patents or patent applications, including licensed patents, may be challenged, in courts or patent offices in the U.S. and abroad, in opposition, derivation, reexamination, inter partes review, post-grant review or interference. Additionally, if we and our licensing partners initiate or become involved in legal proceedings against a third party to enforce a patent covering one of our products or technologies, the defendant could counterclaim that the patent covering our product is invalid or unenforceable. In patent litigation in the U.S., counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including patent eligible subject matter, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. In addition, the U.S. now awards patent priority to the first party to file a patent application, and others may submit patent claims covering our inventions prior to us. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. A successful third-party challenge to our patents could result in the unenforceability or invalidity of such patents, which could have a material adverse impact on our business. Furthermore, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products and services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be aware of all third-party intellectual property rights potentially relating to our immune medicine platform, products and services. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until approximately 18 months after filing or, in some cases, not until such patent applications issue as patents. We might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO. The outcome of such proceedings is uncertain, and other patent applications may have priority over our patent applications. Such proceedings could also result in substantial costs to us and divert our management&#8217;s attention and resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on a third party license in relation to certain sequencing technology and if we lose these licenses then we may be subjected to future litigation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a party to a license agreement that grants us rights to use certain intellectual property, including patents and patent applications, typically in certain specified fields of use. Some of those licensed rights could provide us with freedom to operate for aspects of our products and services. We may need to obtain additional licenses from others to advance our research, development and commercialization activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success may depend in part on the ability of our licensor to obtain, maintain and enforce patent protection for our licensed intellectual property. Our licensor may not successfully prosecute the patent applications we license. Even if patents issue in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether, and the extent to which, our products, services, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our right to sublicense patent and other rights to third parties under collaborative development relationships; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators; and </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the priority of invention of patented technology. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we do not prevail in such disputes, we may lose any or all of our rights under such license agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the agreement under which we currently license intellectual property or technology from third parties is complex and certain provisions in such agreements may be susceptible to multiple interpretations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to patent protection, we take steps to protect our intellectual property and proprietary technology by entering into agreements, including confidentiality agreements, non-disclosure agreements and intellectual property assignment agreements, with our employees, consultants, collaborators, academic institutions, life sciences research partners and, when needed, our advisers as well as other third parties. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure. If we are required to assert our rights against such party, it could result in significant cost and distraction. Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable. In addition, courts outside the U.S. may be less willing to protect trade secrets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems. Besides the possibility that these security measures could be breached, such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may also not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain former employees have obtained employment with companies or academic institutions that could be considered competitive with us. This competition may be limited by contractual provisions which may or may not be enforceable by us in certain jurisdictions. In addition, we may not be aware of such competitive employment arrangements until after our trade secrets have been disclosed to potentially competitive companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We employ, and expect to employ in the future, individuals who were previously employed at universities or other companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers or other third parties, or to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. A loss of key research personnel work product could hamper or prevent our ability to commercialize potential products and services, which could harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to protect and enforce our trademarks.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not yet registered certain of our trademarks in all of our potential markets, although we have registered Adaptive Biotechnologies, our corporate logo, clonoSEQ, pairSEQ and other trademarks in the U.S., the EU and a number of other countries and are seeking to register additional trademarks, including our new corporate logos and certain slogans. As we apply to register our unregistered trademarks in the U.S. and other countries, our applications may not be allowed for registration in a timely fashion or at all, and our registered trademarks may not be maintained or enforced. In addition, opposition or cancellation proceedings may be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. In certain countries outside of the U.S., trademark registration is required to enforce trademark rights. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets or other intellectual property as an inventor or co-inventor. Ownership disputes may arise, for example, from conflicting obligations of employees, consultants or others who are involved in developing our future products and services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Litigation may be necessary to defend against these and other claims by a third party challenging inventorship of our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product or services. Alternatively, we may need to obtain one or more additional licenses from the third party which will be time-consuming and expensive and could result in substantial costs and diversion of resources and could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we become involved in patent litigation or other proceedings related to a determination of rights, we could incur substantial costs and expenses, substantial liability for damages or be required to stop our development and commercialization efforts of our products and services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is a substantial amount of litigation, both within and outside the U.S., involving patent and other intellectual property rights in the life sciences, clinical diagnostics and drug discovery industries, including patent infringement lawsuits, declaratory judgment litigation and adversarial proceedings before the USPTO, including interferences, derivation proceedings, ex parte reexaminations, post-grant review and inter partes review, as well as corresponding proceedings in foreign courts and foreign patent offices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are currently involved in appeals by us or the opponent from Opposition Proceedings at the European Patent Office related to four of our patents: EP2364368, EP2387627, EP3059337, and EP3144673. We may, in the future, become involved with litigation or actions at the USPTO or foreign patent offices with various third parties. We expect that the number of such claims may increase as our industry expands, more patents are issued, the number of products or services increases and the level of competition in our industry increases. Any infringement claim, regardless of its validity, could harm our business by, among other things, resulting in time-consuming and costly litigation, diverting management&#8217;s time and attention from the development of our business, requiring the payment of monetary damages (including treble damages, attorneys&#8217; fees, costs and expenses) or royalty payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It may be necessary for us to pursue litigation or adversarial proceedings before the patent office in order to enforce our patent and proprietary rights or to determine the scope, coverage and validity of the proprietary rights of others. The outcome of any such litigation might not be favorable to us, and even if we were to prevail, such litigation could result in substantial costs and diversion of resources and could have a material adverse effect on our business, operating results or financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we move into new markets and expand our products or services offerings, incumbent participants in such markets may assert their patents and other proprietary rights against us as a means of slowing our entry into such markets or as a means to extract substantial license and royalty payments from us. In addition, future litigation may involve patent holding companies or other adverse patent owners who have no relevant product or service revenue and against whom our own patents may provide little or no deterrence or protection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties may assert that we are employing their proprietary technology without authorization. Given that clinical diagnostics and drug discovery fields are intense and highly competitive areas, there may be third-party intellectual property rights that others believe could relate to our immune medicine platform, products and services. One or more third-party patent owners or licensees may pursue or threaten to pursue litigation against us to enforce one or more patents. It would be costly and time-consuming to defend such claims.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our current or future products, technologies and services may infringe. We cannot be certain that we have identified or addressed all potentially significant third-party patents in advance of an infringement claim being made against us. In addition, similar to what other companies in our industry have experienced, we expect our competitors and others may have patents or may in the future obtain patents and claim that making, having made, using, selling, offering to sell or importing our products or services infringes these patents. Defense of infringement and other claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell products or services and could result in the award of substantial damages against us, including treble damages, attorneys&#8217; fees, costs and expenses if we are found to have willfully infringed. In the event of a successful claim of infringement against us, we may be required to pay damages and ongoing royalties and obtain one or more licenses from third parties, or be prohibited from selling certain products or services. We may not be able to obtain these licenses on acceptable or commercially reasonable terms, if at all, or these licenses may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we could encounter delays in product or service introductions while we attempt to develop alternative products or services to avoid infringing third-party patents or proprietary rights. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing products or services, and the prohibition of sale of any of our products or services could materially affect our business and our ability to gain market acceptance for our products or services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our agreements with some of our customers, suppliers or other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results or financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our products and services for an adequate amount of time.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our products and services are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new products and services, patents protecting such products and services might expire before or shortly after such products and services are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Relating to our Common Stock and Capital Structure</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The market price of our common stock is volatile and is likely to continue to fluctuate substantially.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market price of our common stock has been and is likely to continue to be highly volatile, with a 52-week high closing price of $10.11 and a 52-week low closing price of $3.46, and may fluctuate substantially due to many factors, many of which are beyond our control. These factors include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the commencement or termination of our collaborations; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of achievement of specified milestones in the development of our products and services; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">introductions of new or expanded products or services or new pricing policies by us or by our competitors; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the status of our regulatory clearances, authorizations, approvals or applications, or those jointly developed with our collaborators; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">where required, the results of clinical trials of our future products and services, those jointly developed with our collaborators or those of our competitors; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of competitive products or technologies; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, collaborators or divestitures; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in governmental regulations and regulatory or legal developments in the U.S. and other countries; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments or disputes concerning patent applications, issued patents or other proprietary rights; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the recruitment or departure of key personnel; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">variations in our financial results or those of companies that are perceived to be similar to us; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market conditions in the life sciences, clinical diagnostics or drug discovery industry; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general economic, industry and market conditions; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales of our securities, including sales by our directors, officers or significant shareholders; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">speculation about our business in the media or the investment community; and </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other factors, including factors unrelated to our operating performance or the operating performance of our competitors. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In recent years, the stock markets generally have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of listed companies. If the market for stock in our industry or the stock market in general experiences uneven investor confidence, the market price of our common stock could decline for reasons unrelated to our business, operating results or financial condition. The market price of our common stock might also decline in reaction to events that affect other companies within, or outside, our industry even if these events do not directly affect us. Any decline in the market price of our common stock may impair our ability to raise capital through the sale of equity securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the past, securities class action litigation has often been instituted against companies following periods of volatility in their stock price. This type of litigation, if instituted against us, could result in substantial costs to us and divert our management&#8217;s attention and resources, which could seriously harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Purchase Agreement with OrbiMed could limit cash flow available for our operations and expose us to risks that could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our obligations under the Purchase Agreement could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requiring the dedication of a portion of our cash flow from operations to service the Purchase Agreement obligations, which will reduce the amount of cash available for other purposes, and if our cash inflows and capital resources are insufficient to allow us to make required payments, we may have to reduce or delay additional investments in our operations or seek additional capital;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increasing our vulnerability to adverse economic and industry conditions;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limiting our ability to obtain additional financing;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital; and</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if we fail to comply with the terms of the Purchase Agreement, resulting in an event of default that is not cured or waived, the Purchasers could seek to enforce their security interest. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Purchase Agreement contains customary affirmative and negative non-financial covenants and events of default, including covenants and restrictions that, among other things, grant a first-position security interest in our core assets and restrict our ability to incur liens, incur additional indebtedness, make loans and investments, make certain restricted payments or transfer core assets. Additionally, the Purchasers under the Purchase Agreement have an option (the "Put Option") to terminate the Purchase Agreement and to require us to repurchase future Revenue Interests at a price of 120% to 175% of Cumulative Purchaser Payments, less the sum of all Revenue Interest Payments made by us to the Purchasers prior to such date, upon enumerated events such as a bankruptcy event, a material judgment against us, a material divestiture or a change of control. The triggering of the Put Option, including by our failure to comply with these covenants, could permit the Purchasers to declare certain amounts to be immediately due and payable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If securities analysts do not publish research or reports about our business, or we are the subject of negative publicity, the price of our stock could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts publish about us or our business. We do not control these analysts. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable evaluations of our company or our stock, the price of our stock could decline. If one or more of these analysts cease coverage of our company or fail to publish reports covering our company regularly, our stock may lose visibility in the market, which in turn could cause our stock price to decline. In addition, if we are the subject of negative publicity, whether from an analyst, academic, industry group or the general or financial press, our stock price may decline.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating results could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. If our assumptions change or if actual circumstances differ from our assumptions, our operating results may be adversely affected and could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock and potentially impair our ability to raise capital through the sale of equity securities.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Substantial future sales or perceived potential sales of our common stock or other equity securities in the public market could cause the price of our common stock to decline significantly.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales of substantial amounts of our common stock or other equity securities in the public market, particularly by our directors, executive officers and significant shareholders, including upon the expiration of any lock-up periods entered into in connection with offerings of our common stock or other equity securities, or the perception that these sales could occur, could materially and adversely affect the price of our common stock and impair our ability to raise capital through the sale of equity securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to financial reporting and other requirements for which our accounting and other management systems and resources may not be adequately prepared.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.551%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (&#8220;Section 404&#8221;), we are required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. Our compliance with Section 404 necessitates that we incur substantial accounting expense and expend significant management efforts. We will continue to dedicate internal resources, potentially engage outside consultants, and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our consolidated financial statements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also required to maintain disclosure controls and procedures. Disclosure controls and procedures means our controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC. We do not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. We believe a control system, no matter how well-designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and any design may not succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Evolving expectations around corporate responsibility practices, specifically related to environmental, social and governance (&#8220;ESG&#8221;) matters, may expose us to reputational and other risks.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investors, shareholders, customers, suppliers and other third parties are increasingly focusing on ESG and corporate social responsibility endeavors and reporting. Certain institutional investors, investment funds, other influential investors, customers, suppliers and other third parties are also increasingly focused on ESG practices. In particular, third party proxy advisory services which focus on shareholder rights provisions, such as majority voting, annual election of directors, and overboarding of outside directors, have recommended against voting for our directors in past elections as a result of our governance profile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Companies that do not adapt to or comply with the evolving investor or stakeholder expectations and standards, or which are perceived to have not responded appropriately, may suffer from reputational damage and result in the business, financial condition and/or stock price of a company being materially and adversely affected. Further, this increased focus on ESG issues may result in new regulations and/or third-party requirements that could adversely impact our business, or certain shareholders reducing or eliminating their holdings of our stock. Additionally, an allegation or perception that we have not taken sufficient action in these areas could negatively harm our reputation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Companies across all industries are facing increasing scrutiny relating to their ESG policies. If we are perceived to have not responded appropriately to the growing concern for governance issues, investors may reconsider their capital investment as a result of their assessment of our practices, and our reputation, business, financial condition, results of operations and cash flows may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Provisions in our charter documents and Washington law could make an acquisition of our company more difficult and limit attempts by our shareholders to replace or remove our current management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated articles of incorporation (&#8220;Articles of Incorporation&#8221;) and our amended and restated bylaws (&#8220;Bylaws&#8221;), as well as Washington law, contain provisions that may have the effect of deterring takeovers or delaying or preventing a change in control of us or changes in our management that a shareholder might deem to be in his or her best interest. Our Articles of Incorporation and Bylaws contain provisions that:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">authorize &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors without shareholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock; </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">create a classified board of directors whose members serve staggered three-year terms, with one class being elected each year by our shareholders; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">specify that special meetings of our shareholders can be called only by our board of directors, the Chairperson of our board of directors, our chief executive officer or our president; </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide that a director may only be removed from the board of directors for cause and then only by the affirmative vote of our shareholders; </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even if less than a quorum; </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">specify that only our board of directors may change the size of our board of directors; </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish an advance notice procedure for shareholder proposals to be brought before an annual meeting of our shareholders, including proposed nominations of persons for election to our board of directors; </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">specify that no shareholder is permitted to cumulate votes at any election of directors; </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expressly authorize our board of directors to modify, alter or repeal our Bylaws; and </span></div></div>
  <div style="margin-left:7.87%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.462824270053186%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require supermajority votes of the holders of our common stock to amend specified provisions of our Articles of Incorporation and Bylaws. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management or our board of directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, because we are incorporated in the State of Washington, we are governed by the provisions of Chapter 23B.19 of the Washington Business Corporation Act (&#8220;WBCA&#8221;), which prohibits certain business combinations between us and certain significant shareholders unless specified conditions are met. These provisions may also have the effect of delaying or preventing a change in control of our company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any provision of our Articles of Incorporation or Bylaws or Washington law that has the effect of delaying or deterring a change in control could limit the opportunity for our shareholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Articles of Incorporation provide that the state courts located in King County, Washington and, to the extent enforceable, the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our shareholders, which could limit our shareholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Articles of Incorporation provide that, unless we consent in writing to the selection of an alternative forum, the state courts located in King County, Washington (or, if the state courts located within King County, Washington do not have jurisdiction, the federal district court for the Western District of Washington) shall be the sole and exclusive forum for commencing and maintaining any proceeding (1) asserting a claim based on a violation of a duty under the laws of the State of Washington by any of our current or former directors, officers or shareholders in such capacity, (2) commenced or maintained in the right of our corporation, (3) asserting a claim arising pursuant to any provision of the WBCA, our Articles of Incorporation or our Bylaws (as either may be amended from time to time) or (4) asserting a claim concerning our internal affairs that is not included in clauses (1) through (3) above, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants. These provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Articles of Incorporation provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended (&#8220;Securities Act&#8221;), subject to applicable law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions. Our exclusive forum provision will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our shareholders will not be deemed to have waived our compliance with these laws, rules and regulations. These exclusive-forum provisions may limit a shareholder&#8217;s ability to bring a claim in a judicial forum of its choosing for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees or cause shareholders to incur additional costs to bring claims in the forums designated in our Articles of Incorporation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a court were to find these exclusive-forum provisions in our Articles of Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm our results of operations. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a jurisdiction other than those designated in the exclusive forum provision, and the provision may not be enforced by a court in that jurisdiction. It is unclear whether Washington courts would reach a similar conclusion under Washington law. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Articles of Incorporation provide that we will indemnify our directors and officers to the fullest extent permitted by Washington law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, as permitted by Section 23B.08.510 through Section 23B.08.570 of the WBCA, our Articles of Incorporation and our indemnification agreements that we have entered into with most of our directors and officers provide that:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Washington law. Washington law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to our best interests and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification; </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The rights conferred in our Articles of Incorporation are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and </span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not retroactively amend our Articles of Incorporation provisions to reduce our indemnification obligations to directors, officers, employees and agents. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business, and do not anticipate paying any cash dividends on our common stock for the foreseeable future. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1B. Un</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">resolved Staff Comments</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1C. Cybersecurity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As trusted partners to healthcare providers, patients, biopharmaceutical companies, academic and non-profit institutions, business partners and employees, we appreciate the importance of maintaining a comprehensive and trustworthy information security program. Our information security program is fully integrated into our operations, and a hallmark of our program is its cross-functional approach with our internal privacy objectives and stakeholders.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our cybersecurity program is based on the ISO 27001 security controls set, and in particular, it focuses on the principles of confidentiality, integrity and availability. We maintain an ISO 27001 certification with a fully integrated set of operational policies and procedures to adhere to the 14 domains of ISO 27001. This includes but is not limited to the organization of information security to assign roles and responsibilities within Adaptive, access control to restrict employees&#8217; access to view only that information that is relevant to their roles, information security incident management, and compliance to broadly ensure alignment with applicable laws and regulations. We perform an annual risk assessment conducted by an outside assessor and operate a vendor risk assessment program for third party vendors to evaluate how their systems may impact our business in the event of a cybersecurity incident. We also provide annual, mandatory cybersecurity training for employees to equip our workforce with the knowledge to identify and respond to cybersecurity threats, such as phishing attempts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The internal body with executive oversight of our cybersecurity program is our Privacy and Information Security Steering Committee (&#8220;PISSC&#8221;), which applies a multidisciplinary framework to cybersecurity risks and risk assessment by integrating information security, privacy and human resources expertise, oversight and reporting. The PISSC is made up of our Head of Security, Privacy Officer, Chief Operations Officer, Chief Financial Officer, General Counsel and Chief People Officer and meets on a quarterly basis. Our Head of Security is a senior information security professional with more than 20 years of experience implementing and leading security programs. Our Head of Security holds an undergraduate degree in computer science, has a Six Sigma certification in Total Quality Management and is a Certified Information Systems Security Professional (&#8220;CISSP&#8221;).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our board of directors is kept apprised of cybersecurity risks and assessments through regular presentations to the Audit Committee regarding our information security and privacy governance and reports on information security and privacy incidents. Cybersecurity threats, including as a result of any past cybersecurity incidents, have not materially affected us, including our business strategy, results of operations or financial condition. For more information regarding how cybersecurity risks may affect us, see the &#8220;Risk Factors&#8221; section.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Pr</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">operties</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our corporate headquarters is located in Seattle, Washington, where we lease approximately 100,000 square feet. The lease expires in August 2033, subject to our option to twice extend the lease for five years. In a separate Seattle, Washington location, we lease approximately 65,500 square feet pursuant to a lease that expires October 2032, subject to our option to twice extend the lease for five years. Both of our Seattle, Washington locations contain office and laboratory space.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also lease approximately 27,000 square feet of a warehouse in Bothell, Washington. The lease expires in October 2031, subject to an early termination option in 2028 and an option to twice extend the lease for five years.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we lease approximately 33,300 square feet of laboratory and office space in South San Francisco, California, pursuant to an amended lease that expires March 2026, subject to our option to extend the lease for five years.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also lease approximately 3,100 square feet of office space in New York City, New York, pursuant to a lease that expires November 2025.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Legal</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Proceedings</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Mine Safe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ty Disclosures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T II</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stoc</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">kholder Matters and Issuer Purchases of Equity Securities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market Information for Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock began trading on The Nasdaq Global Select Market under the symbol &#8220;ADPT&#8221; on June 27, 2019. Prior to that date, there was no public trading market for our common stock.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders of Record</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 23, 2024, there were approximately 85 holders of record of our common stock. Because many of our shares of common stock are held by brokers and other institutions on behalf of shareholders, we are unable to estimate the total number of shareholders represented by these record holders.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividend Policy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently intend to retain all available funds and any future earnings to fund the growth and development of our business. We do not intend to pay cash dividends to our shareholders in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. Our future ability to pay cash dividends on our common stock may also be limited by the terms of any future debt securities, preferred stock or credit facility.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock Performance Graph</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The graph below compares the cumulative total shareholder return on our common stock with the cumulative total return on the NASDAQ Composite Index and the NASDAQ Biotechnology Index. The graph assumes $100 was invested in our common stock at the market close on June 27, 2019, which was our initial trading day. Data for the NASDAQ Composite Index and the NASDAQ Biotechnology Index assume reinvestment of dividends. The offering price of our common stock in our initial public offering, which had a closing stock price of $40.30 on June 27, 2019, was $20.00 per share. The stock price performance below is based upon historical data and is not necessarily indicative of, nor intended to forecast, future performance of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img63237988_6.jpg" alt="img63237988_6.jpg" style="width:582px;height:286px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This graph shall not be deemed to be &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC for purposes of Section 18 of the Exchange Act or incorporated by reference into any filing of Adaptive Biotechnologies Corporation under the Securities Act or the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6. [Re</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">served]</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7. Management</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with the consolidated financial statements and related notes and the other financial information appearing elsewhere in this Annual Report on Form 10-K, as well as the other financial information we file with the Securities and Exchange Commission (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SEC</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">) from time to time. Some of the information contained in this discussion and analysis or set forth elsewhere in this report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties relating to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">This section generally discusses 2023 and 2022 items and year-to-year comparisons between 2023 and 2022. Discussions of 2021 items and year-to-year comparisons between 2022 and 2021 may be found in Part II, Item 7 under the caption </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 14, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature&#8217;s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient&#8217;s immune system and understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database and related antigen annotations, which are underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that can be tailored to the needs of individual patients. Our existing and future commercial products and services are aligned to two business areas which we refer to as MRD and Immune Medicine.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current product and service offerings in MRD related to the MRD market are our clonoSEQ clinical diagnostic test, offered to clinicians, and our clonoSEQ or MRD assay, offered to biopharmaceutical partners to advance drug development efforts (&#8220;MRD Pharma&#8221;). Our first clinical diagnostic product, clonoSEQ, is the first test authorized by the FDA for the detection and monitoring of MRD in patients with MM, B cell ALL and CLL, and is also available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers, including DLBCL. With the use of clonoSEQ, we are transforming how lymphoid cancers are treated by working with providers, pharmaceutical partners and payors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immune Medicine leverages our proprietary ability to sequence, map, pair and characterize TCRs and BCRs at scale to drive opportunities in cancer, autoimmune disorders, infectious diseases and neurodegenerative disorders. Our core research product, Adaptive Immunosequencing, serves as our underlying research and development engine and generates revenue from biopharmaceutical and academic customers. Leveraging our collaboration with Microsoft, we are creating the TCR-Antigen Map. We are using the TCR-Antigen Map to identify and validate disease signatures to improve the diagnosis and treatment of many diseases. In Drug Discovery, we use our proprietary capabilities to discover new drug targets and leverage our validated TCR and BCR discovery approaches to discover and develop TCR or antibody therapeutic assets. Drug Discovery includes the Genentech Agreement. Part of our strategy within Immune Medicine is to develop a diagnostic test for many diseases from a single blood test, known as T-Detect. In 2022, we decided to defer further commercialization of T-Detect until we have strong enough data in multiple disease states to impact physician behavior with a clear path to reimbursement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognized revenue of $170.3 million and $185.3 million for the year ended December 31, 2023 and 2022, respectively. Net loss attributable to Adaptive Biotechnologies Corporation was $225.3 million and $200.2 million for the year ended December 31, 2023 and 2022, respectively. We have funded our operations to date principally from the sale of convertible preferred stock and common stock and, to a lesser extent, revenue and proceeds from the Purchase Agreement. As of December 31, 2023 and 2022, we had cash, cash equivalents and marketable securities of $346.4 million and $498.2 million, respectively.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Components of Results of Operations</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We derive revenue by providing diagnostic and research services in our Immune Medicine and MRD business areas. Our Immune Medicine revenue consists of revenue generated from (1) providing sample testing services for our commercial research product, Adaptive Immunosequencing, to biopharmaceutical customers and academic institutions; (2) our collaboration agreements with Genentech and other biopharmaceutical customers in areas of drug and target discovery; and (3) for prior years, providing our T-Detect COVID tests to clinical customers. Our MRD revenue consists of revenue generated from (1) providing our clonoSEQ report to clinical customers; (2) providing MRD sample testing services to biopharmaceutical customers and certain academic institutions, including investigator-led clinical trials; and (3) providing our clonoSEQ report or results to certain international laboratory sites through technology transfers. We disclose our clonoSEQ test volume, which includes the number of clonoSEQ reports and results we have provided to ordering physicians in the U.S. and international technology transfer sites. These volumes do not include sample results from our biopharmaceutical customers or academic institutions utilizing our MRD services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For our research customers, which include biopharmaceutical customers and academic institutions for both our Adaptive Immunosequencing and MRD services, delivery of the respective test results may include some level of professional support and analysis. Terms with biopharmaceutical customers generally include non-refundable payments made in advance of services (&#8220;upfront payments&#8221;), which we record as deferred revenue. For all research customers, we recognize revenue as we deliver sequencing results. From time to time, we offer discounts in order to gain rights and access to certain datasets. Revenue is recognized net of these discounts and costs associated with these services are reflected in cost of revenue. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the total samples expected to be delivered. Certain of our MRD revenue arrangements with biopharmaceutical customers include cash consideration from the achievement of regulatory milestones of the respective biopharmaceutical customers&#8217; therapeutics. Such revenue is constrained from recognition until it becomes probable that such milestone will be achieved.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under certain agreements with our biopharmaceutical customers who seek access to our platform to support their therapeutic development activities, revenues are generated from research and development support services that we provide. These agreements may include substantial non-refundable upfront payments, which we recognize over time as we perform the respective services. Revenue recognized from these activities relate primarily to the Genentech Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For our clinical customers, we primarily derive revenue from providing our clonoSEQ report to ordering physicians. We bill commercial, government and medical institution payors based on reports delivered to ordering physicians. Amounts paid for clonoSEQ by commercial, government and medical institution payors vary based on respective reimbursement rates and patient responsibilities, which may differ from our targeted list price. We recognize clinical revenue by evaluating customer payment history, contracted reimbursement rates, if applicable, and other adjustments to estimate the amount of revenue that is collectible.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test report. This billing contemplates all necessary tests required during a patient&#8217;s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test report is delivered and is based upon cumulative tests delivered to date. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and recognized either as we deliver our estimate of the remaining tests in a patient&#8217;s treatment cycle or when the likelihood becomes remote that a patient will receive additional testing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our Immune Medicine revenue to decrease in the short term primarily due to our expected reduction in revenue generated from the Genentech Agreement. Over the long term, we expect our Immune Medicine revenue to increase as we or our collaborators advance therapies to commercialization. Our Immune Medicine revenue may fluctuate from period to period due to the timing of expenses incurred, changes in estimates of total anticipated costs related to the Genentech Agreement and other events not within our control, including the recognition of milestones under the Genentech Agreement and the timing of receipt of customer samples from our biopharmaceutical customers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our MRD revenue to increase in the long term as we continue to increase our MRD clinical testing volume through increased penetration in our existing covered patient populations, expansion into new patient populations and as we optimize payor coverage. Our MRD revenue may fluctuate period to period due to the uncertain timing of receipt of our biopharmaceutical customer samples, which may cause uncertainty in the delivery of our products and services, the recognition of milestones related to regulatory approvals of our biopharmaceutical customers&#8217; therapeutics and changes in estimates of our clinical revenue reimbursement rates.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cost of Revenue</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cost of revenue includes the cost of materials, personnel-related expenses (including salaries, benefits and share-based compensation), shipping and handling expenses, equipment costs, allocated facility costs associated with processing samples and professional support costs related to our service revenue activities. Allocated facility costs include depreciation of laboratory equipment, as well as allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition. As such, cost of revenue and related volume does not always trend in the same direction as revenue recognition and related volume. Additionally, costs to support the Genentech Agreement are a component of our research and development expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect cost of revenue to increase in absolute dollars as we grow our sample testing volume, but the cost per sample to decrease over the long term due to the efficiencies we may gain as assay volume increases from improved utilization of our laboratory capacity, automation and other value engineering initiatives. If our sample volume throughput is reduced, cost of revenue as a percentage of total revenue may be adversely impacted due to fixed overhead costs.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consist of laboratory materials costs, personnel-related expenses (including salaries, benefits and share-based compensation), equipment costs, allocated facility and information technology costs and contract service expenses. Research and development activities support further development and refinement of existing assays and products, discovery of new technologies and investments in our immune medicine platform. We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. We are currently conducting research and development activities for several products and services and we typically use our laboratory materials, personnel, facilities, information technology and other development resources across multiple development programs. Additionally, certain of these research and development activities benefit more than one of our product opportunities. We have not historically tracked research and development expenses by specific product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The costs to support the Genentech Agreement are a component of our research and development expenses. Additionally, a component of our research and development expenses are costs supporting clinical and analytical validations to obtain regulatory approval for future clinical products and services. Some of these activities have generated and may in the future generate revenue.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect research and development expenses to decrease in the short term and to decrease as a percentage of revenue in the long term, although the percentage may fluctuate from period to period due to the timing and extent of our development and commercialization efforts.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales and Marketing Expenses</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales and marketing expenses include personnel-related expenses (including salaries, benefits and share-based compensation) for commercial sales, product and account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility and information technology costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect sales and marketing expenses to remain relatively consistent in the short term. In the long term, we expect sales and marketing expenses to increase in absolute dollars as we increase marketing activities to drive awareness and adoption of our products and services. However, we expect sales and marketing expenses to decrease as a percentage of revenue in the long term, subject to fluctuations from period to period due to the timing and magnitude of these expenses.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses include personnel-related expenses (including salaries, benefits and share-based compensation) for our personnel in executive, legal, finance and accounting, human resources and other administrative functions, including third-party clinical billing services. In addition, these expenses include insurance costs, external legal costs, accounting and tax service expenses, consulting fees and allocated facility and information technology costs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect general and administrative expenses to remain relatively consistent in the short term and to decrease as a percentage of revenue in the long term.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Right-of-Use and Related Long-Lived Assets Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Impairment of right-of-use and related long-lived assets expenses include our impairment charge for certain leased office and laboratory space, as well as impairment costs for related leasehold improvements. See Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for details regarding our impairment assessments and considerations.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Expense</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest expense includes costs associated with our revenue interest liability related to the Purchase Agreement and noncash interest costs associated with the amortization of the related deferred issuance costs. We impute interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Statements of Operations Data and Other Financial and Operating Data</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth our statements of operations data and other financial and operating data for the periods presented </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share amounts):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.211%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Statements of Operations Data:</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,276</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">185,308</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">154,344</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,553</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,909</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,301</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,117</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141,756</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,343</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales and marketing</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,579</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,603</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,465</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83,934</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,527</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,502</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of intangible assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,699</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,699</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,699</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment of right-of-use and related long-lived assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,429</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">397,311</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">385,494</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">363,310</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(227,035</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(200,186</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(208,966</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest and other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,531</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,056</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,668</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(13,800</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4,238</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(225,304</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(200,368</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(207,298</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: Net loss attributable to noncontrolling interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">177</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(225,250</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(200,191</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(207,279</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1.56</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1.40</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1.48</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">144,383,294</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,515,917</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">140,354,915</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other Financial and Operating Data:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjusted EBITDA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(116,413</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(121,589</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(151,743</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Adjusted EBITDA is a non-GAAP financial measure that we define as net loss attributable to Adaptive Biotechnologies Corporation adjusted for interest and other income, net, interest expense, income tax (expense) benefit, depreciation and amortization expense, impairment costs for right-of-use and related long-lived assets, restructuring expense and share-based compensation expense. Please refer to &#8220;Adjusted EBITDA&#8221; below for a reconciliation between Adjusted EBITDA and net loss attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, and a discussion about the limitations of Adjusted EBITDA.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comparison of the Years Ended December 31, 2023 and 2022</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.92%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:5.880000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:6.119999999999999%;"/>
    <td style="width:1%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:5.68%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.14%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.140000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.34%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Percent of Revenue</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Immune Medicine revenue</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Service revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,959</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,777</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(6,818</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(21)%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,578</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,387</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(23,809</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(36</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Immune Medicine revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,537</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98,164</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(30,627</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(31</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">MRD revenue</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Service revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,739</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81,144</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,595</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Regulatory milestone revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(6,000</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(100</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total MRD revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,739</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,144</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,595</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,276</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">185,308</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(15,032</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(8</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The $30.6 million decrease in Immune Medicine revenue was primarily due to a $20.2 million decrease in revenue generated from the Genentech Agreement which resulted from decreased collaboration expenses partially offset by the $8.2 million of revenue recognized in connection with the regulatory milestone achieved in May 2023. There was also a $9.1 million decrease in revenue generated from our biopharmaceutical customers, $3.6 million of which was driven by the completion of our development activities for two of our collaboration agreements in 2022, and a $1.4 million decrease in revenue generated from our T-Detect COVID clinical customers resulting from our deferral of commercializing T-Detect.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The $15.6 million increase in MRD revenue was primarily due to an $18.2 million increase in revenue generated from providing clonoSEQ to clinical customers and a $2.8 million increase in revenue generated from providing MRD sample testing services to investigator-led clinical trials. These increases were partially offset by a $6.0 million decrease in revenue recognized upon the achievement of regulatory milestones by some of our biopharmaceutical customers. Our clonoSEQ test volume increased by 53% to 56,496 tests delivered in the year ended December 31, 2023 from 36,871 tests delivered in the year ended December 31, 2022.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cost of Revenue</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.029%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:5.901%;"/>
    <td style="width:1%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:5.901%;"/>
    <td style="width:1%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:5.7010000000000005%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.161%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.161%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.361%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Percent of Revenue</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,553</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,909</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,644</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The $17.6 million increase in cost of revenue was primarily attributable to an $8.6 million increase related to higher usage of our production laboratory to process revenue samples versus research and development samples, a $5.1 million increase in overhead costs largely driven by laboratory relocation and consolidation activities, a $2.8 million increase in materials cost resulting from increased revenue sample volume and a $1.2 million increase in shipping and handling expenses.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.029%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:5.901%;"/>
    <td style="width:1%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:5.901%;"/>
    <td style="width:1%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:5.901%;"/>
    <td style="width:1%;"/>
    <td style="width:1.26%;"/>
    <td style="width:7.702%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.161%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.361%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Percent of Revenue</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,117</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141,756</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(19,639</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(14)%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents disaggregated research and development expenses by cost classification for the periods presented:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:61.32%;"/>
    <td style="width:1.72%;"/>
    <td style="width:1%;"/>
    <td style="width:9.38%;"/>
    <td style="width:1%;"/>
    <td style="width:1.72%;"/>
    <td style="width:1%;"/>
    <td style="width:8.76%;"/>
    <td style="width:1%;"/>
    <td style="width:1.72%;"/>
    <td style="width:1%;"/>
    <td style="width:9.38%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development materials and allocated production laboratory expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,243</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,706</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(23,463</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,385</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,177</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,208</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Allocable facilities and information technology expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,617</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,856</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,761</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software and cloud services expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,394</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,678</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">716</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and other expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,478</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,339</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(5,861</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,117</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141,756</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(19,639</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The $19.6 million decrease in research and development expenses was primarily attributable to a $23.5 million decrease in cost of materials and allocated production laboratory expenses, which was driven primarily by decreased investments in T-Detect and TCR-Antigen Map development activities, as well as decreased investments in drug discovery efforts, including collaboration efforts with Genentech. There was also a $3.1 million decrease in consultant costs and a $2.5 million decrease in costs related to collaboration studies and clinical trials, which were the primary drivers of the $5.9 million decrease in depreciation and other expenses. These decreases were partially offset by a $6.2 million increase in personnel costs, a $2.8 million increase in allocable facility expenses and a $0.7 million increase in software and cloud services expenses.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales and Marketing</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.029%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:5.901%;"/>
    <td style="width:1%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:5.901%;"/>
    <td style="width:1%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:5.901%;"/>
    <td style="width:1%;"/>
    <td style="width:1.26%;"/>
    <td style="width:7.702%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.161%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.361%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Percent of Revenue</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales and marketing</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,579</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,603</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(7,024</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(7)%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The $7.0 million decrease in sales and marketing expenses was primarily attributable to a $5.0 million decrease in marketing expenses, which was largely driven by reduced clonoSEQ marketing activities and our deferral of commercializing T-Detect, a $3.8 million decrease in personnel costs and a $1.0 million decrease in consultant costs. These decreases were partially offset by a $2.4 million increase in computer and software expenses and a $0.8 million increase in building, facility and depreciation related expenses.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.029%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:5.901%;"/>
    <td style="width:1%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:5.901%;"/>
    <td style="width:1%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:5.901%;"/>
    <td style="width:1%;"/>
    <td style="width:1.26%;"/>
    <td style="width:7.702%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.161%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.361%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Percent of Revenue</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83,934</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,527</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4,593</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(5)%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The $4.6 million decrease in general and administrative expenses was primarily attributable to an $8.0 million decrease in building, facility and depreciation related expenses, driven largely by office space transitions made to support laboratory consolidation activities, a $2.0 million decrease in consultant costs and a $1.6 million decrease in insurance costs. These decreases were partially offset by a $2.7 million increase in personnel costs, driven primarily by increased share-based compensation, a $1.6 million increase in legal and accounting fees, a $1.3 million increase in computer and software expenses and a $1.2 million increase in third-party billing service fees.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Right-of-Use and Related Long-Lived Assets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.029%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:5.901%;"/>
    <td style="width:1%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:5.901%;"/>
    <td style="width:1%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:5.901%;"/>
    <td style="width:1%;"/>
    <td style="width:1.26%;"/>
    <td style="width:7.702%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.161%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.361%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Percent of Revenue</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment of right-of-use and related long-lived assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,429</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,429</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">* Not applicable</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The $25.4 million increase in impairment of right-of-use and related long-lived assets expenses was attributable to us vacating certain leased space in Seattle, Washington in October 2023 and the resulting impairment of related leasehold improvements.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest and Other Income, Net</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.12%;"/>
    <td style="width:1.54%;"/>
    <td style="width:1%;"/>
    <td style="width:7.68%;"/>
    <td style="width:1%;"/>
    <td style="width:1.54%;"/>
    <td style="width:1%;"/>
    <td style="width:7.68%;"/>
    <td style="width:1%;"/>
    <td style="width:1.54%;"/>
    <td style="width:1%;"/>
    <td style="width:7.68%;"/>
    <td style="width:1%;"/>
    <td style="width:1.08%;"/>
    <td style="width:1%;"/>
    <td style="width:8.14%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest and other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,531</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,056</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,475</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">283</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The $11.5 million increase in interest and other income, net was primarily attributable to an increase in net interest income and investment amortization driven by increased interest rates and related yields of our invested cash and cash equivalents and marketable securities.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Expense</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.12%;"/>
    <td style="width:1.54%;"/>
    <td style="width:1%;"/>
    <td style="width:7.68%;"/>
    <td style="width:1%;"/>
    <td style="width:1.54%;"/>
    <td style="width:1%;"/>
    <td style="width:7.68%;"/>
    <td style="width:1%;"/>
    <td style="width:1.54%;"/>
    <td style="width:1%;"/>
    <td style="width:7.68%;"/>
    <td style="width:1%;"/>
    <td style="width:1.08%;"/>
    <td style="width:1%;"/>
    <td style="width:8.14%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(in thousands, except percentages)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(13,800</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4,238</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(9,562</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">226</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The $9.6 million increase in interest expense was attributable to the Purchase Agreement entered into in September 2022.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adjusted EBITDA</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adjusted EBITDA is a non-GAAP financial measure that we define as net loss attributable to Adaptive Biotechnologies Corporation adjusted for interest and other income, net, interest expense, income tax (expense) benefit, depreciation and amortization expense, impairment costs for right-of-use and related long-lived assets, restructuring expense and share-based compensation expense.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management uses Adjusted EBITDA to evaluate the financial performance of our business and the effectiveness of our business strategies. We present Adjusted EBITDA because we believe it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. We may in the future incur expenses similar to the adjustments in the presentation of Adjusted EBITDA. In particular, we expect to incur meaningful share-based compensation expense in the future. Other limitations include that Adjusted EBITDA does not reflect:</span></p>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">all expenditures or future requirements for capital expenditures or contractual commitments;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in our working capital needs;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">interest expense, which is an ongoing element of our costs to operate;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">income tax (expense) benefit, which may be a necessary element of our costs and ability to operate;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of replacing the assets being depreciated and amortized, which will often have to be replaced in the future;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the noncash component of employee compensation expense;</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">right-of-use and related long-lived assets impairment costs; and</span></div></div>
  <div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations, such as our March 2022 restructuring and reduction in workforce.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, Adjusted EBITDA may not be comparable to similarly titled measures used by other companies in our industry or across different industries.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following is a reconciliation of net loss attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, to Adjusted EBITDA for the periods presented (in thousands):</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(225,250</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(200,191</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(207,279</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest and other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(15,531</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4,056</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,668</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,800</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,238</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,231</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,920</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,953</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment of right-of-use and related long-lived assets</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,429</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restructuring expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,023</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share-based compensation expense</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(4)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62,908</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55,477</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,251</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjusted EBITDA</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(116,413</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(121,589</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(151,743</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 11, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Interest Purchase Agreement </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for details on the Purchase Agreement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Represents impairment costs for right-of-use and related long-lived assets. See Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for details on our impairment expense.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(3)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Represents expenses recognized in conjunction with restructuring activities. See Note 16, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restructuring </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for details on our restructuring expense.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">(4)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 14, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Incentive Plans</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for details on our share-based compensation expense.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred losses since inception and have incurred negative cash flows from operations since inception through the year ended December 31, 2018, and again in the years ended December 31, 2020, 2021, 2022 and 2023. As of December 31, 2023, we had an accumulated deficit of $1.1 billion.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have funded our operations to date principally from the sale of convertible preferred stock and common stock, and, to a lesser extent, revenue and proceeds from the Purchase Agreement. Pursuant to the Purchase Agreement entered into in September 2022, we received net cash proceeds of $124.4 million, after deducting issuance costs. We are also entitled to receive up to $125.0 million in subsequent installments as follows: (i) $75.0 million upon our request occurring no later than September 12, 2025 and (ii) $50.0 million upon our request in connection with certain permitted acquisitions occurring no later than September 12, 2025, in each case subject to certain funding conditions. As of December 31, 2023, we had cash, cash equivalents and marketable securities of $346.4 million.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months. We may consider raising additional capital to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our available cash, cash equivalents and marketable securities balances and anticipated cash flows are insufficient to satisfy our liquidity requirements, we may request an additional installment under the Purchase Agreement, seek to sell additional equity or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing. The sale of equity and convertible debt securities may result in dilution to our shareholders and, in the case of preferred equity securities or convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. This additional capital may not be available on reasonable terms, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We plan to utilize the existing cash, cash equivalents and marketable securities on hand primarily to fund our continued research and development initiatives related to drug discovery, our commercial and marketing activities associated with clonoSEQ and our continued investments in streamlining our laboratory operations. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to capital preservation and liquidity. Currently, our funds are held in money market funds and marketable securities consisting of U.S. government treasury and agency securities, commercial paper and corporate bonds.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we may experience variability in revenue in the near term, over the long-term we expect revenue from our current and future products and services to grow. Accordingly, we expect our accounts receivable and inventory balances to increase. Our levels of accounts receivable may fluctuate relative to our revenue for a number of reasons, including the timing of milestone triggers and related payment of those milestones, as well as reductions in revenue derived from the upfront payment received under the Genentech Agreement and an increase in revenue generated from clinical customers, which may result in more billings in arrears as opposed to upfront payments. Any increase in accounts receivable and inventory may not be completely offset by increases in accounts payable and accrued expenses, which could result in greater working capital requirements.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contractual Obligations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our contractual obligations as of December 31, 2023 include operating lease obligations of $121.3 million, which reflects the minimum commitments for our office and laboratory spaces in Seattle, Washington and South San Francisco, California and our warehouse lease in Bothell, Washington. See Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for more information, including the timing of cash payments related to these lease obligations. In connection with one of our lease agreements, we have an existing letter of credit of $2.1 million with one of our existing financial institutions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, pursuant to the Purchase Agreement, the Purchasers have a right to receive Revenue Interests from us based on the Applicable Payment Percentage of the Revenue Base. If only the First Payment has been made, the Applicable Payment Percentage shall be five percent of the quarterly Revenue Base. If both the First Payment and Second Payment have been made, the Applicable Payment Percentage shall be eight percent of the quarterly Revenue Base. If each of the First Payment, Second Payment and Third Payment have been made, the applicable payment percentage applied to the Revenue Interest shall be ten percent of the quarterly Revenue Base. Revenue Interest Payments shall be made quarterly within 45 days following the end of each fiscal quarter. If OrbiMed has not received Revenue Interest Payments in the aggregate equal to or greater than the Cumulative Purchaser Payments on or prior to September 12, 2028, the revenue interest rate shall be increased to a rate which, if applied retroactively to our cumulative Revenue Base, would have resulted in Revenue Interest Payments equal to the sum of all Cumulative Purchaser Payments. OrbiMed will be entitled to 100% of the Revenue Interest Payments until it has received the Return Cap, unless full repayment of the amount of the Return Cap has not been made by September 12, 2032, in which case the Return Cap shall be increased to 175% of the Cumulative Purchaser Payments. As projected revenues change from our initial estimates, the amount of the obligation and timing of payment is likely to change. See Note 11, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Interest Purchase Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for more information.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also have minimum commitments for laboratory material suppliers, which are generally fulfilled within one year, software and service license commitments, which are generally fulfilled within one to three years, and royalty commitments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our uses and sources of cash for the years ended December 31, 2023 and 2022 (in thousands):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.72%;"/>
    <td style="width:1.72%;"/>
    <td style="width:1%;"/>
    <td style="width:12.92%;"/>
    <td style="width:1%;"/>
    <td style="width:1.72%;"/>
    <td style="width:1%;"/>
    <td style="width:12.92%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(156,324</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(183,945</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">129,647</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,905</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,245</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">132,265</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash used in operating activities during the year ended December 31, 2023 was $156.3 million, which was primarily attributable to a net loss of $225.3 million and a net change in operating assets and liabilities of $46.2 million, partially offset by noncash share-based compensation of $62.9 million, noncash impairment of right-of-use and related long-lived assets of $25.4 million, noncash depreciation and amortization of $13.0 million, noncash lease expense of $6.9 million, noncash interest expense related to the Purchase Agreement of $5.3 million and inventory reserve expense of $1.4 million. The net change in operating assets and liabilities was primarily due to a $29.3 million reduction in deferred revenue driven largely by revenue recognized from the Genentech Agreement, an $8.7 million decrease in operating lease right-of-use assets and liabilities, a $5.4 million reduction in accounts payable and accrued liabilities, a $2.8 million increase in inventory and a $1.9 million increase in prepaid expenses and other current assets driven largely by an increase in prepaid software charges. These changes were partially offset by a $2.0 million decrease in accounts receivable, net.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash used in operating activities during the year ended December 31, 2022 was $183.9 million, which was primarily attributable to a net loss of $200.4 million and a net change in our operating assets and liabilities of $71.5 million, partially offset by noncash share-based compensation of $55.5 million, noncash depreciation and amortization of $21.7 million, noncash lease expense of $7.2 million, a research and development inventory reserve charge of $2.6 million and noncash interest expense related to the Purchase Agreement of $1.0 million. The net change in our operating assets and liabilities was primarily due to a $56.5 million reduction in deferred revenue driven largely by revenue recognized from the Genentech Agreement, an increase in accounts receivable, net of $22.6 million, $7.1 million of which was attributed to growth in receivables related to clonoSEQ with the remaining increase driven largely by growth in receivables from biopharmaceutical customers, and a $4.1 million decrease in operating lease right-of-use assets and liabilities. These changes were partially offset by a $7.1 million increase in accounts payable and accrued liabilities, a $3.6 million decrease in prepaid expenses and other current assets and a $0.8 million decrease in inventory.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash provided by investing activities during the year ended December 31, 2023 was $129.6 million, which was primarily attributable to proceeds from maturities of marketable securities of $569.9 million, partially offset by purchases of marketable securities of $429.6 million and purchases of property and equipment of $10.7 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash provided by investing activities during the year ended December 31, 2022 was $2.9 million, which was primarily attributable to proceeds from maturities of marketable securities of $298.0 million, partially offset by purchases of marketable securities of $278.8 million and purchases of property and equipment of $16.3 million.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash provided by financing activities during the year ended December 31, 2023 was $2.2 million, which was attributable to proceeds from the exercise of stock options.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash provided by financing activities during the year ended December 31, 2022 was $132.3 million, which was primarily attributable to $124.4 million in proceeds from the Purchase Agreement, net of issuance costs, as well as $7.9 million in proceeds from the exercise of stock options.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net Operating Loss Carryforwards</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Utilization of our NOL carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section 382 and similar state provisions. The annual limitation may result in the expiration of NOL carryforwards and credits before utilization. If there should be an ownership change, our ability to utilize our NOL carryforwards and credits could be limited. We have completed a Section 382 analysis for changes in ownership through June 30, 2023 and continue to monitor for changes that could trigger a limitation. Based on this analysis, we do not expect to have any permanent limitations on the utilization of our federal NOLs. Under the TCJA, federal NOLs incurred in 2018 and future years may be carried forward indefinitely, but the deductibility of such federal NOLs is subject to an annual limitation. NOLs generated prior to 2018 are eligible to be carried forward up to 20 years. Based on the available objective evidence, management determined that it was more likely than not that the net deferred tax assets would not be realizable as of December 31, 2023. Accordingly, management applied a full valuation allowance against net deferred tax assets as of December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have prepared the consolidated financial statements in accordance with GAAP. Our preparation of these consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities and related disclosures at the date of the consolidated financial statements, as well as revenue and expense recorded during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas, including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, imputing interest for the Purchase Agreement, the provision for income taxes, including related reserves, the analysis of goodwill impairment and the recoverability and impairment of long-lived assets, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While our significant accounting policies are described in more detail in Note 2, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant Accounting Policies </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies are critical to the judgments and estimates used in the preparation of the consolidated financial statements.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our revenue arrangements may include upfront payments for the performance of services in the future, which have both fixed and variable consideration. Non-refundable upfront fees and funding for related development services are generally considered fixed consideration, while milestone payments are identified as variable consideration.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we fulfill our obligations under these agreements, we perform the following steps to determine the amount of revenue to be recognized: (1) identify the contract or contracts; (2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3) measure the transaction price, including the constraint on variable consideration; (4) allocate the transaction price to the performance obligations based on estimated selling prices; and (5) recognize revenue when (or as) we satisfy each performance obligation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> For our biopharmaceutical customers, our performance obligations may include sequencing services and services associated with regulatory submission and approval processes. Significant management judgment is applied to determine (1) the measurement of the transaction price, including the constraint on variable consideration, (2) the allocation of the transaction price to the performance obligations and (3) the appropriate input or output based method to recognize revenue and the extent of progress to date.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We include the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is not constrained to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, we re-evaluate the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjust our estimate of the overall transaction price.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To select the measure of progress, we consider the expectations of the performance period which may be based on customer-dependent estimates of samples or internal estimates of the performance period based on both the customer and our expected development timeframes. For our collaboration with Genentech, we estimate the extent of progress using a proportional performance model that uses an input method based on costs incurred relative to the total estimated costs of research and development efforts to pursue both the Shared Products and Personalized Product pathways. These estimates are based on our internal estimates and development timeframes, which are subject to revision based on the potential outcomes for both product pathways, decisions made by Genentech, regulatory feedback or other factors not currently known. We regularly review our expectations of the extent of progress, including whether any variable consideration is no longer constrained, and, if any changes in estimates are made, we recognize revenue using the cumulative catch-up method.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For agreements where we provide our clonoSEQ report to ordering physicians, we have identified one performance obligation: the delivery of a clonoSEQ report.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For arrangements with our commercial payors, the payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities. As such, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted, as necessary, based on actual collection experience.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Interest Liability, Net and Related Imputed Interest</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The revenue interest liability balance associated with the Purchase Agreement that we entered into in September 2022 with OrbiMed is presented net of unamortized issuance costs on the consolidated balance sheets. We impute our associated interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. The effective interest rate may vary during the term of the agreement depending on a number of factors, including changes in forecasted GAAP revenues. We evaluate the effective interest rate quarterly based on both achieved and forecasted revenues, utilizing the prospective method. The estimates of future revenues and resulting Revenue Interest Payments are based on key assumptions including population, penetration, probability of success and sales price, among others. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense and the time period for repayment. As of December 31, 2023, a hypothetical ten percent</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> increase in forecasted quarterly revenue would not result in a material change in projected annual interest expense.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October 1 and upon any occurrence of triggering events or substantive changes in circumstances that could indicate a potential impairment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. We evaluate certain qualitative factors such as macroeconomic conditions, the market and industry in which we operate, cost factors, overall financial performance and other relevant entity-specific events to determine if there are any negative trends or events that could indicate impairment. Key assumptions in this analysis include anticipated demand for our products and services, including industry and regulatory changes, revenue growth and cash flow trends. These assumptions are determined based on our historical performance and management&#8217;s forecasted results. Management&#8217;s estimates of forecasted results are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. If we determine that it is more likely than not that the fair value of our reporting unit is less than its carrying amount, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. If impairment exists, the carrying value of the goodwill is reduced to fair value through an impairment charge recorded in the consolidated statements of operations. To date, we have not recognized any impairment of goodwill.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recoverability and Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We review long-lived assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. To test for recoverability, we compare the carrying amount of the asset group to projected future net undiscounted cash flows. If the carrying amount is found to be unrecoverable, we then assess the asset group's fair value. We utilize the income approach to measure fair value, which requires management to make estimates regarding cash flow projections and discount rates. The extent to which the asset group's carrying amount exceeds its fair value represents the impairment cost to be recognized. Impairment losses, if incurred, are classified within the consolidated statements of operations in accordance with the use of the asset group, if not separately stated within its own financial statement line item. We recognized $25.4 million in impairment expense related to certain right-of-use and related leasehold improvement assets during the year ended December 31, 2023.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 2, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for more information.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_quantitative_qualitative_disclosu"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7A. Quantitative and Qualitati</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ve Disclosures About Market Risk</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Rate Risk</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to market risk for changes in interest rates related primarily to our cash and cash equivalents and marketable securities. As of December 31, 2023 and 2022, we had cash and cash equivalents of $65.1 million and $90.0 million, respectively, held primarily in cash deposits and money market funds. As of December 31, 2023, we had short-term marketable securities of $281.3 million, held in U.S. government treasury and agency securities, commercial paper and corporate bonds. As of December 31, 2022, we had short-term marketable securities of $408.2 million, held in U.S. government treasury securities, corporate bonds and commercial paper. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of interest rates in the U.S. As of December 31, 2023, a hypothetical 100 basis point increase in interest rates would have resulted in a $1.2 million decline in fair value of our available-for-sale securities, as compared to a $1.5 million decline as of December 31, 2022. This estimate is based on a sensitivity model that measures market value changes when changes in interest rates occur. Such losses would only be realized if we sold the investments prior to maturity. We do not enter into investments for trading purposes and have not used any derivative financial instruments to manage our interest rate risk exposure.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements_and_suppleme"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8. Fin</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ancial Statements and Supplementary Data</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Index to Consolidated Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022 and</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the Years Ended December 31, 2023, 2022 and 2021</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.92%;"/>
    <td style="width:7.08%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(PCAOB ID: </span><span><ix:nonNumeric id="F_e07eaef1-54ba-4af9-b39a-fdb60aeecce4" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_comprehensive_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Comprehensive Loss</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_convertible_preferred_stock_s"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Shareholders&#8217; Equity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_financial_statements_december_3"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_independent_registered_public_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Regist</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Shareholders and the Board of Directors of Adaptive Biotechnologies Corporation</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Adaptive Biotechnologies Corporation (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive loss, shareholders' equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 29, 2024 expressed an unqualified opinion thereon.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Critical Audit Matter</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:87.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:30.76%;"/>
    <td style="width:69.24%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.031in;padding-left:0.031in;vertical-align:top;padding-bottom:0.031in;padding-right:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.031in;padding-left:0.031in;vertical-align:top;padding-bottom:0.031in;padding-right:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Genentech Agreement</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.031in;padding-left:0.031in;vertical-align:top;padding-bottom:0.031in;padding-right:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Description of the Matter</span></p></td>
    <td style="padding-top:0.031in;padding-left:0.031in;vertical-align:top;padding-bottom:0.031in;padding-right:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">As more fully described in Note 3 of the consolidated financial statements, the Genentech Agreement revenue is estimated to be recognized over a period of approximately nine years from the effective date. The non-refundable consideration of $310.0 million is recognized using a proportional performance model through an input method based on costs incurred relative to the total estimated costs of research and development efforts. For the year ended December 31, 2023, total revenue recognized was $42.6 million and the related deferred revenue at December 31, 2023 totaled $54.7 million.</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Auditing management&#8217;s estimate of the total expected research and development costs at completion is complex and requires judgment as a result of the uncertainties of the ultimate progression of the customized product paths, timing and path of development and commercialization decisions, which are controlled by Genentech.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.031in;padding-left:0.031in;vertical-align:top;padding-bottom:0.031in;padding-right:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">How We Addressed the Matter in Our Audit</span></p></td>
    <td style="padding-top:0.031in;padding-left:0.031in;vertical-align:top;padding-bottom:0.031in;padding-right:0.031in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company&#8217;s process to evaluate the progress of the collaboration and the likely path of future development based on significant decisions made by Genentech communicated through the joint committees and any resulting impacts on the total costs of research and development efforts for the collaboration.</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">To test the estimate of total expected research and development costs, we performed audit procedures that included, among others, observing the quarterly meetings with accounting and the Company collaboration managers discussing the status of the collaboration and the future development for the customized product paths, and investigating any changes to the development path. We also reviewed supporting documentation to corroborate progress and status of the overall timeline, including meeting minutes from the joint committees.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20042812-f0a2-4b34-a22f-d2aa54aef8f9" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2015</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a45e858-8abd-45e0-ae2b-3aa73f714c28" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Seattle, Washington</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 29, 2024</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.25in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheets"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Balance </span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sheets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:69.594%;"/>
    <td style="width:1.58%;"/>
    <td style="width:1%;"/>
    <td style="width:11.622%;"/>
    <td style="width:1%;"/>
    <td style="width:1.58%;"/>
    <td style="width:1%;"/>
    <td style="width:11.622%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88516f43-72a8-48c5-8693-04f293835149" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,064</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d6e9ac2-4b92-45d9-acfb-c53d3fc28ab6" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,030</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term marketable securities (amortized cost of $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30ee1585-f262-4ed3-8d39-7983a1941cce" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,122</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7e47653-a781-4c03-b58b-b9393b4497c0" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">412,282</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">, respectively)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_229c92cf-309e-494d-918f-1d8417a6b584" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,337</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f39e569-f5f8-41a0-86f2-47ce1adcc2f5" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">408,166</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_683bc52e-989f-4587-aa5a-3bf5dd669c3d" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,969</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6fb0b80-575d-433a-b234-9b593d80c76f" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,057</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventory</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d58186c3-7cc7-4b88-bb4f-2bf9ffa6e208" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,448</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d46ca4cb-f97b-4f62-97bc-8c108ee5610d" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,453</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_736de2c5-2a6a-4d99-850f-7d6eaf4bef10" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,370</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76eeb1fa-82a0-4c3b-981f-0cc8475f77a6" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,440</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9aeaf490-ada8-4c96-8783-b0bc62b4b602" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">410,188</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f174703-35e3-41c2-a5b3-c3b7c293a3a2" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">562,146</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48414404-65b1-44a4-8225-2114760e5d15" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,227</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_667d8bb7-2cc8-493a-9236-2e7e6b4b47b8" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,447</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_685b9adc-cd54-4182-a9be-e3589e54350a" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,096</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41954631-331a-4f31-a24b-cfe800e8b859" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,763</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_306e602c-acba-491e-88fa-19d2c0faeb9c" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,932</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e47c090-b01d-49d4-b3a3-9062a8134391" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,398</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58bff690-71a8-4938-af95-4ed3bfdbcc90" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,128</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f437627-ef71-4918-b14c-6e1d2a17df7a" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,827</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Goodwill</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c4b5181-26a3-4842-9ce7-9a862eda7802" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,972</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67ed9a3a-aa29-4f92-b297-4968ad550c61" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,972</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4a9f4b7-49a6-42da-865a-20511c86678c" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,591</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf97e0bb-8aec-4a2a-a2fa-dd47db8c6a79" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,064</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_759581a2-6590-4ecb-94ff-8b3d65c09136" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">661,134</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c6d3b7e-ee9a-427b-8110-3c0be73c65b2" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">856,617</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities and shareholders&#8217; equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_316e7b30-fdf4-47b7-a412-e75b16193fb7" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,719</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91b5c1a2-e578-4645-b9ac-81c9f1bb223f" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,084</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a698c57-3aeb-4531-aba9-0cd50e84e6bd" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,597</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10144f17-3d77-4d9d-976c-09792be14e79" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,424</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation and benefits</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24303748-a497-4293-ac9c-97c09f0f8ebc" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,685</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ce3e491-5f3e-4cf6-a80a-c80f4e4153d5" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,935</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6dd72c63-407b-452c-8bd5-4a0b5166beb6" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,384</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b758265-c34a-4b12-a997-55290cca82a5" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,230</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of deferred revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8de45010-1d33-47db-803a-5d999bfa5311" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,630</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d046c84d-b59a-4b73-8570-a2035fcc49c4" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,115</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ad62dc7-f948-4ee1-bd17-701e8fd0f17c" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,015</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d2c579a-ba8f-42b1-9e84-faed7a46b321" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">109,788</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term liabilities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, less current portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af05375d-deeb-4cf3-95a7-26bcd7cf8d7a" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,388</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23f6b6fc-be29-4f7e-81d0-0bcd838ef6dc" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,772</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue, less current portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e138873-d971-444e-8d74-789ce7b42ebc" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,793</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09bc7ab5-67b8-4772-8d4c-adcb8e81df7a" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,599</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest liability, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc757deb-ef0d-47d9-bb70-9ca5329deff6" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,660</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b290c78-2325-48ff-b430-dc3ed7b6e854" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,360</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_429b1895-c0a8-4d1e-b454-5630a04ed154" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">352,856</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_002965e2-00b2-4f24-92d6-f1ab32e23714" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">392,519</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_55f8f7d6-632f-412e-bc01-7554244a9f4d;"><span style="-sec-ix-hidden:F_d6a13563-c650-4666-8b43-b3a899701ff8;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies</span></span></span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;(Note 12)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shareholders&#8217; equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock: $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_137f8aee-6183-40d6-bac8-06dc15aa060b" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4"><ix:nonFraction id="F_4ad5dc18-e1bb-483c-ba52-6269fd04e2b8" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10ac623d-e827-4534-87b5-e0f6baa00ef7" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1178939a-98a9-460e-a862-cd46b3af735c" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized at December 31, 2023 and 2022; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f16c2a2-6bc7-49e2-be2a-8f05c23659a4" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_eef7452a-6a3f-4786-9788-2cf4c8042b22" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_fcd83360-ee5c-42a6-996e-04acb28515f5" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9174f301-97bf-4bdb-aa67-6d7936e24ef8" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2023 and 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_adfd113e-7a67-4aa1-b775-f1a7ae594c82;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_a75961d9-fdf4-4b72-9a99-3b20df2adb39;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock: $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df1e7f78-4f07-475e-9319-bf8323937a5d" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4"><ix:nonFraction id="F_83310417-d669-4445-b71c-4f5a4fbcc89a" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c60742e1-b589-4df2-910a-f4b5187b850f" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_258739f7-407c-4532-8ffe-aa00700acd51" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">340,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized at December 31, 2023 and 2022; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa2dd67d-e4cf-4d00-bca4-a4062a89df66" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7fea3b14-6c21-46ea-8eb5-e4dc419b9fc5" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">145,082,271</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edc9580a-7692-4673-bcfe-21335c1786c8" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_38d4fe0a-03dd-4df1-aa23-ba3e6fca7659" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">143,105,002</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2023 and 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_343d615e-bcc7-4da9-a9f4-4cfa72f4b89e" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8620b3f1-bbe6-4b28-8ac6-baacff3c37ed" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7086aa9a-e38c-4284-ad0b-eaa4ddcf5c98" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,452,502</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31423605-6d64-4f87-9b3d-7f6f7485d74f" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,387,349</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive gain (loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a365029-f41f-4466-bc22-d6a3a63fb3ab" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">215</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37be76d8-9ea7-4300-9b50-b571e89d585d" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,116</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b21216df-a418-4835-b6d4-3d4ef8b21ea6" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,144,332</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42a5b8de-166e-4252-a41c-5c8c02002d2a" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">919,082</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Adaptive Biotechnologies Corporation shareholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f5ad8cc-64b3-4c37-bc27-eab2b4fb6e96" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">308,399</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d82cab8b-00cd-49f1-960b-fa9189bb5e35" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">464,165</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncontrolling interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4b196e8-2ac5-42e1-be78-c820534f30c6" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:MinorityInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad08783d-5eb9-486d-ac4b-7f05d45e3497" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:MinorityInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total shareholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e265223a-7169-42fc-8eee-8e2f6464f7d6" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">308,278</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1f11d03-f1a2-4fef-b480-429861d12da5" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">464,098</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and shareholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d45c8dd0-af09-4661-bb9a-6135d96cf5d9" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">661,134</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6ca085a-5c9b-4aec-bb4f-70627edf95a7" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">856,617</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.25in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_operations"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements o</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">f Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.131%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:10.762%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.762%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.762%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0bc59ce1-406c-42ab-b995-baf08a820726" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170,276</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bd693ed-9bd7-448e-bbab-77c65cb91a74" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,308</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e16e60b-2c01-46b8-bd7d-af29d6abbf1d" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,344</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca31b980-1fac-40e2-85de-f798d9280749" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,553</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39e8f12e-6320-47f4-b537-0ec389cf6ffd" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,909</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a258af33-4213-4afa-b00f-b2c7ee490ac5" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,301</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b8de064-7c8e-4d1a-9213-812c625e0f08" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,117</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0004502-2a62-4b36-81d7-199ea2fe078d" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,756</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69e0d176-a6eb-4827-861c-edc7ef983dbe" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,343</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales and marketing</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32fa4ce5-66ed-41e2-944d-244bf510f472" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,579</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f22fd15e-2cd6-457d-9f66-cecbe0eeba08" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,603</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_493d29d4-2cb5-4621-b0f3-fd150155e89c" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,465</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc0cfdba-6921-4f2f-8dca-2cbfd80fd7e7" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,934</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6ba828d-6c44-4335-8191-19e44b15446e" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,527</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5836bbe0-bb57-4c65-bc25-537ee2e6a326" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,502</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of intangible assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29a9db24-848e-4fa8-adfc-00dee034c4c6" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,699</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43690e11-8c50-417c-b626-57905b785c25" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,699</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_641883dd-3a0a-4ab8-bd86-cd44ced1769d" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,699</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment of right-of-use and related long-lived assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b06d36fc-79e6-4bc5-88df-203fc945aba9" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:ImpairmentOfRightOfUseAndRelatedLongLivedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,429</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab5874c5-264e-4e18-8bb3-505567ab6ebe" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">397,311</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ee6acab-2adf-4174-b78d-b8680aaaf301" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">385,494</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0ea0d8b-7fae-4f1d-883d-ba571296b03c" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">363,310</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7778a53-b24d-48dd-ba44-63343bdbd337" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">227,035</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7eaa8da9-149c-47b9-9e94-890904bc406f" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,186</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a069f064-756f-4617-806d-9425c0b197b5" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">208,966</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest and other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_925a22cd-d76e-451c-b9b6-a31f5889a2a4" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,531</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a40bdb6a-f035-487d-b02f-fcfeb2e8d530" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,056</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0917e310-4597-421b-9a9d-fbabaaedc444" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,668</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5594ea62-fa90-45fc-9a16-474bac70ff42" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,800</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc223ad8-41ac-4bbc-9e42-c30cbb4565c6" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,238</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20551e3e-0fe9-4eb7-b6c2-b715955b56af" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225,304</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c98255b0-b401-43a5-be93-be9324592e6c" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,368</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6f4fc44-c4a0-4d49-9b92-43393d81eeda" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">207,298</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: Net loss attributable to noncontrolling interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1595f723-3181-4b43-bc2e-02ab4aed0659" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a267627-8bba-4f79-8aa8-1e0723ba312b" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">177</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5018b48-6c87-4a17-9fd8-5d08bd6f2f47" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df4be0f7-534f-4b4c-b9f8-a4ee6ecb597b" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225,250</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a642927-dec3-422a-aa59-5157b6a270ff" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,191</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60845696-c75b-4ebd-beba-de6ea4fffd4e" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">207,279</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5d9662c-9764-469d-a5f8-b4a2abe2fde3" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_610ff099-e731-48b3-a360-a6aa424ff6d2" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.56</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb1feef1-f78c-4933-b9cb-fed215d127b5" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_61fddba3-39de-42a2-932c-5c44d511753d" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.40</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ce31ab6-267a-429c-b099-bc0131da6221" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-"><ix:nonFraction id="F_0225bfb0-e7d6-42e7-943a-bbeb5ccc90b5" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">1.48</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c19ee979-82c6-40df-8a0e-ffa8a19e4c4a" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8492cae6-fa1e-4b0d-9a15-92b5091d93a0" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">144,383,294</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bdb19a74-6596-429d-85a5-a295fd9202d4" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4c012577-000c-4fac-9f63-f15ec2e776fe" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">142,515,917</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7fb28d1-956f-49b5-a497-d266c7b84255" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1ee3a202-48cb-418d-a916-2b52b05d2233" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">140,354,915</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_comprehensive_loss"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of Co</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mprehensive Loss</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.211%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69e1de5f-79ee-4d39-ba6b-e69f68cd866b" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225,304</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebdceb2d-bf3e-493c-bf7d-bcd53946ccc8" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,368</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec51f916-9a36-4567-805f-90109aa4cd6a" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">207,298</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive income (loss)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in unrealized gains and losses on investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9265d431-3f16-4b02-bb7d-57c68bb0a6da" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,331</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f501de29-7560-45d5-b08b-635160a637e2" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,979</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffcb866b-accd-4590-b7a7-c45c239ecf9f" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,030</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7d35d16-5282-41ce-92d3-9c73e9d014cc" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">220,973</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68207d55-ce44-48c1-aab2-a7cc7d85dcb4" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">203,347</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2716d151-5f76-4e60-9ad7-fe9b607bce41" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">209,328</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Add: Comprehensive loss attributable to noncontrolling interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_390059c1-5f34-481b-8c52-2063d9bf3509" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_116f0d6a-9eed-47ba-b418-84824b00248a" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">177</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae780d53-1bb3-4c13-a2f1-e07dabaa99ba" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_191ba326-0629-42ae-b0ed-4b9f242ebd60" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">220,919</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd0fcdc1-3ef7-43e5-850e-4c5aef155ab2" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">203,170</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_644fd4ea-2077-4026-9a6b-42a30e65cde8" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">209,309</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_convertible_preferred_stock_s"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements of</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Shareholders&#8217; Equity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share amounts)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.747%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.581%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.101000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.101000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.101000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.101000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.101000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.161%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Noncontrolling</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Shareholders&#8217;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gain (Loss)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Interest</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_025c2450-6d6e-42b1-869c-92d3e8f462d4" contextRef="C_2ba2e40d-74e7-4c45-8c1b-863af5547a3d" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">137,646,896</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8815c1cf-609b-493b-912a-1bcd8f072c95" contextRef="C_2ba2e40d-74e7-4c45-8c1b-863af5547a3d" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bf9e773-04df-4072-8534-650f2326de49" contextRef="C_f90dae10-b7ce-472b-bbb0-33e4307f7344" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,253,971</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a54f696-5ce8-4b9c-92e3-648ae06f4353" contextRef="C_f120f473-834e-48d7-9c3d-c58cb26bc159" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">893</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30bdc46e-35a5-400b-89d6-f029853ede47" contextRef="C_919788e3-23fd-4409-b58e-83649ea5febe" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">511,612</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04786e42-dd98-44ea-9a8f-550781c2b329" contextRef="C_cd98abbe-6241-4fc8-af88-d9979790e940" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">743,266</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon exercise of common stock warrant</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a50cf9fb-7969-4fa1-9742-910e89a0d826" contextRef="C_546b97c7-d4df-492a-864d-7d19a8b5b897" name="adpt:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">54,162</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock for cash upon exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b23fb0f-78bd-49ec-b57c-052d3358297c" contextRef="C_546b97c7-d4df-492a-864d-7d19a8b5b897" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,674,057</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8209fc5-1b7b-4580-804e-e9217979fc3d" contextRef="C_6f24c325-cbc5-4f36-913f-12d35e35dc7d" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,484</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f6df2e1-0159-415a-afa7-4160d9edd8c1" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,484</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of restricted stock units</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_091a1a33-06ae-4258-9c27-70cd3978cc23" contextRef="C_546b97c7-d4df-492a-864d-7d19a8b5b897" name="adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,750</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35e4e6bf-f41c-4a18-8907-5af85451dbe5" contextRef="C_6f24c325-cbc5-4f36-913f-12d35e35dc7d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,251</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_111b8ebd-ab8d-4530-a539-4e6ca587c15a" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,251</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capital contributions for Digital Biotechnologies, Inc.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c1e49c1-4afe-41b1-9ef9-2a8e42864206" contextRef="C_6f24c325-cbc5-4f36-913f-12d35e35dc7d" name="adpt:AdjustmentsToAdditionalPaidInCapitalCapitalContributions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">300</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ddbc5c6e-ff99-4c94-b822-3b17e4d69fc9" contextRef="C_623eef52-d53d-46c2-8e13-de37ddc266db" name="adpt:AdjustmentsToAdditionalPaidInCapitalCapitalContributions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f78e7a8d-2188-4694-aa22-acda1aac386a" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="adpt:AdjustmentsToAdditionalPaidInCapitalCapitalContributions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">429</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5068a297-d187-4e5e-bf8d-d65bf7ef7660" contextRef="C_3e2c359c-7df3-4fd0-ade8-9c6156b3f9ae" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,030</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd4affe0-cea2-42f9-a8b2-0b41d4f17032" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,030</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d81aa81-4327-40b2-bf4a-b45d5149f18d" contextRef="C_5b34e135-b44f-41a1-b917-b0dc0f2c4bf4" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">207,279</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b38044da-2847-4058-a9d2-4bb1e44ebf45" contextRef="C_623eef52-d53d-46c2-8e13-de37ddc266db" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f9af17c-9b34-461a-9b27-634eb13bad6f" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">207,298</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80c43238-7b83-4bfe-a4aa-4ee98402ff43" contextRef="C_99d18c69-4d22-43ef-8389-5fdf986876eb" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">141,393,865</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61d3aec1-791d-4458-a6da-a1e2060e8e3c" contextRef="C_99d18c69-4d22-43ef-8389-5fdf986876eb" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_204d10ca-16f8-431e-8c96-85793422b241" contextRef="C_a850bcd3-da63-46d2-b9d7-bfe3de139a9e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,324,006</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f924207d-9cd5-4cb0-aaf6-c4b842e1f030" contextRef="C_ac72162c-f6d5-4828-ba60-f9c5be19f188" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,137</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f47e2e1-6cb5-4ba0-bf29-986d90b97d35" contextRef="C_d207b5e8-b241-4c93-8d72-a110d70a2fa2" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">718,891</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50e3db37-51b6-4bc9-98ea-5d0371e5a871" contextRef="C_3e2b380b-13d2-47a9-a0f7-95998f87ee50" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96a1fe48-b178-4801-969b-0045178b1fe4" contextRef="C_6f19237c-a155-4029-b45f-b9fb5332f737" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">604,102</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock for cash upon exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c14ab8ff-1fcc-489f-96f1-0689c4fc9cde" contextRef="C_698d77cb-703e-4d5b-acbd-9c92d097b8bd" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,406,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87bd2923-3d9a-4764-9d37-78f0fc98379e" contextRef="C_e840ef1f-0c35-4d10-9610-9d3bd41786d6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,866</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2425b87-12c8-4673-b4eb-ebcbe4cc77c2" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,866</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of restricted stock units</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46a933e2-6c2b-4888-a00b-0ac1de6dad50" contextRef="C_698d77cb-703e-4d5b-acbd-9c92d097b8bd" name="adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">304,637</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9723c1e-dc23-4f34-aaf0-09a6b1d47e4e" contextRef="C_e840ef1f-0c35-4d10-9610-9d3bd41786d6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,477</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b2ebb94-a86a-41e8-ba80-9eb9d8a430b7" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,477</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f44cdb8-78bd-4bfe-88da-46658d833f42" contextRef="C_7306e5e5-de3a-49c5-8ca6-d62df03366ee" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,979</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d77538e1-dc8e-4483-8116-3815bcdd82da" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,979</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b584bdf-6e9d-490d-a1d3-8396c1957011" contextRef="C_0cf4be7f-ab3d-44bd-8576-4b5ab607235c" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,191</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9a2e09d-cd4c-48d3-9f39-80237f057f92" contextRef="C_4c37a096-1a6a-45aa-8fc2-563181d9f721" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">177</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46dc80ae-27db-41d0-8236-b323dc7ade2c" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,368</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79bf8842-eb4e-4c24-8aab-a96fc107ddd6" contextRef="C_e47f789a-559d-43f2-a31d-acdeac94f7f7" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">143,105,002</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50c5a8c7-4825-4697-959d-46069595bdd5" contextRef="C_e47f789a-559d-43f2-a31d-acdeac94f7f7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d5be5c2-7800-4261-bbd6-d455b63a8f06" contextRef="C_04747ad8-13d5-4de0-966f-56ff96064b6f" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,387,349</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb826581-c2e8-4850-8d64-149f55aa9c70" contextRef="C_27e427e6-2646-46ca-93cd-c733bfaf29eb" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,116</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e849397-81c1-4df2-897d-85056b5f76a8" contextRef="C_2ae500b5-b450-4303-939a-c1ade0ffffce" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">919,082</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa956fc3-1321-41b8-9888-712ed8a2dd0a" contextRef="C_11a7257f-ddc9-4e22-ad34-a161c6bbbc38" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60a59376-eb09-4952-bd34-cdf093319ceb" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">464,098</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock for cash upon exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23f3fd54-66e2-4f9f-9cf6-ab5ee11bd36e" contextRef="C_2650e075-e451-49ad-955d-e9ad14d5bf33" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">470,405</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2433537-c133-4a4f-baf5-b55d9dbf0d28" contextRef="C_1b2a261c-6d6a-470b-b858-a470f3e89fa6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,245</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0a77cb2-8bcd-436c-8220-f97ab835c5ce" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,245</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting of restricted stock units</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d605dc1a-8635-48d6-80f9-33adcd5956e8" contextRef="C_2650e075-e451-49ad-955d-e9ad14d5bf33" name="adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,506,864</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21fba9be-2a40-41e1-91c4-498f9f8cc230" contextRef="C_1b2a261c-6d6a-470b-b858-a470f3e89fa6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,908</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d6d9842-a7c1-4c62-9bd2-d457a8c35290" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,908</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5eb8d86c-e741-4148-81f0-237c967dfb79" contextRef="C_71aa9e96-4108-4a98-82b6-96eb9ed09cbd" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,331</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a27001ca-8873-40eb-a40d-7321bebe891d" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,331</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c6241a7-dd36-425b-8dbe-d33590a83efb" contextRef="C_8c9aa062-7dde-4480-8d81-ee9c2d275da3" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225,250</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d39f454a-6000-41ff-b784-d90158ce78de" contextRef="C_905db261-8b17-447c-a833-556502ab34a5" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_366e97fa-d248-4ca1-86e6-04e4ebc452f0" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225,304</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7014078c-3a83-4385-8b30-d4ff11a388f0" contextRef="C_a720e09d-5c96-4740-a504-9844af0c34ea" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">145,082,271</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9506484d-7e4a-4496-a2e2-caf27241caa4" contextRef="C_a720e09d-5c96-4740-a504-9844af0c34ea" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52076652-504b-4ff0-b691-1d8cfce87b99" contextRef="C_79087f84-8200-4e59-be47-56564ec79f8e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,452,502</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5bb8c686-6d0d-43f1-a2e8-5be49fa7575a" contextRef="C_3c608cb9-e9d3-4e98-b40b-a50be54d13e1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">215</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d26dbfa-0675-4434-989e-79485fa493ec" contextRef="C_f1d9df12-63b0-41e0-839c-848d1971a89b" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,144,332</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2052a4f-d38f-4d24-9c56-b3467dde192f" contextRef="C_dddab8cd-a34a-45e6-93ef-3d378391ba43" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d9403eb-3a0b-40b0-a3eb-7379728b86d3" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">308,278</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_cash_flows"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Statements o</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">f Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.211%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
    <td style="width:1.48%;"/>
    <td style="width:1%;"/>
    <td style="width:10.782%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_732fc02d-c483-420a-873d-082638d23fc7" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225,304</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6b97dd3-96bd-4d1e-b368-67f798224049" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,368</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2383a77b-d09a-4acd-9a89-3086a7e9ba35" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">207,298</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fccfab3e-6e54-48f8-ba57-e6684753d602" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,532</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52231177-23b4-46e1-8279-b8df30b146a0" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,221</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5afe9a82-b3d1-4986-b165-dd96ef094a42" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,254</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncash lease expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f357e68-50f5-409f-8cac-79d9b5d9859b" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:NoncashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,920</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a2095d8-91b1-45b5-bf7b-43322a034a41" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="adpt:NoncashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,227</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc747c73-476a-4a29-bb24-5e94f76dfc5a" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="adpt:NoncashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,028</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13fc3525-be4a-4292-bd62-eebf12a892d8" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,908</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_013b6c6a-d2bc-4422-9171-e8a36282696f" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,477</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d873eb1-13ea-41d3-ae69-f284e9ca7fa8" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,251</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets amortization</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_728bf77c-4cd6-4153-b3f4-08a96a2e8040" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,699</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a256a92-70e1-43e0-80f1-cd8e3570b765" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,699</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2ab2d2c-cea2-49f1-ac95-f0fefffd15c0" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,699</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investment amortization</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_311f9322-a192-45ec-be93-6803f387c52d" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,184</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62218fca-be5b-4ba7-a6a4-02bddf2b58c8" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">741</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95c9762c-9907-4528-85b3-7efdd6124563" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,233</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Impairment of right-of-use and related long-lived assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d312624b-1d3c-473e-9ae2-fa2f0facafa1" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:ImpairmentOfRightOfUseAndRelatedLongLivedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,429</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventory reserve</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ddce295-fdb7-408d-b5f3-789a8ca83b05" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:InventoryReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,387</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52e96cfd-4199-422c-8483-8ade50206de4" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="adpt:InventoryReserve" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,638</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncash interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41d8703c-8a61-42e4-a7b9-50b3e8c2f032" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:NoncashInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,300</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b9eb0b3-1811-4c0e-aab7-bbfcc96ece82" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="adpt:NoncashInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">985</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6efcddc7-47ad-4a39-a43d-7caff9cddf23" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">172</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fce68b43-304b-4056-bd3f-14f044f4a6f4" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_683e8434-25c2-4032-a401-fcc14a0851df" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36323d47-1875-4dfc-b024-670323c50a9c" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,032</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70123913-6c4c-4809-9d17-87ad77bcc05e" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,648</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2e3bad5-1090-4055-8343-d4883412a8cc" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,362</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventory</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ddfda6f0-de18-4cd1-8f6a-4221113e5abe" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,838</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e921d1c3-dbcc-494c-b22f-f78f32856255" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">817</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e84ffda9-837b-4b0c-884a-ff6d6e99513f" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,200</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4310959-c43c-415d-8743-125ac5e6d2c6" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,930</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bbfc809-8ceb-48b4-875d-eed24336dee0" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,551</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4fbba50-95f4-4127-96b4-d30e94a21384" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,286</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable and accrued liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7a3e0a0-b3a5-4c61-bd23-3a9ce9321f53" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,407</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7131df47-9f54-41a6-bb15-5efd248f73ec" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,111</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aefdb342-7d84-419b-a831-2620afc37ee6" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,940</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use assets and liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5cb24daa-c8a2-406f-8cf4-ec9f762f171b" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,676</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7caf1a6-9400-4515-bd60-b885efd0f0d1" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="adpt:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,050</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23db4054-cf54-4132-bde9-4b91e3fd1722" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="adpt:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,522</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a198b08-1136-45ee-b7d3-5d68c8578d37" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,291</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4410a6d7-dc7b-40d6-b990-c0ddf39ea137" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">56,496</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d946c4af-a544-460c-8505-3778ab18a8bf" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">57,727</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75d36b2e-e4d7-42dc-a00d-ed2b6925475e" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5ac6aa9-e1e1-49ad-a939-ff3370cb1160" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">169</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6441bce-303c-403f-992c-01701bd9163c" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">275</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70867fd3-a4cf-43c2-87ac-4d24adcfbfda" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">156,324</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3c368a4-9f12-4c36-bbee-64965ff52370" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">183,945</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3e23ccc-7e68-4ac2-91f4-d742e9e4477f" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">192,727</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Investing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd03b041-427f-489a-b9ce-dbb2ec8e5b81" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,697</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_029247f9-2203-4631-b11d-26dcf91d0d85" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,349</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd1e930b-59ec-46c9-948d-bd96104a71f5" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,746</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a863b074-3ecd-4c30-b6e0-cb4444a0d937" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">429,558</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bad0173-d08b-418b-af93-41de51b27bd1" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">278,778</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e55c933-9b5e-4e57-9776-31007365e94f" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">316,544</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from maturities of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0680763-7772-407f-ac32-b0634e2dbc9b" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">569,902</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25a20645-3e94-408a-b0a4-0050c1b7dd42" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">298,032</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5598e1e-1fae-441b-b1c1-5bd0647e7f6e" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">559,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8541734e-dcca-46a4-9d57-9c23b5ac297a" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,647</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5652cc9-b452-4f79-9c7b-cfd371760f38" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,905</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef2947bb-de8e-43de-af1c-195017ccba5e" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">181,210</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d3cd417-73bc-47bc-b638-ad396df80077" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,245</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d152ceaf-051c-4f7a-b878-e2550077174e" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,890</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87027ecc-bac2-4e13-86b7-b62af00a9978" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,717</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from revenue interest purchase agreement, net of issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d427ff2-efc3-4f96-8ef1-d68922b4c408" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="adpt:ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,375</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from initial capital contributions for Digital Biotechnologies, Inc.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4fc2a30-ad73-45a8-bbd0-24fd9f8b1b00" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:ProceedsFromContributedCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">429</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8430bf6-d421-47e6-a579-3f545a5b1664" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,245</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12b262bb-23f9-47d2-b528-a0bb18aa2c80" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">132,265</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6485092-22bc-4557-ba0d-88f992910287" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,146</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (decrease) increase in cash, cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05ae7844-ef93-4ee8-9330-03f3f6e447f7" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">24,432</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c210ee06-547b-443c-9539-f980e782f5d7" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48,775</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40668c41-0f99-43b6-aa01-ac38f975d25a" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,629</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash at beginning of year</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74c388d1-b31b-4cfa-8e41-6c72adc99962" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,428</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03cc3090-e2d9-4f55-81a2-8daac6f32faf" contextRef="C_6f19237c-a155-4029-b45f-b9fb5332f737" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,203</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b84cd71-7eab-4432-99e6-4fdb56a151cc" contextRef="C_cd98abbe-6241-4fc8-af88-d9979790e940" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,574</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash at end of year</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80396357-36ba-4abf-90d7-6fea88cc7301" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,996</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b0b0832-5583-47af-9143-c426071d4625" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,428</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94e192df-98fb-4f32-9ab7-157d4e3b4864" contextRef="C_6f19237c-a155-4029-b45f-b9fb5332f737" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,203</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Noncash investing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of equipment included in accounts payable and accrued liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d115348e-ef15-4a92-9fa9-0c3820361ba9" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">687</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c8adb99-6c98-402e-a8cc-09d5c0af069a" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,719</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_993a5e12-c9df-4349-8a19-c1c47c8e7a35" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">682</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental disclosure of cash flow information</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_478e29d4-2ec1-47c1-90d8-287407d5c519" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,985</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0f4feae-30f4-48e9-ad63-efcb29352fce" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">494</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.167%;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_financial_statements_december_3"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial State</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ments</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b27f08c-0df7-427f-b7ce-c87b2e60ebff" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Organization and Description of Business</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation (&#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is a commercial-stage company advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature&#8217;s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient&#8217;s immune system and understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database and related antigen annotations, which are underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that can be tailored to the needs of individual patients. We have commercial products and services and a robust pipeline of clinical products and services that we are designing to diagnose, monitor and enable the treatment of diseases, such as cancer and autoimmune disorders.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were incorporated in the State of Washington on September 8, 2009 under the name Adaptive TCR Corporation. On December 21, 2011, we changed our name to Adaptive Biotechnologies Corporation. We are headquartered in Seattle, Washington.</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_46e5faad-171b-4a81-97f8-98ad06e6336b" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant Accounting Policies</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c7fdc308-b5e4-43c2-990e-d3f8ee89ad9a" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements include the accounts of Adaptive Biotechnologies Corporation, Adaptive Biotechnologies B.V., our wholly-owned subsidiary, and Digital Biotechnologies, Inc., a corporate subsidiary we have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c352d2a-7dd7-4964-b707-054cfac9f479" contextRef="C_e3e3db77-5861-422c-a654-f78b40f8db36" name="us-gaap:MinorityInterestOwnershipPercentageByParent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">70</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% ownership interest in. The remaining interest in Digital Biotechnologies, Inc., held by certain of our related parties and their related family trusts, are shown in the consolidated financial statements as noncontrolling interest. All intercompany transactions and balances have been eliminated upon consolidation.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e4625e19-186c-4e80-a52b-df2f19dcdb6e" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, imputing interest for our revenue interest purchase agreement (the &#8220;Purchase Agreement&#8221;) that we entered into in September 2022, the provision for income taxes, including related reserves, the analysis of goodwill impairment and the recoverability and impairment of long-lived assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b65fc2a4-7b39-412b-92c0-ba335327ed7d" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have determined that our chief executive officer is the chief operating decision maker (&#8220;CODM&#8221;). The CODM regularly reviews operating results and other financial information presented on a consolidated basis. While revenue is reviewed at levels lower than the consolidated entity, resource allocation decisions are made by the CODM based on the results presented at the consolidated entity level, which is determined to be a single reporting unit. The consolidated entity operates as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98f704d2-b7eb-4cee-8d42-3eeb9f3fd590" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment and represents </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3ccc03e-8b32-401c-a5cc-ef2a5787c5d8" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segment. We present disaggregated revenue from contracts with customers by market opportunity and type of arrangement. See Note 3, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b0c1eba-6f5d-43a8-ab89-765c16a181da" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. We limit our credit risk associated with cash and cash equivalents by placing our investments with banks that we believe are highly creditworthy and with highly rated money market funds. Cash and cash equivalents primarily consist of bank deposits and investments in money market funds.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e0d864a8-bec7-408c-9847-233d57c3b029" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We had a restricted cash balance of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e2fafcc-ad7e-499d-ae41-2479969fe192" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_874d19ff-3c9d-4f09-a808-d718fbf36203" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023 and 2022, respectively. Our restricted cash primarily relates to certain balances we are required to maintain under lease arrangements for some of our property and facility leases.</span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c1181fd7-f2f0-45ae-9acc-796865a7345a" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investments in Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable securities are classified as available-for-sale, consist of United States (&#8220;U.S.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) government treasury and agency securities, corporate bonds and commercial paper and are reported at fair value. Unrealized holding gains and losses are reflected as a separate component of shareholders&#8217; equity in accumulated other comprehensive gain (loss) until realized. Realized gains and losses on the sale of these securities are recognized in net income or loss. The cost of marketable securities sold is based on the specific identification method.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d572830-5451-4435-85df-7eb8e5aff6b2" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Financial Accounting Standards Board (&#8220;FASB&#8221;) has defined fair value as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. The FASB established a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The hierarchy defines three levels of inputs that may be used to measure fair value:</span></p><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></div></div><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div></div><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A financial instrument categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. In certain cases, where there is limited activity or less transparency around valuation inputs, financial instruments are classified as Level 3 within the valuation hierarchy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our financial instruments consist of Level 1 and Level 2 assets and have included Level 3 liabilities in the past. The carrying amounts of certain financial instruments approximate fair value due to their short maturities. We did not have any nonfinancial assets or liabilities that were measured or disclosed at fair value on a recurring basis as of December 31, 2023 and 2022.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a01ec45-6056-4554-affd-85a6963e29aa" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to a concentration of risk from a limited number of suppliers, or in certain cases, single suppliers, for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, U.S. government treasury and agency securities, corporate bonds and commercial paper with high-quality accredited financial institutions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant customers are those that represent more than ten percent of our total revenue or accounts receivable, net balances for the periods and as of each consolidated balance sheet date presented, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_896984de-5033-49a7-b65a-e696b7cdcec6" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:44.5%;"/>
          <td style="width:1.16%;"/>
          <td style="width:9.94%;"/>
          <td style="width:1.16%;"/>
          <td style="width:9.94%;"/>
          <td style="width:1.16%;"/>
          <td style="width:9.94%;"/>
          <td style="width:1.16%;"/>
          <td style="width:9.94%;"/>
          <td style="width:1.16%;"/>
          <td style="width:9.94%;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Revenue</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accounts Receivable, Net</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Customer A</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*%</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*%</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*%</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*%</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14920464-2dcb-49f3-88e0-0c8526ef7e5f" contextRef="C_5d4928f6-2311-4267-a962-fb87a6ccc8c3" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">15.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Customer B</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_538361c1-2d6c-4549-8f88-d8db6ed26eab" contextRef="C_9a81b7d4-7c86-4a5a-9662-9fa8a4acafae" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.6</ix:nonFraction></span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98a5c54b-ea46-47ec-89e3-bd1ba17b57c9" contextRef="C_ff22cd37-5751-4b76-bb68-14093905829b" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">19.5</ix:nonFraction></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Genentech, Inc. and Roche Group</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f1c3b74-fc3e-40a0-982d-ee79f1e5d1bc" contextRef="C_974e34a3-8a7b-44ac-b595-2e251f3f2e9d" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">27.8</ix:nonFraction></span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1dec047d-3fc0-4353-b4b5-a182f8c0ae61" contextRef="C_ac662e7b-0f00-4834-864f-bfae853d3fae" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">36.4</ix:nonFraction></span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f65a916-d2ed-4e14-bc55-5ab45de8515e" contextRef="C_fa96d089-dfe6-4ac2-947d-35adf78b92c8" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">41.9</ix:nonFraction></span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">* less than 10%</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ff93d70c-0717-4d1a-93fb-633fac4d90eb" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ReceivablesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable consists of amounts due from customers for services performed. We review our accounts receivable for credit impairment and regularly analyze the status of significant past due receivables to determine if any will potentially be uncollectible to estimate the amount of allowance necessary to reduce accounts receivable to its estimated net realizable value.</span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0c15983a-78c3-4a55-89b9-4cbd9b4ad876" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:InventoryPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventory</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventory consists of laboratory materials and supplies used in lab analysis. We capitalize inventory when purchased and record expense upon order fulfillment for servicing revenue or utilization in our research and development laboratories. Inventory is valued at the lower of cost or market on a first-in, first-out basis. We periodically perform obsolescence assessments and write-off any inventory that is no longer usable. Long-term inventory of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ad8e597-632c-4b7c-8762-cd9595fa119f" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:OtherInventoryNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3d88578-5c94-43c5-bdcf-50521b2f793f" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:OtherInventoryNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was included within the other assets balance on the consolidated balance sheet as of December 31, 2023 and 2022, respectively.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9558a066-f73d-4b2d-a48c-e780938d4796" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment consists of computer equipment, computer software, laboratory equipment, leasehold improvements, furniture and office equipment and assets under construction. Property and equipment are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life. Maintenance and repairs are charged to expense as incurred and costs of improvements are capitalized.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_644b971d-da5b-4db2-bc1d-8d433e881c50" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Useful lives assigned to property and equipment are as follows:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:84.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.14%;"/>
          <td style="width:1.72%;"/>
          <td style="width:49.14%;"/>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_cda7e128-53bb-410d-9a92-2c556bf7fd58" contextRef="C_36aa5e03-ecb8-4303-b58a-1c55adb14e7f" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><ix:nonNumeric id="F_8cc82e98-732e-46e3-8b48-8389857a6eab" contextRef="C_91cb6778-e1d1-4172-888b-784d43882ecc" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_de9ea103-2ab7-4e3e-8c48-d7bbaf7c674a;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of estimated useful life or remaining lease term</span></span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment and software</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_ac377e56-d6c8-42b3-b46f-3ee772712375" contextRef="C_b0f7c504-6f69-48ba-bdd7-d64ff949d238" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><ix:nonNumeric id="F_80bb8b89-f687-4860-b228-c9b345664057" contextRef="C_e77e6257-9358-42eb-8b65-6f87bb11fe8b" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and office equipment</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_09e6d171-e34f-4d87-b391-99cc8c0eed43" contextRef="C_c0865de4-d48f-44cc-8042-17b502c84d61" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><ix:nonNumeric id="F_c88de430-c81f-4c60-9fb0-7e902e50f49e" contextRef="C_bc38ff0f-2c7c-4c26-ba5a-4c9791880b39" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7 years</span></ix:nonNumeric></span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We review long-lived assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Gains and losses from asset disposals and impairment losses, if incurred, are classified within the consolidated statements of operations in accordance with the use of the asset, if not separately stated within its own financial statement line item. See Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for more information regarding the leasehold improvements impairment loss recognized during the year-ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fca6b0d8-613a-4f83-bfd2-8d8e81d37053" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intangible Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date, which is regarded as their cost.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets may also result from the purchase of assets and intellectual property in a transaction that does not qualify as a business combination. Intangible assets are amortized over their estimated useful lives on a straight-line basis which approximates their usage pattern. Intangible assets are reviewed for impairment at least annually or if indicators of potential impairment exist. We have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_014150b5-2237-4094-8e76-ae86c9de2dfc" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognized any impairment losses on intangible assets.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c1e4ae2-75be-4bb6-9b95-f68b24d5e7b3" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October 1, or more frequently if events or changes in circumstances would more likely than not reduce the fair value of our single reporting unit below its carrying value. We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we so determine, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. If impairment exists, the carrying value of the goodwill is reduced to its fair value through an impairment charge recorded in the consolidated statements of operations. To date, we have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d71f155-862e-412d-86f3-122b8f539a5a" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognized any impairment of goodwill.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a973cf30-ee28-4715-96db-d40b2a4d253e" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory, office and warehouse facilities that we occupy. Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of January 1, 2020 for commenced leases that existed as of our adoption of Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Topic 842) (&#8220;ASC 842&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain of our leases contain options to extend or terminate the lease; lease terms are adjusted for these options only when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory, office and warehouse facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on the consolidated balance sheets a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We review our right-of-use assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Impairment losses are classified within the consolidated statements of operations in accordance with the use of the asset, if not separately stated within its own financial statement line item. See Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for more information regarding the right-of-use asset impairment loss recognized during the year-ended December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lease expense is recognized on a straight-line basis over the terms of the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the terms of the leases.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58f3f580-da94-43b1-8b7f-bad3dfce69f5" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Interest Liability, Net and Related Imputed Interest</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The revenue interest liability balance associated with the Purchase Agreement that we entered into in September 2022 is presented net of unamortized issuance costs on the consolidated balance sheets. We impute our associated interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. The effective interest rate may vary during the term of the agreement depending on a number of factors, including changes in forecasted GAAP revenues. We evaluate the effective interest rate quarterly based on both achieved and forecasted revenues, utilizing the prospective method. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense and the time period for repayment.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8e39977e-287f-483a-a2d3-1338292d2bb0" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1) identify the contract or contracts; (2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3) measure the transaction price, including the constraint on variable consideration; (4) allocate the transaction price to the performance obligations based on estimated selling prices; and (5) recognize revenue when (or as) we satisfy each performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We derive revenue by providing diagnostic and research services in our Immune Medicine and Minimal Residual Disease (&#8220;MRD&#8221;) business areas. Our Immune Medicine revenue consists of revenue generated from (1) providing sample testing services for our commercial research product, Adaptive Immunosequencing, to biopharmaceutical customers and academic institutions; (2) our collaboration agreements with Genentech, Inc. (&#8220;Genentech&#8221;) and other biopharmaceutical customers in areas of drug and target discovery; and (3) for prior years, providing our T-Detect COVID tests to clinical customers. Our MRD revenue consists of revenue generated from (1) providing our clonoSEQ report to clinical customers; (2) providing MRD sample testing services to biopharmaceutical customers and certain academic institutions, including investigator-led clinical trials; and (3) providing our clonoSEQ report or results to certain international laboratory sites through technology transfers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For research customers who utilize either Adaptive Immunosequencing or our MRD services, contracts typically include an amount billed in advance of services (&#8220;upfront&#8221;) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85c8f9cd-f82d-4c9b-aeb3-52e7be83d0e1" contextRef="C_dfa7b2ec-aa90-4f5c-b852-1f27ae360214" name="adpt:NumberOfRevenuePerformanceObligation" unitRef="U_Performance_Obligation" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> typical performance obligations under the terms of our research service contracts: (1) the delivery of our Adaptive Immunosequencing or MRD data for customer provided samples; and (2) related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the total samples expected to be delivered.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For agreements where we provide our clonoSEQ report to ordering physicians, we have identified one performance obligation: the delivery of a clonoSEQ report. We bill and receive payments for these transactions from commercial, government and medical institution payors. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted, as necessary, based on actual collection experience.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regarding our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test report. This billing contemplates all necessary tests required during a patient&#8217;s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test report is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient&#8217;s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized either as we deliver our estimate of the remaining tests in a patient&#8217;s treatment cycle or when the likelihood becomes remote that a patient will receive additional testing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The contract transaction price for agreements we enter into with biopharmaceutical customers to further develop and commercialize their therapeutics may consist of a combination of non-refundable upfront fees, separately priced MRD testing fees and milestone fees earned upon our customers&#8217; achievement of certain regulatory approvals. Depending on the contract, these agreements include single or multiple performance obligations. Such performance obligations include providing services to support our customers&#8217; therapeutic development efforts, including regulatory support for our technology intended to be utilized as part of our customers&#8217; registrational trials, developing analytical plans for our data, participating on joint research committees, assisting in completing a regulatory submission and providing MRD testing services related to customer-provided samples for our customers' regulatory submissions. Generally, the support services, excluding MRD testing services, are not distinct within the context of the contract and thus are accounted for as a single performance obligation. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated MRD testing services. When MRD sample testing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional MRD sample testing services is not considered part of the contract. We recognize revenue related to MRD testing services over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered, when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method using a cost-based model based on estimates of effort completed. Selecting the measure of progress and estimating progress to date requires significant judgment. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. At contract inception, we fully constrain any consideration related to regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers&#8217; own submission decision-making. Variable consideration related to regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue will not occur. Milestone payments for regulatory approvals, which are not within our customers&#8217; control, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2021, we executed an intellectual property license agreement that includes variable consideration related to sales-based royalties. Any consideration related to such royalties will be recognized as revenue at the later of when (i) the related sales occur or (ii) the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied (or partially satisfied).</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95ed821c-cc40-4e25-8b20-de6003f86cb3" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:ContractBalancesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contract Balances</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In certain circumstances, billing may occur prior to services being performed. Upfront payments are recorded as deferred revenue, or contract liabilities. We classify deferred revenue as current when we expect our performance obligations will be completed within the next twelve months; however, we do not control the timing of customer provided samples. For service and collaboration activities, excluding those related to our worldwide collaboration and license agreement with Genentech, we assess the performance obligations and recognize deferred revenue as current or non-current based upon forecasted delivery times, which are customer coordinated. In certain circumstances, a customer project may be cancelled or terminated prior to the delivery of all related services covered by a customer&#8217;s upfront payment. In these circumstances, we recognize revenue when sufficient evidence is obtained that a reversal of revenue is not probable. We also recognize revenue when our estimate of total samples to be provided under certain of our agreements is reduced or, in the case of contract balances related to Medicare, when the likelihood becomes remote that a patient will receive additional testing. See Note 3, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for our deferred revenue policy related to our worldwide collaboration and license agreement with Genentech.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b410e456-dde8-4eca-943c-55b26bf49404" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation includes compensation expense for stock option, restricted stock unit and market-based restricted stock unit grants made to employees and non-employees. It represents the grant date fair value of the grants and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of actual forfeitures. We estimate the grant date fair value of stock option and market-based restricted stock unit grants using the Black-Scholes option-pricing model and the Monte Carlo valuation model, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_82441e66-f247-47b2-906d-48a8349928c9" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:AdvertisingCostsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Advertising</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Advertising costs are expensed as incurred. Advertising expenses were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe2695e1-2052-4b42-a43f-cdf867ffb9b0" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:AdvertisingExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9dca5f9-c85a-44f6-917b-070587d61975" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:AdvertisingExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da0ee32a-5291-44f5-9e7f-60bdd92d9572" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:AdvertisingExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023, 2022 and 2021, respectively.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e94bca2f-b976-43a8-93e2-56ba7e8c5c6e" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:CostOfSalesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cost of Revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cost of revenue includes the cost of materials, personnel-related expenses (including salaries, benefits and share-based compensation), shipping and handling expenses, equipment costs, allocated facility costs associated with processing samples and professional support costs related to our service revenue activities. Allocated facility costs include depreciation of laboratory equipment, as well as allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f764179-c29c-40ff-941d-12007348ea99" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consist of laboratory materials costs, personnel-related expenses (including salaries, benefits and share-based compensation), equipment costs, allocated facility and information technology costs and contract service expenses. Research and development activities support further development and refinement of existing assays and products, discovery of new technologies and investments in our immune medicine platform. We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. Additionally, a component of our research and development expenses are costs supporting clinical and analytical validations to obtain regulatory approval for future clinical products and services. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Upfront payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized, then are recognized as an expense as the goods are consumed or the related services are performed. Costs to support our worldwide collaboration and license agreement with Genentech are also a component of our research and development expenses.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_47dedc47-a448-44eb-afea-581e356720a7" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:SalesAndMarketingExpensePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales and Marketing Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales and marketing expenses include personnel-related expenses (including salaries, benefits and share-based compensation) for commercial sales, product and account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility and information technology costs.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c9cfd079-2361-4fa4-b182-bc196c952c1f" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:ImpairmentOfRightOfUseAndRelatedLongLivedAssetsExpensesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Right-of-Use and Related Long-Lived Assets Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Impairment of right-of-use and related long-lived assets expenses include our impairment charge for certain leased office and laboratory space, as well as impairment costs for related leasehold improvements.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1672868-f43c-45a0-ac67-db71a0c32a8c" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:InterestExpensePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest expense includes costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. We impute interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cddc780c-df30-45aa-ae1c-dcbb3ab70217" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred tax assets and liabilities are measured at the consolidated balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in the period such tax rate changes are enacted. Our net deferred tax assets are fully offset by a valuation allowance, because of our history of losses.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize the effect of income tax positions only if those positions are more likely than not of being sustained upon examination.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4aa0ce18-4916-4b35-8b1a-f3e7ec4caff8" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We calculate basic net loss per share attributable to our common shareholders by dividing net loss attributable to us by our weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to our common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, outstanding common stock warrants, outstanding stock options, nonvested restricted stock units outstanding and the maximum nonvested market-based restricted stock units outstanding eligible to be earned are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to our common shareholders, as their effect is anti-dilutive.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_08c5767a-9e6d-4344-b7aa-8cd28941a43f" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Topic 280): </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which intends to enhance reportable segment disclosures about significant segment expenses. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the guidance is to be applied retrospectively. We are currently evaluating the impact of this guidance on our consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Topic 740): </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which primarily intends to enhance the rate reconciliation and income taxes paid disclosures. This guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted and the guidance is to be applied prospectively; retrospective application is permitted. We are currently evaluating the impact of this guidance on our consolidated financial statements.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6ac668d9-9efe-4cbb-aec6-7a4fc38e2d6a" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:RevenueFromContractWithCustomerTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We disaggregate our revenue from contracts with customers by business area and type of arrangement, as we believe this best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cdad590d-5533-4ada-bdf0-f80a46495165" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents our disaggregated revenue for the periods presented (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Immune Medicine revenue</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Service revenue</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a68b682-973f-4cca-8211-ae0179fb447a" contextRef="C_c6893910-acd0-4028-a16a-e72e33a1a487" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,959</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b37ef39-1948-4427-9df2-b465844d913e" contextRef="C_c3ef0edc-d7e9-410c-9e8c-a9c962f71593" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,777</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9827efac-3f93-431b-b548-03175dd9a70c" contextRef="C_097b7e33-8328-4df1-98a7-2fb97904b263" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,482</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration revenue</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27eab2d8-e6a0-4543-9b6b-f1d263afade0" contextRef="C_204a4f00-21f5-4dcb-a003-2209a2b96734" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,578</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b332988-1ad7-4dce-a8b0-71c010b96116" contextRef="C_46e84d5a-c9e4-4c07-ab2c-1b337f1e4935" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,387</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8cfde20-62e0-428e-af3d-044985c53073" contextRef="C_d8710412-3f02-4dca-a349-7c6431efb35f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,651</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Immune Medicine revenue</span></p></td>
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67aeeadc-44a3-4022-a409-572a72f735b9" contextRef="C_a82a556c-1601-4580-ab77-910e118cd40c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,537</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e7566c2-fff8-4b1d-8075-82eba78fcd63" contextRef="C_f97d20b9-f753-4b1f-9310-f5374bf7a287" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,164</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8fd8ef46-32e3-4b4a-bc57-973132c8f434" contextRef="C_2253a734-72b4-4815-b0fe-904db241abd5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,133</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">MRD revenue</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Service revenue</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f139a66-e7a1-484a-aba3-27510762e41e" contextRef="C_d3b1db82-a429-41f4-a3a7-519573159ff1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,739</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a4a705e-f0aa-45b1-b767-eb48203508c7" contextRef="C_7e1886f0-fb32-4498-bc32-5c4175f816eb" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,144</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6573212c-89fa-4eda-8429-9bdf88c71ec1" contextRef="C_b0dca8ac-f948-40e9-872d-4956561f7f9e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,211</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Regulatory milestone revenue</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afbf5efc-c843-43d9-bcfa-3c1a952ccc05" contextRef="C_210fa5b6-4781-4834-bdb9-d0bc4fba918c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_984d0ff0-4222-4dc3-a3a2-5c15100db809" contextRef="C_8b01e241-462b-4cbe-9903-9e86be9bdd64" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total MRD revenue</span></p></td>
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab48b4e7-9d9c-483e-bb8c-196797b331d5" contextRef="C_8b6979c8-1fdd-4825-99b4-52c44d8a83f2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,739</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_897f32d0-31c5-44a1-8b14-2c428ac68284" contextRef="C_9d2cc705-f6fa-4bf8-a55b-b2a0844f2132" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,144</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b830d6b3-6fc4-409f-831c-a4fe1fd1c691" contextRef="C_508f5dbc-ed11-4aeb-8235-78423618619e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,211</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenue</span></p></td>
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9181ed4f-4859-4413-8c13-a735d74dbdf9" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170,276</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb378aa2-1ec2-4ba3-bfd2-7d1bf9099358" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,308</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82ac82ed-7e6a-4e18-95b4-b27830795ed3" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,344</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_478820ea-4f10-433c-b304-e0172b4b1601" contextRef="C_ff166e5f-74cd-481e-a4de-3d85ebc33d6f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in Immune Medicine service revenue related to cancelled customer contracts. Additionally, during the year ended December 31, 2023, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dedb5792-6646-4a3d-a0b8-791db9446850" contextRef="C_17868eb1-c4c5-48c6-b75e-f00ebc3afa5a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in MRD service revenue related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote, cancelled customer contracts and changes in estimates of total samples to be provided under certain of our agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2022, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7469994f-18fe-4f92-97df-a53826ce30bf" contextRef="C_a17c4258-455e-423a-b8b4-bc69663eb694" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in Immune Medicine service revenue related to cancelled customer contracts. Additionally, during the year ended December 31, 2022, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_caca7ab0-5e68-45b6-899e-b8b53e04759d" contextRef="C_879ff3e9-d994-4359-a193-fdc194e1100d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in MRD service revenue related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote, changes in estimates of total samples to be provided under certain of our agreements and cancelled customer contracts.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2021, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c9dc707-868c-4315-81fd-95793a7f65a4" contextRef="C_155c8aa1-a117-426c-ae23-7248267399d3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in MRD service revenue related to changes in estimates of total samples to be provided under certain of our agreements, Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote, a change in our estimate of expected cumulative tests per patient for one of our covered indications and cancelled customer contracts.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">102</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we could receive up to an additional </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bff88cff-9bae-4da2-9594-c404a9b2f859" contextRef="C_44860682-94f0-4904-9f2d-90b50cef0eaa" name="adpt:AdditionalMilestonePayment" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">440.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">milestone payments in future periods if certain regulatory approvals are obtained by our customers&#8217; therapeutics in connection with MRD data generated from our MRD product.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Genentech Collaboration Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2018, we entered into a worldwide collaboration and license agreement with Genentech (the &#8220;Genentech Agreement&#8221;) to leverage our capability to develop cellular therapies in oncology. Subsequent to receipt of regulatory approval in January 2019, we received a non-refundable, upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2dbd0b5-fd3e-41ca-8201-4392ebb609a6" contextRef="C_7984164c-34fb-49f5-8c89-ae672ec9ae5f" name="adpt:NonRefundableUpfrontPaymentsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">300.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in February 2019 and may be eligible to receive more than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc2ec1d6-bc49-42f5-a8ff-4ff3c915b07d" contextRef="C_f7590b76-24a6-4b4b-aa70-3aa848e7a0e3" name="adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" unitRef="U_USD" scale="9" decimals="INF" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion over time, including payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b08d28dc-9dda-4ccc-ac6d-8bbb4b919e20" contextRef="C_11c9cefe-d945-4687-baad-0cb3aed4a0b3" name="adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of specified regulatory milestones ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_711e5afe-6f74-4d1f-a202-51d57c8d029c" contextRef="C_8c236b85-61c5-4e71-b6c3-ced8a4945424" name="adpt:AdditionalTransactionPriceOfRegulatoryMilestone" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of which was achieved in May 2023), up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7e41699-39ae-4076-a2f1-a659eaaa744c" contextRef="C_67aee0e6-f162-469f-95d2-8cd5d55d1668" name="adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">300.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of specified development milestones and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86f90ef5-4be0-4623-9c82-392dd464d11d" contextRef="C_9af75d46-039e-4da0-97be-856b25cedf1f" name="adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">1,430.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of specified commercial milestones. In addition, we are separately able to receive tiered royalties at a rate ranging from the mid-single digits to the mid-teens on aggregate worldwide net sales of products arising from the strategic collaboration, subject to certain reductions, with aggregate minimum floors. Under the Genentech Agreement, we are pursuing two product development pathways for novel T cell therapeutic products in which Genentech intends to use T cell receptors (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8220;TCRs&#8221;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) screened by our immune medicine platform to engineer and manufacture cellular medicines:</span></p><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shared Products. The shared products will use &#8220;off-the-shelf&#8221; TCRs identified against cancer antigens shared among patients (&#8220;Shared Products&#8221;). </span></div></div><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Personalized Product. The personalized product will use patient-specific TCRs identified by real-time screening of TCRs against cancer antigens in each patient (&#8220;Personalized Product&#8221;). </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Genentech Agreement, we granted Genentech exclusive worldwide licenses to develop and commercialize TCR-based cellular therapies in the field of oncology, including licenses to existing shared antigen data packages. Additionally, Genentech has the right to determine which product candidates to further develop for commercialization purposes. We determined that this arrangement meets the criteria set forth in Accounting Standards Codification (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8220;ASC&#8221;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) Topic 808, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaborative Arrangements</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASC 808&#8221;), because both parties are active participants in the activity and are exposed to significant risks and rewards depending on the activity&#8217;s commercial failure or success. Because ASC 808 does not provide guidance on how to account for the activities under a collaborative arrangement, we applied the guidance in ASC Topic 606, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8220;ASC 606&#8221;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) to account for the activities related to the Genentech Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In applying ASC 606, we identified the following performance obligations at the inception of the agreement:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">License to utilize on an exclusive basis all TCR-specific platform intellectual property to develop and commercialize any licensed products in the field of oncology. </span></div></div><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">License to utilize all data and information within each shared antigen data package and any other know-how disclosed by us to Genentech in oncology. </span></div></div><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">License to utilize all private antigen TCR product data in connection with research and development activities in the field of use. </span></div></div><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">License to existing shared antigen data packages. </span></div></div><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development services for Shared Products development, including expansion of shared antigen data packages. </span></div></div><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development services for private product development. </span></div></div><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obligations to participate on various joint research, development and project committees. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We determined that none of the licenses, research and development services or obligations to participate on various committees were distinct within the context of the contract, given such rights and activities were highly interrelated and there was substantial additional research and development to further develop the licenses. We considered factors such as the stage of development of the respective existing antigen data packages, the subsequent development that would be required to both identify and submit a potential target for investigational new drug acceptance under both product pathways and the variability in research and development pathways given Genentech&#8217;s control of product commercialization. Specifically, under the Genentech Agreement, Genentech is not required to pursue development or commercialization activities pertaining to both product pathways and may choose to proceed with one or the other. Accordingly, we determined that all of the identified performance obligations were attributable to one general performance obligation, which is to further the development of our TCR-specific platform, including data packages, and continue to make our TCR identification process available to Genentech to pursue either product pathway.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">103</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Separately, we have a responsibility to Genentech to enter into a supply and manufacturing agreement for patient-specific TCRs as it pertains to any Personalized Product therapeutic. We determined this was an option right of Genentech should they pursue commercialization of a Personalized Product therapy. Because of the uncertainty resulting from the early stage of development, the novel approach of our collaboration with Genentech and our rights to future commercial milestones and royalty payments, we determined that this option right was not a material right that should be accounted for at inception. As such, we will account for the supply and manufacturing agreement when entered into between the parties.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We determined the initial transaction price shall be made up of only the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7d1ddaf-733e-48a1-b3a3-1756a851eb15" contextRef="C_4bbcd131-d371-4bbb-964c-f9710f39d70f" name="adpt:NonRefundableUpfrontPaymentsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">300.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upfront, non-refundable payment, as all potential regulatory and development milestone payments were probable of significant revenue reversal given their achievement was highly dependent on factors outside our control. As a result, these payments were fully constrained and were not included in the initial transaction price. In May 2023, one of the regulatory milestones was achieved, resulting in a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eee8f4f5-9581-4900-a8fd-2ccde0c98ff4" contextRef="C_a9f3e4a6-a161-4edd-ae17-b5c6c4d1afc8" name="adpt:AdditionalTransactionPriceOfRegulatoryMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million addition to the transaction price, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_acff17ee-24e6-42a8-b59d-b4f82ebdbd75" contextRef="C_a9f3e4a6-a161-4edd-ae17-b5c6c4d1afc8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.7</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of which was recognized as revenue in the three months ended June 30, 2023, with the remainder included in deferred revenue to be recognized as revenue over the remaining research and development period. We continue to exclude the commercial milestones and potential royalties from the transaction price, as those items relate predominantly to the license rights granted to Genentech and will be assessed when and if such events occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As there are potential substantive developments necessary, which Genentech may be able to direct, we determined that we would apply a proportional performance model to recognize revenue for our performance obligation. We measure proportional performance using an input method based on costs incurred relative to the total estimated costs of research and development efforts to pursue both the Shared Products and Personalized Product pathways. When any of the potential regulatory and development milestones are no longer fully constrained and are included in the transaction price, such amounts will be recognized using the cumulative catch-up method based on proportional performance at such time. We currently expect to recognize revenue generated from the Genentech Agreement over a period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ebd5cf90-0153-4894-ad6e-7e42de1196dc" contextRef="C_2bf1a599-2304-4abc-8e54-646171f11931" name="adpt:RevenueRecognitionExpectedPeriod" format="ixt-sec:durwordsen"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nine years</span></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the effective date. This estimate of the research and development period considers pursuit options of development activities supporting both the Shared Products and Personalized Product, but may be reduced or increased based on the various activities as directed by the joint committees, decisions made by Genentech, regulatory feedback or other factors not currently known.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In total, we recognized </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fb2b13f-b3f3-4f31-a8c2-5a6be1ac760d" contextRef="C_4bbcd131-d371-4bbb-964c-f9710f39d70f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">42.6</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2f68836-ab09-4e56-924f-003e7f74f2d7" contextRef="C_90b18a98-b831-4016-b24b-b23fdc203a9b" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">62.8</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af21d6d6-9828-43ac-b72c-6c4c4dd3b7b4" contextRef="C_aef81851-9d40-4e26-b3cc-121716608ec6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">62.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in Immune Medicine collaboration revenue during the year ended December 31, 2023, 2022 and 2021, respectively, related to the Genentech Agreement. Costs related to the Genentech Agreement are included in research and development expenses.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7eddde79-ec83-4758-8cd3-84e98a71b07a" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:DeferredRevenueTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred Revenue</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue from the Genentech Agreement represents </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12be69b9-2058-4018-8d31-fd16b41af384" contextRef="C_590e8b43-3f28-4c61-98e6-73136a10b460" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_751103ef-3338-48dc-95e9-50e960ce44cb" contextRef="C_590e8b43-3f28-4c61-98e6-73136a10b460" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">41.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the current and non-current deferred revenue balances on the consolidated balance sheet, respectively, as of December 31, 2023 and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80c78c14-2bca-4fa7-b965-ba8ac4e8a577" contextRef="C_ae994e8c-99db-42b9-978b-de43f2096cd2" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">31.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ad0a929-088e-49ea-b754-8d73def253ce" contextRef="C_ae994e8c-99db-42b9-978b-de43f2096cd2" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">55.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the current and non-current deferred revenue balances on the consolidated balance sheet, respectively, as of December 31, 2022. We expect our current deferred revenue to be recognized as revenue within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9550d828-e285-4b26-acef-f8c2883a37d1" contextRef="C_cb59ede3-9e6b-4249-8eda-53f2caa6aa96" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months. We expect the majority of our non-current deferred revenue to be recognized as revenue over a period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_621636de-b55f-4140-bbca-9b2b602aba26" contextRef="C_e97676e6-a32f-4929-a773-40c1fd1dd414" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from December 31, 2023. This period of time represents an estimate of the research and development period to develop cellular therapies in oncology, which may be reduced or increased based on various research and development activities.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d46e323-436a-4344-8b82-b90d046e1bd0" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in deferred revenue during the year ended December 31, 2023 were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"/>
        <td style="width:2.08%;"/>
        <td style="width:1%;"/>
        <td style="width:15.88%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea17f96b-4763-4571-9e8c-340a9176558c" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,714</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions to deferred revenue during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_488c2540-57b2-46e9-a228-73e8add895c3" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,471</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue recognized during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0775667-13a6-40d8-aa1d-156eb4478bbe" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">73,762</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_538c6c24-5816-4459-9cd9-d67144728dcb" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,423</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10166144-c0af-47bf-a789-bab863cc2395" contextRef="C_96f09fd3-7634-4ea2-a021-1e8adb2f4bc6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">53.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recognized as revenue that was included in the deferred revenue balance at December 31, 2022.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_396f832e-b56b-4015-8264-e6dbb4e70713" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95ec8f23-80d8-4ee7-844f-56a76f01c933" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables set forth the fair values of financial assets as of December 31, 2023 and 2022 that were measured at fair value on a recurring basis (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ef176e2-4dac-4c96-9a76-92b1773a23f1" contextRef="C_38611b62-cabf-4f6e-b0a1-2efc9958f5fd" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,123</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6abaa9b-d463-428f-b04b-5695de910886" contextRef="C_61d852e8-fe3d-43d3-9908-9744f1adec07" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,123</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fbd026b-c977-4f37-88b6-4ba95d412e68" contextRef="C_04434413-9490-4c62-8db8-4065a648f009" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,630</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5f37173-14ac-4fa6-ac29-2409eed2a4c9" contextRef="C_b727e5f9-4a98-4fe3-92ea-13e9386f4879" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,630</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government treasury and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67a08f99-c7b8-4ac8-9e2f-cb7e9860987a" contextRef="C_743fa22e-b9d5-4339-a15c-2d857ef34156" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">264,426</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97140e3c-bb3e-41f0-8b68-adab7af4120e" contextRef="C_01aa24c7-60e3-49ec-b493-ede3c4266545" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">264,426</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4629ec0-e230-4430-b4e2-0422b9dc1b97" contextRef="C_c2513f06-b4d4-4816-bbc2-a3007d07bc1a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,281</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_767405a2-45d9-4581-a855-a3ede03d26c1" contextRef="C_7b1ddbb7-6337-4d2b-8237-82b13e821312" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,281</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c6d8a36-a449-4a78-86fe-f9005a8aab65" contextRef="C_1bea693b-1342-45f0-bcda-ded1c10280e8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,123</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a83d3d4-f00b-4e50-a3da-d08a0ba321ff" contextRef="C_b809ccc7-b28c-4fe5-bb88-66507dc666e2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,337</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2bbd43a5-25ba-4ab2-a2a1-83a158ea63e2" contextRef="C_2a889da6-68e6-499f-9f09-345a151867c6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">326,460</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe3bc1c0-9a04-4425-9748-fad815331840" contextRef="C_233dab25-77c1-4413-89c5-c93d77ebf3f3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,502</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2828116e-3055-4343-b82e-44f809873afb" contextRef="C_f1b230a8-3c3c-45c2-a49f-2549b9086405" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,502</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fa20fac-9c9c-430a-a407-e8fdbd3c5961" contextRef="C_461360c8-498f-4146-b38f-94ec6b8507ff" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,969</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c66aa5e1-a7bb-4d7f-8c0d-c3133797b228" contextRef="C_2c6f52ef-cda4-46f2-8c5e-0be3e165c699" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,969</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db0e1a45-39bd-4241-822d-0e66e622cdee" contextRef="C_7318b790-ee25-41a4-acff-80a6c93d4e3a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">385,848</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_625c5a24-7084-49c2-b04f-baa9d594d2a3" contextRef="C_744c7609-f08e-4e56-a57b-92d4b5817a10" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">385,848</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_949abe11-28e4-4a32-9ad2-f69f8c5c95ec" contextRef="C_87feba55-a051-420f-828e-ec84f440b3a0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,349</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d257f311-4ae0-4279-b919-490ced5b2e6b" contextRef="C_db4b7b1a-cb0e-4d01-8b52-9a8b1f192635" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,349</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_862e4e25-e5e5-4edd-9def-7715fd25d96e" contextRef="C_ee1fde54-f065-4656-a66d-cb2acf02bfac" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,502</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c931a387-a9bf-431c-816b-525be9436ad3" contextRef="C_6df997e0-9e1b-4ab7-9d87-d11884be8e4a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">408,166</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0467ed61-1aa4-4e7e-bbe8-548544295a1c" contextRef="C_87dd786a-314b-49f8-baec-1edeb4120c74" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">446,668</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1 securities include highly liquid money market funds, for which we measure the fair value based on quoted prices in active markets for identical assets or liabilities. Level 2 securities consist of U.S. government treasury and agency securities, corporate bonds and commercial paper, and are valued based on recent trades of securities in inactive markets or on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2cf82994-c2f2-4696-bca9-7b450139d28b" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investments</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_85979f03-5c13-4465-9844-c9f3a789c344" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Available-for-sale investments consisted of the following as of December 31, 2023 and 2022 (in thousands):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term marketable securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_552ac076-480f-43ac-80e8-822de2c6afeb" contextRef="C_7ca7acdb-a921-4bb3-90a1-1d13fd95b1fd" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,630</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2430d425-2b55-4ecf-87fe-d46e27786c10" contextRef="C_7ca7acdb-a921-4bb3-90a1-1d13fd95b1fd" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,630</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government treasury and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7eb17cd0-3ed4-4db7-9337-1ae260a1814c" contextRef="C_1ebf03ab-8700-457d-a330-2b6afbc9f9dc" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">264,214</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce4e9da1-e691-434e-bed5-84fa93fd9b57" contextRef="C_1ebf03ab-8700-457d-a330-2b6afbc9f9dc" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">232</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4f543ef-5c08-4936-9569-45561be511c6" contextRef="C_1ebf03ab-8700-457d-a330-2b6afbc9f9dc" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75f081d7-5ff7-43e2-8608-8d4edf811888" contextRef="C_1ebf03ab-8700-457d-a330-2b6afbc9f9dc" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">264,426</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a28e35e-cdd5-4fac-bfec-e1939d0b660c" contextRef="C_1a866f0e-30b1-4ade-9e73-d9a9bba031bb" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,278</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bcd8e0c8-282f-4a85-894d-047eda13ce6d" contextRef="C_1a866f0e-30b1-4ade-9e73-d9a9bba031bb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa647319-3d2f-4fec-ac9a-ab4da2f43cf2" contextRef="C_1a866f0e-30b1-4ade-9e73-d9a9bba031bb" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,281</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff244f2c-5052-4851-874b-be90b2f9262d" contextRef="C_c6dd27e3-1742-4ce3-b818-2cc2fe370e7b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,122</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4403182-00ba-4d9a-8b0c-e5a61a78012a" contextRef="C_c6dd27e3-1742-4ce3-b818-2cc2fe370e7b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">235</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0609286-8942-4f8c-9edf-5d5723f7b1d8" contextRef="C_c6dd27e3-1742-4ce3-b818-2cc2fe370e7b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b306d1d-59c6-499f-8426-66932558773e" contextRef="C_c6dd27e3-1742-4ce3-b818-2cc2fe370e7b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">281,337</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term marketable securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_575dc755-769c-40cc-bc3a-789ac3adaaa6" contextRef="C_a3dfafff-e989-4644-9b5f-c4c61d62483b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,969</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b91ce7e-2e88-4941-aa8a-0eeb8c71ac6e" contextRef="C_a3dfafff-e989-4644-9b5f-c4c61d62483b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,969</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15f38cd9-dd39-44af-8d0d-50f6a33fed01" contextRef="C_d8afb5c3-07c8-4db4-ac88-9ca5562689cf" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">389,898</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4cd95b9-4743-4e6a-aa47-07c330d93713" contextRef="C_d8afb5c3-07c8-4db4-ac88-9ca5562689cf" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc29cf02-ab19-494a-9efa-ae16a5227699" contextRef="C_d8afb5c3-07c8-4db4-ac88-9ca5562689cf" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,064</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e692ec6b-06f7-4b17-ba02-75ddc0b1e69a" contextRef="C_d8afb5c3-07c8-4db4-ac88-9ca5562689cf" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">385,848</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbcc9595-7e3f-4e4a-8294-c01a405027ab" contextRef="C_454dcbb2-775d-4dc6-8e99-ed83e128e3ca" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,415</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3434aebe-9864-4026-9e04-df7c4badbbf2" contextRef="C_454dcbb2-775d-4dc6-8e99-ed83e128e3ca" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ee25851-0e80-499f-9cd9-db60cbd08af1" contextRef="C_454dcbb2-775d-4dc6-8e99-ed83e128e3ca" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,349</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_303a47ef-0744-4702-a8a4-291d0392ec0e" contextRef="C_321cee55-58fd-4472-9917-05fb1e50572d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">412,282</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a7ad4b4-af86-49f0-b796-36bf58f48f3a" contextRef="C_321cee55-58fd-4472-9917-05fb1e50572d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_435c558f-b474-4633-b696-39cf4856bd8c" contextRef="C_321cee55-58fd-4472-9917-05fb1e50572d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,130</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c976733-1cd0-40c6-a5f1-51af0f9134fe" contextRef="C_321cee55-58fd-4472-9917-05fb1e50572d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">408,166</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All the U.S. government treasury and agency securities, corporate bonds and commercial paper designated as short-term marketable securities have an effective maturity date that is equal to or less than one year from the respective consolidated balance sheet date. Those that are designated as long-term marketable securities have an effective maturity date that is more than one year from the respective consolidated balance sheet date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued interest receivable is excluded from the amortized cost and estimated fair value of our marketable securities. Accrued interest receivable of </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06e42ff6-7748-4eed-8a11-80558921eece" contextRef="C_adce8143-c708-4ab4-aad4-7932228c2737" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a11a78b8-20a4-4c78-9bd0-49a38a815d5c" contextRef="C_060ee2a5-56eb-46bd-b35a-e98de401cab1" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was presented separately within the prepaid expenses and other current assets balance on the consolidated balance sheet as of December 31, 2023 and 2022, respectively.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">105</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e107cb54-cf91-4c63-8fbb-a01c1ddbaa11" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the gross unrealized holding losses and fair values for investments in an unrealized loss position, and the length of time individual securities have been in a continuous loss position, as of December 31, 2023 (in thousands):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Less Than 12 Months</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">12 Months Or Greater</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government treasury and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56ea6851-7a4e-4c38-a24f-8764403fdfd0" contextRef="C_a21c196f-6dfe-415c-b90a-3c3da2b36e46" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_661e779b-d127-484e-94da-90556fddc410" contextRef="C_a21c196f-6dfe-415c-b90a-3c3da2b36e46" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total available-for-sale securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01e48f74-541a-422a-8c65-d09d29ca21c0" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,100</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2b3fd4c-d43c-4fda-b5e1-eec572dd16e6" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We periodically review our available-for-sale securities to assess for credit impairment. Some of the factors considered in assessing impairment include the extent to which the fair value is less than the amortized cost basis, adverse conditions related to the security, an industry or geographic area, changes to security ratings or sector credit ratings and other relevant market data.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we did not intend, nor were we more likely than not to be required, to sell our available-for-sale investments before the recovery of their amortized cost basis, which may be maturity. Based on our assessment, we concluded all impairment as of December 31, 2023 to be due to factors other than credit loss, such as changes in interest rates. A credit allowance was not recognized and the impairment of our available-for-sale securities was recorded in other comprehensive loss.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_21b627dc-9742-4280-9359-56d2a0f5c72e" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and Equipment, Net</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_771a0c5d-53ee-4fe8-9124-afda212111a8" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net as of December 31, 2023 and 2022 consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9fadc12-19ce-4b3a-8848-843af54c29a3" contextRef="C_39323104-bdda-4a5f-b4e0-aa2def94b95a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,567</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5ff4e2b-618d-44f2-abfa-38095654d7b8" contextRef="C_1e722b79-1338-44ce-bc10-fb18fa0cad8d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,592</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db5df146-0985-4a94-b11a-0663aa187282" contextRef="C_80445f63-6e69-4b85-a4cc-f71cd5e32898" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,970</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc79addb-5736-4edd-86ae-6dd402e38153" contextRef="C_58ce94ff-2264-4ea2-a84c-edf34c96332a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,766</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and office equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ed2de33-4eb1-4eb2-81c7-535a7b5f48b2" contextRef="C_a75aed5b-f247-4baf-af25-a000ba7211d5" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,820</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bbad5a1-d40f-4537-a45a-2cf79cb1caea" contextRef="C_ab0a4bc0-c687-4b75-97a5-8e7d11a1a0be" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,342</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15bc841e-90bf-4e69-817b-b04ba2f6638c" contextRef="C_fb89157d-97e5-40d0-828e-fcafd3b932a1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,965</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4b962be-230b-4a3a-b741-dc14ba297b19" contextRef="C_8026f205-9131-4390-94dd-4a04d3c584e7" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,069</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16ec5c50-bfa1-4966-ad7f-27a4fe4a9e66" contextRef="C_3ebe0fdc-225c-4155-afc8-97ad3dc284b2" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,405</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c58df467-fdb8-45e5-90b7-3b7742c7897b" contextRef="C_a716e596-2c29-46d5-9c2b-dba9981ab3f1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,625</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_630f4b07-6be9-4d08-b81a-e69d8ad4771a" contextRef="C_1e988e7e-5089-4aac-8a2c-022b8659ce3b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,734</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd94ace4-38d2-419c-b577-0764a7b590c7" contextRef="C_fbb4d461-a817-4980-9efc-c5c5e7bea481" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,403</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment, at cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5d1549a-5a7d-4479-a2f9-646317af7d3f" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,461</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73c9a585-38c3-4cd6-b0ed-fa3b3a0002bc" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137,797</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64957546-c164-46f9-814f-8116b547bb46" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,234</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_236471ef-1bca-4567-9b5a-1d8133466c07" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,350</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a466c19-ed03-4dcc-b8ce-df1e3f71628a" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,227</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3df61528-5f50-47b6-b74b-ae64342e54ae" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,447</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_f485313e-3132-4f66-bad3-0a3286de9d49" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3159e61-33e6-4af6-854b-7f878087d98f" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83264141-c01f-4a79-893e-d279c74818a9" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023, 2022 and 2021, respectively. See Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for details regarding the impairment loss we recognized for certain leasehold improvements for the year ended December 31, 2023.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f684fb63-b4b3-407f-93c0-e25685aa4d47" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill and Intangible Assets</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9049ddfb-4d1f-4c12-800a-4cff6ecf6f90" contextRef="C_2fd988f0-f2ea-429d-b4f6-17267c9ddedc" name="us-gaap:GoodwillPeriodIncreaseDecrease" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> changes in the carrying amount of goodwill since its recognition in 2015.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7f02e59c-0eec-4780-acc3-c21cb4866bb1" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets subject to amortization as of December 31, 2023 and 2022 consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Carrying Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated Amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net Carrying Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquired developed technology</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_497a5121-746d-4c87-8bfd-584e431cb398" contextRef="C_a0652792-ebc5-4eac-b642-e4d6670801ba" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11e1feb6-cd67-4607-8dff-a4cafd0b1b17" contextRef="C_a0652792-ebc5-4eac-b642-e4d6670801ba" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,970</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_995b68db-53ec-4ef7-92b3-f1afdd4be1dc" contextRef="C_a0652792-ebc5-4eac-b642-e4d6670801ba" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,030</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchased intellectual property</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b947e920-a35a-43a1-8fc0-cec98a46643a" contextRef="C_52090110-82a5-4e46-93f8-8226b4b52be6" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">325</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbd3b05b-8381-48dc-82f0-1087bf4ff8ad" contextRef="C_52090110-82a5-4e46-93f8-8226b4b52be6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">227</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e92e53c-95f2-4f2a-8a31-0498cad73c73" contextRef="C_52090110-82a5-4e46-93f8-8226b4b52be6" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0448c5de-8fb0-4556-b0d5-ea304da001ab" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,325</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0c41f8a-0305-4c82-bff1-cf8d3d04e63d" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,197</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ce8c549-0c77-41e4-ae43-f3bf1074ea34" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,128</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Carrying Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated Amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net Carrying Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquired developed technology</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_156d52d3-30fd-4960-bc71-f7a39d2dddc1" contextRef="C_216614d0-45a0-4666-935c-4122d8cd59aa" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b91ad6c-2e4b-4fb0-918d-3cfd870a5929" contextRef="C_216614d0-45a0-4666-935c-4122d8cd59aa" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,304</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dce7f944-205e-4d5d-937d-6278f8d9b9b3" contextRef="C_216614d0-45a0-4666-935c-4122d8cd59aa" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,696</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchased intellectual property</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4d26447-5418-44e7-9c38-a9aaa85109da" contextRef="C_7e26ca88-f723-4c17-a005-4eccedfed38e" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">325</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_432eb850-9fa9-4c75-bdd3-4a04de37de28" contextRef="C_7e26ca88-f723-4c17-a005-4eccedfed38e" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">194</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83c70900-1da7-4eb4-a19b-bbfb4f0d5857" contextRef="C_7e26ca88-f723-4c17-a005-4eccedfed38e" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_117fad7f-82ea-4740-91c0-7aab4adb358a" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,325</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c94880c9-243e-4144-aa8c-86d7c6171215" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,498</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67256c74-c8c4-4a9e-97b1-62951a2c3907" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,827</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">106</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The developed technology was acquired in connection with our acquisition of Sequenta, Inc. in 2015. The remaining balance of the acquired developed technology and the purchased intellectual property is expected to be amortized over the next </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80a01ad7-8a4b-43cc-898d-62799553d884" contextRef="C_52090110-82a5-4e46-93f8-8226b4b52be6" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1747c96d-ce03-48e0-b827-a62f39d77b94" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, expected future amortization expense for intangible assets was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"/>
        <td style="width:2.08%;"/>
        <td style="width:1%;"/>
        <td style="width:15.88%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_556291f7-5910-4ab8-846a-ebfdb27850e5" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,703</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2553016a-9a81-49b4-ba4f-f0555894e92f" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,699</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd5918dc-becb-4b7f-8d9b-cf7db5439c42" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,699</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_661aae4a-8fb9-4d0e-8a41-8189b2aec24e" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total future amortization expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0970a026-ff04-442c-b4e3-336a646a6f6d" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,128</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4f90a5a6-29f5-4cb5-a9b1-416c5cecf684" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued Liabilities</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ba37bb8a-3e84-4ea9-bd83-5e62ccd54e0c" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued liabilities as of December 31, 2023 and 2022 consisted of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d99cc2cf-2c9f-46c2-8a12-ef59b6a8cd1a" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,920</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6806453d-6d66-47f1-8f0f-4783f61b54bc" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,744</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clinical and contract research organization costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7cb28899-0e3f-4755-8ca0-f96495c2f31b" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="adpt:AccruedClinicalAndContractResearchOrganizationCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">863</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be7acfac-e706-4ea3-8fb8-53b72f90b64e" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="adpt:AccruedClinicalAndContractResearchOrganizationCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,533</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Travel and entertainment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0b1766a-4328-4662-ba37-4ce207434a60" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">154</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93af0e1a-250e-4ec5-9f4a-0bce7c7d41d3" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">233</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a542c15-b72a-4b02-a04f-9d9cf9bc9ebc" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5eeccaa6-8fa5-47cd-986f-2bc8ed808aff" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">194</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a70cff50-29e5-4cf2-834d-2dc07c998c18" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="adpt:AccruedPurchaseOfPropertyAndEquipmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">687</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34c5e693-912a-4f48-b05d-e6cc86144704" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="adpt:AccruedPurchaseOfPropertyAndEquipmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,680</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer and software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ac7ae1e-7a93-4e2d-a435-1b16a58fb9ce" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="adpt:ComputerAndSoftware" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,151</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18d8d719-1eda-47c3-aaca-930142936078" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="adpt:ComputerAndSoftware" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,385</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35ecbf7e-1094-4337-8f74-585174eec44c" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">763</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60714ac8-2dc0-48de-b5fe-3081fdbe204d" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,655</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d7e4e4e-d347-40ff-b8d4-545314a3f495" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,597</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7761e37a-c386-40cc-b7ff-72ab53653687" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,424</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3043d5aa-31ca-4587-8576-b38b27f4c2e9" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><div style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have operating lease agreements for laboratory, office and warehouse facilities that we occupy in various locations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2011, we entered into a non-cancelable lease agreement with an, at the time, minority shareholder for office and laboratory space in Seattle, Washington. The lease terms were subsequently amended multiple times, most recently in August 2019, when we expanded the existing premises to approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ca18231-3722-479e-89a2-be56d002f94a" contextRef="C_497af0a4-b8d1-426d-b46e-bab07be8dadd" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">65,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_15680438-f300-4489-b5a5-c6c4fabe3dfd" contextRef="C_fab848dc-7a49-4318-bdad-9aa948d6f630" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash payment for rent of the expanded premises commenced </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b0849427-f787-41ce-b7cc-56f71dd72586" contextRef="C_fab848dc-7a49-4318-bdad-9aa948d6f630" name="adpt:LesseeOperatingLeaseRentCommencementMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 2020</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, four months after the landlord delivered the expanded premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20648bb9-4f8e-4399-8260-27a1dee35f1d" contextRef="C_fab848dc-7a49-4318-bdad-9aa948d6f630" name="adpt:LeaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 2032</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, subject to our option to twice extend the lease for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c60dcffe-6cdb-4094-a892-8739b5350cb3" contextRef="C_fab848dc-7a49-4318-bdad-9aa948d6f630" name="adpt:LesseeOperatingLeaseExtendedTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The amended lease also requires us to pay additional amounts for operating and maintenance expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, we vacated this leased space. As such, we assessed the right-of-use asset and related leasehold improvements (together, the "asset group") for impairment by first comparing the carrying amount of the asset group to future net undiscounted cash flows projected to be generated over the remaining lease term. These projections include management's estimates of cash inflows from potential sublease income and outflows for operating and maintenance expenses. The carrying amount was found to be unrecoverable, thus we assessed the asset group's fair value. The extent to which the asset group's carrying amount exceeds its fair value represents the impairment cost to be recognized. Fair value was determined using the income approach, whereby we discounted estimated net cash flows using a rate commensurate with our estimated incremental borrowing rate. As a result of this assessment, which included unrecoverable operating and maintenance costs, we determined that the asset group was to be fully impaired. As such, an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_644ede94-23a3-4d5b-89f7-eb3175c3cb6c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impairment charge</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a58ae27a-7d98-4fc1-bbe8-f95bed9c2946" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:ImpairmentOfRightOfUseAndRelatedLongLivedAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recognized during the year ended December 31, 2023, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b61b1fe9-005c-414f-8236-fb0495c22834" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:OperatingLeaseImpairmentLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to the right-of-use asset and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10d2d195-ff19-46ec-bc32-8fb41958eeb3" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to the long-lived leasehold improvements, all of which were held for use.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">107</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2019, we entered into an agreement to rent approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da0ccc47-3b04-41c3-9de4-32b7485ef34f" contextRef="C_ea6a3074-5c90-4942-a6a0-917ee25491db" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet in what was a to-be-constructed, new headquarters building in Seattle, Washington. In connection with the lease, we entered into a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45128b82-8615-4101-bfde-9cefc3da32f7" contextRef="C_ea6a3074-5c90-4942-a6a0-917ee25491db" name="us-gaap:LettersOfCreditOutstandingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million letter of credit with one of our existing financial institutions. The lease commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8ed4f8c8-ccb5-4ee8-ad3f-044c3e29a5f3" contextRef="C_041a7632-3fc1-4163-8570-83d81957490c" name="adpt:LeaseCommencementMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 2020</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, when the landlord delivered the premises to us for construction of certain tenant improvements. We occupied the new building in 2021, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_953b6225-bf10-4194-9732-c437f7d1d972" contextRef="C_041a7632-3fc1-4163-8570-83d81957490c" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cash payment for rent began in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_480fc46e-7c44-40f9-8515-104344fce53a" contextRef="C_041a7632-3fc1-4163-8570-83d81957490c" name="adpt:LesseeOperatingLeaseRentCommencementMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the lease term ends in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04d312a1-5c02-4672-ac52-be2b0d4201df" contextRef="C_041a7632-3fc1-4163-8570-83d81957490c" name="adpt:LeaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 2033</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject to our option to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_40214fbd-e101-4211-a8e6-b91d5dbcec24" contextRef="C_041a7632-3fc1-4163-8570-83d81957490c" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a05ee39b-c5b3-4621-885c-6d253df99163" contextRef="C_fab848dc-7a49-4318-bdad-9aa948d6f630" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twice extend the lease</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c066913-6581-4c5c-bf7b-a6bbc17d080f" contextRef="C_041a7632-3fc1-4163-8570-83d81957490c" name="adpt:LesseeOperatingLeaseExtendedTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In connection with this lease, the landlord agreed to fund $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bac1f965-1826-408a-b52a-9dd1b7362cf5" contextRef="C_ea6a3074-5c90-4942-a6a0-917ee25491db" name="us-gaap:LeaseholdImprovementsGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in improvements, which was subsequently reduced to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_699e1d9e-faee-4091-a225-98ddb39afef5" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:LeaseholdImprovementsGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as a result of our change requests made during landlord construction of the building, net of an administration fee. As of December 31, 2022, we incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ec4cbb2-c6d1-4082-85ea-d801f6e759c9" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="adpt:TenantImprovementCostsIncurred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_25830b22-da6d-4868-b8c4-03947f2a811b" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="adpt:ProceedsFromLandlordReimbursements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.9</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in certain tenant improvement costs, all of which had been reimbursed by the landlord. As of December 31, 2021, we incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83fc5479-6d21-4e82-806a-0e205a414812" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="adpt:TenantImprovementCostsIncurred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in certain tenant improvement costs, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_512eaa74-a4e1-492c-bcda-a388a2cf4d6b" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="adpt:ProceedsFromLandlordReimbursements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million had been reimbursed by the landlord. The remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61235abf-8c17-4baf-90e0-7cce5a3db6d2" contextRef="C_6f19237c-a155-4029-b45f-b9fb5332f737" name="adpt:TenantImprovementCostsReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is presented as a reduction in the cash flows used to measure our ROU asset and lease liabilities on the consolidated balance sheet as of December 31, 2021. The lease also requires us to pay additional amounts for operating and maintenance expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2018, we entered into a lease agreement to lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_858ddca6-dedd-4268-bec4-0d01dbb05d3e" contextRef="C_682d1e35-b24e-473d-a5dc-2e2a8f3b17fd" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">13,400</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet in South San Francisco, California. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ba34557-7a73-4db7-9325-946ceb9eecdc" contextRef="C_f352b237-e382-41ae-acc7-96078de3a980" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The lease term is through </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e48e473d-58b7-413c-b337-bef8be194ef9" contextRef="C_f352b237-e382-41ae-acc7-96078de3a980" name="adpt:LeaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and provides for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_13665d1f-19ae-4e10-afce-937ec2992e2f" contextRef="C_f352b237-e382-41ae-acc7-96078de3a980" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d8358503-3217-4763-b0ce-db8b0d0bbd52" contextRef="C_f352b237-e382-41ae-acc7-96078de3a980" name="adpt:LesseeOperatingLeaseExtendedTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> extension option</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We are responsible for our share of allocable operating expenses, tax expenses and utilities costs during the duration of the lease term. In connection with the lease, the landlord funded agreed-upon improvements. The landlord was solely responsible for the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5a20b6e-520b-4da0-89a3-be27196074fa" contextRef="C_682d1e35-b24e-473d-a5dc-2e2a8f3b17fd" name="us-gaap:TenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million cost of such improvements. The lease agreement was amended in February 2020 to lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e86a7578-6502-4aa3-9ccd-4b7926de9a95" contextRef="C_2b549b79-66c4-4298-ba5f-b1b62fef2585" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">19,900</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional square feet and provides for a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bbe5b66-a8ae-4ed8-8c6a-b03395967dad" contextRef="C_26c20ab9-dfe4-46c3-b509-3bf6d6c00d37" name="adpt:TenantImprovementAllowanceAndCommenced" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million tenant improvement allowance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2021, we executed a lease to rent approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1718418-57df-4336-9cf5-97e36fd4b75e" contextRef="C_225e2fb7-7901-40b4-90c2-b52ec6899530" name="us-gaap:AreaOfLand" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">27,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of a warehouse in Bothell, Washington, which we classified as an operating lease upon commencement during the year ended December 31, 2021. Rent obligations commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d0cc4cf-676f-488e-8e90-32a35287df7f" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:LesseeOperatingLeaseRentObligationsCommencementMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the lease expires </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_81b0efcf-d81d-4b28-81a9-288932e8c420" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:LeaseExpirationMonthAndYear" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 2031</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e2c4915-4316-4acf-ad37-64f857b0eb3c" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject to an early termination option after the seventh year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and an </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_333e4078-9b67-49ab-a786-78d20034ac2b" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">option to twice extend the lease for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3e48dd7d-3833-4375-ba19-c5aae5e2c92b" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The lease requires us to pay certain operating expenses. Furthermore, the landlord agreed to fund $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81bec065-a680-4c7f-8c32-e25d0396be1d" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="adpt:LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in improvements in connection with this lease.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we were not party to any finance leases. Our leases have remaining terms ranging from </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_63e3f037-97fe-46a8-adaa-7201c2d7f855" contextRef="C_c035e4ca-1c96-49e2-bf85-b7dc628cce3a" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.2</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c8888885-61b9-4e80-9432-3da0728165cf" contextRef="C_e3bfaebb-d3c1-42af-942f-8e8d8be6dd92" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9.7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and include </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d622c0ba-72da-4204-b532-6e75a5c79b3e" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">options to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6fdff250-74fa-42eb-aa54-a98d2be6b456" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">extend certain of the leases</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> up to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0523c60b-8200-49fc-955c-d0617d3d95d4" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and terminate certain of the leases after </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_208e53c1-4075-4c18-b333-737216989bd6" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:LesseeOperatingLeaseTerminationPeriod" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years of leasing. We adjust lease terms for these options only when it is reasonably certain we will exercise these options.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_72e86cd8-31bf-420c-82f7-068814b04d2c" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other information related to our operating leases as of December 31, 2023 and 2022 was as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"/>
        <td style="width:1.26%;"/>
        <td style="width:1%;"/>
        <td style="width:13.379999999999999%;"/>
        <td style="width:1%;"/>
        <td style="width:1.26%;"/>
        <td style="width:1%;"/>
        <td style="width:13.379999999999999%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_99790eaf-52b5-4396-be92-4b4774b1911e" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.91</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_09d9cbeb-baab-4152-9b74-f4165fba463a" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.75</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8810132a-0f98-4df6-b421-1227d469b5c4" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e1aa9e2-58e3-4282-a122-05aeff436051" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2d5b7c9-01da-4ac0-bfa6-ef1dccca15c3" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities, less current portion balance on the consolidated balance sheet as of December 31, 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"/>
        <td style="width:2.08%;"/>
        <td style="width:1%;"/>
        <td style="width:15.88%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3ecbc54-77e7-4f17-a75b-f4b87c8c1b1b" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,692</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4c28e4e-a7ae-46a7-8baa-cc9ed81ce062" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,098</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_131cc339-46a8-4446-9ff8-e8d17b870ebc" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,330</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85e377dd-6b9e-4322-89af-a1367943e66d" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,944</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bc16dfe-e99f-4807-804c-85418a5ac9f8" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,282</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_297df411-a421-46dc-880c-6c5c36a3f00c" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,962</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_014da525-e8ef-4953-a82f-ef68e21aa579" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,308</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Imputed interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f9f3e1d-2020-491b-8e31-3abd68169d98" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,536</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12241e46-2e80-449b-96be-acce5bfb255a" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,772</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7cd23fcc-0b6d-49d6-93e3-2427593ec3a0" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,384</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, less current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de581b1d-e458-425c-886a-6412cff1bea2" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,388</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating lease expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa85961b-8152-4ea1-a236-6420704419ef" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bc4c9f6-eeb0-440f-9bd0-59ac08012085" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6846f5f-cb6b-4869-921b-9e930cca4a3a" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023, 2022 and 2021, respectively. Variable lease expense for operating leases was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a0d79cf-7d87-4db1-9c39-fe03f0bca93d" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:OperatingLeaseVariableLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f41877c1-75a0-4e21-8fcf-976f4a3a6005" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="adpt:OperatingLeaseVariableLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f34de189-ad52-46c9-861f-5ada2ace7e51" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="adpt:OperatingLeaseVariableLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023, 2022 and 2021, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities for the year ended December 31, 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf2af708-eed7-4a27-9764-c65fedeea50a" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Cash paid for amounts included in the measurement of lease liabilities for the year ended December 31, 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0a16a35-1f6c-4ce7-bfb2-50e02f601a65" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, net of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f4a2610-0b12-4294-9dac-8f068966d945" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:PaymentsForProceedsFromTenantAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of cash received for tenant improvement allowances. Cash paid for amounts included in the measurement of lease liabilities was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c748f08-2d0c-4fdd-8265-421c7a0443c1" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and cash received for tenant improvement allowances was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6095e910-1254-41ee-984c-55f5b7061d4a" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:PaymentsForProceedsFromTenantAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the year ended December 31, 2021. For the year ended December 31, 2021, ROU assets obtained in exchange for operating lease liabilities was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67fb596d-d1e9-419d-b805-9d5082a00a5c" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">108</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_85b6c706-c2ad-4df6-9005-6cdd78b339ea" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:RevenueInterestPurchaseAgreementTextBlock" escape="true"><div style="font-size:0;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue Interest Purchase Agreement</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Interest Purchase Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2022, we entered into the Purchase Agreement with OrbiMed Royalty &amp; Credit Opportunities IV, LP (&#8220;OrbiMed&#8221;), an affiliate of OrbiMed Advisors LLC, as collateral agent and administrative agent for the purchasers party thereto (the &#8220;Purchasers&#8221;). Pursuant to the Purchase Agreement, we received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c55ba6a-0dc9-4684-8bf8-9da31760be39" contextRef="C_5a86b9bb-1277-4e79-955e-d1edb50cca23" name="adpt:UpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">125.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the Purchasers at closing (the &#8220;First Payment&#8221;), less certain transaction expenses. We are also entitled to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b270710-87dc-4048-9d81-9829dd94d2b1" contextRef="C_f2870833-bf7c-4640-b2de-b1f3f45dc7ae" name="adpt:PotentialRevenueInterestPaymentToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">125.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in subsequent installments as follows: (i) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c63b7ccf-42ef-4b0e-b3ec-6959254cb040" contextRef="C_a8a04fa6-b5e0-4214-92b3-ab7f17428e2c" name="adpt:PotentialRevenueInterestSecondPaymentToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon our request occurring no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6740ac28-747e-4a40-b81a-126a3ef100ae" contextRef="C_5a86b9bb-1277-4e79-955e-d1edb50cca23" name="adpt:PurchaseAgreementSecondPaymentDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 12, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the &#8220;Second Payment&#8221;) and (ii) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2bc58829-9dce-400f-88d9-fdf3921bec90" contextRef="C_a8a04fa6-b5e0-4214-92b3-ab7f17428e2c" name="adpt:PotentialRevenueInterestThirdPaymentToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon our request in connection with certain permitted acquisitions occurring no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d7d148cb-018e-4dc3-9393-8a8bfb9ca19d" contextRef="C_5a86b9bb-1277-4e79-955e-d1edb50cca23" name="adpt:PurchaseAgreementThirdPaymentDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 12, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the &#8220;Third Payment&#8221;), in each case subject to certain funding conditions. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To secure our obligations under the Purchase Agreement, we and our subsidiaries have granted OrbiMed a security interest in our core platform technology assets, subject to certain customary exclusions, as defined in the Purchase Agreement.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Interest Payments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As consideration for such payments, the Purchasers have a right to receive certain revenue interests (the &#8220;Revenue Interests&#8221;) from us based on a percentage (the &#8220;Applicable Payment Percentage&#8221;) of all GAAP revenue (the &#8220;Revenue Base&#8221;). If only the First Payment has been made, the Applicable Payment Percentage shall be five percent of the quarterly Revenue Base. If both the First Payment and Second Payment have been made, the Applicable Payment Percentage shall be eight percent of the quarterly Revenue Base. If each of the First Payment, Second Payment and Third Payment have been made, the applicable payment percentage applied to the Revenue Interest shall be ten percent of the quarterly Revenue Base.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payments in respect of the Revenue Interests shall be made quarterly within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_212ebf62-85cb-4cf0-9ba4-93a8fc580465" contextRef="C_5a86b9bb-1277-4e79-955e-d1edb50cca23" name="adpt:RevenueInterestPaymentTerm" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days following the end of each fiscal quarter (each, a &#8220;Revenue Interest Payment&#8221;). If OrbiMed has not received Revenue Interest Payments in the aggregate equal to or greater than the sum of its invested capital (the &#8220;Cumulative Purchaser Payments&#8221;) on or prior to September 12, 2028, the revenue interest rate shall be increased to a rate which, if applied retroactively to our cumulative Revenue Base, would have resulted in Revenue Interest Payments equal to the sum of all Cumulative Purchaser Payments.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Return Cap</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OrbiMed will be entitled to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32d1391f-cd06-4a3c-8277-32e2cf1d89dd" contextRef="C_a8a04fa6-b5e0-4214-92b3-ab7f17428e2c" name="adpt:PercentageOfRevenueInterestPayments" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Revenue Interest Payments until it has received a total cumulative value of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b184216-ec50-499e-88f1-8e96932bbda7" contextRef="C_a8a04fa6-b5e0-4214-92b3-ab7f17428e2c" name="adpt:PercentageOfCumulativePurchaserPayments" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">165</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Cumulative Purchaser Payments (the &#8220;Return Cap&#8221;), unless full repayment of the amount of the Return Cap has not been made by </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b413ae3e-e0f6-4fb3-b9cd-b0b7471a3940" contextRef="C_5a86b9bb-1277-4e79-955e-d1edb50cca23" name="adpt:CumulativePurchaserPaymentsRepaymentDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 12, 2032</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, in which case the Return Cap shall be increased to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc052111-08e7-486f-8498-f7afc55c507e" contextRef="C_a8a04fa6-b5e0-4214-92b3-ab7f17428e2c" name="adpt:IncreaseInReturnCapPercentageOfCumulativePurchaserPayments" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">175</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Cumulative Purchaser Payments.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Put/Call Options</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the occurrence of a Put Option Event (as defined in the Purchase Agreement), including material divestitures by us, a change in control, material judgments, or bankruptcy events, Purchasers representing at least a majority of the purchase commitments under the Purchase Agreement shall have the right but not the obligation ("the Put Option") to require us to repurchase all of the outstanding Revenue Interests at the applicable price (the &#8220;Put/Call Price&#8221;). Additionally, at any time following receipt of the First Payment, we may exercise a call option to repurchase all Revenue Interests at the applicable Put/Call Price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For all Put Option Events other than a change of control or a material divestiture, the Put/Call Price shall be an amount equal to the applicable Return Cap. For a change of control or a material divestiture, prior to March 12, 2024, the Put/Call Price shall be an amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b48ddd42-337b-4cfb-a746-d5d90ddc09bf" contextRef="C_aab74f81-a01f-4770-b79a-d5141418080d" name="adpt:PercentageOfCumulativePurchaserPayments" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">120</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Cumulative Purchaser Payments less the sum of all Revenue Interest Payments made by us to the Purchasers prior to such date, between March 12, 2024 and September 12, 2024, the Put/Call Price shall be an amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_794ecb55-0620-46c5-8865-03b646c88bc2" contextRef="C_3bce53c7-facd-4e2e-ad21-6441c070f91f" name="adpt:PercentageOfCumulativePurchaserPayments" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">125</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Cumulative Purchaser Payments less the sum of all Revenue Interest Payments made by us to the Purchasers prior to such date, and after September 12, 2024, the Put/Call Price shall be equal to the applicable Return Cap.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Treatment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We evaluated the terms of the Purchase Agreement and concluded that the features of the Cumulative Purchaser Payments are similar to those of a debt instrument. Accordingly, we accounted for the transaction as debt recorded at amortized cost using the effective interest rate method. We further evaluated the terms of the debt and determined that the Put Option that is exercisable by the Purchasers upon certain contingent events requires bifurcation as a derivative. However, the value of the Put Option was determined to be immaterial due to the remote possibility of exercise. We assess the value of the Put Option periodically.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To determine the amortization of the Purchase Agreement obligation, we are required to estimate the amount and timing of future Revenue Interest Payments based on our estimate of the timing and amount of future revenues and calculate an effective interest rate which will amortize the obligation to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72c03825-7f27-442a-b502-57a511c0f6fe" contextRef="C_b0c61c69-cbe1-4b8f-9a70-56d35c5b6efc" name="adpt:AmortizationOfPurchaseAgreementObligation" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> over the amortization period. The calculated effective interest rate as of December 31, 2023 was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c3ab7bd-6e55-4b9b-b99c-e9d94b678796" contextRef="C_c0b012e9-1d72-456e-818b-e7c99403c318" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">9.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">109</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Purchase Agreement, we incurred debt issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8fdea54-80a8-4286-aebe-6492b64a4c83" contextRef="C_c0b012e9-1d72-456e-818b-e7c99403c318" name="us-gaap:DeferredFinanceCostsNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Debt issuance costs have been recorded to debt and are being amortized over the estimated term of the debt using the effective interest method, adjusted on a prospective basis for changes in the underlying assumptions and inputs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The assumptions used in determining the expected repayment term of the obligation and amortization period of the issuance costs requires that we make estimates that could impact the short- and long-term classification of these costs, as well as the period over which these costs will be amortized. We periodically assess the amount and timing of expected Revenue Interest Payments based on internal forecasts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different than our original estimates, we will prospectively adjust the amortization of the revenue interest liability and the effective interest rate.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6bb82637-d51e-4283-9ada-0ad72fd83077" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the revenue interest liability, net activity during the years ended December 31, 2023 and 2022 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"/>
        <td style="width:2.08%;"/>
        <td style="width:1%;"/>
        <td style="width:15.88%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest liability at inception</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_965520f4-4ae5-401e-afd1-f3451716e0fd" contextRef="C_18612828-7d58-4576-a6a2-b4505743ef18" name="adpt:RevenueInterestLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23cca901-cac6-45b8-81d5-6004871bac9f" contextRef="C_18612828-7d58-4576-a6a2-b4505743ef18" name="us-gaap:InterestCostsCapitalized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">625</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f4f7491-bc7b-4642-9ad9-e7a993812546" contextRef="C_18612828-7d58-4576-a6a2-b4505743ef18" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,238</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest paid</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_203fe202-6c8b-41b0-97fa-85ee0c386cfc" contextRef="C_18612828-7d58-4576-a6a2-b4505743ef18" name="adpt:RevenueInterestPaid" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">493</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13813004-0da7-47f2-967d-f5a2e6a9deff" contextRef="C_18612828-7d58-4576-a6a2-b4505743ef18" name="adpt:RevenueInterestPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,760</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest liability, net at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e0bb63d-8bb3-445a-b444-8d5d70e45ec3" contextRef="C_5e49e82a-95b6-4034-a713-b8f1ec42273a" name="adpt:RevenueInterestLiabilityNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,360</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79ebc34e-0c17-4113-9300-7749ead119f2" contextRef="C_b0c61c69-cbe1-4b8f-9a70-56d35c5b6efc" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,800</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest paid</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e92d850-e967-42bf-923f-ec6f3bc75a56" contextRef="C_b0c61c69-cbe1-4b8f-9a70-56d35c5b6efc" name="adpt:RevenueInterestPaid" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,225</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6e4e3de-ed76-444b-930f-d2c221db644a" contextRef="C_b0c61c69-cbe1-4b8f-9a70-56d35c5b6efc" name="adpt:RevenueInterestPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,275</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest liability, net at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b8acd5d-1a2f-4ae5-8d7f-ce873c80d2ed" contextRef="C_c0b012e9-1d72-456e-818b-e7c99403c318" name="adpt:RevenueInterestLiabilityNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,660</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue interest payable of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7aee2c52-7d66-4599-962a-777c241ade23" contextRef="C_b0c61c69-cbe1-4b8f-9a70-56d35c5b6efc" name="adpt:RevenueInterestPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83c0b030-d1c8-4258-9e6f-60b8e5db3233" contextRef="C_18612828-7d58-4576-a6a2-b4505743ef18" name="adpt:RevenueInterestPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was included within the accounts payable balance on the consolidated balance sheet as of December 31, 2023 and 2022, respectively.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_40299c13-3960-45bd-b114-0a860abd558a" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commitments and Contingencies</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal Proceedings</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to claims and assessments from time to time in the ordinary course of business. We will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. We were not party to any material legal proceedings as of December 31, 2023.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnification Agreements</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, we may provide indemnification of varying scope and terms to vendors, lessors, customers and other parties with respect to certain matters including, but not limited to, losses arising out of breach of our agreements with them or from intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with members of our board of directors and certain of our executive officers that will require us to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments that we could be required to make under these indemnification agreements is, in many cases, unlimited. We have not incurred any material costs as a result of such indemnifications and are not currently aware of any indemnification claims.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d7b40fbd-53ec-4dc1-a8b5-3298268cb797" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shareholders&#8217; Equity</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock has no preferences or privileges and is not redeemable. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_458a123a-8d57-4ae5-a779-c994a7ecacd3" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:CommonStockVotingRights"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders of our common stock are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ddafc4c-4642-4287-900d-b62aa99020ca" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:NumberOfCommonStockVotingRights" unitRef="U_Vote" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> vote for each share of common stock held</span></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The holders of record of outstanding shares of common stock shall be entitled to receive, when, as and if declared, out of funds legally available, such cash and other dividends as may be declared from time to time.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">110</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54b1e8d3-c7c6-4358-bb74-c8bdb1878beb" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">had reserved shares of common stock for the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"/>
        <td style="width:1.6%;"/>
        <td style="width:1%;"/>
        <td style="width:16.36%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares issuable upon the exercise of outstanding stock options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc0a969e-2519-42a3-a4bc-db235f4ba9eb" contextRef="C_10ea6fb1-7d69-445d-8fcf-bcaaaf8ea019" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">12,875,045</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares issuable upon the vesting of outstanding restricted stock units granted and the maximum outstanding market-based restricted stock units eligible to be earned</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d989faff-ca32-4bb6-82fe-713184b141dc" contextRef="C_8a8f8700-656c-4aa0-a7b1-18a1188de95d" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">11,582,134</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for future grant under the 2019 Equity Incentive Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e26241fb-a21a-4f68-899d-b1879324d59c" contextRef="C_5aa06285-f2dc-4040-87ff-e52ba00117cc" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">15,299,763</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for future grant under the Employee Stock Purchase Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77a3a454-72cf-4231-962d-5fa1b6d3566d" contextRef="C_d18ea8b5-6b95-48a5-8cf4-dca1eb7587d7" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,235,348</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total shares of common stock reserved for future issuance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebbf0f2c-8505-4c7e-8f6a-48d693885327" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">43,992,290</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) provides for annual increases in the number of shares that may be issued under the 2019 Plan on January 1, 2020 and on each subsequent January 1, thereafter, by a number of shares equal to the lesser of (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bab0cebd-17c4-4558-829e-2201f0bf6059" contextRef="C_d77ee3a7-0648-4c68-ad86-6a36e26d4d2f" name="adpt:PercentageOfAnnualIncreasesInNumberOfShares" unitRef="U_pure" scale="-2" decimals="INF">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, our Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) provides for annual increases in the number of shares available for issuance under our ESPP on January 1, 2020 and on each January 1, thereafter, by a number of shares equal to the smallest of (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f31f0dd-5895-403b-90e4-faf12f857bdf" contextRef="C_1bac84b6-f743-48d7-8309-6858a505babc" name="adpt:PercentageOfAnnualIncreasesInNumberOfShares" unitRef="U_pure" scale="-2" decimals="2">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective January 1, 2023, our 2019 Plan and ESPP reserves increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7c5a479-abd1-4781-aa82-923e6cf33b24" contextRef="C_ef1ad520-2e19-4c3f-ad13-c493a883fa78" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,155,250</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97b400bd-f68a-4058-a279-2c1d4a395dec" contextRef="C_5b9b7218-2fe1-41c4-b97c-55fcf735df6e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,431,050</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, respectively. Effective January 1, 2024, our 2019 Plan and ESPP reserves increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4eb1cb2e-a49d-4100-99f0-3af0819795d8" contextRef="C_9ea6d2a9-4933-428d-a214-8f22b0ee534e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,254,113</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ceeb3d7-febf-4b26-b522-95613549145a" contextRef="C_701c755f-589d-411b-a770-4fbc3fc69793" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,450,822</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, respectively.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79439f88-7df8-41a1-a4bd-bdf506d39dd6" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equity Incentive Plans</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2009 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We adopted an equity incentive plan in 2009 (the &#8220;2009 Plan&#8221;) that provided for the issuance of incentive and nonqualified common stock options and other share-based awards for employees, directors and consultants. Under the 2009 Plan, the exercise price for incentive and nonqualified stock options were not to be less than the fair market value of our common stock at the date of grant. Stock options granted under this plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd322638-f5be-4c0a-9c78-cd6d43248691" contextRef="C_52139d7b-c2be-477b-8367-d18a6a83b6e7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the grant date and vesting was established at the time of grant. Pursuant to the terms of the 2019 Plan, any shares subject to outstanding stock options originally granted under the 2009 Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof shall become available for issuance pursuant to awards granted under the 2019 Plan. While </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_224ffc8c-0785-4995-a147-4c195ca52767" contextRef="C_feb3a029-611b-49cd-afb7-35c3b0ac8813" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares are available for future grant under the 2009 Plan, it continues to govern outstanding equity awards granted thereunder.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2019 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2019 Plan became effective immediately prior to the closing of our initial public offering in July 2019. The 2019 Plan provides for the issuance of awards in the form of stock options and other share-based awards for employees, directors and consultants. Under the 2019 Plan, the stock option exercise price per share shall not be less than the fair market value of a share of stock on the effective date of grant, as defined by the 2019 Plan, unless explicitly qualified under the provisions of Section 409A or Section 424(a) of the Internal Revenue Code of 1986. Additionally, unless otherwise specified, stock options granted under this plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f942f4e3-4d82-45d3-b01c-dabaa0c84ad2" contextRef="C_b70f1afc-db7d-4741-a566-077b3ae24fae" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the grant date and vesting is established at the time of grant. Except for certain stock option and restricted stock unit grants made to non-employee directors, stock options and restricted stock units granted under the 2019 Plan generally vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c7b05afe-d9e1-46aa-8566-ad8bcb525609" contextRef="C_1289e3d3-be6d-4b21-8182-0e0ea07d3d38" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period, subject to continuous service through each applicable vesting date. As of December 31, 2023, we had </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_952a89fe-40ae-43b7-be6c-24598c9c94a6" contextRef="C_5aa06285-f2dc-4040-87ff-e52ba00117cc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">34,853,581</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock authorized for issuance under the 2019 Plan.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7b5620c2-79d8-4a93-8bb7-0ee52de51f21" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in shares available for grant during the year ended December 31, 2023 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"/>
        <td style="width:1.6%;"/>
        <td style="width:1%;"/>
        <td style="width:16.36%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares Available for Grant</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for grant at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e956258c-a021-4911-8cf9-9d1c4825e05d" contextRef="C_f712f0be-9f2e-4186-a7b5-0091ce1762f6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">14,581,975</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2019 Equity Incentive Plan reserve increase effective January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bde0f595-bc0c-41dc-b496-5dc9a849b094" contextRef="C_3b24663a-22c4-43fd-8173-22c3ea3e4a68" name="adpt:ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,155,250</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2903add-6866-4581-8df6-daff82811ab5" contextRef="C_3b24663a-22c4-43fd-8173-22c3ea3e4a68" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">9,980,059</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options and restricted stock units forfeited or expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_792448aa-4e94-4082-a792-2b30de74c3f8" contextRef="C_3b24663a-22c4-43fd-8173-22c3ea3e4a68" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,542,597</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for grant at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4424848f-83a0-40ec-837f-1d25ddc5c3a4" contextRef="C_8432b103-20fe-4d39-a798-e24e82f7508a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,299,763</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">111</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_710a5a28-4560-4f3d-976b-aac4543e9633" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option activity under the 2009 Plan and 2019 Plan during the year ended December 31, 2023 was as follows:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.2%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1%;"/>
        <td style="width:11.26%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.780000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.780000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares Subject to<br/>Outstanding Stock Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Exercise<br/>Price per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ee842cf-d9ef-432d-9396-704cfd13660a" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,520,997</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9eb0b977-b95a-4654-a00c-0597995a70d2" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.88</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fac99452-ac04-4d41-a12d-c9144c9520b3" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,612,032</ix:nonFraction></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a97eee4b-6cff-4b81-893b-f69228a5a395" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.46</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4b09401-93cb-4627-be4a-fee2853064e2" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,030,388</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b16cb38-9f52-40f2-9ef5-9a6939d2034a" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.07</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e86402cd-e9a0-4bc4-bb79-ae99ce763553" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">757,191</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf99b9e7-632a-478c-a6ae-d7e6c59d44f9" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">22.92</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28999fe6-2bac-412c-aeef-4888a72a2cb3" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">470,405</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8e75347-1888-417c-baf8-643b5de5424b" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.77</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e47bbb99-b5c8-4944-b325-b4b53d34ad77" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,875,045</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b46038d1-b75b-4463-af6a-eaa1b0736ff2" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.90</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5faa8923-6f53-42fc-8253-f1a715c1e254" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">506</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options vested and exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbd29da0-8088-4742-ab86-3e7e08786da2" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,071,627</ix:nonFraction></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e835718-e84f-447f-9b4d-8b516aedb4da" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.20</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45ca8216-574f-431c-b6dd-6755b00220bf" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">506</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average remaining contractual life for stock options outstanding as of December 31, 2023 was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a2eb4b33-dae5-46a2-a13f-0d817e261783" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6.2</span></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. The weighted-average remaining contractual life for vested and exercisable stock options as of December 31, 2023 was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7fdedcbb-0fdf-4910-ba8d-9c2fb7dc51af" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.3</span></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total intrinsic value of stock options exercised during the year ended December 31, 2023, 2022 and 2021 was </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb0dc546-1f1e-42cc-bce6-45aae70378a2" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8517285c-3909-4d54-806c-9eb7298cb8aa" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.6</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56840197-7061-45ef-8825-bc99b582ddb1" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">156.5</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b39a3cd-5194-4567-aadf-c9be05e2585a" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.7</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million proceeds from exercise of stock options included on the consolidated statements of cash flows for the year ended December 31, 2021, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_caa1b19c-b1b1-4d84-9719-1112429ee97a" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="adpt:ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods" unitRef="U_USD" scale="6" decimals="-5">0.3</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to stock options exercised during the year ended December 31, 2020 but settled during the year ended December 31, 2021.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c31ec8e8-ff18-40ec-8a77-7fab85bf6f3b" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted stock unit activity under the 2019 Plan during the year ended December 31, 2023 was as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"/>
        <td style="width:1.26%;"/>
        <td style="width:1%;"/>
        <td style="width:13.38%;"/>
        <td style="width:1%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Restricted Stock Units<br/>Outstanding</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Grant Date<br/>Fair Value per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested restricted stock units outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12dba867-539b-4a83-bc89-3c3eda358d10" contextRef="C_fdeb24a7-efd0-43c6-90cc-7c4a9389752a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,981,755</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46aa4f41-4ed4-4ab8-8127-1c27620cafe5" contextRef="C_fdeb24a7-efd0-43c6-90cc-7c4a9389752a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.11</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50c4a9c2-d3ed-41a8-a2a1-765e1c221fc6" contextRef="C_43621f8b-6a5f-47d0-a30e-6bf513d24ad8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,949,587</ix:nonFraction></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da43bfd7-65c7-46eb-8497-2d4f627ff885" contextRef="C_43621f8b-6a5f-47d0-a30e-6bf513d24ad8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.29</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49b749a9-379d-497e-8d84-2fca435e2357" contextRef="C_43621f8b-6a5f-47d0-a30e-6bf513d24ad8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,755,018</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9cc62e05-6b05-4767-a779-4144fadcb9b6" contextRef="C_43621f8b-6a5f-47d0-a30e-6bf513d24ad8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.24</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f594dd91-409f-44cf-9a28-1696d171fedf" contextRef="C_43621f8b-6a5f-47d0-a30e-6bf513d24ad8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,506,864</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_560ffd0b-f035-4cab-82f1-63dad775b37a" contextRef="C_43621f8b-6a5f-47d0-a30e-6bf513d24ad8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.95</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested restricted stock units outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_824bad37-7950-477d-b0b0-d7f85cb212f4" contextRef="C_af47b662-9bf3-44d8-8091-3006d4c6e691" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,669,460</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5ab45dc-bdb1-4280-a795-cca51e9fdf1f" contextRef="C_af47b662-9bf3-44d8-8091-3006d4c6e691" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.32</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total fair value of restricted stock units vested during the year ended December 31, 2023, 2022 and 2021 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5701ff6-a6b7-4f25-b45d-ae779fea769a" contextRef="C_efab56ea-21ee-4b9f-a82c-12261558a450" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af8c34c6-6b91-4d3b-b63e-e7d42da40c25" contextRef="C_9b79125c-aadc-43ba-85de-4c5908f2bb4d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e4b1dce-7daf-4385-8c63-dd56e0e98a6d" contextRef="C_d643066a-d834-4dbc-94f7-b192fb198f27" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Market-Based Restricted Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the restricted stock units described above, our board of directors approved awards of market-based restricted stock units to our chief executive officer and chief scientific officer in March 2023. The shares of common stock that may be earned under the awards, each ranging from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73373612-2a54-41ca-8366-6935b91b0e5e" contextRef="C_dd0b38a4-c17a-4584-ace9-9eb7a4dba7cd" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_778a8666-c3a0-4e6d-9303-a702d70e3292" contextRef="C_eb640244-c177-44b5-8d08-c43654ceed7c" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">709,220</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, are calculated based upon our total shareholder return during a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb8f672e-1765-4a3a-a3fa-8020919ea41a" contextRef="C_866da907-3204-49a4-a785-caa968f66943" name="adpt:SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> performance period as measured against that of the group of companies comprising the S&amp;P Biotechnology Select Industry Index as of the grant date, subject to certain adjustments to such index group. Except as expressly provided in the terms of each award's agreement, vesting is subject to the respective grantee's continuous service through the end of the three-year performance period. These market-based restricted stock units, along with those granted to our chief executive officer in March 2022, under which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25e807cb-79f4-4226-acd6-523c63644688" contextRef="C_55a33622-5845-472e-a76b-82768e6681b9" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c26ff7f7-9eac-4aff-b607-629114418780" contextRef="C_51e0ed6a-9fac-4c20-a4e8-435eb73af38d" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">494,234</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares may be earned, remained outstanding as of December 31, 2023.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">112</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Grant Date Fair Value of Stock Options, Restricted Stock Units and Market-Based Restricted Stock Units Granted</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5d6b83e7-5804-4811-816a-b6134d1d2296" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated grant date fair values of stock options granted during the years ended December 31, 2023, 2022 and 2021 were estimated using the Black-Scholes option-pricing model with the following assumptions:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.177%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1%;"/>
        <td style="width:11.255%;"/>
        <td style="width:1%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1%;"/>
        <td style="width:11.255%;"/>
        <td style="width:1%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1%;"/>
        <td style="width:11.255%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of common stock</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_075181bf-eff3-42f5-95c9-3104ff2c4dc5" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.46</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d4ac9f7-8606-48cc-9fdc-563fccdedf75" contextRef="C_6ce95484-a0e7-43c5-830f-bb7a29b093db" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3dfab32b-56ec-4202-806b-7e1cb228e053" contextRef="C_d63aae94-5743-4e75-a64b-3a0caabf8bd7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.95</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43cbb2db-5741-486d-aed4-1dd10c482d34" contextRef="C_82171477-fd8e-4a87-a38e-80b61f287043" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">30.86</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46ef9338-929c-4db3-aac6-b2aac5862836" contextRef="C_2eb19fde-1742-44b2-a814-dd6adf82062d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">66.50</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_52a26aae-7280-4df1-8611-5a4f45565ee5" contextRef="C_5345840c-9735-4c5d-b8ec-b10aa2abbce6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.27 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">- </span><span><ix:nonNumeric id="F_e9cb006e-0c79-4e46-b874-ec0104d4b1eb" contextRef="C_bff5bd4a-2423-48c0-a5ec-9acfc6922d16" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_fe9315f9-ce7d-4007-81f1-bdd3fe8237bd" contextRef="C_6ce95484-a0e7-43c5-830f-bb7a29b093db" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.27</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_d6da1930-ec2a-4aa6-90a1-811569df77a9" contextRef="C_d63aae94-5743-4e75-a64b-3a0caabf8bd7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_1a95c9e7-1f98-4611-abb5-d398e060ef46" contextRef="C_82171477-fd8e-4a87-a38e-80b61f287043" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.27</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_c7b38114-5f69-420d-ae52-c34629d26eef" contextRef="C_2eb19fde-1742-44b2-a814-dd6adf82062d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b6a53ab-1d2c-43b4-8b29-1324bfb744d7" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3d3d7cb-bccc-4249-a6dd-cb07463b780c" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8073a10-16b3-4b4d-9519-93593aa1dcd1" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_569d92aa-c060-4cb4-b79d-a474fc6993f2" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17fcc45e-c8c8-4e7c-9996-48e022d1edcd" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8eb47c6-75e1-4bdd-9ba0-8da0f14e8572" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6717f5b-5dc6-4b5b-b252-cf05454fdf6b" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">71.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a1d518e-e98f-4d76-953e-830f67d745fb" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">71.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d8e2ee8-96b7-4f01-b684-dcd9a214dfca" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">68.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43ff65af-9a5a-4981-bfce-293393d401ab" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">71.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_352934d5-6e5c-4dc8-b774-8c0ccde2ed38" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">67.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebae85bb-ea61-4eb7-8f9e-b0b94c0ce2a4" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">70.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The determination of the grant date fair value of stock options granted using a Black-Scholes option-pricing model is affected by the fair value of our common stock, as well as assumptions regarding a number of variables that are subjective and generally require judgment to determine. The valuation assumptions were determined as follows:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair value of common stock&#8212;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each share of common stock is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected term</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;The expected term of stock options granted to employees and non-employee directors is determined using the &#8220;simplified&#8221; method, as illustrated in ASC Topic 718, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation&#8212;Stock Compensation</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, as we do not have sufficient exercise history to determine a better estimate of expected term. Under this approach, the expected term is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">based on the midpoint between the vesting date and the end of the contractual term of the stock option.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-free interest rate</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;We utilize a risk-free interest rate in the option valuation model based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected terms of the stock options.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected volatility</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;As we do not have sufficient trading history for our common stock, expected volatility is based on the historical volatility of our publicly traded industry peers utilizing a period of time consistent with our estimate of expected term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected dividend yield</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;We do not anticipate paying any cash dividends in the foreseeable future and, therefore, use an expected dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_149c68c3-0274-40d4-ac24-4ade77616cef" contextRef="C_13005d32-f646-429f-a0e2-4fd8c00bf69a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the option valuation model.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant date fair value per share of stock options granted during the year ended December 31, 2023, 2022 and 2021 was </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ab1b4fb-73cb-486c-a5b9-082a1eb62851" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.61</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0daeaa7-1c58-4fa8-b7e8-7cba66727e6d" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.36</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc70e8d9-0898-49bd-affd-ed2c5db3d881" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">24.22</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The grant date fair value of restricted stock units granted </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant date fair value per share of restricted stock units granted during the year ended December 31, 2023, 2022 and 2021 was </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c96e4b8-4c6b-4d32-aaa4-77acbf088a57" contextRef="C_43621f8b-6a5f-47d0-a30e-6bf513d24ad8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.29</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49177267-0d11-493c-9b9e-b9d4e9f28eba" contextRef="C_1347ec09-38d8-439d-8a28-61beab707a2c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.43</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_699b513a-221b-4730-8add-2422a0d5e6d9" contextRef="C_f60e9643-430c-4ac5-b6d2-f2549cc4ce16" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">37.98</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant date fair value per share of the market-based restricted stock units granted during the year ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d88c93db-676e-418b-961c-c1400d97b317" contextRef="C_e8a9a7fc-8e3b-4b0f-9703-17e3dba9a414" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.82</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1846864-b9dc-4bd9-b864-0cbb0178883a" contextRef="C_57eacb73-0b36-49e5-8d6b-de05bc131c61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.89</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, and was determined using a Monte Carlo valuation model, which uses assumptions such as volatility, risk-free interest rate and dividend estimated for the respective performance periods. The weighted-average grant date fair value per share of the target payout level of the market-based restricted stock units outstanding as of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bffa715-6bc2-48dd-b752-c8987b5f2e74" contextRef="C_b2a6703f-315a-4dab-97f7-15768deba909" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">956,337</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c60c982-7b87-4171-a685-cdcf94809b30" contextRef="C_b2a6703f-315a-4dab-97f7-15768deba909" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.13</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The aggregate share-based compensation expense of the market-based restricted stock units granted during the year ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1052254-525e-4d62-91ea-b531c7411b07" contextRef="C_ee2c393f-edb6-49f1-8cc5-881b50f4a194" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1752100-500c-4ab5-bbeb-6fba7149160f" contextRef="C_7763f050-ced0-429d-9db0-76d18214c5c6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, and is recognized on a straight-line basis over the respective grants' </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef4615e8-1b04-41ae-8b4a-aa0dcf52452c" contextRef="C_ee2c393f-edb6-49f1-8cc5-881b50f4a194" name="adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> performance periods, which are also the requisite service periods. Attainment of each grant's respective market condition and the number of shares earned and vested does not impact the related share-based compensation expense recognized. Share-based compensation expense will be reversed only if the respective grantee does not provide continuous service through the respective performance period for reasons other than those expressly provided in the terms of the respective award.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0bec357f-bd7c-4e68-8a3d-df0959cd1986" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The compensation cost related to stock options, restricted stock units and market-based restricted stock units for the years ended December 31, 2023, 2022 and 2021 are included on the consolidated statements of operations as follows (in thousands):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfa4b90f-7580-4ba4-851b-38056753cd8b" contextRef="C_5d872d1b-6381-4a56-9eee-12e5744bc07e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,186</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ef56f68-a3a9-474f-a27b-042cac0cb2b6" contextRef="C_41662c43-8800-4ae7-bc2d-55dfc7db0bb2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,910</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_117edbbc-c004-45fe-be79-a5cd1524f8b5" contextRef="C_c4af3728-9703-4193-8445-5f99fb79c576" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29163e01-5c4e-4424-ad86-8fba83a3f631" contextRef="C_f45bf03e-7ed0-4ba6-8ffc-ba5f9e654d96" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,465</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55941863-4a0b-45ec-a55d-65bfc24420de" contextRef="C_1a66f191-30ec-42f3-b59c-6f6b27af199f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,689</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d627af52-39dc-42ac-aa99-1d789b379a2b" contextRef="C_83e9af4e-f8d0-4e18-894d-bef3e41d1fa4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,061</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales and marketing</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8661de51-0941-4e74-a5cd-2c0ff61f5a61" contextRef="C_97bc012b-5315-4313-9c87-2f9e1fa58826" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,553</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff21e2ad-cdd9-40b2-a007-f90c36133e98" contextRef="C_46c823cf-5ea5-4b9b-b0ea-af9c60b6fd51" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,597</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78f7dd47-d801-44e4-9547-7b2e9d2210f1" contextRef="C_6ea1b178-9b53-435d-bea7-af3f35409ca9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,312</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e29019fd-bed1-4ce3-baad-82d4d173cb78" contextRef="C_d0727108-4458-4e50-b34a-e52b89840f12" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,704</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df17342f-c940-40dd-874e-cd5ac206f604" contextRef="C_ef915afd-ec97-428b-a6f3-a6066e32a6a3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,281</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_807e717b-4660-4c70-97e8-5dd79149c0f4" contextRef="C_4ec6bc83-92c5-47f4-97fb-4663a45fb872" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,778</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total share-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95c5257b-2624-4e7d-b6e2-99cf62158f77" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,908</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fcb168c-396f-4485-8171-97a1754f0632" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,477</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66723a4a-948c-4559-b40f-d0f4c2124a94" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,251</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">113</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad9bd927-2fe2-4988-b68b-1a507e73f876" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, unrecognized share-based compensation expense and the remaining weighted-average recognition period were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
        <td style="width:1.26%;"/>
        <td style="width:1%;"/>
        <td style="width:13.38%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrecognized Share-Based<br/>Compensation Expense<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining Weighted-Average<br/>Recognition Period<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3776433e-10ec-4e4c-9a6e-0a67926919f0" contextRef="C_5c8126e1-b6cc-428b-b0c0-8e108d6c872f" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,892</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_702ddd97-8860-445e-ba2e-c2a629d5af0a" contextRef="C_02b5636a-5e74-4e33-b07e-81d5098e6ddd" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.94</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_095c330b-4b23-4c0a-aa01-741c6f11fce5" contextRef="C_82f4bbd7-e097-4e32-bf62-da8405a3dbfa" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,944</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_6763c86a-8e0e-430f-b208-667a220c0958" contextRef="C_091e55d9-10c4-4aba-84c0-5a9e97322c47" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.67</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested market-based restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_402f18df-a1a9-48ce-865d-9c735e55a54e" contextRef="C_f834ab3e-f5d2-4656-891f-53272cd08ed4" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,941</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_365752ba-0b90-40c5-997c-960f37d3cc89" contextRef="C_89c81479-2ca4-45be-bc13-7804c0d2f507" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.97</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6a9e11fc-4f22-4cf0-9283-a846591277d8" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">15.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Microsoft Collaboration Agreement</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2017, we entered into a collaboration agreement with Microsoft Corporation ("Microsoft") (the &#8220;Microsoft Agreement&#8221;) to computationally derive a comprehensive T cell receptor antigen map for purposes of developing a universal diagnostic based on a single blood test.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contemporaneously with the Microsoft Agreement, we entered into a separate agreement to use Microsoft&#8217;s Azure cloud services at standard volume pricing with a minimum Azure purchase requirement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5dae51d3-aa0d-48c8-9263-897d7973d751" contextRef="C_dfe2e57d-4fb2-4493-8bac-7c38728d7cb1" name="adpt:MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement" unitRef="U_USD" scale="6" decimals="INF">12.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million over the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4f9cd1db-9de7-4e6e-8146-c2ad201381c7" contextRef="C_dfe2e57d-4fb2-4493-8bac-7c38728d7cb1" name="adpt:MinimumServiceConsumptionRequirementTermUnderLicenseAgreement" format="ixt-sec:durwordsen"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seven-year</span></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> term of the Microsoft Agreement, which has been met.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, contemporaneously with entering into the Microsoft Agreement, Microsoft made a preferred stock investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63647af4-1928-4a4a-aad6-61708d626f7d" contextRef="C_c035c769-db33-4f4f-a68d-722fe5a08f44" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="6" decimals="-5">45.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as a part of our Series F-1 convertible preferred stock issuance.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Accounting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The terms of the Microsoft Agreement meet the criteria under ASC 808, as both parties are active participants in the activity and are exposed to significant risks and rewards dependent on the commercial success of the activity. ASC 808 does not provide guidance on how to account for the activities under the collaboration and we determined that Microsoft did not meet the definition of a customer under ASC 606. Accordingly, we looked to other guidance to determine the accounting for the respective elements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We determined that the preferred stock issuance and commitment to use Microsoft&#8217;s Azure cloud services were made at terms consistent with market rates. All consideration received as part of the Series F-1 convertible preferred stock issuance was accounted for as part of the Series F-1 preferred stock issuance. Since the commitment to purchase Microsoft&#8217;s Azure cloud services was at market terms and we expected to meet the commitment in the ordinary course of business during the seven-year term, we recorded the expenses in the period in which the services were consumed. These costs are recorded in the consolidated statements of operations based on the underlying activities for which they support.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The remaining elements of the agreement were highly interrelated, so we evaluated them in the aggregate to determine the appropriate accounting application. Specifically, we determined that the transfer of license rights between the parties, our commitment to provide data and immunomics, diagnostic and bioinformatics expertise to Microsoft and Microsoft&#8217;s commitment to provide machine learning software and related development services to us were highly interrelated because they were necessary for the parties to perform the activities under the Microsoft Agreement and, therefore, should be evaluated as one unit of account.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We accounted for these collaboration activities by analogy to ASC Topic 845, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nonmonetary Transactions</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and determined that major uncertainties exist about the realizability of the value that would be assigned to an asset received from or provided to Microsoft under the collaboration and, therefore, fair value could not be reliably measured. As a result, we did not recognize any non-monetary assets or corresponding non-monetary income or expenses pertaining to the rights provided to us or to be received by us under the Microsoft Agreement.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_691e7ccc-3fee-4698-a467-93a42429f3c3" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" escape="true"><div style="font-size:0;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">16.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restructuring</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2022, we implemented a restructuring plan to reduce operating costs and reduced our workforce by approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2681911-3f90-4047-a3d0-9092fb50188b" contextRef="C_18d7a278-e320-4faa-bd10-c3406fe899df" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" unitRef="U_Employee" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> employees. We incurred aggregate restructuring costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1df77413-101b-46d2-b014-a8933adc5af8" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, all of which was recognized during the year ended December 31, 2022. These costs primarily related to one-time termination benefits and ongoing benefit arrangements, both of which included severance payments and extended benefits coverage support and were contingent upon the impacted employees&#8217; execution and non-revocation of separation agreements. Our aggregate restructuring costs also included certain contract termination costs. The activities related to our reduction in workforce were primarily completed in March 2022 and the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48f2d3e6-6ca1-4f0a-b77e-fb70b8b7fcfe" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:PaymentsForRestructuring" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million aggregate restructuring costs were paid as of December 31, 2022.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">114</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_70005d32-0468-4892-b663-0a68d53f97f1" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">17.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9e6148c5-aa12-41dc-a843-6ea7d77bb029" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of loss before provision for income taxes for the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Domestic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d08b38c-eb5a-44cd-8b6b-afb9f4c47be5" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225,335</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d71fa123-1b25-42fa-bd1c-b79a14edbe27" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,427</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbc2f148-5bc7-4d96-aa30-aa78b0eb2408" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">207,314</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8594ec18-8fc4-408c-ade4-7d063dd307fa" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f1b468f-da0a-4e23-b870-8f8ec2dc2067" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfe35784-7fa5-4f7a-84a1-92f4f1245cd8" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total loss before provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e835a6fd-baf5-47f2-96b5-28d66c8bd40b" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225,304</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4754c82a-8b89-449d-85a2-d688570f231e" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,368</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_736020e7-a660-4df1-88bf-6783216a50e5" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">207,298</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9f7f582f-e1cb-43b2-92d1-2ac116f74b42" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant components of our deferred tax assets and liabilities as of the dates presented were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating losses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36ca4ac3-f252-4dcb-92ae-27f6fce7ba78" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251,724</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d1ce108-27b1-4420-aa21-67d6eb6157ad" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210,609</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credit carryforward</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53019306-a41a-4a49-befb-fb3c487ed4c8" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,528</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1aa697a1-2403-4995-ab17-d328a735f7c2" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,848</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonqualifying stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_498c501f-7cb7-489e-be3b-4cdd8aabe94a" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="adpt:DeferredTaxAssetsNonQualifiedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,166</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_926bfa27-e5bd-4968-8ac6-73d7a7ac9103" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="adpt:DeferredTaxAssetsNonQualifiedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,885</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_465e030a-2a4f-4c8b-ae7f-bf28ecf933d9" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="adpt:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,357</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_557dc104-79e2-4918-a272-f035ddd355ca" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="adpt:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,199</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be894608-b14d-44f3-938e-50d91ec657b7" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,874</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9802d6b-1bf3-496d-a69b-ddcfde642c5f" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,170</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1b61307-5ecc-4ec9-8b0a-10d4042b74e2" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="adpt:Deferredtaxassetscapitalizedresearchanddevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,134</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f68f437-5fde-400b-84cb-8baf71c4f326" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="adpt:Deferredtaxassetscapitalizedresearchanddevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,957</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40ca8185-45da-4aed-9e7b-96b52c454ef9" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,146</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46ec8527-1aa9-40c1-a4f1-181e6b98023e" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,859</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_636cd2d4-04b8-414e-a7fa-5525f3b2959f" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">416,929</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfc3f21a-1ef3-4447-9651-32085dbc7f94" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">371,527</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65a37819-aad2-45b9-b563-0cc92c53ab56" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">402,424</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ec19297-4729-4137-9d70-50cb051bae24" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">346,578</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5469612-5f89-4cea-8c5c-e2fea34e18a6" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,505</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa7396a3-458e-4f96-b1a6-d7f890e9981b" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,949</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tangible and intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af85a1ea-52a9-41e3-994c-2816b79e33fe" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="adpt:DeferredTaxLiabilitiesTangibleAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,281</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f030a1a-3d94-495f-9e3f-50440cc1b469" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="adpt:DeferredTaxLiabilitiesTangibleAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,897</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11b58058-750e-4465-8da1-33d1422a44b2" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="adpt:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,224</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a724ab2-fc5f-4509-be1c-a939c4dd193d" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="adpt:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,052</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_231f0df0-860c-4686-9ad0-7f297e8d8bd9" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80f6a0e0-13df-42a0-bb46-8b82acc92e07" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASC Topic 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, requires that the tax benefit of net operating losses ("NOLs"), temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf410d76-a67a-4911-a2d9-47a01196bf7c" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">55.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63c3ce9e-2bde-49e2-bbc7-6c09b7513c0a" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">49.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the year ended December 31, 2023 and 2022, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal tax laws impose substantial restrictions on the utilization of NOL and credit carryforwards in the event of an ownership change, as defined in Section 382 of the Internal Revenue Code of 1986. Accordingly, our ability to utilize these carryforwards may be limited due to such ownership changes. We have completed a Section 382 analysis for changes in ownership through June 30, 2023 and continue to monitor for changes that could trigger a limitation. Based on this analysis, we do not expect to have any permanent limitations on the utilization of our federal NOLs. Under the Tax Cuts and Jobs Act of 2017 federal income tax law, federal NOLs incurred in 2018 and future years may be carried forward indefinitely, but the deductibility of such federal NOLs is subject to an annual limitation. NOLs generated prior to 2018 are eligible to be carried forward up to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9c749b0-8d4e-4cac-b16f-540fe58b6d97" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:NetOperatingLossCarryforwardExpirationPeriod" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. As of December 31, 2023, we had U.S. federal NOLs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0eaf3629-7195-4efa-b24e-25e65a555962" contextRef="C_fd3f7f0d-8716-4252-b061-74865b34ce51" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">192.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and U.S. federal tax credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f18db20e-ae28-4122-9270-ac49961a93d9" contextRef="C_fd3f7f0d-8716-4252-b061-74865b34ce51" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">47.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million that will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ff5b898-0e28-48bf-a904-4645772c8b24" contextRef="C_95bf0290-eef6-4156-a6ce-f1dc2af43daa" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse"><ix:nonNumeric id="F_9e74ae51-390b-47ee-86be-1804796b4abb" contextRef="C_95bf0290-eef6-4156-a6ce-f1dc2af43daa" name="adpt:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2028</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We also had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50aed942-cb86-478c-aeb8-4d6fe26e4908" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">768.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of NOLs as of December 31, 2023 that do not expire.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">115</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2c88a319-36df-455f-9674-65f10472426c" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.36%;"/>
        <td style="width:1.48%;"/>
        <td style="width:14.4%;"/>
        <td style="width:1.48%;"/>
        <td style="width:14.4%;"/>
        <td style="width:1.48%;"/>
        <td style="width:14.4%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Statutory rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f224f4be-6aa8-47b2-95a1-7d72e2977719" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_056e542c-4db6-4a9c-876e-4c23a66482f5" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_419c3b21-8b81-46df-8167-215eb14498df" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State tax, net of federal tax benefit</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66303bf4-27a7-4ad0-8248-e3e5885e3015" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10415ee5-e790-430f-814f-390ab4760298" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">3.8</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_837bc6f1-ea2a-40cb-9cc8-0f80727c0ede" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">8.3</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f50fe356-9d3f-4eee-a06c-0cac16d5d4f7" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90cbdc60-caf4-4280-b022-a632462eaf3f" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4888909d-19dd-44a0-9796-07018563c16d" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">14.1</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent items</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd70bd55-59d5-4594-8cc3-d4e4fbf09ec1" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:EffectiveIncomeTaxRateReconciliationPermanentItems" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f4d25c2-3f64-46ef-9e7b-4534ab1ff7d8" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="adpt:EffectiveIncomeTaxRateReconciliationPermanentItems" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56c0c0a4-b5ac-47fc-8cfb-f6952be92275" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="adpt:EffectiveIncomeTaxRateReconciliationPermanentItems" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Credits</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce082bd0-9520-49e4-8470-04588289d05c" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11a4e189-1b1e-4fb1-a833-3d2397546698" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3a0a93e-e3d7-4989-9735-d672d640c1bf" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c64a6c14-a9bd-4555-b225-eb7018e591d7" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5eb6e4f0-e844-452a-8cc3-b370bd7bf6eb" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd4b0823-2697-46fe-8a86-aff9bdc2ec2f" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d23bbb1-ab8d-44b1-bcae-4f7a87c97566" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">25.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c51f6764-723e-42c6-912d-e1aa208b2248" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">24.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a6a557b-876b-4095-a275-936215c6d6d0" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">47.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31442bcd-1267-441b-9429-b41f6cb183e4" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74fa712e-a685-4820-ad30-82151a80e1df" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ab01a8a-9a02-4454-959a-529d2e1ca222" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for global intangible low-taxed income as period costs when incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize, in the consolidated financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. We had unrecognized tax benefits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87d74ad3-0fb5-44ff-988f-579779459d8b" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_77683ddd-fc6f-4908-95b7-930026c374f0" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" escape="true" continuedAt="F_77683ddd-fc6f-4908-95b7-930026c374f0_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the dates presented are as follows (in thousands):</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_77683ddd-fc6f-4908-95b7-930026c374f0_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"/>
        <td style="width:2.08%;"/>
        <td style="width:1%;"/>
        <td style="width:15.88%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35edd9e5-ceb4-40b7-b83e-65b30c1936eb" contextRef="C_cd98abbe-6241-4fc8-af88-d9979790e940" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,489</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions in 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f86f7ba-f42a-4cce-bd47-9e23ed964760" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,426</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44cedb13-be5b-4e36-9a47-349dbd24c695" contextRef="C_6f19237c-a155-4029-b45f-b9fb5332f737" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,915</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions in 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1e05c3f-298f-4d1c-82b5-c56038ca2add" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,202</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94fdbc8d-3dac-4ee5-b695-5ee5cbb1200d" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,117</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions in 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3cd1f8d-b88f-4c1c-ad8f-1132423cae4e" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,186</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cde14823-b191-4473-8366-a6eea46738b8" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,303</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, 2022 and 2021, we recognized uncertain tax positions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba9d5f7d-4439-4b53-9733-fc6c53c431ad" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3e2cdd6-dc0f-4ffe-a894-9d8a51761c13" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed53a66f-2989-4c4d-a5b9-af030c030fc6" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, related to a reduction of the research and development credit deferred tax asset. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not expect a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our operating results.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. We had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a8a32e4-99ad-4208-bd11-8bb51bfaeaff" contextRef="C_60b74489-28b2-4615-9786-6fdacef93898" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e35be707-dd68-467b-ae0f-7b64a61dbcf0" contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accrued interest or penalties related to uncertain tax positions as of December 31, 2023 and 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We file federal and certain state income tax returns, which provide varying statutes of limitations on assessments. However, because of NOL carryforwards, substantially all tax years since inception remain open to federal and state tax examination.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_27cea654-11cb-4326-9922-cab2d79100ea" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:EarningsPerShareTextBlock" escape="true"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">18.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c6dca81f-0edb-4b64-8e76-32b4a7e492b4" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the years ended December 31, 2023, 2022 and 2021 (in thousands, except share and per share amounts):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
        <td style="width:1.48%;"/>
        <td style="width:1%;"/>
        <td style="width:10.782%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0a66565-df81-43de-98df-3174d32ceb08" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225,250</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb69e71e-894e-4a26-9b0f-1e889c6449ce" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">200,191</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9bdab36-d95d-4363-8fb8-b291613d181e" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">207,279</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98a4e6af-6315-48c6-8ef4-2840bae07cb8" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5f119098-1d5a-481e-9429-7897fa5803dc" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">144,383,294</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e20b355f-e0d2-4e18-92e2-11a558f51399" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1dce62be-d62e-40d4-b873-642b1d756861" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">142,515,917</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77d24013-c6a8-444c-956b-7bf6a6a60fa4" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_af8a4518-1971-4819-8b11-111bfa167bc9" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">140,354,915</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc07dd57-432f-46f5-8ba6-2f9cb01b926c" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3b582f5f-8017-42d7-b3a5-defe41ecba9a" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.56</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39755afd-753b-4c08-8a43-f8fe1248f501" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3924ca9d-cde0-4a80-9c30-e37b5e2afec8" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.40</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f79799af-3526-4296-b0e3-8dfb9aa47b73" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_aee12fad-5f7c-4d5f-a010-31fe8071621a" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.48</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given the loss position for all periods presented, basic net loss per share attributable to our common shareholders is the same as diluted net loss per share attributable to our common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">116</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="margin-left:0.187%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="margin-left:0.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to Consolidated Financial Statements (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b5b953fd-b202-4c25-8a62-0f84473f3df4" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the years ended December 31, 2023, 2022 and 2021, as they had an anti-dilutive effect:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.177%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1%;"/>
        <td style="width:11.255%;"/>
        <td style="width:1%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1%;"/>
        <td style="width:11.255%;"/>
        <td style="width:1%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1%;"/>
        <td style="width:11.255%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5899371e-cdd2-4467-a9fb-14f7106ba599" contextRef="C_c4963ee4-2b06-4690-ba19-b7f24dff5cc0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,839,067</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c70d709f-b35e-4296-94a7-d7ceacf0604b" contextRef="C_3787167f-f9fe-4167-8297-ba5c7cf2cf41" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,892,287</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3b438a4-8079-45c5-af5b-ea6de27fe18b" contextRef="C_fdc597b9-fce4-4adb-aca1-c9147dc51edc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,097,374</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested restricted stock units outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2242dbef-b6d6-4c2c-a129-716eb8c520c8" contextRef="C_a78ff4ac-0c2c-49b3-b6c9-440cbe865835" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,630,579</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bdcd7587-e4e9-4101-ad67-9f5fcef48968" contextRef="C_7982225b-427f-4a1e-8cd0-412895f4f7f9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,799,850</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_330fafba-311b-4c06-8af3-ac13ca67b34b" contextRef="C_241a14e0-c83c-46be-9595-a7086d9fdf64" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">693,173</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Maximum nonvested market-based restricted stock units outstanding eligible to be earned</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63d045ee-a237-4f2c-b875-52d2dd116518" contextRef="C_be4b3886-95a1-499a-bdda-548e8b19d654" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,663,961</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f71105a8-982e-4d7f-800a-4797352caba3" contextRef="C_c6428414-6c4a-46a9-aaa6-447acbd2d45a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">410,282</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock warrant outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61f5d5bf-b0df-44fe-829d-cf7389c3ecae" contextRef="C_6d31f8e3-6174-4d62-813b-9a04cfbac43b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,570</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef6bec21-f431-42e5-a2d8-827d5b7e5753" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">25,133,607</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fecaab39-e3b2-425e-b2be-6e9dc785cac9" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">19,102,419</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5523a357-e11a-4a52-9bf8-16074cc5c543" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,799,117</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_055b5a7c-ef32-47bb-9ff9-6324a6bee76d" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><div style="display:flex;margin-top:9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">19.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Retirement Plan</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain a salary deferral 401(k) plan (&#8220;401(k) Plan&#8221;) covering employees who have met certain eligibility requirements. Employees may defer up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9913d5e-d313-4684-94f3-068a271ebab3" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" unitRef="U_pure" scale="-2" decimals="2">100</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of their compensation to the 401(k) Plan, subject to federal limits. We made $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#231f20;"><ix:nonFraction id="F_ade3d766-2e8b-4a01-a196-c37aec7a8d28" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b09f4369-1682-44af-ab2d-c25867793031" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf6de775-cb6a-4542-8080-9047d3ad189d" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in discretionary contributions during the year ended December 31, 2023, 2022 and 2021, respectively, which are fully vested after </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb070278-c686-4609-b6ef-235854778d24" contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed" name="adpt:DefinedContributionPlanEmployeeServicePeriodForVesting" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_c0fa8850-5cd4-4b4b-80d4-f41d81ff1bc6" contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703" name="adpt:DefinedContributionPlanEmployeeServicePeriodForVesting" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_fd9468b5-0eb7-455a-88dd-48d3bf2dc227" contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d" name="adpt:DefinedContributionPlanEmployeeServicePeriodForVesting" format="ixt-sec:durwordsen"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one year</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of employee service.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">117</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9. Changes in and Disagreements with Accou</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ntants on Accounting and Financial Disclosure</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> applicable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9A. Control</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s and Procedures</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act as of December 31, 2023. Based on that evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures were effective as of December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) under the Exchange Act. Management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on that assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2023 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements in accordance with GAAP.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The effectiveness of our internal control over financial reporting as of December 31, 2023 has been audited by an independent registered public accounting firm, as stated in their report, which is included below.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in Internal Control</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There was not any change in our internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act, during the three months ended December 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Shareholders and the Board of Directors of Adaptive Biotechnologies Corporation</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Opinion on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited Adaptive Biotechnologies Corporation&#8217;s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Adaptive Biotechnologies Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on the COSO criteria.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive loss, shareholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes	 and our report dated February 29, 2024 expressed an unqualified opinion thereon.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Definition and Limitations of Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Ernst &amp; Young LLP</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Seattle, Washington</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 29, 2024</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">119</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9B. Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9C. Di</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> applicable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">120</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> III</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">icers and Corporate Governance</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 10 of Form 10-K will be included in our definitive proxy statement to be filed with the SEC in connection with the solicitation of proxies for our 2024 Annual Meeting of Shareholders (&#8220;2024 Proxy Statement&#8221;) and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 11. Executiv</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">e Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 11 of Form 10-K will be included in our 2024 Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ers and Management and Related Stockholder Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 12 of Form 10-K, including with respect to our equity compensation plans, will be included in our 2024 Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 13. Certain Relationships and Related</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Transactions, and Director Independence</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this Item 13 of Form 10-K will be included in our 2024 Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 14. Principal Accoun</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ting Fees and Services</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> information required by this Item 14 of Form 10-K will be included in our 2024 Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">121</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> IV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 15. Exhibits, Financ</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ial Statement Schedules</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.2934249759943395%;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  The following documents are filed as part of this </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Annual Report on Form 10-K</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></div></div>
  <div style="margin-left:4.398%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.3733813100144348%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   Financial Statements</span></div></div>
  <p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Index to Consolidated Financial Statements in Part II, Item 8 of this </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Annual Report on Form 10-K</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <div style="margin-left:4.398%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.3733813100144348%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   Financial Statement Schedules</span></div></div>
  <p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All financial statement schedules have been omitted since the required information was not applicable or was not present in amounts sufficient to require submission of the schedules, or because the information required is included in the consolidated financial statements or the accompanying notes.</span></p>
  <div style="margin-left:4.398%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.3733813100144348%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   Exhibits</span></div></div>
  <p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The exhibits listed in the following Index to Exhibits are filed, furnished or incorporated by reference as part of this </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Annual Report on Form 10-K</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Index to Exhibits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.62%;"/>
    <td style="width:39.38%;"/>
    <td style="width:13.48%;"/>
    <td style="width:6.52%;"/>
    <td style="width:10.94%;"/>
    <td style="width:8.66%;"/>
    <td style="width:11.4%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.5pt;vertical-align:bottom;"><p style="margin-left:2.5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:76.95pt;vertical-align:bottom;text-align:left;"><p style="margin-left:76.95pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.9840277777777777in;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:8.8pt;vertical-align:bottom;text-align:left;"><p style="margin-left:8.8pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="text-indent:8.8pt;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="margin-left:8.8pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="text-indent:2.5pt;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="margin-left:2.5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="margin-left:2.5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.9840277777777777in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit Title</span></p></td>
    <td style="text-indent:5.9pt;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="margin-left:5.9pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filed/Furnished</span></p><p style="margin-left:5.9pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">With This</span></p><p style="margin-left:5.9pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Report</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Form</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File No.</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filing Date</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519187427/d27753dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Articles of Incorporation</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38957</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7/1/2019</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519187427/d27753dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Bylaws</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38957</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7/1/2019</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Seventh Amended and Restated Investors' Rights Agreement among the Registrant and certain of its shareholders, dated May 30, 2019</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-231838</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5/30/2019</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000156459020006830/adpt-ex43_880.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of Securities</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38957</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/26/2020</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Strategic Collaboration and License Agreement between Genentech, Inc. and the Registrant, dated December 19, 2018</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-231838</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5/30/2019</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Strategic Collaboration Agreement between Microsoft Corporation and the Registrant, dated December 11, 2017</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-231838</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5/30/2019</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519174174/d706383dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Master Terms &amp; Conditions of Sale between Illumina, Inc. and the Registrant, dated May 28, 2019</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1/A</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-231838</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6/17/2019</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Side Letter Agreement among Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd., Viking Long Fund Master Ltd. and the Registrant, dated May 8, 2019</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-231838</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5/30/2019</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex107.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Amended and Restated Employment Agreement between the Registrant and certain of its executive officers</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-231838</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5/30/2019</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex108.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Amended and Restated Employment Agreement between the Registrant and Francis T. Lo</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-231838</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5/30/2019</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex109.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Restated Non-Employee Director Change in Control Agreement between the Registrant and each of its non-employee directors</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-231838</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5/30/2019</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000156459020038958/adpt-ex101_139.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Executive Severance Agreement between the Registrant and certain of its executive officers</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38957</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8/10/2020</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">122</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.62%;"/>
    <td style="width:39.38%;"/>
    <td style="width:13.48%;"/>
    <td style="width:6.52%;"/>
    <td style="width:10.94%;"/>
    <td style="width:8.66%;"/>
    <td style="width:11.4%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.5pt;vertical-align:bottom;"><p style="margin-left:2.5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:76.95pt;vertical-align:bottom;text-align:left;"><p style="margin-left:76.95pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.9840277777777777in;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:8.8pt;vertical-align:bottom;text-align:left;"><p style="margin-left:8.8pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="text-indent:8.8pt;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="margin-left:8.8pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="text-indent:2.5pt;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="margin-left:2.5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="margin-left:2.5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.9840277777777777in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit Title</span></p></td>
    <td style="text-indent:5.9pt;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="margin-left:5.9pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filed/Furnished</span></p><p style="margin-left:5.9pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">With This</span></p><p style="margin-left:5.9pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Report</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Form</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File No.</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filing Date</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex1013.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Indemnification Agreement between the Registrant and its directors and executive officers</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-231838</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5/30/2019</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000095017023002792/adpt-ex10_10.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Adaptive Biotechnologies Corporation Non-Employee Director Compensation Policy</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38957</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/14/2023</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex1015.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Adaptive Biotechnologies Corporation 2009 Equity Incentive Plan and form of award agreement thereunder</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-231838</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.15</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5/30/2019</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000156459019031827/adpt-ex1012_196.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan and form of award agreement thereunder</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38957</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8/13/2019</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000156459021008124/adpt-ex1016_340.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Stock Option Agreement for Non-U.S. Participants</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38957</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.16</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/24/2021</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000156459021008124/adpt-ex1017_339.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Restricted Stock Unit Agreement for Non-U.S. Participants</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38957</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/24/2021</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.15*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000156459022017870/adpt-ex101_95.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Performance Units Agreement and Notice of Grant of Performance Units</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38957</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5/4/2022</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.16*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519174174/d706383dex1017.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Adaptive Biotechnologies Corporation 2019 Employee Stock Purchase Plan</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1/A</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-231838</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6/17/2019</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000156459022031433/adpt-ex101_62.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Revenue Interest Purchase Agreement, made and entered into as of September 12, 2022, by and among Adaptive Biotechnologies Corporation, the Purchasers from time to time party hereto, and OrbiMed Royalty &amp; Credit Opportunities IV, LP</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38957</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9/12/2022</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519161447/d706383dex1018.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Lease Agreement between ARE-Seattle No. 11, LLC and Adaptive TCR Corporation, dated July 21, 2011, as amended by Amendment No. 1, dated August 26, 2011, Amendment No. 2, dated June 30, 2014, Amendment No. 3, dated November 5, 2015, Amendment No. 4, dated December 23, 2015, and Amendment No. 5, dated June 6, 2016</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-231838</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5/30/2019</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519215526/d777595dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Sixth Amendment to Lease Agreement between Adaptive Biotechnologies Corporation and ARE-Seattle No. 11, LLC, dated August 2, 2019</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38957</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8/7/2019</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.20&#134;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000119312519215526/d777595dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Lease Agreement between Adaptive Biotechnologies Corporation and ARE-Seattle No. 12, LLC, dated August 2, 2019</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38957</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8/7/2019</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1478320/000095017023002792/adpt-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">List of Subsidiaries</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-38957</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/14/2023</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="adpt-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Power of Attorney (included on the signature page)</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="adpt-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer pursuant to Rule 13a&#8209;14(a) or Rule 15d&#8209;14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">123</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:9.62%;"/>
    <td style="width:39.38%;"/>
    <td style="width:13.48%;"/>
    <td style="width:6.52%;"/>
    <td style="width:10.94%;"/>
    <td style="width:8.66%;"/>
    <td style="width:11.4%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.5pt;vertical-align:bottom;"><p style="margin-left:2.5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:76.95pt;vertical-align:bottom;text-align:left;"><p style="margin-left:76.95pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.9840277777777777in;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:8.8pt;vertical-align:bottom;text-align:left;"><p style="margin-left:8.8pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="text-indent:8.8pt;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="margin-left:8.8pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="text-indent:2.5pt;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="margin-left:2.5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="margin-left:2.5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.9840277777777777in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit Title</span></p></td>
    <td style="text-indent:5.9pt;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="margin-left:5.9pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filed/Furnished</span></p><p style="margin-left:5.9pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">With This</span></p><p style="margin-left:5.9pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Report</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Form</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File No.</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filing Date</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.04027777777777777in;text-align:left;"><a href="adpt-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer pursuant to Rule 13a&#8209;14(a) or Rule 15d&#8209;14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="adpt-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="adpt-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><a href="adpt-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Adaptive Biotechnologies Corporation Policy for the Recovery of Erroneously Awarded Compensation</span></a></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:2.9pt;vertical-align:top;text-align:left;"><p style="margin-left:2.9pt;text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.041666666666666664in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (formatted in Inline XBRL and included in Exhibit 101)</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* Management contract or compensation plan or arrangement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#134; Portions of this exhibit have been omitted pursuant to Item 601 of Regulation S-K promulgated under the Securities Act because the information is not material and would be competitively harmful if publicly disclosed.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 16. Form 10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">124</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGN</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATURES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Seattle, State of Washington, on February 29, 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:11.32%;"/>
    <td style="width:2.56%;"/>
    <td style="width:86.12%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Adaptive Biotechnologies Corporation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">    </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.75pt solid #000000;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Chad Robins</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chad Robins</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">POWER OF ATTORNEY</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Chad Robins, his attorney-in-fact, with the power of substitution, for him in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, hereby ratifying and confirming all that said attorney-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.56%;"/>
    <td style="width:1.12%;"/>
    <td style="width:43.34%;"/>
    <td style="width:1.12%;"/>
    <td style="width:18.86%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Signature</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Chad Robins</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chad Robins</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer and Director</span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 29, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Tycho Peterson</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tycho Peterson</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Financial Officer)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 29, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Kyle Piskel</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Kyle Piskel</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">VP, Principal Accounting Officer</span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Accounting Officer)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 29, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Michelle Griffin</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Michelle Griffin</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 29, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Robert Hershberg</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Robert Hershberg, PhD, MD</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 29, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Peter Neupert</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Peter Neupert</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 29, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Katey Owen</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Katey Owen, PhD</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 29, 2024</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Michael Pellini</span></p></td>
    <td rowspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="text-indent:12pt;vertical-align:top;text-align:left;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td rowspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 29, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Michael Pellini, MD</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">125</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>adpt-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-269767) pertaining to the Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan and the Adaptive Biotechnologies Corporation 2019 Employee Stock Purchase Plan and</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-232495) pertaining to the Sequenta Inc., 2008 Stock Plan, the Adaptive Biotechnologies Corporation 2009 Equity Incentive Plan, the Adaptive Biotechnologies Corporation 2019 Equity Incentive Plan and the Adaptive Biotechnologies Corporation 2019 Employee Stock Purchase Plan;</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">of our reports dated February 29, 2024, with respect to the consolidated financial statements of Adaptive Biotechnologies Corporation, and the effectiveness of internal control over financial reporting of Adaptive Biotechnologies Corporation, included in this Annual Report (Form 10-K) for the year ended December 31, 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Seattle, Washington</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">February 29, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>adpt-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER <br>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Chad Robins, certify that:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Adaptive Biotechnologies Corporation;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:22.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.909%;"></td>
    <td style="width:1.01%;"></td>
    <td style="width:4.263%;"></td>
    <td style="width:46.818%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 29, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Chad Robins</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chad Robins</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="margin-left:46%;font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>adpt-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER <br>PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Tycho Peterson, certify that:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Adaptive Biotechnologies Corporation;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.909%;"></td>
    <td style="width:1.01%;"></td>
    <td style="width:4.263%;"></td>
    <td style="width:46.818%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 29, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Tycho Peterson</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tycho Peterson</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:22.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.7in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>adpt-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:17.8pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p></div>
  <p style="font-size:10pt;margin-top:6.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6.2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report of Adaptive Biotechnologies Corporation (the &#x201c;Company&#x201d;) on Form 10-K for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.878%;"></td>
    <td style="width:4.041%;"></td>
    <td style="width:4.263%;"></td>
    <td style="width:46.818%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 29, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Chad Robins</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chad Robins</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:13.9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>adpt-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:17.8pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.2</font></p></div>
  <p style="font-size:10pt;margin-top:6.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0.95pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:6.2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report of Adaptive Biotechnologies Corporation (the &#x201c;Company&#x201d;) on Form 10-K for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.465%;"></td>
    <td style="width:1.01%;"></td>
    <td style="width:5.717%;"></td>
    <td style="width:46.808%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 29, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Tycho Peterson</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tycho Peterson</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:13.9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>7
<FILENAME>adpt-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1.26in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:17.8pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 97.1</font></p></div>
  <p style="margin-left:14.293%;font-size:10pt;margin-top:3.65pt;font-family:Times New Roman;margin-bottom:0;margin-right:14.352%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ADAPTIVE BIOTECHNOLOGIES CORPORATION POLICY FOR THE</font></p>
  <p style="margin-left:0.013%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.028%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</font></p>
  <p style="margin-left:0.027%;font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.019%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective Date December 1, 2023</font></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">OVERVIEW</font></div></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.944%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In accordance with the applicable rules of The Nasdaq Stock Market (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Nasdaq Rules</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), Section 10D and Rule 10D-1 of the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Rule 10D-1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of Adaptive</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.944%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Biotechnologies Corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) has adopted this Policy (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) to provide for the recovery of erroneously awarded Incentive-based Compensation from Executive Officers.</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.944%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All capitalized terms used and not otherwise defined herein shall have the meanings set forth in Section H, below.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:3.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</font></div></div>
  <div style="margin-left:0.935%;display:flex;margin-top:9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.204%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.364457679301469%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event of an Accounting Restatement, the Company will reasonably promptly recover the Erroneously Awarded Compensation Received in accordance with Nasdaq Rules and Rule 10D-1 as follows:</font></div></div>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:4.269%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.204%;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.178374821113328%;display:inline-flex;justify-content:flex-start;">1.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">After an Accounting Restatement, the Compensation Committee (if composed entirely of independent directors, or in the absence of such a committee at the time of Restatement, a majority of independent directors serving on the Board) (the</font></div></div>
  <p style="margin-left:8.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.639%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Committee&#x201d;) shall determine the amount of any Erroneously Awarded Compensation Received by each Executive Officer and shall promptly notify each such Executive Officer with a written notice containing the amount of any Erroneously Awarded Compensation and a demand for repayment or return of such compensation, as applicable.</font></p>
  <p style="font-size:10pt;margin-top:0.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:7.602%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;min-width:4.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.050975129331804%;display:inline-flex;justify-content:flex-start;">1.1.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For Incentive-based Compensation based on (or derived from) the Company&#x2019;s stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in the applicable Accounting Restatement:</font></div></div>
  <p style="font-size:10pt;margin-top:1.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:10.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:6.736653006231404%;display:inline-flex;justify-content:flex-start;">1.1.1.1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The amount to be repaid or returned shall be determined by the Committee based on a reasonable estimate of the effect of the Accounting Restatement on the Company&#x2019;s stock price or total shareholder return upon which the Incentive-based Compensation was Received; and</font></div></div>
  <div style="margin-left:10.935%;display:flex;margin-top:3.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.537%;min-width:6%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:6.736653006231404%;display:inline-flex;justify-content:flex-start;">1.1.1.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company shall maintain documentation of the determination of such reasonable estimate and provide the relevant documentation as required to Nasdaq.</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.96in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:4.269%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.333%;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.178374821113328%;display:inline-flex;justify-content:flex-start;">1.2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Committee shall have discretion to determine the appropriate means of recovering Erroneously Awarded Compensation based on the particular facts and circumstances. For example, under appropriate facts and circumstances, it may be reasonable to promptly establish a deferred payment plan that allows the Executive Officer to repay owed erroneous compensation as soon as possible without unreasonable economic hardship to the Executive Officer, subject to applicable disclosure requirements of Item 402 of Regulation S-K. Under appropriate circumstances, it may also be reasonable for recovery to be obtained by forfeiture or cancellation of equity awards or reduction of future compensation. Recovery may also be foregone if it would violate a home-country law covering the Executive Officer that was effective prior to January 27, 2023, assuming that the Company has obtained a consistent opinion from the applicable home- country counsel. Notwithstanding the foregoing, except as set forth in Section B(2) below, in no event may the Company accept an amount that is less than the amount of Erroneously Awarded Compensation in satisfaction of an Executive Officer&#x2019;s obligations hereunder.</font></div></div>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:4.269%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.463%;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.178374821113328%;display:inline-flex;justify-content:flex-start;">1.3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To the extent that the Executive Officer has already reimbursed the Company for any Erroneously Awarded Compensation Received under any duplicative recovery obligations established by the Company or applicable law, it shall be appropriate for any such reimbursed amount to be credited to the amount of Erroneously Awarded Compensation that is subject to recovery under this Policy.</font></div></div>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:4.269%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.065%;min-width:4%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.178374821113328%;display:inline-flex;justify-content:flex-start;">1.4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To the extent that an Executive Officer fails to repay all Erroneously Awarded Compensation to the Company when due, the Company shall take all actions it deems reasonable and appropriate to recover such Erroneously Awarded Compensation from the applicable Executive Officer. The applicable Executive Officer shall be required to reimburse the Company for any and all expenses reasonably incurred (including legal fees) by the Company in recovering such Erroneously Awarded Compensation in accordance with the immediately preceding sentence. Any action by the Company to recover Erroneously Awarded Compensation under this Policy from an Executive Officer shall not, whether alone or in combination with any other action, event or</font></div></div>
  <p style="margin-left:8.267%;font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.639%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">condition, be deemed (i) &#x201c;good reason&#x201d; for resignation or to serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to such Exeuctive Officer, or (ii) to constitute a breach of a contract or other arrangement to which such Executive Officer is party</font></p>
  <p style="font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.204%;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.364457679301469%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything herein to the contrary, the Company shall not be required to take the actions contemplated by Section B(1) above if the Committee determines that recovery would be impracticable and either of the following two conditions are met:</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.96in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:7.602%;margin-top:3.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.585532154375636%;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Committee has determined that the direct expenses paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered. Before making this determination, the Company must make a reasonable attempt to recover the Erroneously Awarded Compensation, documented such attempt(s) and provided such documentation to Nasdaq;</font></div></div>
  <p style="margin-left:7.6%;font-size:10pt;margin-top:8.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">or</font></p>
  <div style="margin-left:7.602%;margin-top:9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:4.537%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.585532154375636%;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended, and regulations thereunder.</font></div></div>
  <div style="margin-left:0.935%;display:flex;margin-top:7.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">C.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">DISCLOSURE REQUIREMENTS</font></div></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:9.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.944%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company shall file all disclosures with respect to this Policy required by applicable U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) filings and rules.</font></p>
  <div style="margin-left:0.935%;display:flex;margin-top:7.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">D.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PROHIBITION OF INDEMNIFICATION</font></div></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:9.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.676%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company shall not be permitted to insure or indemnify any Executive Officer against (i) the loss of any Erroneously Awarded Compensation that is repaid, returned or recovered pursuant to the terms of this Policy, or (ii) any claims relating to the Company&#x2019;s enforcement of its rights under this Policy. Further, the Company shall not enter into any agreement that exempts any Incentive-based Compensation that is granted, paid or awarded to an Executive Officer from the application of this Policy or that waives the Company&#x2019;s right to recovery of any Erroneously Awarded Compensation, and this Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date of this Policy).</font></p>
  <div style="margin-left:0.935%;display:flex;margin-top:7.75pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">E.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ADMINISTRATION AND INTERPRETATION</font></div></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:9.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.944%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be administered by the Committee, and any determinations made by the Committee shall be final and binding on all affected individuals.</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:7.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.944%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy and for the Company&#x2019;s compliance with Nasdaq Rules, Section 10D, Rule 10D-1 and any other applicable law, regulation, rule or interpretation of the SEC or Nasdaq promulgated or issued in connection therewith.</font></p>
  <div style="margin-left:0.935%;display:flex;margin-top:8.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">F.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">AMENDMENT; TERMINATION</font></div></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.676%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Committee may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary. Notwithstanding anything in this Section F to the contrary, no amendment or termination of this Policy shall be effective if such amendment or termination would (after taking into account any actions taken by the Company contemporaneously with such amendment or termination) cause the Company to violate any federal securities laws, SEC</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.96in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:3.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.944%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">rule or Nasdaq rule; provided, however, that this Policy may be terminated if and when the Company is no longer subject to such rules.</font></p>
  <div style="margin-left:0.935%;display:flex;margin-top:7.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">G.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">OTHER RECOVERY RIGHTS</font></div></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:9.3pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.944%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be binding and enforceable against all Executive Officers and, to the extent required by applicable law or guidance from the SEC or Nasdaq, their beneficiaries, heirs, executors, administrators or other legal representatives. The Committee intends that this Policy will be applied to the fullest extent required by applicable law. Any employment agreement, equity award agreement, compensatory plan or any other agreement or arrangement with an Executive Officer shall be deemed to include, as a condition to the grant of any benefit thereunder, an agreement by the Executive Officer to abide by the terms of this Policy. Such right of recovery is in addition to, and not in lieu of, any other remedies or rights of recovery that may be available to the Company under any applicable law, regulation or rule or pursuant to the terms of any policy of the Company or any provision in any employment agreement, equity award agreement, compensatory plan, agreement or other arrangement.</font></p>
  <div style="margin-left:0.935%;display:flex;margin-top:7.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">H.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">DEFINITIONS</font></div></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.944%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this Policy, the following capitalized terms shall have the meanings set forth below.</font></p>
  <div style="margin-left:0.935%;margin-top:7.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:4.796%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.6319588149194972%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Accounting Restatement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (a &#x201c;Big R&#x201d; restatement), or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (a &#x201c;little r&#x201d; restatement).</font></div></div>
  <div style="margin-left:0.935%;margin-top:8.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.935%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.6319588149194972%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Clawback Eligible Incentive Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means all Incentive-based Compensation Received by an Executive Officer (i) on or after October 2, 2023, the effective date of the applicable Nasdaq rules, (ii) after beginning service as an Executive Officer, (iii) who served as an Executive Officer at any time during the applicable performance period relating to any Incentive-based Compensation (whether or not such Executive Officer is serving at the time the Erroneously Awarded Compensation is required to be repaid to the Company), (iv) while the Company has a class of securities listed on a national securities exchange or a national securities association, and (v) during the applicable Clawback Period (as defined below).</font></div></div>
  <div style="margin-left:0.935%;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.6319588149194972%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Clawback Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to any Accounting Restatement, the three completed fiscal years of the Company immediately preceding the Restatement Date (as defined below), and if the Company changes its fiscal year, any transition period of less than nine (9) months within or immediately following those three completed fiscal years.</font></div></div>
  <div style="margin-left:0.935%;margin-top:7.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.13%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.6319588149194972%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Erroneously Awarded Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to each Executive Officer in connection with an Accounting Restatement, the amount of Clawback Eligible Incentive Compensation that exceeds the amount of Incentive-based Compensation that otherwise would</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.96in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:3.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.944%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">have been Received had it been determined based on the restated amounts, computed without regard to any taxes paid.</font></p>
  <div style="margin-left:0.935%;display:flex;margin-top:7.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Executive Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means each individual who is currently or was previously</font></div></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:1.1pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.944%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">designated as an &#x201c;officer&#x201d; of the Company as defined in Rule 16a-1(f) under the Exchange Act. For the avoidance of doubt, the identification of an executive officer for purposes of this Policy shall include each executive officer who is or was identified pursuant to Item 401(b) of Regulation S-K or Item 6.A of Form 20-F, as applicable, as well as the principal financial officer and principal accounting officer (or, if there is no principal accounting officer, the controller).</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.676%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall apply to all Executive Officers regardless of whether each individual has attested to receipt and understanding of the Policy as set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <div style="margin-left:0.935%;margin-top:7.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.6319588149194972%;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Financial Reporting Measures</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements, and all other measures that are derived wholly or in part from such measures. Stock price and total shareholder return (and any measures that are derived wholly or in part from stock price or total shareholder return) shall, for purposes of this Policy, be considered Financial Reporting Measures. For the avoidance of doubt, a Financial Reporting Measure need not be presented in</font></div></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the Company&#x2019;s financial statements or included in a filing with the SEC.</font></p>
  <div style="margin-left:0.935%;margin-top:9.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:4.269%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.6319588149194972%;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Incentive-based Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.</font></div></div>
  <div style="margin-left:0.935%;display:flex;margin-top:7.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Nasdaq</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means The Nasdaq Stock Market.</font></div></div>
  <div style="margin-left:0.935%;margin-top:9.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.87%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.6319588149194972%;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Received</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to any Incentive-based Compensation, actual or deemed receipt, and Incentive-based Compensation shall be deemed received in the Company&#x2019;s fiscal period during which the Financial Reporting Measure specified in the Incentive-based Compensation award is attained, even if the payment or grant of the Incentive-based Compensation to the Executive Officer occurs after the end of that period.</font></div></div>
  <div style="margin-left:0.935%;margin-top:7.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.269%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.6319588149194972%;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restatement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the earlier to occur of (i) the date the Board, a committee of the Board or the officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1.26in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:3.9pt;font-family:Times New Roman;margin-bottom:0;margin-right:39.593%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font></p>
  <p style="margin-left:2.467%;text-indent:-19.647%;padding-left:15.747%;font-size:10pt;margin-top:9.25pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.639%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ATTESTATION AND ACKNOWLEDGEMENT OF POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:3.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:39.157%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By my signature below, I acknowledge and agree that:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:3.731%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.6319588149194972%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">I have received and read the attached Policy for the Recovery of Erroneously Awarded Compensation (this &#x201c;Policy&#x201d;).</font></div></div>
  <div style="margin-left:0.935%;margin-top:8.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.6319588149194972%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">I hereby agree to abide by all of the terms of this Policy both during and after my employment with the Company, including, without limitation, by promptly repaying or returning any Erroneously Awarded Compensation to the Company as determined in accordance with this Policy.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:3.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Executive Officer Name:</font></p>
  <p style="font-size:10pt;margin-top:9.9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Signature:</font></p>
  <p style="font-size:10pt;margin-top:10.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date:</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.19in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img63237988_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img63237988_0.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHH **JZCJ<>FIYLS!5R!DY/)[ #)/X=N>E<Q8?$B*YG\IE*1, %=NH;ONP2
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MM#V>:&/F;L; #]W&<Y(]: -BBN6L_B);W;K"JR9=E49"XRQP/XJZF@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDJVZ*X9\X+!0. 3V8^E='0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16/X@\3Q:'
ML\T,?,W8V '[N,YR1ZUD?\+.MO[DG_?*_P#Q=.P7.OHHHI %%%% !14-Y="T
M1IFSA%9CCKA1DURW_"SK;^Y)_P!\K_\ %T6 Z^BJ>DZHNJ1+<("%?. V >"1
MV)]*N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !14-Y>)9H9I"%11D
MD_Y_(=2>!7/0?$2UFD$/S $XWL $]CG.0#[CCOCFBP'3T444 %%8>M^,+?1V
M\MR6?C*H,D ]SD@#Z9SR#C%9T?Q,MG(!60 D<E5P/?AB?R!-.P7.MHJJ^IQQ
MQ?:F8"+:&W'(X/(XZ\YX'7/&,UA0?$2UFD$/S $XWL $]CG.0#[CCOCFE8#I
MZ*** "BBB@ HHHH **** "BBB@ HKG-6\=P:7*UNZN63&2H4CD ]V'K4VA>,
M8=:<PQJX(4M\P4# ('9CZT6 W:*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHK"UWQC#HKB&17)*AOE"D8)([L/2@#=HKG-)\=P:I*MNBN&?."P
M4#@$]F/I71T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKR'QY_Q^R_\  /\ T!:]>KR'QY_Q^R_\ _\ 0%IQ$S0^&/\ Q\O_ -<6_P#0
MDKTZO,?AC_Q\O_UQ;_T)*].HEN""L#QY_P >4O\ P#_T-:WZP/'G_'E+_P
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MO7JF0T%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDDG))/4YKU#X>Z*MI +DC]Y+DY(P0N>!SV.-V>,Y'7 I[(6YYW)H=Q&"S12
M $DF-@ !U.<53CD,9#*2""""#@@CH<U[W62?"]N9Q>;!Y@)/^R6./FQTR,=?
M4DG)P0N8=B3P]//- C7*A9".?4CL2,<$]Q_+H./\>^+F9FL(3A1Q(P/7U48Z
M =&[DY' !SW&J71M(9)EQE(W89Z95217ATDAD)9B22222<DD]3FA(&$<9D(5
M0220  ,DD]!BKDFAW$8+-%(  228V  '4YQ7HGP]T5;2 7)'[R7)R1@A<\#G
ML<;L\9R.N!75T.06/!(Y#&0RD@@@@@X((Z'->K>"_%7]LH8Y,"6,#/0;A_>
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MES78W1QNX!QE49AGTR!5KPSIJZE<QP/]UB2?<*"Q'!'7&,]NM>SQQB,!5
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M2W5F]H=LBLA(SAE*G'K@U-I6JR:7()XCAA^1'<$=P?\ ZXP0#7L>LZ2FJQ-
MX'(X)&=K=F'3I]>1QT->(4)W!JQ[KI]\M_&LZ?=< CI^1QGD=#Z&O&O$'_'S
M-_UVD_\ 0C7IW@/_ (\HO^!_^AM1X\_X\I?^ ?\ H:U*T8V>0T45[;X?_P"/
M:'_KC'_Z"*INPDBAX#_X\HO^!_\ H;5SGCWQ<S,UA"<*.)&!Z^JC'0#HW<G(
MX .>XU2Z-I#),N,I&[#/3*J2*\.DD,A+,222223DDGJ<TEJ-A'&9"%4$DD
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M]<$=G_PLZV_N2?\ ?*__ !=4VQ'F<D9C)5@002"",$$=1BO2O ?BLZ@/LL[
MR*/E)/S,._U(_,CG'!-<MXPUNWUAEFA5EDZ-N4#<.QR&/(Z=.0>O %9&CWWV
M":.?G".I.WKC/S#MU&1[T;H#W&BBBH*"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *\A\>?\?LO_ /_ $!:]>KR'QY_Q^R_\ _] 6G$3-#X8_\ 'R__
M %Q;_P!"2O3J\Q^&/_'R_P#UQ;_T)*].HEN""L#QY_QY2_\  /\ T-:WZYSX
M@3K%9NI/+E /<[@W\@:2W&SR6O;?#_\ Q[0_]<8__017B5>V^'_^/:'_ *XQ
M_P#H(JI"1@?$[_CV3_KLO_H+UYC7IWQ._P"/9/\ KLO_ *"]>8TX["9>F:;6
M97E"L[L2Q"!FP/IR<#@#T&!56>W:W8QNI5AU# @C//0U[7HVDII42P(!P.2!
MC<W=CUZ_7@<=!5#QGI*:A;.S ;HE9U;'(VC)';J!CTZ'&0*7,.QYKX;U]]%E
M$BD["0'7KE?ID<CL?7V)!]ECD$@#*000""#D$'H<UX)7MOA__CVA_P"N,?\
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M*%'/\2AB?J<X^@'I4VNQ]#GKR\>\<S2$L['))_S^0Z <"KUIX8N;M3*D3%0
M<D8R",C&<;O^ Y[>HIN@7$%M*)+I6=%&0J@'+<8R"1D=>/7&<C(KO/\ A9UM
M_<D_[Y7_ .+JF(\UGMVMV,;J58=0P((SST-=QX \5G(L9F&,8C9CSGLG_P 3
MGI]T9R *'B_Q);:V@**ZRH>&95Y7NI(?\1P>?3)-<I'(8R&4D$$$$'!!'0YH
MW ][KQ+Q!_Q\S?\ 7:3_ -"->SV=T+M%F7.'56&>N&&17C'B#_CYF_Z[2?\
MH1I1&RO%?-%&\ X60J6Z\[-V!].<_4#TISZ7-&GG-&X3 .XHP7!Z'.,<YXKI
M_AMI*7<KSN ?)"[01_$V<-^&WCCJ<\$"O3*&[ D>!5ZEX!\1MJ<9@E.98L<G
MJ5['KDD'@G'<9R2:X[QUI*:;<E8P LBAPH& ,D@C\QGL!G &!5[X8_\ 'R__
M %Q;_P!"2AZH2+_Q5_Y8?]M/_9*X&O?:\A\>?\?LO_ /_0%HBQLP*Z_X8_\
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MN3S7X4?=4=%']2>Y[^P  ] ^(]T8;7:,8DD53GT&6X_%1^%>6QQF0A5!))
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /*?B%IGV2Y,@'RS -PN!GHPSW/&X_[W/J<[
MPQKG]C3B?!*D%6 QDJ?KZ$ ]LXQD UZ!\0M,^UVQD ^:$AN%R<=&&>PYW'_=
MY]1Y35K5$LDN)VN&:5SEG))/3))R>E>@?#+2=B/>,#ECL7((^48)([')XZ<%
M>O6O/8XS(0J@DD@  9))Z#%>WZ1IJZ9$ENO1!C/J>I/4XR<G':E(:+E%%%2,
M\,U2U%I-)"N<)(ZC/7"L0*[3X5?\M_\ MG_[/7.>-+'['=R@9PQW@GOO&3CV
MW9'X8ZUH?#>^\BY\HYQ*A&!TROS GZ $#Z^YJWL3U/4JS_$'_'M-_P!<9/\
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M (_8O^!_^@-7KU>0^ _^/V+_ ('_ .@-7KU*0(Y#XG?\>R?]=E_]!>N!\/\
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M!GMOA_\ X]H?^N,?_H(KR;Q/ T%U,K#!,C'\&.X?F"*]9\/_ /'M#_UQC_\
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M !._X^4_ZXK_ .A/7))&9.%!)P3P,\ 9)_ #)]JM;$GO=-DD$8+,0  223@
M#J<UY+I/CJYTU!$"KJ  HD!. .P((/YYP  ,"H=;\87&L+Y;D*G&508!([G)
M)/TSC@'&:GE'<SM4NA=S23+G#R.PSUPS$BN^^%UJ%ADFYRT@4^F%4$?^A']*
M\]L[-[QQ#&"SL< #_/YGH!R:]IT72QI4*6RDL$!Y/&222>/J>/;N:<@1Y_\
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M4GD>O'4?B ,FI6X^AYWHFC-K$GD(RJV"1O)&<=A@')[_ $!K?_X5C<_WX_\
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M >H(/!!'0UVWAWQM<:M=10/M5#OR$7KA"1DL2>".V/?--H$SH/'G_'E+_P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC^)_#_\ ;D0@W;-KAL[=W0$8QD>M<Q_PJK_IO_Y#_P#LZ[^BG<+!6/XG\/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC9G&%"]=P]/2K'ACP5_8<IG\S?N0KC9MZD'.=Q]*Z>BBX[!1112 ;)&) 58
M@@@@C((/48KAM5^&*N2]L^WT5^1U_O#D #ID$\<GGCNZ*$P/.[#X7.3^_D4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** .0U[P!_:TS7/F[=^WC9G&%"]=P]/2K'ACP
M5_8<IG\S?N0KC9MZD'.=Q]*Z>BG<+!1112 **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYP&P#P2.Q/I7AU>O> _^/*+_ ('_ .AM5-6$F;]%%%2,**** "BBB@ HHHH
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M8^E>2UO^ _\ C]B_X'_Z U)I#N>O4445(PHHHH **** "BBB@ HHHH ****
M"BBB@ K"UWQC#HKB&17)*AOE"D8)([L/2MVO,?B=_P ?*?\ 7%?_ $)Z:0,Z
MO2?'<&J2K;HKAGS@L% X!/9CZ5T=>0^ _P#C]B_X'_Z U>O4-6$CEKSXB6]H
M[0LLF49E. N,J<'^*M'P_P")XM<W^4&'E[<[P!][.,8)]*\J\0?\?,W_ %VD
M_P#0C77?"K_EO_VS_P#9Z;6@7._HHHJ1A1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445YWJGQ$N+2:2%5CP
MDCJ,ALX5B!_%0E<#T2BL+P=KKZU"TT@4$2%?E! P%4]R?6MV@ HHHH ****
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M+=U0*^[)4,#PI/=CZ4[!<[NBBBD 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117F/
M_"SKG^Y'_P!\M_\ %TTKA<].HK+\-:HVJ6Z7#@!GW9"Y X8CN3Z5J4@"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#"UWQC#HKB&17)*AOE"D8)([L/2H
M=)\=P:I*MNBN&?."P4#@$]F/I7*?$[_CY3_KBO\ Z$]9_@/_ (_8O^!_^@-5
M6T%<]>HHHJ1A1110 4444 %%%% !1110 4444 8_B#Q/%H>SS0Q\S=C8 ?NX
MSG)'K6=9_$2WNW6%5DR[*HR%QEC@?Q5D_%7_ )8?]M/_ &2N1\/_ /'S#_UV
MC_\ 0A5):"N>VT445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBLOQ+JC:7;O<( 63;@-DCE@.Q'K0!J45YC_PLZY_N
M1_\ ?+?_ !=>G4VK!<*Y[5O'5MIKF(EG8$AA& <$=B20/RS@@@X-=#7B6NZ;
M)ITSQ2Y+9)W-_$"3ANIZ_4\Y!Y!H2N)GL.E:K'JD8GB.5/Y@]P1V(_\ KC((
M-7*X;X76;QI+,P(1R@4GOMW9Q],]>F>.QKN:3&%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 8'_">67_/7_P <?_XFM/2]6BU13+"VY0<$X(Y
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MM7-*UZ'5MWD-NV8S\K#&<X^\!Z&O(O$'_'S-_P!=I/\ T(UUWPJ_Y;_]L_\
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M$CUYK1TK7H=6W>0V[9C/RL,9SC[P'H:\B\0?\?,W_7:3_P!"-==\*O\ EO\
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MZI#:6[+)(B$RDX9U4XVKS@FNSM;Q+L;HV5P#C*L&&?3(KPBO3OAC_P >S_\
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MA@01GGH:Z?P5XN;36%M*<PN<#)QL)/7)_A]1VZCN".(7/4))!&"S$  $DDX
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2  !DDGH,5<DT.XC!9HI  "23&P  ZG.*?*A7.P^*O\ RP_[:?\ LE<CX?\
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M >AJQ?WZ6"&>4X1<9.">I ' !/4UQ'PJ_P"6_P#VS_\ 9ZZ#QY_QY2_\ _\
M0UHMJ ?\)Y9?\]?_ !Q__B:OW6OP6L:W$C@(X!7.<D''1?O'J,\<=Z\2JTSR
MZDRI\SL%"J ,G:@X  ] /YD\YI\H7/1H_B9;.0"L@!(Y*K@>_#$_D":Z/3M3
MCU)/-A8,N2,C(Y'8@X(_'MSTKQ">W:W8QNI5AU# @C//0U>T/7Y=%<R1$<C!
M5N5/ID CIV/7\"03E"YZ[JFM0Z4 T[A0QP."2<=> "?QZ=/6L"/XF6SD K(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD)!'7!!P>E*(V=#X0URVT?,TR.TN<*5"D!<=LD<GG)].!U.>I_X6=;?W)/\
MOE?_ (NN,T'PE+K:M)$R#:<$,Q#=,@X"G@]OH?2M3_A6-S_?C_[Z;_XBAV#4
MR?%6HP:C+Y]NK+N'SAE RW][ACU[\#D9Y)-.\%WWV.[B)SACL('?>,#/MNP?
MPSUK4_X5C<_WX_\ OIO_ (BKNB?#N:TGCFE9-B,&^0MNRO(ZKCKC/MFBZ$=C
MX@_X]IO^N,G_ *":\2KVWQ!_Q[3?]<9/_037B5$1L]0^'.DI!;BZP"\I;G'(
M53C;^8SVSQGH*Z>\LTO$,,@#(PP0?\_D>H/(K&\!_P#'E%_P/_T-JWZ3W&CP
MK4+3['*\&<^6[+G&,[21G%>C?#'_ (]G_P"NS?\ H*5P/B#_ (^9O^NTG_H1
MKOOAC_Q[/_UV;_T%*;V$C(^*%\QECM_X F_'/))(Y[< <>F3ZUR6F-$DBFX#
M&('Y@GWCQP.2._7D'&<<UU/Q0@99XY2/E:/ /NK$G_T(5RVF6!U"18%*J7.
M7.%SC@9P>O0>IP*:V$ST*/XE6L8"JD@    5  !T&-]97B?Q=::U$8]CB0<H
MQ5>#W'#]#T/7UP2!5?\ X5C<_P!^/_OIO_B*/^%8W/\ ?C_[Z;_XBEH/4Y"O
M:?#%]]NMHI>22@!+=25^5CWZD$UPO_"L;G^_'_WTW_Q%=]H&E_V7 EOG)0<G
MKR3EL<#C)./:B3!'(?%7_EA_VT_]DKD?#_\ Q\P_]=H__0A77?%7_EA_VT_]
MDKD?#_\ Q\P_]=H__0A36PGN>VT445!1XEX@_P"/F;_KM)_Z$:Z[X5?\M_\
MMG_[/7(^(/\ CYF_Z[2?^A&NN^%7_+?_ +9_^SU;V)6Y!\4+YC+';_P!-^.>
M221SVX X],GUKGO"^D_VK<)"P.S.6P#]U>2#C&,],]B:W?BA RSQRD?*T> ?
M=6)/_H0K-\!ZC]BNE!QB4%#D$_>P5QCU8 >F#^-);!U/6HXQ& J@     8
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M#. >IQ[#D^PKN/BG S+#*!\JEP3[L%(_]!-<?X<U'^SKB.<XPK<D@G"M\K'
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MI<XN)64A V A)Y(QSE1Q@G\<4-JPBQ\3O^/9/^NR_P#H+UYK;P-<,L2#+.0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO#__ !\P_P#7:/\ ]"%>VTY @HHHJ1A1110!YC\3O^/E/^N*_P#H3U@>'_\
MCYA_Z[1_^A"M_P")W_'RG_7%?_0GK \/_P#'S#_UVC_]"%6MB>I[;1114%'
M?%7_ )8?]M/_ &2N!KVW5=!AU;;YZ[MF<?,PQG&?ND>@JA_P@=E_SR_\??\
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M7Z$&J9)UO_"SK;^Y)_WRO_Q=<#KL\-Q*TEL"L;<[2 ,'N!@GCOVQG &!6_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP/<U!11\1?9%57O-N$.5W9)SQG '+#D9&".F164_Q%M+;]V@<JH !1 %QCH
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M2/E:/ /NK$G_ -"%2MQLY;3&B213<!C$#\P3[QXX')'?KR#C..:]"C^)5K&
MJI(    %0  =!C?7GNF6!U"18%*J7. 7.%SC@9P>O0>IP*Z7_A6-S_?C_P"^
MF_\ B*IV$BQXG\76FM1&/8XD'*,57@]QP_0]#U]<$@5Q%=?_ ,*QN?[\?_?3
M?_$4?\*QN?[\?_?3?_$4)H#L=-U@O8"[7)9(&/S\Y:,$$GG)R5]<D>]>/U[
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M:'_KC'_Z"*<@1E?$&S2:T:1@"T94J>XRR@_F#TZ=.X%>3UZ]X\_X\I?^ ?\
MH:UY#1'8&>P^#]*CL+=&0?-*B,Q/4DC/Y#/ _J236^(-FDUHTC %HRI4]QEE
M!_,'ITZ=P*U?#_\ Q[0_]<8__015#QY_QY2_\ _]#6EU#H>0U[;X?_X]H?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6/#T&KC$R@G& PX8=<<^V<X.1GJ*2=@:/,='\:7.EC8K!T P%DRP'0#!R",
M<#./:C6/&ESJ@V,P1",%8\J#U!R<DG(/(SCVK>OOA<PYAE!YX#@C _WAG)_
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M )V4J<D'^Z2.I7V_D<CG&:R-'^',%F=\Q,I!X!&U>Q'RY.>G<X(/(KJXXQ&
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M. PX!Q@D>A[9!R.F156O0O VE1ZI9202C*F9OJ#L7!![$?\ UCD$BJ9)D?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\_G8\QV;'EYQN).,[Z28V5_A5_RW_P"V?_L]=!X\_P"/*7_@'_H:T>%?"O\
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M&00>HQ7*:Q\.8+P[X28B3R -R]R?ER,=>QP .!0F#1SW_"SKG^Y'_P!\M_\
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M,.F.G"GDGID8YYQT.C_#F"S.^8F4@\ C:O8CY<G/3N<$'D5U<<8C 50
M,  =!BAL$AU%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#D/B=_Q[)_UV7_ -!>O,:]E\3^'_[<B$&[9M<-G;NZ C&,CUKF/^%5?]-_
M_(?_ -G5)B:._HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** (Y)-O%,\\T3]?PJ.@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.
MB@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3S
MS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ
M.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3
MSS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YY
MJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"
M3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1Y
MYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@
M"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1
MYYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B
M@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS
M1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.
MB@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3S
MS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ
M.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3
MSS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"W1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 03]?PJ.I)
M^OX5'0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 6Z*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*?I5?RSZ&@"[15$C%*$)[4 7:*AME(SFEFFV<#K0!*3BF[P>]5"2_O1L([4
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M@>E+5(@K4T,V>#0!/1110 4444 6Z*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<<U<89&*HT 6XHMGUJ2CK10 QX@_6G]*** $)QS5/[Q^M3W+X&/6H8F"G)H
M69-AJ>!]P^E132AZ2W?!QZT 6)&VC-5$7<<58N!D5#!U% %I$V\"EHJ"?.>,
M].U $GE '-/JF7([FK,)R!0!7F;<:F@BQSWJL1CBKD?0?2@!U->,/UIU% "
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M0 C+NX-(D83I5;YAZ_K0CDD<]Z +,C;1FJB+N.*L7 R*A@ZB@"TB;>!2T44
M,\H YI]%% !5"K]4* +]0W+8&/6IJKW(Y!H 9#'O/L*M]*KVO>K%  1FFI$$
MZ4ZB@ HHHH **** +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBMN&:BE@+'(I\*%!@T 1W7;\:+7O^%.FB+XQ1#$4SF@"6JDT>TY[5;I",\4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=<_W(_\ OEO_ (NC_A9US_<C_P"^6_\ BZ.5A<].HKS'_A9US_<C_P"^6_\
MBZ/^%G7/]R/_ +Y;_P"+HY6%STZBO,?^%G7/]R/_ +Y;_P"+H_X6=<_W(_\
MOEO_ (NCE87/3J*\Q_X6=<_W(_\ OEO_ (NC_A9US_<C_P"^6_\ BZ.5A<].
MHKS'_A9US_<C_P"^6_\ BZ/^%G7/]R/_ +Y;_P"+HY6%STZBO,?^%G7/]R/_
M +Y;_P"+H_X6=<_W(_\ OEO_ (NCE87/3J*\Q_X6=<_W(_\ OEO_ (NC_A9U
MS_<C_P"^6_\ BZ.5A<].HKS'_A9US_<C_P"^6_\ BZ/^%G7/]R/_ +Y;_P"+
MHY6%STZBO,?^%G7/]R/_ +Y;_P"+H_X6=<_W(_\ OEO_ (NCE87/3J*\Q_X6
M=<_W(_\ OEO_ (NC_A9US_<C_P"^6_\ BZ.5A<].HKS'_A9US_<C_P"^6_\
MBZ/^%G7/]R/_ +Y;_P"+HY6%STZBO,?^%G7/]R/_ +Y;_P"+H_X6=<_W(_\
MOEO_ (NCE87/3J*\Q_X6=<_W(_\ OEO_ (NC_A9US_<C_P"^6_\ BZ.5A<].
MHKS'_A9US_<C_P"^6_\ BZ/^%G7/]R/_ +Y;_P"+HY6%STZBO,?^%G7/]R/_
M +Y;_P"+H_X6=<_W(_\ OEO_ (NCE87/3J*\Q_X6=<_W(_\ OEO_ (NC_A9U
MS_<C_P"^6_\ BZ.5A<].HKS'_A9US_<C_P"^6_\ BZ/^%G7/]R/_ +Y;_P"+
MHY6%STZBO,?^%G7/]R/_ +Y;_P"+H_X6=<_W(_\ OEO_ (NCE87/3J*\Q_X6
M=<_W(_\ OEO_ (NC_A9US_<C_P"^6_\ BZ.5A<].HKS'_A9US_<C_P"^6_\
MBZ/^%G7/]R/_ +Y;_P"+HY6%STZBO,?^%G7/]R/_ +Y;_P"+H_X6=<_W(_\
MOEO_ (NCE87/3J*\Q_X6=<_W(_\ OEO_ (NC_A9US_<C_P"^6_\ BZ.5A<].
MHKS'_A9US_<C_P"^6_\ BZ/^%G7/]R/_ +Y;_P"+HY6%STZBO,?^%G7/]R/_
M +Y;_P"+H_X6=<_W(_\ OEO_ (NCE87/3J*\Q_X6=<_W(_\ OEO_ (NC_A9U
MS_<C_P"^6_\ BZ.5A<].HKS'_A9US_<C_P"^6_\ BZ/^%G7/]R/_ +Y;_P"+
MHY6%STZBO,?^%G7/]R/_ +Y;_P"+H_X6=<_W(_\ OEO_ (NCE87/3J*\Q_X6
M=<_W(_\ OEO_ (NC_A9US_<C_P"^6_\ BZ.5A<].HKS'_A9US_<C_P"^6_\
MBZ/^%G7/]R/_ +Y;_P"+HY6%STZBO,?^%G7/]R/_ +Y;_P"+H_X6=<_W(_\
MOEO_ (NCE87/3J*\Q_X6=<_W(_\ OEO_ (NC_A9US_<C_P"^6_\ BZ.5A<].
MHKS'_A9US_<C_P"^6_\ BZ/^%G7/]R/_ +Y;_P"+HY6%STZBO,?^%G7/]R/_
M +Y;_P"+H_X6=<_W(_\ OEO_ (NCE87/3J*\Q_X6=<_W(_\ OEO_ (NC_A9U
MS_<C_P"^6_\ BZ.5A<].HKS'_A9US_<C_P"^6_\ BZ/^%G7/]R/_ +Y;_P"+
MHY6%STZBO,?^%G7/]R/_ +Y;_P"+H_X6=<_W(_\ OEO_ (NCE87/3J*\Q_X6
M=<_W(_\ OEO_ (NC_A9US_<C_P"^6_\ BZ.5A<].HKS'_A9US_<C_P"^6_\
MBZ/^%G7/]R/_ +Y;_P"+HY6%STZBO,?^%G7/]R/_ +Y;_P"+H_X6=<_W(_\
MOEO_ (NCE87/3J*\Q_X6=<_W(_\ OEO_ (NC_A9US_<C_P"^6_\ BZ.5A<].
MHKS'_A9US_<C_P"^6_\ BZ/^%G7/]R/_ +Y;_P"+HY6%STZBO/M)^)K,X6Y1
M0A(^:/(V^Y!+9[=,$#/7I7?QR"0!E(((!!!R"#T.:35ACJ*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ()^OX5'4D_7\*CH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 <A\1%EMXUNH7==IVL$9@
M,'H3@X&#QG'.0,\"N!_X2"Y_Y[2?]_&_QKU_6]._M*"2WXRZG&20-PY4\<\$
M UXE)&8R58$$$@@C!!'48JHB9[3X<U'^T;>.<YRR\D@#++\K' XY(./;TK2K
M@OA=J.1):'&00XX.3G"MSTXPOOR>O;O:3&@KC/B/K;6:QP1,5=B6)1RK  8
M('."3_X[^79UX[XRU4:E<NZG*+A5Z=%ZX(Z@MD@^A_"A"94_X2"Y_P">TG_?
MQO\ &O7]$MGMH(XY"S.%&XNVYMQY(SWP3@>V*\I\(:3_ &G<HF 50[VR 1M4
MCC!ZY.!^.<8KV2G($%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KB/B5J$MGY/E.R;O,SL8KG&S&<&NWK@/BK_RP_P"VG_LE-;B9
MR/\ PD%S_P ]I/\ OXW^->VUX%7OM.0(****D84444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 <!\5?^6'_ &T_]DK(\%>&(M<\SS2P\O9C80/O;LYR#Z5K_%7_
M )8?]M/_ &2CX5?\M_\ MG_[/5=!=30_X5C;?WY/^^E_^(H_X5C;?WY/^^E_
M^(KKZ*5V.QR'_"L;;^_)_P!]+_\ $4?\*QMO[\G_ 'TO_P 177T4786.0_X5
MC;?WY/\ OI?_ (BC_A6-M_?D_P"^E_\ B*Z^BB["QR'_  K&V_OR?]]+_P#$
M4?\ "L;;^_)_WTO_ ,177T4786.0_P"%8VW]^3_OI?\ XBC_ (5C;?WY/^^E
M_P#B*Z^BB["QR'_"L;;^_)_WTO\ \11_PK&V_OR?]]+_ /$5U]%%V%CD/^%8
MVW]^3_OI?_B*/^%8VW]^3_OI?_B*Z^BB["QR'_"L;;^_)_WTO_Q%'_"L;;^_
M)_WTO_Q%=?11=A8Y#_A6-M_?D_[Z7_XBC_A6-M_?D_[Z7_XBNOHHNPL<A_PK
M&V_OR?\ ?2__ !%'_"L;;^_)_P!]+_\ $5U]%%V%CD/^%8VW]^3_ +Z7_P"(
MH_X5C;?WY/\ OI?_ (BNOHHNPL<A_P *QMO[\G_?2_\ Q%'_  K&V_OR?]]+
M_P#$5U]%%V%CD/\ A6-M_?D_[Z7_ .(H_P"%8VW]^3_OI?\ XBNOHHNPL<A_
MPK&V_OR?]]+_ /$4?\*QMO[\G_?2_P#Q%=?11=A8Y#_A6-M_?D_[Z7_XBC_A
M6-M_?D_[Z7_XBNOHHNPL<A_PK&V_OR?]]+_\11_PK&V_OR?]]+_\177T4786
M.0_X5C;?WY/^^E_^(H_X5C;?WY/^^E_^(KKZ*+L+'(?\*QMO[\G_ 'TO_P 1
M1_PK&V_OR?\ ?2__ !%=?11=A8Y#_A6-M_?D_P"^E_\ B*/^%8VW]^3_ +Z7
M_P"(KKZ*+L+'(?\ "L;;^_)_WTO_ ,11_P *QMO[\G_?2_\ Q%=?11=A8Y#_
M (5C;?WY/^^E_P#B*/\ A6-M_?D_[Z7_ .(KKZ*+L+'(?\*QMO[\G_?2_P#Q
M%'_"L;;^_)_WTO\ \177T4786.0_X5C;?WY/^^E_^(H_X5C;?WY/^^E_^(KK
MZ*+L+'(?\*QMO[\G_?2__$4?\*QMO[\G_?2__$5U]%%V%CD/^%8VW]^3_OI?
M_B*/^%8VW]^3_OI?_B*Z^BB["QR'_"L;;^_)_P!]+_\ $4?\*QMO[\G_ 'TO
M_P 177T4786.0_X5C;?WY/\ OI?_ (BC_A6-M_?D_P"^E_\ B*Z^BB["QR'_
M  K&V_OR?]]+_P#$4?\ "L;;^_)_WTO_ ,177T4786.0_P"%8VW]^3_OI?\
MXBC_ (5C;?WY/^^E_P#B*Z^BB["QR'_"L;;^_)_WTO\ \11_PK&V_OR?]]+_
M /$5U]%%V%CD/^%8VW]^3_OI?_B*/^%8VW]^3_OI?_B*Z^BB["QR'_"L;;^_
M)_WTO_Q%'_"L;;^_)_WTO_Q%=?11=A8Y#_A6-M_?D_[Z7_XBC_A6-M_?D_[Z
M7_XBNOHHNPL<A_PK&V_OR?\ ?2__ !%'_"L;;^_)_P!]+_\ $5U]%%V%CD/^
M%8VW]^3_ +Z7_P"(H_X5C;?WY/\ OI?_ (BNOHHNPL<A_P *QMO[\G_?2_\
MQ%'_  K&V_OR?]]+_P#$5U]%%V%CD/\ A6-M_?D_[Z7_ .(H_P"%8VW]^3_O
MI?\ XBNOHHNPL<A_PK&V_OR?]]+_ /$4?\*QMO[\G_?2_P#Q%=?11=A8Y#_A
M6-M_?D_[Z7_XBC_A6-M_?D_[Z7_XBNOHHNPL<A_PK&V_OR?]]+_\11_PK&V_
MOR?]]+_\177T4786.0_X5C;?WY/^^E_^(H_X5C;?WY/^^E_^(KKZ*+L+'(?\
M*QMO[\G_ 'TO_P 11_PK&V_OR?\ ?2__ !%=?11=A8Y#_A6-M_?D_P"^E_\
MB*/^%8VW]^3_ +Z7_P"(KKZ*+L+'AFJ6HM)I(5SA)'49ZX5B!7L?A_\ X]H?
M^N,?_H(KR+Q!_P ?,W_7:3_T(UZ[X?\ ^/:'_KC'_P"@BG(2-"BBBI&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 03]?PJ.I)^OX5
M'0 4444 '2F^8/44KC((]JJ^0WI0!9\P>HH\P>HJFR[>#3EB+<B@"V&!I/,'
MJ*BBC*@CU%1^0WI0!9\P>HH\P>HJFR[>#3EB+<B@"V&!Z4M101E,YIDL^>!0
M!,T@7K2"8'O558RW2G&$CM0!;ZT53CD*]*N4 %-:0+UJ&6?/ J)8RW2@"T)@
M>]/ZU4,)':DCD*]* +E%%133;.!UH D9@O6F>>OK58 O[T[R&]* +0.>E+5(
M$I[5;C;<,T .I"P'6EJK</DX]* +(<'O2U25MIS5T'/- #=X'>CS!ZBJ[PDD
MGWIC1E.M %OS!ZBE#@]ZIK&7Z5+%$5.30!8I&8+UJ.:;9P.M5P"_O0!9\]?6
MG@YZ55\AO2F@E/:@"[138VW#-1338X% $K.%ZTGGCUJJJE^E.\@^E %L'-%4
ME<I5Q3GF@!:"<4R638,U59R] %KSQZTJN&Z56\@^E-92G6@"[144$A;K^=2T
M !.*;Y@]14=R^!CUJM0!?I"P'6FQ/N%1SQECD>E $OF#U%'F#U%56B*\FFJN
M[@4 7/,'J*=53R&]*L2R;!F@!Y.*9YX]:JLY>G>0?2@"RKANE.JDRE.M6()"
MW7\Z ):0G'6EJO<OVH FW@]Z=5'I5U&W#- "T45!--C@4 2LX7K2>>/6JJJ7
MZ4[R#Z4 6P<T525RE7%.>: %H)Q3)9-@S55G+T 6O/'K2JX;I5;R#Z4UE*=:
M +M%102%NOYU+0 A..M)O![U#<OVJ'I0!>I"X'>A&W#-02Q%CD4 3>8/44>8
M/455:,KR:14+<"@"WO![TI<#O59(2"#[TZ6(L<B@";S!ZBCS!ZBJK1E>32*A
M;@4 6]X/>G552$@@^]3RR;!F@!Y.*9YX]:JLY>G>0?2@"RKANE.JDRE.M6()
M"W7\Z ):0G'6F32[/K58DO[T 6?/7UIZL&Z55\AO2FD%/:@"[13(7+CFG$XY
MH 6F&8#O5>24O2+$6YQ0!:64-WIU4VC*]:D@D.<4 6*.E%1SOM'UH =Y@]13
MNM4*M6[Y&/2@"0L!UI/,'J*9/&7QBH3"1S0!9\P>HH\P>HJF!GBG^0WI0!;Z
MT4T?*.>PJM)*7H L&8#O2K*&[U56(MSBAHRO6@"Y15>"0YQ4SOL&: '=*89@
M.]5GD+]:40D]J +*R!NE.JDT97K4UO(3P: )Z**KRSYX% $S2!>M()@>]55C
M+=*<82.U %OK15..0KTJY0 4W>!WI6;:,U2)SS0!=!STI2<57MGP<>M2RKN&
M!0 OF#U%'F#U%5O(;TIA&.* +GF#U%*#GI540D\U/ A48/K0!)36D"]:AEGS
MP*B6,MTH M"8'O3^M5#"1VI(Y"O2@"Y112,VT9H 3>!WI0<]*I$YYJ:V?!QZ
MT 6***:[[!F@!W2F&8#O59Y"_6E$)/:@"RL@;I3JI-&5ZU-;R$\&@">BCI56
M68MP.E %AI0O>D$P/>JRQENE#1%><4 7**JPR%3BK5 !3=X'>E9MHS5(G/-
M%T'/2EJO;/@X]:L4 %%%% !1110!;HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR7Q[I1
ML;EG PDWS#KU/WN3WW<X'0$?2O6JY3XBZ4;RW$RC+0G/?.T\-P/P)ST //JU
MN)GG_AS4?[.N(YSC"MR2"<*WRL<#G@$X]_6O:Z\"KV7PGJ?]HVT<A.6 VM\V
MXY7C)/J?O<^O?K3D")O$>H_V=;R3C.57@@ X9OE4X/'!(S[>M>*5WWQ0U3_5
MV8'_ $T)_-5 Y^N>/3!ZUPMO UPRQ(,LY  Z9).!UHB)GHGPSTGR8VNV S*<
M+P,[5)R<]>3VX^Z#SQ7:U5TNP&GQ);KC"*!D#&2.IQ[GD^YJU4LH**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y#XG?\>R?]=E
M_P#07KS&O3OB=_Q[)_UV7_T%Z\QJX[$L]M\/_P#'M#_UQC_]!%:%9_A__CVA
M_P"N,?\ Z"*T*@HIZKI4>J1F"494_F#V(/8C_P"L<@D5XUJ^FMIDKV[=4.,^
MHZ@]3C(P<=J]QKRWXE0+%=!@.7C4GW.67^0%5$3(?A_J1M+I8\@)*"IR<#."
M5[XSG@?4@=:]8KQ+P_\ \?,/_7:/_P!"%>VTI @HHHI#"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N ^*O\ RP_[:?\ LE=_7 ?%7_EA_P!M/_9*:W$S@:]]KP*O?:<@
M04445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4\'W10!)1110!4G^\:G@^Z*@G^\:G@^Z* %F;:*JQKN.*L7 R/I4,)P10!:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"A&O7?#_\ Q[0_]<8__0152$C0HHHJ1A1110 4444 %%%% !1110 4444
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M-]E]_P!*?%#LYJ2@"L]OM&:; ^T_6K9&>*@^R^_Z4 3T444 %%%% %NBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#"\;:=]NM9!QF,;QDD8V\GI_LY [9/XUX_7OM
M9_\ PC]M_P \8_\ OVO^%-.PFCQS2[ ZA*ENN<NP&0,X!ZG'L.3["O<8XQ&
MJ@     8  Z#%58-'@MV$B1(K#H5101GCJ!5RANX)!1112&%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <A\3O^/9/^NR_^@O7
MF->[W5FEV-LBJX!SAE##/K@U5_X1^V_YXQ_]^U_PIIV$T>)45[;_ ,(_;?\
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MMZ!_'_P'^M<^'_WY^LOU-*G\#Y(UZ***]PX3Q+Q!_P ?,W_7:3_T(UZ[X?\
M^/:'_KC'_P"@BO(O$'_'S-_UVD_]"->N^'_^/:'_ *XQ_P#H(JI"1H4445(P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""?K^%1U)
M/U_"HZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@"W1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P'Q5_Y8?]M/\
MV2CX5?\ +?\ [9_^ST?%7_EA_P!M/_9*/A5_RW_[9_\ L]5T%U._HHHJ1A7)
M5UM<E7DYQ]CY_H=>#^U\B6S^^O\ O#^==17+V?WU_P!X?SKJ*K*/@EZBQ>Z"
MN7O/OM_O'^==17+WGWV_WC_.C-_@CZAA-V15UM<E76U.3_;^7ZCQGV?F86N?
M?'^Z/YFL^M#7/OC_ '1_,UGUPXW^//U-Z/\ #04445S&AUM%%%?6GDF=KGW!
M_O#^1K#K<US[@_WA_(UAUX&:?QWZ([\+\!H:']\_[I_F*FU_^#_@7]*AT/[Y
M_P!T_P Q4VO_ ,'_  +^E;0_Y%\O7]40_P#>%_70R:***\LZCH=)_P!4OX_S
M-7*IZ3_JE_'^9JY7T^&_@P]%^1YE3XY>H4445L0<O>??;_>/\ZBJ6\^^W^\?
MYU%7RM7XY>IZD=D%%%%04%:VG?ZA_P#@7_H(K)K6T[_4/_P+_P!!%=> _B/T
M9C7^%>J,FK>D_P"M7\?Y&JE6])_UJ_C_ "-98;^-#U7YEU/@EZ'14445].>8
M%%%% &1K_P#!_P "_I636MK_ /!_P+^E9-?.YC_O$OE^2/0P_P##04445R&Q
MUM%%%?6GDA6=KGW!_O#^1K1K.US[@_WA_(USXW^!/T-*/QHPZT-#^^?]T_S%
M9]:&A_?/^Z?YBO#P7\>'J=U;^&R+5O\ 6M^'\A52K>K?ZUOP_D*J5&)_C3]7
M^8Z?P1] HHHK$LT-#^^?]T_S%&N??'^Z/YFC0_OG_=/\Q1KGWQ_NC^9KT?\
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M_P"NTG_H1KUWP_\ \>T/_7&/_P!!%5(2-"BBBI&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 03]?PJ.I)^OX5'0 4444 %%%13R[.
M!UH >T@7K3/M(]ZKJI>I/LQ]J )TE#=*=5)XRG6K,))'- $E->4+UJ*>7' J
M%$+]* +'VD>]/60-TJ#[,?:HV4IUH N,VWDTSSU]:"I=<'K47V8^U $OGKZT
M>>OK54C'%2"W)YH LJX;D4O2HXD\L<U7DE+_ $H L-< 4@N :A2 MS2M;D4
M6@<T54A)!P*MT %1^>OK2S/M%4Z +RMNY%+4%LW:IZ "FM(%ZTR>79P.M5U4
MO0!8^TCWIZ2ANE0?9C[5&\93K0!=HJ.$DCFG2/L&: %9MO)J,W(%5V8O3Q;$
MT 3+.&_^O4E5'A*U);$].U $AF XI//7UJ-K<DYJ.2(IUH L>>OK2K*&X%5H
MXB_2I8X"IS0!/37E"]:BGEQP*A1"_2@"Q]I'O3UD#=*@^S'VJ-E*=: +M%-C
M)(YZTZ@!K2!>#0L@;@55D?<<TD;;3F@"[1103CF@ Z5&UP!5>24O]*5("W-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@/BK_P L/^VG_LE'PJ_Y
M;_\ ;/\ ]GH^*O\ RP_[:?\ LE'PJ_Y;_P#;/_V>JZ"ZG?T445(PKDJZVN2K
MR<X^Q\_T.O!_:^1+9_?7_>'\ZZBN7L_OK_O#^==1591\$O46+W05R]Y]]O\
M>/\ .NHKE[S[[?[Q_G1F_P $?4,)NR*NMKDJZVIR?[?R_4>,^S\S"US[X_W1
M_,UGUH:Y]\?[H_F:SZX<;_'GZF]'^&@HHHKF-#K:***^M/),[7/N#_>'\C6'
M6YKGW!_O#^1K#KP,T_COT1WX7X#0T/[Y_P!T_P Q4VO_ ,'_  +^E0Z']\_[
MI_F*FU_^#_@7]*VA_P B^7K^J(?^\+^NADT445Y9U'0Z3_JE_'^9JY5/2?\
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MU:H 0N!WI-X]144D!8YJ C'% %QVP,U349.*M%=RX]JK*<'- %P#'%+1UHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M** "BBB@ HHHH **** "BBB@#@/BK_RP_P"VG_LE'PJ_Y;_]L_\ V>CXJ_\
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MHHK8@Y>\^^W^\?YU%4MY]]O]X_SJ*OE:OQR]3U([(****@H*UM._U#_\"_\
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MOO4B0A: "+..:?110!2DZGZU;CZ#Z4PVX/-2 8XH &7=Q522/9Q5RD9=W!H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLN/^[^I_QK7\,>'(+V0I(F0$)^\PYR!V(]:FI@YPBY.VAI1S:E5FH).[]/\
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M_$TO]EQ_W?U/^-']EQ_W?U/^-'U"?E_7R#^VZ':7X?YB?\)Y>_\ /7_QQ/\
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M4_XT?V7'_=_4_P"-'U"?E_7R#^VZ':7X?YB?\)Y>_P#/7_QQ/_B:/^$\O?\
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M=V1N8=%)[&E+!3C%O30JGG%&I.,$I7;MTZ_,S_\ A/+W_GK_ ..)_P#$T?\
M">7O_/7_ ,<3_P")KO\ _A [+_GE_P"/O_\ %4?\('9?\\O_ !]__BJY+H].
MS. _X3R]_P">O_CB?_$T?\)Y>_\ /7_QQ/\ XFE_LN/^[^I_QH_LN/\ N_J?
M\:[/J$_+^OD>5_;=#M+\/\Q/^$\O?^>O_CB?_$T?\)Y>_P#/7_QQ/_B:7^RX
M_P"[^I_QH_LN/^[^I_QH^H3\OZ^0?VW0[2_#_,3_ (3R]_YZ_P#CB?\ Q-'_
M  GE[_SU_P#'$_\ B:7^RX_[OZG_ !H_LN/^[^I_QH^H3\OZ^0?VW0[2_#_,
M3_A/+W_GK_XXG_Q-'_">7O\ SU_\<3_XFE_LN/\ N_J?\:OZ#H,-U,L;KE3N
MR-S#HI/8TI8*<8MZ:%4\XHU)Q@E*[=NG7YF?_P )Y>_\]?\ QQ/_ (FC_A/+
MW_GK_P".)_\ $UW_ /P@=E_SR_\ 'W_^*H_X0.R_YY?^/O\ _%5R71Z=F<!_
MPGE[_P ]?_'$_P#B:/\ A/+W_GK_ ..)_P#$TO\ 9<?]W]3_ (T?V7'_ '?U
M/^-=GU"?E_7R/*_MNAVE^'^8G_">7O\ SU_\<3_XFC_A/+W_ )Z_^.)_\32_
MV7'_ '?U/^-']EQ_W?U/^-'U"?E_7R#^VZ':7X?YB?\ ">7O_/7_ ,<3_P")
MH_X3R]_YZ_\ CB?_ !-+_9<?]W]3_C1_9<?]W]3_ (T?4)^7]?(/[;H=I?A_
MF)_PGE[_ ,]?_'$_^)H_X3R]_P">O_CB?_$TO]EQ_P!W]3_C4^GZ-%+(B,N0
MSJ#R>A(![TG@9I7T_KY#CG5&32M+7T_S*_\ PGE[_P ]?_'$_P#B:/\ A/+W
M_GK_ ..)_P#$UW__  @=E_SR_P#'W_\ BJ/^$#LO^>7_ (^__P 57)='J69P
M'_">7O\ SU_\<3_XFC_A/+W_ )Z_^.)_\35C4-&BBD=%7 5V Y/0$@=Z@_LN
M/^[^I_QKK6!FU?3^OD>7+.J,6U:6GI_F)_PGE[_SU_\ '$_^)H_X3R]_YZ_^
M.)_\32_V7'_=_4_XT?V7'_=_4_XT_J$_+^OD+^VZ':7X?YB?\)Y>_P#/7_QQ
M/_B:/^$\O?\ GK_XXG_Q-+_9<?\ =_4_XT?V7'_=_4_XT?4)^7]?(/[;H=I?
MA_F)_P )Y>_\]?\ QQ/_ (FC_A/+W_GK_P".)_\ $TO]EQ_W?U/^-3Z?HT4L
MB(RY#.H/)Z$@'O2>!FE?3^OD..=49-*TM?3_ #*__">7O_/7_P <3_XFC_A/
M+W_GK_XXG_Q-=_\ \('9?\\O_'W_ /BJ/^$#LO\ GE_X^_\ \57)='J69P'_
M  GE[_SU_P#'$_\ B:/^$\O?^>O_ (XG_P 35C4-&BBD=%7 5V Y/0$@=Z@_
MLN/^[^I_QKK6!FU?3^OD>7+.J,6U:6GI_F)_PGE[_P ]?_'$_P#B:/\ A/+W
M_GK_ ..)_P#$TO\ 9<?]W]3_ (T?V7'_ '?U/^-/ZA/R_KY"_MNAVE^'^8G_
M  GE[_SU_P#'$_\ B:/^$\O?^>O_ (XG_P 32_V7'_=_4_XT?V7'_=_4_P"-
M'U"?E_7R#^VZ':7X?YB?\)Y>_P#/7_QQ/_B:/^$\O?\ GK_XXG_Q-+_9<?\
M=_4_XU/I^C12R(C+D,Z@\GH2 >])X&:5]/Z^0XYU1DTK2U]/\RO_ ,)Y>_\
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M0KT(Y75DD[K\?\CG>*BGU-?_ (3R]_YZ_P#CB?\ Q-'_  GE[_SU_P#'$_\
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M\,6^I0M),FYA(1G<PXVJ>Q'K65? SH0YG:WE_P ,73KJ;LC!_P"$\O?^>O\
MXXG_ ,31_P )Y>_\]?\ QQ/_ (FN_P#^$#LO^>7_ (^__P 51_P@=E_SR_\
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M(",GH6 /2O2_^$#LO^>7_C[_ /Q5<N)PTL.TI6U[&M.HJBT. _X3R]_YZ_\
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M_P".)_\ $UW_ /P@=E_SR_\ 'W_^*H_X0.R_YY?^/O\ _%47069P'_">7O\
MSU_\<3_XFC_A/+W_ )Z_^.)_\37?_P#"!V7_ #R_\??_ .*K.\0^#K6T@>6.
M/##;@[W/5@.[4U9NQ%2?LX.3V2N<C_PGE[_SU_\ '$_^)H_X3R]_YZ_^.)_\
M347]GIZ?J?\ &C^ST]/U/^-:>Q9YW]LT>TOP_P R7_A/+W_GK_XXG_Q-'_">
M7O\ SU_\<3_XFHO[/3T_4_XT?V>GI^I_QH]BP_MFCVE^'^9+_P )Y>_\]?\
MQQ/_ (FC_A/+W_GK_P".)_\ $U%_9Z>GZG_&MGPIX>@OY2DJ9 0G[S#G('8C
MUI2I-*YI1S2E5FH).[]/\S+_ .$\O?\ GK_XXG_Q-'_">7O_ #U_\<3_ .)K
MO_\ A [+_GE_X^__ ,51_P ('9?\\O\ Q]__ (JL[H]"S. _X3R]_P">O_CB
M?_$T?\)Y>_\ /7_QQ/\ XFN__P"$#LO^>7_C[_\ Q5'_  @=E_SR_P#'W_\
MBJ+H+,X#_A/+W_GK_P".)_\ $T?\)Y>_\]?_ !Q/_B:[_P#X0.R_YY?^/O\
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M'/&]O,X#_A/+W_GK_P".)_\ $T?\)Y>_\]?_ !Q/_B:[_P#X0.R_YY?^/O\
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M)Y>_\]?_ !Q/_B:B_L]/3]3_ (T?V>GI^I_QH]BP_MFCVE^'^9+_ ,)Y>_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!!/U_"HZDGZ_A4= !1110 445#<2XX% #WF"U']J]OUJ%(R_2I
MOLOO^E #TG#>U254DA*?2IX00.: )*:\@3K22R;!57EC[T 3&Z]J5;D'K31:
M^](]N1TYH L@YHJ"V!Z]JGH 1VVC-1_:1[TRY?M4.* +W6HWG"G%$#[A]*22
M#><YH /M(]Z/M(]ZBEAV#--BCWG% $XN >*EJ%;;!SFBXEQP* 'O,%K)UW3(
M]8C\MQAA]UAU4_U![CO]<$7$C+]*F^R^_P"E 'CNHZ<^GN8I!@C\B.Q!]/\
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MJVX59RBKI7.C_M6'_GHG_?:_XT?VK#_ST3_OM?\ &N&O-'ELAOD7 )QU!Y_
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M Z\A@"/H>E<-_P (S<?W/_'E_P :Y<)AZ=7FYY<MOZZFM6I*-K*YV7]JP_\
M/1/^^U_QH_M6'_GHG_?:_P"-<#>6+V1V2#!(SU!X_#/I4MGH\MZ-\:Y ..H'
M/XD>M=KRNBH\W/IWTL8_6IWMRZG>0WL<YVHRL?16!/Z5/7,^&M'ELI"\BX!0
MCJ#SD>A/I5GQ#KYL<11X+G.<\[?3CU[_ -.:XIX3FK>SIOF\S95;0YI*QK7-
MXEJ,R,%Z]3R<=<#O^%4O^$FM_P"__P".M_A7%QQ27[8&7<_4GTR3Z>YJY_PC
M-Q_<_P#'E_QKM_LW#T])SU]4OS,?K-27PQT.XAN%G&Y"&'JI!'Z5)7F\<LE@
MV1E''U!]<$>GL:[S2KQKR-967:3^1]Q['W_4<GDQF!>'2DG>+-:-?VFEK,N5
M'-<+ -SD*/5B /UJ2N3\8WVYEMQT7YC]3P![8'\ZQPN'=>HH?>75J>SC<Z--
M2B<A0ZDGH PS_.K->8(Y0AAP1T(ZUZ/878O$64=&'Y'N.W0UT8[ _5E%IW3(
MH5_:718HIKN$!8\ =2>E<5K/B)[PF-#B,$XQD%ATY]CZ>_.:QPN$GB)66RW9
M=6JJ:U.IN=;AMCM9QGG@98C'7.,X_&F0^(()C@./^!94?FP%<;::/->#<BDC
MUX _ G&?PIUSH4]L-[(<#T(/X\$\>]>A_9N&7NN?O>J_(Y_K-7?ET^9Z#17#
M^']6DMW$2Y=6XV_KD9Z>I[>OJ.OU"^6Q0RMVZ#U/8?C_ /7K@Q.#G1J*&]]C
M>G64XWVL3NX0%CP!U)Z5GR^(K>,[2XR/0$C\P"*X[4=6DU Y<\<849"C'?'K
M[_TJ6+P[<2#<$.#ZD _D2#7;#*Z<(IU96OZ+\S%XJ4G[JN=E::M%=\(X)].A
M]>AP:N5YS>:9)9?ZQ2 >_4?3(R,\=*Z+PKJTEP3"^6 YW'J/8D]<]N_X=,L3
MET80=2$KQ_KJ52Q#<N62LS<EOXXCM9U!'8L ?RS3?[5A_P">B?\ ?:_XUSFN
MZ%-=3-(BY4XP<J.B@=S63>:/+9#?(N 3CJ#S^!/I54<!0J1C[^K6V@IUZD6_
M=T.Y_M6'_GHG_?:_XTJ:E$Y"AU)/0!AG^=<!9V+WIV1C) SU X_''K6G8>'I
MXI$=DP%=2?F7H",]ZJKEU"G>\[/L["CB:DOLG:T445Y)UD]BVUP?K_*M3[5[
M5E6:[G ^O\JU/LOO7N93_!?K^B.'%_&O0>EP#UXJ7K55X"O/:I;<$#GI7HG.
M2TR24)UI]5)GW&@"=9PQQ4E4?NU=5MPS0!&;@#BC[2/>D:VR<YJ*6+RZ )OM
M(]Z5)PQQ4$47F5-'!L.<T 'VD>]'VD>]-^R^_P"E12Q[#B@"?[2/>G),'X%0
M10[QFI8H=AS0!+TJ)[@#IS44TNXX'2DCA+\]J )/M7M4B2AZB^R^]1F,J<4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9^NZPND1-</SC@#(
M!)/0<_F>N "<'%:%>1^-M?\ [5G*J08HB0F,<]-S9!.<D<=L8XSFFE<3,K5=
M5DU20SRG+'\@.P [ ?\ USDDFNT\*> !A;F[!SD%8STQ_M#]=O;HV<D"#X=>
M&_./VZ0 JI(0$'[PQ\_IQT'7G/0J*]$IM@D-CC$8"J     !@ #H,5F>*/\
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MT7^U[A8C]P?,_P#NCJ.H/)P..1G/:O1O%NMC0K?]U@.V%C  P,=3MXX4=."
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M_P#Z":\PKT_6/]1+_P!<W_\ 037F%=%#9GA9W\</0****V/("BBB@#7\*?\
M'S'_ ,"_] :O1*\[\*?\?,?_  +_ - :O1*YJ_Q'T&2_P)?XOT04445D>H%%
M%% !61XK_P"/:3_@/_H:UKUD>*_^/:3_ (#_ .AK50^)&&+_ (%3_"_R/.Z*
M**[#Y(**** "NB\#?Z]O^N9_]"6N=KHO W^O;_KF?_0EJ*GPLZL!_O$/4[FB
MBBN0^J"BBB@ HHHH R/%?_'M)_P'_P!#6O.Z]$\5_P#'M)_P'_T-:\[KIH?"
M?/9U_'C_ (?U84445J>8%%%% '1>!O\ 7M_US/\ Z$M=S7#>!O\ 7M_US/\
MZ$M=S7+6^(^DRC_=UZL****S/0"BBB@ KG?'/^H7_KH/_06KHJYWQS_J%_ZZ
M#_T%JNG\2.7'_P"[S]#AJ***ZSY4**** "NB\#?Z]O\ KF?_ $):YVNB\#?Z
M]O\ KF?_ $):BI\+.K ?[Q#U.YHHHKD/J@HHHH **** .=\<_P"H7_KH/_06
MKAJ[GQS_ *A?^N@_]!:N&KJH_"?-YO\ [P_1!1116AYX4444 =;X!_Y:_P#
M/_9JZZN1\ _\M?\ @'_LU==7+5^-GT^5_P"ZP^?YL****S.TR=?\-Q:TA5P
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MC=G'(/3KT)]:WO!/_+3_ (!_[-79B,!R4/:*?,EMVWMW,:>(YI\O+9LZ9W"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** ,WQ'J/]G6\DXSE5X( .&;Y5.#QP2,^WK7C5G:F[=85
MQEV51GIEC@5Z5\3)"ELH!(#2J#@]1M8X/X@'ZBN6^'5IY]V'SCRT9NG7(V8]
MOO9_"J6PF>G:?8K81K GW4  Z?F<8Y/4^IJQ114C"LKQ1_Q[O_P'_P!"%:M9
M7BC_ (]W_P" _P#H0K2A_$CZHPQG^[U/\+_(X&BBBO=/C0HHHH **** "M_P
M7_KF_P"N9_\ 0EK K?\ !?\ KF_ZYG_T):PQ7\*7H=>7?[S3]3M*RO%'_'N_
M_ ?_ $(5JUE>*/\ CW?_ (#_ .A"O)H?Q(^J/I\9_N]3_"_R.!HHHKW3XT**
M** "BBB@ K?\%_ZYO^N9_P#0EK K?\%_ZYO^N9_]"6L,5_"EZ'7EW^\T_4[2
MJFJ_ZF3_ *YO_P"@FK=5-5_U,G_7-_\ T$UX\/B7J?55OX<O1GF]%%%>^?%!
M1110 4444 %;_@O_ %S?]<S_ .A+6!6_X+_US?\ 7,_^A+6&*_A2]#KR[_>:
M?J=I535?]3)_US?_ -!-6ZJ:K_J9/^N;_P#H)KQX?$O4^JK?PY>C/-Z***]\
M^*"BBB@ HHHH *U?"_\ Q\)_P+_T$UE5J^%_^/A/^!?^@FLJ_P##EZ,WP?\
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M6N=KHO W^O;_ *YG_P!"6HJ?"SJP'^\0]3N:***Y#ZH**** "BBB@#G?'/\
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M1117TYY@4444 9&O_P '_ OZ5DUK:_\ P?\  OZ5DU\[F/\ O$OE^2/0P_\
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M_7\*S?[!M_\ GC'_ -^U_P *TI^OX5'0!1_L&W_YXQ_]^U_PJY'&(P%4  #
M X  Z#%.HH ;)&) 58 @C!!Y!!ZC%9\OAZW;I%'G_<7_  K2HH QH])AB(98
MT#*<@A%R"._2M#[2?:IVC#=:9]F% %.[A6[&V10PSG# $9]<&F0:!!U,4?\
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M:B@#%_L: ?\ +*/_ +]K_A3_ .RX/^>,7_?M?\*U6C#=:9]F% %=Y"_6N?\
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MY[GIUJOX8OOLTP4GY9/E/7K_  ].^>/Q-=M+$)04;D,"#]#UKFO^$)_Z:?\
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MGOL;AEY!'Z$'_/YUV.BZ(=,+?-N#8_AP>.G.3ZU<U#34OQMD&<9P1P1GT/\
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M_:RI_(9KL=?!XI)STE_74Q5.M2TCJAVJ>+1.ICC7A@02W7D$' !_7/X5DZ+
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M #BH8GVG-7*C\A?2@"2J%7ZC\A?2@"2D9=PQ2T4 4Y(]G%.6X(JT1FHC;@T
M0M.6_P#K4L"DG(J98 *DZ4 %%%% !1110!;HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ,!_]"%:4/XD?5&&,_W>I_A?Y' T445[I\:%%%% !1110 5O^"_]<W_7,_\
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MLT-#^^?]T_S%&N??'^Z/YFC0_OG_ '3_ #%&N??'^Z/YFO1_Y@?F<_\ R_\
MD9]%%%><= 5;TG_6K^/\C52K>D_ZU?Q_D:VPW\:'JOS(J?!+T.BHHHKZ<\P*
MSM<^X/\ >'\C6C6=KGW!_O#^1KGQO\"?H:4?C1AUK:!_'_P'^M9-:V@?Q_\
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M% &3JWWQ_N_U-4ZN:M]\?[O]35.OF\;_ !Y^IZ5'^&@HHHKF- HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** +&G?ZP?C_(UM5BZ=_K!^/\C6U7N93_!?K^B.
M'%_&O0****]$YPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@"W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH_R*I?''U/5J***^7/3"BBB@ K"\;_\ 'G+_ , _]#6MVL+QO_QYR_\  /\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5B^*O#HUR+R\@.IRC$=_0]\'OCN ><8K:HH \&
M^:V;NKH?<,"#^8(->G>$?&JZDHAG(688&3@!\\#'^UZCOU'<";Q5X+36?WR$
M)*!UQPV!P#_CR<<8/&/+[[3Y+!O*E4JP[$>^,CU''4<&JW)V/=:RO%'_ ![O
M_P !_P#0A7!:)\0YK!?+E'FKS@LQ#\_[7.1UZC//7 Q6]J?CBVU*!XU)5R5
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MG4 ;N2P ^Z>Y-9UIQ]G+7HS;"4IJO3=G\2Z>9Z-16?\ \)!;?\]H_P#OXO\
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M?1I+&Q=0 ZY)88ZBIG./*]2Z5*?M(Z/==#T^BL__ (2"V_Y[1_\ ?Q?\:/\
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M '\7_&C_ (2"V_Y[1_\ ?Q?\: -"O-_B1_Q\+_UR7_T)J[C_ (2"V_Y[1_\
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M  D%M_SVC_[^+_C61Z9H45G_ /"06W_/:/\ [^+_ (T?\)!;?\]H_P#OXO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4****V(.7O/OM_O'^=15+>??;_>/\ZBKY6K\<O4]2.R"BBBH*"M;3O\ 4/\
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MI/\ T(UZ[X?_ ./:'_KC'_Z"*\B\0?\ 'S-_UVD_]"->N^'_ /CVA_ZXQ_\
MH(JI"1H4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@""?K^%1U)/U_"HZ "BBB@ IDK[13ZK7+Y./2@!D2[C4ERG>H0<=*4L3U
MH FMG[5/5*-MI!J[0!!==OQHM>_X477;\:+7O^% $]46.3FKU4Y5VF@"U$,
M?2G5'!)N&.XJ2@ I&.!FAWV\F@'=0!1J^!CBJ++MXJY')O%  [[.33/M(]Z>
MZ;^#5>:()C% $\<H?I3Z@M>_X5/0!6N>OX5);=/QJ.YZ_A4EMT_&@"1C@9JC
M5_K5%EV\4 7@,<44V.3>*=0 44UW"=:=UH BN'P,>M16ZY/TI)WW'Z4P,1TH
M DN$P<^M2V[Y&/2JQ8GK3X&VGZT 2W1X J.V&3^%2W"Y'TJ&%]AS0!;J-YPI
MQ4G6HW@#'- "?:1[T_=QGVJHPP<5;3D#Z4 4JO@8XJBR[>*N1R;Q0 ZBBFNX
M3K0 ZHKA\#'K4O6JD[[C]* %MUR?I1<)@Y]:C#$=*"Q/6@"S;OD8]*EJI VT
M_6K= $%UV_&BU[_A1==OQHM>_P"% $S' S5&K_6J++MXH O 8XHIL<F\4Z@
MHIKN$ZT[K0 R5]HJM$NXT^Y?)QZ5$#CI0!-<IWI;9^U0EB>M$;;2#0!/='@"
MH[89/X5+<+D?2H87V'- %NHWG"G%2=:C> ,<T )]I'O3]W&?:JC#!Q5M.0/I
M0!2J^!CBJ++MXJY')O% #J**:[A.M #J*.M% %2?[QJ>#[HJ"?[QJ>#[HH 2
MX.!]:AA&2*L3+N%58VVG- %VBD!SS2T %%-,@!QWIU $%R_:DME[U'(^XYI
MQ'2@!94VFK,+[A50G/6I;9L''K0!9JI/]XU;JI/]XT 3P?=%+*< TD'W13W7
M<,4 4T&2![U=JB#M/TJZC[N10 M%%-:0+P: &7!P/K4,(R15B9=PJK&VTYH
MNTQY@G!IP.>::\(?DT -^TCWJ1&W#-5)%VG%6(/NB@"2J4G4_6KM4I.I^M %
MN/H/I3+@X'UI\?0?2DF7<* *\(R15NJ4;;3FK@.>: %HHIID ..] #JKW+Y.
M/2K!..:HLV[F@">V3C/K4++L./2@.1WI"<T 7$;<,U7N#D_2GVS=127*\YH
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M'BFM;@#-0Q]1]: +%P<#ZU#",D58F7<*JQMM.: +M%(#GFEH **:9 #CO3J
M&R=#]*J1]1]:MR=#]*J1]1]: +M5[H\@58J"Y7O0 EJ.IJQ56"3:>>]6J "B
MBFK(&X% #J*** "BBB@"W1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1S!8\2_X1^Y_YXR?]^V_PH_X1^Y_YXR?]^V_PKVVBCF"QXE_PC]S_P \9/\
MOVW^%'_"/W/_ #QD_P"_;?X5[;11S!8\2_X1^Y_YXR?]^V_PH_X1^Y_YXR?]
M^V_PKVVBCF"QXE_PC]S_ ,\9/^_;?X4?\(_<_P#/&3_OVW^%>VT4<P6/$O\
MA'[G_GC)_P!^V_PH_P"$?N?^>,G_ '[;_"O;:*.8+'B7_"/W/_/&3_OVW^%'
M_"/W/_/&3_OVW^%>VT4<P6/$O^$?N?\ GC)_W[;_  H_X1^Y_P">,G_?MO\
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MO\*/^$?N?^>,G_?MO\*]MHHY@L>)?\(_<_\ /&3_ +]M_A1_PC]S_P \9/\
MOVW^%>VT4<P6/$O^$?N?^>,G_?MO\*/^$?N?^>,G_?MO\*]MHHY@L>)?\(_<
M_P#/&3_OVW^%'_"/W/\ SQD_[]M_A7MM%',%CQ+_ (1^Y_YXR?\ ?MO\*/\
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M<3LA49(!R23SQD_>8^N!GJ!7-?#?P^%7[>_5LJ@XZ="WKG.1VXSU!JA\1?$
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MQD_[]M_A1_PC]S_SQD_[]M_A7MM%',%CQ+_A'[G_ )XR?]^V_P */^$?N?\
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M^>,G_?MO\*/^$?N?^>,G_?MO\*]MHHY@L>)?\(_<_P#/&3_OVW^%'_"/W/\
MSQD_[]M_A7MM%',%CQ+_ (1^Y_YXR?\ ?MO\*/\ A'[G_GC)_P!^V_PKVVBC
MF"QXE_PC]S_SQD_[]M_A1_PC]S_SQD_[]M_A7MM%',%CQ+_A'[G_ )XR?]^V
M_P */^$?N?\ GC)_W[;_  KVVBCF"QXE_P (_<_\\9/^_;?X5LV'PYNK@_O
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M?6GDF=KGW!_O#^1K#K<US[@_WA_(UAUX&:?QWZ([\+\!H:']\_[I_F*FU_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% $$_7\*CJ2?K^%1T %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY#8ZVBBBOK3R0K.US[@_WA_(UHUG:Y]P?[P_D:Y\;_ GZ&E'XT8=:&A_?/\
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MN,?_ *"*\B\0?\?,W_7:3_T(UZ[X?_X]H?\ KC'_ .@BJD)&A1114C"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ()^OX5'4D_7\*C
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** +=%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>(/^/F;_ *[2?^A&O7?#_P#Q[0_]<8__ $$5Y%X@_P"/F;_KM)_Z$:]=\/\
M_'M#_P!<8_\ T$54A(T****D84444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!!/U_"HZDGZ_A4= !1110 C' S5?[2?:K)&>*C\A?2@"
M+[2?:C[2?:F2KM.!4T4089- !',6!/I3/M)]JG6,+QZTWR%]* (OM)]J/M)]
MJ9*NTX%311!ADT +#*7SFGO($ZT@41\U59MYS0!(UR3TXIHN"*ECMQWIQMP:
M $CGW<'K4M5_LQS[5,[;!F@!))0E0-<$TSEC[FK"6X'6@"(7!%31S!^.](UN
M#3$M\'GH* +%(S;>32U4FDWGV% #WN?2F>>WK3HH-W)J7R%]* &)<^M3]:KO
M;8Z5,B;!B@!U0RS[#@5*3CFJ?WS]30!/%.6.#4U4ONGZ5<!SS0! UP0<4GVD
M^U3&$'FH9XPF,4 'VD^U.CG+'%-@C#YS4RQ!>10 YFV\FH'N?2F32;S["G10
M;N30 WSV]:D2Y]:?Y"^E1O;8Z4 6.M-=PG)H1=@Q561]YS0 ][DGI3?/-216
M_<T_R!0 U+C/!J:J[6QSQTJ=5V\4 +TJ%[C' I+F3^&HXHM_TH //-.2Y(ZU
M+Y ICVWI0!,C[N12U'#%L^M24 1S2;*B%R:;.VX_2FLNW\10!=J"2<J<4^!M
MP^E*T0;DT 0_:3[4?:3[4L\849'K3($#'!]* 'K<$G%6.E,$('-1W,G\- "O
M<8X%1>>:(HM_TJ?R!0!$ER1UJPC[N14+VWI3X8MGUH DJ.:394E5)VW'Z4 .
M%R:LU29=OXBK,#;A]* )*:[A.33NE4Y'WG- #WN2>E-\\U)%;]S3_(% #4N,
M\&IJKM;'/'2IU7;Q0 O2H7N,<"DN9/X:CBBW_2@ \\TY+DCK4OD"F/;>E $R
M/NY%+4<,6SZU)0!'-)LJ(7)IL[;C]*:R[?Q% %VH))RIQ3X&W#Z4K1!N30!#
M]I/M1]I/M2SQA1D>M,@0,<'TH >MP2<4LDY4XJ00@<T-$&Y- $/VD^U'VD^U
M+/&%&1ZTR! QP?2@!ZW!)Q5CI3!"!S4=S)_#0 KW&.!47GFB*+?]*G\@4 1)
M<D=:L(^[D5"]MZ4^&+9]: )"<5 ]SZ4VXDR<>E)%#OY/2@!//;UIZ7/K4GD+
MZ5');=Q0!.#GFEID4>P432;![T )).$J$W!-,1-W JPMN!0!$MP14\<H>FM;
M@].*;%!M.30!/37;:,TZH+ENU #?M)]JGC;<,U4V\9]ZEMFZB@!\TI3&*C^T
MGVJ=HP_6F/" "?:@"/[2?:C[2?:HT&2![U9\A?2@!ZG(S3))PE$K^6.*K(F[
M@4 /-P30MP14JVX%#6X/3B@!T<H>GU!%!M.33KB3:,>M !)<!>!S4)N":2./
M?Q5@6X% $2W)'7FITD#]*C>V!Z40P[>30!-37D"=:5FV\U39MYS0!(UR3TXI
MHN"*ECMQWIQMP: $CGW<'K4M5_LQS[58H *KFY/:I)VVCZU65=WX"@"S#+OI
MTC;1FJT+;35IEW<&@"O]I/M1]I/M4OD+Z56<8)'O0!)]I/M4T+[QDTU(00#[
M4YL1#B@ DE"5 UP33.6/N:L);@=: (A<$5-','X[TC6X-,2WP>>@H L445'.
MVT?6@",W)[5)#+OJLJ[OP%.A;:: +='2BH+F3^&@!7N,<"HO/-$46_Z5/Y H
M B2Y(ZU81]W(J%[;TI\,6SZT 24R24)2R/L&:J<L?<T /:X)H%P14J6X'6AK
M<&@!8Y@_'>I*KI;X//058H "<<U6^TGVJ2Y; QZU7"Y!/I0!:B?>,T^JULV#
MCUJS0 4444 %%%% %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^[R.1C)/=:]"HHN%@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <!\5?^6'_;3_ -DH
M^%7_ "W_ .V?_L]'Q5_Y8?\ ;3_V2CX5?\M_^V?_ +/5=!=3OZ***D85R5=;
M7)5Y.<?8^?Z'7@_M?(EL_OK_ +P_G745R]G]]?\ >'\ZZBJRCX)>HL7N@KE[
MS[[?[Q_G745R]Y]]O]X_SHS?X(^H83=D5=;7)5UM3D_V_E^H\9]GYF%KGWQ_
MNC^9K/K0US[X_P!T?S-9]<.-_CS]3>C_  T%%%%<QH=;1117UIY)G:Y]P?[P
M_D:PZW-<^X/]X?R-8=>!FG\=^B._"_ :&A_?/^Z?YBIM?_@_X%_2H=#^^?\
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MX'R1KT445[APGB7B#_CYF_Z[2?\ H1KUWP__ ,>T/_7&/_T$5Y%X@_X^9O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @
MGZ_A4=23]?PJ.@ HHHH **** *D_WC4\'W14E% !1110!4G^\:G@^Z*DHH *
MAF@W<BIJ* *7*^U!<GO5TC-(% Z4 58X2WTJV!CBBB@"O+!W%1 E:NTA&>M
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MTW<&EHH IO$4^E)O([U=I"@/:@"F 7]ZL0Q;.3UJ7I10!2=MQS5N--HQ3J*
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MC)Z_H/\ "MJNG#8N&(ORWT[F=2DZ=KE6W3)SZ5:HHKH,QLB[@151&VG-7:*
M#K5*3J?K5VB@!L?0?2G444 5Y8.XJ($K5VD(SUH IEB>M2109Y/2K 4#I2T
M0W+X&/6H[=,G/I5JB@ ILB[@13J* *2-M.:MLH<8IU% %-XBGTI-Y'>KM(4!
M[4 4P"_O4\,.WD]:FZ44 %5Y8.XJQ10!2!*T%B>M7",]: H'2@"O%!GD]*6Y
M?M5BB@"O;)WJQ110!'.NX?2J\3[35RB@ HHHH **** +=%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1110 4444 %%%% !1110 4444 <!\5?^6'_;3_V2CX5?\M_^V?\ [/1\5?\
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MJT0M32\.>-(M:/E8*2XSM)R#UZ'C.!R1@'TR 36CK&NQ:0OF3-C.< <L2!G
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 9.K??'^[_4U3JYJWWQ_N_U-4Z^;QO\ 'GZGI4?X:"BBBN8T"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *Z*N=KHJ]?)_M_+]3DQGV?F%%%%>L
M<@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% %NBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ,?,/_7:/_T(5W'Q,U;R8UM%(S*<MR,[5(P,=>3WX^Z1SS6=X4\"2^8EU/\
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M&T<?,<#/'')QR[1/"LUS/'')$ZH6&XNKJNT<D9QQD# ]\5Z#_P ('9?\\O\
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M@_X^9O\ KM)_Z$:]=\/_ /'M#_UQC_\ 0152$C0HHHJ1A1110 4444 %%%%
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ME<-:C&CB.67PI_A_PQO";G3NM[?B<_\ \)M_TS_\?_\ L:/^$V_Z9_\ C_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI;2U@HHHKK,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* ,C7_X/^!?TK)KK:*\[$9;[:HY\UK^7_!.BGB>2*5CDJ*ZVBLO['_O_ (?\
M$OZYY?B<O9_?7_>'\ZZBBBNS!X3ZO%J][F-:K[1IV.=U;_6M^'\A5O0/X_\
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MP+ZK\IQ_L]/TQ7'G%'2-1>C-L'/>)IUYSJO^ND_ZZ/\ ^A&O1J\YU7_72?\
M71__ $(UGDWQS]"L9\*.\TK_ %,?_7-/_017.>-)\ND>/NJ3G_>./_9:Z/2O
M]3'_ -<T_P#016+XRM"RK,!]W()QSST_#K^)]ZRP4DL9KW9==-T?N(/!40)D
M?N H'T.<_P A75UQ/A?5%LG*/PKXY]".GT')_3MFNVI9I"2Q#;V=K?</"M.F
MD8EQXLB@9HR&RI(. ,<'']ZF?\)E#_=?\E_^*I]QX3BG9I"6RQ).",<G/]VN
M*KJPN$PF(3M>ZM<RJU:M-ZV/4*\]UJ^^VRM(/N]!]!QWZ9ZX]Z[#Q!??8X68
M'#-\HZ]3].A R17 T9/1^*H_1?J+&3VB=FFB[K008^<C=R,'=UQSW_ASZ?E7
M,Z1??8I5DS@9PW7H>O3\_J*9_:LW_/1_^^V_QJK790PTXQG&;NI._P!^YC4J
MIN+2M8]!UV?R8)&QG*X_[Z^7^M<-81"61$;D,Z@_0D9KK=,;^TK3R^,A2G(X
M! ^7U]CD=ZX^*0VKAL?,C X/J#T(KGRZ')&K3^TG_P ,:XEW<9=#TNBJ]C?+
M>J)$.0?S!]#[_P">E6*\.47%M/<[4TU<*Y+QI/ETCQ]U2<_[QQ_[+70WFJQV
M;*CM@O\ I[GT';_ZP.,?QE:%E68#[N03CGGI^'7\3[UVY<N2O!M:.]C'$.]-
MI="#P5$"9'[@*!]#G/\ (5U=<3X7U1;)RC\*^.?0CI]!R?T[9KMJ>:0DL0V]
MG:WW!A6G32,2X\610,T9#94D' &.#C^]3/\ A,H?[K_DO_Q5/N/"<4[-(2V6
M))P1CDY_NUQ5=6%PF$Q"=KW5KF56K5IO6QZA6#XR_P!2O_70?^@M6]6#XR_U
M*_\ 70?^@M7GX'_>(>IO7_AR,OP;_KF_ZYG_ -"6NRKC?!O^N;_KF?\ T):[
M*MLU_P!X?HB,)_#"BBBN Z K>G?:/K6#6Q<-D_2O7R?[?R_4Y,9]GYB0CGFG
MW&#R*B"$]J/+/H:]8Y"6V?!QZTMUVJ%3M.?2K,J[QQ]: (K;K^%6:I(^PYJV
MCA^10!%).5.*;]I/M4[@#DXJHW7B@"R[97/M5:/J/K5M1D8]JJ$;3CTH NT5
M'%+O^M2=* "BHGN .E2 YYH 6J%7ZH4 7ZKW/458J*X3(SZ4 -M>_P"%3U3B
MDV&K:MNY% $#7!!Q2?:3[5,X5>3BJ= %JXZ5#!]X59D7<,54!VG/I0!=HIL<
M@>G$XH **A-R,^U/E? S0!6E?<:GBP!@D<^]5@,TOEGT- "'@U=1MPS5,J1U
MJ:V?M0!/1110 4444 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBHKBX6V4R.<*HY)H$VDKLEK.U^SDNX6CB.&/;^\.ZY[9_^L>":ATGQ+'J3
M&-<J>P;'(QST[CT].?7&O5:Q9DI4\13=G=/30\F="A*D8(."#UKJO#_A$Y$U
MP.,9"=_^!?X?GW!Z&318Y)A=$9< #MC(Z-TY(_P]!5ZM)UKK0\_"Y3&G-RGK
M9Z+_ #"BBBL3U@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** . ^*O_+#_MI_[)5#P!KT.D^;Y[;=^S'RL<XW9^Z#ZBNM\8^%SKJ+
ML8*\9.-WW2&QG. 2.G'Y8YR."_X0.]_YY?\ CZ?_ !54K6%U._\ ^$\LO^>O
M_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\
MXJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\
MCZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ
M_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\
MXX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?
M3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ
M?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\
MQQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O
M_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\
MXJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\
MCZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ
M_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\
MXX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?
M3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ
M?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\
MQQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O
M_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\
MXJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\
MCZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ
M_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\
MXX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?
M3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ
M?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\
MQQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O
M_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\
MXJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\
MCZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ
M_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\
MXX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?
M3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ
M?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\
MQQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O
M_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\
MXJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\
MCZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ
M_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\
MXX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?
M3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ
M?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\
MQQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O
M_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\
MXJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\
MCZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ
M_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\
MXX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?
M3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ
M?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\
MQQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O
M_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\
MXJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\
MCZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ
M_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\
MXX__ ,31_P )Y9?\]?\ QQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?
M3_XJBR"[._\ ^$\LO^>O_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ
M?_%4?\('>_\ /+_Q]/\ XJBR"[.__P"$\LO^>O\ XX__ ,31_P )Y9?\]?\
MQQ__ (FN _X0.]_YY?\ CZ?_ !5'_"!WO_/+_P ?3_XJBR"[._\ ^$\LO^>O
M_CC_ /Q-'_">67_/7_QQ_P#XFN _X0.]_P">7_CZ?_%4?\('>_\ /+_Q]/\
MXJBR"[,S6)UN)Y94.5>1R#TR"Q(ZU[#X?_X]H?\ KC'_ .@BO.;'X>74[;9
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?R-'V9_[I_(T>RGV8<R[D=%2?9G_ +I_(T?9G_NG\C1[*?9AS+N1T5)]F?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ&-[*^X4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^AY%/K@/;3OJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWV'- %VJKS$$CWJ=90>]#3!?_K4 5_/;UJTW3BJ-7Z *%7ZIRIL/M4L,_8T
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MS1110 4444 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG5"<:D5*+NF%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMT9J"G;1]1*<6[=2W1116904444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M41B([5<HH J+ 34\<(3GO4E% !3)(M]/HH J- 12"(GM5RB@"".WQR:GHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?_%5A@+8?GA-I._5EU_WEG'4[GP1_P ><7_ _P#T-J=XF\3+HRX&&E8?*O\
M[,?;^?0=R.?DU]O#MJED /M(#9&0P0,Q()QD$D'('XGL#Q<\[7!+N2S'J6))
M].IK.E@/;595)?#=V\]?R*G7Y(**WL.N[MKMC+(2S,<DG_/Y#M72_#^UG:4R
MQG$0X?(RI]% _O>_;OUP8/"WA ZO^]DRL(S@C[S'VSG@=S^ [X])M+1;11%&
M JJ, #_/YGO6F/QD(1=*.KV\D30HR;YF34445XIVA1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%9VK:]'I> ^26[+@G'KR1Q_GUJY;W"W*B1#E6'!%.SM<A582
MDXIZK=''>-[>02"0DF,C"^@/<?4XSGOT[5AV%@]^XBC&2?R ]3[?YZUZ;<6Z
MW*F-QE6'(-5]+TB/3%V1CJ>2>I^I]NW_ .NM8UK1MU/,KY4ZN(Y[^Z]7W]/Z
MV*V@Z"NEKGK(P^9OZ#V_GU/8#6HHK)MMW/3I4HTHJ,59(****184444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@""?K^%1U)/U_"HZ "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"W1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9^OPRS0.EN<2D?*<
MX[\@'L2,@'L>XZUXM<;MS>9G?D[MV=V<\YSSG/7->\UCZAX4M]0E6ZD7++U'
M\+8Z;AWQ^O0Y'%-.PFCB_"G@,Z@%N;C*QD@A?XF'KGL#^9&<8X->E1QB,!5
M     P !T&*=10W<9YC\3O\ CY3_ *XK_P"A/1\,?^/E_P#KBW_H25Z=11?0
M5@KSGQKX*^S9N[8?)U=!_#ZL!_=]1_#U'R_=]&HH3L,\$CC,A"J"22  !DDG
MH,5[7H$,L,")<',H'S'.>_ )[D# )[GN>M5]/\*6^GRM=1KAFZ#^%<]=H[9_
M3H,#BMBANXD@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BE0L
M>*9Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'
ME&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L
M44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!
M7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC
M1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&
MK%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44
M 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\
MHT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y
M1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%
M% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5
M_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT
M>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1J
MQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%%
M%?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*
M-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4
M:L44 5_*-'E&K%% %?RC1Y1JQ10!7\HT>4:L44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 9'B+6O[/3:A'F-T]A_>Q_
M+/ZX(K!T/Q,ULVV8ED;N221[^N/4?B/0[7B'P\+\>;'Q(/R;V/OZ'\#QTXNX
MMVMV,;C#+U!KTL+3I5*7+UZ]SP,RKXJCB%/:*V[?,]-1PX# Y!Z$=*=7+^#(
M9%W.>(CT![MZC\.#_7''45PUJ?LYN-[GL86NZ])3:M<****S-PHHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &7JGB6WTMA%,^UB,@;6/!)'8'THTOQ+;ZH
MQBA?<P&2-K#@$#N!ZUPOQ._X^4_ZXK_Z$]'PQ_X^7_ZXM_Z$E.V@KGIU%%%(
M84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 51U'18]0*M(.5[C@D>A]OU]"*O44XR<7=:$U*<:D>62NAJ(
M$ 4# '0#I4-]?)8H97. /S)]![_YZ58KBO%\DC2!7&$&=F.0<XR<^OJ.WZG7
M#TO:SLSFQV)>&HN25WLNWS.JT_4X]0&Z,YQC(/!&?4?Y'H:MUYI8WSV+B5#@
MC\B/0^W^>M=[I.KIJ2[EX(QN![9SWZ'I_P#JK3$X5TM5JC'+\RCB5RRTG^?H
M7J***Y3T0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHJM?WZ6"&60X _,GT'O_GI0E<4I**;>B1)<7"VRF1SA5')-5]+U>/4
MUWQGH>0>H^H]^W_ZZX'5]:DU-BS'"YX4'@>GU/O_ $XINBR31R!H 2_H!D$9
M'7V_EUR*W]C[OF>0\XO62BKQ_%^9Z;69;>'8;:0S*O)((!Y"]^!VY_+M@5IT
M5BFT>K.G";3:O;8****184444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!PGCOPU<:I.LL*;E$8!.Y1R&8]R/6CP)X:N-+G:69-JF,@'<IY+*>Q/I7=T4
M[BL%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %5[ZQ2^0Q.,@_F#ZCW_P ]*L44TVG="E%2
M33U3.&N_"LL4@C3YE;HV, >N>N/Z]N>*ZW2M-73D$2\]R3W/K[?Y^M7**VJX
MF=6*3.3#9?1P\W*.[_ **Y3Q+XA96-O$<;?O,#SGT!'3'?OGCZVM"\4"Z(AE
MX?LW9C_0_H3Z<"AX6HH<XEF5!UG2OKM?I?L=#1116!VA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 445D:[XA335(&&D[+GI[GT'ZGMZAI-N
MQ%6K"E%RD[(UZBN+=;E3&XRK#D&N+T3Q8\#D3DLCG))Y*D]Q[>PZ=O0]NCAP
M&!R",@CI3E!P9CAL53Q4';YIG 77A:9)O)125)^5OX<>YQP1W_0'(SV>D:0F
MF)L7DG[S=R?\/0=OKDF]13E4<E8G#8"E0FY+=_@%%%%0=84444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 <QXG\:_V'*(/+W[D#9W[>I(QC:?2C
MPQXU_MR4P>7LVH6SOW="!C&T>M<Q\3O^/E/^N*_^A/1\,?\ CY?_ *XM_P"A
M)56T%?4].HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '':]X8^RCSH<E1G<#R
M1[CV_4=>><<[7J=9L7AZ&*3SU7!'0?PYSUQZ^G8=AFN^CCN6-I:]CQ<7DRG-
M2IV2>Z[>G^1)H@D\I?.^_P"XYQVS[X^A]><U>HJCJ.M1Z>560\MV') ]3[?K
MZ UQV=23LM7T1ZMXT*:YGHM+LO44U'#@,#D'H1TIU0:A1110 45!->QP':[J
MI]&8 _K21:A'*=JNI)[!@3^0-/E=KV)]I"]KJY8HHHI%!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%0W%XEMCS&5
M<]-Q SCZT";25V3456BU**8[%=23V# G\@:LT6",E+9W"BBB@8445G6NOPW4
MGV=&R<$Y_A.#R >Y[\<8YS32;)E4C%I-VOL7+E696"'#%3M)Z XX/?O7E]W$
M\+LLF=X/.>N?7/?/KWZUZK67J/AR'4'$K@Y'7:<;L>O\N,''?IBZ4U$X<QP4
ML1%.+U7W'):%X:?4L2'Y8\]>Y]<?RST^N"*[Z&(0J$7@* !]!P*5$" *!@ 8
M '2G4IS<F;8/!PPT;+5O=A1114'4%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!S'B?P5_;DHG\S9M0+C9NZ$G.=P]:/#'@K^PY3/YF_
M<A7&S;U(.<[CZ5T]%.X6"BBBD 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXP^/Q]B1V/J/Y=!=HHKF;N>_"/+%*][=6%%%%!04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!QWC'QC-HLRPQJA!C#?,&)R68=
MF'I1X.\8S:U,T,BH (RWRA@<AE'=CZURWCW5%O[D[ 1Y0\LYQU5FR1@GCG_Z
MU0^#M=319FFD#$&,K\H!.2RGN1Z55M!7/8**IZ3JBZI$MP@(5\X#8!X)'8GT
MJY4C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M']WA\8R3M/Y8!)/''ID:%H;:E<+:D$<_/P05"_>['![#(ZD U6C)U/9XY!(
MRD$$ @@Y!!Z'-.IL<8C 50     ,  =!BG5)04444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M37<("Q. .I/2G52UJ(2P2 ]-C'\0,C]13BKM(FI)Q@VNB'?VK#_ST3_OM?\
M&FRZU!$-QD7 ]&!/Y#)KSFBO2_LZ/=G@O/:G\J.ZN/$%K<*8W;*MU!5O\*H6
M6HV>D@M&6=FZG'S8_$*,?K_3E**T6"@E:[MV,)YM5E)2Y8\RV=G?\S:\1ZTF
MI[-@(V[L[@.^/0GTJCH[E)HR#CYUZ>YP?TJG6EI6GR>9&^QMN]#G:<8R#G..
ME:.$:=/EZ:G.JE2O74WJ[K8]!HHHKQ#Z\**** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *9+$)04;D,"#]#P:?10#5]#*_P"$7M_[G_CS?XU/#H<$
M(P(U_P"!#<?S;)J]15NM4?5_>8QPM&+NH17R14_LJ'_GFG_?"_X58BB$0VJ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *\=\1:!<VKO<3)P[L2R<IRWXD D\;L'\:]BHI
MIV!HX#X::']Z^<>JID?]]-R/P!!_O UW]-2,1\* !DG@8Y)R3^).3[TZDW<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5B7'A**=FD)?+$DX(QR<_W:VZ*N%24-G8RJT*=9)25[&!_
MPA</]Y_S7_XFC_A"X?[S_FO_ ,36_15_6:O\S,?[.PW\B,#_ (0N'^\_YK_\
M31_PA</]Y_S7_P")K?HH^LU?YF']G8;^1&!_PA</]Y_S7_XFC_A"X?[S_FO_
M ,36_11]9J_S,/[.PW\B,#_A"X?[S_FO_P 36_1143JSGN[FU'#TJ-^56N%%
M%%0:F?K>B)K""&0L &#?*0#D CN#ZUB?\*WM_P"])_WTO_Q-=716U/$U::M%
MM(B5.,G=HY3_ (5O;_WI/^^E_P#B:/\ A6]O_>D_[Z7_ .)KJZ*OZ[7_ )F+
MV%/L5-*TU=-C6W0DJN<;L9Y)/8#UJW117/*3DVWNRTK*P4444AG._P#"#0?W
MG_-?_B:/^$&@_O/^:_\ Q-=%15^TEW.7ZAA_Y4<[_P (-!_>?\U_^)H_X0:#
M^\_YK_\ $UT5%'M)=P^H8?\ E1SO_"#0?WG_ #7_ .)J2V\&PV[+(&?*L",E
M<<'/]VMZBE[27<:P.'3ORH****DZ0HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .$\2^!)]4
MN'N$9 K[<!BP/"@=E/I5SP;X-ET65IY64Y3: F3U())) ]/?.>V.>OHIW"P4
M444@"BBB@#E_%'^M'^X/YFL>MCQ1_K1_N#^9K'KYS&_QY^I[^$_@Q] HHHKG
M-SJ/"_\ JC_OG^0H\4?ZH?[X_D:/"_\ JC_OG^0H\4?ZH?[X_D:]O_F!^1X_
M_,9\SEZ***\0]@*V/"_^M/\ N'^8K'K8\+_ZT_[A_F*Z,%_'AZF&+_@R]#J*
M***^C/ "BBB@#S'XG?\ 'RG_ %Q7_P!">L_P'_Q^Q?\  _\ T!J]>HIWT%8*
M***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBN8\4L?,4=MG\R:PQ-?V%/GM<VP]'VT^6]CIZ*YO1-;\K$,A^7L3V]C[?R^
MG3I*>'Q$:\>9?-"KT)49684445L9!1110 4444 %%%% !1110 4444 <]XR\
M02Z(B21*I#-@EN@XR!@$'GGGH,>XKC(OB'<M*KNP$>Y=R(B_=&-P&[)Y'OU]
M*[?QMIWVZUD'&8QO&21C;R>G^SD#MD_C7C]4A,]]HK%\(:M_:=LCY)9!L;))
M.Y0.<GKD8/XXSFM>298_O$#/J<5#:6XUJ/HJC)K$:\@D_0?XXJ!]> /"\>YQ
M_0USSQM".\E\M?R-%1J/H9GBC_6C_<'\S6/6K?2?;6#MU QQTZD_UJ#[,OI_
M.O"Q-2-2K*2V9[%"JJ=.,7NBC16AY0]!^5'E#T'Y5C<OZPNQL>%_]4?]\_R%
M'BC_ %0_WQ_(UD@8I:[?K_[CV7+TM>__  #B]G^^]IYWL9E%:'E#T'Y4>4/0
M?E7%<[?K"[&?6QX7_P!:?]P_S%5?LR^G\ZGL9/L3%UZD8YZ=0?Z5MAJD:=6,
MGLB*]55*<HK=G5T5E)KP)Y7CV.?Z"IX]8C;DDCZC_#->[#&T);27ST_,\=T:
MBZ%ZBF1S+)]T@X]#FLKQ9J?]G6TD@.&(VK\VTY;C(/J/O<>G;K70FGL9O0H0
M_$6TD8H2R@9PQ4[3@]L9;GKR![X/%;]CJ$=^OFQ,&4]P?;.#Z'GH>17A5>N>
M ].^Q6JDYS*2YR0?O8"XQZJ ?7)_"K:L),Z&BBBI&%%%% !1110 4444 %%%
M% !1110 445AZWK?E9AC/S=R.WL/?^7UZ95Z\:,>9FE&C*K+E1N45SOAN\>5
MRK,2-N>3GH1Z_6NBI8>NJT.9:#KT71GRL****V,@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***CGN%M
MU,CL%4=2Q  SQU- $E%9_P#PD%M_SVC_ ._B_P"-7HY!( RD$$ @@Y!!Z'-
M#J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2V87#G;Q]WG)!!X/IV..??!KIJX<;&G&L^1Z?D;T')P7-N1QVZQ$LH +=2
M3]?6I***YVVS4****0!1110 4444 %%%% %ZRU9H/E;E?U%;<,ZS#<IR*Y:G
M1RF/E202"./>N_"YC.E[LM5^)A5P\9ZK1E_6];\K,,9^;N1V]A[_ ,OKTYNI
M9H#'SVJ*L,1B)5Y<S^2/1PU*%.%H_>%%%%8FP5-9VQNG$8_B/_ZS^ J)5+'
MY)]*ZS1-*^Q LWWVZ^P],_S_ /K9KHPF&=>=NBW.?%8A487Z]#1CC$8"CH
M/PIU1SW"VXW.0![U@7?B@MQ$,#U;D_ET&/QKW*V)I4%J_D>/2P]2L]%\SHZ*
MX6>\>X^^Q/.<$\?ETJ&N%YNKZ1_'_@'8LK=M9?@>@45Y_12_M?\ N?C_ , ?
M]E_WOP_X)Z!17/>%[9U)EZ(1CZG/7'MSS_\ 7KH:]##UG5IJ=K7.&O25*;C>
MX4445L9!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4453U;5%TN)KAP2J8R%
MP3R0.Y'K0!<HKD/^%G6W]R3_ +Y7_P"+KJ;.Z%VBS+G#JK#/7##(HL!-1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,H88/(/
MK2T4 <IK.C&T/F)RA_3V^GH?P/OE5W[*&&#R#ZURNLZ,;0^8G*']/;Z>A_ ^
M_BX[ \EYQVZKM_P#U\%C>?W);]'W,JBBBO..\*FM+MK1A(AY'Y'V-0T4XR<7
M=;B:4E9G9:9JRWXXX8=1G]?>DU72A?#T<=#_ $/M_+^?(PS&$AU.".AKKM*U
M47P]''4?U'M_+^?L87%1Q,?9SW_/_@GE8C#2P\O:0V_+_@'(S0F$E&&".HIE
M=CJNE"^'HXZ'^A]OY?SYB.TV_>ZC\17G8O"O#RMT>S.RAC(U(7Z]4,@MMW)Z
M5; Q2T5RF<YN;"BBB@D**** "BBB@ HHHH **** "BBB@ HHHH 8T08AB 2N
M<''(SUP:?113N!A>+87FC5$4M\V3MY(P#C@>N>OM[UR$UNT!VN"I]&!!_6O3
M**[\+F3H04.6Z]3GJX95)7N<;X-_US?]<S_Z$M8->H45I'->6I*?+O;KVOY$
MO"7BE?8\SAMVG.U 6/HH)/Z5Z3%)Y@#8(R <'@C/8CUI]%<^-QOUFVEK&E&A
M[*^M[D<\"W"F-QE3U!J*TTZ.T_U:@>_?UZGFK-%<JG)+EOIV->57N%%%%2,*
M*** "BBB@ HHHH **** "BBB@ HHHH 0C-5)[;;R.E7**"H3<&9E*JEC@<D^
ME69[;/*_E70Z-HPM!YC\N?T]OKZG\![].%PTL1*RVZLUJXN%.'-U[!HVC"T'
MF/RY_3V^OJ?P'O;U#4%L5W-U/0=S_GN:-0U!;%=S=3T'<_Y[FN/N[MKMC(YY
M/Y#V%>GB,1#"0]G#?^M6<-"A/%3YY[?UHA;N]>[.YSGT'8?05!117C2DY.[W
M/6C%15EL%%%%(85JZ-HQNSYC\(/U]OIZG\![&C:,;L^8_"#]?;Z>I_ >W5*H
M48' 'I7HX' \]IRVZ+O_ , X,;C>3W([]7V!5"C X ]*6BBO:/("BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *P/'G_ !Y2_P# /_0UK?K+\2Z6VJ6[
MVZ$!GVX+9 X8'L#Z4(#Q:O;?#_\ Q[0_]<8__017 _\ "L;G^_'_ -]-_P#$
M5Z)I=J;2&.%L92-%..F54 U4F)%JBBBI&%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***S]>U7^R86N=N[9MXSC.6"]<'U]* -"BN _X6K_ -,/_(G_
M -A7;Z?=_;(DGQCS$5L9SC< <9IV L4444@"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&4,,'D'UI:* .4UG1C:'S$
MY0_I[?3T/X'WRJ[]E##!Y!]:Y;5=%^S,"OW&[9Y'M[_YS[^+C\#[.]2.W5=C
MUL'C>9<LM^_<S[>#?R>E7:15V\"EKS"ZDW-W"BBB@@**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "J5S!M^8=*NTA&>*"Z<W!
MW,VM71M&-V?,?A!^OM]/4_@/9=*T7[2Q+'Y%]^3[>P]_R]NI50HP. /2O3P&
M!]I:I+;HNY&,QO*N6._?L"J%&!P!Z4M%%>T>2%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6!X\_X\I?^ ?^AK6_6?KVE?VM"UMNV[]O
M.,XPP;ID>GK0@/$J]M\/_P#'M#_UQC_]!%<A_P *J_Z;_P#D/_[.NWT^T^QQ
M)!G/EHJYQC.T 9Q5-B18HHHJ1A1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 -=P@+'H!FN<OKPW3;NPZ"KNM7F3Y
M([8)_P /ZUE5XF9XKGE[-;+?U.W#4K+F>X4445YITA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $]E=&V8-VZ'
MZ5TB.' 8=",URE:FC7NW]TW0]/KZ?Y_K7I99BN27LWL]O4YL32YES+<V:***
M]LX@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Q_%M
M^]A:R3Q'#KMP< ]74'@@CH: -BBO(?\ A/+W_GK_ ..)_P#$UZEH\[7$$4KG
M+/&A)Z9)4$]*;5@N7****0!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_0_459KG=,NOL[\]&X/]#_GMFNBKZ+ XCVU+7=:,\ZO3Y)>04445UF04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5@>//^/*7_@'_ *&M;]5[
M^P2_0P2C*-C(R1T((Y!!ZB@#PJO;?#__ ![0_P#7&/\ ]!%4/^$#LO\ GE_X
M^_\ \56W;P+;JL2#"H  .N !@=:;=Q)$E%%%(84444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 4]3NOLZ<=6X']3_GOBN>J
M[J]QYKX'1>/Q[_Y]JI5\]F%?VM9]EHCT,/#EAZA1117&;!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %=#IEU]H3GJO!_H?\]\USU7-*N?)<#LW!_I79@*_LJJ[/1F->GSP]#H:
M***^A//"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBL#QY_Q
MY2_\ _\ 0UH WZ*\"KVWP_\ \>T/_7&/_P!!%-JPDS0HHHI#"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+VX\A"W?''U/2I
MZQM<N,D1CH.3]?\ /\ZY\96]E2E+KLC2C#GFD9=%%%?-'I!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!TMA<?:$#'KW^H_SFK%8NASX)C/<9'/I[?YZ5M5]+@ZWM
M:,9==F>;6AR3:"BBBN@S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MP/'G_'E+_P  _P#0UK?HH \"KVWP_P#\>T/_ %QC_P#016A13;N)(****0PH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KEKJ;
MSF+^I_3M^E;^IR^7&Q]1CGWX_E7.5X^;U=8P^9V82.CD%%%%>4=04444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 /@E\E@X[&NI!W<CH:Y.NBTN;S8QZCC\O_K5ZN45
M;2E#OJ<N+CHF6Z***]@XPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MJ]_?I8(9Y3A%QDX)ZD < $]35BL#QY_QY2_\ _\ 0UH /^$\LO\ GK_XX_\
M\36W;SK<*LJ'*N 0>F01D=:\&KVWP_\ \>T/_7&/_P!!%-JPDS0HHHI#"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,C7I?NI^
M)_D/ZUDU<U:3?(?08'^?QJG7S>-J<]>3\[?=H>E1CRP04445S&@4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %:NA3?>C_$?R/]*RJM:7)LD7T/'Y]/UKHP=3DKQ?
MG;[S.M'F@T='1117TIYH4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
M/XML'O[62"(9=MN!D#HZD\D@=!6Q10!Y#_P@=[_SR_\ 'T_^*KU+1X&MX(HG
M&&2- 1UP0H!Z5<HIMW"P4444@"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***AO'V(QSCY3_+BE*7*F^PTKNQS4DGF$L>I)/YTVBBO
ME&[NYZH4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IT<GED,.H(/Y4VBFG9
MW ZVBH+%P\:D?W0/RX-3U]5"7-%/N>4U9V"BBBJ$%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^^C_ (U8_P"$?G_N?^/+_C52[LWM#M<8)&>H/\J]:$J$W9<K?E8Y&JBWN/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M #J*;)((P68@  DDG  '4YJC_P )!;?\]H_^_B_XT :%%48]<MY"%66,DD
M2*22>@QFKU !14-U>):#=(RH"<99@HSZ9-5?^$@MO^>T?_?Q?\: -"BJMKJD
M-V=L<B.0,X5U8X]< U:H **JW6J0VAVR2(A(SAG53CUP34/_  D%M_SVC_[^
M+_C0!H45#:WB78W1LK@'&58,,^F14U !15&37+>,E6EC!!((,B@@CJ,9IO\
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M0!H45G_\)!;?\]H_^_B_XUH4 %%1SW"VZF1V"J.I8@ 9XZFJ?_"06W_/:/\
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M4OM+2]^^.1T(X/\ GZUY^,R]57SQT?YG=A<<Z:Y9:K\CBJ*V+KPS)']PAO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*Y#XG?\ 'LG_ %V7_P!!>NOJGJFDQ:HHBF7<H.0,D<@$=B/6I0SPZNO^&/\
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MB!;A6B<95P01TR",'I6)_P ('9?\\O\ Q]__ (JA.P-'F/A__CYA_P"NT?\
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M,*QL5P'Q5_Y8?]M/_9*[^L_5=!AU;;YZ[MF<?,PQG&?ND>@I(;/$J[[X5?\
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M>OH<=/?/Z5J>(/\ 4/\ \!_]"%4/#^ER6DA9UP"I'4'N/0U?\0?ZA_\ @/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 4]5TJ/5(S!*,J?S![$'L1_P#6.02*\U_X5_<?:/LW\'7S<?+M
M]?\ >_V<YS_L_-7JU%-.P6*>E:5'I<8@B&%'YD]R3W)_^L,  5<HHI %%%%
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@"M_9L7]Q?^^1_A1_9L7]Q?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 <FZ%"5/4'%)5G4XO+D8>ISS[\_SJM7RM6')-Q[,]2+YDF%%%%04%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !0!NX'4T58TZ/S)%'OG\N?Z55.'/)1[NPI.
MR;.C1 @"CH!BG445]6E8\H**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#'UZ+E7]L>W'(_K6570ZM#YL9]5Y_+K^E<]7@9G3Y*[??4[\
M-*\/0****X3<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M/08\LS>@Q^?\ ^JLR
MN@TB+RXP?[Q)Y_+^0KMRVGSUT^VICB96AZEVBBBOH#SPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** $(W<'H:Y:>+R6*'L:ZJL/7(=K!
M_P"\/U'_ -;%>=FM+FIJ?9_F=&%E:5NYG4445X9W!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 Z./S"%'4D#\ZZE$" *.@&*Q-$@WN7_ +H_GQ6[7MY32Y:;GW_0
MXL5.\DNP4445Z1S!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %5=2M_/0@=1R/P_P#K5:HJ:D%.+B^HXRY6F<E15G4;?R'(['D?0U6K
MY:I!PDXO='J1:DDPHHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%6+"V^T.%[=3]!50@Y
MR45NQ2:BKFUIEMY" 'J>3^-6Z**^HIP5.*BMD>7*3DVPHHHJQ!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %'5[;SDW#JO/X=Z
MP*ZVN:O[;[.Y7MU'T->/FN'LU47H_P!#LPM33E*]%%%>4=04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !6[HUOY:;CU8_IVK*L+;[0X7MU/T%=(!MX'05ZN58>\G5?31'+BJFG*
M+1117L'&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !5/4[7[0G'5>1_4?Y[XJY145*:J0<7LQQDXM,Y*BM#6+3RFWCHW
M\_\ Z_\ C6?7S-:DZ4W!]#TX34XIA1116904444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445?TBS\UMYZ*?U[?
ME6E&E*K-074F<E%-LTM+M/LZY/WFY/\ 05<HHKZ:E35."BMD>9*3DVV%%%%6
M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKF]
M;UOS<PQGY>Y'?V'M_/Z=<<1B(T(\S^2-:%"5:5D&MZWYN88S\O<CO[#V_G].
MN'117SU>O*M+F9[M&C&E'E19M9_X3^%6JS*MVTV[@]:R9G6I?:18HHHI'.%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !56ZF
M_A'XT^XGV<#K5.FC>C2^TPKI-$UOS<0R'YNQ/?V/O_/Z]>;HK?#XB5"7,OFC
M2O0C6C9GH%%8>B:WYN(9#\W8GO['W_G]>NY7T%"O&M'F1X5:C*E+E84445J9
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *L0Z:]PI=>W3/<_Y_
M7\<49;GRO<^AZ5U&FWZWBY7C'!7T_P#K>E=F P].M-J3^1G7<Z<5)+0XMP5)
M!ZCKGK25U>LZ,+L>8G#C]?;Z^A_ ^W*LI4X/!'K48G#2H2L]NC.W#XB-:-UO
MU0E%%%8&X5TFB:WYN(9#\W8GO['W_G]>O-T5MA\1*A+F7S1E7H1K1LST"BL/
M1-;\W$,A^;L3W]C[_P _KUW*^@H5XUH\R/"K494I<K"BBBM3,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBL+Q+J!CQ O&X9/TZ8_GG_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N7\4?ZT?[@_F:ZBN8\4J?,4]MG\B:XLS_@/U1V
M9=_&7H8U:NC:,;L^8_"#]?;Z>I_ >QHVC&[/F/P@_7V^GJ?P'MU2J%&!P!Z5
MQ8' \]IRVZ+O_P  Z\;C>3W([]7V!5"C X ]*6BBO:/("BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y?Q1_K1_N
M#^9K'K8\4?ZT?[@_F:QZ^<QO\>?J>_A/X,?0****YS<ZCPO_ *H_[Y_D*/%'
M^J'^^/Y&CPO_ *H_[Y_D*/%'^J'^^/Y&O;_Y@?D>/_S&?,Y>BBBO$/8"MCPO
M_K3_ +A_F*QZV/"_^M/^X?YBNC!?QX>IAB_X,O0ZBBBBOHSP HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y?
MQ1_K1_N#^9K'K8\4?ZT?[@_F:QZ^<QO\>?J>_A/X,?0***LZ=9F\<1]N_L!U
M_P ^M81BY245NS:4E%-O9'4:'#Y4*Y&"<G\SP?RQ2ZW!YT+#C(&>?;D_IFKJ
MJ%&!P!Z4M?2JBO9>S\K'SWM7[7VGG<\_HJSJ-F;-S'V[>X/3_/K5:OFI1<9.
M+W1]#&2DDULPK8\+_P"M/^X?YBL>MCPO_K3_ +A_F*WP7\>'J8XO^#+T.HHH
MHKZ,\ **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** .7\4?ZT?[@_F:QZV/%'^M'^X/YFL>OG,;_'GZGOX3^#'T
M"NMT32OL0+-]]NOL/3/\_P#ZV:K:)HGE8FD'S=@>WN??^7UZ;E>AE^"</WDM
M^B.''8OF]R.W4****],\XS]:TW[:G'WU^[SCZC\?YUR#*5.#P1ZUW]96LZ,+
ML>8G#C]?;Z^A_ ^WG8_!.I[\=^J[G?@<7[/W);?D<I6QX7_UI_W#_,5D,I4X
M/!'K6OX7_P!:?]P_S%>;@_X\/4]#%_P9>AU%%%%?1G@!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SOB2S>5
MPRJ2-N.!GH3Z?6IM$T3RL32#YNP/;W/O_+Z]-RBN58&G[9U'KY'2\9/V2IK0
M****ZCF"BBB@ HHHH RM9T878\Q.''Z^WU]#^!]J^@:7):N7<8&W'4'J0>V?
M2MVBN=X.FZJJ=3=8JHJ;I] HHHKH, HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
D@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img63237988_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img63237988_1.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M  LBW_NR?]\K_P#%4?\ "R+?^[)_WRO_ ,57F]%']ET//[P^M5#TC_A9%O\
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M_A9%O_=D_P"^5_\ BJ\WHH_LNAY_>'UJH>D?\+(M_P"[)_WRO_Q5'_"R+?\
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MG_?*_P#Q5'_"R+?^[)_WRO\ \57F]%']ET//[P^M5#TC_A9%O_=D_P"^5_\
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M]\K_ /%5YO11_9=#S^\/K50](_X61;_W9/\ OE?_ (JC_A9%O_=D_P"^5_\
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MM_[LG_?*_P#Q5>;T4?V70\_O#ZU4/2/^%D6_]V3_ +Y7_P"*H_X61;_W9/\
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M  LBW_NR?]\K_P#%4?\ "R+?^[)_WRO_ ,57F]%']ET//[P^M5#TC_A9%O\
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M_A9%O_=D_P"^5_\ BJ\WHH_LNAY_>'UJH>D?\+(M_P"[)_WRO_Q5'_"R+?\
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MG_?*_P#Q5'_"R+?^[)_WRO\ \57F]%']ET//[P^M5#TC_A9%O_=D_P"^5_\
MBJ/^%D6_]V3_ +Y7_P"*KS>BC^RZ'G]X?6JAZ1_PLBW_ +LG_?*__%4?\+(M
M_P"[)_WRO_Q5>;T4?V70\_O#ZU4/2/\ A9%O_=D_[Y7_ .*H_P"%D6_]V3_O
ME?\ XJO-Z*/[+H>?WA]:J'I'_"R+?^[)_P!\K_\ %4?\+(M_[LG_ 'RO_P 5
M7F]%']ET//[P^M5#TC_A9%O_ '9/^^5_^*H_X61;_P!V3_OE?_BJ\WHH_LNA
MY_>'UJH>D?\ "R+?^[)_WRO_ ,51_P +(M_[LG_?*_\ Q5>;T4?V70\_O#ZU
M4/2/^%D6_P#=D_[Y7_XJC_A9%O\ W9/^^5_^*KS>BC^RZ'G]X?6JAZ1_PLBW
M_NR?]\K_ /%4?\+(M_[LG_?*_P#Q5>;T4?V70\_O#ZU4/2/^%D6_]V3_ +Y7
M_P"*H_X61;_W9/\ OE?_ (JO-Z*/[+H>?WA]:J'I'_"R+?\ NR?]\K_\51_P
MLBW_ +LG_?*__%5YO11_9=#S^\/K50](_P"%D6_]V3_OE?\ XJC_ (61;_W9
M/^^5_P#BJ\WHH_LNAY_>'UJH>D?\+(M_[LG_ 'RO_P 51_PLBW_NR?\ ?*__
M !5>;T4?V70\_O#ZU4/2/^%D6_\ =D_[Y7_XJC_A9%O_ '9/^^5_^*KS>BC^
MRZ'G]X?6JAZ1_P +(M_[LG_?*_\ Q5'_  LBW_NR?]\K_P#%5YO11_9=#S^\
M/K50](_X61;_ -V3_OE?_BJ/^%D6_P#=D_[Y7_XJO-Z*/[+H>?WA]:J'I'_"
MR+?^[)_WRO\ \51_PLBW_NR?]\K_ /%5YO11_9=#S^\/K50](_X61;_W9/\
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M3_OE?_BJ\WHH_LNAY_>'UJH>D?\ "R+?^[)_WRO_ ,51_P +(M_[LG_?*_\
MQ5>;T4?V70\_O#ZU4/2/^%D6_P#=D_[Y7_XJC_A9%O\ W9/^^5_^*KS>BC^R
MZ'G]X?6JAZ1_PLBW_NR?]\K_ /%4?\+(M_[LG_?*_P#Q5>;T4?V70\_O#ZU4
M/2/^%D6_]V3_ +Y7_P"*H_X61;_W9/\ OE?_ (JO-Z*/[+H>?WA]:J'I'_"R
M+?\ NR?]\K_\51_PLBW_ +LG_?*__%5YO11_9=#S^\/K50](_P"%D6_]V3_O
ME?\ XJC_ (61;_W9/^^5_P#BJ\WHH_LNAY_>'UJH>D?\+(M_[LG_ 'RO_P 5
M1_PLBW_NR?\ ?*__ !5>;T4?V70\_O#ZU4/2/^%D6_\ =D_[Y7_XJC_A9%O_
M '9/^^5_^*KS>BC^RZ'G]X?6JAZ1_P +(M_[LG_?*_\ Q5'_  LBW_NR?]\K
M_P#%5YO11_9=#S^\/K50](_X61;_ -V3_OE?_BJ/^%D6_P#=D_[Y7_XJO-Z*
M/[+H>?WA]:J'I'_"R+?^[)_WRO\ \51_PLBW_NR?]\K_ /%5YO11_9=#S^\/
MK50](_X61;_W9/\ OE?_ (JC_A9%O_=D_P"^5_\ BJ\WHH_LNAY_>'UJH>D?
M\+(M_P"[)_WRO_Q5'_"R+?\ NR?]\K_\57F]%']ET//[P^M5#TC_ (61;_W9
M/^^5_P#BJ/\ A9%O_=D_[Y7_ .*KS>BC^RZ'G]X?6JAZ1_PLBW_NR?\ ?*__
M !5'_"R+?^[)_P!\K_\ %5YO11_9=#S^\/K50](_X61;_P!V3_OE?_BJ/^%D
M6_\ =D_[Y7_XJO-Z*/[+H>?WA]:J'I'_  LBW_NR?]\K_P#%4?\ "R+?^[)_
MWRO_ ,57F]%']ET//[P^M5#TC_A9%O\ W9/^^5_^*H_X61;_ -V3_OE?_BJ\
MWHH_LNAY_>'UJH>D?\+(M_[LG_?*_P#Q5'_"R+?^[)_WRO\ \57F]%']ET//
M[P^M5#TC_A9%O_=D_P"^5_\ BJ/^%D6_]V3_ +Y7_P"*KS>BC^RZ'G]X?6JA
MZ1_PLBW_ +LG_?*__%4?\+(M_P"[)_WRO_Q5>;T4?V70\_O#ZU4/2/\ A9%O
M_=D_[Y7_ .*H_P"%D6_]V3_OE?\ XJO-Z*/[+H>?WA]:J'I'_"R+?^[)_P!\
MK_\ %4?\+(M_[LG_ 'RO_P 57F]%']ET//[P^M5#TC_A9%O_ '9/^^5_^*H_
MX61;_P!V3_OE?_BJ\WHH_LNAY_>'UJH>D?\ "R+?^[)_WRO_ ,51_P +(M_[
MLG_?*_\ Q5>;T4?V70\_O#ZU4/2/^%D6_P#=D_[Y7_XJC_A9%O\ W9/^^5_^
M*KS>BC^RZ'G]X?6JAZ1_PLBW_NR?]\K_ /%4?\+(M_[LG_?*_P#Q5>;T4?V7
M0\_O#ZU4/2/^%D6_]V3_ +Y7_P"*H_X61;_W9/\ OE?_ (JO-Z*/[+H>?WA]
M:J'I'_"R+?\ NR?]\K_\51_PLBW_ +LG_?*__%5YO11_9=#S^\/K50](_P"%
MD6_]V3_OE?\ XJC_ (61;_W9/^^5_P#BJ\WHH_LNAY_>'UJH>D?\+(M_[LG_
M 'RO_P 51_PLBW_NR?\ ?*__ !5>;T4?V70\_O#ZU4/2/^%D6_\ =D_[Y7_X
MJC_A9%O_ '9/^^5_^*KS>BC^RZ'G]X?6JAZ1_P +(M_[LG_?*_\ Q5'_  LB
MW_NR?]\K_P#%5YO11_9=#S^\/K50](_X61;_ -V3_OE?_BJ/^%D6_P#=D_[Y
M7_XJO-Z*/[+H>?WA]:J'I'_"R+?^[)_WRO\ \51_PLBW_NR?]\K_ /%5YO11
M_9=#S^\/K50](_X61;_W9/\ OE?_ (JC_A9%O_=D_P"^5_\ BJ\WHH_LNAY_
M>'UJH>D?\+(M_P"[)_WRO_Q5'_"R+?\ NR?]\K_\57F]%']ET//[P^M5#TC_
M (61;_W9/^^5_P#BJ/\ A9%O_=D_[Y7_ .*KS>BC^RZ'G]X?6JAZ1_PLBW_N
MR?\ ?*__ !5'_"R+?^[)_P!\K_\ %5YO11_9=#S^\/K50](_X61;_P!V3_OE
M?_BJ/^%D6_\ =D_[Y7_XJO-Z*/[+H>?WA]:J'I'_  LBW_NR?]\K_P#%4?\
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M_P +(M_[LG_?*_\ Q5>;T4?V70\_O#ZU4/2/^%D6_P#=D_[Y7_XJC_A9%O\
MW9/^^5_^*KS>BC^RZ'G]X?6JAZ1_PLBW_NR?]\K_ /%4?\+(M_[LG_?*_P#Q
M5>;T4?V70\_O#ZU4/2/^%D6_]V3_ +Y7_P"*H_X61;_W9/\ OE?_ (JO-Z*/
M[+H>?WA]:J'I'_"R+?\ NR?]\K_\51_PLBW_ +LG_?*__%5YO11_9=#S^\/K
M50](_P"%D6_]V3_OE?\ XJC_ (61;_W9/^^5_P#BJ\WHH_LNAY_>'UJH>D?\
M+(M_[LG_ 'RO_P 51_PLBW_NR?\ ?*__ !5>;T4?V70\_O#ZU4/2/^%D6_\
M=D_[Y7_XJC_A9%O_ '9/^^5_^*KS>BC^RZ'G]X?6JAZ1_P +(M_[LG_?*_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!A>-_\ CSE_X!_Z&M>4UZMXW_X\
MY?\ @'_H:UY37NY1_!?K^B.'%_&O0****]$YPHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#=\$?\?D7_ __0&KU:O*?!'_ !^1?\#_ /0&KU:O"S?^,O3]6=V$
M^!^H4445YQT!1110 4444 %%%% !1110 4444 >-Z]_Q\3?]=9/_ $(U0J_K
MW_'Q-_UUD_\ 0C5"OJZ7P1]#RI;L****L04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!?T
M'_CXA_ZZQ_\ H0KV2O&]!_X^(?\ KK'_ .A"O9*\7-_CCZ'9A-F%%%%>6=04
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!A>-_^/.7_ (!_Z&M>4UZMXW_X
M\Y?^ ?\ H:UY37NY1_!?K^B.'%_&O0****]$YPHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#=\$?\ 'Y%_P/\ ] :O5J\I\$?\?D7_  /_ - :O5J\+-_XR]/U
M9W83X'ZA1117G'0%%%% !1110 4444 %%%% !1110!XWKW_'Q-_UUD_]"-4*
MOZ]_Q\3?]=9/_0C5"OJZ7P1]#RI;L****L04444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!?
MT'_CXA_ZZQ_^A"O9*\;T'_CXA_ZZQ_\ H0KV2O%S?XX^AV839A1117EG4%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 87C?_CSE_X!_P"AK7E->K>-_P#C
MSE_X!_Z&M>4U[N4?P7Z_HCAQ?QKT"BBBO1.<**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH W?!'_'Y%_P #_P#0&KU:O*?!'_'Y%_P/_P! :O5J\+-_XR]/U9W8
M3X'ZA1117G'0%%%% !1110 4444 %%%% !1110!XWKW_ !\3?]=9/_0C5"K^
MO?\ 'Q-_UUD_]"-4*^KI?!'T/*ENPHHHJQ!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %_
M0?\ CXA_ZZQ_^A"O9*\;T'_CXA_ZZQ_^A"O9*\7-_CCZ'9A-F%%%%>6=0444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!A>-_P#CSE_X!_Z&M>4UZMXW_P"/
M.7_@'_H:UY37NY1_!?K^B.'%_&O0****]$YPHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#=\$?\?D7_ __ $!J]6KRGP1_Q^1?\#_] :O5J\+-_P",O3]6=V$^
M!^H4445YQT!1110 4444 %%%% !1110 4444 >-Z]_Q\3?\ 763_ -"-4*OZ
M]_Q\3?\ 763_ -"-4*^KI?!'T/*ENPHHHJQ!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %
M_0?^/B'_ *ZQ_P#H0KV2O&]!_P"/B'_KK'_Z$*]DKQ<W^./H=F$V84445Y9U
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -WP1_Q^1?\#_\ 0&KU
M:O*?!'_'Y%_P/_T!J]6KPLW_ (R]/U9W83X'ZA1117G'0%%%% !1110 4444
M %%%% !1110!XWKW_'Q-_P!=9/\ T(U0J_KW_'Q-_P!=9/\ T(U0KZNE\$?0
M\J6["BBBK$%%%% !1110 4444 %%%% &MX;T+^VI##NV80MG;NZ$#&,CUKI/
M^%8_]-O_ "'_ /9U0^&__'PW_7)O_0EKTBO'Q^,K4JO+%V5NR.NA1A*%VCAO
M^%8_]-O_ "'_ /9T?\*Q_P"FW_D/_P"SKN:*Y/[1Q/\ -^"_R-?J]/L<-_PK
M'_IM_P"0_P#[.L>]\!W5J-P"N,$G8<D8]B 3GL!FO4:*N&9UXO5I^J_R$\-3
M?D>'21F,E6!!!P0>"".HQ3:]CU;08=5&)5!..&'##KCGVSG!R,]J\RUWPW+H
MY^<90G"N.A[].Q]CZ'&0,UZ>%Q\*^FTNW^1S5:$H:[HR:***[3$**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *L6-D
MU[(L*?><@#K^9QG@=3[57KJ/AY.([DJ3R\; >YR&_D#65>HZ=.4END53BI22
M->V^&J;/WDC>81U4#:#CT(R<'W&1V%<MX@\.R:*P5R"KYVL.^#W'8\CU'/!-
M>NUR7Q(D @1<C)E! [X"MDX]LC\Q7DX/'5I5E%NZ9UUJ$%!M=#SFBBBO;.(*
M*** "BBB@ HHHH **** "BN_TSP!!=11S,TF716."N,L 3_#6;XM\)1:/$LT
M9<DN%^8@C!#'LH]*Y(8^E.?(KWV-70FHW.2HHHKK,B[I&DOJL@@CQD@G)S@
M#J2 <>GU(KM/^%:1[,>8WF?WL#;U_N]>G^UUY]JJ?#.<*TL>?F8(0/920?\
MT(5WM>-C\;5A5Y(NR7XG9AZ,)0N]3QO6=&DTB3R9,9P""IR"#^1Z@CD?I5"N
MX^)L@)A7(R Y([X.W!Q[X/Y&N'KTL)5=6E&;W9S58*$VD%%%%;D!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% %_0?^/B'_ *ZQ_P#H0KV2O&]!_P"/B'_KK'_Z$*]D
MKQ<W^./H=F$V84445Y9U!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M75J*G!R>R)C%R:1SU%>K?\(19_\ //\ \??_ .*KE/$7A<?:DM+5,;HPQY)
M^9@6)).!P/Z#)KFHYC2JRLKKKK;_ #-9X><5<Y2BO2]'\!0VH#3#S)."<D[
M1S@#C(]=V<XZ#.*QOB)81VGD^6BIGS,[5"YQMQT%%/,*=2JJ<;^H2P\HQYF<
M;7I7PYC*VS$@@-*Q&>XVJ,C\01^%-_X5O;_WI/\ OI?_ (FNEM+1;11%& JJ
M, #_ #^9[UQ8_'4ZU/DCW-J%"4)796U[_CWF_P"N4G_H)KQNO;;NV%TC0MG#
MJ5..N&&#7-?\*WM_[TG_ 'TO_P 34Y?BZ=",E+JQXBE*;5CS>BMOQ;HB:/*L
M,98@H&^8@G)+#L!Z5B5[-.HJD5);,XY1<79F_I?C6XTY1$"K*   X)P!V!!!
M_/., #%5-:\1S:OCS2-H.0JC"@XQGU/XDXR<8KT+_A"+/_GG_P"/O_\ %5E>
M*?"UM8VSS1IAUVX.YCU8 \$D=#7G4L9A954U%\S>]EU^9T2HU5'5Z(\^HHHK
MU#F"BMWP_P"$9=7P_P!R+GYR,YQV R">>_3KSD8KM]/\$6MGSM+D$\R'=U&,
M8&%/XC^E<=?'TJ+MN^R-:>'G/7H>5T5[)_8-O_SQC_[]K_A65J/@*VNLE 8V
M.?NGY<GI\ISP/08]/3&,,VI-ZIHMX22V/,**UM=\-RZ.?G&4)PKCH>_3L?8^
MAQD#-9-=\)QG'F3NC"47%V8445V.B?#UK@"2X)12,[5^_P!^N>%['&#Z'!J:
MU>%%7D[#A3E-V1QU%>NVOA6UML[8E.<?>^?I_O9Q^%32>'K9P5,4>",<(H//
MN!D?45PO-Z=_A9O]4EW/'**]&U;X>13C,!,; ="2RGKZY(SQSDX':N(U;19=
M);9*,9S@CE3@XR#_ $.#R,@9KJH8RE7T3U[/<RJ490W*%%%%=)F%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 7]!_X^(?\
MKK'_ .A"O9*\;T'_ (^(?^NL?_H0KV2O%S?XX^AV839A1117EG4%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF_ZZR?\ H1JA4UI;&Z=85QEV"C/3+' KVL)@OJSE+FOIV.*K6]K96.R\ ^'
M_P#ITH!&?W?.>02"V/8]/Q..AKNZC@@%NHC4850 ![ 8'6JVL:F-,B:X()"
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M-M0'RW&5ZGZKDCL?KP1DYK$KTWX@60GMC+QF)E(XR<,=I&>W4'\!7!^']/\
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M\?"_]<E_]":N4HHKW*%+V5-0WL<,Y<TFSW.L+QO_ ,><O_ /_0UK=K"\;_\
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M** "BBB@ HHHH **** "BBB@ HHHH **** -WP1_Q^1?\#_] :O5J\I\$?\
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M/A/C?H;M1_+;KV5$'L%  _( "I*\N\7^)&U&5HD8^2IP #PV.K'!(/(X]L<
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MH:'J7]I0I<8P6'/U!P<<GC(./:K]>9&4J-2_5,Z6E./DSPRBBBOJCRPHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +^@_P#'Q#_UUC_]
M"%>R5XWH/_'Q#_UUC_\ 0A7LE>+F_P <?0[,)LPHHHKRSJ"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** ,+QO\ \><O_ /_ $-:\IKU;QO_ ,><O_ /_0UK
MRFO=RC^"_7]$<.+^->@4445Z)SA1110 4444 %%%% !1110!U?PW_P"/AO\
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MC_\ 0A5"IK2Y-JZS+C*,&&>F5.17K35XM>1RQ=FCVVN4^)'_ ![K_P!=5_\
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MX.#TJ<GDN6:ZCQBU3(Z***]8Y3W.L+QO_P ><O\ P#_T-:W:PO&__'G+_P
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -WP1_Q^1?\#_\
M0&KU:O*?!'_'Y%_P/_T!J]6KPLW_ (R]/U9W83X'ZA1117G'0%%%% !1110
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MUYU2G5PT[/1G1&4:D?(\>UW0I-'D\M^5/W6'1A_0CN.WTP3U'PQ_Y;?]L_\
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MQR>I]Z;J5Z+&)YSC"*3@G&2.@S[G@5\O4?M*LFNKT^;/4BN6*OT1XK5_0?\
MCXA_ZZQ_^A"J%7]!_P"/B'_KK'_Z$*^GJ_!+T/,CNCV2N4^)'_'NO_75?_06
MKJZP/&^G_;+5B,YC(<8('W>#G/HI)_SBOF\))1KP;[GHUE>#/*Z***^G/-.K
M^&__ !\-_P!<F_\ 0EKTBO-_AO\ \?#?]<F_]"6O2*^?S3^._1'?A?X9YO\
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M HHHH **** "BBB@ HHHH OZ#_Q\0_\ 76/_ -"%>R5XWH/_ !\0_P#76/\
M]"%>R5XN;_''T.S";,****\LZ@HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M -_B#P,#%>9CLO=5\\-^J.FAB%%<KV/2+W38KX;945A@@;ADC/7!ZCZBLO\
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MB,/5=6;47N^C[GHTZD%!:K8\IHHHKZ,\X**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@"_H/_ !\0_P#76/\ ]"%>R5XWH/\ Q\0_]=8_
M_0A7LE>+F_QQ]#LPFS"BBBO+.H**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH PO&_\ QYR_\ _]#6O*:]6\;_\ 'G+_ , _]#6O*:]W*/X+]?T1PXOXUZ!1
M117HG.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 >YUA>-_P#CSE_X!_Z&M;M87C?_ (\Y?^ ?
M^AK7R^&_C0]5^9Z=7X)>AY31117U!Y@4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH OZ#_Q\0_]=8__ $(5[)7C>@_\
M?$/_ %UC_P#0A7LE>+F_QQ]#LPFS"BBBO+.H**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH PO&__'G+_P  _P#0UKRFO5O&_P#QYR_\ _\ 0UKRFO=RC^"_
M7]$<.+^->@4445Z)SA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M% !1110 4444 %%%% !1110!XWKW_'Q-_P!=9/\ T(U0J_KW_'Q-_P!=9/\
MT(U0KZNE\$?0\J6["BBBK$%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5U>B>.O[+A6W\K=LSSOQG+$]-I]:Y2BLJU&
M%:/+)714)R@[H[K_ (6=_P!,?_(G_P!A7"T44J.&IT;\JM<<ZDI[A1116Q 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 7]!_X^(?^NL?_H0KV2O&]!_X^(?^NL?_ *$*]DKQ<W^./H=F$V84445Y
M9U!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% &%XW_X\Y?^ ?\ H:UY37JW
MC?\ X\Y?^ ?^AK7E->[E'\%^OZ(X<7\:] HHHKT3G"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** -WP1_Q^1?\  _\ T!J]6KRGP1_Q^1?\#_\ 0&KU:O"S?^,O
M3]6=V$^!^H4445YQT!1110 4444 %%%% !1110 4444 >-Z]_P ?$W_763_T
M(U0J_KW_ !\3?]=9/_0C5"OJZ7P1]#RI;L****L04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!?T'_ (^(?^NL?_H0KV2O&]!_X^(?^NL?_H0KV2O%S?XX^AV839A1117E
MG4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 87C?\ X\Y?^ ?^AK7E->K>
M-_\ CSE_X!_Z&M>4U[N4?P7Z_HCAQ?QKT"BBBO1.<**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH W?!'_'Y%_P/_P! :O5J\I\$?\?D7_ __0&KU:O"S?\ C+T_
M5G=A/@?J%%%%><= 4444 %%%% !1110 4444 %%%% 'C>O?\?$W_ %UD_P#0
MC5"K^O?\?$W_ %UD_P#0C5"OJZ7P1]#RI;L****L04444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!?T'_CXA_P"NL?\ Z$*]DKQO0?\ CXA_ZZQ_^A"O9*\7-_CCZ'9A-F%%
M%%>6=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M (JC_A"+/_GG_P"/O_\ %4?VO1[/\/\ ,/JD_(\IHKU;_A"+/_GG_P"/O_\
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M ,??_P"*H_M>CV?X?YA]4GY'E-%>K?\ "$6?_//_ ,??_P"*H_X0BS_YY_\
MC[__ !5']KT>S_#_ ##ZI/R/*:*]6_X0BS_YY_\ C[__ !5'_"$6?_//_P ?
M?_XJC^UZ/9_A_F'U2?D>4T5ZM_PA%G_SS_\ 'W_^*H_X0BS_ .>?_C[_ /Q5
M']KT>S_#_,/JD_(\IHKU;_A"+/\ YY_^/O\ _%4?\(19_P#//_Q]_P#XJC^U
MZ/9_A_F'U2?D>4T5ZM_PA%G_ ,\__'W_ /BJ/^$(L_\ GG_X^_\ \51_:]'L
M_P /\P^J3\CRFBO5O^$(L_\ GG_X^_\ \51_PA%G_P \_P#Q]_\ XJC^UZ/9
M_A_F'U2?D>4T5ZM_PA%G_P \_P#Q]_\ XJC_ (0BS_YY_P#C[_\ Q5']KT>S
M_#_,/JD_(\IHKU;_ (0BS_YY_P#C[_\ Q5'_  A%G_SS_P#'W_\ BJ/[7H]G
M^'^8?5)^1Y317JW_  A%G_SS_P#'W_\ BJ/^$(L_^>?_ (^__P 51_:]'L_P
M_P P^J3\CRFBO5O^$(L_^>?_ (^__P 51_PA%G_SS_\ 'W_^*H_M>CV?X?YA
M]4GY'E-%>K?\(19_\\__ !]__BJ/^$(L_P#GG_X^_P#\51_:]'L_P_S#ZI/R
M/*:*]6_X0BS_ .>?_C[_ /Q5'_"$6?\ SS_\??\ ^*H_M>CV?X?YA]4GY'E-
M%>K?\(19_P#//_Q]_P#XJC_A"+/_ )Y_^/O_ /%4?VO1[/\ #_,/JD_(\IHK
MU;_A"+/_ )Y_^/O_ /%4?\(19_\ //\ \??_ .*H_M>CV?X?YA]4GY'E-%>K
M?\(19_\ //\ \??_ .*H_P"$(L_^>?\ X^__ ,51_:]'L_P_S#ZI/R/*:*]6
M_P"$(L_^>?\ X^__ ,51_P (19_\\_\ Q]__ (JC^UZ/9_A_F'U2?D>4T5ZM
M_P (19_\\_\ Q]__ (JC_A"+/_GG_P"/O_\ %4?VO1[/\/\ ,/JD_(\IHKU;
M_A"+/_GG_P"/O_\ %4?\(19_\\__ !]__BJ/[7H]G^'^8?5)^1Y317JW_"$6
M?_//_P ??_XJC_A"+/\ YY_^/O\ _%4?VO1[/\/\P^J3\CRFBO5O^$(L_P#G
MG_X^_P#\51_PA%G_ ,\__'W_ /BJ/[7H]G^'^8?5)^1Y317JW_"$6?\ SS_\
M??\ ^*H_X0BS_P">?_C[_P#Q5']KT>S_  _S#ZI/R/*:*]6_X0BS_P">?_C[
M_P#Q5'_"$6?_ #S_ /'W_P#BJ/[7H]G^'^8?5)^1Y317JW_"$6?_ #S_ /'W
M_P#BJ/\ A"+/_GG_ ./O_P#%4?VO1[/\/\P^J3\CRFBO5O\ A"+/_GG_ ./O
M_P#%4?\ "$6?_//_ ,??_P"*H_M>CV?X?YA]4GY'E-%>K?\ "$6?_//_ ,??
M_P"*H_X0BS_YY_\ C[__ !5']KT>S_#_ ##ZI/R.4^'NEF:;[20=D8.#VW$8
MQ[\$GCIQGKSZ14-I:+:*(HP%51@ ?Y_,]ZFKRL7B/;U.;IT.JE3]G&P4445S
MF@4444 %%%% !1110 4444 %%%% 'D7BFR:TN90W\3EAUP0QR.OY'W!%9->S
M:GH\6I@+,H8*<CD@C\00?P^GI6?_ ,(19_\ //\ \??_ .*KV:.:TXP2DG==
MO^'..>%DY-IGE-%>K?\ "$6?_//_ ,??_P"*H_X0BS_YY_\ C[__ !5:?VO1
M[/\ #_,GZI/R/*:*]6_X0BS_ .>?_C[_ /Q5'_"$6?\ SS_\??\ ^*H_M>CV
M?X?YA]4GY'E-%>K?\(19_P#//_Q]_P#XJC_A"+/_ )Y_^/O_ /%4?VO1[/\
M#_,/JD_(\IHKU;_A"+/_ )Y_^/O_ /%4?\(19_\ //\ \??_ .*H_M>CV?X?
MYA]4GY'E-%>K?\(19_\ //\ \??_ .*H_P"$(L_^>?\ X^__ ,51_:]'L_P_
MS#ZI/R/*:*]6_P"$(L_^>?\ X^__ ,51_P (19_\\_\ Q]__ (JC^UZ/9_A_
MF'U2?D>4T5ZM_P (19_\\_\ Q]__ (JC_A"+/_GG_P"/O_\ %4?VO1[/\/\
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M$6?_ #S_ /'W_P#BJ/\ A"+/_GG_ ./O_P#%4?VO1[/\/\P^J3\CRFBO5O\
MA"+/_GG_ ./O_P#%4?\ "$6?_//_ ,??_P"*H_M>CV?X?YA]4GY'E-%>K?\
M"$6?_//_ ,??_P"*H_X0BS_YY_\ C[__ !5']KT>S_#_ ##ZI/R/*:*]6_X0
MBS_YY_\ C[__ !5'_"$6?_//_P ??_XJC^UZ/9_A_F'U2?D>4T5ZM_PA%G_S
MS_\ 'W_^*H_X0BS_ .>?_C[_ /Q5']KT>S_#_,/JD_(\IHKU;_A"+/\ YY_^
M/O\ _%4?\(19_P#//_Q]_P#XJC^UZ/9_A_F'U2?D>4T5ZM_PA%G_ ,\__'W_
M /BJ/^$(L_\ GG_X^_\ \51_:]'L_P /\P^J3\CRFBO5O^$(L_\ GG_X^_\
M\51_PA%G_P \_P#Q]_\ XJC^UZ/9_A_F'U2?D>4T5ZM_PA%G_P \_P#Q]_\
MXJC_ (0BS_YY_P#C[_\ Q5']KT>S_#_,/JD_(\IHKU;_ (0BS_YY_P#C[_\
MQ5'_  A%G_SS_P#'W_\ BJ/[7H]G^'^8?5)^1Y317JW_  A%G_SS_P#'W_\
MBJ/^$(L_^>?_ (^__P 51_:]'L_P_P P^J3\CRFBO5O^$(L_^>?_ (^__P 5
M1_PA%G_SS_\ 'W_^*H_M>CV?X?YA]4GY'E-%>K?\(19_\\__ !]__BJ/^$(L
M_P#GG_X^_P#\51_:]'L_P_S#ZI/R/*:*]6_X0BS_ .>?_C[_ /Q5'_"$6?\
MSS_\??\ ^*H_M>CV?X?YA]4GY'E-%>K?\(19_P#//_Q]_P#XJC_A"+/_ )Y_
M^/O_ /%4?VO1[/\ #_,/JD_(\IHKU;_A"+/_ )Y_^/O_ /%4?\(19_\ //\
M\??_ .*H_M>CV?X?YA]4GY'E-%>K?\(19_\ //\ \??_ .*H_P"$(L_^>?\
MX^__ ,51_:]'L_P_S#ZI/R/*:*]6_P"$(L_^>?\ X^__ ,51_P (19_\\_\
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M (JC_A"+/_GG_P"/O_\ %4?VO1[/\/\ ,/JD_(\IHKU;_A"+/_GG_P"/O_\
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M ,??_P"*H_M>CV?X?YA]4GY'E-%>K?\ "$6?_//_ ,??_P"*H_X0BS_YY_\
MC[__ !5']KT>S_#_ ##ZI/R/*:*]6_X0BS_YY_\ C[__ !5'_"$6?_//_P ?
M?_XJC^UZ/9_A_F'U2?D>4T5ZM_PA%G_SS_\ 'W_^*H_X0BS_ .>?_C[_ /Q5
M']KT>S_#_,/JD_(\IHKU;_A"+/\ YY_^/O\ _%4?\(19_P#//_Q]_P#XJC^U
MZ/9_A_F'U2?D>4T5ZM_PA%G_ ,\__'W_ /BJ/^$(L_\ GG_X^_\ \51_:]'L
M_P /\P^J3\CRFBO5O^$(L_\ GG_X^_\ \51_PA%G_P \_P#Q]_\ XJC^UZ/9
M_A_F'U2?D>4T5ZM_PA%G_P \_P#Q]_\ XJC_ (0BS_YY_P#C[_\ Q5']KT>S
M_#_,/JD_(\IHKU;_ (0BS_YY_P#C[_\ Q5'_  A%G_SS_P#'W_\ BJ/[7H]G
M^'^8?5)^1Y317JW_  A%G_SS_P#'W_\ BJ/^$(L_^>?_ (^__P 51_:]'L_P
M_P P^J3\CRFBO5O^$(L_^>?_ (^__P 51_PA%G_SS_\ 'W_^*H_M>CV?X?YA
M]4GY'E-%>K?\(19_\\__ !]__BJ/^$(L_P#GG_X^_P#\51_:]'L_P_S#ZI/R
M/*:*]6_X0BS_ .>?_C[_ /Q5'_"$6?\ SS_\??\ ^*H_M>CV?X?YA]4GY'E-
M%>K?\(19_P#//_Q]_P#XJC_A"+/_ )Y_^/O_ /%4?VO1[/\ #_,/JD_(\IHK
MU;_A"+/_ )Y_^/O_ /%4?\(19_\ //\ \??_ .*H_M>CV?X?YA]4GY'E-%>K
M?\(19_\ //\ \??_ .*H_P"$(L_^>?\ X^__ ,51_:]'L_P_S#ZI/R/*:*]6
M_P"$(L_^>?\ X^__ ,51_P (19_\\_\ Q]__ (JC^UZ/9_A_F'U2?D>4T5ZM
M_P (19_\\_\ Q]__ (JC_A"+/_GG_P"/O_\ %4?VO1[/\/\ ,/JD_(\IHKU;
M_A"+/_GG_P"/O_\ %4?\(19_\\__ !]__BJ/[7H]G^'^8?5)^1Y317JW_"$6
M?_//_P ??_XJC_A"+/\ YY_^/O\ _%4?VO1[/\/\P^J3\CRFBO5O^$(L_P#G
MG_X^_P#\51_PA%G_ ,\__'W_ /BJ/[7H]G^'^8?5)^1Y317JW_"$6?\ SS_\
M??\ ^*H_X0BS_P">?_C[_P#Q5']KT>S_  _S#ZI/R/*:*]6_X0BS_P">?_C[
M_P#Q5'_"$6?_ #S_ /'W_P#BJ/[7H]G^'^8?5)^1Y317JW_"$6?_ #S_ /'W
M_P#BJ/\ A"+/_GG_ ./O_P#%4?VO1[/\/\P^J3\CRFBO5O\ A"+/_GG_ ./O
M_P#%4?\ "$6?_//_ ,??_P"*H_M>CV?X?YA]4GY'E-%>K?\ "$6?_//_ ,??
M_P"*H_X0BS_YY_\ C[__ !5']KT>S_#_ ##ZI/R/*:*]6_X0BS_YY_\ C[__
M !5'_"$6?_//_P ??_XJC^UZ/9_A_F'U2?D>4T5ZM_PA%G_SS_\ 'W_^*H_X
M0BS_ .>?_C[_ /Q5']KT>S_#_,/JD_(\IHKU;_A"+/\ YY_^/O\ _%4?\(19
M_P#//_Q]_P#XJC^UZ/9_A_F'U2?D>4T5ZM_PA%G_ ,\__'W_ /BJ/^$(L_\
MGG_X^_\ \51_:]'L_P /\P^J3\CRFBO5O^$(L_\ GG_X^_\ \51_PA%G_P \
M_P#Q]_\ XJC^UZ/9_A_F'U2?D>4T5ZM_PA%G_P \_P#Q]_\ XJC_ (0BS_YY
M_P#C[_\ Q5']KT>S_#_,/JD_(\IHKU;_ (0BS_YY_P#C[_\ Q5'_  A%G_SS
M_P#'W_\ BJ/[7H]G^'^8?5)^1Y317JW_  A%G_SS_P#'W_\ BJ/^$(L_^>?_
M (^__P 51_:]'L_P_P P^J3\CRFBO5O^$(L_^>?_ (^__P 51_PA%G_SS_\
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M%G_SS_\ 'W_^*H_X0BS_ .>?_C[_ /Q5']KT>S_#_,/JD_(\IHKU;_A"+/\
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M )Y_^/O_ /%4?VO1[/\ #_,/JD_(\IHKU;_A"+/_ )Y_^/O_ /%4?\(19_\
M//\ \??_ .*H_M>CV?X?YA]4GY'E-%>K?\(19_\ //\ \??_ .*H_P"$(L_^
M>?\ X^__ ,51_:]'L_P_S#ZI/R/*:*]6_P"$(L_^>?\ X^__ ,51_P (19_\
M\_\ Q]__ (JC^UZ/9_A_F'U2?D>4T5ZM_P (19_\\_\ Q]__ (JC_A"+/_GG
M_P"/O_\ %4?VO1[/\/\ ,/JD_(\IHKU;_A"+/_GG_P"/O_\ %4?\(19_\\__
M !]__BJ/[7H]G^'^8?5)^1Y317JW_"$6?_//_P ??_XJC_A"+/\ YY_^/O\
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M^/O_ /%4?\(19_\ //\ \??_ .*H_M>CV?X?YA]4GY'E-%>K?\(19_\ //\
M\??_ .*H_P"$(L_^>?\ X^__ ,51_:]'L_P_S#ZI/R/*:*]6_P"$(L_^>?\
MX^__ ,51_P (19_\\_\ Q]__ (JC^UZ/9_A_F'U2?D>4T5ZM_P (19_\\_\
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M_P#GG_X^_P#\51_PA%G_ ,\__'W_ /BJ/[7H]G^'^8?5)^1Y317JW_"$6?\
MSS_\??\ ^*H_X0BS_P">?_C[_P#Q5']KT>S_  _S#ZI/R/*:*]6_X0BS_P">
M?_C[_P#Q5'_"$6?_ #S_ /'W_P#BJ/[7H]G^'^8?5)^1Y317JW_"$6?_ #S_
M /'W_P#BJ/\ A"+/_GG_ ./O_P#%4?VO1[/\/\P^J3\CRFBO5O\ A"+/_GG_
M ./O_P#%4?\ "$6?_//_ ,??_P"*H_M>CV?X?YA]4GY'E-%>K?\ "$6?_//_
M ,??_P"*H_X0BS_YY_\ C[__ !5']KT>S_#_ ##ZI/R/*:*]6_X0BS_YY_\
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M_P#\51_:]'L_P_S#ZI/R/*:*]6_X0BS_ .>?_C[_ /Q5'_"$6?\ SS_\??\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %>0^//\ C]E_X!_Z M>O5Y#X\_X_9?\
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M%% !1110 4444 %%%% !1110 4444 %>?_%;_EA_VT_]DKT"O/\ XK?\L/\
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M"4SV(R6 X[CGJ "/4T- I:V9Z-6';^-;2X98DDRSD #8XR2<#JM;E>(>'O\
MCY@_Z[1_^ABDE<).Q[?1112*,.X\:VENS1/)AD)!&QS@@X/1:W*\0\0_\?,_
M_7:3_P!#->WTVK$Q=S'O_%UKI[F"63:ZXR-KGJ 1R%(Z&M :A'Y8N"P$; $,
MQVC#8QUQC.>]>4>/?^/V7_@'_HM:;9VMSXI985QMAC51G(10!@>O+8]R?H.'
MRAS:GH/_  GME_SU_P#')/\ XFMBQU"._7S8F#*>X/MG!]#ST/(KS63X972
MD-&2 > S9/MRH'YD"L32=6ET24,I8;6&],[<[>"I!_$<C(/(YHY4+F:W/;:*
MCM[A;A5E0Y5P"#TR",CK6/XK\3+H48;&Z1\A!VXQDD^@R..IZ>I$EW-#4M7A
MTQ=\SA0>F>IZ#@#).,\X''>LO_A/;+_GK_XY)_\ $UYQIVEW'B:9F!W,>7=^
M%'ID@'TP !]!@''0O\*W"9652^!P5(7/?YLD_3Y>?055D3S-G?6.H1WZ^;$P
M93W!]LX/H>>AY%6*\4N(;CPW,5R4D7NIX89R#[J<=#Z8(R"*]7\-ZVNLPK./
MO='&,88 9QUXYR.3P>><TFK I7-2BBBD4-DD$0+L0  223@ #J<UBW'C:S@8
MH91D?W0S#UZJ"#^=<G\2==9Y/L*-\B@%P,C+'D GN ,$8XR>>0,5/#_P^DU2
M/SW;RU;[N5W$CUQD8'IZ]>F":L2Y.]D=[8>*[6_.R.5<Y  ;*$D]  P&?PS6
ME<7"VZM*YPJ DGK@ 9/2O+M6^'=Q9G]UB520,K\K#.!RI/J>H)  R<"O0_#V
MF/ID"02.791U[#_9'? [9Y^@P FD--E6W\:VEPRQ))EG( &QQDDX'5:W*\2U
MO3SHUP\*DYC8%2#S@X93G Y (SCOTKU_0]2_M*".XXRZC. 0-PX8<\\$$4-6
M%%W+U8]_XNM=/<P2R;77&1M<]0".0I'0UI7ET+1&F;.$5F..N%&37BB1OK4^
M% WSR$\ X!8Y)[G ZGK@4)7"3L>TV%^FH()XCN1LX.".A(/! /45#J6N0:;S
M-(JG ."<M@G&0HR3SZ"H]3NET2V9UP!%'A <D9 VH/7K@=?Q[UY):VL_B&?
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MEXGMM,;RY9 &] "Q'0\A0<=>,XSVJK'XYLI"%$HR2!RK@<^Y4 ?4\5Y]X?\
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M="0>" >HJ:201 NQ  !)).  .IS4/R:=%_=CB3W.%0?B3@#ZUY1XF\32>(9
MB B,'"(.22> 2!U8]AVZ#N2)7&W8]!D\<V49*F49!(X5R./<*0?J.*M:;XGM
MM3;RXI 6]""I/4\!@,].<9QWKB;#X7RRC,TBH2!@*-YYZ@\J!CV)']<KQ!X+
MFT9?-.'CSC<N>/0L".,_4C/&>F79"NSU^BN#^'_BMKAC93L68Y,9.23C)92W
MZC/N,]!7>4FK#3N8=OXUM+AEB23+.0 -CC))P.JUH:EJ\.F+OF<*#TSU/0<
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MN<*@))ZX &3TKQ:ZNI_$,^3EY'.%4= /0>@'^))ZFFE<4G8]-_X3VR_YZ_\
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M_P#UQ;_T-*] \0_\>T__ %QD_P#0#7G_ ,+_ /CY?_KBW_H:5Z!XA_X]I_\
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M:;XCM]2XBD4DD@*?E8X&3A6P3QWQC\JTJ\6USPQ/HN#*!M)P&4Y4G&<=B/Q
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "O(?'G_ !^R_P# /_0%KUZO(?'G_'[+_P  _P#0%IQ$S HJ]H<8
MDN(58 @RQ@@C((+#(Q7K_P#PC]M_SQC_ ._:_P"%4W821XE17MO_  C]M_SQ
MC_[]K_A1_P (_;?\\8_^_:_X4N8=CQ*N^^%7_+?_ +9_^SUP-=]\*O\ EO\
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MKWVG($%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KS_XK?\L/^VG_ +)7H%>?_%;_ )8?]M/_ &2G
M'<4MC0^%_P#Q[/\ ]=F_] 2NPKC_ (7_ /'L_P#UV;_T!*["A[A'8*\@\>_\
M?LO_  #_ -%K7K]>0>/?^/V7_@'_ *+6G'<4]CN_A[;K%9HRCERY;W.XK_)1
M725S_@+_ (\HO^!_^C&KH*3W&MCRSXEVZQ7091R\:EO<Y9?Y**[/P%_QY1?\
M#_\ 1C5Q_P 4/^/E/^N*_P#H;UV'@+_CRB_X'_Z,:F]A+XF<-\1+HS7C(<8C
M5%&/0C=S^+'\*F\.>.5T2$0+#N.26;S,9)]MIQP /PS4?Q%L6@NFE/W90I4\
M_P *A2/J,9^A'K6SX-T*RUF ,\8\U#M?YW'T; ?N/H,@X&!3TL3K<;_PM;_I
MA_Y$_P#L*P/%/BA=>VMY6QTR-V\-D'L?E!X/3GC)XYKO_P#A K+_ )Y?^/R?
M_%5#<^#M/M<%T W,JC+R<LQP /F_R.>@I70VF8_PJD)$Z9. 8R!GC)W9./?
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M[_Q^R_\  /\ T6M>G^'O^/:#_KC'_P"@"A[(([LT*\H^(UIY%V7SGS$5NG3
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M<VAXE5MT3' )X8'D@'UX'4>AX'&>I^&FK/=Q/;N2?)*[23_"V<+^&WCGH<<
M"AKJ";O8J_%#22ZI>*/N_*YYZ'E?8 '(SQR0.>Q\+]6+J]FQ^[\R#GH>&]@
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M)Z9)4$]*C\0_\>T__7&3_P! -'A[_CV@_P"N,?\ Z */$/\ Q[3_ /7&3_T
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M%"Q.2< $'\CCN3C).3715):U"O!KRZ-V[3-C+LS''3+')KWFO"KRS;393#(
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M%/TQ@CKFN?\ B/!;V:)#$B+(S;OD50=H!'.,'DGCL<'TIJPG>P[X4_\ +?\
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MNGW?VR))\8\Q%;&<XW '&>/6O&/#W_'S!_UVC_\ 0Q1'J$NA[;'&(@$4
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MVGVR5(,X\QU7.,XW$#../6O=Z\0\/?\ 'S!_UVC_ /0Q1$)]#VV.,1 (H
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MV@X[C&>>Q&.M=!\+_P#CV?\ Z[-_Z E#V$OB-#Q[_P >4O\ P#_T8M<-\/+
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MD <CU 'X5[W7,V_@[3[G<$0'8Q5L/)PP )'WNV>?0\=0:Z:E)W"*L>(>(?\
MCYG_ .NTG_H9KV72[ :?$ENN,(H&0,9(ZG'N>3[FO&O$/_'S/_UVD_\ 0S7M
M].0H[L*\8\7VGV6[F3.<ONZ8^^-^/PSBO9Z\@\>_\?LO_ /_ $6M$=QSV/4]
M&N&N((I7.6>-"3TR2H)Z5<K/\/?\>T'_ %QC_P#0!6A4E!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW'@FSG8N8AD_W2RCTZ*0!^5:UK9I:#9$JH"<X50HSZX%+F0<K91\-Z(NC0K
M/O=7.<Y8@9QTXXP.!P.><UJ445)9Y;\1])>WN#=8)24+SC@,HQM_(9[9YQT-
M5-)\=W.F((05=0 %$@)P!V!!!_/.  !@5ZW)&)048 @@@@C((/48K'?P;9N_
MFF)<Y!P,A>/]D';]1C![U7,2XNX[PC?OJ%K'/*=SMNR< ='8#@ #H*\X\>_\
M?LO_  #_ -%K7K=O;K;J(T4*HZ!0 !GGH*KW&C07#&1XD9CU+(I)QQU(I)V8
MVKHR_ 7_ !Y1?\#_ /1C5T%1V]NMNHC10JCH%  &>>@J2DQH\U^)ND^3(MVH
M.)1AN#C<H&#GIR.W'W2>>:YC0]-_M*>.WYP[#." =HY8\\< $U[7=6:78V2J
MK@'.&4,,^N#4-OHT%NPD2)%8="J*",\=0*I2T)<=2U'&(@$4     #  '08I
MU%%24>?^-O!+S.;RV&[=RZ# (('+ <9SCD=<\C.>.8T7Q7<:1\L;93^X_*]^
M@ZCDYX(R>N:]GK/O_#]OJ&3+&K%L9;&&XQCYAANWKTXZ52D2XGFU_P#$.[NQ
MM!6,8(/EK@G/NQ8C'8C!_2IO!.EW5S.+Q"57.7=\X<%OF4$@[B<'Z$9)!Q7=
MVGA"TM<[8E.<??R_3TWYQ^%;%%P46%%%%24%>(>(?^/F?_KM)_Z&:]OJC)H5
MO*2[11DDDDF-223U.<4T["DKC?#W_'M!_P!<8_\ T 5Y_P#%#_CY3_KBO_H;
MUZ='&(@$4     #  '08JO=:5#=G?+&CD#&616./3)%"=F#5T9/@+_CRB_X'
M_P"C&KH*CM[=;=1&BA5'0*  ,\]!4E)C1Y!X]_X_9?\ @'_HM:]/\/?\>T'_
M %QC_P#0!4EQHT%PQD>)&8]2R*2<<=2*M1QB(!%      P !T&*;>@DK,=7@
M%>_UG_\ "/6W_/&+_OVG^%"=A25S0KR#Q[_Q^R_\ _\ 1:UZ_5.XT:"X8R/$
MC,>I9%)...I%"=AR5R/P]_Q[0?\ 7&/_ - %:%-CC$0"*     !@ #H,4ZD,
M\0\0_P#'S/\ ]=I/_0S7M]49-"MY27:*,DDDDQJ22>ISBKU-NXDK&?XA_P"/
M:?\ ZXR?^@&O(/#W_'S!_P!=H_\ T,5[;)&)048 @@@@C((/48JG'H5O$0ZQ
M1@@@@B-001T.<4)V$U<O5Y?X^\+M9R->H,Q2'+8S\K'KGKPQY!Z9...,^H44
M)V&U<\BTGQW<Z8@A!5U  42 G '8$$'\\X  &!3I-6O/%D@M@>&_A7*Q@#&2
MW4D C/.>>%Y(%>@W7@VSN3N:)00,?+E!^2D#\>M:EK9I:#9$JH"<X50HSZX%
M.Z%RL\.U"T^QRO!G/ENRYQC.TD9QSZ5[O5&30K>4EVBC)))),:DDGJ<XJ]2;
MN.*L>0>/?^/V7_@'_HM:]/\ #W_'M!_UQC_] %27&C07#&1XD9CU+(I)QQU(
MJU'&(@$4     #  '08H;T!*S'5Y?\4/^/E/^N*_^AO7J%5;K2H;L[Y8T<@8
MRR*QQZ9(H3L#5T9/@+_CRB_X'_Z,:IO%7AP:Y%Y>0'4Y1B._H>^#WQW /.,5
MK6]NMNHC10JCH%  &>>@J2B^H6TL>).EQX>EP=T<@ /!ZCKVR&&1R.1D8/2M
MK_A9=UMV83.,;MIW9Q][[VW/?ICVQQ7IMU9I=C9*JN <X90PSZX-9/\ PA-G
MN\SRAG.>K;<YS]W.W'MC';&*?,B>5H\PDN+GQ%(%):5^P'09P,X&%4=,G@=S
M7KNB6\MM"D=PP>1006!SGDXY(!/&,D\D^O6K%K9I:#9$JH"<X50HSZX%34F[
ME)6"BBBD,\S^(%I=1S"Y8DQ+@QL@("<CKCHV<<]^,=-JU+'XBW5JOEG:^.AD
M!+8QC&01GZG)]37J]8MUX-L[D[FB4$#'RY0?DI _'K5)HEQ9Y=K&MS:_(&?D
M\!40' SZ#DY)^I/3H !Z7X+\/MHT.V3'F2'<V.W  7/?'/MDG'J=2QT>&P_U
M4:J0,9"C=CW;J>G<\U<I-@HV"O+/B/I(L[@3*,+,,]L;APW _ G/4D\^GJ=>
M:_$G7A<NMG&05C.7QS\_(QT_A&<X/4X/(HCN$MC$\(:3_:=RB8!5#O;(!&U2
M.,'KDX'XYQBO9:XOX9Z2(86NV'S2$A3Q]U?3N,MG/K@<5VE$GJ$5H9OB&">>
M!TMF"R$<>I'< YX)['^7WAY1I^LW.@/L4LA!RR.#CG!Y4],@#D8..AKVFJM_
MI<6H#;,BN,$#<,D9ZX/4?48-"=AM7/-+SXCW5RAC 1-PQN0,&'T)8X^O4=L'
MFJ_@SPT^K2K(0/)C8%BPR#CG9COGOV Z]@?0[7P;9VQW+$I)&/FRX_)B1^/6
MMB.,1 (H     &  .@Q3YA<KZCJ\]^)^DNS)>*"4"[&P/NX)()^N['3 (Z\B
MO0J*2=AM7/'-$\8W&CKY:$,G.%<9 )[C!!'TSCDG&>:]!\#ZS)J\+S3$$^:P
M&   -JD#\,]\GU-6+KP;9W)W-$H(&/ER@_)2!^/6M2ULTM!LB54!.<*H49]<
M"AM,231E^*O#@UR+R\@.IRC$=_0]\'OCN ><8KRQTN/#TN#NCD !X/4=>V0P
MR.1R,C!Z5[;4-U9I=C9*JN <X90PSZX-"=@<;GF7_"R[K;LPF<8W;3NSC[WW
MMN>_3'MCBL>2XN?$4@4EI7[ =!G S@851TR>!W->G_\ "$V>[S/*&<YZMMSG
M/W<[<>V,=L8K6M;-+0;(E5 3G"J%&?7 I\R#E;*^B6\MM"D=PP>1006!SGDX
MY(!/&,D\D^O6N-^*W_+#_MI_[)7H%5[O3XKS'FHK[<XWJ&QGKC(/I23U&U=6
M.7^%_P#Q[/\ ]=F_] 2NPJ&ULTM!LB54!.<*H49]<"IJ3!*R/+_BA_Q\I_UQ
M7_T-Z[#P%_QY1?\  _\ T8U:UUI4-V=\L:.0,99%8X],D5-;VZVZB-%"J.@4
M  9YZ"FWH"6MR2O$/$/_ !\S_P#7:3_T,U[?5&30K>4EVBC)))),:DDGJ<XH
M3L$E<;X>_P"/:#_KC'_Z *T*;'&(@$4     #  '08IU(85Y!X]_X_9?^ ?^
MBUKU^J=QHT%PQD>)&8]2R*2<<=2*:=A25S+\!?\ 'E%_P/\ ]&-4GBOPRNNQ
MA<[9$R4/;G&01Z' YZCKZ@[%O;K;J(T4*HZ!0 !GGH*DHOJ%M+'B$-Q/H$QV
MDQRID'H>OL<@@]1U'0CL:VG^)-VR;!L!P/G"_-QWY)7GOQCTQ7I=_I<6H#;,
MBN,$#<,D9ZX/4?48-9]KX-L[8[EB4DC'S9<?DQ(_'K3YD3RL\NFL;C44DU&3
M)48)=N-Q+! %]<>W  QQP*V_A?\ \?+_ /7%O_0TKTRXMUN%,;J&4]0P!!QS
MT-0VNE0VAWQ1HA(QE453CTR!1S#Y=2U7E_C#P2]DS7, W0G+$# *<\C Q\O/
M&!P.O3)]0HI)V&U<\>T?QK<Z6-BL'0# 63+ = ,'((P!P,X]JDU+Q[=WOR[A
M&"!Q&-O0YSN)+#\"!C\:])OO#%M??ZR)<DY) VL3[LN">O<T6/ABVL?]7$N0
M<@D;F!]F;)'3L:=T3RLXWX=Z/<Q2?:>4A(PP;(W@J2I QS@D'/'!(!/(KT:B
MBDW<I*QXAXA_X^9_^NTG_H9KV^J,FA6\I+M%&22228U))/4YQ5ZANX)6"O(/
M'O\ Q^R_\ _]%K7K]4[C1H+AC(\2,QZED4DXXZD4)V"2N1^'O^/:#_KC'_Z
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MU%?;G&]0V,]<9!]*$Q.-SS2X^)=U*I4!%)_B53D?]],P_2LNRANO$$P=2S2
MCYR3A.20<C[H') '_ 1GBO2[?P39P,'$0R/[Q9AZ=&)!_*MBWMUMU$:*%4=
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M8B-BN#\R-]W((R"IZ'C!(P>V16M=?$F[F&%V(<]57)^GS%A^F:])OM'AO_\
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MMPIC=0RGJ& (..>AJ&UTJ&T.^*-$)&,JBJ<>F0*2>@VM;EJL_P 0_P#'M/\
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M-!<,9'B1F/4LBDG''4BA.P25R/P]_P >T'_7&/\ ] %:%-CC$0"*     !@
M#H,4ZD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!Y!X]_X_9?^ ?\ HM:]/\/?\>T'
M_7&/_P! %:%%-NXDK,****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(
M/$&LW-O<S1^;*H$CX&]Q@$DK@9Z8QCVH\+^$9-:8,P*PCDOCKSC"YZGCKT'?
ML#Z_15<Q/*1V]NMNJQ(,*@  ZX &!UJ2BBI*"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#SOXC:A/9SIY;NB-&/NLRJ2&;/0@9P1G\*Y:PTV?7I,+N=B
M1N=B2!QP68YQP..YQ@9/%>VT52D2XW,WP_H::+$($)/.6)[L< G';IP/3U.2
M=*BBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LWQ!H::U$
M8')'.5([,,@''?KR/3T."-*B@#QS6_!]QI;'*EXQDAT&1@<Y(&=OOGWP2!FJ
M?_"0W/\ SVE_[^/_ (U[?15<Q/(>.:)X/N-4884I&<$NXP,'G(!QN]L>V2 <
MUZOI.DQZ5&((AA1^9/<D]R?_ *PP !5RBDW<:C8****0PHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** &R1B0%6 (((((R"#U&*Q9_!5G.Q<Q#)_NEE'Y
M*0!^5;E% &%'X'LXR&$0R"#RSD<>Q8@_0\5LP6ZVZB-%"J.@4  9YZ"I** "
MBBB@ HHHH **** "BBFB0$E<C( )&><'.#CWP?R- #J*** "BBB@ HHHH **
M:) 25R,@ D9YP<X./?!_(TZ@ HHHH **** "BBB@ HIHD!)7(R "1GG!S@X]
M\'\C3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#FOB!J3V-MF,E2\BKD$A@,%N"",?=Q],UY3'(8R&4D$$$$'!!'0YKV_5=*CU
M2,P2C*G\P>Q![$?_ %CD$BN6M?AA%&^YY&9,\+C:>O +9.>.#@ ]QBJ3$T=3
MH\[7$$4KG+/&A)Z9)4$]*N4V.,1@*H     &  .@Q3JD9@?\)Y9?\]?_ !Q_
M_B:U["_2_03Q'*-G!P1T)!X(!ZBO"J]>\!_\>47_  /_ -#:FU829OUS7Q U
M)[&VS&2I>15R"0P&"W!!&/NX^F:Z6J>JZ5'JD9@E&5/Y@]B#V(_^L<@D4D,\
M0CD,9#*2""""#@@CH<U[?H\[7$$4KG+/&A)Z9)4$]*Y:U^&$4;[GD9DSPN-I
MZ\ MDYXX. #W&*[..,1@*H     &  .@Q3;N)(=1112&%%%% !7-?$#4GL;;
M,9*EY%7()# 8+<$$8^[CZ9KI:IZKI4>J1F"494_F#V(/8C_ZQR"10@/$(Y#&
M0RD@@@@@X((Z'->WZ/.UQ!%*YRSQH2>F25!/2N6M?AA%&^YY&9,\+C:>O +9
M.>.#@ ]QBNSCC$8"J     !@ #H,4V[B2'5@?\)Y9?\ /7_QQ_\ XFM^O J$
MK@V>ZV%^E^@GB.4;.#@CH2#P0#U%6*P/ ?\ QY1?\#_]#:M^D,**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#Q3^U[KS_,WOY^=O?=G=G9M]-W\.,=L5[76/_:%CO\_?!YG]
M_='NZ8^]G/3CZ5L4VQ15@HJG<:S!;L8WE16'4,Z@C//0FK4<@E =2"" 00<@
M@]#FD,=16?\ \)#;?\]HO^_B?XU>CD$H#J000""#D$'H<T .HHHH *KZA=_8
MXGGQGRT9L9QG:"<9Y]*L5@Z[KMO+;S(LL9)BD  D4DDJ<#&: 9FZ#\0?[6F2
MV\K;OW<[\XPI;IM'IZUV%>.>"KA;>[CD=@JC?DL0 ,HPZFO5[?68+AA&DJ,Q
MZ!74DXYZ TY(F+N7*\ KW^O *<13/?Z*CN+A;=3([!5'4L0 ,\=356/7;>4A
M%EC))  $BDDGH,9J2R]1110 4457N]0BL\>:ZINSC>P7..N,D>M %BBJ,>NV
M\I"++&22  )%))/08S5Z@ HHHH *\@\>_P#'[+_P#_T6M>OUY!X]_P"/V7_@
M'_HM:J.Y,]CO_ 7_ !Y1?\#_ /1C5T%<_P" O^/*+_@?_HQJT/\ A(;;_GM%
M_P!_$_QI/<:V-"BH[>X6X42(P93T*D$'''45)2&%%%% !16?_P )#;?\]HO^
M_B?XU:M;Q+L;XF5P#C*L&&?3(H FHHHH ***S_\ A(;;_GM%_P!_$_QH T*\
M0\0_\?,__7:3_P!#->UV]PMPHD1@RGH5((...HKQ3Q#_ ,?,_P#UVD_]#-5$
MF9[?139)!$"[$  $DDX  ZG-4X]=MY2$66,DD  2*22>@QFI*+U%%% !15.X
MUF"W8QO*BL.H9U!&>>A-6+>X6X42(P93T*D$'''44 24444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M #9)!&"S$  $DDX  ZG->;^(_B%)<,T5J=L?3?CYSU!(S]T>G&[C.1T'6^.)
M#'9RE20<*.#C@NH(_$'!]J\?JHH3-#_A(+G_ )[2?]_&_P :FM?%=U;'<LSD
MXQ\QWC\FR/QZUO\ @WPQ:ZK&6D<M*0P* [2O( ;'4^N>5YP1D5;U3X8# ^S.
M<YY$IXQ[%5_ISZC'+NA&IX3\:_VR?(D4B7!.5!*8&/<D=>_'OD@5U-9?A_P_
M'HD?E)RQ^\QZL?Z =AV]R23'XKUK^R+=I1]\_*G^\>AZ$<#)YX.,=ZDHRO$_
MCU--)@A >52,D_<'J.""2/0<#/)R"*X6Z\5W5R=S3.#C'RG8/R7 _'K67)(9
M"68DDDDDG))/4YKN?#_PX%Q'YMT65FZ*N 0/]K(/)].W?G@/1$[G+1^)+F,A
MA-)D$'EV(X]B2#]#Q76>&/B$TC""[(P>DF,<Y_BQQCMD 8[]R+&N_#>-U:2U
MR''(0G*G Y )Y!/7))&>.!R/.Y(S&2K @@D$$8((ZC%/1AL>]UA^-+AK>TDD
M1BK#9@J2",NHZBLCX;:TUU&UJYR8L%<GG:>,8ZX4CKSU X %:GCS_CRE_P"
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MT87Q$O'M+=6C9D)E RK%3C:W&17G?_"07/\ SVD_[^-_C7??$[_CV3_KLO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM5'<F>Q335;B\B33DR4&<(BY+')?)QDG&>G3@'&1FKG_  @5[_SR_P#'X_\
MXJNQ^'&DI;VXNL O*6YQR%4XV_F,]L\9Z"NNH<K"4;GB%C>S:%-O4%)%ZJP(
MR#S@@XX/^!'.#7K?AO6UUF%9Q][HXQC# #..O'.1R>#SSFL7XCZ2EQ;FZP \
M17G')5CC;^9SWQSCJ:YWX9W_ )-PT!.!*AP,=67D<XXPN[V_'%#U5P6CL>E7
MEXEFAFD(5%&23_G\AU)X%>3>*/%TFM,54E81P$SUYSEL=3QTZ#MW)ZGXH7YB
MBCMQG$C$D@XX3'!'?)8'ZC\J?PPT</OO6P2IV+[' +'IZ$ $'H6!H6BN-ZNQ
M@1^!KV0!A$<$ \L@//L6!'T/-4;NPN-#<%PT;\X8'';G#*<'@\X/?!KV^J>K
M:3'JL9@E&5/Y@]B#V(_^L<@D4<P<AA^"_%W]LKY,G^N09) X8<#=['D9'XCT
M'322"(%V(  )))P !U.:\4TRZ;1+E7;(,4F' P3@':X].F1U_'O7H_Q#OS:6
MA5<YE94R#C .6/UR%P1Z'\*&M04M#AO%'BZ36F*J2L(X"9Z\YRV.IXZ=!V[D
MPV?@V[O$$R1DJPR"65<CUP2#]/4<]*T_AQHXO)S<-@B  @?[39VG!!Z8)[$'
M!KU*ANPE&^IX\D5YX5<2E60$C/.8VZX4[20>,\9R.HQUK)U"[^V2O/C'F.S8
MSG&XDXSQZU[?J%BM_&T#_=<$'I^8SGD=1Z&O#KRU-H[0MC*,RG'3*G!IIW%)
M6/=Y(Q*"C $$$$$9!!ZC%>)7]H^AW!CS\\+@J<#MAE;'(Y&#CGT->WUYW\4-
M)",EXH^]\KGCJ.5]R2,C//  X[J+*DM#NM+OQJ$27"XPZ@X!S@GJ,^QX/N*F
MN+A;=6E<X5 23UP ,GI7&_#+5O.C:T8C,1RO(SM8G(QUX/?G[P''%6OB/JQL
M[<0J<-,<=\[1RW(_ '/4$\>BMK8=]+GG5Y.^L3EP"7FD^4$Y^\<*N3CIP!T&
M/2O:=/L5L(U@3[J  =/S.,<GJ?4UYO\ #32_M$YN2>(1T]2X(';IC/ISCWKU
M"G(4%U"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"OJ%BM_&T#_ '7!!Z?F,YY'4>AKR+Q!X8ET
M5OG&8R<*XZ'OT['V/H<9 S7LM8=IXRMKJ4VJO\V0 2/E8^S?ISC)QMS33$SQ
MZNCTKQ[<V) 9O,0=GY/7)^;[V>PSD#TZ5W.H^ [6]^;:4)(YC.WH,8VD%1^
M!S^->;^(M$_L:4V^\/P#D<$9[$9.#^/0@]ZJZ8MCU/P]XCCUM-T>0R@;U.?E
M)SWQ@]#C';J >*YCXJ2$"%<G!,A(SQD;<''MD_F:YCP??FSNHF&<.P0@'&0_
MR\^N"0<>H_&NS^)FG>? MP,YB;GD8VO@$^O4*./4_@K68^AYG6__ ,)Y>_\
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MSG/SC/\ ">"%R0<XR.]>1UH7.L-<01VAX6$N>">=QR,CU'.#Z''KF;POI/\
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MH]3TC2UTN);9"2J9P6P3R2>P'K5RBBI+"O(/'O\ Q^R_\ _]%K7K]>0>/?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.<X.#QMU]+\-6^EL984VL1@G<QX)![D^E:E#>H6/ JO1ZY<1@*LL@    D8
M =!C->NZCX<M]1YEC4DD$D?*QP,#++@GCMG'Y5A?\*QMO[\G_?2__$4^9!8\
MQKT3X;Z ]MNO9 1O7"#U4D$L1CO@8YZ9.,$&M_3?!]KIY#I&"Z@?,Q+'(P=V
M#P#D=0!CMBMJAL$CD/B=_P >R?\ 79?_ $%Z\QKW'5-)BU11%,NY0<@9(Y (
M[$>M9G_"!V7_ #R_\??_ .*H3L#1?\/_ /'M#_UQC_\ 015RX@6X5HG&5<$$
M=,@C!Z46\"VZK$@PJ  #K@ 8'6I*D9XAK.DOI4K0.#P>"1C<O9AUZ_7@\=15
M&O<=2TB+4UV3(& Z9ZCIT(Y&<<X/-<])\,[9R2&D )/ 9<#VY4G\R35<PK&;
M\*O^6_\ VS_]GK0^)W_'LG_79?\ T%ZW]*T&'2=WD+MWXS\S'.,X^\3ZFI-4
MTF+5%$4R[E!R!DCD CL1ZTKZA;0\.KVWP_\ \>T/_7&/_P!!%4/^$#LO^>7_
M (^__P 56W;P+;JL2#"H  .N !@=:&[@D25Y7\0])^QW'G #9,,C  ^88##^
M1)XR3]:]4JCJFBPZJ LZ!@IR.2",]>00?PZ=/2A.PV>(5Z)\,M)V(]XP.6.Q
M<@CY1@DCL<GCIP5Z]:VO^$#LO^>7_C[_ /Q5:]A8)8(((AA%S@9)ZDD\DD]3
M3;$D6*Y#XG?\>R?]=E_]!>NOJGJFDQ:HHBF7<H.0,D<@$=B/6I0SPZO;?#__
M ![0_P#7&/\ ]!%4/^$#LO\ GE_X^_\ \56W;P+;JL2#"H  .N !@=:;=Q)!
M<0+<*T3C*N"".F01@]*\4UG27TJ5H'!X/!(QN7LPZ]?KP>.HKV^J>I:1%J:[
M)D# =,]1TZ$<C..<'FA.P-'AU=]\*O\ EO\ ]L__ &>M*3X9VSDD-( 2> RX
M'MRI/YDFMW2M!ATG=Y"[=^,_,QSC./O$^IIM@D:%<I\1=*-Y;B91EH3GOG:>
M&X'X$YZ 'GUZNL+QGJR:?;.K$;I59%7/)W#!/?H#GTZ#.2*2&SQ^NE\ :3]O
MN0[ [81OZ'&X'Y1D8QSS[[2,8S7-5ZI\/-)^QV_G$'?,<G((^49"C^9!XR#]
M*I[$HZFBBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !5.XT:"X8R/$C,>I9%)...I%7** ([>W
M6W41HH51T"@ #//05)110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 1SMM!(JI]I;U_E5JX&5(%4_*/H?RH =]I;U_E1]I;U_E3?*/H?RH\H^A_
M*@!WVEO7^5'VEO7^5-\H^A_*CRCZ'\J '?:6]?Y4?:6]?Y4WRCZ'\J/*/H?R
MH =]I;U_E1]I;U_E3?*/H?RH\H^A_*@!WVEO7^5'VEO7^5-\H^A_*CRCZ'\J
M '?:6]?Y4?:6]?Y4WRCZ'\J/*/H?RH =]I;U_E1]I;U_E3?*/H?RH\H^A_*@
M!WVEO7^5'VEO7^5-\H^A_*CRCZ'\J '?:6]?Y4?:6]?Y4WRCZ'\J/*/H?RH
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M[2WK_*F^4?0_E1Y1]#^5 #OM+>O\J/M+>O\ *F^4?0_E1Y1]#^5 #OM+>O\
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M^TMZ_P J/M+>O\J;Y1]#^5'E'T/Y4 .^TMZ_RH^TMZ_RIOE'T/Y4>4?0_E0
M[[2WK_*C[2WK_*F^4?0_E1Y1]#^5 #OM+>O\J/M+>O\ *F^4?0_E1Y1]#^5
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MIOE'T/Y4>4?0_E0 [[2WK_*C[2WK_*F^4?0_E1Y1]#^5 #OM+>O\J/M+>O\
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M [[2WK_*C[2WK_*F^4?0_E1Y1]#^5 #OM+>O\J/M+>O\J;Y1]#^5'E'T/Y4
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M[2WK_*F^4?0_E1Y1]#^5 #OM+>O\J/M+>O\ *F^4?0_E1Y1]#^5 #OM+>O\
M*C[2WK_*F^4?0_E1Y1]#^5 #OM+>O\J/M+>O\J;Y1]#^5'E'T/Y4 .^TMZ_R
MH^TMZ_RIOE'T/Y4>4?0_E0 [[2WK_*C[2WK_ "IOE'T/Y4>4?0_E0!)'<,2!
MGO5VJ$<9!'!ZCM5^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[/-#'S-V-@!^[C.<D>M &Q17(?\ "SK;^Y)_WRO_ ,71_P +.MO[DG_?*_\
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M/$\6A[/-#'S-V-@!^[C.<D>M &Q17(?\+.MO[DG_ 'RO_P 71_PLZV_N2?\
M?*__ !=.S"YU]%<I!\2K65@I#J#W91@?]\L3^E=/!<+<*)$8,IZ%2"#CCJ*5
M@)**** "BFR2",%F(  )))P !U.:YC4OB+;6A*)ND(!Y4#;D9&-Q/Z@$8Z9H
M ZFBN _X6K_TP_\ (G_V%7M.^)D$_$RM&<GD?.N,=R #UXX4_7T=F*YV-%1P
M7"W"B1&#*>A4@@XXZBI*0PHK"UWQC#HKB&17)*AOE"D8)([L/2LW_A9UM_<D
M_P"^5_\ BZ=@N=?17(?\+.MO[DG_ 'RO_P 74D'Q*M96"D.H/=E&!_WRQ/Z4
M687.KHJ."X6X42(P93T*D$'''45)2 **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH ***Q=7\76^E.(9&.\D9"C.T'N?
M\.6P00* -JBH;.\2\031D,C#((_S^8Z@\&IJ "BN6U_Q_%I;F%%,CJ?FP=JC
MKD9P>1W&,>^01572?B0M[*L#Q%=Y"@A@W+$ 9!"\<]>?I3LPN=G16?K&NQ:0
MOF3-C.< <L2!G ']3@#(R1FC1]=BU=?,A;.,9!X8$C."/ZC(.#@G%(#0HHHH
M **** "BBB@ HHHH **** "BN6O/B);VCM"RR91F4X"XRIP?XJZ.SNA=HLRY
MPZJPSUPPR*+ 345A:[XQAT5Q#(KDE0WRA2,$D=V'I5O0M=36D,T88 ,5^8 '
M( /8GUHL!I4444 %%%% !1110 445RUY\1+>T=H663*,RG 7&5.#_%0!U-%0
MV=T+M%F7.'56&>N&&14U !1110 455U'4X]-3S9F"KD#)R>3V &2?P[<]*IZ
M'XG@UG/E$[@,E6&& SC/<'\"<9&<$T :U%%% !1110 4444 %%%% !116%KO
MC&'17$,BN25#?*%(P21W8>E &[15/2=475(EN$!"OG ; /!([$^E7* "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHJGJVJ+I<37#@E4QD+@GD@=R/6
M@"Y17.:3X[@U25;=%<,^<%@H' )[,?2NCH **** "BBL#_A.K3S?(W_\#P=F
M<XQN_7/W<?Q4 ;]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1574=3CTU/-F8*N0,G)Y/8 9)_#MSTJGH?B>#6<^43N R5888#.,
M]P?P)QD9P30!K4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16%?^-;6RD\AV.02
M&*@E5('0D?EQG!X.*VXY!( RD$$ @@Y!!Z'- #J*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BFR2",%F(  )
M))P !U.:XJ^^*$<3;8HRZC^(MLSSV&#Q]<'V%%@.WHKG/#'C-=<8P["CJ"W4
M,N 0.O!SD],?C71T %%%% !1110 45#>70M$:9LX168XZX49-<Y9_$2WNW6%
M5DR[*HR%QEC@?Q46 ZFBBB@ HHHH **PK_QK:V4GD.QR"0Q4$JI Z$C\N,X/
M!Q6W'() &4@@@$$'((/0YH =1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !114-Y>)9H9I"%11DD_Y_(=2>!0!-16+I'BZWU5S#&QW@G 88
MW =Q_APV 216U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<YJWCN#2Y6MW5
MRR8R5"D<@'NP]: .CHJ&SNA=HLRYPZJPSUPPR*FH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(RN.W')]<$8K1^&_A\*OV]^K95!QTZ%O7.<CMQGJ#7=TVP2.0_X5C;?WY/\
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MN-V[H <YP/6EK89L445DZYXG@T;'FD[B,A5&6(SC/8#\2,X.,D4AFM17 ?\
M"U?^F'_D3_["KVG?$R"?B96C.3R/G7&.Y !Z\<*?KZ.S%<[&BFQR"0!E(((!
M!!R"#T.:CO+Q+-#-(0J*,DG_ #^0ZD\"D,FHKBK_ .)\41Q#&SC)R6.P<=".
M&)S[@'^D,'Q35F >$A>Y5PQ_(JO\Z=F*YW=%4]*U6/5(Q/$<J?S![@CL1_\
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MZ*X2#XIJS /"0O<JX8_D57^==?INKQ:FN^%PP'7'4=>H/(SCC(YIV"Y<HHK
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M0J1A1110 45R6L?$:"S.R$&4@\D':O<'YL'/3L,$'@UF_P#"U?\ IA_Y$_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>0^//\
MC]E_X!_Z M>O5Y#X\_X_9?\ @'_H"TXB9D:?=_8Y4GQGRW5L9QG:0<9KMO\
MA:O_ $P_\B?_ &%<''&9"%4$DD  #))/08J]_P (_<_\\9/^_;?X532$==_P
MM7_IA_Y$_P#L*/\ A:O_ $P_\B?_ &%<C_PC]S_SQD_[]M_A1_PC]S_SQD_[
M]M_A19!=F?7??"K_ );_ /;/_P!GK@:[[X5?\M_^V?\ [/0]@1W]>)>(/^/F
M;_KM)_Z$:]MKQ+Q!_P ?,W_7:3_T(THC9O\ PQ_X^7_ZXM_Z$E>F22",%F(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGK[5T^KZDNF1/<-T09QZGH!T.,G SVKSWX8_\?+_ /7%O_0DKH?B9(4ME )
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M\'V4D;XB<#OM)SGW^8D<=.,]>>OH>XT%%%%( HHHH \Q^)W_ !\I_P!<5_\
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M%*["QF^'M,?38$@D<NRCKV'^R.^!VSS]!@#S/QY_Q^R_\ _] 6O7J\A\>?\
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M(\+&&3.8R5P3G&"<@=NN>G&>:]WKRWXE0+%=!@.7C4GW.67^0%"8-'9^ _\
MCRB_X'_Z&U;]8'@/_CRB_P"!_P#H;5OU+&%<M>?#NWNW:9FDR[,QP5QECD_P
MUU-% 'AFEVHNYHX6SAY$4XZX9@#7I5G\.[>T=9E:3*,K#)7&5.1_#7G?A_\
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MG&#TSGG&":[+0?B0ER1%<J$8G&]?N<YZY.5[#.2.YP*>H:'9QQB,!5
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M7(89';*LN>1R,C//J*]MKQWQK L%Y*JC )!_%E#'\R37J7A__CVA_P"N,?\
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MY6,GYE/) Y/RM^0&0<<DD]#V-G9I9H(8P%11@ ?Y_,]2>37$:/\ $W>=MT@
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M ,?L7_ __0&KUB\NA:(TS9PBLQQUPHR:\G\!_P#'[%_P/_T!J[_QY_QY2_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO_+#_MI_[)7?UQ'Q*T^6\\GRD9]OF9V*6QG9C.!36XF6/AC_ ,>S_P#79O\
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MF5N.1C:F0#Z]2PY]!^.)\2=',$PNQDK* #[,HQCI@9 &.<DANU>E1QB,!5
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ME ZXX; X!_QY..,'C'G<^D76CL9"CH4_C7.!GC[Z\<YQU]J-PV/9Y)!&"S$
M $DDX  ZG-8^G>*X-0G>UC8$J!@YX8\[MOKCCZ\D# S7EG^DZO\ \])MG^])
MC/YXSC\<5UWA?X?/"ZW%R=I0AE52"<JV?F/(QQT&<YZC&*5K!<[^O$O$'_'S
M-_UVD_\ 0C7MM>/ZYH=Q)<3,L4A!ED((C8@@L<'.*<09[!1114C/(?'G_'[+
M_P  _P#0%KT[P_\ \>T/_7&/_P!!%>>^--'GN+N21(G93LP51B#A%'4"O1-#
MC,=O"K @B*,$$8((49&*I["1>HHHJ1GBVNZ6VB7#1 D;3N1N0<=5.<#D="1W
M!QTKU/PWKZ:U$)%(W@ .O3#?3)X/8^GN"!#XF\*QZZHR=LB]' SQW!&1D>G/
M!Z=P?-K[PU=:4V2C?)\P= 2H"G[VX=.F><$=2!5;BV/8Y)!&"S$  $DDX  Z
MG->6^/\ 7TU258XB"D0(W#NS8S@YY' P?7/48-8WVBYU;]UNDEQ\VW+/C'&<
M<^N,^]=/X?\ AP\C>9=_*JG[@()8?[RG@?J>>G!HM8-S;^'6E&SMS,PPTQSW
MSM'"\'\2,=01SZ9?Q5_Y8?\ ;3_V2N_KB/B5I\MYY/E(S[?,SL4MC.S&<"DM
MP>Q8^&/_ ![/_P!=F_\ 04KKZY;X=V;VENRR*R$RDX92IQM7G!KJ:'N-!111
M2 P/'G_'E+_P#_T-:\QT#5/[+G2XQD(>1UX(PV.1S@G'O7IWCS_CRE_X!_Z&
MM>?>$-#36I'@<D?NB5([,&4 X[]>1Z>AP12V$SUBQU"._7S8F#*>X/MG!]#S
MT/(J/5=5CTN,SRG"C\R>P [D_P#US@ FO)[S1KO0&+8= !@O&3MP3@?,O3)
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M22IP,5Y;H>AW$=Q"S12 "6,DF-@  PR<XH0,]@HHHJ1GB7A__CYA_P"NT?\
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MT$>8>!CL0.O.>>,8'6O3*3&CR'QY_P ?LO\ P#_T!:].\/\ _'M#_P!<8_\
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M]8LA#)D221(3GY?G #<C''S#D8Z9Q7F&A:HVB7"RD$;3M=>0<=&&,CD=0#W
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M<5YYX.U_^QIPSD^4XP_4_1L ]C]3@G R:]@K@O$_P\\PF>TQDD9CX YZE22
M/H>.N#T%),&=S!<+<*)$8,IZ%2"#CCJ*COM0CL%\V5@JCN3[9P/4\=!R:\:_
MTG2/^>D._P#WH\X_+.,_AFI(-(NM882!'<O_ !MG!QQ]]N.,8Z^U/E"YZKH'
MB"/6D,D?!!(*G[PY.TGZCGC(ZC)P:=XCT[^T;>2 9RR\ $#++\RC)XY(&?;T
MK*\(>#?[$)F=LRL"I"_< )![@$GCKQZ8[UT](9XIX>U@Z1.DXS@'# =U/48R
M,^HSQD U[+9WB7B":,AD89!'^?S'4'@UR'C'P-]M)N;8#S"?F3( ;/\ $,X
M/KV/7K][@_W^DM_'$Y'^TC$$_@<9'Z4]Q;'LNJZK'I<9GE.%'YD]@!W)_P#K
MG !->,:I?G4)7N&SEV)P3G /09]AP/85IV'AB[UMO,(;Y@#YDI(!&.#DY+<#
M' /;H*-:\)364K11)(Z*%^8(Q!)4$]!CKGUQTR:%H#/4/#__ ![0_P#7&/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*;)&) 58 @@@@C((/48IU% 'FOB/X>R6[-+:C='UV9^<=20,_>'ISNYQ@]3R
M$]NUNQC=2K#J&!!&>>AKWFBGS"L>"1QF0A5!))   R23T&*Z?0? $]\0\P,<
M>>=W#D<YPO;I_%CKD UZI13Y@L0V=FEF@AC 5%& !_G\SU)Y-3445(PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M .@-7KU-JPD%%%%(84444 %%%% !1110 445Y;H_C2[N)XHGDRKR("-B#(+
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ ILD@C!9B  "22<  =3FH=0OEL(VG?[J D]/R&<<GH
M/4UY!K_B276G+.2$S\J _*,9Q]3SR>OT& &E<39ZO_PD%M_SVC_[^+_C4UKJ
MD-V=L<B.0,X5U8X]< UX913Y0N>^U'/<+;J9'8*HZEB !GCJ:XSX?:Q=7N8Y
M/GA7/[QR=P)Y"@\[OH>@/7H#L>//^/*7_@'_ *&M*VHR_P#\)!;?\]H_^_B_
MXU<@N%N%$B,&4]"I!!QQU%>#5L-XGE%NMBAVQ@,&QU;<Q;KV'.,#KSG(. ^4
M5SU>37+>,E6EC!!((,B@@CJ,9J:TU"*\SY3J^W&=C!L9Z9P:\*IT<AC(9200
M000<$$=#FCE"Y[W17'>"/&+:F3:SX,@!*MP-P[C QR/8<@'/3)[&I8PJ.>X6
MW4R.P51U+$ #/'4U@>,/%G]AJJ( TK\@'H .Y (//0=._/&#Y;?:A)?MYLK%
MF/<GWS@>@YZ#@4TKB;/9?^$@MO\ GM'_ -_%_P :N07"W"B1&#*>A4@@XXZB
MO!JL6.H26#>;$Q5AW!]\X/J..AX-/E"Y[K16%X5\5)KB8.%E4?,O_LP]OU!X
M/8G=J1A4<]PMNID=@JCJ6( &>.IK"\6^+1H0554-(X. 3@ #H2.O7H.,X/(Q
M7E=]J$E^WFRL68]R??.!Z#GH.!32N)L]E_X2"V_Y[1_]_%_QJU:WB78W1LK@
M'&58,,^F17A%207#6["1&*L.A4D$9XZBGRA<]YJGJ5Q B^7<,@5^TI4 XP>C
M=<<5A>"_%QUG,$H E10<C^(9P3C&!CC//)/  XK)^*O_ "P_[:?^R4K:A<W-
M-ATW36\R)H0WJ90Q'4<%F..O..O>NCKP*O;?$'_'M-_UQD_]!-#0)F!\3O\
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MH>'_ /CYA_Z[1_\ H0H:N),]CNM4AM#MDD1"1G#.JG'K@FHX]<MY"%66,DD
M 2*22>@QFN4^)ND[T2\4'*G8V 3\IR03V&#QTY+=>E>?V\[6[+*APR$$'K@@
MY'6DE<=SWFBJ^GWRW\:SI]UP".GY'&>1T/H:DN)UMU:5SA4!)/7  R>E(97G
MUB"W8QO*BL.H9U!&>>A-$&L07#"-)49CT"NI)QST!KQ2\NC=NTS8R[,QQTRQ
MR:[CX7Z7_K+PG_IF!^3,3Q],<^N1TJFA7._HHHJ1A1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M49^I/JQY$@;.V_X6=;?W)/\ OE?_ (NM+1_&EMJAV*Q1R<!9,*3T P<D')/
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M+VYW@#[V<8P3Z5L5@>%?"O\ 8&_Y]_F;?X=N-N?<^M9?COQ<UA_H<!Q(PRS
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M8QK N2J  ;CD\>_^0.@ '%)V!&5KOC&'17$,BN25#?*%(P21W8>E6;;Q'#+
M+UCLC;.-^ ?E)&, G)X. ,DUPOQ._P"/E/\ KBO_ *$]8FFV4^N%+6/D1@X!
M("J"WS'\SSC)^N!3MH%SO)/B9;(2 LA )Y"K@^_+ _F :T-'\:6VJ'8K%')P
M%DPI/0#!R0<D\#.?:N=_X55_TW_\A_\ V=<UXB\*RZ&07PR,3M=>GT/H<<XY
M'H3@T60:GLE%<EX"\3G4D-M*298QD$CJO R3W()P>F1@\G)K=UW6%TB)KA^<
M< 9 ))Z#G\SUP 3@XJ;#)-2U>+3%WS.%!Z9ZGIT Y.,\X'%<Y_PLZV_N2?\
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MI ]<9.1Z^G7IDB;X;:P8)C:')64$CV91G/7 R <\9)"]J5@N>F4V201@LQ
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MX _LF9;GS=VS=QLQG*E>NX^OI1\3O^/9/^NR_P#H+TM+@:NA^*X=8#L@91$
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MM$98Y5<[AD%5!7K@C)8<CO\ 4>M87PWU][G=92$G8N4/HH(!4G/;(QQTR,X
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MZ'@Y!^A'7H02[)A=GM-4]6U1=+B:X<$JF,A<$\D#N1ZUE>"_$9UJ(^9CS8R
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M#_UVC_\ 0A0D#9[;7+7GQ$M[1VA99,HS*<!<94X/\5=37B7B#_CYF_Z[2?\
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M>4O_  #_ -#6J?@WQE_:W^CS8$J@8.?O]<G&, @8R,\\D  <7/'G_'E+_P
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M "[X!STR>:HH2L%R]HFH_P!FSQW'.$89P 3M/##GCD$BO;9)!&"S$  $DDX
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M _\ 0UHO=AT. \!_\?L7_ __ $!J]>KR'P'_ ,?L7_ __0&KUZB0(\"KWVO
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M<"DV%CSOQ[X7DBE:\C7,;\MM'W2!R2!V.,EO7.>Q.3H_C2YTL;%8.@& LF6
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MKQ+Q!_Q\S?\ 7:3_ -"->VUXEX@_X^9O^NTG_H1HB#/7?#__ ![0_P#7&/\
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M8_\ T$5H5A^#-26_M8R.#& A'N@ ]!U&#[9QVK<J6,\Q^)W_ !\I_P!<5_\
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M[Y-.Z \B\/\ _'S#_P!=H_\ T(5[;7B7A_\ X^8?^NT?_H0KVVB0(\A\>?\
M'[+_ , _] 6N_P# ?_'E%_P/_P!#:N \>?\ '[+_ , _] 6N_P# ?_'E%_P/
M_P!#:A[ MSG_ (J_\L/^VG_LE'PJ_P"6_P#VS_\ 9Z/BK_RP_P"VG_LE'PJ_
MY;_]L_\ V>CH'4[75+ :A$]NV,.I&2,X)Z''L>1[BO'M,NFT6Y5VR#%)A@,$
MX!VN/3ID?U[U[77EOQ%TH6=P)E&%F&>V-PX;@?@3GJ2>?11!GHVH:FMI"UUD
M%50L/F #<?* >?O< ?6O'M(LFU:X2(Y)D?YCGYL=7.3WQD_XUJZEXD^TV,-I
MD[@Q#<@?+'C8,#J"&')[J>IYK6^&.E!V>\8?=^53QU/+>X(&!GC@D<]GL@W/
M0(XQ& J@     8  Z#%.HHJ1A6%K_C&#1LQMEI0/N+[@D9/0?J<$'!%;M>'6
MZ-JDZJY^::0 MCN[<G QZ].*:5Q,ZN[^*,K8\J)5ZYWDO],8VX_6L'4_%]SJ
M2M%(XV.>5"J!P<@9QG@CUSZUZ98^$K6S7RQ$K>I=0[$XQG)'Z# ]!69\1]26
MWMO(/WIB /8(0Q/3Z#''7/:FF@.<^&/_ !\O_P!<6_\ 0DKTJX@6X5HG&5<$
M$=,@C!Z5YK\,?^/E_P#KBW_H25Z=2EN"/$+R!]'G* D/#)P2,?=.5;!SUX(Z
MC'K7LMGJ2740NE(",N[)(X'?)S@8[\\$&N%^)ND['2\4###8V !\PR03W.1Q
MTX"]>E9=KXD\O3WL\G?Y@4<@81LL<8Y/((/LPY[4WJ&QD7D[ZQ.7 )>:3@$Y
M^\<*N3CIP!T&/2O9]/L5L(U@3[J  =/S.,<GJ?4UYS\-=+^T3FX)XA'3U+@@
M=NF,^G./>O3J4@1Y+\0)VEO'4GA @'L-H;^9->A>$K%;.UB"?Q(KD\9)< GI
M^0]@!7"_$?36M[GSS]V8 CV* *1U^ASQUQVKJ? &O"^@%NQ'F0C&.Y4?=.,#
MI]WOT!/6F]@6YU-8OC"P%Y:RJ<912X)&<%/FX],@$9]#^%;5<I\0M:6T@-L#
M^\EP, X(7/)X['&W'&<GK@U*&SDOAY=&&[51C$BNISZ ;N/Q4?A7<^//^/*7
M_@'_ *&M<=\-M.^T7!G.<0J>01]YOE (Z]-W3N/S['QY_P >4O\ P#_T-:I[
MB6QP'@/_ (_8O^!_^@-7H7C6=H+.5E."0!^#,%/Y@FO/? ?_ !^Q?\#_ /0&
MKTCQ58&^M98ESDKD8&22I# 8]\8_&A[@MCS_ .'=BMU=9?GRT+@<8R" .OIG
M(]P#7JU>->%-:_LBX64_</RO_NGJ>A/!P>.3C'>O8XY!( RD$$ @@Y!!Z'-*
M0(=7C7BVQ6QNI8DX4$$#CC<H; QC@9P/:O7[R\2S0S2$*BC))_S^0ZD\"O%M
M;U'^TIY+CG#L<9 !VCA1QQP !3B#/7_#_P#Q[0_]<8__ $$5H5G^'_\ CVA_
MZXQ_^@BM"I&%>8_$[_CY3_KBO_H3UZ=7F/Q._P"/E/\ KBO_ *$]..XF;?PO
M@58))0/F:3!/LJ@C_P!"-=G7GWPRU@)OLFP"QWK[G ##KZ $ #H&)KT&A[@C
M+\3P+/:S*PR!&Q_%1N'Y$"O+O"-W]ENX7QG+[>N/OC9G\,YKT;QMK"Z=;LIY
M:8,BC('W@06^@_G@<9S7 >!;#[9=ID96/+GG&-H^4]?[V/Z\9IK8&>G>(/\
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M_A5_RW_[9_\ L]=!X\_X\I?^ ?\ H:US_P *O^6__;/_ -GKH/'G_'E+_P
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MC]!S[UM5F^'-._LZWC@.<JO()!PS?,PR.."3CV]:TJ3&%<!\5?\ EA_VT_\
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MI[J9F.2)&'X*=H_( 4DKL-CI;KXI.P_=Q*ISU9BPQ] %_G^%8NH>.;J]#(6
M1P0555Q@C!Y(+<_7Z5Z#I/@RVT] I19&P-S2*&R?8'('7MVQDD\T>+[Y-,M'
M7  =?+51P/F!'88&!D^G&*=T!Y]X#_X_8O\ @?\ Z U>O5Y#X#_X_8O^!_\
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MSTJSO$$T<43(PR"(U_P_,=0>#5,E'#_\+.N?[D?_ 'RW_P 77,:A>&]D:<@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/3.>&Q'>_P#">67_ #U_\<?_ .)KA/&'BS^W&5$!6).0#U)/<@$CCH.O?GG
MYZ2,QDJP(()!!&"".HQ4UCI\E^WE1*68]@/?&3Z#GJ>!0DD%PT^Q:_D6!/O.
M0!U_,XSP.I]!7N/V==OE;1LQMVX&W&,8QTQCC%<YX,\)?V,OG2?ZYQ@@'A1P
M=ON>.3^ ]3T]2V-(\0UG27TJ5H'!X/!(QN7LPZ]?KP>.HK9\&>+?[&;R9/\
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M?2#B92!G 8<J>N.??&<'!QU%-.Y.QZ9_PGEE_P ]?_''_P#B:YW7/B4=P6T
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M0-Q&3CHHSCT XKTCP5X=DT6-O-;)DVG8.BD9SSG!)&,X';J1@UT,<8C 50
M   ,  =!BG4-A8*\S\3^ 'M"9K8%XR1\@R77/MW _/GD<$UZ910G89XQ8>*K
MJQ&V.5L8 PV&  Z !@<?ABH;N_N-;<!RTC\X4#/;G"J,#@<X';)KV6[T^*\Q
MYJ*^W.-ZAL9ZXR*D@MUMU$:*%4= H  SST%/F%8Y3P9X,;26^TS']X1@*I.
M#C.[U/MR!C/)QCKZ**D9XUXC\.2:-(RD'RL_(_4$'. 3@#=@<CCID<8-'_"7
M7>SR?-;;Z\;NN?O_ 'OUZ<=*]EJK:Z7#:'='&B$C&515./3(%5S"L6J\2\0?
M\?,W_7:3_P!"->VT4D[ T9_A_P#X]H?^N,?_ *"*T***0SRWXBZ4+.X$RC"S
M#/;&X<-P/P)SU)//I5\!Z=]MNE)QB(%SDD?=P%QCT8@^F!^%>N44[Z"L%%%%
M(9P'B_P(TC-=VW.[+,G.[.<DKZYY./RSD <G8:U<:,2D;LAR05(R,\9^5@0#
MQC.,]J]KJ&ZLTNQMD57 .<,H89]<&G<5CQR]U^YU8B-W9MV!M7@'G(^5< G/
MMGI[5UG@;PC/9R"\E)C !&SNP9>^#Q@X.#DY'(&!7;VMFEH-L:J@)SA5"C/K
M@5-0V%@KP*O?:*$[ T%%%-DD$8+,0  223@ #J<TAGD_CW2C8W+.!A)OF'7J
M?O<GONYP.@(^E7/AKI?VB<W!/$(Z>I<$#MTQGTYQ[UF^,=?_ +9G+(3Y2#"=
M1]6P3W/T. ,C(KT3P;I1TVV1&&';+-UZMTR#T(7 (]1^-4]A=3<K%\7ZM_9E
ML[Y(9QL7!(.Y@><CI@9/X8SFMJO+?'^HMJ%R+90<1?*HP<EFP20, \\ =0<9
M'6DD#)/AU)<-*8XFQ"/FD!&5] !Z,?J.F3G&*].K)\,:'_8T @R"Q)9B,X+'
MZ^@ ';.,X!-:U#8T%8'CS_CRE_X!_P"AK6_12 \0T72SJLJVRD N&P3TRJEA
M^>,>W7!Z5:AO[OPXQB!:,\Y4@%3SC< 05/3&X>G!Q7LM-DC$@*L 00001D$'
MJ,57,*QXM?ZU<:R0DCLYR % P,\X^50 3SC.,]JZSP5X*>%Q=W(V[>40X))(
MX8CG&,\#KGDXQSV]II\5GGRD5-V,[%"YQTS@58I-A8*YKQIX5_ME!)'@2Q@X
MZ#</[I/\NV2<]<CI:*0SQ*TO[C1'(0M&_&5(QVXRK#!X/&1WR*MR:M>>(2+?
M<TG^RH '4<MM & <<MP/:O7+JS2[&V15< YPRAAGUP:=!;K;J(T4*HZ!0 !G
MGH*KF%8\>\2Z#_8CI"3N8QAF/;)9A@>PQWZ]>.@]&\!_\>47_ __ $-JWZ*3
M=PL%>->(_#DFC2,I!\K/R/U!!S@$X W8'(XZ9'&#7LM%"=AM'C7_  EUWL\G
MS6V^O&[KG[_WOUZ<=*]EJK:Z7#:'='&B$C&515./3(%6J&Q(*S_$'_'M-_UQ
MD_\ 036A12&>0^ _^/V+_@?_ * U>O444V[@@KQ+P_\ \?,/_7:/_P!"%>VT
M4)V$T%<=XQ\$'4V-U 1YA'S*QX; P,'L> .P/7(YSV-%*XSQ2UU.YT5MBL\9
M!R5.0,D=2C<=/4>GM4E]XBNM7Q#([,"<!5 &22,#"@9Y QG//2O8Y[=;A3&Z
MAE/4, 0<<]#4=II\5GGRD5-V,[%"YQTS@57,*QY[X4\"23LMQ<#;&ISL8?,V
MT\ J1PI[YY([8(->E444F[C/,?B=_P ?*?\ 7%?_ $)ZZ_P'_P >47_ _P#T
M-JWZ*+Z"L%<A\3O^/9/^NR_^@O77T4D,X#X5?\M_^V?_ +/7?T44,#@/BK_R
MP_[:?^R5H?#'_CV?_KLW_H*5U]%.^@K!7D/CS_C]E_X!_P"@+7KU%"=ALP/
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MI'9AD X[]>1Z>AP1Y9JFB7'AYPQRN.DD9.WD'@-Q@]>.#^%>RT4T[":/'?\
MA-;S;Y?FG&,=%W8QC[V-V??.>^<TS2O#EQK;;E!P^XF1\A3SS\V#DD^F3G\:
M]9_L>#=YOE)OSNW;%W9SG.<9SGG-7*?,%C/T+1UTB);=.<<DX ))ZGC\AUP
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *;)&) 58 @@@@C((/48IU% #8XQ& J@
M   8  Z#%.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** /._B)I<UW
M<*T<;N!$!E49AG<W&0*ZCP7;M;VD<;J58;\A@01EV/0UN44[A8****0!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %>*2>&[F,E3#)D$CA&(X]P"#]1Q7M=%-.PFCSWPCX"9F%Q=KA1
M@K&>_?+#L!_=/)/4 #!]"HHI-W&%1O;J["0J"R9VD@$C/!P>V>]244 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5R7B?P$FI$SPD)*Q&0?N'U/ )!/J.#CD9)-=;10!XQ=>%+JV.
MUH7)QGY1O'YKD?AUHM?"EU<G:L+@XS\PV#\VP/PZU[/15<PK',>$O!BZ-^^E
MPTQS@C[JCVR!R>Y_ =\]/114C"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KR_QOH<\UV\B1NRL$(*J6'"@'IG'(/!Y_"O4**:=@/)]
M\#3Z@X\U6CB!^8L,-QC@*>><]<8'/4C!]2L[-+-!#& J*, #_/YGJ3R:FHH;
MN%@HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %1SVZW"F-U#*>H8 @XYZ&I** ,__ (1^V_YX
MQ_\ ?M?\*N06ZVZB-%"J.@4  9YZ"I** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** &R1B0%6 (((((R"#U&*H_\ "/VW_/&/_OVO^%:%% $-K9I:#;&J
MH"<X50HSZX%3444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% #6;;R:9]I7U_G1<_=/^>]4* +_VE?7^='VE
M?7^=4** +_VE?7^='VE?7^=4** +_P!I7U_G1]I7U_G5"B@"_P#:5]?YT?:5
M]?YU0HH O_:5]?YT?:5]?YU0HH O_:5]?YT?:5]?YU0HH O_ &E?7^='VE?7
M^=4** +_ -I7U_G1]I7U_G5"B@"_]I7U_G1]I7U_G5"B@"_]I7U_G1]I7U_G
M5"B@"_\ :5]?YT?:5]?YU0HH O\ VE?7^='VE?7^=4** +_VE?7^='VE?7^=
M4** +_VE?7^='VE?7^=4** +_P!I7U_G1]I7U_G5"B@"_P#:5]?YT?:5]?YU
M0HH O_:5]?YT?:5]?YU0HH O_:5]?YT?:5]?YU0HH O_ &E?7^='VE?7^=4*
M* +_ -I7U_G1]I7U_G5"B@"_]I7U_G1]I7U_G5"B@"_]I7U_G1]I7U_G5"B@
M"_\ :5]?YT?:5]?YU0HH O\ VE?7^='VE?7^=4** +_VE?7^='VE?7^=4**
M+_VE?7^='VE?7^=4** +_P!I7U_G1]I7U_G5"B@"_P#:5]?YT?:5]?YU0HH
MO_:5]?YT?:5]?YU0HH O_:5]?YT?:5]?YU0HH O_ &E?7^='VE?7^=4** +_
M -I7U_G1]I7U_G5"B@"_]I7U_G1]I7U_G5"B@"_]I7U_G1]I7U_G5"B@"_\
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MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\
M.J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_SJA10!?\ M*^O\Z/M*^O\
MZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_SJA10!?^TKZ_SH^TKZ_S
MJA10!?\ M*^O\Z/M*^O\ZH44 7_M*^O\Z/M*^O\ .J%% %_[2OK_ #H^TKZ_
MSJA10!?^TKZ_SH^TKZ_SJA10!?%PIXS4M9T74?45HT %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% #67=P:9]F7T_G4M% $7V9?3^='V9?3^=2T4
M1?9E]/YT?9E]/YU+10!%]F7T_G1]F7T_G4M% $7V9?3^='V9?3^=2T4 1?9E
M]/YT?9E]/YU+10!%]F7T_G1]F7T_G4M% $7V9?3^='V9?3^=2T4 1?9E]/YT
M?9E]/YU+10!%]F7T_G1]F7T_G4M% $7V9?3^='V9?3^=2T4 1?9E]/YT?9E]
M/YU+10!%]F7T_G1]F7T_G4M% $7V9?3^='V9?3^=2T4 1?9E]/YT?9E]/YU+
M10!%]F7T_G1]F7T_G4M% $7V9?3^='V9?3^=2T4 1?9E]/YT?9E]/YU+10!%
M]F7T_G1]F7T_G4M% $7V9?3^='V9?3^=2T4 1?9E]/YT?9E]/YU+10!%]F7T
M_G1]F7T_G4M% $7V9?3^='V9?3^=2T4 1?9E]/YT?9E]/YU+10!%]F7T_G1]
MF7T_G4M% $7V9?3^='V9?3^=2T4 1?9E]/YT?9E]/YU+10!%]F7T_G1]F7T_
MG4M% $7V9?3^='V9?3^=2T4 1?9E]/YT?9E]/YU+10!%]F7T_G1]F7T_G4M%
M $7V9?3^='V9?3^=2T4 1?9E]/YT?9E]/YU+10!%]F7T_G1]F7T_G4M% $7V
M9?3^='V9?3^=2T4 1?9E]/YT?9E]/YU+10!%]F7T_G1]F7T_G4M% $7V9?3^
M='V9?3^=2T4 1?9E]/YT?9E]/YU+10!%]F7T_G1]F7T_G4M% $7V9?3^='V9
M?3^=2T4 1?9E]/YT?9E]/YU+10!%]F7T_G1]F7T_G4M% $7V9?3^='V9?3^=
M2T4 1?9E]/YT?9E]/YU+10!%]F7T_G1]F7T_G4M% $7V9?3^='V9?3^=2T4
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MEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH
MB^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+
MZ?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH
M^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z
M?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6
MB@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+
M[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI
M_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[
M,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_
M.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:*
M (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OL
MR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\
MZ/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR
M^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\Z
MEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH
MB^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+
MZ?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH
M^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z
M?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6
MB@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+
M[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI
M_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[
M,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_
M.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:*
M (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OL
MR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\
MZ/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR
M^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\Z
MEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH
MB^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+
MZ?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH
M^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z
M?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6
MB@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+
M[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI
M_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[
M,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_
M.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:*
M (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OL
MR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\
MZ/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR
M^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\Z
MEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH
MB^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+
MZ?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH
M^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z
M?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6
MB@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+
M[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI
M_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[
M,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_
M.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:*
M (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OL
MR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"(6ZCG%2T44 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7(:]X_\ [)F:V\K=LV\[\9RH;IM/KZUU]>0^//\ C]E_X!_Z M-(3.EL
M_BBDCA9(BB$\L'W8]\;1GW[XZ9Z5W->!5WWP_P#%?_+C.WH(B?\ T#/Y;?RS
M]T4V@3._HHHJ1G(:]X__ +)F:V\K=LV\[\9RH;IM/KZT:#X__M:9;;RMN_=S
MOSC"ENFT>GK7(>//^/V7_@'_ * M'@/_ (_8O^!_^@-565A7/7J***D84444
M %%%% !117.>.]6ETN!986VL9 "< \%6/<'TH Z.BO+='\:7=Q/%$\F5>1 1
ML09!8 ]%KU*FU8+A1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M(U#XE?8Y7@\G/ENRY\S&=I(SC97;UXEX@_X^9O\ KM)_Z$::0F>G>%?%7]O[
M_DV>7M_BW9W9]AZ5OUP'PJ_Y;_\ ;/\ ]GKOZ'N-!1112 **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** .'U#XE_8Y7@\G/ENRY\S&=I(SC8?2NPT^[^V1)/C'
MF(K8SG&X XSQZUXQXA_X^9_^NTG_ *&:]?\ #W_'M!_UQC_] %4T3%MLT***
M*DHY_P 5^*_[ \OY-_F;OXMN-N/8^M'A3Q7_ &_YGR;/+V_Q;L[L^P]*Y_XK
M?\L/^VG_ +)1\*?^6_\ VS_]GJK:$W?-8] HHHJ2@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** ,_7M6_LF%[G;NV;>,XSE@O7!]?2N?T'X@_P!K
M3);>5MW[N=^<84MTVCT]:T/'O_'E+_P#_P!&+7 > O\ C]B_X'_Z+:J2T);=
MSU^BBBI*"BBB@#F=?\=Q:1)]GVL[ KNQP ",]^IQ@XX'/W@:W-,U)-2C6XCS
MM<<9&#P<$?@1CT].*Y/Q9X#?5)C<PLH+@;@Y(P0 !@@'J!W[]^<#J-$TH:5"
MELI+! >3QDDDGCZGCV[GK3=K"5[EZBBBD,**** "BBB@ HHHH *X?3_B7]LE
M2#R<>8ZKGS,XW$#.-@]:[BO$/#W_ !\P?]=H_P#T,4TB9.Q[?7,Z_P".XM(D
M^S[6=@5W8X !&>_4XP<<#G[P-=-7$^+/ ;ZI,;F%E!<#<')&"  ,$ ]0._?O
MS@"L-W.LTS4DU*-;B/.UQQD8/!P1^!&/3TXJU5'1-*&E0I;*2P0'D\9)))X^
MIX]NYZU>I#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKR_XH?\?*?]
M<5_]#>NP\!?\>47_  /_ -&-3MH)/6QT%<OXH\;?V%*(/+W[D#9W[>I(QC:?
M2NHKR_XH?\?*?]<5_P#0WH2NPD[([CPOX@_MV(S[-FURN-V[H <YP/6MBN/^
M%_\ Q[/_ -=F_P#0$KL*'N"V"BBBD,**** "BBB@ HHHH **** "BBB@"OJ%
MW]CB>?&?+1FQG&=H)QGGTKE]!^(/]K3);>5MW[N=^<84MTVCT]:Z#Q#_ ,>T
M_P#UQD_] ->8> O^/V+_ ('_ .BVII:$MZH]?KD]3^(L-C,8-K,$+!V&!@CT
M!Z\\'./49KK*X'6OAP]W.TT;J$D;<V[.X%CEL #!]N1Z'U(K#=SNK>X6X594
M.5< @],@C(ZU)4-G:BT185SA%51GKA1@5-2&%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% %74]2338VN),[4'.!D\G 'XDX]/
M7BL/0/'<6KR?9]K(Q+;<\@@#/;H<9..1Q]XFMC6]*&JPO;,2H<#D<X(((X^H
MY]NXZUR_A/P&^ES"YF924!VA"3DD$')('0'MW[\8+5K"=[G;5E^(/$$>B1^:
M_+'[JCJQ_H!W/;W) .I7F/Q0D)N$3)P(@0,\9+-DX]\#\A0E=A)V02?%"X))
M5(P,G (8G';G<,_D/I7:>$]?.N0F9E"E6VG!R"0JDGVZ].?J:YOP9X,M[VW%
MS."YD)P,E0H4E?X2,YQGGV '4GKM-T*'3D:"-?W;DDJWS#E0I'.>#COGJ>W%
M-V%&YS__  LRW\WR]K>7TWX[YQG;UVXYSU[;:["O._\ A5S>=_K!Y&>O/F8]
M,8VY[9S[X[5Z)2=AJX4444AA1110 4444 <OXH\;?V%*(/+W[D#9W[>I(QC:
M?2L?_A:W_3#_ ,B?_85T6O>#8=;<32LX(4+\I4# )/=3ZUF_\*OMO[\O_?2?
M_$52L2^8S_\ A:W_ $P_\B?_ &%'_"UO^F'_ )$_^PKGO&6@IHDRPQ%B#&&^
M8@G)9AV ]*W?#/@.#5+=+EV<,^[(4J!PQ'=3Z4[(5Y7)/^%K?],/_(G_ -A7
M8:#JW]K0I<[=N_=QG.,,5ZX'IZ5S_P#PJ^V_OR_]])_\172:1I:Z7$MLA)5,
MX+8)Y)/8#UJ78:N7****104444 %%%% !1110 4444 %%%% !7/^*_%?]@>7
M\F_S-W\6W&W'L?6N@KS_ .*W_+#_ +:?^R4UN*3LCH/"GBO^W_,^39Y>W^+=
MG=GV'I6AKVK?V3"]SMW;-O&<9RP7K@^OI7'_  I_Y;_]L_\ V>N@\>_\>4O_
M  #_ -&+0UJ)/0S]!^(/]K3);>5MW[N=^<84MTVCT]:["O(/ 7_'[%_P/_T6
MU>OT25@B[H****104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M#Z?\2_MDJ0>3CS'5<^9G&X@9QL'K7<5XAX>_X^8/^NT?_H8II$R=CV^BBBD4
M%<OXH\;?V%*(/+W[D#9W[>I(QC:?2NHKR_XH?\?*?]<5_P#0WII78I.R-#_A
M:W_3#_R)_P#84?\ "UO^F'_D3_["H_ ?AFWU2!I9DW,)" =S#@*I[$>M=)_P
M@5E_SR_\?D_^*IZ$KF9CV/Q1CE;;+&44_P 0;?CGN,+Q],GV-=E9WB7B":,A
MD89!'^?S'4'@UYSXK\!+I<1NH7)5-N5?!/)QD$ >HXQZG/:H?AQJSV]P+7)*
M2AN,\!E&=WY#';/&>@H:5AIM.S/4J***DH**** "BBB@ HHHH **** "BBB@
M HHHH S]>U;^R87N=N[9MXSC.6"]<'U]*Y_0?B#_ &M,EMY6W?NYWYQA2W3:
M/3UK0\>_\>4O_ /_ $8M<!X"_P"/V+_@?_HMJI+0EMW/7Z\__P"%K?\ 3#_R
M)_\ 85Z!7@%$5<)-H]_HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X_7OB#_9,
MSVWE;MFWG?C.5#=-I]?6NPKR#Q[_ ,?LO_ /_1:TXJY,G9'J^GW?VR))\8\Q
M%;&<XW '&>/6K%9_A[_CV@_ZXQ_^@"M"D4%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &?KVK?V3"]SMW;-O&
M<9RP7K@^OI7/Z#\0?[6F2V\K;OW<[\XPI;IM'IZUH>/?^/*7_@'_ *,6N \!
M?\?L7_ __1;526A+;N>OT45Y_P#%;_EA_P!M/_9*25QMV1Z!17'_  O_ ./9
M_P#KLW_H"5V%)@G<S];UN/1H_/ESC( "C))/Y#H">2.GK6?X9\8QZZ3&%*2*
M,E3R,9QPW'J,Y Z\9ZU8\5:!_;</D@[64AE/;(!&#['/;IUYZ'+\&>#&T1FG
ME8%V&T!,[<9!))(!SD?A[YX>E@UN=91112&%%%% !1110!Q^O?$'^R9GMO*W
M;-O._&<J&Z;3Z^M=!H.K?VM"ESMV[]W&<XPQ7K@>GI7F'CW_ (_9?^ ?^BUK
MO_ 7_'E%_P #_P#1C536A*;N=!1114E!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%>0>/?\ C]E_X!_Z+6FE<3=CU^BL_P /?\>T'_7&
M/_T 5H4AG/\ B;QC'H1$94O(PR%' QG'+<^AQ@'ISCK6AHFMQZS'Y\6<9((8
M8((_,="#P3U]:P_&?@QM;99XF =1M(?.W&2000"<Y/X^V.=3PKH']B0^23N9
MB68]LD 8'L,=^O7CH'I86MS8HHHI#"BBB@ KE_%'C;^PI1!Y>_<@;._;U)&,
M;3Z5U%>7_%#_ (^4_P"N*_\ H;TTKL4G9'<>%_$']NQ&?9LVN5QNW= #G.!Z
MT>*/$']A1"?9OW.%QNV]03G.#Z5C_"__ (]G_P"NS?\ H"4?%#_CV3_KLO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_4<\'I]#D#6KQ+3;^309]XR&C8JZ@CD X92>1SCKS@\CD"O:;>X6X594.5<
M@],@C(ZTFK%1=SA_$WCR?2[A[9%0JFW!8,3RH/9AZUU'AG5&U2W2Y< ,^[(7
M('#$=R?2O-/'O_'[+_P#_P!%K7?^ O\ CRB_X'_Z,:FUH)/4K^-O%$NA>7Y0
M4^9OSO!/W=N,8(]:KZ5X]4VQNKK ;S"JK&.3@*>C-VSR<@=.Y&<_XK?\L/\
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M^('B!]+B6.(D/,2-P[*N-V#G@\C!],]#@UR'@KPK_;3F23(AC(SU&X_W0?\
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M3BM"O%O"^LG2)UER I(5\C/R$C=TYXQD8[CN.#[#?WZ:>AGE.U%QDX)ZD <
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MX,UTZ3.O39(0KY.  3][T^7W[9'&<T63"[3U/8:S=<\01:*@DE)Y. J\L?7
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MHJ2@HHHH \O^*'_'RG_7%?\ T-Z[#P%_QY1?\#_]&-7'_%#_ (^4_P"N*_\
MH;UV'@+_ (\HO^!_^C&JGL2OB9T%%%5[^_33T,\IVHN,G!/4@#@ GJ:DHL45
MS_\ PGME_P ]?_')/_B:/^$]LO\ GK_XY)_\33LQ71T%%9>E^)K?5&,4+[F
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ME=-X0UDZO;K*Y!<$J^!CD?IR""<<9/;H.9^*W_+#_MI_[)26XY;!\*?^6_\
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M ?O29P>O100?0@D@]BM9\?Q0N 062,C(R &!QWYW''Y'Z5N:%\.88DS<@N[
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M<D]!CTHB@DSUOPQJ$VHP"XG"J7)*A0P^7L2&)Z\D=B,&M:H[>W6W58D&%0
M=< # ZU)4E!6;KGB"+14$DI/)P%7ECZX!(Z=ST_$@&Y>70M$:9LX168XZX49
M->-37$WB2X&XYDD( Z[5'T&<*.IZ]R<G)II7%)V-^X^*,[,2D:!>P;<Q_,%?
MY"I+'XHRAOWT:E._EY##GKR2#QVXSZBNHTGP/;6"C*"1\8+.,Y[YVG*CVXSC
MN><U?$/@2"\1W@0)-C*[>%) ^[MR%&?48YY/?+NA6D;6C:[#K"^9"V<8W \,
M"1G!']1D'!P3BK&H-(L;&'!D )4,,@D=NJ]>F<\=:\>\+ZR=(G67("DA7R,_
M(2-W3GC&1CN.XX/M-)JPXNYYO;_$R>*0+/&NT'#A0RN.Q^\QY'H?IQUKT:.0
M2@.I!! ((.00>AS7G_Q$\,"/_3X@ ,_O!G')( 8#W)PWO@X^\:I^#_&W]F1M
M;S8*HK-'U!+9SLX!ZDYR>G.<C&&U="3L[,ZKQCXM_L-51 &E?D ] !W(!!YZ
M#IWYXP:O@_Q+=:XY+JBPH.656Y;LH)?\3P>..,@UP7[[Q)<]C+,?HH '\@H]
MSQW->OZ3I,>E1B"(84?F3W)/<G_ZPP !0]$";;,WQEKSZ)"LT04DR!?F!(P5
M8]B/2LGP_P"/3<1S3W6U5BV8V Y);=P 6.3QQT[D\<B3XH?\>R?]=E_] >O/
MM%TE]6E6W0'D\D#.U>['IT^O)XZFA)6$VTSJ;[XHREOW,:A.WF9+'GKP0!QV
MYQZFBQ^*,H;]]&I3OY>0PYZ\D@\=N,^HKHK/X>VD*!'4NP'+%F&3] P ]O;N
M3S6;XD^'<7EM+:@JZ#.S)8-C)(&<MN/;G'&,<YHT"TCK-)U:/58Q/$<J?S![
M@CL1_P#7&00:N5X]X,UTZ3.O39(0KY.  3][T^7W[9'&<UZW>70M$:9LX168
MXZX49-)JQ2=T4]<\01:*@DE)Y. J\L?7 )'3N>GXD \+<?%&=F)2- O8-N8_
MF"O\A6!-<3>)+@;CF20@#KM4?09PHZGKW)R<FO0=-^'-M;IME!D?)RQ+)]
MK?XG/Y!V2)NV<_:_%*93F6-&&.BED.?J2W\OQKN-#\01:TADB)X."K<,/3(!
M/7L>GX@@8>K?#BWN$/D QN <?,64GWSD_ETSG!Z5P5C=S>';C<05>,X9<XR.
MZ]Q@CH>>Q'8T63"[6Y[77!^)O'D^EW#VR*A5-N"P8GE0>S#UKN+>X6X594.5
M< @],@C(ZUY)X]_X_9?^ ?\ HM:45J.3T.SO_'\=A%&6&^:2-&*J<*-P!Y)S
MCKD#D^N,@US?_"T+G^Y%_P!\O_\ %U)X*\%+J*_:[CF(Y"J#C=C@DD<@ ]!U
M)]NO52> +)P0(R"0>0[Y'OR2/S!%/1"]YE?PUX]CU3$,N(Y20 .2K''8]N>Q
M]@"3755XAJ^G-HL[0;OFC((9<CL&4^QY'T/<]:]CT>^^WPQS\9=%)V],X^8=
M^AR/:DT.+N7*XG7OB2EL3%;*'8'&]ON<8Z8.6[C.0.XR*C^)/B![;;91DC>N
MYSZJ20%!SWP=W'(P,X)%9?@?P:NI@W4^3&"0J\C<>YR,<#V/)!STP6EU!MWL
MAO\ PM"Y_N1?]\O_ /%UT&A_$>&[Q'<#RWX&>J$\#KU7G/7@ <M6T_A2T=/*
M,*8P!D##<?[0^;ZG.3WKSCQKX;&BRCR\^5("5SV(ZKUR<9&">QQR031HQ.Z/
M7:Y?QMXHET+R_*"GS-^=X)^[MQC!'K3?AYK)OX#$Y!:$A1@8^3'RY[=B/H.>
M>3D_%;_EA_VT_P#9*26HV]+FAI7CU3;&ZNL!O,*JL8Y. IZ,W;/)R!T[D9P[
MCXHSLQ*1H%[!MS'\P5_D*R/"GAEM=D*YVQI@N>_.< #U.#ST'7T!]#_X0*R_
MYY?^/R?_ !5-V0E=F'HGQ,$K;+I0H.?G0-@>@*_,?7D'TXZFNZCD$H#J000"
M"#D$'H<UY-XV\,KHDBM&?W<NXJ#U7&,C/<<C!Z]CTR>Q^'.I&[MO+8@F)BHY
MRVW *YR?J!VP,=J&NHTW>Q7\9>,IM$F6&)4(,8;Y@Q.2S#LP]*\^U?5&U25K
MEP SXR%R!P .Y/I7K^J>&;?5&$LR;F P#N8< D]B/6O+/%U@FGW4D$0VHNW
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M#CMD$?K7E"2/HL^5(WP2$<$X)4X(['!Z'ID4[)BNT>XUY?\ %#_CY3_KBO\
MZ&]>H5Y?\4/^/E/^N*_^AO2CN.6QT'PO_P"/9_\ KLW_ * E'Q0_X]D_Z[+_
M .@/1\+_ /CV?_KLW_H"4?%#_CV3_KLO_H#T^H?9.?\ A?\ \?+_ /7%O_0T
MKI/&GBB?0F3RPA20'[P8ME3ST(&,$8_&N;^%_P#Q\O\ ]<6_]#2NT\9Z2=3M
MG11ETPR]>J]< =25R /4_C0]Q+X2'P9XE;7$<R;0Z-T4$#:1P>2>I![]JZ*O
M(O 6I?8KM <8E!0Y!/WL%<8]6 'I@_C7KM*2LRHNZ,7Q;KQT2#SE +E@JY&5
MR<DYP0>@/XXK%\(^+KG7)O+94$:@EBJN#Z  [B,D^O8'TK ^(^K"\N!"IRL(
MQVQN/+<C\ <]"#QZ]3\.])^QV_G$'?.<G((^49"C^9!XR#]*=K(5[LZJBBBI
M*"BBB@#R3XA6[17CLPX<(5]QM"_S4UT?@+Q3#'"+25A&T><%V 5@S$\$XY&<
M8_$9YQT'B3PS'KJA7)5DSM8=LCN.XX'H>.".:\VU+P1=V/\  7&0,Q_/G(ST
M'S?B0!G\*K1HAW3N>PT5X98ZQ-8?ZJ1E .<!CMS[KT/3N.:ZW0?B4Z$1W8#*
M3]]1AAUY*@8/;I@@#N:'$:FCT:BFQR"4!U(((!!!R"#T.:X?XD^('MMME&2-
MZ[G/JI) 4'/?!W<<C S@D4DKC;L2:]\24MB8K90[ XWM]SC'3!RW<9R!W&16
M+_PM"Y_N1?\ ?+__ !=-\&^"O[6 N9B1$&P%P07QUYXP,\9&2>1P1FNR_P"$
M"LO^>7_C\G_Q5/1$^\S+T3XE1W3"*=?+)P-P.4SW)S@J,].O7D@#-=I7E'B[
MP6VC?OHLM"<9)^\I]\ <'L<>Q[9Z'X;:\;E&LY"2T8RF>?DX&.G\)QC)Z' X
M%#74:;O9G;4445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M  #_ - 6O7J\A\>?\?LO_ /_ $!:408> _\ C]B_X'_Z U>O5Y#X#_X_8O\
M@?\ Z U>O42!&!X\_P"/*7_@'_H:UY#7K'Q#NA#:,ISF1D48]0=W/X*?QKR>
MG'8&>V^'_P#CVA_ZXQ_^@BN!^)W_ !\I_P!<5_\ 0GKOO#__ ![0_P#7&/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /&O&5J+:\F1<X+;N?5P&/ZGCVKTWPA
M=_:K2%\8PFWKG[AV9_'&:Y?XF:']V^0>BO@?]\L<#\"2?[H%8G@[Q;_8;,C@
MM$_) Z@CN 2!ST/3MSQ@UNB%HSUNBL^W\06UP 5E0Y&<;P#@#)R"<C Y.>G>
MJ.K>-+;3T+AUD;!VK&P;)]R,A>O?MG )XJ;%7.9^*EPK-#$#\RAR1[,5 _\
M03^53?"J,@3O@X)C ..,C=D9]LC\Q7%7][)J\QF89DD(X4?0  #\ .I^IKUO
MPIHO]D6ZQ'[Y^9_]X]1U(X&!QP<9[U3T5B5J[FQ7A6E(DDT:RXV&1 V3@;2P
MSSQCCO7NM> 41"9[_17,^%_&D6I(L<C!9\ $-QN/ R#@#YB?N]<YP,#-;E_J
MD6GC=,ZH,$C<<$XZX'4_09-38JYP_P 58P# ^!DB0$XYP-N!GVR?S-:7PO\
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M21GC(9<''MD_F:WOBA_Q[)_UV7_T!ZC^&NB-:QM=.,&7 7(YVCG.>N&)Z<=
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M*<5H*3U/;Z\@\>_\?LO_  #_ -%K7K]>0>/?^/V7_@'_ *+6B.XY['?^ O\
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MWY# @C+L>AK/3XB027 @!_=$?ZP@@;CC'7&%'()(Z^@&3UE#8XI'(^+/'?\
M9#FVB4-( ,EL[5S@@8&"<CW ''7D#D!XBU#5051I&"D$^4F",YQDQ@'UX/'Y
M5F^(?^/F?_KM)_Z&:]CTCR?)3[/CRL?+MZ8_GG/7/.<YYS1L+5L\JO/"M[(I
MNI48C;N9G=2V ,\@MNX Z=>V*=X"_P"/V+_@?_HMJ[/Q]XB6SA:V1@99/E(!
M!*J1EB1@XR#@9P><CI7&> O^/V+_ ('_ .BVIWNA6LSUNXMUN%:)QE7!!'3(
M(P>E>7:]\/Y[ EX09(\\;>7 XQE>_7^'/3) KT^\O$LT,TA"HHR2?\_D.I/
MK%T3QM;ZJ=F=CDD!7XR,X7!Z$G(XSG.>H&3*;1;29YM:ZW=Z*?*5W0J,;&'
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MI%4X!P3EL$XR%&2>?047'R^9Y!)H5U*2[12DDDDF-R23U.<5Z[XA_P"/:?\
MZXR?^@&LOPWXTCUEWA^XV3L!ZLH [Y^]U)'8=,X)KH+BW6X5HG&5<$$=,@C!
MZ4FPBCR+P-&)+V(, 1ECR,\A&(/X$9'O7L->(7]H^AW!CS\\+@J<#MAE;'(Y
M&#CGT->KZ%XIAUA5*L%D;K&6&[(&3@=QWR.WH<@.0H/H;%%4]2U>'3%WS.%!
MZ9ZGH. ,DXSS@<=ZYO2/B/#=R-'*/+4D>6Q[C@8;'0]\] .">,E6*NC0\>_\
M>4O_  #_ -&+7 > O^/V+_@?_HMJ[_Q[_P >4O\ P#_T8M<!X"_X_8O^!_\
MHMJ:V)E\2/7Z\O\ BA_Q\I_UQ7_T-Z]0KR_XH?\ 'RG_ %Q7_P!#>E'<<MCL
M/ 7_ !Y1?\#_ /1C5T%<_P" O^/*+_@?_HQJZ"A[C6QXAX>_X^8/^NT?_H8K
MV^O$/#W_ !\P?]=H_P#T,5[?3D*!X=H48EN(48 @RQ@@C((+#(Q7N->,>*]%
M_LBX:(?</S)_NGH.I/!R.>3C/>O0_"WC"+4XU61@LPVJ0Q W$\ KTSGT'0\>
MA)+44=-#I**KWVH1V"^;*P51W)]LX'J>.@Y-<K!\2H7G:-@1#CY7P2<C.25
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M$UQ/_"J?^F__ )#_ /LZ[JSM1:(L*YPBJHSUPHP*FI7L5:YY_P#\*I_Z;_\
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M,8Z=B<\\;/PI_P"6_P#VS_\ 9Z?V2;WD=!X]_P"/*7_@'_HQ:X#P%_Q^Q?\
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MH%'_ -;J23CFO7]#TW^S8([?C**,X)(W'ECSSR235/8B.K/+O'O_ !^R_P#
M/_1:UW_@+_CRB_X'_P"C&K@/'O\ Q^R_\ _]%K7?^ O^/*+_ ('_ .C&H>P1
M^)DWB_2?[3MG3!+(-ZX!)W*#Q@=<C(_'.,UYUX&U3^S[I,C(E_=GU^8C!ZC^
M(#/MGC->OUXUXOTG^S+ETP KG>N  -K$\8'3!R/PSC%$>PY=SL?B9JPAA6T4
M_-(06''W5]>XRV,>N#S67\+],\R1[HCA!M7*]VY)![$ 8/LWY\YXBUMM9E\]
MO[B#&,8P/FQUXW$D9).#7JOA;2?[*MTA8#?C+8 'S-R0<9SCIGN!0]$):LUJ
M***DLY_Q[_QY2_\  /\ T8M>5:;',[YMPY=03^[#;@.A/R\]\?C7M.KZ:NIP
MO;-T<8SZ'J#P1G! .._2O'+"[?0[@28^>%R&&1VRK+GD<C(SSZBJCL1+<T/^
M)E_T\_\ D6C_ (F7_3S_ .1:]-T?Q#!JXS"P)QDJ>''3/'MG&1D9Z&I-2UR#
M3>9I%4X!P3EL$XR%&2>?047'R^9Y!)H5U*2[12DDDDF-R23U.<5[;7-^&_&D
M>LN\/W&R=@/5E '?/WNI([#IG!-=)2;"*([C;M;S,;,'=NQMQCG.>,8ZYKPS
M4-GFOY7^KWMLZ_=R=O7GIZ\UVOQ$\3B3_0(B",_O#C/(((4'V(RWO@9^\*I^
M#_!/]IQM<38"NK+'U)#9QOX(Z$8P>O.<#&6M$*6KL:7PN\G;)T\_//\ >V8&
M,>V[.<>V>U=Y7BG[[PW<]A+"?JI!'\BI]CSV->OZ3JT>JQB>(Y4_F#W!'8C_
M .N,@@T20XOH<W\4/^/9/^NR_P#H#UD_"M$+RL<;PJ@<\[23NX^H7GMQZUK?
M%#_CV3_KLO\ Z ]<-X8US^Q9Q/@E2"K 8R5/U]" >V<8R :%L)NTCVFBJ>FZ
MO#J:[X7# =<=1U'(.",XXR.>U9/B7QG%I*$(5>;) 4'.".I;'3'IU)X]2)L5
M<\PUV,17$R*  )9  !@ !C@8KU'Q[_QY2_\  /\ T8M>;>'M-;6;E(VRP9MS
MDD_=!RQ)'//3/J1S7KNKZ:NIPO;-T<8SZ'J#P1G! .._2J?0F.S/.?AE&'NF
M) )6)B,CH=RC(_ D?0UZE7B%A=OH=P),?/"Y##([95ESR.1D9Y]17K^DZ]#J
MJAHG!)&=N1O'8Y7.1@_AZ$@BB2'!FA7E7Q)1%N\IC)C4O@Y^;D<^GR@<>G/>
MO0]8\0P:0,S, <9"CESUQQ[XQDX&>IKR2\GDU^X+JI+RMPHQTZ 9P!P!R3C@
M9-$0FST_P-(9+*(L23AAR<\!V 'X 8'M7GWCW_C]E_X!_P"BUKU72[ :?$EN
MN,(H&0,9(ZG'N>3[FO*O'O\ Q^R_\ _]%K1'<4MCTWPW&([6$* !Y2'@8Y*@
MD_B3D^]:59_A[_CV@_ZXQ_\ H K0J2T>6_$V,)=*0 "T2DX'4[F&3^  ^@KL
MO 7_ !Y1?\#_ /1C5Q_Q0_X^4_ZXK_Z&]=AX"_X\HO\ @?\ Z,:J>Q*^)G >
M/?\ C]E_X!_Z+6H;.._C0"(3A,978) N#SD8XYSFMWXF:+Y3K>KTDPK?[P'!
MZ]U&.!@;?4U)X#\81V:?8[@[0#\C'[OS'E3@<<DG)XY.2,#+OH3;4Q/^)E_T
M\_\ D6H;JSO[L;)5G< YPRR,,^N#7L/VA=OF[ALQNW9&W&,YSTQCG-<SKGQ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ;)&)048 @@@@C((/48K@=<^&?62T;U.QS]3@-^0 /U+5Z
M!133L)JYXM=>%+NV.UH7)(S\HWC\UR/PZU:L/ EW>8.S8K9YD(7&,]5Y;MZ>
M_3FO7Z*?,+D1S/A7P4FB_OG(>8CKCA<CD#_XK@XXP.<]-114E)6"O#M"C$MQ
M"C $&6,$$9!!89&*]QKQ#P]_Q\P?]=H__0Q51)ET.E\0?#B2-R]H R$\*6 9
M<YSRV 0.W.>>AQFN>M_"]U.P00OD_P!Y2H]>K8 _.O:Z*.9AR(X?PM\/?LC+
M<W)^=2K*BG@$<_,>Y![#CCJ0<5W%%%2W<:5BGJVDQZK&8)1E3^8/8@]B/_K'
M()%><ZM\.+BW<^0!(A)Q\P5@/?.!^77&<#I7J5%-.P-)GBEOX7NIV""%\G^\
MI4>O5L ?G74Z%\,SG?=D8P"$0\YZD,<?A\IY[,,<^A44W)B44-CC$0"*
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M SSU/)]L 5U%%%3<I*P4444 %8?B;PI'KJC)VR+T<#/'<$9&1Z<\'IW!W**
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M+CUG,R_)-C@_PMCIN&/PR.1[X KI**0VKGCE]X*N[/DQEAG ,>'S[X&6QQW
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M#AL<]@?;FO8Z*KF9/(CF_"_@N/1L3-\\V.3_  KGKM&/PR>3[9(KHI(Q*"C
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M69\;F/? [#L.3ZGGDGBMBBBI*.;\4>"X]9S,OR38X/\ "V.FX8_#(Y'O@"N
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5YSI7PYN+2:.9FCPDB,<,V<*P)_AKT:BFG835PHHHI#"BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "L'QEH+ZW"L,14$2!OF) P%8=@?6MZB@&<OX)\+
MRZ%YGFE3YFS&PD_=W9SD#UKJ***'J"5@HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2NDH!.X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4453U;5H]*C,\IPH_,GL .Y/_ -<X )H N45P,GQ5 )"P
MDC)P3)@X[<;3C\S]:ZKP[KZZY%YZ K@[2#CJ "<$=1SUX^@IV8DTS4HHHI#"
MBBB@ HHHH **** "BBB@ HHHH **** "BBL_6==AT=?,F;&<[0.6) S@#^IP
M!D9(S0!H45GZ-KL.L+YD+9QC<#PP)&<$?U&0<'!.*T* "BBB@ HHHH ****
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MLSSV&&X^N#["M3POXT776,.PHZ@MU#+@$#KP<Y/3'XT[,7,CI****0PHHHH
M***Q_$'BB+0MGFACYF[&P _=QG.2/6@#8HK-T'7DUM#-$& #%?F !R #V)]:
MN7EXEFAFD(5%&23_ )_(=2>!0!-16+I'B^WU5S#&QW@G 88W =Q_APV 216U
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7+60%6EB((((,B$$'J,9J;ZCL>.:?8M?R+ GWG( Z_F<9X'4^@KW6LFPO+.
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M$RYQTSA*Z>AL2"BBJM_JD6GC=,ZH,$C<<$XZX'4_09-(9:HK _X3RR_YZ_\
MCC__ !-6;#Q5:WQVQRKG(&&RI)/0 ,!G\,T6 UJ*** "BLO5/$MOI;"*9]K$
M9 VL>"2.P/I5>W\:6EPRQ))EG( &QQDDX'5:+ ;E%4]2U>+3%WS.%!Z9ZGIT
M Y.,\X'%9G_">67_ #U_\<?_ .)HL!OT5'!<+<*)$8,IZ%2"#CCJ*DH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM_B<UPRQ)!EG( 'FXR2<#JE"5P;2-SQ[_P >4O\ P#_T8M<!X"_X_8O^!_\
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M"@C&06_P!Y&#BG9BYD=-17 Q_%4$@-"0,C)$F3COQM&?S'UKL-)UJ+5D$D+
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MAS7MNK:-%JJ&.50>#@_Q+GN#VZ#V/?(KQ:\M3:.T+8RC,IQTRIP:$[@T>O\
MA36O[7MUE/WQ\K_[PZGH!R,'C@9QVJQX@_X]IO\ KC)_Z":Y+X5R$B9<G ,9
M SQD[LG'O@?D*ZWQ!_Q[3?\ 7&3_ -!-2]QGB57HM9EAA-HC%4+%FV\$[E"X
M)],#ITYYSQBC78^ O"J:EF[EP41L!/5@ <GV&1QW/7@8-,1QU%>]QQB,!5
M    P !T&*X3QSX-1$-Y;@+L WHHX(Z;@!TQW[8YX(.4I#L4/ WBM[>1;25B
MT;D*NXDE3C"@=>#P,=!UXYSZ97@5>U^'-1_M&WCG.<LO)( RR_*QP..2#CV]
M*)($<'\3O^/E/^N*_P#H3UG^ _\ C]B_X'_Z U:'Q._X^4_ZXK_Z$]9_@/\
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M+_C]B_X'_P"BVKT'QS(8[*4J2#A1P<<%U!'X@X/M3DM0B]#S;6-9F\1S#/\
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MXZX/?D/^$]O?^>O_ (Y'_P#$T?\ ">WO_/7_ ,<C_P#B:=F%XE'1M5?0YQ,
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M9O\ T!*'JA1T9>\:^)#HL0\O'FR$A<]@.K=,'&1@'N<\@$5YYH'AV7Q$[$,
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M97D2$(P]G('H>AP??&.]>NWEJ+M&A;.'5E..N&&#7B6LVZV\\L2#"I(X ZX
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M 8-\I .0".X/K7F'C+04T2988BQ!C#?,03DLP[ >E>PUY?\ %#_CY3_KBO\
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MJ,CK@+CK[D_7UY3QGX/71 DL18HQVG=C(;J.F.HSVXQUY%-F^(%[=L!&0I.
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M?',ACLI2I(.%'!QP74$?B#@^U(;/-M8UF;Q',,_Q$+&@/ W' &3CD]R>OL
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MJ-K'!_$ _45.[*T2T.$:2?Q/< $@R2' R<*H&3@>@ R>Y/N3SW]A\.+6W&)
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MS_\ 9Z] H>X16AX5JMJ+2:2%<X21U&>N%8@5Z+_PJ^V_OR_]])_\17 >(?\
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M@8C#1D X*L6&3TR&ST]B/KZ<5_PGM[_SU_\ '(__ (FC_A/;W_GK_P".1_\
MQ-.S%>)G_O=!N/22%_< X_(E6'TR#[U[+I=^-0B2X7&'4' .<$]1GV/!]Q7B
MFI:G)J3^=*07( )"JN<=,[0,_7KCCM7JO@+_ (\HO^!_^C&I2"&YQ_Q0_P"/
ME/\ KBO_ *&]=!\+_P#CV?\ Z[-_Z E<_P#%#_CY3_KBO_H;UT'PO_X]G_Z[
M-_Z E#V!?$'Q0_X]D_Z[+_Z ]<_\+_\ CY?_ *XM_P"AI70?%#_CV3_KLO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'_\ CYA_Z[1_^A"O;:\2\/\ _'S#_P!=H_\ T(5[;3D"/$O$'_'S-_UVD_\
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MF<\9QQZ8S[55KDIM'L.K:U%I*&29@.#@?Q-CL!WZCV'? HT75DU:);A".1R
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M7GDYW)@$^G0J./0_CS5]J;7B11L3B%"HRQ/\1.<=N"%^BCZ#U/QSI+:E;,J
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M%+,=F H))PZGH*5K,=[H\\\!?\?L7_ __1;5Z_7EG@K1I[>[CD>)U4;\ED8
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M-[2W9)59"96.&4J<;5YP:3V!7N6O'O\ QY2_\ _]&+7'_"__ (^7_P"N+?\
MH:5VGC6W:XM)(T4LQV8"@DG#J>@KE?ASI4UI<,\L;H#$PRR,HSN7C)%"V&_B
M/1JX_P"*'_'LG_79?_0'KL*Y7XC6;W=NJ1*SD2J<*I8XVMS@4EN.6QD_"G_E
MO_VS_P#9Z] KA_AII\MGYWFHR;O+QO4KG&_.,@>M=Q1+<(['E_Q0_P"/E/\
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M@\'(/X$9]/7BDAL\L\":;%?W(2;!"J652>&8$<8[\9./;GC(KUN.,1 (H
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M9_B'_CVG_P"N,G_H!K0JCKL9EMYD4$DQ2  #))*G Q4E,\N\!?\ '[%_P/\
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M@5[_ ,\O_'X__BJ>C$KHV_'GC".\3[';G<"?G8?=^4\*,CGD Y'' P3DXQ/
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MN$]CT/P]_P >T'_7&/\ ] %:%4="C,5O"C @B*,$$8((49&*O5)2"O(/'O\
MQ^R_\ _]%K7K]>6>-=&GN+N21(G93LP51B#A%'4"JCN3/8[/P%_QY1?\#_\
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M%JC:'<+*01M.UUY!QT88R.1U /<#/2O9;.\2\031D,C#((_S^8Z@\&N3\6>
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M .'GBA+0-9SL%7.Y"QPH_O+DG ]1T&<\Y(KT:O+/$'P^FL#O@S+'[#YQS@#
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MT%K=GJ5>?_$3Q0LBG3XCDY'F$8QQSL^N<$XZ8QZ@<==WEQ$/LLK2   ;'9@
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M'-Y +A<DP$DC_9;&XX /3 /8 9-<UX \2+IDA@E;$4N.3T5NQZX (X)QV&<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ;)&) 58 @@@@C((/48KRG7_ T^GN?*5I(B?E*C+<
MYX*CGC'7&#QT)P/6**:=@L>#06[7#"-%+,>@4$DXYZ"NKTKP%(T4EQ.I!$;&
M.,?>+;202!R,'HO4GJ !@^G44<PK'B7_  C]S_SQD_[]M_A7J/@NW:WM(XW4
MJPWY# @C+L>AK<HH;N"1RWQ$LWN[=5C5G(E!PJECC:W.!7G?_"/W/_/&3_OV
MW^%>VT4)V"Q1T.,QV\*L""(HP01@@A1D8HUR,R6\RJ"28I  !DDE3@8J]12&
M>)?\(_<_\\9/^_;?X5ZCX+MVM[2.-U*L-^0P((R['H:W**;=Q)!7C^N:'<27
M$S+%(099""(V((+'!SBO8**$[#:.(^&NGRV?G>:C)N\O&]2N<;\XR*Z?Q!_Q
M[3?]<9/_ $$UH5G^(/\ CVF_ZXR?^@FCJ!XE74Z!X0_MNV,L9"RK*1\V=I7:
MIP<9QC)(('L>Q'+5Z=\,?^/9_P#KLW_H*53)1Y[J6D2Z8VR9"I/3/0].A'!Q
MGG!XIVG:)/J7^I1F&2,@87(&<%C@#CU->WT4N8=CF/"7@Q=&_?2X:8YP1]U1
M[9 Y/<_@.^>GHHJ1GG?Q$TN:[N%:.-W B RJ,PSN;C(%4?!>CSV]W'(\3JHW
MY+(P RC#J17J5%.XK!7C^N:'<27$S+%(099""(V((+'!SBO8**$[#:/._AWI
M<UI<,TD;H#$1ED91G<O&2*]$HHI-W \M\:://<7<DB1.RG9@JC$'"*.H%7OA
MWI<UI<,TD;H#$1ED91G<O&2*]$HIW%8*XCXE:?+>>3Y2,^WS,[%+8SLQG KM
MZ*2&>/Z'H=Q'<0LT4@ EC))C8  ,,G.*]@HHIMW!(AO+-+Q##( R,,$'_/Y'
MJ#R*\WUSX=2VF9(#YB<G'1P.3TZ-QCIR2>%KTZBA.P6/"+JS>T.V160D9PRE
M3CUP:L:=HD^I?ZE&89(R!A<@9P6. ./4U[?13YA6.0\,> 5TUA<3D/(/N@#Y
M5.>N3U/3' P?4X(W]=T==7B:W?C/(. 2".AY_(],@D9&:T**FXSQ;5?#5QI9
M/F(=H_C493&< [ATSZ'!Z<55L-+EU [849SD [1D#/3)Z#ZG KW.BJYA6/+]
M1\#/8VRR;6>=I%RJ MM7:W'&<\XR>F>!ZG"_X1^Y_P">,G_?MO\ "O;:*7,%
M@HHHI#/,_%?@:2W=I[=2\;$G:H&Y23T"CJ.>,#@=>F3R$D9C)5@002"",$$=
M1BO>Z*?,*QQ'PUT^6S\[S49-WEXWJ5SC?G&11\2M/EO/)\I&?;YF=BEL9V8S
M@5V]%%]0L>)?\(_<_P#/&3_OVW^%>VT44-W!(IZKI4>J1F"494_F#V(/8C_Z
MQR"17FNM?#^XL/FC_>IZH/F[=4Y/4]L\#)Q7JU%"=AV/!I[=K=C&ZE6'4,""
M,\]#6EIOA:YU @)&P# '<P*K@XYR>O7/&21T!KV>BGS"L<UX5\%IHW[YR'E(
MZXX7(Y _QX..,#G/2T45(SSOXB:7-=W"M'&[@1 95&89W-QD"L/0]#N([B%F
MBD $L9),;  !ADYQ7L%%.XK!5'7(S);S*H))BD  &225.!BKU%(9XE_PC]S_
M ,\9/^_;?X5ZCX+MVM[2.-U*L-^0P((R['H:W**;=Q)!1112&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KF?B!<2QVQ2)6(<X=E&=J@9.<'(SC!.",9!QD5TU%"!G"_#GP
MUY(^WR@AF!" @?=./G]>>@Z<9ZAA7=444V[B2L%%%%(84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >0>/?\ C]E_X!_Z+6O3_#W_ ![0?]<8_P#T 5P_B[PC=:A=23Q1[D;;
M@[D'1%!X+ ]17>:-;M;P11.,,D: CK@A0#TJGL3%:LN4445)04444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5G^(/\ CVF_ZXR?^@FM"B@#
MP*O3OAC_ ,>S_P#79O\ T%*Z^BFW<204444AA1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7*V?Q&M[MUA59,NRJ,JN,L<#^*NJKQ#P]_Q\P?]=H__ $,4TKDR=CV^BBBD
M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &#?^-K6QD^SNYR"0Q5
M254@="1^7&<'@XK<CD$H#J000""#D$'H<UYKKW@*YGN7>(!DE<MNR%V[B200
M3GCV!R/?@>B:?:?8XD@SGRT5<XQG: ,XY]*;L)-F3KWC*'1'$,JN25#?*%(P
M21W8>E7-!UY-;0S1!@ Q7Y@ <@ ]B?6N!^*'_'RG_7%?_0WKH/A?_P >S_\
M79O_ $!*=M!)ZV.PHHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *AO+H6B-,V<(K,<=<*,FIJS_$/_'M/_UQD_\ 0#0!BV?Q&M[MUA59,NRJ
M,JN,L<#^*NJKQ#P]_P ?,'_7:/\ ]#%>WTY*Q,7<****105@Z]XRAT1Q#*KD
ME0WRA2,$D=V'I6]7E_Q0_P"/E/\ KBO_ *&]-*XI.R.^T'7DUM#-$& #%?F
M!R #V)]:TJX_X7_\>S_]=F_] 2NPH>X+8****0PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHJ.XN%MU:5SA4!)/7  R>E %/6==AT=?,F;&<[0.
M6) S@#^IP!D9(S7(R?%4 D+"2,G!,F#CMQM./S/UKD-2OY->GWG):1@J*2.
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MGD%N>1[ \\=<XR8_BJ"0&A(&1DB3)QWXVC/YCZUS7AGPI)KK'!VQKU<C//8
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MCWH:5KC3=[,]$JKJ6IQZ:GG3,%7(&3D\GL ,D_AVYZ5-<7"VZM*YPJ DGK@
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M)CNUN>WUY?\ %#_CY3_KBO\ Z&]>D:??+?QK.GW7 (Z?D<9Y'0^AKS?XH?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN,*S*?7+@$?^@G]*2W&]BU\+_P#CV?\ Z[-_Z E=A7GOPPU@)OLFP"QWK[G
M##KZ $ #H&)KT*B6XX[''_%#_CV3_KLO_H#UG_"G_EO_ -L__9ZS?B)KJ:C(
MD,6&$0/S @J2X4\8STQ^>1CCG2^%/_+?_MG_ .ST_LDW]XZ#Q[_QY2_\ _\
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M4F",YQDQ@'UX/'Y5N_#3289U>X8!I5<  X.T  A@.Q)SS[<8YSWTD@B!=B
M"22<  =3FAM(239X5?\ F[SY^[S.,^9G=T&,[N>F/PKV?P]_Q[0?]<8__0!7
MD&OZI_:D\ESC <\#IP  N>3S@#/O7K_A[_CV@_ZXQ_\ H HEL$=SS_XH?\?*
M?]<5_P#0WKJOAW:B&S5QG,C.QSZ@[>/P4?C7*_%#_CY3_KBO_H;UV'@+_CRB
M_P"!_P#HQJ'L"^(Z"O+_ (H?\?*?]<5_]#>O4*X/XH:275+Q1]WY7//0\K[
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MZ***DL*\0\0_\?,__7:3_P!#->WUXAXA_P"/F?\ Z[2?^AFJB3,]MCC$0"*
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M;4/4DGDJ3U-6/^$]O?\ GK_XY'_\374_#_Q0DD8LY6 =#A-QQN4G@ D\D$X
MXXQ@'!KMJ&Q)7ZGB6J^(I]5 6=@P4Y'R(",]>0 ?PZ=/05UOPI_Y;_\ ;/\
M]GKIM<\60:051V!<L 5!R5!QECC)& <@8R>W<C8CD$H#J000""#D$'H<T-Z#
M2U'4445)1Y%X_D+WL@))"A ,GH-@.!^))^IJK8>+KK3T$$4FU%S@;4/4DGDJ
M3U-;/Q*T<V\PNQDK* #[,H QTP,@#'.20W:MCX?^*$DC%G*P#H<)N.-RD\ $
MGD@G ''&, X-7T,[:G+?\)[>_P#/7_QR/_XFJ.J^(I]5 6=@P4Y'R(",]>0
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M<$*"/P[<=*V?A?\ \?+_ /7%O_0TKNO$'B6+14+.07Q\J _,<YQ]!QR>GU.
M="SO$O$$T9#(PR"/\_F.H/!HOH-1U)J*KWVH1V"^;*P51W)]LX'J>.@Y-%CJ
M$=^OFQ,&4]P?;.#Z'GH>14E%BBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,">< 'Z'=UXKO**+Z6#EUN%%%%(84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7F_B[PC=:A=23Q1[D;;@[D'1%!X+ ]17I%%-.PFKE/1K=K>"*)QADC0$=
M<$* >E7***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** .%\>>%[C5)DF@4,!&%/S
M$$,3_$1USV]#GMG'TGX<7%PX\\"- 1GY@S$>V,C\^F<X/2O4J*?,R>5$-G9I
M9H(8P%11@ ?Y_,]2>34U%%(H**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BHK@X4D53\T^I_.@#1HK.\T^I_.CS3
MZG\Z -&BL[S3ZG\Z/-/J?SH T:*SO-/J?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z
M -&BL[S3ZG\Z/-/J?SH T:*SO-/J?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z -&B
ML[S3ZG\Z/-/J?SH T:*SO-/J?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z -&BL[S3
MZG\Z/-/J?SH T:*SO-/J?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z -&BL[S3ZG\Z
M/-/J?SH T:*SO-/J?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z -&BL[S3ZG\Z/-/J
M?SH T:*SO-/J?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z -&BL[S3ZG\Z/-/J?SH
MT:*SO-/J?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z -&BL[S3ZG\Z/-/J?SH T:*S
MO-/J?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z -&BL[S3ZG\Z/-/J?SH T:*SO-/J
M?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z -&BL[S3ZG\Z/-/J?SH T:*SO-/J?SH\
MT^I_.@#1HK.\T^I_.CS3ZG\Z -&BL[S3ZG\Z/-/J?SH T:*SO-/J?SH\T^I_
M.@#1HK.\T^I_.CS3ZG\Z -&BL[S3ZG\Z/-/J?SH T:*SO-/J?SH\T^I_.@#1
MHK.\T^I_.CS3ZG\Z -&BL[S3ZG\Z/-/J?SH T:*SO-/J?SH\T^I_.@#1HK.\
MT^I_.CS3ZG\Z -&BL[S3ZG\Z/-/J?SH T:*SO-/J?SH\T^I_.@#1HK.\T^I_
M.CS3ZG\Z -&BL[S3ZG\Z/-/J?SH T:*SO-/J?SH\T^I_.@#1HK.\T^I_.CS3
MZG\Z -&BL[S3ZG\Z/-/J?SH T:*SO-/J?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z
M -&BL[S3ZG\Z/-/J?SH T:*SO-/J?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z -&B
MJUHY;.?:K- !1110 4444 %%%% !1110 4444 %%%% !15"20@GD]3WIOFGU
M/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT
M:-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9
MWFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU
M/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>
M:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_
MG0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!H
MT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>
M:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_
MG1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI
M]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^=
M &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C1
M6=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI
M]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^=
M'FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU
M/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT
M:-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9
MWFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU
M/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>
M:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_
MG0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!H
MT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>
M:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_
MG1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI
M]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^=
M &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C1
M6=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI
M]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^=
M'FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU
M/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT
M:-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9
MWFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU
M/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>
M:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_
MG0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!H
MT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>
M:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_
MG1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI
M]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^=
M &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C1
M6=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI
M]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^=
M'FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU
M/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT
M:-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9
MWFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU
M/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>
M:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_
MG0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!H
MT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>
M:?4_G1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_
MG1YI]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI
M]3^= &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^=
M &C16=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C1
M6=YI]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI
M]3^='FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^=
M'FGU/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU
M/YT :-%9WFGU/YT>:?4_G0!HT5G>:?4_G1YI]3^= &C16=YI]3^='FGU/YT
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)DWC JM]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@"G]C/M1]C/M5RB@
M"&WA,><]ZFHHH **** "BBB@ HHHH **** "BBB@ HHHH J/:%B3QR:3[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:KE% %/[&?:C[&?:
MKE% %1+0J0>.#5NBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !Y1?\#_ /0VK?J6,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#G/'>K2Z7 LL+;6,@!. >"K'N#Z53\ :]-JWF^>V[
M9LQ\JC&=V?N@>@H^)W_'LG_79?\ T%ZS_A5_RW_[9_\ L]/H+J=_1112&%%%
M% !1110 4444 %>6ZQXTN[>>6)),*DC@#8AP Q ZK7J5>)>(/^/F;_KM)_Z$
M:<1,]MHHHI#,?Q;?O86LD\1PZ[<' /5U!X((Z&O.?^$\O?\ GK_XXG_Q->M3
MVZW"F-U#*>H8 @XYZ&J?_"/VW_/&/_OVO^%-,3/,?^$\O?\ GK_XXG_Q-'_"
M>7O_ #U_\<3_ .)KL_&FCP6]I)(D2*PV8*HH(RZCJ!7+?#NS2[N&615<"(G#
M*&&=R\X-/0"K_P )Y>_\]?\ QQ/_ (FNC\">);C5)VBF?<HC) VJ.0RCL!ZU
MU?\ PC]M_P \8_\ OVO^%36NEPVAW1QHA(QE453CTR!2N@L6J***0PHHHH *
M*** "BBB@ HHHH **** /(?^$\O?^>O_ (XG_P 37KU>!5[[52$CSGQ;XMNK
M"ZD@BDPB[<#:AZHI/)4GJ:Z[PE?O?VL<\IR[;LG '1V X  Z"O.?'G_'[+_P
M#_T!:[_P'_QY1?\  _\ T-J'L"W-^BBBI&%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5R'C_7IM)\KR&V[]^?E4YQMQ]X'U-=?7 ?%7_EA_P!M
M/_9*:W$S<\":M+JD#2S-N82$ X X"J>P'K71UR'PQ_X]G_Z[-_Z"E=?0]QH*
MIZQ.UO!+*APR1N0>N"%)'6KE9_B#_CVF_P"N,G_H)I >8_\ ">7O_/7_ ,<3
M_P")H_X3R]_YZ_\ CB?_ !-4/#__ !\P_P#7:/\ ]"%>VU3T$CR'_A/+W_GK
M_P".)_\ $UT?ASXB^<RP70 SQY@X&>,;AVSSDC@<< 9-=C?Z7%J VS(KC! W
M#)&>N#U'U&#7DOB[1AI-PT2 A" R9.>#^O!! SS@=^I-&&Q[)16'X*G:>SB9
MCD@$?@K%1^0 K<J1A1110 4444 %%%% !1110 4444 %<)X[\2W&ESK%"^U3
M&"1M4\EF'<'TKNZ\Q^)W_'RG_7%?_0GIK<3.K\":M+JD#2S-N82$ X X"J>P
M'K1X[U:72X%EA;:QD )P#P58]P?2J?PQ_P"/9_\ KLW_ *"E'Q._X]D_Z[+_
M .@O1U#H4_ GB6XU2=HIGW*(R0-JCD,H[ >M=W7F/PQ_X^7_ .N+?^A)7IU#
MW!!1112&%%%% !1110!CW_BVUL',$LF'7&1M<]0".0I'0UJ6\ZW"K*ARK@$'
MID$9'6O)?'G_ !^R_P# /_0%KT[P_P#\>T/_ %QC_P#013:%<T*X3QWXEN-+
MG6*%]JF,$C:IY+,.X/I7=UYC\3O^/E/^N*_^A/0MP9U?@35I=4@:69MS"0@'
M ' 53V ]:Z.N0^&/_'L__79O_04KKZ'N-!1112 **** "BBB@ HHHH ****
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M>N !D]*DK/\ $'_'M-_UQD_]!- %>P\6VM^X@BDR[9P-KCH"3R5 Z"MBO(?
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M*;L(AU"^6PC:=_NH"3T_(9QR>@]37D^K>,[G4'+!VC7)VK&Q7 ]R,$]._?.
M!Q7H/CS_ (\I?^ ?^AK7%?#FS2YN27 .R,LN>S!E /X9X]^>H%- R;P1K]Q+
M=) \C,C[LASN^ZC$8+9(Y],9[UZ=36C#X) )4Y&1T.",C\"1]#3J38PHHHI
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YSXM\6W5A=201281
M=N!M0]44GDJ3U->C5Y#X\_X_9?\ @'_H"TXB9ZEH\[7$$4KG+/&A)Z9)4$]*
MN5G^'_\ CVA_ZXQ_^@BM"D,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"J]_?I8(9Y3A%QDX)ZD < $]35BL#QY_QY2_\ _]#6@"WI?B6WU1C%"^Y@,D
M;6' ('<#UK4KS'X8_P#'R_\ UQ;_ -"2O3J;5@04444@"BBB@ HHHH ****
M"BBB@ K#N/&EI;LT3R89"01L<X(.#T6MRO$O$'_'S-_UVD_]"--*XFSVVBBB
MD,**** ,_5=>ATG;Y[;=^<?*QSC&?N@^HJ32]6BU13+"VY0<$X(Y ![@>M<9
M\5?^6'_;3_V2M#X8_P#'L_\ UV;_ -!2G;05]3KZYSQWJTNEP++"VUC( 3@'
M@JQ[@^E='7(?$[_CV3_KLO\ Z"]"W&RGX$\2W&J3M%,^Y1&2!M4<AE'8#UKN
MZ\Q^&/\ Q\O_ -<6_P#0DKTZA[B04444AA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=#]#D4-7$F>XR1B0%6 (((((R"#U&*=7FNE?$N6$A;A0Z]RHVOUZ_P!TX';
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M1H%[!MS'\P5_E6)XMOFO+J4O_"[(!S@!"0.OYGW)-5]$T2369/(BQG!)+'
M'YGJ0. >OI0D%S?_ .%G7/\ <C_[Y;_XNNCT3XAPW[>7*/*;G!9@4X_VN,'K
MU&..N3BN>O/AE/'DQNC@#C.58\=,8('/ ^;'KBH_"O@9[Y_,N59(E/W6!5F/
MIS@@>I_ <Y(- U/0->U7^R86N=N[9MXSC.6"]<'U]*\[\1^/'UB/[.J!%)^;
MYMQ.""!T&.>?4\=LY[?QA9F2SDAB4DX0*J+G@.O  ] /RKRFZTN:T&Z2-T!.
M,LC*,^F2*(@RK7??\+5_Z8?^1/\ ["N!K0_X1^Y_YXR?]^V_PIM"/9=/N_MD
M23XQYB*V,YQN .,U8JCH<9CMX58$$11@@C!!"C(Q7-?$7Q ;1!9)]Z498\@A
M<]/^!8(//0$$<BIL46-;^(<-@WEQ#S6XR58!.?\ :YR>G08YZY&*YS_A9US_
M '(_^^6_^+KDHXS(0J@DD@  9))Z#%=?:_#*>09=T4[<@<L=W93P /<@GV!I
MV2)U+%A\47!_?QJ02.8R5('?ABV?;D?7T[C2M5CU2,3Q'*G\P>X([$?_ %QD
M$&O(-<T"717$<H'(R&7E3ZX) Z=QU_ @EWA_Q!)HDGFIRI^\IZ,/Z$=CV]P2
M"-#N>TUPGB7QW/I=P]NBH53;@L&)Y4'LP]:[>WG6X594.5< @],@C(ZUY+X\
M_P"/V7_@'_H"TD#.A\/>/YM0G6&41JA#%B PP%4MG)8@=.?:H]6^)K*Y6V12
M@)^:3)W>X *X[]<DC'3I7!UT=IX N[A3)M"\ @.P#'(S@ 9P?][;U^N'9"NR
M]'\3[@$;DC(R,@!@<=^=QQ^1^E=QH_B.'58S.AP$SN#X!7W/.,8YSG'X@X\@
MU'3)--?RIE*M@'!P>#W!&0?P[\=:ABG:(,H/#C!]QD-_,"BP7/0-?^)'V9S%
M:JK[3R[9*GKD  C/;G..N 1@UE?\+.N?[D?_ 'RW_P 767HG@^XUA?,0!4YP
MSG )'88!)^N,<$9SQ536-"ETAO+F7&<X(Y4@'&0?Z'!&1D#-.R#4],\.>-(M
M:/E8*2XSM)R#UZ'C.!R1@'TR 370UX5I]\UA(LZ?>0@CK^1QC@]#ZBO<;>=;
MA5E0Y5P"#TR",CK4M6&F<YXU\3RZ'Y?E!3YF_.\$_=VXQ@CUKF/^%G7/]R/_
M +Y;_P"+J_\ %7_EA_VT_P#9*X&FEH#9[[117GOQ(\0%F^P)T7#.>>O4+Z8Q
M@]^<="*E*XR_K7Q)CM6,4"^81D;B<)GL1C)89Z].G!(.:Q/^%G7/]R/_ +Y;
M_P"+KDHXS(0J@DD@  9))Z#%=3!\-;J50Q**3V9CD?\ ?*D?K562)U+UA\47
M!_?QJ02.8R5('?ABV?;D?7T[C2M5CU2,3Q'*G\P>X([$?_7&00:\@UCP]/I!
MQ,I S@,.5/7'/OC.#@XZBNE^&^CR^9]L^[%@KR/OY[#T (!)]1CUP-(:9Z-1
M114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUY?XQLH;><O;LC1R#.(V4A3W& 3CU'0<X'2C<-CV"O._'D=SIDGGQRR"*4\
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MQG()%)+J#*]K>7]V-T;3N <95I&&?3(JQH_CFYT\_,QD0GD2$D]LX;J.!QU
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M*\>TR :A.JS.%#MEW=L<=6.XYY/;/4XS22!LMKK=[J3G8\K-C)$98<# SM3
M'Y=?>G0^);S2Y/F=]PQE)2QXX."K=,^HP<=#7IEGJMG9H(8Y8E11@ 2+_C^9
MZD\FH-9NK/58F@>:+D<$NIVMV8?,.GUY''0T[A8A\)^,%US,3+ME49('*D<
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M@N?^>TG_ '\;_&KNG>-KJQ_C+C).)/FSD8ZGYOP! S^->O1QB,!5      P
M!T&*Q]>\*0:P"64+(1PZCYL\8STW=,<]NA'6G=!8F\/^((];C\U.&'WE/53_
M %!['O[$$#G/B5J$MGY/E.R;O,SL8KG&S&<&NKTK2H]+C$$0PH_,GN2>Y/\
M]88  KC/BK_RP_[:?^R4EN#V+'PUU"6\\[S79]OEXWL6QG?G&36WXTN&M[22
M1&*L-F"I((RZCJ*YSX5?\M_^V?\ [/70>//^/*7_ (!_Z&M#W#H<1X:\8/8.
M\L[O(/+.U6=CEMRXZY XSSZ9ZG@T+[Q;=7C>8967T",44#.<8!_4Y/J:KZ!I
M?]J3I;YP'/)Z< 9;'!YP#CWKV/3M,CTU/*A4*N2<#)Y/<DY)_'MQTINR!$>A
MR&2WA9B23%&22<DDJ,G-8WBWQFNC?N8L-,<9!^ZH]\$<GL/Q/;.SK>H_V;!)
M<<913C()&X\*..>20*\DT+2VUNX6(DG<=SMR3CJQS@\GH">Y&>M)(&$_B>ZG
M8N9GR?[K%1^2X _*G6OBNZMCN69R<8^8[Q^39'X]:]=T[3(]-3RH5"KDG R>
M3W).2?Q[<=*;J6D1:FNR9 P'3/4=.A'(SCG!YIW"QB>$O&:ZS^YEPLPS@#[K
M#VR3R.X_$=\6_&EPUO:22(Q5ALP5)!&74=13O#OA6+0]Q3+.Q/S-UVYX7_'U
M//H!%X\_X\I?^ ?^AK2Z@<U\.]4FN[AEDD=P(B<,[,,[EYP37HE>8_#'_CY?
M_KBW_H25Z=1+<$4=<D,=O,RD@B*0@@X((4X.:\[\%ZQ/<7<<;RNRG?D,[$'"
M,>A->A>(/^/:;_KC)_Z":\Q\!_\ '[%_P/\ ] :FM@9Z=X@_X]IO^N,G_H)K
MR+P__P ?,/\ UVC_ /0A7KOB#_CVF_ZXR?\ H)KR+P__ ,?,/_7:/_T(41!G
MMM<%XK\?/;NUM;8!0D,Y&3N!Y !XXQ@D@Y[= 3WM8NJ>$;?4Y!<2J=P&#@X#
M<8&<<\=B"#V.0 *2&SS6#5+[4"S1O,YSD^67(&<]EX'L.!Z5-I7C>YL&&7,B
M9R5<YSVQN.6'MSC/8\Y]2FU""PQ$[I'@#"EE7CH, D<<8K@?'FL6NJJDD+;I
M5.#\K#Y2">25&<'ISW/%-.XCOM*U6/5(Q/$<J?S![@CL1_\ 7&00:Y3XE:A+
M9^3Y3LF[S,[&*YQLQG!J'X5R$B9<G ,9 SQD[LG'O@?D*[VELPW/"+J\>[.Z
M1F<@8RS%CCTR:F@UB>W41I*ZJ.@5V &>>@-='\3O^/E/^N*_^A/77^ _^/*+
M_@?_ *&U5?05A_@NX:XM(Y'8LQWY+$DG#L.IK6O+Q+-#-(0J*,DG_/Y#J3P*
MFKS7XEZJ9I5M0?EC )'/WF]>QPN,>F3S4K5CV*NO>/Y[XE(28X\\;>'(XQEN
MW3^''7!)K/>\OXT\YFG"8!W%I N#T.>G.>*Z/P#!;6:?:YI(Q*Q(4,Z@JO3H
M<8)YY_NXQC)SV/\ PD%M_P ]H_\ OXO^-.]@.!T/XBRVF(YQYB<#/1P.!UZ-
MQGKR2>6KTJWG6X594.5< @],@C(ZUYCX^MH&D%S;NC>9G>$93\W7=@$_>[\8
MR,DY:MWX87YEBDMSG$; @DYX?/ ';!4GZG\QKJ".UHHHJ1GB$FN7$@*M+(00
M009&((/48S56"X:W82(Q5AT*D@C/'45[3X@_X]IO^N,G_H)KS'P'_P ?L7_
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M(&<]EX'L.!Z5Z5JGA&WU.07$JG<!@X. W&!G'/'8@@]CD "KTVH06&(G=(\
M84LJ\=!@$CCC%.XK'ENE>-[FP89<R)G)5SG/;&XY8>W.,]CSGU+2M5CU2,3Q
M'*G\P>X([$?_ %QD$&N!\>:Q:ZJJ20MNE4X/RL/E()Y)49P>G/<\5=^%<A(F
M7)P#&0,\9.[)Q[X'Y"F]@1T/C2X:WM))$8JPV8*D@C+J.HKA?#7C![!WEG=Y
M!Y9VJSL<MN7'7('&>?3/4\'M_'G_ !Y2_P# /_0UKS7PWH_]KSK;G(4Y+%1G
M  S^&>F3W(Z]*%L#)]2\9W5^VXR% .@B)0=O0Y/3N3CMBF6/BVZLV\P2LWJ'
M8NI&<XP3^HP?0UZ_9V:6:"&,!448 '^?S/4GDUSGQ T9+NW:YVDRQ 8*]=N1
MN!]0 2?;KTSDN@L:/AGQ&NNQF0#:RG#+D''H>W!^@Y!':MBO+?AO?>1<^4<X
ME0C Z97Y@3] "!]?<UZ)K>H_V;!)<<913C()&X\*..>20*36H(YKQ=X[^P,;
M:VP9!D,QY"GT'JP[YX'0@G('#R>)+F0EC-)DDGAV Y]@0!]!Q3M"TMM;N%B)
M)W'<[<DXZL<X/)Z GN1GK7K^G:9'IJ>5"H5<DX&3R>Y)R3^/;CI3T0;GENC^
M.;G3S\S&1">1(23VSANHX''4#.<54\4ZBFI7#W$>=KA,9&#PB@C\",>GIQ7K
M.K:-%JJ&.50>#@_Q+GN#VZ#V/?(KQC4+%K"1H'^\A(/7\QG'!ZCU%"$SV7P_
M_P >T/\ UQC_ /016A6?X?\ ^/:'_KC'_P"@BM"I*"O._B)JDUI<*L<CH#$#
MA791G<W. :]$KS'XG?\ 'RG_ %Q7_P!">G'<3')X_>TMHX8R6FP^]Y,MC+-M
MQGJ<8/.0!@8/.,"3Q)<R$L9I,DD\.P'/L" /H.*Z'P!X834-UU, R*=H4Y^\
M,-D]L8XP<@Y.>G/I5.Z0'D>C^.;G3S\S&1">1(23VSANHX''4#.<5ZAI6JQZ
MI&)XCE3^8/<$=B/_ *XR"#7+>/\ PPDD9O(E =#E]HQN4GDD <D$Y)XXSDG
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M[)2:L""BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/7M7<:'XG@UG/E$[@,E6&& SC/<'\"<9&<$UYGK?@^XT=?,<!DXRR'(!/8Y
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M!G! ]<]2!V&2U<#MO"OB(:Y%YF '4X=0>_J.^#VSW!'.,UYWX\_X_9?^ ?\
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MD]"?X>3T/;'\1Z'/'HU)JQ1X9I=T+2:.9LX21&..N%8$U[G7@D<9D(50220
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M??'S)_O#H.H'(R.>!G/:O+M$UB309O- Y&5=6&,C/*^H.1^!'.1D$6P,V_\
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M CM:***D9YOXS\9RF5K6!BB(=I*\,6&,\X!&",<=>>2#QEZ3X%N=202@*BD
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M">E>XUY/XYT!]/G:?!,4S$ANOS'EE/ QSG'J.Y(.-;PO\05M8UM[D'Y,*K*
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M:Z!! K+&,DCNV #R!G 7!/4CN<8XI^ _^/V+_@?_ * U"6@=3T[Q!_Q[3?\
M7&3_ -!->1>'_P#CYA_Z[1_^A"O7?$'_ ![3?]<9/_037D7A_P#X^8?^NT?_
M *$*(@SVFXG6W5I7.%0$D]< #)Z5Y#K7B>XUQO+R0C'"QITY(P#CECD#KWZ
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M%'((7/7_ (%@$<= "#S3V0;LI_%7_EA_VT_]DJY\+YU:"2('YEDR1[,H _\
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MQW@+Q4^I;K:;)=0SA_4%N0?3!;C'&.,#'/8TF""BBBD,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH Q_%?VC[.WV7[_?'WMO?;_M?KC./FQ7C5>^UC
MZUX4M]7^:1</_?3ANW4]#P,<@X'3%-.PFCRC3M;GTW_4NRC). <KDC&2IR#Q
MZBK\GCB\D!4RG!!'"H#S[A01]1S6U=_"Z5<>5*K=<[P4^F,;L_I5?_A6-S_?
MC_[Z;_XBJNA:G)22&0EF))))))R23U.:U_"F@G6)U0@F-2"Y[8],Y'WL8XYZ
MGL:ZG2OABJ$/<ON]53@=?[QY((ZX //!XY[6SLTLT$,8"HHP /\ /YGJ3R:3
MD.Q-4=Q MPK1.,JX((Z9!&#TJ2BI&>&:I8'3Y7MVSE&(R1C('0X]QR/8U5KJ
M?B.Z-=83&1&H? Q\W)Y]?E(Y]..U86D::VIRI;KU<XSZ#J3U&<#)QWJR3TSP
M!I/V"V#L!NF._H,[2/E&1G/'/MN(QG-='(VP$@$D \#&3[<D#\R!1'&(P%4
M    #  '08IU04>,>)-<EU:4M*"NPD!/[OJ.>_J>N?0  6=*\<7.FJ(PP9%&
M KC./Q&&XZ#G '&.F/2-<\,0:SCS0=P& RG# 9SCN#^(.,G&":Y&_P#A<X/[
MB12"3Q("I [<J&S[\#Z>E70K,P]<\9SZP@A?:J9R0@(SZ9R3T].F>>PQB1QF
M0A5!))   R23T&*[.U^%TS']Y(BC'50S'/T(7^?X5U>@>#H-&Q(N6E ^^WN
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MQ1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ K \5>%?[?V?/L\O=_#NSNQ[CTK?HH Q_#'A_
M^PXC!NW[G+9V[>H QC)]*V*** "N0U[P!_:TS7/F[=^WC9G&%"]=P]/2NOHH
MN!GZ#I7]DPK;;MVS=SC&<L6Z9/KZUH444 <QXG\%?VY*)_,V;4"XV;NA)SG<
M/6M?0=*_LF%;;=NV;N<8SEBW3)]?6M"BBX!7*:W\/(;]O,B/E-QD*H*<?[/&
M#TZ'''3)S75T4 >:_P#"KY]V/,39GK\V[&>NW&,X[9]L]ZW='^',%F=\Q,I!
MX!&U>Q'RY.>G<X(/(KK:*=V*P5DZYX8@UG'F@[@,!E.& SG'<'\0<9.,$UK4
M4AGF]U\+IE/[N1&&.K!E.?H W\_PJ_IOPP2,AIY"PP,JHVC/&1NR21U'0'OQ
M7<T4[L5AL<8C 50     ,  =!BG444AG*:W\/(;]O,B/E-QD*H*<?[/&#TZ'
M''3)S6!_PJ^?=CS$V9Z_-NQGKMQC..V?;/>O2J*=V*QR6C_#F"S.^8F4@\ C
M:O8CY<G/3N<$'D5UM%%*XPHHHH ;)&) 58 @@@@C((/48KD-6^&T5VYDB<Q[
MB25V[E_ 97'?CD>F ,5V-%%P/-8/A?.S /(@7N5W,?R(7^==+H/@.#2R)6S)
M(IR"W"@C."%_Q)Y&1BNEHIW8K!7%:G\/'U*1KB2<;G/.(L#@8 ^_V QZ^O-=
MK12N,IZ5I4>EQB"(84?F3W)/<G_ZPP !5J2,2 JP!!!!!&00>HQ3J* .&O/A
M<DCEHY2B$\*4W8]L[AGV[XZYZUV=G&\:!9&#N!RP7;GWQDX]^V>F.E3447 \
M2\/_ /'S#_UVC_\ 0A7HFO\ @"+5',R,8W8_-@;E/7)QD<GN<X]LDFO._#__
M !\P_P#7:/\ ]"%>VU4A(\U@^%\[, \B!>Y7<Q_(A?YUUWA_PC#HPW*-TG]]
M@,CC!V_W1U]^<$GBMRBE<=@K"\2^$8]<^8DK*  '&3P"3@KD ]3Z'/?'%;M%
M(#S=_A=,'PLB%,CDA@V._P N"/I\W/J*W],\ 16*.NXM+)&R;R.%W C(7/H>
M>2?0@$BNIHIW8K'(:#X _LF9;GS=VS=QLQG*E>NX^OI77T44KC.(U#X:_;)7
MG\['F.S8\O.-Q)QG?7;T447 *Y#7O ']K3-<^;MW[>-F<84+UW#T]*Z^BBX%
M?3[3['$D&<^6BKG&,[0!G%321B0%6 (((((R"#U&*=10!PFJ_#%7)>V?;Z*_
M(Z_WAR !TR">.3SQ6L/A<Y/[^10 1Q&"Q([\L%Q[<'Z>OHE%.[%8YB_\!Q2P
M"UA/E_.K%B-[,54KSR/7/' YP.:L>%?"O]@;_GW^9M_AVXVY]SZUOT47'8*P
M_$'A&'61N8;9/[Z@9/&!N_O#I[\8!'-;E%(#S>Z^%TRG]W(C#'5@RG/T ;^?
MX5?TWX8)&0T\A88&54;1GC(W9)(ZCH#WXKN:*=V*Q#9V:6:"&,!448 '^?S/
M4GDU-112&8OB+PK%K@!?*NH.UUZ_0^HSSC@^A&37'S_"^=6(21"O8MN4_D W
M\Z]*HIW"QR6C_#F"S.^8F4@\ C:O8CY<G/3N<$'D55U#X:_;)7G\['F.S8\O
M.-Q)QG?7;T4786"BBBD 4444 9^O:5_:T+6V[;OV\XSC#!NF1Z>M9'ACP5_8
M<IG\S?N0KC9MZD'.=Q]*Z>BBX!1110 4444 1SVZW"F-U#*>H8 @XYZ&N*U+
MX8)(2T$A48.%8;AGG W9! Z#H3WYKN:*+@>;VOPNF8_O)$48ZJ&8Y^A"_P _
MPKK/#_A&'1AN4;I/[[ 9'&#M_NCK[\X)/%;E%.X6"J.K:-%JJ&.50>#@_P 2
MY[@]N@]CWR*O44@//;[X7,.890>> X(P/]X9R?P&>O'2BQ^%S'F:4#GD("<C
M_>.,'\#CKSTKT*BG=BL9^CZ%%I"^7"N,XR3RQ(&,D_T& ,G &:T***0S@/\
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M1"O8MN4_D W\Z]*HIW8K'':3\-HK1Q)*YDVD$+MVK^(RV>W' ]<@XKKXXQ&
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M$*]BVY3^0#?SK7TWX910-NF<R#L -@[]<$D^V".G>NSHIW8K#8XQ& J@
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MG1L8RQ);@N"2<YY88Z_3I@#OUM%%P/-[7X73,?WDB*,=5#,<_0A?Y_A6_=^
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MQCZXPS?A_#[>]=_13NQ6*NG:9'IJ>5"H5<DX&3R>Y)R3^/;CI5JBBD,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *>L3
MM;P2RH<,D;D'K@A21UKS6;XBW<BA 54C&6"C<<#OG*\]> /; XKT[4+3[9$\
M&<>8C+G&<;@1G%><_P#"L;G^_'_WTW_Q%-6$SDI)#(2S$DDDDDY))ZG-=Y\-
M-#^]?./54R/^^FY'X @_W@:;I/PR97#7+J4!'RQY.[V)(7';IDD9Z=:[^.,1
M@*H     &  .@Q3;!(=1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .6L_AW;VCK,K
M291E89*XRIR/X:ZFBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "J>I:1%J:[)D# =,]1TZ$<C..<'FKE
M% ')2?#.V<DAI "3P&7 ]N5)_,DU<T[P':V7S;2Y!/,AW=1C&T *?Q!.?PKH
M:*=V%@HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5S&H?#VWO9&G)<%R20K#&3UZJ3R>>O
MTXKIZ* ,G0_#$&C9\H'<1@LQRQ&<X[ ?@!G SDBM:BB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "L/7O"$.MLLLA8,HQE"!D9R,Y!Z9/
M3UY[5N44 <]I/@6VTUQ* SL""ID(.".X  'YYP0",&NAHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L+7?!T.M.)I&<$*%^4
MJ!@$GNI]:W:* *>DZ6NEQ+;H253."V">23V ]:N444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117
M'>+/'3:5)]FA5690"Q;.!D$[<#';!SG'.,9HL!V-%<1X0\<R:C*+6=02P^5E
M&.5!)W#..0.V,'M@\=O0U8 HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW/)''&>>10!OT5@>$?%/]O*V5VO'MS@Y4[@>1W'(/'...36_0 4444 %%%%
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M** "BBB@ HHHH **** "BBB@ HKSO2_B)<7<T<++'AY$4X#9PS '^*O1*&K
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!X%7OM>!5W?B#XD,Q\NTX'=V'/7^$'C&/49YZ BJ:N)'H5%>0_\)Y>_P#/
M7_QQ/_B:ZOPS\01?MY%R KL0$* [220 I')!SWZ>N,<JP7.SHHILD@C!9B
M"22<  =3FD,=17G>O?$EW)CM0%4'[[#+'IR%/ []<DCT-8O_  GE[_SU_P#'
M$_\ B:?*Q7/7J*\]T7XEL&$=TH*G WJ""/5BO.<\9QC'. >!7H$<@D 92""
M00<@@]#FDU88ZBBN$\1_$7R6:"U ../,/(SSG:.^.,$\'G@C!H2N!W=%>0_\
M)Y>_\]?_ !Q/_B:Z/PY\1?.98+H 9X\P<#/&-P[9YR1P.. ,FGRL5SC?#_\
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MU]P?I7H'A_Q!'K<?FIPP^\IZJ?Z@]CW]B" -6'<U**IZKJL>EQF>4X4?F3V
M'<G_ .N< $UYWJ/Q)N+CB(+&,C&!N;IR"6XZ\_=!_J)7"YZA17D<?CZ\0@F0
M$ C@HF#[< '\B#7:^$O&:ZS^YEPLPS@#[K#VR3R.X_$=\#0KG3UY#X\_X_9?
M^ ?^@+7KU>0^//\ C]E_X!_Z M$09W_@/_CRB_X'_P"AM7/_ !5_Y8?]M/\
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M+P_X@CUN/S4X8?>4]5/]0>Q[^Q! 35AW-2BBL/Q-XJCT)1D;I&Z(#CCN2<'
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M/ZU-8?$:ZMS^\*R D<,H4X'7!7'7W!^E+E87/5**HZ/K,>KIYT))&<'(((.
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M.0(****D845R'B?Q\NFL;> !Y!]XD_*ISTP.IZYY&#ZG(')2>/KQR2)  2>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,222223DDGJ<U5M17+FC:2^JRK @/)Y(&=J]V/3I]>3QU->SZ?8K81K GW4
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MI!.#DXZ;0.?I79:/XA@U<9A8$XR5/##IGCVSC(R,]#2NQV1:T^R6QC6!<E4
M W')X]_\@=  .*\I\>?\?LO_  #_ - 6O7J\A\>?\?LO_ /_ $!:4=P8> _^
M/V+_ ('_ .@-7KU>0^ _^/V+_@?_ * U>D>*K\V-K+*N<A<#!P06(4'/MG/X
M4Y;@CS_QKXH;4Y3#&Q$*?+@'Y6(/+<=1P,9STR,9-<Y!;M<,(T4LQZ!023CG
MH*CKU;P%H2V,"W!7][*,DG!^4G*@8Z C!/?/7H 'L+<X:3P/>1@L8C@ GAD)
MX]@Q)^@YK$DC,9*L"""001@@CJ,5[W7$?$C0E>/[<B_.I <C RIX!([D' &.
M<'G@#"4AM%#X?^*&C?[%,Q*O@(6/"D#[O/8\ #/!P .37HU>"1R&,AE)!!!!
M!P01T.:]ST^[^V1)/C'F(K8SG&X XS2D@1XUX@_X^9O^NTG_ *$:IQ3M$&4'
MAQ@^XR&_F!5SQ!_Q\S?]=I/_ $(UK_#NQ6ZNLOSY:%P.,9! '7TSD>X!JN@C
M.M?"MU=)YZ1,4QGL"1C.0"03D=, Y[5FSV[6[&-U*L.H8$$9YZ&O>:X;XHV
M*1W/&58H>.2&!8<^VT\>Y_%)CL<YX&U@Z?<JO.R8A"/<GY3C('![\X!.*]<K
MP*O?:) @HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]=H__0A7MM>)>'_^/F'_ *[1_P#H0KVVG(2/&_%^D_V9<NF %<[UP !M8GC
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MS_!?AP:U*?,SY48!;'<GHO7(S@Y([#'!(-=;\3O^/9/^NR_^@O6?\*O^6_\
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MJ@C$2-M'5U5F/N21_P#6],"N4^%<@!F7(R1&0,\X&[)Q[9'YBO0:38(Y[6/
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MY_XJ_P#+#_MI_P"R5T'@/_CRB_X'_P"AM7/_ !5_Y8?]M/\ V2A;AT#X5?\
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M=L_SQGC/3/&<\5W7P]\3?:%%A)]Y =A)Z@?P\GJ.V/X1T&.39 =K'&(P%4
M   #  '08K@OBK_RP_[:?^R5W]<!\5?^6'_;3_V2DMP8?"K_ );_ /;/_P!G
MKH/'G_'E+_P#_P!#6N?^%7_+?_MG_P"SUT'CS_CRE_X!_P"AK0]PZ'E^BZ6=
M5F2V4A2Y/)YP "3Q]!Q[]Q7K-GX5MK5!&(D;:.KJK,?<DC_ZWI@5P_PQ_P"/
ME_\ KBW_ *$E>G4Y,$<1X\\+PQPF[B4(T>,A  K L!R!CD9Z_@<\8R/AI?\
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M9Y",0?P(R/>O8*J3$B%(TLDPH5$4$\ *H'4GL!ZFO&M1OY->GWG):1@J*2.
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M@\!_\>47_ __ $-JY_XJ_P#+#_MI_P"R4+<.AB>"O#*ZU(S2']W%M+ =6SG
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MCCG/7&1QU P>EHJ;C/%M"U1M$N%E((VG:Z\@XZ,,9'(Z@'N!GI7M->)>(/\
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MCG/':O&/#_\ Q\P_]=H__0A36J!GI'C_ %;[!;%%(W3'9U&=I'S'!SGCCVW
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MPKFAX\M;0JDULT>X':RQ%>002#A3QC&,XYR.>!5_X63LRS1$_*I0@>[!@?\
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M8KS/XG?\?*?]<5_]">O3J\Q^)W_'RG_7%?\ T)Z4=P9O_#'_ (]G_P"NS?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKA=5U635)#/*<L?R [ #L!_]<Y))I*X:$GA__CYA_P"NT?\ Z$*]MKQ+P_\
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M'_H"TEN-[!X#_P"/V+_@?_H#5Z%XU@:>SE51D@ _@K!C^0!KSWP'_P ?L7_
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M(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,1L.K2@,%4?-\PXPV#Q@]<D'&<<UY#)(9"68DDDDDG))/4YKN=%^&C%A)=,
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M&TE-*B6! .!R0,;F[L>O7Z\#CH*;5A(O4444AGD/CS_C]E_X!_Z M>G>'_\
MCVA_ZXQ_^@BN4\2^!)]4N'N$9 K[<!BP/"@=E/I78Z7:FTACA;&4C13CIE5
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MFY'8\IU'4=/3(!-:'C7PQ+KGE^45'E[\[R1][;C& ?2CJ'0Q_A5_RW_[9_\
ML]=!X\_X\I?^ ?\ H:U7\%>&)=#\SS2I\S9C82?N[LYR!ZUI^)=+;5+=[="
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M"<^E2&XFV@-&5V@Y8'<#SCCH.Q-=#XETMM4MWMT(#/MP6R!PP/8'TI=0/-?
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M<ZA\-YYI7DC,81G8J,L, DD# 7 P/2O1J4F"/(?'G_'[+_P#_P! 6N_\!_\
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M'&))&88]!A>?Q4_A6/I/PR97#7+J4!'RQY.[V)(7';IDD9Z=:[^.,1@*H
M  &  .@Q0V"/(_'G_'[+_P  _P#0%KO_  '_ ,>47_ __0VK#\2^!)]4N'N$
M9 K[<!BP/"@=E/I73^&M+;2[=+=R"R;LE<D<L3W ]:&] 6YRGQ5_Y8?]M/\
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M_P#T(5[;7G>E_#NXM)HYF:/"2(QP6SA6!/\ #7HE*0(*S_$'_'M-_P!<9/\
MT$UH44AGBWAF]CL;F.:;[BDYXSC@@''L<'UXXYKU]M4A1!,9$",<!BZ[2>>
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M<89E4>N5!)_]"'ZU7^*.G8,=V,X(*'D8&,LO'7G+>W Z=^[L[-+-!#& J*,
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M+.1PQ4A5SG/#8)([<8YZG&*YJ?X?WD3%0@8#NKK@_P#?1!_2MC3?A>Q;-Q(
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M=0<YY[#'O6'_ ,('>_\ /+_Q]/\ XJO7J*?,Q6//=-^%[%LW$@"CM%DD]>[
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M+*>ZCTKL:*=Q6"L+QCH3ZU"L,94$2!OF) P%8=@?6MVBD,\Q_P"%8W/]^/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ([AV169!N8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 ><^+?"5U?W4D\4>4;;@[D'1%!X+ ]11X2\)7
M5A=1SRQX1=V3N0]48#@,3U->C44[BL%%%%(84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !13)7V#-0?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH
M M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^
MWZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]
M: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?M
MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV
M_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157
M[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M
M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M45
M5^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?
M;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]: +5
M%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M
M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"
MU157[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?
MK1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH
M M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^
MWZT?;?;]: +5%5?MOM^M'VWV_6@"U144$_FYXZ5+0 4444 %%%% !1110 44
M44 %%%% !1110 456>[VDC'3WI/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OU
MH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT
M6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;
M]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M
M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVW
MV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?
MK0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]
MM]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^
MWZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J
M_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/M
MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JB
MJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C
M[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:
MHJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OU
MH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT
M6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;
M]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M
M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVW
MV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?
MK0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]
MM]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^
MWZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J
M_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/M
MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JB
MJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C
M[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:
MHJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OU
MH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT
M6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;
M]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M
M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVW
MV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?
MK0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]
MM]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^
MWZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J
M_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/M
MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JB
MJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C
M[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:
MHJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OU
MH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT
M6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;
M]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M
M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVW
MV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?
MK0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]
MM]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^
MWZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J
M_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/M
MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JB
MJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C
M[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:
MHJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OU
MH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT
M6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;
M]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M
M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVW
MV_6C[;[?K0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?
MK0!:HJK]M]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]
MM]OUH^V^WZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJK]M]OUH^V^
MWZT 6J*J_;?;]:/MOM^M %JBJOVWV_6C[;[?K0!:HJLEWN(&.OO5F@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH BN?NG_/>J%:9&>#3?*'H/RH
MSJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T
M?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H
M/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\
MH>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_
M*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.
MHK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\
MH>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_
M*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRA
MZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J
M ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZB
MM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RA
MZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J
M/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H
M/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH
MSJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T
M?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H
M/RH\H>@_*@""R[_A5JFJ@7I3J "BBB@ HHHH **** "BBB@ HHHH **** ,Z
M7J?J:96D8P>P_*D\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH
MSJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T
M?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H
M/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\
MH>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_
M*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.
MHK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\
MH>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_
M*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRA
MZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J
M ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZB
MM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RA
MZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J
M/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H
M/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH
MSJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T
M?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H
M/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\
MH>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_
M*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.
MHK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\
MH>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_
M*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRA
MZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J
M ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZB
MM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RA
MZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J
M/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H
M/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH
MSJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T
M?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H
M/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\
MH>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_
M*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.
MHK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\
MH>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_
M*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRA
MZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J
M ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZB
MM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RA
MZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J
M/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H
M/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH
MSJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T
M?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H
M/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\
MH>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_
M*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.
MHK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\
MH>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_
M*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRA
MZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J
M ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZB
MM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RA
MZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J
M/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H
M/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH
MSJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T
M?*'H/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H
M/RH\H>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\
MH>@_*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_
M*@#.HK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.
MHK1\H>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\
MH>@_*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_
M*CRAZ#\J ,ZBM'RAZ#\J/*'H/RH SJ*T?*'H/RH\H>@_*@#.HK1\H>@_*CRA
MZ#\J *,74?45HTT1@=A^5.H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *Y#7O'_]DS-;>5NV;>=^,Y4-TVGU]:Z^O(?'G_'[+_P#_P! 6FD)F_\
M\+5_Z8?^1/\ ["C_ (6K_P!,/_(G_P!A7 T55D*YWW_"U?\ IA_Y$_\ L*VM
M)\?VU_A6)C; _P!9@+G&3ANG&.^W/&!GBO)Z*.5!<]]HK@/A[XG:1A82G(P?
M+)SGCG9],9(STQCT [^H:L4%%%% !1110 4444 %%%% !1110 4444 %%%%
M%?4+Y;"-IW^Z@)/3\AG')Z#U-<1+\4\-\L.4YZOACR,'[I XSD<]>O'/4^*=
M.?4;:2"/&]@, G&=K!L9]\<=L]<5Y!_9\N_R-C>9_<VG=TS]W&>G/TJDD)GM
M>F:BFI1K<1YVN.,C!X."/P(QZ>G%6JR?"VG/IUM'!)C>H.0#G&YBV,^V>>V>
MF:UJD84444 %%%% !15/6)VMX)94.&2-R#UP0I(ZUY;_ ,)Y>_\ /7_QQ/\
MXFFE<+GKU%4]'G:X@BE<Y9XT)/3)*@GI5RD 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %5]0OEL(VG?[J D]/R&<<GH/4U8KBOB9JWD
MQK:*1F4Y;D9VJ1@8Z\GOQ]TCGFA 5?\ A:O_ $P_\B?_ &%=GI&I+J<27"]'
M&<>AZ$=!G!R,]Z\4%FY0SX.P,%W=MQ!./R'X<9ZBN\^&.JEU>S8_=^91ST/#
M>P .#CCDD\]J:$F=W1114C"BBB@"&\O$LT,TA"HHR2?\_D.I/ KS^^^*$I;]
MS&H3MOR6//7@@#CMSCU-;/Q,D*6R@$@-*H.#U&UC@_B ?J*YCP'X<CUAW:;)
M6,+\HR,EL]2#GC';J>^.#26@F=/X.\9/K3M!(B@A2VY<@8!48P<^O7/X5UM9
M.F>%[?2W\Z%2I*E3\Q(()!_B)Z8[>ISVQK5+&%%%% !1110 4444 %%%% !1
M110 4444 %%<A\3O^/9/^NR_^@O6?\*O^6__ &S_ /9Z=M!7._K/UO6X]&C\
M^7.,@ *,DD_D.@)Y(Z>M:%8_BG0?[;A\D':P(93VR 1@^QSVZ=>>A0R#PSXP
MCUPF,*4D49*GD8SCAORSD#KQGK6_7*>#?!K:*S3RL"[#: F=N,@DDD YR/P]
M\\=738(****0!1110 4444 %%%% !1110 4444 %%%% !1110 4451UR0QV\
MS*2"(I""#@@A3@YH Y37_B1]F<Q6JJ^T\NV2IZY  (SVYSCK@$8-5]%^(TUU
M,D,B(1(RK\NY2"S 9Y+9QZ<?6N5\.Z6-5N$MF) <G)'7"@L?SQCVZX/2O3HO
M!%I"RR(A5D96!#L>5(/0DCG&#QT]ZIV0M3=HHHJ1A117B7A__CYA_P"NT?\
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MM:\^'=O=NTS-)EV9C@KC+')_AJ'_ (5C;?WY/^^E_P#B*K06IG_\+5_Z8?\
MD3_["C_A:O\ TP_\B?\ V%<7JEJ+2:2%<X21U&>N%8@5Z)_PK&V_OR?]]+_\
M11H&IG_\+5_Z8?\ D3_["N_KD/\ A6-M_?D_[Z7_ .(KKZ3L""BBBD,****
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M_B5]LE2#R<>8ZKGS,XW$#.-E=/X@_P"/:;_KC)_Z":\B\/\ _'S#_P!=H_\
MT(4) SVVBBBD,**** "BBB@ HHKS'XG?\?*?]<5_]">FE<&>G45@> _^/*+_
M ('_ .AM6_2 P/%7BK^P-GR;_,W?Q;<;<>Q]:/"OBK^W]_R;/+V_Q;L[L^P]
M*Y_XJ_\ +#_MI_[)1\*O^6__ &S_ /9Z=M!=3OZ***0PHHHH **** "BBB@
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M?S'F=%%4E81ZEH_C2TMX(HGDPR1H"-CG!"@'HM='87Z7Z">(Y1LX.".A(/!
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MPSTRIR*:6@KGK^M>*[?2/ED;+_W$Y;MU'0<'/)&1TS61_P +.MO[DG_?*_\
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M_KM)_P"A&NK\(>!$NXQ=7.2'Y5.5XY&2>#SU&".,')S@4R2G_P +.N?[D?\
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MCXQFT6988U0@QAOF#$Y+,.S#TKKXXQ& J@     8  Z#%>9_$[_CY3_KBO\
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MFT6988U0@QAOF#$Y+,.S#TKSF\NC=NTS8R[,QQTRQR:]CU3PU;ZHPEF3<P&
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M\D-Z#C@@G /). >OT+1UTB);=26QU)/<]<#L/8?J<DIV!%Z201@LQ  !)).
M .IS7":Q\3=AVVJ @'[TF<'KT4$'T()(/8K53XC:^\DAL5)"(%+#IN8C<.<\
M@ CCCG/7 J?P=X&CNHQ<W()#CY4RRX&?O'&#SV[8YYSP6 I?\+.N?[D?_?+?
M_%UU.@^/(-4(B;,<C' #<J2<X ;_ ! Y.!FK]UX4M;D;6A0#.?E&P_FN#^'2
MO+O$^A_V-.8,DJ0&4G&2I^GH01VSC. #3T8:H]GKS'XG?\?*?]<5_P#0GKM/
M".LG5K=97(+@E7P,<C].003CC)[=!Q?Q._X^4_ZXK_Z$]);@S?\ AC_Q[/\
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MWXH,&Q<1@J>\601U[,3G/'<8]ZWX/A_9Q*%*%B.[.V3_ -\D#]*Y;QOX.73
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M+_Z"]8'PQ_X^7_ZXM_Z$E-;!U.^\0?\ 'M-_UQD_]!->1>'_ /CYA_Z[1_\
MH0KUWQ!_Q[3?]<9/_037D7A__CYA_P"NT?\ Z$*(@SVVN2\2>/TTQS!$HD<
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M_BZ=21T!>@:G7>)=4;2[=[A "R;<!LD<L!V(]:\SUWQC-K2"&14 #!OE# Y
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MFM?VO;K*?OCY7_WAU/0#D8/' SCM6Q4C"O,?B=_Q\I_UQ7_T)Z].KS'XG?\
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METSG!Z5YC)&8R58$$$@@C!!'48H5F&I[CI=T;N&.9L9>-&..F64$U:K/\/\
M_'M#_P!<8_\ T$5H5(RKJET;2&29<92-V&>F54D5Y?JWCN?5(FMW5 KXR5#
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MXZ LD&YB6/Q0E#?OHU*=]F0PYZ\D@\=N,^HKNM*U6/5(Q/$<J?S![@CL1_\
M7&00:XGQKX*BL8OM5O\ *$P&4DG.3@$$Y.<GD=,>A',/PRU(QRO:DC:Z[@"?
MXEQT&<<@G/&< =A0TK >D4445(PHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:%24>/\ C;4?MUU(><1G8,@#&W@]/]K)'?!_"HO"QMEFWW9_=J"0,$@MD8!
M!R.I]..>.##XDC,=S,&!!\USR,<%B0?Q!R/:H=+TF75&,4*[F R1D#@$#N1Z
MU?0D]2_X3RR_YZ_^./\ _$USOC'5;'6(RR.//0?*=KC(SRI.WZXST/< FL+_
M (0.]_YY?^/I_P#%4?\ "!WO_/+_ ,?3_P"*I60]3 KV/P;=&YM(6;&0NWCT
M0E1^@Y]Z\[_X0.]_YY?^/I_\57HWA*P>PM8X)1AUW9&0>KL1R"1T-$@1Q/Q.
M_P"/E/\ KBO_ *$]<QI]I]LE2#./,=5SC.-Q SBNG^)W_'RG_7%?_0GK \/_
M /'S#_UVC_\ 0A36PF>RV.GQV"^5$H51V ]L9/J>.IY-9'C?2EO[9VP-\0+*
M3VQRW3U4'CIG'ID;]9_B#_CVF_ZXR?\ H)J"CQ*O8/ \ADLXBQ).&')SP'8
M?@!@>U>/UZ]X#_X\HO\ @?\ Z&U5(2..^).H_:+@0#.(5'! ^\WS$@]>FWKW
M'YXWAO1_[7G6W.0IR6*C. !G\,],GN1UZ5=\?1E+R0D$!@A&1U&P#(_$$?45
M-\.[Y;6ZP_'F(4!XQDD$=?7&![D"GT%U/4+.S2S00Q@*BC  _P _F>I/)IM]
MI\=^OE2J&4]B/;&1Z'GJ.15BBH*,7P[X5BT/<4RSL3\S==N>%_Q]3SZ 6/$>
MH_V=;R3C.57@@ X9OE4X/'!(S[>M:587CB,R6<H4$G"G@9X#J2?P R?:F!X_
M7=^"M8LM)BWR-B=\[LJQP,\ $+C&,$^IZ] !PE;%AX2NK]!/%'E&S@[D'0D'
M@L#U%4R4>C?\)Y9?\]?_ !Q__B:\Z\5"V:7S+-@4<9*@,-K=\ J.#V S@YZ#
M J;_ (0.]_YY?^/I_P#%4?\ "!WO_/+_ ,?3_P"*I*R&5O"ET;:ZA9<9,@7G
MT?Y3^AX]Z]GKRW1_!=W;SQ2O'A4D0D[T. &!/1J]2I2!!1112&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4457U"^6PC:=_NH"3T_(9QR>@]30!YS\2M4
M^T3BW XA'7U+@$]^F,>G.?:L#2M>FTG=Y#;=^,_*ISC./O ^IJ&-7U.8 D;Y
MI!R>!N=NO ]3V%>PQ^&[:,!1#'@ #E%)X]R"3]3S5;$[GF?_  GE[_SU_P#'
M$_\ B:H:KKTVK;?/;=LSCY5&,XS]T#T%>N_\(_;?\\8_^_:_X4?\(_;?\\8_
M^_:_X470['G?P\U;['<>22-DPP<D#YADJ?Y@#C)/TKU2O#M0M&TN9HLD-$YP
M<%3P?E8>F>"/YU[+I&I+J<27"]'&<>AZ$=!G!R,]Z) BY1114C.0^)W_ ![)
M_P!=E_\ 07K/^%7_ "W_ .V?_L]:'Q._X]D_Z[+_ .@O6?\ "K_EO_VS_P#9
MZKH+J=_7F/Q._P"/E/\ KBO_ *$]>G5YC\3O^/E/^N*_^A/2CN#.K^'\"Q6:
M,!RY<GW.XK_("NCK \!_\>47_ __ $-JWZ3W&C%\3>)DT) S L[D[5!QG&,D
MG!QC/U)_$C@9/&M]J+&.-B"X("1(">G.."WOG.1VQ5KXG?\ 'RG_ %Q7_P!"
M>NC^''E?9OW>/-R?,_O9R=N<]MO3''7OFJV0CCCX>U#50&=9&"D@>:V",XS@
M2$'TY''Y5A7$#6[-$XPR$@CK@@X/2O:=:UJ/28S+(1G!*J3@L1V'4]2,G!QG
M)XKQ:XG:X9I7.6<DD],DG)Z4T[B9[S7B7B#_ (^9O^NTG_H1KVVO*?B!HOV"
MX\U?N3Y8?[W\8ZD]3GL.<#I4Q&SU2.,1@*H     &  .@Q3JXSP5XOB>(6T[
M!'B& 7(564<#!X&0,#'4]>><=?/<+;J9'8*HZEB !GCJ:5ADE%<=/\285G6-
M03#CYGP0<G&"%/.!W[GMT^;J[.\2\031D,C#((_S^8Z@\&BP'+?$[_CV3_KL
MO_H+UG_"K_EO_P!L_P#V>M#XG?\ 'LG_ %V7_P!!>LCX9:A';M+$[!6D\O:"
M<9P6&![\CCJ>U5T%U/1JY#XG?\>R?]=E_P#07KJ_M"[O*W#?C=MR-V,XSCKC
M/&:Y3XG?\>R?]=E_]!>DMQLP/AC_ ,?+_P#7%O\ T)*W_B=_Q[)_UV7_ -!>
ML#X8_P#'R_\ UQ;_ -"2NV\5Z+_:]NT0^^/F3_>'0=0.1D<\#.>U-[B6QRWP
MKC!,S8&0(P#CG!W9&?? _(5Z#7C'AC7/[&G$^"5(*L!C)4_7T(![9QC(!KUV
MPU2+4!NA=7& 3M.2,],CJ/H<&E($6J\;\9(B7<PCQC=DX.?F(!;_ ,>SD=CQ
M7I6O>*X-'!#,&D X13\V>,9Z[>N>>W0'I7EVG6$FO3[!DM(Q9V ' )RS$<#C
M/3CG@<D4X@SUW0Y#);PLQ))BC)).225&3FO(/$'_ !\S?]=I/_0C7M<<8C 5
M0     ,  =!BO%/$'_'S-_UVD_\ 0C1$&>UQQB,!5      P !T&*=114C/'
M_'$8CO)0H &5/ QR44D_B3D^]>H>'_\ CVA_ZXQ_^@BO,?'G_'[+_P  _P#0
M%KT[P_\ \>T/_7&/_P!!%4]A(T****D9XAH<8DN(58 @RQ@@C((+#(Q7M]>-
M>*]%_LBX:(?</S)_NGH.I/!R.>3C/>O0O"_B^+4XU61@LPPI#$#<3P"O3.?0
M=#QZ$TQ(Z.N*^**(88V.-XD('/.TJ=W'U"\]N/6NMOM0CL%\V5@JCN3[9P/4
M\=!R:\K\:>(QK4H\O/E1@A<]R>K=,C.!@'L,\$D4D#-_X5R$B9<G ,9 SQD[
MLG'O@?D*ZWQ!_P >TW_7&3_T$UF>!-%;3+?,@Q)(=Q!&& Z*#_/!Z9(QG-:?
MB#_CVF_ZXR?^@FA[AT/,? ?_ !^Q?\#_ /0&KUZO(? ?_'[%_P #_P#0&KUZ
MB0(****0PKQ+P_\ \?,/_7:/_P!"%>VUX=H\ZV\\4KG"I(A)ZX 8$]*J(F>X
MT57_ +0BV>?O7R_[^X;>N/O9QUX^M6*D9XEX@_X^9O\ KM)_Z$:]=\/_ /'M
M#_UQC_\ 017D7B#_ (^9O^NTG_H1KUWP_P#\>T/_ %QC_P#0152$C0KR'QY_
MQ^R_\ _] 6O7J\A\>?\ '[+_ , _] 6E$&>G>'_^/:'_ *XQ_P#H(KR+Q!_Q
M\S?]=I/_ $(UZ[X?_P"/:'_KC'_Z"*\Y^(&B_8+CS5^Y/EA_O?QCJ3U.>PYP
M.E-;@RK''J,8"J+@    "4  =!BG?\3+_IY_\BUU/@SQG$8EM9V".@V@MPI4
M9QS@ 8 QSUXY)/'8SW"VZF1V"J.I8@ 9XZFAL+'CUWI]]>8\U)WVYQO61L9Z
MXR*[SX=V;VENRR*R$RDX92IQM7G!IM_\0H+>5(D.Y,GS' ) Z@8]><$D9&.F
M2>.ICD$@#*000""#D$'H<TFP1SGB_P (?VWB6,A95&/FSM*YS@XSC&200/8]
MB/.Y](NM'8R%'0I_&N<#/'WUXYSCK[5Z9K7C&#29%@?))/S;>=@(X)_3@<XY
M] =6QU"._7S8F#*>X/MG!]#ST/(H3:"QYGI/Q#N+/ EQ*@ &&X;@?W@/S)!)
MQ^->D:5JL>J1B>(Y4_F#W!'8C_ZXR"#7!_$B.VC=1& )\Y?: !@Y.6_VB3D=
M\=?X:O\ PM1PDK'.PLH'/&X [N/H5Y[\>E-[7!'%^(/^/F;_ *[2?^A&KL<>
MHQ@*HN     )0 !T&*M?$#1?L%QYJ_<GRP_WOXQU)ZG/8<X'2NA\&>,XC$MK
M.P1T&T%N%*C..< # &.>O'))X?01RW_$R_Z>?_(M07>GWUYCS4G?;G&]9&QG
MKC(KV&>X6W4R.P51U+$ #/'4US%_\0H+>5(D.Y,GS' ) Z@8]><$D9&.F2>%
M<=AWP[LWM+=ED5D)E)PRE3C:O.#74TV.02 ,I!! ((.00>AS3JD85XEX@_X^
M9O\ KM)_Z$:]MKR7Q[I1L;EG PDWS#KU/WN3WW<X'0$?2G$3/6(XQ& J@
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M,_W1GYL\<\?-BN0^'B.UVI3. KE\''RXQSZ_,1QZ\]J>Z M?$[_CY3_KBO\
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M/;:P/'G_ !Y2_P# /_0UK?K \>?\>4O_  #_ -#6I0SD/AC_ ,?+_P#7%O\
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M)J4;6\F=KCG!P>#D'\",^GKQ7G?PQ_X^7_ZXM_Z$E>A:KJL>EQF>4X4?F3V
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M&0D*3@D%1T]?NG..G>NS2X5V,88%DQN ()&>1D=L]J'N-'*?$[_CV3_KLO\
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MDI+<&'PJ_P"6_P#VS_\ 9Z[^N ^%7_+?_MG_ .SUW]#W!'(?$[_CV3_KLO\
MZ"]9_P *O^6__;/_ -GK0^)W_'LG_79?_07K/^%7_+?_ +9_^ST^@=0^*O\
MRP_[:?\ LE<GI<=T 6MA+@G!,0?&1V)7TS^M>B?$#1?M]OYJ_?@RP_W?XQU
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MO_04JN@NIU]>8_$[_CY3_KBO_H3UZ=7F/Q._X^4_ZXK_ .A/2CN#.O\  ?\
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MQ4C ,+8&2) 3CG VX&?;)_,UI?#'_CV?_KLW_H*5G_%7_EA_VT_]DK0^&/\
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M*X+2L%#1L 6.!G*GKT' /7Z=:]2>X5&$98!GSM!(!..3@=\=Z<MQ(X3XJ_\
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M_CS_ (\I?^ ?^AK7 > _^/V+_@?_ * U"V![GKU%%%2,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\A\
M>?\ '[+_ , _] 6O7J\Y\6^$KJ_NI)XH\HVW!W(.B*#P6!ZBG$3.8\/_ /'S
M#_UVC_\ 0A7MM>6Z/X+N[>>*5X\*DB$G>AP P)Z-7J5$@04444AA1110!X[X
MN\/G1IBH_P!6^63KP,_=R>Z_4\8)ZXJ#P_X@DT23S4Y4_>4]&']".Q[>X)!]
M=U72H]4C,$HRI_,'L0>Q'_UCD$BO/]8^&TT!S;D2*3T)"L.OK@' QSD$G^'%
M4F*QLP?%"!E!>-PW<+M8?F2O\JR-:^),ETIB@7RP<C<3E\=B,8"G'7KUX((S
M7/2>&[F,E3#)D$CA&(X]P"#]1Q6GIOP_NKLC>HC0@'+$9P<?P@YSCL<>A(HL
MA:G6^!/$_P#::?9I"3-&,Y/.Y<XSGU&0#GD]<G)QU=8?A_PC#HPW*-TG]]@,
MCC!V_P!T=??G!)XK<I,H\"KOOA5_RW_[9_\ L]8'_"!WO_/+_P ?3_XJNO\
M &@S:3YOGKMW[,?,ISC=G[I/J*;>A*.OK+\0>((]$C\U^6/W5'5C_0#N>WN2
M =2JNHZ9'J2>5,H9<@X.1R.X(P1^';CI4E'E]IX]N893.S;E8@E#]W XP.NW
MZCJ<%MU=/!\4(&4%XW#=PNUA^9*_RK(U7X:2PDM;L'7L&.U^O3^Z<#OD9YXK
MGI/#=S&2IADR"1PC$<>X!!^HXJM&3J2>)]:&L3F=5"C  _O$#H6]_P"0P.<9
MI_@^P-Y=1*,X1@Y(&<!/FY],D 9]3^%36'@6[O,'9L5L\R$+C&>J_>_3WZ<U
MZ%X9\*QZ$IP=TC=7(QQV &3@>O/)Z]@!NP6&>//^/*7_ (!_Z&M>0U[+XML'
MO[62"(9=MN!D#HZD\D@=!7G/_"!WO_/+_P ?3_XJB(V=_P" _P#CRB_X'_Z&
MU<UXQ\<F4FVM6(4'YI%."2.RD=O4]^W'WNL\)6#V%K'!*,.N[(R#U=B.02.A
MK.\2> X]3S+%B.4DDGDJQQW';GN/<D$TM+@8FC?$QH@$N5+\G+K@-CM\N #S
M[CCMGJ_Q#\08;Z!X(T8EQC]X%V@>O#'D=O0\]L' U'P3=6/\!<9 S'\V<C/0
M?-^) &?PJM!X8NIV""%\G^\I4?FV /SIV0M3+KUCX>V!M;4,V<RLSX(Q@'"C
MZY"Y!]#^-8&@_#9W(DNB%4'[BG+'KP6' [=,DCT->A1QB,!5      P !T&*
M&QI&+XU@:>SE51D@ _@K!C^0!KQZO?:\WU_X<R1N7M0&0GA2P#+G.>6P"!VY
MSST.,T18-%?0?B$^F1B!T$@084[BK8R>"2&SC@#&, 8KMO"VOG7(VG*A0)"H
M .> JGD\9Y)[#C\Z\NC\-W,A"B&3)('*,!S[D #ZGBO2/ FDRZ7 T4R[6,A(
M&0>"JCL3Z4.P(P/B1X?*M]O3HV%<<]>@;TQC [<XZDUQ5G>/9N)HR5=3D$?Y
M_,=".#7NLD8D!5@""""",@@]1BN"USX:=9+5O4['/U. WY  _4M0F#1-8?%%
M"/W\; @#F,A@3WX8KCVY/U]8]1^*('%O&<X',AQ@YY^52<\?[0Y[<<\K=>%+
MJV.UH7)QGY1O'YKD?AUJ6Q\%W=YR(RHS@E\)CWP?FQ] ?;FBR"[-[P7XS<RF
M"Y9F\YAM)YPQXQC' /&,<*>P!)'HE<EH'P]BL<23XD?'0C]V,@=CUQS@GC_9
M!%=;28(\Q^)W_'RG_7%?_0GK \/_ /'S#_UVC_\ 0A79>._#5QJDZRPIN41@
M$[E'(9CW(]:R-'\%W=O/%*\>%21"3O0X 8$]&IIZ"/4JS_$'_'M-_P!<9/\
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M[PY'HB;8\EF WL<_,1GMG ZG&.W4D\UK444AG)>)_ 2:D3/"0DK$9!^X?4\
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M9 R,\Y)!_AQ7HEA8)8(((AA%S@9)ZDD\DD]35BBANX['.>.])EU2!8H5W,)
M2,@<!6'<CUK'\">&KC2YVEF3:IC(!W*>2RGL3Z5W=%%PL4]8@:X@EB099XW
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MCS'2OAO/.P,^(TSR,@OCVQE>>G)XZX/?T+2M*CTN,01#"C\R>Y)[D_\ UA@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %<=XQ\'3:U,LT;( (POS%@<
MAF/93ZUV-% &7X:TMM+MTMW(+)NR5R1RQ/<#UK4HHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P_$'A&'61N8;
M9/[Z@9/&!N_O#I[\8!'-<C/\+YU8A)$*]BVY3^0#?SKTJBG<+'G=A\+G)_?R
M* ".(P6)'?E@N/;@_3U[C2M*CTN,01#"C\R>Y)[D_P#UA@ "KE%#=PL%%%%(
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN(T_XE?;)4@\G'F.JY
M\S.-Q SC918#MZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ***Q_$_B#^PXA/MW[G"XW;>H)SG!]* -BBN8\,>-?[<E,'E[-J%L[]W0@8Q
MM'K73T %%%% !1110 4444 %%%% !1110 45E^(/$$>B1^:_+'[JCJQ_H!W/
M;W) /#R?$^X).U(P,G (8G';G<,_D/I32"YZ916+X4U\ZW"9F4*5;:<'()"@
MD^W7IS]36U2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#=-I]?6NGT^[^V1)/C'F(K8SG&X XS18"Q1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !17$:A\2OL<KP>3GRW9<^9C.TD9QLKMZ+ %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKSO
M2_B)<7<T<++'AY$4X#9PS '^*K>O_$C[,YBM55]IY=LE3UR  1GMSG'7 (P:
M=F*YW-%>:P?%"=6!>-"O<+N4_F2W\J[!?%UNT!O=QV XP1AMV =@!ZGGL<=\
MX!-%AW-JBO.;[XH2EOW,:A.V_)8\]>" ..W./4U)IOQ08-BXC!4]XL@CKV8G
M.>.XQ[T68KGH5%0V=XEX@FC(9&&01_G\QU!X-34AA16+XB\51:& 'RSL#M1>
MOU/H,\9Y/H#@UQLGQ/N"3M2,#)P"&)QVYW#/Y#Z4[!<],HKSW3?B@P;%Q&"I
M[Q9!'7LQ.<\=QCWKN-.U./4D\V%@RY(R,CD=B#@C\>W/2AJP7+5%%>=Z7\1+
MB[FCA98\/(BG ;.&8 _Q4K >B45PVO\ Q(^S.8K55?:>7;)4]<@ $9[<YQUP
M",&LZ#XH3JP+QH5[A=RG\R6_E3LQ7/2J*Q5\76[0&]W'8#C!&&W8!V 'J>>Q
MQWS@$UR=]\4)2W[F-0G;?DL>>O! '';G'J:+#N>C45Y[IOQ08-BXC!4]XL@C
MKV8G.>.XQ[UWEG>)>()HR&1AD$?Y_,=0>#0U8":BBL7Q%XJBT, /EG8':B]?
MJ?09XSR?0'!I ;5%>9R?$^X).U(P,G (8G';G<,_D/I5BP^*+@_OXU()',9*
MD#OPQ;/MR/KZ/E8KGHE%4]*U6/5(Q/$<J?S![@CL1_\ 7&00:N4AA17G>E_$
M2XNYHX66/#R(IP&SAF /\56]?^)'V9S%:JK[3R[9*GKD  C/;G..N 1@T[,5
MSN:*Y32?$\]_9RW@""2(M@8;;A55CW)S@G'/7%9>@?$*6]G2"8($<XRJMG)'
MR_Q'JV!THL.YW]%%%( HKS>3XE7$CE840@L0@*L6()^48#]?IWZ5Z);[MJ^9
MC?@;MN=N<<XSSC/3--JP7)***;)((P68@  DDG  '4YI .HKA-5^)RH2ELF[
MT9^!U_NCD@CID@\\CCG,_P"%G7/]R/\ [Y;_ .+IV8KGIU%<YX9\:QZTQB(\
MN3LI;.X=\' Y'<8Z<C/..CI#"BN8\:^)Y=#\OR@I\S?G>"?N[<8P1ZU7TKQX
MIMS=76 WF%56,<G 4]&;MGDY Z=R,NP7.OHKS6?XH3LQ*1H%[!MS'\P5_E5_
M1/B6)6V72A0<_.@.!Z KR?7D'TXZFBS%<[NBFQR"0!E(((!!!R"#T.:=2&%%
M<IXC\?1Z8S01#?*O!Y^0'G@GJ2#C(&/3((Q7.?\ "SKG^Y'_ -\M_P#%T[,5
MSTZO$O#_ /Q\P_\ 7:/_ -"%>A>'/'T>ILL$HV2MP.?D)XX!Z@DYP#GTR2<5
MY[X?_P"/F'_KM'_Z$*:!GMM%%%2,***IZKJL>EQF>4X4?F3V '<G_P"N< $T
M 7**\YOOBA*6_<QJ$[;\ECSUX( X[<X]34<'Q0G5@7C0KW"[E/YDM_*GRL5S
MTJBL7P[XJBUP$)E74#<C=?J/49XSP?4#(K8DD$8+,0  223@ #J<TACJ*X35
M?B<J$I;)N]&?@=?[HY((Z9(//(XYS/\ A9US_<C_ .^6_P#BZ=F*YZ=17.>&
M?&L>M,8B/+D[*6SN'?!P.1W&.G(SSCHZ0PHKF/&OB>70_+\H*?,WYW@G[NW&
M,$>M5]*\>*;<W5U@-YA55C')P%/1F[9Y.0.G<C+L%SKZ*\UG^*$[,2D:!>P;
M<Q_,%?Y5?T3XEB5METH4'/SH#@>@*\GUY!]..IHLQ7.[HIL<@D 92"" 00<@
M@]#FG4AA7(?$[_CV3_KLO_H+UU]<A\3O^/9/^NR_^@O36X,P/AC_ ,?+_P#7
M%O\ T)*].KR?P%J<>FS/+,P5?*(R<GDNG  R3^';GI6E??%"4M^YC4)VWY+'
MGKP0!QVYQZFFU=B3/1J*\WM?BC,I_>1HPQT4LIS]26_E^-=UI.LQ:J@DB8'@
M9'\2Y[$=NA]CVR*35AW+U%%4]5U6/2XS/*<*/S)[ #N3_P#7. ":0%RBO.;[
MXH2EOW,:A.V_)8\]>" ..W./4U'!\4)U8%XT*]PNY3^9+?RI\K%<]*HK)T/Q
M/!K.?*)W 9*L,,!G&>X/X$XR,X)K6I#"BBL+QCKKZ+"LT84DR!?F!(P58]B/
M2@#D/B?(3<(N3@1 @9XR6;)Q[X'Y"K_@WP;;WMN+F8%S(3@9*A0I*_PD9SC/
M/L .I/(Z[KKZTXFD"@A0OR@@8!)[D^M:.D^.Y]+B6W14*IG!8,3R2>S#UJK.
MQ)Z9I.C1Z4K1P@A6;=@DG!P!P3SVSR3S[5>K+\-:HVJ6Z7#@!GW9"Y X8CN3
MZ5>O+Q+-#-(0J*,DG_/Y#J3P*DHFHKSW4OB@Q;%O& H[RY)/3LI&,<]SGVJK
M'\3[@$;DC(R,@!@<=^=QQ^1^E/E8KGIE%<]X<\:1:T?*P4EQG:3D'KT/&<#D
MC /ID FNAI#"BN.\8^,9M%F6&-4(,8;Y@Q.2S#LP]*W?#6J-JENEPX 9]V0N
M0.&([D^E%@-2BBN8\:^)Y=#\OR@I\S?G>"?N[<8P1ZT =/16%X.UU]:A::0*
M")"OR@@8"J>Y/K1XQUU]%A6:,*29 OS D8*L>Q'I18#=HKC/#_CPW$<L]UM5
M8MF-@.26W< %CD\<=.Y/'(S+[XH2EOW,:A.V_)8\]>" ..W./4T[,5ST:BO/
MM)^)K,X6Y10A(^:/(V^Y!+9[=,$#/7I7=V=XEX@FC(9&&01_G\QU!X-#5ADU
M%%<]XC\:1:*?*P7EQG:#@#IU/.,CD#!/K@$&D!T-%>8_\+.N?[D?_?+?_%UL
MZ#\2$N2(KE0C$XWK]SG/7)RO89R1W.!3LQ7.'\0?\?,W_7:3_P!"->VUXEX@
M_P"/F;_KM)_Z$:]MIR!!1114C.*\5^!'U28W,+*"X&X.2,$  8(!Z@=^_?GC
MI]%TL:5"ELI+! >3QDDDGCZGCV[FN2\2^.Y]+N'MT5"J;<%@Q/*@]F'K73^&
MM4;5+=+AP S[LA<@<,1W)]*;O81J45S'C7Q/+H?E^4%/F;\[P3]W;C&"/6J^
ME>/%-N;JZP&\PJJQCDX"GHS=L\G('3N1DL.YU]%>:S_%"=F)2- O8-N8_F"O
M\JOZ)\2Q*VRZ4*#GYT!P/0%>3Z\@^G'4T68KG=T4V.02 ,I!! ((.00>AS3J
M0PHHKA/$OCN?2[A[=%0JFW!8,3RH/9AZT)7 XWQ!_P ?,W_7:3_T(U[;7A%Y
M=&[=IFQEV9CCIECDUU/_  LZY_N1_P#?+?\ Q=4T),].KR'QY_Q^R_\  /\
MT!:]>KR'QY_Q^R_\ _\ 0%I1!G?^ _\ CRB_X'_Z&U;]>?:-XTBT6SBBP7EP
MYV@X _>-U/.,CD#!/K@$&J7_  LZY_N1_P#?+?\ Q=%F%STZBN4\.>/H]398
M)1LE;@<_(3QP#U!)S@'/IDDXKJZ0PHHKBM>^)"6Q,5LH=@<;V^YQCI@Y;N,Y
M [C(HL!VM%>8_P#"SKG^Y'_WRW_Q=;^A_$6*[Q'./+?@9ZH3P.O5><]> !RU
M.S%<Z^BBBD,*X#XJ_P#+#_MI_P"R5W]<!\5?^6'_ &T_]DIK<3#X5?\ +?\
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M_9?^ ?\ H"UZ=X?_ ./:'_KC'_Z"*\O\<2"2\D92""(R"#D$&-<'->H>'_\
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M,C#((_S^8Z@\&DT,FHHHH ***XK7OB0EL3%;*'8'&]ON<8Z8.6[C.0.XR*+
M=K6?X@_X]IO^N,G_ *":X'_A9US_ '(_^^6_^+K=3QI%K5O-%@I+Y$IVDY!^
M5NAXS@<D8!],@$T[,5SDO ?_ !^Q?\#_ /0&KUZO(? ?_'[%_P #_P#0&KUZ
MB0(X+6?AR]W.TT;J$D;<=V=P+'+8 &#[<CT/J>WL[46B+"N<(JJ,]<*,"N!U
M3XB7%I-)"JQX21U&0V<*Q _BKNM+NC=PQS-C+QHQQTRR@FAW!%JBL/Q-XJCT
M)1D;I&Z(#CCN2<' ]..3T[D<?)\3[@D[4C R< AB<=N=PS^0^E%AW/3**\^T
M[XHD<7$8QD\QG&!CCY6)SS_M#CMQSW=G>)>()HR&1AD$?Y_,=0>#0U8":BFR
M2",%F(  )))P !U.:X36/B;L.VU0$ _>DS@]>B@@^A!)![%:25P.]HKS'_A9
MUS_<C_[Y;_XNNIT'QY!JA$39CD8X ;E23G #?X@<G S3LQ7.EHHK-US7XM%0
M22D\G 5>6/K@$CIW/3\2 4,TJ*\WNOBC,Q_=QHHQT8LQS]05_E^-%K\49E/[
MR-&&.BEE.?J2W\OQI\K%<](HJGI6JQZI&)XCE3^8/<$=B/\ ZXR"#5RD,**Y
M+Q)X_33',$2B1P#DYPJMV' YQW&1CIG.<<]_PLZY_N1_]\M_\73LQ7/3J*XS
M1?B3'=,(IU\LG W Y3/<G."HSTZ]>2 ,UV=*PPHK-US7XM%022D\G 5>6/K@
M$CIW/3\2 >'G^*$[,2D:!>P;<Q_,%?Y4T@N>E45YS8_%"4-^^C4IWV9##GKR
M2#QVXSZBNVT?78M77S(6SC&0>&!(S@C^HR#@X)Q0T%S0HHHI %>>_P#"KV\W
M_6#R,^_F8],8VY[9S[X[5Z%7F/\ PLZY_N1_]\M_\735Q,].HHKG/$WC6/16
M$0'F2=U#8VCMDX/)[#'3DXXRAG1T5YC_ ,+.N?[D?_?+?_%UIZ5\3E<A+E-O
MJR<CK_=/( '7!)XX'/#LQ7.[HIL<@D 92"" 00<@@]#FG4AA116;KFOQ:*@D
ME)Y. J\L?7 )'3N>GXD @&E17FL_Q0G9B4C0+V#;F/Y@K_*G6OQ1F4_O(T88
MZ*64Y^I+?R_&GRL5STBL#QY_QY2_\ _]#6KNAZ_%K2&2(G@X*MPP],@$]>QZ
M?B"!2\>?\>4O_ /_ $-:%N,X#P'_ ,?L7_ __0&KUZO(? ?_ !^Q?\#_ /0&
MKUZB0D%%9NN:_%HJ"24GDX"KRQ]< D=.YZ?B0#P\_P 4)V8E(T"]@VYC^8*_
MRH2'<]*HKSFQ^*$H;]]&I3OLR&'/7DD'CMQGU%=MH^NQ:NOF0MG&,@\,"1G!
M']1D'!P3BAH+FA117+:_X_BTMS"BF1U/S8.U1UR,X/([C&/?((I =317F/\
MPLZY_N1_]\M_\76OH7Q)6Y98KE0F?XP?ESGC(/0>^3SUP.CLQ7.WHHK+\2ZH
MVEV[W" %DVX#9(Y8#L1ZTAFI17$>&O'CWSO]IV)''&6)4,.C*.['UZ 9)QBJ
M%]\4)2W[F-0G;?DL>>O! '';G'J:=F*YZ-1572[HW<,<S8R\:,<=,LH)JOKF
MOQ:*@DE)Y. J\L?7 )'3N>GXD H9I45YK/\ %"=F)2- O8-N8_F"O\JDL?BA
M*&_?1J4[[,AASUY)!X[<9]13Y6*YZ-16?H^NQ:NOF0MG&,@\,"1G!']1D'!P
M3BM"D,**Q?$7BJ+0P ^6=@=J+U^I]!GC/)] <&N-D^)]P2=J1@9. 0Q..W.X
M9_(?2G8+GIE>0^//^/V7_@'_ * M=#H_Q-WG;=( "?O1YP.G522?4D@D]@M<
MYXXD$EY(RD$$1D$'((,:X.::5F)GJ'A__CVA_P"N,?\ Z"*T*S_#_P#Q[0_]
M<8__ $$5H5(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,\X.W!Q[X/Y&DMP9I?#'_CV?_KLW_H*4?$[_ (]D_P"NR_\ H+T?#'_CV?\
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M;< KG)^H'; QVKJ:X#X5?\M_^V?_ +/7?T/<:"L>_P#"5K?N9Y8\NV,G<XZ
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M((/7!!R.M"U!GM/B#_CVF_ZXR?\ H)KR+P__ ,?,/_7:/_T(5Z[X@_X]IO\
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MG')SQG^ _P#C]B_X'_Z U>F>)(Q);3!@"/*<\C/(4D'\",CWKS/P'_Q^Q?\
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M-R"0X^5,LN!G[QQ@\]NV.><\<GX@_P"/F;_KM)_Z$:NQQZC& JBX     E
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M+%%F%STJ.,1@*H     &  .@Q3JAL[Q+Q!-&0R,,@C_/YCJ#P:FJ1A7)>*?
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MC+<_[1^;Z'.1VKA?'7A1-)VSP@B-SM()SM;&1@DY.0#]".O( H_\3+_IY_\
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MH4 SGY1L/YK@_ATKR[Q/H?\ 8TY@R2I 92<9*GZ>A!';.,X -6?^)E_T\_\
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M I.W&>IZ9SC(!Z=3\WW=#QY_QY2_\ _]#6M^L#QY_P >4O\ P#_T-:.HC@/
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M'!]AO+H6B-,V<(K,<=<*,FO&I-#NI"6:*4DDDDQN22>ISBO3/'G_ !Y2_P#
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M$+C&>J_>_3WZ<UZ#X:\(QZ'\P):4@@N<C@D' 7) Z#U.>^.*32 W:\2\/_\
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MS#3K"37I]@R6D8L[ #@$Y9B.!QGIQSP.2*MZ=X)NK[^ H,D9D^7&!GH?F_$
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MHIEVL9"0,@\%5'8GTH\=Z3+JD"Q0KN82 D9 X"L.Y'K2ZAT,/X5?\M_^V?\
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M@+D<[1SG/7#$]..@/((JO\3M*+JEXH^[\K'GH>5]@ <C/') Y[=S'&(P%4
M   #  '08HDC$@*L 00001D$'J,4KZA8\S\ ^)UTUC;3'$<A!#<85NAS['CG
M.!CT)(](2\21/.5E*8)W!@5P.ISTXQS7GNO_  YDC<O:@,A/"E@&7.<\M@$#
MMSGGH<9KGH/#%U.P00OD_P!Y2H_-L ?G3LF!U7CSQ='.ALH2'W8+,#E1@A@
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MB0@'+<MR/[H/Y@D$9_"G9!<YR\NC=NTS8R[,QQTRQR:]G\/_ /'M#_UQC_\
M017G^M> 9TE86T9,0"[277)^49/)!ZY[ >G%>B:/ UO!%$XPR1H".N"% /2A
M@CA?B7HOE.MZO23"M_O <'KW48X&!M]34G@3Q?':)]CG.T _(Q^[\QY4X'')
M)R>.3DC SWEY9I>(89 &1A@@_P"?R/4'D5YWK?PWE@;=:_.AQPQ <>O)PI'Y
M'G&.,T)W ]&^T+M\W<-F-V[(VXQG.>F,<YKFM;\?P6)5(B)#N&XKRH7@G!X!
M)'3!P#U/&#Y__P (Q=;O+\E\YQ]T[<YQ][[N/?..^<5NZ/\ #::<YN"(U!Z
MAF/3TR!D9YR2#_#BBR"YZ-9WB7B":,AD89!'^?S'4'@UY_\ $O1?*=;U>DF%
M;_> X/7NHQP,#;ZFN^L+!+!!!$,(N<#)/4DGDDGJ:=>6:7B&&0!D88(/^?R/
M4'D4D[#.$\ ^*TMT^Q3L% )*,Q 7!Y*D\8YR03USCC@'O?M"[?-W#9C=NR-N
M,9SGIC'.:\YUOX;RP-NM?G0XX8@./7DX4C\CSC'&:P/^$8NMWE^2^<X^Z=N<
MX^]]W'OG'?.*=DQ'=:O\18K218XAYB@G>P[#D87/4]\]". ><CI=.U./4D\V
M%@RY(R,CD=B#@C\>W/2O/]$^&\L[;KKY$&>%(+GTY&5 _,\8QSFO1+.S2S00
MQ@*BC  _S^9ZD\FD[ CQ#3]GFIYO^KWKOZ_=R-W3GIZ<U[C;[=J^7C9@;=N-
MN,<8QQC'3%<#XG^'SLYFM "KGF,87;QU!)P03GCC&0 ,=.?AT"^.;14D"DG*
M\B,D=\G"'IP<\\8[4WJ&QT_Q%\1*4%E$P)8_O,$' 4\*>.N[GJ",<C!K,^&/
M_'R__7%O_0DJ:/X<R1V[NP#3D+L16  Y!;). 3C(]/<DC%WP)X:N-+G:69-J
MF,@'<IY+*>Q/I1I8#?\ &6E'4K9T49=<,O7JO7 '4E<@#U/XUYIX8US^QIQ/
M@E2"K 8R5/U]" >V<8R :]GKC/%W@3[>QN;; D.2RG@,?4>C'OG@]20<Y28,
MZFPU2+4!NA=7& 3M.2,],CJ/H<&LCQ)XRBTI"$*O+D@*#G!'4MCICTZD\>I'
MF\_ABZ@8H87R/[JEA^:Y!_.MW1_AM-.<W!$:@] 0S'IZ9 R,\Y)!_AQ3L@N<
M=7OM>4ZAX#NO-?RHOW>]MGSI]W)V]6ST]>:]6HD"/*?B!HOV"X\U?N3Y8?[W
M\8ZD]3GL.<#I70^#/&<1B6UG8(Z#:"W"E1G'. !@#'/7CDD\=3JNE1ZI&8)1
ME3^8/8@]B/\ ZQR"17G>K?#FX@<^0!(A)Q\P5@/?.!^77&<#I1>X'ID]PMNI
MD=@JCJ6( &>.IKF+_P"(4%O*D2'<F3YC@$@=0,>O."2,C'3)/' P>&+J=@@A
M?)_O*5'YM@#\ZZ70?AL[D271"J#]Q3ECUX+#@=NF21Z&BR"YZ%'() &4@@@$
M$'((/0YK O\ QS;V4_V9B< '<X&55AT7C)/OCH<#UV[MO MNJQ(,*@  ZX &
M!UKB/$?PZ\YFGM2!GGRSP,\YVGMGC / YY P*2L-G;P7"W"B1&#*>A4@@XXZ
MBO*_'D=M'/MM@ P&) H 0$=  ._][''3ONK.G\,74#%#"^1_=4L/S7(/YULZ
M3\.;B=QYX$: C/S!F(]L9'Y],YP>E-*PMSI_APCK:Y?.#(Q3)S\O X]/F!X]
M>>]=34-G9I9H(8P%11@ ?Y_,]2>34U2QA7A6G[/-3S?]7O7?U^[D;NG/3TYK
MW6O/?$_P^=G,UH 5<\QC"[>.H).""<\<8R !CHXL3.^M]NU?+QLP-NW&W&.,
M8XQCIBN(^(OB)2@LHF!+']Y@@X"GA3QUW<]01CD8-<Q#H%\<VBI(%).5Y$9(
M[Y.$/3@YYXQVK:C^',D=N[L TY"[$5@ .06R3@$XR/3W)(P[) 0_#'_CY?\
MZXM_Z$E>G5PG@3PU<:7.TLR;5,9 .Y3R64]B?2N[I/<$>8_$[_CY3_KBO_H3
MUU_@/_CRB_X'_P"AM6'X[\-7&J3K+"FY1& 3N4<AF/<CUKH_"5@]A:QP2C#K
MNR,@]78CD$CH:'L'4V*Y#XG?\>R?]=E_]!>NOK/UW1UU>)K=^,\@X!((Z'G\
MCTR"1D9I(9Q/PRU".W:6)V"M)Y>T$XS@L,#WY''4]J]"^T+N\K<-^-VW(W8S
MC..N,\9KR/4?!-U8_P !<9 S'\V<C/0?-^) &?PKH?A[H$]E*;B5"J-&P&[
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M/E/^N*_^A/7IU<YXP\)_VXJNA"RIP">A![$@$\=1U[\<Y#0F1_#_ %".6U2
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M0P:N,PL"<9*GAATSQ[9QD9&>AK.\3^#(]9S*OR38X/\ "V.FX8_#(Y'O@"N
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5STGCZS0$B0D@'@(^3[<@#\R!70UY
MG)\,+@$[7C(R<$E@<=N-IQ^9^M-6$S UG5'UR<RD'+D!5&6P.@4?_6ZDDXYK
MUO0-+_LN!+?.2@Y/7DG+8X'&2<>U97A7P6FC?OG(>4CKCA<CD#_'@XXP.<]+
M0V"04444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img63237988_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img63237988_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &^ AD# 2(  A$! Q$!_\0
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M88#/?/0<4 8>J_\ );[#Z)_Z :U]9\<ZDWB*30_#.F1WUU#D2O*3M!'4=1@
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M_P"D1O$'BFZ=&R"O?@#OUJ3X<R-KGCC4-<NYH4G*L5A#@,2WH.I 4$?E1KU
M]=KRO2/B%XLUV&6/3=$M+FYB.YV4,J*F.!R_))SW[=*]4KQ3X;^+--\.1W\6
MIEXHYBK)*L98$@'Y3CZC%) SNO"7CE-<M+X:C"MG>6*EYU .W8,Y(!Y&,<BL
M-?'_ (GU.*ZU#1=!ADTNW)W/)DO@?1ADXYP <5F^%[*Z\27?B_4K6)XX;V":
M*$GC<[G<%S]!S]:R/#M[H]GI-Q:ZMKGB#3KF)V!M;24JC^VW:<-U!SBG8#T>
M/QK]O\!W>OV,*+<6ZD/#+EE5P1P<8R,$'\:YU/B#XJN]#.J6>AVS6UN/])G8
M-M)SSM7=G &,]?PIT%EH]M\+M;GT66_>VG7)^V  A@0., #'Y]*L>%O^2-:A
M_P!>UW_Z"U(#;L_'-K+X(/B*Y@,>S*-"I^])G "GT/'T_"N;_P"%@>*H;&/6
M;GP_;_V,[##J2&QG'7<<?4K@UBV&GW.H_!RZ%LK.T%^9BB\DJ%7/Y9S^%16V
MH>&)O#=O#J/B'Q)OV+'+8QS;HQC'0%=NT8X&<CBG8#;^)>JW6J>&-.NK.%&T
M>X*RF9OOK)AL+C/IG/'4=:MIXF\2Z%X!2^N]/LHS'Y$5IG+"2(K]XX?.>!Z?
M2J_C*RM;+X5:?!IYN7M$N$=&N5Q)M;>?FX'=O3TJ#Q'K=AJ_PL@CLI2[6AMH
MI@4*[6V].>O3M0!T'ASQ/XGUETOY]'@BT7RF<RQ@M*Y4'A%W9.2.!C\35:Y\
M4^,DTBZUH:/8VEC W_'O=K()RN<9QD#O6EIEW<Z?\*X+NR3?<Q:?OC&,\XZX
M[XZ_A7G;7-AJG@R[U'5]=NKK5V8I#:/.<*<C!"#MC)STI =EKOB&]U[X8-J6
MG6:?O@T=VCM_JHP&#,IR,\A<=>O2LGP/?:S;^"]1,NGVDFC0V5S+%)( WFRC
MG8R[N5/S9X'UJSX>!D^"U^J#<PCGR!SCG/\ *JWA+6K&3X;:KHRS$WT5C=RM
M'M/"X/.>G\0I@;7A?Q9;6_@.[UJZL;.SCAG91!8Q>6KMA<8&>I)Z^@]JSAX[
M\82:>=9C\/6YTD9.X[MVWUSNSCWVXK#T[3+G4_@_=+:HTDD&H&8HHR64* <?
MGG\*V;7XAZ-#X 2P;S/M\=G]E^S^6<,0FW=NZ8[^OM0!TMSXR6?P%/XBTR-#
M)&H_=3 D(^X J<$9Z_RKF?\ A87BJXT0:M::';&RA $\[AMI;OM&[..V>:KV
M.F7.F?!;5/M4;1M<R"=%88(4M&!GZ[<_C6GI/_)#9/\ KVN/_1CT =AX9UQ?
M$6@6^I"+RFDRKIG.U@<'!]*YOXM?\B?'_P!?:?\ H+5+\*C_ ,46G_7Q)_2H
MOBU_R)\?_7VG_H+4NH=##M?&7BG2_#.GWD6@1?V/;P10F:0DLX50N[@\ GH=
MN.:V=<\>W=IHNCZYIMO!)I]VQ2=958O&P/(!! SPW4=JQ;WQWI,OPY_LK$BZ
MC]E6U:W,9 4@ %L],<9QUK4TSPQ/>?"/^SIXBMU(CW$2%?F#;BRCZD<?\"I@
M;'C7Q=)X=T>TN=/6&>XNY (A("5*8R3@$'NOYUTMDURUA;M>",71C4RB,$*&
MQR!DGC/O7C7A)[CQ;XCT.UNE+6VCV^6SR#M;Y?\ V08]%KVRDP1P?BO6OL/C
MS0K'^S--N/M#1#[1<0;Y8\RX^1L\8ZCWIGB'QUJFC^,3H]KI\-VC1KY:*K>8
MSL.!G.,9]NE9WCG_ )*?X8_WX/\ T<:9JO\ R6^P^B?^@&F!I:3XYUM/%D.A
M>(=+@MI)^$,).5)^Z3\Q##C'%3>(_'&HVWB,:!X>T^.\OE \PR9*@XS@ $=!
MU)-97C X^+OAW']R#_T:]5+B[3PA\6;J_P!461;.Z5BDRJ2,,!S[X(P<4 4K
M[4M1U+XG:$=6T_[#>P/#%)&&RK?O&.Y3Z?-ZGIUKK)-:Q\6XM*_LS33E<_;#
M!_I _<EOOY_#ITXKF-4U^T\1?%#0[JP#-;12Q0K*RE?,(<DD9YQ\W^<UIR_\
MEZA_W#_Z3F@#0U#QSK-[XAN-(\+:5#>/;$B668_*2#@X^90!GC)/-:/A+Q?>
MZS]NM]4TR2VN[,$OY4;%6P<%0.?F![9.:X[PWJEMX(\9ZU;:V9($F)V2["P(
MW$@X S@@UU-EX_;6[763I6F3EK*WDDBF8@JY ^7(Z@GKCGI2 KW'BCQB=,O=
M8CT>RL[&V)/DWRR+.RCOC('^>].U'Q)?^(/AG<ZCIMC'YDB217<<C<1QA&WL
MIR,\8(Z_0UQ27=EJ_A&_U'6]>NKC5=S)!9M.0H)^Z0@ZCD^PKIO!W[SX0ZNB
M?,WE72X'7/E]*8%+P!>ZW!X7O0=/M9-&C@N)!+)@EI N=I7=ROX?C6WX0\56
M\?@C4-9NK&RLHK>Y93%8P^6KG:F.,_>).,_2L7P1K=A_P@FI:-YI^W>1<R^7
ML/W=G7/2L[0],N=4^$6J16J,\L>H&4(HR6 2/('X<_A0!MKX[\87-B^L6WAV
MW.DKEBQW%MHSDYW#(&.H7'%=&?&27G@2Z\0Z=$HEA4@PS?,$<$9!QC/7/;J*
MYC2/B#HMCX$2PF\W[=#;F 0>62'." <],=,YY]C5;1=+N=/^$6M37*-&;K]Y
M&K#!V?* ?QYH M)\0?%5WH9U2ST.V:VMQ_I,[!MI.>=J[LX QGK^%;R^/H_^
M$#_X2)K0^;N\GR W!DSCKZ=_TK+\+?\ )&M0_P"O:[_]!:L_PG-I4/PLNSK4
M$LUB;QE98T+$'"X/'3GO_C0!?A\6>/6AMKT^&;>:SGPR"$,7*GD'AR1QW(KT
M.VE>:UBEDA:%W0,T3$$H2.AQZ5XA=:EI6D6 N?"_B?58ILJ182H<#GG<?N\<
M^M>P>';N\O\ P]8W6H1>7=RQ!I%VXY]<=LC!_&DP1J4444AA1110 55O--L=
M0 %[96UR%Z":)7Q^8JU10!6L].L=/4K96=O;*W40Q*@/Y"I9[>&ZB,5Q#'-&
M>J2*&!_ U)10!0M=$TFRE\VTTNRMY!_'%;HA_,"K]%% #)H8KB)HIXDEC889
M'4,#]0:K6FD:9I[E[+3K2V<\%H8%0G\A5RB@"J^F:?)?+?/8VS7:_=G,2F0=
MN&QFG7=A9ZA&([VT@N4'(6:,.!^!%6** (+6SM;&'R;2VAMXNNR) @_(4Q-,
MT^.^:^2QMENV^].(E$A[<MC-6J* *ITRP-^+\V-M]L'2X\I?,Z8^]C/3CZ4Z
M[L+/4(Q'>VD%R@Y"S1AP/P(JQ10!!:V=K8P^3:6T-O%UV1($'Y"DN["SOT"7
MMI!<H.BS1AP/S%6** *MGIFGZ?G[%8VUMG@^3$J9_(4R\T;2]0F$U[IMG<RA
M=H>:!7('7&2.G)_.KM% &5_PC'A__H!:9_X"1_X5I111P0I##&L<2*%1$& H
M'   Z"GT4 9TF@:-+-YTFDV#RYSO:V0M^>*JIX3T:+Q FMQ6BQW:J1\G"$D8
MW;?7&>?>MNB@ KSOX?>#[O3K+4;?Q!I<)29XVC2;RY0<!LG )'<5Z)10!'!;
MPVL*PV\,<,2_=2-0JCZ 55N=%TJ\G\^ZTRRGF_YZ2P*S?F15ZB@"&2TMIK4V
MLMO$]N1M,3("A'ICIBF1:?90636<-G;QVK AH$B4(0>H*@8YJS10!!:6-II\
M)ALK6"VB)W;(8PBY]<"JW]A:.+C[1_95CY^<^9]G3=GUSC-:%% #)H8KB%H9
MXDEB<89'4,I'N#5(:%HZVK6PTJQ%NS!FB%NFPD="1C&:T** (X8(K:%(8(DB
MB085$4*JCT '2JB:'I$<KRII=DLC@AG6W0%L]<G'-7Z* *]I86=A T%G:06\
M+$L8X8PBDG@G 'M4$6B:3 93%I=E&9E*2;+=!O4]0>.0:OT4 06EC::?"8;*
MU@MHB=VR&,(N?7 JN=#TEKG[2VEV1GSGS3;INS]<9J_10!%<6T%W \%S#'-"
M_P!Z.10RM]0>#4::?91V/V%+.W6S((^SB)1'@G)&W&.235FB@""TLK6P@\FS
MMH;>+.=D,81<^N!1=V-IJ$(AO;6"YB!W;)HPZY]<&IZ* *+:+I3SI.^F633)
M@+(8%++C@8.,BJ/B>?Q#!8QGP[:07%PS%9!*0-JXZC+ 9S]?I6Y10!QW@#PK
M<^';*ZN-1V?;[MPSA2#L49P,CC.22<<=*[&BB@"K/IEA=745U<6-M-<18\N6
M2)6=,'(P2,CGFA],T^2^6^>QMFNU^[.8E,@[<-C-6J* *LVF6%Q>1W<]C;2W
M,6/+F>)6=,'(PQ&1R2:==V%GJ$8CO;2"Y0'(6:,. ?H15BB@"D-&TL/ XTVS
M#V_^I;R%S'SGY>..?2GG3+ WXOS8VWVP=+CRE\SIC[V,]./I5JB@"K>:98:B
M%%[8VUR%^[Y\2OCZ9%26UI;64(AM;>*"(<A(D"K^0J:B@"@NB:2D[3KI=DLS
M?>D%N@8_4XS4UII]EI\3165G;VT;'+)#$J GU( JS10!1BT32H'D>+3+*-Y5
M*R,ENH+@]0>.0:FL["ST^$PV5I!;1%MQ2&,(">F<#OP/RJQ10!0?1-)EN?M,
MFEV3SYSYK6Z%L_7&:MSV\-U \%Q#'-"XPT<BAE8>X/6I** *T6GV4%DUG#9V
M\=JP(:!(E"$'J"H&.:+;3[*SMFMK6SMX(&)+111*JG/!R ,59HH SH] T:*8
M31Z18)*#D.ML@8'ZXK1HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***Y+Q_<QQZ-! 9MDDDZG:&P2H!R?ITK2C3=2:@NIABJZP]&5
M5]#K:*\]T9=-A\:V2:1>37%NT+ER['[V&XZ#VKT*JKT?9-*^ZOM8SP>*^LP<
MK6L[:.ZZ=?F%%%%8G6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%<OKGB67[4-)T1?M&H/\K.O*Q>OMG]!6E.E*H[1,,1B(4(<T_DNK?9%KQ!XE
MBTC;;6Z?:=0DXCA7G&>A./Y=ZI:-X8>:=M4U_%S>R<B)\%8QZ8Z9]N@JYX?\
M-1Z46N[I_M.HR\R3-SMSU S_ #K?K:56--<E+YOOZ>1RT\/.O)5<2O2/1>;[
MO\BM#I]E;R>9!9V\3]-R1*I_,"K-%%<S;>YZ$8J*LE8****0PHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "D)"J68@ #))[4R>>*U@>>>18XD&69C@ 5Q<U
MWJ'C2Y:UL=]KHZ-B6<C!D]O_ *WY^E;4J+J:O1+=G+B<5&C:*5Y/9+K_ )+S
M)M1UV[U^[;2?#Y.SI/>= H]CZ>_4]JW=#T"TT*V\N ;Y6_UDS#YG/]![5:T[
M3;32K1;:TB"1CJ>['U)[FK=54K*WLZ>D?Q?J9X?"R4_;5W>?X+R7^>["BBBN
M<[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM85BB7HJ_P SZFK%%15K.?NK1+H;8?"1HMS;YIO=O?\ X"\@HHHK$Z@HHHH
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M7,4LU;3M+)P96^_(/;U^@X]ZN:;X0WW O]=G-]>'!V,<HOM[_P O:NI "@
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MBZW"G_=^;^55FUZ G;#%+(WL,5G+$T8[R1:I3>R-6BLC^T-2F_U.G[?>0_\
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M$<:11K'&BHBC"JHP /0"G45G.<IO4I12V"BBBH&%%%% !1110 4444 %%%%
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M[7/VB[@AQ_STD"_SK,G\9>&+7/G>(=+4CM]K0G\@<UYE!X ^&46/,U/49_\
MKHS#_P!!C%:D'A;X4P8/V;S#ZR/<'].E3[."[_<'LJW\OYG2S_%'P5;9WZ]
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M!4E<\?&^@_\ /TY_[9-_A33XXT+_ )^)/^_35ER2[%>QJ?RLZ.BN;/CK0_\
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M5!@2 E@#CH/NGI[5BWUS#I'Q;@O[V6.&SO++;'.[83./7H.GZBI?A\@O-?\
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MAOH\AU@6)HCSV7J,CO5R^U_1O!O@R%M*DANXT_<6PCE#AY.I+$?B3]>V:P_
MMO9W>K_\)!K6M65QK%UQ!;BX0M&#_L@\'' 7L/?H >FT444AA1110 5S>O#Q
M1<ZK:VFC-%9V++F>^=4D93SP$)Y[=NI[5TE<-\0/&4FAI'I>G,HU&Y7/FLP
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M.XI]% &5_P (QX?_ .@%IG_@)'_A5QM/LGLA9-9V[6H  @,2E !T&W&*LT4
M4QI.FK8M8KI]J+1CEH!"OED]>5QCL/RJM_PC'A__ * 6F?\ @)'_ (5JT4 5
MKG3[*]@6"[L[>>%?NQRQ*RCZ BI8((;:%8;>)(HD&%2-0JCZ 5)10 4444 %
M%%% !65_PC'A_P#Z >F?^ D?^%:M% %:'3[*WLS9PV=O':G.84B4(<]?E Q3
M(-*TZUMY;>WT^UAAF&)8XX557'3! &#U/6KE% &5_P (QX?_ .@%IG_@)'_A
M6C#!%;0I#!$D42#"HBA54>@ Z5)10!7L["ST^$PV5I!;1%MQ2&,(">F<#OP/
MRJQ110 4444 %%%% &;-X>T2XF>:?1]/EE<[G=[9&9CZDD<U8L]-L-/1TLK*
MVME<Y=88E0-]<#FK5% %2UTK3K*9IK2PM8)7X9XH55F^I JJ?#.@,23H>FDG
MDDVD?/Z5JT4 9S:!HSVZ6[:18&!"62,VR%5)ZD#& 3@40>']%MITF@TC3XI4
M.5>.V164^H('%:-% !1110 4444 %4+K1-)OIS/>:797$Q !DFMT=L?4BK]%
M %*ST?3-.D:2QTZTMI&&UF@@5"1Z9 I1I.G+>F]&GVHNR<^>(5WY_P![&:N4
M4 9T_A_1;J=Y[C2+"65SEI)+9&9CZDD<U-9Z7I^GK(ME8VULLGWQ#"J!OK@<
M]:MT4 4[;2-,LIS/:Z=:03-UDB@56/X@5<HHH **** "BBB@ HHHH ***R;[
MQ/H^FW;6MW>".9 "R^6[8R,CH#VJHPE-VBKF=2K3I+FJ227F[&M17&ZKXW5I
MK2WT$PW<TS[&$J.N"2 H&=O4D_E267C*YM=6GLO$4=O9^6@.8E9CN."!P6['
M-="P=;EO;Y=?N.)YKA5/EYM-K_9OOOL=G1638^)]'U*[6UM+P23."57RW7.!
MD]0.U</XUUO6)/$%P-&NY8H=$@2>X6-R%D8NORL!PP QP>P:L)0E%VDK';3K
M4ZJYJ<DUY.YZ=17$>.-:ED^'T6J:;=36YG,3J\,A5@&[9'Y&NS@)-O$2224&
M2?I4&A)17&_#V]N[VUU@W=U-.8]0D1#+(6VK@<#/0>U=E0 4444 %%%% !17
M%-\6_ R.RG7!D'!Q:S$?F$YKGM6^-$2WT@\/:1+JVGVJ"2ZNAOC"J>. 5R,$
M]3_]>M50J/H0YQ74]6HKA8?C!X(D@C=]7:)V4%HVM9B4..A(0CCV-27WQ'T>
MZ\+:EJ7A^\6\FM=D9!B==C.<*2& R."?PJ73FM6AJ47LSMJ*\U'AKQM'9PZO
M;>)9KC4'(E:R=B(OFZ@9.WC/3:!Z=!6O=WM^GQ,T2TDN'2.2Q=IH(Y&\IGP_
M.._(X)'85-AG9T5SWCFYGM/!>I3VTTD,R(NV2-BK+\Z]".16EHDCRZ!ITDCL
M\CVL3,S')8E1DDTAE^BBB@ HHHH **HG6; ''VC_ ,<;_"JT^J2W,@BTU?,(
M&YG(XQZ<USRQ5)+1W\EJS14IOI8UZ*S8=;M&B!F<Q2?Q*5)P?P%9_B?4U;PA
MJT]A<NDL4)(>,E&4^H/!JX5Z4VE&2%*G..Z.BHKR71/%5_8^"-=COKZ:6^BC
MCDMY99"SXF4!<$G/&<UFPZOK<'@G7#-JM\;NWOHHA(;A]R]00#G('%;6,[GM
ME%>5-XCU)?A^=.^W3?VR-1_L_P [S#YI^;=NSG/3Y<UTOPTO;J_\(K->7,UQ
M+Y[C?-(7;''&318+G84444AA115'4M8L-(6,WUP(A)D)\K-G'7H#ZBA*^PTF
MW9%ZBN>E\:Z$D3LEX9'"DJ@B<;CZ9*UGZ-XTC$,J:[)]GGR'C(B;#(PR. #_
M /J(J^25MC14*EKV.QHK"'C+0&8 :@,GCF)Q_P"RUR.J6FKZ]\1]1TNT\0WV
MFPPVR3 1.Y7H@(VA@!][-3RM;D2C*/Q*QZ717G&EWVLZ-J&N>'-1U*2],-@]
MU;73$[QQZDD]_4XQP:Z3P'<W%YX*TZXNIY)YG#[I)7+,W[QAR3S02='17DGB
MS49AX]OK2X\4WVC6:0QLAB\UU+;5XVH1C.2<^U;'P]U&^FU'5H#K$VK:3 J-
M'=SJP8N0"0 Q+ <'CIQGC/)85ST.BO+].M/$WCN"XUF/Q%/I=OYC1VMM 6 P
M/[VUA^?)Z]L"K'B.[\2:=\/+=]3NF@U-;M4,MM+M9DYQN*X&?I[=\T6"YZ11
M112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5)]+T^Z
ME,MQ86LTA&"\D*L?S(JW133:U1,H1DK25SF]8\'VNH-;26+Q:;+ Q;?!  6/
M&#P1R,<?6H]+\&QVNH2WFI78U-Y$V8N(<\\<Y8GG Q7445LL554>2^G]==SD
M>7X9U/:N&OSMVVV_ I1Z;8V1:>TTVV295.WRHE1CQT!XZUP&G?#(:Q'/J/B2
M2[@U*YG>1HH)8RJ@GCLWOT/3%>F45BY-[G7&$8JT58\OE\+^(SX!O/#S6?FR
M07@-H_G)B2+).>3QSD\X^][5L:5J'Q -_:0WVAZ?%9;U6:1'!94[D?O3SCVK
MN**+CL>7:5:>/?#LM_%INB6DL%Q=/.&GE0GGTQ(.P%>AZ-+J,VDV\FK6\=O?
ML#YL49RJG)QCD]L=ZO447&%%%%( HHHH Q6\'^&'=G?PYI#,QR2;&,DG_OFN
M(\0?!];[5Y[C0]5_L>RO56.[M(8L(5&/NA2!@XS@\9_*O4:*TC5G%W3)<$]S
MG+'P'X6L;""U_L#39_)C">;-:1N[X'5B1DDTNJ^#M*N_#U[I6GV5IIXN,-NM
MX%C&]3E20H&?\#7145+E)[L=D>:M;?$F>TBT8I:V\*$1G48I0'*KT.0V<' Z
M*#Z]ZN>)=+\3P^*=+U;1K2/4);6S\EY)F1 S'<"2NY>QSQQ7?44KA8\_O(_&
MNO\ AO5K#5-'M('DB3[.()%!=MX)!)D(' ]J;IEW\1+2.SLWT'3Q;0A(BYD4
ML$&!GB7KCVKT*BBX6"BBBD,**** (#96I.3;0D_]<Q5.[TD.XDM&%O)C:VT8
M!'X5IT5E.A3FK-%QJ2B[IE2'3+2&)4\B-R.K.H)-9_B72WO/"VI66GVR&>>(
MJB+M3<?J<"MNBJC3A'X4)R;W9Y9+X$U2;4O#LAMR+=+>!-17S$^4QGZ\\<<9
MZ4EWX/UZ70O$5LECF:[U(3P+YR?.FYCG.[CJ.#S7JE%:7(L><GP7J'_"P!J'
MDG^S-OGD^8O^N\O;C&<_>YSBMWX?Z1?:)X86SU&#R;@3.VS>K<'&.5)%=311
M<=@HHHI %07-E:WBJMU;0SA>5$L8;'TS4]% )VV.8\0>%(]0MX8]-@L;5E?<
MY\D*6&.!D#/X55C\+:I<:S;7NI36$Z1 *R"+ADYXQMQWKL:*M3:5C95YI6*(
MT72E8,NF60(Y!$"\?I7%:MI_BVP\=WVLZ%I<%U'/ D(:>10, +GC>ISE:]#H
MJ;F3;>YP6D^'=>N9]8UO7$A34KRS>V@MHF&$!'KD@=!CD]3DUFZ+_P +%T+2
M(--M= L7A@!"M+*I8Y8GG$H'?TKT^BBY-CR_6M"\32>+9]6M_#NGZ@L]O&C)
M>>6Z*VU=V%+@@@@C/I6CX-\.ZQ;^(KO5]4TZRTR-[?R%M+0*$<Y!W;5)'8]^
MIKOZ*+A8\VATGQMX2^TZ=X?M[2_TZ1VDA>5@&ASV^9EYZ>H_,BIM8\->)+KX
M?PZ?-,=2U3[4)FW2*-B\_+N;&<9[^N!P!7H=%%PL<7I>I>/Y=4MX]2T/3X;)
MG FDC<%E7U'[T_R-=I112&%%%% !1110 4444 %%%% !1110 4444 %%%% '
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img63237988_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img63237988_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  6 .\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WJXN$MHP\
M@8@NJ#:I/+$ ?AS2274,5S#;N^)9MWEK@\[1DT^6))DV.,C(;\0<C]15'4+6
M9M0L+V)#+]F+AHU(!(9<9&2!P0.,C@GZ$ <VL6*CB21S\_RQPN[?*Q5N%!.,
M@C-7(I4FB26)P\;J&5@>"#T-<^NDW,8A>2V+L/-D#6TYCEC=Y"^TG(#)R 0>
MXZ'/%V]L;VZ\/):R2J]V!$92#@2E64LOT;!'XT :#W4,=PENS'S74NJA2<@$
M GCW85([!%W'./8$G\A7/R:1<23VTD5JEO&C$F,29VYGB?Z#A&.!P#Q51?#M
MVEM$D<42OY3K+A@-S&='7/K\H:@#K:A>ZA2[BM6?$TJLZ+@\A<9.>G\0_.L"
M32+K['>11V<7VAA+^_,G,P:3<!CO\O'S< \<@FFZ1H][:ZT+F5"MNIFV!F7<
M RP@9"@*"2C$@<4 =/17-/I-W(IADMLQ(+GE95!?S)E==N01T!X88SQT.:JS
M:!?S( ZGR_+ECC2,0HR%FR&;Y2H)[LG(P.#0!U]%9>K6,UREB47STMYQ)+"Q
M'[Y=K+CG@D$AN>.*R(_#UU]FE\R*$RE8_)^;/E8G=]H)Z;591^% '3P3QW,0
MEB;<A)&<$<@X/ZBI*Y:/2KA-1MK<%/*FW27B=>$D+1X]R6 /J![5LWR2ZGHU
MW#;[X99$DB0OQR"1GOP<=?0T :%1SSQVT#SS-MCC4LQQG _"N6E\/W<EN1%#
MC$XF$<[(-RA "F(P% ?H>HP,GGBK!T:Y,5XGV6,S2+/BY,F"X=LJN!UP..>F
MT8Z\ '2U%%<13O,D;;FA?RY!@C#8!Q^1%<[-I&H2Q&$01[8_M!RT@VR[YED"
M\<@%00<^O>JTV@7DMS).EL8;9I96%I&8N=T<:AB&!7JC9[C=QW! .PHKG+'1
M[RRU.VD5 P4*L\LS+)N C"Y5MH<-D#(^[C)ZFGZ[;O/K6G8L1=K]GN5VMC:I
M/EX))X_R>M &^2 "3T%1P7$=S&LD1+(RAU;:0"",C&:Y5/#VHK- LVV<QO%N
MF9EPR",*W4%RQ.>,A<'UI(_#UZJ0DQE(XQ"'AC\LEML;*2 P*GYB#S]>M '8
M5%;W$5W D\#AXGY5@.M<[;:!/&NZ2-&D5;0(S,&*[)"S@' ['' &:BL]"O+3
M[#Y5K&LT.Q79]C1E0[%CC&Y3@D@J>2><8H ZRBLS6+*6[^Q.B"6."X$LL!(_
M>KM9<<\'!8-S_=K(C\/W7V:3S8H3-MB\KYL^5B=WV@GIA64?A0!TYFC6=("W
M[QU9U7U (!/_ (\/SI0X+,H!RO7(('Y]ZPO$6D2ZD288$D9K2:#<< J6*$<G
MMA6''K4-YHMP;Z5X(%^RM)&VR+8#@1L. PV]2.HZ9(YH Z%)XI)I85;,D6-X
MP>,\BI*XY?#]\+-5F@WS+$JKL:-U#!,8*R#!7WX..G4UUT(<01B7;Y@4;MGW
M<XYQ[4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
7 **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img63237988_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img63237988_4.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **:SA>IQ]:C-VH[_S
MIJ+8G)(FHJM]O7W_ ,_C3#J'M^M5[.78GVL.Y<HJG_:'M^O_ -:C^T/;]?\
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ME4G 'W!Z'D DCU/3/3(!KJ:**\FM6G5ES2=V=<(*"L@HHHK,H**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5#<7 B'O1<3^4/<]*SF8L<FM*=/FU>QE5J\NBW!W+\FDHHKH
M.8****!!1110 4444 %%%% !1110 4444 %%%1W%PMLID<X51R332N 7%PML
MID<X51R37GVO:\VJ-CI&I^5?ZGW_ )=!W)->UYM4;'2-3\J_U/O_ "Z#N3DU
MZN$PGL_>EO\ D92E<****["0HHHH ***EM[=KEA&@RS'@"DW8!;2U:[=8EZL
M<?\ U^.PZGVKU?0+9-/C6W4 8ZD#&X]R?<_RX["LC0=!72USUD8?,W]![?SZ
MGL!JUY&-KJO[JV1O2O!W-BBN>U+Q?'I8VO\ -)V52,],C=Z#ISU] :X/5_$\
M^J\2-A/[B\+V_$\C/).#TQ7-0RZK5?9=_P#(Z)XF,5YGH6H>,K6R_C#G .(_
MF[XZCY?P)'\JPKOXE@9$41(QP7;'..Z@'O\ [7/J*X2BO2IY70CO=^O_  #G
MEBIOR.K_ .%D7']V/_OEO_BJ/^%D7']V/_OEO_BJY2BMOJ5#^5$>VJ=SJ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6EHUVPBC!9F. !_G\SVKUW0=.;3H5@D<NRCKV'^R.^!VS^@P!'H_AR'22S1
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI^5?ZGW_ )=!W)R:]7"83V?O2W_(RE*X4445V$A1110 445+;V[7+"-!EF/
M%)NP!;V[7+"-!EF/ %>@Z#H*Z6N>LC#YF_H/;^?4]@#0=!72USUD8?,W]![?
MSZGL!JUY6+Q?M/=CM^9K&-@KE_$_B?R,V\)^;HS#M[#W]3V^O0\3^)_(S;PG
MYNC,.WL/?U/;Z].,K3"82_OR^2%.?0****](S"BBB@ HHHH *Z'PMX;_ +18
M2RY$(/T+>WT]3^ YY#/#?ALZ@?-DXB!_%O8>WJ?P'.2.[1 @"@8 & !TKAQF
M+Y4X1W[]BX1ZFQ'&(P%4  #  X  Z#%.J.WD\Q0:DKP'N>DG=7"BBBD,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KAOB=_P L?^VG_LE=S7#?
M$[_EC_VT_P#9*Z\N_P!YC\_R9CB/X;.%KV30?^/>'_KE'_Z"*\;KV30?^/>'
M_KE'_P"@BN_./@CZF&$W9?JEK4AC@E9201$Y!'!!"G!S5VJVIVQNHI(5QET9
M1GIE@0*\>#2DK]SLELSQ6NJ^',8:Y8D E8F(SV.Y1D?@2/QKE:Z+P'>BUN@I
MQB12N2<8)P1]<D8 ]Z^DQB;H3MV/-HNTT>HT445\R>F%%%% !1110!RGQ(_X
M]U_ZZK_Z"U>;UZ1\2/\ CW7_ *ZK_P"@M7F]>_E?\!>K.#%?Q#MO#OC:'38$
MMW5RR[L[0N.6)[L/6M+_ (61;_W9/^^5_P#BJ\WHJIY=1G)R=[O7<2Q$TK':
M:Y\0OM"F*V#+N'+M@,.N0 ,X^N?7 S@UQ=%:6B^'Y=8)6+&%QN+' &<X]3SC
ML#[UM3I4L-!VT75D2E.H^YK?#[3C<7'G_P ,()/U8%0.OU.>>F.]>EU0T725
MTF)8%YQR3@ DGJ>/R'7@ 9.*OUX.-Q'MZKDMMD=]&GR1L%%%%<QH%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !3)ONGZ&GTR;[I^AIK<3V9E4445UG"%%%% !
M1110 445'<7"VRF1SA5')--*X!<7"VRF1SA5')->?:]KS:HV.D:GY5_J??\
MET'<DU[7FU1L=(U/RK_4^_\ +H.Y.37JX3">S]Z6_P"1E*5PHHHKL)"BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWAOPV=0/FR<1 _BWL/;U/X#G)!X;\-G4#YLG$0/XM[#V]3^ YR1W:($ 4#
MP .E<.+Q?)[D=_R+A"^H(@0!0, #  Z4ZBBO,- HHHI %%%% !1110 4444
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MZ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)'=H@0!0, #  Z5PXO%\GN1W_(N$+Z@B! % P , #I3J**\PT"BBBD 4444
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MS@^E<-XB\9MK$8A";%SEOF)SCH.@X[]^<=,5U/C^T>Z@58U9B)0<*"QQM;G
MKSJZL)+3'F(R9SC<I7..O45GEM"C*"F_BOW_ $*Q,YIM="O7=?\ "SO^F/\
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M>K45'! +=1&HPJ@ #V P.M25XC.T**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DJ;P5]:RJV*R=4D6TS*YP
MH&23_GU[5M0>MC"O'2Y#<7"VRF1SA5')->?:]KS:HV.D:GY5_J??^70=R37M
M>;5&QTC4_*O]3[_RZ#N3DU[F$PGL_>EO^1Q2E<****["0HHHH ***EM[=KEA
M&@RS'@"DW8 M[=KEA&@RS'@"O0=!T%=+7/61A\S?T'M_/J>P!H.@KI:YZR,/
MF;^@]OY]3V U:\K%XOVGNQV_,UC&P5R_B?Q/Y&;>$_-T9AV]A[^I[?7H>)_$
M_D9MX3\W1F';V'OZGM]>G&5IA,)?WY?)"G/H%%%%>D9A1110 4444 %;WAOP
MV=0/FR<1 _BWL/;U/X#G)!X;\-G4#YLG$0/XM[#V]3^ YR1W:($ 4#  P .E
M<.+Q?)[D=_R+A"^H(@0!0, #  Z4ZBBO,- HHHI %%%% !1110 4444 %%%%
M !112JNXX]:!EVP3 W>O]*M4BKM&/2EKDD[NYV1CRI(****104444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7#?$[_EC_P!M/_9*[FN&^)W_ "Q_
M[:?^R5UY=_O,?G^3,<1_#9PM>R:#_P >\/\ URC_ /017C=>R:#_ ,>\/_7*
M/_T$5WYQ\$?4PPF[+]%%%>*=IXWKW_'Q-_UUD_\ 0C5SP?I(U*X56QM0;V![
MA2,#&"#DD9'IFJ>O?\?$W_763_T(UN?#?_CX;_KDW_H2U])6DXX9M;\IYL$G
M4MYGI%8GC+3_ +;:N.,QC>,D_P /)Z?[.0/K^-;=4->_X]YO^N4G_H)KY^A)
MQJ1:[H]":O%H\;KTOX>3F2V*D\)(P'L,!OYDUYI7I'PW_P"/=O\ KJW_ *"M
M>WFB_<?-'%A?C,WXEWN6CMQG@%C_ '3DX7\1@_G[FN)KL?B5;%98YN,,A4>N
M5))_]"'ZUQU:8!)8>%OZU)Q%_:,]!L?'=K91K"B2;4  ^5/S.&')ZGWJ?_A9
M%O\ W9/^^5_^*KE/^$(O/^>?_CZ?_%4?\(1>?\\__'T_^*KF>&P3=W)?^!(T
M56LNGX%;Q'?17\QGA#*' )# #YNY &>O7USFH-&N_LD\<I)4*ZDD9Z9^;IST
MSD=ZT/\ A"+S_GG_ ./I_P#%5+:>!KEG42(0A8;B'3(&>3U/;V-=7MJ$:?+S
M*UK;HRY*CE>S^X]1KQO7O^/B;_KK)_Z$:]DKQO7O^/B;_KK)_P"A&O/RCXY>
MAT8O9$_AC2/[5G6(_<'S/_NCMU!Y.!QR,Y[5ZS! MN B *HZ!0 /7H*\[^&_
M_'PW_7)O_0EKTBHS6I)U>7HD5A8I0N%%%>;^./$C7<C6B'$<9P<9^9AUS[ \
M =,C//&.7#8:6(GRKYLUJU%35SHI/%-EHP,46#\V2(AD9;DG/"GTX/' Q@<4
M;GXEHI_=Q,PQU9@IS] &_G^%<3I^G2:@WE1*6;!.!@<#N2>!^/TKJ+;X:RL?
MWDB*,=5!8Y^A"_S_  KTYX7"47[[N_-_Y'*JM6?PK0YW6=7;5I/.=55L '8"
M,X[G).3V^@%&@_\ 'Q#_ -=8_P#T(5/XDT+^Q9!#NWY0-G;MZDC&,GTJ#0?^
M/B'_ *ZQ_P#H0KM3@Z-X[6T,=5/7>Y[)7F_Q(_X^%_ZY+_Z$U>D5YO\ $C_C
MX7_KDO\ Z$U>-E?\=>C.S%?PSG=-LC?2I ,Y=@,@9P#U./8<FO9+2T6T411@
M*JC  _S^9[UY)X<O?L5S%+P ' );H WRD]N@)KV&M\WE+FBNEOQ(PB5F^H5Y
MW\0]'%M(MR@P)<AL#C<.<YZ98'IQT)Y)->B5P_Q*U#B.U&,Y+G@YXRJ\].?F
M_(?CS9;*2KQM\S3$I>S=SAHY#&0RD@@Y!'!!'0YKUO7-4$5H]RA.&C^4KP?G
MX4]B.2#ZCZUY%7JFOZ85L&MP03'$O)XR(\$^O4+Q_.O0S%1<Z5^_X:'/AV^6
M?H>5UTWA'Q!!HP=I%<R.<94*0%';)(/)Z]N!7,UI:;X=GU)3)"FY0<9W*.<
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M9<D9&1R.Q!Y'X_6O&[FT>U.V164D9PP*G'K@U+I>J2:9()HCAA^1'<$=P?\
MZXYQ45\LIS5X:/\  J&)E%VD>T454TK41J,27"]'&<>AZ$=!T.1GO5NO%E%Q
M;3W1V)W5PHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXQ@=1KS4<)3M>R_$BTZLKG5^#H##:1*PP2"?P9BP_,$5LTV.,1@*H  & !P
M!T&*=7SU2?/.4N[N>C%<J2"BBBH&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*0C-+10!YIXJ\'-IQ,T(+0G)P,DIW.?]GT/;H>Q/+U[G7&^(_ 0G_>VH"MSE
M"<*>IX]#VQPOTQS[&#S).T*GW_YG'6PW6/W'GU%23P-;DHX*L.H8$'UZ&HZ]
M5.YRA1113 *WO#?ALZ@?-DXB!_%O8>WJ?P'.2#PWX;.H'S9.(@?Q;V'MZG\!
MSDCNT0( H& !@ =*X<7B^3W([_D7"%]01 @"@8 & !TIU%%>8:!1112 ****
M "BBB@ HHHH **** "BBB@ HHJQ;VADY/ I.22*C%R=D1PP&4\=/6M&.(1C
MIRJ%&!2USSJ.1TTZ:CZA1114&@4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\^\8^,?M.;2W/R='<?Q?[(_V?4]_IUD\#^*6!6QERP/"$ DC_9/^SZ'^'O\
M+]WL>7U51]I^'D8_6(\_+^)WM%%%<9L%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !63X
MGL);Z!HH&PQZCIN'=<]L_KT/!-3:=KT.HL\43 M&>?<>H]1GC/\ 0@G0K1<U
M*:=M5KJ2[31XI!8R3R"!5)D)QMQ@Y'7.>F.^>G>O4/#/AE=&7)PTK#YF_P#9
M1[?SZGL!J)8QI(9PH$C  MCD@?Y_' ST&)ZZL7F$JZ45HNIE2PZ@[[L****X
M3<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *\^\8^,?M.;2W/R='<?Q?[(_V?4]_IU[^2,2 J
MP!!&"#R"#U&*\]USP%)'*!;#,<A[G[G?D_W?0]>W)QGMR[V/M+SW6U]C'$<_
M+H8.@VTUQ,HMLB0'(/8#N3[>OKTP<XKUZ#=M&_&_ W;<[<XYQGG&>E4="T*/
M1X_+3EC]YCU8_P! .P[?7).E2QV*5>>BT77J%"DZ:U"BBBN,V"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** (;N[6T4RR$*JC))_S^0[UY;XF\3-K+8&5B4_*O_LQ]_P"70=R?4KNT
M6[4Q2 ,K#!!_S^1[5Y[=?#^59Q"AS$V3O/8#J"/[WIZ]>.<>CELJ$&Y2^);7
M_K<Y\2IM)+8H^#K6>:<-;G;M^^Q&5VGL1WSV'7/.1C(]6JII>EQZ9&(8AA1^
M9/<D]R?_ *PXP*MUAC<3[>I=*R6Q=&G[.-@HHHKE-0HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@"&[NUM%,LA"JHR2?\_D.]<9:_$7=.=ZX@. /[R_[1QUSW Z#&,D'=C>,=<E
MOI3"X*)&>$/7_>.."2.F. .F<DFIH7AN76#\@P@.&<]!WZ=S[#U&< YKV*&!
MI0I.=3JON_X)QU*\I3M$];CD$@#*001D$<@@]#FG56T[3UT^-8(\[4'&3D\G
M)/XGG^56:\B5KNVQUK8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJFJ:I'ID9FE.%'YD]@
M!W)_^N>*<8N3LMQ-VU++2!< D L<#/<X)P/P!/X4ZO(-:\0RZI*)R2NT_(%/
MW?H?7U/\@ !Z!X/U]M7B)D4[HR 6Q\K?_7]1[@]\#LQ& G1IJ;^?D94\1&<K
M$^O^&8M9VE\JRD?,O7&>5_P]#SZ@Z5I:+:*(HP%51@ ?Y_,]ZFHKE=2;BHMZ
M+H:J*3OU"BBBH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4454U35(],C,TIPH_,GL .Y/_USQ3C%
MR=EN)NVI;KB?B!H<L^+M261!RG]WU88Z@]^X^GW>KTO5(]3C$T1RI_,'N".Q
M'_UQQBK=:T:LL/4YK:KHR9Q52-CR?PSX9;66R<K$I^9O_91[_P NI[ ^I6EH
MMHHBC 55& !_G\SWIT$"VX"( JCH%  ]>@J2M,7BY8B79+9$TJ*IKS"BBBN4
MU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAIH$TQ:***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-V,ZM54U<W;K6([;()R1V7D]<?3]:R+KQ([Y$8"CU/)Z_E_/ZU4M='DN<$#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMJ.J*Y;"_6I:S]0R3QV%;RGR+FM>QER\VE[7+L*[0!3ZQX[MH^A_/FKEM?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]WZG/4445[YPA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBF/+MH ?3#*!4+.6IM $QGIOGFHZ* )//-'GFHZ* )//-'GFHZ*
M)//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'
MGFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ*
M )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-
M'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ
M* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//
M-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFH
MZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )/
M/-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GF
MHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )
M//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'G
MFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ*
M)//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'
MGFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ*
M )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-
M'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ* )//-'GFHZ
M* )//-*LQ/%14J=10!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ\PXZ^HR<?RZ<YXJ;1O%3V.(Y/GC  'J.>Q[\=C[8(%=W63_ ,(O;[_-V_\
M <_+G.<X_ITQVKKCC(SARU%<7LVG=&M1117":!1110 4A..:6FNNX8H!BAMW
M2EJB"8#5N*42#-5*%B(SOIU'T445)84444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%-9PM0M*6H F+A:89ZAHH E,])YYJ.B@"3SS1YYJ.B@"3SS1
MYYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B
M@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS
M1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.
MB@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3S
MS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ
M.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3
MSS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YY
MJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"
M3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1Y
MYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@
M"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1
MYYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B
M@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS
M1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.
MB@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3SS1YYJ.B@"3S
MS1YYJ.B@"3SS4RG/-5:LIT'TH =1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445#
M+)V% !)+V%1444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4J=124
MJ=10!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#F?%OBT:6/(BP9B/J%![GW]!^)X
MP#YI)(9"68DDG))Y))ZG->K>)O#*ZRN1A95'RM_[*?;^74=P<KPEX+^QG[3<
M@>8#\J\$+C^(XX)]/3KUZ>M@\30H4&_M=5U?_ .2M2J3G;H7O!&F36$.)B<,
M<JAZJ._TSUQV^I(KHJ**\RK4=2;F^ITPCRI(****@H**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BJ]Q<8^446B%1GUJN72Y//>5BQ1114E!1110 5#<N5'%344T
M[,35T5(;;=R:M 8I:*)2;%&*B%%%1W%PMLID<X51R32*)**XK4_&;RG$'RKQ
MR0"Q]?4 ?KQU[5T^B7S7T*S-@%L].G#$=\^E7*G**NQV)=0M3=1M&#@G'Z'-
M9%OH/DY,N&'&,$_CZ5T%(R[N#4*US*=&,W=[D=M"L2@( ![?YZU+5:(^4=AZ
M&K-.2L5!W056G&PAQ5FLK4-<CB!5?F/MT_/_  S1%V8JLHJ.KL:@.>:6N;MM
M;>21%'"D@$<'J>N< ]ZZ2EH*E551:'-:AJLDDC1H.A(&.3P3S_GI^M4[?299
M^BD#U/ _7^E=8UJK'=M&[UP,^G6F6K8RI[4<MT82P_-+WF9EMX95>9&)Z<#@
M>X]3^E:"1"V8*HPN,<5;J&Z3<,^E.%DS;V48+1$U%,C?>,T^D:IW*]Q\I#5Y
MCXW_ ./R7_@'_H"UZC<KN'TKS?X@*//5@,%HE)]R&89/X 5Z65O][\FOR9RX
ME:/[SF:***]PXPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#U;P1_QYQ?\#_\ 0VK<8[>:QO!T)AM(E;K@GUX9B1T]C6I=-@8]:^7K^]6G
MZO\ ,]*#M37H):#@GU-3TR-=H I]92=V7%62(VMU8Y(&:DHHJ4DBFVQ&;:,^
ME0+=YZBK%1/;!O:KC;J1)2Z#T</TIU4_LS*>/SJY1));!%M[A59QYS8["I9Y
M?+'O26\>P>YH6BN*6KL2TUT#]:=14ED,=L$.:9.WF$(/QJ::3RQFF6T>!N/4
MU:?VF9M+X42JNT8I:J2NR'/_ .JIH9Q)QWI.+M<:FKV):***DL*Y+QC?2V\B
MA&95*?PD@$Y.>1UXQ]/QKK:IZG;I<KY3C<"?\GCFML/-0J)M7)G\)BZ!XJ\[
M]U<$!NS' !]CT /IV/UZ]-7!>(=">T8RJO[HXZ= 3V([<_AR![5T'@^9Y(?G
M^Z&PI/7 [=.@/3D^G&*VQ-&#C[2.W8F$GLS=HHHKC-!KH'&#5-E,!J]370.,
M&JC*WH1.%_4;%,)*DJO%;E#FK%$DKZ#BVUJ%%%%24%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5'))MX[TLC[?K5>@ )S1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !5E.@^E5JLIT'TH =1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
MV1MHJM4DS9./2HZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"E3J*2E3J* +5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !116)XPN9K>W9X,YS\Q'4+@Y(_3GL,G
MC&1=.'/-1[BE+E39E>+?&GV,_9K8CS ?F;@A<?PC/!/KZ=.O2UX2\6C5!Y$N
M!,!] P'<>_J/Q'&0/-(XS(0J@DDX '))/08KTOPEX2&ECSY<&8CZA0>P]_4_
M@.,D^KB\/AZ%#E?Q='U;_P OZW.6E4J3G?H=-1117CG6%%%% !1110 4444
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M/0Y';\".M=IH6NKJ:XZ2*/F7^H]OY?D3U5\+[.*E%W1$9WT-6BBBN4L****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *0G%+44[=J (F;=S2444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %64Z#Z56JRG0?2@!U%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%(3CFEIDIP* *Y.:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "E3J*2E3J* +5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%<;XQ\8_9LVEN?GZ.X_A_V1_M>I[?7
MIK0H3K3Y8DSFH*[.NBG6;.T@[20<$'!'4''0CTJ2O(/#VM2Z7*&B!;<0"G][
MT'U]#_,$@^OUKC,(\/)*]T]B*-7VB,FP\,06,K7,:X9N@_A7/7:.V?TZ# XK
M6HHKGG.4W=NYHHI;!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "K*=!]*K593H/I0 ZBBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"F2]*?3)>E %>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ I4ZBDI4ZB@"U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>@'_ -<]S72>)](DO'147Y0#\Q/ )YP0,G^'KTYQ5SPSH@T]2[$%VX..@ [
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MGL3GOT/3_'%0ZOX8CO\ YQ\C^H P><DD<9/7G(]\US$NEW&FD;"3OR/W>X]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M64Z#Z56JRG0?2@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %,EZ4^F2]* *]%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !2IU%)2IU% %JBBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %64Z#Z56JRG0?2@!U%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,EZ4^F2]* *]%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2IU%)2IU% %JBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K*=!]*K593H/I
M0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "F2]*?3)>E %>BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ I4ZBDI4ZB@"U1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4452E?S&P/PJHQN3*7*7:***DH***AEN/+..M-)
ML3:1-12#FEI#"HI+</\ 6I:R?$VJ?8(C@_._RKZ^YZ@\#OV.*J-V[(&D]#G?
M%.H?:F6W0EBC,"!G&[.,>Y'/Y\5L^$M*:Q5F?[SD?+UQMSW]\_Y[<QX>TPWT
MJ@9VJ06([8Y SD<GH,<]^U=^]MW7@UM4:2Y0E>*LB>BJZW!7AJF:0*-Q(P!D
MG/''O6#BT)23'45P&M>)9+J0^6Q5%)"[21GW/0\_I^9/<6+,\:,_WBB[LC!S
M@9X[<U4J;BDV4U8GI",\4M%0(K-"8^5_*E6\48W$ DX&3C)/0#W]JK:YJXTR
M,OP7/"@]S_@.I_+/(KA]-CDU*9 <N<@G<<_*#DYSV_SU-;1ASJ[$H6U6QZ31
M5=)RGRM^=3@YK)IH%),9+")*BCE\KY6JS37C#\&FI=&)QZK<4'-4+FY\S@=/
MYTV28KE >*AK:G3MJ85*MU9!1116AB%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 53U?_42_P#7-_\ T$U<JGJ_^HE_ZYO_ .@FKA\2]0>QYA11
M17OF 4444 %%%% !1110 4444 %=%X&_U[?]<S_Z$M<[6UX0E*7*@=&# _3!
M/\P*QQ*O2EZ#CNCT&BBBO#-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@"U%>'&WOV-6(8=G)ZUFUH6USYG!Z_SK*I&RT-Z4[O7Y%BBBFL
MX3DU@=!7U*Q%_&T).-PZCV.1^HKS^>VETEP>C G:PY!QQQ_@>QY'->@%C/P.
M!6=XAT#[>@*'YTS@'H<XR/KQQV]>N1V86M[)\LMF923EJB]I.IKJ2"5>.<$'
ML?3W_P _2KM<OX3TF:S=GD&U2N,$]2#UP/3!Y]^,@UT[-MY-85X1C-J+NBXM
MM:BUC>(M+%\HVX$BG@GT]#C\QU_4UH-,9.%_.GQVX7D\FH<5;4<*LHRO'[SB
M=,U$Z:S(PR"0&P>1M/Y'J?\ &NYB QE<8/<=_P :Y'Q3I/V9O/7[KGGG^(Y)
M_ ]?SZ<5<\):ID?96ZC)7IT[CZ]^_?TK*,FO=._$4HU8>VCOU.EHHHJSA.'\
M1Z7]ADROW'R1TX/<<=AV^N.U;GA;4_M*>2WWH\8]UZ#\NA_#O6CJE@+Z-HNY
MZ'T(Z=C^/MFN$L[EK"028Y0\@\'T(YZ>GM6;]V1Z--_6:+B_B1Z-13(I1* Z
M\A@"/H:5W"=:T/.>AF>(M,^VQY'WTR5_J,=\XX]\5@>%9FCE./N$'=Z>WXY_
M3-=6TYDX44Y+8#D\FATU>[-88N2INFE=/KV&[VF^[P*?';!.>IJ4#%+5.71&
M"AU>HR6(2@HW(8$'Z&O/KF!M.E*Y^:-L@\=N0<<_7%>B5S_BK2C<A9D!++P0
M.3CM^1]!W]JRFKH[<%64)\KV9L6-V+Q%E'1A^1[C\#5BL/PI:26Z-Y@P&.0"
M,'T)_'C\OSW*I.Z,*T5&;2V"BBBF9A1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 54JW52@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **S?$6I-IL#W" %EVXW9QRP'8CUKBO\ A8]Q
M_=C_ .^6_P#BJ:5PN>CT5YQ_PL>X_NQ_]\M_\51_PL>X_NQ_]\M_\51RL5ST
M>BN(T_XE#I/&<X/,9SSGCY6/''^T?\.LT_58M1&^%@P'7'4=>H/(Z<9'-%AW
M+=%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK-\1
M:DVFP/<( 67;C=G'+ =B/6N<\.^-IM2G2W=4"MNSM#9X4GNQ]*=@N=K1112
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **Q/%NMOH\2R
MQA22X7Y@2,$,>Q'I6=X2\6RZQ*T4@0 (6^4$'(*CNQ]:=@N=9117->(/&RZ3
M)Y"H78#YN=H&0"!T.>.?\G" Z6BLOP[K@UF+S@I4ABI!.>1@\'CL1V']:U*
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M-N!&0#V&.H]?P[]%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1\14E^6Y78?[RY*]^W)'8=\GT%%F%SLJ*;'() &4@@C((Y!!Z'-.I#"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JRG0?2JU64Z#
MZ4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ IDO2GTR7I0!7HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *5.HI*5.HH M4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 1SOL%0VD>?F]*LD9XH QQ5*5E8EQO*XM%%%24(
MS;1FJ4:^:W-2W;_PT^VCVC/K6B]V-S.7O2MV)J***S- KS?7M2_M"5I!]T<+
M]!^ Z]>>F<5Z163_ ,(S%YOVGYMV[=C/RYZYZ9Z\]?TXK2E-1;;&G8/#.E_8
M(AD?._S-Z^PZ \#MV.:UJ**B3N[B&L@?@USOB;4$LE,'):13P., \9)_/COC
M!X-;UW=+:HTK=%&?_K<]ST'O7FUQ.^IR[CR\C 8' ] /Z?SK6C%MWZ!R)NYK
M>&M"^T,L\F/+&< \YQQ],9]>N,8P:[FJ=EIBVL:PC^$=?4]2>_4_E3OF@]Q2
MF^=DRDT]=BU3)I1"I=N H)/T')HCF$G2N7\;ZB5VVP[C<WOR0!U]02>/2HC!
MN5BEJ<_K.IG4I#*>G11C&%!X_'U]_:NU\.:-_9L?S?ZQ^6YSTS@?AG\\\XQ6
M%X/T7SF^U./E4_+D#!/KSZ?S[\&NSK2M/[**;Z#7C#\&J_,'N*M4A&:S4K&<
MHWUZC4D#\BH+NXV?*.M)<KY/S#C/:J1.:TA33UZ&52HTK=0HHHK8YPHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\6N%MG!/4J![_,#_
M "%;%<MXZNP%2#N6W=>1@8''OD_E6V&CS58^HI;'&T445[AB%%%% !1110 4
M444 %%%% !6CX>N/(N(VQG+8_P"^OES^&:SJ?#*86#KP5((^HY%3./-%KN"/
M6**CMIQ<*L@Z,H(SUY&:DKP&K&X4444@"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *53MY%)10,OI> C/?TH6(R_,WY52C?80?2M2-PXW#O6$U
MR;'13ES[B@8XI::SA.34!E:7A>!ZUFHMFCDD/EN G ZTP0F7EJDB@$?/>N)U
M\R1SL7)R#E3TP.JXZ=/;OFB4U!:&N'PSKRLW8[I5"\"EK/T34A?QAL_..&'?
M/KVZ]?3MVK0I7OJ3*#@W%]"*ZMA<J8VZ,,?_ %_J.U9>E^&EL7\W<6(SMR,8
MSZ^IQ]/IZ;-%*R94:LXQ<4]&%%%(3BF0+7+>*M)9F$\8)W<-@9Y'0_B..F./
M>NB>Y[+R::("_+&FX76I5+$.E.\=3.T&&2TC\IN3G(YS@$#C\_PK26WW<M4Z
MJ%X%+3O961$[SDY2W8@&.*6BBI&5UN<MM/2K%5+J/:<^M6(GWC-7)*R:(@W=
MICZ***@L**1FVC--CE$G2G85U>P^BBBD,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "JE6ZJ4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% &'XW_ ./.7_@'_H:UY_X6L4OKE(9!E&W9
M&2.BDCD8/45Z!XW_ ./.7_@'_H:UPW@C_C\B_P"!_P#H#52V$]SN?^$(L_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %,EZ4^F2]* *]%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !2IU%)2IU% %JBBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*** "BBB@ HHHH **** "BBB@ JI5NJE !1110 4444 %%%% !1110 4444
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MO9:30(****0RGJ^J+ID33OC@< G&3V4=>OZ=>@KR?4-3FUB3<Y+,3\JC.!G
MPJ_E[GODUT7Q'U O*EL"-J+N(!_B;/49[#&._)]:O?#S1 BF]<#<Q(3/8#AB
M.>YXZ9X]#5+1"W,B#X>7,@#$HI/9F.1_WR"/UJ#4/ US9#> ''?RR21T[$ G
MKV!]\5ZE12YF%CQ^?79+BW%F_*HX*D]0 "-ON.>/3ITQC9^''_'PW_7)O_0E
MIWQ T46L@NDSB4G<,<!@!W'][KZY!/T;\./^/AO^N3?^A+3Z"ZGH]><?$?\
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M44 %%%% !7E7C?\ X_)?^ ?^@+7JM>5>-_\ C\E_X!_Z M.(F=SX(_X\XO\
M@?\ Z&U;E>,0:M-;@(DCJHZ!78#UZ T_^WKC_GM)_P!_&_QI\H7/9*YCQOKZ
MVD+6Z,#))\I ()"D9)(P>HX&<'G(Z5P7]O7'_/:3_OXW^-2:;HL^LL2@+9/S
M.WW<DC)+'J><D<GOBBP7)_".GF]N4 Z1D.3[*0?4=3@?CFO6:R/#.@#1HMF0
M78Y8@=_0=\#MGW/&<5KTF[@@HHHI#"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "K*=!]*K593H/I0 ZBBB@ HHHH **** "BBB@ HHHH
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M&;&<9V@G&:Y2P^(GVN1(?*QO=5SYF<;B!G&VNDU[_CWF_P"N4G_H)KRG0?\
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MKSCXC_\ 'PO_ %R7_P!":A SLO#>N_VU&9MNS#E<;MW0 YS@>M:<D@C!9B
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M* "BBB@ HHHH *X;_A9O_3'_ ,B?_85W->&TTA,]RJIJ>IQZ9&9I3A1^9/8
M=R?_ *YXJW6)XNT9M6@\N,C<K!@#WP",9[=>/Z=0AC-(\9P:I(($#AF!QN P
M<#..">W/X5O5Y_X7\(W%K<)-*NU$R<[QD\$ ?*2>IYSP1D'T/H%-@@HHHI %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %*G44E*G44 6J*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **8\H3J:K27_]T?G51@Y$RG&.Y<ICRA.IK.>=GZFHZT5'N9.O
MV1H->J/?Z?\ UZC.H>@_6J=%6J42'6D6FOSV I/M[>W^?QJM13]G'L3[27<L
M_;V]O\_C2KJ![C\N*JT4>SCV#VLNY=74!W%2+>J?:LZBDZ42E6D:RN&Z'/TI
MU8]2I<LO?\^:AT>Q:KKJC3HJG'?Y^\/RJRD@DY!K.4'$UC.,MA]%%%24%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1N;!!Y.0 >XP.>O.[ITK&\'ZL--N%9L;7&QB>P8C!SD 8(&3Z9JC=SMJTY<
MEI7X!.?O'"KDXZ< =*=M17T.Q^'&E[%>[.<L=JY!' P21V.3QTXV]>M=I5;3
M;(6,20#&$4#(&,D=3CW/)JS4LH\;U[_CXF_ZZR?^A&K<'@^ZN%$BQY5@"#N3
MH1D=6J[X]TO[)/YPQMF&1@ <C ;^A)[Y^M;GP_UQ9(Q9,0'0L5]P3N/?D@D\
M<<>N#5WT).:_X0B\_P">?_CZ?_%4?\(1>?\ //\ \?3_ .*KU6BIYAV/*O\
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MD)!+$H2>.<?+[<\CU)/?&:>PNIW=%%%2,Y3XC_\ 'NO_ %U7_P!!:L/X<?\
M'PW_ %R;_P!"6HO'.N+J4JQQD%(@1N'<GK@YY' P?KU&*E^''_'PW_7)O_0E
MJN@NIZ/7G'Q'_P"/A?\ KDO_ *$U>CUYQ\1_^/A?^N2_^A-2CN#-SX<?\>[?
M]=6_]!6NKKE/AQ_Q[M_UU;_T%:ZNA[C1Y5XW_P"/R7_@'_H"UW/@C_CSB_X'
M_P"AM7#>-_\ C\E_X!_Z M=SX(_X\XO^!_\ H;4WL);FY7*?$?\ X]U_ZZK_
M .@M75URGQ'_ ./=?^NJ_P#H+4EN-E'X9?\ +;_MG_[/7<UPWPR_Y;?]L_\
MV>NYH>XD<-\3?^6/_;3_ -DKE-,T2;5-WDKNV8SRHZYQU(]*]"\=:7]MMRZX
MW1'=T&< ?,,GIQS[XQBN(\)ZR-)G$C_<8%6.,D X.?P(&>O&<#--; ]R3_A"
M+S_GG_X^G_Q5'_"$7G_//_Q]/_BJ]3CD$@#*001D$<@@]#FG4N9A8\J_X0B\
M_P">?_CZ?_%5J^%O"US8W*32)A%W9.Y3U4@< D]378:SKD6D*))2>3@*O+'U
MP,CIW/\ 4BK=I=K=J)8R&5AD$?Y_,=J+L+$M>-Z]_P ?$W_763_T(U[)7C>O
M?\?$W_763_T(TX@SV2BBBI&<-\3?^6/_ &T_]DKE-,T2;5-WDKNV8SRHZYQU
M(]*]"\=:7]MMRZXW1'=T&< ?,,GIQS[XQBN(\)ZR-)G$C_<8%6.,D X.?P(&
M>O&<#-4MA/<D_P"$(O/^>?\ X^G_ ,51_P (1>?\\_\ Q]/_ (JO4XY!( RD
M$$9!'((/0YIU+F86/*O^$(O/^>?_ (^G_P 56KX6\+7-C<I-(F$7=D[E/52!
MP"3U-=AK.N1:0HDE)Y. J\L?7 R.G<_U(JW:7:W:B6,AE89!'^?S':B["Q+7
MC>O?\?$W_763_P!"->R5XWKW_'Q-_P!=9/\ T(TX@SV2BBBI&4=>_P"/>;_K
ME)_Z":\IT'_CXA_ZZQ_^A"O5M>_X]YO^N4G_ *":\IT'_CXA_P"NL?\ Z$*J
M(F>R51U[_CWF_P"N4G_H)J]5'7O^/>;_ *Y2?^@FI&><>"/^/R+_ ('_ .@-
M7JM>4>"Y EW$20!EASQR48 ?B>!7J].0D%<I\1_^/=?^NJ_^@M75URGQ'_X]
MU_ZZK_Z"U"W&S#^''_'PW_7)O_0EKT>O./AQ_P ?#?\ 7)O_ $):[G7O^/>;
M_KE)_P"@FA[B1Q/B#Q[).3%;';'TW8^<]02,]!Z?Q<9R.@R+?1[O6_WH#R #
M 9V[9/ +D9P<].E,\,VR7-S''+C:6[XP2 2!SQR0!COG%>O4V[!N>:0?#RYD
M 8E%)[,QR/\ OD$?K6=XDT+^Q9!#NWY0-G;MZDC&,GTKUJ201@LQ  &23P !
MU.:\E\3ZO_:L[2C[@^5/]T=^@/)R>>1G':A-L&CL?AQ_Q[M_UU;_ -!6NKKE
M/AQ_Q[M_UU;_ -!6NKI/<:/./B/_ ,?"_P#7)?\ T)JZOP1_QYQ?\#_]#:N4
M^(__ !\+_P!<E_\ 0FKJ? T@:TC ()4N#CL=Y.#^!!_&F]A=3>KAOB;_ ,L?
M^VG_ +)7<USOCK2_MMN77&Z([N@S@#YAD]..??&,4EN-GGNF:)-JF[R5W;,9
MY4=<XZD>E7_^$(O/^>?_ (^G_P 54?A/61I,XD?[C JQQD@'!S^! SUXS@9K
MU>.02 ,I!!&01R"#T.:;=A)'EG_"$7G_ #S_ /'T_P#BJ/\ A"+S_GG_ ./I
M_P#%5ZK6?K.N1:0HDE)Y. J\L?7 R.G<_P!2*.9A8X_PMX6N;&Y2:1,(N[)W
M*>JD#@$GJ:Z3QO\ \><O_ /_ $-:U[2[6[42QD,K#((_S^8[5'J5D+Z)X#C#
MJ1DC.">AQ['D4KZA8\S\$?\ 'Y%_P/\ ] :O5:\:M)VTF<.00T3\@''W3AER
M,]>0>M>M:9J<>IQB:(Y4_F#W!'8C_P"N.*<@1;HHK+\0ZXND1&0D;R"$7KD_
M3(X'<_U(J1GE^O?\?$W_ %UD_P#0C7JV@_\ 'O#_ -<H_P#T$5XW7LF@_P#'
MO#_URC_]!%5(2+U%%%2,**** .&^)O\ RQ_[:?\ LE'PR_Y;?]L__9Z/B;_R
MQ_[:?^R4?#+_ );?]L__ &>JZ"ZG<T445(SG?'ED;JU+#.8V#8 SD#(/TP#D
MGVKBO!^K#3;A6;&UQL8GL&(P<Y &"!D^F:]5DC$@*L 01@@\@@]1BO*/%6A'
M2)BH_P!6^2G7@9^[D]Q]3Q@GK5+L)GK-%<1X2\:*BBUN"%V@!&[$= #CICUZ
M8ZX(R>UCD$@#*001D$<@@]#FI:L,=1110 45R?B/QTEJ#%;D-)@?,,%!GW[D
M?EZ]"*K^ ]?FNR;>0,ZJ,[R<E<]B3USV[_A]UV%<[2O*O&__ !^2_P# /_0%
MKU6O*O&__'Y+_P  _P#0%HB#.N\'Z3#<6L;O&C,=^2R*3]]AU(K9_L&W_P">
M,?\ W[7_  JCX(_X\XO^!_\ H;5N4,9Q'CSPZD48NH55=APP4!1@G@X&!P>.
M!DY]!67X%UTV,OV=ON3$#OPW0$#WX!_ YP*])DC$@*L 01@@\@@]1BO']>TD
MZ5,T!S@'*D]U/0YP,^AQQD&FM=!,]BHK#\':S_:< W',D?RMSR<=&ZD\CN>I
M!K<J1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M93H/I5:K*=!]* '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4R7I3Z9+TH KT444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %><?$?\ X^%_ZY+_
M .A-7H]><?$?_CX7_KDO_H34X[B9N?#C_CW;_KJW_H*UU=<I\./^/=O^NK?^
M@K75T/<:"BBBD!1U[_CWF_ZY2?\ H)KRG0?^/B'_ *ZQ_P#H0KU;7O\ CWF_
MZY2?^@FO*=!_X^(?^NL?_H0JHB9[)4<\ZVX+N0JCJ6( ].IJ2L/QO_QYR_\
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M UG>-_\ CSE_X!_Z&M<-X(_X_(O^!_\ H#4TM!7/5:\X^(__ !\+_P!<E_\
M0FKT>O./B/\ \?"_]<E_]":B.X,W/AQ_Q[M_UU;_ -!6NKKE/AQ_Q[M_UU;_
M -!6NKH>XT4?[>M_^>T?_?Q?\:O5X;7N5#5A)E2?5H;<E'D16'4,Z@^O0FO+
M_%MVMW=221D,I*@$=.% /ZCKW[5M^*?"US?7+S1IE&VX.Y1T4 \$@]17*7UB
M]BYAD&'7&1D'J,CD9'0TT@9ZAHNM01P1*TL8(B0$%U!!"C(QFM:VNTNANC96
M .,J0PSZ9%>5P>#[JX42+'E6 (.Y.A&1U:NY\$Z7)IL+1S+M8R$XR#QM4=B?
M2DT"-+^WK?\ Y[1_]_%_QJ]7EOC?3#97+.!A)?F'7J?O<GOGG Z BNR\$:F+
MVV5"<O%\IZ=!]W@=L<9/4@T-!<Z"BBHYYQ;J9&.%4$D^P&3TI#()]6AMR4>1
M%8=0SJ#Z]":G@G6X ="&4]"I!'IU%>/7<[:M.7 ):5^ 3G[QPJY..G '2O7-
M-LA8Q) ,810,@8R1U./<\FFU8299J.>=;<%W(51U+$ >G4U)65XIL7OK9X8Q
MEVVX&0.C GDX'04AF7XRUF":U>-)$9F*@!6#'A@>V>PZUSG@&[2UG9I&508B
M,L0HSN7C)K/OO"US8H9I$PBXR=RGJ<#@$GJ:J:;I<FI,8X5W,!G&0.,@=R/6
MKMH2>MQZU!(0JRQDDX #J22>@QFKE>::3X/NK>:.1H\*LB$G<G0,">C5Z74L
MI!39)!&"S$  9)/  '4YK/UW78]'C\Q^6/W5'5C_ $ [GM]< ^8W^ISZ[(-V
M7;G:JCIW( '\^3@<GBA*XFSTNZ\56MMC=*ISG[OS]/\ =SC\:N6VI171VQNC
M$#.%8,<>N :\QC\%W;@,(S@C/+(#S[%LCZ&JE]H\^DD/(K(<@A@<C/;YE)&>
M,XSGO3L@N>Q45PWA3QLTC+:W'.<*K\[LYX#>N>F?SSDD=S4M6&%%%% !117#
M>,?&+PN;6W.W;P[C!.2/NCTQW/7/ICD2N!UU[JT-E_K752!G!8;L>PZGIVJK
M:^*K6YSME48Q][Y.O^]C/X5YE8Z//JQ+QJSG))8G SW^9B!GG.,Y[U;D\%W:
M L8S@#/#(3Q[!LGZ"JLA7/5Z\-K>\/\ B:71'\M]QC!PR'JO/. >A!SD<9[\
MX(P::5A-GN51SSK;@NY"J.I8@#TZFI*P_&__ !YR_P# /_0UJ"C1@U:&X(1)
M$9CT"NI/KT!JW7E7@C_C\B_X'_Z U>JTVK @K-O?$=M9??D7(." =S ^X7)'
M2N,\:>*'GD:UB)6-"5;!(+'&&!Z<#D8Z'KSQC)M/"5U=J)4C)5AD$LHX]<$@
M_3UZT6%<]-L=<@OL>7(I+9P,X;CK\IP>WITYZ5>KQ_4/#EQIPWRQD+ZC# =!
MR5)QUXSU[5V7@">YE0^8<P*,)N^]D'L>ZCISTX Z&AH+G7445S7BWQ:-+'D1
M8,Q'U"@]S[^@_$\8!0SH+F[2U&Z1E4$XRQ"C/IDUG_\ "56N_P KS5W>O\/3
M/W_N_KUXZUY>L<VL2D@-)(YR<?@,GL .!V ]A6A_PA%Y_P \_P#Q]/\ XJJL
M*YZA;7:70W1LK '&5(89],BI:\;_ '^B2?Q1R#\,@'\F7(]P<=Z] \(>*?[7
M'DR?ZY!DD#AATW>QYY'XCT":"YTE%-DD$8+,0 !DD\  =3FO./%'C1K\M# 2
ML."">A;U]P/;N.O7 $KCN=[=ZS!:9$DB*5&2"PW=,_=Z].@QS5>V\3VMP-RR
MH!G'S'8?R;!_&O-;+PS<WHW1QMC .3A00>A!8C/X5+/X/NX07,1P/[I5C^2D
MD_E3LA7/6:*\FT+Q5-I!PIW1_P!QB<#G)QZ'K[<Y(->H:=J"ZA&L\>=KCC(P
M>#@C\#Q_*DU8$QUU?QVF/,=4SG&Y@N<=>IHM;^.[SY;J^,9VL&QGIT-9OB[3
M#J-LZ*,NN&7KU7K@#J2,@#U->?\ A'4QIURCL<(V5;IT;IDGH <$GT%"07/6
M:***0R.>=;<%W(51U+$ >G4U!!JT-P0B2(S'H%=2?7H#7+?$?5-BI:#.6.YL
M$C@9 ![')YZ\;>G2JOPXTO>SW9QA1M7(!Y."2.XP..G.[KUIVT%<[ZBFR2",
M%F(  R2>  .IS7G'BCQHU^6A@)6'!!/0MZ^X'MW'7K@"5QW.[OM<@L<^9(H*
MXR,Y;GI\HR>_ITYZ5#;>)[6X&Y94 SCYCL/Y-@_C7F]EX5N;U?,2,[3T)(7/
M&<C<1D<]>E/G\'W<(+F(X']TJQ_)22?RIV0KGK-%>3:%XJFT@X4[H_[C$X'.
M3CT/7VYR0:]4M+M;M1+&0RL,@C_/YCM2:L-,?)((P68@ #))X  ZG-5H-6AN
M"$21&8] KJ3Z] :9KW_'O-_URD_]!->5Z#J8TR9;@@D(&X'<E2!^IY_K0E<3
M9Z]/.MN"[D*HZEB /3J:HP>([>XD%LD@9ST"Y(Z9^\!MZ>_MUKS.XN;CQ#+_
M !.Q/"KG:H.!P.BCIDGZD]ZWO"WA:YL;E)I$PB[LG<IZJ0. 2>IHL%ST"BBB
MD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ I4ZBDI4ZB@"U1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 44A.*JSWN.%_.G&+EL3*2C
MN3RS"/K526]+<#@?K5<MNY-)71&DD<\ZS8$YHHHJS,****!!1110 4444 %%
M%% !1110 4444 %*&V\BDHH&6HKXCAN?I5M)!)R#652HY3D5G*DGL:PK-;FO
M156"]#<-^=6JPE%QW-XR4EH%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M15G"5;M,'-3PMN --N5W#Z5'9MU6KWAZ&>T_4LT445!H%%%% !1110 4444
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M8X],D5);6B6HVQJJ@G.% 49]<"GS"L2T444AE34],CU.,PRC*G\P>Q![$?\
MUCQ7EFN>'I=(8JX)3/RN!\ISG'T/'(_F.:]>ILD8D!5@"",$'D$'J,4T[":/
M,;+QY=6HVDJXP -XR1CW!!.>Y.:BOO&MU=Y&_8IQP@VXQZ-][]?TXKOKGPE:
MW!W-$H.,?+E!^2D#\:?9>&;:R.Z.-<Y!R<L01T(+$X_"G=!9GG_ASPE)JQ$C
M96')RW&3CJ /Z]!SU(Q7J4:; %&< 8Y))X]SR?J:=12;N-(P_&__ !YR_P#
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M5KG38KH[I$1B!C+*&./3)%"=ALYWX<?\>[?]=6_]!6NKJ*VM$M1MC55!.<*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 593H/I5:K*=!]* '4444
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M;_\ 'G+_ , _]#6I0SS?0]-_M*9+?. QY^@&3C@\X''O7K]I:+:*(HP%51@
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M!_\ H#5W/C?_ (\Y?^ ?^AK7#>"/^/R+_@?_ * U4MA=3U6O./B/_P ?"_\
M7)?_ $)J]'KSCXC_ /'PO_7)?_0FI1W!G5^"/^/.+_@?_H;5N5A^"/\ CSB_
MX'_Z&U;E)C"O&]>_X^)O^NLG_H1KV2O&]>_X^)O^NLG_ *$:J(F>K:#_ ,>\
M/_7*/_T$5S_Q&U PQ);CI*22?9,''3N2#GV]ZZ#0?^/>'_KE'_Z"*X;XC_\
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MD,0?SZ]:J:WHCZ.XBD*DE0WRDD8)([@>E-(&>A>!;W[3:J.28RRG/MR,>P!
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MO12<4U8J,G%W1KJP89%+69!<&+Z>E:$<@D&17/.#B=5.HI>H^BBBH+"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *:[;1FG5#=-@8]:<5=BD[*X03&3@U-4%HN!GUJ>G.UQ0ORA5:_OUL4,K]!C
M@8R<^F2/_P!56:YKQG<X"1<<DL?7C@?@<G\JB3LC>A3]I4431T;7!J6X8VLO
M;.<CU[?CQZ>M:E<UX,ML!Y>.2%'KQR?P.1^5=+1%MH>)A&%1I;!5#7+S[)"S
M]R,#G!R>./<=?PJ_7,^,KOA(!_O'U]!_6B3LA8>'/4BC)\.VGVF=?1?F./\
M9Z?KBN\KF_!ML KS=R=O3D8&3S[Y_2NDI05D:XZ?-5MV$(SQ5'5'6TC:;!^7
ML/<X'\ZOUS/C*[X2 ?[Q]?0?UJG)Q5S&C156HHLH>'W,]P93][YFX!QD]?PY
M/XXKKENAT/%8'@VTX><_[H]?4_TKI&0-UI4VK:EXYWJZ=%8%<-TJ.\N1:HTI
M_A!/)QGT&??I2-:CJ.*Q/$]WY4?DL>6Q@#'0'O[?KD>F:J5DKIF-&+G.,6MV
M<[;0-J,H7/S2-DGCOR3CCZXKT2N5\*V/EG[2Q&""%XR>N"?;I^1KJ0<\U$(M
M*YTXVLISY5]D6BBBJ.4IWJA!QU-4ZFNY-['VXJ&NJFK1..H[R844451 4444
M %%%% !6'XA\2C3?W:8:3T/0#WQW/8?CZ9;XD\2#3QY4?,I'X+[GW]!^)XP#
MPCN7)8G))R2>M=V$PG/[TMB)3MH275V]VV^1BQ]_SQ[#V'%0T45Z:26AF%%%
M%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K8T/Q
M(^FD(?FBR<KW&>X/].AY[G-8]%1.$9JSV!.QZE87Z7Z"6,Y!_,'T/O\ YZ59
MKS/2-7?3'WKR#]Y>Q'^/H>WTR#Z+8WBWJ"9/NL._!]"/P->3B<,Z+OT-HRN3
MT445S#"BBB@ HHHH  <5>C0S@,3Q5&K=A+U3\:BIM<TI6O9EI(0G2GT45S-W
M.M*Q0UG3/[1C\O."#D>F1D<^W/\ GI5?P_HS::&WD$MC[N<<9[G'K6O12LKW
M-%6DH.'0***C:X"__6JDFS)M(@U:T^UQ/&.I'&/4<CK[BN,T&Y-O.A'\1VGG
M'WN/TZ_A7;>>7^Z*J6^A1Q-Y@ !]O?KQT'X4I4]4SHH8M0A*%F[E]K@+_P#6
MJ/SR_P!T5(MN%_\ KU)57BCEM)E.>V:52,C)!P#R,X[^WK7$Z3??9)%;/RY&
M[KC'0\#KC/'O7H5<'XBM/LT[>C?,,_[77]<UG4;T9WX!1?-!]3O**J:3,9H4
M8YR5&=W4XXS^/7W%6ZHY)+E;0UT#@J>0>H/2H++3H[($1KC/7J3^9S5FF22B
M/K1:[#F:35]!]%(#GFEH$(1FJD'RMCZU<I,=ZI2LF3*-VF+1114E!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !52K=5* "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "L/QO_QYR_\  /\ T-:W*HZWIG]J0M;[MN_'.,]&!Z9'I0@.
M&^''_'PW_7)O_0EKT>N;\-^#_P"Q9#-YF_*%<;-O4@YSN/I724V)!1112&%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !5E.@^E5JLIT'TH =1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)>E/IDO2@"O
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SOCK2_
MMMN77&Z([N@S@#YAD]..??&,5T5% 'D/AS6?[(F$V"5P0P&,D'Z^AP>V<8SS
M7K-I=K=J)8R&5AD$?Y_,=JX;Q;X+,9^T6RDJ3\R*,D$]U [>W;MQTYG3=<FT
MW/DN5![<%>W.#D9XZ]:IJXMCV2BO./\ A8]Q_=C_ .^6_P#BJS]6\87&I#8S
M!5(Y6/*@]<Y.23D'D9Q[4N5A<V_'_B 2XLHSG:<R8Z9'1<YYQU(QP<=P:K?#
MS23/*;HYVQ @>[,,8Z<X!.><C(K(T+PW+K!^080'#.>@[].Y]AZC. <UZCIF
MF1Z9&(8AA1^9/<D]R?\ ZPXIO16 MUA^-_\ CSE_X!_Z&M;E8?C?_CSE_P"
M?^AK4H9RGPX_X^&_ZY-_Z$M>CUYQ\./^/AO^N3?^A+7H].6XD%<-\3?^6/\
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M6489T#8[@$D#/H>.GY\\4)6!L[SX<?\ 'NW_ %U;_P!!6NKKE/AQ_P >[?\
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M@@CJ,5WGPXTO8KW9SECM7((X&"2.QR>.G&WKUJGH2=I1114%!1110!A^-_\
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MV R!G /4X]AR:OS)/0O &F&T@,S##3'/?.T<+P?Q(QU!'-=/4<$ MU$:C"J
M /8# ZU)4,HXKXD:87"7:C[ORL>>AY7V !SSZD#FJ'P]U@6TC6SG EP5R>-P
MXQCIE@>O'0#DD5W]W:+=J8I &5A@@_Y_(]J\M\3>&6T9LC+1,?E;_P!E/O\
MSZCN!2UT$SU>BO,](\>3V("28D4$_>)W\]MW/?U!]/3%RZ^)4C8\N-5ZYW$M
M].FW'ZTN5A<[6_U6+3]OFL%WG S_ )X [D\#N:MUXZ[SZ]+D[I)" .!T'3M@
M 9/)X'.37J6@Z<VG0K#(Y=E'7L/]D=\#MG]!@ :L"8[7O^/>;_KE)_Z":\X\
M$?\ 'Y%_P/\ ] :O1]>_X]YO^N4G_H)KSCP1_P ?D7_ _P#T!J:V!GJM%%%2
M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 8'6I** "HYX%N 4<!E/4, 1Z]#4E% '-W7@"UFQM#)C/W6SG_OK=^F*=9>
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M>6T9#$NP'9F&#_WR ?UK>LM-BL1MB15& #@8)QTR>I^IJS11< HHHH ****
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M9]3U)ZGJ<G':N#\ :-]JE-RP^2+ID<%CTZC' YZY!VFO1Z)"04444AA1110
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M1110!4U+2X]241S+N4'.,D<X([$>M5M/\,V^GMYL2 , 1DEFQGTW$X^M:E%
M!1110 4V2,2 JP!!&"#R"#U&*=10!S][X%M;GD*4).<HV/PP<@#Z >W%00?#
MRVC(8EV [,PP?^^0#^M=/13NPL5K+38K$;8D51@ X&"<=,GJ?J:LT44@(YX!
M<*8V&58$$>Q&#TK.L?"UM8N)HTPZYP=S'J,'@DCH:U:* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ I4ZBDI4ZB@"U1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 445%<3>4,]^U-*[L)NRN5[V?/R#\?\*J4$YHKJC'E5CC
ME+F=PHHHIDA114]K;>;R>@I-I*Y48N3L%O:F7D\"M!5"C H Q2US3FY'5"FH
MH****DL**** "BD+;>34+WJK[_2FHMB<DMR>BJ9U#V_6F?;V]O\ /XU7LI$.
MM OT50%^WH*>-0]1^M#I2!5H%RBH$NU?V^M3!MW(J6FBU)/86BBBD,**** &
M21B08-9]Q;F(^U:=(RAA@U<)N)%2FI>ID45+<6YB/M45=*::N<C33L%%%% @
MJ[93Y^0_A_A5*E4[>12G'F5BX2Y7<UZ*9#+YHW"GUR-6.Q.X4444 %%%% !1
M110 4444 5)]6AMR4>1%8=0SJ#Z]":C_ +>M_P#GM'_W\7_&O./&_P#Q^2_\
M _\ 0%K"KUJ650G",N9ZI,Y)XIQDU8]D_MZW_P">T?\ W\7_ !H_MZW_ .>T
M?_?Q?\:\;HK3^QX?S,GZV^Q[)_;UO_SVC_[^+_C1_;UO_P ]H_\ OXO^->-T
M4?V/#^9A];?8]MMKM+H;HV5@#C*D,,^F14U<I\-_^/=O^NK?^@K75UY5>FJ5
M24.QUTY<T4PHHHK(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BL36_%L6CN(9 Y)4-\H!&"2.[#THT3Q;%K#F&,."%+?, !@$#
MLQ]:U^KU>3GMIW(]I&]KZFW1116184444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 (3BF1SB3@43MA34-F.IJE'
MW6R')\R1:HHHJ2QDL0E!1N0P(/T-8NF^%1:.)6;=MZ#;CGUZGI_.MVBDTF7"
MK.":3T85&T"GM4E%-.QFTF9.M7 TY/,'))P/3)R?Z?YZU3\/:M)>Y1LDJ,[N
MW7IZ9]/4?3F/QG/PD8/J2._& #^IJ3P9!A'DS]Y@,?[HS_[-2]I+F.M8>FL,
MY6U9M><R]13EN@>O%34TH&ZBKNNQQVDNHBR!NAI]<YX@U4V#K&@'*Y).3U)'
MJ/2M'3)3=QK,.-V>,^A(_IZ4O=;M<TE2J1@IM:,TJ*K[G7MFC[5C@C%/D9GS
MHL45RGBC471U",57;T4X.<G.<<^GMZ=ZV] G:>!'<Y//)Z\$@?RJ+ZV.B5!J
MFJE]&:%%%%,Q"LRY?<Q_+\JT)7V GT%95;45NS"N]D%%%%;'.%%%% !1110!
ME>)M1-C"67[S':".V<\]1V!Q[XKSFND\;WGFRK"/^6:\]<Y;G'Y 5S=>Q@J?
M)23ZO4RF[L****ZB0HHHH *LZ=I[:A(L$>-SGC)P.!DG\!S_ "JM7<?#C20V
M^\;!*G8OL< L>GH0 0>YS6&*K>QI.7W>I=*'/)(R[[P%<6<;3$H0@)(5CG Z
M]5 X'/7Z<US=>S66J+=O+"N,PL <'/4 _3KD$=L<UY7XBTLZ;.\.,+G*]<;3
MR.3UQT/N#S7-@<7.K)PGONO0TKTHQ2:V,VBBBO0, HHHH **** "BO2-9_Y!
M8_ZY0?S2O-ZY\-B/;1;M:SL74I\C2\@HHHKH("BBB@":TM&NV$48+,QP /\
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MZ,)_U_6AJ45&TZKWJ/[5GH,UJHMGG.:1P-P/L<K!#_JW.">3\IX_E7H<4HE
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M .A-3CN)FY\./^/=O^NK?^@K75URGPX_X]V_ZZM_Z"M=70]QH****0!1110
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M Y.>PZ]NYJ*VM$M1MC55!.<* HSZX%2TF 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 593H/I5:K*=!]* '4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R7I3Z9+TH
M KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!F^(M-;
M4H'MT(#-MQNSCA@>P/I7.>'?!,VFSI<.R%5W9VEL\J1W4>M=K13N%@HHHI %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% ',>*_"#:PXG1P&5 H5@<
M'#$YW#..OH:R]/\ AJ>L\@QD\1C/&./F8<<_[)_P[NBG=BL16EHMHHBC 55&
M !_G\SWJ6BBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<'XBG\Z=R#D# ^F!@C\\UV.DP>1"B8Q\HR#UR>3U]S7.WGAB6:8GC8[$[L]
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M]KGSI/\ 4H<$ \L>NWV'/)_ >H[Z/P];( HBCP!CE%)X]R,GZFGH@W//]/\
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M9;/7YEY.>%.0/P''0<5W&B^"(;)5,JB23J2<E>1T"G@@>I&<\\< :W]@V_\
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MO^%.Z0M3B-)^(<L!Q.!(I/4 *PZ>F <<\8&3WJ#Q[=K=S1RQD,K0J01_O/\
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M%))/4YQ0@9XW)(9"68DDG))Y))ZG-;?_  F]Y_ST_P#'$_\ B:S]:C$<\JJ
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M,O\ EM_VS_\ 9Z[>201@LQ  &23P !U.:'N"*VIZG'ID9FE.%'YD]@!W)_\
MKGBN#U/XA33$B'")G@X!?'OG(YZ\#CID]\KQ)KIUB4R<A!PBGL.YX[GJ>OID
M@"NN\/\ @*. "6Y&Z3KMS\@Z$ XZGU_AYQ@]2[6#<Y'_ (2JZW^;YK;O3^'I
MC[GW?TZ\]:U])^(<L!Q.!(I/4 *PZ>F <<\8&3WKM_[!M_\ GC'_ -^U_P *
MY_Q!X"CG!EMAMDZ[<_(>I(&>A]/X>,8'4%T%F='IFIQZG&)HCE3^8/<$=B/_
M *XXJW7*>!O#LFG SRDAI !L]!U!8?WO0=@3GDX'5U+&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %64Z#Z56JRG0?2@!U%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,EZ4^F2]* *]%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOUJHB9[):7(ND65<X=0PSUPPR*\8N[DW3M*V,NQ8XZ98Y->T00"W41J,*H
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M110!XWKW_'Q-_P!=9/\ T(U[)7C>O?\ 'Q-_UUD_]"->R54A(*HZ]_Q[S?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,EZ4^F2]* *]%%%
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MXB2"2=&4@@PJ01R""S8.::5F#-[X<?\ 'NW_ %U;_P!!6NKKE/AQ_P >[?\
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MQ@'GC.*+"N=!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !2IU%)2IU% %JBBB@ HHHH **** "BBB@
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M -=5_P#06KS>O2/B1_Q[K_UU7_T%J\WK7*_X"]63BOXA[)H/_'O#_P!<H_\
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M>?\ /3_QQ/\ XFO5J\/$X2>'MS-:]CNIUE4O8****YC0**** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<9XSZ]NM5&#E?R&E<[:BBBI$,F7<"*BM%*YS[58HIJ6EB7'6X4444B@HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCMV"D8'YGW-9_P -;(!)+CC)8*..0% )Y]\CCV_+M*;8)'+:I\/X)U/D QN
M<?,2I/OG)_+IG//2N!@FDTJ8,.)(GY&>ZG!!P>0>AP>17L]>5>-_^/R7_@'_
M * M"8,]0M+D72+*N<.H89ZX89%1ZCJ"Z?&T\F=J#G R>3@#\3Q_.LSP1_QY
MQ?\  _\ T-JR?B5=;8XX<?><MG/]T8QCWW?I2MJ,X^YN9M>FR<M(YP .@'H/
M0#_$D]37;Z9\/880#-EWQR,D)GVQ@\=.3SUP.V5\-K)9)))C]Z,*%Z<;LY/U
MXQ]":] IMB2,&3P-:," A!(ZAWR/?DD?F#7%^*/"9T7$BMNC8X!/# \D ^O
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M.W8*1@?F?<UR_A'Q!!HP=I%<R.<94*0%';)(/)Z]N!70_P#"Q[?^[)_WRO\
M\53=Q(MS^!+20%0A4GNKMD?]]$C]*\_UW0I-'D\M^5/W6'1A_0CN.WTP3VO_
M  L>W_NR?]\K_P#%5B^*_%$&LQ!$5PZMD%E7IT(R&)&>O?H/J!7!V.G\'^(#
MK$1WX\R,@-CN#T;I@9P<@>F> 0*WJ\Z^&\A$[KDX,1)';(9<''MD_G7HM)[@
M@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MST^G?VJ9JZ-<+*,*J;V&>#O]2W_70_\ H*UN,H;K532+#[!&(N"1DD@=2?\
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M HHHH **** "BBB@ HHHH **** "KFD?Z^+_ *Z)_P"A"J=7-(_U\7_71/\
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MQQ:/3**C-PH[TGVE?6L>5D\R[DM0QW:2L8U92PSD @D8X/%0WD_F(R(2&*L
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M?<'RI_NCOT!Y.3SR,X[54?SKHBW.]F3(5#N8C'4!>V,<CV]JZSPEX+9&%U<
MKM(*+W)Z@G'3'IUSUP!@U:PMSIO#&D?V5 L1^^?F?_>/;J1P,#C@XSWK5HHJ
M1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'C>O?\ 'Q-_UUD_]"->R5XWKW_'Q-_UUD_]"->R
M54A(****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5E.@^E5JLIT'TH
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MXC&6Y.,L!CCV'?G[V/6M+X=:7Y,;738S(<+P,X4G//N>W'W<^E<5=SMJTY<
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MC^7?D^N!%X(_X_(O^!_^@-3Z"ZGJM>5>-_\ C\E_X!_Z M>JUY5XW_X_)?\
M@'_H"THC9W/@C_CSB_X'_P"AM6Y6'X(_X\XO^!_^AM6Y28SPVO<J\-KW*JD)
M'EOCN QW;L1PX0CW&T+_ #!KLO DXDM$4'E"X/L=Q;^1%5/'^C?:HA<J/GBZ
MX')4]>@SP>>N -QKD_#/B9M&;!RT3'YE_P#9A[_SZ'L0;H-F>KT53T_68=0_
MU3JQP3@'#8!QDJ>1^(J'4_$4&F@^8XW#^$<OTR!@=,^IP.G-2,P?B5<A8HXN
M<LY8>F%!!_\ 0A61\./^/AO^N3?^A+6)KFLMJ\IF< <84#L!G SWZ\G^0XK;
M^''_ !\-_P!<F_\ 0EJK:"ZGH5W<BU1I6SA%+''7"C)KR"\O9=:FW-\SN0JC
MH!DX"C/0<_U)SDUZQK49D@E5023$X '))*G Q7E?AS4!IUQ'.WW5.#[!@5)X
M!Z9SCOTHB#.KT_X;*!FX<[O2/  Z]V!SV[#'O6K!X$M(P%*%B.[.V3_WR0/T
MK<@G6X ="&4]"I!'IU%9VM>)8=*5BS!G'1 1NR1D9'8=\GMZG *NP.&\>01V
M]P$B"J!&N0@ YRQY [XQ^&*Z/X<?\>[?]=6_]!6O/[Z]:]D:9_O.23U_(9SP
M.@]J] ^''_'NW_75O_05IO8%N=77G'Q'_P"/A?\ KDO_ *$U>CUYU\2(R)T;
M!P8@ >V0S9&?;(_.E'<&=3X(_P"/.+_@?_H;5N5RG@'6(Y(1:D@2(6 !/+ D
MMD#\\@9QC)ZUTS7:*PB+*'89"DC<1SR!U['\J'N-'._$. R6P8#A)%)]A@K_
M #(KBO#.FQZE,+>4L P.-F.H&><@\8!_'%>JWUDM[&T+_=<$'I^8SGD=1[UY
M%>64NBS;6^5T(93U!P<AAGJ./Z$9R*:$SN?^%<6_]Z3_ +Z7_P")H_X5Q;_W
MI/\ OI?_ (FI]"\;0WXVRD1R <[B A[<$G]#SSQG!-=!/.MN"[D*HZEB /3J
M:5V&AS'_  KBW_O2?]]+_P#$U-:> 8+5UE5I,HP89*XRIR/X:A\2>-X[13';
ML'D/&1RJ\=<]"?0#(SUZ8-GP?XE.KJ4D!\R,#) ^4@]#Z ^H[]1QD U#0Z*B
MBBD,*X;XF_\ +'_MI_[)7<UPWQ-_Y8_]M/\ V2FMQ,O?#C_CW;_KJW_H*UU=
M<I\./^/=O^NK?^@K75T/<:"O*O&__'Y+_P  _P#0%KU6O*O&_P#Q^2_\ _\
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MS&<\CJ/>O(KRRET6;:WRNA#*>H.#D,,]1Q_0C.10@9W/_"N+?^])_P!]+_\
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MR!WQC\,5T?PX_P"/=O\ KJW_ *"M>?WUZU[(TS_><DGK^0SG@=![5Z!\./\
MCW;_ *ZM_P"@K3>P+<ZNJFH:5%J(V3*& Z9ZCIT(Y'3G!YJCXG\1#18P<9D?
M(0=N.I/L,].IZ>I&;X;\;QW:B.X8)(.,GA6XZYZ ^H.!GIUP%896U3X<*^6M
MV*G)^5^5Y/0$#(P,]=V>/K7':AI\ND2^6^5=2""#^3 _YQ[$5[#YZ[?-R-F,
M[LC;C&<YZ8QWKSKQYK<>HND<1#",-EAG&20".G.-O49!S338FCL/">LG5H!(
M_P!]258XP"1@Y_$$9Z<YP,5RGQ)@*S))CY6CP#[JQ)_]"%:GPWLC'%).<XD8
M  CLF>0>_+$?A6KXMT/^UH=J >8ARO0?5<D=Q].0,G%+9AT./\(>&X=:5_,+
MAT(^Z5"X8<=03G(.?PKH/^%<6_\ >D_[Z7_XFN*T;5I-#F\P#D95E88R,\CU
M!R/P(YR,BO3-(\20:H 8V 8DC8Q ?CGIGGCG(S^AINX(R/\ A7%O_>D_[Z7_
M .)H_P"%<6_]Z3_OI?\ XFNDNK^.TQYCJF<XW,%SCKU-<7K_ ,0"&5;0C:I!
M+,OWO]G!Y ]3P?3'4I78:'0:)X2BT=S+&7)*E?F((P2#V4>E;=4=%U8:K$LZ
M@KGJ".XZX/<>X_0Y O4AA1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4J=124J=10!:HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ K*G.6/U-:M94WWC]36M'=F-?9#****
MW.8*?#]X?44RGP_>'U%#V''=&K1117&=P4444 9MW]X_A_*H:ENEVL?\]:BK
MKC\*.*?Q,****9)PGC64/. .JH ?KDG^1%3^!8"TCR=E3'O\QR/_ $$U3\80
M&.X9C_&JD?EM_F*O> YPK21]V53[?*2#_P"A"O5GIA-.R,U\1V5%%%>4:!11
M10 4444 %%%% ' ^,K?RK@MG[ZJ?I_#C_P =JWX$N-KR18^\H.?]TXQ_X]^E
M0>-W#3@ ](P#[<L?Y&G^!D)F9L<",C/;EAC^1KU9:X37L9_:.WHHHKRC0*GL
MFPWUJ"IK,?,/Q_E2G\++A\2-*BBBN0[ HHHH QZ***[#@"BBB@":T^\/Q_E6
ME6;:?>'X_P JTJPK?$=5#X0HHHK(U"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@"&[M%NU,4@#*PP0?\ /Y'M7#:W\/&0F2U(*D_<
M8X(Z<!CP>_7''J:[^BMZ&*J4'[K^70BI2C/<\5N=,EM1NDC=03C+*5&?3)%%
MMIDMT-T<;L <952PSZ9 KVJBN[^V)6^'7U,/J:[GGNA_#^21@]T J _=# L>
MG=<@ ]^<\=!G-=Y:6BVBB*,!548 '^?S/>IJ*X<1BJE=^]]W0WITHPV"BBBL
M"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSZ'_ .M50^)$5/A9GT445U'$%%%% !1110 5D>*_^/:3_@/_ *&*UZR/%?\
MQ[2?\!_]#%:T/XD?5"ELSSNBBBO=,0HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ***UM(\,3ZKS&N$_OMPO?\3R,< X/7%1.<8*[=D-1<G9&317;0?#-
MF +R@-W"H6'YDK_*JE]\.IX<F-E<#&!]UCZ\'@8_WNGOQ6"Q^';MS%NA42O8
MY2BI)X&MR4<%6'4,"#Z]#4==*=S,****8!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5S2/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4J=124J=10!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTW*XUJ=S1114 %%%5+0Y/X4U&Z;)<K-(MT444B@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "JE6ZJ4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M R!C)'4X]SR:LTAA1110 4444 %%%% !1110 4444 %%%<-\3?\ EC_VT_\
M9*$!W-%<I\./^/=O^NK?^@K75T, HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "K*=!]*K593H/I0 ZBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "F2]*?3)>E %>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/PW_ ./AO^N3?^A+3A1]GA)VE=/704I\U:.EB?XDWK&1+?\ @";N_))(Y[<
M<?4^M<;75_$C_CX7_KDO_H35RE=F!25"'H8UW^\84445U&84444 >@>#X!';
MJP_C9B?SV_R%<)<P&W9HSU5B#CIP<5Z5I$/DPQIC!"+D8QSCGCUSU]ZX#7X#
M!<2*>[D\?[7S#]#7!@Y\U6IYES6B,^BBBN\@**** "BBB@ HHHH *N:1_KXO
M^NB?^A"J=7-(_P!?%_UT3_T(5,_A?H"W/3Z***^?-PHHHH **** "G1#<0#Z
MBFT^$@$$]J'L-;FK2$9XJ);I33A<*>]<G*SLYHOJ+Y0]!^5<GXROF@=(D)7"
MDDJ2,Y..WIC]:ZSS1ZC\ZXCQI*'G '54 /UR3_(BM*-^8J*39T'A7=+ 'D.[
M+-@GDXSC!/U!]>*U_*'H/RK-\+H4MHP1CACS[L2/S%:M3-^\P:0SRAZ#\JX+
MQ;,6N&0GY4"X'894$_K7H%><>(YQ/<2,.S8Y_P!D!3^HJZ'Q#BE<[C1H0L$?
M'_+-3SSU&>_^15LVZGM4.EH4AC4C!$: @]?NBK59MN[)<4R+[,OI7!:GJ\L4
MS[7(".P [8!(''0_CS7H5>8.3J$QQP99.,G@;F]<>_I6M!WO<<8Q['I7V9?2
MC[,OI4M%8\S%RKL1?9E]*\XTV0RW$;GJ95)^I85Z4Z[P5/<=B0?S'(KEM(\'
MO;2K+*5*H<X4G.1T[#H>?PQBM:<TD[E121U=%%%8B&N< GVJM:=?PJQ+T/T-
M068ZFKC\+,Y?&BU1114&@4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !52K=5* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@"CJ>MPZ7M\YMN_..&/3&>@/K3]-U2/4E,D+;E!QG!'. >X'K7(_$W_EC
M_P!M/_9*YB#79+>W-FG"NY+$=2" -OL..?7ITSEVT%<]+O?%5M9-Y;R#<.H
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M,D#H&;)]N5 _,BL'][I,O=)8S^(_H01^!'J#19!<]GHK+\.:S_:\(FP V2&
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MTR7I0!7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **S]9UR+2%$DI/)P%7ECZX&1T[G^I%5M#\5PZPQCC#!E&<, ,C.#T)Z9
M'Y_6BP&S1139)!&"S$  9)/  '4YH =17":I\1V5BMNJE03\SYY]P 1COUSG
MCITI-)\?S7,T<3JFUW53M# _,<9R6/3/I^76G9BN=Y15;4=073XVGDSM0<X&
M3R< ?B>/YUD:9XWM]0D$(W*S=-X !/ID$\GM^77%*PSH**** "BBB@ HHHH
M**** "BBB@ HHHH ***RO$FN_P!BQB;;ORX7&[;U!.<X/I0!JT5S?AOQA_;4
MAA\O9A"V=^[H0,8VCUKI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^1S5JTN>R9ZQX>O9+Z%9Y@ SY( 4K@9P.I.<]<^A'U-R[NUM%,LA"JHR2?\
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MRD3"/^%\Y'KA2179_9E]*X+1Y3'-&1UW@?@3@_H:]"J:<G8Z<PIKVB=MT1K
MH[5E>*;?,!8<;2I.._.,?KG\*V:H:[!YT$BYQA<_]\_-_2JDVTSGH6C4B_-&
M%X-N"':+^$KG\00/Z\_A765P_A>4I.H'1@P/TP3_ # KN*BF]#?'1M5]4%<W
MXSA)5).P)'O\P!'\JZ2L;Q7!YD!;/W&4_7^'^M.6S,\++EJQ*W@R?*/'C[K
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M[RP"X.#DGCGMSWJD)GM4D@C!9B  ,DG@ #J<UXU/-)JLQ8\R2OP,]V. !D\
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M4KTQM/(&3R1WX K<^&MUNCDAQ]UPV<_WAC&/;;^M<UXC\,G1!'N<,9 V0!@
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MU;GPX_X]V_ZZM_Z"M#V#J=77C>O?\?$W_763_P!"->R5XWKW_'Q-_P!=9/\
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MGL);G5T445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.0D%<I\1_P#CW7_KJO\ Z"U=77*?$?\ X]U_ZZK_ .@M0MQLP_AQ_P ?#?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ IDO2GTR7I0!7HHHH **** "BBB@ HHHH ****
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MD.!D5ZMX5\-KI$88C]\X&XG''?:,9X'?U//H!;T)1PW_  A%Y_SS_P#'T_\
MBJS[W3IM*8>8K(P.0?<8.0PX.,CH>*]EJMJ&GIJ"&*0 @@]@2"01D9!P1G@T
MN8=CEO!WC'[3BUN#\_1'/\7^R?\ :]#W^O7LJ\:U&R;2IFBR0T;<$<'U5N"<
M9&#UXKUG1M0_M"%)^,NHS@$#(X8<^AR*30(GN[M;13+(0JJ,DG_/Y#O7F'B/
MQ;)JQ,:Y6'(PO&3CH2?Z=!QU(S6Q\2=0)9+7^$#>?<DE1V[8/?G/M1X \/B7
M-[(,[3B//3(ZMC'..@.>#GN!36FH,PH/!]W, XB.#_>*J?R8@C\J9>^%;FR7
MS'C.T=2"&QQG)VDX''7I7KE%+F"QYCX:\8R:<5BD.Z$D [LDJ.G!YX'I@].,
M9S7ID<@D 92"",@CD$'H<UYKXYT-=-E62, )*"=H[$=<#' Y&!]>@Q70?#K4
M/.A: YS$W' QA\D#\P3SZ_DWW!'65P?BKQN23!:MA1D,X[]L*>P']X<D]..3
MO>-=4;3K<M'D,[!00<$9!)/Y#';&<@\5PWA+0_[6FVN#Y:#+=1]%R!W/TX!P
M<TDNH,I:;H<VI9\E"P'?@+VXR<#//3K5V3P7=H"QC. ,\,A/'L&R?H*]5CC$
M8"J  !@ <  =!BG4^8+'C^FZU/HS$(2N#\R-]W((R"IZ'C!/![9KU#0]975X
MA,@(YPP/8C&1GOUX/\CQ4&O^&8M9VE\JRD?,O7&>5_P]#SZ@Z5I:+:*(HP%5
M1@ ?Y_,]Z3=P1S/Q'_X]U_ZZK_Z"U8?PX_X^&_ZY-_Z$M;GQ'_X]U_ZZK_Z"
MU8?PX_X^&_ZY-_Z$M-;!U.R\4V+WUL\,8R[;<#('1@3R<#H*\PU/1)M+V^<N
MW?G'*GIC/0GUKV2N&^)O_+'_ +:?^R4HL&<IIFB3:IN\E=VS&>5'7..I'I5_
M_A"+S_GG_P"/I_\ %5N?#+_EM_VS_P#9Z[FFV"1Y-/X/NK=3(T>%4$D[DZ 9
M/1JD\$?\?D7_  /_ - :O1]>_P"/>;_KE)_Z":\X\$?\?D7_  /_ - :B]T%
MCU6JFIZG'ID9FE.%'YD]@!W)_P#KGBK=>;?$#5&GG-MR$B"\9X)(SN_(X[X[
M=322N-F9KOB276#\YP@.50=!VZ]S[GU., XI\'@^[F <1'!_O%5/Y,01^5=7
MX"\/B",7CC]X^=N>R],X(ZGUY^7&.ISUU-NPK'C^H>'+C3AOEC(7U&& Z#DJ
M3CKQGKVK9\-^-Y+1A'<,7C/&3RR\]<]2/4')QTZ8/H]8=KX.@MIS=*/0JG\*
MMW8?T'0'..V"X6-RBBBI&%07UZME&TS_ '4!)Z?D,XY/0>]3UP?Q)U EDM?X
M0-Y]R25';M@]^<^U-*X,P-;\43:L2&)6,GA >,<8S_>Z9Y[],=*=!X/NY@'$
M1P?[Q53^3$$?E6[X \/B7-[(,[3B//3(ZMC'..@.>#GN!7>4V["L>0WN@7.E
M8E=&4 Y#*0<$$8.5)QR1C./:I]0\3-J%LMK+DNC@AO4!6'/N,]>_?GD^KUYC
MXWT(:9*)$P$ER0HXP1C</H<Y'Y8  H3N#1/\./\ CX;_ *Y-_P"A+7H]><?#
MC_CX;_KDW_H2UZ/2EN"/*O&__'Y+_P  _P#0%HU3Q5)<Q1VL9*1I&JM@X+$+
M@YQ_#Z#OU/8 \;_\?DO_  #_ - 6NE^'^AK'&+U@"[E@OL =I[<$D'GGCTR:
M?01RT'@^[F <1'!_O%5/Y,01^5>G:3 ;>&.-AAEC0$>X4 ]*MT4F[CL>-Z]_
MQ\3?]=9/_0C7LE>-Z]_Q\3?]=9/_ $(U[)3D""J.O?\ 'O-_URD_]!-7JHZ]
M_P >\W_7*3_T$U(SRG0?^/B'_KK'_P"A"O9*\;T'_CXA_P"NL?\ Z$*]DJI"
M1FZ[KL>CQ^8_+'[JCJQ_H!W/;ZX!\MU#4YM8DW.2S$_*HS@9P,*OY>Y[Y-:G
MCO4#=7+1Y!6(!1@Y&< MWQG/!^@!Z5U?@71!90B=@/,E&<]PI^Z,Y/7KVZX/
M2C9!N<;'X+NW 81G!&>60'GV+9'T-12V-UX?82D-&>/F!RIYS@D9!Z?=/XC%
M>N5%=VBW:F*0!E88(/\ G\CVI<P6/']8U,ZG*UPP +!<@=,A0#^>,^WO7I/@
MC_CSB_X'_P"AM7FFJZ>=.E>W;JAQGU'4'J>HP<=J]+\$?\><7_ __0VIRV!&
MY1114C,KQ38O?6SPQC+MMP,@=&!/)P.@KSB^\+7-BAFD3"+C)W*>IP. 2>IK
MURL/QO\ \><O_ /_ $-::8FCS33=+DU)C'"NY@,XR!QD#N1ZUN:3X/NK>:.1
MH\*LB$G<G0,">C5)\./^/AO^N3?^A+7H]-L$@K@_&7BZ1':SBRFPC+ D,> <
M#@$#/<?>&,'!Y[RL_4=!AU%DEE4%HSQ[CT/J,\X_H2"D-GE^G^'+C41OBC)7
MU.%!ZC@L1GISCIWJ>?P?=P@N8C@?W2K'\E))_*O5XXQ& J@  8 '  '08HDD
M$8+,0 !DD\  =3FGS"L>6>&_%4FD,%8EH3P5STYSE<]#STZ'OV(]3CD$@#*0
M01D$<@@]#FO*O&$427#/"RLL@W':=P!).1G)[C/XXQ7;^!;W[3:J.28RRG/M
MR,>P! _#'2A]P1T%>+:;<BUECE;.$=6..N%()KVFO#:(@S7U;69]?DQAB"?E
MC7) P#V'4XSDX_(<#0TGP?=6\T<C1X59$).Y.@8$]&KM_#VAKI$0C &\@%VZ
MY/UP.!V']2:U*5PL17=VMHIED(55&23_ )_(=Z\O\2>*I-78JI*PC@+GKSG+
M8ZGCIT';N3T/Q(U HL=LI&')9@#SA<;<C/0G/7N..E4?A[H@N&:[< K&<+G^
M]USU_A&,9'?(Y%-::@S%LO"MS>KYB1G:>A)"YXSD;B,CGKTI;GPS=:</.9&
M4YRI!(QSGY22,8Z]J];HI<P6/']3UV34HXXY>6BW?-W(;;C/N,=>_?GD]/\
M#+_EM_VS_P#9ZR/&^B#39MZ ".49 ' !'WAC/T/8<X'2M?X9?\MO^V?_ +/3
M>P=3N:YKQ;XM&ECR(L&8CZA0>Y]_0?B>, [U_=?9(WFQG8C-C.,[03C->/P0
MR:K,%',DK\G'=CDDX' '4X' I) R6&TGUR1F4-(['+'MTXR> .G XZ8%7?\
MA"+S_GG_ ./I_P#%5Z5IFF1Z9&(8AA1^9/<D]R?_ *PXJW3Y@L>-_O\ 1)/X
MHY!^&0#^3+D>X..]>C>%/$W]LJ0^T2J>57/([, ?R/)_#(JUXAT-=7B,9 W@
M$HW3!^N#P>X_J!7EVC:A_9\R3\X1AG !.#PPY]1D4;AL>M:M ;B&2-1EFC<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !2IU%)2IU% %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ JM>Q;AN'459HIQ=G<4H\RL8]%374'E'CH>E0UUIW5SB::
M=@HHHH$%7;6ZW?*W7L:I44I14D7";B[FQ152UNMWRMU[&K=<LHN+L=49*2N%
M%%%(H*0C-+10!7DLE;IQ]*@>Q(Z<U?HJU4DB)4HLRVMV7L?YTGDMZ'\JU:*K
MVS(]@NYE>2WH?RI5MF;M^?'\ZU**/;,/8+N44L">IQ^M3I:*GO\ 6IZ*EU),
MN-**"BBBH+"BBB@ HHJG<7G\*_G51BY,F4U%:B7EQ_ /Q_PJI1173&*BK')*
M3D[A1113)"BBK%I!YAR>@I2=E<J,7)V+-I#Y8YZFIZ**Y6[NYV15E8****0P
MHHHH **** "BBB@ KPRO<Z\;_L&X_P">,G_?MO\ "O5RB48\]WV_4Y<6F^4=
MHFMOH[F:,*25*_,"1@D'L1Z5M?\ "R+C^['_ -\M_P#%5A_V#<?\\9/^_;?X
M4?V#<?\ /&3_ +]M_A7H5*>'J.\K-G/&52*LKEFY\6W5P-K2L!G/RX0_FH!_
M"L>M2V\,75P=JQ.#C/S#8/S; _"N@TOX<,^&N&"C ^5.6Y'0DC P<=-V>?K2
ME7P]!;I>2_X *%2;ZG+:7I<FIR"&(98_D!W)/8#_ .L.<"O6](TM=+B6!,<#
MD@8R>['KU_3IT%2:?IT>GKY42A5R3@9/)[DGD_C]*LUX^-QKQ#LM(H[*-!4]
M>H5XWKW_ !\3?]=9/_0C7LE>3ZUHL\D\K+%(097((1B""QP<XK?*9*,Y7?0C
M%IM(T/AO_P ?#?\ 7)O_ $):[W5-4CTR,S2G"C\R>P [D_\ USQ7%^ -,EM9
MV:2-U!B(RRE1G<O&2*[35-+CU.,PRC*G\P>Q![$?_6/'%9X]P>)N]M+V'035
M/S/,H?&%Q%,UUN!+#!4YV8'08SVSQSGKDG)SU,'Q)A8 NCANX7:P_,E?Y5AZ
MQX"FM26A'F1\D8(W@#G!'&3Z;<YQT&<5S<\#6Y*."K#J&!!]>AKT?887$I-6
M^1S^TJT]S>\8>)4UHQ^6K 1AN6QDEL=@3TQZ]^G'/.U8M;"2[SY:,^,9VJ6Q
MGIT%=EX;\!%&$UT!@=$SGG/\6.,=\ G/?N#I*I1PE/EOMTZB49U97.LTRTV0
M1P2 9$2JP.".% (]#7E6O:2=*F: YP#E2>ZGH<X&?0XXR#7L59^M:'%K"B.4
M'@Y#+PP]<'!Z]Q_4"O(P>,]C4;>SW.NM1YXI+='E>DZU+I+;XCC.,@\J<'."
M/ZC!Y.",UVEM\2HF'[R-U.>BD,,?4E?Y?C7-ZMX+N+ _*ID7/!C!)[XRO4<#
MGJ.V:PI(S&2K @@X(/!!'48KU9T,/BO>T?FCD4ZE+0Z+7?&\NICRD'EH1A@#
MDG/^U@8'L/?.0<5H>"_%IC*V4V2I("-U()X"GV]/3ITZ<YI_A^?4.8HV(()R
M?E4X..&; //;->@>&?!ZZ1^]<AY2.N.%XY _QXX[#G.&+^JTJ+IV7DEO?^NY
MI2]K.?,:6O:2-5A: XR1E2>S#H<X./0XYP37CTD9C)5@00<$'@@CJ,5[C7/^
M)/"$>KYE7Y9L<'^$XZ;OY9'(]\ 5R9?C51;C+9_@:XBBYZK<XGP_XNETC"??
MBY^0G&,]P<$CGMTZ\9.:Z9_B5$%R(W+X'!("Y[_-DGZ?+SZ"N0U#PS<6!(>-
MB%!.Y067 SSD=.F><''4"LNO2EA,/7?/OZ,YE5J4]#1UK7)=8822D<# 5>%'
MK@9/7N?Z 5'I&EMJDJP)GD\D#.!W8].GZ].IK0TOP;<WQ&4*)G!9QC'?.TX)
M]N,9[CG'HFA:%'H\?EIRQ^\QZL?Z =AV^N2<\1C:6'ARPM?HET*IT95)7>Q>
M@@%NHC4850 ![ 8'6I***\%NYWGC.LZ?_9\SP<X1CC)!.#RIX]1@U4,A(VY.
M 20.V3C)Q[X'Y"N[^(.B27+1SQ*SG!5@HSC!RO YYR<GITZ=^1_L&X_YXR?]
M^V_PKZ7#8F-2E&3:N>;4IN,FB?PMIW]H7,<9&5!W-QN&%YP1Z'ISZ_A7KM<A
M\/M&:T62:12KL0H#*58 #).3S@D_^._EU]>1F5;VE:RV6AUX:'+"_<@OK);V
M-H7^ZX(/3\QG/(ZCWKQN^LFLI&A?[R$@]?S&<<'J/:O:ZQ]?\,Q:T 7RKJ#A
MEZ_0^HSSC\B,FC 8Q4)-/X6%>C[176YY[X=\3R:*3@;HVZH3CGU!YP?7CD=>
MQ'7_ /"R+?\ NR?]\K_\57(:CX1N;([2A<'H8P6';T&1U[@>U8U>G/"X?$OG
MW]&<RJU*>AVFK_$9I04ME*\C#M@G'?Y<$#GW/';/2_X&\3F[_P!$E)+@$JS-
MDL,Y(.3DD9XQV';'/'67ARYO?N1M@C()&U2/8M@'KZUVWAOP,-.83S$.XZ #
MY5.>O/4^G P?4X(Y\53PE*BX*U^EM7<TI2JRFGT.KKS?XD?\?"_]<E_]":O2
M*X#Q_IDMU.K1QNP$0&54L,[FXR!7'EC2KIOLS7$J\#FM!_X^(?\ KK'_ .A"
MO9*\GT719XYXF:*0 2H22C  !ADYQ7K%;9M)2G&SZ$X1-)A1117F'2<SX^TO
M[7!YPSNA.1@$\' ;^A)[8^M>95[?/ +A3&PRK @CV(P>E>,7]K]DD>'.=CLN
M<8SM)&<5[64UKP<.QQ8N%FI=RO7I_@+3OLML)"/FE);D8..BC/<<9'UX]3YS
MIMD;Z5(!G+L!D#. >IQ[#DU[1'&(P%4  #  X  Z#%&;5K15/OJPPD+MR'44
M45XIVA1110 4444 %%%% !1110!4U6]-E$TH&2N,9Z<D#^M4-$UXWP(8#>#T
M7(XXYYSWJWKL'G02+G&%S_WS\W]*Y?PK,8YPH_C# _EN_I4N5I(ZJ5&,Z$GU
M1U^]V[?Y_&CRW;J:L45IS>1Q\GFRO]ESU.:<+4"B[G^SHTN,[%)QTZ#-8^C^
M*AJ$GDE=I(./FSDCG'0=LG\*N,*DHN2V0N6*9MB$#M3@,<4M%97*22.5\=.0
M(ESP2YQVXVX_G5_PA=-/!AOX&*CZ8!'Y9Q],5'XRMC-"& R4;)]0,'/X=,_G
MVK,\%3^69!C@A><]",X&/?)_+WKO45/">:?ZF;=IG9457^TEN@H*N_M7%R,O
MG70EEF6$;F( '<G _,TT7*GD$$$9!'(_2L+Q=F&'KG<P!S^+>OM5;P9>&?="
MYSM *@^G(//XCK^%;K#WI.I<GG=['1_:L\ 9HWN_08J<#'%+6',NQ7*WNRO]
MG9NIIRVJBEN20,BDMI-XY[4[RM<FT>:Q($"]!3J**@T&2IO!'J*RJV*S+E-K
M'\_SK:B]T85ULR*BBBMCG"BBB@ K(\5_\>TG_ ?_ $,5KUD>*_\ CVD_X#_Z
M&*UH?Q(^J%+9GG=%%%>Z8A1110 4444 %%%% !79^!+?:DDN?O,!C_=&<_\
MCWZ5QE>E>'K?R+>-<YRN?^^OFQ^&:X\?.U*W=E4UJ:-%%%>2:GG'B:(17,@7
MID'\6 )_4UEUT/C= LX('6,$^_+#^0KGJ]W#N]*+\C&6X4445J(**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N]\%P&.WW'^-V(_1?YBN"KTCPW 8+>-3W7/'^T2P_0UQ9A*U-+S+I[FG111
M7E&AY=JEO]FE>,# 5VP#GIGCK[55KH/&EKY4_F<XD4')Z9'&!^ 'YUS]>]1G
MSTXOR,6K,****T$%%%% !1110 5<TC_7Q?\ 71/_ $(53JYI'^OB_P"NB?\
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MY]P;()'([X!Q_CWK0JJE1222+Z6"BBBLQ!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %5*MU4H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** .&^)O\ RQ_[:?\ LE7OAQ_Q[M_UU;_T%:H_$W_EC_VT
M_P#9*O?#C_CW;_KJW_H*U7074W]0T:'4/]:BL< 9(PV <X##D?@:I0>#[2$A
MQ$,C^\68?DQ(/Y5LT5(QL<8C 50  , #@ #H,4ZBB@ JG)HL$A+-%&23DDHI
M))ZG.*N44 %%%% !1110!1OM#@OL^9&I+8R<8;CI\PP>WKTXZ54@\'VD)#B(
M9']XLP_)B0?RK9HHN V.,1@*H  & !P !T&*=110 4444 075A'=X\Q%?&<;
ME#8SUZBLK_A"+/\ YY_^/O\ _%5N44 16UHEJ-L:JH)SA0%&?7 J&?28;@EW
MC1F/4LBD^G4BK=% $<$"VX"( JCH%  ]>@J2BB@ K+O?#-M>G=)&N<DY&5))
MZDE2,_C6I10!FZ?X<M]..^*,!O4Y8CJ."Q..O..O>KMS:)=#;(JL <X8!AGU
MP:EHH K6VFQ6IW1HBDC&54*<>F0*LT44 %17-HET-LBJP!SA@&&?7!J6B@#$
MD\%VCDL8QDG/#.!S[!L#Z"M"RTF&R_U2*I QD*-V/<]3T[U;HH **** "J.I
M:'#J6/.0,1WY#=^,C!QSTZ5>HH R+;PE:VYW+$I.,?-EQ^3$C\:UZ** (YX%
MN 4<!E/4, 1Z]#61)X+M')8QC).>&<#GV#8'T%;=% %/3]&AT_\ U2*IP1D#
M+8)S@L>3^)JY110 4444 %-DC$@*L 01@@\@@]1BG44 8T_@^TF)<Q#)_NEE
M'Y*0!^57=/T:'3_]4BJ<$9 RV"<X+'D_B:N44 075A'=X\Q%?&<;E#8SUZBB
MUL([3/EHJ9QG:H7..G05/10 5 E]&\A@# R* 2N>0#_G\,C/49?.A=2JG:Q!
M ;&<''!P>N/2O([V*?19\N2)5.X-G.<_Q9/4'OGKR".HII7$V>P45P.G_$AD
M 69 QR,LIVG'&3MQ@GOU [<5+??$KJ(8_3#.?SRH_P#BO?VHLPN:'Q U18(#
M;<%Y2O&>0 <[OS&.V>W0US_P\T_SYS-SB)3T(ZM\H![],_E^>,[SZ]+D[I)"
M .!T'3M@ 9/)X'.37J'A_1AI$(A'WNK'.<L0,XZ<<8''3KSFGL@W-*FR1B0%
M6 ((P0>00>HQ3J*D9C3^#[28ES$,G^Z64?DI 'Y5=T_1H=/_ -4BJ<$9 RV"
M<X+'D_B:N44 075A'=X\Q%?&<;E#8SUZBBUL([3/EHJ9QG:H7..G05/10 53
MDT6"0EFBC))R244DD]3G%7** &QQB,!5   P .  .@Q1)&) 58 @C!!Y!!ZC
M%.HH J0:3#;D.D:*PZ%44'TZ@5;HHH *BN;1+H;9%5@#G# ,,^N#4M% %:VT
MV*U.Z-$4D8RJA3CTR!5FBB@".>!;@%' 93U# $>O0UD2>"[1R6,8R3GAG Y]
M@V!]!6W10!3T_1H=/_U2*IP1D#+8)S@L>3^)JY110 4444 9NH>'+?43OEC!
M;U&5)Z#DJ1GIQGIVIMEX9MK([HXUSD')RQ!'0@L3C\*U** "BBB@ HHHH BN
M;1+H;9%5@#G# ,,^N#4=MIL5J=T:(I(QE5"G'ID"K-% !1110 5GZAX?@U#F
M6-220<CY6.!CEEP3QVS6A10!D6WA*UMSN6)2<8^;+C\F)'XUJR1B0%6 ((P0
M>00>HQ3J* *<>BP1D,L48(.00B@@CH<XJY110!6N=-BNCND1&(&,LH8X],D5
M);6B6HVQJJ@G.% 49]<"I:* "J<FBP2$LT49).22BDDGJ<XJY10 V.,1@*H
M & !P !T&*=110 5E77A6UN<;HE&,_=^3K_NXS^-:M% &79>&;:R.Z.-<Y!R
M<L01T(+$X_"M">!;@%' 93U# $>O0U)10!4@TF&W(=(T5AT*HH/IU JW110
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M@ HHHH **** "BBB@ HHHH *LIT'TJM5E.@^E #J*** "BBB@ HHHH ****
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M8G##[RGJI_J#V/?ZY TJ\S^']Z8+D1<XE5@><#*C<#COT(_&O3*35AH\8TF
M7$T<;#*M(@(]BP!Z5[/7AM>Q:#JPU6%9QC)&& [,.HQDX]1GG!%.0D:%%%-D
MD$8+,0 !DD\  =3FI&><?$6,+<J0 "T2DX[G<PR?P 'X5UO@C_CSB_X'_P"A
MM7F^N:E_:4SW&,!CQ] ,#/)YP.?>O5/#^G_V?!'"<Y5><D'!;YF'''!)Q5/8
M2W/.O&__ !^2_P# /_0%J"Q^V;!Y/G>7SC9OV]><8XZ_K6Q\1=,,4JW0'RR#
M!//WE]>PRN,>N#Q5_P"'6L JUFQ^8'<F3U!'( ]L9]\DXX-%]!=3G_\ B8_]
M/'_D6C_B8_\ 3Q_Y%KU6BES#L>27-I>W0VR+.P!SAA(PSZX-=3\.["2T\[S$
M9,^7C<I7.-V>HKI[C58K>18'8!Y/N@]_\,]!GJ>!DU;H;"QPWQ-_Y8_]M/\
MV2CX9?\ +;_MG_[/6EX_TPW< F49:$Y[YVGAN!^!.>@!YKEO!&MC39MCD".4
M8)/ !'W3G'U'8<Y/2GT#J>H4445(PHJCJVM1:4 TIQN(  Y/N<>@ZG_$@&Y'
M() &4@@C((Y!!Z'- '+?$?\ X]U_ZZK_ .@M6'\./^/AO^N3?^A+6Y\1_P#C
MW7_KJO\ Z"U8?PX_X^&_ZY-_Z$M4MA=3T>N&^)O_ "Q_[:?^R5W-<-\3?^6/
M_;3_ -DI+<&'PR_Y;?\ ;/\ ]GKN:X;X9?\ +;_MG_[/7<T/<$4=>_X]YO\
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MQ?JBV-NZMC=(I51GD[A@GOT!S^F>14H9YMH/_'Q#_P!=8_\ T(5[)7C>@_\
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M#_UUC_\ 0A7LE>-Z#_Q\0_\ 76/_ -"%$09[)1114C/./B/_ ,?"_P#7)?\
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MQ^M/F"Q9JCKW_'O-_P!<I/\ T$U>JCKW_'O-_P!<I/\ T$U(SSCP1_Q^1?\
M _\ T!J]5KRKP1_Q^1?\#_\ 0&KU6G(2"L;Q%X8CUH#)VR+T<#/'H1QD>GH>
MG<'9J![Z-)! 6 D8$A<\D#_/XX..APAGE^H>#KJR_@+C(&8_F[9Z#YOQ('\J
MBT[Q3<Z?@(Y*C'RM\RX7H.>@[<8_E7KE96M>&H=55@RA7/1P!NR!@9/<=L'M
MZ'!%<PK%+PSXP75_W3@)*!TSPW')'^'/'<\XZ*O%M-O38RI.,Y1@< XR!U&?
M<<&O::35@04444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %*G44E*G44 6J*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DT7FC::RW38<'M6
MO4%S!YHXZBM*<^70RJT^97ZF=101BBN@Y@HHHH$%6K>\V\-^=5:*4HJ2*C)Q
M=T:X;=R*6LJ*8Q]*NQ7@?KP?>L)4FCIA54BQ11169H%%%% !1110 4444 %%
M%% !112$XH 6FNX3DU!+>A>!R?TJE)*9#DUI&DWN93K);$UQ=F3@<"J]%%;J
M*2.>4G)W84444R0HHI54L<"@8L49D.!6I&@0;1VIEO#Y0QW[U+7/4GS/R.JE
M3Y5YA11169H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5GZIKT6EE1,2H<-@X)'RXXXR>_IZUH
M5PWQ._Y8_P#;3_V2M\)2C6JQ@]G?\C.K-P@VC0U3X@00*?()D<@X^4A0??.#
M^77&,CK7F\DAD)9B22<DGDDGJ<TVM'1=$DU9_+C!P"-S<84$XSR1GZ=3@XKW
MJ.'I86+:^;9PSJ2JM'1_#C2][/=G&%&U<@'DX)([C XZ<[NO6N_JMIVGKI\:
MP1YVH.,G)Y.2?Q//\JLUX.*K^VJN73IZ'?2AR12"BBBL"PHHHH **** "BBB
M@ HHHH :Z!P5/(/4'I7G=N?L<JEQ_JW&0.3\IY_E7HU<%X@MO(G<<X8[AG_:
MY/X9R*BIW.[+WK*/='>T54TF?SX4?.?E&2>N1P>ON*MU9Q27*VB"^@-Q&\8Z
MLC 9Z<C%<#X<8I<(1ZGK_NG/Z?Y->BUP&J:!*DS*B$JS$KM'RX)X&>@Q[XQ]
M.:[<%)6G!NUT954]&=N96;H,?6CRG;J:L45R<Q7)W96>P#@J>X([=_8@_K5#
M1/#@TPEMQ8GCIA>V..>1ZY[UL44U5FDU?1@H104445!1G>((//MY%SC"Y_[Y
M^;]<5R/A*4I<*!T8,#],$_S KOZHVVBPVK^:B -SSSQGK@9P/P[<=*Z:.(4*
M4H-;[$2C=IEZBBBN8L;(N\$56M&P<>M6ZC\H*=]5%Z-$2CJF245"]T%Z<TW<
M\G3BCD8^=$Y;;UJA>L'((JPMKGECFG2VX*D <U4'&+(FI21FT445T'*%%%%
M!61XK_X]I/\ @/\ Z&*UZY[QNY6  'K( ??AC_,5KAU>K'U%+9G"T445[IB%
M%%% !1110 4444 36=O]I=8LXWL!GKC)QFO5:X'P;;^;<!L_<5C]?X<?^/5W
MU>7F$[S4>R-*:T"BBBN$LY#QZ@!B;')#C/?C;C^9KDZ[?QR@,*MCD2 9[\J<
M_P A7$5[."=Z*,I[A111722%%%% !1110 4444 %%%% %_3-$FU3=Y*[MF,\
MJ,9SCJ1Z5!?6+V+F&08=<9&0>HR.1D=#79?#'_EM_P!L_P#V>L+QO_Q^2_\
M /\ T!:Y(8B4L3*EI9*_Y?YFLJ:5-2ZLRK&Q>^<0QC+MG R!T&3R<#H*U?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !5E.@^E5JLIT'TH =1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)>E/IDO2@"O1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4U6WDN(GCB;8[
M#AO3_#/3(Y'4<BO)HIYM$E.TE)%R#T[^QR".XZCH1VKV2JFH:5%J(V3*& Z9
MZCIT(Y'3G!YIIV$T<9;?$MU'[R)6.>JL5&/H0W\ZQ->\4RZS\K86,'(4#TS@
MDGDG!QV'M782?#JV8D@R $] RX'MRI/YDU>T_P '6ME_ '.",R?-WST/R_B
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M'E7C?_C\E_X!_P"@+7H^@_\ 'O#_ -<H_P#T$5!?>%K:^<S2)EVQD[F'08'
M('05HP0"W41J,*H  ]@,#K0V*Q)1112&<5X_\/F7%[&,[1B3'7 Z-C'..A.>
M!CL#7+:-XCFTC/E$;2<E6&5)QC/J/P(S@9S7KU8VI^$;;4269=KG^)#M/7).
M.A)[D@FFF*QSD_Q,9@0D0#=BSEA^0"_SKG2L^O,\[$L8T+,QX "@G' P,XX
MZG)]37;P?#RVC(8EV [,PP?^^0#^M= ;&/RS % C((*J-HPW7IC&<]J=T@L>
M1:#_ ,?$/_76/_T(5[)6-!X/M;=A(L>&4@@[GZ@Y'5JV:3=P2,_7-&75XC"Y
M(YRI'8C.#COUY'\CS7E^L^'YM(.)!\O&&7)0Y[9P.>#P>>_3FO7I)!&"S$
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M2IU% %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** *]S;>9R.O\ZSR,5L5!<6HEY[UK3J6T9C5I7U1G44K*5.#25N<X
M4444""BBB@"2.<Q]#_A5A+_^\/RJG14RA%EQJ2B::W*MW_/C^=2UCTJL5Z5#
MH^9HL0^J->BLM;EE[_GS_.G?:V]?T%3[%E>WB:5%9OVMO7]!36N&;N?Y4>Q8
M>WB:E1/<JO?\N:S2V[DTE4J*[DNN^B+;W_\ ='YU7DF,G4TRBM%!(SE.4MPH
MHHID!1110 444Z.,R' HV&E<15+' K1M[<1#WH@MQ%]?6IJYZE3FT6QTTJ7+
MJ]PHHHK,U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "H;FT2Z&V158 YPP##/K@U-133:
MU QO^$.M-WF>4,YSU;;US]W.,>V,=L8K5@@6W 1 %4= H 'KT%2454ZLY[MO
MU$HI;(****@84444 %%%% !1110 4444 %%%% !6=J>A1ZB0[Y! Q\I[?B#6
MC10U<J$Y0=UHR*UMA;*(UZ*,?_7^I[U+29[4M!+=W<**** "BF+(&X%/H"]P
MKG_%FK26 01'&XMDX!/&..<CO705B>+K+[1"7'6,@],G'0_0=S]*VPW+[6-]
MB9WLR7PWJQU&/+XWJ<''?C@X[9_+(./0:U<1X+NO+E,1/#KTQU*\C],_YQ7;
M$XYIXNDJ=5I;!"5T+14+W(7WJIJ4[^5(R\81CD=>A[UG&#;!S1H$XYJ)[D+[
MUQWAC5B&6U?&PYP>A!/('OD]NN3U[5VBQ!.@K2M1]C*SU)4G+8B\QI.@Q0MM
MGECFK%%9<W8KD[ZC5C"=*=5:&X+'![U8)QS2DFF$9)K06BH'NAT')IOEM+UX
M%/E[ASKIJ5+A-C$5'5NZM@@R.U5*Z(.Z.6<;,****H@*Y3QY*0L:=B6)^HP!
M_,UU=<%XTG$EQM'\"*#^K?R-=6!C>JO(F>Q@T445[!D%%%% !1110 4444 =
MMX&M=D;2\Y=L<],*.H_$D?A72U1T.U^RP1Q\YV@D'J"W)'X$U>KPJ\^>I)^9
MM%604445D,Q/&$ DMV8_P,I'Y[?Y&O/Z]$\5_P#'M)_P'_T,5YW7K9>_W3]?
M\C.IN%%%%=A 4444 %%%% !1110 4444 =U\,?\ EM_VS_\ 9ZPO&_\ Q^2_
M\ _] 6MWX8_\MO\ MG_[/6%XW_X_)?\ @'_H"UYU+_?ZGI_D=$_X$?7_ ##P
M1_Q^1?\  _\ T!JW?B=_RQ_[:?\ LE87@C_C\B_X'_Z U;OQ._Y8_P#;3_V2
MBK_O]/T_S"'\"7K_ )'"T445Z)SGK7A_41KML"_)(*2#IDXP>@'4'/'3..U>
M6W]K]DD>'.=CLN<8SM)&<5Z3X#LC:VH8YS(Q;!&, X ^N0,@^]>=ZU())Y64
M@@RN01R""QP<UYF M&O5C'X3IKZPBWN4J***],Y@HHHH **** "BBB@ HHHH
M N:1_KXO^NB?^A"O3Z\Z\+('N8P1GECS[*2/R->BUY>8OWTO(TI[!1117"6%
M>8:O:?9)GBQ@!C@9SP>5_3%>GUQ/CFUV2++QAUQQURIZG\"!^%=N7SM4Y>Y-
M1:'-4445ZID%%%% !1110 4444 >HZ7<?:8DD)R61<D8ZXYZ>]6JP/!=UYL'
ME\9C8C ZX/.3^)/Y5OUX-:').2\S=.Z"BBBLP"KMA'@%JI5JPD8PO05G6=E8
MVH*\KCZ:T8?K3J*YSI*[6N.5.*Q=5G\QL9R5R#Z=:WYI/+4MZ G\JYBVB-PX
M4_Q'GU]SS6.)J-I1[G3@Z23<^QNZ<1"@C/49^G4FK@.::\0?K47V8K]TUNHQ
MM9'+*4FVWJ6*P=<GWOL[*/U//^%:WG-']X5SQ0W#GU+=NG)Z_2L,2FDEW.G!
M<KDY/HC;T>+RXP?[Q)Y_+^0J]340( HZ 8IU:QCRI(QG+FDWW"L'7)][[.RC
M]3S_ (5NLVWD]!7+-_I+\<%V_F:QQ,M$NYT8./O.78W-'B\N,'^\2>?R_D*O
M4U$" *.@&*=6T8\J2.><N:3?<*JWC<@5:IC1AN35Q=G<SFFU8(5V@"GT45+U
M*2L%5+MLG'I5NJ7^M;ZFKI[W,ZKTL6HUV@"GT45!HM HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ JI5NJE !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 51_MZW_Y[1_]_%_QJ]7AM-*X
MFSW*BBBD,**** "BN;\2>,/[%D$/E[\H&SOV]21C&T^E:VB:G_:D*W&W;OSQ
MG/1B.N!Z46 O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 45E>)-=_L6,3;=^7"XW;>H)SG!]*@\,>)_[<W_)L\O;_
M !;L[L^P]*+ ;E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !5E.@^E5JLIT'TH =1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !3)>E/IDO2@"O1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!XWH/_'Q#_P!=8_\ T(5[)7 Z
M;X!GM98Y6:/".K'!;.%()_AKOJ<A(****0PHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:EZF115Z:Q#<KQ_*J;QF/@BMXS4CFE!Q&T4451 4444 %%%% !1110 4444
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M70."I&01@@]*=17GW-K6/,;B)M.E*C[T;\$C'0\'!]>M>D6ETMTBRKT89_\
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M!GKC)QFH:V_!\!DN%8?P*Q/Y;?YFHJRY(.79 E=GH%%%%> ;A1110!D>*_\
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MV#<?\\9/^_;?X5T'A_P%).1+<C;'UVY^<]" <?='K_%QC ZC9_X61;_W9/\
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M*** "BN4\=:W-I?E>2VW?OSPIZ;<=0?6H-'\9&&U:XN6WOYC*@  )PJG' '
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K
M*=!]*K593H/I0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "F2]*?3)>E %>BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ8]![\<_G7)U=UF\^VS/*.A;C&1P. >?852KW</3]G32.>3NPHHHK804444
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MRB%"!QEB>P&,G'?KP/Y#FNI^)O\ RQ_[:?\ LE6?AK;!8I)><LX4^F% (_\
M0C57T%U-NR\+6UHNP1JWNX#,>,9R?Y# ]!4.J>$+>^4J$5&P<,@"X/N!@'IW
M]\8ZUMT5-QGC$\,FE3%3Q)$_!QW4Y!&1R#U&1R*]>TV]%]$DXQAU!P#G!/49
M]CP:\S\;_P#'Y+_P#_T!:[GP1_QYQ?\  _\ T-JI["1>UK5ETJ)IVYQP!D D
MGH.?S/7@$X.*\I@BEUN8+G=)*>K'';)/T '0=A@#M78?$NY*I%%QAF9CZY4
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MAVQNE.[H,X(^49'7CGVSC%>>Z59G5)TB.29'^8Y^;'5CD]\9/^->Q1QB,!5
M  P .  .@Q3?82,;Q;KG]DP[D(\QSA>A^K8)[#Z\D9&*\ZT;29-<F\L'DY9F
M8YP,\GU)R?Q)YP,FM[XE7):6.+C"H6'KEB0?_016?X:\4C1%9?+W,Y!+;]O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %64Z#Z56JRG0?2@!U%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %,EZ4^F2]* *]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !2IU%)2IU% %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N$\9*PG^8
M\%%V^PYX_/-=W6#XPL/M$7F 9,9SW^Z>O'Y'V -=.#FH55?KH145XEOPY?\
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MH5$JBYMKZBJ4KQTW/'Z*=)&8R58$$'!!X((ZC%-KZ<\X****8!1110 4444
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MA$;DGACQQSG?@#\\<\>F;MUXJM;;&Z53G/W?GZ?[N<?C2U#0@_X0BS_YY_\
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M.B^/8KL;9\1OD#N5.>^<?+SZ]!W/.&[@B[_PA%G_ ,\__'W_ /BJ/^$(L_\
MGG_X^_\ \55BY\3VMN-S2H1G'RG>?R7)_&N1\3>.C=?N;4LJYY?[K'!XQW [
M]B>G'.4KAH=;8^%K:Q<31IAUS@[F/48/!)'0UJUB>$M8DU2'S)5((.-W #8[
M@?S[9Z=P-NDQG*?$?_CW7_KJO_H+51^&7_+;_MG_ .SUI?$. R6P8#A)%)]A
M@K_,BN8\$^($TF1EEX20#G!."N<=.QR>QYQVS5=!=3TZBLNY\3VMN-S2H1G'
MRG>?R7)_&K.JW_\ 9\3S[2VP9PO7_P"L!U)[#)J1ENL34/!UK>_P!#@#,?R]
M\]!\OXD'^5<KH_C^2&1FN,LCG.% RIQQM!/3M@GWSG.>QMO$]K<#<LJ 9Q\Q
MV'\FP?QIV:$<#XB\'R:.!*#OC[L!C!]QD\'L?7@XXSK?#K6"&:S8_*1N3)Z$
M'D >^<^V"<<FG^,_%D5S&UI"=Q8C<V/EPIS@'(R<@<X(QT-9_P /-/\ /G,W
M.(E/0CJWR@'OTS^7YOH'4])HHHJ1A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !5E.@^E5JLIT'TH =1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !3)>E/IDO2@"O1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4J=124J=10!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWAG/_COZUQE>S@G^Y7S_ #,I[A111722%%%% !113HXS(0J@DDX '))/08I
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M444 %%%% !1110 54JW52@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M /6'%6Z*&[CL%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ JRG0?2JU64Z#Z4 .HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ID
MO2GTR7I0!7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M5.HI*5.HH M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%17#E!
MD>M-*[$W97):*B@E\P<]14M#5F"=U<*@O+U+-?,D.%SC\_8<U/6-XKLC=0$K
MU0[OJ "#^AS^&*JE%2FD]F#=D:5G>I>+YD9RN<?E['FIZX#PQJWV"3:WW),
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ JRG0?2JU64Z#Z4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDO2GTR7I0!7HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *5.HI*5.HH M4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<_ZA?^N@_P#06KAJZ_QZY B7/!+G';C;C^9KD*]C JU%&4]PHHHKJ)"BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC/;;P?PSD_C677N8:/+2BO(QD[L****V$%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7IVBN'@B(.?W:CCV
M!_(UYC7>>"[KS8/+XS&Q&!UP><G\2?RKBS"-Z:?9ETWJ;]%%%>4:!1110 5R
M?CJRX2X'KM/7/J/;CG\ZZRL[Q!8_;('0#D#(XR<KS@>YZ?C6V'GR5(L4E='F
MM=%X9\'MJ_[UR4B!ZXY;GD#_ !YY['G%WPYX%:Z!FN05'\*=&.#SG/(';L3U
MX&,]Y9D*!&!C:,  8&!P!^%=.-S#E3C!Z]7V*HT+M.0ZTM%M%$48"JHP /\
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MKHJKV%I]E4)WZGZU8I48<D?,K$5?:3\@HHHK0Q"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *J5;JI0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %64Z#Z56JRG0?2@!U%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %,EZ4^F2]* *]%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !2IU%)2IU% %JBBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *9-$)E*-R&!!^AX-/HH \[OK9]$GX[<J3SE3D<]/H>GMV-
M=AX?U1=0CW8PR\,/Z^N#VS[CM3?$>C_VE'\O^L3E><=<9'XX_/'.,UQVB:L=
M-D#\E#PP'<?XCJ/RSS7I66*HW^TC'X)>1Z/134<. P.01D$=*=7FFQ'/%Y@]
MZKV\NPX/2KE036^\Y%7&2M9D3B[W6Y/1114%A7/W_@]+I_-#%=S98=<YZX].
M_K].U=!15TZLJ;O%V$TF,AB$*A%X"@ ?0<"GT51MM:ANG\I'!;GCGG'7!Q@_
MAVYZ4E&4KO<=TB]1114@1- "=U2$XH)Q5=F,YVCI5*\B6U$'E,ORK4T40C&*
M$PGRBGT-].@175[A6-K7AI-2(D!V/W(&<CW&1S[^G'IC9HHA4E!W3LQM)E32
M].73XQ"O..IQC)/4_P">V!5NBLK7==&E!?EW%R>^!QC/.#ZTTI59]VPT2-6B
MLS1=>35 <?*XZJ3GCU!XR/Y'\,WYIO+^M*5.49<K6H<RM<;<3;?E'4U&0(1C
M^(TL:^6"[=:6!-YWFJT2\C/5OS_(KO9$#</RJN1BMBH9[42\]#ZU4:W<F=#L
M9M%/EA,?6F5LG<P::"H[F<6ZM(>BJ2<=>!FI*Q?%UUY%NPYRY"C'YG\" 15T
MX<\U'NQ-V1P#N7)8G))R2>M-HHKWC ****8!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5TO@:ZV2-%QAUSS
MURIZ#\"3^%<U5_0[K[+/')QC< 2>@#<$_@#65>'/3DO(<79GIE%%%>$;!114
MT%J9>>@]:&TAI-NR(0,U?@LPG)Y/Z4_[, -HI+9_X3U%8SJ<RT-X4U%ZD]5[
MB/'SCJ*L45DG9FTE=#(I/,&:?59QY!R.AK.UK6?*_=1_>[GTSV'O_+Z]"2MK
MT,W54(ZEC4-;6T.T?,W< ]/QYY]JM65V+Q X[]1UP?3_ #VKE;#3FO#@<#NW
M8?\ U_:NMMK<6RB->@J4V10J3J-M[$3CR#D=#5E6W#-#+NX-5N;<_P"R:T^+
MU-?@?D6JBN+@6XWMT_SQ3GF"#>3P.]<YJ%[]K;/0#H/Z_6L*M3D7F=.'HNJ_
M(2[NVO&R?P _SUK;TZS,";6ZDY(_I5?2M,\K]Z_7L/3Z^_\ GZ:E11IM/F>Y
MIB:L6N2.R*I!@Y'2K".'&12D9JN\1B^9:ZM)>IQ6<?0LU'/ )U*-T-9ESK9C
M;:H&!C/K[UKUDI*5UV-G"4%&7?5%>TL%M?N]?4]:L444TDE9$RDY.["D)QS2
MU2GE\PX'2KC'F9$Y<J+@.>:6F1)L&*?4LI;!1139'V#- ;#J*JP2%VSV_2K5
M.4;$QES*X4444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ JI5NJE !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 593H/I5:K*=!]* '4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R7I
M3Z9+TH KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %*G
M44E*G44 6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "K*=!]*K593H/I0 ZBBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "F2]*?3)>E %>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ I4ZBDI4ZB@"U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5E.@^E5JLIT
M'TH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !3)>E/IDO2@"O1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4Y.HIM/A&30!8HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN1\<>9N3KY6/
MPW<_KCIGWQWK2A2]K-1O84I65SKJ*YGPUXE\_%O,?FZ*Q[^Q]_0]_KUZ:BK2
ME2ERL(R305%(5C^;O2S3>7]:CB@W?,W6I2ZLF3N[(2*(R'>U6:9+D#CK4,-S
MV:G9RU!-1=BS1114%A5$@P&KU-= XP:J,K$SCS"12B09I]5HK<HV>U6:4DD]
M BVUJ%5YY<_(O4TZ>;9P.II8(MG)ZFFE;5B;N[(R-9\,C4 &!Q(HQGJ#U('M
MSW_0UR*R3:2Q7E&/4$#!P>O.0?8UZ55>]T^.]&V10P]^H^A'(Z=JZ:&,<%RR
MUB*5-/8JZ!JAU*+S&&&#$''3UXY/8C\:TJ9%"L(VJ  .P&!^0I7<("Q. !DD
M]*YIM.3:5D6MAU%1P7"W W(P89QE2"/TJ2I:L,:Z!P5(R",$'I7/W_A6&X;Y
M,J3_ '?NY]<'^0('88K?FD\L9IEM'@;CU-:TZDJ>J=B)>\[%;1=)&F)Y0.[+
M$DXQUP.GT%7Z*:X)!QUQQ6<YN3<GN6E;0'?8,U#:I_&>]9I4PGGBK$&HE>&&
M1[=:YXXN*5FFF6Z#;NM4:55A^\?V%+]K5AE3SZ=Z=;1[1GUKH@TX\R,I)\R1
M-1112*"H;R)94*N RGLP!'MP?>IJ@NCT4=S51W1,W9,PIO UM=#.TH2<Y0X_
M#!R /H!^58U[\-&',,@//1P1@?[PSD_@/PZ5WBC;Q2UT0QU>#TE]^I#H0:V/
M);SPA=6N<ID ]4(;/.,@ [OTSZUG75A):8\Q&3.<;E*YQUZBO8_O/]!_G^=6
M*ZUFTU:\4_P_S,?JJ=[,\,HKV:318)"6:*,DG))1223U.<5G_P#"$6?_ #S_
M /'W_P#BJVCF]/JF2\)+NCRFBO18_A[;S9;+CD\!EP/;E2?UIMS\-8F'[N1U
M.>K ,,?0!?Y_A6O]IT+VN_N(6&FU<\\HKN&^&>T9\[I_TS_^SI(_AIO&?._\
MA_\ V=7_ &CA_P";\'_D+ZO4O:QQ%%=U_P *Q_Z;?^0__LZ/^%8_]-O_ "'_
M /9TO[1PW\WX/_(/J]3L<+17H;?#F"-<EW+ #."H&>_&TX_,_6K%EX M4^=M
M[Y'1FP/K\H4_K4O,Z"5]?N&L-.]CS2BO5+#PE:QG=Y0)7^\68<\=&)'YBM:V
MTR*U.Z.-%)&,JH4X],@5E/-H+:+?]?,J.%;5[GCUMIDMT-T<;L <952PSZ9
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J5;JI0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %6E&!58#/%6
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "F2]*?3)>E %>BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ J> 8&:A4;N*L@8XH 6BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** )(1DYJ>FQKM%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9+TI],EZ4 5Z***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "I84SS21Q[N>U3T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M3)>E/ID@R* *]%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0 E%+L/I1L/I0
ME%+L/I1L/I0 E%+L/I3A"30 RE"[NE2K!CK4@&* &)%MY-2444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9NL^'X=7&)!\W
M&&7 <8[9P>.3P>._7FO.=3\(3V4@B"EP[81EZ'C//]WCKGT/) S7K%%=>&QU
M2AHM5V9E4H1GZF;X?T8:1"(1][JQSG+$#..G'&!QTZ\YK2HKB_'/B@V_^APE
ME<$%V4XP,9"@]>>"2/ISD@9TJ<\35MU>K94I1IQ.THKAO#'CK[MO<_02$_D&
M_P#BOIGNU=O'() &4@@C((Y!!Z'-*OAYT)6D@IU(S5T.HHHK$L**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D9=W!I:*
M *4D1B.1^=7%.1DTM%5*5R8PY6%%%03RX^4=322NQMV5Q)9#(=B_C5;4M"CO
MTV,,-CA@.1_B/;^O-788?+^M252FXOW>A*C?5GG%[H\VG. 0<Y&UDR02>@!]
M?;K7>:3O\I/-^_M&>N?;.><XZ^^:MT5K7Q+K12:U74<8<K"BH9+G8<8J17#\
MBL'%H:DF[#J***0R"^@-Q&\8ZLC 9Z<C%>=3VLNF,-P9&[$'';G##Z\X->F5
M'<6ZW"F-QE6'(-=&&Q/L;JUTR)PYCEM-\8@-B5< @<KSSGDX]/S(QWSQU:.'
M 8'((R".E<W=>!T=LQN5'H1N_7(X_,^]=%;P"W58QT50!GKP,4\2Z,K.&_4(
M)K1DE,D?8,T^JTC><0HZ5SQ5V.3LA]LG\1ZFIJ0#%+0W=CBK*Q#<80$XY/&:
M= FP5%)^];;V%6:;T5A+6397O9C$N1US52/467KS^E:3*&X-5I-/5^G'TKEK
M4ZKES1?R-X2A:S01Z@K]>/K5E6#<BLV33F7IS^E5]K1G."#4+$5(.THE.E"6
MS-.W^<EJL53TZ4OD'MC]:N5U*HJBYEL8*#AH]PJN/F?Z"G"[0G&13;;YLMZF
MJA)--IDS3ND6****1057N1DJ/?\ PJQ5>4;G JH;DSV+%%%%2417/W33H1@#
MZ4VY^Z:=%T'T%5]DG[7R'T445)057B&UR*L574X<^XJH]29=/4?<CY33H3D#
MZ4L@R#]#4=J<K]*/LA]KY$U%%%24%(1FEJI?ZDMD 6S\W0#VH%*2BKL?:G&5
M]#5BN>D\0@99!@]L\C'OTJ*TUN62102,,P&,#')Q]?UIRDFSGCB8*R.FJGJE
MT+9-S9Z@<?C5RHKBV6Y&QQD4KV-YIN+2.7NM9DF. Q"YXQP?S'/ZU#:Z;)=8
MVJ<'N>!UQU_PKI+6R1&/RC(QC@=N]7Z)1LSECAG/63,2T\-!>9#D^B]/SZ_R
MK0\H6I 7A?3_ #_G-6ZCG3>*<+)FZI1BM$24R1-XQ3;9]P^E2T/1FB]Y$%L^
M1M/45/5.XF6W;)('&2,]NF?\]ZGM[E;D;T.13EW)A+[/4D)QS566ZW<#BK3+
MNX-,C@"<T1:6XY*3V((8"3N-6Z**4I7",5%!3)$WC%/HI%-7*]N^/D/44^YN
M!;*9&Z"F7"8^<=14=Y:C4$V].00>N"/R[54M=3.[2:6_0Y_4]8:\)4<)Z?3U
M_P .G\ZDTS0VN?G?(0CCU/\ G_\ 56E9>'E@.YSO] 1Q^63FM:HL80P\I/FG
M]PR&$0@(HP!T%/HHIG7L%%(S;>3522X+\#BJC%LF4U$N44U. ,^E.J2@HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ JI5NJNP^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44NP^
ME&P^E "44NP^E&P^E "44NP^E&P^E "44NP^E&P^E "44\1$TX0>M $52I#Z
MU(J!>E.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .4\7^$&U0_:(3\X&"K$X('3'H?;@
M'.>#G/G<\#6Y*."K#J&!!]>AKV^LO6O#D.KX\T'<!@,IPP&<X]#^(.,G&*]'
M!YBZ24):Q_(YZV'YM5N9'@2]N;I"9N8AG:S9+DYZ9[J.>3WX!XP.KJ&TM%M%
M$48"JHP /\_F>],U'4%T^-IY,[4'.!D\G 'XGC^=<E:?MJK<5:[T2-8+DCJR
MS16/H'B:+6@0F5=0,JW7ZCU&>,_F!D5L5G.G*G+E:LRHR4E=!1114C"BBB@
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M?AW_ )UT\,(A 11@#H*?10E8ZJ5&--:;A1113- HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/R-2BBJFG:K%J(WPL& ZXZCKU!Y'3C(YKRU%M-]#INBW1112&%%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &N@<8/0UG3Z<4Y7D?K
M6G16=6C&IN7"HX[&-%.T)X_*KL6HAQ@CG]*L36ZR]1^/>J$^G%.5Y'ZUSJ%6
MB]-5V-'*%1=F7+9,#<>IJ>J>G1E <@CIUJY75"HZBYK6,7!0T"BBBJ$%%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %(:6B@"D=T7^>*D2[]1^56:B:W5JOF3W1GR26S) <\TM(!B
MAFVC)[5!H+15$:H,]./K5B.[63H?SXK.-:$MF4Z<ET)JKQ_.Y/I4SMM!-16J
MX&?6MEHFS.6K2)Z***DH8\(?J :@?3T;U'T/^.:M45$J<9;HI2:ZD4%L(.G?
MUJ6BBJC%15D)MMW*&HPLY!'(QVJGEHN.1GZBMNBN>IA5*3DG9FD:UE:QB^>W
M<Y^O-/\ MS^OZ"K\R[V [5(;93Q@?E1+#5$DE,(U8-OW2*SN3.#GJ/2K--2,
M(, 8IU;P344GJS.33>A6-Y[?K1]L]OUJ4VZGM2?9E]*UO#L96GW'H^\9IU(J
M[>!2U#-$4;F^,3%0!QZU"VI,?05?DM5D.2.::+)!SC]37+.E6;=I:&T9TTMC
M.6\9> <?A33<L><G\ZUOLZ^@_(4]5"\"AX>I)ZR!5816B(K1BR@GK3Y4WC%/
MHKIBN5)=C&6MRJ+/U-2"T J:BK<Y,E4XH****DH**** "BBB@ HI"<<U7:\]
M!^=-1;)E)1+-%4@S2=,_RJXOO3E&P1ES#9@2I"\-@X/OVKDHM(ED;9M(]SP/
MS[_AFNPHJ&KD5:*J-7Z&+:>&E3F0[O8<#\^I_2MB.,1C:H  [#@4ZBG8J%.,
M-D%%%%!84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCJ1O8****YC4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *0C/%+10!2DTP'[IQ]:JR63)VS].:UZ*YYX6
MG+R-8UI(Q%D,?'Z5;MK\Y"D#'3BKSQA^H!^M1I9HAR!R/K4QH5862EH-U(2U
M:U)J**@G5C]VNM*Y@W9$]%4O-9/7\?\ Z]303F0X-4X-:DJHF[$]%%,DE$8R
M>E0VEJ7N/HJ%+M&[C\>/YT]90_ (/T-2IQ>S&XM$7WG^@JQ5>,Y<_3_"K%:2
MZ$0Z^H4445)04444 %%%% !1110 4444 %%%-9PO4T .HJ$W2BGQRB3I3Y6)
M23T'T45#<*6Z4)78-V1*S!>M1-=**A6T)J1;0#K56BNI'--]!AO#V%6(7+C)
MH6()T%/I2:Z(J*DMV(1FF"!1SBI**FXVDPHHHH&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S=9\/PZN,2#YN,,N
MXQVS@\<G@\=^O-:5%5"<H.Z=F)I-69PVA^ C!.3< -$GW>>&/;*\\#N#WP.1
MFNYHJ.>7R5+X)V@G"C+' S@#N3VK2OB)UY)R)A3C!: \ZH0A(#-G:"1DXY.!
MWQWJ2O&]4UB2_F-R20V<KS]T Y4 C'3UXYYZFNI\.>/M@$%UG !_><D\= 0!
MD_7Z9'4UU5<KJ0@I+5]490Q46[/0[NBFQR"0!E(((R".00>AS3J\\Z HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>C&FFKA1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445!?7JV4;3/]U 2>
MGY#..3T'O32;=D#=B>BN-@^),;R!6C*QDXW;LD#L2H'Y@$X[9[]E6E;#U*-N
M96N3"I&>P4445D4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5QOQ!UTVX%FF07&YB/[IR-OKR1STXXY!-=E5#5M%BU9=DHSC
M.".&&1C(/]#D<#(.*VPM2%.JI25TB*L7*+2///#?B^32,1-\T.>1_$,]=O\
M/!X/MDFO2=/U&/4%\V)@RY(R,CD=B#R/Q^M>8>(/"DNCG/+QX^^!@#H,$<XY
M/'//;G('6^ _#_V*/[4_WY1QSG"'!''J>O?C'0Y%>ACZ="=/VT7J^W4YZ$JB
MER,ZNBBBO).L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-OXCH<^CC,OA&+J0>G;_ ".>CB&WRL[VBBBO*.H**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BHVN%7N/YU$;Y1ZU2A)]"7.*ZEFBJ9U#V_6FMJ![#\^
M:?LI$^V@7J*H?;V]O\_C3EU ]Q3]E(/;1+M1SSBW4R,<*H))]@,GI5<:A[?K
M6;XIU3RK64J.2NWGIAB%/?T/'O3A1E*:CW8.M&S=SRR20R$LQ)).23R23U.:
M;117U!YH4444P"MOP9:?:;J,$$A26.,\;02"<?[6/Y=ZQ*[+X:6NZ22;/W4"
MXQ_>.<Y]MOZUSXR?)0F_+\]"Z,;S2/0:***^9/3"BBB@ HHHH *J:KIPU&)[
M=NCC&?0]0>HZ'!QWJW13C)Q::W0FKJQXA/ ;=C&PPRD@CW!P>E=9X3\0@@6D
MG!'"$GK_ +//?T[8XZXSK>-_"YOQ]IA \Q1\P Y8=OJ1^9'&> *\YKZ&G.&,
MI>?Y,\Z<'2D>MT5QNB^,C'B.XY   8<GKW]>.XYXZ$FNLM;M+M=\;!A[?GCV
M/L>:\^K0G2>J^92DF34445B,**I:CK$6GC,C8..%'+'KV_#J>/>N.USQ2^H?
M(F4CY[\MVYQVQVZ?7C&]'#3JOR[B<DA_BO7?MS>2A!C0]1SDXZY]!D@8Z]>>
M,4-!TDZK,L S@G+$=E'4YP<>@SQDBJEI:-=L(HP69C@ ?Y_,]J]5\,Z -%BV
M9!=CEB!W]!WP.V?<\9Q7;B:\,)2Y5OT_S"C3=25^AK1QB,!5   P .  .@Q3
MJ**^?/0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH S]:T.+6%$<H/!R&7AAZX.#U[C^H%1^
M']!71H_+7!8G+-C!/)QW/0<8SZGN:U**T]M/DY+^[V)Y(\W-U"BBBLR@HHHH
M **** "BBB@ HHHH ***KRW@3IR?:FHM["<E'<L5 ]VJ>_TJE+<&3KT]!4=:
MQH]S"5?L6'OF;IQ4+R%^IIM%:J*1DYM[A1113)"BBB@ HHHH *Y?QW<;4CBQ
M]YB<_P"Z,8_\>_2NHKA?&UQYDP0'[B#(YP"<G]1C_(KIP4>:JO(F;T.>HHHK
MV3(**** "O3?A];&&UW'&)'9ACT&%Y_%37F5>N^&]MO!%#@J0@R#GJ>6Z^Y/
M'X5YV:R?LDN[-\+;G-:BBBO".\**** "BBB@ HHHH *YOQ'X+CU3]Y'A).<D
M#Y6SD\X[Y_BY/J#QCI**TI59TI<T79DR@I*S/%]1TJ73CLF4J3TST/3H1P>O
M.#Q59'*$,#@@Y!'6O;Y(Q("K $$8(/((/48K"U#P1:WG.TH21S&=O08Q@Y4?
M@/ZUZM+-XO2:MZ'+/"/HSSRW\0W$&<2-S_>^;_T+.*;+KD\IW&1LGT8J/R&!
M7<_\*WM_[TG_ 'TO_P 31_PK>W_O2?\ ?2__ !-7]?PM[V_ CZM4/-ZUM(\,
M3ZKS&N$_OMPO?\3R,< X/7%>B67@^UM.1&&.,9?YL^^#QGZ >W%;-95LWTM!
M?-FD,)W9DZ%X;BT<?(,N1AG/4]^G8>P]!G)&:UJ**\J<Y3ES-W9U1BHJR"BB
MBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\21:P/D.' RR'J.W7N/<>HS@G%>14Z.0QD,I((.01P01T.:X\5@*=?7:7?\
MS-:5>4--T>XT5PFA_$/;B.Z!//WU [D=5&.G/(]N">:[F.02 ,I!!&01R"#T
M.:\.OAJE!VDCNA4C-:#J***Q+"BBB@ HHHH **** "BBJVI7HL8GG.,(I."<
M9(Z#/N>!32;:2!NQ9HKRG_A-[S_GI_XXG_Q-'_";WG_/3_QQ/_B:]#^R*W=?
MC_D<_P!;AYGJU%5M-O1?1).,8=0< YP3U&?8\&K->>TTVF="=PHHHI %%%%
M!1110 4444 %%%% !1110 45D^)=<_L:'S@-S$[5';)!.3[#';KTXZCSC_A*
MKK?YOFMN]/X>F/N?=_3KSUKKPV J5XN2LEYF-2O&F['KM%9?AS6O[7A$V &R
M0P&< CZ^HP>^,XSQ5/QMJLFFPK)"VUC(!G /&UCW!]*QC0FZOL]G>Q;FE'FZ
M'045Y3_PF]Y_ST_\<3_XFO2])G-Q#'(QRS1H2?<J">E:XG!3PZ3DUKV)IUHU
M'9%NBBBN4U"BBB@ HHHH **** "BBB@ HHHH **** "BBO*?^$WO/^>G_CB?
M_$UTX;"3Q%^5K3N9U*RIVN>K45RG@76YM4\WSFW;-F.%&,[L] /2NKK*M1E1
MFX/=%0FIQN@HHHK,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU$U9Z?J88MIJ+7F=U\,?^6W_ &S_ /9Z[FN&^&/_ "V_[9_^SUH:]XV.DRF
MQ$@ $,7VY!'4#:>^1U[5RXRC.KBIQBKO3\D:49J%)-G4T5QMC\1UGD6-X]BL
M0"V\'&>YRHX]>>!S795RUL/4HM*2M<VA4C/8***Y?Q!XW&DRFW";R "3NVX)
MYQ]TYXP<^]*E1G5ERQ5V$YJ"NSJ**XNT^(ING6%81EV"C,G&6.!_!7:4ZV'J
M46E)6N*%2,]@HHHK(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBF2G"GZ&A ]#+9MQSZTE%%=APA1110(**** "BBB@ HHHH
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MQ!%=?17'/,<1+K;T.B.'IKH9-KX5M;;.V)3G'WOGZ?[V<?A6I'&(P%4  #
MX  Z#%.HKEG4E/=M^IJHI;!1114C"BBB@ HHHH **** "BBB@ HHHH ****
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MLF&3[&?N29(XZ,!GKZ$#WYQC'-=/XW_X\Y?^ ?\ H:UYQH/_ !\0_P#76/\
M]"%>R5RYBE2Q$:B\G]S-<.W.FXGAE%>D?$C_ (]U_P"NJ_\ H+5YO7I87$>W
MI\]K'-5I\DK!7I'PW_X]V_ZZM_Z"M;F@_P#'O#_URC_]!%7Z\K&8_P!K%T^6
MVN]_^ ==&AR-2N87C?\ X\Y?^ ?^AK7E->K>-_\ CSE_X!_Z&M>4UV91_!?K
M^B,<7\:]#U;P1_QYQ?\  _\ T-JH_$C_ (]U_P"NJ_\ H+5>\$?\><7_  /_
M -#:J/Q(_P"/=?\ KJO_ *"U<%/_ 'W_ +>?YF\OX'R/-ZLWVH->[2^/W:*B
MX'91@?XGZ^G%5J]+\#Z MI"MPZ@R2?,"0"0I&  <GJ.3C!YP>E>OBL1"A'G:
MN^AR4J;F['!_V#<?\\9/^_;?X50KW.N4\<>&UNXVNT&)(QDXQ\RCKGW Y!ZX
M&.>,<F'S7GFHR5K]36IA>573.-\-ZZ='E$G)0\.H[CL>>XZCIZ9 )KUN.02
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M>"/%!OQ]FF(\Q1\I)Y8=_J1^9'..":YWQOH0TR42)@)+DA1Q@C&X?0YR/RP
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M3Z+1'10ARP04445RFH4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/&?F)[X''J<^W#UUT*\,1#F6VVIE.#IRLSVVTN1=(LRYPZAAGKAAD5D>-_\
MCSE_X!_Z&M4?AWJ7VB$VY',)_1R2._7.?3C%7O&__'G+_P  _P#0UKPHTO98
MI0[27YG<Y<U)OR/*:]6\$?\ 'G%_P/\ ]#:O*:]6\$?\><7_  /_ -#:O2S?
M^"O7]&<V$^-^ANUYO\2/^/A?^N2_^A-7I%>;_$C_ (^%_P"N2_\ H35P97_'
M7HS?%?PS#T'_ (^(?^NL?_H0KV2O&]!_X^(?^NL?_H0KV2MLW^./H1A-F<I\
M2/\ CW7_ *ZK_P"@M7F]>G^/[7SK4MG'ENK=.N?EQ_X]G\*\PKKRIIT/FS+%
M+WSV30?^/>'_ *Y1_P#H(J_7GWAOQTMA$()U8[.%*X)QZ'<1TZ#';C QSU>A
M>)(]:W>6&&S;G< /O9QT)]*\K$X6K3E*36E]SJIU8R25]2#QO_QYR_\  /\
MT-:\IKU;QO\ \><O_ /_ $-:\IKT\H_@OU_1'-B_C7H>K>"/^/.+_@?_ *&U
M4?B1_P >Z_\ 75?_ $%JO>"/^/.+_@?_ *&U4?B1_P >Z_\ 75?_ $%JX*?^
M^_\ ;S_,WE_ ^1YO7L/AN<36T+*<@1J/Q4;3^1!KQZNB\,^,&TC]TX+Q$],\
MKSR1_AQSW'.?3S##2K4UR[IG-AZBA+4]1K-\23B&VF9C@&-A^+#:/S)%9[^/
M;55WAF)P/E"G=SVYPO'?GZ9KC_%'BPZUB-5VQJ<@'EB>0"?3@]![\GC'EX;
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[G*^$O!?V,_:;D#S ?E7@A<?Q''!/IZ=>O3L***\RO7G6ES2.F$%!60V2,2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[U>9B\7S^Y';\S2$+:A1117"6%%%% !1110 4444 %%%% !6K#]T?05EJ-W
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** ,NX7:Q^O\ZCJU?QX(;UJK77!WBCCFK284451U?5T
MTQ-[<D_=7N3_ (>I[?7 -QBY.RW(#5]733$WMR3]U>Y/^'J>WUP#YW?W[W[F
M60Y)_(#T'M_GK1?W[W[F60Y)_(#T'M_GK5:O7PV&5)7ZF4I7"BBBNDD****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN[%ZVCV*!4M%%<C=W<[4K*P4444AA1110 4444 %%%% !1110 4444 %%%%
M!1110 5Q/B+QM-IL[VZ*A5=N-P;/*@]F'K7;5YIXPTF:XNI'2-V4[,%48C[B
MCJ!7;ET*<ZK4[6MU]48XB4E'3N/_ .%D7']V/_OEO_BJ/^%D7']V/_OEO_BJ
MP_[!N/\ GC)_W[;_  J"ZL)+3'F(R9SC<I7..O45ZRPN%;LDCD=6JNK.C_X6
M1<?W8_\ OEO_ (JC_A9%Q_=C_P"^6_\ BJY2KL>BSR ,L4A!&00C$$'H<XIO
M"8:.\4)5:CZLWO\ A9%Q_=C_ .^6_P#BJZWPEK;ZQ$TT@4$.5^4$# "GN3ZU
MYM_8-Q_SQD_[]M_A7?> +1[6!ED5E)E)PP*G&U><&N+'T:$*5XI7OT-J$YN>
MIC:GX_GM99(56/".RC(;.%) _BK2\)>+9=8E:&0( $+?*"#D%1W8^M<1KW_'
MQ-_UUD_]"-;GPW_X^&_ZY-_Z$M:U\+2CAW)15[$PJS=2U^IZ11117AG<%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "N2^(6D&YC6Y1<M&?FP!]T\Y/<X/Y9)]:ZVFR1B0%6
M((P0>00>HQ6M"LZ-1370FI!3BT>'45HZ]I)TJ9H#G .5)[J>AS@9]#CC(-9U
M?3PDIQ4ELSS&FG8****H0445?TC2'U-]B\ ?>;L!_CZ#O],D3*2BKO8 TC2'
MU-]B\ ?>;L!_CZ#O],D>AV%@E@@BC& /S)]3[_YZ46%@E@@BC& /S)]3[_YZ
M5.[A 6)P ,DGI7D8G$NL[+8UC&P.X0%B< #))Z5PGB3Q(=0/E1\1 _BWN?;T
M'XGG !XD\2'4#Y4?$0/XM[GV]!^)YP!@UUX3"<GORW_(F<[Z!1117<0%%%%
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M5MUYO\2/^/A?^N2_^A-7+@:,:U7EEM8UKS<(W1T5IX_@NG6%5DR[!1D+C+'
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MT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW2/-C%2J6\SO[+38K$;8D51@ [1@G'3)ZGZFN?\ '>AK<0M<JH\Q""2J\D<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"BBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%075A'=X\Q%?&<;E#8SUZBIZ*:;3N@:N4/[!M_\ GC'_ -^U_P *NQQB,!5
M  P .  .@Q3J*;G*6[$DD%%%%2,I2:+!(2S11DDY)**22>ISBI+;3(K4[HXT
M4D8RJA3CTR!5FBJ<Y-6NQ<J"FR1B0%6 ((P0>00>HQ3J*D90_L&W_P">,?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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K HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img63237988_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img63237988_5.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\
M(<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31
M]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)
M[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"
MQK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_
M^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/
M^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#S
MU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_
M ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY
M![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17
MB7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__
M )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X_
M_B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7
M_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\
M(<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31
M]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)
M[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"
MQK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_
M^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/
M^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#S
MU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_
M ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY
M![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17
MB7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__
M )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X_
M_B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7
M_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\
M(<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31
M]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)
M[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"
MQK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_
M^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/
M^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#S
MU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_
M ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY
M![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17
MB7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__
M )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X_
M_B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7
M_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\
M(<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31
M]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)
M[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"
MQK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_
M^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/
M^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#S
MU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_
M ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY
M![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17
MB7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__
M )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X_
M_B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7
M_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\
M(<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31
M]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)
M[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"
MQK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_
M^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/
M^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#S
MU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_
M ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY
M![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17
MB7_"QK__ )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__
M )Z_^0X__B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X_
M_B:/^%C7_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7
M_P#SU_\ (<?_ ,31]4GY![:)[;17B7_"QK__ )Z_^0X__B:/^%C7_P#SU_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !16-XPU1]+M);B+ =0N"1G&Y@N<>HSD=L]01Q7E?_"QK
M_P#YZ_\ D./_ .)K6G0E45T1*:BSVVBO$O\ A8U__P ]?_(<?_Q-'_"QK_\
MYZ_^0X__ (FK^J3\A>VB>VT5XE_PL:__ .>O_D./_P")H_X6-?\ _/7_ ,AQ
M_P#Q-'U2?D'MHGMM%>)?\+&O_P#GK_Y#C_\ B:/^%C7_ /SU_P#(<?\ \31]
M4GY![:)[;17B7_"QK_\ YZ_^0X__ (FC_A8U_P#\]?\ R''_ /$T?5)^0>VB
M>VT5XE_PL:__ .>O_D./_P")H_X6-?\ _/7_ ,AQ_P#Q-'U2?D'MHGMM%>)?
M\+&O_P#GK_Y#C_\ B:/^%C7_ /SU_P#(<?\ \31]4GY![:)[;17B7_"QK_\
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M\+&O_P#GK_Y#C_\ B:/^%C7_ /SU_P#(<?\ \31]4GY![:)[;17B7_"QK_\
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M\+&O_P#GK_Y#C_\ B:/^%C7_ /SU_P#(<?\ \31]4GY![:)[;17B7_"QK_\
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M\+&O_P#GK_Y#C_\ B:/^%C7_ /SU_P#(<?\ \31]4GY![:)[;17B7_"QK_\
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M\+&O_P#GK_Y#C_\ B:/^%C7_ /SU_P#(<?\ \31]4GY![:)[;17B7_"QK_\
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M\+&O_P#GK_Y#C_\ B:/^%C7_ /SU_P#(<?\ \31]4GY![:)[;17B7_"QK_\
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M\+&O_P#GK_Y#C_\ B:/^%C7_ /SU_P#(<?\ \31]4GY![:)[;17B7_"QK_\
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M\+&O_P#GK_Y#C_\ B:/^%C7_ /SU_P#(<?\ \31]4GY![:)[;17B7_"QK_\
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M\+&O_P#GK_Y#C_\ B:/^%C7_ /SU_P#(<?\ \31]4GY![:)[;17B7_"QK_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7-?$;_ (\)O^V?_HQ:Z6N:^(W_ !X3?]L__1BU
M=/XX^HI?"SQ*BBBO3.4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /I*BBBO)
M.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** .:^(W_'A-_P!L_P#T8M>)5[;\
M1O\ CPF_[9_^C%KQ*NW"? _4PK?$%%%%=)F%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %?25?-M?25<F,^S\S6CU"BBBN0V"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKFOB-_QX3?\ ;/\ ]&+72US7Q&_X\)O^V?\ Z,6KI_''U%+X6>)4445Z9RA1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!])4445Y)UA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!S7Q&_X\)O^V?_ *,6O$J]M^(W_'A-_P!L_P#T8M>)5VX3
MX'ZF%;X@HHHKI,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ2KYMKZ2KDQGV?F:
MT>H4445R&P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %<U\1O^/";_MG_P"C%KI:
MYKXC?\>$W_;/_P!&+5T_CCZBE\+/$J***],Y0HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ^DJ***\DZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YKXC?\
M'A-_VS_]&+7B5>V_$;_CPF_[9_\ HQ:\2KMPGP/U,*WQ!111729A1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7TE7S;7TE7)C/L_,UH]0HHHKD-@HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *YKXC?\ 'A-_VS_]&+72US7Q&_X\)O\ MG_Z,6KI_''U
M%+X6>)4445Z9RA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;C/W2?45FT)IJZ!JP4444P"BBB@ HHHH **** "BBB@ HK0B\/W,H#K#(58
M@B-B"#T(.*K7=C)9G9*C(Q&<.I4X]<''I2N@L04444P"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ^DJ***\DZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YKXC?\ 'A-_VS_]
M&+7B5>V_$;_CPF_[9_\ HQ:\2KMPGP/U,*WQ!111729A1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 459L]-EO<^4COMQG8I;&>F< ^E6?^$:NO\
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M&2?Z#).#@'%=E9?"(D*9I@#GYE1<\9[,2.H[E>#V-1.K"&[&H-GG=>L?"?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 <U\1O\ CPF_[9_^C%KQ
M*O;?B-_QX3?]L_\ T8M>)5VX3X'ZF%;X@HHHKI,PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ]'^#_\ R\?]LO\ V>O1J\Y^#_\ R\?]LO\ V>MC
MXFWTEG;(\3LC&91E&*G&U^,C'I7!5CS5FC>#M"YUU5M0TV/44,4RAU/9AGL1
MD=P<'J.1VKPW_A);K_GO+_W]?_&N[^&?BF:^9K.8E]JEU=B2WW@"I)Z_>R">
M1TY&,.>'E!<UP512=CGO'7@S^PV$\7,#M@ GE2<G;ZD8!P?P/.">3KW?Q9;K
M<6DZL,@1.WIR@W*>/0@&O"*WP]1SCKT,ZD;,**Z/0/ =SJ^'QY<1Q\[\9'!R
MJ]3P<@\*?[U=,GP@ !S.<XXQ'C!R.OSG/&>..<'/&#4JT(NS8E"3/-J*[G5/
MA1-;KN@<2GNI'EGMTR2#WSDCIQFN+N+9[9C'(I5AU# @C//0\]*J%2,]F)Q:
MW(J*TO#NC_VS.EKNV[]WS8W8VJ6Z9'IZUUFI?"O[%%)/Y^?+1FQY>,[03C.\
M^E$JL8NS!1;5S@:*['PW\-Y-7C^T2/Y2MC8"NXL/[V,K@>GKUZ8)M^+?AU'I
M,+7<4C;4"_*X!))8+]X;<=>F#TZ\\3[:'-RWU'R2M<X.BM+0_#\VMOY<"YQC
M<2<*H)QDG^@R3@X!Q7>V?PCB3/FRNW3&Q0F/7.=^?T_&G.K"&[",&SS"BO2=
M3^$@(S;2G.!\LHSDYY^90,<=MIY[\\<#J>E2Z6_DSJ5? .#@\'N",@_AWR.H
MHA5C/9BE!Q*E%%=5X>^'D^K 2MB.)AD,W+$'."%X]!U(X.1FJE)15V))LY6B
MO2X_A"@5@TQ+'&TA  /7(W$G(Z8(Q[UFZI\*)K==T#B4]U(\L]NF20>^<D=.
M,U"Q%-O<KV<CAJ*=+$8B48$,I(((P01U!%3Z;9_;98X,X\QU7.,XW$#../6M
M+DE:BO1_^%/_ /3?_P A?_9UB:;\.9[]W52%BCE9-[ @MM8JQ51G.,=R!GC/
M!QFJ\'U*]G(Y.BO34^$480@S-YF>&"@*!QU7))[\[AVXXYYCQ1X$FT(>=D21
M9QN4$$9Q]Y><9/ .2/7!(%$:\).R8.$D<S113HHC*0B@EF(  &22>@ K0D;1
M7<Z7\*)KA=T[B(]E \P]^N" .V,$]><5H/\ " $#$YSCG,><G)Z?.,<8XYYR
M<\X&;Q%-=2O9R/-J*ZI?AY/'<):S85)2P$B_.N50OC'RGMCG'<C(%:FI?"O[
M%%)/Y^?+1FQY>,[03C.\^E-UH*VH<DC@:^C:^<J^C:PQGV?F71ZGBOQ$_P"/
MZ;_MG_Z+6O0OASJ$=S9I&A&Z+(91G()8D'DD_,.?3.0,8P//?B)_Q_3?]L__
M $6M:7AWX;_VS EUYVW?N^7R]V-K%>NX>GI53472C=VV%%M3=C6^*^L1LB60
M.90X<@= -K 9]SNR!Z<G&1GS2NC\8>#_ /A'/+_>;_-W?P[<;=O^T<YS5GPG
MX#_X2")I_-V;7*XV;N@4YSN'K5TW"G33OH*2<I')T5Z/_P *?_Z;_P#D+_[.
MC_A3_P#TW_\ (7_V='UBGW%[.1YQ17H__"G_ /IO_P"0O_LZX'4K/[%+)!G/
MENRYQC.TD9QSZ5<*L9["<6MRM15W2]%FU5MD"%R.N. .IY8X S@XR>>U=K;_
M  A=E!DF ;N%0L/S+*3Q["B=6,-V"BV>>T5Z/<_"'[QCF]=H9/R!8-^9"^^.
MU<9K?AJ?13B9"%S@,.4/7&&]\9P<''44H582V8.#1ET45/963WSK#$I9W. !
M_G\ST Y-6(@HKO-.^$TTPW32+&2!@*"YYZ@\J!CV)!]?6W<?"'@F.;G;P&3@
MG'J&X!/L<#UQSF\13ON5[.1F_"?_ (^G_P"N#?\ H:5VOQ$_X\9O^V?_ *,6
MN9\ :%-H][)%,I'[E\-SM;#Q\J>_4>XZ$ \5TWQ$_P"/&;_MG_Z,6N>HTZR?
MH:1T@SQ6BBBNTQ"O>_#7_'K!_P!<(O\ T 5X)7O?AK_CU@_ZX1?^@"N7%[(U
MH[LTJ*\C\=ZW<6U[+''+(JC9@*[ #**>@..M847BB[C(83R9!!YD8CCU!)!^
MAXK..%;2=RG52=CUSQ#X.@UL$LH64CB11\V>,9Z;N@&#VZ$=:\:U73'TN5K:
M7&]#S@Y'(R"/J#GU]0#7MWAG5SJ]O'=, K.#D#IE6*G'UQG';ID]:XCXO6ZJ
M\$H'S,KJ3[*5('IP6/YU6'G*,^1BJ137,>>T5VOAWX;_ -LP)=>=MW[OE\O=
MC:Q7KN'IZ52U3P');7*6$+>8SH'+;=H4;B"3RW QU]\ 9QGH]K"[5S+D=KG+
MT5Z;!\(HU#!YF+$?*54* >>H);/;@%?KSQPGB+1_[&G>UW;MFWYL;<[E#=,G
MU]:(58S=D.4&MS-HK8T#PG/KI)A V X+L<*#C..Y/X XR,X!KL[?X0HK R3$
MKW"H%/YEF Y]C1.M".C8*#9YI17H5Q\(7528Y@6[!D*C\PS$<>QKB-3TJ72W
M\F=2KX!P<'@]P1D'\.^1U%.%6,]F)Q:W*E%%3V5D]\ZPQ*6=S@ ?Y_,] .35
M"(**[S3OA--,-TTBQD@8"@N>>H/*@8]B0?7UMW'PAX)CFYV\!DX)QZAN 3['
M ]<<YO$4[[E>SD9OPG_X^G_ZX-_Z&E=K\1/^/&;_ +9_^C%KF? &A3:/>R13
M*1^Y?#<[6P\?*GOU'N.A /%=-\1/^/&;_MG_ .C%KGJ-.LGZ&D=(,\5HJSIM
MG]MEC@SCS'5<XSC<0,XX]:[[_A3_ /TW_P#(7_V==4ZL8;F2BWL><4459TVS
M^VRQP9QYCJN<9QN(&<<>M4W816HKT?\ X4__ --__(7_ -G7G%3"I&>PY1<=
MPHJ>RLGOG6&)2SN< #_/YGH!R:[?3_A+)*@::4(Q_A5=^.!U.Y1G/'&1Z$T3
MJ1ANP46]C@:*]+F^$*'&R8CY1G<@;)[D89<#VYQZFN5\1^")]#!D8!X@?OKV
MR2!D=1^HR0,DU,:T).R8W"2.>KT?X/\ _+Q_VR_]GKBO#NC_ -LSI:[MN_=\
MV-V-JENF1Z>M>L>#_!__  CGF?O-_F[?X=N-N[_:.<YJ,3.*BX]2J47>X?$3
M_CQF_P"V?_HQ:\5KWOQ%H_\ ;,#VN[;OV_-C=C:P;ID>GK7%_P#"G_\ IO\
M^0O_ +.L\/5A"-F^I52#;T/.**TO$6C_ -C3O:[MVS;\V-N=RANF3Z^M9M=:
M::N8M6"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5])5\VU])5R8
MS[/S-:/4****Y#8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N:^(W_'A-_VS_\
M1BUTM<U\1O\ CPF_[9_^C%JZ?QQ]12^%GB5%%%>F<H4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>Q_#
M[Q&FI0+;Y EA4*5Z95>%8<G/& ?0]@",^.4Z*4Q$.I(92""#@@CH0:SJTU45
MBH2Y6?06H:;'J*&*90ZGLPSV(R.X.#U'([5PVL?"=7)>UDVYZ))R.O\ ?'(
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M/8=<>+T5J\+"UB/:RN>V>.-.@O+=C<,J%03&['&&P3CH2<XY4 DCH,@8\_\
M"?CS_A'XF@\K?N<MG?MZA1C&T^E<YJ&I2:BYEF8NQ[L<]R<#L!D]!P.U5J<*
M"4>5ZA*I=W1]":;>?;8HY\8\Q%;&<XW '&>/6N<\6>//^$?E6#RM^Y V=^WJ
M6&,;3Z5M>&O^/6#_ *X1?^@"O.?BQ_Q])_UP7_T-ZYJ4(RJ6>QK.34;EG4OB
MI]MBD@\C'F(RY\S.-P(SC8/6N!HHKMA3C#8P<F]PHHHJQ!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]
M)4445Y)UA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S7Q&_X\)O^V?\ Z,6O
M$J]M^(W_ !X3?]L__1BUXE7;A/@?J85OB"BBBNDS"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M *,:O./B)_Q_3?\ ;/\ ]%K7H_P[_P"/&'_MI_Z,:BM_!C\OR"'QLYSXP?\
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MP1[5QG_"I[7^_+_WTG_Q%<]-P;;D:23M9%30OBJ+AEBN4"ECC>A^7); )#=
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M_HQJP/B]<,J01 _*S.Q'NH4 ^O 8_G6?)SU6O-E7M"Y=_P"%L6O]R7_OE/\
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MX]8/^N$7_H KSGXL?\?2?]<%_P#0WJ*'\5_,JI\!Q5>L?"?_ (]7_P"N[?\
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M $8U>3^)?^/J?_KO+_Z&:]8^'?\ QXP_]M/_ $8U;XC^&B*?Q,YSXP?\N_\
MVU_]DKSBO1_C!_R[_P#;7_V2O.*TP_\ #1%3XF>@?"*["R30<[G56'IA"0?_
M $,8_&N[\013R0M]D;;,,%?NX..JG<".1TZ<XR0,UX?I6IOI<JW,6-Z'C(R.
M1@@_4''KZ$&O:O#GBF'74#(0'Q\T9(W#&,_4<C!Z?0Y QQ$&I<_0TIR35CRW
M_A8E]_SU_P#(<?\ \31_PL2^_P">O_D./_XFO5M3\,6VJ'=-$K,2"6'RL<#
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MCSRNT$?PJ#ANO?<<<#@9Y!%.^+'_ !ZI_P!=U_\ 0'KL;BY2V4R2,%4=2Q
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M\'_^7C_ME_[/6C\6/^/5/^NZ_P#H#UG?!_\ Y>/^V7_L]:/Q8_X]4_Z[K_Z
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ME=W. ^&'AQY91J#@B- P0]-S$;3QCD $Y/'.,9P0._\ $O\ QZS_ /7"7_T
MU+<ZQ';RQVA/[V7.%'7"@DL?0<8'J>G0XB\2_P#'K/\ ]<)?_0#6<YN<TV4H
MJ,;'@E?1M?.5?1M;8S[/S(H]3Q7XB?\ ']-_VS_]%K7H_P ._P#CQA_[:?\
MHQJ\X^(G_']-_P!L_P#T6M>C_#O_ (\8?^VG_HQJ*W\&/R_((?&SG/C!_P N
M_P#VU_\ 9*XSPYH#Z[,+="!QEF/900"<=^H 'KZ#)'9_&#_EW_[:_P#LE;GP
MULDALTE50'E+%CW.UV4?D!P.G4]2:<:G)13!QYILW]*TQ-+B6VBSL0<9.3R<
MDGZDY]/0 5YS\1_%XO"=/BSLC;YVY&67C;CT!ZYZD#' R?4:S?\ A&K7_GA%
M_P!^D_PKGIS49<SU-)1;5D>"5N^![L6M["[9P6V\>K@H/U//M7KW_"-6O_/"
M+_OTG^%>1^.[9+:]ECC4*HV8"@ #**>@XZUUPK*K>/D8R@X:GMDJ%P5!()!Y
M&,CW&01Q[@CVKR+5?&&I:7*UM+*-Z'G"1D<C((^7N#GU]0#77^"_'B:JH@N"
M%G& "< /G@8[;L]5[]5XR!TNHZ3#J0VS(KC! W $C/7!ZCZC!KFB_92:DKFK
M]]73/(/^%B7W_/7_ ,AQ_P#Q-68O&6IRQM<*Y,:?>;RX]HR0,9VXSEAQU[]*
M]$M/ ]E:G<L*DD8^?+C\G)'X]:MZK<VUE$89V1(F1EVD[<J!@A0,'H<87GIB
MM'6@WI$GDEU9XCJVLRZNXEG;<P7:#@#@$G'R@#J37O-C=B\C2=<[9%5AGKAA
MD9Z^M?/USLWMY>=FX[=V-V,\9QQG'7%=O\/_ !N+ "QN"!'D['Z;23DAO8D]
M>QZ\?=O$4N:*MT)IRL]3-^(/AQ]-G:XP3%,Q8-UPS<LIX&.<D>H[D@XY6OHG
MY+I.S(Z^S*0P_(@C\ZJ1>'[:(AUAC#*001&H((Z$'%1#%65FBI4KLY#X6^'W
MM5:]D7'F*!'DG.WJ3CI@G&._&1P>=OXB?\>,W_;/_P!&+6I#KL,\QLT8-(JL
MS;<$+M8*03V.3TZC'..,Y?Q$_P"/&;_MG_Z,6L^9RJIONBK)1:/%:***] YP
MKWOPU_QZP?\ 7"+_ - %>"5[WX:_X]8/^N$7_H KEQ>R-:.[/)_B)_Q_3?\
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M<F,^S\S6CU"BBBN0V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KFOB-_P >$W_;
M/_T8M=+7-?$;_CPF_P"V?_HQ:NG\<?44OA9XE1117IG*%%%% !1110 4444
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M144E%+9 VV%%%%4!H:9K\^EG,$C*,DX!RN2,9*G*GCU'IZ5=N_'%[=#:TS
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "N:^(W_ !X3?]L__1BUTM<U\1O^/";_ +9_^C%JZ?QQ]12^%GB5
M%%%>F<H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 ?25%%%>2=84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 <U\1O^/";_MG_ .C%KQ*O;?B-_P >$W_;/_T8
MM>)5VX3X'ZF%;X@HHHKI,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ2KYMKZ2K
MDQGV?F:T>H4445R&P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<U\1O^/";_MG_
M .C%KI:YKXC?\>$W_;/_ -&+5T_CCZBE\+/$J***],Y0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ^DJ***\DZPHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MYKXC?\>$W_;/_P!&+7B5>V_$;_CPF_[9_P#HQ:\2KMPGP/U,*WQ!111729A1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7TE7S;7TE7)C/L_,UH]0HHHKD-@HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML'L6?/\ 17T!_P (S:?\\(O^_2?X4?\ ",VG_/"+_OTG^%'UM=@]BSY_HKZ
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ML'L6?/\ 17T!_P (S:?\\(O^_2?X4?\ ",VG_/"+_OTG^%'UM=@]BSY_HKZ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y
MKXC?\>$W_;/_ -&+7B5?1\L0E!1@"K @@C((/4$>E4/^$9M/^>$7_?I/\*WH
MUU3C:QG.GS.Y\_T5] ?\(S:?\\(O^_2?X4?\(S:?\\(O^_2?X5K];78GV+/G
M^BOH#_A&;3_GA%_WZ3_"C_A&;3_GA%_WZ3_"CZVNP>Q9\_T5] ?\(S:?\\(O
M^_2?X4?\(S:?\\(O^_2?X4?6UV#V+/G^BOH#_A&;3_GA%_WZ3_"C_A&;3_GA
M%_WZ3_"CZVNP>Q9\_P!%?0'_  C-I_SPB_[])_A1_P (S:?\\(O^_2?X4?6U
MV#V+/G^BOH#_ (1FT_YX1?\ ?I/\*/\ A&;3_GA%_P!^D_PH^MKL'L6?/]%?
M0'_",VG_ #PB_P"_2?X4?\(S:?\ /"+_ +])_A1];78/8L^?Z*^@/^$9M/\
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M  C-I_SPB_[])_A1_P (S:?\\(O^_2?X4?6UV#V+/G^BOH#_ (1FT_YX1?\
M?I/\*/\ A&;3_GA%_P!^D_PH^MKL'L6?/]%?0'_",VG_ #PB_P"_2?X4?\(S
M:?\ /"+_ +])_A1];78/8L^?Z*^@/^$9M/\ GA%_WZ3_  H_X1FT_P">$7_?
MI/\ "CZVNP>Q9\_T5] ?\(S:?\\(O^_2?X4?\(S:?\\(O^_2?X4?6UV#V+/G
M^BOH#_A&;3_GA%_WZ3_"C_A&;3_GA%_WZ3_"CZVNP>Q9\_T5] ?\(S:?\\(O
M^_2?X4?\(S:?\\(O^_2?X4?6UV#V+/G^BOH#_A&;3_GA%_WZ3_"C_A&;3_GA
M%_WZ3_"CZVNP>Q9\_P!%?0'_  C-I_SPB_[])_A1_P (S:?\\(O^_2?X4?6U
MV#V+/G^BOH#_ (1FT_YX1?\ ?I/\*/\ A&;3_GA%_P!^D_PH^MKL'L6?/]%?
M0'_",VG_ #PB_P"_2?X4?\(S:?\ /"+_ +])_A1];78/8L^?Z*^@/^$9M/\
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M  C-I_SPB_[])_A1_P (S:?\\(O^_2?X4?6UV#V+/G^BOH#_ (1FT_YX1?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M00>001U!I] !16?K^MIHD#WDH8I'MR$ +?,P48R0.I]:- UM-;@2\B#!)-V
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV J;2W3)."R\#C)[$CUH VZ*HZ+K$>L0I=PYV2#(R,$8)!!'J""/3T)'-7J
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"/_P#QZ@#JKCPK:W$ZW[QJ9UQAN>HZ$C."1V)!(P,'@8ROBE_R#I_^V?\
MZ-2N:TVUN=$U6WL9;J69)(W<[V<+]V0 %2[ X*Y__572_%+_ )!T_P#VS_\
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ML2;99=VYMS'.Y@S<$D#)&>!6M7FG@C5IKG5KN"21VC3S]JL[%1B90,*3@8'
M]JT_B[J,MA:(\+LC&=02C%3C8YQD$<<4 =Q17DFEZ;?>/HE\R1H;6.-4&<N9
M67&YB,KNY&<DX!X&3N-/UKX;S>&5?4=/G8>4-Q4X#;%PS9885AD9VE0"..2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^NL?_H0KV2O&]!_X^(?^NL?_ *$*]DKKS?XX^AEA-F%%%%>6=04444 %%%%
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M!M#L0'Y/RKG.]2>#E@3_ !>L5Y_\9]+^TVB7(7+02#)SC"OP>,\Y;9V)_#-
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M48(YVLI_A8 $C/<<@@]P><'('F_BGQ9<Z3JSB)G=5VA8=[["SP@+\@//S-G
MY)[@G- 'L%%>91?"B;6!]IU"X8S.A^4 -L8DD#.<%1DY50HR<*V.31@GN/AQ
M<1P2R>993< G("@$;F"Y8J5+9(&0X/\ >^Z >MUYYJTROKUL 02L# @'.#MF
M.#Z'!!^A!KL]?TU]2@>WBD:%VVXD3.X88$XP5/(&.O>O%XO"TL6J_P!G+<,)
M<D^> 0^6B,A/W\Y.2#\W/7VH ]XHKG_"GAN;1?,\^Y>XW[<>9N^7;G.,NW7(
M].E=!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,>V,<5T=%% 'G_QK_P"/./\ Z^%_] DKJO"?_'G;?]>\/_H"UROQK_X\X_\
MKX7_ - DJ7P]\1["TMH(9)L/'#&K#RY#@J@!&0N.M '=U@^.-872;.:4L58H
M50J<-O<$+CD<C[W'( )'2LJ]^+>GVZ[D=I#G&$C8'Z_/L&/QS[5R4-I=_$J9
M)9U\JTBW8('4%N0K'[S': 3]U<9P#\K '1_!G3S;V;3,H!EE8AN,E5 4<CG
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M .@25E> /^0S>?\ ;Q_Z/6M7XU_\><?_ %\+_P"@24 =1X.A6*RM@H 'D1G
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MP55N 2.KYXYSW]*\)_\ 'G;?]>\/_H"UYE\4?&4>N*+.VRZ0.7D<#*\812K
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M_P"@25M^#/%K^(_-D,31Q*P\IFS\ZG(/L2"O."0,A>V3B?&O_CSC_P"OA?\
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MG%@JLEU+3WY/08_6O&O%]X^NWYB!Z.L2[@!C!P>F>-Q)SR<'\*]9DD$0+L0
M 223@ #J<UY1\.+3S[L/G'EHS=.N1LQ[?>S^%1.*T2+IS;3;/4=/L5L(U@C^
MZB@#I^9QCD]3ZFK%%%;&(4444""BBB@ HHHH T;1]Z_3BIZ\HT[QO<PZA]F9
MMT)N#'MPHX+%%YVY^7(/7G&">:]7KEE:[.V%^5!1114E!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%(3CDT 1W-P(!N-8<TYF.6/
M^%/N[G[0V>W85!6D58EL****8@HHHH **** "BBB@ K5L+_?\C=>Q]?_ *]9
M5%#5P3.EHJM877GKS]X=:LUDRPHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "J&O?\>\W_7*3_T$U?JAKW_'O-_URD_]!-72^./J*6S/*M!_
MX^(?^NL?_H0KV2O&]!_X^(?^NL?_ *$*]DKT<W^./H<V$V84445Y9U!1110
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M  CXF;P3(VDZB"L8)9'&Y@,^@&<HV,C R&SN&2=H _\ X3[6?^?/_P EY_\
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MT_\ 1KUU= 'E7QS_ .77_MM_[3KT^TM5M$6&,82-0JC). HP!D\]*\P^.?\
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ME_@#_D,WG_;Q_P"CUKH/BAX:EU6*.YMMWG6S%@%.&(."2N!DL"H(P1WQDX%
M'/\ _"?:S_SY_P#DO/\ _%4?\)]K/_/G_P"2\_\ \571>%?B=;:M&!.ZPS ?
M,'.U#C'*LW&#G[I.X<]0-QF\0?$ZSTE?D<32$<+$0P[XRX^4#(P>K#(.TB@#
M$^#>G7%@MPDZ2(I,942*RC/SAB P'/ SCVSVK/EA67Q%A@",@X(SRML"#]00
M"/0\UZ+X;U&74;>.>>,Q2L#N0@C!!(SAN0#C(!Z ]3UKSW_F8_\ /_/K0!ZK
M7G_QK_X\X_\ KX7_ - DKT"O/_C7_P ><?\ U\+_ .@24 =EH=ZU_;PW#X#2
MQ(Q Z9903C.>.:\X_P"9C_S_ ,^M=_X3_P"/.V_Z]X?_ $!:\]UV9=$UV.ZF
M($<H4@@] T9ARV<  ,,GGA>>O% 'K%%4;+7+>_;9#+&[ 9(1U8XZ9P">.:O4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &)XSO!
M9VDDK9PNSIUY=1[>M>8?\)?%_=?\A_\ %5Z?XSLQ>6DD39PVSIUX=3[^E>8?
M\(A%_>?\Q_\ $U$^6^IVX7V_(^2UKA_PE\7]U_R'_P 51_PE\7]U_P A_P#%
M4?\ "(1?WG_,?_$T?\(A%_>?\Q_\34^X;_[5Y$]CXCCO'$2ALMGJ!C@9]3Z5
MJUE6/AR.S<2J6RN>I&.1CT'K6K4RMT.BC[3E]_<****1J6M+_P!='_UT3_T(
M5Z)7G>E_ZZ/_ *Z)_P"A"O1*TI['F9C\4?0****T.$**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBJ5Q>?PK^=5&+DR9345=EJ281]35=M0'852)S16
MRHI;F$J\GL6?M[>W^?QI5OSW JK15>SCV(]I+N7?[0&.G-1O?$].*K5D^++H
M6MI,[9P8RO'J_P @_4\^U+V<5J5[2<M+GFD"/XNO2S9_>MEL?PHO&,A<<* H
M)')QGK7K\<8B 10     ,  =!BO.OA5:AI)IN<JJJ/3#DD_^@C]:]'I4EI<=
M9^];L%%%%:&(4444 %%%%  #BM6&3S &K*KAOAYXVN+ZZ%K<.65T;: J###Y
MLD@ XP#Z\GIW&5:UD;T+W9ZC1116!T!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSC-9%E\+-/M6W^67._<-[L0/1< @%1_M!B>Y-=;10 R&%85"( %4   8  X
M '0"J6MZ!!K:"&Y7>@8,!N9>0",Y4@]":T** (;2U6T188QA(U"J,DX"C &3
MSTJ:BB@#)T+PM;:#N^S)L\S;N^9FSMSC[Q/J>E:<T*S*4< JP(((R"#P00>H
M-/HH Y(_"K3BP;RC@ C'F28.<<_>SD8XP<<G(/&.MHHH *S-<\-V^NJJ7*!P
MARO)4C/7E2#@]QG!P/05IT4 8.@>";706,MNA#L&!8LQ^5FW;<$XP, #C.!R
M2<D[<T*S*4< JP(((R"#P00>H-/HH Y2Y^%^GSMYGE8^8DA7<*<@\8!P!DY
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS@X'H*TZ* ,'0/!-KH+&6W0AV# L68_*S;MN"<8& !QG Y).2=ZBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R_$O_'N__ ?_
M $(5PM=CXWO?L5G+-C.W9QG'5U'7GUKRC_A,_P#IG_X__P#8UG.+;._!XBG3
M@U)VU.FHKF?^$S_Z9_\ C_\ ]C735#BT=U.M"I?E=[!1112- HHHH M:7_KH
M_P#KHG_H0KT2O.]+_P!='_UT3_T(5Z)6E/8\S,?BCZ!1116APA1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU"=P::"BBB@04444 >6?$3Q!]OE%LA.R$D'J,OG![\[>@..N[J"*[OPGHO\
M8]NL)^^?F?\ WFZCJ1P,#C@XSWJY<Z/#=2)<.@,D?W6/;_''49S@\C!JY4QA
M:3;-)3O%) #BM*WG\T>XZUFT^&7RCN%%2',@ISY7Y&K12*=W(I:Y3K"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BN7\6^*)='N+2WC"E;J7:Y8$D#<@XP1S\
MQZY[5U% !1110 4444 %%%% !1110 45Y_\ !3_CSD_Z^&_] CKT"@ HHHH
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M** "BBB@ HHHH P/'EX;.REE7&5V=>G+J/;UKR'_ (2^7^ZGY'_XJO:?$O\
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MMKJ436\CXPQ4JF"3@D/RHX SEAG))4"O0*YKX@^&UUNT<;<RQ*7C(4LV1R5
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M22/*2*C-)N(VAG*D[0I)P!GKSTKL*\B^)]DM_JEM;OD+*D*DCKAI7!QG//-
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MP ,_QE@.#P1AJROCG_RZ_P#;;_VG7H7AS08]"@2UC ^4#<0,;FQ\S'D\GZG
MP!P!0!P]K\3[G3)1#JEOY:,Q =%=0-O#$ E@XR1RIX'(W9 KTB&99E#H058
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M?&<9VJ3C.#C./2O/X_C$;R/;!;LUR[,%C!+@ +D.<*"><_*.P)+#C/:^+/\
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M0Z;Y6[S_ "_GWXQO<I]W:<XQGJ,UU=>5>/O^0S9_]N__ */:O5: ,GQ3KO\
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M5_-BDLV/,;!ERW.UN" O8 C)QQENW?L/%'_'I<?]<)?_ $ UYE\'_P#C[?\
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MF,$]MH!;(.,]!D_$G1X[C58(3D"Y$(<@\_,YCR,Y .T#MCC..M>P0PK"H1
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M7G/IQSQTNF:Q#J:[X7# =<=1U'(.",XXR.>U)23*<&BY1113)"BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:#G*QLN,#&>Q.:]3K/UW0HM<B-M.,JW0C[RGLP/8C_ZQR"00"[#,LRAT(*L
M00<@@\@@CJ#6/XRUT:):2W&</M*IT)WMPN W!P>2.> 3@XKBH_!FK>'59+&X
M5XQC:AP&ZY.%D#(O)).&&>IYP*NZ7\.)[VY^W:M(LQ4#:JY*G'3(*J HZ[0,
M,22>X8 ?\%/^/.3_ *^&_P#0(ZQ/B/I\%EJ4-U<QYMYU D^9ADK\A;Y26&Q2
MAP -V,=2:[/X>>%Y?#=NUO,5+-*6!0DC!51W"\_+6QKNA1:Y$;:<95NA'WE/
M9@>Q'_UCD$@@&%#\,],F4.D0*L 01+(00>000_(-0ZA\/=*TZ-KB:(+&@R29
M)?\ XODGH .2>!S6%'X,U;PZK)8W"O&,;4. W7)PL@9%Y))PPSU/.!5B'X:W
M6KS"?59Q(J$$)&6P>,$=$" X&=HRW/(/- ':^']&M]*BV6@ B<[QABX.X#Y@
M23P0!T.*\]\??\AFS_[=_P#T>U>GVEJMHBPQC"1J%49)P%& ,GGI7,?$/P2W
MB>-/+8++$3MW?<(?&X' )!X!!Y]".<@ ZVO'-:TJULM8>.]0?9[@;E)D90&<
M ER5.<%PPP2 ,YX4"NP\.Z?J\<X:\FC:!20P4+ELIP1B,' 8CJ0>#P1C.QXL
M\)Q>)(O)EX9<E' ^93_4'N._L0" #/\ ^%6Z=_SQ_P#(DO\ \7574O >D:8H
MEGC5%+*H+2R@98X ^_\ B?0 DX )K'A\,:UHRB"VN%>+>%7."57H&(D4[5
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M6Z=_SQ_\B2__ !=5;SP'I%DT<4L:JTS;4!EE!8XS@?/^'U('4@')AT/7K/9
MEPC*=V6)#[>_S-)&7.2<#&['? Q5[PQ\,?LTHOK^0S3@J1\S$*R'Y6W$AF.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,OQ+_Q[O\
M\!_]"%<+7=>)?^/=_P#@/_H0KA:RJ;GJ9?\ PWZ_Y!1114':%%%% !1110!:
MTO\ UT?_ %T3_P!"%>B5YWI?^NC_ .NB?^A"O1*TI['F9C\4?0****T.$***
M* "BBB@ HHHH **** "BBB@"M>R[1CUJA5B^;+8]!5>NFFK1.2J[R844459F
M%%%% !1110!F^(M'&KP/;G&2,J3V8=#G!QZ''."17GWPTU+[/<& YQ,IX 'W
MDRP)/7INZ=S^7J=>1:NBZ9J19S\JW".3CH&(D/ STS^..E9U-&I&U+5.)Z[1
M116AB%%%<=XP\=?V6S6L(S+MY8]%)P1P1\QP<^@XZ\BE*2BKE1BY.R-O7?%$
M&BX$I.XC(51EB,XSV _$C.#C)%>?:MX^N=5/E0YC#$ "/)<DXP-W7KTV@=<'
M-1^&O!TNO'[1(2L1;YF.2[==VW.<\\$GC/J017I.C^'8-(&(5 .,%CRYZ9Y]
M\9P,#/05G[T_)&ON4_-GG$'@:^U-O,E&"R@[IGR3TP#C<V<>H&,8]JU+?X4L
MR@R3 -W"H6'YEE_D*]%HJE2B2ZT@HHHJS(**** "BBB@ JS8?>/T_P *K5<T
M]>I^E34^%FE)>\BY1117*=84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !5/4.WX_P!*N5XU\4;%[&]^T@D>:J,K $8* +@-W(V@]L9'U-1ERNY,
MX\RL>FT55TN_&H1)<+C#J#@'."1R,^QX/N*M5U'&%%%% @HHHH **** /+OB
MC_Q\I_UQ7_T-Z]#T*,Q6\*,""(HP01@@A1D8KFO%/@.35Y&N5E&2%"HX.T
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M(****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \,^)/_(0F_P"V?_HM*]SKPSXD_P#(0F_[
M9_\ HM*]SH **** "BBB@ HHHH **** "BBB@ KS+_A='_3O_P"1?_M=>FUS
M/_"MM/\ ^>/_ )$D_P#BZ .8_P"%T?\ 3O\ ^1?_ +71_P +H_Z=_P#R+_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX<O1')@8;RWSP-K$?-EATZ,#QD#T-9R;C*_0UC%2BUU1Z_6C9)M7Z\UGJ-W
MK65=HQZ4JSTL506K8M%%%8'0%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44R:985+N
M0%4$DDX  Y))/0"J5KXAMKMA%%-$[G.%21&8X&3@ YZ4 :%%%% !15>]U&*P
M7?,ZHI. 78*,]<9)'/%,L=6AU#/D2))MQGRW5L9SC."<9P: +=5[W48K!=\S
MJBDX!=@HSUQDD<\58KS?XV:A&+>.UW#S3*'V]]H5UW>PR<#/7G'0X /2*Q_%
M'BB+PW$+B8,59PH" $Y()[E>/EK8JO>Z=%?KLF174'(#J&&>F<$'GF@ TZ]6
M_B2X3(65%8 ]<, 1G&>>:L4R&%85"( %4   8  X  '0"GT %%9D/B>TF8(D
M\19B  )4))/   /)-:= !113)IEA4NY 50223@ #DDD] * 'T51LM<M[]MD,
ML;L!DA'5CCIG )XYJ]0 4457O=1BL%WS.J*3@%V"C/7&21SQ0!8HJI8ZM#J&
M?(D23;C/ENK8SG&<$XS@U;H **9-,L*EW("J"22<  <DDGH!5*U\0VUVPBBF
MB=SG"I(C,<#)P <]* -"BBB@ HHK/NO$-M:,8I9HD<8RKR(K#(R,@G/2@#0H
MID,RS*'0@JP!!!R"#R"".H-/H ***S)O$]I"Q1YX@RD@@RH"".""">"* -.B
MBB@ HJO>ZC%8+OF=44G +L%&>N,DCGBF6.K0ZAGR)$DVXSY;JV,YQG!.,X-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \,^)/\ R$)O^V?_ *+2O<Z\,^)/_(0F_P"V?_HM*]SH **** "BBB@
MHHHH **** "BBB@ HHK,_P"$HM/^?B+_ +^I_C0!IT5F?\)1:?\ /Q%_W]3_
M !H_X2BT_P"?B+_OZG^- !XH_P"/2X_ZX2_^@&O,O@__ ,?;_P#7!O\ T-*[
MSQ'XCM9K6=%GB+-#( !(A))0@  'K7!_!_\ X^W_ .N#?^AI0![!1110 444
M4 %%%% !1110 4444 %%%% !1110 5D:G:^6=XZ-_.M>L[6'P%7U)/Y?_KIQ
MW$S+HHHK0D**** "BBB@ HHHH ?%'YA"COZUNV\ @7:*Q+;[Z_[P_G705,RD
M%%%%0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "L_7];31('O)0Q2/;D( 6^9@HQD@=3ZUH5#=6B7:F
M*55=#C*N RG!R,@\=: *N@:VFMP)>1!@DF[ < -\K%3G!(ZCUK0J&UM$M%$4
M2JB#.%0!5&3DX XZU-0 45GW7B&VM&,4LT2.,95Y$5AD9&03GI6A0 451O=<
MM[!MDTL:,1D!W53CIG!(XXJW#,LRAT(*L 00<@@\@@CJ#0 ^BBB@ HK/M?$-
MM=L(HIHG<YPJ2(S' R< '/2M"@ HK/\ ^$AMM_D>=%YF[;M\Q-V[.-NW.<YX
MQUS6A0 4444 %%%% !114-U=I:*9965$&,LY"J,G R3QUH FHJC9:Y;W[;(9
M8W8#)".K''3. 3QS5Z@ HHJC>ZY;V#;)I8T8C(#NJG'3."1QQ0!>HJ&UNTNU
M$L3*Z'.&0AE.#@X(XZU-0 445F0^)[29@B3Q%F(  E0DD\   \DT :=%%% !
M116?:^(;:[81131.YSA4D1F.!DX .>E &A1110 45#=7:6BF65E1!C+.0JC)
MP,D\=:KV6N6]^VR&6-V R0CJQQTS@$\<T 7JY_Q7XUA\,>7YZNWF[L>6%/W<
M9SEE_O"N@JI?:3#J&//C23;G'F(K8SC.,@XS@4 6Z*** "BLR'Q/:3,$2>(L
MQ  $J$DG@  'DFM.@ HHHH **J7VK0Z?CSY$CW9QYCJN<8SC)&<9%/LM1BOU
MWPNKJ#@E&##/7&03SS0!8HHHH **S[KQ#;6C&*6:)'&,J\B*PR,C()STJ[#,
MLRAT(*L 00<@@\@@CJ#0 ^JZ:C$\AMPZF51DH&!<#CDKG('(_,58KS?POJ$>
MH:W=30L&0P8##H=ODJ<'N,@\]#U'% 'I%<__ ,)K#]M_LC:_F^N%V?ZOS.N[
M/3VZ_G7054_LF'S/M7EIYO\ ?V+OZ;?O8STXZ].* +=%%5[W48K!=\SJBDX!
M=@HSUQDD<\4 6**J6.K0ZAGR)$DVXSY;JV,YQG!.,X-6Z "BBJE]JT.GX\^1
M(]V<>8ZKG&,XR1G&10!;HJ&UNTNU$L3*Z'.&0AE.#@X(XZU-0 445GW7B&VM
M&,4LT2.,95Y$5AD9&03GI0!H44R&99E#H058 @@Y!!Y!!'4&GT %%5+[5H=/
MQY\B1[LX\QU7.,9QDC.,BGV6HQ7Z[X75U!P2C!AGKC()YYH L4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!E^)?^/=_P#@/_H0KA:[KQ+_
M ,>[_P# ?_0A7"UE4W/4R_\ AOU_R"BBBH.T**** "BBB@"UI?\ KH_^NB?^
MA"O1*\[TO_71_P#71/\ T(5Z)6E/8\S,?BCZ!1116APA1110 4444 %%%% !
M1110 4444 >>?%S0//C74%ZQ85_]UC\IY/9CC@9.[G@5#\//$GVZ/['(?WD2
M_+QC*# '/J.G;C'4Y->C2Q"8%& *L""",@@\$$'M7B?B?PQ-X0F6>)CY>[]W
M(.H/]UNV<?@PSQU J$N5W)G#F5CU>BN9\->.8M6Q%)B.; X) 5B3CY23].#S
MSQG!-=-74FF<CBT[,****"0HHHH **** "L7QG=&ULYG7&2NWGT<A#^AX]ZV
MJX[XH_\ 'LG_ %V7_P! >E-VBRX*\D9/PMTT2/)=,#E %4D<9;.[!QU  Z'H
MW/6O1ZY?X<6GD6@?.?,=FZ=,'9CW^[G\:ZBE35HH=5WDPHHHJC,**** "BBB
M@ HHHH *\P^)^F^1.MP,8F7GDYW)@$^G0J./0_CZ?7'?%'_CV3_KLO\ Z ]1
M45XFE)VDCJ/!M\=3@CN3G)3!) &6'RL<#CJ#^!' KH:XKX27#2V95CPDS*O
MX&%;\>6/7^5=K7/*7,SIC%15@HHHI%!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >>:
MIX)N_$MW)]MD*V:']VL3#YN#MPISAAGYF89SPORX*FL?!FVFC_T9F254 &YM
MR,P[MQG+=#MP!U"]C5O/'U[X@EDM](C!C0#]XP&[KU^<A &Z!2"Q&3P>%L2>
M$=8U!E$]XJ(,\PEE;D?W46,-R!U/'./0@&A\+_$LNJQ26USN\ZV8*2PPQ!R
M&R<E@5(.0.V<G)KG_CG_ ,NO_;;_ -IU:^$2>7-?+O\ ,Q(@\S.=^&E^?.3G
M=UZGKU-5?CG_ ,NO_;;_ -IT 6M&\"-XJQJNINQ:7:R1QD!1'U"GJ0"#T!!
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M_P!IUZK0!Y5XL^'?_".+_:FG.ZO"Q8J?FPI/\.!G"@_,&R"N<G@Y[_PKK?\
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M=M^:!<;L9^Z1Z#K0!ZKXL_X\[G_KWF_] :O(/ >DS^)$.FA]EHD@DF*_>8L
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M:5[G0 4444 %%%% !1110 4444 %%%% !7C_ /PI^[_OQ?\ ?3__ !%>P44
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MC2*ZAOGW!LD]"RXQA?1=N1U.>:X_PG#K*6ZFP $#%B"!;C)R02=_S$Y&.>P
M'&*V/^*C_P _9: +O@77+G1K@:!>J2<'RGZ_*H)QDXRA .T]5/RD=EL?&O\
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M<8_UF2/,P"#@84*P; !## QDAONU#=_#B[T21KG29MJMD^6Q]!PO.Y7ZG;O
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M>IJY10-.Q7L+!-/001#:BYP,D]22>22>IJQ110 4444""BBB@ HHHH ****
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M=/SY$:1[L9\M%7.,XS@#.,FK= 'E7C[_ )#-G_V[_P#H]J[?QKX9'B.V:V!
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M_>;/>O3:9#"L*A$ "J   ,  <  #H!3Z "BBB@ HHHH **** "BBB@ HHHH
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M[28=0QY\:2;<X\Q%;&<9QD'&<"@#C=>^*]N(S%9%I9Y 53:A&&. I(=>3SD
M!LD8.,YKE_@_:M:7\T,@P\<,BL,@X*R(",CCK7JNF>'[?2\&")$(7;N50&(X
MX+=3T&<DY/)YJ6WTF&V=IXXT61\[F5%#')R<L!DY/)]Z .*^-?\ QYQ_]?"_
M^@25U7A/_CSMO^O>'_T!:O7NG17Z[)D5U!R ZAAGIG!!YYJ6&%85"( %4
M8  X  '0"@!]>5? S_EZ_P"V/_M2O5:J6.DPZ?GR(TCW8SY:*N<9QG &<9-
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M_0)*] JO>Z=%?KLF174'(#J&&>F<$'GF@"CX3_X\[;_KWA_] 6M:F0PK"H1
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MJ$0 *H   P !P  .@%5[?28;9VGCC19'SN944,<G)RP&3D\GWH MUY5\<_\
MEU_[;?\ M.O5:J7VDPZACSXTDVYQYB*V,XSC(.,X% %NO(K>_3PAK,[W!(BG
M#G>588$A$@( #%@&&SCOD\8(KUVJE]I,.H8\^-)-N<>8BMC.,XR#C.!0!4T+
MQ3;:]N^S/O\ +V[OE9<;LX^\!Z'I7 ?\S'_G_GUKT?2]$@TI=EO&J# !VJ 3
MMZ9/5C[DD]?6G_V3#YGVKRT\W^_L7?TV_>QGIQUZ<4 5/$_AY/$$#6DAQNP5
M; )5AT(S^1Z$@D9&:\]T?QE<^"3_ &?J,;/$I(CD7GY0.BEL!UY&.04!P>@4
M>E:UK$>CPO=S9V1C)P,DY(  'J20.P]2!S3="UV+7(A<P'*MU!^\I[J1V(_^
MN,@@D \\UCXFS>(!]BTN*3>X&7.-Z@G!P%)"CD?.6XR>APU4OA)ICV-_<1,,
M^3&\;,N2NX2*,9P.NTXS@D \<5Z5XD\21:#$T\K+N"L40MAG(_A'4]2 2 <9
MR>*Y7X0V,C1S:E,<M=R9Z 9V%LMP>,LQ&,#&/0B@"7XE>$Y;XQZG:?\ 'Q;8
M. ,LP4[EP#D$J<G&/FSCD@ MT'XOVMU&/M1,4H W?*S(3SDKM#''&<-C&< M
MC-=[63JGA2TU7<9X49GQEMN'.,8^<8;L!UZ<=* .0UGXJ?;6^Q:6C2S2<*Y&
M%!(!R%89.!G);:%QD[ES7>Z<\CQ(TP"RE%+@= Q W <G@'W/UIECI,.GY\B-
M(]V,^6BKG&<9P!G&35N@#RKP!_R&;S_MX_\ 1ZUZK52WTF&V=IXXT61\[F5%
M#')R<L!DY/)]ZMT >5?'/_EU_P"VW_M.O1=?O);*"2:W3S)57*IZG^9P.<#E
ML8')J6^TF'4,>?&DFW./,16QG&<9!QG JW0!YYX8^+MO/$%O"8Y4"@G!</QR
MWR+\ISG(Q@9&"><87COQ)'XSD@TZR&]O,_UC(1U Z'[P4<E\K_"#R!7I6J>%
M+35=QGA1F?&6VX<XQCYQANP'7IQTJW8Z3#I^?(C2/=C/EHJYQG&< 9QDT 6Z
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH SO$,1D@<#K@'\
M 03^@K@J],= X*GD'J#TKSO4+%K)S$W;H?4=C^/_ -:LZBZGHY=-6<?F5Z**
M*S/0"BBB@ HHHH NZ)"9IXU']X'G_9^8_P J]!KF?!]@5W7![_*/YD]/8 ?C
M735K35D>3CJG-4MV"BBBK.0**** "BBB@ HHHH **** "BBB@ HHHH ****
M"F2C<"!Z&GT4 S'HJ2>/RR14==B=SA:L[!1110(**** "BBB@ HHHH ****
M"BBB@ HHHH *\@UFY?Q5>[(N=S!(^#C:#]XX&<=6.1D#/I7KKQ"8%&&0PP01
MD$'C&*H^'_A_!HDYNXR22I"JV"%))R0<9Z8 [XSDG/&59Z(WH+5LZ.UMEM46
M%!A44*HY. HP!D\]*EHHK Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5CZUX2MM9!\Z,;F_
MC4;7SC .X<G Z Y' R.*V** /.;SX-1N<Q3,JXZ.@<Y]<@IQ[8_&L7_A3]W_
M 'XO^^G_ /B*]@HH Y;P/X3?0X6AG*LQD+?(21@JH[@'/%=*ENJ=!4E%/F>P
MN57N%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5#5;C8 @[]?I_P#7KF2N=A0N[G[0V>W85!116A 4444 %%%% !1110 4444
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M* >%RKY(!(/S9P.X !( /1:**XS4/B3'IU\VG3(%C09,I?\ Z9>9]S;R3]T
M')/3GB@#LZ*\T/Q"U'5"9;"TS %8AI%8E@I()!#*"?\ 87<<@X)[:'A/XE&^
ME^P7T?D7!QC(*JQ/(7:W*D@C&2=W;!(! .[HHKA_%7Q/CTN0V5LAFN,[<#[@
M8Y 7C)9@<948ZXW!@10!W%>?_$?_ (_--_Z^/_9X:I?\)[JMFJW%Q9@PD.3M
M1U8!>I.6?8!U^9>1G'J*GB'Q5!XCN=-F@)^6Y(96P'7]Y%C(!/![$$@].H(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 9MW]X_A_*H:FN_O'\/Y5#77#X4<4_B85%-;K-U
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M5!!_.BX&[15'3-=@U,9AD5C@G .&P#C)4X8<^H_G5Z@ HHHH **** "BBB@
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M9*<DKD#E3UQ@ Z"7XAZ;IY\@3* @  C1F0# P 44K@#T/'2O-_'_ (UMM?\
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MR:BP!D#^6F1]W"@L0<]6W =,@ \X8BN]\6?\>=S_ ->\W_H#5ROP4_X\Y/\
MKX;_ - CH ] KS+PPD>BZU<62$K'*F53^'<0LN,*  %!?;GH.,Y//IM>5?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **J:M??V
M?#)<XW>5&[XSC.U2<9P<9QZ5YK_PO/\ Z=O_ "-_]KH ]5HKRK_A>?\ T[?^
M1O\ [76KX6^*_P#;UREEY&SS-WS>;NQM4MTV#TQUH ] HHHH **** "BBB@
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M/Y4,#HJ***R+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5.63&6(. P4[1@X/S*Q!(X&#P 6+;X80V#MJ.H3-<>6-YWJ<813G=DNS@ #
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M*BWM)T:+S#@?+E0Q^\1(AP.Y52W). >36GX=^'LZW(U+49A+*A.U1EE'<'+
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M_"3PM<[/+VR%,;MW15.<X7^]Z5T%9^B:!!HB&&V78A8L1N9N2 ,Y8D] *T*
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M2ILT/1FGKGQ.CMRBVH$@SERP91C^Z,@')]<8'H>UCQ9XI/V%;NU) F8+DC#
M8;=CT(*XSSZ@]#4.F?"V&W;=.YD'90-@[]<$D]L8(Z<YKHM=\.QZO!]E/RA<
M%"O 4@8'' Q@XQZ=,'!#U#0X+PQX+CUB(WUS,=I+[MI&X$')9F;..Y(QT(.>
MU86DJB7L:Q$F,7*;2>I7S!@G@=1["NNC^$H!!:<E<C($>#CO@[CC\C]*M6WP
MS6VG6Y27"I*'";,X ;<%W%_PSCWJ;,=R3XJ?\>J?]=E_] >M'X?_ /'C%_P/
M_P!&-5CQ5X=_MZ(0;]FUPV=N[H",8R/6K/A_2/[(@2UW;MF[G&,Y8MTR?7UJ
MK:BZ'GGQ4_X^D_ZXK_Z&]=#\4;%IK=9E)Q$XW#.%PW&2.Y!P!Z9-6?%7@;^W
MI1/YFS:@7&S=T).<[AZUT\D8E!1@"K @@C((/4$46W"YP_P_\5P1P"SE81M%
MN(+L K!F)X)QR,XQ^(SSCH4\86LDPM%D!=NA'*YXP-W0DYXQGD8ZX!YZ_P#A
M3'*Q:&0HI_A9=^.3T.Y>/KD^I-3:/\,(K-Q),YEVD$+M"KWZC+9[<<#CG(.*
M2N&AQ_CZQ:TO)-Q)$F'4L<G!'Z $$ =@!5^/P7:R ,+V/! /(4'GU!D!'T/-
M>AZ]X>BUQ!',#\IRK+@,/7!(/7N.GX@$<?\ \*D_Z;_^0O\ [.AQU'</ _AJ
M$S?;()_,$+$$>7L)W(1GEB0.3U')!QZUG?%3_CZ3_KBO_H;UVWAOP?#H7SIE
MI"N"['L<9 4< 9&>Y]S5/Q5X&_MZ43^9LVH%QLW="3G.X>M%M!7U.GCC$0"*
M %4   8  Z "G4450@HHHH **** "BBB@ HHHH **** .A@;<H)ZD#^5257L
M&W(I/^<'%6*R984444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0C/_ -L__125M_!*Z9;F6$'Y&AW$8'5'4*<]> Q_/Z5B?%+_ )",_P#VS_\
M124 >I_$?Q@WAR >5CSIB0F1G  ^9^F"1D  ]SG! (KS'3?"6H>-";QFRIW8
MDF8A3@\JH )QDG& %&".",5T?QPM9-T$V28L.N-O"MP<[O5AT!_N$CO78?#G
M6(+^SCC@P#"BJZX (;')P.S')![\YYR  >::#XDN_ DXM;I6\K S&2#@$D[D
M.2N<DYP<,<@X(ROJ?B_Q8NA6AO4VN7VB/DE6+<@Y7MC+=1D# ()%>:?&/68K
MZX2"+:6@5@[CKDG[AX_@QGJ<%B."#6M\0["5=*LS\P6)8A(A3D'R]H8GJNTY
M7'<MSR!0!R]EI6H>/'\UF+JAP7D.V-3MZ!0.IP,[5ZD%NN:EMKJ^^'DZK(#Y
M;%CLW9BD&0"1Z-P,' 8<;A@X/=_"#6()K46:8$T98N, %MS'#_[0QA2>HP >
M-N<?XUZS%((K)=K2HQ=B/O(",!>G\><XS_""1R#0!W5UXLBALCJJ\Q^6& SR
M2> A*[L'<=IZ[3G/2O%TBOO'LY(R^#DY.(HPQ X!/ XZ#+-@GYB":ZN[M9$\
M/)R4P0S K]Y6F.T<] =RL".H'H:E^"NL01K)9G G=]PR -RA1P#W*X)QZ$D9
M^; !R7BG1+_0(5LK@YMA)N0J0R;MO."0&7J?E. 3N(!Y->@?!3_CSD_Z^&_]
M CH^,6LQ06OV-MK2RLI4'[RA3DOT.,XV]LY.,X(H^"G_ !YR?]?#?^@1T >@
M4444 %%%% !1110 4444 %%%% !1110 4444 %0W5HEVIBE570XRK@,IP<C(
M/'6IJ* .$^(_AZVM+":6*&)''EX9(T5AF10<$#/2N'^$6G17]VZ3(KJ(&(#J
M&&=Z#."#SS7I'Q2_Y!T__;/_ -&I7G_P4_X_)/\ KW;_ -#CH ]3N;*WT"*6
M\AAC5HXG8[$5"0HW;=P'0X]_I69X%\=?\)5YO[KR_*V?Q[\[]W^RN,;:U?%G
M_'G<_P#7O-_Z U<!\#/^7K_MC_[4H [7QKXK_P"$8A6YV>9ND"8W;>JL<YPW
M]WTJUX6UW^WK9+W;L\S=\N[=C:Q7K@>F>E<K\:_^/./_ *^%_P#0)*U?A;_R
M#H/^VG_HUZ ,71_C+%=ES/'Y2QQE@1)O9B"H"!=JY)SZ\8R<#)%>+XX1&3:T
M#"+)^8."^.<'9@#)XR-W'J>_#_#WPTOB"[$,G^K12[C)!(&  "!W)&>G&<$'
M%=5\5O!UKI,$=S;IL;S%0@$[2-AP2#GD;.HQG)+9)S0!TWB+XK6NE +&&ED9
M58* 44!PK*2S#C*MD8!]#BCPA\4(O$$@M61HY6W;1G>I"C/WL @XR>1C ZY.
M*P?AGX M[ZV^VW*"0REPH). HRAX&/F)SSSC"E<&N:O-'CT?68[6'(C6YMR
M3G&XHV,^@S@9YQU)/- 'N&H:A'IT;7$S!8T&23_GDGH .2>!S7GFI_&V*%RD
M$+2(/XF?R\G)Z#:QQC!&<'U JK\;]4_U%D&_O2,N/^ H<X_WQ@'ZCI6Q\/\
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M!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** .%^,'_'HG_7=?_0'K4^&W_(/A_[:?^C'K+^,'_'HG_7=?_0'K4^&W_(/
MA_[:?^C'H Z:BBB@ HHHH **** "BBB@#G[G[[?[Q_G452W/WV_WC_.HJU1
M4444 <I\2?\ CW3_ *ZK_P"@O5[P/_QYQ?\  _\ T-JH_$G_ (]T_P"NJ_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\\+R^&[=K>8J6:4L"A)&"JCN%Y^6NHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ***K7NI16(W2NJC!(W'!..N!U/T%-)MV0-V+-%8D?C2T<A1
M(,DXY5P.?<K@?4ULQR"0!E(((R".00>AS53I3A\2:]1*2ELQU%%%0,**** "
MBBB@ HHHH **ANKM+13+*RH@QEG(51DX&2>.M8O_  G]AYGV?STW>N3LZ9_U
MF-G3_:Z\=>* .@HJ&UNTNU$L3*Z'.&0AE.#@X(XZU-0 4444 %%%5+C5H;9U
M@DD19'QM5G4,<G PI.3D\#WH MT444 %%%% !1110 4444 %%%% !116?=>(
M;:T8Q2S1(XQE7D16&1D9!.>E &A163_PEEG_ ,_$/_?Y/_BJ/^$LL_\ GXA_
M[_)_\50!K451LM<M[]MD,L;L!DA'5CCIG )XYJ]0 457O=1BL%WS.J*3@%V"
MC/7&21SQ6)%\1-/DD\@3KNR1DA@G&<_.0$QQP<X/;.10!T=%0VMVEVHEB970
MYPR$,IP<'!''6IJ "BL^Z\0VUHQBEFB1QC*O(BL,C(R"<]*A_P"$LL_^?B'_
M +_)_P#%4 :U%5+'5H=0SY$B2;<9\MU;&<XS@G&<&K= !1110 4444 %%%%
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MO!=\-'N6WPSX\MLL0,EMA"\[=S95ACKSG R>J^*7_(.G_P"V?_HU* #X6_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@DYZ@$VB?"V37,W^IR.))LG8N XZ8+$@@<<; ORC R,%1U$WPJTYU*B(J2"
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M,4Z[EYP<(ZL>1E2&."IY&1R>< 'MM%%% !1110 4444 %%%% !1110 4444
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MC^]P0>O!ZX)JFOW/BIT@P"<_*D8(!/\ >.2>@[DX STYSVGPK_X]7_Z[-_Z
ME=E4J-T.YS6E^'&T_3WM%&99(G+#/\;KC'4CCA<YP<9[UY]X8\2'PU(Y:(,S
M#:0WRNI4\C.#CW&.H'I7LU%-Q"YXGXJU&;4I1<SKL#H#&OHF3M]SDY.3UZCC
M%>L:+;K<V<43C*O;H".F04 (XK4HH2L#9XK:W5QX2N"< . R_,IVLN<9&<$@
MD9!&.GU%>BQ:JVK:;)<R !GAFR%R!QO7N3Z>M=+10E8+GGOPD_Y>/^V7_L]5
M/&OAB73ISJ-N"5+;SM!8HP^8D@YX)&[/0=" ,9]-HHY=+!<\JD^*-TX*A8P2
M#R%;(]QEB./<$5VG@JYNIHC]K0@AB59N&;<22"O48/3@#!&!@9/0T4)!<\LU
MW_D+K_UVM_Y)7J=%%"5@/+/A7_Q]/_UQ;_T-*ZCXC:(VHP+)&I:2)N ,EBK<
M, !G/.#[ '\>KHHMI8+GE'@_QE/:&*P 4QM*H^8'< [#(!!'J3R#U].*]7HH
MH2L#"BBBF(**** "BBB@ HHHH **** -/1S]X?3^M:58^DG#GZ'^8K8J);E+
M8****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&#Q^C_$V;P^/L6J12;T!PXQO8 X&0Q 8<'YPW.!U.6H ;_P@&L_\_G_DQ/\
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M10,L 0."<]-N5)'&:X71_&5SX)/]GZC&SQ*2(Y%Y^4#HI; =>1CD% <'H%
M_P#X0#6?^?S_ ,F)_P#XFM7P%X"N=!N7O+ET?S(V!*L[,69U;)W*/0Y.<YJI
M??&+[5B'3X'>5LX$BYZ8/"1DEN,]QCKSS76^#;2[MH"+]P\K.6&"#M# ':2
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/K'P7MKD[K=VB)(X/[Q ,8( )#9)YR6/?CICH_#_ (ZM->9HH7PZL0%?Y68
M$[E!.2, ^XQ\P'%=!0!Y%:^(;_P3<I;W[F2"0\LQ9Q@X!97(WY3NOUX^8-6[
M\9]4^S6B6P;#3R#(QG*IR><<8;9W!_#-87Q=OEU>XM[&W(>52P.UE(W2,JA,
MYX8%>0<8R/PZ7XO:.U_9^:B@M X8G&6V$$-C /'(9N@PN3T% &/H'Q2L-%@C
MM$28B-<9V)R3RS8,IQDDG&>,X'%79OC+8S*4>*4JP((*1D$'@@@R<@UH>#ET
M_P 1P"98(/,4 2+Y*#:V.>,'Y3SM.3D<=00-BZ\/6%HIEEAMT08RSQQJHR<#
M)(QUH \_^$6H*;RYA@7;!(I=0V=P"/A!G)[.<]>0.?6;Q]_R&;/_ +=__1[5
MVOA*:QU!6NK&-%PS1EEB$;<$'' !P1AA^&0""!Q7C[_D,V?_ &[_ /H]J ._
M\5ZI_95I-<AMK)&VTXSACPG&#_$1U&/7BO*OA[XWM/#$3+(LK2RMEBBKMPO"
MJ,R#.,DYP.N.< UZWX@TS^U+>6UPI,D;!=_W0Q'RD\'H<'.,C&1S7G7PODM+
MM3IMU#%]IC9L>9$N]AG)!+ DLISD<84# .&P :O_  NNS_N3?]\I_P#'*Y)?
M$T%YJ\%[9QE!(Z*X< 9:0E';"L1DJP_X%R0><^K_ /")V?\ S[P_]^4_^)K*
MTB;2[RX-M;1PM+$JR;HXDV]1RK@8RI(S@\9&#D-@ Y_XLS?VA-::4'V^;("P
MVYQN81HW;.,OP#]>QKT/3]/CTZ-;>%0L:#  _P \D]23R3R>:\_^,-C)"+?4
MX0 UN^"P7+#)#1D\$;0P/7C+ 8.37:^'->CUV!+J,CY@-P!SM;'S*>!R/H,C
M!'!% &A-"LRE' *L""",@@\$$'J#1#"L*A$ "J   ,  <  #H!5?4]5BTM#-
M.ZH@[L<9."< =2< X R3V%,T76(]8A2[ASLD&1D8(P2""/4$$>GH2.: /./^
M9C_S_P ^M>JUY5<?Z-XB5Y/E5\;2W .8-@P3URWRCWXZUZK0 4444 <I\4O^
M0=/_ -L__1J4?"W_ )!T'_;3_P!&O1\4O^0=/_VS_P#1J4?"W_D'0?\ ;3_T
M:] '5UY5\'_^);<W>GOS(N.5^[^Y=D;DX/)<8XZ9SBO5:\L^(VES:#=)K]MD
M\C?D JI"A!GOM=>/8_Q LN #U.BL'PKXQ@\1QAXR!)CYHR1O7&,\=UY&&Q@Y
MYP<@;U !17*>-O'T7AU"BE7N#PL><X. =SXY P00."W;C)&WH%Y+>P1S7">7
M*RY9/0_S&1S@\KG!Y% 'DGBG3YM0UIX+9_+E;;M;<RXQ "?F4$C(!'%:W_"
M:S_S^?\ DQ/_ /$T?\S'_G_GUKU6@#P?0-%D\3W1L+^XD$D);"NWF9VMB159
MGX;CL&! )/ Y]PT_3X].C6WA4+&@P /\\D]23R3R>:\\^*.F/I<L.NVPP\;*
M),9P<?=)V@'!&48EN0545W>@:RNM01W:<"1<XYX(X9<D#."",XYQD<4 >?\
MC/2KC0;\:]"GFQ]64 Y4"/8V<9P"H)#= ?O#INV]&^+=EJ&%D+0N=HQ(,KEN
MN&7(P#W;;QSZXW[7Q1;W4[V*.IECQD9').XE1SEBH7YL#Y<X/.0*7B[PM::C
M#+-.BJP1F,H4[UVH0&.W#,%'\))!P!CI0!T$,RS*'0@JP!!!R"#R"".H-/K@
MO@O,SV3 DD+.X )S@;4.!Z#))^I)KO: *.M2P10N]UM\E1EO, 9>",<$')SC
M QDG&.:Y*Z^,EC"Q11*X&/F1 %/';>RGCIR!^59OQ:8W%Q9VDI*6SO\ ,^\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KQ_XJ^'?L,XO$'R3_>P. XZ]  -P
MYZDD[C7L%9VOZ(FM0M;2 ?,#M)&=K8X8<CD?49&0>": */@KQ(-=MUD)!E0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS+#K@,24903@9'RC. I(ZU8M?A-'^\EN9FGGD1U#R#(7<NU6VEB69>V6QTP
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MZEYNWR/+^39G.QR_WMPQG..AQ6WKNA1:Y$;:<95NA'WE/9@>Q'_UCD$@Z%%
M'G2_"^YM,1VU]*D08X7YQM4Y/&UP"<XSPH.2WL95^$$1AD5Y6>XFQF9UW8._
M>2%SG+ 8)+$]<$ D'T"B@"II-C_9\,=MG=Y4:)G&,[5 SC)QG'K7/_\ ""_\
M3'^V?-_[9[/^F7E_>W?CT]O>NKHH *S]=T*+7(C;3C*MT(^\I[,#V(_^L<@D
M'0HH \T_X55<V'R6=XZ1M)DKETPIZGY&PS  #HH/J*T] ^%,%A(;FY8W,A+'
M]XHV?-U)4EMS=>22.<XR :[BB@ KG/%_@:#Q,H,F5E0$*ZXSWP"#]Y<\XX/7
M!&3GHZ* /-/^%7WG_'O]N?[/Y>W'S_39Y>_;MV_[7MMQS6A=?"B)K1;")]C"
M17>0IN9R%9<8W# &[@9X]R23W=% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.=5Q=D<E_P *VMO)\KGS=O\ K,G.>N=N=N.V/3OGFN.\#:PFG3D2,521=O\
MLYR""?U&>V>PR:]>K@O'G@WS=U]  "%9I!G&<8.X#&,XR6Y&<< DG+J0ZH5*
MIK9G845P_P /-<DG9K1R65$RN<< '&.F3]X8R>,8%=Q4IW-6%%%% !1110 4
M444 %%%% !1110 4444 %%%% "@9X%+(FPE3V.*?;??7_>'\ZFU./8_U&:+Z
M@5**** "BBB@ HHHH *V=+?<F/0D?U_K6-6IH[Y#+Z$'\_\ ]5*6PT:-%%%9
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_%5KHF!<R*A.,+RS8.>=J@G'!YQC/&<U%HWC2SUEO*@E5G_ND,C'@G@. 3@
MYQG'>N=\,?#Q+I1J&I S7,Q5R'W +W"E>,GL01M&-H&!DU/'?PZAMH6U"R4Q
M30DR$(Q (!R2,GY2OWAMQTP!TP >D5Y5\7O%%O?0QVD+K(_F!R8R&4 *RX+
MXR2>GH.<<9[KP7K+:S9PW4GWV4ANG)1BA;@ #)&<8XSBO+_BOX6MM!\C[,FS
MS/-W?,S9V[,?>)]3TH ];M?$-M=L(HIHG<YPJ2(S' R< '/2K%[J,5@N^9U1
M2< NP49ZXR2.>*Q]+\!66E2+<P1;9$S@[Y#C((/!8CH3VKG_ (U_\><?_7PO
M_H$E '>PS+,H=""K $$'((/(((Z@TRZNTM%,LK*B#&6<A5&3@9)XZUG^$_\
MCSMO^O>'_P! 6O,M.MG^)5Y)),S+:P [0NT$!CA!@EL,V,LV&^[C@;< '=P_
M$W3I6""<98@#*2*.?4E0 /<G [UM7.N6]JJO)+&JR#*%G50PX.02>1R.GJ*P
MI_A?I\J>4(MOWL,KON!8 9R2<XQP#D YXY.?)?'6DR:%*-.9V:"/+P[L9"R8
MSTZ<K@] 2"P W4 ?0M4=4UN#2EWW$BH,$C<P!.WK@=6/L 3T]:;K^LKHL$EV
M_(C7..>2>%7(!QDD#..,Y/%>>>$/" \7 ZMJ)9_,=]B;SLVY.><E@H8D*H*X
MV]P: .PLOB)I]ZVQ)U! S\X:,?FX49YZ9S71UR6L?"^ROX]B1B)P@573/&.A
M*YPQ]2?F(_BS@C'^'>LSZ=.^@WA4M"N8VW9.!@A!_>!4[EZ%0"",#"@'=7VK
M0Z?CSY$CW9QYCJN<8SC)&<9%5-;\56NB8%S(J$XPO+-@YYVJ"<<'G&,\9S7
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M49ZXR2.>*S]5\7VFE*KS3* X!7&7)#9PP"9.TX^]C'O7+_&O_CSC_P"OA?\
MT"2J_@/X=0W$$=]>J999 C*'8E511B,8!PP*@<-P!A=HP<@'9:)XJM=;R+:1
M7(SE>5; QSM8 XY'.,9XSFGZQXEMM'&;B54. =I.7()P"$&6(SZ#L?0UY_\
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M-(=TF,'']U<@=%'N1N+8.#0!U%%%% 'E7P,_Y>O^V/\ [4KU6O*O@9_R]?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_CSC_P"OA?\ T"2NJ\)_\>=M_P!>\/\ Z M<K\:_^/./_KX7_P! DKJO"?\
MQYVW_7O#_P"@+0!E?%+_ )!T_P#VS_\ 1J4?"W_D'0?]M/\ T:]'Q2_Y!T__
M &S_ /1J4?"W_D'0?]M/_1KT :OBS_CSN?\ KWF_] :N5^"G_'G)_P!?#?\
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M_P"7K_MC_P"U*]5KY_\  OCK_A%?-_=>9YNS^/9C9N_V6SG=75_\+S_Z=O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHJ&[;:C$^A_7B@##E?>2WJ2?SIE%%:D!1110 44
M44 %6M.CWN/;G\O_ *]5:U-'CX+?A2D]!HT:***S*.:HHHK4@**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#5TA,*6]3C\O_
M -=:%4=(^X?][^@J]6<MRD4]43<F?0@_T_K6-71R)O!4]QBN<JH"844450@H
MHHH **** -O39-Z#VXJU69H[_>7Z'_'^E:=9RW*04444AA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %,AA6%0B !5   &  .
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'<&4****LD**** "BBB@ KI:YJND5MPR.AJ9E1%HHHJ!A1110 4444 %%%%
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M_"S=3TV3;.WS+UCEB5>HXR J,.H(Y';M0![K16/X5\31^(X!=1@CG:RG^%@
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M*<C(PQCP<CD>U=QX%^)XUZ06<Z!)F!*E,E&QDD8.2I"CN2#@\C@$ [VBN?\
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M98/E#<1X&[!ZQ@%2/NY(*Y_O97(!ZK1532KQKV))G1HV=02CXW*3V./ZX/J
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3_\ ;/\ ]&I7#_!?1XKR6:XD4,T(CV!@" 6).[D<,-@P1C&37<?%+_D'3_\
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MCY I3/3H21DC !R"0#M?#UTUW;032'+R0QLQP!DL@).!QUK0ID,*PJ$0 *H
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M+Q*@7.,#S-V3TR#A<9!Z$CO7L%>5? S_ )>O^V/_ +4KU6@ HHHH \J^.?\
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M@%2I4L[J6(9<Y&-H]B#QW/?^-]!.N6DELH!DQN3(!^93D $D8+<KG/ )[<4
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MN<'G(%+Q=X6M-1AEFG158(S&4*=Z[4(#';AF"C^$D@X QTH Z"&99E#H058
M@@Y!!Y!!'4&O+?CG_P NO_;;_P!IUL?!>9GLF!)(6=P 3G VH<#T&23]2363
M\<H6*VS@':#*"<< G80,^IP<?0^E 'J=%,AF690Z$%6 ((.00>001U!I] !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB&<'Y3E67 =?7!(/![@@@]>H!&Q10!Y)<? YUV^7<*<L-VZ,KA>Y&&;)'8<
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M@CVH5X0%52(8VG;@J&VCNO('''<>)O"L'B.,0S@_*<JRX#KZX)!X/<$$'KU
M(J>!O""^&8/*)#2N=SL!WQ@*#C.U>V>Y)P,X'1T >=1_#.\AVQIJ$HC5<<;Q
MC& H"B3&,9[C&  #GAT_P;@-N+>.0B4NK-*R!B<*05 !7:I)SU)Z9)P,>AT4
M %<IH'@7^R+R;4O-W>?YGR;,8WN'^]N.<8QT&:ZNB@#G_&OA3_A)X5MM_E[9
M ^=N[HK#&,K_ 'O6M72;'^SX8[;.[RHT3.,9VJ!G&3C./6K=% !7*>!? O\
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M*SO-/J?SH\T^I_.@#1HK.\T^I_.CS3ZG\Z -&BJEHY8\GM5N@ HHHH ****
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MZ"V^XO\ NC^53,<26BBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K+K4K+H NQVZD X[4[[,OI_.G1=!]!3Z (OLR^G\Z/LR^G\Z
MEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH
MB^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+
MZ?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH
M^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z
M?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6
MB@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+
M[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI
M_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[
M,OI_.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_
M.I:* (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:*
M (OLR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OL
MR^G\Z/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\
MZ/LR^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR
M^G\ZEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\Z
MEHH B^S+Z?SH^S+Z?SJ6B@"+[,OI_.C[,OI_.I:* (OLR^G\Z/LR^G\ZEHH
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M_='\JY^N@MON+_NC^53,<26BBBH*"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***Q[GQ1%;W<>ED-YLJ%@0!LP QY.<Y^0]CVH V***Y37
M]?O+.\AM8(=]O)Y>]_+=MNYRK?,I"C"@'D<=3Q0!U=%%% !1110 4444 %%%
M% !16/XH\41>&XA<3!BK.% 0 G)!/<KQ\M;% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%<IX%U^\U?S?ML/E;-FS]VZ9SNW??)SC Z=,T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %9=:E9= &C%T'T%/ID70?04^@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ 5Z+K^D_P!KP26F]D\Q<;EZC_$'HPXR"1D9H Y_6?BK8Z8WEAFE/?R0&4<
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MSSP<2^*M;_L2UEO,9,:_*,9&YB%7/(XR1GG.,XYKC?A[X*COXSJM\@DFG=G
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M[31'$-S)L<J& V.W!)&<JI'4&L__ (6EIW_/;_R'+_\ $4 =76#XF\:VWAP
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MNV-\XB.^//1I5 7)(&,JS8Z]3@  Y(KM:YSQ;X*@UZ)QL43L,K( %;<!A=S
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M"3C(!P3BM/1-?@UM#-;-O0,5)VLO( .,, >A%<)\2? L=M"VH62>7(F=XCR
M8V78V%48&!UQM&W>6S5OX*?\><G_ %\-_P"@1T >@4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5EUJ5ET :,70?04^F1=!]!3Z "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ72^!M N=-62>\E+RW)5F7J$89!Y!P21M!P !M &0!0!C_&O_CSC_P"OA?\
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M'<<D$=P>,'!'!:;KVI^#E-K<6[3PQ*Q5UW$!0>/W@# * "0& 8 CH !0 ?\
M"C/^GG_R#_\ ;*ZKP+X%_P"$5\W][YGF[/X-F-F[_:;.=U<U<>*-5\3[8;.!
MK>-U!,C9Z-QD2,JC&&!&P%^,J>U=[X;TAM'MX[1G,AC!&XC&1DD#&3@ $ <]
M!0!Y_P#"ZZ73[V\L)'+2LYP[<;S$SACR2=QW;L<\!B3Q7J=<%XX\#S3S+JVG
MDBZ4KN7<!NP-H(+< @<,I^5E]\AJ,/Q0O(-D,]BYE?=@#>F[;R=J%&/ QGD^
MO% '3?$>^2SL)C(%;>NQ58@99C@$9!R5^^._RYXZB'X<?Z)IL+2_( LC$O\
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M_P"/./\ Z^%_] DKJO"?_'G;?]>\/_H"USOQ=TZ6_M$2%&=A.I(12QQL<9P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LNM2LN@
M#1BZ#Z"GTR+H/H*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVDQGOR/K6K6;5F6@HHHI <[*^\EO4D_G3***U("BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJZ*S]&U^#6E\RVD5P.N.&') RIP1G!QD#/4<5H4 %%8FL^-+/1F\J>55?^Z
MSL. >0@)&01C.,]JKZ/\0;+5F6..4"1@,*X*')P-N2-I;)QA2<]LB@#HZ**S
M!XDM_.DLRX$L*;W!! 5< [BQ 7&&'?\ K0!IT5R1^*NG!@OFG!!.?+DP,8X^
M[G)SQ@8X.2.,]%IFJQ:H@F@=70]U.<' .".H.",@X([B@"W1110 45DZWXJM
M=$P+F14)QA>6;!SSM4$XX/.,9XSFLVP^)>GWK!!,%)+ >8K(/ESSN(V@$#(R
M0>0" >* *7ACQK-JM_<:?(J".#S=I4,&.R0(,DL1T// YKM:\J\ ?\AF\_[>
M/_1ZUZK0 45RFJ?$^PT_</,\QEQ\L0+9SCHW"' //S>HZ\5IZ'XNM=<9DMI
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M/-_C4N:1T4L).K'F5CI_^%P6G]R7_OE/_BZ/^%P6G]R7_OE/_BZYC_A&[?\
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M45S]QO\ =/\ *I&<_1116I 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 :>C?Q?A_6M*LW1OXOP_K6E6<MREL
M%9^KOA0OJ<_E_P#KK0K-UG^'\?Z41W![&91116A(4444 %202>6P;T/:HZ*
M.EHJMI\OF(/;C\O_ *U6:R984444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %9=:E9= &C%T'T%/ID70?04^@ HHHH **** "BBF33+"I=R
M J@DDG  ')))Z 4 >?ZU\+665[O39C;LX^X"R+R06PZ'*KWV[2,CC QBE/XM
MU;PQ\U]$LT09LNN!QPH^9.%!)!&],G)'T](T_4(]1C6XA8-&XR"/\\$="#R#
MP>:L4 8_AGQ5!XCC,T!/RG#*V Z^F0">#V()!Z=00.'\1Q-XTU+^RQ)MM[9=
MS[2#DC 8C QN!;9SG;ACU)4GPQS]OO?)V_9MS?<V[<^8?*QCMMW8QQCKVHT&
M-="UN=)FQ]H5C&6!4,975PH/3KE0<\D8ZG% '<0^#K*)0@MXL* !F-6/'J2"
M2?<G)[UE:/\ #F'1[O[=;NR)L(\H$D$D8.6))*]]I_B .< "NMJ'[6F_R-R^
M9MW;<C=MSC=MZXSQGIF@#SCXQQ22RV20Y\UGD"8.T[B8MN#D8.>^>*ZC0OA[
M::7$(6C25ARSRHK,2>O4' ] .GN<DXGQ'_X_--_Z^/\ V>&O0* /.O'MRVN7
ML&@H^V-\/-M89(&6VG@X(5=P!X)921P#756O@FQM5$:V\1 S]] [<G/+/DG\
M3[=*\Z\=Z!$=50W;LEO=*"7 VA2J[ NXAAU523C@-S@<UT'_  I2S_OS?]])
M_P#&Z ,KQCHG_"%3QZS9G;&\@5X@< YRQ4<$;6"GC'RG!7L%[?QOKQT.TDN5
M($F-J9('S,< @$')7EL8Y /;FN8D^#]A$RQ--*'DSM4R1AFVC)P-F3@=<=*T
MOBUI;7UBS+G,+K)@#.0,J?H &+$^@_$ %?P+X%@\A+VY19I[A=[-)^\&),,.
M&&,XP22"<EOFQ5OQ9\-K?5XML")#*N2K(H52?[K!1R#Z]5ZCN#S7A?X8V&N6
M\=RLLI9E&\*R85\#<N"F1@],]L'D$$Z4WP:L85+O+*%4$DEXP !R228^ * -
M;X8:])K-F&F)+Q.T98G); # G@<X8#N3C).37'ZIH3:YK<MMD^5B-I0#C**D
M9VG!!(+!1QR#AL<5Z%X1\.PZ##Y5LS/'(WF!F96SN51D%0!C &/YUS6C?\AZ
MZ_Z]U_E!0!U$/@ZRB4(+>+"@ 9C5CQZD@DGW)R>]<5X=MCX5U=].C!$%TFY0
M6!QM5F!S@G (=0"0<')S@$^FUY_K/_(>M?\ KW;^4] 'H%9^OZRNBP27;\B-
M<XYY)X5<@'&20,XXSD\5H5S_ (^TQ]3L9H(AERH('))V,'(  ))(7 '<XH Y
M?X>^%8]9C.KWP$TT[L1O^90%RG*8"YR#@<@ +MQBNCUWX>VFJ1&%8TB8\J\2
M*K CIT R/4'K['!%'X3:A'<6"0HP+Q%PZ]QN=F7CT(/!Z=1U!QV$TRPJ7<@*
MH)))P !R22>@% 'COP?M6M+^:&08>.&16&0<%9$!&1QUKJ/BEJTA$.DP,%DN
MW"L=V,*2% ( )"L3R1V4CD$BN?\ AA>K?ZI<W"9"RI,P!ZX:5",XSSS6A\3;
M465]9ZFY(B#HKG:2%\N3?G(SR0QP,9^4XSV .HT+X>VFEQ"%HTE8<L\J*S$G
MKU!P/0#I[G).#\0_ D2PG4+-1%-;#=B(! 54Y)XQAEY8$<G&.?EQZ!#,LRAT
M(*L 00<@@\@@CJ#6%X]U--/L9VD/WXVC4<9+2 J ,D9QG)[X!..* '>"->.N
M6D=RQ!DQM?!!^93@D@ 8+<-C' ([<UYUX>\+C7]2NUER;:.>5G7<0&8NZQCA
M@<C+$'G&"/XJ[#X2Z6UC8JS9S,[28(Q@'"CZ@A0P/H?Q-+X<?\?FI?\ 7Q_[
M/-0!U$W@ZRE4H;>+# @XC53SZ$ $'W!R.U<?\-R^C7EUHI!\M"9$)*D@94 G
M Y+HRGJ,8Z DUZ17G^C?\AZZ_P"O=?Y04 /^*6K2$0Z3 P62[<*QW8PI(4 @
M D*Q/)'92.02*V-"^'MII<0A:-)6'+/*BLQ)Z]0<#T Z>YR3R_Q-M197UGJ;
MDB(.BN=I(7RY-^<C/)#' QGY3C/;TJ&99E#H058 @@Y!!Y!!'4&@#S_XA^!(
MEA.H6:B*:V&[$0" JIR3QC#+RP(Y.,<_+CI?!&O'7+2.Y8@R8VO@@_,IP20
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M51/<I!45S]QO]T_RJ6HKG[C?[I_E4H9S]%%%:D!1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGYATSWKJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?XP\6Q^&H?/?#.Q 1-VTMR-W.#@ ').,=!U(KD+;0M9\0E9KB<VT9+$*A*N
MP!'RIC(Z##MN7G//7'^)NNH-2C$BM)':JFZ,L K,?G[AA@@J&XR0,>AK0_X7
MG_T[?^1O_M=  VMZEX'>/[<WGVS9!*G<02<_?8*VX=0&.",@'C*^FZ?J$>HQ
MK<0L&C<9!'^>".A!Y!X/->2:W\8%U6"2U:V&)49<F7=@D<-CR^JG!'N.HKJ/
M@W=--8E&.1',ZKP. 0KX]^6)Y]?2@#"\7?$6ZT/4)(48-"@&(RJXRT0()8#=
M@,=V,C/3(K0TS1-7U.:&_GF$<>]&:$.Z80/N*E%7!)']XEL8#'(XS+FU6Z\1
M!'&0&5NI'*0!U/'H0#_/BO6Z //_ !IXIN?#E] Q?_0Y<;@RJ0,';)C:-_"D
M,.3R>X^6O0*Y3XFZ)_:MC)@X:#]Z.< [ =P/!_A)QTYQSC-'PRUO^U;&/(PT
M'[H\8!V ;2.3_"1GISGC&* *_P 3_%DGA^!! P6:5\ E=V%498C(*YR5'.>"
M<#N.ET1)4@C%P29MBER=OWB,L/D 7 / QV'4]3YQ_P C5K?]U++\&/DO_P "
M!S(WM\GHU>JT %>+Z#\3+^Z5[5<S7,Q18?D0!?O;VX R>F,_*,$DX!!]HKQ_
MX):8DTLUTPR\2H%SC \S=D],@X7&0>A([T 71X'UBY4RO=E9&(.SSI !NR6'
MR#:"#@ *"O7!  S>\/>-;K3+LZ5JO+R,!'(J@ EN%^Z "K'H<9!R&[[?1:\Z
M^-MJK6T4Q'SK-M!R>CHQ88Z<E1^7UH ]%KQ+1?B9J5V3:QXEFF("$HHV\-D@
M*%&>0<ME5"G(P3CUWP]=-=VT$TAR\D,;,< 9+("3@<=:\T^!UJK/<3$?.JQJ
M#D]'+%ACIR5'Y?6@#J/!_AW4-/N'N+V<2HZ, HD=@&+*<A2JJ!@$<=,X Q5+
MQGX^D$HTO3?GN2V&8 ,%(ZJ,\9_O$\*,YYSM[C4;U;")[A\E8D9B!UPH).,X
MYXKS_P"#%DLD4U^^6FDE*EFY. %<\GG+%LMSS@>E %>3P)K$NZ1KS#ELX6:4
M+@Y)Z* N#C "XP3TP ;>C>/I](N/[-U;:#_#,!A3DG#'&!M/0, -N,,,[BOH
MM<%\9-'%W:"Z&-UNX.23]UR%( Z$EMIY[ X/8@'>UY??^,[WQ7*]GI0VQ+@-
M*?E;!RI;)^Z#G( 'F?+D=U'0:]K++HYNI/F>6UC#=%YF54+<#'!;.,>W%1?"
M/3$M;%9U'SSLQ8G&?E8H!G&< #.#GDGUH P7\'ZUIP$\5T9'4<H96;DDC $H
MV,-N#EL8.<#(!-5/B9=7]Y;0#,0+Q1S1E%^_YA5\%@6 (QQD%3D=LGUVO'_&
M&F)8ZU;M&,>=)!(PX W&7:2, ==N3U)))SS0!Z!X]U232K*6Y@;;(FS!P#C,
MB@\$$=">U>?Z+XMU3Q6HLK<JK*I\R8C:>2V.57"Y! &U=V5W9QG':_%+_D'3
M_P#;/_T:E1?">U6'3XW48,C2,W)Y(<IGVX4#CT]: -#P5I%SI4+17DGFR&0D
M-O=\*54 9< ]0>.G-<?+K.I^,GEAL_\ 1H(F*EGW(Y((^4L Q##&2%Q@'#$Y
M&?4*X+6/B]!;R?9[:-IY-X4;2 C9_ND;BQSP/EP>H)&,@&/JFD:MX5W7L=PU
MQ$F-P<LQV\%B8VW  $8)5MP'.0,X[_PQXA3Q! MW&,;LAER"58=0<?F.A((.
M!FN-F\7:IJS&&&Q"H4.Y;A6P<\'YG,2D$'[N">IZ=+'P4_X\Y/\ KX;_ - C
MH /BOXIN=!\C[,^SS/-W?*K9V[,?>!]3TJE;6.J>,"MX9C:V[%BBH6#[2!@X
M7;N!QU9AW90%(!K_ !S_ .77_MM_[3KU*&%85"( %4   8  X  '0"@#RH>)
M]0\#R)!?D30.3AMVY\#EBK'#$@L.''.,*0.:?8RZKXVS<1R_9K8R#;@E3@9!
MVE0&?'?)"ENF,875^-?_ !YQ_P#7PO\ Z!)74>#H5BLK8* !Y$9P!CEE!)^I
M))/J>: //[W4=4\"-OF<7%LSX!=B22><9)WJVU?]I!GN:]2M+I;M%FC.4D4,
MIP1D,,@X//2N:^*7_(.G_P"V?_HU*/A;_P @Z#_MI_Z->@#JZ*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7!:.-V&>F54D9QCCBL7P[\0;;6<)N\N4X^23C).!A6Z-R< <,>NV@#IJ***
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MQ5X'A\3,C3O(!&"%"% /FQD\H3DX'?'' ZY ,?X=^#($LHY+B%'DFRY,B(Y
M;[H!P< J <9X)/3H.E_X1.S_ .?>'_ORG_Q-:U% ''^,O MO=VDH@A1)44NA
MBC 8E>=N%P3N&5QSR0<$@57^$>O#4;3[,23);':<DGY6)*')' '*@9. O8$"
MNXKG]!\%0Z'-)=0,X\[.4RHC&6W#"A1C;R%Y. 2.] '&>+GD\*ZHNL$,T$P
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ML+'CC#;0%P>N0V?;K73^&?!5MX<!,"DNPP7<Y<C.<=@!] ,X&<D9H WJ***
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M\^;+Y>W[OR;MV>N[;C&.VW.><]JZWP_X2MM 7%N@#8P7/+GIG+'L< X&%SR
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M% !115>]U&*P7?,ZHI. 78*,]<9)'/% %BBBB@ HHHH **** "BBB@ HHHH
M**J?VM#YGV7S$\W^YO7?TW?=SGISTZ<U;H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_:ZW;?X>V#'!B_\ 'Y/_ (JK7_"MM/\ ^>/_ )$D_P#BZ .8_P"%T?\ 3O\
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MSI^- $=GU_"KE4[/K^%7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M><'&%8\C*D,<%3R,CD\X .MHK'\5>)H_#D!NI 3SM51_$Q!(&>PX))[ <9.
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M;CDXR0 ,;LCC)ST;0DT37HMTHN8F;;]T8YVY( #1!03GKQGC)P!@ ]%HKE_
M?BYO$,<BS*$G@?:Z@,.N<'#=#P01DG*Y.,@4SQ[XIDT98[>V7=<73%(R<;0<
MJ,\\9RPQGCN>!@@'5T5YU)HFO1;I1<Q,VW[HQSMR0 &B"@G/7C/&3@#'3Z1<
MWFH69>95ANG1]@&< D'864AMIZ97YO?DE0 9OC77Y]-N;&&%MJ3S;9!M4Y&^
M,8R02.&/3%=A7BGBO2]2@N;0W4R/*\@$)7[JL'7DKY:CJPR<$D#GH!7I?A2R
MO[;S/[0E23.W9Y8 QC.[.$3KQZ].U '04444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!SFH2;Y&/OC\N*KTZ1_,)8]R3^=-H **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *RZU*RZ -&+H/H*?3(N@^@I] !1110 4444 %%%% 'E_P $+% D]SE3
M(65,8&Y5 SG.<X<GT RG?''J%>!>!O$DWA<_;"A:UE?RWP!]Y!N&#V8!L@'
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M>MUX?X-N)KG64EN0RRNTI96# C,3$##<@ 8V@]L5[A0 R:985+N0%4$DDX
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M\Z?C0!'9]?PJY5.SZ_A5R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MRZU*RZ -&+H/H*?3(N@^@I] !1110 4444 %%%% %2WTF&V1H(XT6-\[E5%"
MG(P<J!@Y'!]JJ?\ ")V?_/O#_P!^4_\ B:UJ* "J][IT5^NR9%=0<@.H89Z9
MP0>>:L44 %0W5HEVIBE570XRK@,IP<C(/'6IJ* ,G_A$[/\ Y]X?^_*?_$UK
M444 %9]UX>MKMC++#$[G&6>-&8X&!DD9Z5H44 5+'28=/SY$:1[L9\M%7.,X
MS@#.,FK=%% $-U:)=J8I55T.,JX#*<'(R#QUJE#X8M(6#I!$&4@@B) 01R""
M!P16G10!4_LF'S/M7EIYO]_8N_IM^]C/3CKTXJW110 5GW7AZVNV,LL,3N<9
M9XT9C@8&21GI6A10!130[=(S;B*,1,<E BA">.2N,$\#\A5N&%85"( %4
M8  X  '0"GT4 <OHWQ#MM3GDLR3&Z/M7S?DW\A> <$-NXVGYL8.,[@NAJVL6
MOAF-II-J;BS[5"AW;C)"\;F.1D_BQ YJOXC\"VFO_-*F)#_RTC^5^W4X(;@8
M^8' Z8K*TSX16-BXE.^3'196!7((.<*JYZ=#D$$Y!H S_AA9OJ4UQKDNX>>S
M*@))^7<">2!D+A54@XX88&!7H4T*S*4< JP(((R"#P00>H-$,*PJ$0 *H
MP !P  .@%/H R?\ A$[/_GWA_P"_*?\ Q-7GTZ)Y!<%%,JC <J"X'/ ;&0.3
M^9JQ10!#=6B7:F*55=#C*N RG!R,@\=:?#"L*A$ "J   ,  <  #H!3Z* *]
MMIT5JS/&BJTARY50I8\G)(')Y/7U-6*** *Z:=$DAN BB5A@N% <CC@MC)'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:N.K&IN>M@?X7S"BBBI.L**** "BBB@"UI?^NC_ZZ)_Z$*]$KSO2_P#71_\
M71/_ $(5Z)6E/8\S,?BCZ!1116APA1110 4444 %%%% !1110 57O.GXU8JO
M>=/QH CL^OX5<JG9]?PJY0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 <V1C@TE2W/WV_P!X_P ZBK4@
M**** "BBB@ HHHH **** "BBB@ K=L4V(H]L_GS6%70P+M4 ]0!_*IF-$E8>
MH#$A_#^5;E8^JKA\^H'^%*&XV4J***LD**** "BBB@ HHHH **** "BBB@#7
MTC[A_P![^@J]5/2DVIGU)/\ 3^E7*S>Y:"BBBD 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !676I670!HQ
M=!]!3Z9%T'T%/H **** "BBB@ HHHH **** "BN/^*&OSZ);)-;-L<S*I.U6
MX*.<88$=0*["@ HHHH **** "BBB@ HHHH **** "BBB@ HKG_'NJ2:592W,
M#;9$V8. <9D4'@@CH3VH\!:I)JME%<SMND??DX SB1@.  .@':@#H**** "B
MBB@ HHHH **** "BL>Y\416]W'I9#>;*A8$ ;, ,>3G.?D/8]JV* "BN4T_Q
M!?37[V<EOMMEW8DYZ #:V_.UMW]T#(SS]UJZN@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)BVHZL&/NR@;3_$">0./F"T >FUS\WCBWMYYK.0LAMHP[NP&S!V8 P22?G
MQR>!DXS%\-[IKK3X'<Y(5EZ <([(HX]  /Y\UQ.H>&E\0:Y+#)_JT5'<9()
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M=+:6$$TAPD=K&S'!. L8).!STK@OA[=VM[)-JM_)%Y[R_*LK*-F,-N4.QXY
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#(U?[X_W?ZFJ-
M:6L#[I^O]*S:TCL2]PHHHIB"BBB@ HHHH **** "BBB@"UIW^L'X_P C6W6/
MI(RY^A_F*V*B>Y2"J>JIN3/H0?Z?UJY5>_7<C ?YP<TEN-F%1116A 4444 %
M%%% !1110 4444 %%%.C3>0H[G% '01)L 7T 'Y4^BBLBPHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML=0O)&2!7=8HU SMY/#;0N <#=M8MM(.,"@#TJRURWOVV0RQNP&2$=6..F<
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MG'_U\+_Z!)75>$_^/.V_Z]X?_0%KE?C7_P ><?\ U\+_ .@25U7A/_CSMO\
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MA:0LR%2'*D8)![*O/RU4\=Z)?:U)%:V[A+5@?-8'#=P=PR"RE3@*."<[\#!
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M_P#H$E:&@?"^VT2=+R)Y2\>[ =D*_,I4YP@/0^M9_P :_P#CSC_Z^%_] DH
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M^M<?X(UE=9UBYNH_N-"P7KR$:) W(!&0,XQQG%79?A=<70\N>_EDB)&Y"&Y
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M-<7#<"20'(&,<99CG'&<].!@9R =71110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** *&KK\H/<'^8_P#K5DUMZFN4
M)],?SQ6)6D=B6%%%%,04444 %%%% !1110 4444 :.CKRQ[C'Z__ *JU*S](
M3"EO4X_+_P#76A6<MREL%1W RK >A_E4E%(9S5%*1C@TE:D!1110 4444 %%
M%% !1110 5-:+N=0/4?IS4-6],7+@^F?Y8H>P(VJ***R+"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %9=:E9= &C%T'T%/ID70?04^@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4_ITSGZBNNJKIM@+!!$O..IQC)/?_/:K5;Q5D>+B*OM:C?3H%%%%,Q"BBB@
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MR@*\# PIR%]]H&>IR:VZ** *][IT5^NR9%=0<@.H89Z9P0>>:EAA6%0B !5
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5EUJ5ET :,70?04^F1=!]!3Z "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#F;O[[?[Q_G452W?WV_WC_.HJ -
M?0T(#-V./TS_ (U<OTWQL#Z9_+FH='3;'GU)/]/Z5=(W<&@#E:*** -2'[H^
M@I]1V[;E'T_E4E %BS')/M5B==RFHK)>":L$9H R9ONGZ&LNM:1=P(]1630
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M HHHH **** "BBB@ JO>=/QJQ5>\Z?C0!'9]?PJY5.SZ_A5R@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "LNM2LN@#1BZ#Z"GTR+H/H*?0 4444 %%%% !1110 4444 %
M%%% !1110!7MM1BNF9(W5FC.'"L&*GD8(!X/!Z^AJQ7.>&_ =MX>E>X@W;I
M1AFR%4G.T<#C@?>R>!SUST= !1110 4444 %%%% !7/ZIX]LM*D:VGEVR)C(
MV2'&0".0I'0CO705S^J> K+59&N9XMTCXR=\@S@ #@,!T [4 5/^%I:=_P ]
MO_(<O_Q%'_"TM._Y[?\ D.7_ .(KC_BAX,M-$MDFMH]CF95)WNW!1SC#,1U
MKL/^%6Z=_P \?_(DO_Q= &WHFOP:VAFMFWH&*D[67D '&& /0BM"L_1- @T1
M##;+L0L6(W,W) &<L2>@%>=75U/\19Y;2WD\NQBVY.WECSM)7(9MS D D
MD!@ 0#LKWXB:?9-L>=22,_(&D'YH&&>.F<U8T;QI9ZRWE02JS_W2&1CP3P'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %5[SI^-6*KWG3\: ([/K^%7*IV?7\*N4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/
MW/WV_P!X_P ZZ"N?N?OM_O'^=5 3(J***LD**** "BBB@ HHHH *GLDWNH]\
M_ES4%7-+3<^?0$_T_K0]@1LT445D6%%%% %'5_N#_>_H:R*W-1_U9_#^8K#K
M2.Q+"BBBF(**** "BBB@ HHHH *W-._U8_'^9K#K8TDY0_4_R%3/8:+M%%%0
M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ K+K4K+H T8N@^@I],BZ#Z"GT %%%% !1110
M4444 </\(M1EO[1WF=G83L 78L<;$.,DGCFNXKS_ ."G_'G)_P!?#?\ H$=>
M@4 </X!U&6ZN]021V98Y\(&8L%&^48 )X' Z>@IGC?5;B[NX=$MG\GSEWM*"
M=V!N.!C!'"$\'YC@949S7^&4RS7>HNA!5IP00<@@O*001U!K6\;> QX@9+J)
MS%<Q#Y6YP<991P<J0QR&'(R>#Q@ Q)_AY?V*M/;WLCR@A@K;E#LN!R3(P)P
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M.#CJ<  C@BUIG@"\NFAN[VZ8LDJ2F(@N@96W8!WA0<<?*N!D@9'4UZ%9==M
MP!'D$X(SROG$'Z@@$>AYKT.@#SK^U)- UC[/-*[P7:_(K2,P0R-Q\N,#YU*K
MCHK D\&O1:X?XLZ.UU;+>19\VU?>"I8,%/WB-O<$*V>,!2<CO;O?&JII?]IA
M@))(L+M'_+4C:0%?J%<$]_E4GD=0#)T[4YO$&KR*KR);68(*J7569#M^;:V,
MEB2,_>50"O6O0ZXSX4Z"=+LQ(X&^X/F=!G:0-@R"<C'S#TW$8SFNSH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M):27D04O'LP'!*_,ZJ<X(/0^M>"^$_\ C\MO^OB'_P!#6O:OBE_R#I_^V?\
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MC7<,;HT5''H0P'!'Y'H01D5XGX OOL-_;R8SF0)C./\ 6 QYZ'INS[XQQUH
M^BJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "LNM2LN@#1BZ#Z"GTR+H/H*?0 4444 %%
M%% !1110!Y5;WS_#FZEC>-VL9F!1ER0I() &6QGJK D,0H;H #H77Q3.KJ;?
M3(96N&P 75=J@G!<X9AP2/O849R3@8/HM% 'F7P<LFL);VW?!:)XU)'3*F4'
M&<<<5M>+O&T_AF=3)"&M'  =6._=G+9SP"!G"_Q=0_4#LZ* /,M;^+-OJD$E
MI!%*TLZ-&H*J.9!M_A9B3SP .3QQG-=?X&T>31[.*UFP)%#$@'.-SLV,^HS@
MXXST)'-;U% 'G_PX_P"/S4O^OC_V>:CXC_\ 'YIO_7Q_[/#7H%% !7G_ ,:_
M^/./_KX7_P! DKT"B@"&[M5NT:&09212K#)&0PP1D<]*\UM[>^\ R-;V\37-
MI*Q<;5)<'&,$J#@],Y!# ?+M)8#TV9RBE@"Q ) &,G'89(&3[D#U-<5X:^*,
M-\S07F+>978 .2%P,\%B!M9<8.[&3TZ[0 8\GC?4?$ZK!96[0K-D&8EF4#/)
M$FU0N,$$_,?[N& J7X16/]GS7UMG=Y4B)G&,[6E&<9.,X]:V/%7Q.MM)C(@=
M9IB/E"'<@SGEF7C Q]T'<>.@.X'PN\+MHEL9)5*S3D,P/!"C(12,GGDGH"-V
M".* .SHHHH \_P#C7_QYQ_\ 7PO_ *!)7H%%% !7F_B?P?<Z/<G6-,R68LTL
M><YS\S<$_,K=U'S!L%.VWTBB@#S>R^,\4:[+N&1)E.&" $9'!X=E*G.?E.<>
MIIEU\5I-7)M=,@=I&489\94DX+%1N&!D?,S  GD8'/I=% '*>!_"\NF[[V[=
MGNKG!<;OE4#HN!P2/7HH^5,#);E?CG_RZ_\ ;;_VG7JM% !7/^.O#G]OVCP+
M_K%^>/\ WES@=0/F!*\\#.>U=!10!QGPN\4-K=L8Y6+30$*Q/)*G)1B<#G@C
MJ2=N2>:[.BB@#)\6?\>=S_U[S?\ H#5Y;\//B';^&[=K>99"S2E@4"D8*J.[
M+S\M>T44 >?_ /"Z[/\ N3?]\I_\<KH/"GC6'Q/YGD*Z^5MSY@4?>SC&&;^Z
M:Z"B@#S_ .''_'YJ7_7Q_P"SS52^,=DU_+96Z8#2O(H)Z98Q 9QGCFO3:* /
M+]&^)DF@+]BU6.7S8^%8 %F4$C)W, <$8#@D-]02U?7_ !7-X[ T[3XF$3%?
M->10,<Y )!8*HVYSG<Q& .S>L44 9^@:,NBP1VB<B-<9YY)Y9L$G&22<9XS@
M<5Q_PX_X_-2_Z^/_ &>:O0** *FK6/\ :$,EMG;YL;IG&<;E(SC(SC/K7E_A
MCQ./  ETV^C?=YF]6CPRL& 7(W%>/EX/U! ((KUNB@#R3Q1XQD\9126UDC+!
M%&9)WE !PF6"\%@,E>.<L?10Q/8?"W_D'0?]M/\ T:]=710!Y_K/_(>M?^O=
MOY3UZ!110!#=VJW:-#(,I(I5ADC(88(R.>E>%0V,\\Z>&G+&*.Z8]-K;>[#<
M2 -FYU X)8GYLBO:-0\36NG%EFFC5D&2I==_3/W<[B2.@ R>U<?\-;>35I[C
M7901YQ*(/]D$9_A&0NU5##J0V1F@#T"&%85"( %4   8  X  '0"GT44 %%%
M% !1110 4444 %%%% #9$\P%3W!'YURU=)>S^0A;OCCZ]JYN@#H-+_U:_C_,
MU;K/T4Y0^S'^0JY._EJ6'8$_D* .9)W<FMS1TVQY]23_ $_I6%6OHEQD&,]N
M1]/\_P Z +MV,K^-4JMWDF/E]:J4 7;0Y7\:GJM9-P15F@#-=MQ)]:?;+EA4
M5,FG\D$CJ>/SH RZU?\ EV_S_>K*K86(M;X]B>?8Y_E0!CUU=<I71V$WG(#W
MQ@\YZ?YS0!8HHHH J:HFZ,\9Q@_K_A7/UT=^^R-B?3'Y\5S\,?F,%]2!^= '
M17?W&_W3_*N:KIKH;D8#^Z?Y5S- '3P)Y:A3V 'Y"H;T=/QJPCAP&'0BJ][V
M_&@ LN_X5!+U/U-3V7?\*@EZGZF@"_&, ?04ZFHVX ^HIU !1110 4444 %%
M%% !1110 4444 %%%% 'S5X6UW^P;E+W;O\ +W?+NVYW*5ZX/KGI79:W\9&U
M&"2V6 *949=QDW8##!XV+S@G'/!YYZ5SOPXM$N[^&*55=#YF5<!E.(V(R#QU
MKVJZ\$V-TIC:WB ./N($;@YX9,$?@?;I0!Y[\&_#2RR'47928P0B!LN"V1O8
M _*,;@ PYY.!@$V/CG_RZ_\ ;;_VG7'^#;\Z5J,0@?<C3"/=@J'1VVY*YSTP
MP!Z$#.<5V'QS_P"77_MM_P"TZ .H^&<RPZ9"[D!5$I))P !(Y))/0"O/]>^)
M=YK\AMK(,B$G:L0)F8#!R2N2#P3A<8!()8<UU&A[_P"P&\O;N\F?.[.-N]]_
M3OMSM[9QGBL'X)S0I/*'($S(HC!)&5R2X'8GA3ZX!(XS0!FW&J:OX4=99VEP
M<?ZUO-C.3G;G+ $[3T(;&<8!KUKPUXLBUVW^VK\BKD2!S@(5 +98X! !SGTZ
MX.0*OQ'N8H;"83\AUVJ,X)<G*8Y&<$!B/0'@CBO-/ ._[#J7E[=WDIG=G&W$
MF_IWVYV]LXSQ0 _7OB7>:_(;:R#(A)VK$"9F P<DKD@\$X7& 2"6'-5[C5-7
M\*.LL[2X./\ 6MYL9R<[<Y8 G:>A#8SC -:7P3FA2>4.0)F11&"2,KDEP.Q/
M"GUP"1QFN^^(]S%#83"?D.NU1G!+DY3'(S@@,1Z \$<4 7?"OB:/Q' +J,$<
M[64_PL "1GN.00>X/.#D#S+QM\29]1F-E8LRQAM@,9R\C;ARK+D@$C"[3E@>
M<YVBU\%]^R\\K;YFV+;OSMW8DVYQSC/7'.*POA+-#%?*9B =C",DD?.V !Z9
M*E@,\$\#G% $MQ>:OHD$AN1(T-S$5)F)DVAAC/WB8V^; #8R>""1Q8^"G_'Y
M)_U[M_Z''7K?B"YBMK>5[C_5"-MXS@D$8V@Y'+9P.1R1BO)/@I_Q^2?]>[?^
MAQT >UT444 %%%% !1110 4444 %5[SI^-6*KWG3\: ([/K^%7*IV?7\*N4
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MW< 1@]\$$].1UYQ@\_H6A:S8O%"\\7V>+R@0 O* X* ^5NR%'4XZC#9S@ ]
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MUP<?=.+=<9X/^'*:*_VR=S+=$D[\L I92&[_ #$Y.6;KQP#G/9T %<I\4O\
MD'3_ /;/_P!&I75UB>,]$?6[22SB*AY-F"Y(7Y75CG )Z#TH S_A;_R#H/\
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M-IC/&VT9VQNKN?0!0>2?R'4D#)KBO$_P;:XE,MDZJKEBR2?*%).0%V*?EYP
M1QCJ<\5?#GP9E,B27K*(L E$8ER?[A.  /4J3Z \[@ </X3_ ./RV_Z^(?\
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M^?\ XI?\A&?_ +9_^BDKZ KR_P 9_"^YUN[DO(GB"2;,!V<-\J*ISA".H]:
M.Z\6?\>=S_U[S?\ H#5Y5\%/^/R3_KW;_P!#CKUW7+)K^WFMTP&EB=03TRRD
M#.,\<UQ7P\^'EQX;N&N)FC*M$5 0L3DLI[JO'RT >AU\U>$_^/RV_P"OB'_T
M-:^E:\BT/X17=A<0W#O$5BE1B SYPK G&4'/% 'KM%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ SAIIPZKD<]&<\X X'IGBO<** ,?PKX9C\.0"UC)/.YF/\ $Q !..PX  [
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M444 %%%% 'E7@#_D,WG_ &\?^CUKU6BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MAN[?[2C199=ZD;D.&&1C(/8CL?6IJ* ,3PIX3B\-QF&+DLQ+.1\S#)V@_P"Z
M#CC SDX!)K;HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *RZU*RZ -&+H/H*?3
M(N@^@I] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %5[SI^-6*KWG3\: ([/K^
M%7*IV?7\*N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !6)J/\ K#^'\A6W6)J/^L/X?R%5#<3*M%%%
M62%%%% !1110 4444 7](7YB>P'\S_\ 6K6K/T=, MZG'Y?_ *ZT*SEN4M@H
MHHI#"BBB@ J"\3>C#VS^7-3TA&>#0!S=%%%:D!1110 4444 %%%% !706IRB
M_0?RKGZW-._U8_'^9J9[#19HHHJ"@HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K+K4K+H T8N@^@I
M],BZ#Z"GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 57O.GXU8JO>=/QH CL^
MOX5<JG9]?PJY0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<"6,Q*<%PZE >."V< \C\Q0!>HK)T+Q3;:]N^S/O\O;N^5EQNSC[P'H>E:U
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M4 7J*Y>'XFZ=*P03C+$ 9211SZDJ ![DX'>NEAF690Z$%6 ((.00>001U!H
M?6?HFOP:VAFMFWH&*D[67D '&& /0BH==\46^AJ7G=0RKN" CS&&<#"YR<GC
M/3U( )'$?"+7+>PM'2:6-&,[$!W53C8@S@D<<4 >FT4R&99E#H058 @@Y!!Y
M!!'4&GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %9=:E9= &C%T'T%/JHEWM &.GO2_;?;]: +5%5?MOM^M'VWV_6@"U157
M[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M
M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M45
M5^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?
M;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]: +5
M%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M
M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"
MU157[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?
MK1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH
M M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^
MWZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]
M: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?M
MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV
M_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157
M[;[?K1]M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M
M]OUH M455^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M45
M5^V^WZT?;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?
M;?;]: +5%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M455^V^WZT?;?;]: +5
M%5?MOM^M'VWV_6@"U157[;[?K1]M]OUH M57O.GXTW[;[?K4<UQY@QB@!UGU
M_"KE4[/K^%7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2X4#KC.  6YQD#&030!P^A_!>:=F-VXC57P F'+J.I!R-H/;()]5&.<WXA>
M$\,A9HI=R2-@(^/,&!DG(P&&>IP,94<YS1I,6J^,RY65_+/RNS.8XON_=VKP
M<CJ%4]06ZYJOXH^'4OANW%U-(I9I0@5 2,%2V[<=O/RXQCWSVH ]0^&&O2:S
M9AIB2\3M&6)R6P P)X'.& [DXR3DUP/QK_X_(_\ KW7_ -#DKJ_@I_QYR?\
M7PW_ *!'7*?&O_C\C_Z]U_\ 0Y* /5?"?_'G;?\ 7O#_ .@+7*_\+KL_[DW_
M 'RG_P <KJO"?_'G;?\ 7O#_ .@+7*_\*4L_[\W_ 'TG_P ;H /^%UV?]R;_
M +Y3_P".5=\4^$U\<Q6]PDAB4(6 *;B1*$(SAA@C'O5+_A2EG_?F_P"^D_\
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MD:,'&YW&T<CMA.3G('"X+$CUWQ9_QYW/_7O-_P"@-7*_!3_CSD_Z^&_] CH
MV+KX::?/&(?)"[0P#*S!QN[ELG<1VW;@.F,<5R_P\OY="O9-!G?*+N,>1SGA
MQC!(4,F6()X/HQ.?4*\J_P"9C_S_ ,^M 'JM%%% '@36TU]J=Q90,5-S/-&Y
M&/N>86?J1P N2 02!M[X/J%E\+-/MD\LQER1@L[MN/S;OX2H!XQE0#C@]3GE
M/ DRIK-V"0"QN  3C)\X' ]3@$_0$UZQ0!Y/XN\,MX)D75M.)6,$*Z'<P&?4
MG.4;&#DY#8VG)&WTW2M335(DNHCE)%!'3(SU!P2,@\$9X((KG_BE_P @Z?\
M[9_^C4JO\/KU;#24N'R5B29B!UPKN3C..>* *6E_"L3RRW6I/]H=V.W!91CL
MQP00<<!0=JC@9XQ8\6_"^VU")Y+:,1SXRNSA25'";20@#>HQ@\DGD'"L9=5\
M;9N(Y?LUL9!MP2IP,@[2H#/CODA2W3&,+:N_A4IW76H7<LJ1QDDX.X!?FZL9
M"0!G@#J>/< WOAAKTFLV8:8DO$[1EB<EL ,">!SA@.Y.,DY-<O\ %OPM;:?"
M+V)-LLMQ\S;F.=RNS<$D#)&>!6K\%/\ CSD_Z^&_] CH^-?_ !YQ_P#7PO\
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MP" <$YY%<?\ "_P9::W;/-<Q[W$S*#O=> B'&%8#J37HOBS_ (\[G_KWF_\
M0&KE?@I_QYR?]?#?^@1T =U:6JVB+#&,)&H51DG 48 R>>E3444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4_L9]JN44 4
M_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4
M_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4
M_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4
M_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4
M_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4
M_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4
M_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4
M_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4
M_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4
M_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4
M_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4
M_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4
M_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4
M_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4
M_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4
M_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 4_L9]J/L9]JN44 5
M[>W,9R?2K%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5S]S]]O\ >/\ .N@KG[G[[?[Q_G50$R*B
MBBK)"BBB@ HHHH **** 'Q/L(;T(/Y5T5<];C+*#ZC^==#43*B%%%%2,****
M "LW6?X?Q_I6E6;K/\/X_P!*<=Q/8S****T)"BBB@ HHHH **** "M?2/N'_
M 'OZ"LBMO31B,?C_ #I2V&BU1116904444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5RGQ2_Y!T__;/_ -&I75T4 >5? S_EZ_[8_P#M
M2O5:** /%/'W@&7193?V@8Q%B_[L8:(CYOX<848RK#&W&#C +16OQDOH5",(
MG(S\SH0QY[[&4<=. /SKW"H9+1)665E4O'G:Q ++N&#@]1D=<=: /(/ MSJ6
MJWR:@=S*Z[7DD7$9C!&Y5( &<C@+_%R>-U=Q\3]!DUFS*P@EXG60*!DM@%2!
MR.<,3W)Q@#)KK:* /GSPWXZNO"BO:HJX+DE95;*L/E;H5(/ !!Z8XQSD\47M
MYX@B&JW.!#O$<8&0N2"6*J<\?+\S$\G &=N%]]DM$E99652\>=K$ LNX8.#U
M&1UQUJ:@#S_X*?\ 'G)_U\-_Z!'7*?&O_C\C_P"O=?\ T.2O:Z* ,GPG_P >
M=M_U[P_^@+6M110 4444 >%?$GPU+H=VUZFX1S2%T<'E7/S$9 &T@Y*^W0D@
MXW?!?Q'N];O(+24J$PX;:H!?$9())S@Y&?EVCKQC@>L5#:VB6BB*)51!G"H
MJC)R< <=: /,/CG_ ,NO_;;_ -IUU7PM_P"0=!_VT_\ 1KUU=% 'S_\ \QG_
M +B'_M>OH"BB@#Y__P"8S_W$/_:]?0%%% 'S_P#%+_D(S_\ ;/\ ]%)7NNJZ
M8FJ1/:RC*2*0>F1GH1D$9!Y!QP0#5NB@#Y_U/2+WP).98RP'1957*,&SP001
MGC)4YP1D9 #5H77QDOIE**(D)Q\R(2PY[;V8<].0?SKW"H8[1(F:554/)C<P
M #-M&!D]3@=,]* . ^$MI?6WG?:598G8M^]!$AD.,MSR01]XGOC;_%7HM%%
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M* "BBB@ HHHH *WK)-B*/;/Y\U@UT,"[5 /4 ?RJ9C1)1114%!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!S^D>"H=*N9=0C9S)/OW!BI4;W#G "@]1QR>*Z"BB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LO6$P5;U!'Y?
M_KK4K/UA,@-Z''Y__JIQW$]C*HHHK0D**** "BBB@ HHHH N:6FY\^@)_I_6
MMFLO1TR6;T 'Y_\ ZJU*B6Y2"BBBI&%%%% !5;4?]6?P_F*LU'.NY2!U(/\
M*A <]1116I 4444 %%%% !1110 H&>!725S]M]]?]X?SKH*B940HHHJ1A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDJ;P5]01^=/HH YJBGS
M)L8J.Q(IE:D!1110 4444 %/B3>0OJ0/SIE7-+3<^?0$_P!/ZT,#9HHHK(L*
M*** "BBB@ HHHH S-83[K?4?X?UK-K;U*/>A]N:Q*TCL2PHHHIB"BBB@ HHH
MH T]''WC]/ZUI52TI<)GU)_PJ[6<MRD%%%%(84444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<_JO
MC:'39&MW5RRXSM"XY /=AZUFW7Q+C7'EQLW7.XA?ITW9_2NB&"KS2:CN9NM!
M=3LJ*X;_ (6=_P!,?_(G_P!A1_PL[_IC_P"1/_L*O^SL3_+^*_S)^L4^YW-%
M<-_PL[_IC_Y$_P#L*/\ A9W_ $Q_\B?_ &%']G8G^7\5_F'UBGW.YHKF_!_B
M236O,\P*-FS&T$?>W9ZD^E=)6%6E*E-P>Z-(24E=!1116904444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% &%?KM=@/\Y&:KU?U=?F![$?R/\ ]>J%
M:K8EA1110(**** "M+1Q]X_3^M9M:VD+\I/<G^0_^O2EL-;E^BBBLR@HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1167JGB6#3,K(XW 'Y5^9NF
M<8'3.>,XS50A*;LE=B<DE=FI17+P?$.VD(4AU![LHP/^^23^E=#97T=ZOF1,
M&4]P?;.#Z'GH>:NI0J4_B30HU(RV9/1116104444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%4;W7+>P;9-+&C$9 =U4XZ9P2..* +U%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT)'\ZCJQ8+N=0?\ .!FA@;M%%%9%A1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@""^MS<QM&K%&8$!EZCW_P X/H0>:\NA\'W$LS6NT J,ECG9@]#G'?''
M&>N0,''K%5-5U)=-C:X<$JN,[<9Y('<CUKJPF*J4;QBKW_,RJTHSU?0X'6_
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MZY;QP@%T,)DP-O*,9"23C)$>/7@ #D8H ]8HJCK6L1Z/"]W-G9&,G R3D@
M>I) [#U('->=)\1]3U$&>UM 8<9&4D?H0IPP*ACN[*,@9ST)H ]3HKC/!OQ$
M&N2&RFB:.X4'< "4^7 ;/=#G/#<#@;BQ KLZ "N7U#Q1+;ZG!I8"^5+$6)(.
M_($AX.<8^0=CWK8U_4GTV![B*-IG7;B-,[CE@#C 8\ YZ=J\<;Q;=2ZHM[)
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MFJMU=6BB YSA71A@[1DEFV<D8W+\W;UK5OOB_:10"XB#/(S$"(_*PQC)8C<
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M5S2TW/GT!/\ 3^M4ZO:1]\_[O]12>PT:]%%%9E!1110 4444 %%%% !1110
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M* "BBB@ HHHH \4^%'A:VU[S_M*;_+\K;\S+C=OS]TCT'6O0/^%6Z=_SQ_\
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MPN"@!_U@*C=GCD_WJ /0***X+XD>++C3I8+&R8":8Y/R@GYCM09<;<,<Y[C
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M$EW*".#GR\XP2,8)(R>2 H 9@5/(!V=%>9?\(7J]\K3RW925@A"+(ZKZ$'8
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M#AP<*6&<;MO!!!&&&, D8QG TO&OB1O#ULUTB%VR%''R@MT9L=%'ZD@9&<@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\_\ /K78?$30CK-E)&@W2)AT'.<KU "YR2I8 8ZD?4<?_P S'_G_ )]:]5H
MX_X6:Z-3LDC)S);_ ",#@' ^X<#MMP,D#)4]<9KG_BM=-K$]OHL!RY;<PP"
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M<T&/0H$M8P/E W$#&YL?,QY/)^IP, < 5Y[\<_\ EU_[;?\ M.O5: "BBB@
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M-K3T;^+\/ZTI;#6YI4445F4%%%% !1110 4444 %%%% !1110 4444 %%%%
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M\A94921UPP(.,YYYKSKX1WK6$MQHTF"T3LVY>F5(C?DXXX7;QZY["O3:\O\
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M"TQ-/L8%C'WXUD8\9+2 ,2< 9QG [X &>*E\::,VLV<UK']]E!7IR48.%Y(
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M!TOQ6U/[#8.H+!IF6,%>.IW,#R."JD'KG.,8)K0\!:8FGV,"QC[\:R,>,EI
M&). ,XS@=\ #/%2^--&;6;.:UC^^R@KTY*,'"\D 9(QG/&<UROPO\8*(_P"R
M[IMD\+;4$F5)&<!,L?O*3MV\<8 !P< 'HM%5-3U6+2T,T[JB#NQQDX)P!U)P
M#@#)/85E>%O&<7B1IEA#;8&4!CP&# X8#J.5/![8/4D  Z"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!&"&& 0,DG,G\,ZUJ:M;7%S&(F(5BH )4X)(VQJ<<D8)7."#\IR?2** //\
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MP4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N:KI:YJK@*044451(4444 %=+7-5N:=)O0>W'Y?_6J9C19HHHJ"@HH
MHH **** "BBB@ K*UA\D+Z#/Y_\ ZJU:P;V0NYSV./RJH[B9!1115DA1110
M5J:.O#'L<?I_^NLNM?2/N'_>_H*4MAHO4445F4%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 >1>)_/\]OM/W^V/N[>
MVW_9_7.<\YK5\#^(I+:1;,@O&YP .2I/<?[/=AVZCOGMM=T*/6(_+?AA]UAU
M4_U![CO]<$5O#/AE=&7)PTK#YF_]E'M_/J>P'JRQU*>&Y6M=K?J<JH3C4NGH
M;=%4M3UB+3 &F8*&.!P23^ !/X_3UJW'() &4@@C((Y!!Z'->6XR23MHSINK
MV'4444AA1110 4444 %%%% $%U81W>/,17QG&Y0V,]>HHM;".TSY:*F<9VJ%
MSCIT%3T4^:5K7T%97N%%%%(84444 %%%% !1110!Y_\ \*4L_P"_-_WTG_QN
MC_A2EG_?F_[Z3_XW7H%% &3HGA6UT3)MHU0G.6Y9L''&YB3C@<9QGG&:UJ**
M "N2U[X86>LR&=@T;L26,3 ;B<<D,&&>.P&223DUUM% 'G^E_!BTMMK3L\K#
M.1G8ASG' ^88X_CZCTXKO885A4(@ 50  !@ #@  = *?10!S^K^"H=5N8M0D
M9Q)!LVA2H4['+C(*D]3SR.*V-1LEOXGMWR%E1E)'7# @XSGGFK%% &/X7\+Q
M>&XC;PEBK.6)<@G) '8+Q\M;%%% '-:U\/[;6+A;Z7=O79E1LV-L.1N!4ELC
M@\_= %=+110 5P^L?"&SOV:2/=$S X"$%-QR<[2#QS]U2HP,#'6NXHH X?1_
MA#9V#+))NE90,AR FX8.=H XX^ZQ88.#GK7<444 <_\ \(5#]M_M?<_F^F5V
M?ZOR^FW/3WZ_E70444 %%%% &/HGA>+1Y9[B,L6NGW.&((!RQXP!Q\QZY[5L
M444 <UXE^'MIX@;SI0RR<9>,X8@ @ @@@_7&> ,X&*Q[#X,V<#!I&DDP6^4L
M%4@YV@[0&R!CD,,D9P <5WM% '.0^!+>&\&J(6$B@ (-HC $?E@!0N0 OOU]
MN*T]?T1-;@>SE+!)-N2A ;Y6##&01U'I6A10!GZ!HB:) EG$6*1[L%R"WS,6
M.< #J?2L_5_!4.JW,6H2,XD@V;0I4*=CEQD%2>IYY'%=!10 5P_Q?O8H;(Q/
M@R2.OEC@D%2"S<\@!<J2/[P!X-;OBN:\AC1[!5>02#<K[0I7:V<Y9>AP>"#^
M&:XW3_!]_P"(;I;K5L+%"<K&"C*<MG8%4L-O'S%LL1@9/50#JOA_H(T6SCC(
M(=QYCY!!W.!P02<%1A>W3. 2:Z.BB@ KRKQ]_P AFS_[=_\ T>U>JUY_XO\
M"USJ&I6U[$FZ*+R=S;E&-LK,W!()P#G@4 6-8^$-G?LTD>Z)F!P$(*;CDYVD
M'CG[JE1@8&.M/T+X36FF,)7W3,%P1+M,>2.6V8^N 2V,]R :[6B@ JCK&BPZ
MQ'Y%P@=,@X.1@CH0000?H>F1T)J]10!YU)\$K8LI664(,[@=A8\<8;: N#UR
M&S[=:Z?PSX*MO#@)@4EV&"[G+D9SCL /H!G SDC-;U% %?4;);^)[=\A9492
M1UPP(.,YYYK/\+^%XO#<1MX2Q5G+$N03D@#L%X^6MBB@ KA]8^$-G?LTD>Z)
MF!P$(*;CDYVD'CG[JE1@8&.M=Q10!P^C_"&SL&623=*R@9#D!-PP<[0!QQ]U
MBPP<'/6NXHHH P?$W@JV\1@&=2'48#H<.!G..X(^H.,G&"<US$?P2M@S%I92
MAQM V!AQSEMI#9/3 7'OUKT6B@#/T;0(-%7R[:-4!ZXY8\DC+').,G&2<=!Q
M5C4;);^)[=\A94921UPP(.,YYYJQ10!C^%_"\7AN(V\)8JSEB7()R0!V"\?+
M6Q110!S_ /PA4/VW^U]S^;Z979_J_+Z;<]/?K^5:6L:+#K$?D7"!TR#@Y&".
MA!!!!^AZ9'0FKU% 'GA^"=IN!$DNW!R,IG/&#G9P!SD8.<CD8YUI_AA9R6XL
ME#(N]79E8;V95*C)8-Q\Q.   2< 9-=;10 5S_A3P5#X8\SR&=O-VY\PJ?NY
MQC"K_>-=!10!C^*/"\7B2(6\Q8*KA@4(!R 1W#<?-5C^Q$^S?V?EO+\GRLY&
M[;LV9SC&<>V,]JT** //_P#A2EG_ 'YO^^D_^-T?\*4L_P"_-_WTG_QNO0**
M .?\*>"H?#'F>0SMYNW/F%3]W.,85?[QJUXA\,0>($$5PN=N=K X921C(/\
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M\0-YTH99.,O&<,0 0 000?KC/ &<#%=+10!YY9?!6UB;=+)(X#Y &U1M[*V
M23ZD%<]@*[O3]/CTZ-;>%0L:#  _SR3U)/)/)YJQ10 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %>;>)O!;V3;[=6>-CT4%F4^G')'H?P/."?2:*WPV*GAY77S1G4I*HK,R
M?#%A+8P+%.V6'0==H[+GOC].@X K6HHK*<W.3D^I<596"BBBI&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -D?8"Q
M[#-<Y707/W&_W3_*N?JX$R"BBBJ$%%%% !6OI'W#_O?T%9%;MA'L0>_/YU,M
MAHL4445!04444 %%%% !1110 5SUQ]YL^I_G70UA7T?EN?<Y_.J@)E>BBBK)
M"BBB@ K4T=N&'88_7_\ 5675_2#\Q'M_44I;#6YK4445F4%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D^N6
MEU=W1BF!:5CA0OW<<XV_[/7GMSNYS7HGAS1SI,(@9BQR2?0$]0/;^9R>,XK4
MHKKQ&-E6A&%DDNQE3HJ$G+=A1117(:A1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<+@EB,R!CMP<$DKU.XU1\(:9+XOO#KETI6%"/*7<<;D(V@>JK@EB, OV^\
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MV[^7*RX5_0_S&1QD<KG(Y%<UX8^%EKIB*UPJS3C)8MDIDC&T(>"!V+#.>>.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M DUPFH6K?#F]6ZB#FRGX9000#S\F3G)7[RDX)&5W?>- '8?%+_D'3_\ ;/\
M]&I3?A5,KZ=$ 02ID! .<'S&.#Z'!!^A!IGQ'NEN]*EFC.4D6%E.",AI$(.#
MSTKSSPGJ]YX2B6^"&6SG#$@$[0RL4R3@[&R!VPP(')'R@'N=>5>/O^0S9_\
M;O\ ^CVK0NOC;;*I,44K/Q@/L1>O.6#,1Q['^M.\$^%[FYNGUO4%"R,/D3H1
MN4#. > $^4*V6ZEL$ D V/BE_P @Z?\ [9_^C4H^%O\ R#H/^VG_ *->CXI?
M\@Z?_MG_ .C4H^%O_(.@_P"VG_HUZ *_Q;21M/<H0%#QEP>Z[L #@\[RI[<
M\]CQ^B>#M4OH(YH+L")D7:!<2C QC;A5(!7H0.A&*]8U73$U2)[649212#TR
M,]",@C(/(.." :\OL=6N_ARYM+A&ELRPV.. -Q).TG(!(!)C)'(R" 2S $W_
M  @&L_\ /Y_Y,3__ !-6O"WPZO-/O4U"YE23;NW'>[.<QE!RRC.,CJ>E/O?C
M/%(NRTAD>9CA0X &3P.$9BQSCY1C/J*Z#P,E\ZR7-^0//*LD?0IU!&,?*,;<
M#)/4MABV0#0\3>%8/$<8AG!^4Y5EP'7UP2#P>X((/7J 1P__  @VJ>'A_H%S
MYB!<!&^7EFR=J/NC'KG(/4?6[XV\27_AVZ%TJ![,(!@!MHRR[BQ'W7SPI.5P
M> 3NIMU\;;95)BBE9^,!]B+UYRP9B./8_P!: -CX>>-F\3QOYBA98B-VW[A#
MYVD9)(/!!'/J#S@6O%_@:#Q,H,F5E0$*ZXSWP"#]Y<\XX/7!&3G'^%>C3VJS
MWMT&62ZD!*NNUOE+$L1QC<6/&!TR."*S];\8WWAB]>2Y3?:2,H4J#M"C=C:<
MX\SJ6#<MC (7:0 5[G0M6\)*TUO.)H(@I*N>B1J2?E?.U1@C"-N(QCV[/P/X
MI_X26W%P5VNK%' ^[N !R.^"".O(Z<XR>4U/XR1W"&*SBE,\GRKN"C!8$*0
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M?[#_ *WOC[^WG=L_VO3OC.WYMM '+ZA\)6M&:?39VA8C&TLPZMDCS%.X*!C
M(8Y')YR&:5XSOM&NTTS4@K^<P"NFT-\[;$8;<#;D'@@-SGL%)IOQF2)3'>Q.
MLZLP81*-O!]'<%2.A'/3.><"E;ZC-X\OX+B.-DM;5]VX@$95@_)X^9L(-H+;
M?O#(S0!ZQ116?K_G^1)]DV^?M^3=TSWZ\9QG;GC.,\9H X_6?A.K2&[L)6MY
M/F( R%R1C"E2"@/.?O<'   Q64_BS4?!DB1:AMF@? # @MA -Q4_*21N&=X^
M8C@C):G:%\66TM?LNHQ2"6,* 57YR-HY<2,#N/7/?/0=Z6O:])\1)([&UC=8
M$D!=R <9& S <+M&_ W_ #_7 H ]*\6?\>=S_P!>\W_H#5ROP4_X\Y/^OAO_
M $".NJ\6?\>=S_U[S?\ H#5ROP4_X\Y/^OAO_0(Z /0*\J_YF/\ S_SZUZK7
ME7_,Q_Y_Y]: .U\<>*?^$:MS<!=SLP1 ?N[B"<GO@ 'IR>G&<CDM/\+:OK86
MXN;IH R<*F5<<\!D3RU!(.<Y+#@$=AL?%7PP^M6ZR0KNE@8D $[BI'S #H3D
M*<=>,#DX.?:_&:&)0EU%*LZY#JBKM# X.-S@CZ$9'3)QD@'/^,?AW%H%J]Y-
M.\EP\@"DC"L6.3D?.2<!CDL,_7KZ?X3_ ./.V_Z]X?\ T!:\H\9ZS=>+(FNQ
M&8[*W.5+;AOW,(QW*LP.>G" L"Q)&?5_"?\ QYVW_7O#_P"@+0!P'@#_ )#-
MY_V\?^CUKU6O*O '_(9O/^WC_P!'K7JM 'A6A:%?ZE<W44%PL<Z2-YN)'CWG
M>P+ (O(!SV&-P]:Z#_A -9_Y_/\ R8G_ /B:N^,/#%SH]S_;6F@EF(\R)5SG
M. 3M7[RMU8?>#?.#W5]K\;;9E!EBE5^<A-CKUXPQ92>/8?UH Q[WX8:I?KLF
MN5=0<@/-*PSTS@H>>:[#Q'I4L&D-:JP$D5L@8@D B(*7 .,X95(Y'.<' )K$
MT3Q%J/BR>.>%!!:1.K'.?G&=K+N*_.?O8P %/4[@IKT6:%9E*. 58$$$9!!X
M((/4&@#DOA/=+-I\:*<F-I%;@\$N7Q[\,#QZ^M=A7DC1W?PVE9HU::QDYYX
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M!GZ#TKU.O*O@9_R]?]L?_:E &K\:_P#CSC_Z^%_] DKJO"?_ !YVW_7O#_Z
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MVL5._P"8<8(X!Z@ 'J=%<YX.\4R^(%9Y+=H5 0H6)(</DY!*+D# Z9ZBNCH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "H?LB;_ #]J^9MV[L#=MSG;NZXSSCIFIJ* "BBB
M@ HHHH Y3XI?\@Z?_MG_ .C4H^%O_(.@_P"VG_HUZV]?T1-;@>SE+!)-N2A
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RKQ]_R&;/_ +=__1[5ZK63
MJ'A:VU"9+V5-TL6W:VYAC:Q9> 0#@G/(K6H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".>$3 J?\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\*\1^([J&ZG19Y0JS2
M2.  '(  !Z5ZG\/[I[JQBDD8LQWY9B6)Q(P')YZ4 =%1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YO\
M2/%UUHUPL-O)M4Q*Q&U&Y+,,Y92>@%>D5Y7\5-&GO;I'BB=U$*C*(S#.]SC(
M!YYH N?#?Q==:S<-#<2;E$3,!M1>0RC.54'H37I%>5_"O1I[*Z=Y8G13"PRZ
M,HSO0XR0.>*]4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \KUGX5W5[/+.KQ!9)'899\X9B1G"'GFN\
M\(Z.^C6L=K(063=DJ21\SLPZ@'H?2IY?$=K"2C3Q!E)!!D0$$<$$$]:N6UTE
MTHDC8,IZ,I# X.#R..M $M%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !117E?Q4UF>RND2*5T4PJ<([*,
M[W&< CGB@#U2BO*_A7K,][=.DLKNHA8X=V89WH,X)//->J4 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M?//BC_C[N/\ KO+_ .AFO8/AM_R#X?\ MI_Z,>J=_P#"NUO9'G9Y0TCLQPR8
MRQ).,H>.:Z/0]'31H5M8R2J9P6()^9BQZ #J?2@"_1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P?CSP
M'/X@G6>)D"K&%^<L#D,Q[*>.:[RJ=YK,%D=DLJ(Q&<.ZJ<=,X)''% ''^ _
M<_A^=IY60JT97Y"Q.2RGNHXXKO*IV>LP7IV12H[ 9PCJQQTS@$\<U<H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *\?^,'_ !]I_P!<%_\ 0WKV"N;\2> X/$$@GE9PRH%^0J!@$GNIYYH X/X/
M_P#'V_\ UP;_ -#2O8*YOPWX#@\/R&>)G+,A7YRI&"0>RCGBNDH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH SI?#EK,2[01%F)))C0DD\DDD=:N6UJEJHCC4*HZ*H"@9.3P..M>8:S\5
M+JRGE@5(BL<CJ,J^<*Q SAQSQ7>>$=8?6;6.ZD #/NR%! ^5V4=23T'K0!L4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %<WXD\>0>'Y!!*KEF0-\@4C!)'=ASQ725X_\8/\ C[3_ *X+
M_P"AO0!WGAOQY!X@D,$2N&5"WSA0, @=F//-=)7C_P '_P#C[?\ ZX-_Z&E>
MP4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 >%>(_#EU-=3NL$I5II""(W((+D@@@=*]3^']J]K8Q1R*5
M8;\JP*D9D8C@\]*Z*B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 45XE\1O^/^;_ +9_^BUH^'/_ !_P_P#;3_T6U='U;W.:
M_2YG[7WK'MM%%%<YH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCPG\1+C5[F.UD6,*^[)4,#PC-W8CJ/2M?83Y>;H1[17L>B5\_P#B;_C[N/\
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MC4?<#!MS'CJQ&, Y[YQ[UK*A.*NR%43=CLJ***R+"BH+V]2Q1IY6"H@R2?\
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MJ.C:S'K$8N(3E3U!Z@]U([$?_7&00:O5@U;0T"BBN1\2_$>'1V\F,>;(K$,
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MD84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E?Q4T:>]ND>*)W
M40J,HC,,[W.,@'GFO5** /*_A7HT]E=.\L3HIA89=&49WH<9('/%>J444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%?//BC_C[N/\ KO+_ .AFNF^#_P#Q]O\ ]<&_]#2@#V"BLSQ1
M_P >EQ_UPE_] -?/- 'TS17"_!__ (]'_P"N[?\ H"4?&#_CT3_KNO\ Z ]
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M#-=+\)/^/M_^N#?^AI7H5/X3]#FC\9ZW7DGQ'\)R6<C7X)>*1LL3R4)X /\
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M;_X]$_Z[K_Z ]=O7$?%O_CT3_KNO_H#UQT?C1O/X6>25] >&?^/2W_ZX1?\
MH KY_KZ \,_\>EO_ -<(O_0!71B]D9T=V<U\6_\ CT3_ *[K_P"@/7DE>M_%
MO_CT3_KNO_H#UY)5X;X":OQ'T!X9_P"/2W_ZX1?^@"M*LWPS_P >EO\ ]<(O
M_0!6E7#+=FZV/$OB-_Q_S?\ ;/\ ]%K1\.?^/^'_ +:?^BVH^(W_ !_S?]L_
M_1:T?#G_ (_X?^VG_HMJ[_\ ES\OT.?[?S/;:^?_ !-_Q]W'_7>7_P!#-?0%
M?/\ XF_X^[C_ *[R_P#H9K#";LTK;(Z7X2?\?;_]<&_]#2O6Z\D^$G_'V_\
MUP;_ -#2O6ZG$_&.E\)YM\3?"<DS'48R74* ZGDH%'5?]GN1V.6Z$XX_P_X2
MN->),*C8#@NQPH.,X[DGZ XR,X!KW#4-2CTY#+,P11W8X[$X'<G X Y/:N*E
M^*-I8*8K:)B%)V@*L<9YY(QD@'D_=SZ@5=*K4Y;)7%.$;W;,"7X37: L&B)
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M /IFBN%^#_\ QZ/_ -=V_P#0$H^,'_'HG_7=?_0'H [JBOF:OH;PO_QZ6_\
MUPB_] % &G17C_Q@_P"/M/\ K@O_ *&]<SX7_P"/NW_Z[Q?^AB@#Z&HHKYY\
M4?\ 'W<?]=Y?_0S0!]#45X_\'_\ C[?_ *X-_P"AI7L% !17S-7IGP7_ .7G
M_ME_[4H ]-HKF?B3_P @^;_MG_Z,2O#* /IFBN9^&W_(/A_[:?\ HQZYCXT?
M\NW_ &U_]IT >FT5\S5],T %%>&?$G_D(3?]L_\ T6E'PV_Y"$/_ &T_]%O0
M![G117S-0!],T5X_\'_^/M_^N#?^AI7IOBC_ (]+C_KA+_Z : -.BOF:O7_@
M_P#\>C_]=V_] 2@#NJ*X7XP?\>B?]=U_] >O(* /IFBLSPO_ ,>EO_UPB_\
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M4'H37I%>/_!__C[?_K@W_H:5[!0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9##!&1STJ6B@#F?^%;:?_P \?_(DG_Q=:^CZ'#HR&&W7:I8L1EFY( SEB3T
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M=N"0<89B.H%:=U;+=(T+C*NI5AR,AA@C(YZ5+10!S/\ PK;3_P#GC_Y$D_\
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MMO"-J+G R3U))Y))ZFK5% &9K7AJWUO;]H3?LSM^9EQNQG[I'H*S/^%;:?\
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MY/(&.=865_(T]JK&-J=Y]NEDN,8\QV;&<XW$G&>,XS77?"3_ (^W_P"N#?\
MH:5Q%=O\)/\ C[?_ *X-_P"AI7365J;,H?$CU2^NQ91O.V2L:,QQUPHR<=.>
M*\"UG69-8D-Q,<L>@'0#LH'8#_ZYR237NGB&(RVTZ*"6:&0  9))0X 'K7S[
M6.$2U9=9['1>%_!$WB &5"JQJX4EB<]B< =2 1U(!SUZX["S^$$29\Z5VZ8V
M*$QZYSOS^GXUD>"OB&FC0_99U=@K$H4"GAN2#DKWR<Y.<XXP*G\2?%0W2&&T
M5DW#EVP&'7( !.#T^;.1S@ X-5/VSE9:(4>1*YPVIP)!+)'&=R*[!3D'*@D
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M^?\ Q-_Q]W'_ %WE_P#0S7-A-V:5MD=+\)/^/M_^N#?^AI7K=>2?"3_C[?\
MZX-_Z&E>MU.)^,=+X3P;Q5XD?7IC*Q/EJ2(UZ87/'&3\Q_B.3S[  'AOPI-X
MA++#M C R7) YZ#@$Y.#VQQUZ9R98C$2C AE)!!&"".H(]:ZWP)XW70 \,P9
MHV(8; I(;H>N,@C'?C'3DUURO&'NF2LWJ=!:?!^-#F69F7'1%"'/U)?CVQ^-
M<)XHTV/3+F2VA8LB$ $D$YVC<"0 ,@Y'MC'6NVUKXM*R%;5&#L#\TFT;>G(4
M%LGKUP <<$<5YO+*9278DLQ)))R23U)/K4454O>0Y\NR.B^'/_'_  _]M/\
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MFS%6W1ZW\)/^/1_^N[?^@)7;UQ'PD_X]'_Z[M_Z E=O7/6^-FD/A1YM\8_\
MEW_[:_\ LE>;5Z3\8_\ EW_[:_\ LE>;5V8?^&C"I\3/I*O!O&5H;2\G1L9,
MC-QZ/\X_'#<^]>\UY_\ %/PTUTHU"/),:[74 $! 2=WKP3SUX.> #GFPTU&?
MJ:U5='G.DZ:=3E6V5E5G. 7.%SC@9P>3T'J2!75_\*DN_P"_%_WT_P#\17$5
MW>E?%J:W7;.@E/9@?+/4]<*0>V, =.<UU5?:?9,H\O4C_P"%27?]^+_OI_\
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M5T7Q;_X^T_ZX+_Z&]<17125Z:7D9S=I'TE17C'ASXC7&D 0OB6)1@*W# #.
M&P>.1U!X&!BM/4?BY-,-L$:QD@Y+$N>>A'"@$>X(/IZ\KPT[V-?:QL.^+NH)
M+)%;J<M$K%NF!OVX'7.<+G![$'O7"6ULUTZQ(,L[!0.!DDX YXZTV64RDNQ)
M9B223DDGJ2?6NO\ AEH#7MP+IE_=0Y.2 07QA0,]QG=D9Q@=,@UU*U*GZ&7Q
MR/8*^?\ Q-_Q]W'_ %WE_P#0S7T!7S_XF_X^[C_KO+_Z&:Y\)NS2MLCI_A-J
M@M[A[8XQ,G'!SN3) ] -I8G/H.?7UFOG"*4Q$.I(92""#@@CH0?6NXTKXM36
MZ[9T$I[,#Y9ZGKA2#VQ@#ISFKKT')\R%3J)*S/5Z\)\:Z@FH7DLT9RI8 '@@
M[%"Y!!(()&0?2M+Q%\2)]71H% CC?&=I)<C'*EN!@GK@#C@Y&<\C3P]%PU8J
MDU+1'4_#2V:6^C91D1J[-TX!4KG\V KU?Q-_QZ7'_7"7_P! -<M\*M :SC>\
MD7!FP$R!G8.<@]<,3TXSM!Y!%=3XF_X]+C_KA+_Z :QK2YJOH7!6B?/]>M_"
M3_CT?_KNW_H"5Y)7K?PD_P"/1_\ KNW_ * E=&)^ SI?$=O7'_%.T,]GO&,1
M2(QSZ'*<>^6'X9KL*@OK07L;P-D+(C*<=<,,''7GFN*$N629O)75CYTKW+P)
MJJZC9QE>#$HC8<]4 'H.HP?;.,\5X[KVBOHTS6T@/RGY21C<N>&')X/U.#D'
MD&G:'XBFT1_,@;&<;@1E6 .<$?U&" 3@C-=U6G[6.AA"7*SZ KG_ !WJJZ=9
MR%N3*IC4<]7!'H>@R??&,\UR/_"X7V8\@;]O7>=N['7;MSC/;=G'&>]<;KGB
M*;6W\R=LXSM &%4$YP!_4Y) &2<5A3PTN:[V+E55M#-KV3X76?V>R#YSYKNW
M3I@[,>_W<_CBO*]!T5]9F6VC!^8_,0,[5SRQY' ^HR< <D5[[;6RVJ+$@PJ*
M% Y. !@#GGI5XN>BB*BM;GF'Q1\2/+*=/0D1H%+CIN8C<.<\J 1@<<Y)S@$<
M;I.EOJLJVT6-[GC)P.!DD^P )]?0$UM_$F(I?2D@@,$(R.HV*,CU&01]0:H^
M$O$!T&X6XP2A!5P,9*GTSW! /;.,9 -:TU:FK;V(EK+4ZZR^#Y(4S3 '/S*B
MYXSV8D<D=RO!['OA^/?"T'A\QI"S,SABP=E) &-IP , \]>N..AKK+GXNVZJ
M3''(S=@VU1U]0S$<>QKS;6=9DUB0W$QRQZ = .R@=@/_ *YR2344O:N5Y;%3
MY$M"C7TE7S;7TE48S[/S'1ZG@WC*T-I>3HV,F1FX]'^<?CAN?>M#X;:JNGWB
MA^DRF///!8@KT!SD@#MUSGBNI^*?AIKI1J$>28UVNH (" D[O7@GGKP<\ '/
MEM:P:J4[$2O&1])45Y%H?Q2N+$>7,!,H'!)VOV RV#D<=QDDY+4[6?BK/>*8
MX5$09<$@EG'/)#?*!QQTR.H.<8YOJT[V-?:QL>L)*') ()4X.#T. <'T."#]
M"*?7@WA_Q5-HLQN%);>?WBL3\_.3D\_-SD-U!]02#[AIM^NH1I<("%D4$!@5
M//L?_P!1Z@D8-35HNGZ#A-2/&_B-_P ?\W_;/_T6M'PY_P"/^'_MI_Z+:CXC
M?\?\W_;/_P!%K1\.?^/^'_MI_P"BVKK_ .7/R_0Q^W\SVVLWQ-_QZ7'_ %PE
M_P#0#6E6;XF_X]+C_KA+_P"@&N".Z.A['S_7K?PD_P"/1_\ KNW_ * E>25Z
MW\)/^/1_^N[?^@)7=B?@,*7Q%3XP6A>.&?C:CLI]<N 1^'R'/X5Y?7T%K^CC
M6('M&)4.!R.<$$,..XR.1W'<=:\$O;)[%V@E4JZ'!!_ST]#T(Y'%+"S3C;L.
MJK.YT^F_#2XU&-+B-XBLB@CYFR,]CA",@\$=CQ5G_A4EW_?B_P"^G_\ B*R/
M#'C6;P_\B8:(MDHP[G )##D' P.H[X-=3_PN/_IW_P#(O_V%$_;)Z:H%R6,W
M_A4EW_?B_P"^G_\ B*/^%27?]^+_ +Z?_P"(K*\2>.;C708V(2(G[B]\$D9/
M4G\AD [0:] ^'/BHZO%]GE),T(Y+$$LI)P?7(X!Z]B22:4Y581OH$5!NQV%9
M'B#PM!KJ[9E^88PZX#C!Z9(/')X.1SGK@T[Q)X@3083<2 GG"J.[$$@9[#@D
MGT'<X!\;M_%UQ;W#7JN0[ON9<DH>N%()Y4 X'.0.A!YK"C2E+5:&DYI:'1:S
M\)YH"6MF$B]E8[7Y/3GY3@=\KGGCIGC=0TV33G,4RE&'9ACN1D=B,C@C@]J[
MNV^,+JH$D 9NY5RHZ^A5B./<USOC#Q@?$A0[ BQAL#=N)+8SS@<<# QZ\^G3
M3=6]I+3N92Y+:&;H.M/HTRW,9/RGY@#C<N>5/!X/T.#@CD"O?;:Y6Z194.5=
M0P/(R",@\\]*^=8HC*0B@EF(  &22>@ ]:^AM,L_L,4=OG/EHJYQC.T 9QSC
M.*SQ:6CZE4;ZEFBBBN0V"BBB@ HHHH *Q]8\(VNLN)KB/<P4*#N=> 2<85@.
MI-;%% &/H_A&UT9S-;Q[6*E2=SMP2#C#,1U K3NK9;I&A<95U*L.1D,,$9'/
M2I:* .9_X5MI_P#SQ_\ (DG_ ,76GHOAJWT3=]G39OQN^9FSMSC[Q/J:TZ*
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MTCT%:=% ',_\*VT__GC_ .1)/_BZZ:BB@#"U+P19ZG(UQ-'N=L9.]QT  X#
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MWYF7&[&?ND>@K,_X5MI__/'_ ,B2?_%UTU% !6%J7@BSU.1KB:/<[8R=[CH
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MVNC.9K>/:Q4J3N=N"0<89B.H%;%%% &/H_A&UT9S-;Q[6*E2=SMP2#C#,1U
MK8HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#SOXB>$[G5[A98$W*(@I.Y!R&8X^9@>A%<M_PKF__P">
M7_D2/_XJO;:*WCB9126A#I)NYXE_PKF__P">7_D2/_XJC_A7-_\ \\O_ ")'
M_P#%5[;13^MS\A>QB>7Z=\(9&.;B50H(XC!8D=^6"X/H<-]..>^T/P[#HB>7
M N,XW$G+,0,9)_H, $G &:TJ*SG5G/=E1@D%%%%9E#)8A*"C %6!!!&00>H(
M]*\N\2?"Z6)S)9@/&QX0L RYSGEL J.QSGG!!P2?5**NG4E!Z$RBI'@47A6[
MD(402Y) YC8#GU)  'N>!7;>$OAB8RMQ>XR"<1<$<="Q!(([[1P>,GJM>CT5
MI/$RDK;$JDD>/ZYX"O;JXFE2+*O+(P.^,9!8D'EL]*W/AWX3N=(N&EG3:IB*
M@[D/)93CY6)Z UZ)12EB)./+H-4TG<*\O\5?#&0.9[/#*[DF/Y4VYYX)(!7.
M>."!@<\FO4**BG4E!W0Y14CP*+PK=R$*()<D@<QL!SZD@ #W/ KK?#GPJ=R)
M;PA5!_U:G+'&>"P. .G0DD'JIKU"BM98J;5EH2J21X[K'P]O))Y6BA'EF1RF
M'C VECMP-PP,=NU;WP[\)W.D7#2SIM4Q%0=R'DLIQ\K$] :]$HJ98B3CRZ#5
M-)W"O$O^%<W_ /SR_P#(D?\ \57MM%33JNG>PY04CB/AKX<GT;SOM";=_E[?
MF5L[=^?ND^HKMZ**F<W.5V.*LK!1114C"N6^(FBS:O;K% NYA*&(RHX"L,_,
M0.I%=3151DXM,35U8\2_X5S?_P#/+_R)'_\ %5Z)\.]%FTBW:*==K&4L!E3P
M549^4D=0:ZFBM*E>4U9DQIJ+N%%%%8EA4%[9)?(T$JAD<8(/^>OH>H/(YJ>B
M@#S37OA,06EM'&,Y$;\8&,X#Y.3G@9 XZMQD\C=^#;RT.UH')(S\B[Q^:;AG
MVZU[S16\<5-;ZF;I)GS_ /\ ",W?_/"7_OT_^%:>G?#R]OL'R]BMGF0A<8SU
M7EQG''R^_3FO;:*IXN787L4<IX<^'-OI!$SYEE4Y#-PH(S@A<GGD=2>1D8KJ
MZ**PE)R=V:))&'XTTZ34K22WA&YVV8&0.CJ3R2!T%>7?\*YO_P#GE_Y$C_\
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MR PW)CR%P<_PYXQWP2,8XZ@#TFBIA4E!W0Y14CP*7PK=QDJ8)<@D<1L1QZ$
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MQ18(E"H@P /\]?4]2>3S4]%14JRGN5&"B%?/_B;_ (^[C_KO+_Z&:^@*^?\
MQ-_Q]W'_ %WE_P#0S6N$W9%;9&S\.M+3599K:7.Q[=LX.#Q)&01[@@'T]014
M^O\ PRN+)F:W'FQ<D8(W@ 9P5.,GL-N<XZ#(%2_"3_C[?_K@W_H:5ZW55:LH
M5-!0@I1/!+;PC>7#!%@D!/\ >0H.!G[S8 _$UV_A;X7>0RW%X0V.1$.1G QN
M/0X.<J,@\<D9!]$HK.>)G)6V*5)(*HZY;-=6\T2#+/%(H' R2I '/'6KU%8)
MV9H>)?\ "N;_ /YY?^1(_P#XJO1/AWHLVD6[13KM8RE@,J>"JC/RDCJ#74T5
MM4KRFK,B--1=PHHHK$LRO$'AN'7D$4P/RG*LN P]<$@\'N""/Q (\TU7X6W5
MJV(<2J>X(0C@=0QQUZ8)Z<XKV"BM*=:4-B904CY__P"$9N_^>$O_ 'Z?_"N@
MTKX6W5TV)L1*.Y(<G@] IQUZY(Z\9KV"BM)8J3V)5%&5X?\ #<.@H8H0?F.6
M9L%CZ9( X'8  ?B23JT45@VV[LT2L<QXT\%CQ$%=6"2Q@@$C(8'HI/7&>AYQ
MD\'->6W?@V\M#M:!R2,_(N\?FFX9]NM>\T5K3Q$H*W0B5-2U/%M&^'%WJ!!=
M?*0]6DX/!P?D^]GN,@ ^O(K;\2_#=X8X8K--[+O,CDJI).W'WB..#@#./J23
MZ=13>)FW<2I1L>)?\*YO_P#GE_Y$C_\ BJ]MHHJ*E5U+7*C!1"N!\1_"M+LF
M:U81LQSL;_5\XZ$#*CJ<8([#:*[ZBIA.4'=#E%/<\)O/!-[9XW0N=V?N 2=/
M786Q^/7M19^";V\SMA<;<?? CZ^F\KG\.G>O=J*W^MRMLC/V*.!\.?"M+0B:
MZ82,ISL7_5\9ZDC+#H<8 ['<*[ZBBL)SE-W9I&*6QY;XT\%W>I7<EQ#'N1MF
M#O0=$4'@L#U%'@OP7=Z;=QW$T>U%WY.]#U1@. Q/4UZE16GUB7+RZ;6)]FKW
M"J.N6S75O-$@RSQ2*!P,DJ0!SQUJ]16*=F6>)?\ "N;_ /YY?^1(_P#XJO1/
MAWHLVD6[13KM8RE@,J>"JC/RDCJ#74T5M4KRFK,B--1=PK!\4>#H?$(!?*R*
M"%=<9[X!'=<\XX/H1DYWJ*RC)Q=T4TF>,:K\-+NR)V*)4 )W(1G SQM)!W8'
M09ZX!)K&_P"$9N_^>$O_ 'Z?_"OH"BNA8N78AT4>/Z5\+;JZ;$V(E'<D.3P>
M@4XZ]<D=>,UZ/X?\)6^@@F%3O(P78Y8C.<=@!] ,X&<D5LT5E.M.>Y48*)!>
MV27R-!*H9'&"#_GKZ'J#R.:\VUKX2O&2UJX9<'Y9.&X X# 8))SUV@<<]Z]0
MHI0JRAL$HJ1X)<^$;RW8HT$A(_NH7'(S]Y<@_@:GT[P/>7YVB)E (R9!L SW
M^;!('? )]NE>Z45M];E;8CV*.*\)?#A-**W%P0\RDD ?ZM?0C(!+#KD\#/ R
M :[6BBL)S<W=FBBD%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "LWQ-_P >EQ_UPE_] -:5%-.S
MN#/FVO6_A)_QZ/\ ]=V_] 2NWHK:KB.>-K&<:?*[A1116!H%%%% 'DWQ<B(N
M8WP=IA !QP2';(SZC(S]17#5])45TPQ/+%*QE*E=WN>/^"O +ZJPGN 5@&"
M<@OD9&.^W'5N_1><E?8***RJ574=V7&*B@HHHK,H**** "BBB@ HHHH ****
M /)/BW_Q]I_UP7_T-ZYKPS_Q]V__ %WB_P#0Q7T!171'$VCRV,W2N[A1117.
M:!1110 5\_\ B;_C[N/^N\O_ *&:^@**UHU?9MNQ,X<QY)\)/^/M_P#K@W_H
M:5ZW114U:G/*X1CRJP4445!04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
E110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img63237988_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img63237988_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /6!] # 2(  A$! Q$!_\0
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MJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\
M"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"K
MU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *
MO44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O4
M4 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]
M10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10
M!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU%
M %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %
M'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44
M4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?
M[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1
M_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_L
MJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^
MRH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH
M/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*
M@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_
MOR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#
M^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_
M)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[
M\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\G
MYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR
M?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F
M/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^
M8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_
MPH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC
M_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"
MC^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\
M*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/
M[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH
M_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_L
MJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^
MRH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH
M/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*
M@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_
MOR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#
M^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_
M)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[
M\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\G
MYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR
M?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F
M/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^
M8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_
MPJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC
M_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"
MKU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\
M*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O
M44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ
M]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]1
M0!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU
M% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU%
M%'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44
M 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4
M?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!
M1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_
MLJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'
M^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^R
MH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[
M*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@
M_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ
M#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^
M_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"JU[9QVL*R1L^[=CD_6M>J.
MJ_\ 'JO^^/Y&@ TK_CU;_?/\A5ZJ.E?\>K?[Y_D*O4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %4=5_X]5_WQ_(U>JCJO\
MQZK_ +X_D: #2O\ CU;_ 'S_ "%7JHZ5_P >K?[Y_D*O4 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4=5_X]5_WQ_(U>JCJ
MO_'JO^^/Y&@ TK_CU;_?/\A5ZJ.E?\>K?[Y_D*O4 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD_@* /6JQO$/B?3O#,$,NH-)^^8JBQKN)QU[^X_.MFO+_C'_ *G1_P#>F_\
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MOWT%W;Q3PM<W),<J!U.-W8T =;_PM?P[_<OO^_0_^*K;\.^+M,\3M<+8"<-
M%+B5 O7.,8)]*L_\(SH'_0#TW_P$C_PJU9Z7I^G%S8V-M:[\;_(A5-V.F<#G
MK0!R1^*WAP$C;>G'<0CG_P >I/\ A:_AW^Y??]^A_P#%5T!\)>'F8DZ+8Y/)
M_<K7EOB_2[&S^(UA9VUI#%;.8-T2( IRV#Q[T =E_P +7\._W+[_ +]#_P"*
MKIK/7K*^\/?VW"9/L?E/*<KAL)G=QZ_*:@_X1#P[_P! 6Q_[\BG:Q:P67A#4
MK>UA2&%+*8+'&N /D;H* &^'?%.G^)XYWL!,! 0'\U O7.,<GTK:KS'X._\
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M<#^=)HFLVNOZ8E_9>9Y+DJ!(N#D'!K ^)G_(C7?_ %TC_P#0Q3?AA_R)%O\
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M.2.E;G@.[GUSP%Y-Q(6D026N]NXQQ^0('X4 <M\'H0VIZG.<;DA1!_P)B?\
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M =+X*A$'@S247&#;A^/]KYOZUO5S/P_O8[WP5IY1LM"IA<?W2IZ?E@_C734
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MU?V;6(N92)864J%20]L]@<'_ (#0![M7C_PE_P"1FU'_ *]C_P"AK7L%>/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4>@&*=0!PGQ9!/A&' Z7B9_[Y>M?P#QX&TO_ *YM_P"AM71LJNI5@"#U!%*
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MI,@'[HQC&:7X2:2;?1[K4Y%P]U)LC)'\"]Q]23_WS7HC*KJ58 @]010
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M.V1SM/"_H,_C77.BR##J&'H1FG4 %>9_%W2?,L[+5HU^:)C!*1_=/*_D<_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 51U7_ (]5_P!\?R-7
MJHZK_P >J_[X_D: #2O^/5O]\_R%7JHZ5_QZM_OG^0J]0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6TUJQUN_NT,X2XBNI-P?(_\ K$>HR.: /4**YCQIXBFT30HI+$ WEY(L-N6
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MJ&I-8:OHY!U#3WW+&<?.,@\9XR".AZY- $6_XA6!6XF33-0BR-]O#E7 [X)
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M_+(-ZQ[9V)Z,O#$_7&?QK%\ W-YK-WK&N7$\QM[BX,=M$SG:JCG@=.A4?@:
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MU;;MC,!]0<?44 =Q17!Z/X3CO+&TU2Q\4ZI)=,%=IO/WHQX)4KU]L$_6N\H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "J.J_\ 'JO^^/Y&KU4=5_X]5_WQ_(T &E?\>K?[Y_D*O51TK_CU
M;_?/\A5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH S/$6JKHOA^]U D;H8CLSW<\*/S(K@_"?@O5)=!@OH
MO$5Y8->?OFBB7KGH2<C)(P?QKT'5=(L=;LOL>HPF:#<'V;V7D=.5(-6XHD@A
M2*)0L:*%51T ' % 'E'B;1=0\):EI?B.75;C4FBG$;M*N&5>3MSD\$;A^-;/
MQ!E2;4/"<L;!D>\#*P[@E,&NVU/2[/6+%[*_@$UNY!9"Q'(.1R""*JS>&])N
M(=/AFM-Z:>0;4&1_W>,8YSST'7/2@!OBO_D4=8_Z\Y?_ $$UG_#S_D1-,_W9
M/_1C5T-W:PWMI-:W";X)D,<BY(RI&",CFH].T^UTJPBLK*+RK:+(1-Q;&22>
M22>I- '%^$/^2A^*O]\?^A&J^DW<7A_XH:S;Z@X@34 )())#A6YR!G\6'U&*
M[>TT73[#4;N_MK?R[J[.9WWL=_X$X'X4S5] TO78ECU*SCG"?=)R&7Z,,$4
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MN)7!/Y!C71:9H6EZ,"-/L8+<L,%D7YB/<GDT:IH>G:R;<ZA;>?\ 9W\R(%V
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M!P?K0!R=]J]GJWQ;T;[%*)DMU:)I%Y4MAR0#WQD5'XIT[35^)EM)KT0.F7L
M57>1D57 QR01CM[?-7=1>&=&@GLIH;%(Y+$,+<HS )GKP#@D^IS5K4M*L=8M
M#:ZA:QW$)YVN.A]0>H/N* .8F\$^!K:W^T3VUO'#C/F/>R!<?7?6CK^M6?A/
MPLDMJJ$"-8;*('(8X^7Z@#G_ /75>'X<^%H9A*--W8.0KS.RC\,\_C6Q>:!I
M>H7=G=75J));/FWR[!4_X"#CL.H["@#S&PL+[X>ZEI>M7JA[:^0Q7@"#,)8[
ML<>@ /']UAZ5ZI?ZK8Z9IK:C=W"QVB@$R@%A@D 8QDG.1TIVHZ;9ZM8R65]
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MZAX1OUM?,.9+*;F)OIU_(].Q% '=UYW>RQP?&>UDED2-!9G+.P ^ZW>O1!G
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M8X@\FZ.0MDXRQ.<\]ZSQ\-_"HE\S^SFQG.PSR8_]"K:NM"TN]TI-,N+*)[)
M D0& N.F,<@^XH \^\5Z-:>#8XM:\/7[V<[RJ/L@EW)*#Z#J1]<CZ5Z= [R0
M1O(FQV4%E]#CD5S^G> _#FF7:74&G@S(<HTLC.%/J 3C-=)0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4
M=5_X]5_WQ_(U>JCJO_'JO^^/Y&@ TK_CU;_?/\A5ZJ.E?\>K?[Y_D*O4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% $4UK;W&//@BEQTWH&Q^=/C
MC2) D:*BCHJC %.HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J,01"8S")/-
M(P7VC=CTS4E% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !13)98X4+RR
M)&@ZLYP*2&X@N%+031R@<$HP;'Y4 24444 %%%% !1110 4444 %%%% !111
M0 4444 %%,FFBMX6FGE2*)1EG=@JCZDT12QS1++$ZR1N,JZ'((]0: 'T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!7%C:"3S!:P"3^\(QG
M\ZL444 1I!#'(\B1(KO]YE4 M]3WJ2BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CD@BF*F6)'*'*EE!
MVGU%244 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% #)(HYDV2QJZG^%AD4V&V@MP1!#'
M$#UV(%_E4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
MCJO_ !ZK_OC^1J]5'5?^/5?]\?R- !I7_'JW^^?Y"KU4=*_X]6_WS_(5>H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HKFWBN[
M66VF7=%*A1U/=2,$5+10!YEIT7B/X?7%Q:1Z9+J^D2.9(V@R60].@!QQC(QC
MT/6MBV\3^(M;O;>'3_#TUE;>8IGN;T$83/S!00.>H[_A7:T4 <-XJTG5;#Q1
M:>*=&MC=M&GE7-LOWF7D9 [\'\" <&J^J>)=:\1:=+I6E>'-0MY;E3%+-=)L
M2-3PW/T__57H-% '/V^B?V/X%DTB#,LB6<B_*,EW8$G'U).*K?#RTN;+P;:P
M7=O+!,'D)CE0JPRQ['FNIHH \[^**SM<^'EM65;@W3")FZ!LI@G\:FNO&7B
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ JCJO\ QZK_ +X_D:O51U7_ (]5_P!\?R- !I7_ !ZM
M_OG^0J]5'2O^/5O]\_R%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "J.J_\>J_[X_D:O51U7_CU7_?'\C0 :5_QZM_OG^0
MJ]5'2O\ CU;_ 'S_ "%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ%CJ\&G>)](^P-.<1SQME,YQ[\=.0>* .\HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% %ZBJ/]E0?WY/S'^%']E0?WY/S'^% %ZBJ/]E0?WY/S'^%']E0?WY/S'^%
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M4 7J*H_V5!_?D_,?X4?V5!_?D_,?X4 7J*H_V5!_?D_,?X4?V5!_?D_,?X4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "J.J_P#'JO\ OC^1J]5'5?\ CU7_ 'Q_(T &E?\ 'JW^^?Y"
MKU4=*_X]6_WS_(5>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *HZK_QZK_OC^1J]5'5?^/5?]\?R- !I7_'JW^^?Y"KU4=*
M_P"/5O\ ?/\ (5>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *HZK_QZK_OC^1J]5'5?^/5?]\?R- !I7_'JW^^?Y"KU4=*_
MX]6_WS_(5>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBO;>X4&5!@D'IGUP0,?4T >B455TR[^WZ39WA 7[1 DN!VW*#_6K5 !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=NH_\](_\_A1MU'_ )Z1_P"?PJ]10!1VZC_STC_S^%&W4?\ GI'_ )_"KU%
M%';J/_/2/_/X4;=1_P">D?\ G\*O44 4=NH_\](_\_A1MU'_ )Z1_P"?PJ]1
M0!1VZC_STC_S^%&W4?\ GI'_ )_"KU% %';J/_/2/_/X4;=1_P">D?\ G\*O
M44 4=NH_\](_\_A1MU'_ )Z1_P"?PJ]10!1VZC_STC_S^%&W4?\ GI'_ )_"
MKU% %';J/_/2/_/X4;=1_P">D?\ G\*O44 4=NH_\](_\_A1MU'_ )Z1_P"?
MPJ]10!1VZC_STC_S^%&W4?\ GI'_ )_"KU% %';J/_/2/_/X4;=1_P">D?\
MG\*O44 4=NH_\](_\_A1MU'_ )Z1_P"?PJ]10!1VZC_STC_S^%&W4?\ GI'_
M )_"KU% %';J/_/2/_/X4;=1_P">D?\ G\*O44 4=NH_\](_\_A1MU'_ )Z1
M_P"?PJ]10!1VZC_STC_S^%&W4?\ GI'_ )_"KU% %';J/_/2/_/X4;=1_P">
MD?\ G\*O44 4=NH_\](_\_A1MU'_ )Z1_P"?PJ]10!1VZC_STC_S^%&W4?\
MGI'_ )_"KU% %';J/_/2/_/X4;=1_P">D?\ G\*O44 4=NH_\](_\_A1MU'_
M )Z1_P"?PJ]10!1VZC_STC_S^%&W4?\ GI'_ )_"KU% %';J/_/2/_/X4;=1
M_P">D?\ G\*O44 4=NH_\](_\_A1MU'_ )Z1_P"?PJ]10!1VZC_STC_S^%&W
M4?\ GI'_ )_"KU% %';J/_/2/_/X4;=1_P">D?\ G\*O44 4=NH_\](_\_A1
MMU'_ )Z1_P"?PJ]10!1VZC_STC_S^%&W4?\ GI'_ )_"KU% %';J/_/2/_/X
M4;=1_P">D?\ G\*O44 4=NH_\](_\_A1MU'_ )Z1_P"?PJ]10!1VZC_STC_S
M^%&W4?\ GI'_ )_"KU% %';J/_/2/_/X4;=1_P">D?\ G\*O44 4=NH_\](_
M\_A1MU'_ )Z1_P"?PJ]10!1VZC_STC_S^%&W4?\ GI'_ )_"KU% %';J/_/2
M/_/X4;=1_P">D?\ G\*O44 4=NH_\](_\_A1MU'_ )Z1_P"?PJ]10!1VZC_S
MTC_S^%&W4?\ GI'_ )_"KU% %';J/_/2/_/X4;=1_P">D?\ G\*O44 4=NH_
M\](_\_A1MU'_ )Z1_P"?PJ]10!1VZC_STC_S^%&W4?\ GI'_ )_"KU% %';J
M/_/2/_/X4;=1_P">D?\ G\*O44 4=NH_\](_\_A1MU'_ )Z1_P"?PJ]10!1V
MZC_STC_S^%&W4?\ GI'_ )_"KU% %';J/_/2/_/X4;=1_P">D?\ G\*O44 4
M=NH_\](_\_A1MU'_ )Z1_P"?PJ]10!1VZC_STC_S^%&W4?\ GI'_ )_"KU%
M%';J/_/2/_/X4;=1_P">D?\ G\*O44 4=NH_\](_\_A1MU'_ )Z1_P"?PJ]1
M0!1VZC_STC_S^%&W4?\ GI'_ )_"KU% %';J/_/2/_/X4;=1_P">D?\ G\*O
M44 4=NH_\](_\_A1MU'_ )Z1_P"?PJ]10!1VZC_STC_S^%&W4?\ GI'_ )_"
MKU% %';J/_/2/_/X4;=1_P">D?\ G\*O44 4=NH_\](_\_A1MU'_ )Z1_P"?
MPJ]10!1VZC_STC_S^%&W4?\ GI'_ )_"KU% %';J/_/2/_/X4;=1_P">D?\
MG\*O5#<7=M:)ON9XXE]78"DVDKL:3;LBOMU'_GI'_G\*-NH_\](_\_A63>>-
M=-M\K;B2Y;_9&U?S/^%<]>>-=3N,K ([9#_=&YOS/^%<=3'T*?6_H=M++L14
MZ6]3M)'O84+RSP(@ZLQ  K%N_%D5J2JW23L.T2Y'YXQ7#W%W<7;[[B>25O5V
M)ID<4DSA(HV=ST51DFN"IFLWI3C8]&GE$(ZU)7_ Z.X\;:C)D0".(>I4,?\
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M=NH_\](_\_A1MU'_ )Z1_P"?PJ]10!1VZC_STC_S^%&W4?\ GI'_ )_"KU%
M%';J/_/2/_/X4;=1_P">D?\ G\*O44 4=NH_\](_\_A1MU'_ )Z1_P"?PJ]1
M0!1VZC_STC_S^%&W4?\ GI'_ )_"KU% %';J/_/2/_/X4;=1_P">D?\ G\*O
M44 4=NH_\](_\_A1MU'_ )Z1_P"?PJ]10!1VZC_STC_S^%&W4?\ GI'_ )_"
MKU% %';J/_/2/_/X4;=1_P">D?\ G\*O44 4=NH_\](_\_A1MU'_ )Z1_P"?
MPJ]10!1VZC_STC_S^%&W4?\ GI'_ )_"KU% %';J/_/2/_/X4;=1_P">D?\
MG\*O44 4=NH_\](_\_A1MU'_ )Z1_P"?PJ]10!1VZC_STC_S^%&W4?\ GI'_
M )_"KU% %';J/_/2/_/X4;=1_P">D?\ G\*O44 4=NH_\](_\_A1MU'_ )Z1
M_P"?PJ]10!1VZC_STC_S^%&W4?\ GI'_ )_"KU% %';J/_/2/_/X4;=1_P">
MD?\ G\*O44 4=NH_\](_\_A1MU'_ )Z1_P"?PJ]10!1VZC_STC_S^%&W4?\
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MT&*FHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^>:WCF>'>[:^1SRRO$+9)_,[NBN2B\>69_UUG.G^X0W\\5?B\8Z-)]Z>2/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ***SM1US3]+!^TW"^9_SS7YF/X=OQ
MJ93C!7D[(J$)3=HJ[-&J]W?VMA%YEU.D2]MQY/T'4UQ&I>-[N?*6,8MT_OM\
MSG^@_6N9FGEN93+/*\DAZLYR:\RMFD(Z4U?\CU:&4SEK5=E^)V6I>.E&8].@
MS_TUEZ?@/\:Y.]U*\U&3?=W#RGL">!]!T%2:?H]_J;8M;=G7NYX4?B:ZW3?
MT$6'U"8S-_SSCX7\^I_2N*V*QGI]R.Z^$P7K][.$H ).!R:]=CTG3H0!'86R
MX[B)<_GBK211QC$:*H_V1BMUE,NL_P #G><1Z0_$\?CLKN7_ %=K,_\ NQDU
M:30=6D^[IUP/]Z,K_.O6**U64PZR9D\XGTBCS!/">M/_ ,N>T>K2*/ZU:C\$
M:L_WC;I_O2'^@->BT5HLKH+=LR>;5WLE_7S.#C\!79_UEY O^ZI/^%6H_ *#
M_6:BQ]EBQ_6NRHK59=AU]G\69/,L2_M?@CEH_ FG+_K+BY;Z%0/Y59C\&:.G
MWHI7_P!Z0_TQ7045HL'07V$9O&XA[S9DQ^&-&C^[81G_ 'F9OYFK]M96MF"+
M:VBASUV(!FIZ*UC2A'X8I?(QE5J3^*3?S"BBBM#,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG\*/[0?_ )]9/\_A0!>HJC_:#_\ /K)_G\*/[0?_ )]9/\_A0!>HJC_:#_\
M/K)_G\*/[0?_ )]9/\_A0!>HJC_:#_\ /K)_G\*/[0?_ )]9/\_A0!>HJC_:
M#_\ /K)_G\*/[0?_ )]9/\_A0!>HJC_:#_\ /K)_G\*/[0?_ )]9/\_A0!>H
MJC_:#_\ /K)_G\*/[0?_ )]9/\_A0!>HJC_:#_\ /K)_G\*/[0?_ )]9/\_A
M0!>HJC_:#_\ /K)_G\*/[0?_ )]9/\_A0!>HJC_:#_\ /K)_G\*/[0?_ )]9
M/\_A0!>HJC_:#_\ /K)_G\*/[0?_ )]9/\_A0!>HJC_:#_\ /K)_G\*/[0?_
M )]9/\_A0!>HJC_:#_\ /K)_G\*/[0?_ )]9/\_A0!>HJC_:#_\ /K)_G\*/
M[0?_ )]9/\_A0!>HJC_:#_\ /K)_G\*/[0?_ )]9/\_A0!>HJC_:#_\ /K)_
MG\*/[0?_ )]9/\_A0!>HJC_:#_\ /K)_G\*/[0?_ )]9/\_A0!>HJC_:#_\
M/K)_G\*/[0?_ )]9/\_A0!>HJC_:#_\ /K)_G\*/[0?_ )]9/\_A0!>HJC_:
M#_\ /K)_G\*/[0?_ )]9/\_A0!>HJC_:#_\ /K)_G\*/[0?_ )]9/\_A0!>H
MJC_:#_\ /K)_G\*/[0?_ )]9/\_A0!>HJC_:#_\ /K)_G\*/[0?_ )]9/\_A
M0!>HJC_:#_\ /K)_G\*/[0?_ )]9/\_A0!>HJC_:#_\ /K)_G\*/[0?_ )]9
M/\_A0!>HJC_:#_\ /K)_G\*/[0?_ )]9/\_A0!>HJC_:#_\ /K)_G\*/[0?_
M )]9/\_A0!>HJC_:#_\ /K)_G\*/[0?_ )]9/\_A0!>HJC_:#_\ /K)_G\*/
M[0?_ )]9/\_A0!>HJC_:#_\ /K)_G\*/[0?_ )]9/\_A0!>HJC_:#_\ /K)_
MG\*/[0?_ )]9/\_A0!>HJC_:#_\ /K)_G\*/[0?_ )]9/\_A0!>HK.DU7R8S
M)+ R(.K,< 5B7OCBVA!6VMS,_J6PH_3FLJM>G25YNQM2H5*SM!7.LZ5AZEXK
MTS3\HLGVB4?P1<@?4]*X74=?U'5,B><K$?\ EE'\J_\ U_QK.1'D<(BEF/ 5
M1DFO*K9JWI27S9ZU#*4M:S^2_P S=U+Q=J5_E(W%M$?X8CS^+=?RQ6"22222
M2>I-;5GX8OIR&GC>"/W7+?E74Z;I=AIF&CTZ224?\M9?F/X<8'X5A'"8G$OF
MJ.WK_D;SQF%PRY::N_+_ #.3TWPSJ>I898?)B/\ RTE^4?@.IKK]-\':=98>
MX!NI1_?&%'_ ?\<UJ?V@_P#SZR?Y_"C^T'_Y]9/\_A7IT<OHTM6KOS/+KYC6
MJZ)V7D75544*JA5 P !@"EJC_:#_ //K)_G\*9+JP@C,DT+1H.K.< ?B:[DC
M@-&BLV+5EN(Q)#"9$/1D;(/XBI/[0?\ Y]9/\_A0!>HJC_:#_P#/K)_G\*/[
M0?\ Y]9/\_A0!>HJC_:#_P#/K)_G\*/[0?\ Y]9/\_A0!>HJC_:#_P#/K)_G
M\*/[0?\ Y]9/\_A0!>HJC_:#_P#/K)_G\*/[0?\ Y]9/\_A0!>HJC_:#_P#/
MK)_G\*/[0?\ Y]9/\_A0!>HJC_:#_P#/K)_G\*/[0?\ Y]9/\_A0!>HJC_:#
M_P#/K)_G\*K3>(+:W.)@$/H6Y_*@#7HKF9O&=LG^JMI)#[MM'\JR[GQ?J$N1
M"L4 [$#<?UX_2@#NJHW.LZ=:9\V[C!'\*G<?R%>>7.H7EW_Q\7,L@]"W'Y=*
MK4 =I<^,[5,BVMY)3ZL0H_K61<^+-2FR(S' O^PN3^9S67#IUY<#,5K*X]0I
MQ^=7X?#EX_\ K08Q[*6- %7^VM3S_P ?T_\ WV:?_;VJ _\ '[+^E:J^&[?:
M-PNR>Y  _I2'PW#GC[5C_='^% &</$>K Y^V-_WRO^%/'B?5P<F[!]C&O^%6
MSX:'9Y_^_=,_X1F3'$TG_?G_ .O0!$/%6J@\S(?8QBGKXMU0'DPGZI2'PU/C
MB1L_]<C33X:NL<-^:&@"9?&.I#K';-]4/^-/7QG?_P 5O;'Z!A_6JA\-WO;:
M?J&_PII\.7X_A4_3/^% &@OC2ZQ\UK"?H2*>/&LV/FLD)]G(_I64?#VHC_EE
MGZ9_PI#H&I#_ )=R: -D>-CCG3P3[3?_ &-31>-8"1YMG(H[['#?X5SQT+4P
M?^/1S^(J.32-0C&6LYL>RY_E0!VL'B?2IN#<&,^DBD?KTK2AN[:Y&8)XI/\
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M^?PH O451_M!_P#GUD_S^%']H/\ \^LG^?PH O451_M!_P#GUD_S^%']H/\
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M]H/_ ,^LG^?PH_M!_P#GUD_S^%>M1PE*C\*U[GCUL76K?&].W0O451_M!_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!1_6MBVT73;3!BM(\C^)AN/YF@#SRWL+N[/^CVTL@]54X_.M>V\(ZA-@S-%
M/1FW']/\:[O&!@44 <Y;>#K*/!N)I9CZ#Y1_C^M:]MI5A:8\BTB4C^+;D_F>
M:N44 %%%% !1110 4444 %%%% !1110 4444 %%%% #)(HYEVRQHZ^C#-9\_
MA[2I\[K-%/K'E?Y5IT4 <U/X,M'R8+F6,_[0##^E9L_@Z^3F&:&4>A)4_P"?
MQKMZ* /-I]"U2WSOLY"!W0;OY50='C;:ZLK>C#!KUBF211S+MEC1U]&&: /*
M <'(ZU<@U;4+;_57DP'H6R/R-=W/X>TJ?.ZS13ZQY7^59L_@RT?)@N98S_M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIR+YOQ13_2NA;P# ?NW\@^L8/]:0^ 8L<:@^?^N0_P :/JV.75_?_P $/K6
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTW@J'^&]D'U0'^M1-X);^&_!^L6/ZT 9Z^+=47&6B;ZI_A4J^,M1&-T5LW_
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M>QC;_"G+XETAC@7@_&-A_2O.R"#@C!]Z2@#T;_A(M)_Y_$_[Y;_"G_V]I?\
MS^Q?G7FU% 'I:ZWIC#B^A_%L4HUC32<?;K?\9!7F=% 'I_\ :NG?\_\ :_\
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MO_'JO^^/Y&KU4=5_X]5_WQ_(T &E?\>K?[Y_D*O51TK_ (]6_P!\_P A5Z@
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M?^M$>/.<J\K+8?X(\%?;S'JFIQ_Z*#F&%A_K?<_[/\_IU]4  &!P*0 *
M. !2UY%>O*M+FD=U.FJ:L@HHHK$T"BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&574JP!!Z@BLZXT#3+G.^T
M13ZQ_+_*M*B@#E[CP7 QS;W<B>SJ&_EBH%\$OGYK]1](L_UKKZ* .2_X0G_J
M(?\ D'_[*C_A"?\ J(?^0?\ [*NMHH Y1?!*8^:_8_2+']:7_A"H_P#G^?\
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MX% '4>&)#+X4TASG)LXLY_W!6K532[0Z?I%E9$@FW@2(D=]J@?TJW0 4444
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MSW_K1'G3G*O+ECL1^#?"L.H2K?ZH0MFIRD1ZRGW_ -G^=>KK>VBJ%610 ,
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M/!_,5V6F>(O#FK86WN(%E/\ RRE&QL^G/7\,UP5,+5I_$CIA6A/9FS]NMO\
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MO_SQ3\J/LEO_ ,\4_*@!OVZV_P">H_(T?;K;_GJ/R-.^R6__ #Q3\J/LEO\
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M\J/LEO\ \\4_*@!OVZV_YZC\C1]NMO\ GJ/R-.^R6_\ SQ3\J/LEO_SQ3\J
M&_;K;_GJ/R-'VZV_YZC\C3OLEO\ \\4_*C[);_\ /%/RH ;]NMO^>H_(T?;K
M;_GJ/R-.^R6__/%/RH^R6_\ SQ3\J &_;K;_ )ZC\C1]NMO^>H_(T[[);_\
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M_GJ/R-.^R6__ #Q3\J/LEO\ \\4_*@!OVZV_YZC\C1]NMO\ GJ/R-.^R6_\
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MGZ9J2ZE=75SJ-ZG*27#9"GU ]?J376T4 %%%% !1110 4444 %%%% !1110
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M3^)'3"K">S+]%%%8F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 51U7_CU7_?'\C5ZJ.J_P#'JO\ OC^1H -*_P"/5O\ ?/\ (5>JCI7_
M !ZM_OG^0J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!5U'3K35;)[2\A66%^H/4'U![&O&_%'A&[\.W&\;IK%S^[F Z>S>A_G7
MMU1W%O#=6[P7$:R12#:R,,@BNG#8J5%^78QJT547F>!Z-K5[H5\MU92;3T=#
M]UQZ$5[/X=\2V7B*S\VW;9.@_>P,?F0_U'O7G'B_P1-HK/>V :73R<D=6A^O
MJ/?\_?E["_NM,O([NSF:*9#D,O\ (^H]J]2K1IXN'/!Z_P!;G'"I.A+EEL?1
M%%<-IWQ-TR6TC_M"*:&YQA_+3<A/J.<U?3XB>'6&3<S+[&%OZ5Y+PM9.W*SM
M5:F^IU5%<VOCWPTY &I $^L,@_\ 9:G3QGX=?.-5AX]0P_F*ET*J^R_N*]I#
MNC=HK(7Q3H+XQJ]GSZR@?SJ=->T>3.S5K%L>EPA_K4NG-;ICYH]S0HJJNI6#
M@%+VV8'H1*IS^M3K+&YPDB,?0,#4M-;CNA]%%%(84444 %%%% !1110 4444
M %%%% !1110 445F:YKEIH&G-=W3<](XP?FD;T'^-.,7)V6XFTE=B:]KUIX?
MT\W5TV6/$40/S2-Z#^I[5XCK&L7>N:B]Y=OEVX51]U%[ >U.UK6KS7=0>[NW
MR3PB#[J+Z"MGP?X0E\07'VFY#1Z=&WS-T,A_NC^IKW*%&&%ASSW_ *T1Y]2I
M*M+ECL/\&^#Y->G%W=JR:=&W)Z&4C^$>WJ?\CV&**."%(845(T 5548  ["D
M@@BMH$@AC6.*-0JHHP !4E>5B,1*M*[V.RE25-604445SFH4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=I15.QU73]23=97D$_J$<$CZCJ*N5RM-.S-DT]@HHHI#"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU#X62#+:;J"MZ)<+C_QX?X5U+&8>JK37WF+P]6&L1^G_ !4'"ZEIV/5[=O\
MV5O\:ZK3_&>@:C@1ZA'$Y_@G_=G]>#^!KRC4/!^O:;DS:=*Z#^.']X/TZ?C6
M(002""".H-#P6'JJ\']P+$58:2/H]6#*&4@@\@CO2U\]V&L:CI;AK*]F@P<[
M4<[3]1T/XUZ;X8^(-MJ6RTU39;79X67I'(?_ &4_I_*N*O@*E-<T=4=%/$QF
M[/0[>BBBN$Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 17%O#=V[P7$22Q.,,CC((KS+Q/\.Y;7?>:*&F
M@ZM;'ET_W?[P]NOUKU*BMZ.(G1=XF=2E&HK,^< 6C?(RKJ?H0:[_ ,,?$62W
MV6>MEI(NBW0&67_>'<>_7ZUT_B;P38Z\&N(=MM?_ //51\K_ .\/Z]?K7DNJ
MZ1?:+=FVOH&C?^$]5<>H/<5Z\:E'%QY9;_C\CA<:E!W6Q[_!/%<P)/!(DL3C
M*NAR"/8U)7A/A_Q1J'AZ?-N_F6['+V[GY6^GH??^=>O:#XET_P 0V^^UDVS*
M,R0/PZ_XCW%>9B,).CKNCKI5XU-.IL4445R&X4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 51U7_CU7_?'\C5ZJ.J_\>J_
M[X_D: #2O^/5O]\_R%7JHZ5_QZM_OG^0J]0 4444 %%%% !69JWA[2=<CVZA
M8Q3'&!)C#CZ,.:-?TR?5]'FL[:]DLYV*LD\><J00>Q'I7 M=>/+3Q%#X=76+
M.6X> S+,T8("9(^8[,YX]#VH 9HUM-X/^)L>B6=S)+I]XA8Q,<X!4D$^X*]?
M2O4988IMOFQ))M.1N4'!KE/#7@R32]4EUG5KXW^JR CS,?*F>.,]\<=L#C%3
M>(;'Q4=36]T#4(!#Y01[2X'RD@GD<>X].E $_BG0=+U#P_?-<6D >.!Y$F"
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MWG[OIC.*OT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBU140N;<@$3Q$'H0XJ7K4V&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *1E5UVLH8>A&:6B@"L^GV4N?,M+=
M\]=T8.?TJ!]!T>0Y?2;%CZFW0_TK0HJE.2V8N5=C+7PWH:# T>P_&W4_S%2K
MH>DHNU=+LE'H+=!_2K]%/VDWU%RQ[%5=,L% "V5L .PB7_"I1:VZ@ 01 #H
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M\G?X6ZP/N7EBWU9Q_P"RFJK_  V\0)]U;9_]V7_$"O8J*M9A678EX6F>)R>
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MY^(_R_\ K4 7J*H^5J/_ #\1_E_]:CRM1_Y^(_R_^M0!>HJCY6H_\_$?Y?\
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MY^(_R_\ K4 7J*H^5J/_ #\1_E_]:CRM1_Y^(_R_^M0!>HJCY6H_\_$?Y?\
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MY^(_R_\ K4 7J*H^5J/_ #\1_E_]:CRM1_Y^(_R_^M0!>HJCY6H_\_$?Y?\
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MY^(_R_\ K4 7J*H^5J/_ #\1_E_]:CRM1_Y^(_R_^M0!>HJCY6H_\_$?Y?\
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MY^(_R_\ K4 7J*H^5J/_ #\1_E_]:CRM1_Y^(_R_^M0!>HJCY6H_\_$?Y?\
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MY^(_R_\ K4 7J*H^5J/_ #\1_E_]:CRM1_Y^(_R_^M0!>HJCY6H_\_$?Y?\
MUJ/*U'_GXC_+_P"M0!>HJCY6H_\ /Q'^7_UJ/*U'_GXC_+_ZU %ZBJ/E:C_S
M\1_E_P#6H\K4?^?B/\O_ *U %ZBJ/E:C_P _$?Y?_6JQ;K<*K>>ZN<\;?_U4
M 34444 %%%% !5'5?^/5?]\?R-7JHZK_ ,>J_P"^/Y&@ TK_ (]6_P!\_P A
M5ZJ.E?\ 'JW^^?Y"KU !1110 4444 %%%% !7*>(=9\2Z/JPDLM&_M+2S&,B
M+/F*_.>F3Z=C75TR9#+!)&K;&92H;&<9'6@#SI_'&N^)-.D@T+PY.#,#%]J9
M\HF1@X. ,\]SQ73>#?#9\-^'Q93,LD\KF6;'*[B ,#V  _6K7AC01X;T.+31
M<?:"C,QDV;-Q)STR?YUL4 >6V+ZM\.M7OK<Z7/>Z/<R;XG@!.WT_''!!QG'%
M27IU7XB:K8P'3+BPT6VD\R5[@$&3UQ[XR!C.,DFO3J* $ "@   #@ 4M%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %4=5_X]5_WQ_(U>JCJO_'JO^^/Y&@ TK_CU;_?/\A5
MZJ.E?\>K?[Y_D*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU .QHKF_#WC&UUNXDL+B"2PU2+A[2?J?7:>,_P ZZ2@ HHHH **** "BBB@
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MU[*DUFV?G@0X!_#!'MCZB@#;\17;>&O'=IK]U$\FFSVOV2215SY)W9SC\O\
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MKEM+M[[Q'XDAU^^LY+*RLD9+&"9<2.6&"[#MQT'T_$ ["BBB@ HHHH ****
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MZ:5U34HMMR2SVUJ6++:J><<_Q>] '=4444 %%%% !1110 5!<WEK9A3=7,,
M;A3+(%S],U,3A2<$X["N T;PI'XJBFUOQ-%/)<7+L(;=G9!;Q@D  #'/'?\
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M'^-6UN2-GTC5%2.XD7GRI!P#],#/XGT% #E\3:WX8O8K3Q;%%/92G;'J,"<
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MCKFNSMJ]Y&MGIDD06WM,99SP3(6QG'4#U!_$]30    , =!10 4444 %%%%
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M;*_665E(\ME9"PQSC<!G\*Y[PGJ!\+:G+X2U0^6HD+V$[<+*C'IGUS^N1Z4
M:&@^+[A]4.A^(;5;'51_JR/]7./]D^I_7]*3XBX&D:;(3CR]3@89_P"!5?\
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M_C+P[;:A]AFU6!;@-M(Y*J?0MC:/Q-<]K<TGA/QJOB%HVDTO48U@NG49\M@
M%;Z8 _7VH <OBC7?#%[%;^*X(I;*5MJ:A:J=JGT88_H#]:Z^]>.YT:X>-U>*
M6W8JRG((*GD4L\%CK6EM%(([JSN4['*LIZ$'^M<EX,6;3]0UKPI<RM-!9D-
MY/(C<9V_J#]2: ,W0_$\ECX*T?2M*B%UK5RCK%$.1$-[?._H/\]*[_3(;RWT
MRWBO[D7-VJ 2RA=H9OI67X9\(Z=X7BE%J&EGE/SSR8W%>R\=!_.M^@ HHHH
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MK=!D_A_3#_#FFZI<7S^(-;D>.ZF39!9*Q"6\9.<$=V_S].HH **** "BBB@
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M"!" O)''L#^-:KZ?8^,O"EF=0B#"X@24,O#1N5'*GL:N>(@#X8U8'H;.;_T
MUPFC:CJ'B/0=.\.Z,[P0Q6Z+J%_C_5C'W$_VC0!HQ>%?&%O"=,A\31?V81L$
MC1YF5?0<>G^U77Z1I5KHFEP:?:*1#$, GJQZDGW)J>SM8[&R@M8BYCA0(I=M
MS$ 8Y-3T %%%% !1110 54U.^73-+NKYHGE6WB:0HG4@#-6Z1E5T*,H96&""
M."* .8UJ6[\3>#(FT1L?;_+#MN *1L</^(Y!'UJ2]\$Z+/X>?2X;&&,B,B*8
M(-ZOCABW4G/7UK,\(,=!\0:GX5F;]TK?:K$GO&W51]/YAJ[>@#D?![1>(_ 5
MM;:G$+A0K6\JOSG:<#\<8YZYJA#X1\3Z(SVV@:_&NGL25CNDW-$#_=X(_E6)
MX>UR^CTR;P[H<6_59KR8M*1\EO'D#>3_ "__ % ^C:%I(T728K+[1+<.N6>6
M5B2S$Y)]AGM0!#X=T"+P_8O$)GN+F=S+<7#_ 'I7/4^P]JV*** "BBB@ HHH
MH :[;$9R"=H)PHR37/IKLGB#P==:AH2-]J:-TCC8@,CCCGMGN/PKHJX?3_\
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M7=>MM M[>>[20Q33K 70<)G^)O88K4K.U[28M<T.[TZ7'[Y"%8_PL.5/X'%
M&3XFT:ZU_5M)LI%8Z,K/-=[6QO8#Y%/?'7_(%97CGPY9V6B+K.DVT-E>Z<ZR
MHT"!-RY (..N.OX>]:W@75I=1T 6UWD7VGN;6X5CSE> 3^'Z@U:\9+N\&ZL/
M^G9C^7- #=6T/3_&&AVYND*L\:RPS+]^(L >/;VK!'ASQH]NVE2^(+9M.8;#
M<;"9RG<=.OX_C5*PU"_\6Z9I^A:.\EM806L*:A? 8.0@S&GOZ_X=?18(A!!'
M"K,RQJ%!=LDX&.3W- $&F:=;Z3IMO86BE8(%VKGJ?4GW)R?QJW110 4444 %
M%%% %+5]172=(NM0>)Y5MXRY1.IQ6+XA6Z\3>%;5='<^3?R1><X8!E@;[Q^H
MXR/K72R1I-$\4BAD=2K*>A!ZBN,\%ROH^J:EX4N')^RN9[,G^*%N<?@2/Q)]
M* +VK^"M'N?#<NGVUA#$\<1\B14&\.!P2W4Y/7/6F>&#!XJ\ V<>J1BX5XS%
M*'ZDJ2H.?7 !S755Y+X7UN^D\.P>'- 0_P!HRR2-+.1\EK&6^]GU]/\ &@#=
M@\)>*M'#6>B>(8QIQ)VK<IN>(?[/!'\A[5T_A[08/#^F_9HI&FED<RSSO]Z5
MSU)J?1=+71M)@L5GEG\L'=+*V69B<D^W)Z5?H **** "BBB@ IKMLC9MK-M!
M.%&2?I3J* .;36Y_$?@NZOM#1EO'C>..-F 9''&,],XY'U%)IG@K2+;P\FG7
M-C#-(\8\^5E!=G(Y(;J.>GI69I__ !3'Q!N=/.$T_609[?T68?>7\>?S45W%
M '&> U)T?4]"O<3KI]W);8D&0T?8$>G6JY\&:UHEY+)X4UA+:UF.YK6Z!9$/
MMP?Y9]S67#X@ET?Q)XDL=/MFN=4O+Q1;0@< X.68^@S_ )Y-=KX:T6XT>QD^
MVWDEW?7+^;<2,Q*[CV4=@/\ /8  B\.>'&TA[F]O;MKW5+L@SW!&!@=%4=@/
M\^E;]%% !1110 4444 %8^EZ_#J\^J6UO$\=S83&)HY>-WHWT)!_*MBN'U[_
M (IKQM8:^N5LK_%I>^@;^%C^0_[Y/K0!<\,>%(H--DN=<LX;G5;QVDN6G59,
M9)PHZC&/2JGA.W&A>+]<\/Q%OL>U+NW0G.P' 8?J!_P&NWKSO6M<A\._$>ZN
MGB>:272UCAAC&3+*9!M7]#0!?U#P3=VFJ/JGA;4%TV>3_6V[C,+GZ8./I@^V
M*NZ'X9O8=5_MG7K];[4PGEQ>6NV.%>^T8')]<#J:?X8TC4HIY]9UNX=M1NU"
M^0K?NX$SD*!TS[__ %R>EH **** "BBB@ HHHH R[?7;:X\17FBA9$N;:)92
M6& ZGNOKC(_.L72?#)N];U75_$%K'/<27#1VT<H#HD(^Z0.G/^>IJ'QO%)I5
M[IOBJV4E[%Q%<JO\<+''Z$_^/>U=C%+'/"DT3AXY%#(PZ$'D&@#A[&RC\,_$
ME;*R7R[#5;9I/)'W4D7)./P!_P"^JNZWX+>;4_[9T"\_LW5.=Y _=S?[P_GP
M<^G>J?C+4;;1_&7AO4;IBD,27)=@,DC8  /<DX_&KN@6^K:UJB^(M4>6T@"E
M;*P5B $/\3^I/^>U #+#PUK5_JMKJ'BB_MY_L;;[>UMEP@?^\V0,D?Y]*["B
MB@ HHHH **** "LF^U^WT_7=.TJ>-PU\'\N4\(&7^'ZG_#UK6KF_&^CR:KX?
M>2VXOK)A<V[#J&7D@?4?KB@"*Z\/2ZQXU-YJD*RZ9:0*+2-B"K2'[Q*^HQW]
MJS/$VG6_A_Q'H>O:?"EMYETMK<K$NU75^Y XZ _IZ5U/A[6(]=T*TU%, RI^
M\4?PN.&'YYK"^([I%X=MIGX6.^A<GTP30!>\3>$K7Q ([A)6L]2AYANXN&7'
M0''4?J*QU\)^)-5\NS\1:Y%/ID;!FBMUPTV.@8X']?ZTZTDO_'&JQ7H>:S\/
MVDH>$*2CW;J?O'T4'_.>G<4 (B+&BHBA548 '0"EHHH **** "BBB@#*UW7K
M?0(;6:ZCD:*>X6 NO2//\3>W%9WB/1+G7M:TFWF7=HT1>:Y4-C>X'RJ1Z?\
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M>CWV;\WU@/N[>[*.P_E],@;D'CG1;J/3OLTDD\U\X1((EW21GN7'8#O^8R*
M-/0M6BUS1+348L 3)EE_NL.&'X$&E@T33K;5KC5(K5%O;@ 22\DD#T].V<=<
M5SOAFVGT'Q5JVAB*0Z?*/MMJX'RIDX9,_7I_N^]=E0 4444 %%%% !116)K?
MBW1?#\J1:A=A9GY$:*78#U('0?6@!WBG69-!\/SWL$:R7 *QPHW1G8@#_'\*
MK^%?%4'B*U>.1/L^I6_RW-LW!4C@D \XS^70U8F@TWQ786%U#<^;;17*74;1
MGAF3/RL#]>163XJ\*SW-TFNZ$_V?6K?GY>!.!_">V<<<]>A]@#H-;TN+6M&N
MM.FX6="H;^ZW4'\" :QO FJ2WNA&QO 5O]-<VLZD\_+PI_+CZ@U4L/B+ILFB
MR7%\CP:C PBEL57]XTG3" ]<G\N_N36]QI?CVQU2TMIC::Q%Y-U'MYCD RK$
M=N!S]&H Z:?2-/N=3@U*:UC>\MU*Q2MU4']/\,U=HHH **** "BBB@ K+\0Z
MU%X?T2XU&5#)Y8 2,'&]B< ?G1K7B'3/#]NLVI7*Q!^$0 LS_0#^?2LC4VT_
MQ]X1NX=+N5D;JF?E*R+R P/3/3\: ,][?X@QPC4UOK*60C>VF^4 H']T-C)/
MX_B:V?#OB2R\56,]O+"8;M%,=W9RCE<\'ZCM_.HO!_BA=:M#97O[G5[0;+B!
M^&)'&X#^?H?PK*\<VBZ)>6?BRQ'EW<,RQW"+P)T/&#ZGM_\ J% %CP1-)I5]
MJ7A2Y=F>R<RVK-_'"QS^A(_[Z]JZ;4='T_5Q +^UCN!!)YD8?LW]1['BN<\8
MV=Q9:II7B6PADEGM91!/'&,M)$QQC'U)'_ O:NQH **** "BBB@ HHJIJ6J6
M6CV37=_<)! O&YNY] !R3["@"2\NXK&RGNYSB*"-I'(] ,FN(@?QMK]HNLV%
M_:6$$GSVUDZ!MR=MS$'D_P"<5MVNN:)XTTV^T^RN]QDA:-T92KJ&&-P!ZCFL
MGP7K3Z=(?">LX@U"T^6!B?EG3MM/<X_,?0T 7_#?BYM1O)-(U>V^PZS%]Z$_
M=D'JO\\>G(SVI:5_Q3/CV[TEOEL-6!NK4=EE'WE_G^2U9\?:-'=Z*^K0MY&H
MZ<OG0SJ<' Y*Y_E[_4U7\00W'B+P/8:W:H8]2M42^AVCD$ %@/Y^^!0!UFHZ
M=::M8R6=] LUO)C<A)'0Y'(Y%3PPQ6\"0PQK'%&H5$48"@= !4.GW37NFVUT
M\+PO-$KM$XP4)&<&K- !1110 4444 %%17%S#:6\EQ<2I%#&-SNYP%'N:R-)
M\7Z%K=XUI87ZR3C)",C(6 ],@9_"@#&;X@16WBRXTV]MQ%IR2_9X[SG E &X
M,>F.?P[]>.U!! (.0>AK"7PGIITF^TZX5IX;RXDN9&?&X.QSD'L1V-<WI>J7
MG@?48]"UV4RZ5(<6-^>B#^ZWH/Y?3H 6=0_XICX@VVH#"Z?K($%QV"S#[K?C
MQ^;5V=S;0WEK+;7$8DAE0HZ'N",$5RVL2V'C;2]6TBQ+R2VN"EP%_=^:,D!6
M[GC!]C6KX4U&XU7PU9W5W%)'<[=DHD4J2RG!/XXS0!?T[3;32;&.RL85A@C&
M%4?S)[GWJU110 4444 %%%(2%4LQ  Y)/:@!:XSQ/XVF\/\ B&WM$L_M%FD(
MFO'0$M&K-M&.PQ[]<@<5?B\>>')]4&GQZBIE+; ^TB,MZ!NGX]*TDT.T&J:A
M?R RO?1I%*DF"H501@#T.>: +=E>VVHV<5W:3++!*NY'7H17)^.8)=-N-.\4
MVJDRZ?($N%7J\+'!'X9_\>S69/!>_#C4FN[19+GPW</^^A!RULQ[C_'OT/.#
M72#Q%HWB"Z_L6W+WL=U;,TLD2Y2-".C'L3GIV- &];SQW5M%<0L'BE0.C#N"
M,@U5TW1]/T@3"PM(X//<R2;?XF/U[>W05A>!5OK*QO=%O8Y/^);<&**9A@21
MGE<?YZ$5U= !1110 4444 %%%<[?^.O#NFZC]AN-07S@=K[$+*A]"0,?X=Z
M(?$&LZDVL6_A_0C$E_-$9I;B496"/.,X[DG^GKQD3:MXI\'R)+K;1ZMI+-A[
MF% LD6?4#'Z_F*E\5>=HNN6/C&Q3[3:B(07BQD',1.0P_/K["NNM+RQUO3%G
MMWCN;2=".F00>H(_0@T <]XLMH_$7A2/5-)F$D]J1>6DJ=3MY(^N!T]0*W-!
MU:+7-$M-1BP!,F64?PL.&'X$&N7\+V[>'_&VJ>'H)"VGO +V!&;/E98 C]?T
M%6?#-I<:#XIU;1EAD.G2@7MLX7Y(]QP4S_(?[/O0!T4&CZ?;:G<:E#:1I>7
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MXCRK?Y[8IFC>/K1M.N5UW%CJ5B,7$+#!<CC*#OD]O?TYJ#5&EAUW0O%EA:W
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M*^JGK_P'%=O9SFZLH+AHGB:6-7,;C#)D9P?<4 21QI#$D42*D: *JJ,!0.@
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M%%% !5'5?^/5?]\?R-7JHZK_ ,>J_P"^/Y&@ TK_ (]6_P!\_P A5ZJ.E?\
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M>;SI8HE1Y<8WD#!-4_#VBC0=+%J;B6YF=S+--(Q)>0]3["M6@ HHHH ****
M"BBB@#"TW7SK^EZDVGQ&&^MGE@$4Q&5D .TGV)Q^OI57PYX2L[#0$AU"SAGO
M;A=]X\RAV9VY()]LXX^O>L^]_P"*9^(4%\/EL-: @F[!9A]T_C_5J[>@#BO
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MB@ HHHH *R-2U^'2]9TS3YX7Q?LR)-QM5AC /N2<5KUSWC/16UOPY-' "+R
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MQ)'##/(@6:YD;'RC@<G@=OKQ7*37<7C+Q?IATP%[#2)#-->8PK/QA%]>G/\
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MSMS^(KKZX>\_XICXAP7HPNGZV/)F]%G'0_CQ^;4 .USPWX>T7P'<P3V\"^5
M=LY4>8\V."#UR6[?TK.T?QO+HF@Z;%J&BZD+)(DC:^9"%Z<8!ZCTYY KNK_2
M;'5'MFO;=9OLTGF1!B<!L8R1T/XUS7C/7;2XT^;P_8%;W4[T>2L$1W>7GJS'
MMCK0!OZM<7DNA23:-##=W$J#R0[ (P;^+G@C!SCO6?X2\)6OAFS)^26^F&9Y
MPN/^ J.RC_/MK:/8G2]%LK$OO-O"D9;U(&#5V@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "J.J_\ 'JO^^/Y&KU4=5_X]5_WQ_(T &E?\>K?[
MY_D*O51TK_CU;_?/\A5Z@ HHHH **** "BBB@ HHHH **** "N3\37MY?ZY9
M^&-/N6M6N(S/=7"'YTB&1A?<D=:ZRN+\90W6D:O8>++.)IEM$,-W$O4PG)S^
M&3^G;- '0K/IGAS3K:UN=0C@B1=D;7<XW-^+'G^E8?CJS>YT:WUW3F5[O3'%
MS$Z\AD_B''48 /X52\.:'IWBRREU_652^N+QV"QER5MD!P$&#P<<^O/YN\)6
M[:-XHUGPRDC3Z='&L\2R'/E[L94_7/Z9[T =?I>HPZMI=M?VYS%/&''MZCZ@
MY'X4EII5A8W5S<VMK'%-=-OF=1RY]ZYSP;:7FB:AJVA212FQ@E$UI,1\NQ^=
MN?;^>:Z^@ HHHH **** "BBB@#G/%VK7=C;6=AIS*E_J4XMXI&Z1C^)OP_K5
MO3K2S\+:/LNM2=DW;I+F]G^\YZ\D\9]*S_'&EWEYIMMJ&F@M?Z;,+F) ,[P.
MJX[]OKC'>L30%M/B#J%UJVJJ)+>V*PV]@TG$?R@L[ =<GH?;VH Z/Q%I]MXL
M\+7$-G/%.2/,MY8G# 2+R.1^7XT_PAK1UWP[;W,O%S'^YN%/42+P<_7@_C7/
M66GKX4^(EK8:8S#3]4A=Y+8MD1LH)R,_3]3[5>L+&ZT/X@W26]N[:9JL1G9E
M'RQ2KUSZ9S_X\/2@#I!I5B-4;4Q:Q_;63RS-CYMOI5RBB@ HHHH **** "L3
MQ/KLFB6,/V6 7%]=S+;VT1. 7/<^PK;KF?&FB7FJV%M=:8P&HZ?,+B '^(CJ
MOZ#\L=Z ,B[E\>:#'_:,]Q::K;J-T]K'$%9!WVD $X]>?I706.H:9XU\-S>4
MQ:"X0Q2QM]Z,D=#[CJ#7/2>(]?\ $=BVDVF@W5C>3+Y=S<SJ5BA4\,03R3CH
M.OUIMII<?@_QWI=I8,WV/4[9HI8R?XXUSO\ QX_-J -+P%?3"PN="O3_ *;I
M,I@.?XH^=A'MCCZ 5TDVFV-Q>17DUG!)<Q#$<KQ@LH]CVKFM9LKG3?&^EZW8
MP22I=G['>)&,\'[KGZ8Y/^R*Z^@ HHHH **** "BBJE[J=EIOD_;;J.#SY!'
M'O.-S'M0!7U_6X/#^CRW\ZE]N%2->LCGHHKC[K7/'.DVXUK4+&S;3^#+:1_Z
MR)#W)]?S^@KM=2TFTU9;9;M"XMITN(\'&'7IGU')XJQ>6ZW=E/;. 4EC9"#W
M!&* &V-Y#J%A!>6[;H9XQ(A]B,_G7'Z5_P 4QX^N]);Y;#5@;JUXX67^)1^O
MY+4G@;5;>Q^'%K>7\RQ06_F!G;T#M@>Y[ 4GB&.3Q5X1M=;TNWN(KZU<75HK
MIB0X/(P,YR!D>N!0!U-]I6GZDT+7UG!<&%MT?FH&VG\:M@     #H!45K)+-
M9P2S1&&5XU9XR<[&(Y'X'BIJ "BBB@ HHHH *@O+N&PLI[NX;;#"AD<^@ R:
MGJMJ%A;ZG83V5TI:"92C@'!Q]: .$GU?QS>V#:_816EOIRJ98[)QNEDC'.X\
M=QSP1[5V>A:JFN:'::DB%!.F2A_A(."/S!JIXD74H]"%EHEH))I\6X8L L"$
M8+'Z"N4OO ]UHOAQKVU\0WZWMA 9% DVPX49*A>W3UY[]: -!?\ BF/B(1]W
M3]=&<]EN!_CG\V]J["[L[:_MFM[N".>%L9CD4,#CV-<GJ-M/XP^'MM>!-FHB
M);J$KP1*OI]><?45TFB7D]_HEE=W4+PSRQ*TD;K@AL<\?K0!<BBC@B6*&-(X
MT&%1!@ >P%/HHH **** "BBB@ KB[DW/BWQ5=Z:MW-:Z3I943"!]KSRGG&1R
M%&#^7OQVE>;^([N_\#Z]J.JVL)ELM5CQGM%< '!/MU/OD^E '=SZMIEG<I:7
M&H6L4[8VQ23*&/IP3FN5\5 ^'O$^F^)XP1;N?L=\!_</W6/T_P#913[+P!HE
MYH:F]_TR\N4\R6_$I+,Y&<J<XQZ5#X5MY=?\&:GHFI2F9;>>2R2?KD+@J?P/
M3Z"@#MY(XKB%HY$62*12&5AD,#V]Q4=I96MA;B"SMXK>$=$B0*/R%8G@F6_;
MPW';:E!)%<6<C6Q+C_6!. P]1VS[5T5 !1110 4444 %%%% '(ZGJVM:MKUQ
MHOAZ6&U^QJK7=Y*F[:S#*HH((_R?3FC%XGUOPQJ,5EXL2*:TG;;%J4"X4'T8
M  ?H/QHU./5?"?BFZUNQLI+_ $S4 OVJ&$9>-P/O ?F?3D@XX-/%A=^.[Y+C
M5M/FL=&MT80V\WRRS2,,;R.P Z>_K0!9\=VDHL+3Q%I^&NM+D$P*\[XC]X?3
M'/TS746%[#J6GV][;MNAG0.A]C_6N6\!22RZ+J&C7C"==/NI+,,>0Z#C'\_P
MQ3_!-M>Z1)JFA7$4IM;.?=:3L/E:-^=H/J.OU)H Z2STVQT\2?8K."W\QMS^
M5&%W'WQ5JBB@ HHHH **** "N7\0^(-0CU2+0M MXY]3D3S9'E/[N!/4^_\
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MI-I8WU[>0(5FO75YB3G) P,>E '-^'_$>K1Z\?#WB2&)+UH_,MYXONS*.O\
M(^G0\5K>+-$&O^';FS4#SP/,@;TD7D?GR/QK)\8IY7B/PI=J,2"^\G(_NO@$
M?I6U>^(K*RUJSTC$DUY<G_5PKN\M?[S>@H B\(ZW_;WAVWNI#_I*?NK@=")%
MZ_GP?QK0M-)T^PN)KBTLH(9IB6DD1 &8GU-<_IFF7FC>.K_[/ S:5J,7VAF'
MW8I@<'\\D_C[5UE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !5'5?^/5?]\?R-7JHZK_ ,>J_P"^/Y&@ TK_ (]6_P!\_P A5ZJ.E?\
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MVG/'X8KK-(TFTT33(;"S0K#&.IY+'N2>Y-7J* "BBB@ HHHH **** "BBB@
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M$<ABMM"CM464$27<S\Q?1<<_7GZ5/X>T&#P_IHM8G:65V,D\[_>E<]6-:U%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MBN;:"\MV@N88YH7QNCD4,IYSR#4H    P!T%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !4)M;=KM;LP1FX5"@EVC<%SG&>N*F
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M(;:UM[.(Q6T$<,98MMC4*,DY)P*FHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH BN+6WNXA'<PQS1A@P610PR#D'FI:** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H1:VXNVNQ!&+
MAD$9EVC<5!SC/7%344 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 51U7_CU7_?'\C5ZJ.J_P#'JO\ OC^1H -*_P"/5O\
M?/\ (5>JCI7_ !ZM_OG^0J]0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 51U7_CU7_?'\C5ZJ.J_\>J_[X_D: #2O^/5O]\_
MR%7JHZ5_QZM_OG^0J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZA>!)7&5B52SG\!T_&@#8HK T;QEHFNW1M;2Z(N><0RH48XZXSUK?H ****
M"BBB@ HHHH **** "BBB@ HK+CUZSE\13:&HE^V10B9CL^3;QW_X$*OK<P/<
M/;K/&TZ %XPX+*#TR.HH EHHHH ***S[S6K*QU2RTZ=V%Q>EA" I(..N3VH
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M1UQ4M !1110 445BZ9XA74O$&JZ4+8QG3R@\S?G?N'ICC]: -JBBB@ HHHH
M***Q?$'B%=!;3E-L9_MERMOP^W9GOT.?I0!M4444 %%%% !1110 445GP:U9
M7.MW>D1LYN[5%>52N  P!&#WZB@#0HHHH ***QM9\0)I&J:39-;M*=1F,08-
MC9C'/O\ >H V:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD<7^T>8?\+1UO_GUT_\ []O_ /%T?\+1UO\ Y]=/_P"_;_\ Q='_  J[6_\
MGZT__OX__P 11_PJ[6_^?K3_ /OX_P#\11_L7D'^T>8?\+1UO_GUT_\ []O_
M /%T?\+1UO\ Y]=/_P"_;_\ Q='_  J[6_\ GZT__OX__P 11_PJ[6_^?K3_
M /OX_P#\11_L7D'^T>8?\+1UO_GUT_\ []O_ /%T?\+1UO\ Y]=/_P"_;_\
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M;RW?@M];U3Q9>[I[4OY4,B11;BO$>W'//!% '6Q:[]K\'OKEM&%;[(\ZQOR
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M1_:?-\WRNG&S'/YULZ+*FJ_%#5=1LV$EI;V:V[3(<J[DJ<9[]#^5)H<T5O\
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MT[K'&SL<*H))]JX/X=6BZFM]XGO562^N[AE1F'^K4=E]/3Z 5WCHLD;(PRK
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MW_+)0<F0^G0_KZ5!\/Y1I,VH>%[N-8[^UE:4../M"''S_P OP(]#0!W5%%%
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MMRSJS)N/J=I&?QK=HH JV&G6>EVBVMC;QP0+R$08Y]3ZGWIEEI-CIUQ=W%I
M(Y;N3S9VW$[VYYY/'4]*NT4 <7XTM7NO$GA4?9VEB%T_F_)N4 [.OMUZUJVG
M@KPY8WRWMOI<23JVY6+,P4^H4G _*M^B@"*XMX;NW>WN(DEA<89'7(8>XK"M
MO GAFUN5N(M)B\Q3D;W=P#_NDD?I7144 5M0T^UU2PELKV+S;:4 .FXC.#D<
MCGJ!4L$,=O!'!$NV.-0B+Z # %244 8%[X*\.ZA?M>W6EQO<.<LP=E#'U(!
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M#3K35;)[.^@6:W?!9&)&<'(Z>XK(B\#>&87WKH]N3_MY8?D2170T4 1I#%'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB@ _M6?^Y'^1_P :/[5G_N1_D?\ &BB@ _M6?^Y'^1_QH_M6?^Y'^1_QHHH
M/[5G_N1_D?\ &C^U9_[D?Y'_ !HHH /[5G_N1_D?\:/[5G_N1_D?\:** #^U
M9_[D?Y'_ !H_M6?^Y'^1_P :** #^U9_[D?Y'_&C^U9_[D?Y'_&BB@ _M6?^
MY'^1_P :/[5G_N1_D?\ &BB@ _M6?^Y'^1_QH_M6?^Y'^1_QHHH /[5G_N1_
MD?\ &C^U9_[D?Y'_ !HHH /[5G_N1_D?\:/[5G_N1_D?\:** #^U9_[D?Y'_
M !H_M6?^Y'^1_P :** #^U9_[D?Y'_&C^U9_[D?Y'_&BB@ _M6?^Y'^1_P :
M/[5G_N1_D?\ &BB@ _M6?^Y'^1_QH_M6?^Y'^1_QHHH /[5G_N1_D?\ &C^U
M9_[D?Y'_ !HHH /[5G_N1_D?\:/[5G_N1_D?\:** #^U9_[D?Y'_ !H_M6?^
MY'^1_P :** #^U9_[D?Y'_&C^U9_[D?Y'_&BB@ _M6?^Y'^1_P :/[5G_N1_
MD?\ &BB@ _M6?^Y'^1_QH_M6?^Y'^1_QHHH /[5G_N1_D?\ &C^U9_[D?Y'_
M !HHH /[5G_N1_D?\:/[5G_N1_D?\:** #^U9_[D?Y'_ !H_M6?^Y'^1_P :
M** #^U9_[D?Y'_&C^U9_[D?Y'_&BB@ _M6?^Y'^1_P :/[5G_N1_D?\ &BB@
M _M6?^Y'^1_QH_M6?^Y'^1_QHHH /[5G_N1_D?\ &C^U9_[D?Y'_ !HHH /[
M5G_N1_D?\:/[5G_N1_D?\:** #^U9_[D?Y'_ !H_M6?^Y'^1_P :** #^U9_
M[D?Y'_&C^U9_[D?Y'_&BB@ _M6?^Y'^1_P :/[5G_N1_D?\ &BB@ _M6?^Y'
M^1_QH_M6?^Y'^1_QHHH /[5G_N1_D?\ &C^U9_[D?Y'_ !HHH /[5G_N1_D?
M\:/[5G_N1_D?\:** #^U9_[D?Y'_ !H_M6?^Y'^1_P :** #^U9_[D?Y'_&C
M^U9_[D?Y'_&BB@ _M6?^Y'^1_P :/[5G_N1_D?\ &BB@ _M6?^Y'^1_QH_M6
M?^Y'^1_QHHH /[5G_N1_D?\ &C^U9_[D?Y'_ !HHH /[5G_N1_D?\:/[5G_N
M1_D?\:** #^U9_[D?Y'_ !H_M6?^Y'^1_P :** #^U9_[D?Y'_&C^U9_[D?Y
M'_&BB@ _M6?^Y'^1_P :/[5G_N1_D?\ &BB@ _M6?^Y'^1_QH_M6?^Y'^1_Q
MHHH /[5G_N1_D?\ &C^U9_[D?Y'_ !HHH /[5G_N1_D?\:/[5G_N1_D?\:**
M #^U9_[D?Y'_ !H_M6?^Y'^1_P :** #^U9_[D?Y'_&C^U9_[D?Y'_&BB@ _
MM6?^Y'^1_P :/[5G_N1_D?\ &BB@ _M6?^Y'^1_QH_M6?^Y'^1_QHHH /[5G
M_N1_D?\ &C^U9_[D?Y'_ !HHH /[5G_N1_D?\:/[5G_N1_D?\:** #^U9_[D
M?Y'_ !H_M6?^Y'^1_P :** #^U9_[D?Y'_&C^U9_[D?Y'_&BB@ _M6?^Y'^1
M_P :/[5G_N1_D?\ &BB@ _M6?^Y'^1_QH_M6?^Y'^1_QHHH /[5G_N1_D?\
M&C^U9_[D?Y'_ !HHH /[5G_N1_D?\:/[5G_N1_D?\:** #^U9_[D?Y'_ !H_
MM6?^Y'^1_P :** #^U9_[D?Y'_&C^U9_[D?Y'_&BB@ _M6?^Y'^1_P :/[5G
M_N1_D?\ &BB@ _M6?^Y'^1_QH_M6?^Y'^1_QHHH /[5G_N1_D?\ &C^U9_[D
M?Y'_ !HHH /[5G_N1_D?\:/[5G_N1_D?\:** #^U9_[D?Y'_ !H_M6?^Y'^1
M_P :** #^U9_[D?Y'_&C^U9_[D?Y'_&BB@ _M6?^Y'^1_P :/[5G_N1_D?\
M&BB@ _M6?^Y'^1_QH_M6?^Y'^1_QHHH /[5G_N1_D?\ &C^U9_[D?Y'_ !HH
MH /[5G_N1_D?\:/[5G_N1_D?\:** #^U9_[D?Y'_ !H_M6?^Y'^1_P :** #
M^U9_[D?Y'_&C^U9_[D?Y'_&BB@ _M6?^Y'^1_P :/[5G_N1_D?\ &BB@ _M6
M?^Y'^1_QH_M6?^Y'^1_QHHH /[5G_N1_D?\ &C^U9_[D?Y'_ !HHH /[5G_N
M1_D?\:/[5G_N1_D?\:** #^U9_[D?Y'_ !H_M6?^Y'^1_P :** #^U9_[D?Y
M'_&C^U9_[D?Y'_&BB@ _M6?^Y'^1_P :/[5G_N1_D?\ &BB@ _M6?^Y'^1_Q
MH_M6?^Y'^1_QHHH /[5G_N1_D?\ &C^U9_[D?Y'_ !HHH /[5G_N1_D?\:/[
M5G_N1_D?\:** #^U9_[D?Y'_ !H_M6?^Y'^1_P :** #^U9_[D?Y'_&C^U9_
M[D?Y'_&BB@ _M6?^Y'^1_P :/[5G_N1_D?\ &BB@ _M6?^Y'^1_QH_M6?^Y'
M^1_QHHH /[5G_N1_D?\ &C^U9_[D?Y'_ !HHH /[5G_N1_D?\:/[5G_N1_D?
M\:** #^U9_[D?Y'_ !H_M6?^Y'^1_P :** #^U9_[D?Y'_&C^U9_[D?Y'_&B
MB@ _M6?^Y'^1_P :/[5G_N1_D?\ &BB@ _M6?^Y'^1_QH_M6?^Y'^1_QHHH
M/[5G_N1_D?\ &C^U9_[D?Y'_ !HHH /[5G_N1_D?\:/[5G_N1_D?\:** #^U
M9_[D?Y'_ !H_M6?^Y'^1_P :** #^U9_[D?Y'_&C^U9_[D?Y'_&BB@ _M6?^
MY'^1_P :/[5G_N1_D?\ &BB@ _M6?^Y'^1_QH_M6?^Y'^1_QHHH /[5G_N1_
MD?\ &C^U9_[D?Y'_ !HHH /[5G_N1_D?\:/[5G_N1_D?\:** #^U9_[D?Y'_
M !H_M6?^Y'^1_P :** #^U9_[D?Y'_&C^U9_[D?Y'_&BB@ _M6?^Y'^1_P :
M/[5G_N1_D?\ &BB@ _M6?^Y'^1_QH_M6?^Y'^1_QHHH /[5G_N1_D?\ &C^U
M9_[D?Y'_ !HHH /[5G_N1_D?\:/[5G_N1_D?\:** #^U9_[D?Y'_ !H_M6?^
MY'^1_P :** #^U9_[D?Y'_&C^U9_[D?Y'_&BB@ _M6?^Y'^1_P :/[5G_N1_
MD?\ &BB@ _M6?^Y'^1_QH_M6?^Y'^1_QHHH /[5G_N1_D?\ &C^U9_[D?Y'_
M !HHH /[5G_N1_D?\:/[5G_N1_D?\:** #^U9_[D?Y'_ !H_M6?^Y'^1_P :
<** #^U9_[D?Y'_&HY[R6[58V5 -V1@&BB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>adpt-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-02-28T18:44:08.5739+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.adaptivebiotech.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:adpt="http://www.adaptivebiotech.com/20231231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" namespace="http://xbrl.sec.gov/stpr/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" id="StatementConsolidatedStatementsOfShareholdersEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness" id="Role_DisclosureOrganizationAndDescriptionOfBusiness">
        <link:definition>100070 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" id="Role_DisclosureSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenue" id="Role_DisclosureRevenue">
        <link:definition>100090 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenue" id="Role_DisclosureDeferredRevenue">
        <link:definition>100100 - Disclosure - Deferred Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100110 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestments" id="Role_DisclosureInvestments">
        <link:definition>100120 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100130 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" id="Role_DisclosureGoodwillAndIntangibleAssets">
        <link:definition>100140 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilities" id="Role_DisclosureAccruedLiabilities">
        <link:definition>100150 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100160 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreement" id="DisclosureRevenueInterestPurchaseAgreement">
        <link:definition>100170 - Disclosure - Revenue Interest Purchase Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100180 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquity" id="Role_DisclosureShareholdersEquity">
        <link:definition>100190 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlans" id="Role_DisclosureEquityIncentivePlans">
        <link:definition>100200 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreement" id="Role_DisclosureMicrosoftCollaborationAgreement">
        <link:definition>100210 - Disclosure - Microsoft Collaboration Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRestructuring" id="DisclosureRestructuring">
        <link:definition>100220 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100230 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders" id="Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders">
        <link:definition>100240 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRetirementPlan" id="Role_DisclosureRetirementPlan">
        <link:definition>100250 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" id="Role_DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>100260 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables" id="Role_DisclosureSignificantAccountingPoliciesTables">
        <link:definition>100270 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueTables" id="Role_DisclosureRevenueTables">
        <link:definition>100280 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueTables" id="Role_DisclosureDeferredRevenueTables">
        <link:definition>100290 - Disclosure - Deferred Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100300 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsTables" id="Role_DisclosureInvestmentsTables">
        <link:definition>100310 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100320 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" id="Role_DisclosureGoodwillAndIntangibleAssetsTables">
        <link:definition>100330 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables" id="Role_DisclosureAccruedLiabilitiesTables">
        <link:definition>100340 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100350 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementTables" id="DisclosureRevenueInterestPurchaseAgreementTables">
        <link:definition>100360 - Disclosure - Revenue Interest Purchase Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityTables" id="Role_DisclosureShareholdersEquityTables">
        <link:definition>100370 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables" id="Role_DisclosureEquityIncentivePlansTables">
        <link:definition>100380 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100390 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables" id="Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables">
        <link:definition>100400 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100410 - Disclosure - Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" id="Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails">
        <link:definition>100420 - Disclosure - Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" id="Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails">
        <link:definition>100430 - Disclosure - Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails" id="DisclosureRevenueScheduleOfDisaggregatedRevenueDetails">
        <link:definition>100440 - Disclosure - Revenue - Schedule of Disaggregated Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" id="Role_DisclosureRevenueAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails" id="Role_DisclosureDeferredRevenueAdditionalInformationDetails">
        <link:definition>100460 - Disclosure - Deferred Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1" id="Role_DisclosureDeferredRevenueAdditionalInformationDetails1">
        <link:definition>100470 - Disclosure - Deferred Revenue - Additional Information (Details1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1Default" id="Role_DisclosureDeferredRevenueAdditionalInformationDetails1Default">
        <link:definition>100470 - Disclosure - Deferred Revenue - Additional Information (Details1) [Default]</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails" id="Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails">
        <link:definition>100480 - Disclosure - Deferred Revenue - Schedule of Changes in Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100490 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" id="Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails">
        <link:definition>100500 - Disclosure - Investments - Schedule of Available-for-sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails" id="Role_DisclosureInvestmentsAdditionalInformationDetails">
        <link:definition>100510 - Disclosure - Investments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails" id="DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails">
        <link:definition>100520 - Disclosure - Investments - Schedule of Gross Unrealized Holding Losses and Fair Values for Investments in Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
        <link:definition>100530 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100540 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails">
        <link:definition>100560 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails">
        <link:definition>100570 - Disclosure - Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" id="Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
        <link:definition>100580 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetails" id="Role_DisclosureAccruedLiabilitiesAdditionalInformationDetails">
        <link:definition>100590 - Disclosure - Accrued Liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100600 - Disclosure - Leases- Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails" id="Role_DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails">
        <link:definition>100610 - Disclosure - Leases- Summary of Other Information Related to Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" id="Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails">
        <link:definition>100620 - Disclosure - Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails" id="DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails">
        <link:definition>100630 - Disclosure - Revenue Interest Purchase Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2" id="Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2">
        <link:definition>100640 - Disclosure - Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails" id="DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails">
        <link:definition>100650 - Disclosure - Revenue Interest Purchase Agreement - Schedule of Revenue Interest Liability, Net Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails" id="Role_DisclosureShareholdersEquityAdditionalInformationDetails">
        <link:definition>100660 - Disclosure - Shareholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" id="Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails">
        <link:definition>100670 - Disclosure - Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" id="Role_DisclosureEquityIncentivePlansAdditionalInformationDetails">
        <link:definition>100680 - Disclosure - Equity Incentive Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails" id="Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails">
        <link:definition>100690 - Disclosure - Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails" id="Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails">
        <link:definition>100700 - Disclosure - Equity Incentive Plans - Summary of Stock Option Activity Under 2009 Plan and 2019 Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" id="Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails">
        <link:definition>100710 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails" id="DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails">
        <link:definition>100720 - Disclosure - Equity Incentive Plans - Summary of Estimated Grant Date Fair Values of Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails" id="DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails">
        <link:definition>100730 - Disclosure - Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Consolidated Statements of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails" id="DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails">
        <link:definition>100740 - Disclosure - Equity Incentive Plans - Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails" id="Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails">
        <link:definition>100750 - Disclosure - Microsoft Collaboration Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" id="DisclosureRestructuringAdditionalInformationDetails">
        <link:definition>100760 - Disclosure - Restructuring - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails">
        <link:definition>100770 - Disclosure - Income Taxes - Schedule of Components of Loss Before Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100780 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100790 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail">
        <link:definition>100800 - Disclosure - Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail" id="Role_DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail">
        <link:definition>100810 - Disclosure - Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails" id="Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails">
        <link:definition>100820 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>100830 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails" id="Role_DisclosureRetirementPlanAdditionalInformationDetails">
        <link:definition>100840 - Disclosure - Retirement Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="adpt-20231231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="adpt-20231231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="adpt-20231231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:href="adpt-20231231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="adpt-20231231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" xlink:href="adpt-20231231.xsd#StatementConsolidatedStatementsOfShareholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="adpt-20231231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness" xlink:href="adpt-20231231.xsd#Role_DisclosureOrganizationAndDescriptionOfBusiness" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" xlink:href="adpt-20231231.xsd#Role_DisclosureSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenue" xlink:href="adpt-20231231.xsd#Role_DisclosureRevenue" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenue" xlink:href="adpt-20231231.xsd#Role_DisclosureDeferredRevenue" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="adpt-20231231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestments" xlink:href="adpt-20231231.xsd#Role_DisclosureInvestments" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="adpt-20231231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" xlink:href="adpt-20231231.xsd#Role_DisclosureGoodwillAndIntangibleAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilities" xlink:href="adpt-20231231.xsd#Role_DisclosureAccruedLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeases" xlink:href="adpt-20231231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreement" xlink:href="adpt-20231231.xsd#DisclosureRevenueInterestPurchaseAgreement" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="adpt-20231231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquity" xlink:href="adpt-20231231.xsd#Role_DisclosureShareholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlans" xlink:href="adpt-20231231.xsd#Role_DisclosureEquityIncentivePlans" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreement" xlink:href="adpt-20231231.xsd#Role_DisclosureMicrosoftCollaborationAgreement" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRestructuring" xlink:href="adpt-20231231.xsd#DisclosureRestructuring" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="adpt-20231231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders" xlink:href="adpt-20231231.xsd#Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRetirementPlan" xlink:href="adpt-20231231.xsd#Role_DisclosureRetirementPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:href="adpt-20231231.xsd#Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables" xlink:href="adpt-20231231.xsd#Role_DisclosureSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueTables" xlink:href="adpt-20231231.xsd#Role_DisclosureRevenueTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueTables" xlink:href="adpt-20231231.xsd#Role_DisclosureDeferredRevenueTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="adpt-20231231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsTables" xlink:href="adpt-20231231.xsd#Role_DisclosureInvestmentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:href="adpt-20231231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:href="adpt-20231231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables" xlink:href="adpt-20231231.xsd#Role_DisclosureAccruedLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="adpt-20231231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementTables" xlink:href="adpt-20231231.xsd#DisclosureRevenueInterestPurchaseAgreementTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityTables" xlink:href="adpt-20231231.xsd#Role_DisclosureShareholdersEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables" xlink:href="adpt-20231231.xsd#Role_DisclosureEquityIncentivePlansTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="adpt-20231231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables" xlink:href="adpt-20231231.xsd#Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails" xlink:href="adpt-20231231.xsd#DisclosureRevenueScheduleOfDisaggregatedRevenueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureRevenueAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureDeferredRevenueAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1" xlink:href="adpt-20231231.xsd#Role_DisclosureDeferredRevenueAdditionalInformationDetails1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureInvestmentsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails" xlink:href="adpt-20231231.xsd#DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" xlink:href="adpt-20231231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="adpt-20231231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureAccruedLiabilitiesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails" xlink:href="adpt-20231231.xsd#DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails" xlink:href="adpt-20231231.xsd#DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureShareholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails" xlink:href="adpt-20231231.xsd#DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails" xlink:href="adpt-20231231.xsd#DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails" xlink:href="adpt-20231231.xsd#DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" xlink:href="adpt-20231231.xsd#DisclosureRestructuringAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail" xlink:href="adpt-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail" xlink:href="adpt-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails" xlink:href="adpt-20231231.xsd#Role_DisclosureRetirementPlanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2" xlink:href="adpt-20231231.xsd#Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1Default" xlink:href="adpt-20231231.xsd#Role_DisclosureDeferredRevenueAdditionalInformationDetails1Default" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods" xlink:label="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_InventoryReserve" xlink:label="adpt_InventoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:label="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CustomerAMember" xlink:label="adpt_CustomerAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CollaborationArrangementDisclosureAbstract" xlink:label="adpt_CollaborationArrangementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssetsExpensesPolicyTextBlock" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssetsExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ComputerEquipmentAndSoftwareMember" xlink:label="adpt_ComputerEquipmentAndSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PotentialRevenueInterestThirdPaymentToBeReceived" xlink:label="adpt_PotentialRevenueInterestThirdPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PercentageOfAnnualIncreasesInNumberOfShares" xlink:label="adpt_PercentageOfAnnualIncreasesInNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SeriesFOneConvertiblePreferredStockMember" xlink:label="adpt_SeriesFOneConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NonvestedRestrictedStockUnitsRSUMember" xlink:label="adpt_NonvestedRestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock" xlink:label="adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SequencingRevenueMember" xlink:label="adpt_SequencingRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" xlink:label="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="adpt_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DigitalBiotechnologiesIncMember" xlink:label="adpt_DigitalBiotechnologiesIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ProceedsFromLandlordReimbursements" xlink:label="adpt_ProceedsFromLandlordReimbursements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueInterestPayable" xlink:label="adpt_RevenueInterestPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments" xlink:label="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DeferredRevenueTextBlock" xlink:label="adpt_DeferredRevenueTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueInterestPurchaseAgreementTextBlock" xlink:label="adpt_RevenueInterestPurchaseAgreementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TenantImprovementCostsIncurred" xlink:label="adpt_TenantImprovementCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PutOrCallOptionMember" xlink:label="adpt_PutOrCallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" xlink:label="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement" xlink:label="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock" xlink:label="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TwoThousandAndNineEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MRDRevenueMember" xlink:label="adpt_MRDRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock" xlink:label="adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" xlink:label="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember" xlink:label="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:label="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_GenentechCollaborationAgreementMember" xlink:label="adpt_GenentechCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember" xlink:label="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AmortizationOfPurchaseAgreementObligation" xlink:label="adpt_AmortizationOfPurchaseAgreementObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueInterestLiability" xlink:label="adpt_RevenueInterestLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CumulativePurchaserPaymentsRepaymentDate" xlink:label="adpt_CumulativePurchaserPaymentsRepaymentDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RegulatoryMilestonesMember" xlink:label="adpt_RegulatoryMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PotentialRevenueInterestSecondPaymentToBeReceived" xlink:label="adpt_PotentialRevenueInterestSecondPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_OperatingLeaseVariableLeaseExpense" xlink:label="adpt_OperatingLeaseVariableLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueInterestPaid" xlink:label="adpt_RevenueInterestPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock" xlink:label="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ComputerSoftwareMember" xlink:label="adpt_ComputerSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NumberOfCommonStockVotingRights" xlink:label="adpt_NumberOfCommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" xlink:label="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ResearchAndDevelopmentInventoryReserve" xlink:label="adpt_ResearchAndDevelopmentInventoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CommonStockWarrantOutstandingMember" xlink:label="adpt_CommonStockWarrantOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NonvestedStockOptionsMember" xlink:label="adpt_NonvestedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueInterestPaymentTerm" xlink:label="adpt_RevenueInterestPaymentTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm" xlink:label="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" xlink:label="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MonteCarloValuationModelMember" xlink:label="adpt_MonteCarloValuationModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueInterestLiabilityNet" xlink:label="adpt_RevenueInterestLiabilityNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_OperatingLossCarryforwardsExpirationYear" xlink:label="adpt_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PercentageOfCumulativePurchaserPayments" xlink:label="adpt_PercentageOfCumulativePurchaserPayments"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NetOperatingLossCarryforwardExpirationPeriod" xlink:label="adpt_NetOperatingLossCarryforwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LaboratoryEquipmentMember" xlink:label="adpt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpensePolicyTextBlock" xlink:label="us-gaap_InterestExpensePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:label="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" xlink:label="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PotentialRevenueInterestPaymentToBeReceived" xlink:label="adpt_PotentialRevenueInterestPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:label="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SalesAndMarketingExpensePolicyTextBlock" xlink:label="adpt_SalesAndMarketingExpensePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_FurnitureAndOfficeEquipmentMember" xlink:label="adpt_FurnitureAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CommercialMilestonesMember" xlink:label="adpt_CommercialMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SignificantAccountingPoliciesLineItems" xlink:label="adpt_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PurchaseAgreementMember" xlink:label="adpt_PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TenantImprovementCostsReceivable" xlink:label="adpt_TenantImprovementCostsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestCostsCapitalized" xlink:label="us-gaap_InterestCostsCapitalized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NonvestedMarketBasedRestrictedStockUnitsMember" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NoncashInterestExpense" xlink:label="adpt_NoncashInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NonEmployeeDirectorsMember" xlink:label="adpt_NonEmployeeDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CustomerBMember" xlink:label="adpt_CustomerBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" xlink:label="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RegulatoryMilestoneRevenueMember" xlink:label="adpt_RegulatoryMilestoneRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LesseeOperatingLeaseTerminationPeriod" xlink:label="adpt_LesseeOperatingLeaseTerminationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DevelopmentMilestonesMember" xlink:label="adpt_DevelopmentMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ImmuneMedicineRevenueMember" xlink:label="adpt_ImmuneMedicineRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NumberOfRevenuePerformanceObligation" xlink:label="adpt_NumberOfRevenuePerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DefinedContributionPlanEmployeeServicePeriodForVesting" xlink:label="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LesseeOperatingLeaseExtendedTermOfContract" xlink:label="adpt_LesseeOperatingLeaseExtendedTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_GenentechIncMember" xlink:label="adpt_GenentechIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ComputerAndSoftware" xlink:label="adpt_ComputerAndSoftware"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ContractBalancesPolicyTextBlock" xlink:label="adpt_ContractBalancesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TenantImprovementAllowanceAndCommenced" xlink:label="adpt_TenantImprovementAllowanceAndCommenced"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SpecificPatientsMember" xlink:label="adpt_SpecificPatientsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MarketBasedRestrictedStockUnitsRSUMember" xlink:label="adpt_MarketBasedRestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" xlink:label="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement" xlink:label="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ImmuneMedicineServiceRevenueMember" xlink:label="adpt_ImmuneMedicineServiceRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LeaseCommencementMonthAndYear" xlink:label="adpt_LeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="adpt_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SignificantAccountingPoliciesTable" xlink:label="adpt_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NonCashInterestExpenseRecognized" xlink:label="adpt_NonCashInterestExpenseRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_UpfrontPaymentReceived" xlink:label="adpt_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PurchaseAgreementThirdPaymentDate" xlink:label="adpt_PurchaseAgreementThirdPaymentDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CollaborationRevenueMember" xlink:label="adpt_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MedicareRevenueMember" xlink:label="adpt_MedicareRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DevelopmentRevenueMember" xlink:label="adpt_DevelopmentRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NoncashLeaseExpense" xlink:label="adpt_NoncashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PercentageOfRevenueInterestPayments" xlink:label="adpt_PercentageOfRevenueInterestPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock" xlink:label="adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AdditionalMilestonePayment" xlink:label="adpt_AdditionalMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AdditionalTransactionPriceOfRegulatoryMilestone" xlink:label="adpt_AdditionalTransactionPriceOfRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MicrosoftCollaborationAgreementMember" xlink:label="adpt_MicrosoftCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" xlink:label="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MedicareReimbursementsMember" xlink:label="adpt_MedicareReimbursementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_IncomeTaxesLineItems" xlink:label="adpt_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MRDDevelopmentAgreementsMember" xlink:label="adpt_MRDDevelopmentAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueRecognitionExpectedPeriod" xlink:label="adpt_RevenueRecognitionExpectedPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SeriesCConvertiblePreferredStockMember" xlink:label="adpt_SeriesCConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LeaseExpirationMonthAndYear" xlink:label="adpt_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PurchaseAgreementSecondPaymentDate" xlink:label="adpt_PurchaseAgreementSecondPaymentDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" xlink:label="adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease" xlink:label="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_Deferredtaxassetscapitalizedresearchanddevelopment" xlink:label="adpt_Deferredtaxassetscapitalizedresearchanddevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NonRefundableUpfrontPaymentsReceived" xlink:label="adpt_NonRefundableUpfrontPaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear" xlink:label="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_GenentechIncAndRocheGroupMember" xlink:label="adpt_GenentechIncAndRocheGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WA" xlink:label="stpr_WA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CumulativePurchaserPaymentsReceivableDate" xlink:label="adpt_CumulativePurchaserPaymentsReceivableDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInventoryNoncurrent" xlink:label="us-gaap_OtherInventoryNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" xlink:label="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DeferredTaxAssetsNonQualifiedStockOptions" xlink:label="adpt_DeferredTaxAssetsNonQualifiedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" xlink:label="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_UnvestedRestrictedStockUnitsMember" xlink:label="adpt_UnvestedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_IncomeTaxesTable" xlink:label="adpt_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized cost of short-term marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from settlement of stock option exercised in prior periods.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Settlement Of Stock Option Exercised In Prior Periods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from settlement of stock option exercised in prior periods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining contractual life stock options outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of public offering costs, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_InventoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_InventoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_InventoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inventory reserve.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares restricted stock award vested.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets and Liabilities, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CustomerAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer A</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CustomerAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CustomerAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer A.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, useful lives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue from collaboration agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and nineteen equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Nineteen Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Disaggregated Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and exercisable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Subject to Outstanding Stock Options, Stock Options vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CollaborationArrangementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Arrangement Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CollaborationArrangementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Arrangement Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total current deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized cost of long-term marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssetsExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Right-of-Use and Related Long-Lived Assets Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssetsExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Right of Use and Related Long Lived Assets Expenses [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssetsExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment of right-of-use and related long-lived assets expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less than 12 months, Fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Market Based Restricted Stock Units Granted [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nonvested market based restricted stock units granted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonvested Market-based Restricted Stock Units Outstanding Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer equipment and software.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment And Software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment and Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, less current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Add: Net loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PotentialRevenueInterestThirdPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential revenue interest third payment to be received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PotentialRevenueInterestThirdPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Revenue Interest Third Payment To Be Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PotentialRevenueInterestThirdPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Potential revenue interest third payment to be received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Stock Options Restricted Stock Units Granted And Maximum Market Based Restricted Stock Units Granted Eligible To Be Earned</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, stock options restricted stock units granted and maximum market based restricted stock units granted eligible to be earned.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfGoodwillTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Goodwill [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfGoodwillTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Goodwill [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PercentageOfAnnualIncreasesInNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of annual increases in number of shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PercentageOfAnnualIncreasesInNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Annual Increases In Number Of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PercentageOfAnnualIncreasesInNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual increases in number of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Applicable payment percentage of quarterly revenue base for first, second and third payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Applicable Payment Percentage of quarterly Revenue Base for First, Second and Third Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Applicable payment percentage of quarterly revenue base for first, second and third payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and shareholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon public offering, after deducting underwriters' discounts and net offering costs paid by us</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares Subject to Outstanding Stock Options, Stock Options outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares Subject to Outstanding Stock Options, Stock Options outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital, initial public offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Initial Public Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss attributable to Adaptive Biotechnologies Corporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SeriesFOneConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series F one convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SeriesFOneConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series F One Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SeriesFOneConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series F-1 Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions to deferred revenue during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedRestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonvested Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedRestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Units R S U [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedRestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nonvested Restricted Stock Units R S U.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net of valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Available-for-Sale Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Unrecognized Share Based Compensation Expense And The Expected Weighted Average Remaining Recognition Period Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of unrecognized share-based compensation expense and the expected weighted-average remaining recognition period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of RSUs vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SequencingRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sequencing revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SequencingRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sequencing Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SequencingRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sequencing Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical and contract research organization costs, current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical And Contract Research Organization Costs Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical and contract research organization costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling and Marketing Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and Marketing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total shares of common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvertisingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advertising Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvertisingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Advertising expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring, reduction in workforce</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities right of use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, lease not yet commenced termination option description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Lease Not Yet Commenced Termination Option Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease not yet commenced, termination option description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease renewal term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Subject to Outstanding Stock Options, Stock Options expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DigitalBiotechnologiesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Digital Biotechnologies, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DigitalBiotechnologiesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Digital Biotechnologies Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DigitalBiotechnologiesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Digital Biotechnologies, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DigitalBiotechnologiesIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Digital Biotechnologies Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Stock Options forfeited or cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ProceedsFromLandlordReimbursements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from landlord reimbursements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ProceedsFromLandlordReimbursements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Landlord Reimbursements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ProceedsFromLandlordReimbursements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from landlord reimbursements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chief Executive Officer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue Interest Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue interest payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPayable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Revenue interest payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in return cap percentage of cumulative purchaser payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase in Return Cap Percentage of Cumulative Purchaser Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase in return cap percentage of cumulative purchaser payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">12 months or greater, Fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Limitations on Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-lived asset impairment loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments in Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advertising Cost [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advertising</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, shares, common stock warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Common Stock Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued during period, common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of common stock warrant, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredRevenueTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredRevenueTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredRevenueTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Treasury and Agency Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury and Government [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPurchaseAgreementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPurchaseAgreementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Purchase Agreement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPurchaseAgreementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue Interest Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, expected to be recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total loss before provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Unit Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Requisite service period term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Requisite Service Period Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award requisite service period term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TenantImprovementCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvement costs incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TenantImprovementCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvement Costs Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TenantImprovementCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement costs incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PutOrCallOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Put or call option.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PutOrCallOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Put or Call Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PutOrCallOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Put/Call Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease rent commencement month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Rent Commencement Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, rent commencement month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum service consumption requirement term under license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Service Consumption Requirement Term Under License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum service consumption requirement term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of deferred revenue by revenue classification.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Revenue By Revenue Classification Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Revenue by Revenue Classification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized share-based compensation expense related to unvested stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrecognized Share-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Issuance Costs, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TwoThousandAndNineEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and nine equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TwoThousandAndNineEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Nine Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TwoThousandAndNineEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2009 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less than 12 months, Unrealized loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MRDRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MRD Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MRDRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">M R D Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MRDRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MRD Revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of revenue interest liability, net activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Revenue Interest Liability, Net Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Revenue Interest Liability, Net Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued tax withholding liability related to unsettled option exercises.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Tax Withholding Liability Related To Unsettled Option Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued tax withholding liability related to unsettled option exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Restricted Stock Units Outstanding, Nonvested Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Restricted Stock Units Outstanding, Nonvested Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total shareholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Finite-Lived</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses on intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Issuable Upon the Vesting of Outstanding Restricted Stock Units and the Maximum Outstanding Market-based Restricted Stock Units Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Vesting Of Outstanding Restricted Stock Units And Market Based Restricted Stock Units Granted [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock vesting of outstanding restricted stock units and market-based restricted stock units granted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Available-for-sale Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Landlord contribution for leasehold improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forecast</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Options Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in redemption value for vested convertible preferred stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Redemption Value For Vested Convertible Preferred Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in redemption value for vested Series E-1 convertible preferred stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_GenentechCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Genentech collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_GenentechCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Genentech Collaboration Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_GenentechCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Genentech Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Issuable Upon the Exercise of Outstanding Stock Options Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Exercise Of Outstanding Stock Options Granted [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock exercise of outstanding stock options granted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AmortizationOfPurchaseAgreementObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of purchase agreement obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AmortizationOfPurchaseAgreementObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Purchase Agreement obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AmortizationOfPurchaseAgreementObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortization of purchase agreement obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update Extensible List</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities debt securities noncurrent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Noncurrent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Term Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from public offering of common stock, net of underwriting discounts and commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue interest liability at inception</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intangible assets amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares available for grant at September 30, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares available for grant at December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2023 and 2022; 145,082,271 and 143,105,002 shares issued and outstanding at December 31, 2023 and 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CumulativePurchaserPaymentsRepaymentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative purchaser payments repayment date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CumulativePurchaserPaymentsRepaymentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Purchaser Payments Repayment Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CumulativePurchaserPaymentsRepaymentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cumulative purchaser payments repayment date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue recognized during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease not yet commenced, option to extend description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PotentialRevenueInterestSecondPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential revenue interest second payment to be received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PotentialRevenueInterestSecondPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Revenue Interest Second Payment To Be Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PotentialRevenueInterestSecondPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Potential revenue interest second payment to be received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_OperatingLeaseVariableLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease variable lease expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_OperatingLeaseVariableLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Variable Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_OperatingLeaseVariableLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease variable lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring costs paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue Interest Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue interest paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Carrying Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASC 842</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Approach and Technique</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of reserved shares of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Reserved Shares Of Common Stock Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reserved Shares of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ComputerSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer software.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ComputerSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ComputerSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Stock Option outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NumberOfCommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock voting rights.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NumberOfCommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Common Stock Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NumberOfCommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of vote for each share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognition milestone method expected milestone receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Milestone Method Expected Milestone Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected revenue through milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Add: Comprehensive loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ResearchAndDevelopmentInventoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development inventory reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ResearchAndDevelopmentInventoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Inventory Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ResearchAndDevelopmentInventoryReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development inventory reserve.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Subject to Outstanding Stock Options, Stock Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Equity Incentive Plan reserve increase effective January 1, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payement Equity Incentive Plan Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement By Share Based Payement Equity Incentive Plan Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockWarrantOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrant Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockWarrantOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrant Outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockWarrantOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrant outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonvested Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nonvested Stock Options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Other Information Related to Operating Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Developed Technology Rights [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired Developed Technology</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring and Related Cost, Expected Cost, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Cost, Expected Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated aggregate restructuring costs recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods and Services Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of Goods and Services Sold, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPaymentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest payment term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPaymentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Payment Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestPaymentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue interest payment term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciles Undiscounted Operating Lease Cash Flows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance period term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Performance Period Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sharebased compensation arrangement by sharebased payment award performance period term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of share-based compensation, shares available for grant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Shares Available For Grant Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 12)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MonteCarloValuationModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monte Carlo Valuation Model</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MonteCarloValuationModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Monte Carlo Valuation Model [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MonteCarloValuationModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Monte Carlo Valuation Model.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue interest liability, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue interest liability, net, less current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest liability, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Liability, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total revenue interest liability, net at December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term marketable securities (amortized cost of $281,122 and $412,282, respectively)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for (Proceeds from) Tenant Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash received for tenant improvement allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">All Award Types</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in measurement of lease liabilities, net of tenant improvement allowances received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Loss Carryforwards, Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NOLs expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Sales [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PercentageOfCumulativePurchaserPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of cumulative purchaser payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PercentageOfCumulativePurchaserPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Cumulative Purchaser Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PercentageOfCumulativePurchaserPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of cumulative purchaser payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NetOperatingLossCarryforwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Operating Loss Carryforward Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NetOperatingLossCarryforwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryforward Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NetOperatingLossCarryforwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity period for NOLs carryovers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective Income Tax Rate Reconciliation Permanent Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Permanent Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Treasury Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stockholders' Equity Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, value, common stock warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Common Stock Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of common stock warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">OrbiMed Royalty &amp; Credit Opportunities IV, LP.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OrbiMed Royalty &amp; Credit Opportunities IV, LP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">OrbiMed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for cash upon exercise of stock options, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Subject to Outstanding Stock Options, Stock Options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and shareholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and exercisable intrinsic value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Stock Options vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PotentialRevenueInterestPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential revenue interest payment to be received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PotentialRevenueInterestPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Revenue Interest Payment To Be Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PotentialRevenueInterestPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Potential revenue interest payment to be received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling and Marketing Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and marketing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling and Marketing Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Gross Unrealized Holding Losses and Fair Values for Investments in Unrealized Loss Position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Imputed interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity value change in redemption value for vested convertible preferred stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Value Change In Redemption Value For Vested Convertible Preferred Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in redemption value for vested Series E-1 convertible preferred stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units Outstanding, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SalesAndMarketingExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales and marketing expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SalesAndMarketingExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales And Marketing Expense Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SalesAndMarketingExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and Marketing Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of right-of-use and related long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Right-of-Use and Related Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment of right-of-use and related long-lived assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_FurnitureAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Furniture and office equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_FurnitureAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_FurnitureAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Office Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Stock Options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Income Tax Contingencies [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Change in Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Valuation Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryValuationReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TenantImprovementCostsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvement costs receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TenantImprovementCostsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvement Costs Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TenantImprovementCostsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tenant improvement costs receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestCostsCapitalized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Costs Capitalized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestCostsCapitalized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Capitalized issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestCostsCapitalized_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Capitalized issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonvested Market-Based Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Market Based Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nonvested market-based restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital conversion of convertible preferred stock warrant to common stock warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Conversion Of Convertible Preferred Stock Warrant To Common Stock Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock warrant to common stock warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive gain (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Security Category [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Security Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Service [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Service Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NoncashInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash interest expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NoncashInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NoncashInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Effective interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized share-based compensation expense related to unvested stock options, weighted-average period for recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Remaining Weighted-Average Recognition Period (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonEmployeeDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-employee directors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonEmployeeDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Employee Directors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonEmployeeDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non Employee Directors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intellectual Property [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchased Intellectual Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Microsoft Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods and Service [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Convertible preferred stock, Ending Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Convertible preferred stock, Beginning Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options and restricted stock units forfeited or expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment awards forfeited, canceled or expired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Awards Forfeited Canceled Or Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CustomerBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer B.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CustomerBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CustomerBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer B</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Inventory, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from revenue interest purchase agreement, net of issuance costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Revenue Interest Purchase Agreement, Net of Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from revenue interest purchase agreement, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RegulatoryMilestoneRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory Milestone Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RegulatoryMilestoneRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestone Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RegulatoryMilestoneRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory Milestone Revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period, Accounting Standards Update, Adjustment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period, Accounting Standards Update, Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseTerminationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease termination period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseTerminationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Termination Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseTerminationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease termination period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock voting rights description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Applicable payment percentage of quarterly revenue base for first payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Applicable Payment Percentage of quarterly Revenue Base for First Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Applicable payment percentage of quarterly revenue base for first payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DevelopmentMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Milestones</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity Under 2009 Plan and 2019 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Grant Date Fair Values of Stock Options Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImmuneMedicineRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Immune Medicine Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImmuneMedicineRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Immune Medicine Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImmuneMedicineRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Immune Medicine Revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating lease right-of-use assets and liabilities .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Right Of Use Assets And Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NumberOfRevenuePerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of revenue performance obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NumberOfRevenuePerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Revenue Performance Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NumberOfRevenuePerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of revenue performance obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan employee service period for vesting.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employee Service Period For Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee service period for vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseExtendedTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, extended term of contract.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseExtendedTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Extended Term Of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseExtendedTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, extended term of contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_GenentechIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Genentech Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_GenentechIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Genentech Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_GenentechIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Genentech, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letters of Credit Outstanding, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Applicable payment percentage of quarterly revenue base for first and second payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Applicable Payment Percentage of quarterly Revenue Base for First and Second Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Applicable payment percentage of quarterly revenue base for first and second payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ComputerAndSoftware_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer and software.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ComputerAndSoftware_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer And Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ComputerAndSoftware_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer and software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ContractBalancesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract balances.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ContractBalancesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Balances Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ContractBalancesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Balances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease not yet commenced, option to extend term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Compensation Costs Related to Stock Options and RSUs Included on Consolidated Statements of Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Investment amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities debt securities current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TenantImprovementAllowanceAndCommenced_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvement allowance and commenced.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TenantImprovementAllowanceAndCommenced_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvement Allowance And Commenced</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TenantImprovementAllowanceAndCommenced_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance and commenced</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SpecificPatientsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Specific patients.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SpecificPatientsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Specific Patients [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SpecificPatientsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specific Patients</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest or penalties related to uncertain tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MarketBasedRestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market-Based Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MarketBasedRestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Market Based Restricted Stock Units R S U [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MarketBasedRestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Market-Based Restricted Stock Units R S U.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities, tangible and intangible assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Tangible And Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tangible and intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum service consumption requirement amount under license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Service Consumption Requirement Amount Under License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum service consumption requirement amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImmuneMedicineServiceRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Immune Medicine Service Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImmuneMedicineServiceRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Immune Medicine Service Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ImmuneMedicineServiceRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Immune medicine service revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique, Option Pricing Model [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Valuation Model</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commenced moth and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements Not Yet Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, at cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ROU assets obtained in exchange for operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Travel and entertainment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonCashInterestExpenseRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash interest expense recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonCashInterestExpenseRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Interest Expense Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonCashInterestExpenseRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Noncash interest expense recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for cash upon exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total intrinsic value of options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Upfront payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PurchaseAgreementThirdPaymentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase agreement third payment date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PurchaseAgreementThirdPaymentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement Third Payment Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PurchaseAgreementThirdPaymentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchase agreement, third payment date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Ownership Percentage, Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership interest percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Amortization Expense for Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred tax asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MedicareRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Medicare revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MedicareRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Medicare Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MedicareRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Medicare</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue interest liability, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Excluding Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt, Excluding Current Maturities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in unrealized gains and losses on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DevelopmentRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DevelopmentRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DevelopmentRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash lease expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs and Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PercentageOfRevenueInterestPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of revenue interest payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PercentageOfRevenueInterestPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Revenue Interest Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PercentageOfRevenueInterestPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of revenue interest payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Concentrations of Risk Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and exercisable weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Stock Options vested and exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue interest liability, net and related imputed interest.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Interest Liability, Net and Related Imputed Interest [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Interest Liability, Net and Related Imputed Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized share-based compensation expense related to unvested RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdditionalMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdditionalMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdditionalMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payment receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Subject to Outstanding Stock Options, Stock Options forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital capital contributions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Capital Contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital contributions for Digital Biotechnologies, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Carrying Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease lease not yet commenced tenant improvement receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Lease Not Yet Commenced Tenant Improvement Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease not yet commenced landlord agreed to fund for improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdditionalTransactionPriceOfRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional transaction price of regulatory milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdditionalTransactionPriceOfRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Transaction Price Of Regulatory Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdditionalTransactionPriceOfRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional transaction price of regulatory milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MicrosoftCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Microsoft collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MicrosoftCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Microsoft Collaboration Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MicrosoftCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Microsoft Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued purchase of property and equipment current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Purchase Of Property And Equipment Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MedicareReimbursementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Medicare Reimbursements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MedicareReimbursementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Medicare Reimbursements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MedicareReimbursementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Medicare Reimbursements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Deferred Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award increase reserve shares available for grant,</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Increase Reserve Shares Available For Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Grant, 2019 Equity Incentive Plan reserve increase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, less current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-current deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Convertible preferred stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Convertible preferred stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Intangible Assets Subject to Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses and Other Current Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MRDDevelopmentAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MRD Development Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MRDDevelopmentAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MRD development agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_MRDDevelopmentAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">M R D Development Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueRecognitionExpectedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue recognition expected period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueRecognitionExpectedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Expected Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_RevenueRecognitionExpectedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognition expected period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Inventories, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration by Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration by Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current and non-current deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Deferred revenue balance at December 31, 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Deferred revenue balance at December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, General Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, off-Balance-Sheet Risks [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Fair Value Off Balance Sheet Risks [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SeriesCConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SeriesCConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_SeriesCConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer discretionary contribution amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration month and year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Stock Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PurchaseAgreementSecondPaymentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase agreement second payment date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PurchaseAgreementSecondPaymentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement Second Payment Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_PurchaseAgreementSecondPaymentDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchase agreement, second payment date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and principles of consolidation policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Principles Of Consolidation Policy Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill and Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Restricted Stock Units Outstanding, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in share reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derecognition of lease financing arrangements upon adoption of guidance on accounting for lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derecognition Of Lease Financing Arrangements Upon Adoption Of Guidance On Accounting For Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derecognition of lease financing arrangements upon adoption of guidance on accounting for leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_Deferredtaxassetscapitalizedresearchanddevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets capitalized research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_Deferredtaxassetscapitalizedresearchanddevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_Deferredtaxassetscapitalizedresearchanddevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_Deferredtaxassetscapitalizedresearchanddevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred tax asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price per Share, Stock Options expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, impairment loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid In capital share based compensation stock option and restricted stock unit requisite service period recognition value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Share Based Compensation Stock Option And Restricted Stock Unit Requisite Service Period Recognition Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock option, restricted stock unit and market-based restricted stock unit share-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Loss Before Provision for Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonRefundableUpfrontPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable upfront payments received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonRefundableUpfrontPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront Payments Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_NonRefundableUpfrontPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable upfront payments received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease rent obligations commencement month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Rent Obligations Commencement Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent obligations, commencement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock that may be earned under the award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Earned Under The Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares earned under the award.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, stock issued during period, shares, new issues.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of equipment included in accounts payable and accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_GenentechIncAndRocheGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Genentech, Inc. and Roche Group.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_GenentechIncAndRocheGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Genentech Inc And Roche Group [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_GenentechIncAndRocheGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Genentech, Inc. and Roche Group</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization period of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Adaptive Biotechnologies Corporation shareholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stockholders' Equity Attributable to Parent, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stockholders' Equity Attributable to Parent, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to Adaptive Biotechnologies Corporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss attributable to Adaptive Biotechnologies Corporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Description of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_WA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">WASHINGTON</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_WA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Seattle, Washington</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax, net of federal tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Land</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of square feet</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CumulativePurchaserPaymentsReceivableDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative purchaser payments receivable date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CumulativePurchaserPaymentsReceivableDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Purchaser Payments Receivable Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CumulativePurchaserPaymentsReceivableDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cumulative purchaser payments receivable date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherInventoryNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Inventory, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherInventoryNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Contributed Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial capital contributions for Digital Biotechnologies, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability milestone method revenue recognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Milestone Method Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award outstanding number.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Outstanding Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity awards outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxAssetsNonQualifiedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, non qualified stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxAssetsNonQualifiedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Non Qualified Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_DeferredTaxAssetsNonQualifiedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonqualifying stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees maximum annual contribution of their compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment awards granted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Awards Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Available for Grant, Options and restricted stock units granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock options and restricted stock units granted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Options And Restricted Stock Units Granted [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of Outstanding Common Stock Options and Vesting of Outstanding Common Restricted Stock Units Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonvested Restricted Stock Units Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest and Other Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award vested and exercisable options outstanding weighted average remaining contractual term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Vested And Exercisable Options Outstanding Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining contractual life vested and exercisable stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price per Share, Stock Options outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price per Share, Stock Options outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Approach and Technique</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">12 months or greater, Unrealized loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of estimated useful lives of property plant and equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Estimated Useful Lives Of Property Plant And Equipment Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Useful Lives Assigned to Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Restricted Stock Units Outstanding, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of RSUs vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon public offering, after deducting underwriters' discounts and net offering costs paid by us, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in carrying amount of goodwill since recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Period Increase (Decrease), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal NOLs</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods" xlink:to="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_InventoryReserve" xlink:to="adpt_InventoryReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:to="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CustomerAMember" xlink:to="adpt_CustomerAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CollaborationArrangementDisclosureAbstract" xlink:to="adpt_CollaborationArrangementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssetsExpensesPolicyTextBlock" xlink:to="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssetsExpensesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember" xlink:to="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ComputerEquipmentAndSoftwareMember" xlink:to="adpt_ComputerEquipmentAndSoftwareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PotentialRevenueInterestThirdPaymentToBeReceived" xlink:to="adpt_PotentialRevenueInterestThirdPaymentToBeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_ScheduleOfGoodwillTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PercentageOfAnnualIncreasesInNumberOfShares" xlink:to="adpt_PercentageOfAnnualIncreasesInNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment" xlink:to="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SeriesFOneConvertiblePreferredStockMember" xlink:to="adpt_SeriesFOneConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:to="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NonvestedRestrictedStockUnitsRSUMember" xlink:to="adpt_NonvestedRestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock" xlink:to="adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SequencingRevenueMember" xlink:to="adpt_SequencingRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" xlink:to="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="adpt_DeferredTaxLiabilitiesRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription" xlink:to="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DigitalBiotechnologiesIncMember" xlink:to="adpt_DigitalBiotechnologiesIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ProceedsFromLandlordReimbursements" xlink:to="adpt_ProceedsFromLandlordReimbursements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueInterestPayable" xlink:to="adpt_RevenueInterestPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments" xlink:to="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:to="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DeferredRevenueTextBlock" xlink:to="adpt_DeferredRevenueTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryAndGovernmentMember" xlink:to="us-gaap_USTreasuryAndGovernmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueInterestPurchaseAgreementTextBlock" xlink:to="adpt_RevenueInterestPurchaseAgreementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TenantImprovementCostsIncurred" xlink:to="adpt_TenantImprovementCostsIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PutOrCallOptionMember" xlink:to="adpt_PutOrCallOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" xlink:to="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement" xlink:to="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock" xlink:to="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TwoThousandAndNineEquityIncentivePlanMember" xlink:to="adpt_TwoThousandAndNineEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MRDRevenueMember" xlink:to="adpt_MRDRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock" xlink:to="adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" xlink:to="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember" xlink:to="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:to="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_GenentechCollaborationAgreementMember" xlink:to="adpt_GenentechCollaborationAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember" xlink:to="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AmortizationOfPurchaseAgreementObligation" xlink:to="adpt_AmortizationOfPurchaseAgreementObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" xlink:to="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueInterestLiability" xlink:to="adpt_RevenueInterestLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CumulativePurchaserPaymentsRepaymentDate" xlink:to="adpt_CumulativePurchaserPaymentsRepaymentDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RegulatoryMilestonesMember" xlink:to="adpt_RegulatoryMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PotentialRevenueInterestSecondPaymentToBeReceived" xlink:to="adpt_PotentialRevenueInterestSecondPaymentToBeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_OperatingLeaseVariableLeaseExpense" xlink:to="adpt_OperatingLeaseVariableLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueInterestPaid" xlink:to="adpt_RevenueInterestPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock" xlink:to="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ComputerSoftwareMember" xlink:to="adpt_ComputerSoftwareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NumberOfCommonStockVotingRights" xlink:to="adpt_NumberOfCommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" xlink:to="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ResearchAndDevelopmentInventoryReserve" xlink:to="adpt_ResearchAndDevelopmentInventoryReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CommonStockWarrantOutstandingMember" xlink:to="adpt_CommonStockWarrantOutstandingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NonvestedStockOptionsMember" xlink:to="adpt_NonvestedStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueInterestPaymentTerm" xlink:to="adpt_RevenueInterestPaymentTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm" xlink:to="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" xlink:to="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MonteCarloValuationModelMember" xlink:to="adpt_MonteCarloValuationModelMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueInterestLiabilityNet" xlink:to="adpt_RevenueInterestLiabilityNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_OperatingLossCarryforwardsExpirationYear" xlink:to="adpt_OperatingLossCarryforwardsExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PercentageOfCumulativePurchaserPayments" xlink:to="adpt_PercentageOfCumulativePurchaserPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NetOperatingLossCarryforwardExpirationPeriod" xlink:to="adpt_NetOperatingLossCarryforwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LaboratoryEquipmentMember" xlink:to="adpt_LaboratoryEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpensePolicyTextBlock" xlink:to="us-gaap_InterestExpensePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:to="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" xlink:to="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PotentialRevenueInterestPaymentToBeReceived" xlink:to="adpt_PotentialRevenueInterestPaymentToBeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:to="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SalesAndMarketingExpensePolicyTextBlock" xlink:to="adpt_SalesAndMarketingExpensePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" xlink:to="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_FurnitureAndOfficeEquipmentMember" xlink:to="adpt_FurnitureAndOfficeEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CommercialMilestonesMember" xlink:to="adpt_CommercialMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_SignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PurchaseAgreementMember" xlink:to="adpt_PurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TenantImprovementCostsReceivable" xlink:to="adpt_TenantImprovementCostsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestCostsCapitalized" xlink:to="us-gaap_InterestCostsCapitalized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NonvestedMarketBasedRestrictedStockUnitsMember" xlink:to="adpt_NonvestedMarketBasedRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_ServiceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NoncashInterestExpense" xlink:to="adpt_NoncashInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NonEmployeeDirectorsMember" xlink:to="adpt_NonEmployeeDirectorsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CustomerBMember" xlink:to="adpt_CustomerBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" xlink:to="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RegulatoryMilestoneRevenueMember" xlink:to="adpt_RegulatoryMilestoneRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LesseeOperatingLeaseTerminationPeriod" xlink:to="adpt_LesseeOperatingLeaseTerminationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment" xlink:to="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DevelopmentMilestonesMember" xlink:to="adpt_DevelopmentMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ImmuneMedicineRevenueMember" xlink:to="adpt_ImmuneMedicineRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:to="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NumberOfRevenuePerformanceObligation" xlink:to="adpt_NumberOfRevenuePerformanceObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting" xlink:to="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LesseeOperatingLeaseExtendedTermOfContract" xlink:to="adpt_LesseeOperatingLeaseExtendedTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_GenentechIncMember" xlink:to="adpt_GenentechIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment" xlink:to="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ComputerAndSoftware" xlink:to="adpt_ComputerAndSoftware_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ContractBalancesPolicyTextBlock" xlink:to="adpt_ContractBalancesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" xlink:to="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TenantImprovementAllowanceAndCommenced" xlink:to="adpt_TenantImprovementAllowanceAndCommenced_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SpecificPatientsMember" xlink:to="adpt_SpecificPatientsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MarketBasedRestrictedStockUnitsRSUMember" xlink:to="adpt_MarketBasedRestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" xlink:to="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement" xlink:to="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ImmuneMedicineServiceRevenueMember" xlink:to="adpt_ImmuneMedicineServiceRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LeaseCommencementMonthAndYear" xlink:to="adpt_LeaseCommencementMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="adpt_DeferredTaxAssetsOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="adpt_SignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NonCashInterestExpenseRecognized" xlink:to="adpt_NonCashInterestExpenseRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_UpfrontPaymentReceived" xlink:to="adpt_UpfrontPaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PurchaseAgreementThirdPaymentDate" xlink:to="adpt_PurchaseAgreementThirdPaymentDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CollaborationRevenueMember" xlink:to="adpt_CollaborationRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MedicareRevenueMember" xlink:to="adpt_MedicareRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DevelopmentRevenueMember" xlink:to="adpt_DevelopmentRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NoncashLeaseExpense" xlink:to="adpt_NoncashLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PercentageOfRevenueInterestPayments" xlink:to="adpt_PercentageOfRevenueInterestPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock" xlink:to="adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AdditionalMilestonePayment" xlink:to="adpt_AdditionalMilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable" xlink:to="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AdditionalTransactionPriceOfRegulatoryMilestone" xlink:to="adpt_AdditionalTransactionPriceOfRegulatoryMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MicrosoftCollaborationAgreementMember" xlink:to="adpt_MicrosoftCollaborationAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" xlink:to="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MedicareReimbursementsMember" xlink:to="adpt_MedicareReimbursementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_IncomeTaxesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_MRDDevelopmentAgreementsMember" xlink:to="adpt_MRDDevelopmentAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_RevenueRecognitionExpectedPeriod" xlink:to="adpt_RevenueRecognitionExpectedPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_SeriesCConvertiblePreferredStockMember" xlink:to="adpt_SeriesCConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LeaseExpirationMonthAndYear" xlink:to="adpt_LeaseExpirationMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_PurchaseAgreementSecondPaymentDate" xlink:to="adpt_PurchaseAgreementSecondPaymentDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" xlink:to="adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease" xlink:to="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_Deferredtaxassetscapitalizedresearchanddevelopment" xlink:to="adpt_Deferredtaxassetscapitalizedresearchanddevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_NonRefundableUpfrontPaymentsReceived" xlink:to="adpt_NonRefundableUpfrontPaymentsReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear" xlink:to="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_GenentechIncAndRocheGroupMember" xlink:to="adpt_GenentechIncAndRocheGroupMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_WA" xlink:to="stpr_WA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CumulativePurchaserPaymentsReceivableDate" xlink:to="adpt_CumulativePurchaserPaymentsReceivableDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInventoryNoncurrent" xlink:to="us-gaap_OtherInventoryNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributedCapital" xlink:to="us-gaap_ProceedsFromContributedCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" xlink:to="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_DeferredTaxAssetsNonQualifiedStockOptions" xlink:to="adpt_DeferredTaxAssetsNonQualifiedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" xlink:to="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_UnvestedRestrictedStockUnitsMember" xlink:to="adpt_UnvestedRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_IncomeTaxesTable" xlink:to="adpt_IncomeTaxesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Goodwill" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SequencingRevenueMember" xlink:label="adpt_SequencingRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DevelopmentRevenueMember" xlink:label="adpt_DevelopmentRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_DevelopmentRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestAndOtherIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:label="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:label="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:label="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:label="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_25"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_26"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_27"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_28"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_25" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_26" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_27" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_28" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NoncashLeaseExpense" xlink:label="adpt_NoncashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease" xlink:label="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" xlink:label="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ResearchAndDevelopmentInventoryReserve" xlink:label="adpt_ResearchAndDevelopmentInventoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_InventoryReserve" xlink:label="adpt_InventoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NoncashInterestExpense" xlink:label="adpt_NoncashInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="adpt_NoncashLeaseExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromContributedCapital" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="adpt_ResearchAndDevelopmentInventoryReserve" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="adpt_InventoryReserve" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="adpt_NoncashInterestExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenue" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenue" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DeferredRevenueTextBlock" xlink:label="adpt_DeferredRevenueTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="adpt_DeferredRevenueTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestments" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreement" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueInterestPurchaseAgreementTextBlock" xlink:label="adpt_RevenueInterestPurchaseAgreementTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="adpt_RevenueInterestPurchaseAgreementTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlans" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreement" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRestructuring" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRetirementPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" xlink:label="adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock" xlink:label="adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ContractBalancesPolicyTextBlock" xlink:label="adpt_ContractBalancesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SalesAndMarketingExpensePolicyTextBlock" xlink:label="adpt_SalesAndMarketingExpensePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssetsExpensesPolicyTextBlock" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssetsExpensesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpensePolicyTextBlock" xlink:label="us-gaap_InterestExpensePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_ContractBalancesPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_SalesAndMarketingExpensePolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssetsExpensesPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InterestExpensePolicyTextBlock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock" xlink:label="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock" xlink:label="adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock" xlink:label="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" xlink:label="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock" xlink:label="adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SeriesCConvertiblePreferredStockMember" xlink:label="adpt_SeriesCConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SignificantAccountingPoliciesTable" xlink:label="adpt_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SequencingRevenueMember" xlink:label="adpt_SequencingRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SignificantAccountingPoliciesLineItems" xlink:label="adpt_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DigitalBiotechnologiesIncMember" xlink:label="adpt_DigitalBiotechnologiesIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ResearchAndDevelopmentInventoryReserve" xlink:label="adpt_ResearchAndDevelopmentInventoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInventoryNoncurrent" xlink:label="us-gaap_OtherInventoryNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NumberOfRevenuePerformanceObligation" xlink:label="adpt_NumberOfRevenuePerformanceObligation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="adpt_SeriesCConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_SignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="adpt_DigitalBiotechnologiesIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="srt_OwnershipAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_ResearchAndDevelopmentInventoryReserve" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="adpt_SignificantAccountingPoliciesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherInventoryNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdvertisingExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_NumberOfRevenuePerformanceObligation" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SignificantAccountingPoliciesTable" xlink:label="adpt_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SignificantAccountingPoliciesLineItems" xlink:label="adpt_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CustomerAMember" xlink:label="adpt_CustomerAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CustomerBMember" xlink:label="adpt_CustomerBMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_GenentechIncAndRocheGroupMember" xlink:label="adpt_GenentechIncAndRocheGroupMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adpt_SignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_CustomerAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_CustomerBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_GenentechIncAndRocheGroupMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="adpt_SignificantAccountingPoliciesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LaboratoryEquipmentMember" xlink:label="adpt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ComputerEquipmentAndSoftwareMember" xlink:label="adpt_ComputerEquipmentAndSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_FurnitureAndOfficeEquipmentMember" xlink:label="adpt_FurnitureAndOfficeEquipmentMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_ComputerEquipmentAndSoftwareMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_FurnitureAndOfficeEquipmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ImmuneMedicineRevenueMember" xlink:label="adpt_ImmuneMedicineRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MRDRevenueMember" xlink:label="adpt_MRDRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CollaborationRevenueMember" xlink:label="adpt_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RegulatoryMilestoneRevenueMember" xlink:label="adpt_RegulatoryMilestoneRevenueMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_ImmuneMedicineRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_MRDRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_CollaborationRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_RegulatoryMilestoneRevenueMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MedicareReimbursementsMember" xlink:label="adpt_MedicareReimbursementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ImmuneMedicineServiceRevenueMember" xlink:label="adpt_ImmuneMedicineServiceRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RegulatoryMilestonesMember" xlink:label="adpt_RegulatoryMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MRDDevelopmentAgreementsMember" xlink:label="adpt_MRDDevelopmentAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DevelopmentMilestonesMember" xlink:label="adpt_DevelopmentMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" xlink:label="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_GenentechCollaborationAgreementMember" xlink:label="adpt_GenentechCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CommercialMilestonesMember" xlink:label="adpt_CommercialMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AdditionalMilestonePayment" xlink:label="adpt_AdditionalMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NonRefundableUpfrontPaymentsReceived" xlink:label="adpt_NonRefundableUpfrontPaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AdditionalTransactionPriceOfRegulatoryMilestone" xlink:label="adpt_AdditionalTransactionPriceOfRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" xlink:label="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueRecognitionExpectedPeriod" xlink:label="adpt_RevenueRecognitionExpectedPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_MedicareReimbursementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_ImmuneMedicineServiceRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="adpt_RegulatoryMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_MRDDevelopmentAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="adpt_DevelopmentMilestonesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_GenentechCollaborationAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="adpt_CommercialMilestonesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_AdditionalMilestonePayment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_NonRefundableUpfrontPaymentsReceived" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_AdditionalTransactionPriceOfRegulatoryMilestone" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_RevenueRecognitionExpectedPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DevelopmentRevenueMember" xlink:label="adpt_DevelopmentRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_GenentechIncMember" xlink:label="adpt_GenentechIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SequencingRevenueMember" xlink:label="adpt_SequencingRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SpecificPatientsMember" xlink:label="adpt_SpecificPatientsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MedicareRevenueMember" xlink:label="adpt_MedicareRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_DevelopmentRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_GenentechIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_SpecificPatientsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_MedicareRevenueMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_GenentechIncMember" xlink:label="adpt_GenentechIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_GenentechIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiability_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_InterestReceivableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LaboratoryEquipmentMember" xlink:label="adpt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_FurnitureAndOfficeEquipmentMember" xlink:label="adpt_FurnitureAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ComputerSoftwareMember" xlink:label="adpt_ComputerSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_FurnitureAndOfficeEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_ComputerSoftwareMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_GoodwillLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" xlink:label="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" xlink:label="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ComputerAndSoftware" xlink:label="adpt_ComputerAndSoftware"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="adpt_ComputerAndSoftware" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" xlink:label="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WA" xlink:label="stpr_WA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" xlink:label="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LesseeOperatingLeaseExtendedTermOfContract" xlink:label="adpt_LesseeOperatingLeaseExtendedTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LeaseExpirationMonthAndYear" xlink:label="adpt_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LeaseCommencementMonthAndYear" xlink:label="adpt_LeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ProceedsFromLandlordReimbursements" xlink:label="adpt_ProceedsFromLandlordReimbursements"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TenantImprovementCostsIncurred" xlink:label="adpt_TenantImprovementCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TenantImprovementCostsReceivable" xlink:label="adpt_TenantImprovementCostsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear" xlink:label="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TenantImprovementAllowanceAndCommenced" xlink:label="adpt_TenantImprovementAllowanceAndCommenced"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LesseeOperatingLeaseTerminationPeriod" xlink:label="adpt_LesseeOperatingLeaseTerminationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_OperatingLeaseVariableLeaseExpense" xlink:label="adpt_OperatingLeaseVariableLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_WA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfLand" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseExtendedTermOfContract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LeaseExpirationMonthAndYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LeaseCommencementMonthAndYear" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_ProceedsFromLandlordReimbursements" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_TenantImprovementCostsIncurred" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_TenantImprovementCostsReceivable" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_TenantImprovements" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_TenantImprovementAllowanceAndCommenced" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseTerminationPeriod" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_OperatingLeaseVariableLeaseExpense" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PurchaseAgreementMember" xlink:label="adpt_PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_UpfrontPaymentReceived" xlink:label="adpt_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PutOrCallOptionMember" xlink:label="adpt_PutOrCallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" xlink:label="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PotentialRevenueInterestPaymentToBeReceived" xlink:label="adpt_PotentialRevenueInterestPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PotentialRevenueInterestSecondPaymentToBeReceived" xlink:label="adpt_PotentialRevenueInterestSecondPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PurchaseAgreementSecondPaymentDate" xlink:label="adpt_PurchaseAgreementSecondPaymentDate"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PotentialRevenueInterestThirdPaymentToBeReceived" xlink:label="adpt_PotentialRevenueInterestThirdPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PurchaseAgreementThirdPaymentDate" xlink:label="adpt_PurchaseAgreementThirdPaymentDate"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueInterestPaymentTerm" xlink:label="adpt_RevenueInterestPaymentTerm"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CumulativePurchaserPaymentsReceivableDate" xlink:label="adpt_CumulativePurchaserPaymentsReceivableDate"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PercentageOfRevenueInterestPayments" xlink:label="adpt_PercentageOfRevenueInterestPayments"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PercentageOfCumulativePurchaserPayments" xlink:label="adpt_PercentageOfCumulativePurchaserPayments"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CumulativePurchaserPaymentsRepaymentDate" xlink:label="adpt_CumulativePurchaserPaymentsRepaymentDate"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments" xlink:label="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AmortizationOfPurchaseAgreementObligation" xlink:label="adpt_AmortizationOfPurchaseAgreementObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueInterestPayable" xlink:label="adpt_RevenueInterestPayable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NonCashInterestExpenseRecognized" xlink:label="adpt_NonCashInterestExpenseRecognized"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_PurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_UpfrontPaymentReceived" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="adpt_PutOrCallOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PotentialRevenueInterestPaymentToBeReceived" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PotentialRevenueInterestSecondPaymentToBeReceived" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PurchaseAgreementSecondPaymentDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PotentialRevenueInterestThirdPaymentToBeReceived" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_InvestmentTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PurchaseAgreementThirdPaymentDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestPaymentTerm" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_CumulativePurchaserPaymentsReceivableDate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PercentageOfRevenueInterestPayments" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PercentageOfCumulativePurchaserPayments" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_CumulativePurchaserPaymentsRepaymentDate" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_AmortizationOfPurchaseAgreementObligation" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestPayable" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_NonCashInterestExpenseRecognized" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PurchaseAgreementMember" xlink:label="adpt_PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueInterestLiability" xlink:label="adpt_RevenueInterestLiability"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" xlink:label="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestCostsCapitalized" xlink:label="us-gaap_InterestCostsCapitalized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueInterestPaid" xlink:label="adpt_RevenueInterestPaid"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueInterestPayable" xlink:label="adpt_RevenueInterestPayable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueInterestLiabilityNet" xlink:label="adpt_RevenueInterestLiabilityNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_PurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_InterestCostsCapitalized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestPaid" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestLiabilityNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NumberOfCommonStockVotingRights" xlink:label="adpt_NumberOfCommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_2"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PercentageOfAnnualIncreasesInNumberOfShares" xlink:label="adpt_PercentageOfAnnualIncreasesInNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="adpt_NumberOfCommonStockVotingRights" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="adpt_PercentageOfAnnualIncreasesInNumberOfShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" xlink:label="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember" xlink:label="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember" xlink:label="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NonEmployeeDirectorsMember" xlink:label="adpt_NonEmployeeDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TwoThousandAndNineEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MonteCarloValuationModelMember" xlink:label="adpt_MonteCarloValuationModelMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MarketBasedRestrictedStockUnitsRSUMember" xlink:label="adpt_MarketBasedRestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods" xlink:label="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm" xlink:label="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="adpt_NonEmployeeDirectorsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="adpt_MonteCarloValuationModelMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_MarketBasedRestrictedStockUnitsRSUMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NonvestedStockOptionsMember" xlink:label="adpt_NonvestedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NonvestedRestrictedStockUnitsRSUMember" xlink:label="adpt_NonvestedRestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NonvestedMarketBasedRestrictedStockUnitsMember" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_NonvestedStockOptionsMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_NonvestedRestrictedStockUnitsRSUMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_NonvestedMarketBasedRestrictedStockUnitsMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MicrosoftCollaborationAgreementMember" xlink:label="adpt_MicrosoftCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CollaborationArrangementDisclosureAbstract" xlink:label="adpt_CollaborationArrangementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SeriesFOneConvertiblePreferredStockMember" xlink:label="adpt_SeriesFOneConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement" xlink:label="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement" xlink:label="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_MicrosoftCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_CollaborationArrangementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adpt_SeriesFOneConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_PreferredStockValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_PaymentsForRestructuring" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" xlink:label="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="adpt_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DeferredTaxAssetsNonQualifiedStockOptions" xlink:label="adpt_DeferredTaxAssetsNonQualifiedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="adpt_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_Deferredtaxassetscapitalizedresearchanddevelopment" xlink:label="adpt_Deferredtaxassetscapitalizedresearchanddevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="adpt_DeferredTaxLiabilitiesRightOfUseAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="adpt_DeferredTaxAssetsNonQualifiedStockOptions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="adpt_DeferredTaxAssetsOperatingLeaseLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="adpt_Deferredtaxassetscapitalizedresearchanddevelopment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_IncomeTaxesLineItems" xlink:label="adpt_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_IncomeTaxesTable" xlink:label="adpt_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NetOperatingLossCarryforwardExpirationPeriod" xlink:label="adpt_NetOperatingLossCarryforwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_OperatingLossCarryforwardsExpirationYear" xlink:label="adpt_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_Deferredtaxassetscapitalizedresearchanddevelopment" xlink:label="adpt_Deferredtaxassetscapitalizedresearchanddevelopment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="adpt_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_NetOperatingLossCarryforwardExpirationPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesTable" xlink:to="adpt_IncomeTaxesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_OperatingLossCarryforwardsExpirationYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_Deferredtaxassetscapitalizedresearchanddevelopment" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_2"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_UnvestedRestrictedStockUnitsMember" xlink:label="adpt_UnvestedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CommonStockWarrantOutstandingMember" xlink:label="adpt_CommonStockWarrantOutstandingMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="adpt_UnvestedRestrictedStockUnitsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="adpt_CommonStockWarrantOutstandingMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DefinedContributionPlanEmployeeServicePeriodForVesting" xlink:label="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SequencingRevenueMember" xlink:label="adpt_SequencingRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DevelopmentRevenueMember" xlink:label="adpt_DevelopmentRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_DevelopmentRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestAndOtherIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:label="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:label="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:label="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:label="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" xlink:label="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions" xlink:label="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SignificantAccountingPoliciesLineItems" xlink:label="adpt_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SignificantAccountingPoliciesTable" xlink:label="adpt_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SeriesCConvertiblePreferredStockMember" xlink:label="adpt_SeriesCConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SequencingRevenueMember" xlink:label="adpt_SequencingRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DigitalBiotechnologiesIncMember" xlink:label="adpt_DigitalBiotechnologiesIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ResearchAndDevelopmentInventoryReserve" xlink:label="adpt_ResearchAndDevelopmentInventoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInventoryNoncurrent" xlink:label="us-gaap_OtherInventoryNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NumberOfRevenuePerformanceObligation" xlink:label="adpt_NumberOfRevenuePerformanceObligation"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_SignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="adpt_SeriesCConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="adpt_DigitalBiotechnologiesIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryValuationReserves" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="srt_OwnershipAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_ResearchAndDevelopmentInventoryReserve" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherInventoryNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdvertisingExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_NumberOfRevenuePerformanceObligation" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails">
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SignificantAccountingPoliciesLineItems" xlink:label="adpt_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SignificantAccountingPoliciesTable" xlink:label="adpt_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CustomerAMember" xlink:label="adpt_CustomerAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CustomerBMember" xlink:label="adpt_CustomerBMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_GenentechIncAndRocheGroupMember" xlink:label="adpt_GenentechIncAndRocheGroupMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="adpt_SignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_CustomerAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_CustomerBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_GenentechIncAndRocheGroupMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LaboratoryEquipmentMember" xlink:label="adpt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ComputerEquipmentAndSoftwareMember" xlink:label="adpt_ComputerEquipmentAndSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_FurnitureAndOfficeEquipmentMember" xlink:label="adpt_FurnitureAndOfficeEquipmentMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_ComputerEquipmentAndSoftwareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_FurnitureAndOfficeEquipmentMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ImmuneMedicineRevenueMember" xlink:label="adpt_ImmuneMedicineRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MRDRevenueMember" xlink:label="adpt_MRDRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CollaborationRevenueMember" xlink:label="adpt_CollaborationRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RegulatoryMilestoneRevenueMember" xlink:label="adpt_RegulatoryMilestoneRevenueMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_ImmuneMedicineRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_MRDRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_CollaborationRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_RegulatoryMilestoneRevenueMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MedicareReimbursementsMember" xlink:label="adpt_MedicareReimbursementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ImmuneMedicineServiceRevenueMember" xlink:label="adpt_ImmuneMedicineServiceRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RegulatoryMilestonesMember" xlink:label="adpt_RegulatoryMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MRDDevelopmentAgreementsMember" xlink:label="adpt_MRDDevelopmentAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DevelopmentMilestonesMember" xlink:label="adpt_DevelopmentMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" xlink:label="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_GenentechCollaborationAgreementMember" xlink:label="adpt_GenentechCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CommercialMilestonesMember" xlink:label="adpt_CommercialMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AdditionalMilestonePayment" xlink:label="adpt_AdditionalMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NonRefundableUpfrontPaymentsReceived" xlink:label="adpt_NonRefundableUpfrontPaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AdditionalTransactionPriceOfRegulatoryMilestone" xlink:label="adpt_AdditionalTransactionPriceOfRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" xlink:label="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueRecognitionExpectedPeriod" xlink:label="adpt_RevenueRecognitionExpectedPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_MedicareReimbursementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_ImmuneMedicineServiceRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="adpt_RegulatoryMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_MRDDevelopmentAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="adpt_DevelopmentMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_GenentechCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="adpt_CommercialMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_AdditionalMilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_NonRefundableUpfrontPaymentsReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_AdditionalTransactionPriceOfRegulatoryMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="adpt_RevenueRecognitionExpectedPeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DevelopmentRevenueMember" xlink:label="adpt_DevelopmentRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_GenentechIncMember" xlink:label="adpt_GenentechIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SequencingRevenueMember" xlink:label="adpt_SequencingRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SpecificPatientsMember" xlink:label="adpt_SpecificPatientsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MedicareRevenueMember" xlink:label="adpt_MedicareRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_DevelopmentRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_GenentechIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_SequencingRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_SpecificPatientsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="adpt_MedicareRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_GenentechIncMember" xlink:label="adpt_GenentechIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_GenentechIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1Default">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_GenentechIncMember" xlink:label="adpt_GenentechIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="adpt_GenentechIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" xlink:label="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_InterestReceivableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryAndGovernmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LaboratoryEquipmentMember" xlink:label="adpt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_FurnitureAndOfficeEquipmentMember" xlink:label="adpt_FurnitureAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ComputerSoftwareMember" xlink:label="adpt_ComputerSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_FurnitureAndOfficeEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adpt_ComputerSoftwareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_ScheduleOfGoodwillTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WA" xlink:label="stpr_WA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" xlink:label="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LesseeOperatingLeaseExtendedTermOfContract" xlink:label="adpt_LesseeOperatingLeaseExtendedTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LeaseExpirationMonthAndYear" xlink:label="adpt_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LeaseCommencementMonthAndYear" xlink:label="adpt_LeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ProceedsFromLandlordReimbursements" xlink:label="adpt_ProceedsFromLandlordReimbursements"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TenantImprovementCostsIncurred" xlink:label="adpt_TenantImprovementCostsIncurred"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TenantImprovementCostsReceivable" xlink:label="adpt_TenantImprovementCostsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear" xlink:label="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TenantImprovementAllowanceAndCommenced" xlink:label="adpt_TenantImprovementAllowanceAndCommenced"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LesseeOperatingLeaseTerminationPeriod" xlink:label="adpt_LesseeOperatingLeaseTerminationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable" xlink:label="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_OperatingLeaseVariableLeaseExpense" xlink:label="adpt_OperatingLeaseVariableLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_WA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfLand" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseExtendedTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LeaseExpirationMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LeaseCommencementMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_ProceedsFromLandlordReimbursements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_TenantImprovementCostsIncurred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_TenantImprovementCostsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_TenantImprovements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_TenantImprovementAllowanceAndCommenced" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseTerminationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="adpt_OperatingLeaseVariableLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PurchaseAgreementMember" xlink:label="adpt_PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_UpfrontPaymentReceived" xlink:label="adpt_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PutOrCallOptionMember" xlink:label="adpt_PutOrCallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" xlink:label="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PotentialRevenueInterestPaymentToBeReceived" xlink:label="adpt_PotentialRevenueInterestPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PotentialRevenueInterestSecondPaymentToBeReceived" xlink:label="adpt_PotentialRevenueInterestSecondPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PurchaseAgreementSecondPaymentDate" xlink:label="adpt_PurchaseAgreementSecondPaymentDate"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PotentialRevenueInterestThirdPaymentToBeReceived" xlink:label="adpt_PotentialRevenueInterestThirdPaymentToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PurchaseAgreementThirdPaymentDate" xlink:label="adpt_PurchaseAgreementThirdPaymentDate"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment" xlink:label="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueInterestPaymentTerm" xlink:label="adpt_RevenueInterestPaymentTerm"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CumulativePurchaserPaymentsReceivableDate" xlink:label="adpt_CumulativePurchaserPaymentsReceivableDate"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PercentageOfRevenueInterestPayments" xlink:label="adpt_PercentageOfRevenueInterestPayments"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PercentageOfCumulativePurchaserPayments" xlink:label="adpt_PercentageOfCumulativePurchaserPayments"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CumulativePurchaserPaymentsRepaymentDate" xlink:label="adpt_CumulativePurchaserPaymentsRepaymentDate"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments" xlink:label="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AmortizationOfPurchaseAgreementObligation" xlink:label="adpt_AmortizationOfPurchaseAgreementObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueInterestPayable" xlink:label="adpt_RevenueInterestPayable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NonCashInterestExpenseRecognized" xlink:label="adpt_NonCashInterestExpenseRecognized"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_PurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_UpfrontPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="adpt_PutOrCallOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PotentialRevenueInterestPaymentToBeReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PotentialRevenueInterestSecondPaymentToBeReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PurchaseAgreementSecondPaymentDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PotentialRevenueInterestThirdPaymentToBeReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PurchaseAgreementThirdPaymentDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestPaymentTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_CumulativePurchaserPaymentsReceivableDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PercentageOfRevenueInterestPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_PercentageOfCumulativePurchaserPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_CumulativePurchaserPaymentsRepaymentDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_AmortizationOfPurchaseAgreementObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_NonCashInterestExpenseRecognized" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PurchaseAgreementMember" xlink:label="adpt_PurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueInterestLiability" xlink:label="adpt_RevenueInterestLiability"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" xlink:label="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestCostsCapitalized" xlink:label="us-gaap_InterestCostsCapitalized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueInterestPaid" xlink:label="adpt_RevenueInterestPaid"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueInterestPayable" xlink:label="adpt_RevenueInterestPayable"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_RevenueInterestLiabilityNet" xlink:label="adpt_RevenueInterestLiabilityNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_PurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_InterestCostsCapitalized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adpt_RevenueInterestLiabilityNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NumberOfCommonStockVotingRights" xlink:label="adpt_NumberOfCommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_PercentageOfAnnualIncreasesInNumberOfShares" xlink:label="adpt_PercentageOfAnnualIncreasesInNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="adpt_NumberOfCommonStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="adpt_PercentageOfAnnualIncreasesInNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" xlink:label="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember" xlink:label="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember" xlink:label="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NonEmployeeDirectorsMember" xlink:label="adpt_NonEmployeeDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TwoThousandAndNineEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="us-gaap_ValuationTechniqueOptionPricingModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MonteCarloValuationModelMember" xlink:label="adpt_MonteCarloValuationModelMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MarketBasedRestrictedStockUnitsRSUMember" xlink:label="adpt_MarketBasedRestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods" xlink:label="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm" xlink:label="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="adpt_NonEmployeeDirectorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueOptionPricingModelMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="adpt_MonteCarloValuationModelMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_MarketBasedRestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ValuationTechniqueAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" xlink:label="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:label="adpt_TwoThousandAndNineteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NonvestedStockOptionsMember" xlink:label="adpt_NonvestedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NonvestedRestrictedStockUnitsRSUMember" xlink:label="adpt_NonvestedRestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NonvestedMarketBasedRestrictedStockUnitsMember" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_NonvestedStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_NonvestedRestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="adpt_NonvestedMarketBasedRestrictedStockUnitsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MicrosoftCollaborationAgreementMember" xlink:label="adpt_MicrosoftCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_SeriesFOneConvertiblePreferredStockMember" xlink:label="adpt_SeriesFOneConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement" xlink:label="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement" xlink:label="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adpt_MicrosoftCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adpt_SeriesFOneConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_IncomeTaxesLineItems" xlink:label="adpt_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_IncomeTaxesTable" xlink:label="adpt_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NetOperatingLossCarryforwardExpirationPeriod" xlink:label="adpt_NetOperatingLossCarryforwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_OperatingLossCarryforwardsExpirationYear" xlink:label="adpt_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_Deferredtaxassetscapitalizedresearchanddevelopment" xlink:label="adpt_Deferredtaxassetscapitalizedresearchanddevelopment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_IncomeTaxesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adpt_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_NetOperatingLossCarryforwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adpt_IncomeTaxesLineItems" xlink:to="adpt_Deferredtaxassetscapitalizedresearchanddevelopment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_UnvestedRestrictedStockUnitsMember" xlink:label="adpt_UnvestedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember" xlink:label="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_CommonStockWarrantOutstandingMember" xlink:label="adpt_CommonStockWarrantOutstandingMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="adpt_UnvestedRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="adpt_CommonStockWarrantOutstandingMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:label="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="6" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="7" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_InterestAndOtherIncome" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingAndMarketingExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_InterestExpense" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="adpt_NoncashLeaseExpense" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="5" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromContributedCapital" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="adpt_InventoryReserve" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="adpt_NoncashInterestExpense" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="adpt_ResearchAndDevelopmentInventoryReserve" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="12" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="13" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="14" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="15" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="16" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" order="18" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="19" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" order="20" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NoncashLeaseExpense" xlink:label="adpt_NoncashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" xlink:label="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" xlink:label="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_InventoryReserve" xlink:label="adpt_InventoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_NoncashInterestExpense" xlink:label="adpt_NoncashInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ResearchAndDevelopmentInventoryReserve" xlink:label="adpt_ResearchAndDevelopmentInventoryReserve"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" xlink:label="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="adpt_ComputerAndSoftware" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" xlink:label="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" xlink:label="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_ComputerAndSoftware" xlink:label="adpt_ComputerAndSoftware"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="adpt_DeferredTaxLiabilitiesRightOfUseAssets" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="adpt_DeferredTaxAssetsNonQualifiedStockOptions" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="adpt_DeferredTaxAssetsOperatingLeaseLiabilities" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="adpt_Deferredtaxassetscapitalizedresearchanddevelopment" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" xlink:label="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="adpt_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DeferredTaxAssetsNonQualifiedStockOptions" xlink:label="adpt_DeferredTaxAssetsNonQualifiedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="adpt_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_Deferredtaxassetscapitalizedresearchanddevelopment" xlink:label="adpt_Deferredtaxassetscapitalizedresearchanddevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="adpt-20231231.xsd#adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="adpt_CollaborationRevenueMember" name="CollaborationRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_GenentechCollaborationAgreementMember" name="GenentechCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment" name="ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment" name="ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="adpt_TenantImprovementCostsIncurred" name="TenantImprovementCostsIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember" name="OrbimedRoyaltyCreditOpportunitiesIvLpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_SalesAndMarketingExpensePolicyTextBlock" name="SalesAndMarketingExpensePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_CommercialMilestonesMember" name="CommercialMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription" name="LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_MonteCarloValuationModelMember" name="MonteCarloValuationModelMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable" name="LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_PotentialRevenueInterestThirdPaymentToBeReceived" name="PotentialRevenueInterestThirdPaymentToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_MRDDevelopmentAgreementsMember" name="MRDDevelopmentAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock" name="ScheduleOfReservedSharesOfCommonStockTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" name="TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement" name="MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_ImmuneMedicineServiceRevenueMember" name="ImmuneMedicineServiceRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_PercentageOfCumulativePurchaserPayments" name="PercentageOfCumulativePurchaserPayments" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments" name="IncreaseInReturnCapPercentageOfCumulativePurchaserPayments" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="adpt_DevelopmentRevenueMember" name="DevelopmentRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" name="AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_LesseeOperatingLeaseExtendedTermOfContract" name="LesseeOperatingLeaseExtendedTermOfContract" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="adpt_AdditionalTransactionPriceOfRegulatoryMilestone" name="AdditionalTransactionPriceOfRegulatoryMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" name="ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_DigitalBiotechnologiesIncMember" name="DigitalBiotechnologiesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent" name="AccruedPurchaseOfPropertyAndEquipmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_ComputerSoftwareMember" name="ComputerSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_PutOrCallOptionMember" name="PutOrCallOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="adpt_NonEmployeeDirectorsMember" name="NonEmployeeDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods" name="ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_NonCashInterestExpenseRecognized" name="NonCashInterestExpenseRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember" name="CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_SeriesFOneConvertiblePreferredStockMember" name="SeriesFOneConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_LeaseExpirationMonthAndYear" name="LeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_LesseeOperatingLeaseTerminationPeriod" name="LesseeOperatingLeaseTerminationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" name="ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_PurchaseAgreementThirdPaymentDate" name="PurchaseAgreementThirdPaymentDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease" name="DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_UpfrontPaymentReceived" name="UpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_DeferredRevenueTextBlock" name="DeferredRevenueTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_GenentechIncMember" name="GenentechIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets" name="ImpairmentOfRightOfUseAndRelatedLongLivedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_MarketBasedRestrictedStockUnitsRSUMember" name="MarketBasedRestrictedStockUnitsRSUMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember" name="NonvestedMarketBasedRestrictedStockUnitsGrantedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock" name="ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" name="ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" name="BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets" name="DeferredTaxLiabilitiesTangibleAndIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" name="StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_CustomerAMember" name="CustomerAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_NonvestedMarketBasedRestrictedStockUnitsMember" name="NonvestedMarketBasedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_RevenueInterestPaid" name="RevenueInterestPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_GenentechIncAndRocheGroupMember" name="GenentechIncAndRocheGroupMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_CumulativePurchaserPaymentsRepaymentDate" name="CumulativePurchaserPaymentsRepaymentDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ComputerAndSoftware" name="ComputerAndSoftware" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_NumberOfCommonStockVotingRights" name="NumberOfCommonStockVotingRights" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_ResearchAndDevelopmentInventoryReserve" name="ResearchAndDevelopmentInventoryReserve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_PurchaseAgreementSecondPaymentDate" name="PurchaseAgreementSecondPaymentDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember" name="CommonStockExerciseOfOutstandingStockOptionsGrantedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions" name="AdjustmentsToAdditionalPaidInCapitalCapitalContributions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_MedicareReimbursementsMember" name="MedicareReimbursementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_PotentialRevenueInterestSecondPaymentToBeReceived" name="PotentialRevenueInterestSecondPaymentToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_SeriesCConvertiblePreferredStockMember" name="SeriesCConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_OperatingLeaseVariableLeaseExpense" name="OperatingLeaseVariableLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember" name="CommonStockOptionsAndRestrictedStockUnitsGrantedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_SequencingRevenueMember" name="SequencingRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_NumberOfRevenuePerformanceObligation" name="NumberOfRevenuePerformanceObligation" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssetsExpensesPolicyTextBlock" name="ImpairmentOfRightOfUseAndRelatedLongLivedAssetsExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" name="ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" name="StockIssuedDuringPeriodSharesRestrictedStockAwardVested" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_InventoryReserve" name="InventoryReserve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="adpt_CollaborationArrangementDisclosureAbstract" name="CollaborationArrangementDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_UnvestedRestrictedStockUnitsMember" name="UnvestedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_NoncashLeaseExpense" name="NoncashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_CumulativePurchaserPaymentsReceivableDate" name="CumulativePurchaserPaymentsReceivableDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock" name="RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_RevenueInterestPaymentTerm" name="RevenueInterestPaymentTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_NonvestedRestrictedStockUnitsRSUMember" name="NonvestedRestrictedStockUnitsRSUMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock" name="ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" name="ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_CustomerBMember" name="CustomerBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_DeferredTaxAssetsNonQualifiedStockOptions" name="DeferredTaxAssetsNonQualifiedStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve" name="ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_RevenueInterestLiability" name="RevenueInterestLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_NoncashInterestExpense" name="NoncashInterestExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_ProceedsFromLandlordReimbursements" name="ProceedsFromLandlordReimbursements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_ImmuneMedicineRevenueMember" name="ImmuneMedicineRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_RevenueInterestPayable" name="RevenueInterestPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment" name="ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" name="RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_CommonStockWarrantOutstandingMember" name="CommonStockWarrantOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_MicrosoftCollaborationAgreementMember" name="MicrosoftCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_Deferredtaxassetscapitalizedresearchanddevelopment" name="Deferredtaxassetscapitalizedresearchanddevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" name="AvailableForSaleSecuritiesDebtSecuritiesCurrentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_FurnitureAndOfficeEquipmentMember" name="FurnitureAndOfficeEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_SpecificPatientsMember" name="SpecificPatientsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_TwoThousandAndNineEquityIncentivePlanMember" name="TwoThousandAndNineEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" name="AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_NonvestedStockOptionsMember" name="NonvestedStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_RevenueInterestLiabilityNet" name="RevenueInterestLiabilityNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock" name="ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_RegulatoryMilestonesMember" name="RegulatoryMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_MRDRevenueMember" name="MRDRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_RegulatoryMilestoneRevenueMember" name="RegulatoryMilestoneRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_PotentialRevenueInterestPaymentToBeReceived" name="PotentialRevenueInterestPaymentToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_AdditionalMilestonePayment" name="AdditionalMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_PercentageOfRevenueInterestPayments" name="PercentageOfRevenueInterestPayments" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="adpt_TenantImprovementAllowanceAndCommenced" name="TenantImprovementAllowanceAndCommenced" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_RevenueInterestPurchaseAgreementTextBlock" name="RevenueInterestPurchaseAgreementTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" name="AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent" name="AccruedClinicalAndContractResearchOrganizationCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_TenantImprovementCostsReceivable" name="TenantImprovementCostsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_LeaseCommencementMonthAndYear" name="LeaseCommencementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_ContractBalancesPolicyTextBlock" name="ContractBalancesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_TwoThousandAndNineteenEquityIncentivePlanMember" name="TwoThousandAndNineteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_NonRefundableUpfrontPaymentsReceived" name="NonRefundableUpfrontPaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_NetOperatingLossCarryforwardExpirationPeriod" name="NetOperatingLossCarryforwardExpirationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="adpt_PurchaseAgreementMember" name="PurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_PercentageOfAnnualIncreasesInNumberOfShares" name="PercentageOfAnnualIncreasesInNumberOfShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" name="StockIssuedDuringPeriodValueCommonStockWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="adpt_LesseeOperatingLeaseRentCommencementMonthAndYear" name="LesseeOperatingLeaseRentCommencementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear" name="LesseeOperatingLeaseRentObligationsCommencementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_MedicareRevenueMember" name="MedicareRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_EffectiveIncomeTaxRateReconciliationPermanentItems" name="EffectiveIncomeTaxRateReconciliationPermanentItems" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement" name="MinimumServiceConsumptionRequirementTermUnderLicenseAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" name="AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_AmortizationOfPurchaseAgreementObligation" name="AmortizationOfPurchaseAgreementObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="adpt_RevenueRecognitionExpectedPeriod" name="RevenueRecognitionExpectedPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="adpt_DevelopmentMilestonesMember" name="DevelopmentMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="adpt_DefinedContributionPlanEmployeeServicePeriodForVesting" name="DefinedContributionPlanEmployeeServicePeriodForVesting" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624891168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 23, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADPT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ADAPTIVE BIOTECHNOLOGIES CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001478320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 756,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,092,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-0907024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1165 Eastlake Avenue East<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Seattle<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">WA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">659-0067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">WA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">The information required by Part III of this Annual Report on Form 10-K, to the extent not set forth herein, is incorporated herein by reference from the Registrant&#8217;s definitive proxy statement relating to the Annual Meeting of Shareholders to be held in 2024.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Seattle, Washington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624927040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 65,064<span></span>
</td>
<td class="nump">$ 90,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term marketable securities (amortized cost of $281,122 and $412,282, respectively)</a></td>
<td class="nump">281,337<span></span>
</td>
<td class="nump">408,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">37,969<span></span>
</td>
<td class="nump">40,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">14,448<span></span>
</td>
<td class="nump">14,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">11,370<span></span>
</td>
<td class="nump">9,440<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">410,188<span></span>
</td>
<td class="nump">562,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Long-term assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">68,227<span></span>
</td>
<td class="nump">83,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">52,096<span></span>
</td>
<td class="nump">80,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,932<span></span>
</td>
<td class="nump">2,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">5,128<span></span>
</td>
<td class="nump">6,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">118,972<span></span>
</td>
<td class="nump">118,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3,591<span></span>
</td>
<td class="nump">2,064<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">661,134<span></span>
</td>
<td class="nump">856,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7,719<span></span>
</td>
<td class="nump">8,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">8,597<span></span>
</td>
<td class="nump">12,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">13,685<span></span>
</td>
<td class="nump">15,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">9,384<span></span>
</td>
<td class="nump">9,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">48,630<span></span>
</td>
<td class="nump">64,115<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">88,015<span></span>
</td>
<td class="nump">109,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">89,388<span></span>
</td>
<td class="nump">98,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, less current portion</a></td>
<td class="nump">44,793<span></span>
</td>
<td class="nump">58,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Revenue interest liability, net</a></td>
<td class="nump">130,660<span></span>
</td>
<td class="nump">125,360<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">352,856<span></span>
</td>
<td class="nump">392,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2023 and 2022; 145,082,271 and 143,105,002 shares issued and outstanding at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,452,502<span></span>
</td>
<td class="nump">1,387,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive gain (loss)</a></td>
<td class="nump">215<span></span>
</td>
<td class="num">(4,116)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,144,332)<span></span>
</td>
<td class="num">(919,082)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Adaptive Biotechnologies Corporation shareholders&#8217; equity</a></td>
<td class="nump">308,399<span></span>
</td>
<td class="nump">464,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="num">(121)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">308,278<span></span>
</td>
<td class="nump">464,098<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 661,134<span></span>
</td>
<td class="nump">$ 856,617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624651664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost of short-term marketable securities</a></td>
<td class="nump">$ 281,122<span></span>
</td>
<td class="nump">$ 412,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="nump">340,000,000<span></span>
</td>
<td class="nump">340,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="nump">145,082,271<span></span>
</td>
<td class="nump">143,105,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="nump">145,082,271<span></span>
</td>
<td class="nump">143,105,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754626415584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 170,276<span></span>
</td>
<td class="nump">$ 185,308<span></span>
</td>
<td class="nump">$ 154,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">75,553<span></span>
</td>
<td class="nump">57,909<span></span>
</td>
<td class="nump">49,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">122,117<span></span>
</td>
<td class="nump">141,756<span></span>
</td>
<td class="nump">142,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">88,579<span></span>
</td>
<td class="nump">95,603<span></span>
</td>
<td class="nump">95,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">83,934<span></span>
</td>
<td class="nump">88,527<span></span>
</td>
<td class="nump">74,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">1,699<span></span>
</td>
<td class="nump">1,699<span></span>
</td>
<td class="nump">1,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets', window );">Impairment of right-of-use and related long-lived assets</a></td>
<td class="nump">25,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">397,311<span></span>
</td>
<td class="nump">385,494<span></span>
</td>
<td class="nump">363,310<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(227,035)<span></span>
</td>
<td class="num">(200,186)<span></span>
</td>
<td class="num">(208,966)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="nump">15,531<span></span>
</td>
<td class="nump">4,056<span></span>
</td>
<td class="nump">1,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(13,800)<span></span>
</td>
<td class="num">(4,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(225,304)<span></span>
</td>
<td class="num">(200,368)<span></span>
</td>
<td class="num">(207,298)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Add: Net loss attributable to noncontrolling interest</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Adaptive Biotechnologies Corporation</a></td>
<td class="num">$ (225,250)<span></span>
</td>
<td class="num">$ (200,191)<span></span>
</td>
<td class="num">$ (207,279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic</a></td>
<td class="num">$ (1.56)<span></span>
</td>
<td class="num">$ (1.4)<span></span>
</td>
<td class="num">$ (1.48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic</a></td>
<td class="nump">144,383,294<span></span>
</td>
<td class="nump">142,515,917<span></span>
</td>
<td class="nump">140,354,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted</a></td>
<td class="num">$ (1.56)<span></span>
</td>
<td class="num">$ (1.4)<span></span>
</td>
<td class="num">$ (1.48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted</a></td>
<td class="nump">144,383,294<span></span>
</td>
<td class="nump">142,515,917<span></span>
</td>
<td class="nump">140,354,915<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of right-of-use and related long-lived assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624781824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (225,304)<span></span>
</td>
<td class="num">$ (200,368)<span></span>
</td>
<td class="num">$ (207,298)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gains and losses on investments</a></td>
<td class="nump">4,331<span></span>
</td>
<td class="num">(2,979)<span></span>
</td>
<td class="num">(2,030)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(220,973)<span></span>
</td>
<td class="num">(203,347)<span></span>
</td>
<td class="num">(209,328)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Add: Comprehensive loss attributable to noncontrolling interest</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Adaptive Biotechnologies Corporation</a></td>
<td class="num">$ (220,919)<span></span>
</td>
<td class="num">$ (203,170)<span></span>
</td>
<td class="num">$ (209,309)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754619889552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 743,266<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 1,253,971<span></span>
</td>
<td class="nump">$ 893<span></span>
</td>
<td class="num">$ (511,612)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,646,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised', window );">Issuance of common stock upon exercise of common stock warrant, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options</a></td>
<td class="nump">26,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,674,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">43,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions', window );">Capital contributions for Digital Biotechnologies, Inc.</a></td>
<td class="nump">429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="num">(2,030)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,030)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(207,298)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(207,279)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">604,102<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">1,324,006<span></span>
</td>
<td class="num">(1,137)<span></span>
</td>
<td class="num">(718,891)<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,393,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options</a></td>
<td class="nump">7,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,406,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">55,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="num">(2,979)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,979)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(200,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200,191)<span></span>
</td>
<td class="num">(177)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">464,098<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">1,387,349<span></span>
</td>
<td class="num">(4,116)<span></span>
</td>
<td class="num">(919,082)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,105,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options</a></td>
<td class="nump">$ 2,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options, Shares</a></td>
<td class="nump">470,405<span></span>
</td>
<td class="nump">470,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,506,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 62,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="nump">4,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(225,304)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(225,250)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 308,278<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 1,452,502<span></span>
</td>
<td class="nump">$ 215<span></span>
</td>
<td class="num">$ (1,144,332)<span></span>
</td>
<td class="num">$ (121)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,082,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital capital contributions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, shares, common stock warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares restricted stock award vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754626442224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (225,304)<span></span>
</td>
<td class="num">$ (200,368)<span></span>
</td>
<td class="num">$ (207,298)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">20,532<span></span>
</td>
<td class="nump">19,221<span></span>
</td>
<td class="nump">12,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_NoncashLeaseExpense', window );">Noncash lease expense</a></td>
<td class="nump">6,920<span></span>
</td>
<td class="nump">7,227<span></span>
</td>
<td class="nump">7,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">62,908<span></span>
</td>
<td class="nump">55,477<span></span>
</td>
<td class="nump">43,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible assets amortization</a></td>
<td class="nump">1,699<span></span>
</td>
<td class="nump">1,699<span></span>
</td>
<td class="nump">1,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Investment amortization</a></td>
<td class="num">(9,184)<span></span>
</td>
<td class="nump">741<span></span>
</td>
<td class="nump">7,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets', window );">Impairment of right-of-use and related long-lived assets</a></td>
<td class="nump">25,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_InventoryReserve', window );">Inventory reserve</a></td>
<td class="nump">1,387<span></span>
</td>
<td class="nump">2,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_NoncashInterestExpense', window );">Noncash interest expense</a></td>
<td class="nump">5,300<span></span>
</td>
<td class="nump">985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">172<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">2,032<span></span>
</td>
<td class="num">(22,648)<span></span>
</td>
<td class="num">(7,362)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(2,838)<span></span>
</td>
<td class="nump">817<span></span>
</td>
<td class="num">(5,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,930)<span></span>
</td>
<td class="nump">3,551<span></span>
</td>
<td class="nump">1,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(5,407)<span></span>
</td>
<td class="nump">7,111<span></span>
</td>
<td class="nump">3,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities', window );">Operating lease right-of-use assets and liabilities</a></td>
<td class="num">(8,676)<span></span>
</td>
<td class="num">(4,050)<span></span>
</td>
<td class="nump">8,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(29,291)<span></span>
</td>
<td class="num">(56,496)<span></span>
</td>
<td class="num">(57,727)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other</a></td>
<td class="num">(73)<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="num">(275)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(156,324)<span></span>
</td>
<td class="num">(183,945)<span></span>
</td>
<td class="num">(192,727)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(10,697)<span></span>
</td>
<td class="num">(16,349)<span></span>
</td>
<td class="num">(61,746)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(429,558)<span></span>
</td>
<td class="num">(278,778)<span></span>
</td>
<td class="num">(316,544)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">569,902<span></span>
</td>
<td class="nump">298,032<span></span>
</td>
<td class="nump">559,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">129,647<span></span>
</td>
<td class="nump">2,905<span></span>
</td>
<td class="nump">181,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">2,245<span></span>
</td>
<td class="nump">7,890<span></span>
</td>
<td class="nump">26,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts', window );">Proceeds from revenue interest purchase agreement, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from initial capital contributions for Digital Biotechnologies, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,245<span></span>
</td>
<td class="nump">132,265<span></span>
</td>
<td class="nump">27,146<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(24,432)<span></span>
</td>
<td class="num">(48,775)<span></span>
</td>
<td class="nump">15,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">92,428<span></span>
</td>
<td class="nump">141,203<span></span>
</td>
<td class="nump">125,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">67,996<span></span>
</td>
<td class="nump">92,428<span></span>
</td>
<td class="nump">141,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Noncash investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">687<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
<td class="nump">$ 682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 8,985<span></span>
</td>
<td class="nump">$ 494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of right-of-use and related long-lived assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease right-of-use assets and liabilities .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_InventoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_InventoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_NoncashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_NoncashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from revenue interest purchase agreement, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624402384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization and Description of Business</a></td>
<td class="text"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Organization and Description of Business</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adaptive Biotechnologies Corporation (&#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is a commercial-stage company advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature&#8217;s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient&#8217;s immune system and understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database and related antigen annotations, which are underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that can be tailored to the needs of individual patients. We have commercial products and services and a robust pipeline of clinical products and services that we are designing to diagnose, monitor and enable the treatment of diseases, such as cancer and autoimmune disorders.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were incorporated in the State of Washington on September 8, 2009 under the name Adaptive TCR Corporation. On December 21, 2011, we changed our name to Adaptive Biotechnologies Corporation. We are headquartered in Seattle, Washington.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754628413200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant Accounting Policies</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements include the accounts of Adaptive Biotechnologies Corporation, Adaptive Biotechnologies B.V., our wholly-owned subsidiary, and Digital Biotechnologies, Inc., a corporate subsidiary we have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">70</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% ownership interest in. The remaining interest in Digital Biotechnologies, Inc., held by certain of our related parties and their related family trusts, are shown in the consolidated financial statements as noncontrolling interest. All intercompany transactions and balances have been eliminated upon consolidation.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, imputing interest for our revenue interest purchase agreement (the &#8220;Purchase Agreement&#8221;) that we entered into in September 2022, the provision for income taxes, including related reserves, the analysis of goodwill impairment and the recoverability and impairment of long-lived assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have determined that our chief executive officer is the chief operating decision maker (&#8220;CODM&#8221;). The CODM regularly reviews operating results and other financial information presented on a consolidated basis. While revenue is reviewed at levels lower than the consolidated entity, resource allocation decisions are made by the CODM based on the results presented at the consolidated entity level, which is determined to be a single reporting unit. The consolidated entity operates as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment and represents </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segment. We present disaggregated revenue from contracts with customers by market opportunity and type of arrangement. See Note 3, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. We limit our credit risk associated with cash and cash equivalents by placing our investments with banks that we believe are highly creditworthy and with highly rated money market funds. Cash and cash equivalents primarily consist of bank deposits and investments in money market funds.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We had a restricted cash balance of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023 and 2022, respectively. Our restricted cash primarily relates to certain balances we are required to maintain under lease arrangements for some of our property and facility leases.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investments in Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable securities are classified as available-for-sale, consist of United States (&#8220;U.S.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) government treasury and agency securities, corporate bonds and commercial paper and are reported at fair value. Unrealized holding gains and losses are reflected as a separate component of shareholders&#8217; equity in accumulated other comprehensive gain (loss) until realized. Realized gains and losses on the sale of these securities are recognized in net income or loss. The cost of marketable securities sold is based on the specific identification method.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Financial Accounting Standards Board (&#8220;FASB&#8221;) has defined fair value as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. The FASB established a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The hierarchy defines three levels of inputs that may be used to measure fair value:</span></p><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></div></div><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div></div><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A financial instrument categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. In certain cases, where there is limited activity or less transparency around valuation inputs, financial instruments are classified as Level 3 within the valuation hierarchy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our financial instruments consist of Level 1 and Level 2 assets and have included Level 3 liabilities in the past. The carrying amounts of certain financial instruments approximate fair value due to their short maturities. We did not have any nonfinancial assets or liabilities that were measured or disclosed at fair value on a recurring basis as of December 31, 2023 and 2022.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to a concentration of risk from a limited number of suppliers, or in certain cases, single suppliers, for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, U.S. government treasury and agency securities, corporate bonds and commercial paper with high-quality accredited financial institutions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant customers are those that represent more than ten percent of our total revenue or accounts receivable, net balances for the periods and as of each consolidated balance sheet date presented, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:44.5%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:9.94%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:9.94%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:9.94%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:9.94%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:9.94%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Revenue</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accounts Receivable, Net</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Customer A</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*%</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*%</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*%</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*%</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.8</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Customer B</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.6</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19.5</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Genentech, Inc. and Roche Group</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27.8</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36.4</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41.9</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">* less than 10%</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable consists of amounts due from customers for services performed. We review our accounts receivable for credit impairment and regularly analyze the status of significant past due receivables to determine if any will potentially be uncollectible to estimate the amount of allowance necessary to reduce accounts receivable to its estimated net realizable value.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventory</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventory consists of laboratory materials and supplies used in lab analysis. We capitalize inventory when purchased and record expense upon order fulfillment for servicing revenue or utilization in our research and development laboratories. Inventory is valued at the lower of cost or market on a first-in, first-out basis. We periodically perform obsolescence assessments and write-off any inventory that is no longer usable. Long-term inventory of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was included within the other assets balance on the consolidated balance sheet as of December 31, 2023 and 2022, respectively.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment consists of computer equipment, computer software, laboratory equipment, leasehold improvements, furniture and office equipment and assets under construction. Property and equipment are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life. Maintenance and repairs are charged to expense as incurred and costs of improvements are capitalized.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Useful lives assigned to property and equipment are as follows:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:84.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.14%;"></td>
          <td style="width:1.72%;"></td>
          <td style="width:49.14%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_de9ea103-2ab7-4e3e-8c48-d7bbaf7c674a;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of estimated useful life or remaining lease term</span></span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment and software</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and office equipment</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7 years</span></span></p></td>
         </tr>
        </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We review long-lived assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Gains and losses from asset disposals and impairment losses, if incurred, are classified within the consolidated statements of operations in accordance with the use of the asset, if not separately stated within its own financial statement line item. See Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for more information regarding the leasehold improvements impairment loss recognized during the year-ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intangible Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date, which is regarded as their cost.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets may also result from the purchase of assets and intellectual property in a transaction that does not qualify as a business combination. Intangible assets are amortized over their estimated useful lives on a straight-line basis which approximates their usage pattern. Intangible assets are reviewed for impairment at least annually or if indicators of potential impairment exist. We have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognized any impairment losses on intangible assets.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October 1, or more frequently if events or changes in circumstances would more likely than not reduce the fair value of our single reporting unit below its carrying value. We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we so determine, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. If impairment exists, the carrying value of the goodwill is reduced to its fair value through an impairment charge recorded in the consolidated statements of operations. To date, we have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognized any impairment of goodwill.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory, office and warehouse facilities that we occupy. Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of January 1, 2020 for commenced leases that existed as of our adoption of Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Topic 842) (&#8220;ASC 842&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain of our leases contain options to extend or terminate the lease; lease terms are adjusted for these options only when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory, office and warehouse facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on the consolidated balance sheets a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We review our right-of-use assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Impairment losses are classified within the consolidated statements of operations in accordance with the use of the asset, if not separately stated within its own financial statement line item. See Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for more information regarding the right-of-use asset impairment loss recognized during the year-ended December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lease expense is recognized on a straight-line basis over the terms of the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the terms of the leases.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Interest Liability, Net and Related Imputed Interest</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The revenue interest liability balance associated with the Purchase Agreement that we entered into in September 2022 is presented net of unamortized issuance costs on the consolidated balance sheets. We impute our associated interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. The effective interest rate may vary during the term of the agreement depending on a number of factors, including changes in forecasted GAAP revenues. We evaluate the effective interest rate quarterly based on both achieved and forecasted revenues, utilizing the prospective method. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense and the time period for repayment.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1) identify the contract or contracts; (2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3) measure the transaction price, including the constraint on variable consideration; (4) allocate the transaction price to the performance obligations based on estimated selling prices; and (5) recognize revenue when (or as) we satisfy each performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We derive revenue by providing diagnostic and research services in our Immune Medicine and Minimal Residual Disease (&#8220;MRD&#8221;) business areas. Our Immune Medicine revenue consists of revenue generated from (1) providing sample testing services for our commercial research product, Adaptive Immunosequencing, to biopharmaceutical customers and academic institutions; (2) our collaboration agreements with Genentech, Inc. (&#8220;Genentech&#8221;) and other biopharmaceutical customers in areas of drug and target discovery; and (3) for prior years, providing our T-Detect COVID tests to clinical customers. Our MRD revenue consists of revenue generated from (1) providing our clonoSEQ report to clinical customers; (2) providing MRD sample testing services to biopharmaceutical customers and certain academic institutions, including investigator-led clinical trials; and (3) providing our clonoSEQ report or results to certain international laboratory sites through technology transfers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For research customers who utilize either Adaptive Immunosequencing or our MRD services, contracts typically include an amount billed in advance of services (&#8220;upfront&#8221;) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> typical performance obligations under the terms of our research service contracts: (1) the delivery of our Adaptive Immunosequencing or MRD data for customer provided samples; and (2) related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the total samples expected to be delivered.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For agreements where we provide our clonoSEQ report to ordering physicians, we have identified one performance obligation: the delivery of a clonoSEQ report. We bill and receive payments for these transactions from commercial, government and medical institution payors. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted, as necessary, based on actual collection experience.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regarding our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test report. This billing contemplates all necessary tests required during a patient&#8217;s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test report is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient&#8217;s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized either as we deliver our estimate of the remaining tests in a patient&#8217;s treatment cycle or when the likelihood becomes remote that a patient will receive additional testing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The contract transaction price for agreements we enter into with biopharmaceutical customers to further develop and commercialize their therapeutics may consist of a combination of non-refundable upfront fees, separately priced MRD testing fees and milestone fees earned upon our customers&#8217; achievement of certain regulatory approvals. Depending on the contract, these agreements include single or multiple performance obligations. Such performance obligations include providing services to support our customers&#8217; therapeutic development efforts, including regulatory support for our technology intended to be utilized as part of our customers&#8217; registrational trials, developing analytical plans for our data, participating on joint research committees, assisting in completing a regulatory submission and providing MRD testing services related to customer-provided samples for our customers' regulatory submissions. Generally, the support services, excluding MRD testing services, are not distinct within the context of the contract and thus are accounted for as a single performance obligation. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated MRD testing services. When MRD sample testing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional MRD sample testing services is not considered part of the contract. We recognize revenue related to MRD testing services over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered, when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method using a cost-based model based on estimates of effort completed. Selecting the measure of progress and estimating progress to date requires significant judgment. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. At contract inception, we fully constrain any consideration related to regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers&#8217; own submission decision-making. Variable consideration related to regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue will not occur. Milestone payments for regulatory approvals, which are not within our customers&#8217; control, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2021, we executed an intellectual property license agreement that includes variable consideration related to sales-based royalties. Any consideration related to such royalties will be recognized as revenue at the later of when (i) the related sales occur or (ii) the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied (or partially satisfied).</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contract Balances</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In certain circumstances, billing may occur prior to services being performed. Upfront payments are recorded as deferred revenue, or contract liabilities. We classify deferred revenue as current when we expect our performance obligations will be completed within the next twelve months; however, we do not control the timing of customer provided samples. For service and collaboration activities, excluding those related to our worldwide collaboration and license agreement with Genentech, we assess the performance obligations and recognize deferred revenue as current or non-current based upon forecasted delivery times, which are customer coordinated. In certain circumstances, a customer project may be cancelled or terminated prior to the delivery of all related services covered by a customer&#8217;s upfront payment. In these circumstances, we recognize revenue when sufficient evidence is obtained that a reversal of revenue is not probable. We also recognize revenue when our estimate of total samples to be provided under certain of our agreements is reduced or, in the case of contract balances related to Medicare, when the likelihood becomes remote that a patient will receive additional testing. See Note 3, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for our deferred revenue policy related to our worldwide collaboration and license agreement with Genentech.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation includes compensation expense for stock option, restricted stock unit and market-based restricted stock unit grants made to employees and non-employees. It represents the grant date fair value of the grants and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of actual forfeitures. We estimate the grant date fair value of stock option and market-based restricted stock unit grants using the Black-Scholes option-pricing model and the Monte Carlo valuation model, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Advertising</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Advertising costs are expensed as incurred. Advertising expenses were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023, 2022 and 2021, respectively.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cost of Revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cost of revenue includes the cost of materials, personnel-related expenses (including salaries, benefits and share-based compensation), shipping and handling expenses, equipment costs, allocated facility costs associated with processing samples and professional support costs related to our service revenue activities. Allocated facility costs include depreciation of laboratory equipment, as well as allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consist of laboratory materials costs, personnel-related expenses (including salaries, benefits and share-based compensation), equipment costs, allocated facility and information technology costs and contract service expenses. Research and development activities support further development and refinement of existing assays and products, discovery of new technologies and investments in our immune medicine platform. We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. Additionally, a component of our research and development expenses are costs supporting clinical and analytical validations to obtain regulatory approval for future clinical products and services. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Upfront payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized, then are recognized as an expense as the goods are consumed or the related services are performed. Costs to support our worldwide collaboration and license agreement with Genentech are also a component of our research and development expenses.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales and Marketing Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales and marketing expenses include personnel-related expenses (including salaries, benefits and share-based compensation) for commercial sales, product and account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility and information technology costs.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Right-of-Use and Related Long-Lived Assets Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Impairment of right-of-use and related long-lived assets expenses include our impairment charge for certain leased office and laboratory space, as well as impairment costs for related leasehold improvements.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest expense includes costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. We impute interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred tax assets and liabilities are measured at the consolidated balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in the period such tax rate changes are enacted. Our net deferred tax assets are fully offset by a valuation allowance, because of our history of losses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize the effect of income tax positions only if those positions are more likely than not of being sustained upon examination.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We calculate basic net loss per share attributable to our common shareholders by dividing net loss attributable to us by our weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to our common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, outstanding common stock warrants, outstanding stock options, nonvested restricted stock units outstanding and the maximum nonvested market-based restricted stock units outstanding eligible to be earned are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to our common shareholders, as their effect is anti-dilutive.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Topic 280): </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which intends to enhance reportable segment disclosures about significant segment expenses. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the guidance is to be applied retrospectively. We are currently evaluating the impact of this guidance on our consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Topic 740): </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which primarily intends to enhance the rate reconciliation and income taxes paid disclosures. This guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted and the guidance is to be applied prospectively; retrospective application is permitted. We are currently evaluating the impact of this guidance on our consolidated financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754628637648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We disaggregate our revenue from contracts with customers by business area and type of arrangement, as we believe this best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents our disaggregated revenue for the periods presented (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Immune Medicine revenue</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Service revenue</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,959</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,777</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,482</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration revenue</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,578</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,387</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,651</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Immune Medicine revenue</span></p></td>
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,537</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98,164</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,133</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">MRD revenue</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Service revenue</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,739</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81,144</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56,211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Regulatory milestone revenue</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total MRD revenue</span></p></td>
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,739</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,144</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenue</span></p></td>
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,276</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">185,308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">154,344</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in Immune Medicine service revenue related to cancelled customer contracts. Additionally, during the year ended December 31, 2023, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in MRD service revenue related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote, cancelled customer contracts and changes in estimates of total samples to be provided under certain of our agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2022, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in Immune Medicine service revenue related to cancelled customer contracts. Additionally, during the year ended December 31, 2022, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in MRD service revenue related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote, changes in estimates of total samples to be provided under certain of our agreements and cancelled customer contracts.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2021, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in MRD service revenue related to changes in estimates of total samples to be provided under certain of our agreements, Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote, a change in our estimate of expected cumulative tests per patient for one of our covered indications and cancelled customer contracts.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we could receive up to an additional </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">440.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">milestone payments in future periods if certain regulatory approvals are obtained by our customers&#8217; therapeutics in connection with MRD data generated from our MRD product.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Genentech Collaboration Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2018, we entered into a worldwide collaboration and license agreement with Genentech (the &#8220;Genentech Agreement&#8221;) to leverage our capability to develop cellular therapies in oncology. Subsequent to receipt of regulatory approval in January 2019, we received a non-refundable, upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">300.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in February 2019 and may be eligible to receive more than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">1.8</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion over time, including payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">75.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of specified regulatory milestones ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of which was achieved in May 2023), up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">300.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of specified development milestones and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">1,430.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of specified commercial milestones. In addition, we are separately able to receive tiered royalties at a rate ranging from the mid-single digits to the mid-teens on aggregate worldwide net sales of products arising from the strategic collaboration, subject to certain reductions, with aggregate minimum floors. Under the Genentech Agreement, we are pursuing two product development pathways for novel T cell therapeutic products in which Genentech intends to use T cell receptors (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8220;TCRs&#8221;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) screened by our immune medicine platform to engineer and manufacture cellular medicines:</span></p><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shared Products. The shared products will use &#8220;off-the-shelf&#8221; TCRs identified against cancer antigens shared among patients (&#8220;Shared Products&#8221;). </span></div></div><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Personalized Product. The personalized product will use patient-specific TCRs identified by real-time screening of TCRs against cancer antigens in each patient (&#8220;Personalized Product&#8221;). </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Genentech Agreement, we granted Genentech exclusive worldwide licenses to develop and commercialize TCR-based cellular therapies in the field of oncology, including licenses to existing shared antigen data packages. Additionally, Genentech has the right to determine which product candidates to further develop for commercialization purposes. We determined that this arrangement meets the criteria set forth in Accounting Standards Codification (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8220;ASC&#8221;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) Topic 808, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaborative Arrangements</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASC 808&#8221;), because both parties are active participants in the activity and are exposed to significant risks and rewards depending on the activity&#8217;s commercial failure or success. Because ASC 808 does not provide guidance on how to account for the activities under a collaborative arrangement, we applied the guidance in ASC Topic 606, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8220;ASC 606&#8221;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) to account for the activities related to the Genentech Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In applying ASC 606, we identified the following performance obligations at the inception of the agreement:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">License to utilize on an exclusive basis all TCR-specific platform intellectual property to develop and commercialize any licensed products in the field of oncology. </span></div></div><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">License to utilize all data and information within each shared antigen data package and any other know-how disclosed by us to Genentech in oncology. </span></div></div><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">License to utilize all private antigen TCR product data in connection with research and development activities in the field of use. </span></div></div><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">License to existing shared antigen data packages. </span></div></div><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development services for Shared Products development, including expansion of shared antigen data packages. </span></div></div><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development services for private product development. </span></div></div><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obligations to participate on various joint research, development and project committees. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We determined that none of the licenses, research and development services or obligations to participate on various committees were distinct within the context of the contract, given such rights and activities were highly interrelated and there was substantial additional research and development to further develop the licenses. We considered factors such as the stage of development of the respective existing antigen data packages, the subsequent development that would be required to both identify and submit a potential target for investigational new drug acceptance under both product pathways and the variability in research and development pathways given Genentech&#8217;s control of product commercialization. Specifically, under the Genentech Agreement, Genentech is not required to pursue development or commercialization activities pertaining to both product pathways and may choose to proceed with one or the other. Accordingly, we determined that all of the identified performance obligations were attributable to one general performance obligation, which is to further the development of our TCR-specific platform, including data packages, and continue to make our TCR identification process available to Genentech to pursue either product pathway.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Separately, we have a responsibility to Genentech to enter into a supply and manufacturing agreement for patient-specific TCRs as it pertains to any Personalized Product therapeutic. We determined this was an option right of Genentech should they pursue commercialization of a Personalized Product therapy. Because of the uncertainty resulting from the early stage of development, the novel approach of our collaboration with Genentech and our rights to future commercial milestones and royalty payments, we determined that this option right was not a material right that should be accounted for at inception. As such, we will account for the supply and manufacturing agreement when entered into between the parties.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We determined the initial transaction price shall be made up of only the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">300.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upfront, non-refundable payment, as all potential regulatory and development milestone payments were probable of significant revenue reversal given their achievement was highly dependent on factors outside our control. As a result, these payments were fully constrained and were not included in the initial transaction price. In May 2023, one of the regulatory milestones was achieved, resulting in a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million addition to the transaction price, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">7.7</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of which was recognized as revenue in the three months ended June 30, 2023, with the remainder included in deferred revenue to be recognized as revenue over the remaining research and development period. We continue to exclude the commercial milestones and potential royalties from the transaction price, as those items relate predominantly to the license rights granted to Genentech and will be assessed when and if such events occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As there are potential substantive developments necessary, which Genentech may be able to direct, we determined that we would apply a proportional performance model to recognize revenue for our performance obligation. We measure proportional performance using an input method based on costs incurred relative to the total estimated costs of research and development efforts to pursue both the Shared Products and Personalized Product pathways. When any of the potential regulatory and development milestones are no longer fully constrained and are included in the transaction price, such amounts will be recognized using the cumulative catch-up method based on proportional performance at such time. We currently expect to recognize revenue generated from the Genentech Agreement over a period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nine years</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the effective date. This estimate of the research and development period considers pursuit options of development activities supporting both the Shared Products and Personalized Product, but may be reduced or increased based on the various activities as directed by the joint committees, decisions made by Genentech, regulatory feedback or other factors not currently known.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In total, we recognized </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">42.6</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">62.8</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">62.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in Immune Medicine collaboration revenue during the year ended December 31, 2023, 2022 and 2021, respectively, related to the Genentech Agreement. Costs related to the Genentech Agreement are included in research and development expenses.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754628676528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_DeferredRevenueTextBlock', window );">Deferred Revenue</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred Revenue</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue from the Genentech Agreement represents </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">41.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the current and non-current deferred revenue balances on the consolidated balance sheet, respectively, as of December 31, 2023 and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">31.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">55.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the current and non-current deferred revenue balances on the consolidated balance sheet, respectively, as of December 31, 2022. We expect our current deferred revenue to be recognized as revenue within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months. We expect the majority of our non-current deferred revenue to be recognized as revenue over a period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from December 31, 2023. This period of time represents an estimate of the research and development period to develop cellular therapies in oncology, which may be reduced or increased based on various research and development activities.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in deferred revenue during the year ended December 31, 2023 were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,714</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions to deferred revenue during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,471</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue recognized during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73,762</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93,423</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">53.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recognized as revenue that was included in the deferred revenue balance at December 31, 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DeferredRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DeferredRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624759824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables set forth the fair values of financial assets as of December 31, 2023 and 2022 that were measured at fair value on a recurring basis (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,630</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,630</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government treasury and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">264,426</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">264,426</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">281,337</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">326,460</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,502</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,502</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,969</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,969</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">385,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">385,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,349</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,349</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,502</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">408,166</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">446,668</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1 securities include highly liquid money market funds, for which we measure the fair value based on quoted prices in active markets for identical assets or liabilities. Level 2 securities consist of U.S. government treasury and agency securities, corporate bonds and commercial paper, and are valued based on recent trades of securities in inactive markets or on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624429072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investments</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Available-for-sale investments consisted of the following as of December 31, 2023 and 2022 (in thousands):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term marketable securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,630</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,630</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government treasury and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">264,214</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">232</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">264,426</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,278</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">281,122</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">235</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">281,337</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term marketable securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,969</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,969</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">389,898</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,064</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">385,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,415</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,349</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">412,282</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,130</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">408,166</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All the U.S. government treasury and agency securities, corporate bonds and commercial paper designated as short-term marketable securities have an effective maturity date that is equal to or less than one year from the respective consolidated balance sheet date. Those that are designated as long-term marketable securities have an effective maturity date that is more than one year from the respective consolidated balance sheet date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued interest receivable is excluded from the amortized cost and estimated fair value of our marketable securities. Accrued interest receivable of </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was presented separately within the prepaid expenses and other current assets balance on the consolidated balance sheet as of December 31, 2023 and 2022, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the gross unrealized holding losses and fair values for investments in an unrealized loss position, and the length of time individual securities have been in a continuous loss position, as of December 31, 2023 (in thousands):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Less Than 12 Months</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">12 Months Or Greater</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government treasury and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total available-for-sale securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,100</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We periodically review our available-for-sale securities to assess for credit impairment. Some of the factors considered in assessing impairment include the extent to which the fair value is less than the amortized cost basis, adverse conditions related to the security, an industry or geographic area, changes to security ratings or sector credit ratings and other relevant market data.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we did not intend, nor were we more likely than not to be required, to sell our available-for-sale investments before the recovery of their amortized cost basis, which may be maturity. Based on our assessment, we concluded all impairment as of December 31, 2023 to be due to factors other than credit loss, such as changes in interest rates. A credit allowance was not recognized and the impairment of our available-for-sale securities was recorded in other comprehensive loss.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754626445392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and Equipment, Net</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net as of December 31, 2023 and 2022 consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,567</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,592</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,970</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,766</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and office equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,820</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,342</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,965</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,069</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,405</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,625</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,734</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,403</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment, at cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141,461</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">137,797</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73,234</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,350</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,227</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83,447</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">20.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023, 2022 and 2021, respectively. See Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for details regarding the impairment loss we recognized for certain leasehold improvements for the year ended December 31, 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624232768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill and Intangible Assets</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> changes in the carrying amount of goodwill since its recognition in 2015.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets subject to amortization as of December 31, 2023 and 2022 consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Carrying Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated Amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net Carrying Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquired developed technology</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,970</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,030</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchased intellectual property</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">325</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">227</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,325</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,197</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,128</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Carrying Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated Amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net Carrying Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquired developed technology</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,304</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,696</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchased intellectual property</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">325</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">194</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,325</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,498</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,827</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The developed technology was acquired in connection with our acquisition of Sequenta, Inc. in 2015. The remaining balance of the acquired developed technology and the purchased intellectual property is expected to be amortized over the next </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.0</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, expected future amortization expense for intangible assets was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,703</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,699</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,699</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total future amortization expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,128</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624510928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued Liabilities</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued liabilities as of December 31, 2023 and 2022 consisted of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,920</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,744</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clinical and contract research organization costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">863</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,533</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Travel and entertainment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">154</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">233</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">194</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">687</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,680</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer and software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,151</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,385</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">763</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,655</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,597</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,424</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624510928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have operating lease agreements for laboratory, office and warehouse facilities that we occupy in various locations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2011, we entered into a non-cancelable lease agreement with an, at the time, minority shareholder for office and laboratory space in Seattle, Washington. The lease terms were subsequently amended multiple times, most recently in August 2019, when we expanded the existing premises to approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">65,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash payment for rent of the expanded premises commenced </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 2020</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, four months after the landlord delivered the expanded premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 2032</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, subject to our option to twice extend the lease for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The amended lease also requires us to pay additional amounts for operating and maintenance expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, we vacated this leased space. As such, we assessed the right-of-use asset and related leasehold improvements (together, the "asset group") for impairment by first comparing the carrying amount of the asset group to future net undiscounted cash flows projected to be generated over the remaining lease term. These projections include management's estimates of cash inflows from potential sublease income and outflows for operating and maintenance expenses. The carrying amount was found to be unrecoverable, thus we assessed the asset group's fair value. The extent to which the asset group's carrying amount exceeds its fair value represents the impairment cost to be recognized. Fair value was determined using the income approach, whereby we discounted estimated net cash flows using a rate commensurate with our estimated incremental borrowing rate. As a result of this assessment, which included unrecoverable operating and maintenance costs, we determined that the asset group was to be fully impaired. As such, an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_644ede94-23a3-4d5b-89f7-eb3175c3cb6c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impairment charge</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recognized during the year ended December 31, 2023, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to the right-of-use asset and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to the long-lived leasehold improvements, all of which were held for use.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2019, we entered into an agreement to rent approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet in what was a to-be-constructed, new headquarters building in Seattle, Washington. In connection with the lease, we entered into a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million letter of credit with one of our existing financial institutions. The lease commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 2020</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, when the landlord delivered the premises to us for construction of certain tenant improvements. We occupied the new building in 2021, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cash payment for rent began in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the lease term ends in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 2033</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject to our option to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twice extend the lease</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In connection with this lease, the landlord agreed to fund $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in improvements, which was subsequently reduced to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as a result of our change requests made during landlord construction of the building, net of an administration fee. As of December 31, 2022, we incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in certain tenant improvement costs, all of which had been reimbursed by the landlord. As of December 31, 2021, we incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in certain tenant improvement costs, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million had been reimbursed by the landlord. The remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is presented as a reduction in the cash flows used to measure our ROU asset and lease liabilities on the consolidated balance sheet as of December 31, 2021. The lease also requires us to pay additional amounts for operating and maintenance expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2018, we entered into a lease agreement to lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13,400</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet in South San Francisco, California. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The lease term is through </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and provides for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> extension option</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We are responsible for our share of allocable operating expenses, tax expenses and utilities costs during the duration of the lease term. In connection with the lease, the landlord funded agreed-upon improvements. The landlord was solely responsible for the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million cost of such improvements. The lease agreement was amended in February 2020 to lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19,900</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional square feet and provides for a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million tenant improvement allowance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2021, we executed a lease to rent approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of a warehouse in Bothell, Washington, which we classified as an operating lease upon commencement during the year ended December 31, 2021. Rent obligations commenced in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the lease expires </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 2031</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject to an early termination option after the seventh year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and an </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">option to twice extend the lease for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The lease requires us to pay certain operating expenses. Furthermore, the landlord agreed to fund $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in improvements in connection with this lease.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we were not party to any finance leases. Our leases have remaining terms ranging from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.2</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9.7</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and include </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">options to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">extend certain of the leases</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> up to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10.0</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and terminate certain of the leases after </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7.0</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years of leasing. We adjust lease terms for these options only when it is reasonably certain we will exercise these options.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other information related to our operating leases as of December 31, 2023 and 2022 was as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.379999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.379999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.91</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.75</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities, less current portion balance on the consolidated balance sheet as of December 31, 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,692</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,098</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,330</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,944</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,282</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56,962</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121,308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Imputed interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,536</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98,772</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,384</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, less current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,388</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating lease expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023, 2022 and 2021, respectively. Variable lease expense for operating leases was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023, 2022 and 2021, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities for the year ended December 31, 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Cash paid for amounts included in the measurement of lease liabilities for the year ended December 31, 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, net of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of cash received for tenant improvement allowances. Cash paid for amounts included in the measurement of lease liabilities was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and cash received for tenant improvement allowances was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the year ended December 31, 2021. For the year ended December 31, 2021, ROU assets obtained in exchange for operating lease liabilities was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754710136352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Purchase Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueInterestPurchaseAgreementTextBlock', window );">Revenue Interest Purchase Agreement</a></td>
<td class="text"><div style="font-size:0;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue Interest Purchase Agreement</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Interest Purchase Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2022, we entered into the Purchase Agreement with OrbiMed Royalty &amp; Credit Opportunities IV, LP (&#8220;OrbiMed&#8221;), an affiliate of OrbiMed Advisors LLC, as collateral agent and administrative agent for the purchasers party thereto (the &#8220;Purchasers&#8221;). Pursuant to the Purchase Agreement, we received $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">125.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the Purchasers at closing (the &#8220;First Payment&#8221;), less certain transaction expenses. We are also entitled to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">125.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in subsequent installments as follows: (i) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon our request occurring no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 12, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the &#8220;Second Payment&#8221;) and (ii) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon our request in connection with certain permitted acquisitions occurring no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 12, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the &#8220;Third Payment&#8221;), in each case subject to certain funding conditions. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To secure our obligations under the Purchase Agreement, we and our subsidiaries have granted OrbiMed a security interest in our core platform technology assets, subject to certain customary exclusions, as defined in the Purchase Agreement.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Interest Payments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As consideration for such payments, the Purchasers have a right to receive certain revenue interests (the &#8220;Revenue Interests&#8221;) from us based on a percentage (the &#8220;Applicable Payment Percentage&#8221;) of all GAAP revenue (the &#8220;Revenue Base&#8221;). If only the First Payment has been made, the Applicable Payment Percentage shall be five percent of the quarterly Revenue Base. If both the First Payment and Second Payment have been made, the Applicable Payment Percentage shall be eight percent of the quarterly Revenue Base. If each of the First Payment, Second Payment and Third Payment have been made, the applicable payment percentage applied to the Revenue Interest shall be ten percent of the quarterly Revenue Base.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payments in respect of the Revenue Interests shall be made quarterly within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days following the end of each fiscal quarter (each, a &#8220;Revenue Interest Payment&#8221;). If OrbiMed has not received Revenue Interest Payments in the aggregate equal to or greater than the sum of its invested capital (the &#8220;Cumulative Purchaser Payments&#8221;) on or prior to September 12, 2028, the revenue interest rate shall be increased to a rate which, if applied retroactively to our cumulative Revenue Base, would have resulted in Revenue Interest Payments equal to the sum of all Cumulative Purchaser Payments.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Return Cap</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OrbiMed will be entitled to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Revenue Interest Payments until it has received a total cumulative value of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">165</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Cumulative Purchaser Payments (the &#8220;Return Cap&#8221;), unless full repayment of the amount of the Return Cap has not been made by </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 12, 2032</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, in which case the Return Cap shall be increased to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">175</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Cumulative Purchaser Payments.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Put/Call Options</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the occurrence of a Put Option Event (as defined in the Purchase Agreement), including material divestitures by us, a change in control, material judgments, or bankruptcy events, Purchasers representing at least a majority of the purchase commitments under the Purchase Agreement shall have the right but not the obligation ("the Put Option") to require us to repurchase all of the outstanding Revenue Interests at the applicable price (the &#8220;Put/Call Price&#8221;). Additionally, at any time following receipt of the First Payment, we may exercise a call option to repurchase all Revenue Interests at the applicable Put/Call Price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For all Put Option Events other than a change of control or a material divestiture, the Put/Call Price shall be an amount equal to the applicable Return Cap. For a change of control or a material divestiture, prior to March 12, 2024, the Put/Call Price shall be an amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Cumulative Purchaser Payments less the sum of all Revenue Interest Payments made by us to the Purchasers prior to such date, between March 12, 2024 and September 12, 2024, the Put/Call Price shall be an amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">125</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Cumulative Purchaser Payments less the sum of all Revenue Interest Payments made by us to the Purchasers prior to such date, and after September 12, 2024, the Put/Call Price shall be equal to the applicable Return Cap.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Treatment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We evaluated the terms of the Purchase Agreement and concluded that the features of the Cumulative Purchaser Payments are similar to those of a debt instrument. Accordingly, we accounted for the transaction as debt recorded at amortized cost using the effective interest rate method. We further evaluated the terms of the debt and determined that the Put Option that is exercisable by the Purchasers upon certain contingent events requires bifurcation as a derivative. However, the value of the Put Option was determined to be immaterial due to the remote possibility of exercise. We assess the value of the Put Option periodically.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To determine the amortization of the Purchase Agreement obligation, we are required to estimate the amount and timing of future Revenue Interest Payments based on our estimate of the timing and amount of future revenues and calculate an effective interest rate which will amortize the obligation to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> over the amortization period. The calculated effective interest rate as of December 31, 2023 was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Purchase Agreement, we incurred debt issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Debt issuance costs have been recorded to debt and are being amortized over the estimated term of the debt using the effective interest method, adjusted on a prospective basis for changes in the underlying assumptions and inputs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The assumptions used in determining the expected repayment term of the obligation and amortization period of the issuance costs requires that we make estimates that could impact the short- and long-term classification of these costs, as well as the period over which these costs will be amortized. We periodically assess the amount and timing of expected Revenue Interest Payments based on internal forecasts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different than our original estimates, we will prospectively adjust the amortization of the revenue interest liability and the effective interest rate.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the revenue interest liability, net activity during the years ended December 31, 2023 and 2022 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest liability at inception</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">625</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,238</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest paid</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">493</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,760</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest liability, net at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125,360</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,800</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest paid</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,225</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,275</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest liability, net at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130,660</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue interest payable of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was included within the accounts payable balance on the consolidated balance sheet as of December 31, 2023 and 2022, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueInterestPurchaseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue interest purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueInterestPurchaseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754626445392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commitments and Contingencies</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal Proceedings</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to claims and assessments from time to time in the ordinary course of business. We will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. We were not party to any material legal proceedings as of December 31, 2023.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Indemnification Agreements</span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, we may provide indemnification of varying scope and terms to vendors, lessors, customers and other parties with respect to certain matters including, but not limited to, losses arising out of breach of our agreements with them or from intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with members of our board of directors and certain of our executive officers that will require us to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments that we could be required to make under these indemnification agreements is, in many cases, unlimited. We have not incurred any material costs as a result of such indemnifications and are not currently aware of any indemnification claims.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754710139872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shareholders&#8217; Equity</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock has no preferences or privileges and is not redeemable. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders of our common stock are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> vote for each share of common stock held</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The holders of record of outstanding shares of common stock shall be entitled to receive, when, as and if declared, out of funds legally available, such cash and other dividends as may be declared from time to time.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">had reserved shares of common stock for the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.36%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares issuable upon the exercise of outstanding stock options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,875,045</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares issuable upon the vesting of outstanding restricted stock units granted and the maximum outstanding market-based restricted stock units eligible to be earned</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,582,134</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for future grant under the 2019 Equity Incentive Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,299,763</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for future grant under the Employee Stock Purchase Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,235,348</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total shares of common stock reserved for future issuance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,992,290</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) provides for annual increases in the number of shares that may be issued under the 2019 Plan on January 1, 2020 and on each subsequent January 1, thereafter, by a number of shares equal to the lesser of (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, our Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) provides for annual increases in the number of shares available for issuance under our ESPP on January 1, 2020 and on each January 1, thereafter, by a number of shares equal to the smallest of (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective January 1, 2023, our 2019 Plan and ESPP reserves increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,155,250</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,431,050</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, respectively. Effective January 1, 2024, our 2019 Plan and ESPP reserves increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,254,113</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,450,822</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624438800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equity Incentive Plans</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2009 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We adopted an equity incentive plan in 2009 (the &#8220;2009 Plan&#8221;) that provided for the issuance of incentive and nonqualified common stock options and other share-based awards for employees, directors and consultants. Under the 2009 Plan, the exercise price for incentive and nonqualified stock options were not to be less than the fair market value of our common stock at the date of grant. Stock options granted under this plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the grant date and vesting was established at the time of grant. Pursuant to the terms of the 2019 Plan, any shares subject to outstanding stock options originally granted under the 2009 Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof shall become available for issuance pursuant to awards granted under the 2019 Plan. While </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares are available for future grant under the 2009 Plan, it continues to govern outstanding equity awards granted thereunder.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2019 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2019 Plan became effective immediately prior to the closing of our initial public offering in July 2019. The 2019 Plan provides for the issuance of awards in the form of stock options and other share-based awards for employees, directors and consultants. Under the 2019 Plan, the stock option exercise price per share shall not be less than the fair market value of a share of stock on the effective date of grant, as defined by the 2019 Plan, unless explicitly qualified under the provisions of Section 409A or Section 424(a) of the Internal Revenue Code of 1986. Additionally, unless otherwise specified, stock options granted under this plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the grant date and vesting is established at the time of grant. Except for certain stock option and restricted stock unit grants made to non-employee directors, stock options and restricted stock units granted under the 2019 Plan generally vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period, subject to continuous service through each applicable vesting date. As of December 31, 2023, we had </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">34,853,581</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock authorized for issuance under the 2019 Plan.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in shares available for grant during the year ended December 31, 2023 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.36%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares Available for Grant</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for grant at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,581,975</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2019 Equity Incentive Plan reserve increase effective January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,155,250</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,980,059</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options and restricted stock units forfeited or expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,542,597</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for grant at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,299,763</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option activity under the 2009 Plan and 2019 Plan during the year ended December 31, 2023 was as follows:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.2%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.780000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.780000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares Subject to<br/>Outstanding Stock Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Exercise<br/>Price per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,520,997</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.88</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,612,032</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.46</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,030,388</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.07</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">757,191</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22.92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">470,405</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.77</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,875,045</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.90</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">506</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options vested and exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,071,627</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">506</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average remaining contractual life for stock options outstanding as of December 31, 2023 was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6.2</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. The weighted-average remaining contractual life for vested and exercisable stock options as of December 31, 2023 was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.3</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total intrinsic value of stock options exercised during the year ended December 31, 2023, 2022 and 2021 was </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">7.6</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">156.5</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">26.7</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million proceeds from exercise of stock options included on the consolidated statements of cash flows for the year ended December 31, 2021, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million related to stock options exercised during the year ended December 31, 2020 but settled during the year ended December 31, 2021.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted stock unit activity under the 2019 Plan during the year ended December 31, 2023 was as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Restricted Stock Units<br/>Outstanding</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Grant Date<br/>Fair Value per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested restricted stock units outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,981,755</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,949,587</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.29</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,755,018</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,506,864</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.95</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested restricted stock units outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,669,460</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.32</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total fair value of restricted stock units vested during the year ended December 31, 2023, 2022 and 2021 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">12.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Market-Based Restricted Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the restricted stock units described above, our board of directors approved awards of market-based restricted stock units to our chief executive officer and chief scientific officer in March 2023. The shares of common stock that may be earned under the awards, each ranging from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">709,220</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, are calculated based upon our total shareholder return during a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> performance period as measured against that of the group of companies comprising the S&amp;P Biotechnology Select Industry Index as of the grant date, subject to certain adjustments to such index group. Except as expressly provided in the terms of each award's agreement, vesting is subject to the respective grantee's continuous service through the end of the three-year performance period. These market-based restricted stock units, along with those granted to our chief executive officer in March 2022, under which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">494,234</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares may be earned, remained outstanding as of December 31, 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Grant Date Fair Value of Stock Options, Restricted Stock Units and Market-Based Restricted Stock Units Granted</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated grant date fair values of stock options granted during the years ended December 31, 2023, 2022 and 2021 were estimated using the Black-Scholes option-pricing model with the following assumptions:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.177%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.255%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.255%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.255%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of common stock</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.46</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.30</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.95</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30.86</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66.50</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.27 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">- </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.27</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.27</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.9</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71.2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71.6</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68.2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67.1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The determination of the grant date fair value of stock options granted using a Black-Scholes option-pricing model is affected by the fair value of our common stock, as well as assumptions regarding a number of variables that are subjective and generally require judgment to determine. The valuation assumptions were determined as follows:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair value of common stock&#8212;</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each share of common stock is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected term</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;The expected term of stock options granted to employees and non-employee directors is determined using the &#8220;simplified&#8221; method, as illustrated in ASC Topic 718, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation&#8212;Stock Compensation</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, as we do not have sufficient exercise history to determine a better estimate of expected term. Under this approach, the expected term is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">based on the midpoint between the vesting date and the end of the contractual term of the stock option.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-free interest rate</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;We utilize a risk-free interest rate in the option valuation model based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected terms of the stock options.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected volatility</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;As we do not have sufficient trading history for our common stock, expected volatility is based on the historical volatility of our publicly traded industry peers utilizing a period of time consistent with our estimate of expected term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected dividend yield</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;We do not anticipate paying any cash dividends in the foreseeable future and, therefore, use an expected dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in the option valuation model.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant date fair value per share of stock options granted during the year ended December 31, 2023, 2022 and 2021 was </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">5.61</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">7.36</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">24.22</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The grant date fair value of restricted stock units granted </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant date fair value per share of restricted stock units granted during the year ended December 31, 2023, 2022 and 2021 was </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">8.29</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">11.43</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">37.98</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant date fair value per share of the market-based restricted stock units granted during the year ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.82</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18.89</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, and was determined using a Monte Carlo valuation model, which uses assumptions such as volatility, risk-free interest rate and dividend estimated for the respective performance periods. The weighted-average grant date fair value per share of the target payout level of the market-based restricted stock units outstanding as of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">956,337</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.13</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The aggregate share-based compensation expense of the market-based restricted stock units granted during the year ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, and is recognized on a straight-line basis over the respective grants' </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> performance periods, which are also the requisite service periods. Attainment of each grant's respective market condition and the number of shares earned and vested does not impact the related share-based compensation expense recognized. Share-based compensation expense will be reversed only if the respective grantee does not provide continuous service through the respective performance period for reasons other than those expressly provided in the terms of the respective award.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The compensation cost related to stock options, restricted stock units and market-based restricted stock units for the years ended December 31, 2023, 2022 and 2021 are included on the consolidated statements of operations as follows (in thousands):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,186</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,910</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,465</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,061</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales and marketing</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,553</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,597</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,312</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,704</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,778</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total share-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62,908</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55,477</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,251</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, unrecognized share-based compensation expense and the remaining weighted-average recognition period were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.38%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrecognized Share-Based<br/>Compensation Expense<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining Weighted-Average<br/>Recognition Period<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,892</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.94</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,944</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.67</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested market-based restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.97</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624186272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Microsoft Collaboration Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Microsoft Collaboration Agreement</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">15.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Microsoft Collaboration Agreement</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2017, we entered into a collaboration agreement with Microsoft Corporation ("Microsoft") (the &#8220;Microsoft Agreement&#8221;) to computationally derive a comprehensive T cell receptor antigen map for purposes of developing a universal diagnostic based on a single blood test.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contemporaneously with the Microsoft Agreement, we entered into a separate agreement to use Microsoft&#8217;s Azure cloud services at standard volume pricing with a minimum Azure purchase requirement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">12.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million over the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seven-year</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> term of the Microsoft Agreement, which has been met.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, contemporaneously with entering into the Microsoft Agreement, Microsoft made a preferred stock investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">45.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as a part of our Series F-1 convertible preferred stock issuance.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Accounting</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The terms of the Microsoft Agreement meet the criteria under ASC 808, as both parties are active participants in the activity and are exposed to significant risks and rewards dependent on the commercial success of the activity. ASC 808 does not provide guidance on how to account for the activities under the collaboration and we determined that Microsoft did not meet the definition of a customer under ASC 606. Accordingly, we looked to other guidance to determine the accounting for the respective elements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We determined that the preferred stock issuance and commitment to use Microsoft&#8217;s Azure cloud services were made at terms consistent with market rates. All consideration received as part of the Series F-1 convertible preferred stock issuance was accounted for as part of the Series F-1 preferred stock issuance. Since the commitment to purchase Microsoft&#8217;s Azure cloud services was at market terms and we expected to meet the commitment in the ordinary course of business during the seven-year term, we recorded the expenses in the period in which the services were consumed. These costs are recorded in the consolidated statements of operations based on the underlying activities for which they support.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The remaining elements of the agreement were highly interrelated, so we evaluated them in the aggregate to determine the appropriate accounting application. Specifically, we determined that the transfer of license rights between the parties, our commitment to provide data and immunomics, diagnostic and bioinformatics expertise to Microsoft and Microsoft&#8217;s commitment to provide machine learning software and related development services to us were highly interrelated because they were necessary for the parties to perform the activities under the Microsoft Agreement and, therefore, should be evaluated as one unit of account.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We accounted for these collaboration activities by analogy to ASC Topic 845, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nonmonetary Transactions</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and determined that major uncertainties exist about the realizability of the value that would be assigned to an asset received from or provided to Microsoft under the collaboration and, therefore, fair value could not be reliably measured. As a result, we did not recognize any non-monetary assets or corresponding non-monetary income or expenses pertaining to the rights provided to us or to be received by us under the Microsoft Agreement.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624273056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text"><div style="font-size:0;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">16.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restructuring</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2022, we implemented a restructuring plan to reduce operating costs and reduced our workforce by approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> employees. We incurred aggregate restructuring costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, all of which was recognized during the year ended December 31, 2022. These costs primarily related to one-time termination benefits and ongoing benefit arrangements, both of which included severance payments and extended benefits coverage support and were contingent upon the impacted employees&#8217; execution and non-revocation of separation agreements. Our aggregate restructuring costs also included certain contract termination costs. The activities related to our reduction in workforce were primarily completed in March 2022 and the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million aggregate restructuring costs were paid as of December 31, 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//420/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624186272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">17.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of loss before provision for income taxes for the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Domestic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">225,335</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">200,427</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">207,314</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total loss before provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">225,304</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">200,368</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">207,298</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant components of our deferred tax assets and liabilities as of the dates presented were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating losses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">251,724</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210,609</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credit carryforward</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,528</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonqualifying stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,166</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,885</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,357</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,199</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,874</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,170</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,134</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,957</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,146</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,859</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">416,929</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">371,527</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">402,424</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">346,578</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,505</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,949</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tangible and intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,897</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,224</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,052</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASC Topic 740, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, requires that the tax benefit of net operating losses ("NOLs"), temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">55.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">49.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the year ended December 31, 2023 and 2022, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal tax laws impose substantial restrictions on the utilization of NOL and credit carryforwards in the event of an ownership change, as defined in Section 382 of the Internal Revenue Code of 1986. Accordingly, our ability to utilize these carryforwards may be limited due to such ownership changes. We have completed a Section 382 analysis for changes in ownership through June 30, 2023 and continue to monitor for changes that could trigger a limitation. Based on this analysis, we do not expect to have any permanent limitations on the utilization of our federal NOLs. Under the Tax Cuts and Jobs Act of 2017 federal income tax law, federal NOLs incurred in 2018 and future years may be carried forward indefinitely, but the deductibility of such federal NOLs is subject to an annual limitation. NOLs generated prior to 2018 are eligible to be carried forward up to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years. As of December 31, 2023, we had U.S. federal NOLs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">192.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and U.S. federal tax credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">47.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million that will begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We also had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">768.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of NOLs as of December 31, 2023 that do not expire.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.36%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:14.4%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:14.4%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:14.4%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Statutory rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State tax, net of federal tax benefit</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.8</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.3</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.1</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent items</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Credits</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.7</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.4</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47.7</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for global intangible low-taxed income as period costs when incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize, in the consolidated financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. We had unrecognized tax benefits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the dates presented are as follows (in thousands):</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,489</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions in 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,426</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,915</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions in 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,202</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,117</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions in 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,186</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,303</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, 2022 and 2021, we recognized uncertain tax positions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, related to a reduction of the research and development credit deferred tax asset. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not expect a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our operating results.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. We had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accrued interest or penalties related to uncertain tax positions as of December 31, 2023 and 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We file federal and certain state income tax returns, which provide varying statutes of limitations on assessments. However, because of NOL carryforwards, substantially all tax years since inception remain open to federal and state tax examination.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624790800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</a></td>
<td class="text"><div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">18.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the years ended December 31, 2023, 2022 and 2021 (in thousands, except share and per share amounts):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">225,250</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">200,191</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">207,279</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">144,383,294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,515,917</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">140,354,915</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.56</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given the loss position for all periods presented, basic net loss per share attributable to our common shareholders is the same as diluted net loss per share attributable to our common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the years ended December 31, 2023, 2022 and 2021, as they had an anti-dilutive effect:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.177%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.255%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.255%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.255%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,839,067</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,892,287</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,097,374</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested restricted stock units outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,630,579</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,799,850</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">693,173</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Maximum nonvested market-based restricted stock units outstanding eligible to be earned</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,663,961</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">410,282</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock warrant outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,570</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,133,607</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,102,419</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,799,117</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754623515680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Retirement Plan</a></td>
<td class="text"><div style="display:flex;margin-top:9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">19.</span><div style="width:100%;display:inline;"><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Retirement Plan</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain a salary deferral 401(k) plan (&#8220;401(k) Plan&#8221;) covering employees who have met certain eligibility requirements. Employees may defer up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of their compensation to the 401(k) Plan, subject to federal limits. We made $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#231f20;">2.3</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">2.8</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;">2.5</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in discretionary contributions during the year ended December 31, 2023, 2022 and 2021, respectively, which are fully vested after </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one year</span></span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of employee service.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754626201328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements include the accounts of Adaptive Biotechnologies Corporation, Adaptive Biotechnologies B.V., our wholly-owned subsidiary, and Digital Biotechnologies, Inc., a corporate subsidiary we have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">70</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% ownership interest in. The remaining interest in Digital Biotechnologies, Inc., held by certain of our related parties and their related family trusts, are shown in the consolidated financial statements as noncontrolling interest. All intercompany transactions and balances have been eliminated upon consolidation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, imputing interest for our revenue interest purchase agreement (the &#8220;Purchase Agreement&#8221;) that we entered into in September 2022, the provision for income taxes, including related reserves, the analysis of goodwill impairment and the recoverability and impairment of long-lived assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#8217;s estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have determined that our chief executive officer is the chief operating decision maker (&#8220;CODM&#8221;). The CODM regularly reviews operating results and other financial information presented on a consolidated basis. While revenue is reviewed at levels lower than the consolidated entity, resource allocation decisions are made by the CODM based on the results presented at the consolidated entity level, which is determined to be a single reporting unit. The consolidated entity operates as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment and represents </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segment. We present disaggregated revenue from contracts with customers by market opportunity and type of arrangement. See Note 3, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. We limit our credit risk associated with cash and cash equivalents by placing our investments with banks that we believe are highly creditworthy and with highly rated money market funds. Cash and cash equivalents primarily consist of bank deposits and investments in money market funds.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We had a restricted cash balance of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023 and 2022, respectively. Our restricted cash primarily relates to certain balances we are required to maintain under lease arrangements for some of our property and facility leases.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments in Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investments in Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable securities are classified as available-for-sale, consist of United States (&#8220;U.S.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) government treasury and agency securities, corporate bonds and commercial paper and are reported at fair value. Unrealized holding gains and losses are reflected as a separate component of shareholders&#8217; equity in accumulated other comprehensive gain (loss) until realized. Realized gains and losses on the sale of these securities are recognized in net income or loss. The cost of marketable securities sold is based on the specific identification method.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Financial Accounting Standards Board (&#8220;FASB&#8221;) has defined fair value as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. The FASB established a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The hierarchy defines three levels of inputs that may be used to measure fair value:</span></p><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></div></div><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div></div><div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A financial instrument categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. In certain cases, where there is limited activity or less transparency around valuation inputs, financial instruments are classified as Level 3 within the valuation hierarchy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our financial instruments consist of Level 1 and Level 2 assets and have included Level 3 liabilities in the past. The carrying amounts of certain financial instruments approximate fair value due to their short maturities. We did not have any nonfinancial assets or liabilities that were measured or disclosed at fair value on a recurring basis as of December 31, 2023 and 2022.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to a concentration of risk from a limited number of suppliers, or in certain cases, single suppliers, for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, U.S. government treasury and agency securities, corporate bonds and commercial paper with high-quality accredited financial institutions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant customers are those that represent more than ten percent of our total revenue or accounts receivable, net balances for the periods and as of each consolidated balance sheet date presented, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:44.5%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:9.94%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:9.94%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:9.94%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:9.94%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:9.94%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Revenue</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accounts Receivable, Net</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Customer A</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*%</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*%</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*%</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*%</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.8</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Customer B</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.6</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19.5</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Genentech, Inc. and Roche Group</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27.8</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36.4</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41.9</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">* less than 10%</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounts receivable consists of amounts due from customers for services performed. We review our accounts receivable for credit impairment and regularly analyze the status of significant past due receivables to determine if any will potentially be uncollectible to estimate the amount of allowance necessary to reduce accounts receivable to its estimated net realizable value.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inventory</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventory consists of laboratory materials and supplies used in lab analysis. We capitalize inventory when purchased and record expense upon order fulfillment for servicing revenue or utilization in our research and development laboratories. Inventory is valued at the lower of cost or market on a first-in, first-out basis. We periodically perform obsolescence assessments and write-off any inventory that is no longer usable. Long-term inventory of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was included within the other assets balance on the consolidated balance sheet as of December 31, 2023 and 2022, respectively.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment consists of computer equipment, computer software, laboratory equipment, leasehold improvements, furniture and office equipment and assets under construction. Property and equipment are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life. Maintenance and repairs are charged to expense as incurred and costs of improvements are capitalized.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Useful lives assigned to property and equipment are as follows:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:84.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.14%;"></td>
          <td style="width:1.72%;"></td>
          <td style="width:49.14%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_de9ea103-2ab7-4e3e-8c48-d7bbaf7c674a;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of estimated useful life or remaining lease term</span></span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment and software</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and office equipment</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7 years</span></span></p></td>
         </tr>
        </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We review long-lived assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Gains and losses from asset disposals and impairment losses, if incurred, are classified within the consolidated statements of operations in accordance with the use of the asset, if not separately stated within its own financial statement line item. See Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for more information regarding the leasehold improvements impairment loss recognized during the year-ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intangible Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date, which is regarded as their cost.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets may also result from the purchase of assets and intellectual property in a transaction that does not qualify as a business combination. Intangible assets are amortized over their estimated useful lives on a straight-line basis which approximates their usage pattern. Intangible assets are reviewed for impairment at least annually or if indicators of potential impairment exist. We have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognized any impairment losses on intangible assets.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Goodwill</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October 1, or more frequently if events or changes in circumstances would more likely than not reduce the fair value of our single reporting unit below its carrying value. We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we so determine, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. If impairment exists, the carrying value of the goodwill is reduced to its fair value through an impairment charge recorded in the consolidated statements of operations. To date, we have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognized any impairment of goodwill.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory, office and warehouse facilities that we occupy. Operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of January 1, 2020 for commenced leases that existed as of our adoption of Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Topic 842) (&#8220;ASC 842&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain of our leases contain options to extend or terminate the lease; lease terms are adjusted for these options only when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory, office and warehouse facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on the consolidated balance sheets a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We review our right-of-use assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Impairment losses are classified within the consolidated statements of operations in accordance with the use of the asset, if not separately stated within its own financial statement line item. See Note 10, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for more information regarding the right-of-use asset impairment loss recognized during the year-ended December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lease expense is recognized on a straight-line basis over the terms of the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the terms of the leases.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock', window );">Revenue Interest Liability, Net and Related Imputed Interest</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Interest Liability, Net and Related Imputed Interest</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The revenue interest liability balance associated with the Purchase Agreement that we entered into in September 2022 is presented net of unamortized issuance costs on the consolidated balance sheets. We impute our associated interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. The effective interest rate may vary during the term of the agreement depending on a number of factors, including changes in forecasted GAAP revenues. We evaluate the effective interest rate quarterly based on both achieved and forecasted revenues, utilizing the prospective method. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense and the time period for repayment.</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1) identify the contract or contracts; (2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3) measure the transaction price, including the constraint on variable consideration; (4) allocate the transaction price to the performance obligations based on estimated selling prices; and (5) recognize revenue when (or as) we satisfy each performance obligation.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We derive revenue by providing diagnostic and research services in our Immune Medicine and Minimal Residual Disease (&#8220;MRD&#8221;) business areas. Our Immune Medicine revenue consists of revenue generated from (1) providing sample testing services for our commercial research product, Adaptive Immunosequencing, to biopharmaceutical customers and academic institutions; (2) our collaboration agreements with Genentech, Inc. (&#8220;Genentech&#8221;) and other biopharmaceutical customers in areas of drug and target discovery; and (3) for prior years, providing our T-Detect COVID tests to clinical customers. Our MRD revenue consists of revenue generated from (1) providing our clonoSEQ report to clinical customers; (2) providing MRD sample testing services to biopharmaceutical customers and certain academic institutions, including investigator-led clinical trials; and (3) providing our clonoSEQ report or results to certain international laboratory sites through technology transfers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For research customers who utilize either Adaptive Immunosequencing or our MRD services, contracts typically include an amount billed in advance of services (&#8220;upfront&#8221;) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> typical performance obligations under the terms of our research service contracts: (1) the delivery of our Adaptive Immunosequencing or MRD data for customer provided samples; and (2) related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the total samples expected to be delivered.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For agreements where we provide our clonoSEQ report to ordering physicians, we have identified one performance obligation: the delivery of a clonoSEQ report. We bill and receive payments for these transactions from commercial, government and medical institution payors. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted, as necessary, based on actual collection experience.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regarding our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test report. This billing contemplates all necessary tests required during a patient&#8217;s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test report is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient&#8217;s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized either as we deliver our estimate of the remaining tests in a patient&#8217;s treatment cycle or when the likelihood becomes remote that a patient will receive additional testing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The contract transaction price for agreements we enter into with biopharmaceutical customers to further develop and commercialize their therapeutics may consist of a combination of non-refundable upfront fees, separately priced MRD testing fees and milestone fees earned upon our customers&#8217; achievement of certain regulatory approvals. Depending on the contract, these agreements include single or multiple performance obligations. Such performance obligations include providing services to support our customers&#8217; therapeutic development efforts, including regulatory support for our technology intended to be utilized as part of our customers&#8217; registrational trials, developing analytical plans for our data, participating on joint research committees, assisting in completing a regulatory submission and providing MRD testing services related to customer-provided samples for our customers' regulatory submissions. Generally, the support services, excluding MRD testing services, are not distinct within the context of the contract and thus are accounted for as a single performance obligation. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated MRD testing services. When MRD sample testing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional MRD sample testing services is not considered part of the contract. We recognize revenue related to MRD testing services over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered, when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method using a cost-based model based on estimates of effort completed. Selecting the measure of progress and estimating progress to date requires significant judgment. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. At contract inception, we fully constrain any consideration related to regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers&#8217; own submission decision-making. Variable consideration related to regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue will not occur. Milestone payments for regulatory approvals, which are not within our customers&#8217; control, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2021, we executed an intellectual property license agreement that includes variable consideration related to sales-based royalties. Any consideration related to such royalties will be recognized as revenue at the later of when (i) the related sales occur or (ii) the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied (or partially satisfied).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ContractBalancesPolicyTextBlock', window );">Contract Balances</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contract Balances</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In certain circumstances, billing may occur prior to services being performed. Upfront payments are recorded as deferred revenue, or contract liabilities. We classify deferred revenue as current when we expect our performance obligations will be completed within the next twelve months; however, we do not control the timing of customer provided samples. For service and collaboration activities, excluding those related to our worldwide collaboration and license agreement with Genentech, we assess the performance obligations and recognize deferred revenue as current or non-current based upon forecasted delivery times, which are customer coordinated. In certain circumstances, a customer project may be cancelled or terminated prior to the delivery of all related services covered by a customer&#8217;s upfront payment. In these circumstances, we recognize revenue when sufficient evidence is obtained that a reversal of revenue is not probable. We also recognize revenue when our estimate of total samples to be provided under certain of our agreements is reduced or, in the case of contract balances related to Medicare, when the likelihood becomes remote that a patient will receive additional testing. See Note 3, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for our deferred revenue policy related to our worldwide collaboration and license agreement with Genentech.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation includes compensation expense for stock option, restricted stock unit and market-based restricted stock unit grants made to employees and non-employees. It represents the grant date fair value of the grants and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of actual forfeitures. We estimate the grant date fair value of stock option and market-based restricted stock unit grants using the Black-Scholes option-pricing model and the Monte Carlo valuation model, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Advertising</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Advertising costs are expensed as incurred. Advertising expenses were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023, 2022 and 2021, respectively.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Revenue</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cost of Revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cost of revenue includes the cost of materials, personnel-related expenses (including salaries, benefits and share-based compensation), shipping and handling expenses, equipment costs, allocated facility costs associated with processing samples and professional support costs related to our service revenue activities. Allocated facility costs include depreciation of laboratory equipment, as well as allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consist of laboratory materials costs, personnel-related expenses (including salaries, benefits and share-based compensation), equipment costs, allocated facility and information technology costs and contract service expenses. Research and development activities support further development and refinement of existing assays and products, discovery of new technologies and investments in our immune medicine platform. We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. Additionally, a component of our research and development expenses are costs supporting clinical and analytical validations to obtain regulatory approval for future clinical products and services. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Upfront payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized, then are recognized as an expense as the goods are consumed or the related services are performed. Costs to support our worldwide collaboration and license agreement with Genentech are also a component of our research and development expenses.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_SalesAndMarketingExpensePolicyTextBlock', window );">Sales and Marketing Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales and Marketing Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales and marketing expenses include personnel-related expenses (including salaries, benefits and share-based compensation) for commercial sales, product and account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility and information technology costs.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssetsExpensesPolicyTextBlock', window );">Impairment of Right-of-Use and Related Long-Lived Assets Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Right-of-Use and Related Long-Lived Assets Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Impairment of right-of-use and related long-lived assets expenses include our impairment charge for certain leased office and laboratory space, as well as impairment costs for related leasehold improvements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpensePolicyTextBlock', window );">Interest Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest expense includes costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. We impute interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred tax assets and liabilities are measured at the consolidated balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in the period such tax rate changes are enacted. Our net deferred tax assets are fully offset by a valuation allowance, because of our history of losses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize the effect of income tax positions only if those positions are more likely than not of being sustained upon examination.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We calculate basic net loss per share attributable to our common shareholders by dividing net loss attributable to us by our weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to our common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, outstanding common stock warrants, outstanding stock options, nonvested restricted stock units outstanding and the maximum nonvested market-based restricted stock units outstanding eligible to be earned are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to our common shareholders, as their effect is anti-dilutive.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Topic 280): </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which intends to enhance reportable segment disclosures about significant segment expenses. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the guidance is to be applied retrospectively. We are currently evaluating the impact of this guidance on our consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Topic 740): </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which primarily intends to enhance the rate reconciliation and income taxes paid disclosures. This guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted and the guidance is to be applied prospectively; retrospective application is permitted. We are currently evaluating the impact of this guidance on our consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and principles of consolidation policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ContractBalancesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ContractBalancesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssetsExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of right-of-use and related long-lived assets expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssetsExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue interest liability, net and related imputed interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_SalesAndMarketingExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales and marketing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_SalesAndMarketingExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 835<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482914/835-10-05-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754627016272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentrations of Risk Percentage</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:44.5%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:9.94%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:9.94%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:9.94%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:9.94%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:9.94%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Revenue</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accounts Receivable, Net</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Customer A</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*%</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*%</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*%</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*%</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.8</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Customer B</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.6</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19.5</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Genentech, Inc. and Roche Group</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27.8</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36.4</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41.9</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">* less than 10%</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock', window );">Summary of Useful Lives Assigned to Property and Equipment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Useful lives assigned to property and equipment are as follows:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:84.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.14%;"></td>
          <td style="width:1.72%;"></td>
          <td style="width:49.14%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_de9ea103-2ab7-4e3e-8c48-d7bbaf7c674a;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shorter of estimated useful life or remaining lease term</span></span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment and software</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="vertical-align:top;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and office equipment</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7 years</span></span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated useful lives of property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624359792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregated Revenue</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents our disaggregated revenue for the periods presented (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Immune Medicine revenue</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Service revenue</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,959</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,777</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,482</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration revenue</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,578</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,387</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,651</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Immune Medicine revenue</span></p></td>
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,537</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98,164</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,133</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">MRD revenue</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Service revenue</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,739</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81,144</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56,211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Regulatory milestone revenue</span></p></td>
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total MRD revenue</span></p></td>
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,739</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87,144</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenue</span></p></td>
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,276</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">185,308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">154,344</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624593984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Deferred Revenue</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in deferred revenue during the year ended December 31, 2023 were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,714</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions to deferred revenue during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,471</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue recognized during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73,762</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93,423</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754710160352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables set forth the fair values of financial assets as of December 31, 2023 and 2022 that were measured at fair value on a recurring basis (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,630</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,630</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government treasury and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">264,426</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">264,426</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">281,337</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">326,460</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,502</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,502</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,969</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,969</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">385,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">385,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,349</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,349</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,502</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">408,166</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">446,668</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754628506128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-sale Investments</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Available-for-sale investments consisted of the following as of December 31, 2023 and 2022 (in thousands):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term marketable securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,630</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,630</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government treasury and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">264,214</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">232</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">264,426</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,278</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">281,122</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">235</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">281,337</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gain</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term marketable securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,969</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,969</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">389,898</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,064</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">385,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,415</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,349</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total short-term marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">412,282</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,130</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">408,166</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Gross Unrealized Holding Losses and Fair Values for Investments in Unrealized Loss Position</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the gross unrealized holding losses and fair values for investments in an unrealized loss position, and the length of time individual securities have been in a continuous loss position, as of December 31, 2023 (in thousands):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.07%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Less Than 12 Months</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">12 Months Or Greater</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Loss</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government treasury and agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total available-for-sale securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,100</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624536256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net as of December 31, 2023 and 2022 consisted of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,567</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,592</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,970</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,766</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and office equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,820</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,342</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,965</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,069</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,405</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,625</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74,734</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,403</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment, at cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141,461</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">137,797</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73,234</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,350</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,227</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83,447</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754620476896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Intangible Assets Subject to Amortization</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intangible assets subject to amortization as of December 31, 2023 and 2022 consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Carrying Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated Amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net Carrying Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquired developed technology</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,970</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,030</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchased intellectual property</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">325</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">227</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,325</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,197</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,128</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross Carrying Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated Amortization</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net Carrying Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquired developed technology</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,304</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,696</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchased intellectual property</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">325</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">194</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,325</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,498</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,827</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Amortization Expense for Intangible Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, expected future amortization expense for intangible assets was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,703</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,699</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,699</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total future amortization expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,128</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624514672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued liabilities as of December 31, 2023 and 2022 consisted of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,920</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,744</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clinical and contract research organization costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">863</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,533</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Travel and entertainment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">154</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">233</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">194</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">687</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,680</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer and software</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,151</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,385</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">763</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,655</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,597</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,424</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754628484272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Other Information Related to Operating Lease</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other information related to our operating leases as of December 31, 2023 and 2022 was as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.379999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.379999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.91</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.75</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Reconciles Undiscounted Operating Lease Cash Flows</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities, less current portion balance on the consolidated balance sheet as of December 31, 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,692</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,098</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,330</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,944</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,282</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56,962</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121,308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Imputed interest rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,536</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98,772</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,384</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, less current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,388</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624536256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Purchase Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock', window );">Schedule of Revenue Interest Liability, Net Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the revenue interest liability, net activity during the years ended December 31, 2023 and 2022 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest liability at inception</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">625</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,238</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest paid</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">493</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,760</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest liability, net at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125,360</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,800</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest paid</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,225</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,275</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue interest liability, net at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130,660</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of revenue interest liability, net activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624528944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock', window );">Summary of Reserved Shares of Common Stock</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">had reserved shares of common stock for the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.36%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares issuable upon the exercise of outstanding stock options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,875,045</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares issuable upon the vesting of outstanding restricted stock units granted and the maximum outstanding market-based restricted stock units eligible to be earned</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,582,134</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for future grant under the 2019 Equity Incentive Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,299,763</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for future grant under the Employee Stock Purchase Plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,235,348</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total shares of common stock reserved for future issuance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,992,290</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of reserved shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754619515760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock', window );">Summary of Changes in Shares Available for Grant</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in shares available for grant during the year ended December 31, 2023 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.36%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares Available for Grant</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for grant at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,581,975</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2019 Equity Incentive Plan reserve increase effective January 1, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,155,250</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,980,059</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options and restricted stock units forfeited or expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,542,597</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for grant at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,299,763</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity Under 2009 Plan and 2019 Plan</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option activity under the 2009 Plan and 2019 Plan during the year ended December 31, 2023 was as follows:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.2%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.780000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.780000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares Subject to<br/>Outstanding Stock Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Exercise<br/>Price per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,520,997</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.88</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,612,032</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.46</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,030,388</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17.07</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">757,191</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22.92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">470,405</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.77</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,875,045</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.90</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">506</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options vested and exercisable at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,071,627</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">506</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted stock unit activity under the 2019 Plan during the year ended December 31, 2023 was as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Restricted Stock Units<br/>Outstanding</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average Grant Date<br/>Fair Value per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested restricted stock units outstanding at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,981,755</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,949,587</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.29</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,755,018</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,506,864</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.95</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested restricted stock units outstanding at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,669,460</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.32</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Estimated Grant Date Fair Values of Stock Options Granted</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated grant date fair values of stock options granted during the years ended December 31, 2023, 2022 and 2021 were estimated using the Black-Scholes option-pricing model with the following assumptions:</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.177%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.255%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.255%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.255%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fair value of common stock</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.46</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.30</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.95</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30.86</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66.50</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.27 </span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">- </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.27</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.27</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.9</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71.2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71.6</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68.2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67.1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Compensation Costs Related to Stock Options and RSUs Included on Consolidated Statements of Operations</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The compensation cost related to stock options, restricted stock units and market-based restricted stock units for the years ended December 31, 2023, 2022 and 2021 are included on the consolidated statements of operations as follows (in thousands):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,186</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,910</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,465</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,061</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sales and marketing</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,553</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,597</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,312</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,704</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,778</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total share-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62,908</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55,477</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,251</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock', window );">Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, unrecognized share-based compensation expense and the remaining weighted-average recognition period were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.38%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrecognized Share-Based<br/>Compensation Expense<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining Weighted-Average<br/>Recognition Period<br/>(in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,892</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.94</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,944</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.67</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested market-based restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.97</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of share-based compensation, shares available for grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of unrecognized share-based compensation expense and the expected weighted-average remaining recognition period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754628414208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Components of Loss Before Provision for Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of loss before provision for income taxes for the periods presented were as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Domestic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">225,335</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">200,427</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">207,314</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total loss before provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">225,304</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">200,368</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">207,298</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant components of our deferred tax assets and liabilities as of the dates presented were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.72%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating losses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">251,724</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">210,609</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credit carryforward</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,528</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonqualifying stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,166</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,885</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,357</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,199</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,874</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,170</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,134</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,957</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,146</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,859</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">416,929</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">371,527</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">402,424</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">346,578</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,505</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,949</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tangible and intangible assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,897</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,224</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,052</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.36%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:14.4%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:14.4%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:14.4%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Statutory rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State tax, net of federal tax benefit</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.0</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.8</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.3</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share-based compensation</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.1</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent items</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Credits</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.7</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.4</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47.7</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Schedule of Change in Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the dates presented are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.04%;"></td>
        <td style="width:2.08%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.88%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,489</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions in 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,426</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,915</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions in 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,202</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,117</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions in 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,186</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,303</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754617682400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the years ended December 31, 2023, 2022 and 2021 (in thousands, except share and per share amounts):</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.211%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.782%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to Adaptive Biotechnologies Corporation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">225,250</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">200,191</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">207,279</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">144,383,294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,515,917</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">140,354,915</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.56</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.48</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the years ended December 31, 2023, 2022 and 2021, as they had an anti-dilutive effect:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.177%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.255%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.255%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.255%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,839,067</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,892,287</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,097,374</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonvested restricted stock units outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,630,579</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,799,850</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">693,173</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Maximum nonvested market-based restricted stock units outstanding eligible to be earned</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,663,961</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">410,282</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock warrant outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,570</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,133,607</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,102,419</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,799,117</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754618984832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>Performance_Obligation</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 2,932,000<span></span>
</td>
<td class="nump">$ 2,398,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventoryNoncurrent', window );">Long-term inventory</a></td>
<td class="nump">2,800,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment losses on intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expenses</a></td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
<td class="nump">$ 22,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=adpt_DigitalBiotechnologiesIncMember', window );">Digital Biotechnologies Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest percentage</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adpt_SequencingRevenueMember', window );">Sequencing Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_NumberOfRevenuePerformanceObligation', window );">Number of revenue performance obligations | Performance_Obligation</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_NumberOfRevenuePerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of revenue performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_NumberOfRevenuePerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle (such as inventory related to long-term contracts or program rights).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=adpt_DigitalBiotechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=adpt_DigitalBiotechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_SequencingRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_SequencingRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754626337456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=adpt_CustomerAMember', window );">Customer A | Accounts Receivable, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=adpt_CustomerBMember', window );">Customer B | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=adpt_CustomerBMember', window );">Customer B | Accounts Receivable, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=adpt_GenentechIncAndRocheGroupMember', window );">Genentech, Inc. and Roche Group | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">27.80%<span></span>
</td>
<td class="nump">36.40%<span></span>
</td>
<td class="nump">41.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adpt_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adpt_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adpt_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adpt_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adpt_GenentechIncAndRocheGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adpt_GenentechIncAndRocheGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754626465760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_LaboratoryEquipmentMember', window );">Laboratory Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_LaboratoryEquipmentMember', window );">Laboratory Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">us-gaap:UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754619955216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Disaggregated Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 170,276<span></span>
</td>
<td class="nump">$ 185,308<span></span>
</td>
<td class="nump">$ 154,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_ImmuneMedicineRevenueMember', window );">Immune Medicine Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">67,537<span></span>
</td>
<td class="nump">98,164<span></span>
</td>
<td class="nump">88,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_ImmuneMedicineRevenueMember', window );">Immune Medicine Revenue | Service Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">24,959<span></span>
</td>
<td class="nump">31,777<span></span>
</td>
<td class="nump">24,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_ImmuneMedicineRevenueMember', window );">Immune Medicine Revenue | Collaboration Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">42,578<span></span>
</td>
<td class="nump">66,387<span></span>
</td>
<td class="nump">63,651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_MRDRevenueMember', window );">MRD Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">102,739<span></span>
</td>
<td class="nump">87,144<span></span>
</td>
<td class="nump">66,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_MRDRevenueMember', window );">MRD Revenue | Service Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 102,739<span></span>
</td>
<td class="nump">81,144<span></span>
</td>
<td class="nump">56,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_MRDRevenueMember', window );">MRD Revenue | Regulatory Milestone Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adpt_ImmuneMedicineRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adpt_ImmuneMedicineRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adpt_MRDRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adpt_MRDRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_RegulatoryMilestoneRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_RegulatoryMilestoneRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754619126576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,276,000<span></span>
</td>
<td class="nump">$ 185,308,000<span></span>
</td>
<td class="nump">$ 154,344,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_MedicareReimbursementsMember', window );">Medicare Reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_MedicareReimbursementsMember', window );">Medicare Reimbursements | Immune Medicine Service Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_MRDDevelopmentAgreementsMember', window );">MRD Development Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_AdditionalMilestonePayment', window );">Additional milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember', window );">Genentech Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaboration agreement</a></td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,600,000<span></span>
</td>
<td class="nump">$ 62,800,000<span></span>
</td>
<td class="nump">$ 62,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_NonRefundableUpfrontPaymentsReceived', window );">Non-refundable upfront payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_AdditionalTransactionPriceOfRegulatoryMilestone', window );">Additional transaction price of regulatory milestone</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember', window );">Genentech Collaboration Agreement | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_AdditionalTransactionPriceOfRegulatoryMilestone', window );">Additional transaction price of regulatory milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember', window );">Genentech Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueRecognitionExpectedPeriod', window );">Revenue recognition expected period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember', window );">Genentech Collaboration Agreement | Maximum | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable', window );">Expected revenue through milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember', window );">Genentech Collaboration Agreement | Maximum | Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable', window );">Expected revenue through milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember', window );">Genentech Collaboration Agreement | Maximum | Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable', window );">Expected revenue through milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,430,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember', window );">Genentech Collaboration Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable', window );">Expected revenue through milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_AdditionalTransactionPriceOfRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional transaction price of regulatory milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_AdditionalTransactionPriceOfRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_NonRefundableUpfrontPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable upfront payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_NonRefundableUpfrontPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueRecognitionExpectedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition expected period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueRecognitionExpectedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition milestone method expected milestone receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adpt_MedicareReimbursementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adpt_MedicareReimbursementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_ImmuneMedicineServiceRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_ImmuneMedicineServiceRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adpt_MRDDevelopmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adpt_MRDDevelopmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=adpt_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=adpt_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=adpt_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=adpt_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=adpt_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=adpt_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754618988592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current deferred revenue</a></td>
<td class="nump">$ 48,630<span></span>
</td>
<td class="nump">$ 48,630<span></span>
</td>
<td class="nump">$ 64,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Non-current deferred revenue</a></td>
<td class="nump">44,793<span></span>
</td>
<td class="nump">44,793<span></span>
</td>
<td class="nump">58,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">53,200<span></span>
</td>
<td class="num">(73,762)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adpt_DevelopmentRevenueMember', window );">Development Revenue | Genentech, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current deferred revenue</a></td>
<td class="nump">13,600<span></span>
</td>
<td class="nump">13,600<span></span>
</td>
<td class="nump">31,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Non-current deferred revenue</a></td>
<td class="nump">$ 41,100<span></span>
</td>
<td class="nump">$ 41,100<span></span>
</td>
<td class="nump">$ 55,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adpt_DevelopmentRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adpt_DevelopmentRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adpt_GenentechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adpt_GenentechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754619238128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deferred Revenue - Additional Information (Details1)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=adpt_GenentechIncMember', window );">Genentech, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Deferred revenue, expected to be recognized</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adpt_GenentechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adpt_GenentechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754619281984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue - Schedule of Changes in Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue balance at December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination', window );">Additions to deferred revenue during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized during the period</a></td>
<td class="nump">$ 53,200<span></span>
</td>
<td class="num">(73,762)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue balance at December 31, 2022</a></td>
<td class="nump">$ 93,423<span></span>
</td>
<td class="nump">$ 93,423<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754619051456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring basis - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 326,460<span></span>
</td>
<td class="nump">$ 446,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">45,123<span></span>
</td>
<td class="nump">38,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">281,337<span></span>
</td>
<td class="nump">408,166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">45,123<span></span>
</td>
<td class="nump">38,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">45,123<span></span>
</td>
<td class="nump">38,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">10,630<span></span>
</td>
<td class="nump">9,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">10,630<span></span>
</td>
<td class="nump">9,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Treasury and Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">264,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Treasury and Agency Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">264,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Government Treasury Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">6,281<span></span>
</td>
<td class="nump">12,349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 6,281<span></span>
</td>
<td class="nump">$ 12,349<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754626251216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of Available-for-sale Investments (Details) - Short-Term Marketable Securities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 281,122<span></span>
</td>
<td class="nump">$ 412,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(4,130)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">281,337<span></span>
</td>
<td class="nump">408,166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">10,630<span></span>
</td>
<td class="nump">9,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">10,630<span></span>
</td>
<td class="nump">9,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Government Treasury and Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">264,214<span></span>
</td>
<td class="nump">389,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(4,064)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">264,426<span></span>
</td>
<td class="nump">385,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">6,278<span></span>
</td>
<td class="nump">12,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 6,281<span></span>
</td>
<td class="nump">$ 12,349<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624519776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivable</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754619543120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of Gross Unrealized Holding Losses and Fair Values for Investments in Unrealized Loss Position (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair value</a></td>
<td class="nump">$ 48,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized loss</a></td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Government Treasury and Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months, Fair value</a></td>
<td class="nump">48,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months, Unrealized loss</a></td>
<td class="num">$ (20)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754617758448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 141,461<span></span>
</td>
<td class="nump">$ 137,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(73,234)<span></span>
</td>
<td class="num">(54,350)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">68,227<span></span>
</td>
<td class="nump">83,447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">49,567<span></span>
</td>
<td class="nump">43,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">7,970<span></span>
</td>
<td class="nump">7,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_FurnitureAndOfficeEquipmentMember', window );">Furniture and Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">3,820<span></span>
</td>
<td class="nump">5,342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_ComputerSoftwareMember', window );">Computer Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">1,965<span></span>
</td>
<td class="nump">1,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">3,405<span></span>
</td>
<td class="nump">7,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 74,734<span></span>
</td>
<td class="nump">$ 72,403<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adpt_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624373952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 20,532<span></span>
</td>
<td class="nump">$ 19,221<span></span>
</td>
<td class="nump">$ 12,254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754626434976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">108 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Changes in carrying amount of goodwill since recognition</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Purchased Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period of intangible assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754619109200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 20,325<span></span>
</td>
<td class="nump">$ 20,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(15,197)<span></span>
</td>
<td class="num">(13,498)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">5,128<span></span>
</td>
<td class="nump">6,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Acquired Developed Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(14,970)<span></span>
</td>
<td class="num">(13,304)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">5,030<span></span>
</td>
<td class="nump">6,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Purchased Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(227)<span></span>
</td>
<td class="num">(194)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754618984384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">1,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">1,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 5,128<span></span>
</td>
<td class="nump">$ 6,827<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754619546528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">$ 4,920<span></span>
</td>
<td class="nump">$ 4,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent', window );">Clinical and contract research organization costs</a></td>
<td class="nump">863<span></span>
</td>
<td class="nump">1,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Travel and entertainment</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Tax liabilities</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent', window );">Purchases of property and equipment</a></td>
<td class="nump">687<span></span>
</td>
<td class="nump">1,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ComputerAndSoftware', window );">Computer and software</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="nump">2,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">763<span></span>
</td>
<td class="nump">1,655<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 8,597<span></span>
</td>
<td class="nump">$ 12,424<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical and contract research organization costs, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued purchase of property and equipment current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ComputerAndSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Computer and software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ComputerAndSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754617513072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases- Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Number of square feet | ft&#178;</a></td>
<td class="nump">19,900<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">13,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">cash payment for rent began in October 2021 and the lease term ends in August 2033, <span></span>
</td>
<td class="text">The lease term is through March 2026 and provides for one five-year extension option.<span></span>
</td>
<td class="text">options to extend certain of the leases up to 10.0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseRentCommencementMonthAndYear', window );">Lessee, operating lease, rent commencement month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseExtendedTermOfContract', window );">Lessee, operating lease, extended term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LeaseExpirationMonthAndYear', window );">Lease expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2033-08<span></span>
</td>
<td class="text">2026-03<span></span>
</td>
<td class="text">2031-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease, impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Long-lived asset impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets', window );">Impairment of right-of-use and related long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LeaseCommencementMonthAndYear', window );">Lease commenced moth and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2020-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Landlord contribution for leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ProceedsFromLandlordReimbursements', window );">Proceeds from landlord reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,900<span></span>
</td>
<td class="nump">$ 10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_TenantImprovementCostsIncurred', window );">Tenant improvement costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,900<span></span>
</td>
<td class="nump">14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_TenantImprovementCostsReceivable', window );">Tenant improvement costs receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear', window );">Rent obligations, commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_TenantImprovementAllowanceAndCommenced', window );">Tenant improvement allowance and commenced</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseTerminationPeriod', window );">Operating lease termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription', window );">Lease not yet commenced, termination option description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">subject to an early termination option after the seventh year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend', window );">Lease not yet commenced, option to extend description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">option to twice extend the lease for five years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable', window );">Lease not yet commenced landlord agreed to fund for improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1', window );">Lease not yet commenced, option to extend term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="nump">12,400<span></span>
</td>
<td class="nump">12,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_OperatingLeaseVariableLeaseExpense', window );">Operating lease variable lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100<span></span>
</td>
<td class="nump">7,200<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in measurement of lease liabilities, net of tenant improvement allowances received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,400<span></span>
</td>
<td class="nump">9,200<span></span>
</td>
<td class="nump">8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Cash received for tenant improvement allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,200)<span></span>
</td>
<td class="num">(11,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets obtained in exchange for operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Impairment of right-of-use and related long-lived assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_WA', window );">Seattle, Washington</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Cash payment for rent of the expanded premises commenced January 2020, four months after the landlord delivered the expanded premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends October 2032, subject to our option to twice extend the lease for five years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseRentCommencementMonthAndYear', window );">Lessee, operating lease, rent commencement month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2020-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LesseeOperatingLeaseExtendedTermOfContract', window );">Lessee, operating lease, extended term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_LeaseExpirationMonthAndYear', window );">Lease expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2032-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of right-of-use and related long-lived assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LeaseCommencementMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease commencement month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LeaseCommencementMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LeaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LeaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LesseeOperatingLeaseExtendedTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, extended term of contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LesseeOperatingLeaseExtendedTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease lease not yet commenced tenant improvement receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, lease not yet commenced termination option description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LesseeOperatingLeaseRentCommencementMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease rent commencement month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LesseeOperatingLeaseRentCommencementMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease rent obligations commencement month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_LesseeOperatingLeaseTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease termination period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_LesseeOperatingLeaseTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_OperatingLeaseVariableLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease variable lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_OperatingLeaseVariableLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ProceedsFromLandlordReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from landlord reimbursements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ProceedsFromLandlordReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_TenantImprovementAllowanceAndCommenced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant improvement allowance and commenced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_TenantImprovementAllowanceAndCommenced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_TenantImprovementCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant improvement costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_TenantImprovementCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_TenantImprovementCostsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant improvement costs receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_TenantImprovementCostsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of long-lived asset held for use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease that has not yet commenced. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624499040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases- Summary of Other Information Related to Operating Lease (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">8 years 10 months 28 days<span></span>
</td>
<td class="text">9 years 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624712336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 13,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">14,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">12,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">11,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">12,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">56,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">121,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest rate</a></td>
<td class="num">(22,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">98,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="num">(9,384)<span></span>
</td>
<td class="num">$ (9,230)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">$ 89,388<span></span>
</td>
<td class="nump">$ 98,772<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754617709792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Purchase Agreement - Additional Information (Details) - Purchase Agreement - OrbiMed - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 12, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 12, 2024</div></th>
<th class="th"><div>Mar. 12, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_PotentialRevenueInterestSecondPaymentToBeReceived', window );">Potential revenue interest second payment to be received</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_PurchaseAgreementSecondPaymentDate', window );">Purchase agreement, second payment date</a></td>
<td class="text">Sep. 12,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_PotentialRevenueInterestThirdPaymentToBeReceived', window );">Potential revenue interest third payment to be received</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_PurchaseAgreementThirdPaymentDate', window );">Purchase agreement, third payment date</a></td>
<td class="text">Sep. 12,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueInterestPaymentTerm', window );">Revenue interest payment term</a></td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_PercentageOfRevenueInterestPayments', window );">Percentage of revenue interest payments</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_PercentageOfCumulativePurchaserPayments', window );">Percentage of cumulative purchaser payments</a></td>
<td class="nump">165.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_CumulativePurchaserPaymentsRepaymentDate', window );">Cumulative purchaser payments repayment date</a></td>
<td class="text">Sep. 12,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments', window );">Increase in return cap percentage of cumulative purchaser payments</a></td>
<td class="nump">175.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_AmortizationOfPurchaseAgreementObligation', window );">Amortization of purchase agreement obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueInterestPayable', window );">Revenue interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,275,000<span></span>
</td>
<td class="nump">$ 2,760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_PurchaseAgreementMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_PercentageOfCumulativePurchaserPayments', window );">Percentage of cumulative purchaser payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_PurchaseAgreementMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_PotentialRevenueInterestPaymentToBeReceived', window );">Potential revenue interest payment to be received</a></td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_AmortizationOfPurchaseAgreementObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of purchase agreement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_AmortizationOfPurchaseAgreementObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_CumulativePurchaserPaymentsRepaymentDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative purchaser payments repayment date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_CumulativePurchaserPaymentsRepaymentDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in return cap percentage of cumulative purchaser payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_PercentageOfCumulativePurchaserPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of cumulative purchaser payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_PercentageOfCumulativePurchaserPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_PercentageOfRevenueInterestPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue interest payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_PercentageOfRevenueInterestPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_PotentialRevenueInterestPaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential revenue interest payment to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_PotentialRevenueInterestPaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_PotentialRevenueInterestSecondPaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential revenue interest second payment to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_PotentialRevenueInterestSecondPaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_PotentialRevenueInterestThirdPaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential revenue interest third payment to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_PotentialRevenueInterestThirdPaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_PurchaseAgreementSecondPaymentDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase agreement second payment date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_PurchaseAgreementSecondPaymentDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_PurchaseAgreementThirdPaymentDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase agreement third payment date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_PurchaseAgreementThirdPaymentDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueInterestPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueInterestPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueInterestPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue interest payment term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueInterestPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adpt_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adpt_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754628118336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Purchase Agreement - Schedule of Revenue Interest Liability, Net Activity (Details) - OrbiMed - Purchase Agreement - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueInterestLiability', window );">Revenue interest liability at inception</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Capitalized issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="nump">4,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueInterestPaid', window );">Revenue interest paid</a></td>
<td class="num">(6,225)<span></span>
</td>
<td class="num">(493)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueInterestPayable', window );">Revenue interest payable</a></td>
<td class="num">(2,275)<span></span>
</td>
<td class="num">(2,760)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_RevenueInterestLiabilityNet', window );">Revenue interest liability, net</a></td>
<td class="nump">$ 130,660<span></span>
</td>
<td class="nump">$ 125,360<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueInterestLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue interest liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueInterestLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueInterestLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue interest liability, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueInterestLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueInterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueInterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_RevenueInterestPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_RevenueInterestPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adpt_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adpt_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624968448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>Vote</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Holders of our common stock are entitled to one vote for each share of common stock held<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_NumberOfCommonStockVotingRights', window );">Number of vote for each share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in share reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,431,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in share reserve</a></td>
<td class="nump">1,450,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_PercentageOfAnnualIncreasesInNumberOfShares', window );">Percentage of annual increases in number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in share reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,155,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in share reserve</a></td>
<td class="nump">7,254,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_PercentageOfAnnualIncreasesInNumberOfShares', window );">Percentage of annual increases in number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_NumberOfCommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_NumberOfCommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_PercentageOfAnnualIncreasesInNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual increases in number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_PercentageOfAnnualIncreasesInNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754619417792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">43,992,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember', window );">Shares Issuable Upon the Exercise of Outstanding Stock Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">12,875,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember', window );">Shares Issuable Upon the Vesting of Outstanding Restricted Stock Units and the Maximum Outstanding Market-based Restricted Stock Units Granted</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">11,582,134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common Stock Options Granted | 2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">15,299,763<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common Stock Options Granted | Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">4,235,348<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754620115808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life stock options outstanding</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted-average remaining contractual life vested and exercisable stock options</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="nump">$ 5.61<span></span>
</td>
<td class="nump">$ 7.36<span></span>
</td>
<td class="nump">$ 24.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="nump">$ 156,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">2,245<span></span>
</td>
<td class="nump">7,890<span></span>
</td>
<td class="nump">26,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods', window );">Proceeds from settlement of stock option exercised in prior periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized share-based compensation expense</a></td>
<td class="nump">$ 62,908<span></span>
</td>
<td class="nump">55,477<span></span>
</td>
<td class="nump">43,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Option Valuation Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=adpt_MonteCarloValuationModelMember', window );">Monte Carlo Valuation Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized share-based compensation expense</a></td>
<td class="nump">$ 9,800<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm', window );">Requisite service period term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of RSUs vested</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=adpt_MarketBasedRestrictedStockUnitsRSUMember', window );">Market-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units outstanding</a></td>
<td class="nump">956,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share</a></td>
<td class="nump">$ 15.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=adpt_MarketBasedRestrictedStockUnitsRSUMember', window );">Market-Based Restricted Stock Units | Monte Carlo Valuation Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="nump">$ 13.82<span></span>
</td>
<td class="nump">$ 18.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=adpt_MarketBasedRestrictedStockUnitsRSUMember', window );">Market-Based Restricted Stock Units | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm', window );">Performance period term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=adpt_MarketBasedRestrictedStockUnitsRSUMember', window );">Market-Based Restricted Stock Units | Minimum | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward', window );">Common stock that may be earned under the award</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=adpt_MarketBasedRestrictedStockUnitsRSUMember', window );">Market-Based Restricted Stock Units | Maximum | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward', window );">Common stock that may be earned under the award</a></td>
<td class="nump">709,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">494,234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineEquityIncentivePlanMember', window );">2009 Equity Incentive Plan | Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineEquityIncentivePlanMember', window );">2009 Equity Incentive Plan | Grant | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="nump">15,299,763<span></span>
</td>
<td class="nump">14,581,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="nump">34,853,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Grant | Non Employee Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Grant | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="nump">$ 8.29<span></span>
</td>
<td class="nump">$ 11.43<span></span>
</td>
<td class="nump">$ 37.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units outstanding</a></td>
<td class="nump">9,669,460<span></span>
</td>
<td class="nump">5,981,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share</a></td>
<td class="nump">$ 10.32<span></span>
</td>
<td class="nump">$ 14.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from settlement of stock option exercised in prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares earned under the award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award requisite service period term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award vested and exercisable options outstanding weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award performance period term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=adpt_MonteCarloValuationModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=adpt_MonteCarloValuationModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=adpt_MarketBasedRestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=adpt_MarketBasedRestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adpt_TwoThousandAndNineEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=adpt_NonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=adpt_NonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624856144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details) - 2019 Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant at December 31, 2022</a></td>
<td class="nump">14,581,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve', window );">2019 Equity Incentive Plan reserve increase effective January 1, 2023</a></td>
<td class="nump">7,155,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned', window );">Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned</a></td>
<td class="num">(9,980,059)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired', window );">Stock options and restricted stock units forfeited or expired</a></td>
<td class="nump">3,542,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant at September 30, 2023</a></td>
<td class="nump">15,299,763<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payement Equity Incentive Plan Reserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, stock options restricted stock units granted and maximum market based restricted stock units granted eligible to be earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment awards forfeited, canceled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754617718928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Stock Option Activity Under 2009 Plan and 2019 Plan (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Subject to Outstanding Stock Options, Stock Options outstanding, Beginning Balance | shares</a></td>
<td class="nump">13,520,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares Subject to Outstanding Stock Options, Stock Options granted | shares</a></td>
<td class="nump">1,612,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Shares Subject to Outstanding Stock Options, Stock Options forfeited | shares</a></td>
<td class="num">(1,030,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Shares Subject to Outstanding Stock Options, Stock Options expired | shares</a></td>
<td class="num">(757,191)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares Subject to Outstanding Stock Options, Stock Options exercised | shares</a></td>
<td class="num">(470,405)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares Subject to Outstanding Stock Options, Stock Options outstanding, Ending Balance | shares</a></td>
<td class="nump">12,875,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable', window );">Shares Subject to Outstanding Stock Options, Stock Options vested and exercisable | shares</a></td>
<td class="nump">9,071,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Stock Options outstanding, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 16.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Stock Options granted | $ / shares</a></td>
<td class="nump">8.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Stock Options forfeited or cancelled | $ / shares</a></td>
<td class="nump">17.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Stock Options expired | $ / shares</a></td>
<td class="nump">22.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Stock Options exercised | $ / shares</a></td>
<td class="nump">4.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Stock Options outstanding, Ending Balance | $ / shares</a></td>
<td class="nump">15.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Stock Options vested and exercisable | $ / shares</a></td>
<td class="nump">$ 16.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Stock Option outstanding | $</a></td>
<td class="nump">$ 506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue', window );">Aggregate Intrinsic Value, Stock Options vested and exercisable | $</a></td>
<td class="nump">$ 506<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and exercisable intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and exercisable weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624839344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Granted</a></td>
<td class="nump">$ 5.61<span></span>
</td>
<td class="nump">$ 7.36<span></span>
</td>
<td class="nump">$ 24.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | 2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted Stock Units Outstanding, Nonvested Outstanding, Beginning Balance</a></td>
<td class="nump">5,981,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted Stock Units Outstanding, Granted</a></td>
<td class="nump">6,949,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted Stock Units Outstanding, Forfeited</a></td>
<td class="num">(1,755,018)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted Stock Units Outstanding, Vested</a></td>
<td class="num">(1,506,864)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted Stock Units Outstanding, Nonvested Outstanding, Ending Balance</a></td>
<td class="nump">9,669,460<span></span>
</td>
<td class="nump">5,981,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Beginning Balance</a></td>
<td class="nump">$ 14.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Granted</a></td>
<td class="nump">8.29<span></span>
</td>
<td class="nump">$ 11.43<span></span>
</td>
<td class="nump">$ 37.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Forfeited</a></td>
<td class="nump">11.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Vested</a></td>
<td class="nump">14.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Ending Balance</a></td>
<td class="nump">$ 10.32<span></span>
</td>
<td class="nump">$ 14.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adpt_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754619461696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Estimated Grant Date Fair Values of Stock Options Granted (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of common stock</a></td>
<td class="nump">$ 8.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">71.20%<span></span>
</td>
<td class="nump">68.20%<span></span>
</td>
<td class="nump">67.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">71.60%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="nump">$ 30.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.95<span></span>
</td>
<td class="nump">$ 66.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754623076656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Consolidated Statements of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 62,908<span></span>
</td>
<td class="nump">$ 55,477<span></span>
</td>
<td class="nump">$ 43,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">4,186<span></span>
</td>
<td class="nump">3,910<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">20,465<span></span>
</td>
<td class="nump">17,689<span></span>
</td>
<td class="nump">14,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and Marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">14,553<span></span>
</td>
<td class="nump">13,597<span></span>
</td>
<td class="nump">12,312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 23,704<span></span>
</td>
<td class="nump">$ 20,281<span></span>
</td>
<td class="nump">$ 14,778<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754628006768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=adpt_NonvestedStockOptionsMember', window );">Nonvested Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized Share-Based Compensation Expense</a></td>
<td class="nump">$ 33,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (in years)</a></td>
<td class="text">1 year 11 months 8 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=adpt_NonvestedRestrictedStockUnitsRSUMember', window );">Nonvested Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized Share-Based Compensation Expense</a></td>
<td class="nump">$ 76,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (in years)</a></td>
<td class="text">2 years 8 months 1 day<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=adpt_NonvestedMarketBasedRestrictedStockUnitsMember', window );">Nonvested Market-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized Share-Based Compensation Expense</a></td>
<td class="nump">$ 8,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining Weighted-Average Recognition Period (in years)</a></td>
<td class="text">1 year 11 months 19 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=adpt_NonvestedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=adpt_NonvestedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=adpt_NonvestedRestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=adpt_NonvestedRestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=adpt_NonvestedMarketBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=adpt_NonvestedMarketBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754619050384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Microsoft Collaboration Agreement - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_MicrosoftCollaborationAgreementMember', window );">Microsoft Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement', window );">Minimum service consumption requirement amount</a></td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement', window );">Minimum service consumption requirement term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adpt_MicrosoftCollaborationAgreementMember', window );">Microsoft Collaboration Agreement | Series F-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock investment</a></td>
<td class="nump">$ 45,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum service consumption requirement amount under license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum service consumption requirement term under license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adpt_MicrosoftCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adpt_MicrosoftCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adpt_SeriesFOneConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adpt_SeriesFOneConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754622878176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>Employee</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Restructuring, reduction in workforce | Employee</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Estimated aggregate restructuring costs recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Restructuring costs paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754628267248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Loss Before Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (225,335)<span></span>
</td>
<td class="num">$ (200,427)<span></span>
</td>
<td class="num">$ (207,314)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total loss before provision for income taxes</a></td>
<td class="num">$ (225,304)<span></span>
</td>
<td class="num">$ (200,368)<span></span>
</td>
<td class="num">$ (207,298)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754620376528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 251,724<span></span>
</td>
<td class="nump">$ 210,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">Tax credit carryforward</a></td>
<td class="nump">43,528<span></span>
</td>
<td class="nump">36,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_DeferredTaxAssetsNonQualifiedStockOptions', window );">Nonqualifying stock options</a></td>
<td class="nump">29,166<span></span>
</td>
<td class="nump">23,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">25,357<span></span>
</td>
<td class="nump">27,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">18,874<span></span>
</td>
<td class="nump">26,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_Deferredtaxassetscapitalizedresearchanddevelopment', window );">Capitalized research and development</a></td>
<td class="nump">42,134<span></span>
</td>
<td class="nump">40,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">6,146<span></span>
</td>
<td class="nump">5,859<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">416,929<span></span>
</td>
<td class="nump">371,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(402,424)<span></span>
</td>
<td class="num">(346,578)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">14,505<span></span>
</td>
<td class="nump">24,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets', window );">Tangible and intangible assets</a></td>
<td class="num">(1,281)<span></span>
</td>
<td class="num">(4,897)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="num">(13,224)<span></span>
</td>
<td class="num">(20,052)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DeferredTaxAssetsNonQualifiedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, non qualified stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DeferredTaxAssetsNonQualifiedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, tangible and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_Deferredtaxassetscapitalizedresearchanddevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_Deferredtaxassetscapitalizedresearchanddevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754619447136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 55,800,000<span></span>
</td>
<td class="nump">$ 49,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_NetOperatingLossCarryforwardExpirationPeriod', window );">Maturity period for NOLs carryovers</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">U.S. federal NOLs</a></td>
<td class="nump">$ 768,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">9,303,000<span></span>
</td>
<td class="nump">8,117,000<span></span>
</td>
<td class="nump">$ 6,915,000<span></span>
</td>
<td class="nump">$ 3,489,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Uncertain tax positions</a></td>
<td class="nump">1,186,000<span></span>
</td>
<td class="nump">1,202,000<span></span>
</td>
<td class="nump">$ 3,426,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties related to uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_Deferredtaxassetscapitalizedresearchanddevelopment', window );">Deferred tax asset</a></td>
<td class="nump">42,134,000<span></span>
</td>
<td class="nump">$ 40,957,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">U.S. federal NOLs</a></td>
<td class="nump">192,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">U.S. federal tax credits</a></td>
<td class="nump">$ 47,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit carryforwards expiration year</a></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_OperatingLossCarryforwardsExpirationYear', window );">NOLs expiration year</a></td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_Deferredtaxassetscapitalizedresearchanddevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_Deferredtaxassetscapitalizedresearchanddevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_NetOperatingLossCarryforwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Operating Loss Carryforward Expiration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_NetOperatingLossCarryforwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiration Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754624640672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal tax benefit</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="num">(2.90%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">14.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_EffectiveIncomeTaxRateReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(25.30%)<span></span>
</td>
<td class="num">(24.40%)<span></span>
</td>
<td class="num">(47.70%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_EffectiveIncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Permanent Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_EffectiveIncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754619033712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance</a></td>
<td class="nump">$ 8,117<span></span>
</td>
<td class="nump">$ 6,915<span></span>
</td>
<td class="nump">$ 3,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions</a></td>
<td class="nump">1,186<span></span>
</td>
<td class="nump">1,202<span></span>
</td>
<td class="nump">3,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance</a></td>
<td class="nump">$ 9,303<span></span>
</td>
<td class="nump">$ 8,117<span></span>
</td>
<td class="nump">$ 6,915<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754627814848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Adaptive Biotechnologies Corporation</a></td>
<td class="num">$ (225,250)<span></span>
</td>
<td class="num">$ (200,191)<span></span>
</td>
<td class="num">$ (207,279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic</a></td>
<td class="nump">144,383,294<span></span>
</td>
<td class="nump">142,515,917<span></span>
</td>
<td class="nump">140,354,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic</a></td>
<td class="num">$ (1.56)<span></span>
</td>
<td class="num">$ (1.4)<span></span>
</td>
<td class="num">$ (1.48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted</a></td>
<td class="nump">144,383,294<span></span>
</td>
<td class="nump">142,515,917<span></span>
</td>
<td class="nump">140,354,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted</a></td>
<td class="num">$ (1.56)<span></span>
</td>
<td class="num">$ (1.4)<span></span>
</td>
<td class="num">$ (1.48)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754620376688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">25,133,607<span></span>
</td>
<td class="nump">19,102,419<span></span>
</td>
<td class="nump">13,799,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common Stock Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">13,839,067<span></span>
</td>
<td class="nump">13,892,287<span></span>
</td>
<td class="nump">13,097,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_UnvestedRestrictedStockUnitsMember', window );">Nonvested Restricted Stock Units Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">9,630,579<span></span>
</td>
<td class="nump">4,799,850<span></span>
</td>
<td class="nump">693,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember', window );">Nonvested Market-based Restricted Stock Units Outstanding Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">1,663,961<span></span>
</td>
<td class="nump">410,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_CommonStockWarrantOutstandingMember', window );">Common Stock Warrant Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,570<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_UnvestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_UnvestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_CommonStockWarrantOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=adpt_CommonStockWarrantOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139754617758320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Employees maximum annual contribution of their compensation</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer discretionary contribution amount</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adpt_DefinedContributionPlanEmployeeServicePeriodForVesting', window );">Employee service period for vesting</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adpt_DefinedContributionPlanEmployeeServicePeriodForVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan employee service period for vesting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adpt_DefinedContributionPlanEmployeeServicePeriodForVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adpt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>100
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MH9T4Y2,Q$+%60NYH 1>$A([K#QG9@(Z#HV%7M0.C. @F./4Z!\\+G==<,R@
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M%\K-[FRRW'J91N9EVO^DW.;".!9SDP5G@TX4G UJ+[CER2EHR>2^/DU6P./
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M)2UK W']@3'^_*5^5>_X>NGL7U!+ P04    " #Q@5U8(;K!/G8(  #L*0
M&    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;+6:;W/KJ!6'OXK&W>GLSEQ?
M"]#?V\0S-U;O]+[8;F;3;5\3"=OTRL(+.+GIIR](BF4!(LY6?9/8\N%(O\/A
M\("X>6;\F]@3(H/OA[H1MXN]E,=/JY4H]^2 Q4=V)(WZ9<OX 4OUE>]6XL@)
MKMI&AWH%PS!9'3!M%NN;]MH]7]^PDZQI0^YY($Z' ^8O=Z1FS[<+L'B]\"O=
M[:6^L%K?'/&./!#YV_&>JV^KLY>*'D@C*&L"3K:WB\_@4Q&%ND%K\4]*GL7%
MYT!+>63LF_[RM;I=A/J)2$U*J5U@]>^);$A=:T_J.7[OG2[.]]0-+S^_>O_2
MBE=B'K$@&U;_BU9R?[O(%D%%MOA4RU_9\]](+RC6_DI6B_9O\-S9ILJX/ G)
M#GUC]00'VG3_\?<^$!<-0#+1 /8-H-D@FFB ^@;HV@91WR!J(]-):>-08(G7
M-YP]!UQ;*V_Z0QO,MK623QO=[P^2JU^I:B?7&]8(5M,*2U(%#U+]4YTJ1<"V
MP0:+??!%)88(EL%O#T7PXP\_!3\$M G^L6<G@9M*W*RD>@;M:57V][OK[@<G
M[@=@\#-KY%X$?VTJ4HT=K-3#GQ7 5P5WT.NQ(.7' ($/ 0PA<CS0YOKFT-&\
MN+XY\*A!Y_Y K3\TX>^7(^%8TF;7C0@J*7%&N?,2N;WH8O%)''%);A>J&@C"
MG\AB_><_@23\BRM"<SHK9G(VBEYTCE[D\[[^NRJ4-1/.B'4MX[:EKH9/ZR6$
M,0JCF]7393!<=F&(DFQL5SCM4I@/=B,)\5E"[$V S]6_U:CO!J%DJK26K"EI
M38*FUZ:OZL^E'IXGH8:M&I'LRK2)YTR;.9T5,SD;Q3PYQSSQIDU!E-.2XG8F
M(M_5G"J(*WJ=E^2BRV$8(V@DD&T%<JB+PRA]'%8J'2-W\J1G(:D__U6NZ+2H
MB9H*?4I2Z^Y)#D-#B&V40I@:.AQ&(9P8 ]E91N:5\;#'G"SU=%X%)3MH%6_V
M368K@GEH#-J-;17'46IJLJTB!&/@%I6?1>5>45\;B9L=?51#&0M!U/#&!\8E
M_4\KS24IMU,DR7-#T35&Q1M&(ST@'- A?$/1$^E*U9M2>D^73[#,06;67H=9
M&IDCQV4$$9I0<P%"P*_F<,24MVH4_'#-BTNV7:H*&RC4486X;AFI9LUN62M6
MK?IN=,H%=J6((VCVG?^)WEM!Y_(VCA\<X@??S(9&,OX2]-Z=@8%V)J(L->-B
M6\$$F1.P_WG^J-X!U("79,ZUEC:2*/_25YQZ5Z.Z@T*SWCJL\BPV5?\_^ H,
M@ 7\A/6+W!/NE!C9/9N:4Z/#: G,8N4R2B=F%#!@%?!SU6:OJB\1!BSUA5B-
M[YKB1UI/@A.8E9QF]5;,Y6T<V0&>@)^>/I<E.VE<50Q%Z!-6,]P'3:C.,+H0
MRB(HAY5B]22R*H##+D4)G,B5@:* 'Z/.I<PIP2:>)<S,ZK1QF&7 ! V7KQA>
M%(:Q@(&?@!^@[CE1DUGU6I*Z#&=ZZ ;EB?-VQIZ>O&S\48,46=7*-D-Q;$W6
MMA6 63(A<& IX(>I<\X=\0MND4H)Q&7)3^3MH6S3T#*.0FL2LLU2 "Q]MA7*
MHXD.A -:03]:#=L '<J/<>3JJ@4=V)4E:6)(=9E%86ST>.$PRV(X,=K@ %[0
M#UX%V1*5DQJQU+ [.2=0: /5$N8P!Z82AUV<1'EB2G'9I>G%ZF8L9J @Z*>@
MR?D1VDRC:I7Y^ X\2LSYT>4)IO'$DP\\ ]_@F3^ZIP!M;%F".$'0I'NG8::&
MB\DX3L,<3G?/@"\P\E) MV2Y0I.7@MX[W<_JK9C+VSB$ TA!+TZL[T^\W&,]
MJ:AETI'K+)$O;3$BOY_H42^@G!&-'7T:)KE9=IUV"8JL4>"P2T :34PM<, 9
MZ,>9D;X#YM^(;&<80=34.9TP#A11"[XX-KG 90C3+$U-N'$9(I#$T<0>$1SP
M!OKQYIZSDI!*!%O.#DJB['6]3["-+G&2YZ')<@X[F&<6\Q4N?W$>3[$0'%@(
M^EGH7-=4KC[12M6VQQ=5WJZL RY\R9/(REK;#N:A5=<<WC( P93& 8=@[BUK
M7VB#F_(*.5ZJ>G=9F]-;,9>W\6N7@;B0G[C&@X)\)[RDBK74D!"2E=_4;*CW
MMMSO8FPN@M"<U#8.JS3+3<9R^4I2,#'QH0&RD!^RQO)ZTAKV+HY]T0OPCI/V
M%6"[A-/RJ1 GE5PD*)EP+QC\MW[WRR@;S0",4&H.IKGN.@[H 'K(#WKC@-)&
MC3E<JT)SI%+_9XWD]/'4YDRP93PHZ*[]Y8XR2<I]PVJV4Z/T0_"U*3\ZHSK3
M]E8?U3F]%<A&T,O=S7%(+UY]7DF@EY5Z>V5I0S8SN@:A;040A(F57 YO*9B"
M"S3P)WK[!>6/%2FY7M7]I-*F^Z1Q6RO_T.G7(/6$Z_8=8+?W+%0VE7K[6?_N
ME._8-(-19&VMN.PB11]6 !S;>7$RV<<#/2(_/6ZN5AE@&3R2'6T:W?FJ$+T0
M[%Q9(9L$<QA!$[P<9B ",$2F<H<=C.-T KO0 );(#Y;ODT[TCHU'M$V'29J;
MZ]R-P\P1F\)A9L1FK'E 391ZP638)+^.MY"77-]=].;T5LSE;1S*@6/1&WMZ
ME^N2\U)+EY#Z5'4K=OP_[(HAQPM4Z\6,PPBDU@9^;Q6/7$UL$Z&!<9&?<1].
MQV/=HHF:12LJRIJ)$V\)K4VQ;:T\TJ8["C?Q&A+-RK^S>BOF\C8^.#/P;^3G
MW_:T5[MIK&GE%0R=!VE"JWLSZSW5QF$5Y<:.4.%_IO=J7ET<@SL0OFN/$XJ@
M'1/=>;+SU?.1Q<_M03WC^AWX5'0'#P<WW3G(GS%7,Y((:K)5+L./J=+'NZ.%
MW1?)CNUANT<F)3NT'_<$5X1K _7[EBG\Z[_H&YP/>*[_"U!+ P04    " #Q
M@5U8R%CMI\D$  #O"@  &    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;*56
M76_;-A3]*X0*%!N0^4-)VRRQ#<3)BNVA6)!LR\.P!UJZEHA2I$I2=MU?OW-)
MR7:PU BP%UNB>,\]]]P/<K:U[K.OB8+XVFCCYUD=0GLU'ONBID;ZD6W)X,O:
MND8&O+IJ[%M'LHQ&C1[GD\G[<2.5R1:SN';O%C/;!:T,W3OANZ:1;K<D;;?S
M;)H-"P^JJ@,OC!>S5E;T2.'/]M[A;;Q'*55#QBMKA*/U/+N97BTO>'_<\)>B
MK3]Z%AS)RMK/_/);.<\F3(@T%8$1)/XV=$M:,Q!H?.DQL[U+-CQ^'M _QM@1
MRTIZNK7Z296AGF>7F2AI+3L='NSV5^KC><=XA=4^_HIMOW>2B:+SP3:],1@T
MRJ1_^;77X34&>6^01][)461Y)X-<S)S="L>[@<8/,=1H#7+*<%(>@\-7!;NP
M^-U5TJAO,DED2G%'OG"JC>]V+9:=AX7WLW& -[89%SWR,B'GWT&>YN*3-:'V
MXA=34OD<8 R:>Z[YP'69GT2\HV(DSJ=G(I_DYR?PSO>QGT>\\U?$?B9NK?%6
MJ_(@Q;TC3R;(08N/RDA3**G%(Q8)I1F\^/MFY8-#<?WSDD2)P,7+!+CAKGPK
M"YIG+?MR&\H6;]],WT^N3X1WL0_OXA3Z_TKM:>3I2+P67-R4LN7&$TME Q6U
ML=I6BCST=JUU">"'MV\N\WQRO:6S^#2]%OU*YX<%ZX8UV[E^\4>AO)"BL$U#
MCC/SDP\8);S02K,3LMQPQDPE0DUBK4B73$XU36=(-%0J?"2QVHE:.J8[;%6F
M)H?\BI5BOCNVXG4Y1--#^)U'(8A@!6K >!Z2<5^I9&6L9W;0)F!<!BX7ABF5
M)XR1D7B"8]**@'8"&A!&ALX1ASS]<.U%8WU +(;T3@3L+ =O017)';C+ECI^
M!Z-DT+OU9V+5A3Y&N5):A1W3+ZFP)=8"E/ "U;@!78I822=4/<O<&398.]N(
M=:?!0&.GDQ4+I] .A6P3*E*,*NG<?\1NM0Q1)]FVF@L!Z81#VSI% >>">%8E
MH,9G32\J7'D2%1GBV")C*"I%BS("W[U$SR5D33K,((?BP"."*R &N-=HJ*C$
ML^TE@4$XRIP?Q(-DV"_#X"_F$!%S>A@H[O!\#GC>RH&5.R,;YHH>BB)&7Q9+
M0,7 YA,E>G($72"X-$$A0/P;FT8/4K:M55$+"2\QCE893CO*E@N]2]N /10K
MXS6RJ%EN3:AL9.<LR> CT2:E?(,SN8WKAPY2W^A %FDINT$+GD^JX)RP!(4T
M*%\1I-+6<:'8**4A*GWL,8-TJ;)CE*26CW+5<D-'[K[C@E^D<':%$U"TJB4>
M00S[&FI;BE*5A%28V-%V:!$Z0S>@A-$5;$=H 9W:[Z4>A?*^8^&YKDU!R4AV
MP?85@WW6<6'%T+88&8B[Z <;1(GU0NFX8-PGZ9&4*O",-.*16M3;"K"7?*9-
M?D[933K*A@ZS\X_;A^-YB<8R&+A%,L[CB3C%+P(O:FDJ>.;:BQB(_34C. ;
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M";ZWKMX[CJ&2? :)JIE^'+.$L3J;P4>:UN]9R@6Q'W?F)"KG3NYM=1#35'&
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MVM'Q< W'_!.E&(OH[28N@WX']C2YV:C*KQN2F^2&2.Y+,[_AK#0E_&J['>B
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MSFHFI!3",!X]5O?!#F8.GD7(S(90XCB!-A=.U.#MH&ESR?MKWER&(0C%GHK
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MU-^!']Z0T.#P8W8YX>B/><<GPIA;"V#J*U7&@AL!N((QR^R'>EVVWHX$B#7
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MKFL5UE>FHWU.PYMW3+>K<]4Z (@[$/F42WJ<2[L76Z 'LR+D=HN(5@7QJ""
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M,4"&P)F(^Z+09"%9EH=,%/]7]FZ/V2.E76")V:9H:)6N-EUK.1HMOEJD(^*
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MV7+26'*X]F,PAO31'@M(@)@+CF+]Z/$PVL>EW?13F-9^[(KZQ?BBQW<-L,#
MN-TS$(#.(6KEJ?O2H/?2^8>AC@U>EMZJGLR6Z3'"&]H9@SJ/7'YBP',X*EOZ
M,6\Z7#P9(Y*J^?+6XSU[H&_FQV8_OHCG0<ZAGYN-A@ZK\4A_I%," BEH:-T2
MX=".T?J@T(V*M2_A/$R-1WWUR;-G GT^D3ONTT+Y&0[TN <&'DUB-\H]H@OW
ME\F^]7GJ%50%:X_DZ JLS$/,T#T$*A7P MXK6?#8FPM/\$';GL[R>-R9G<Q!
MHSKY=IZKOSYUI#/6^LRH;YAB,@S! S9,E>JHM!7K;TP>X)>@[5,"^-3MT1R0
MK!42O6_6&(3J/O>:SE$Z#@[&Z8/-(X/?LD/:4[:V'7('IW(HD15+ O$C<@T/
M8WXF>E'CW.+$J6DFDJ)J?!*;#ERS)+)PCA0G4]I8L,0.Z\GA&<V'DVO)H[%N
M<G7%W[RZ@SQN#R<4E7\%QU^ _8G&;(MI?X="T>GEH+>S"H;&02F%VE+--;P#
MX2^RQ@_UP^Z>%LE[OD3@:Y98:/7I@ANX0H4R\1P@))[:SWA[S!I1'Y=LE*&U
M4U7L:.GUC<+0Q5GMRD-4?KP&"? 4YU-'281=2/L E!;U(G5='.7<TVU]G4A*
MH1E_GG<M>ZHO5WDLV_/?%ZX/1]D7P*4H-<KVD#V9N(9KB)@P"Q0YN1O%1 (M
M1CGI08H;7=.&*C"M#BI3 ,C]#-U;]NBM%PJZ\6*"+5@I:3L/ N/D.^M+8+A4
MT]%("N8HA!_6&>HI+7?2T)3WM7BA& *"KU+C[6,1EO-=T!GO4EL:;]FDA. "
MCHB=-H:T=31EQBH/$GK3'F+(_S:@]%.MVHC2U#L$R#@DT9I3-!KQ9-^!\-M1
MMO?!)!J]HCEZAGM9E%OY_AI9XE3O9^U%^9%.HI&QCU&R#,>)O_@==Y636\PS
MM;K'"1D@@(L6*B"^LW5Q0DU34KJR3X):\?M<'"581&-Q9/OT/CJT79? IN_H
M;+@7<:%>L*=M7-(&4'XG%4&KO]F%,K$A9_?ARG<[I'8&V%:Q#7I+Q.Z*.NKD
M= "7#V\_UJ%5?BXP=-TT&<BU93&X&L"Z7NE9ZJ%;-"8;%.K<VW-!'7,KI<+!
MPC12JCGA<> ]?4%B.1]>0Z+<M)HG;TR0,OBGZ:77:/+1U]:>_5X4OT)')_DW
M.(9^FSJ!YPPL/S*$_..53^+R/.0@+GAV,/9:YTWR[BURVH[?,*8V&''L7\/M
M?^U?8K[W[^X.R_T;T+^@K:=NHU1;;)U.UK=7/EG%+\XT_"8OW-69BC_N%1RC
MI05XOC6 K_"%#NA?[7[_=U!+ P04    " #Q@5U8?X[),,L#  "]"0  &0
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M:&5E=',O<VAE970Q,BYX;6RM5MMNVS@0??=7#-2BV *"=;7JI+:!7#;8!39
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MGYM,SW%J;97+3>=DW#F<+-ITQX2[8\'=P4QHY^[A*/>;A22JK-W%2:YUO)3
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M$JYZV%:#8&?Q,3FV 4_3^%F01'/R!JQ/K WK 1O8_'?A[%]02P,$%     @
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MG3CY]:?+\7CX+.[D7Z-GC_N(MI"SF2XTPDJ1;D7?Y/?:&>O$FS>W6.4$*JW
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MCZ5&+PZT /,+[U/W0@?TO\]<_ =02P,$%     @ \8%=6&EO))9T P  V <
M !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULC551<]LV#/XK.'77I]22
M93?-I;;ODG:[]:&W7+JN#[L]T!0L\4J1&DA%\7[]0%*6G2YU]V*+)+X/'T
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M.@Z(;IO-=F!5[1N\I;+8+GJSQ/X<M-N ZRN%-=8-G(.^XU_\#5!+ P04
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M3+WW$2@A]??Z\[G^[ E?L6]I*40@;!X OD)FVBP \6 )S%,FA=I=%V0M(B"
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M,8J)'8Y)9L0/N-$?P6]W6UP<H6:!U.ZWI(5-72-+\M.NK$V^ PLT>90FE_*
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M>EL!JW>;8UKQMZ]*2 F_1%%-H. J-S70W&L'_WA2_OK\ZK5WLD!U82";K*)
M<>J6VT]BVK/;R(K'=1BVHO.RY.R@C#$5^SQX6. 3D70BOQ/M?..#"6 #\L7V
M$VA'6C75L(C$3F 3<,D&C]GDZ)(#4[FN\=K$U1+)T,?YM8E\494#99>]L!6
MV^XP3"6+4&@-G\5&&CU^0WS,'BI:?4QNB"QT0H#0BF:-C!6C"6SWVH#^WS-(
M/E2#&V23D83T)S +?F%OK>,@E%N@!TK46U3@2S=HIX*7&X031RW!7#VXMZL.
M[L:;*]D!'GTL.W 7 4X^ZT9,&S'=85%9A[:!'MI"HA8(/R,F6O0%>^]/7R;?
MX@+)V8OD[YVCF"6>:,-RA+P=1CCK(68_=$[%/8X.K\"H27_5^8OD^X.-LD@B
M+T.>+<],P2$%.Q\(]Y\]4$@! @[!2QI_;#JXH:@\T$QGL'6,S<B&,,Y!,,08
MPVNB0\'HBD&B0^E?NX5CRPNLN^@B(44@-<- =@L,'[7L#^-Y+[NR3-!GT;C:
MK=#VZ 6HBT,*\7 VW5:4#, #2[0,<.44(MJH=RC\;5&R"'E['1/$#0">]SQ/
M%5V H]:NP/#^A<4QFJHB"G!1_C)0KI?J%%_&J]#C;,3_]#3,$,/%TP!'W#X#
M<1JB86@(*3.V]']82^-R'C7J#)", 6E":M_4('KS"'AE[;'=CUDF<H W8()M
MR/$U(SM&V0-/41@J#N]2O$+\HMP_.0[ZJE@VC;K$8%GNR5\*05K%VY$M;L'>
M_$0!G!CY>6?E2."K9@W4J&X7D0N8Y3EH$&0Z@A)S$)6KPB-&R4S=HMH?;HY7
M2*AZ:%-QK*-&RX$D)@4Z;C3F)VV%*.UZ-NWL.K#GT;7G,"T\\1+<Q%'S8'*A
M\93C^.J(U$'4CD(]X5(*N>.5%'LPGN:KCG"!AB-(#O X,31,0=8ATT@T);IL
MZ'V 9D-9Z.I]GTQ0TTDLD,P\C# A*(5F/4A8M:9>63)M#,AL(S$9A*O>EF A
M-*W+/K(SFXZ$"^@AQUR$<?HEDMJ"=E"QK.CKV$4[0'7D]A,=LU\\[A*G"3H5
MO[LOX3W^$\ 11ZHS!JN7C,%M%FU'D,^2N!0@Q)D,R4!@'C5O-&BU<?0+AOHL
MY1\R\2WPD%O74KB7 TUH[FFRERU&MF[0OO>N+1MU(:/#J2M<T!I0ZH.0)/OF
M7+A"R1 ?#APZVU_#NK1",[*_U,-(SI+L M!.VJRWB2%\4?P1(3VVOZ/K3MTA
MJC0G]S,\B 2;0525H/>:%Y]I).]<U[J,UOK.MI_]PX+)0]47?8D6__$9B3<4
M;?B_L\3_^=F%8 F4]]_^$OX[>S)[GOPE_/HZ^5MR=C9["O_ A\]G3S[[QJ*C
M:;,UI[D)0Y<N@RU] _IQF\R?P0J/GLX>)X_/9I_C?9_]390I$M39Z5^2*2D[
M#U)V/BEE1_ R*F+OO$K >#@]5;R<1!7UF/M KN<H$H@@I\G2E+R=Y"TYI$X<
M-$(>G+)CZ3+(384< *6"Q%G R&A'X,2TC\J<X HK<TY18^-)L21]2TFP6/*A
M0P#N>$DE50@0W*7)&;;]:->T?Z10XM$*GM(T6$A!":2\R^SHYC"QUX9D3TZ\
MP'$%^IU=F2FR"%4_9Y-E.A1*JE #C1+#+>]-PJ?XX"/UYM49'9&HQ,9G@N%*
MG[BCT\_,%DM%T-4K_-KDU6F .9?#!B7@T^%L"Y/#B]["$@Z-R"*0&2>"O"@&
M>5^JO8T5)QR,M&A7TO(YVH%N2XOXW9!1%G8,2IG.PR=?./-#U1,->>2:G$ 3
M:UG437M25*E\<EWKLTHJ4-$G!!(3?D GR0%=9IRBQ_A1$^R$'2A#>^*63*8!
M5VKV@Q^#>5@ J&N0=F;)MYB6)3<J7"V!W>>#P.Y9%-C=^12]Q.W%'F;O3TQ0
M'R@>27KU%=4=X\13M!YJQLZFJ[G>Q\%>3*K0P8X2_N1"XX;F^.I)[VOKOX[Y
M!".*'9Q(^#D-WS5NV>[ \DAC=HHNI%CUFN)\&TS[:T7)LJNK@C+;E/"D+&OT
M?*F&P4/C8#D"!(8>Q8=FQZ#6N&2=,[D3A3.C "(PJ4.<U,3!RZ[1 A6L)<3*
MT!/$IX0;0V@R2#N0"L"]8'$O@5S?84S?5D;K4[! J1!C# 1!O>*HC$H IE+P
M8D1 ((0<T8FPPS=[$0,*YX,^\IK2F:@C>-WM<43$UL>W(V<#_N,>1 DIE&?\
M\;-O1T\KN4*GCX7&*!I0BH2:.LYK( M_=G% .BQ@A6AB$)X("%]/$\:3 Z C
M;7Q8TD&!K%@!5QT)+U>3N,8*GP3E+?NGO;(@."@4=:(O!]XT*4X-HJ[(4L(X
M'#K!BZCV! 7:-\/H.GML=">XNUO7J-Z) .5+4]3O2B_I, 012;F>)(O*WYRO
M54"/A_,%P!U$K>1Y1(%*'Q&BI^).-"&!GE3K$Z*P"FI_+& <*19+B'E Z&^B
M3/;9:9H0:?&!D#\2US1@/KW.E0_'1<80.S$/1U5F2!(G]M",1ND]FS150VGC
MV71EXEMP#ZH5657G1&6C(OJ.:R31-QKWR21UB.>6+%!0H=T-HG>!M9ND!_N)
MF.C B,A\?91FK(!!Q4",[F*[H*A[&856"G\!A*;@R@]8.*K/X#/C2!C?CK)L
M-K(/9 P@<2?U( P:^6=:3=8O942!2H8KUB%Y 4=(B),$9$+DSC9$J^0]+_?L
MQ(WA:@PR$I,;+"9!/"#+RE9&I-PUY\7,0$UP)(JQ$L7/%"=@U6 ^QK0@!(^"
MX,MSAM*J)5[HBRV2""287,W%AFKVQ[?:3T7#E2L4DP,SJ^T=.1IC0VF3D)4Y
M '#2M F57&?355C?""&.<LKM;DW\AZAB1[)>>-0BP3Q-<0Y,SY3==2^Z-;5H
MQMCMH)P6:TPGV=!', >)X)_4( Z<>%0A5<GW6>M07)VEB0K))>:HX#HL.5S&
MBHKR?%S>W--9G.ZC>\OBHZ74!.@IY!!QZ Y3 >A6C)968<D*G#1*>Z_^PLXL
M![OMT;TM]NQ$" [P;HYQ&4K-+(&/73WP9T$I<[J&O(/1?1#?C^]B #ZF GRD
MHK<+I@3@QR76:301!*GPV [--T?!- <[ 4^<J2W>07!V4KQ>'2(?[N2KQHI4
M6RK=?[L\8%DI<NVC6VD[K-3(:>;JBT>X:-=@CJS008Q79ULT6,=W,1QFR0].
MQ?_M!$I4FSLI0$+MVMETQ1E;#Z/BXS8W4I*B'S2)"V^H=H_--*W*H7(&NV7-
MH6(T5!#*55H%'6*BP0M*U7@E/YB*.-#2DBJ>* 62N"SKMI@H&BQ?DYIQRQ.\
M3^L!+K__X,L!(J4Y!*TGP/I60MP"0/9?11EXX@NR2A<6"SFBTAM?+XZ J"W1
M*]K04'./7J5TF;+BW48 VYJ]D)B*YN OS!+8G=\5F@Q:"LC1 S)>P&BN,:C/
MKE//F\*K!D^A"E5#<8Z%77(@7!])P7@X95]$D+*\X%\+RA:0WM?:B1D8:YP9
M8:H*!>&Y(]E$A>T$+G(#MJFUH;:^IB>,8@O7G,96OR*6G58N.LPX+PJ(66#Z
M>D<Q)*F(0$&!QUQPD8,& 'WC1XF50[64 ?5O1\)D;4(HQH..H!P[2^,S]Q2^
M(5-N4-L3&_V!ND"&=;Y2\^C18&J"!--_&-"9X,FR57_*L5:Y/M>C(=XBD6HU
M.4&QVMQM-7TV6GSS84M\H=QV?A6X[3LW@P>>/3TYG7MWYOX/;EMDR?/'\P?1
M/1?X1:C_ONAWC F$(G,2I^TK3@KZ<:=\TLJA=,?+B%'$=,U_[FA_(GS0DI;%
MJ'26 I*L!WT73.A?P_-%96(_84**LD;1"IRV/A!S0N<*.]!QD:.9SI2\@G,!
MS6<M&RE %176[ 0!RMP()BNPQC[Q#;_!_V,MCFT_I(P45Z3W7:B0JV!_2B=<
M*B=N]?#;5(L)"+5$87O)('Y"?OYN9*%>'0E=1W])""?OQW PNEJS'<D+R641
M_E@YW$DQ[+<29%7YYQ\RLO-02X-<X*H3;%CB8E,)3)&H#*= DM5*Z:&@5B+5
M-T9&@XHD-*U-](76ONPL=IX,"[$Q#*?>FM*/B7S ;?#J?.WL =$2DS"]#M,P
M/6WYOR?\\_; S?I_$L8Y/(_?)83S;<QE@UCN4?_<VQHL/ 5-4D>-B4_5]"N2
M7[D$G4GA!;;DZ_LM:K"5-1W97EI[8T.K$1$MY0FN+R)^);A3]G2HS3^[J;:>
MDTQOU3CY-I1\?F<Y2GLI_7=O*8:;^VM'K?#)QXUG)'X+#-+&/>A>#+6E*K.&
MS1R(Q\,FQELV+R*UA10_1A2HOC-$D+ -, C<6PA3KCJAO;%Y$L#UF_+)0Y^H
ML-057%S;OFVI%=*<H"PS*@LGN^_(]1RUX@"A[*'7TAZZ4Y%V?[&U"Y2)#BZ6
MY'(;E!B"OHGPARDH05!>H_T6L7RO;-*?2FYAYVP6(*>$TB8)'<2<&$5$T,K/
M#!E&V)KM.Y/[48LI1(+_COD.S*.K];IPU#J^QA8>=C:BQ^@34LG8^I;GVFF2
MT!_.>2_#3^8[J;\:6^MJ\3P&,9X6N_57M/.#ATKN/SRI9$\\:\4_&)"1;S/&
MCBAI_UQ2_D8.<3I*'CI+SJ:;0)2[+UD>'NO>O/LJ5"9D2E_N<\)>&-GQO@>O
M%Y A7Y128=3\U]KM(.K4+XA0Q&K_N,KS%\G]LP<:.MPK:]/SV-R59[],[H,W
M<!C3$HK8%$A2&!XAH\/7EZ#R.-(;'A-ZM!I;LCGX./!S&X5T6K!VH^Y^ @N@
M>O3 5X>/-IK'CU'!A=JIHN( ;X)2;C@7<P26??Q &T2/K*LV^+'.]Y$<:V-Y
MS@57>;\DJKW_Y$$XC4#^Z.3<)^?P 07S8-$&CH<*R<:?R#6K0/K781GLY2/G
MG;IZ"[.J0(2#9\<Y7:FY\&<EQ1AO-YL.#O@=]FOC2>/%[]!_!U/J4EVC-W#>
M)@K@O+M\XUU*'TVF&0/L,PP750CCE+Q^)Z2/+B!Z/TB?81>-P>9TBC5RTZL
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MNE2X24;)&HX=]&;5!/1$AXQC),8/^L4!A9KA@W@HDM9L"->&0'N(]/;&?,D
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M++VR>)]Q;[)"/.+4IPG2'A;#?.^B^7@X=MR/#A))TA]EF<2C%@5;0QO";YR
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M,T-35?BZ4<@RYU17?C@>7_HUX\)+9F[M1B4SV9J*"[Q1H-NZ9NIQB97<SKW
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MBOX 4%D'FE](:;:&7:#[IYC\"U!+ P04    " #Q@5U8=EZ@SQL$  #["@
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M:W-H965T<R]S:&5E=#,V+GAM;)56VV[C-A!]]U<,U&V1 *IUM2.[MH%<NFB
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M[D!9:4*S"^>JTR9RO+9)>3:*;CGIF=7O2"YIN/C(U@+UY2(P!&JO@KP'N.D
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M94E#'Y45H/N-E&:_L0:&OQ&K?P!02P,$%     @ \8%=6$9)4E4/ P  )0<
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MQ>)G ;=<"-M4;5, 4;EE*[O-Z.FV[=K*]..EX\=1P\8GS1EK7.R9V8&D!6*
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M0?BUM]B-_(8IA1KN ;8+N_<8J?N]1VF8('AM!5%$ASZJD=# #VD<)%88ZU>
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MUPCHW<A/GDX]=<*P)EA/3[_1TW^KGZI$K^, SW=M_\Q.PZA) #WGS$W#J""
MMCUNIJ 9>_ 6,X'_P4JJ%*V5]E*BKUT..F%8$ZPGZ:21='(C>TUTZJD3AC7!
M>GI"J^W/K+<:K,[LN@(Y$W=RYK"1,!OZ_ID1\2C-"="XQV"GP81O=)GLU6/R
MPK)JK:@*5=[AVL6AE89UT?KJHE9=="/#U6!=HNJD85VTOJAMSPV5+:C2<_;
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M5D>01&GU/WRN.V(O0'', ;0.H%\'](X$>'6 ]W7 X$A KP[HO;6&?AW0?VO
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M=BE](I*$RUD4QJ]D='NMK:6&VFE06@"E,11-/QL:R\T[U2HN#^JV06D^E!9
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M =%=&^PF5K6^DZR5Q;[DAPU^.4"[ -ROE+*[B6M.P[<H_P=02P,$%     @
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M +Y[R69W(-FJ>$_EA4G)TN+CDI(9Y7F .C]G3+X?Y*^^5*\ZC?X'4$L#!!0
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MVF,9K'DM\4%MOT&GY\+RI4H:]\NV;>X554QK@ZKHP!07HFR_?-?YL <8CHX
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M@/I]Q9A\/JFFE^VT>O8?4$L#!!0    ( /&!75A82* 6@P(  *P&   9
M>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;*U574_;,!3]*U:&)I 829R4;:R-
MU!+0>&"J8&P/TQ[<Y+:Q2.Q@.RW\^UT[:5988#SPDOC:]QS?KYR,-U+=Z@+
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M,CCZB#&I5AM;P\C:J<5"&M0>MRSP=P+*.N#Y4DJS->P%_0\J^0-02P,$%
M  @ \8%=6+EP2+F? @  S@8  !D   !X;"]W;W)K<VAE971S+W-H965T-38N
M>&ULM55M;],P$/XK5D!HDV!)TS6=1AJI76%,8E*U:? !\<%-KHDUQPZVTZS\
M>LY.FQ4I"Q*"+ZU?[IY[GCO?)6ZD>M0%@"%/)1=ZYA7&5)>^K],"2JK/9 4"
M;S92E=3@5N6^KA30S#F5W ^#(/)+RH27Q.YLI9)8UH8S 2M%=%V65.T6P&4S
M\T;>X>".Y86Q!WX25S2'>S /U4KASN]0,E:"T$P*HF S\^:CR\74VCN#+PP:
M?;0F5LE:RD>[N<EF7F ) 8?46 2*?UNX LXM$-+XL<?TNI#6\7A]0/_HM*.6
M-=5P)?E7EIEBYEUX)(,-K;FYD\TGV.N96+Q4<NU^2=/:1I%'TEH;6>Z=D4')
M1/M/G_9Y.'((PQ<<PKU#Z'BW@1S+)34TB95LB++6B&873JKS1G),V*+<&X6W
M#/U,<BUEUC#."149N1&&BIRM.9"YUF T>4?F6<9L_BC'Z_81V&R>+,%0QO5I
M[!ND8<'\=!]RT88,7P@Y"B[(K12FT.2#R"#['<%' 9V*\*!B$0Y"+B$](^/1
M6Q(&X9@\W"_)R>O3 =QQEYVQPQW_*3O?/N,-N3%0ZN]]BEN8\WX8VUB7NJ(I
MS#SL' UJ"U[RYM4H"MX/D#SO2)X/H2=7!18--&&"I%2I'1,YH:6LA2%R0_*#
M!,U$"MA'J<R%JVB?CC;2Q$6R_;Q-@MC?]I";=.0F@^16M4H+[!KWN+#WL!EK
M?$HKA6-%F5T?AT' O\QEU-&-_DW!H_] <MJ1G [F=%Y*9=C/MA$QC4QFMM+L
MN7NIZ]X^WL/(8[(#JG0?1_]HQI2@<C=)-4GM.VO'37?:#>MY.Z.>S=M)?TM5
MSH0F'#;H&IQ-L>*JG9[MQLC*3:RU-#C_W++ #PXH:X#W&RG-86,#=)^PY!=0
M2P,$%     @ \8%=6.5O-V%\ P  B X  !D   !X;"]W;W)K<VAE971S+W-H
M965T-3<N>&ULM5=1C]HX$/XK5EJ=6NFZB1,(9 \B;4'MK=16J+1W#U4?3##$
MK1-3VX'N_?H;)]F0L(;=2ND+V/',EV_&,_GLR4'([RJE5*.?&<_5U$FUWEV[
MKDI2FA%U)78TAY6-D!G1,)5;5^TD)>O2*>.N[WFAFQ&6._&D?+:0\404FK.<
M+B121981>?>:<G&8.MBY?_"1;5-M'KCQ9$>V=$GUY]U"PLQM4-8LH[EB(D>2
M;J;.#;Z>X:%Q*"W^8?2@6F-D0ED)\=U,;M=3QS.,**>)-A $_O9T1CDW2,#C
M1PWJ-.\TCNWQ/?J;,G@(9D44G0G^+UOK=.J,';2F&U)P_5$<_J9U0"7!1'!5
M_J)#;>LY*"F4%EGM# PREE?_Y&>=B)8#'IQQ\&L'_ZD.0>T0E(%6S,JPYD23
M>"+% 4EC#6AF4.:F](9H6&ZV<:DEK#+PT_%;(=8'QCDB^1K=YIKD6[;B%-TH
M1;5"K]"RVE\D-I;E9;'Z!ON!M$ WF9":_4?*S7DQIYHPKEX"P.?E'+UX_A(]
M1RQ'GU)1*'B5FK@:V!L.;E(S?5TQ]<\PG=/D"@7X3^1[?F!QGSW=W>^ZNY"S
M)G%^DSB_Q O.X+UA.=,4O8,BM"7NRSNP1[>:9NJK+=8*?& '-[U[K78DH5,'
MFE-1N:=._,<S''I_V2+O":R3AZ#)0W )/7XKA5)H1J2\8_G6E$&1:UO$%<RP
MA#$?EWWL>X$_G+C[=BB/674X#AJ.@XL<;Y*DR I.-&Q5NTYM-"NDL$7@%1[B
M:'3"TV86#**QG>BP(3J\2/0#?+>?D,KA@Y</L3\^8?C0*!S[(SN_L.$7/I+(
M'P63D,4YW8,"[&#TB29I+KC8WMF87H3[U3+O":P3^:B)?/0[VWW49QYZ NOD
M8=SD8=Q/NX\?E!^<+#SOI$@?L^IPC!J.46_M'EGZ>!"-3GG:S(+ &]B)8N^H
MOEX?#5^C=#K>"TY)6JS", K/<&R=$/!%CHM")BF<E,JZA_,6"'Y!.%I(Z'^I
MK6U_&?%7Z[TOM&[\1Z''OU7I<:]2WQ=:-Q='L<<]J7V-TZ[%AV+_B%&7XU'L
M<7]JCRTZ[ONG8F^SPM&YYC^*/>Y%[6N4]IDH.A5[BPT.\ E!MW5-,'>T]T1N
M6:X0IQOP\JY&X"ZK:T\UT6)7WAQ60L,]I!RF<%6DTAC ^D8(?3\QEY'F\AG_
M#U!+ P04    " #Q@5U8H< H$*8"  !!"   &0   'AL+W=O<FMS:&5E=',O
M<VAE970U."YX;6RMEEU/VS 4AO^*E:$)I(VD:9, :R-!.Q@7FQ =V\6T"S<Y
M;2P<N[.=!O;K=YR$*$ HJ-I-XX_SOG[.B6-W7$IUJS, 0^YR+O3$R8Q9G[BN
M3C+(J3Z4:Q XLY0JIP:[:N7JM0*:5J*<N[[GA6Y.F7#B<35VI>*Q+ QG JX4
MT46>4W5_!ER6$V?@/ Q<LU5F[( ;C]=T!7,P-^LKA3VW=4E9#D(S*8B"Y<0Y
M'9Q,(QM?!?Q@4.I.F]A,%E+>VLYE.G$\"P0<$F,=*#XV, 7.K1%B_&D\G79)
M*^RV']S/J]PQEP75,)7\)TM--G&.')+"DA;<7,OR"S3Y!-8OD5Q7OZ1L8CV'
M)(4V,F_$2) S43_I75.'CF P>D'@-P+_K8)A(QA6B=9D55HS:F@\5K(DRD:C
MFVU4M:G4F T3]BW.C<)9ACH37TB9EHQS0D5*+H6A8L46',BIUF T^4CFN&_2
M D?DDIP7IE XETMEV%]:O8?/=[BA-!#<4#WZ_1D8RK@^0*>;^8SL[QV0/<($
M^9[)0N.:>NP:3,/"N$F#?%8C^R\@SR Y),/!!^)[_K!'/GV[W'\L=[%X;07]
MMH)^Y3?<K8(SIA,NM:W;K].%-@HW[N^^I.M51OVKV(_Y1*]I A,'OU8-:@-.
M_/[=(/0^]97@/YD]*LBP+<APFWN,=1WU)5BK@DIE#Y=-/(@\?(&;+OA6ZQW!
M1RWXZ#7PH ^\5H5=\/#X^ GX5NL=P8,6/'@-/.P##]X"OM5Z1_"P!0]? X_Z
MP,-GX#;N$?96XQVQHQ8[VHK]#6_7*57JGHF5/0T+8?JRB)YM^&#@'SW)XWE0
M>-1)MN9S.P>\O5R_4K5B0A,.2Y1YAQ'J57UAU1TCU]69OY &;Y"JF>$=#\H&
MX/Q22O/0L==(^Z\A_@=02P,$%     @ \8%=6$>9;(<S P  IPD  !D   !X
M;"]W;W)K<VAE971S+W-H965T-3DN>&ULK99;C],Z$,>_BA40 @DV]S1=VDA+
M5X@C'43%<GE /+CI9&/AQ,%VVMWSZ<\XR89NXQ8>>&EM9^;OW\SXMM@+^4.5
M )K<5;Q62Z?4NKET79674%%U(1JH\4LA9$4U=N6MJQH)=-LY5=P-/"]Q*\IJ
M)UMT8VN9+42K.:MA+8EJJXK*^S? Q7[I^,[#P$=V6VHSX&:+AM["#>C/S5IB
MSQU5MJR"6C%1$PG%TKGR+U>^9QPZBR\,]NJ@34PH&R%^F,X_VZ7C&2+@D&LC
M0?%O!RO@W"@AQ\]!U!GG-(Z'[0?UMUWP&,R&*E@)_I5M=;ET4H=LH: MUQ_%
M_AT, <5&+Q=<=;]D/]AZ#LE;I44U."-!Q>K^G]X-B3AP\*,3#L'@$/RI0S@X
MA%V@/5D7UC75-%M(L2?26*.::72YZ;PQ&E:;,MYHB5\9^NGL*L]E"UOR+Z,;
MQIEFH,@K<H.K9=MR(*(@-HOGUZ IX^H%VGZ^N2;/G[X@3PFKR:=2M(K66[5P
M-=*9.=Q\('G3DP0G2*XAOR"A_Y($7A!:W%=_[AX\=G<Q)V-B@C$Q0:<7GM!;
MTWNZX1@K1M/G@')%OEUME):X]K[; NP5([NBV9"7JJ$Y+!W<<0KD#ISLV1,_
M\5[;POU+8H^"#\?@PW/JV5J* I39JI23 L!:SEXB[B3,:;'+HGG@+=S=8106
MHUD4C4:/Z**1+CI+M\(!EB.9*4TNZJX@Q&2!RKPD>*;1FOU'NV,B%TI;Z?LI
MD@.P- F/X*<V?AR&=OAXA(_/PG^2= <].M0:).ZC&H]%;6.,+?-'1XQ3F^ 4
M8C(B)N<1Z1WAOW:[C2R9S!K/C\"F)O[\1.%G(]CL_+)LL;YX9BMS+C42[S*I
M[_M4_FQ9<RJ-LPE)DLZ.:*<V?I)Z=MQTQ$W/KU-1-2V6N"-4HM![*L$&F$XG
M]V/_B'!J%(1I;"><CX3SLX0?= G21C2?3#:;[(ZIC9_$)X!\[]=]Y)U??$*;
MG3U<.K]9AH/6X?&2QO/CVEJL_" *CA>C>W"+FB?,>RIO6:T(AP+]O(L9"LC^
M5=!WM&BZBW4C-%[37;/$EQ1(8X#?"R'T0\?<U>/;+/L?4$L#!!0    ( /&!
M75CVG)[X?0P  #%V   9    >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;+6=
M6V_;.![%OPJ1'2QF@+BQ),=QNFF IKIUT6Z+7G8>BGU0+-K6CBX>BLH%V ^_
MI"1;ID735N9T'J:V(_Y(44<D]3\D=?-8L#_*%:6</&5I7KXY6W&^?GUQ4<Y7
M-(O*5\6:YN(OBX)E$1=?V?*B7#,:Q76B++VPQ^/I118E^=GM3?W;9W9[4U0\
M37+ZF9&RRK*(/=_1M'A\<V:=;7[XDBQ77/YP<7NSCI;T*^7?UY^9^':QI<1)
M1O,R*7+"Z.+-V5OK=3BYD@GJ(_Z=T,=RYS.1IW)?%'_(+^_C-V=C62*:TCF7
MB$C\\T#?T325)%&./UOHV39/F7#W\X;NUR<O3N8^*NF[(OT]B?GJS=GLC,1T
M$54I_U(\AK0]H4O)FQ=I6?^?/+;'CL_(O"IYD;6)10FR)&_^C9[:BMA)8$\/
M)+#;!/9>@H,Y.&T"Y]0$DS;!9"_!U#Z0X+)-<+E_#H<23-L$TU,37+4)KO82
M6+,#"69M@EE]=9O+45]+-^+1[0TK'@F31PN:_% +HDXM+F&22^U^Y4S\-1'I
M^.T'*BY\.2)OXSB18HI2\CYO;@DIK5]=RJ,D+7\COY D)]]6155&>5S>7'"1
MN41<S-N,[IJ,[ ,96>1CD?-52;P\IK$FO7<DO6T 7(BSWIZZO3GU.]M(].G]
M*V)?GQ-[;(_)]Z\N^?67W\B"__UOUM7L'YH2OC/SWE;+5\2Q),^Z/H7G'N&M
MF>"-:][L%)YGYKETOBF?[6QX&HQ_.L8V8(+3,98!$YHQ'R.V@]%7CJ(.9WMC
M.#78.7ACE"6EI+X_B$O+.4O6]2WQXX,XDKSG-"O_H[L-&NQ$CY5=T>MR'<WI
MFS/1UY24/="S6U'HZ5BK."3,1<(\),Q'P@(D+ 3!% E.MA*<F.BW_ZJR>\I(
ML1 ]>A4Q2A9R,/,_4Q-PUQ"G-5&.6QYNK>OK\?CFXF%75IJCQO(_]3!7<Y@S
MV3_*,Y[$4"4@80$2%O8KP[[:K3+E$E]N+_&E\1(WK<PY$6-1)GK<?$E2V>#(
M'^K&AA>$/G&:ZSK,.R-Z:$OS M@\*E=D'3V+H2PG8LP@QK+BPSU=1KD<+'R:
M\T+JMVZ9Q:"!\!5M3H]PRC(BSJJ4QXE^4XQSQ&&.<TYT[9:Y"K^IU*04^;"B
M6JZ(Z!OF*YG]M,Y^S8J')*9E7=1"M.$+,6H>/=.(-75<#\>;>G^E:_',Q6@2
MEMT5(W/*Q-@IE_?O]LQ+4JWE(=;XU9C(K'4C*1]Y80,D+ 3!E'MENKU7IB^[
M5VK9S8M,Z'!.:S%F<J187W19Q[I[QYC5T'O'7&ZI_Y$UUBD;60H/"?.1L  )
M"T$P18)76PE>G23!3UL)?F@DZ#TE)9?RDW?[IVW;[34MP0_.*M'<1&E)M4-&
M8Z9#Q6@^ UD2G1)?E,I[42H?>;H!$A:"8(JV9EMMS5[6O#7="8V;_DWH:RY:
M-Q;-N4Y*QCR&2LE<X,N#'9C[TH0>LO@^$A8@82$(INCL>JNSZR,ZDV,E^K1.
M6!/C.=Y9&H%#164NG1P%CL8SG:B.);2GH[&C$]71' ]TSS[RO ,D+ 3!% %9
MXRYF.#96V:?])BK)UE'"ZJ%76I3ZZ* 1.51$4)H+I7DM[7+W2=&R]Q^;?6BF
M 906HFBJOG9BTI:YB2KRY2@53V<QB42GR$_2EQ$Y6%](F@NE>2UM-Q(QT<@+
MF6< I84HFBHONY.7;937^TY-8C3%I+LU*A:C2G2+LA=D-(VXD%ZZIT*][(Q9
M#98=DN9":5Y+4P)@EQ/[>E]WR$P#*"U$T53==8Z"98P6BY$7YTT\=\YHG&C'
M[V;$8#TYFJZH%^:%YNE!:3Z4%D!I(8JFRJES!RRS/= ,Y#=QKUB,XX\,X\V\
MP=HRETZ:JB/+UK9+R')X4)H/I0506HBBJ7KKK KKB%<AM)46+&[B#\E]53\]
MRF!Z_12P*M)8#M18\5 '8?7=)=2S:&E*\Z:QL:"9>II,K<FL/_Z"!O&AM!!%
M4X74Q?$M<T#\,ROFE,8E6; B(^E&5HPFV7W%2H-ZH%%[*,V%TCPHS6]IJF1[
MKG"@.VS<.RQ$E4U53Q>"M\Q1Y6\TCW*^V]*(!JGDTDJ<5XQIYQ;=F9F#E8.D
MN5":!Z7Y+6UZ3#DG'1:BRJ8JIPNP6^:X\T'E,#JGR4-TG^KLBCLS=;!VD#07
M2O.@-!]*"UJ:$O7H=?4A*D]585UHW3+'DC4*B]*T>(S$ %TK+6AD'4IS6YHR
MN.I/_H'FZ4-I 906HFCJ7-4NYFZ;8^Y?ZG#5?9HL:]>F/%=G/,01URK,3!VJ
M,"C-A=*\(_5W>!:&#RU' *6%*)JJNBX2;YLC\:8&K8XU;,,/6O%9O29DVIN+
M:"[!8$U!0^U0F@^E!5!:B**I.NM"\K8Y)+_G*,HI7?0Q2NLI#UIE0</N4)H+
MI7E'*LXR3".$%B2 TD(43=5;%XJWS:'X?;U)G25Y,Q]"_"DI].T9-#@/I;E0
MFG>D^JX,HH,&[*&T$$531=<%[.U3 O9YP47M=1-6XW-%?>W$[[A;<:)5(C24
M#Z6Y4)IWI$[+ZOZ_=,[E9,LH)T*4Z;.N.J.%=-[D-.R2/E YW^F 2>)#2Q]
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M$^JH&-U,E&W$D@KE)&G"$UJ>DYS6?^&&*/'&7=5'B,UE'*HO*,V%TCRGORI
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M&R%8NJG$9VFHG7^66Q!$;EE*]* _?U-,<B<AR?\R=.BV:L#8W(!BXKW*,Q;
M=4_-K#F(9^@M?OK!F0Y_,4F+"7,Q81XFS$>":4-BW R)L8V^^)*MA4I8DK%O
MI? " E ZAR9M*]*D)!5KX+-*]\FP_)L/G@^%L];953A,F(<)\Y%@FG"31KB)
M5;@'+I5>D9KC1;TH1/M%(8> JWS>2RHY68%5V,F)L#.SKM8F==45$^9APGPD
MF*;KM-%U:M=UOS*S_<K\Z5C0D$DPR6@'-VM1L9I,3-.M-;ZKNI@P#Q/F(\$T
M=6>-NK/_FK5R&XDN23L[2=HZ9X^3UMJBKK)BPCQ,F(\$TV2]:&2]Z)RTNI[G
M<M;.?3MGK?%=Q<6$>9@P'PFFB7O9B'MI%>'Q.%.;' 61F#2UX\83-1B^Y28Q
MK8%=Q<2$>9@P'PFFB>D,VU?HH3U7001*/;8!PM>GTW MKDF?VYI<?+2/P$>S
MK;WVKB*BTCQ4FH]%TW4\L$*<#CH&NV075Z^H63T9"[N6CD'+_G1R+*>U$9WE
MQ*1YJ#0?BZ;+25LYJ57.I4U E:9O+:1OX ]7TI'11[(#.BN-2?-0:3X635>Z
M-:$<JZ&QN$L# <7#4E2XW7(G4A*PC&3_,Y]'IGR>G>0SJJ>$2O-0:3X635>Y
M]94<N[%TDW AHW\JZUD)FIT\(A.^BJ--6< H**95LW1.S:NC]R07M4(/E>9C
MT70Q6Z_)L9M-WGH-Y8]*[7.2.#</8SHQRYKF.(>Z]8>7]%@[5#,)E>9CT73M
M6C_)L?L^+JPDB?)\Q]( 2,#S,_,GIL>RK&F'Z38U>!,N:JT>*LW'HNFZM4Z1
M8[>*3*^=;!6;DP[325DZI]82I:4C?*R>H>!L>BJSA]H^'XNF"]-Z/8[=E/&Y
M@(#ETB@$INNQ1*6YJ#0/E>9CT71)6X?'N?S>/XPZF!;*$I7FHM(\5)J/1=,W
M'[1N$>WB%G5^*['3NZJ.2G-1:1XU>6-]>O3^Y9\IUI3296K-(&HW@^[9:Y3L
MC&ZL/;*S!*A^$"K-0Z7Y6#1=T=8/HO1[3\D4TU59HM)<5)J'2O.Q:/K(:/TC
M:O>/++^AOO_7T[J.]VQFL3>GL["HEA$JS<>B5<(.#O8Y)B VY8[47+V![E)9
M[?]KKC:[7F_*O9Y'UY?.E5OM76TQU5;:>R8V49J3&-8*.>S/E)ZBVIU:G4B>
ME;LI5UQ*GI2'6V AB** ^G[-U6"J3XH*FCW"BW\!4$L#!!0    ( /&!75B4
M3%?E0@,  -\)   9    >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;*U6T6[C
M-A#\E85Z*.Z 7"1+MFRGM@''Z:$!+KT@Z;4/11]H:6T11Y$J2=E)O[Y+R5:=
MF#::HB\V2>V.9H8K<B=;I;^9 M'"4RFDF0:%M=55&)JLP)*92U6AI"<KI4MF
M::K7H:DTLKQ)*D481U$:EHS+8#9IUN[U;*)J*[C$>PVF+DNFGZ]1J.TTZ 7[
MA0>^+JQ;"&>3BJWQ$>W7ZE[3+.Q0<EZB-%Q)T+B:!O/>U6+LXIN 7SENS<$8
MG)*E4M_<Y#:?!I$CA (SZQ 8_6UP@4(X(*+QYPXSZ%[I$@_'>_1/C7;2LF0&
M%TK\QG-;3(-1 #FN6"WL@]K^A#L] X>7*6&:7]CN8J, LMI85>Z2B4')9?O/
MGG8^'"3TTA,)\2XA?IW0/Y&0[!*21FC+K)%UPRR;3;3:@G;1A.8&C3=--JGA
MTNWBH]7TE%.>G3W@!F6-<"LM:C06[FN=%>0+S-<:D?;+PD=XI.+):X&@5G"4
M\9FS)1?</E_ SU1V<[<Q-(/W-V@9%^8# 7S12WZ'.8V\^%\?;^#]NP_P#KB$
M7PI5&R9S,PDM*70\PVRGYKI5$Y]0TXOA3DE;&/A1YIB_! C)FLZ?>._/=7P6
M\0:S2TAZ%Q!'<>(AM/CWZ?$9.DFW74F#EYS HVH5;*DT<\4/<ZV97+<FDF$O
MYE]L@1ILP22\3/K],V'"K<72_.%SN"70]Q-PA\J5J5B&TX!.#8-Z@\'L^^]Z
M:?2#SYW_">R%5_W.J_XY]*ZT^;Y0Q;Y0@5E:S;!R)XG/@[/ ;_6@!1LT8.Y0
MW5"9#J(HFH0;C[I!IVYP5MV"5=PRP?^BKXH;4S/2 YDRUOO9G,5ZJZ 6+#T0
M]#&-!WXY:2<G/2NG.TWPB2XH@SX1Z;&1R>C QY9=>L2N'R<C/[MAQV[XME*J
M&,]]%(<^:PZ\:2EZHOKCQ$]QU%$<O97B,UL*KY&CX_?'\? U2U_4,#U1MN..
MYO@_?I07(-'ZV(X]VQZEZ>M]]X3%@^2(;WAP5Y:HUTT+8>C+J:5MKX5NM>M2
MYLWE_&K]FKJ7MMGX!Z9M?>Z87G-I0."*(*/+(9'2;3O13JRJFAMYJ2S=[\VP
MH X,M0N@YRNE['[B7M#U=+._ 5!+ P04    " #Q@5U8AZM'G@@%  #7)0
M&0   'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6RMFFUOJS84Q[^*Q:0]2%L!
MYZ%IET1JBZ]NIW6+;K6[%]->N. DJ(!S;9.TTC[\;" 0]Q*K;.=-P]/Y'7/^
M\8%_ZOF!BV>Y94RAESPKY,+;*K6[]GT9;UE.Y07?L4*?67.14Z5WQ<:7.\%H
M4@7EF8^#8.KG-"V\Y;PZMA++.2]5EA9L)9 L\YR*UUN6\</""[WC@4_I9JO,
M 7\YW]$->V3JC]U*Z#V_I21IS@J9\@()MEYX-^$UP2,34%WQ.64'>;*-S*T\
M<?YL=NZ3A1>8$;&,Q<H@J/[8LSN698:DQ_&E@7IM3A-XNGVD?ZAN7M_,$Y7L
MCF=_IHG:+KR9AQ*VIF6F/O'#1];<T,3P8I[)ZB\ZU-=.IAZ*2ZEXW@3K$>1I
M47_2EZ80)P$X/!. FP#\WH!1$S!Z$Q".SP2,FX#QFX!9<"9@T@14M^[7]UX5
M+J**+N>"'Y P5VN:V:BJ7T7K>J6%^:(\*J'/ICI.+1^W5+ MSQ(FY'>(?"E3
M]8I^0C=)DAHA:8;NB_KK:&3]/F**IIG\8>XKG=P@_+A)1.I$^$RB$*,'7JBM
M1*1(6&(#?#WJ=NCX./1;["3^0HL+%(0_(AS@,9+F1F3/N.[>3QF=IT3OIP1]
MQ7&'1RR^0*/C(#YSQ1SU&;72CBKHZ ST+J-2HM_7Z%'Q^!G]]:L^C^X5R^7?
M/2.\K6'C?ICI5]=R1V.V\'1#DDSLF;?\]IMP&OS<5W-(6 0)(T P2Y%QJ\C8
M15_>\3S7LTA6>NRY2HL-$J:32=W;9"S2G9EE?>(XN4/%@81%D##B+M_'NDTA
MOD:\%"@^K::>MH@5*E492Y#BB.OONJXP0[IY(4;C;3VU3:P5MV69JQ=-6F4G
MSJ']5N9/3!AZ7])_>J9TK:N3.E172%@$"2,U;%K!S*O+?AG._7U/O:=MO:?.
M>I-\E_%7QIK>MBI%O-6O"VB5T=[YXZ0-K3,D+(*$$2"8)<EE*\DEY./F$E(1
M2%@$"2- ,$N16:O(S#E)[HM8>P<]*]*B:41-CCX]G*BA>LR^GN_C41A,@G;6
MUZ6&3$J 8%:IK]I27_WG?J3;_V/Y)-F74C^@$-GKOWT".!,,%0 2%D'""!#,
M4BD,.K<30#:IA@8D"B@M J41*)JMRXD+#>%:5<.RV\LDF&%LMY<[=]+!!8>D
M$2B:77#<%1S_GX;U0%_2O,Q[J^\$#YX3D+0(E$:@:+9$G7T/0?U["&K@06D1
M*(U T6Q=.A,?NFWHBHE8/\/IIG*3M"A*FNF^53<P:3I8T;K!L[\GW;J3#)8+
MU-,W-/-,:#ML<!&$=GLE4$EM'3K+';H]-P["J^,OEOKY8=S__KP#=,,&UQO4
M:X/2"!3-EJ5SYN$4M&V!6G-06@1*(U T6Y?.GH=.KSGP%0O4GC>TTQ>VRW R
MP5_Y0="T!(IF%[QSWZ';?I_O3^]TA&[^8!$@:1$HC4#1;*4Z\QY>@;8L4*L.
M2HM :02*9O]_KW/KV.DZA[6LAF4U&3P9A^'HC2MT)QU:<% :@:+9!>]L.';;
M<&?+<GA"-W;HC "E1: T D6S!>IL.\:0G0J#>G506@1*(U T6Y?.JV.GYP3R
MA.XD@^4"M? -[:TGG+SQA%!):QW\DX4M.1.;:D611#$O"U6O<6F/MJN6;JJU
M.GYW>;WDZ8&*35I(E+&U#@TN+K5+$O4JHGI'\5VU3.:)*\7S:G/+:,*$N4"?
M7W.NCCLF0;N6:_DO4$L#!!0    ( /&!75B3[# ]80,  #D-   9    >&PO
M=V]R:W-H965T<R]S:&5E=#8V+GAM;+U76V^;,!3^*Q:3=I&V@B$DH4N0ULNV
M2IL:-6OW,.W!A9-@U6!FFZ:5]N-G&T+2-F%2E/8E\>U\YSO'GWW,:,'%C<P
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M)Q6]>4G/O4 /NN +)6+#P2<B!],$L*56M6#NLV!SMQ<QPLD5\.!OP'5<KV-
M-R]/=SO2HY>GPQXV7CW]GL;S+N#%&\0PF$OCI,UIGC&&R%K/$Y@_@=.X!7K2
MW;,#8BGX]R\)"6[EE/+_NN:G?+[?_7SU5KOF6Y3@B25?6QRS/;:FO_X"0^?W
M+FU-@D6&P!JZ^[7N?A_Z]!L5* =<J?KQ7JN:G*J/']4U[M*SQ TTKGJI[Z>A
M.W*&8WM_*M1Y5!#X@T$S*CJ/\CTW@'54@UI04PMZJ:D7A'+V$N\QV75RZ 5X
M[9HP"189 FL(%];"A6_LQ="D[B;!(D-@#=T'M>Z#G^3%$C<\]0\<ABTKG@=Y
M(^BTG'@>Y$+'Z3;BL.8U[.6UE$HAEFST-SF2;LSI5BV6+B:]2*]=&2;!(D-@
M#05'M8*C-W;DR*3N)L$B0V -W:%SW)4Z/\F3%7##2HX?!BU7=H3!03@<M7S9
M%>8[X85/)#S9=<->?C'*<;E9_H+8 Q8967>2Z45Y[?HPBA:90FLJZ!X5=-_8
MF]4 3(EO$BTRA=84_WAJ@+V;XQ^QI]=AJ"#PVO;L"/."47L#VQ7F>M"]8,_C
M[ASV;\__P$0>2W-MT%DJC]T9%^J8NN_FU OVZH5B$BTRA=84\G@6@,%;N]3H
M8<(H6F0*K2G^\3P!>[?-/^+2\.QDZ'H#QV^[M"/,<8>P[=+S,"@/H\.62^V3
M*E:!V5I7 [D<\XZ(LCY3]]85QYFNL[7ZYZH2J:MC1YBRC"D_MNN,<)#CE81T
MK@9R3*RL#)8-0;>Z5G9/A:"%OMQ@E&*F N3]%:7BN:$>4-=GI_\#4$L#!!0
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M[K>?T'_QXDG,/3=XJ?(/(K79,.@%D.*<KW)[JS:_8B6HX_ 2E1O_"YMJ;A1
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M.'V'?E7]K-03(TO7F=?28)]WPRV^Q*"L >YOI#2'B770ONW)+U!+ P04
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M]*BPRT)/?Q F03]?<JZV@3F@^S^1_ 502P,$%     @ \8%=6-&S&LH!!
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M@OIQK^YLA&L!]3UC3+X,]*V@NP6N_P-02P,$%     @ \8%=6-+L5("6!
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M0YO3[^:&DTU]O/M(."=E?;D&+*8V:2#>+PGA+S>R@>Y_$(O_ %!+ P04
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M-1J/42]C"MD8Q>$[% 51['!H?3L\<L#3V^%ACYJXRVUL^>+!W.I$R(QR60M
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M.2TRW'/G!#W_W76>,LD4%9NF3>T?\RJ_V7']1OP7GNVOE5W'7I-1]_@]UJ>
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MS@1Z9]0[$^B=4>],H'=&O3.!WGGRL9) [XQZ9P*],^J="?3.J'<FT#NCWIE
M;T>]G4!O1[V=0&]'O9U ;T>]G4!O1[V=0&]'O9U ;Y_\;$*@MZ/>3J"WH]Y.
MH+>CWDZ@=Z#>0:!WH-Y!H'>@WD&@=Z#>0:!WH-Y!H'>@WD&@=Z#>0:!W3'X6
M)- [4.\@T#M0[R#0NT&]&P*]&]2[(="[0;T; KT;U+OY3KV'\?-0AEO/UQJO
M_YU4CY=SR^WRU^77SLFM<L6YOJ\8GO\"4$L#!!0    ( /&!75@@< [9) (
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MR&I19&U09&U09&U09&W^IZP_O#_\X_CE68^NGY[SV?(/_9M?4$L! A0#%
M  @ \8%=6 =!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " #Q@5U8"1HW">X    K @  $0
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M=#(N>&UL4$L! A0#%     @ \8%=6/C$8%@E P  B@H  !@
M ("!6Q@  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( /&!
M75A^9GC_F 4  .L7   8              " @;8;  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    " #Q@5U87R3G<(D#  "-"P  &
M        @(&$(0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ \8%=6$)>?W6:!P  :CH  !@              ("!0R4  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( /&!75@ANL$^=@@  .PI   8
M              " @1,M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    " #Q@5U8R%CMI\D$  #O"@  &               @(&_-0  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ \8%=6$:VYKVM)P
M!($  !@              ("!OCH  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( /&!75@<-GE">@\  .8M   9              " @:%B
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ \8%=6'^.
MR3#+ P  O0D  !D              ("!4G(  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    " #Q@5U8.%C];@($   -"@  &0
M    @(%4=@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M /&!75A^0GT5. 8  &D0   9              " @8UZ  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ \8%=6"2];3B- P  WP<  !D
M             ("!_(   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    " #Q@5U84ZA!>],#  "$"0  &0              @(' A   >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( /&!75C:JQR=[@(
M %D&   9              " @<J(  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ \8%=6-W,BH3W"@  EQ\  !D              ("!
M[XL  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #Q@5U8
M> [HL@8+  #A(   &0              @($=EP  >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( /&!75CQ(5XFHP0  , *   9
M      " @5JB  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ \8%=6,9CHU/>!   R P  !D              ("!-*<  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #Q@5U8A1=)B0T/  !L+P
M&0              @(%)K   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( /&!75CY4AXN% <  *L1   9              " @8V[  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ \8%=6&EO))9T
M P  V <  !D              ("!V,(  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    " #Q@5U8?8<K(S *  !U&0  &0
M@(&#Q@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( /&!
M75C2T)NB:@0  /T+   9              " @>K0  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ \8%=6),<:YOR @  8@8  !D
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M=#,P+GAM;%!+ 0(4 Q0    ( /&!75C*?B/!8@,  %\(   9
M  " @6D, 0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
M\8%=6'9>H,\;!   ^PH  !D              ("! A ! 'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    " #Q@5U8INIXAR$#  ##!@  &0
M            @(%4% $ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( /&!75@(,7[B>P,  .\(   9              " @:P7 0!X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ \8%=6 ]AI3_Z @
M5P8  !D              ("!7AL! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    " #Q@5U8AGRPM84#  !2"   &0              @(&/
M'@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( /&!75A&
M25)5#P,  "4'   9              " @4LB 0!X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ \8%=6)<;Y?40 P  ^P8  !D
M     ("!D24! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /&!75AJ<%D'F ,  )83   9              "
M@24_ 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ \8%=
M6'B@>&JF P  !!(  !D              ("!]$(! 'AL+W=O<FMS:&5E=',O
M<VAE970T-"YX;6Q02P$"% ,4    " #Q@5U8&.1T35P$   .&P  &0
M        @('11@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0
M   ( /&!75C[80=Y%P<  !1%   9              " @61+ 0!X;"]W;W)K
M<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ \8%=6$CJ![P^ P  E@P
M !D              ("!LE(! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q0
M2P$"% ,4    " #Q@5U8TG<ZUGH"  "7!@  &0              @($G5@$
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( /&!75B@(549
MY0(  %L(   9              " @=A8 0!X;"]W;W)K<VAE971S+W-H965T
M-#DN>&UL4$L! A0#%     @ \8%=6+NTH:@A!0  ]B0  !D
M ("!]%L! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " #Q
M@5U8[=$6VR,$   "%   &0              @(%,80$ >&PO=V]R:W-H965T
M<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( /&!75@^[64!= (  # &   9
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M970U-BYX;6Q02P$"% ,4    " #Q@5U8Y6\W87P#  "(#@  &0
M    @($N=0$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    (
M /&!75BAP"@0I@(  $$(   9              " @>%X 0!X;"]W;W)K<VAE
M971S+W-H965T-3@N>&UL4$L! A0#%     @ \8%=6$>9;(<S P  IPD  !D
M             ("!OGL! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"
M% ,4    " #Q@5U8]IR>^'T,   Q=@  &0              @($H?P$ >&PO
M=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( /&!75@4*#);;@(
M !X&   9              " @=R+ 0!X;"]W;W)K<VAE971S+W-H965T-C$N
M>&UL4$L! A0#%     @ \8%=6.Q52[IO P  Y@P  !D              ("!
M@8X! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " #Q@5U8
MKZCM-+T%   O+   &0              @($GD@$ >&PO=V]R:W-H965T<R]S
M:&5E=#8S+GAM;%!+ 0(4 Q0    ( /&!75B43%?E0@,  -\)   9
M      " @1N8 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%
M  @ \8%=6(>K1YX(!0  UR4  !D              ("!E)L! 'AL+W=O<FMS
M:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " #Q@5U8D^PP/6$#   Y#0
M&0              @('3H $ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+
M 0(4 Q0    ( /&!75@/V -Q8 H  "%?   9              " @6ND 0!X
M;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ \8%=6$ES0? P
M P  ' @  !D              ("! J\! 'AL+W=O<FMS:&5E=',O<VAE970V
M."YX;6Q02P$"% ,4    " #Q@5U80MD5 C($  "8$   &0
M@(%IL@$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( /&!
M75CM9+:]5@0  (,7   9              " @=*V 0!X;"]W;W)K<VAE971S
M+W-H965T-S N>&UL4$L! A0#%     @ \8%=6-96,B$W!   ;!0  !D
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M=#<U+GAM;%!+ 0(4 Q0    ( /&!75@1SE16Y0(  %L(   9
M  " @7/. 0!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @
M\8%=6-&S&LH!!   $0X  !D              ("!C]$! 'AL+W=O<FMS:&5E
M=',O<VAE970W-RYX;6Q02P$"% ,4    " #Q@5U8TNQ4@)8$  "/&   &0
M            @(''U0$ >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4
M Q0    ( /&!75CSE4"TG@,   X-   9              " @93: 0!X;"]W
M;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ \8%=6 7?_R'+ @
M&0@  !D              ("!:=X! 'AL+W=O<FMS:&5E=',O<VAE970X,"YX
M;6Q02P$"% ,4    " #Q@5U88 \!:7L#   \#   &0              @(%K
MX0$ >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( /&!75@9
M$*9$5 0  (X6   9              " @1WE 0!X;"]W;W)K<VAE971S+W-H
M965T.#(N>&UL4$L! A0#%     @ \8%=6)R6]A+F @  ]@@  !D
M     ("!J.D! 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q02P$"% ,4
M" #Q@5U8F O(F$8#  #,%   #0              @ '%[ $ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( /&!75B7BKL<P    !,"   +              "
M 3;P 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( /&!75A:$]Q@  8  *\V   /
M              "  1_Q 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #Q
M@5U8-$X[?7H"    ,0  &@              @ %,]P$ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #Q@5U8(' .V20"  "I+P  $P
M            @ '^^0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     6P!;
+ /08  !3_ $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>240</ContextCount>
  <ElementCount>409</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>84</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Deferred Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenue</Role>
      <ShortName>Deferred Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Revenue Interest Purchase Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreement</Role>
      <ShortName>Revenue Interest Purchase Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Microsoft Collaboration Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreement</Role>
      <ShortName>Microsoft Collaboration Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRestructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders</Role>
      <ShortName>Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenue</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Deferred Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueTables</Role>
      <ShortName>Deferred Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenue</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilities</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Revenue Interest Purchase Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementTables</Role>
      <ShortName>Revenue Interest Purchase Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreement</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquity</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlans</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails</Role>
      <ShortName>Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails</Role>
      <ShortName>Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Revenue - Schedule of Disaggregated Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails</Role>
      <ShortName>Revenue - Schedule of Disaggregated Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails</Role>
      <ShortName>Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Deferred Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails</Role>
      <ShortName>Deferred Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Deferred Revenue - Additional Information (Details1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1</Role>
      <ShortName>Deferred Revenue - Additional Information (Details1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Deferred Revenue - Schedule of Changes in Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails</Role>
      <ShortName>Deferred Revenue - Schedule of Changes in Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Investments - Schedule of Available-for-sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails</Role>
      <ShortName>Investments - Schedule of Available-for-sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Investments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Investments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Investments - Schedule of Gross Unrealized Holding Losses and Fair Values for Investments in Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails</Role>
      <ShortName>Investments - Schedule of Gross Unrealized Holding Losses and Fair Values for Investments in Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Leases- Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases- Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Leases- Summary of Other Information Related to Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails</Role>
      <ShortName>Leases- Summary of Other Information Related to Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails</Role>
      <ShortName>Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Revenue Interest Purchase Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails</Role>
      <ShortName>Revenue Interest Purchase Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Revenue Interest Purchase Agreement - Schedule of Revenue Interest Liability, Net Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails</Role>
      <ShortName>Revenue Interest Purchase Agreement - Schedule of Revenue Interest Liability, Net Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Shareholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Shareholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails</Role>
      <ShortName>Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Equity Incentive Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails</Role>
      <ShortName>Equity Incentive Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Equity Incentive Plans - Summary of Stock Option Activity Under 2009 Plan and 2019 Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Stock Option Activity Under 2009 Plan and 2019 Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Equity Incentive Plans - Summary of Estimated Grant Date Fair Values of Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Estimated Grant Date Fair Values of Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Consolidated Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails</Role>
      <ShortName>Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Consolidated Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>100740 - Disclosure - Equity Incentive Plans - Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails</Role>
      <ShortName>Equity Incentive Plans - Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>100750 - Disclosure - Microsoft Collaboration Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails</Role>
      <ShortName>Microsoft Collaboration Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>100760 - Disclosure - Restructuring - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails</Role>
      <ShortName>Restructuring - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>100770 - Disclosure - Income Taxes - Schedule of Components of Loss Before Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Loss Before Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>100780 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>100790 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>100800 - Disclosure - Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>100810 - Disclosure - Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>100820 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>100830 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="adpt-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>100840 - Disclosure - Retirement Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails</Role>
      <ShortName>Retirement Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="adpt-20231231.htm">adpt-20231231.htm</File>
    <File>adpt-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img63237988_0.jpg</File>
    <File>img63237988_1.jpg</File>
    <File>img63237988_2.jpg</File>
    <File>img63237988_3.jpg</File>
    <File>img63237988_4.jpg</File>
    <File>img63237988_5.jpg</File>
    <File>img63237988_6.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="773">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>106
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "adpt-20231231.htm": {
   "nsprefix": "adpt",
   "nsuri": "http://www.adaptivebiotech.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "adpt-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "adpt-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "keyStandard": 326,
   "keyCustom": 83,
   "axisStandard": 32,
   "axisCustom": 0,
   "memberStandard": 40,
   "memberCustom": 40,
   "hidden": {
    "total": 9,
    "http://xbrl.sec.gov/dei/2023": 3,
    "http://fasb.org/us-gaap/2023": 6
   },
   "contextCount": 240,
   "entityCount": 1,
   "segmentCount": 84,
   "elementCount": 679,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 773,
    "http://xbrl.sec.gov/dei/2023": 38
   },
   "report": {
    "R1": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
     "longName": "100030 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss",
     "longName": "100040 - Statement - Consolidated Statements of Comprehensive Loss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity",
     "longName": "100050 - Statement - Consolidated Statements of Shareholders' Equity",
     "shortName": "Consolidated Statements of Shareholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_cd98abbe-6241-4fc8-af88-d9979790e940",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cd98abbe-6241-4fc8-af88-d9979790e940",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "longName": "100060 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "adpt:NoncashLeaseExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness",
     "longName": "100070 - Disclosure - Organization and Description of Business",
     "shortName": "Organization and Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies",
     "longName": "100080 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenue",
     "longName": "100090 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenue",
     "longName": "100100 - Disclosure - Deferred Revenue",
     "shortName": "Deferred Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "adpt:DeferredRevenueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "adpt:DeferredRevenueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "100110 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestments",
     "longName": "100120 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_030867b4-3ba3-4e62-9885-bbfe6fa3e703",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_030867b4-3ba3-4e62-9885-bbfe6fa3e703",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "longName": "100130 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets",
     "longName": "100140 - Disclosure - Goodwill and Intangible Assets",
     "shortName": "Goodwill and Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilities",
     "longName": "100150 - Disclosure - Accrued Liabilities",
     "shortName": "Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeases",
     "longName": "100160 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreement",
     "longName": "100170 - Disclosure - Revenue Interest Purchase Agreement",
     "shortName": "Revenue Interest Purchase Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "adpt:RevenueInterestPurchaseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "adpt:RevenueInterestPurchaseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "100180 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquity",
     "longName": "100190 - Disclosure - Shareholders' Equity",
     "shortName": "Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlans",
     "longName": "100200 - Disclosure - Equity Incentive Plans",
     "shortName": "Equity Incentive Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreement",
     "longName": "100210 - Disclosure - Microsoft Collaboration Agreement",
     "shortName": "Microsoft Collaboration Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRestructuring",
     "longName": "100220 - Disclosure - Restructuring",
     "shortName": "Restructuring",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "100230 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders",
     "longName": "100240 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders",
     "shortName": "Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRetirementPlan",
     "longName": "100250 - Disclosure - Retirement Plan",
     "shortName": "Retirement Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies",
     "longName": "100260 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "adpt:BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "adpt:BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables",
     "longName": "100270 - Disclosure - Significant Accounting Policies (Tables)",
     "shortName": "Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueTables",
     "longName": "100280 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueTables",
     "longName": "100290 - Disclosure - Deferred Revenue (Tables)",
     "shortName": "Deferred Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "adpt:DeferredRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "adpt:DeferredRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "longName": "100300 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsTables",
     "longName": "100310 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables",
     "longName": "100320 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables",
     "longName": "100330 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables",
     "longName": "100340 - Disclosure - Accrued Liabilities (Tables)",
     "shortName": "Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesTables",
     "longName": "100350 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementTables",
     "longName": "100360 - Disclosure - Revenue Interest Purchase Agreement (Tables)",
     "shortName": "Revenue Interest Purchase Agreement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "adpt:ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "adpt:RevenueInterestPurchaseAgreementTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "adpt:ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "adpt:RevenueInterestPurchaseAgreementTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityTables",
     "longName": "100370 - Disclosure - Shareholders' Equity (Tables)",
     "shortName": "Shareholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables",
     "longName": "100380 - Disclosure - Equity Incentive Plans (Tables)",
     "shortName": "Equity Incentive Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "100390 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables",
     "longName": "100400 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)",
     "shortName": "Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "100410 - Disclosure - Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:OtherInventoryNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InventoryPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails",
     "longName": "100420 - Disclosure - Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details)",
     "shortName": "Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_5d4928f6-2311-4267-a962-fb87a6ccc8c3",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d4928f6-2311-4267-a962-fb87a6ccc8c3",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails",
     "longName": "100430 - Disclosure - Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details)",
     "shortName": "Significant Accounting Policies - Summary of Useful Lives Assigned to Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_36aa5e03-ecb8-4303-b58a-1c55adb14e7f",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "adpt:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_36aa5e03-ecb8-4303-b58a-1c55adb14e7f",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "adpt:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails",
     "longName": "100440 - Disclosure - Revenue - Schedule of Disaggregated Revenue (Details)",
     "shortName": "Revenue - Schedule of Disaggregated Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a82a556c-1601-4580-ab77-910e118cd40c",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails",
     "longName": "100450 - Disclosure - Revenue - Additional Information (Details)",
     "shortName": "Revenue - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_17868eb1-c4c5-48c6-b75e-f00ebc3afa5a",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
     "longName": "100460 - Disclosure - Deferred Revenue - Additional Information (Details)",
     "shortName": "Deferred Revenue - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ae994e8c-99db-42b9-978b-de43f2096cd2",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "adpt:DeferredRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1",
     "longName": "100470 - Disclosure - Deferred Revenue - Additional Information (Details1)",
     "shortName": "Deferred Revenue - Additional Information (Details1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_cb59ede3-9e6b-4249-8eda-53f2caa6aa96",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "adpt:DeferredRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cb59ede3-9e6b-4249-8eda-53f2caa6aa96",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "adpt:DeferredRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails",
     "longName": "100480 - Disclosure - Deferred Revenue - Schedule of Changes in Deferred Revenue (Details)",
     "shortName": "Deferred Revenue - Schedule of Changes in Deferred Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_27c4f267-cdd6-4003-8d32-93af9d170fbe",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "div",
       "adpt:DeferredRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_27c4f267-cdd6-4003-8d32-93af9d170fbe",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "div",
       "adpt:DeferredRevenueTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "100490 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_2a889da6-68e6-499f-9f09-345a151867c6",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2a889da6-68e6-499f-9f09-345a151867c6",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails",
     "longName": "100500 - Disclosure - Investments - Schedule of Available-for-sale Investments (Details)",
     "shortName": "Investments - Schedule of Available-for-sale Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_c6dd27e3-1742-4ce3-b818-2cc2fe370e7b",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c6dd27e3-1742-4ce3-b818-2cc2fe370e7b",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails",
     "longName": "100510 - Disclosure - Investments - Additional Information (Details)",
     "shortName": "Investments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_adce8143-c708-4ab4-aad4-7932228c2737",
      "name": "us-gaap:InterestReceivableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_adce8143-c708-4ab4-aad4-7932228c2737",
      "name": "us-gaap:InterestReceivableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails",
     "longName": "100520 - Disclosure - Investments - Schedule of Gross Unrealized Holding Losses and Fair Values for Investments in Unrealized Loss Position (Details)",
     "shortName": "Investments - Schedule of Gross Unrealized Holding Losses and Fair Values for Investments in Unrealized Loss Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
     "longName": "100530 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Details)",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "longName": "100540 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
     "longName": "100550 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)",
     "shortName": "Goodwill and Intangible Assets - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_2fd988f0-f2ea-429d-b4f6-17267c9ddedc",
      "name": "us-gaap:GoodwillPeriodIncreaseDecrease",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2fd988f0-f2ea-429d-b4f6-17267c9ddedc",
      "name": "us-gaap:GoodwillPeriodIncreaseDecrease",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails",
     "longName": "100560 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details)",
     "shortName": "Goodwill and Intangible Assets - Summary of Intangible Assets Subject to Amortization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails",
     "longName": "100570 - Disclosure - Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details)",
     "shortName": "Goodwill and Intangible Assets - Schedule of Future Amortization Expense for Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails",
     "longName": "100580 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "shortName": "Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
     "longName": "100600 - Disclosure - Leases- Additional Information (Details)",
     "shortName": "Leases- Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_2b549b79-66c4-4298-ba5f-b1b62fef2585",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "U_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2b549b79-66c4-4298-ba5f-b1b62fef2585",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "U_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails",
     "longName": "100610 - Disclosure - Leases- Summary of Other Information Related to Operating Lease (Details)",
     "shortName": "Leases- Summary of Other Information Related to Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails",
     "longName": "100620 - Disclosure - Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details)",
     "shortName": "Leases- Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
     "longName": "100630 - Disclosure - Revenue Interest Purchase Agreement - Additional Information (Details)",
     "shortName": "Revenue Interest Purchase Agreement - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_5a86b9bb-1277-4e79-955e-d1edb50cca23",
      "name": "adpt:UpfrontPaymentReceived",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "adpt:RevenueInterestPurchaseAgreementTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a86b9bb-1277-4e79-955e-d1edb50cca23",
      "name": "adpt:UpfrontPaymentReceived",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "adpt:RevenueInterestPurchaseAgreementTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails",
     "longName": "100650 - Disclosure - Revenue Interest Purchase Agreement - Schedule of Revenue Interest Liability, Net Activity (Details)",
     "shortName": "Revenue Interest Purchase Agreement - Schedule of Revenue Interest Liability, Net Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_18612828-7d58-4576-a6a2-b4505743ef18",
      "name": "adpt:RevenueInterestLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "adpt:ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock",
       "div",
       "adpt:RevenueInterestPurchaseAgreementTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18612828-7d58-4576-a6a2-b4505743ef18",
      "name": "adpt:RevenueInterestLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "adpt:ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock",
       "div",
       "adpt:RevenueInterestPurchaseAgreementTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
     "longName": "100660 - Disclosure - Shareholders' Equity - Additional Information (Details)",
     "shortName": "Shareholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails",
     "longName": "100670 - Disclosure - Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)",
     "shortName": "Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
     "longName": "100680 - Disclosure - Equity Incentive Plans - Additional Information (Details)",
     "shortName": "Equity Incentive Plans - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails",
     "longName": "100690 - Disclosure - Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details)",
     "shortName": "Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_f712f0be-9f2e-4186-a7b5-0091ce1762f6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3b24663a-22c4-43fd-8173-22c3ea3e4a68",
      "name": "adpt:ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails",
     "longName": "100700 - Disclosure - Equity Incentive Plans - Summary of Stock Option Activity Under 2009 Plan and 2019 Plan (Details)",
     "shortName": "Equity Incentive Plans - Summary of Stock Option Activity Under 2009 Plan and 2019 Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_27c4f267-cdd6-4003-8d32-93af9d170fbe",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_27c4f267-cdd6-4003-8d32-93af9d170fbe",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails",
     "longName": "100710 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Details)",
     "shortName": "Equity Incentive Plans - Summary of Restricted Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_43621f8b-6a5f-47d0-a30e-6bf513d24ad8",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails",
     "longName": "100720 - Disclosure - Equity Incentive Plans - Summary of Estimated Grant Date Fair Values of Stock Options Granted (Details)",
     "shortName": "Equity Incentive Plans - Summary of Estimated Grant Date Fair Values of Stock Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails",
     "longName": "100730 - Disclosure - Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Consolidated Statements of Operations (Details)",
     "shortName": "Equity incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUS Included on Consolidated Statements of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5d872d1b-6381-4a56-9eee-12e5744bc07e",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails",
     "longName": "100740 - Disclosure - Equity Incentive Plans - Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period (Details)",
     "shortName": "Equity Incentive Plans - Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "C_5c8126e1-b6cc-428b-b0c0-8e108d6c872f",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "adpt:ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5c8126e1-b6cc-428b-b0c0-8e108d6c872f",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "adpt:ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails",
     "longName": "100750 - Disclosure - Microsoft Collaboration Agreement - Additional Information (Details)",
     "shortName": "Microsoft Collaboration Agreement - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "C_dfe2e57d-4fb2-4493-8bac-7c38728d7cb1",
      "name": "adpt:MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dfe2e57d-4fb2-4493-8bac-7c38728d7cb1",
      "name": "adpt:MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails",
     "longName": "100760 - Disclosure - Restructuring - Additional Information (Details)",
     "shortName": "Restructuring - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "C_18d7a278-e320-4faa-bd10-c3406fe899df",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "U_Employee",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_18d7a278-e320-4faa-bd10-c3406fe899df",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "U_Employee",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails",
     "longName": "100770 - Disclosure - Income Taxes - Schedule of Components of Loss Before Provision for Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Components of Loss Before Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "100780 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_60b74489-28b2-4615-9786-6fdacef93898",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "100790 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail",
     "longName": "100800 - Disclosure - Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail",
     "longName": "100810 - Disclosure - Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail)",
     "shortName": "Income Taxes - Schedule of Change In Unrecognized Tax Benefits (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "C_27c4f267-cdd6-4003-8d32-93af9d170fbe",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R81": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
     "longName": "100820 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details)",
     "shortName": "Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R82": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails",
     "longName": "100830 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails",
     "longName": "100840 - Disclosure - Retirement Plan - Additional Information (Details)",
     "shortName": "Retirement Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "adpt-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate201602Member",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASC 842",
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842)."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update Extensible List",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r237",
      "r238",
      "r239",
      "r292",
      "r293",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r372",
      "r493",
      "r494",
      "r495",
      "r524",
      "r525",
      "r532",
      "r533",
      "r534",
      "r543",
      "r544",
      "r545",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r577",
      "r578",
      "r580",
      "r581",
      "r582",
      "r583",
      "r591",
      "r592",
      "r595",
      "r596",
      "r597",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r929"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r872"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable, Net",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Investment amortization",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "adpt_AccruedClinicalAndContractResearchOrganizationCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "AccruedClinicalAndContractResearchOrganizationCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical and contract research organization costs, current.",
        "label": "Accrued Clinical And Contract Research Organization Costs Current",
        "terseLabel": "Clinical and contract research organization costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Travel and entertainment",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Tax liabilities",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r153"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "adpt_AccruedPurchaseOfPropertyAndEquipmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "AccruedPurchaseOfPropertyAndEquipmentCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued purchase of property and equipment current.",
        "label": "Accrued Purchase Of Property And Equipment Current",
        "terseLabel": "Purchases of property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "AccruedTaxWithholdingLiabilityRelatedToUnsettledOptionExercises",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued tax withholding liability related to unsettled option exercises.",
        "label": "Accrued Tax Withholding Liability Related To Unsettled Option Exercises",
        "terseLabel": "Accrued tax withholding liability related to unsettled option exercises"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r192",
      "r677"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive gain (loss)",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r107",
      "r201",
      "r672",
      "r702",
      "r706"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r14",
      "r36",
      "r548",
      "r551",
      "r615",
      "r697",
      "r698",
      "r916",
      "r917",
      "r918",
      "r926",
      "r927",
      "r928"
     ]
    },
    "adpt_AdditionalMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "AdditionalMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional milestone payment.",
        "label": "Additional Milestone Payment",
        "terseLabel": "Additional milestone payment receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r872",
      "r1021"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r719",
      "r926",
      "r927",
      "r928",
      "r995",
      "r1023"
     ]
    },
    "adpt_AdditionalTransactionPriceOfRegulatoryMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "AdditionalTransactionPriceOfRegulatoryMilestone",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional transaction price of regulatory milestone",
        "label": "Additional Transaction Price Of Regulatory Milestone",
        "documentation": "Additional transaction price of regulatory milestone."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r237",
      "r238",
      "r239",
      "r240",
      "r251",
      "r292",
      "r293",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r372",
      "r493",
      "r494",
      "r495",
      "r522",
      "r523",
      "r524",
      "r525",
      "r532",
      "r533",
      "r534",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r577",
      "r578",
      "r580",
      "r581",
      "r582",
      "r583",
      "r591",
      "r592",
      "r595",
      "r596",
      "r597",
      "r598",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r653",
      "r654",
      "r655",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706"
     ]
    },
    "adpt_AdjustmentsToAdditionalPaidInCapitalCapitalContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalCapitalContributions",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital capital contributions.",
        "label": "Adjustments To Additional Paid In Capital Capital Contributions",
        "terseLabel": "Capital contributions for Digital Biotechnologies, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantToCommonStockWarrant",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital conversion of convertible preferred stock warrant to common stock warrant.",
        "label": "Adjustments To Additional Paid In Capital Conversion Of Convertible Preferred Stock Warrant To Common Stock Warrant",
        "terseLabel": "Conversion of convertible preferred stock warrant to common stock warrant"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalInitialPublicOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital, initial public offering costs.",
        "label": "Adjustments To Additional Paid In Capital Initial Public Offering Costs",
        "terseLabel": "Initial public offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionAndRestrictedStockUnitRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid In capital share based compensation stock option and restricted stock unit requisite service period recognition value.",
        "label": "Adjustments To Additional Paid In Capital Share Based Compensation Stock Option And Restricted Stock Unit Requisite Service Period Recognition Value",
        "terseLabel": "Common stock option, restricted stock unit and market-based restricted stock unit share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r456"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising Expense",
        "verboseLabel": "Advertising expenses",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Recognized share-based compensation expense",
        "totalLabel": "Total share-based compensation expense",
        "verboseLabel": "Total share-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r501"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Intangible assets amortization",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r56",
      "r59"
     ]
    },
    "adpt_AmortizationOfPurchaseAgreementObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "AmortizationOfPurchaseAgreementObligation",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of purchase agreement obligation.",
        "label": "Amortization of Purchase Agreement obligation",
        "verboseLabel": "Amortization of purchase agreement obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstAndSecondPayment",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Applicable payment percentage of quarterly revenue base for first and second payment.",
        "label": "Applicable Payment Percentage of quarterly Revenue Base for First and Second Payment",
        "verboseLabel": "Applicable payment percentage of quarterly revenue base for first and second payment"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstPayment",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Applicable payment percentage of quarterly revenue base for first payment.",
        "label": "Applicable Payment Percentage of quarterly Revenue Base for First Payment",
        "verboseLabel": "Applicable payment percentage of quarterly revenue base for first payment"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ApplicablePaymentPercentageOfQuarterlyRevenueBaseForFirstSecondAndThirdPayment",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Applicable payment percentage of quarterly revenue base for first, second and third payment.",
        "label": "Applicable Payment Percentage of quarterly Revenue Base for First, Second and Third Payment",
        "verboseLabel": "Applicable payment percentage of quarterly revenue base for first, second and third payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfLand",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Land",
        "terseLabel": "Number of square feet",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r196",
      "r229",
      "r268",
      "r280",
      "r284",
      "r328",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r537",
      "r541",
      "r579",
      "r667",
      "r761",
      "r872",
      "r885",
      "r957",
      "r958",
      "r1006"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r204",
      "r229",
      "r328",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r537",
      "r541",
      "r579",
      "r872",
      "r957",
      "r958",
      "r1006"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total financial assets",
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Long-term assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r890",
      "r891",
      "r892"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r890",
      "r891",
      "r892"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r890",
      "r891",
      "r892"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gain",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Loss",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r344",
      "r666"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r344",
      "r658",
      "r939"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term marketable securities (amortized cost of $281,122 and $412,282, respectively)",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r344"
     ]
    },
    "adpt_AvailableForSaleSecuritiesDebtSecuritiesCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrentMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities debt securities current.",
        "label": "Available For Sale Securities Debt Securities Current [Member]",
        "terseLabel": "Short-Term Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrentMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities debt securities noncurrent.",
        "label": "Available For Sale Securities Debt Securities Noncurrent [Member]",
        "terseLabel": "Long-Term Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r460",
      "r461",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85"
     ]
    },
    "adpt_BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation and principles of consolidation policy.",
        "label": "Basis Of Presentation And Principles Of Consolidation Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization and Description of Business",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r120",
      "r121"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of equipment included in accounts payable and accrued liabilities",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r190",
      "r835"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r151"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r117",
      "r226"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r117"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncash investing activities",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ChangeInRedemptionValueForVestedConvertiblePreferredStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in redemption value for vested convertible preferred stock options.",
        "label": "Change In Redemption Value For Vested Convertible Preferred Stock Options",
        "terseLabel": "Change in redemption value for vested Series E-1 convertible preferred stock options"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r198",
      "r199",
      "r200",
      "r229",
      "r255",
      "r256",
      "r258",
      "r260",
      "r266",
      "r267",
      "r328",
      "r389",
      "r391",
      "r392",
      "r393",
      "r396",
      "r397",
      "r406",
      "r407",
      "r410",
      "r413",
      "r420",
      "r579",
      "r711",
      "r712",
      "r713",
      "r714",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r749",
      "r770",
      "r789",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r897",
      "r923",
      "r931"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r266",
      "r406",
      "r407",
      "r408",
      "r410",
      "r413",
      "r418",
      "r420",
      "r711",
      "r712",
      "r713",
      "r714",
      "r853",
      "r897",
      "r923"
     ]
    },
    "adpt_CollaborationArrangementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "CollaborationArrangementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement Disclosure [Abstract]",
        "label": "Collaboration Arrangement Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_CollaborationRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "CollaborationRevenueMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Revenue",
        "label": "Collaboration Revenue [Member]",
        "documentation": "Collaboration Revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Microsoft Collaboration Agreement",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r168",
      "r178"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "adpt_CommercialMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "CommercialMilestonesMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestones.",
        "label": "Commercial Milestones [Member]",
        "terseLabel": "Commercial Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r879",
      "r880",
      "r881",
      "r882"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 12)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r93",
      "r668",
      "r748"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r383",
      "r384",
      "r820",
      "r954"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total shares of common stock reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "adpt_CommonStockExerciseOfOutstandingStockOptionsGrantedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "CommonStockExerciseOfOutstandingStockOptionsGrantedMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Issuable Upon the Exercise of Outstanding Stock Options Granted",
        "label": "Common Stock Exercise Of Outstanding Stock Options Granted [Member]",
        "documentation": "Common stock exercise of outstanding stock options granted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r875",
      "r876",
      "r877",
      "r879",
      "r880",
      "r881",
      "r882",
      "r926",
      "r927",
      "r995",
      "r1020",
      "r1023"
     ]
    },
    "adpt_CommonStockOptionsAndRestrictedStockUnitsGrantedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "CommonStockOptionsAndRestrictedStockUnitsGrantedMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock options and restricted stock units granted.",
        "label": "Common Stock Options And Restricted Stock Units Granted [Member]",
        "terseLabel": "Exercise of Outstanding Common Stock Options and Vesting of Outstanding Common Restricted Stock Units Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r749"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r101",
      "r749",
      "r767",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2023 and 2022; 145,082,271 and 143,105,002 shares issued and outstanding at December 31, 2023 and 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r670",
      "r872"
     ]
    },
    "adpt_CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Issuable Upon the Vesting of Outstanding Restricted Stock Units and the Maximum Outstanding Market-based Restricted Stock Units Granted",
        "label": "Common Stock Vesting Of Outstanding Restricted Stock Units And Market Based Restricted Stock Units Granted [Member]",
        "documentation": "Common stock vesting of outstanding restricted stock units and market-based restricted stock units granted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock voting rights description",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "adpt_CommonStockWarrantOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "CommonStockWarrantOutstandingMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Warrant Outstanding",
        "label": "Common Stock Warrant Outstanding [Member]",
        "documentation": "Common stock warrant outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRetirementPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Retirement Plan",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r138"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Adaptive Biotechnologies Corporation",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r209",
      "r211",
      "r219",
      "r661",
      "r686"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Add: Comprehensive loss attributable to noncontrolling interest",
        "totalLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r80",
      "r83",
      "r209",
      "r211",
      "r218",
      "r660",
      "r685"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r146",
      "r209",
      "r211",
      "r217",
      "r659",
      "r684"
     ]
    },
    "adpt_ComputerAndSoftware": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ComputerAndSoftware",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer and software.",
        "label": "Computer And Software",
        "terseLabel": "Computer and software"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ComputerEquipmentAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ComputerEquipmentAndSoftwareMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and software.",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer Equipment and Software"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ComputerSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ComputerSoftwareMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer software.",
        "label": "Computer Software [Member]",
        "terseLabel": "Computer Software"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r50",
      "r89",
      "r90",
      "r289",
      "r819"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Accounts Receivable, Net",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r50",
      "r89",
      "r90",
      "r289",
      "r707",
      "r819"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r50",
      "r89",
      "r90",
      "r289",
      "r819",
      "r901"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r170"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r50",
      "r89",
      "r90",
      "r289"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r50",
      "r89",
      "r90",
      "r289",
      "r819"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ContractBalancesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ContractBalancesPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract balances.",
        "label": "Contract Balances Policy [Text Block]",
        "terseLabel": "Contract Balances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Changes in Deferred Revenue",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability",
        "totalLabel": "Total current and non-current deferred revenue",
        "periodStartLabel": "Deferred revenue balance at December 31, 2021",
        "periodEndLabel": "Deferred revenue balance at December 31, 2022",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r423",
      "r442"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current deferred revenue",
        "terseLabel": "Current portion of deferred revenue",
        "verboseLabel": "Total current deferred revenue",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r423",
      "r442"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination",
        "terseLabel": "Additions to deferred revenue during the period",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "adpt_ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ContractWithCustomerLiabilityMilestoneMethodRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability milestone method revenue recognized.",
        "label": "Contract With Customer Liability Milestone Method Revenue Recognized",
        "terseLabel": "Milestone revenue recognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, less current portion",
        "verboseLabel": "Non-current deferred revenue",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r423",
      "r442"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueScheduleOfChangesInDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized",
        "verboseLabel": "Revenue recognized during the period",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r410",
      "r879",
      "r880",
      "r881",
      "r882"
     ]
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate Bonds",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Bonds",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r864",
      "r1019"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of revenue",
        "totalLabel": "Cost of Goods and Services Sold, Total",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r651"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of Revenue",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Revenue",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r399",
      "r408",
      "r616",
      "r837",
      "r839"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_CumulativePurchaserPaymentsReceivableDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "CumulativePurchaserPaymentsReceivableDate",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative purchaser payments receivable date.",
        "label": "Cumulative Purchaser Payments Receivable Date",
        "verboseLabel": "Cumulative purchaser payments receivable date"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_CumulativePurchaserPaymentsRepaymentDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "CumulativePurchaserPaymentsRepaymentDate",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative purchaser payments repayment date",
        "label": "Cumulative Purchaser Payments Repayment Date",
        "verboseLabel": "Cumulative purchaser payments repayment date"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_CustomerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "CustomerAMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer A",
        "label": "Customer A [Member]",
        "documentation": "Customer A."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_CustomerBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "CustomerBMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer B.",
        "label": "Customer B [Member]",
        "terseLabel": "Customer B"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r289"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Effective interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r398"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "terseLabel": "Amortized cost of short-term marketable securities",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r941"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent",
        "terseLabel": "Amortized cost of long-term marketable securities",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r941"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "12 months or greater, Fair value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r346",
      "r847"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "12 months or greater, Unrealized loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r346"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less than 12 months, Fair value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r346",
      "r847"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Less than 12 months, Unrealized loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r346"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Gross Unrealized Holding Losses and Fair Values for Investments in Unrealized Loss Position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r847",
      "r947"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Issuance Costs, Net, Total",
        "label": "Debt Issuance Costs, Net",
        "verboseLabel": "Debt issuance costs",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r960"
     ]
    },
    "adpt_DeferredRevenueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "DeferredRevenueTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred revenue.",
        "label": "Deferred Revenue [Text Block]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r993"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "terseLabel": "Deferred tax asset",
        "verboseLabel": "Deferred tax asset",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_DeferredTaxAssetsNonQualifiedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "DeferredTaxAssetsNonQualifiedStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets, non qualified stock options.",
        "label": "Deferred Tax Assets Non Qualified Stock Options",
        "terseLabel": "Nonqualifying stock options"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating lease liabilities.",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r993"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r993"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, General Business",
        "terseLabel": "Tax credit carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r993"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent",
        "terseLabel": "Deferred rent",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r993"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net",
        "totalLabel": "Net deferred taxes",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r992"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_DeferredTaxLiabilitiesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities right of use assets.",
        "label": "Deferred Tax Liabilities Right Of Use Assets",
        "negatedLabel": "Right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_DeferredTaxLiabilitiesTangibleAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "DeferredTaxLiabilitiesTangibleAndIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities, tangible and intangible assets.",
        "label": "Deferred Tax Liabilities Tangible And Intangible Assets",
        "negatedLabel": "Tangible and intangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_Deferredtaxassetscapitalizedresearchanddevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "Deferredtaxassetscapitalizedresearchanddevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets capitalized research and development.",
        "label": "Deferred Tax Assets Capitalized Research And Development",
        "terseLabel": "Capitalized research and development",
        "verboseLabel": "Deferred tax asset"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_DefinedContributionPlanEmployeeServicePeriodForVesting": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "DefinedContributionPlanEmployeeServicePeriodForVesting",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan employee service period for vesting.",
        "label": "Defined Contribution Plan Employee Service Period For Vesting",
        "terseLabel": "Employee service period for vesting"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer discretionary contribution amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Employees maximum annual contribution of their compensation",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "verboseLabel": "Depreciation",
        "totalLabel": "Depreciation, Total",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r61"
     ]
    },
    "adpt_DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "DerecognitionOfLeaseFinancingArrangementsUponAdoptionOfGuidanceOnAccountingForLease",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derecognition of lease financing arrangements upon adoption of guidance on accounting for lease.",
        "label": "Derecognition Of Lease Financing Arrangements Upon Adoption Of Guidance On Accounting For Lease",
        "terseLabel": "Derecognition of lease financing arrangements upon adoption of guidance on accounting for leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Acquired Developed Technology",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "adpt_DevelopmentMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "DevelopmentMilestonesMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestones.",
        "label": "Development Milestones [Member]",
        "terseLabel": "Development Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_DevelopmentRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "DevelopmentRevenueMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development revenue.",
        "label": "Development Revenue [Member]",
        "terseLabel": "Development Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_DigitalBiotechnologiesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "DigitalBiotechnologiesIncMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Digital Biotechnologies, Inc.",
        "label": "Digital Biotechnologies Inc [Member]",
        "terseLabel": "Digital Biotechnologies, Inc.",
        "verboseLabel": "Digital Biotechnologies Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation Of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation Of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregated Revenue",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Equity Incentive Plans",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r458",
      "r489",
      "r490",
      "r492",
      "r866"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r890",
      "r891",
      "r892"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r890",
      "r891",
      "r892",
      "r894"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r241",
      "r242",
      "r244",
      "r245",
      "r247",
      "r253",
      "r255",
      "r258",
      "r259",
      "r260",
      "r264",
      "r565",
      "r566",
      "r662",
      "r687",
      "r842"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r241",
      "r242",
      "r244",
      "r245",
      "r247",
      "r255",
      "r258",
      "r259",
      "r260",
      "r264",
      "r565",
      "r566",
      "r662",
      "r687",
      "r842"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholders"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r261",
      "r262",
      "r263"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r509",
      "r528"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r991",
      "r994"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Share-based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r991",
      "r994"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r991",
      "r994"
     ]
    },
    "adpt_EffectiveIncomeTaxRateReconciliationPermanentItems": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation Permanent Items",
        "label": "Effective Income Tax Rate Reconciliation Permanent Items",
        "terseLabel": "Permanent items"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State tax, net of federal tax benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r991",
      "r994"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfEffectiveTaxRateOfProvisionForIncomeTaxesDiffersFromFederalStatutoryRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "Credits",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r991",
      "r994"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized share-based compensation expense related to unvested stock options, weighted-average period for recognition",
        "verboseLabel": "Remaining Weighted-Average Recognition Period (in years)",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized share-based compensation expense related to unvested RSUs",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized share-based compensation expense related to unvested stock options",
        "verboseLabel": "Unrecognized Share-Based Compensation Expense",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "verboseLabel": "Grant",
        "terseLabel": "Common Stock Options Granted",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r183",
      "r213",
      "r214",
      "r215",
      "r234",
      "r235",
      "r236",
      "r238",
      "r248",
      "r250",
      "r265",
      "r332",
      "r338",
      "r421",
      "r493",
      "r494",
      "r495",
      "r524",
      "r525",
      "r546",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553",
      "r564",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r615",
      "r697",
      "r698",
      "r699",
      "r719",
      "r789"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r570",
      "r573"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r570",
      "r573"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Level 2",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r570",
      "r621",
      "r622",
      "r623",
      "r849",
      "r850",
      "r862",
      "r863",
      "r864"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r570",
      "r571",
      "r572",
      "r574"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r446",
      "r451",
      "r570",
      "r621",
      "r862",
      "r863",
      "r864"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r446",
      "r451",
      "r570",
      "r622",
      "r849",
      "r850",
      "r862",
      "r863",
      "r864"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r570",
      "r623",
      "r849",
      "r850",
      "r862",
      "r863",
      "r864"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r621",
      "r622",
      "r623",
      "r849",
      "r850",
      "r862",
      "r863",
      "r864"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r574"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r23"
     ]
    },
    "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]",
        "terseLabel": "Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r871"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r347",
      "r348",
      "r403",
      "r418",
      "r554",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r683",
      "r847",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r942",
      "r943",
      "r944",
      "r945"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Amortization period of intangible assets",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r368"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r367",
      "r368",
      "r369",
      "r652",
      "r656"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount",
        "totalLabel": "Finite-Lived Intangible Assets, Gross, Total",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r656"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFutureAmortizationExpenseForIntangibleAssetsDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r652"
     ]
    },
    "adpt_FurnitureAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "FurnitureAndOfficeEquipmentMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture and office equipment.",
        "label": "Furniture And Office Equipment [Member]",
        "terseLabel": "Furniture and Office Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_GenentechCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "GenentechCollaborationAgreementMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genentech collaboration agreement.",
        "label": "Genentech Collaboration Agreement [Member]",
        "terseLabel": "Genentech Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_GenentechIncAndRocheGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "GenentechIncAndRocheGroupMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genentech, Inc. and Roche Group.",
        "label": "Genentech Inc And Roche Group [Member]",
        "terseLabel": "Genentech, Inc. and Roche Group"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_GenentechIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "GenentechIncMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genentech Inc.",
        "label": "Genentech Inc [Member]",
        "terseLabel": "Genentech, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r772"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "totalLabel": "Goodwill, Total",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "periodEndLabel": "Goodwill, Ending Balance",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r353",
      "r657",
      "r848",
      "r872",
      "r949",
      "r950"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r365",
      "r848"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment of goodwill",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r354",
      "r360",
      "r365",
      "r848"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r848"
     ]
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillPeriodIncreaseDecrease",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in carrying amount of goodwill since recognition",
        "label": "Goodwill, Period Increase (Decrease)",
        "totalLabel": "Goodwill, Period Increase (Decrease), Total",
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r890",
      "r891",
      "r892"
     ]
    },
    "adpt_ImmuneMedicineRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ImmuneMedicineRevenueMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Immune Medicine Revenue",
        "label": "Immune Medicine Revenue [Member]",
        "documentation": "Immune Medicine Revenue."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ImmuneMedicineServiceRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ImmuneMedicineServiceRevenueMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Immune Medicine Service Revenue",
        "label": "Immune Medicine Service Revenue [Member]",
        "documentation": "Immune medicine service revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of long-lived asset held for use."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Impairment losses on intangible assets",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r921",
      "r951"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-lived asset impairment loss",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r60",
      "r128"
     ]
    },
    "adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ImpairmentOfRightOfUseAndRelatedLongLivedAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of right-of-use and related long-lived assets",
        "label": "Impairment of Right-of-Use and Related Long-Lived Assets",
        "documentation": "Impairment of right-of-use and related long-lived assets."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ImpairmentOfRightOfUseAndRelatedLongLivedAssetsExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ImpairmentOfRightOfUseAndRelatedLongLivedAssetsExpensesPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Right-of-Use and Related Long-Lived Assets Expenses",
        "label": "Impairment of Right of Use and Related Long Lived Assets Expenses [Policy Text Block]",
        "documentation": "Impairment of right-of-use and related long-lived assets expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r527"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Total loss before provision for income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r108",
      "r156",
      "r268",
      "r279",
      "r283",
      "r285",
      "r663",
      "r679",
      "r844"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r527"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r377",
      "r773"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r773"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r505",
      "r510",
      "r514",
      "r520",
      "r526",
      "r529",
      "r530",
      "r531",
      "r716"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r507",
      "r508",
      "r514",
      "r515",
      "r519",
      "r521",
      "r710"
     ]
    },
    "adpt_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r920"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory",
        "totalLabel": "Increase (Decrease) in Inventories, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease right-of-use assets and liabilities .",
        "label": "Increase Decrease In Operating Lease Right Of Use Assets And Liabilities",
        "terseLabel": "Operating lease right-of-use assets and liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other",
        "totalLabel": "Increase (Decrease) in Other Operating Assets and Liabilities, Net, Total",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "adpt_IncreaseInReturnCapPercentageOfCumulativePurchaserPayments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "IncreaseInReturnCapPercentageOfCumulativePurchaserPayments",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in return cap percentage of cumulative purchaser payments.",
        "label": "Increase in Return Cap Percentage of Cumulative Purchaser Payments",
        "verboseLabel": "Increase in return cap percentage of cumulative purchaser payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Security Category [Axis]",
        "terseLabel": "Debt Security Category",
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntellectualPropertyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntellectualPropertyMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intellectual Property [Member]",
        "terseLabel": "Purchased Intellectual Property",
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest and Other Income",
        "terseLabel": "Interest and other income, net",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestCostsCapitalized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestCostsCapitalized",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Costs Capitalized",
        "verboseLabel": "Capitalized issuance costs",
        "negatedLabel": "Capitalized issuance costs",
        "documentation": "Amount of interest capitalized during the period."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest Expense, Total",
        "label": "Interest Expense",
        "terseLabel": "Interest expense",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r158",
      "r216",
      "r271",
      "r593",
      "r774",
      "r883",
      "r1022"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest Expense, Debt, Total",
        "label": "Interest Expense, Debt",
        "verboseLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r402",
      "r404",
      "r851",
      "r852"
     ]
    },
    "us-gaap_InterestExpensePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpensePolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Policy [Policy Text Block]",
        "terseLabel": "Interest Expense",
        "documentation": "Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "netLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r224",
      "r225"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Receivable, Current",
        "terseLabel": "Accrued interest receivable",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Inventory, Net, Total",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r836",
      "r872"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r189",
      "r202",
      "r349",
      "r350",
      "r351",
      "r650",
      "r840"
     ]
    },
    "adpt_InventoryReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "InventoryReserve",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory reserve",
        "label": "Inventory Reserve",
        "documentation": "Inventory reserve."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Inventory reserves",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r914"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r733",
      "r734",
      "r736",
      "r738",
      "r794",
      "r796",
      "r798",
      "r801",
      "r802",
      "r803",
      "r804",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r877"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "terseLabel": "Investments",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r733",
      "r734",
      "r736",
      "r738",
      "r794",
      "r796",
      "r798",
      "r801",
      "r802",
      "r803",
      "r804",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r877"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r159",
      "r160",
      "r180",
      "r294",
      "r296",
      "r575",
      "r576"
     ]
    },
    "adpt_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_LeaseCommencementMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "LeaseCommencementMonthAndYear",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commencement month and year.",
        "label": "Lease Commencement Month And Year",
        "terseLabel": "Lease commenced moth and year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Other Information Related to Operating Lease",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "adpt_LeaseExpirationMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "LeaseExpirationMonthAndYear",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration month and year.",
        "label": "Lease Expiration Month And Year",
        "terseLabel": "Lease expiration month and year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements, Gross",
        "terseLabel": "Landlord contribution for leasehold improvements",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "adpt_LesseeOperatingLeaseExtendedTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "LesseeOperatingLeaseExtendedTermOfContract",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating lease, extended term of contract.",
        "label": "Lessee Operating Lease Extended Term Of Contract",
        "terseLabel": "Lessee, operating lease, extended term of contract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Option to Extend",
        "terseLabel": "Lease not yet commenced, option to extend description",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease that has not yet commenced. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term",
        "terseLabel": "Lease not yet commenced, option to extend term",
        "documentation": "Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "adpt_LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease lease not yet commenced tenant improvement receivable.",
        "label": "Lessee Operating Lease Lease Not Yet Commenced Tenant Improvement Receivable",
        "terseLabel": "Lease not yet commenced landlord agreed to fund for improvements"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating lease, lease not yet commenced termination option description.",
        "label": "Lessee Operating Lease Lease Not Yet Commenced Termination Option Description",
        "terseLabel": "Lease not yet commenced, termination option description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Summary of Reconciles Undiscounted Operating Lease Cash Flows",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Imputed interest rate",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lessee, operating lease, option to extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease remaining lease term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease renewal term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "adpt_LesseeOperatingLeaseRentCommencementMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "LesseeOperatingLeaseRentCommencementMonthAndYear",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease rent commencement month and year.",
        "label": "Lessee Operating Lease Rent Commencement Month And Year",
        "terseLabel": "Lessee, operating lease, rent commencement month and year"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_LesseeOperatingLeaseRentObligationsCommencementMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "LesseeOperatingLeaseRentObligationsCommencementMonthAndYear",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease rent obligations commencement month and year.",
        "label": "Lessee Operating Lease Rent Obligations Commencement Month And Year",
        "terseLabel": "Rent obligations, commencement date"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_LesseeOperatingLeaseTerminationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "LesseeOperatingLeaseTerminationPeriod",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease termination period.",
        "label": "Lessee Operating Lease Termination Period",
        "terseLabel": "Operating lease termination period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r229",
      "r328",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r538",
      "r541",
      "r542",
      "r579",
      "r747",
      "r843",
      "r885",
      "r957",
      "r1006",
      "r1007"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r155",
      "r675",
      "r872",
      "r924",
      "r946",
      "r997"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and shareholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r188",
      "r229",
      "r328",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r538",
      "r541",
      "r542",
      "r579",
      "r872",
      "r957",
      "r1006",
      "r1007"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue interest liability, net",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "totalLabel": "Long-Term Debt, Excluding Current Maturities, Total",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "adpt_MRDDevelopmentAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "MRDDevelopmentAgreementsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MRD Development Agreements",
        "documentation": "MRD development agreements.",
        "label": "M R D Development Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_MRDRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "MRDRevenueMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MRD Revenue",
        "label": "M R D Revenue [Member]",
        "documentation": "MRD Revenue."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "auth_ref": [
      "r289",
      "r857",
      "r962",
      "r1017",
      "r1018"
     ]
    },
    "adpt_MarketBasedRestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "MarketBasedRestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market-Based Restricted Stock Units",
        "label": "Market Based Restricted Stock Units R S U [Member]",
        "documentation": "Market-Based Restricted Stock Units R S U."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Investments in Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r452",
      "r648",
      "r694",
      "r739",
      "r740",
      "r795",
      "r797",
      "r799",
      "r800",
      "r805",
      "r830",
      "r831",
      "r846",
      "r853",
      "r865",
      "r874",
      "r959",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "adpt_MedicareReimbursementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "MedicareReimbursementsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare Reimbursements",
        "label": "Medicare Reimbursements [Member]",
        "documentation": "Medicare Reimbursements."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_MedicareRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "MedicareRevenueMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare revenue.",
        "label": "Medicare Revenue [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_MicrosoftCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "MicrosoftCollaborationAgreementMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Microsoft collaboration agreement.",
        "label": "Microsoft Collaboration Agreement [Member]",
        "terseLabel": "Microsoft Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r452",
      "r648",
      "r694",
      "r739",
      "r740",
      "r795",
      "r797",
      "r799",
      "r800",
      "r805",
      "r830",
      "r831",
      "r846",
      "r853",
      "r865",
      "r874",
      "r959",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "adpt_MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum service consumption requirement amount under license agreement.",
        "label": "Minimum Service Consumption Requirement Amount Under License Agreement",
        "terseLabel": "Minimum service consumption requirement amount"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_MinimumServiceConsumptionRequirementTermUnderLicenseAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "MinimumServiceConsumptionRequirementTermUnderLicenseAgreement",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum service consumption requirement term under license agreement.",
        "label": "Minimum Service Consumption Requirement Term Under License Agreement",
        "terseLabel": "Minimum service consumption requirement term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest",
        "totalLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Total",
        "periodStartLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance",
        "periodEndLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r154",
      "r229",
      "r328",
      "r389",
      "r391",
      "r392",
      "r393",
      "r396",
      "r397",
      "r579",
      "r674",
      "r751"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Ownership Percentage, Parent",
        "terseLabel": "Ownership interest percentage",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "adpt_MonteCarloValuationModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "MonteCarloValuationModelMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monte Carlo Valuation Model",
        "label": "Monte Carlo Valuation Model [Member]",
        "documentation": "Monte Carlo Valuation Model."
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "auth_ref": [
      "r289",
      "r857",
      "r962",
      "r1017",
      "r1018"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r119"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Income (Loss)",
        "label": "Net Income (Loss)",
        "totalLabel": "Net loss attributable to Adaptive Biotechnologies Corporation",
        "verboseLabel": "Net loss attributable to Adaptive Biotechnologies Corporation",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r119",
      "r157",
      "r186",
      "r207",
      "r210",
      "r215",
      "r229",
      "r237",
      "r241",
      "r242",
      "r244",
      "r245",
      "r249",
      "r250",
      "r257",
      "r268",
      "r279",
      "r283",
      "r285",
      "r328",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r566",
      "r579",
      "r682",
      "r769",
      "r787",
      "r788",
      "r844",
      "r883",
      "r957"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Add: Net loss attributable to noncontrolling interest",
        "totalLabel": "Net Income (Loss) Attributable to Noncontrolling Interest, Total",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r147",
      "r207",
      "r210",
      "r249",
      "r250",
      "r681",
      "r918"
     ]
    },
    "adpt_NetOperatingLossCarryforwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "NetOperatingLossCarryforwardExpirationPeriod",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Loss Carryforward Expiration Period",
        "label": "Net Operating Loss Carryforward Expiration Period",
        "terseLabel": "Maturity period for NOLs carryovers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_NonCashInterestExpenseRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "NonCashInterestExpenseRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash interest expense recognized",
        "label": "Non Cash Interest Expense Recognized",
        "verboseLabel": "Noncash interest expense recognized"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_NonEmployeeDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "NonEmployeeDirectorsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-employee directors.",
        "label": "Non Employee Directors [Member]",
        "terseLabel": "Non Employee Directors"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_NonRefundableUpfrontPaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "NonRefundableUpfrontPaymentsReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable upfront payments received.",
        "label": "Non Refundable Upfront Payments Received",
        "terseLabel": "Non-refundable upfront payments received"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_NoncashInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "NoncashInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash interest expense.",
        "label": "Noncash Interest Expense",
        "terseLabel": "Noncash interest expense"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_NoncashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "NoncashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash lease expense.",
        "label": "Noncash Lease Expense",
        "terseLabel": "Noncash lease expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r421",
      "r926",
      "r927",
      "r928",
      "r1023"
     ]
    },
    "adpt_NonvestedMarketBasedRestrictedStockUnitsGrantedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "NonvestedMarketBasedRestrictedStockUnitsGrantedMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonvested Market Based Restricted Stock Units Granted [Member]",
        "documentation": "Nonvested market based restricted stock units granted.",
        "terseLabel": "Nonvested Market-based Restricted Stock Units Outstanding Granted"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_NonvestedMarketBasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "NonvestedMarketBasedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonvested Market-Based Restricted Stock Units",
        "label": "Nonvested Market Based Restricted Stock Units [Member]",
        "documentation": "Nonvested market-based restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_NonvestedRestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "NonvestedRestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonvested Restricted Stock Units",
        "label": "Nonvested Restricted Stock Units R S U [Member]",
        "documentation": "Nonvested Restricted Stock Units R S U."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_NonvestedStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "NonvestedStockOptionsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonvested Stock Options",
        "label": "Nonvested Stock Options [Member]",
        "documentation": "Nonvested Stock Options."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_NumberOfCommonStockVotingRights": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "NumberOfCommonStockVotingRights",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock voting rights.",
        "label": "Number Of Common Stock Voting Rights",
        "terseLabel": "Number of vote for each share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "adpt_NumberOfRevenuePerformanceObligation": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "NumberOfRevenuePerformanceObligation",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of revenue performance obligations",
        "label": "Number Of Revenue Performance Obligation",
        "documentation": "Number of revenue performance obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r279",
      "r283",
      "r285",
      "r844"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, impairment loss",
        "label": "Operating Lease, Impairment Loss",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities",
        "negatedLabel": "Less: Current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfReconcilesUndiscountedOperatingLeaseCashFlowsDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in measurement of lease liabilities, net of tenant improvement allowances received",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r606"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "adpt_OperatingLeaseVariableLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "OperatingLeaseVariableLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease variable lease expense.",
        "label": "Operating Lease Variable Lease Expense",
        "terseLabel": "Operating lease variable lease expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesSummaryOfOtherInformationRelatedToOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r871"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "U.S. federal NOLs",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "adpt_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiration Year",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "NOLs expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_OrbimedRoyaltyCreditOpportunitiesIvLpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "OrbimedRoyaltyCreditOpportunitiesIvLpMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OrbiMed Royalty &amp; Credit Opportunities IV, LP.",
        "label": "OrbiMed Royalty &amp; Credit Opportunities IV, LP [Member]",
        "verboseLabel": "OrbiMed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive (loss) income",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r13",
      "r146",
      "r208",
      "r211"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Change in unrealized gains and losses on investments",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r327"
     ]
    },
    "us-gaap_OtherInventoryNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherInventoryNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Inventory, Noncurrent",
        "terseLabel": "Long-term inventory",
        "documentation": "Carrying amount as of the balance sheet date of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle (such as inventory related to long-term contracts or program rights)."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other",
        "totalLabel": "Other Noncash Income (Expense), Total",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments",
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for (Proceeds from) Tenant Allowance",
        "negatedLabel": "Cash received for tenant improvement allowances",
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r115"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Restructuring",
        "terseLabel": "Restructuring costs paid",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r919"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of public offering costs, net",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "adpt_PercentageOfAnnualIncreasesInNumberOfShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "PercentageOfAnnualIncreasesInNumberOfShares",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of annual increases in number of shares.",
        "label": "Percentage Of Annual Increases In Number Of Shares",
        "terseLabel": "Percentage of annual increases in number of shares"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_PercentageOfCumulativePurchaserPayments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "PercentageOfCumulativePurchaserPayments",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of cumulative purchaser payments",
        "label": "Percentage of Cumulative Purchaser Payments",
        "verboseLabel": "Percentage of cumulative purchaser payments"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_PercentageOfRevenueInterestPayments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "PercentageOfRevenueInterestPayments",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue interest payments.",
        "label": "Percentage of Revenue Interest Payments",
        "verboseLabel": "Percentage of revenue interest payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989"
     ]
    },
    "adpt_PotentialRevenueInterestPaymentToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "PotentialRevenueInterestPaymentToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential revenue interest payment to be received.",
        "label": "Potential Revenue Interest Payment To Be Received",
        "verboseLabel": "Potential revenue interest payment to be received"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_PotentialRevenueInterestSecondPaymentToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "PotentialRevenueInterestSecondPaymentToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential revenue interest second payment to be received.",
        "label": "Potential Revenue Interest Second Payment To Be Received",
        "verboseLabel": "Potential revenue interest second payment to be received"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_PotentialRevenueInterestThirdPaymentToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "PotentialRevenueInterestThirdPaymentToBeReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential revenue interest third payment to be received.",
        "label": "Potential Revenue Interest Third Payment To Be Received",
        "verboseLabel": "Potential revenue interest third payment to be received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r406"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r749"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r406"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r749",
      "r767",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock investment",
        "terseLabel": "Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r669",
      "r872"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_ProceedsFromContributedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromContributedCapital",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Contributed Capital",
        "terseLabel": "Proceeds from initial capital contributions for Digital Biotechnologies, Inc.",
        "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from public offering of common stock, net of underwriting discounts and commissions",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "adpt_ProceedsFromLandlordReimbursements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ProceedsFromLandlordReimbursements",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from landlord reimbursements.",
        "label": "Proceeds From Landlord Reimbursements",
        "terseLabel": "Proceeds from landlord reimbursements"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from revenue interest purchase agreement, net of issuance costs.",
        "label": "Proceeds from Revenue Interest Purchase Agreement, Net of Issuance Costs",
        "terseLabel": "Proceeds from revenue interest purchase agreement, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of marketable securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from settlement of stock option exercised in prior periods.",
        "label": "Proceeds From Settlement Of Stock Option Exercised In Prior Periods",
        "terseLabel": "Proceeds from settlement of stock option exercised in prior periods"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r20"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r286",
      "r651",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r833",
      "r855",
      "r873",
      "r902",
      "r955",
      "r956",
      "r962",
      "r1017"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "auth_ref": [
      "r286",
      "r651",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r833",
      "r855",
      "r873",
      "r902",
      "r955",
      "r956",
      "r962",
      "r1017"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfComprehensiveLoss",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r207",
      "r210",
      "r222",
      "r229",
      "r237",
      "r249",
      "r250",
      "r268",
      "r279",
      "r283",
      "r285",
      "r328",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r536",
      "r539",
      "r540",
      "r566",
      "r579",
      "r663",
      "r680",
      "r718",
      "r769",
      "r787",
      "r788",
      "r844",
      "r869",
      "r870",
      "r884",
      "r918",
      "r957"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r171",
      "r175",
      "r176"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, at cost",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r191",
      "r678"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r665",
      "r678",
      "r872"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r171",
      "r175",
      "r676"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "adpt_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase agreement.",
        "label": "Purchase Agreement [Member]",
        "verboseLabel": "Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_PurchaseAgreementSecondPaymentDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "PurchaseAgreementSecondPaymentDate",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase agreement second payment date.",
        "label": "Purchase Agreement Second Payment Date",
        "verboseLabel": "Purchase agreement, second payment date"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_PurchaseAgreementThirdPaymentDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "PurchaseAgreementThirdPaymentDate",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase agreement third payment date.",
        "label": "Purchase Agreement Third Payment Date",
        "verboseLabel": "Purchase agreement, third payment date"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_PutOrCallOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "PutOrCallOptionMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Put or call option.",
        "label": "Put or Call Option [Member]",
        "verboseLabel": "Put/Call Options"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r445",
      "r452",
      "r484",
      "r485",
      "r486",
      "r624",
      "r648",
      "r694",
      "r739",
      "r740",
      "r795",
      "r797",
      "r799",
      "r800",
      "r805",
      "r830",
      "r831",
      "r846",
      "r853",
      "r865",
      "r874",
      "r877",
      "r953",
      "r959",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r445",
      "r452",
      "r484",
      "r485",
      "r486",
      "r624",
      "r648",
      "r694",
      "r739",
      "r740",
      "r795",
      "r797",
      "r799",
      "r800",
      "r805",
      "r830",
      "r831",
      "r846",
      "r853",
      "r865",
      "r874",
      "r877",
      "r953",
      "r959",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r936",
      "r937",
      "r938"
     ]
    },
    "adpt_RegulatoryMilestoneRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "RegulatoryMilestoneRevenueMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory Milestone Revenue",
        "label": "Regulatory Milestone Revenue [Member]",
        "documentation": "Regulatory Milestone Revenue."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_RegulatoryMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "RegulatoryMilestonesMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestones.",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r399",
      "r408",
      "r616",
      "r838",
      "r839"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r504",
      "r1014"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "adpt_ResearchAndDevelopmentInventoryReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ResearchAndDevelopmentInventoryReserve",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development inventory reserve",
        "label": "Research And Development Inventory Reserve",
        "documentation": "Research and development inventory reserve."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period"
       }
      }
     },
     "auth_ref": [
      "r184",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r264",
      "r333",
      "r334",
      "r525",
      "r560",
      "r564",
      "r565",
      "r566",
      "r598",
      "r614",
      "r615",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r708"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period"
       }
      }
     },
     "auth_ref": [
      "r184",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r264",
      "r333",
      "r334",
      "r525",
      "r560",
      "r564",
      "r565",
      "r566",
      "r598",
      "r614",
      "r615",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r708"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r912",
      "r922"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRestructuring"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "verboseLabel": "Restructuring",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r374",
      "r376",
      "r379",
      "r382"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restructuring and Related Cost, Expected Cost, Total",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Estimated aggregate restructuring costs recognized",
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r378",
      "r380",
      "r381"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Restructuring, reduction in workforce",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r134",
      "r673",
      "r701",
      "r706",
      "r715",
      "r750",
      "r872"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r234",
      "r235",
      "r236",
      "r238",
      "r248",
      "r250",
      "r332",
      "r338",
      "r493",
      "r494",
      "r495",
      "r524",
      "r525",
      "r546",
      "r549",
      "r550",
      "r553",
      "r564",
      "r697",
      "r699",
      "r719",
      "r1023"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "verboseLabel": "Revenue from collaboration agreement",
        "terseLabel": "Revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r278",
      "r281",
      "r282",
      "r286",
      "r287",
      "r289",
      "r440",
      "r441",
      "r651"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r832"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r444"
     ]
    },
    "adpt_RevenueInterestLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "RevenueInterestLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest liability.",
        "label": "Revenue Interest Liability",
        "verboseLabel": "Revenue interest liability at inception"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_RevenueInterestLiabilityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "RevenueInterestLiabilityNet",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue interest liability, net",
        "terseLabel": "Revenue interest liability, net, less current portion",
        "documentation": "Revenue interest liability, net",
        "label": "Revenue Interest Liability, Net",
        "totalLabel": "Total revenue interest liability, net at December 31, 2022"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest liability, net and related imputed interest.",
        "label": "Revenue Interest Liability, Net and Related Imputed Interest [Policy Text Block]",
        "terseLabel": "Revenue Interest Liability, Net and Related Imputed Interest"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_RevenueInterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "RevenueInterestPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Interest Paid",
        "label": "Revenue Interest Paid",
        "verboseLabel": "Revenue interest paid"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_RevenueInterestPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "RevenueInterestPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Interest Payable",
        "label": "Revenue Interest Payable",
        "verboseLabel": "Revenue interest payable",
        "negatedLabel": "Revenue interest payable"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_RevenueInterestPaymentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "RevenueInterestPaymentTerm",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest payment term.",
        "label": "Revenue Interest Payment Term",
        "verboseLabel": "Revenue interest payment term"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_RevenueInterestPurchaseAgreementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "RevenueInterestPurchaseAgreementTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest purchase agreement.",
        "label": "Revenue Interest Purchase Agreement [Text Block]",
        "verboseLabel": "Revenue Interest Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_RevenueRecognitionExpectedPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "RevenueRecognitionExpectedPeriod",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognition expected period.",
        "label": "Revenue Recognition Expected Period",
        "terseLabel": "Revenue recognition expected period"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue recognition milestone method expected milestone receivable.",
        "label": "Revenue Recognition Milestone Method Expected Milestone Receivable",
        "terseLabel": "Expected revenue through milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Deferred revenue, expected to be recognized",
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date",
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RevisionOfPriorPeriodAccountingStandardsUpdateAdjustmentMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Accounting Standards Update, Adjustment [Member]",
        "terseLabel": "Revision of Prior Period, Accounting Standards Update, Adjustment"
       }
      }
     },
     "auth_ref": [
      "r184",
      "r237",
      "r238",
      "r244",
      "r251",
      "r333",
      "r334",
      "r525",
      "r560",
      "r566",
      "r598",
      "r614",
      "r615",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "ROU assets obtained in exchange for operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r871"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_SalesAndMarketingExpensePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "SalesAndMarketingExpensePolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales and marketing expenses.",
        "label": "Sales And Marketing Expense Policy [Text Block]",
        "terseLabel": "Sales and Marketing Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r900"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "auth_ref": [
      "r453",
      "r930"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r453",
      "r898",
      "r930"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule of Available-for-Sale Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Available-for-sale Investments",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "adpt_ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ScheduleOfDeferredRevenueByRevenueClassificationTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of deferred revenue by revenue classification.",
        "label": "Schedule Of Deferred Revenue By Revenue Classification Table [Text Block]",
        "terseLabel": "Schedule of Deferred Revenue by Revenue Classification"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Effective Tax Rate of Provision for Income Taxes Differs from Federal Statutory Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Compensation Costs Related to Stock Options and RSUs Included on Consolidated Statements of Operations",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "adpt_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of estimated useful lives of property plant and equipment.",
        "label": "Schedule Of Estimated Useful Lives Of Property Plant And Equipment Table [Text Block]",
        "terseLabel": "Summary of Useful Lives Assigned to Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r570"
     ]
    },
    "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, off-Balance-Sheet Risks [Table]",
        "terseLabel": "Schedule Of Fair Value Off Balance Sheet Risks [Table]",
        "documentation": "Schedule detailing the information required and determined to be disclosed regarding the fair value of financial assets and financial liabilities, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r148"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsSubjectToAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r652"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of Intangible Assets Subject to Amortization",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule Of Goodwill [Table]",
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r848"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Components of Loss Before Provision for Income Taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesSummaryOfUsefulLivesAssignedToPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "adpt_ScheduleOfReservedSharesOfCommonStockTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ScheduleOfReservedSharesOfCommonStockTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of reserved shares of common stock.",
        "label": "Schedule Of Reserved Shares Of Common Stock Table [Text Block]",
        "terseLabel": "Summary of Reserved Shares of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of revenue interest liability, net activity.",
        "label": "Schedule of Revenue Interest Liability, Net Activity [Table Text Block]",
        "verboseLabel": "Schedule of Revenue Interest Liability, Net Activity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r457",
      "r459",
      "r460",
      "r461",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487"
     ]
    },
    "adpt_ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of share-based compensation, shares available for grant.",
        "label": "Schedule Of Share Based Compensation Shares Available For Grant Table [Text Block]",
        "terseLabel": "Summary of Changes in Shares Available for Grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity Under 2009 Plan and 2019 Plan",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r71"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Estimated Grant Date Fair Values of Stock Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r132",
      "r133",
      "r134",
      "r198",
      "r199",
      "r200",
      "r266",
      "r406",
      "r407",
      "r408",
      "r410",
      "r413",
      "r418",
      "r420",
      "r711",
      "r712",
      "r713",
      "r714",
      "r853",
      "r897",
      "r923"
     ]
    },
    "adpt_ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period",
        "label": "Schedule Of Unrecognized Share Based Compensation Expense And The Expected Weighted Average Remaining Recognition Period Table [Text Block]",
        "documentation": "Schedule of unrecognized share-based compensation expense and the expected weighted-average remaining recognition period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Unit Activity",
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Future Amortization Expense for Intangible Assets",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Concentrations of Risk Percentage",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r50",
      "r51",
      "r89",
      "r149"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r732",
      "r735",
      "r737",
      "r796",
      "r798",
      "r802",
      "r806",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r834",
      "r856",
      "r877",
      "r962",
      "r1017"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r287",
      "r845"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense",
        "terseLabel": "Sales and marketing",
        "totalLabel": "Selling and Marketing Expense, Total",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingAndMarketingExpenseMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense [Member]",
        "terseLabel": "Sales and Marketing",
        "documentation": "Primary financial statement caption encompassing selling and marketing expense."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "adpt_SequencingRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "SequencingRevenueMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sequencing revenue.",
        "label": "Sequencing Revenue [Member]",
        "terseLabel": "Sequencing Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_SeriesCConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "SeriesCConvertiblePreferredStockMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C convertible preferred stock.",
        "label": "Series C Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_SeriesFOneConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "SeriesFOneConvertiblePreferredStockMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series F one convertible preferred stock.",
        "label": "Series F One Convertible Preferred Stock [Member]",
        "terseLabel": "Series F-1 Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ServiceMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service [Member]",
        "terseLabel": "Service Revenue",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Equity Incentive Plan reserve increase effective January 1, 2023",
        "label": "Share Based Compensation Arrangement By Share Based Payement Equity Incentive Plan Reserve",
        "documentation": "Share Based Compensation Arrangement By Share Based Payement Equity Incentive Plan Reserve"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Restricted Stock Units Outstanding, Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted Stock Units Outstanding, Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Granted",
        "terseLabel": "Weighted-average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Restricted Stock Units Outstanding, Nonvested Outstanding, Ending Balance",
        "periodStartLabel": "Restricted Stock Units Outstanding, Nonvested Outstanding, Beginning Balance",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r472"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Stock Units Outstanding",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value per share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Ending Balance",
        "periodStartLabel": "Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Beginning Balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r472"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Restricted Stock Units Outstanding, Vested",
        "terseLabel": "Fair value of RSUs vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of RSUs vested",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseReserveSharesAvailableForGrant",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award increase reserve shares available for grant,",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Increase Reserve Shares Available For Grant",
        "terseLabel": "Shares Available for Grant, 2019 Equity Incentive Plan reserve increase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfCompensationCostsRelatedToStockOptionsAndRsusIncludedOnConsolidatedStatementsOfOperationsDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r457",
      "r459",
      "r460",
      "r461",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in share reserve",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized for issuance",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Shares available for grant at September 30, 2023",
        "periodStartLabel": "Shares available for grant at December 31, 2022",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock that may be earned under the award",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Earned Under The Award",
        "documentation": "Share based compensation arrangement by share based payment award number of shares earned under the award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Shares Subject to Outstanding Stock Options, Stock Options expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total",
        "negatedLabel": "Shares Subject to Outstanding Stock Options, Stock Options forfeited",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Stock Options forfeited or cancelled",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Shares Subject to Outstanding Stock Options, Stock Options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Fair value of common stock",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Stock Option outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodStartLabel": "Shares Subject to Outstanding Stock Options, Stock Options outstanding, Beginning Balance",
        "periodEndLabel": "Shares Subject to Outstanding Stock Options, Stock Options outstanding, Ending Balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r464"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Weighted Average Exercise Price per Share, Stock Options outstanding, Beginning Balance",
        "periodEndLabel": "Weighted Average Exercise Price per Share, Stock Options outstanding, Ending Balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r464"
     ]
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and exercisable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable",
        "terseLabel": "Shares Subject to Outstanding Stock Options, Stock Options vested and exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and exercisable intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Stock Options vested and exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and exercisable weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Stock Options vested and exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOutstandingNumber",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award outstanding number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Outstanding Number",
        "terseLabel": "Equity awards outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Requisite service period term",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Requisite Service Period Term",
        "documentation": "Share based compensation arrangement by share based payment award requisite service period term."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Stock Options Restricted Stock Units Granted And Maximum Market Based Restricted Stock Units Granted Eligible To Be Earned",
        "documentation": "Share based compensation arrangement by share based payment award, stock options restricted stock units granted and maximum market based restricted stock units granted eligible to be earned."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award vested and exercisable options outstanding weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Vested And Exercisable Options Outstanding Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life vested and exercisable stock options"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options and restricted stock units forfeited or expired",
        "documentation": "Share based compensation arrangement by share based payment awards forfeited, canceled or expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Awards Forfeited Canceled Or Expired"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardsGranted",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment awards granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Awards Granted",
        "negatedLabel": "Shares Available for Grant, Options and restricted stock units granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfUnrecognizedSharebasedCompensationExpenseAndTheRemainingWeightedaverageRecognitionPeriodDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "Award Type",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r460",
      "r461",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Stock Options exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Stock Options expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price per Share, Stock Options granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r462",
      "r481",
      "r482",
      "r483",
      "r484",
      "r487",
      "r496",
      "r497",
      "r498",
      "r499"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Option expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfEstimatedGrantDateFairValuesOfStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life stock options outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "adpt_SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance period term",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Performance Period Term",
        "documentation": "Sharebased compensation arrangement by sharebased payment award performance period term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_SignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "SignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_SignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "SignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesScheduleOfConcentrationsOfRiskPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r227"
     ]
    },
    "adpt_SpecificPatientsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "SpecificPatientsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureDeferredRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific patients.",
        "label": "Specific Patients [Member]",
        "terseLabel": "Specific Patients"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r198",
      "r199",
      "r200",
      "r229",
      "r255",
      "r256",
      "r258",
      "r260",
      "r266",
      "r267",
      "r328",
      "r389",
      "r391",
      "r392",
      "r393",
      "r396",
      "r397",
      "r406",
      "r407",
      "r410",
      "r413",
      "r420",
      "r579",
      "r711",
      "r712",
      "r713",
      "r714",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r749",
      "r770",
      "r789",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r897",
      "r923",
      "r931"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r33",
      "r183",
      "r213",
      "r214",
      "r215",
      "r234",
      "r235",
      "r236",
      "r238",
      "r248",
      "r250",
      "r265",
      "r332",
      "r338",
      "r421",
      "r493",
      "r494",
      "r495",
      "r524",
      "r525",
      "r546",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553",
      "r564",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r615",
      "r697",
      "r698",
      "r699",
      "r719",
      "r789"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r732",
      "r735",
      "r737",
      "r796",
      "r798",
      "r802",
      "r806",
      "r818",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r834",
      "r856",
      "r877",
      "r962",
      "r1017"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r265",
      "r651",
      "r709",
      "r730",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r749",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r768",
      "r771",
      "r772",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r789",
      "r878"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r453",
      "r898",
      "r899",
      "r930"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r265",
      "r651",
      "r709",
      "r730",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r749",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r768",
      "r771",
      "r772",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r789",
      "r878"
     ]
    },
    "adpt_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesCommonStockWarrantsExercised",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period, shares, common stock warrants exercised.",
        "label": "Stock Issued During Period Shares Common Stock Warrants Exercised",
        "verboseLabel": "Stock issued during period, common stock",
        "terseLabel": "Issuance of common stock upon exercise of common stock warrant, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock, Shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r32",
      "r66",
      "r134",
      "r401"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock upon public offering, after deducting underwriters' discounts and net offering costs paid by us, Shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r100",
      "r101",
      "r134",
      "r711",
      "r789",
      "r812"
     ]
    },
    "adpt_StockIssuedDuringPeriodSharesRestrictedStockAwardVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardVested",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares restricted stock award vested.",
        "label": "Stock Issued During Period Shares Restricted Stock Award Vested",
        "terseLabel": "Vesting of restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockOptionActivityUnder2009PlanAnd2019PlanDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock for cash upon exercise of stock options, Shares",
        "negatedLabel": "Shares Subject to Outstanding Stock Options, Stock Options exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r100",
      "r101",
      "r134",
      "r468"
     ]
    },
    "adpt_StockIssuedDuringPeriodValueCommonStockWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "StockIssuedDuringPeriodValueCommonStockWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period, value, common stock warrants exercised.",
        "label": "Stock Issued During Period Value Common Stock Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of common stock warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r33",
      "r134"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock upon public offering, after deducting underwriters' discounts and net offering costs paid by us",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r100",
      "r101",
      "r134",
      "r719",
      "r789",
      "r812",
      "r884"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock for cash upon exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r33",
      "r134"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total Adaptive Biotechnologies Corporation shareholders\u2019 equity",
        "periodStartLabel": "Stockholders' Equity Attributable to Parent, Beginning Balance",
        "periodEndLabel": "Stockholders' Equity Attributable to Parent, Ending Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r104",
      "r105",
      "r122",
      "r751",
      "r767",
      "r790",
      "r791",
      "r872",
      "r885",
      "r924",
      "r946",
      "r997",
      "r1023"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total shareholders\u2019 equity",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79",
      "r81",
      "r183",
      "r184",
      "r214",
      "r234",
      "r235",
      "r236",
      "r238",
      "r248",
      "r332",
      "r338",
      "r421",
      "r493",
      "r494",
      "r495",
      "r524",
      "r525",
      "r546",
      "r548",
      "r549",
      "r550",
      "r551",
      "r553",
      "r564",
      "r584",
      "r585",
      "r589",
      "r615",
      "r698",
      "r699",
      "r717",
      "r751",
      "r767",
      "r790",
      "r791",
      "r816",
      "r884",
      "r924",
      "r946",
      "r997",
      "r1023"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Shareholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r228",
      "r405",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r419",
      "r421",
      "r555",
      "r792",
      "r793",
      "r817"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r617"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r617"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r617"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Schedule of Change in Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r143",
      "r144"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "U.S. federal tax credits",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardLimitationsOnUse",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Limitations on Use",
        "terseLabel": "Tax credit carryforwards expiration year",
        "documentation": "Description of the limitation related to use of the tax credit carryforward."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Convertible preferred stock, Ending Balance",
        "periodStartLabel": "Convertible preferred stock, Beginning Balance",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r391",
      "r392",
      "r393",
      "r396",
      "r397",
      "r500",
      "r671"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Convertible preferred stock, Ending Balance, Shares",
        "periodStartLabel": "Convertible preferred stock, Beginning Balance, Shares",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "adpt_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, stock issued during period, shares, new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Series E-1 convertible preferred stock for cash upon exercise of Series E-1 convertible preferred stock options at fair value",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "adpt_TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "TemporaryEquityValueChangeInRedemptionValueForVestedConvertiblePreferredStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity value change in redemption value for vested convertible preferred stock options.",
        "label": "Temporary Equity Value Change In Redemption Value For Vested Convertible Preferred Stock Options",
        "terseLabel": "Change in redemption value for vested Series E-1 convertible preferred stock options"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_TenantImprovementAllowanceAndCommenced": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "TenantImprovementAllowanceAndCommenced",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvement allowance and commenced.",
        "label": "Tenant Improvement Allowance And Commenced",
        "terseLabel": "Tenant improvement allowance and commenced"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_TenantImprovementCostsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "TenantImprovementCostsIncurred",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvement costs incurred.",
        "label": "Tenant Improvement Costs Incurred",
        "terseLabel": "Tenant improvement costs incurred"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_TenantImprovementCostsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "TenantImprovementCostsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvement costs receivable.",
        "label": "Tenant Improvement Costs Receivable",
        "verboseLabel": "Tenant improvement costs receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TenantImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TenantImprovements",
     "crdr": "debit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tenant Improvements",
        "terseLabel": "Tenant improvement allowance",
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": [
      "r934",
      "r1005"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r403",
      "r418",
      "r554",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r683",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r942",
      "r943",
      "r944",
      "r945"
     ]
    },
    "adpt_TwoThousandAndNineEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "TwoThousandAndNineEquityIncentivePlanMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and nine equity incentive plan.",
        "label": "Two Thousand And Nine Equity Incentive Plan [Member]",
        "terseLabel": "2009 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_TwoThousandAndNineteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "TwoThousandAndNineteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfChangesInSharesAvailableForGrantDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureShareholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and nineteen equity incentive plan.",
        "label": "Two Thousand And Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r237",
      "r238",
      "r239",
      "r240",
      "r251",
      "r292",
      "r293",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r372",
      "r493",
      "r494",
      "r495",
      "r522",
      "r523",
      "r524",
      "r525",
      "r532",
      "r533",
      "r534",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r577",
      "r578",
      "r580",
      "r581",
      "r582",
      "r583",
      "r591",
      "r592",
      "r595",
      "r596",
      "r597",
      "r598",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r653",
      "r654",
      "r655",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementScheduleOfRevenueInterestLiabilityNetActivityDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregatedRevenueDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureMicrosoftCollaborationAgreementAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government Debt Securities",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r862",
      "r1015"
     ]
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasuryAndGovernmentMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureInvestmentsScheduleOfGrossUnrealizedHoldingLossesAndFairValuesForInvestmentsInUnrealizedLossPositionDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureInvestmentsScheduleOfAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Government Treasury and Agency Securities",
        "label": "US Treasury and Government [Member]",
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r862",
      "r1019"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Government Treasury Securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r862",
      "r864",
      "r1015"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r512"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest or penalties related to uncertain tax positions",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangeInUnrecognizedTaxBenefitsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions",
        "verboseLabel": "Uncertain tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "adpt_UnvestedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "UnvestedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersWeightedAverageCommonStockEquivalentsWereExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested restricted stock units.",
        "label": "Unvested Restricted Stock Units [Member]",
        "terseLabel": "Nonvested Restricted Stock Units Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "adpt_UpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.adaptivebiotech.com/20231231",
     "localname": "UpfrontPaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/DisclosureRevenueInterestPurchaseAgreementAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment received.",
        "label": "Upfront Payment Received",
        "verboseLabel": "Upfront payment received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r54",
      "r167",
      "r169",
      "r172",
      "r173"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ValuationTechniqueOptionPricingModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueOptionPricingModelMember",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Technique, Option Pricing Model [Member]",
        "terseLabel": "Option Valuation Model",
        "documentation": "Valuation technique calculating price of option."
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "stpr_WA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "WA",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WASHINGTON",
        "terseLabel": "Seattle, Washington"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r260"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToAdaptiveBiotechnologiesCorporationCommonShareholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonShareholdersDetails",
      "http://www.adaptivebiotech.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r260"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "835",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482914/835-10-05-3"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-8"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "44",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-44"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-20/tableOfContent"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//420/tableOfContent"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//705/tableOfContent"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482190/360-10-35-3"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479365/842-20-25-6"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>107
<FILENAME>0000950170-24-023095-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-023095-xbrl.zip
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M& >I.L;-!OUK04>(IG;+=@-H\;"CENU/5?OD9UP9H+'CR2C_GA.\8I3W\@=
MQ'E.UY?V<(.. 2SB&4^3.-YM]G/SH8IYJ<^7]7#H0SVEPYMU^>S"W)]=MM G
M'1Q8K-/8-^-70&P_X^X3D-:4+=ZS>+;8L736E'' X6==3)_,/\\[>7:.2BXG
M&AVS4])*()4,O%%$1:R@A81@/'>!.I%"WX@&]VX/"66Z8?CQ]VI4'4^.U[Q%
M_.9;Q%>W18Q;ET4"_(,<3P;.B&46QI)I]M0D>&3[MD7S<[W]T3<)#_=TJ^9?
MOP8F6)_FW,&#W4Z$WO9 +P0W".RW(*.6#O/[C_7[HWK2^E$"]OX6F,@XYQ%*
M]/$IB!^<Y8>,OUL%4WF/JB/*.M#AJC3QPZ6!O*U'\YF_JIH<QW73/DJNHJ0.
MSD1#D@3%23KNB=4R@7;'G+=!!>M,7TEV 5BF!()@!51OU"O.D3 J'/6H(^ U
M;R&[^1:RU6UA2LD'&Q/Q0GHB5=8 S7,AP&U@R1T+7HH'OH5P'''.#<AZ4!9W
M8/: L,:KW\VIJ7)\R1F;/_F6#<J91^%$(3FA!<45$ L1Q;=E0=$B/7.]A7NH
M$7;0ZCW \E'US\DRN_X=I_G2-\-ZT>SW.N7AX^24WE/-K2*%IPAJL*3$F@*;
MJG@ ],Z8B;&ON_BHA'MOSG6RAE&)KRN4HQKGD04[8J*6@N42A"I]I8B-&G=/
MTMI2*571@NBL'>@(P%"\C)$4PV)267 T"/:4:*XTM?UR^CES05D^ 4&]:/10
MCK61,AI-'2G49B*STL0K$XCC209EF?&,]G6'WOBJZ8RXOYQVQK"70]]>P%)_
M[+]OLF\GS>E^CI.F&E?Y2ZK-MW3_>]='QUK>-!EPPRB>GA_(HO%2TW8/Q]0
MR%LKM?#548L5V?DB,RDV4: 69HEUH$"%7$26++'B>PONIA;=!0;_K8X=^SV_
M37NYS;Z)1W#>7P%?'M;=87[]Z03>]CA9-&>T>(50W5A&I!62A!0<231$68)W
MS/8.Z7U!O.[EP\G0C^OF]/=J"*I3O3*Y?A- \?O>J[L1Z?=C]M-)L&(SB'1F
M).! S8EE @2&IS("O40I>F>976@&\(94#2>(O<_DP>M/<3A).;UIZN.I'/?3
MR[/7OAD!<V[?Y6;_R#<H9BY]P3EDMS"__)='\ACO3L;(;]-:N'P/^$=V1AN
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M*I.+D$SIOFW<-Z6  *;X:_TA-Z-51$YL?/C[(;(Y5\(;(8GA00)L8R ;:,D
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MXV4*WL3>>L_?WPW^-T5,W.C-]^\;L"; + 4/#+1ECHZ>,J'#LG&69"ZSY<
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MM32(WJ5FN .O@]X[1Z^2! PW615$"\X263(6=<N>,)&=L+I(:WI' IOL'/=
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MOWE3-SGZ+UIX;WP"KC.HO)N 'NS;?#=!;Y)@C0B^DGOV ,H$!6TR,H9V?YT
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M\$-#%%\=A+0!%=>X")@LX?^:\*Z^MHX A45,)!HA0O&%NP<O>>X%5*PI&4H
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M-+UDL_E/U(%'A[ME=S)&2)+@PV4(>WOTI5#"7X')8,#A [&=2B53#($38P!
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M6FLD T@W/R2S79F$"]7JFD6*\0&:MN('BXB\)^3 )5(#8*?,*I=U<]E;K25
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MJ'W?-FI>N> Y<F;SKIQ&,#7EL- *N,#H:U%"'<\!Y$/I=76AA[&I?0':EUF
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M8W<Z>AY=^4'4D"R"OL57.#A4H9D#S @'JB/ P=3;4N#S+&M#]T^V(G4E4GI
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MFVC5U=,%$4_L].B;'E\JP/+EP:%ZT[*A$!J4:9QG-4;2M-7T_2CFY[#KG"\
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M>^NW430ZQ'I5B"97& KPF7&[*!<7BH&Y135E9_?"3-WKZ!M@(^HY,4Y^K&[
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M\;?=L8-]0Y,OJ*')3DI [QV^>/QXJWL(ZV@6L9]ZMFF%(<BC_MF5,8>+_.H
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M\N+HR>CP^3=JCQR.'C]Y/GK\^,4X.;G5IZ4^<=ZY#/N=MR*C 6-4(@!D@?5
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M/S$7IOM$O91H5XR2[SL<WJ/D!/TK95I2RO/I@BW6J:2!O7B;X8"O<F13650
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MLB+/KO5D:F3"&:MT7)'\AE6&X@77$#,8NE[*G;5)F!U6L\'?.W%A8/12,%Q
M%,.!$_%PE0\87K:HAU'@O,(V:WJ+!X9D$3[1"9S,GG":DT'/ R6J2#4NLY8&
MC+B4'9+MH>H4O16ZMH$78T+"&/<_LD IP%V^L;/]IHNY9K3PU#".@>0+'%D!
MCM]J&#HB@5(':E;1TK'P<[&V=V:N3XUKTNI<C;B,J,^8%7#+*71.D<\TZ?W
MQ6QXV'BQ:\$[ZY,</,ZVJ/PMS-MR.,75"W9$ZO'I53&B\%F]=\WN9MD':RA&
MP,82-D;SL>-4C0E#P/V$$IJ#:;K"]8.SV=\S3BZ,.)>*WC)*J/?S*.Q(^X^2
M+-?P0F'D\MSR6IK7!T%;A0.ZU2AAKS\Q16%< ;3#FGFVNI>7R.&D)H>",3_
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MI6\8QSR:(E6:YI\[31\]LW<O$AFNO:!.5]1H8#"X7M+'._**+/%M $76YAB
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M!73PTE=!U9[TULK:3WE%93,']>&((9WGC*G9[\^[^'0*I:=;4A? +' 6AB.
M%Y^FL?SVF1('TJX!0,U(.YNP2&^,;2-B.^7+&@VH^%J_;&8G.G"'@\=OCF:(
MU!S+-J=*T6?'>,M_I"0!;&%Q\)6W?5O \YKLFMB[[XE.;]4 <@]">'"CH@&G
M3G\H5P5:*,>GEF_/[O WF#A= K3/7)K)$G.9J"5FE/%ZZ1F(6;Q]^B/M35,(
M%@L" KH! 979EKH$(]($7SG>!'V8"Z.]0_GL91[<L1%:S;.9)CDD^_8I0S1\
M!6=*M([&T*(IAM/7Q,&76;0B[B5C"R2(N#3&K:OA(RY*]+3 !4MCP3F31B/K
M70^-8Z_[?V\] TS$6.(-U 'R5X&LS;3.&:T:ENSTA>_A*I-+H[ZV+1VLQ")>
M0R=,OIM=>U#-#\SKW_#XT/I'Q#YX>=P T2:QWCS9!Y:"CSC,_T9_,)]^3'ON
M@$4>4ML9%@*6G6*2JTW+P-Y:'M"FCTQIZJXH=)JE<BO*R=F!P@4P8Z?+G?'F
M&(T^;M'ZO2V':[\W"CZ9R1<O]D-)C_TF7WKFFXAYV29J2-ZK;'?X:;@EO&GS
M*3O8A6K4\$KK=9$B$/UV4<VRY+S1G]YD9=FLBVLQ8-)HD?BA^(BJEC_L;8 [
MJ8C@CI*+F9;0"#J5O.WC6 7?LEL]UB!L;_ EU#S4JIT;V;8QB6W$4M0^@O,U
MN:&B8>@!Q1A&WW] 5??<V9CXJ'1J%NKP"6S!B*W4,;ZYY5DWCCPJ*NK4XG-G
M.??&'.P/DF]0M=PP ;-@X4YLXFZ\;2_K=^*/SK<'X'  S$%K998<V !<Q6T4
M(1D$Y1BXHM?6\WS@7O7#V(FJ;3EO1L/$7TSIJ:ZG[+>1M0>PSN4PD,CRB>J<
MV<@7[VC+R^O*P#>#@?4&-=H<"K<L W5V^[:XI L5L<I&QJ3=^WS-45R8:7B!
M*1AC';3=*J-6<@@T_8_RY5#W:"/LX:F?&YYZN(>G[MN@?W;F\;-W6SG5[N5@
M'_!A[*B8X" M<A :X?A!S]@/@%\@)A)7V8)JM<Y<*!E5LX[#2<E=L>Q,L<'6
M&O%'#>$H+VA6#F@=/<='8)$+=:8]5\] HL94 /#;071/Y8ADF;<9DB1Q&+!-
MP194\_,<IB9SUH:1O;EXFK*' )SK.WJ/'"V9L3FRK!PF"7.%L&J+.)8U2+\X
M]"K)<2WPC3Q,E$;T= N!+"UJ S)@MW)CT3+ZKK2I#T@B^>+K-"\TL49V2GC)
M$6&LFA68/O#:S3UK4K%>KA95/NN5L<5N,)C7'-.HIV-S3@69I6!G*![@,DO;
M%C&!.,84YNCA;KQS0WN('8G0AMBP8I?5"H-N"9R"6Y]=Y8T!>9!M=;E[D3>/
M1_1I<VQCF).:,(EV%!O9615FCS,M9@@[?=>$)(SGLD?P\7UN'&#<1H_PJE^R
M6NPI//O$LKC)JRRE+9#-KH O.WT' *"G\S_!%P:&D5].7IV?X9>AU/)G7_GH
M_SA2<ESZ<>ZK.-"8UA5KTH>J^P0Z(/9Z@T68P*/69(%,DC2PEBT7%[8&V*!N
MF#9&3P-^=%D!$L^G4+$%S/NLAGD$*M</V@_4](RF_>G,R\S[KY'7-@UZAMVX
MKDHHV9_-&<Q5M>"R4!I. P 5WF_XC*",Q-O5QRC.D/DJ94IKM7L85R"BU5 .
M:\X/W86FZ1RE49K$3?)Z*78G6MZMX&,]5A!/TKX*7DFJR)A6Y*W3:N4Y$'I/
M'R?GK*)CCTR+"]\L,FH3\L3)3RDIKI=]N="$/E&-F%._<T:D<G#3K V)7$M8
MBQAHS&]*Q$8O<\&9\>$T:VY$C;E!^QO&,:LR'3[>.?)SK4I[BA:DY%S4@W37
M.8IW07!$CCC-/)Z4-T36^?]G[_V;W3:N;-&OPIJ:6]>IHLZ5Y-BQDWI3I4AV
MXDD<:23-N-Y?MT 2/,0(!#@ <8Z93_]ZK;UW]VX0/)(3RSK/!_\DUB$)-!K=
MN_>/M=<B&V>TWF&-0"J)71-<%BS8RFK.RH8CNO0#V$D$TN",@OAHO3^2 2+@
MFSB>%M=10=D?U+!&1W!I5"*]W!VZ,NK(D=W-F*)9.R"4I*V1$9TYB'W"[PRS
M^0I DW4(]]^ )<9RQ'_LF.#^6^MVY5_#Q,[^]/T\UJD2JKE.P(A2V;776J4U
M$:_5^0(<CM4$2K)G+)90%+ZI-@)IT*RL(*5V6EQ,WP^'TS&KC+*7:^D8!3S:
MBTJCR*O%1>7P[FJLM8#Y76.D=:_:8!I6J7X!XOZAB7^"10P_??+UUU]&O^+/
MW[UZEM/B9U=.3_LV'4&P4]^$&6WWRL\9^;KU=WJCIX\??^UN]/:;YW_.821$
MI$P697'5/U.5X R,\N<_1S"*E:/.BM+)#\L!DV$.28"JA'X'V=$J3:2;.@Q"
M[Z3?#C<X?YN.><WD*()GKSQ6=EC*SPBQ4?B @M?$(]?;4$>58=R1J#^[M+Z,
M*GXQ 8W[O@WGT-')1[S==24?J $TJ!91*'O<MGED1(A^JIBMU>Z.<^RQ)N93
M?5\G&TADH;+'N2^KEZM(7AI?\^_CU&9L>'&.QPB?^,%*K&GCK:EG)GZX=NNM
M6Z]^^IS-0KBG8L!8BUH['B]F6S'G:YI+5Q?CU-)=>GKR^',S/DQ?T\=1K82^
MI&\()77=#QV.-8OA&V<]F=W@<M1HBW4BX2S&3KEK)PK(0,A?6%K.'V&1/4->
M+"YE1%9Y$P&5$+4U"70O0(9>BF;""G3G8,@(QGU44DHG)V"TMY0,AKZDNZXI
MZ+W)O9/LW%GW(:@OKH>BBX^*'EPYH@I1A8%S>!W]&,U%5"9J<N=3\@V&UT,$
M4=<VFI)B?Y8B::A$FWV*W!5")S$1T]6;3#<YLZ+9_=]C+SS*Z=DBLZ\G09#S
M!Z=%.$NDT(^+%.0(H86+ZY+1E]X$#"$-[UQN[IX>MTW8@U5NJ@(1 _ZA%].N
M$-5S):CAB\>/W:WO4\GG 9E9.<F2+,L8/BXU/F+=(Y6>U?G"8G-HGJ5%]^3T
M/RI9I34>NLWA;:T*/3$H*TZ"FL.F*M;.N]E(8G?<5NFN*)*0LALI..'\(+_%
MID_OI=U;^ >B]-8F^! G=7>@I;R9E^BG09!)O?B+SXK?6"A@T>K;K@B1__-V
M;^\]4\!ZZQ2P"*H6#OW@V]&-Y<&EQ0+U'R?\XV(BBG$:8;;JL\;'LV&Y(:60
M8!M.(+L"E<^0;0MC$*V*\L#E",$'%@= 9-]KUF,Z0!-;32YE">3BJ:M]0.<_
M81JV39V9YR)9-B<X0=8" ,9HD',Y LL;'J*3'0(HCY;W%1V)7;P6J10X&L))
MQ>H(>VG+L]OSU8:WIHH<;Y\C0\K>P_.!\8W%MZ2*.*E[N,##6@^/GUF"D> %
MZ?WZDCW6-^88W*"JK]3J,NOYC!T%[B81'5:V:<N[WBMDFU+THD$F%-<YQ[$*
M J%;82'>JZ*[S[2(QOWB9JA1(UIICU18>C6$*:X9Q#!:D7X<<0I1^!%B%FU:
M'C7SR,N,F; L7-E.L^"&L>\U>:GYZH&#3G*X?%'GU+?,-V .'G 8XWI=EM'#
MZQ.4.4O!3$?G4PZ7]+N>[>>KQ9MV'Y/;9[=AJ]7YU:;-W@4,OQR>GZ6P(K5.
M,N,@R=]L.<AP>C\@2;VTVR-P]!6 L@*C$\>3+C+F*;P[^KGA(D!\Q,XSN /"
MMH#'#!&,$MXM!4HORWY=F+&Q/1"^%.(S2TRG(P$:4ZR@\&Q@I+:MAQ]C)\+T
M#'%B)3*P EGB2DHWC99A5+3$T%T-4D'V)\L(A?]Z 0OWS-0($R(6]04Q3)JB
MY:D'&9IVOPHN6L:]ZG]G7W\M<2E^1>MHZ97-6:*"%\!&*8(3YNY&G9^TL%DQ
M$M>1CS$5IG"Z*FL]Y/>R %O+,R\J@[&A"368XA6PP7\:"JE^O1K"'FK#$ZS;
M<-Q>-%B]+#-*1G8>6K<<,79KHZ[1(..-NT4WP2.=@=RL%Q.F^3K&0J:HMBG#
M;J^3-)%)G:-.\FVPD6T7<U^]^#AC0SECSSXV]NSIC#V;A;(_;G]K.B=D^Z)T
M(N!8?ZR,$M@+KU/1-NK]\@@18YN:S:\[T5UD\1-9N*J9=/!D#.IP\'8%W.0$
M,4IRR\NH02"GU[%DMTY48_;1TM7B94/;7Z2#GK>7[VM,K;WT1M&PC3II^'/X
M;]96<-GL9+'@RH*O/^F/?*'F;^"T[=5 'S4&]$?266.A>R-T(N+QCZIY>,#/
MRJOKJ[-#=^K>[D2T8E(Q(A;2P$XA9'R7TD)AH5R$U,#_AUSE4)?.1;%JA'D6
M!'D0<!"1'?I0I$IT$B$)"!?.XN"&HPV1/F X=@7U4-%[#"\W++62,E.D:<(Z
M"L^*^7JK>4JV++$^%6%58 ^^A_F0!UBZ_Y. ",5??)5,B"-=2DQEJ1PG[UD9
M.>)2]K7\AQ>N(>WP =-IZ9P_O7CUVA5GT>=77J-4&+%PW(]]>9S@2Y2<0%V[
M/L(/J<)O?=+< YNB'$2L53^#48ZR$-\\2^ V/F<8O P-C2T:@:*<6FO;'JU\
MF*W@ L6FP%A$BE7Y-!I2Y]6JVRM.-:1SZ>X[IUHDP<52BC(%.76&4MAGB<*B
MPRYG!Q-K\?A3RA\E:+TT0_+W1-#WS3,)CYI&)SM&1VS2S)3)/"U+)*W4"T9N
MGUPJFNA$_8J9]549;'?5=GR<J*=./)+HV!?^R4X)3GPQ4:=%+>P3F_ND.\_$
M4F,U'Y_S3G/@7CM8'/81 <9D5*L,E%^0@?(K8PY.)L22<%VY4\U>ETZ"TF\A
MDJ6,B+-7"-XFHG OK>IQ7"Q'37!FVJ%;DVN4[=7HK@WN2'LJ-?XJ#1 6SRSL
MUS;L*K@0G<PG[]F&56UI4=*[QI=\'P^Q7[^A_3XU8A*STUE(#7H#9A^P7>C^
MW.4E2Y#?:])+L!V2N=J4=6S<SJQCM,U8X6CQ%DF3WHU#C:K\)/G' JSLXNX+
M6\HADU$#:$B$\I>PRC:MY"O>A&O]O>RDWUD-J& B8YN=%*4D"T;2ISN>-PY^
M7K:?*K0#8J-%SZ3QM5(D7L]U)."G?6O-78X]<1>F8,%?U^TJ_% 3E5F%*F(I
M+,B*(&E6!1"$06HS7)Y\*+<1M(#V4*9GD<"*Y*5]OBLH(?6_^\6S[YC>F[WK
M,3!VJ:A8O,9OP_8-XUY\VQ6#@,Z?K?!J9ASLO=ZY5J;UN\[(";?Q519\E4P1
MY(!!)0UFGIDLQF=<>\Y;6IW2I6T!)11NW0(]6@S!N>S."@//OW]C9 OPK",$
M]L]_?I,?-R^WVTHZ)I3V*SBG%KR8U__RNS^]%X/Z[\@(KY/DV(N7_YXA9!T^
MB+]^%MYK<+90G-K2379!2/CMTC&VIH=-O$C!6/U0&F?DF$5PJUMKZGW,1]Y]
MV#B+9R'&>/27:OUN5:S?T2H""6"+Y]E?$ES9=*#[:?#;NX:)2]M.55V#T?PD
M,9G0U!0G_G_/A@WENV.^+BQ("I;NAT99147-EU6X5LG(CT/79%7)X'F578>X
M.?Q5^C9#@+$K>MX%-%W\#^;F]69%^'YS;>7-H]#&XB>E_(!W$T(3L+S"K77X
M)FALN(@R#*#:KX:N9\0ECE_AM@8*3*#U-$[#J\7S$ $=M6656TISC 6/\X9N
MA@Q18G3L*(%4B,<07@>0>/2VFXSREKZ+^V75"W]J<(,[M"N=SUELR+1T; Z:
M)0FCH1[0$7===!MR;M(U+_7=F^75WL[@[A^K/8NL,K:4''&CDVAT4X:'CH4Z
M77!^#42L;]%+UG35M<4&"7=K#%+.,Y7?#=/"Q8C+W13U4'H[?%UML7*17$9D
MT#/$14OOL2O8R2!,&GZ8O8.2 4!2]+NEP$AJ+MYM"5-_6U1HZQ.(R2/[P1*\
M=N'/N^H04_E124TK['&\))7KE1T*:!/"<+3MD$]RM7BMA)$Q*(_KH9=YB>5T
M>I**6HW:[22;K9JF70_:C[@*9XMZMOZ9O?GW2S_LQ?X(NA">5=_]*9)IL<=1
M G/7$J:ODQ)VNZ);@=PVH?T)'T@?976-<^!UZAU1.8<E-L&^/"ZE2Z_H"41^
M3[\"F4<MY70$SIL_EL[QJ"CL2/HXO;)4#4LC[8P)TIA,2FD<@=OJZ+JVK;'1
M/VQLZVM*Y(B"7U$3\=2D]WK'+1#CUI*7Y,:2_)FI(>>#ER=<<3/B9;$:(RDP
M<!ZQA+$<OWWY18EE1P/5D@4PF,9'J],C_#]HJL6\;,(.!!EO&0V"!XJ<W?Q5
MK+;#)F!\8Z0JT 2*P")N0_8U\%15W]*F+E/Q7C6S[^2M*7\,E^@EU@XQ?&*?
MU2S<9=O7CU-F#GM*LFGW1EU(/P;<[C"UBBE#&4=@<XOM<!QBTD#8E%-KET^7
M%#B>W]GQW,OQ?)8D84:2R4B80XHV^L2GG5.)-"NLSV[S"--QDC/*F\HDCB$-
M$J607QFTPXX2JF:%'P.E?H;[P]M5?_"Z ^M2.@@<IR9IE&Y!#%&7J[J]51ZQ
M/HS\:"<C0<5Z[I_,R9UZQFB6\:;I6:=1)9 C\I[;,+\\Z>F7#C4NZFYC)Y<^
M2N2[YT+[EK]]+DAG'US/;NPO7-FYN/%UES#'W:CQC^A&^U ,I>88)_G"SL,9
M9]W"HI_P@8\?-*R].D:LG!37!6PQ=Z4DT\.@P..:K*N(:4CRE#WX8 4 C*DP
MX/,J^TAA^-A)=SEW\;31V\*!EYJ(DMOA#TNA32-=YMC]E>ITH3WJQGD?_LT!
M"-0>OS[?;6);WSM3-(,Q[!!"S]YLN<45 DXVGVH<0V!:(U-X9 VO-LG]Z4XQ
MMP:-0[6A@ PRT9<7Q<B (>&!12XE/;9S@\1!%GKD#"CVFU?"KPTLJ'3WR'S,
M\+2/#4_[?(:GS?"TCW 2)B_7+&=D1CYF'Z/DJGW:HUQ@SU,G 93"#6XJ=@B&
MW^@A\LA.#L..P14OM<TU'B_;LFZ;DZ;\V+5 \BS4[\)1*E$'_.+N6H%1(W-O
MPD_C@4O<,F)MSX8)6\^V;@P9MU^:*RK$7>U*>5X9>Z.)$0"VZ\3H&=S?8\+U
M3PX<IXZ(5LEX;OF_[O&-@S,F+82]<R-&G^R>2FT3+R#/LR6X6,_N+?FNB1ZY
MB;/%7J#&HL93JGDKL>YMV45]FA\9.FU&2GF">-<#*A(%!1?#Y&R$QT>C!3K;
M<HQA9M63L/C(1PSQA,4-[(A=*L&1^D@*9G A&%&.!LG0JZ919;3VM-I(I+3R
M6MB5Q(3^T#.JC23$](,Z-BX15,+YB)F.43(OGY'E.#R!!QB52W1*-4VNJ85W
MY<F!&,*ZRR2*<RY]N8"!(G*ECS<(5\Z;;FPZ8AIG4+^B;*Z+Z\09[O:Q*5YJ
MN+DAL162LA)XIHA3Z_,&G?>8GJX\#$>#DH&JZAYY*0_(M$?*MMC:$CQD&CO+
M ZCG*OCCF!B!W)5TPF]'ICDOPXCUU0Z5Y_B"E$"M") \[TNY_?)'YITDR[XH
MPF[='X[:!"F?H2N$0%CA'M^4-H8LL2X[]&A6P)N6L4#66:ZAR@,^.W\L&YI6
MN.:+?#9I(6;6IX@NI^_[K%PW:?)&R2.)?)C3D>Q:_\$SBY\*!QY3SNLP5QKK
MD!" '.>'!0!]P3!60OW/Q]D7[S2W'#_3RX57L06;P]$8Z5SV(X[Q$K)N$XX(
M8O^@YY!2,:,%-GJ/F.UQ7/3H,*S"&2E1&U_M)WVGLV7[9+2PHT1:S(LD\T4<
M;4R+M-&'@-5[7Q%2\R%]RI3TYYF2]Z8"=9F3F>5<$^B\P(<'"Y[WXAB\Y'/*
MJ[-'+J@_4$0CER<:5MSF12)@ 0JUWH[SDLYA*5 9R"I$P> &CQ.'NDB;\3%%
M>VGJ N%!55I:6 !E>F1"1MT;_K91L%5,I \K0(*YDPH27V9X:RB_A8FKHMJ2
MO=9V[(#9#A<# J97R;W]ATXQ\1OHE9;Z@;C0DMGK2X T8K=VT:O,!5\5#E4F
MM5PSB4@GJAAUD2X-"P3FE*)6O[V8JC3YG [PN"U%G6X+*1K!TI/&$RFEJ\4/
M.VE,U>>>SO5IW7<SN7)@6"U!Z6FOPG+$N<"9!*76D1M2P<4#F;7V!4*)$(HD
MUJ%\UI>+0SV8'L AJ]FP#]2M">WL/]O)_865XGD(]@AAY";HG%_DC&/B)O"U
M79W?()D()?BL@^MCW4Q,6[D2H&NZ'A]&,GZWX.AIL?Q U1N[2ZJJG6]AS=]F
MCK\K.[+2$HN/B/8T;1M3TRS"L'((M'TVO?/A]*F;_ WVY37LS OWQE%;](JZ
MO6Z'?FPKS[=O8;0/+,Q/]-2GY@(Q1[R+L*FFL'BRE*=A=UB2X:=P+.\ZL>85
M]@D>_66S>+D^MCAXK$%#<@]O8I[I/_ORT8O@TC*M\2K)5/-@?Q6<VA9+X.6A
M I,ZL"%TSO'FWT85:UCL5T9&3:;+=K\?&DG_19;+)U]%M->;_WSUZN7KMYXY
MF_4=7?!B+=V7K$(O9]0WM39M!L_! &7$4,?A3=WSF[^\?I8PC4JD[43$(4)8
MUX]L9?MJN$51<5[(525BK6>0%G:=<!0[G,W+B9*?9443B7F:RJAJ?;7 B%.?
MP;@?=6#M$+F[@Q*Q"*EA)\0W0(]K'XV26D>"@?2;J\5SH0%W?V..!D5_<66(
MXXI(=*/)[S/Z#:O#9R"<Q9N4Z*D5SN,F,MJ=$9TA.U//<7N'H^!^7-%-BH4G
MAS0CEO;"Y$]-L;CL4Z]GZ1F\11XB=C'S2D1FQ$T$J.E&-U'2UIYX9@Y._FP8
M@RXUDUW )1;Q$=EC+3#%\,($\D%(8DX3*0U+G$G+P0)D*/UFYJYH'PL@_Z 6
MSU46E95;B/T5EK*K#G&%ZW"LT6H=<ZE=NPJ^<_C!>K;XGT2 SXP7A+.&@W0[
M)?4%!^:V;H3G\L5@ZXUW*R-#>_[JF6]5E2Y&4N-O<.9K*AG\^;=&A$^'I.KZ
MHZQA([D)(SJTG?">J+^[M+:8RN41<T=6P%4@>PY+CLV31?RF>T:62YA:MX;"
MU/N9:(]Z:QW=E76B)M2<&$,$$A;HD+1,,7$7(I?$.2J(B>2CNQ/,HWX-.:L)
M,R37FS!;VZ&6RUL5J"Y2WZ$,EL]N931C!?"D@P9[]TBGK50@>@4X5<+L('J*
MT:+:/PQW&T+%R(^()S#XDPV.;*^Q5^G)UU^K'\&EMH*6;7>:RD.$U1/,YZWO
M8O5H_:K;YZ\GABW+Q'K!F>SHP^)4(RR\09C)J%U,K6E 2.+47EDBAU2JO!!H
M*Z>9 D]M49EG+%OCK0U=:9ZTQ)E6E!3CE-*)2XP%N?Z8&F=Y(;PSR D35"(L
MXY'[RN-,I:)F6CU>3 ]7"Q-4[E.&],*<+[7.(N*:MMG2J9,B</>>PIU CRAT
M$RPSE8?%JFW?6=5&:'U-/I<2*;I= !WF;ME*X2I'D\8EX ;"GWVV^@T%C?HQ
M 1V"(<C>@\50J.C8LTZR@=K/GHDDW:,#9D:T?&Q$RV]G1,N,:/GY\R_2R)JR
M+ZF96T#1F_8@,FG.Y#)IDM,7*IX<X%]0FHLCH@>! 44FN.#PRS'#A2!(?&);
M"3GEY%''0Y+F-B)U2ZX6_Y5@[C'3<S9V*:$2VA^_FJ.8$3?1HY=)6#3\Z@T1
MI:S^-41[^*8=U,EXI;.ZOU7X10S*V@'B].3-[U[GXX\Z9KBC(9)_' $'H* @
M0D/8&W&E?Q_"412^]&0YGA;X7CBX>J//L"(/@JXP]&OJ$DFB:E]I\>::A+2N
M5RKV,+%M^XA&IZQOK"MOBRZE6O/R"FE:PVUK5IBX'LROV@Z-'9>=H^7P=6E"
M8O1KTA>BA<VF0 [X*LX3P$CJ6%GI,_J"=&2V19U3OV2:5N/I3E)F54]Z!8AY
MYW&FJ!Q7C:-^G[H2(NXPKWGM=*OE@_ Q"R+GU)#^3NJV.XAT@184R\9CY[!7
M)^HN<^4Z+[VQU4#R2%S.-1]XB(PC-LLOMA521D'^W+"&)<_)D8?G_'()6 ,U
M'H00#"Z-WWR1\%<8/A%YQX18<0C3^-UW*4%E!:5OD7S9G<5TJN\<VR>_?98G
MTA*3BR;3] :\*]P]((DYFB$LC<[BJ>C@7E@D) C@BJZMBJ\.&HEH-L:EO"55
M<AJO$ T8]0^K(YQF-D=+J30$?/">^^2^4Z4 >8A]<<@X/VUBW??6[<;(EX%
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M1&H^UK%$P ,! B3X'@]N.N\;TWUN' Y/G[C@2'!S*+LJ;/)U?,"(X>8PE_I
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M8EHV8C#-LB)A6_Z()%C)+G#8:.:F^_ R$(^)W5^5=562X,.<+E:/S@<"._N
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MHYY8+I7>*B0SDQ .S>B1>5-4]+MBS23)N$00LTA6KBWJ8YE;,^=PQL["KCQ
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MRTR5D,FYF9E(B9NX%Y21>^>^GT>Q2]TU@+5&M0. Z"IZY.S8-TC@*"H@D:5
MK[7(0OQ<N=%S4>,C&&KA=7..OC;Q+T131\"MB_\>PM\WU5H('1R(4,R *+<J
M_N6F1#Z!44)=G*;\<0U_SJ1_LM>.']6M*HLZM%<TO'D60-R)V/5(L@Z%5#G$
M.MD?8FWH"&'1WAHBAN.T<ZU@4X-5FCJM21U%%)G3:1'-6R-04(AEO.TEENNQ
MI[YX)J%BXE:01Q8??T*<+V/A^2!]N.G(:%/VZQ#"AM6#.@_6PN$@:DR#DL*R
MZH4_.=)M!\N?2@+.!O\3>6=E<ZVBY6S"Z?I(:DN+$PZ !N\LB?MZ<&SF7G#)
M1^K]L&ZK/CGW_M+G0+?",T*YA@LC)2Z\7GF%T82HMU3J8[F,J+XX=-T=ZDP9
M0<UERFW#CYR;4+NV*BKXV"$I6+XQ"=)$NY*BN!4ZFL04*>AYA#O.IE8EUL,T
M!8M0GWI5<U;-X][=2"Z<JDE).23U!"1ZT$+5DL^QD%ESY?W9FS.V\&-C"S^?
ML84SMO!C5RG>N S.A#CL.>JF(6WRPF2"C2^LGW37O.H+ZC:K,GG(231W4H@5
MYC&30X;2S$]UFXA@&26*2E_^G,H1C52<YRK3_7691EIA1<QE$J O:=$-M!&:
M+"_*'(_)P>2 $H=3.\?:4<]HK4HA($GO?^KN<9BUM#<TV!OOGR@8/+%EN WA
M&*'-LF%(,5'-QY93F9SU3I!E23+=-VM.J*+ET(2+3V2,!%V)6G"D+Z<\^B@H
MFF)?G- <C%M2DGMA1X_RB?%]7"U>Y#\G+3O*:_4I"Q%/QKXJ7I;B?!K?O9':
M3J.P=1A(F(A]GQ,$7IR)JN\'7V>*_ &.9'Y-PX.J7<\P/ZI,BQ3[YNQQ>O\B
MWA3;$JB^$7*OQ,4A6F\CB MI-W2;6MFH.'C7^I>G]3W1O"4/I?4**:2T4F*2
M7\I97*%9MS,R 672$YG,<RIXP!Y;"""VQKJJ>!N_M71T63YTF<?JH[+'I4W]
M]A$+B1?1M"Z[+.*>()R 2]_11P>PX8[JAXJDCQ +2:*9:0@ ;"VK5P/GR:QL
MN&=7'D\I/^:$D>^/T_^ 3I=72#6FW* $M>?>1S]R/WKO?Z0ZM0NJ@44P;M8/
M$[]!=2Q$1F'Q!SM$*+.2DN3)V' R$$'1!S-AAD$Y2Z1/C[D%Q.O6(V]R@>%%
M:H_CU>+Y&)!MCEN"Z;!R,QI*1KMP/@)WW6/91ZB<6"7G)=IQHCR^JE8K9DE;
MZ*D,$N5%DQ$A#Z^$_)A>";*KI-L!E%6C;FOJY,1EVS6M7"([$<A#;D-2?D-Y
MKJ>AZX+%.W.%MQ>R'+FKZ3,EX0;,X]Y$;A=W=Z2,NT>"^!O=RV!D0DT>8>S-
MV9C<O>S]R[WB?;CP<5H#I37^N70ZR.2+F"LZ2'N@+0Q:"?Z((]KYPS_0Y;J0
M4O<V-IP*X<;YZA_-"MLF6.>3).9H*%?66\\?<FH$#-E[K.=T5,)J:#30@.[O
MVEOU3'J5+<:AFQ^T84#;JN9W#L'Z&#&SZ6.YH39M\VARG=@+NG-XZ,YM3N[X
MNY"@GUY;HOBE]9[4.YNZ.8#$JF*>*?7;NG.M/MW'T^<!QNG?4*=-JC7;4M?Z
MQ0A60H<))C<VEHNWILW: *$<CE:;NWC%5DLUYAE&%;FH9+2NBVH_P^3OJS^C
MT3)>_M%8.E)*>J\Y$3DUA1ZYTLQ+C,/($,1C]"A-8KX&)RWV"3,Y;9/,1"XM
M[P/[+Z:*M 9[B<@%*K<O-JD+RLF3B7*AXPUJG88GC>F^ZN$K2.03_M&+,7U+
MW8_^Z%A;PG>B/IT3MY>3[4<9?'O8H3*PEC;_JEWO /DJZF6J'\)#: \2GTIV
M 0&WT!C9C:9F&<<BDUMDC;@I10Q5J]U6_Q?85Z=ZE*OR>%N"2U\?I!OP:*\I
M>J_,.:WO-M23(+W/%/7E(;"$CQDO+4,3%[MV*=CC@&3KL]"<(J7EXL7?GIE>
MIJC'FR]6+-Z5A)X>VF8<Y-HDQ;1'>)ZHS<:$@3)EA $Z9BHW#CH3):0"9)!2
M@#T2@F2#T3J]5-ZU'$[JF_CJA9FK-_G-2+Z%VM@U4TFD[T"@VFX\ZJ8IKZW<
MJFB-R,TQXOY0=PG)G&7VF#S]NYB T=>'84A4[A]6[7^$"$2_C8F)*6J-^WB4
M__H-;\;DQ/8*Y\ Y;AJ'A1]3QS!4C NT'+L"DJ([YWT3$IR%H]X[\ZJC>3#_
M5]4Q3!PCW)TURJ/^@@DQV8VZ3Y9&91?Y:<(SN8L[*15G$8"BOBVP_*E\.!QJ
M +<1.C>HJE; ]Q2W"X@A:503-O2UA$C- ,-(KBGD0/LP>GMV;2"Y%BE$S7F9
MM>EU)F1@(XHM0J5P+:>4>W95G?H,L\IO8I:4_8PWV" -M&B-*#ZI8BK1&PQ*
MG#_@]_;8\6JT#UTEP+SP'S >^^K',@*:HEA3FAF=/$E=A=D+1YG@9VP*R'#J
MVR[>NP(M?V<@R4F74&"3C<%#T7HG*]-P-(D#[&*J3I9>+0J9$H7B(#;0]$[E
MMB5-$6X>":^#L[#V"0SWH]M=:RGS/C4($,&Y*FOFOK/A\2!6NC_AD\NR?MG9
M;!O).36V"Y?V^)(8%G*GM/JKN]PB>ZPX!4* !#73M<7DU6;@Y,D3QP,1#GS8
M[^%TYGY-P2;(Z/:E)*0DNVIWJ2'%RL4IOSUFLY_?&@#". HWW:*;WL-3 +".
MNRE'"R\%G:B3(BY(6+-@UDI0PDFXWUG +-R!9@P-:R&!.0*345P>TVZ5F^]1
M42^<P-4H1(X+PL9A,;/NO@Q9&Y/C/@ELW%T5+*9@K8ZL8 KB#+Z/(V(,LQIN
MBV/:)19+>)3K,E:+V#LDJDJ 2-)]QP[);FMN1D3=F*DV@JZ4UQ\!3$A6P%XZ
M S@S(T*D3JSDC&,\:2VBA]%'_"(<U_?%J)+.B$Z?>Q]G(6LF]GWFX]PC3V;&
MP7QL',QO9QS,C(/YV)FAEZ[-TY%*7,ZL"KG$E#QDYJ6-<FQS>NR>1FEX_U8L
M$<(?PFAQALM+C#V?X3=;M/VL4Z)*\P1TE7/4B8.T1Z_7$ +G=8]LD?'B2OF=
M7"(#M88PBQ2?N[*HC[NU5&,LLU$VS""LRB-J(>>4NYDC9)6PN_)V2ZFI(_W[
MWVW%6EK"YTX[<TO?<1+<^)BPD8,^JS$P7U)U=^0S1HD,[\NKVQ]Q#U5!0(TU
M9L)UJHY#ZKN:8"".V.J?$ F,O/YE]*;7! XX0,6Q_3&,ZF@ HFY2??M2Z_70
M8:7L-5.4HLRSEIK^0I26XSQDT;@E;"V=7+4)%&6<#_A<Z;3ND<_U@.S2#Y=
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MD4*U5]DSY)37J>$Y?+A^!UC^6MFZ42_YYWJ79XZ*?Y3X:%?5Y)TM%M=E\*U
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MUA-?8W@>,C>5#@UA* TL6FO/+8@WB8@U*6T =8+=Q .VN6Y9DVLWW%RRSU/
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M)FD\2,\;"EI)')-.R?XLT*03]2 <3D8W7;6KA NO30,)=!J'A3UY%2*21UZ
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MJ]Z-HV(W,4F5?%GJ<%QDWS)E(="*L@EOH6-JV[2VJU'2@$OX(J +__3A1T'
M68L6&&%*_XSX-Y7*?/\:T5XX(-CQQ:G[0(.%$8M(4.&B$@O+ -81TZTE_+-
MH!E?Q7DI\T"D[1#S<<=.RA$/9<<A?4/U1&8$V$ID2IE8TT)+3-$-K9M=^(66
MYZ?0E)&W.!K\%X_Z?65\?#K]H7UHN![;!6S"Q#$-)T(IF L7JW" 3H4.%R';
MI:>DO,Q=U /!_1(UE) H!FX*ARL<#("P<-PX (#/TU>C$#937T0CK,NNJPEP
M05:DHI_>"6&V[G;%P6]2?HL6Y!&=P 4C\+XQ G]8, (+B^V'F6@!YRA1=P7O
M@[%.CUDI6HN94(^+WRTY/_0U@)!LIT53!NN;#:K0QNR(=)E<G3.#:N-W*L%M
M*OY5:J%1 J>_O7A>L&Q]UM.+"Z,[F?-'6K%ECN-)'7%ZE7P"6I(N?PI;M*+3
M-QF.S!@#F!Z)UUT XX_4J?I:!2.\,TON]R%TZW0L-KJ8HAN51=RC@9HBD^)\
MJXN!9*M-0Z5K8.1Y09#2F9JV;;O,C\7%-A59$L=:@M3QU0HFD<7@2US/?2FS
MIB)?,%T>(^HO/ %_CLLM;$ZVC6@3^.0F<EN.!X8"FV)!1:JGVI<S0+*!O8TT
ML$;&^4H8,G,]P9Q3WS)O7_&&&.ZA&;7PPYM:<]7(Z)SMG!LUSKE!,@?!GYYK
M;BK&N9/(I'BI(]$_KSI^B959D_G39Y7:ZZO@2AZ1 /Q[V=^&"QW;QM^_SHHX
M89OOJYCYN%.\?47'4]3>J4(_IG.<0["X#<%=^GIT<)DHRSZ( [\H4PQAK4>0
M8BO;W2;*@5C>5F=\'02FX426V876?E!ZA&D)'NE&8+R%3'_-$CVH]F-/1ULH
M%;?<J/!B3V):./LT"S!2YN[Z^4M@^1O= [S_:;=G/.JC#D:?%9@>F$0/7MCT
M,3 =.T.*M,!]FVQD0C*)*4R[H)V<_6073/D ^5XAA5!VLSS+Q7B>4FYV/2B/
MW:S%>-BZ[V[MXWZ5-\@BQ^2<F.<0D^78?<"G[NMM4##]*&VL):BL4FG64\V^
M94H<__/8>J?NX@G-+GFK7R$^$[2.?VGIS!6"( D>!X5S[BI)VTJW*Q<2 1B$
MJ\$7:FXT8=GP565P<WV">$5WB5G 6KO;*>302A29/II+4^;-()LN>&[NW*H'
M9%/%!0DU'<<UUW::D<KG[]"IX3A%W)F*D4K-%;YF1'6V>MOEN,5#51UUWR_!
M^J2-&7HF6/]&2P*9V/33QZ^KCWE\UW, <?44BRJ(8(FW<[,G0C7C_?IS:4)?
M6#7,:=FN8J/9C&XK9^XC$<9,2'%YKJ*6G):YBH\Q$G%*4CSR-&9%4X5GP.I6
MJN7 @8LZZ^,]ZQD$7P@7>$C65=6H=M59O-K7ZH!A/O$Z0GMI"7F2;1U5ML,W
MOJ7)>O;TLZ?*F7?]'.2++.1(6R8\F*Q=,D;7^/Y#>?)W":Z.S#\1-Y)X@K,-
MO=9)J", LXD7@HGI4_%]SL/7RM"H7J3#.F+I-CQ2@3(G$%#6KMC<]#'UJS5\
M>%2'X1 9:8*DK\4\/<C#9#,$'4%%_ 'K_S_P5ZN7$N(44N#<5C8AA!]:"8L@
MX.A^!1>G:_=[ <C&BUXBA4A58 2<S0!D565@T?(7*3ODRP:@4*WO&@%(M3V7
M:)\ ]Y)SYEP&(:]7/^C0<A ST^+6.+%Z&8*XU9=)-=R4=['X9COQ&%7];U_Y
MO-(V684<CMA5H F2+G)1P,\#4#QZEJ_#L4)Y1T+:H!GV@+ZQN^@84P9#0Y00
MN\@=[MK=4P+?]1/WZ<U0;Z4QFEHDK$ITT6Z/^>Y"6D'=**A0-]9F1">4U9\3
M6;T^HK7;*$L]YD[;8.#FDF>=IQB=6DY,!(@>@#'= U;#TE&6U#AHY^]MM;\S
MHH+S&&[W?#*-XJ!>O68X'WO?ZD=TKE(_0];<Y<QD!PSR(;/:$7_2WKD>"9ON
MI"!C2^_,!7;>'1AQ.[G1)9+UV]>OJ[URM#S$&G8XRNT,=-S,Y'Q!%P9#B5H(
M#HJ]W"1;D@?M,_^_F?'[X5M8>\BT!^P,ZX2'PP/+8[0=QD%A!!WG."BL,]S/
MN+YGFOCL$#<7V]K5$3,)T-GMN*/3/TNB'S%-_S)']R.,?EXT$7JZ"RX?$8JM
MS<GQ7*_GR=!N:]?HX 3HMN[LI%)\7E<GLM:%HW%;WWG&KU0CN.L$=>>!![F=
MX*$1U()*J !R,X:,K0#MV7)'Q[81N"WO]U#3G!B\#R<K/I'0Y$F5@VTJH"3=
MIRIEV*.$HTKL*+'D83GW^ .<OXZZZ#(X?AF<^"]@^$CUY!&6<DA2CXN4:J00
M8G!QAQ;/Q5K;<_RT^I)%M$HNOY/F:&\'W"'4=B9:2#VXQB?SAC/HCIM5 ,F8
M6'@%'QDT3PGTE/F'OF2H]T?=P Y2/!ZT.FF":#H/L]8-EQIEFI-M7[&K4.E[
M\O*4M ZBNABA4WWOZA/6L(WVE7UPO'GIH5'_A37!1VB/?OLGZDL9F2XQTG'&
M[$2!HB.#8*L''0$KU.@]2H6GR-@0(WQKS9#4DAQ1*UV_H:LCG,5TY1G3EP]^
M?T/%(LM)L?-#2E;],9@U.F0LGO;SK1B ^?6WPY'N:?S!D1LLR,IN[)VE569#
M)+Y\KK6F6Z&.W0W=GK1.:.J5T#"LL3U9BJ4/8I4^2X>//<9L;]L'E[KR]+5<
M*1=*_J*>/8%B\^;R7X+0G]6H:KN=8C64O_0-QX<-6N!0,T ?=:#]RV;C%WCC
M^X8W_G&!-R[PQO^!R>^'<.H2,=Z8K_H<XT56PG9:D8U1X:,06RM2BXF1!.,Z
MP_EP,0X/*A/>%]MM)SX5 CJ]D+B$KG)Z]K&PU.P18+HMWF*'EO4?9USL[R=3
ML(1#[T^-DF12FO ?M*X7:4S/R?8GA *MMG5.8?0I.1AQ6CSLB<U9&S S62/X
MV^2=,E+H_'*<L^HHFS33D4!K6L_J+<EH*<,[,$4X<5V'K==K&(+!S1IV&.59
M_GF*^_@+\T[;M94%_Y9J4E^A 48>6\MPW$N\L/^#?LI7 D 6+TCZ0) /&1J?
MA72G%NE1) &EFPL-C,V-0-QR&)9,K*UB*$:/JVY^CCD1NJ-Q#$'78N@//KGB
MKK@]S#=0L&GS-<RQ<K$M_L]7/[CZH()$'--K2MB&SX]RK7V)B0(C."FB7K2C
MJ18R;SHZB_>25&8J=1_3/S:$>N:7P5<K]Q.PV:;N-L,!1>98[" (4HLH:%P7
M3E7Y.?6\!+U#+^FL#6)V <W$A.\9XCM-37,=;TQ-CR!-!O<:M8_FF6F-JYL5
MZ5LO!$$S>689:Y%W>A%?S.B.@1K?SC8S,GCG\?!K=D+Y*/@[C1:]3NB]4NAC
M6G/>"I[)K5^M@%8RJW>^I3Y;*\_O6V7(Y=T@%JJ9GQ1!*-5$UG,O!SPM1I)!
MQB-;18;Y7S+;___+V?=,7&.0+4Q^T9+4% #*L'+3!=W5_&-L(HOW\?Z\#V/,
MF[B.  /)/(?]*7$IL$4(;WU=DC0>Y4NA)XL-_Y%2GG[!#(W\U>HEZ*=*J6M#
M)5D1'Y?/APF5-%W _!OI!]G4(LPG8^"SJ?'"1%IFU_(T(0XDU!ETW@^IZH<[
M6"2GUH('%+RJ]J#8&+_&2!6'!WFHQ%\*3RI4!M'&X"=A>4'9^I:J0[NM=R<B
M"XREWR.H@TG,M^.A4F7GNHB%,2061,F7'B%+SO"G;"!!7GF6YV+NC6Q<; *0
M-OC@"8GSE1+2C&KFK-2+618(%]STYRD+=W'GHEAF!>\B7LN$ ^P@!QE*0)8J
MLI6_E0W!:H(C5%DO];3R1=PKD-[[_2/*<GW,MNGK21L?9,'[UQQ_6 E%0GA[
M'$VF>50U5Z/""AP0^!W2#>!:*L[$((M=>Z1VS84-L1'#R&RT;(%^_UX5C470
MPC:%_A\*S+<_?,F@P;"0^[8%QA*,W**-Z34G.RG]'D',[-J:>0+SD5TS-=0H
M'['@3R&ZM[R[%@S##\^(\IC;F6)-+E47/6_;2D=I;+1&KE>CM<EAFV<C;!(J
MX3QP!,[5ZIOVH5)VLM7WFV,+,-NSIY_]+FGBNN\'!!T/P0AVY>Z8;/NV#:$;
MKXHT6VR*C#]T_8C.+/ZZS:#VQC@ZY;=0[ *H74(<BRO$,+CZ12+;B77>C;&M
M(8K9!_/!"1[QA>UA,F#Y]LYLD?W*GKO&(-9[X1L.>_7[-/Z#K6H*V;H;0@B^
MX8,-?6_=V(T8J+NN9@\%A0J<B=Y9B/,600"(!$,.MC23)VPTAT-]/%:*RF[I
MY@S-"*I49B QHX=B#4JFAA&E6>_BC2P!1 \(,:B^/YXUG0GF5WR\]:R*V+#T
MTAZ8U(PLBUY-3\>+.=BCDG.& \1K10J.)#/A-N)VS"OR> BOL4G</6.+#Q]\
M24^Q[>SM7K/NPC?XI:.N^Z'<)@HBG0T>>96__.&;R*$FS6J_W"D/>=:\UT*]
M-+U.'21$IP9?D*2AU]7Q@5!;P'+MW;]_?^0=C$YXC_?UL6L_H)/D>7,H30FB
M; 7LXFVJURK5\SZ^4J1I]NF[O[RBN9!A818@FSP:Q;.;9*":+?HE.YU9!<^=
MQRWCK^=(^2(-#PA?3M!G1$'2_+')>Q4'9#!Q=F15$JJ3Z\:%ZRE7.ZDY:)(F
MPV$E]-<\$=K;Q4.PD3;9\&WB(&S1KXI__@=#G5U,NA5>QT'5G(MQK!KOLW5K
M.BKS&D\5I:7D);*3UF02%LRG?\=#L.[VNI;49AZ#WQ ,!;'RC>9KV SMY6(0
MR>J$F$Q+)4;"6;QUX^VM-$V=OO;)%Y\]_>3UIY\ZN &/7+8G_/FCTFA;'-[[
M#ZG0?*C*QO*7WSZ/>&\$*P6[: 44DEA''<$>&_.M7\O71O[W\[^]^!)DGU;K
MD*%\U#K:SBM3.D:X-B> ZZ';5H+F5!JR##MB.,WSZ7)S/3RR[S(,Y0S\Y)^0
M;S!?Y#'D&?+J1[USWK(HJ7Q@-)/=-DO8?*!)>3C\_HF%0#'N@8$H^!C3^E0"
M%)6O*Z/MUD$,-HY";W;VVDXJ0&%X@"1&0S#BX'A$Z94%1/2^041_6D!$"XCH
MO6<*@1TM.2A&J@'*6J)V)R8CHHU@I3TZ, J?Q$42<,B;0]7NR5#,81<2!LC,
MB-B.2W8CK2%:D!& 2+N*$LXVK]6R?#P:QIT#E\X[Q7Z.=J>C?9?NBD>>^/QW
M&5SR4,E\#RFIQ]YNA6\XEN+9(&".F&:7M0?YK[CBGU 4/,0A<#ZN44FM:BE"
M):F_,+,J=<'Y ..-6#V&F7XFDP#&=5:4^9=#LQ?&YA!.8NP-(2\<V-(+DY4\
MTX9SY:/OQ418^$'8!K#D(V8]DYH4<,NN(TT_'T"^R.[)8S_*/TVF"1"L$5/+
MX]RP7CB2X>>7GN1W75 _ES$M7!L6[XM,*7K,(J/$\20 ,LONC#G41('6B:N[
M\'*GK2*]SOJFUTLV7:JE$%SOC:@I(V]Z1)[@1Z1"?DQCUQ@SQ'@_!)WY00RO
M.Y7+NOJF[=J!<#.0015QOHVT"5D5A=1:N((D UQZ(,YZTR@.]XL:(+8CQ6 ,
M0,=1%H[]%((D5-$'&K?<2?E;@D8;J59[%D3H,-8*>.S1?<]![BDWMBV/I4O*
MR:PA&/$4 86E59M;:E#V8)HZ+9)B/2)X]2?#6+<CJ@[WN4)J70UR5$/G=NM7
M;$@<MN'Y6I)K8\,W=%#7C8YFU12[_EB:OH(.MF_;Y1L94S%&BJDBL>!PU[J9
M4YSS$#Y\P[J*N#"Y;/98?'AF"8AW+0]5_G)+FQ>AR];?"011;5+^<[[,F,W'
MB EPRW5UG!X3XO%:.HM2DN3RC\XNXNP3K;GR&0DN%3T)$0R& (WW<1%,,5CU
M$;\]DIDM_IBY7!S#8G8Y5PDO"VGD$6H/E31+>8L>@3)NB&U\7;@.;-H>4V^>
MH!B76LE2@2=EDX/]#EKIJ). 09.Z+S<$;88[7:,XMWKQXH49JCC/C4IB70GF
MKVDG#T-ZD?O@+W-(EM5S;"7;5B!, (N:86I235#.W!-Q#T85PD++<WLIV\#A
MD5PID8=,&%JVARDNM'/I%4YN#?GS<4BF_'?>',?7[)\Y*DF[UUNI V6X%0\*
M='N2PL9 C5YY''="@WGT,%:I2<@.]D;C%2?H4;XRZ6S4=)11P&,/*?L.6>*5
M4644#/P8Y\B_/SZ@!%$/0:/H@[D-Q^-I+H4?J?; 1C_)7Y53:+JYV.>PVY*I
M=EE'<7/^(?F$79#G1/@7GFY\G$:NL9Z2E,.36@V6)IN6@78OY1;K?E2 L)0E
M40HF/5R#.[QE\/Q/:89*7@@(X=_B@WTH'TRT3Q%/.%X/M)V>]"HVO[/U('9;
M>*_+7CK5O)()C<ABP05V,1:*I?%(83MU1<KC+2KW0R_LVY(H5E<1=;\@;PV4
MT"$\X*U^DFI >FB$!XGSA=D2V]GYY*1R"T#TI$Y79=LT G)<6%M?_X*5??9,
MUR7K$->D.25=TZ>%#7?\Q1_M25B\[!Y3ROHC.R2S@8IX!8G.W;WSMM%Q.!!+
M;1B';X0N+)&Z(L4X;(ZW2$3Z^@B@\?6.<'2.]3YB=501NU&HS4D[$7)FZDGB
M;HX8J"\N=F,\_(H6[>(L;5$L?2_2_*&DF;8^W)@"4^B\379[OFV!T7E=29.)
M_^9)4/[M\;QB5\+1]X)W\&]_N/KC[S_[7WF!;?2*9RMI(1+ICG_FRWQ28S+T
MOR&N!U/VY+6G%3Z[>O;[/_VO#R4'SZY^]_MG7_SQ\S\\_>+I%[_[_-G39^FY
MZP9+?\+'O_"\*/T$)_?WL?;C=E5N\MG3I^.K?A@Y/W*L6%;]/\C,O6.<5-8'
MP>YW6G[VE!96T<\:51@>^P#7D@]UER4!^C\GV4-9+!7'%AG\^&300&GF%"<(
MJT*#)9-=Q$D,2/G,,H3FZ;W4$(W(2ANA1FRCZ(9"'"9,:2E5&'8AJ&>:_126
MZ=^R'B6YTR+/BSQ3GOM*I@9)IEV8.JM8UC5_P#AK$WJ2,"09J%C?E3(7:!&R
M1<C.*\UWUEI94DD5I*; 0.WNTXV6DGH;1[>0CI>8\5JD=)'2MW OS7^,$IG:
M8M=54^WJ1!:D2K,=CL2K"*2[[E\O"G$1-1$U80*I>Z9LK+>*.-T-ZK=-UD12
M*&LG,30@B=;!6Q-<=P*/:0(R=HMGOY\#-Q?2OY@-KTL*TR%]9I3WC'M9Y#0_
M3>J-B>5J(L0Q1V,]Q#P2*G%^6GI*L(6=F=TS=O5CY;ORONU89XH/JL4V7\\(
MLK/?2W.C4L*ZD' YG<OIC(; )*9&WA"%PFVE4_YJZ9)"9M3AS]*!6\1H$:-W
M$Z,Y1B,M3HT /[& EXUS9?]?=)\/57!\MXNOL8AA$L.[%O^H=2B$[P7-9ONE
M5%8;?0B8U#3<,1::UNW69B*S<W3,+]RPKL3F^0YIU$[:_CR<H<U [KL:;D&?
MAW;"4?CFF.[/=!\6@5\$WNE=-SGR#-J;$)?@PQY'_JO(I\['D\F]T6DV8!N<
MR"2II,J6Z=891$8 5V\6S*5'['U(PA=/EQZQ_^$>L8^BVMY)$U@S'"K@UJ7I
MR\9Z .C(/@8WF"0A;$MKO]VYZ&&.0[]L. >+%*2&@!<>#YO5?AQ/_+'>$HS0
MNY$V7,Z*CGTEVR%2&>G"(G#^R_31)CBCTK@B7\I#:$.FTGHKK#2E!Z+BK-%5
M<HAXUPB>3<-$;+9UG^IA?35[ <OZ E2#%]$/!T._1P";H+IF,3V_ A[#WB=I
M<AIWQ"AR3L=6\\FR9<6I9]:K!R"VF@5%[BAUZ%NNI76-WDJ>&/N\I]SB=>-W
MF=P2VK(X-*-EO/40,0!!LFXNQ1<3R<I&L;ZJ7K]E\GU""[(&=W47=ODQ@H<^
MPI;7;T&I8A1C%!<O7Y%B/F$X32M %0 1G7UZ6;B+E)V4WPL)\X;S !W_0&>\
MS.0EX *K[>6NPT1]$K\6/Q/@75HCST<$WBT-JH_3\ (/>7#"*6U&VFEA[4&J
MI>FNYR%IJ35L%&K.M+84 L HR:45Q DT2#T#V9\1B$J@&S3GN $LD;U;GP7.
MP1CL7.C?(RK[,A2/D<./MR,.$K#HY;.BQ5B]KH0MT-HVY*+&1E)W/3CHA?]<
MP,JY3=<I/_F5'4!Z0S.=UF/&;43.9%_T'&0/MQ5K$GCTM[5Y]*X,W_H8[<)O
M_[1]G1O^5,&Y<QS,E%*V;0N@>-2X3;< L;!"G_:Y7T&$*=#YX@Z/[8YV[>A=
M1^!]S\KC!Y#/2GS.NF8"*36SM+Q9[@5)2S'@KZJM$+W9!>@LBU*(K3D(^\$0
M6I<1_OU<1J?_P,_D\.'K.;59Y*N.APZ,2WU/+VXY !^""#9E0^U5]5[3.3T;
MN]2.43&J2A5/XZ&*'7XH=%(<1%0\ Z:B!=E+HS1-:AB,^142?RI\?TZO'A-/
MVKMHV)V1YTT]O;#R$-3N3V_D.7PCZT.,$]AH8+FT[3N;@J&)QN <1\2,RYB5
MEV. ^2:G,<T R7S-D>_X4+U+%'6U^GN5^NGRF0=3UJRL67R6E6^>7GJ'F(K<
M+U4(Q3DI\!$JCH\PHL+ E3C:$0W^X?W6=VCW:>[1;WVC \.90]@?2YMXDX\X
M@?Q4S4TI+NBA[AVZ6!7$02@Q\D&MB0VT;9Z,Y_GXB1OAQMO@L_5>O^A,=^9C
MR.NQ.G8EKK9$28_4;/U=LCW5+T()8*S):);&4..N'+9)8IP4K4]4_TY.Q^(H
M(XF4"S"3S:O5M]F%1-,2'5P9;[Z.F9*X2;.%VM363R>%5><*D\)<T#SAF-8H
MO3:I2G]_2P+E#?9!'AB_*M> %^W+!Q/P='W'0:1?[=IR:Z.I7-N;3TK"PC!9
MB4FK0NDH1F>SQSX-C;.:Z4#B40<A*A'T=%A$5W#^7Y\1&H5EQ#19V7$FF!Q&
M7:Q[QB#/0S!U)^W#G^'G/?/4B3C=Y@-&%1)74L@6%DY6BM7K>O-Z76Y>H_$U
MF-@*=KFO]KLGV[ J6[Y"T? 4]TC-8A,VVA5\[DU(-"H(,)V\<ENO28T0QZ(%
M_;GAPK#7+>PQ_I%O7?C=H15CRJT5Q)CV#-M(%L@D9)&KXR"WWJ,ZYW9?AWNY
M<Z/<P##L2J7+UQ,W<NB5_<A)CDWI,YZHF'"?XJ(]E6F:)>?5=IF-?R.;A8'Z
MD5<UOR[(\B" /'HCGA^*3:";=BM+T.=RY7_AG;>3/QI2/+#7N^MC*[;61J62
M9F/">)$(@I'Q<,=, 8TH2T7'C):D901Y/T BEH,\>G#'V&2M<=[&R@O&Y@HJ
M#SF")Y^73VU?,N -;!84WZ%YW7"*<GA_3="V)<8L$\*[(C&)0'#8G0/1P1WY
M,VT53@.9,R-OSJT>C#1 "$=A8%[J6!T.D9FK]%V_(_UH!RB'<,AHZ.8DA&73
M.]L]16MHABLA2K4/1 L&4N$V FBI+.PJG34/B0VR+E<-VZ%S^"!HL.TDW8 :
MM#N.)5C/2-M'N&E&+6"NK&Q5E/%9:E__0YUK/6'WG9?XZ OI\2=L9;-INVT^
M\;#:I\&1(#J(8F._:X?COG:HW6^^>;7Z_L5?1LNM]G=!X/E"4.@Z!*G28Q/6
MCMTV@<5I\R?C[YIP"!M"+OA*-?W\N[&W*5S-2<IR<7"<Z$$-#EW&Q:/LY\EW
M))F3,CX ]0#YU18A&4!A$VJ3F@G?A_XIE*-%]6)Y5/,O%5"<+&6_"U<[BDZ<
M$[,(>FY./I;CV*[)LSVBN&?!>+QOC,=G"\9CX0%^WP$EDX%UMWT"IQV-CR<&
M'4E!!J?T'FI=/J'.2UZ =];-TRR,0BP.%\372[JX4N'?AA!<J$KKPQJ*\*"0
M2/6.+B2RS'^*I*MJ*V3*SKJ*S/I^_L82T3_.B![I(_>.;5S)ML+8Z-Y8)XD3
MV=S6U3W$D0%L$BFQS",QDCQV3L:J#NQ4OL.6W$8A'TFW?/MJ92-!0T1[4XU/
M!#T '?(5 <BLM6[94:1.+MAVC=5?D>P1>WG2JB)ZE:0365WLL0. C.OW$B3(
MS0G!Q[V#LQCVONPT&:;;8^NA^ZP_></I''U\Z;"6F6O%D=6) 0#!;$RJC%]&
M3':C]A33_$;'%<F&[L)#XP_2U\IH1X,P=FLQY1X<TQ OL%4+<4Z)*%Z<4^:E
MQRS>V^I NG"5$IWB=FV;D%4_>ER\E'V3RA8E4X!+S<#Y94@]E9MC+E3S5*AZ
M)5=\]A5MY28U2M@QEW#=^\%GA8&W]B='E]3*(-,GT8V?1TG9JU5Y8##@H.D5
M/G1LAE$=AY!T;]ZP4>&=?\$4:PM)Q\(6X3'V@>U3^H*66#C >XZ*7;6%)C9R
M;G8:!3!-_:A#SWXY5C;\A,2\B)"J$"3B^>GBN:XGHU44ADRY)F-UIW(DC^</
M!'MI,ZF2C!XQDM-ZC$B3S&3"J7^H. 1DX%HT#T289#]T.DM(#9^M^Q&% A^1
MR?J*(Q-4(;Q6LG,D5 P@XO A3K..I,+1=N),FMZ##"F'K5/OL]HX7;L[8_^F
MD[+2?.8XM5&UL&E.T06F@LQ6/K3=:^)=\*$N['C;\0+QEY;2(#$H\FHBN?G:
M,/1S"G5UB--V.&(6FQ5'=26C#)H ;L_IZ8AA,*/[!I<RO9 #CA\2?50Z<>7&
MG'00,%V(M(#;W58ZCC*-+7VR/CU)_Q)(*Y<.NOP^&C'\+ZW8*C?3U-\/E1G@
MF,N1#4::SE1,OJG"@F^$)4?MIH.X=$5F1;'[ISNU&F"[!Z.]=D&%2]QPR%6(
M+F_E.36#VT<F(!F(E&QKRGG9R$XE]=MY!5W$V7.QO*+U?^9BA,I-OX"[[.O7
MU;Z^Q5A9:EW[.K+K(G.XS/-M><=$U?,>\TOC,UI_B@8C]#/2D'.=OC1U#;FI
M.C0/AY"OHL8A.9*Q^H8R'=9UPPW;MP_A37-JH-Y8?;E\6_2L2,51TZC._GI#
M*Y>.QD;&,L1+M[A47&%8U)-V]^2NW1#'3;%=S,$'BV T5S<]F"[@,&!'V I@
M+H9P]#*R5X^L5X^8:7_7@- ?J[M>01P54[1B-=+HNF!1M$@E&K(!88'6=>0S
M7P5*E+DX[F.H?\Z?F[ _3K0%AO\R/5^(6U *DL8SII2#PQY<%=4X=V6]M<UB
M+?)X)(>X/%([W 4U@K"/#*0K9K0$\<:_<FYF4.)*@1\A,$BL[HS,%RL!"T.E
M.5GW4]X=LU:ZKNU$Z60TX&(ESBF(F+"_"++AC9)C[L ](PMFL5IX]%VU)?VX
M&5L9XL(013]A->0.:SWZQ(<98NM1J.]KI:L.T6--1@M#RZ0<<XZOE8T[(?N]
ME_]*0V&W%:NC.KW4C*N]VB3V1% @ .W]6$/I/=S5S=8WCECM);9K(#,^=%(S
MR7Z2' P17)L>"C'AV<H5[1N97M46!<\G'BB=(\&AP6*@IYLK4*]PBOWBS]A:
M@;'L6:*3;+Y0Y<96*=TP!T.C3,:2H<IB=$3X0OB5!PQ):%L.%C&2>Q1#Z^-@
M)8]X ,1Y278^+!F%R<&P!G7",IOG@Y!]UU<(L\,NPF7R*\C6=N([DW6;3(G]
MT4\?V.D XZ[NISPUZU2Y8W.H@#"M^X-.P[T;2$94D2GEB(&W(DE;% 426N>A
M<C4EC#*"7]4PGKS%0"ZX9T4*VCF8,8&+[/IX(8_29'Z$&>BO)3KYEGJS&T5#
MHT#@X_4TPJG_:]#=2/,\>_KL:;&Z_O85!9E8J'#ZO[/:9,QE?9GEEVSH^G?7
M7\:9ZX*5#3H+6!UOTD:S%]PDTE[20/\MG.(8\2W)3 QX.46XL$"B^K=(YV,)
M\=4+WUC0P%T<61;T>4E6Q@W^K[N:/O?UEQ$2I!,\PB52;(4;W(1]8";VD[H)
M5AR9ID_MP>2*-+O*("50#VQ]W0PZY9E]* I631.-@G+K@G9-@2RQ,(S]T]1Q
M6R1,K[*K45?B@8FN<5>19)6.6M&HD--KQ2><#5Q>R0R.U2?/-X(:_G1UK7L5
M+#<>SF:.\R&BI>0F&D!:[E5(CE6*YY%: ZP7@CX@#_&FO5-(CWI+MM6/49_^
M]A7#3^ @24?H)2HF_UZD7#J/.,;>G#W=3*HSHS'P6GC+<3[+W])WOZZJU:O-
M;8A"@_MFZN3Z;U^_,GUBQU_ZQ/NXAN@BM'J_V.D=(MZ]I,JV*%+\%.__,F&/
MGDN!+_PX/N3S#9,2SYY^]KNXD)?/OWV>%K*)%1M=?BS*6/A$$#S:WS3D%M\H
MWL**41;$B0<RWJ7P\"NGP&)J_^7MJ8<>:_)-*[L<VZ\P3$S+"<=4.N#&8QBD
MJR*<0;Q)?=:H%"^\U#@:;.S6C@TLLOE ;%2B3N0-B?-I 9UQZU%E&0E 5+6C
MEX@7P=%%-DTI-L/W.HE;5.JO>18,%JMV'I $Q3T<J]B*WU?^?EHO8/!0XOA5
M1T%2RM_HH8=WOR^#BW$;,X$HP+5;@?Z +$#*7ZQOJ:8WW7F5SD<4,$#;_,N]
M=>_<MGZ& \#!6S/ $N.Z0]M41]C^U $1E'L<A&=#V:-*UA:W//'L7U[I+>6V
M.MOHI@]Q5H:$[ZA13)Q6TU[:<4GR!!E!XH-'!PBP:K\OFPI83HJ-SA[64".^
MW6^?7T=H'&TE@P='_)!HFF0%F6P_(H.TH*7>-UKJV8*66AAQ_LF[ *N,(1F)
M'ROVP1)VX%5_4$3E'H$4TG>9'J(:Y*QU^@M21K'&M])T)]2@C *>UX^(+]2I
MX6\!L'6$.6K#-5P/?T8>LO1HC(194>VH[0KJ!MS=J8^1.2#5+YOJ3BOGN=_
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M(-V?+Y#N_QE(]Z(=/S+M./1"9"<L-]NN?'B;Q-)HWB5I%5J6723.J82)V\5
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MZS>8#8MQNN&AM&5)IKFR_TJAP;-^M&O.RB#/O-6;YM+/PH9D:)$]EXU%>8P
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MO]EANI,D\:RW.\G1N1/11X?*XO;YC$U*PB%[@A\PU]81*:5<^!1U?@ADBSZ
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MN6N\^79;/^(3S9*-,@)IJTTV49;SQX*5]AV>:;!"09SA6E"Q3_35"O#MB<1
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M29+'LSA5AZF[OG[YW*&#;"AB2H33@TNQR+H*WN*G) K:A">Q'6@SVE7M?P'
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MQW!ICPFQR;<V?%@G;R')P=FL;G3F.;K9R)N;!@S&.]L(4>67W"K3;+E*T];
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M9&7,D%(C2M&P78U<%%!NI+ ]N*RKI$W7?H_LT4,5&QF ,+.R>R\YRS'+@KR
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MAE9QZ%2'WA-4K5?M JEB+SEBE#34LND*\.ZH^D%Q,ZXNA=ZXIPPBK?)/CX0
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MQ*QMS*4"88JC[S,H'X%@\$_6K0+XA@O?'B<,E_#H:R#X;'3S'#6!M343Y @
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M,$HTF,9N3H7<=M>QN0#8(;,2,T)4Q *933<4Z'-IX#KGDC!T=5E 8&8<R^_
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MIV$01M$OA$B/G;[*J+*4J:>RG#%Z:UE8FP+VX&_HJ-8</77?]6$?'XLNZ"T
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MUJ"K9$.B4^H!8.H#9HP<-CVY',@'"XBXS441O :U?_P.?SU*[2BU++6ZXB+
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MM*,^EK&K-4FJ*F%*B5HZ?['#MZ^%?23 'S_0DJIK6K_$+?0V'H\]C-G^VNV
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MA]Q%CRK#!,QQY\&:6,QQ!LK3/;%E#A<I?%[7(G*$P;W;?8V,RD!WX=B[[#I
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M;Y])OY2;,T=,%(B:+Y:-.A/0-2"U/\/G "H%KLLLC0(*P_[U50X%6 )M"W8
MYT?Q2DZRO*T"5#0-UN:6/00;:6NI3/1'F5.2O;%[?!21-%:T0%8H(^I6%>BY
MTZLE)ADR&0; I1V%@RB#%"82^8-K78'J].5Z>WRQ/3)@?VPKN$I 8<7N-N,X
M^W"Y@@]A."V)O0Q%P<A)F#\<#DKH-%?CZR*JK/[$V)L<M>\AYNB>: 5, AW-
M@'6%(",*+BYM.=5EG]^LB*9,45R'NL5]&'5,)0M@OVIOZ+1;HD'C=F-8(AM*
M!!8R,,536),74%6575GSG\*YBY(KB'5U9F6OI@Z=O<KF43,'@TW1C9/DJUI:
MTZ]-C2K6KO',9-="_RUO)\"@PERBCE/P?YQQ"+:YEW1@7/F9VI;%H@0IM7;&
M>&:?'=@<%:^'R,3#%YPB:^W:?U98I0;>9( = *<+)0J_AU%NZAERRIT/.0?B
M.(3&B @+Z\ZM.M"B?+$+3QO8Q0/%>GW/+K07H8K6'ELRS<E"3DT]J[(I^)53
MJW_(,:66?L!;L\^V"LH>LIP1CM</-T!L+Q#Y*$&TX1L\VFQO(FPN5?R3(6A7
MQ;Z'#%*?M-2@D+UB8[6*BM]H$+VSK.XY[*[&30:K&09J&3M0GQV#6T$_#?(7
M[T8"<@\+9[DZ">U\CWSG0/\Z:'^#J&^<@Q[,"*!MIU$$O<4 D?BQ/'5++Y/W
M[+VP,2"8;5 G"H-Q3C57G\XQJH>-N*8@FQY2.Z#*N,%WF612P)4T;64U@=4M
M6:60.Z5LU#J%IK Z!/R*R1%'2-&W@9HK^R][65G7')N1P>=TP''VF?,,'>44
M$8#_FXO5\-*I75LR.,=0L@'^+=!M-[X"5HTC\)$$_=-J]02*KJ%(S8Z35\4W
M2HC/AY9P+PH7G(O$!0$1F1&63!70X&BNL-]E"?> CD)8!5LP?(PK9Q/7SQ].
M?JE/0G:/GK]CYES=J$Q+B /7C52C5>:RS:EBETMC[3.@=&$-4HTL@ZR< /P,
MKP25W=!$I98(', K>VGB)=,(@\[ZE0P"6"DVN2=\_\2J00J^UVF/BN!NGI=Y
M5O; 3UNQFUHH9\K@PY[($",=J9&H[V;?6T+/<'6CZP*98#(&MLG!'9.-3YUL
M?#DF&T=<G(>9+>L6X4-6?ZJC#^A)4#((]-UK<L<_@CN.:N]UL@1KQ_ZFLBJI
MK<S];>!G,F2>W,R#TE .2JX-:<!U;WU)N\8Y)4CP^O]D<D9RLSH=BL.@JC^'
M]053-\CYC);NEEJZ=]I],,40X7?CU@/P-15JB:@P_U$2G4WL)II/^'? $:K)
M/N#W_>7XZ/#XF$&"Y*-Y>3/PR9/#TQ=DFX*YLD;8HI0&A"4&<P*EC.E?]AF4
MF4G0VEJ5CD(44B,Y%DK71K[$P1?S[58:*2.#Z9XPF*)AS6%THEL,VG-#"MR1
MM7F4GD!ZK+>+OKAU[F=74.HJ/4[0P4\%2O:9D"TIC.N('>B:&G0_1TD;)0TE
M+2PMX  ) @=!2X=)US1T5!Q(R1 X;5GF$&E0;:=,_:UJ)D:)&R4.)6YVE6 =
M'VLL._ZF=6@0*F8WRTU2)=06'W0HP+^!(.8:&IW+$,&1"WT H@?)Z@-&&$?J
MV2&>'P5S%$S[2DJ82GPY[A8]N%Z8!JJ'G,1N CV+[RF*7GB]-S?JSU%,>[8A
M5X(&\ "=BC]=$3_*SB@[*#MA89>SUGH4*?.@L"*9695(6?,A;$PH>D>ZK6J4
MM%'2^E;>):25D6(=>071P-,HU&+P07LE<@_J8L';0+Q'@1L%#@4N$!HB*2)$
MW!E4*53%FCZTN-MN-DAB1 GT4=9&67,F6&5F59LU$MM-#50SML30"&Q+CF1I
ME)I1:LCXHOX!K"PDY!.H35,7)5A1T)V"Z"60DW7EI^R&QD%\%TO4H'P5X:D,
M91M2OENM;3=08C_*XBB+*(N B,>2PNUM/6$+@A&^WYAHL2'BP0T:*>>05:-R
M.PK:*&AKHKU<Q\-M1'ES-4-A8@B_VFHINXNC^(SB@^+#)2ZN_>)>T+]@E@TB
M_ZY&^1KE"^6+:_8C:ST5Y2*;Q1Y(@XJ5.N(W"LXH."@XT'/N<D#>TM9]?_01
MSH1343H6M!',*,5.=9BUOK(W(0 !FC';,\J9R-G2RA8S_B530.L+6C'Y-@2D
MNT3@OJF'FKHF2T#"RQI[X8$Z&V5JE"G[2HION@);K[&D?!8(-1W>._8AN>Y8
M^P-B%S <*,'+#_ZQE\$^7"=_>U2V_;: 2 T<36P0C-DI@F)MP:'U;81=*"]$
MI#4+@3! -&GH<#*NH!HM9/30\;OE'" IL0+<;RG'QJL2,;?*@OME-^YD#E2F
MJ8\"8--WXTO0H1>/&PXZ<&0L(WJ*F!,2N\O-#J2.@*H9 L)!9LP(8.[V<G=J
M] :F#NAE)^)6@ 0:$.@'-'Y'=RJYI[9 ;.*7@62PYYX="H%O)(["K>@=3#?B
M3(DI-8N<*7&'<X [-PFM@)_(Y*AD:?@^]Y;) =1P[K2:B/ZV ,K@+AY.E0 !
MZHQ;<YJK"GF*"0&)D'B@AJ;1$<@M:A?<+VU#W;EU$^MP\"Q/ .F(1%*APT&_
MB-(9@"61-6VC.(6]C,[+G$&UX027*1K#W$"2-0(<F(E>0#F#,S2(88.]V .O
M:VLAJ=B$2(\11X]+3R;2 -V$9YF@S#.CV(6@7[7!]FM4OQU>C)%N[79A9PMI
M:[OFWMG]?&^W_0JH7"X$:H;J\=Y5T^QG(SB!V"9OM5Q]9:_7\L9WWSO@K\YN
MV[L,HN6$+5-A?^/=\4<&)$NDM"]<A_NKTF#_-'5M6R!3A]5R [NJD*&THRWH
M4<AT:Z\J,C]D5UE/KB)VQ1TBG*:?67?BA[9QF$UG[$T;_;]G\O]"]J044/(U
MH FY!<XF= J0T&J]O". +P%4KCE_ZJ#&FCRV,FG+W_+H'OBBCI*E0IRV L7*
M^(^9&E96P, 8W)7-4<5&@VP$"@8#L"_!:&$5O0 X:P<G(BP>#K,$U09H<AIL
MR1B=FBW71UI<&E6M#S;,F$_Z"SS([VX/Q(Q(%D^"9'$^(EE\'B2+\4[9KSN%
MF0@%/>JZS2' XV,&#HN3$VU,4\KQ#)5@&V/4HSS95Z+W)=*DY$BPI?V=RB9W
M<3F*SB@Z,% [ .Q*;I$D%@S:NL[ I-2M4G:@2,_1 "\C>O^Z <85N2%;!%"Q
M G]C2FP)U#.#YN'4- #SYF'@Q< #]3:*XRB.<#,B/"[ XPO\84[4:P0,C BF
M#+'==Z$ZG+MV[(X/(C7S!$*B**M9C;'_6<OHNS<)5&;&P5.KVH4XK5>BB,@X
M3BMQ#X3PMG[-F*_KH%.OC3(5<"?5C$X-_2*)]3D1X/V:TG0NX@3(GSI&= VX
MHX):3&D<O[4Z-1M^%+:GRF8^WS?,UTR\\(F](JNZ.7#(M[V=]A07E4$^P<YK
MNI<P82_GUJEF1L\J](I3,VU,2K$R]++S,N$ F7*9^6]"#R(O4[XX9@_M'.JY
M"09W&%VXU^6KGI1OC D2-*R=[Q+7XFOXV%?OVR9ZA[_XZAM,AC)2S]K(1D+L
M+2&>>&66\DGN"O_ [)MO>:'E1I*DV_'DZ*_PS>.79W^%?[]N%UCL<:WF$[UW
MD0F\C:C_%\E? +VV^PKW<>*5HAY/SN^J-;)#(,9BA"@%Y-DX:I? <E2T"PAA
M&">0^ FD1ITFQ:>J738SRD""U'F*W]_;]++'0J/^KMI$L0>".Q^HNMRC>$%[
M_>4EX]"*6I3=T2>""ZL4[TA'MT*.4DZ-I)&6L+%-=S$:2M8B)"M+(\6EA&\@
M6V"%36,8I R3.\D* E7[D]K9:C3$-902G!-'7HOZ"G2,2>RV4\<,1#KK@:HJ
M3+PSI#U3A_R.&9NY5^3$E&'U8=PGE1BH1AAQ%+?T@B>-DZ1$6.>*67K5$*D!
M,D.\[I"W(!8Z$2=2=&&23!']BY?'LM)UQ2R;(I0D@+X3WY/!_6I$@%E#LEJ3
M1V 9CF;I8H7I7@$LT5CZ#H]/RYO"6@2I44(*-$\\#'O?S>R X=*SOVT+3R5O
MKI-<BHM461?B,E;^87<\"<-C5K.R.CAAW0U>U\ KQ9CVQYJ6/0 PE\]3AWD%
M=H(?$O).0K86,-BGNF*!I4#R%?#+MA*:'F84:H.J!KD^:'+:8/1\;W=0(S=7
MANKR(,T"W .T'/8.G=D]"VO3+ZNR74IME=12!75+RXH466>H,.^N2AIO#[@]
MD!K>-6#:M11[1OA./$KQ#$XU-)O8 P-60@"!A@"E"2"U0P:_MI;:4I7EB<V#
M[>77 K]JC9JR@E1/W*FVE$0S2=\<[+VI@0P6 ONA["!!-*%ZI-%EFZ6Z-)-X
M/_W1';HBO56.U:"AOWG?JK'QGMOB>\X^SUY=+M4+U0]6:E.T];WF $ VXW*:
M4(19@LW,=K6O3B4F/"C64J? :M]9MLQ]P]\_"F3@^-C0L9I'%T"Y.DNBKS&
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M4&#V^,86[VYHER<ON^))GN(-XAA U81=5M@(D^=Z\=<(L1* XQ!EI8 \.(0
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M0[N69]@CT62YHTBW\RDAQU,@V"166MI9(2PM *PZ&6KP5)#\ .S%\FI5H]F
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MNX5$&&)[U^49AK8X2>[]1#I5(H[(CR62"H63$(W+X5L!\XUP<P>E:-$O""Z
MJG[3]'QEEKP)J!2MDV[=??1ZE\E*^+%33.A*\@B 4T092KZH7=HC!)DR_E*7
M6.G&0:DD-07%*A]M(9X/Z+ ;W#$5H/&Q@)H";;B>D5IT7D+[R$$@7<R4T;75
M%IQ\KE)*@R(+=T5):=I\X8,3A0I1. I5LEU)3' N>E00H#4EN/U+*-0!%U=2
MUR7R3?JJ'(CAZ>2MW8&<^%204ZANU&V'84:@-"H!AP/+7S'T2<I,H&[D.=;2
M@+A-!:$_7DZ0'T00SFI*#.0Y9M)3N)0BDU&4,JE-[/1S919,G28)SN[VK=DB
M"HPG&CQ@EC2SJX-VZ1DI Q)%B%8#IQ7%16E6M6PRQU,AYD1%L]>.@)!!#?CS
M5"CK&C3=UP^13(E(%YRB=O)455#0KLRDS281G1@,'*%5DK(;Z.-24%5@'RYA
M>R;J@]O7ZC*[5=:=K ?TP(;7"D^A"IU;2?P(-'.5%T<8#K+=B4G$.\/=G1!B
MSJ"-%:"4H7ZEG%+@$4H5D++.#<\AO?!4TCV.$O\#RS^=7=<QJ6^S'&ZN(+MG
M/BF5P@7H5. #R3_6Y424J+,C.B.6@) P/@SO.9WVCAF\-J4FKPE+5&Z<&29F
MDYIA<!FU4R@-0FB*SG71O0$ZFI]T Z:%4"F3 A>ZRLXA<.:3T[-*R<H)@U&Z
MY6#E!)['@O G6#<,Y8WV5XS%,NI[0#$)@:Q>QRO'-;_5KQHPWZEX#_2(=X=C
MIC=S3'=2-J>,+*Y>\/>#N!#!;3#XPHL%W;K+)$O15',CI3*P!XSB&O*G:BA.
M4(,D6D0):JJ]P,*1'D&M' K$FJ(>!N=ZD$L--2G6QR4L%EP]?WK<KJE@";.L
MPB+X2YZ.(".UK&*BOTWP4AP8L;W[YZI#.E9Q@22%U +WLW3 ]!)<9^V+"S<N
MQ!]@@0;:K??RK$G55\DI=>HEP B4U=UX\O"( .70,JNY6--G_:VE5VASUQ=5
MV5]<8G:-W0<X(\R[#$]$J8 !+>"J =D$% L&Z5EQ\(7QU.P]T59DL76+1/U(
M9JM9[KW^6D'AB6BD4),2PD7.4;KQ74OCBJK";B+C$(^D"D9J)X0N$Q[0NP^X
MA<R>Z0+M9ZK7):M?/1/6(NDL$PS?*Q.N&%,P1QKS"L?>LT,).*\M!M+'S@H<
M'@%[#16$/0;\(8Z3N*>R71[Z/+"H[CPZ.U)L=1HRF"JW[28X""A@2&64?;*/
MOX)*![$0[3/+AL^V>QB9AG:(!M8G<:Q.$BT;XQ[/%$TGYV<P*.ZT--:P5[Y,
MVT"/--S@IEIH$X ^BW(F+A4ZE4*!MB8$N[9:YYWHKKQ$":T6J/KN-F2K+&C(
M= I<C#UW8<W:!2C(>N8RIU[-S>8T -S,\[R%IL-&[!YTN!'YD7[BE6%5PP6J
M,(VBQIP$:D7K4E.3-!Y#[YO#445_%<QHJ)R A:/H0*>">& 1U=6,?0<$N\85
M3[0@2'3?5:Y:74(-F?= ?5_;NM>%T\0SO\1KW]D;XGG?)8HZ:H;GUPPZ\*&/
M%FL#=SSYK,%CLNYGY3D^8<%Y$@JXN^2"?,':Q-",4CGNZU)W.*!I9+S=O"R7
M>/EBNL2.W!KV]#4[!"A7'/@<\S2C<EB"O/[+D/GN[*Y^0BD\[)O.N>O:'CX*
MFX5>#HBV_@D7VS>#KV3U=8R82SC[;1[Q+:=::1(5>$*SS/H+]>U#'@PV237R
MH%(+W,K*F6D];V.LA_K<]5 OQGJHL1[JJ8M87G.FHE-PLW]7[>LP91/FQB6?
M(\ 54!YAE6U9%"8_$*7M+,FOO1%7)[FURK$IU5ZC\TSN X#P/2"O%3H<[??P
M-OPFMG_*EDM)0UJ=G6(T0)X=8[WK4A,@)KGPA@N^^)JD%=;@4@>P6'Y<FMM/
M3?8,6\Q7<0N=<W==&->ZU.M&(2'HU&!;JBN?5V4-;DH!V-' O,K9K+6",5MQ
M18''B5'U!/C:P^CUG=>@,H%7STL-@7K-8MDUIWOQ#"Q?ADQ,W$W_!>VO;&>E
MI2$G@)0V>/>% RZQ0S.1NU!A4 /O&WBJ'4) U$P[$&8IAOT%Z#Y%2<1J2;$+
MUG?XL#CN<9C0F^;=W>Z8YLFTMIL#[4/@]%8U&[M ':&SP*$=[IO8\>E+XS^G
MP@!ESS/7MJ\!?N8,\NNF%C):S)4G-36@BBS*:-D3Y(:FE.MCW(F%P:I3"WU)
M,Z0-@Q8U 3ES?B[$MPVW@E&PGV)J"(MT&+V=Z\F'SL>RY5 ;9L('CA,TA-HE
M >L,6YW$-=?^P=0(L2R42F"/C7&NP3S[ W("]L]7T'M/*F-KT#2>WRKXH _^
M&W7P?^"#_PQ(C&-A[AVTTH?;-+848W:N8&?8B%7Q5.;-7<R7VRYW+LRAW)BS
M2MR=%*U=!)5WEAM16OR"C^'%"@ D4@7B(1U ;SJ["1W\6#54VH]"F"-H_Z+9
M"+N$JWU>AQI"#:K0 2^6$X9L;]M6N2KZ)@^TQB)]>(>AB#.'KBW,KT@7L2+H
M30YLM#6+JYZFJU=G22Z&+33&S_/RQK7C^HP4H'9"L'I3A[%ZUQSQ!:^13&@-
MM :\SZK]U1)B'/8-TF4[)/]*\F.12)SU&H'T%YX>GR(?A^;D6O5_JD_9X5Y6
MR:+NF6V^WDG8S&Y?!SZ T:)$J)8$6%Y,)Q@5[J1O%00[U-.#Y%B3._MDTCO(
MW=3NJ[6"(-_GWC*SG\:^XWVV#W]Q!_(I[>^.Y#SD&73\<*0\3(SL2DC0%:E2
MH)%;RD5IE%.4U(%@)1Y,T24;X78"D-&P.@BET^>IJ+_3A5SYZ?)W5VVYOT+G
MG9([W!@;\XE)D0:?&+"Y?:2DFQU,\N:*6A2NC/[2PY)T,!3J*1:9[E[6_?Y\
MQL49;7H%<IQ(Q(=H;&%I[V#./__ ]]B<]WNV<'NF$]9H'SZ-J4XE>-X(!&P
MZ@ISD%K)# OE(\\G$/MQQF$2*79U>N#5^V"!:_4+#".9D90W2U!R (8C*,B5
M^P4+[J6\)>9[I;=PH%2J G'_Z/8#=5E3V*#)ZC#NZI*"X?CM&Q<E%]'X#PN
MF&"IJL>4A5#]S TF!*L$>D3\;0P+>W^?:,S//^]]6V\ZJ9C.79"A1+5IY.>
M(P[RWKM^47[7EMS<]JX[1!_=1_P30O^-4*D2<!P=H'J2ELO@V U;<_]9WH _
M=I\1/\S,J%O$6<> 'EL5U.=U#\-BD4 XO4V5_7EK<'L/C8>_,5TO(D2G]E,9
MXC:!C(PVQ';K*+UU2;AUG].40(7A[G6H0OG#S%H81ASEYA(*^XD-P6C; @V)
MJ];.3\=45)U[,)]Y6\QZO=K-55:E!P"QN/*.J%19>ZUU%X,A*^JVPB%R\-)9
M$#@#%])T8^>>^S]Z04HT!*#C$3X$AL"?OO?W3[#]Y7MY!Q&_]QW\9US@L5CJ
M<Q=+O1R+I<9BJ:>V(MXN -Q5$B@?X&T'Y?S@'XQP_H'OS)^L&CCX*8,4^@5"
M9/9LI/U3UN'25;)T;0<<'C3H08Y+1^BB_4N8DF?N:8"R>VDH6L%YDYP*ETNH
M?Z#'ZRP43"U(8NF'82!@CK L/"!XUI65*"F+8+ZEC\9$?X<&F^.C^ DH91XN
MHS]1)<?SA0.$2&*&Y#T%0@432QY[7[<3[/%6I_=BRL-M2PW@]==<NR4]KVJ'
M0:KJVO/X!2@ G\'E@\/[O)PJ]U!W<)]#WQNKKSW67K(2K(U\=>APSIT2;V(;
M\G?S3$##.PU#?2A4PO(N"P2J< ]8BT4"/;U5HX*BU&70@?W(ZKKUS@MF?S,@
MUU!#E.EY<&PSGW//M/L0YMH6IKDJ4^8'R6<M=O$GQ=K/,Z@ MLO28 VO$HVR
MG.8 IX4N3AG]RU2EKV[3'5>5D2YI"NL<1A>(QXT-IVC&2VU<%:2WX'KP'1"^
MD-,J#6-7N5%=G#A(J^L]%JQ@-*,NZ:S5:.I_;E/_?#3U1U/_<9%7/WK;(P"'
MC=X ?CLHXW<8;_*$>/@[^AP0B-B/;?'M>.MR_OE2%\^U*=C;9$CS95@'"ZSP
MR%-9X"ZO,?[.+3!^3&#1!4EK"44.2.+U?-;NUVB8EFUMQXL!P9E9-A0*I?P@
M5&[3OPC?Y)MO[V]C?IF*!";'PD!OYH'"H+Z%FO'O6*/"6$#!VJ'#QP_L[5BV
M]I:#(NWOZ%7'1T>'1W^5+V#[^+(VW];6&@#S0M8 _4IZ]E?P?CL =RU<9XSG
MLOI6OL\?LI]*W>K@Z\Y>'DZ.C__*5\; !XX/3\\W_7G3WXX.7YY/'OKEG7[O
M__JWININ&]_&<,],D]FGRPJ87@_X<,_Q?\.'^\;*"ID!WY(Q +\8V'%,]EL;
MEH^,/6]KKO?SSWTH[W%E-^EM\Z*1#(WC":<Z;"<^YF2M(,!?_OVKXZ.O-L_<
MF6]B:8.>ACA$)'?$-JS-0YS_=4OW/T ?\D.//N1A@K-A^>@4'IULQ0(^DG"-
MJFA410]519-1$W56#EA\1K4SGIKQU-SSU$S&4S.>FO'4W//4'(^GYL^9N!@$
MZMNX,[L$\]EGLG&?- CVF *W,7C\[:BO[J6O=FWBXV1W=;*C2(^3W;')CB*]
MXY.]O\DG8<T[6G>#X_QB3+X[LI&N$Y\MGOP3'!;]R*+<HKF&&[UNDG]YK-T<
M/+M/.6=,<C^B=!^_/(HG';39+VF_'T^,QT,['MHOY=">G\4G1^=?['Z/AW8\
MM/MW:,].XY/3TR]VO\<8\V=R.'QEL>EW#M[#=?W"]=^=XQ%?^#S'N7V9<QOE
M<U?GM@/&XRB<7_3<GCQ4J_N2\(D/<:IT2P<^1#_U:$.CT[986AW:E\=P5;YX
MT;N?+_)\TWWZ&$(_ _1E.IXOS^*SLULK<,>]'H_M+FWE%W]LSU[&KXY>C7L]
MAGEW?Q]WY<R>OHI/CFXM0-ZMO7YXE'?T5>Y5AC+,Z3!:/SM]NO95DQY/)O'Q
M\<MQL\=SNP73'<_MG<_MZ7'\\NP1ZLEV>;-'MV4W]G%W#NTD/CG=LQ#AF&/Y
M+'[+ (O5:/KL],':5RUZ?AZ?O1P#MN.QW8;ICL?VKGO]ZBQ^<;1GML_HL.SG
M/N[0F3U]<;9?>SWF63Z+O[*>,6^T?W;Z?.VK+CT_B5^=/$);TA[L]7AL=V8K
MO_QC>QZ?3<;\Z.BV[,$^[LJ9?7D:GQW=BNJZ6WL]IED^B]MRT2&!RXHF*2XS
M(& A+LW1#-KI8[:O*O4X?O%JS+F,IW8;ICN>VO'4CK[+N(_CD=V-K1XS+I_%
M=7GK"=JA%Q_6]Z"<'[0UD6@*271>%I<'>79M?QP]FC]W^F[G!?DBSN<#-_M>
MK"A?IK*>G,6GD\?3UG?A1MEEB1G5PZ@>=DD]_-__U_GD>/)9!&:W]<,>.FFC
M<AB5PWXJA\^:R9H\ACLX^1+=P5_*)LFC\MX@N*,]-ZKL/579)Z]>QB?'CX<[
MLS,J>]0/HWX8]<-_G)R?Q:>O'J_&=V_UP^COC<IAYY3#BQ-K/!R-RN&SI_^V
M6./\"7GZJ:SK:%Z5"_'ARF+TW78[4;ZO-1%?3R8OXZ.3+[H1]6XT7M^,)_@+
MVM/Q!-_]!!\=Q<?G7S1>W6<\P7OH_XS'=[N/[WG\ZL6^'M\GSTAML4[X,P6'
M(.JF;K"\L&RN3!5EQ:Q<F#@JS BH_24=GE%5WKE^^RP^.]DS:H+QV.[[5G[Q
MQ_8T/AK1M+?2 !F/['ADUW5*O3C?KZT>4R5_SA'A&K?1AAFSU&.6>CC2<WP2
MGQ_M?)9ZS,:,BF)4%']*49S&DY/',[]&/;&'[M6H)'9<28P]3L_5X[3%&N=/
MR-/?31/E93W6N>UVF&-?(UI?3R9G\<G1%PT2/GI6XPG>YQ-\=!2??-EAZ='G
M&8_O_A[?E_'DU;X>WQ&([_-@B*?IMY&X,E'2-%4V;9L$,,2;,BK* CY:E7D.
ML P9YZYV[IB.@:<Q\/1DBOQL;,(>W:M1-8RJ8:!LZ.7CL3GMK6[80\=M5 R[
MKAA&(-\Q3_6X>:J><W>1)DO@N(V^S\K&S*X*^X[+S([R=5DM2T)Q&&VWQSEV
MD\,)G+NT;&'QGU%)WRTB\Y<GT];#"_'%ZVO,EDW.GJI6L;-J>U*%-"J.47'L
MON( ,(I73X7CN9^*8^\]PE%K[+S6>!E/7CZ5D[@;6F-L4/MS_N+2V&6[2BKS
M(,\QFI6+A?T//N&JS*UXU7$T3>ILAA@<:9:WC4E'.W'4^*/&OTLOW.$C8@+L
MHKH?M<:H-4:MT=,:IV-,:M0:H]88M<;]M,93==/NAM884Y$/$JQ?<8E,>I#8
MJ227AIS#.FIKDT89NHS+%@G BM$)'2^&+ZX494?O@^/3T_CD_"2>/!F=T!;=
M"F,MZZ@I1DWQ8$TQB<^.S^)7QT]5USIJBE%3C)IB%S3%47QR=FHUQ>,QZ>R0
MIGAX[G)H$^[J=7XQ#B:^[8;68VK=NK5B]@Z1_G_,BJ2894F.3M\[1S/])FF2
M;V\3OYW4R7:-X2___M7DJYV>YSBW+W-NHWSNZMQVH#9O%,XO>FY;$;Q?9&F:
MFRTUK]:#1?S>UHU)HQ^^?_O+FPM9W/5/A\$?G!Z^.'^E_W>V#FS#K\"+PY?V
M0\NRSB",_VUE\@1B_1M25F-V=]<<[C&[^T39W>,7\>GQR>Z[W6-9R*@X1L7Q
MB(IC<AR?G8]-!Z/B&!7'J#CNHSC.CN.7IZ/%<9>2,OM?J'#"'[=")2BGS+YZ
MX]ONJCSN.+=;WQ?,[H6@+_XIU[<C<'6[M.>MZY<^9!&4A_J09(=?H(>\/.IX
M[E%61PF@.Q[\[>+B?31W^9&%2>JV,E%SE331C8E28_]FHJ3V%7D/JL-+Y/WS
MLG(PDL-<S+'_.U.DQ?SGJ$G^B+[F7WX334UA1V<_GQJ[5G;X]";[S&11VEW\
M%_W"/V2Q3+)J85<DFI5U4^-84-<=E/.#MC;X70PUV('F97%YD-MYV<?5M6GJ
M.((Q5>VL:2M('O%S\4M87W@P3:".$8H8[1^"EQ]&[W.[LL8^8FYG:U<-V"@F
M1]]U]@5_>_R=G5I>WN#X$OL5NX^S+.?Y34US8TS1VU$8QI_:H]ANNHD6=F6B
M-+,O;?(5SB6I\"G#@A+3>MMOU+.VKG$#IF7;X+/R;)$U^.PZ*N?=$1_>7R$<
MG]]+(]Q574].CN>3NV8:'^$TOL95S6J[6'998*7^QR15'?U0I'9UWIB964RM
ME)P<Q]'D:'*"2VQ_F#RU!GWN]:*/PJN^M7*39[.U*_C!7)NB-?=?D,]Y73Y8
M/@;O2SK+4E!  T78X:1M2K&(8"Q6-\'0X>,'>;*RA]$^_@^3?D>O.CXZ.CSZ
MJWS![FB>+&OS;6W@H#=&U@#U(CW[JVZP_#JKLZE52,WJ6_G^4!0<7W=Z>OAJ
M\M?OOOJW-7\_/IR\V/3G#7\[.SP_/U+_V_39C7][^!!>'!X?!Z'MSS^$L\,7
MYP]]Z\-G??H,KWR4O7[P^T_N-N4-R:7SC;FESU*W<_YEQ1-V;EXN<_SBELSQ
MO2 N9=1/N# ^\/!4E5I@ @U80 ]+3M\%\W(;%O"S9>MW;;+C05KO75PEQ>6M
MM.+CN7G$<_-H7L9X<)[QX+PW%;P$?/*^?SD>H@>44^VXQ7OGV.U=0AI?9T74
M7)5MG11I'4?FCYFQ<K,DF4PN37UKNG$KUN19ZBSW3U=!7'#43J-I/)Z:>YZ:
MR7AJQE,SGIK[G)I;ZUW&([/GON1X9KHK]]?QS(QG9CPSHT^SS<?FRYGL>&I&
MG^;SMWWN%:3&N@5]NUBTA8E^-FDV@U+0ZL^$QK_P-H<[JZ'M*-E_CNMF'Z8[
M2O%.;NN^3'<O$#AV8)+CQ/Y_]MZ\R6TCR1O^*@BOO2N] 7!Q']*[&]$CV_/J
M>6Q+:WEV8O]2%(!"-\8@P ' ;O5^^C>S"A?/9K-!-H^<V)4E$BS4D?G+H_(X
MMX416=+"3G!A1):TL!-<&)'EF2[LX 6TQ#+2/(:)R!'W:8<QS)$2@PQ'U9?S
MM$[0\_*%E_=IM+/'A:I-G-!RCU])XC2LUQ>0NVFK@3-><9E7.'0J"$_\>[W\
M:QFJYXW7]N$B^?>\];YS.4=BWF<S[QM7]8WQ>OZ=[*&/4K/M KAXC>V]Z\K/
MG]9-X^V3\7GGM1L'!GABA M<.:WV<E=+5'WQJ]T_G(V<L,\X@ ]8X"ILRQB2
M*_:%AL'3\;D7:??O$YU\GLHU-@#U#M4\?GV,\B53#,$#P<,EP8/KJI9_J-[
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MNF?;X41R;<: *!FBB\*_S7A>P6)G# 0+RV!"19)4O%;"1_&"[_W!I(JDFPO
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MS0+-5C&JPN$KV(^6M[< RT3YA,S?;2J,H-RCPM:O(<;A'.L'7+_CJG;@BL<
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M@-K=%U;+^JU_R0X?\U)C[^U<<R7:;NEUR;:09RG(%0%H_%M:"<Q^-CX\ "K
M4(!/">H/7(H<A*:AP.SM:SE6U.B@XD, KWG)!:@"=DAL;W4E5H,L9 "U*,1R
MV#G 1P5$9GTG!<J4/0H;(P5*54H&.(L>F5CB(;R@?1',"=[%FEF%<W@.1*R0
MMC,4E;" &B;*;],(</<>P%W,0SQ0LS]!:L7W($Z!TQ 1&T,&7E7,T#9!ZU&
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MY8V0[L6\@D^JM^]>.<WGN1NZ1\Y^LYNKM>78O"[:6@PX X0=F# ^KH',*.:
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MU&6/1=E<-[<-C[N8;V#"61,V)9\3X@K8[W$1:Y ABSG&.*33$%!3&KUE!V>
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M@< 0,YC/Q&7=H[Q'*'D3DM,DWR!.(;_5,IBAS;>ZYT,\6PA)'F;P )VD(FZ
M#?PF_:RNV(@<2MY-9R;2H<NJ;LX6CP)0,!,Y/G  K8=HX9:T]>?(FZ;MB38]
M!;5I3_TMD;C2AQ$R<=&(/Q6I8IA$)GR,@L(7%8@VRGO='$42$V;^L*@LP+K,
MBVD:H2(8ITT$C' #BSH13=F_&$RK$F^E6[6,-P6*0 2C.MDK/>U541^_.'1K
MK(F\1T*L'S64L"BX6P)?V,BT3;M#M0+9(^>WC0]4Q%$C.[2_6T/P R)7_N^*
M+K*8N];=80YUR)A/&Z5*7MP/O:/M3?Q0W^LV3*I+G6>Q85.U$YM-\2B1BX?9
M]TE6/#1K:AVK"^D?,IZX3>-:\+(.3.[E'5\3V;V@ZXC0\(GRZY8 \!7]J(EO
M[]0\B5R#N38AM/%*^H1,>^B-^S3'HQ4>U7G>TJT P[P)G6]](<*T9\W+U=:@
M7Q/:+IP[?? ZIFT^\(48-%8?ARM5<8DA7A_=%44E73R/,U9).3;D3XDL,JMB
M$%''\"%D$OG4NAP)6&0M5CGXC']+10$$8>2UD^J6@I_V(U6RP)L\K,&:V\Q1
M7%L_<E//KDOL2==8DH,H;-RX6>-K0JJ6@1*]%U0JC=U5.K+W8F)'.T_2#(=.
MFI5LF(\+F_8+9L/\(K)A;H2J\Y*(J(,O1[EJY:.Y-%JM%[Q1;RQ%*":&IPP4
MPD7-KY-^"P#0:\,LEV]!&807/.RQ3^=M:"OC@EWK-@5L,06K\6=/,7URTTN$
MRV3P%EF+IS$ &]\"*ND8"%Z)($4^D(15FW"_,K1(=Y_GK7"9YX,YBWG5&*G:
MJ.%+D_BW:EE=;]/S\<$F>4W$B6'8#B9D-A?B_:]:WW27N3F(G5O)X$0%@)72
M#]3)^&87NOBT=OG2)]XX8N1E(0PHW[:ZCN5M0:L("]J@(!K ^)+M-(1RU-V6
M8Z\G0RC!BJ]"N4FZ&VA5)KUD,!=Y>85NR.<(@759M")DK.)KB$;&*168#B R
M9E!2BY&[%^-RBX=\7<X,B';4'^$?S45M)V<6"G&+8I-#V;E2A;553#97^T8_
MR5V1B;3$$HA1LFQ33WFWHE843G7L<"J7PJDNO<S0ZVLWH*SQI?S*$JQNM'8$
M.EZO\O.%\W-,BWW%[(+72HL5"J PEM-<.!>V)O<<DLF5-/Z/[U"B?[6^#BWC
MKP-;^FM;UN(T"K)\A-DJWLU$^:^A)8_:PW^U<W[))<_(LX6I_3BH"G(3%O-:
M^56Z W]/JS]/:*H;[<9CX^2A%KX[9'5WL+^CT3<\IQ,4*P>^M_R[]!2#&E]4
M4GUOO-DE;,MRH;2%V_6^(T!?H13#^#"@#(VWSE.+EA]85UV6_]JRRANO>\5/
M,(2C<8/%6T8737V<0;U^?.K[0!]6?>Z#V+"\UAW/AO/'2Z&F%T91I>U\BYP_
MMMN"B=B;)]O-L;H#J:")<(@M5:1]8UCR5<P%9O"WR9>)<HLV>B[-Y%)8U4W/
MFEN>1X^#D=3%\+U9$\$-)N.L$$$08;%EQN;S9FSK_K",\),S7ISFPHR:62Y.
MO2T.A>?Q*(E2I 4O4J6X>F@HL7%"@,D.YX6%=Q];CP/>5(BX$%DA<1C'<-?E
MR(,M"H0@KCP7:;MY3*QLUT $0]=EF25E5J3#J(I5UI%! ,*I*YWR[?WI]T:_
MP1B*(8WR?(U[O:MFIP&7:ACJL;#=K&H]3G'3IF30/*8;>7U!.!.]*FE_I[$0
ML,B&FST,S6^</U5[5G*V78L-=#-MQI(F&^P+7KA)1TJS1T6>/?:5\W";Q!5!
MA>X#Z87"ZO-27>O*!385X1^%)Z,MKX@O;,/#^M^(T@XEDS$V\Q)A4-)FYW$7
MM4C0UX[QR??-!6&G+6*]O7(^;6_BI'MK,>9%$+V@W):BR7MQ;.^%1]Z+"_)>
M](:-_[5CQ:^]X?85&/AK-9_-,OCW"1DV_D3Y.<U/R"IH0.Q+;_(B]'UI=BZO
M40S_R&JVA_7Z:D@Q\A;=Q&PF,/\O:8$)4#E,XQ85H@^-0K.EGM+F[;$O9'<^
M@G'T#07?AZ$SY>=.//:4=;U[])1E@W]YA3OG$3T%EW)2/S=UOOY'%,#^:?W5
MD]H=&O[%>/YNG:>(Q\4U1J%\<S-1G-0[-J^+]XVN@W-!U0>F+LP3T%N+.>B?
M6(#LO7P56$H3_8?V!R*!>%;Q=^VU9;L'X@91COV=[#E>=PH;)KG*V_5W[>^;
MAQ9:KHO7!>8D,']H=+DUWWL3W>^^;ON:#U_6:'=B,S'?%6];\UAKJ#01_UM/
MI0^P1*E7OI/:)7ZP9J*+6J5N@!:YU!M^FL9QQCOEOVST3?'HD51+L'=+GOS'
M=_\B0[N^HF>L24O_6O+;M!(I.%]G\S!+HZ\LBC9S]:;]$F^-,5Y*IG2*.FIH
MJFZY,I(>^$3YV$]'^;V;CO)93&=X.?%S6DX[RF;/1I[M+//F\X>;3W]1/O[X
M;N&>YC__W_3;N[S(?P-;L83IH ;[\U>N>YSQQ- <.V2:S9) "ZV :4D<NCKC
M/(JX_5U;.^UWW/L/7ZV0!;YNNEID&(%F<Q<(+ @=S62QZWD!3TP>?Z?D; JK
MB7GZ[F8>8TH@+OIC_'R<W;1:V^RV<&%E_[FG*-OTGK<+9D8=C\PZ:T71(9E)
MO'T/>;?1M W6;1"AV-,HUN3P?94Y?,? J@4E^2]-"N$7\?HA'A&EK]V]P"!*
MWX_2!YZ1/K;LZ 3_92'([5,W$2+]ITG?)-)_,>GC?4C)[_#VXIY_Q5N&5V:!
M#\,)B39KQ I/LX)%K# "*^1BHF"??X55RTY17T4CSZ^OS16BL!:&!_.R:M*K
ME)_^.0=+G[CC:>ZPB3M>SAVLNOLJTBI>6T!@,,K/.!$B_:=)WR'2WX_T153L
MU[I8?Y<:-P[PK]8QN.&W-D)W]PLE8HF-+.%N8PGX+SKH+__:@A9WKHNCP*A#
M!T;YQPJ,,BDRZG!+;$E(7"N]_';NF'?NV^[O3B@J8I>KQ),OMO#BXN==X>O&
M/N_JN/VEP/;;&.8B$!J+Y\ _#A,[=;'9CY]F:2[:M\C@\^=$49U ILKAJS^(
MD&R&U]E-%^J%W+XM]3EWI47E#8[Z08[Y=E.[]$%*BBR+W/<,>3*A7Z1K#)R^
MZ(56898]2_V;2&EI*I7T!1Y$H+IHC]+6- ;C3>;(=]D*31W%#2GSZJ!!L)RQ
MS(9\T];Y%44;RZYM?('KWRE/\NT$L%NVP),4K.Z87]D46Q#9#9B.DXIF]GTQ
MQ"99IZG-,RB4A=DY@T9'S8EA?;EMI]6O7]9!PK0/_$]?;D'4\!*UB<;<=]E#
M&G-!\5Q%$0>9,M,U:@1"QGJU\4+CU#*%U6)[A^LN.,>RJEA@?75358RJ:]G6
MG%4CKUOR&,CM3]BO".&\D5QO_I:GG?^M>JO(*)ZWZI"\_JWJ&S2(-G1%)@LH
M]H39U[S:@!V#*MO8"Q?)'--LP Y/ :I$$M#']AT?Y#LT_."VE'X0[/SP4)1_
MRL;;(K.IF2'05LU%=M 7K*I>B#(:G\I;EJ?_N]A:X0_0YF-0XN6O9-NS-Z9N
M6$K2#O^V:P/2%.AOW# \+.<8$VX&8CDV9K1@;P:1(:/,<Y%8+,OT-[),5*-[
MI?SG$Q7S?Q$Y8H@KC<"_7O:6A?O6RH:V5M)"EX#')<3_MV%!(9D]N/1\*IR)
M#9DBD1:+2E8S4%_N;]U<%LH'"A225:A%D45%6E1#Z$[ *E!ZFVM0P%S$!K:M
MZ9NB2&UMIH'!UG8H%.*OK5?0PM@&]!,B)>&QR&L<)&YF[*'7TT6/PDB$\9;S
MK"M3?=O4ENXPXDO_>WSBIV]-7>(!9+1#BC5=MXC"BJ!SD6G:$\CN0DKLG_+'
M'=8\[+]MB*,K<#_+F-SS8?]@\2J1=AW*FDM=[4A18;*4A2U%68)AO]^-#)>4
M4H1T&A@>=ON(VHT1RS[$H"ABG4^L(@D3D>S7+;ZIG-',5BHT1<1CD2(JE,NN
MY!CF1E8;7]ONT[I)/S$E=;AARU/ ?95@T?0[Q/T74VGR4 </]X5 O@%QY#"4
M*G-A1<4WD?2K*AS;V^"&]V7,ZJX/8U^\K*T6T38-7]>^?KB50O_I)R#KUG:#
MK],7VY35>*'(>U]FK6WJU$.GR!=^X-A!H%I^15NGME'6%SJ,KI\\<$13TU3N
M\H IVB9 ;$BJ82<0!S8$:0R#*V*$8DPQ%['<RJ\,5+UR+.?8TH58-0=^&2S#
MG7A4O'(434=H_++3CSC&J3A&401AGHL*E#'R3?$@VUXW7S. )*%3M&V8FK9J
MK=4IQ]K"CXT$D04!^C>)*I4+^L?"UXW.(4>/.O-""GU6RZ[STI$@X5P"D2BO
M.40YV2Q6-%1KL+T9>;T,P@;$YEO,T"^R^T:>"BTH%78R:"%9QO-; <!-"R=T
MHXA&]]@*\5O7D;DI#=DO:@!;ZP\B+KAL7,<R62I 9/VCH32 I;7=8-:+IIK]
M*4IKPED^W!58;A.7]R#51GB/*NI2]/-KF\JMG9P@#+7!3]DOL4V76IG:V@$0
M7?.AS%@]JK9\9EJW)WOH0@4F7<AM3^>@"[GSO)![]9OSA53-W3,S?6]K8N:+
MTC M?>*Y6](PW6!BVCOG88X9GV5AM$_[F4AH;3]<4H[@^5546_QY%T%D'3&4
MZTDR>P9[/!U&=5';M;^2OXO&V_7-[5O6[1.E2,3^4N5]E\/ZD5>@.\V&FN*B
MJ47\\2QPN6F:AB1SU-UCL;NAO.00I6RM3A_?09F&Q]8P4]])LAHT]EZNTRZO
M:5AK,F%-?ZQ:_TT\#E/+L1::O-+KS*R^J2!.2QH3>9%K)<<:@&L:3F.!/,L8
M%!N4W4*Z.>S<YKSO)'+4)N>RH_M3A=?5Y@7MO@\6B";F][8Y<1?J+PXOG./V
M<GG01'?UPE:\ .O.._;$:\>:[.GNV,45\7K%4/?B*K3JD)36-"M::7PLB:%O
M*KR!!"21B'Y0:$6W#=1;FUI>$C0='%H#>]ABJ'U?UY:H+1DI/LR:2;6=W(>6
M.-A^Q520S[ -/3*\[#;9-(R^DSV6^QDOEH]LKCC[QO7#GLC-76TFKTL[$)F0
M(#Y50?S_%0_H1+Z)X^9RN1?%*#S0.2ZX@.3R7@@"6ROOB]IK>XP[PHLGX59K
M.^/)70>I#3-H8F=XU7[<Q,Q@F\563N9-F\F&W:J^N>3R':NX6*GDQ>RPCV^+
M#[U: !9EV,9FM<*D:4'6@D+3&V>(#9VH'%Y_=-#077_TZL2BY[,1P/BN?XA"
MKIW[L^F?GC\..OO*+K==EVB)N#L+75E_='FM).R&,:=XQ58/VBT+\GB.8!LV
MB>.MQWSY*K"]85OLE*P"IXB^A8USMN_G.^4<S[^2-[N#>[B63MOK^D4JED(;
M%$WTO,ZKKADXZKKS)RA_#:EWY+-1CLJVE%CP5C0!%Q/LRR$W2N-P2/R=C&[
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ME7;+V.P=LMU-'N-_?NIY[J;^P,H2*T#_-\OF_#MEGJ?R+7_[^K<O/X*T@W.
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M0T\SH\C7[,!B6F!:KF9RC[NA'=I>N!*_O=]M[,&!RK=4V[YVH**PR:/HN9^
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M^/^O1)1RT@KKEJ2P6OF11WP:\E*Q#%4Q==,2OC[XB_G^.*1K)88;F0S0)HR
M= -N8@XIT_Q$=R+3<IV C7(EN^YT/U;5_-DGBWY9/%T4VA7/-ZV+ \O9#BS$
M95:BV3@]F*.OF5%B1[YNFZ%I'HIJ#[FN!!-Z+5?7.'<BS389K"MPN:;;+ I-
MWS&<9*5URECG]6E>5S709YK?'F9Q@>'9B:4;,+T0#BV,0XTQ. \W]@++Y:;-
MDP-(PM$7EQ>[0,QK@E J*%1@3=&O>SL@T5W^18<@GF5L[1-7=BQ.8L.PN.8A
MBMB,&5KH>0[>AWN,.P%( G-$4TGX#\WW&R[GB(I.:FT$"-<(")X3N$8<:$F<
MV-A_ _0$%@2:%9IZG)@L#JV  .%L(]NOUTN'T2)%?EP779P8W$L\7[,3':2K
MYW!0NHU "Q/?,JW \I@3CU,E M?V>OXYL+<,W38\+7;= *MA.*!%&&!\)0ZS
MDS"*_&"DS/)CK?.JG'.1JWNVB2TJ'* [&V!>"PR=:8D=.H;OA;ZC)R.3Z9$\
M<Z;C>U:0>-CP.4*WHZGY2<(U]#AZNLZBV!FE0/PA5V;9Y)=;6W^2F7! 7JQQ
M.TJ :G5="R-F:\S679/Y09RXHR0@KYSM7LZK72G62SBS0L/6W,@T8(:<:3Y'
M1[D=1[81A$$2C>*]6EG5_MZ=-9YDVU%UWU1-[[4@%&GQ*%3(XRAP? !+SPUP
M[ST+J! 0QC0LRXD,.(9H%(?<<:G0\F,[X; JW8ICE @&0*8)2V,6=Y.(>:X3
M'&15XU*AI1HZ4**^KD[BB?L2505^.>,PN7N>/1EI18Z$$UKNE3@2#G?A9ELQ
MR##,0, +MY@%&N8?8(EIYIF@E/H!'UD$"A-BK'Q]^\I3]0F8KOTH+Q28?-?4
M0PMTH3#DH.&$IJ_Y+,*P*Q8EB159'E]QY[Q0*R)@.HF\/_*T/H-Y;N(X1>IB
MF3)C:0Q35R(V2VN6D;2X:/XB:;'@R=%]E[& :=SR,0[)MS46ZZ'&&;/C.$J<
M*%CQ#.RCQO;L]AFX[6/^0?+:6$)#M1U3==::T$3;!%.OOER"J1=:VX9M6J[N
M:&[L@HV=^)X6A%:L>8F;>+;OQ)Z]<OFSCU)[:)BR?$^U;"H$3<$$QU!QHV@^
MG6=X^ZP4]1TO@4&F\*L[GE?I/5=N&2B];[*BJIZL"D'"Y(262\+DA>7KF.6"
MKAAHB6TDFFV[KA9&IJG%+K.8:R6AQ4;)21OPWR=DOP]#[ON8 S/R7X#Y?N/U
MI^0/]FTD(6,:SI6+%P*N:S_*LP>N-\=)&O-"[KFQKP6<>9IMZ3IHU8ZNA8YG
M<#^('7\U\F\OK?I00%C!WL/?GFH8I1K&\TM^GC(C+5+"ID-?J]61>_GHNG?,
MDS1*J?'*WAQV@552J0SJ\<5=:!JFX<:)QFS#QP(-CA:ZL:U9,2:DPK><C1*+
M^3NOP;+F\4^LS-/\MAI@P8\2"L:6<(9JV+9J60?T?Y]H7=472$+"7L)>PMXC
M8:]M,B?T8ZX9KLLUVW1,1.%(<R(_TDU=-V-SE.2;XV-O8 081D[(>T@;A-KD
M[,&)LDW.3<QF&)^M_"4M:A[=Y3#@;0I3^E"4LZ)D@DFKO<MGDN0\H>62@^V%
MC1<2A\5^%&FN'5J:'5D>W@QX&F>A&=I)Z/)@% M!1$TV[/:38+.Q^B_HOFI=
M?:-APJ=K/\H+Q:?8-R,6^J&FZU&LV4%B: '@#\PW,/P@#!UNK>1=[J-%'PR?
M;-=6#??:+RC)!W\4_1>;G,(_RB++,).Q[8=.$H-\0>0+>DT_O!T:@<M]S621
MH\F:'MSSM<@W=<?"RI'1*%KVKVE>E""[/C:,/[K7W5Q7.("\/N1O)XPEC'U=
MC&6Q[GN^%6L.#P/-]MU88Y$=:EZB.[$-=H(=K)0RW\=2.#3&NAY!+#G63\RP
MD(YU\IF3]"/I-TY]*M-U3--BFF=@:48SB32?<PY_F(EKNS8V?3V,W_UC'F5S
M+'3TN2AQ0C=U7:;AO&9AQO\H%CT(SY=Q3_KJ3<^_.OE&_GS"3L+.\>X$C,0P
M8M#5$X-ALWB>:*'MZX"B@>\:L6'&[$!W J^(G7B/H >$G2=VUW#M)D&6LC#-
MTAK#:[!&(ID(AQ9SYL1$UHR+.8#.:PJZW:SV[P\F\=9OQ*7*/-N)_#C6-9;H
MV,O.Q6IG =-<PW+BP(T2^',,>^&7GI]O\OA@M^(P?]6P#ECX;"NIG)<\(Y D
MD"20W*UA0L1TWV&:$P6A9C,> 4C:B>;IKNGQ. D<-LH5P)% TG=<U36.=AUP
MUB#9*OWP7S3&Q%]/ O[Z=[OPZJUOVW71AUY;#PEKN-6TC,3<P*U+<]EGL7_<
M<85%6+6'Y8\8PY07-9H6)7R<BX"FVU(4L"QKI4B4^HY7'#E:6*HB]SA)<Y9'
M*5Y78(.9*8Q;399V+T[ON_W+^#<M3DLN>.L=K'(^S=_':37+V.,[_/;]C,5H
M\P],XU0NH+$J=6 <^.0?\ZI.D\=V,>*W&L]C8+-ON"LPQ+N.X[[MR%:&^=1&
M[GF.VU!WA',,C 4NA0T7&W_76>0S=LNEL0TJ+4SS'<L>V&/U_KM_7SZA=OL%
M3:_N/7[P] X/S6U]8OC>#X<PL5_&.0]R22&(DC&.8)<TF+6'= QL$1*[9]"O
MQ8S+&56GL7D?AI#RI9NG4FR)93CV'!/E4[=K9R,>1MZ#-VD.0J"85RR/*U7A
MWR*.?LL[*3!B!3:H_=>TF,,)OCWB3HV@)-R4(,F>IQH(!6@=[K%Y7;0Z'TX
MX1+FBX]K(.R*.<BL]!N/W\M7&;H^T7]H?Q!A>[99Q=]5'(0O\$.[<*':R[&_
M6W:[WJ=5*C3EQW?M[]?X4^7K'&]B6,8/C0!8\X Q<<UM7V_[3I]X^_]X8ON7
M^]XMWG)_J[-\'1WOZD%_CL?"/R^'Q24N#4X>O_F/[PS]N^WK?-:=9#OM ^[,
MRU3@H:S:M'7_PUFI_)3'H"8,NT;M1R:[W,&=P@:.1%R$/80].V./2="SM'/8
MF(YPAGB$>&0KCYC$(\0CQ"-;><0@'CE(9-DSDTWV"20[_4BQW_D]S^=\C#ON
M5UK\JP0VG,1!'S1B 5=XH:$(>A@Y0<0-S=9=[#+&0BT, D<+6:+[S#=USUS)
M[[!"%OBZZ6J1802:S5W C"!T-)/%KN<%/#&QC^5R]3_!6S^7Q?0##(:3^'M:
MWWV85[!P7O[TK0E8OJDJ#O\7C]=UP?!TU?0.467\E0C_\)%9A%Z$7F>!7D$8
MNX'%8PW^XFFV[7,M# '"/"]RG2@,#.;9R^BE6[KO>J&M 8Q9B%ZF%O@^(%Z8
M<#=A%O=TZX30RW=4F#"A%Z'7":V5T&L4W8L;+L<B<6:D@P+FAKX&,!9K+#&#
MV&4 2,9*DY> &[;I8Y/%6&> 7HX'CP>1%B7,LPQN)(EU2KJ78ZN6?8CP^;-!
MK_VSO$:\/#H)F'@6QS010_FMPK_-> Z$^4S/SP5(@:==@1>P2%K8N2V,R)(6
M=H(+([(\TX51S^FC:%0?BDJDHI1TRW'1!@<9V'V>);.,,/!US4A8I-DZ-S7?
MB;F6>($?!Z:O>_9*,OH^EQO(6I^2OQ9%+/(L>7F?1KSZ4F3Q2':TYZB.8UVS
M&4W0=*6'>*'09 7<3PR3:ZYEZIKM);86.I:GZ3RR_"!*W"19\?WM<W-Q<&AR
M/#70#]'6YJ*IFJ#I @[Q0J&)F8[/$@L0QC3@#Y8P+=3U1 O-R./<#G06K92M
MV^=:XN#09 >JI1^B$<#94#6ULSE2X&#%61G=B4S>&.SKK)AA&C9)BPOE*Y(6
M??M@[!VLN[;F13[7[-A@6H!RP___V7OSYC:2(WWXJR!FUQMV!%);]Z%Y=R,X
MTGA_BAB/%#-C._:OB3K)MD& 1@,Z]M._50U>$BB2 AL@T,AU[ C$T=U56<^3
M1V5E4A84DXED8OI)(%QAK*B*US<(^W&U.=C7=C5C8[J50D:#7ME(3P,0XD#I
M*97K"$E8X9;B+@O/56&FJ(%:FQS+B6C3BY^]$WH2=*PE9C(C/1V?$ =*3\HF
M$JE6X%3R( S38!0-D&+QM;,U/-:JCGVD .Z"GMB8BZ/>I<"M[)WXV[^6U;DJ
MXU[N^<]4TP1160P44J@L;O:,6'8B) E*I0B"IF*7"A&!">&SI"0+S?IPM7]-
M76.0HBO^<@6O?C6%,6.I<<\(J>GXA#A0:LJ,Y4AE A9J=7*I(]BL"NNDX!-)
MR;OU*. F;O;6J<G*L2)';<,B-1VI$ =*3<+RR&P4A9J*W2,4H^!)YE#YBE I
MD[&A#Q=[%]0DE#QF:L+M[)VXU_^3IJDV+Z@.MHOE6TV[J(?QWF/2^%"1A?KB
MIH-9("%'[T#9HBI$9AE,#*ZJCQP-R5&GM>8\FWC9ER@K^N+D,XSU[&KSL=U*
M_[)!+VWDIP$(<:#\E)1WAID(*@@!@G,)AEH*U"8A/)5"J+4MHTU<[1WQDQE+
MAADWR$_')\2!\I,T7'F?2"&7XC:+H K-!"9!<IT22\KQ]8J"F_C;N^$G+<:2
ML&/F)]S3WHG3?7(^*P/\OZY+5CVFW4P7;GK:U!9)KFW3XL'Z-Z@[]F*LJ#N>
MH#N8=39Z)L#44HXB.P,NY@"$Q)0(%Z&HDSY\[]M@>YO?7$/MI$-:7_E08V5Q
MDQO9Z?B$.%!V$EQ9DB@%$R0!074 KPKQ2&V)]-K(8N;VX7DC.^WKPD9V&H 0
M!\I.2E!C>(S 7?6A75=-UA2S* H14DTRM[U4DT5VVD^O&[>Z-X#2F_,+U\SK
M68BN-%J=7YAE6+:KKLSS-.D::T]FTU.8-._+2W3&-\7=PPVK#@*9FXCYFWIU
M#4DI>:(B5\6#+XZX N&#!&-B!D9X#E9(5YSWISCT+EXL7MZ ^&W^I0[K;?YK
MFTZF\9<5?'\JZ/VI@K=7%<7D6+!MZ:C'-"P;+%J.A10?W<AOD)+>I(WA85+C
M?_R;893M9,$@.2 Y#$'22 Y'3PX[W7=F?7C [! ]X-]F"S<9S;ZYW0KR-7JX
MZ.'^^7?GI=&B^+5,B52\56K >,]!$BF5=EZE]0H>F]88KW4R+].;^O)BN=5C
M3K=5)',PR@B9#YD/F>^+1,^4E O.5]K*=3M<@->F4)E1ACCG,B>TKQ+FVV ^
M(\?";NMH##(?,A\RWT"9SY'D2#0>='8U39%&J%OOX)W4E%GE">_E2/FVF$_Q
M8O,19+YGWH+?8SI] F1^FK7M*,]GYU=!A=D4@PE#35,YRORK/U[-Q':WSK76
MQDD.GHD(PL2J7X0 Q;G@/OK(>2_GT*\[+;^9AMEYJO!]O)YIR_R65P]ME3,]
M)GQ I4L^%_;7Y/HGI+V#D";2WA[1GD[.F>@L4%&L8Z&]!9NL &.))<('053N
M(ZJP"]HC9$S-@.JU(^TA[2'M;2FDH&SNVNA(E4$HJL&08KY9P60@GEKM>VFZ
MMA/:,V.KD/9VDL2PQUSZE+3\2A2I771)^+/%69J/FFZ]CD?3A&W5#@,VJ%^>
MH \LDXZQ$"%JE4!(&JHGK\!QFJ4QUC$G^O#^KY!V,HUO*\Y6:J&O4UQR+/E1
M-^!$6CI2(0Z4EIP@/GKE(!,N01A=*(:P##GDY%DR47+2AW>^55H28X)=U)"5
MCE"( V4E8JE.G))B)UE=VY9[J(6$('OGG4LQ"+%F+&WB/&_76!HK98Z9E7"_
M_6F^\F7F/A+^0/%QE(2_F^BKE%:DVB X.UNU2 Y%@5 %0HO".IKD+'KIK':%
MU9X;;_*Q(=M*YWIV,L1MIGY/E Z2ZR['AG3W*+H+@3'NH@%!70#A?:&[)!@$
M3H+W0BJY7F;S*5Y\OW0GQHQOPU!^/GP@X2'A'2GA]7W\_2"$C;O"&ZV5G]-B
M-)FUF$W^V6@OSUMTCWK'$9R]M?)W-FKTCY]>EYU(21-/0'*JOJ[7X%5@X#65
M5DHOE5M+RMS$/WXWGY7'V4X*NAQS\NVG/;^VSJZ/,NTMOM"H1#)%,MU#,@W6
ML,*9!+P@% 1WQ8E.EG?_84):EM3:Z=%-O.\MDBDA8[[!9A62*9(IDBF2:9]D
MJK+(M1%F$(Z B,*"]9;5OIB61T-3BJZ/K?]MDJD>,XMDNJ5\>BR+OP'63F)\
M.;H*MXS<8C%O_'+A:C.ZQ6Q45FG]ZGPVF=2*@<UEE!^5'U:/^08Q'VWUF!HR
MR9IQX-04^]\+7AND)B#,>>%2)$H^J2;^E<HJ^+TYY'5R"\._S7[^#,%7VW1]
M:S:)Q;4P$1<+8&,![$W./SFFM&*Z%E,M-GK6%HQS!F@BA3J]XY3Y/H(DSTZ2
M5.OMY3(@42)1(E$.FBB#)-1X84 %HT$XJL'F:$!&8GQ4F66Q5B9JDP#(\Q/E
M-GHM#8TG,;/D29DE:Z&.D^@N%LW[-/JAF2U2.)N6>YPVY2E?S>87LU5U0]17
M/6".O6 5='&VK#/_C!KK<<')?]^:ZKI[(@Y>>>UF-R!FX1/)&B07N896:M6$
M;,")E%0*7EJ]YC4\.;2RC505)K=QGN,Q"^XY]1WNLB+A(N$>$N$*IP2S3%?V
MXB 8<^"<M""IU%XY5H_.]1ZFV4J=1KN-.C5(N$BX2+A(N/T1KB)&2&6+M:JE
MKYG8Q5I-WA4R4\F)0B11K+4;>W*X9RLI+WIG\9QA$"Z6QWA::.<BE6D[<_.T
M49"G0.K\O/S37>%L-BG+JQV/O&N;T!6IC,UDN4@1-25J2M24>Z$IG8Q6*1;
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MI8NFS!$)&Z$\9.DBE(](V CE(4L7H7Q$PD8H#UFZO0<8**7>)!_!>1-!2$[
M26Y!)!6<-#I0Z?HX^HH!AL-!")Z4W0A@EZNX TO7\;D>Y>X*1[]N3KM/?FAF
MBQ3.IN4>ITUJQZ,WT_ "MYB'BZ1CU35H-AZ:L!'*0Y8N0OF(A(U0'K)T>_<
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M<D3"1B@/6;H(Y2,2-D)YR-)%*!^1L!'*0Y9N[P$#3YS6P3,P/M0#@RJ 88Q
MMMIYPV6086TC@WMG#6$* J4U"TA%\-9+8"XJK6W*K/K[&##8EQ6/-3,V LS?
M4KLH"[7N<M<$C7D3%BE>;GC7M8G;W0/&#&J)SPK9*2)CH Z,XK(6LE-@2+;
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M&1Z:L!'*0Y8N0OF(A(U0'K)T$<I')&R$\I"ENX5&K]Y$HP(D+6K+0F' T$R
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M6P\26%M"/4!3RV5=?:0<LR&UF[4-=P ^:BZ ^;6(0ZKP]W<L@F9(O-,LL03
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MOFA$EO_<A.-O7E,[Z*I^^3+O>PQ_$I"2=H3YT#,%+W4@JV8#T48!>*KEB,\
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M6(YEVE9F"*A(V#=GJ:UTLXLR.+B.X4[?<TM[I]HW<ZG_9._U1476+PW&,+!
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M)].L$ \KW#X=2?QRKM KU.Q'OOEJ^6:JTC0IA6"Q- 7R0,ND4!$K8AW%$?#
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MT$ CA%D@$4^QR^$WK9CJR#90&>NP.MNT"@RUMG+.T,T2V"S*/!#+].0A4D;
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M41#BY7/"93X]TSM<OKYXQ-U"<=\7V'R!:UM@LP<?5R2L25!(I*3 *HP4:0F
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M,]0KAK&!,+1@V"-,W@><2GZ=)N_[\<5D#F)>#-X3E)VB([;L7"="(EPB;+0
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M;@*T>;!S\SA D:$B0T6&[B9#O\1944&'LY)+;X6;B?O._S&OI^W!_,]Q.)[
M;[/HST?PQ$^7)07[!1:Z>)[TZE>:.LUSHTA""5)<!L2]5DB[%%#NJ\,9\8[E
M8R/7ZI5C*:@R%$7G1>ZK[I&3'/[D04J%-2:NTU?]AMV=/HN[4#P PI3:+@7%
MCGU)"XH=\2ETDO,AHY/(!ZD0EQA0,:2$+,_]$K$CCG2RMWI&Q0W7<]/S[*V
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M7\B0"9$C1IWB6L3$>*>0;K32,IP/U7J#4=YN1/ )1H:H&*G@A@1WH!UV@O$
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MTTOYN9W=81B+'(.G:)Q4B!OKD,U9GTH'BC$#UJ*=S)"^NL/L8J8CV!%ZQL+
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M1)V^][FZ\\36H26A;9.]FJH>^>$\M*F>+5DO@)'FTYA3E'-YYDY4]D[T+Y;
M-C"X1&U26(-3$\ 2L%1E;<"1ER+%$*,5N&/C/MZ%766:]V7DLJ,T<L^JIV-L
M>IP1$M <1%HF$$G2(PZ*!N4D'"1PQ#1)3*P\@,_<,WN9HS0T!M4HMOQR=(LN
MP)BDDF"$'0%C@QH.)H3U8&MBJ8V4P?!>%GVUS#^.I[].QQX0K/EQ.K[X&$=V
M-'N7FPWDFOX],8$X2B;(Z]_V1I@"'H -L0":64N!JKZ83,>?%[AB5^1H>D.E
MHP0<X14'/M.(!@R DT) FDH!7$B\LIASYA]EZ#X)X.@S=HR\EHW6>S+;<3*)
MQ$9$ P!%J."(DQ@!;+A'0B3A%)8D\%X">T\*4(0<IU<4YM.VY\O-]@LYJWZ\
MW<J!G[]]^&=EFR8"8HW=S-:C!6+%K_[<CC[M#/\=/VI)E9PP8$<'$L&B)@8L
M:HT%\)K FEJ,K>@4)W@(0_Z6M^\_I'\V\5TFX8<E 7\:_6U)/EB#^V8VWU>-
M'J6EOK4-O6N7^?^JJJU&5</X%85Z&ML9Y,XS\XO1VU WDZ&]?)._?3NQ(0 5
M-[+0ZL5 EOE:BP_^/6]F=;I<C:F]%0'SOW7CKWERN8G.>FO_ZQWW[PE]>!3@
M*H_DZ9>#X.V*:"O"GZ]SW2;V4URDL:&V),X;._QB+YME'YW-%5J1?YD(OXOV
MMY-X,XD-GQ&M#I)1<"/)*2.)WD3R+XLIN?$P]+$&[X*=Y&A4]4,]GD5_/H)A
M?,K ^7X\G8PS,FQGNNVCU8&R+XZ*5K\ A=J&9.\W>XDM^BS6=EC]/H,/6@N@
M^@XN 5"=Q_#]3NH=9Z+*70FQ(Y=G%VC>G>+?[.[NIX63'@PTY*D-BW[ !H.>
ME#X$I1UC)CXJ6M6&L7^+GR,LU$_+ ^:_SJ>@&T%C?IK&=C'W-_3;.5>\A<P:
M)KX3\YN9G<[>MBN'8(TNFC<.7CH$]7RHF.VCA6$9C%YIO7J41XM:Y7?#%%M+
M=<4J&Q1;=X6[_L1GF]\VCR_9HEKQ1;5BC&K-&6L!://2KF6G]16SEZM<ZF?C
M@,6E^55OZAF,PO=!LZ,<?W6B&S(_C:K?XV2V\+UR='E0?8E5JWH7I3?&K:?6
M7<WJ2ST[KSY,7?T/N/"W\:4=SBZK_VDO)F^K]W!O/:L^3'*^?'8FLE7QT_\>
M5#__6GWW/_^'IJ"ZEW>V?Y&WWP\JF+E-"3P0T*0Y#+5Z]+OPN6[&TZ;Z^>?W
M@]RPLVW^".,#M0LV8@Y"C$)E \RP;F;9; &39O'%*IH^68X>'C(!8+K,'TXC
M3.V[_.UR0+^N+UJ-Z2Q/NYGGF,=>,K3D6D=)CL[=I%X(9Z5%./C<TT%SI%W2
M.4K+B)+81=:I-B2LEJ W'2)4*5"CRB C1,P>:W BIT/1[3R ?T[2%)ZPC('\
MMB1&;VE-XFQ_OX;GW .>CB^VF *XR\XJ/QPW.1ZQR5H_UM.,B OZ7''\XFA)
MG&;7O +.'37+M5LF.#5GU;^ E:?P_V$SSD)9SX; 9<",2XZKYI/\U_&QG:,*
M*X*15L$CCGGF.$V0T=2$8'B@KA.;350KK!E#+BFX1W*,' W@ Y+$$A?!*QNW
MV.[7<1X#6-_7S;@%G3^.?XBGPHO /\W<-?&/>8:]>@3VUW"X<$=LLVS'W+RI
MOJN_/SY>\9(YY7U"G.:": [#DK/HD33"4,&]P[QSY-%JBWEN]NU$Q#GBSY&A
MCB'K5"**4QVIOQ.O_)X[4X?#<8PZ4H:93_*.TGP*0 (\ ^ T]OD@3 :NT;AJ
MU2M@&PSOD=RRQ[N3BF/KJ4:*JXBXS;*NB06-(RV+"5R#+.N/5$L==VYKL?\*
M<]Q>O.S3HPMXYWE^" KV$N4 -8JC9[',KLPR0MN0^%7ORNMARV=CITTEMZ#N
M=2W7&F??U<<(/-1YH4$A@6KRP(08)Z1U,"B%Q'+V=_3F<,#S\;R>'A!W!'XA
MN .:"RX;+:+K"Y]B91%-XO2BGN4XF_5_S.NFSI<T3XQ4007"M7<($PU,$CQ#
MAAF&M 4[VAEOB>GD3S\>J3:YHP!5ST#5$K=KC>>M1>O/\[YWS-;4OX$GLW&]
M8L>4JQD#UV646[#BV3.F%WX<5TT$08BM-(W=L/YD%_(!PXS3F[S5C,CYIFPQ
MUJ&VT^R=GUOP)CZ!#Y+E;>5ZV\4[:O"8UT4XZX7\^C&\>@+BEQFS6F\?7"YW
M; >[*.CGS0PF-;W,>[C#>9.'VWKT(:;5[N[N<>].E[UA6TP_3RSF&<)LU^II
M'^6H3S6X]BX'JT8@9'&QF]8&I)JY/U^701]<CR"T<FBK]O3]IJ._DJ'ID@%6
M\MAL0=MU]EB'LA;1BGE3Y:T&$/\1O /T:]YCLY_BUC/>32:PENUQJR5S5;^N
MKUP_;YQR[D_U]W?O?EV/:==(?H#W7<73?DKPZF$;?ZNV@B(P;QA;C*/JPH:X
MH,J- ZF:\_Q^%ZN4R;.<2QY6OO6/N9T"!>!-F^-HWP\<<K[C_1D4MRW8Q5(\
M;$RM0-UC4*WB65ZV-:[!]4'E<6XIL)W#M%?#7'+:YFJWWR[B2/GB#J:LIP%L
M?,=)G*B K]"W:B6S/=ZQ(E1'%*_(FM=I@Y#9Z*T/9;]20J-+DB(MP(CE/F%D
MG 6OA5F=P/_!O)N6?6_[=4\ #NSW+<,5@37Q)LRG8+ ^RVKQ(S1,@1:K -TJ
M=RYF^VR)":G.[M^*6:KO\H=@,NW#^^M6;0LN*VLN0^QH/+O:K=AK3*P,,?L)
M#+!/>3\&O#48!@ &*##X[,KKRI<U\XL\X+J]\3,\*.;LT4DV"K9TPOOYQ7RX
MV)]9:[SU.Z\TRRB_9#*M\^;-N.IX%_\_>V_:W,AQI0O_%83N]1TI DGGODCS
M*J(M2W/[QEA22&T[YF.N3=@@0&/I;OK7O^=D%38"X H2(%DS$3(;*%1E99[S
MG"7S/,<V$'?=$%9V^)6.#49QDJNM@WOXYDM81)R]05DBX"3/)F/?UF35UT/7
M=C7,=8P#WWD\'Z8&;^&)\V%#3G_#-"YG;6V6<'PW3L03^[HO:U-Y-I^,>C_X
MRR.XMYTS>XVOI861SX/6QUG;CCJUU)[@B0G'"HF):B*]B,2B+1,\\UA8LBYM
M96WNG]I;>E2_E-T6<+-*X!*B]64ZC_#U?!Z_;>.)GE(V[P_[?)P5\LU!.(9@
M$:K161H<#[*"1F$-83_YX;QN]Y^:"/' + B!)CDJ[(_@,K&V,&*STT[P$)(W
M!Q6AE5%8VH2#BY$^I;J!I1C=: ZO194+@[#*V\U'=1^]S &6)GD1[K2W;DJ>
M5O*Z^/G2&5H&3KUP]40N>)!,^"PRR;0 &!40B.!B(@%Y[ SSPFUO<-[;!;]!
M>GY;3,J+RR0+?G(.>\T35T>R211?$ZO=_N>I85N(5''&&*$V&Z0[*L1*9TDQ
M'F)"!8!GMK9?[XUM[]L9>#]JY@>FY[GASKP\N.LRW8O4RGSVQQ]0F7ZYK/L:
M701P] C@K[AYBQ+<;,'F4:R>FP<QGK7+U/OQ$UK?K^^RJ5/WW+ 2&1,?%YA2
MP$J*-, ,P@ 0 \8$-GF.6T2]MN2OV2V&F'W87_WB'_/TL4VFCR>]X$?_G,PO
M9_&JA]XI?KJ67@<' >Z+H0L\T\]JU> ,[G_A_S&N^URMCBY.C,+C+BX&LX53
MNW]GK47^FARHZ8F: 0XP,>AEU$E;[M'UOOZJN<EBUK[ZIDGU_VL^F&3,TM=_
M+<> -V['-9[/IC/?;$1N9QC];"O["]8R7SOFVNK5K_C5*E'T+C6[FO#551_O
MY$=7O1E(QEIVJCKRE[,]F>K/F-G$O3U ^0$.&RPDCKP1C.U7NLOX-T=[=L1$
MW1O5>2S5K?-_3<6GO3$>HFZ2@$O]1(Z"1C]1%?U.K5YL>:TO[,IOPKLU/OM&
M\FQ-)%;>5E-(?,^'+Q.+?_$@BXNDHKSWJ$[.IY,VI20Y$<+41'\@WDA-DDJ.
MIA2I"UL,M1Z<-UDL(YZR0J0QE 3C//R&2?A_2RU-1XU7^4FF/6Z.5VLT>BWA
MNS]1L@@]&]"_MAF\E-6Z9XS!6A^D<?898]9-\6WW+Z^ERE^^5!LG<PQ*$:JQ
M2Z6."OGAX9\B:/B7M2%N\<.+$+,2T< @(<J6F6?B$V=$2\DB-;0X5HXKU2\O
M+'EJJ:XE/%CF?6\AOH.9Z$*J]CA*K*U6T9/[@'MX&X6,;\NM^3L(#J:>:QDW
M2@Z(WL5TH0H[W/O*B#->$">!U].XJ@6FL48J=U(B+.69#F"@?M)(['C:1E I
MAZ9N8S*OY]UZN%83=//1&\=#>[%MD[LL:ELO&*KA5JA;NTAOD*K_?H'-:OZ-
M>[%CT,WY=+F_7$I#0WEM[_0BPX!2K3DJ\TGU[FZ8H_H\G)64\?,:ZBVG9<U;
MK)\-IHNPH.IFN+J."?5<\/*<X+@**4Y[$\(M0B,(" <PM.@7+XT3-QE\JA-^
MUON_X\]P_:3!B^7&PK7Q?*YSM1KRN&;K+E;.(ORJ19-)OAC#O%R.I]-!0XU2
M]^7;^*8ISII.%\"X[X&7<-]QPC8>:[2?70#SC =EE\N]V!) O6AD:+_"K\+U
M1O\F>2&%56@PH$"96=]E0&V 3U'/X+YECLAP@Y%<'L7#0P?+^[4C:N]3[>)R
M#Z.]97OT8=K2= TC0DYUY_:I=I.PKCNW"UBXGI,X1>>/1RHL5\04;HB4W).@
M*"?*>,7 E2NZ;*6I XV:1>U(#)D1&6PASD-<HW02*JJ@<]E,4[];$X=?RM9)
M_%^6,[1=F;%R^=[__-/V22=P_+#UVA0W4_Z=)^,3<OIZXT]M)FM#&QJH.NM]
M@"^6<I7V2I6OQN#NQ+O'E"49!02[(1&=(9J0P042G(LDN^1DT,8:IZ_+4J2!
M,IX=8<EP(I7.Q#(;2#;1.4E%%&RKT=2?P2R^7]KQA=+_!M-5*6+2*M:X:SAQ
M:Y?%DZ*K_,.&MPW#JD?]4_Z^X]1Z>DXMMXN7IW=76JV.4^OQ:]!Q:G6<6H?B
MU*JHOH3/-^2RO]^N";VAG&W0M'!,;0P]1<*6F&O0.SU)TNQL2\I>26*IQYZ7
M5A.?0R9:.AZT]#):<1A7I&2<F$:C\@\X(3_G_9TN[U=A3,_T";D=*R+^/^^0
M@E6)S#)!,ANO,A@8VX5<PZUESF3I("\"LU33'QO9CQM3*DTVI=_S"9V49<W5
M9+QH H+QWZ!A_&\VL);'[NL^\_"J#@A>Y*(Y %&'.AA=SM<.B71IA&=+(YSG
MC<683YNC#8O<PE(2ON#RUM*"Q5'$=;E9"[C;T/YZ]+6X\IH(+S-@-9]6M]K_
MN1+.]N-8"Q0&%_#V31YN>@[W)_51PS&Z<SB4.(07&91!7$^!3-L'U7K<SQD3
M!4U::S$JU(<FC;!V]?(P^%)Q:E9L/>6UGB+;F2=9SM@=,B55NT;@&X#6Y.BG
MG2H<)Z/62/JLGGM9+V>M4+JH#P)@:W>-?)/C&B 3'"S>2FH7J>RE,&S>;3!=
M;N*#(*4!H&QMP[Z\XW@R@/E9OV5U":I4KD$M2F&%X;T)P*UJH@61^%4CK?O3
MYAOQ[D$I4'4(EFMA<#L^HY\@B//)$^K!!RC)"FJV3J#?FP+U]WB>TWRX7<*P
MZI&=9^_PO>'/#YB]WT^*^I9TX'S]7%1M6MVK3/4 3*V[NE^DFGXNOIW4Z[3Y
MT[T-K=I68KSW=744QO,I?#+]YMN3PZ&GFO6M0&G1-KQ=@.U0VL]GXT7#=!P/
M9BM@^'@Y&?JK\7P&C_B2TW=+3MHS^H?%#RK1Y.4T?SL%6XZZOIB'>KBON?=7
MJS[FLV62Y=-@L6'T[>(>:Q=N-'VOC[7P5/F'EMI\SS7\C-I;+F&W?:_.[/WN
ML=Z;??T%VT107<C@XS\_3L"P)]+J7BR%EO@=)K^;5-.W3<()/]@W#[LD!ER.
M&3H1K:2!H-XQ@W?0H/\1\=]O-U@5W.Z-^?)Z0NB/L_3@"6K>Z!AS=*]9V9'N
MN,-+C\:G]<J;8G%K%\ #K>W.7-Y3OGJ%N@.JQ.Z4B--*<5HDD3XK(BGX.[XD
M1HJ0BAFF,RU;]9K,:L8M<@@F98E41A.O/2=!*JJ,1!I!>Q-+P>W]3L1&0N2V
M?1C&59_>4*?Y4@7]86K\,,M1ZO_=RW*L^SGUK@\Q)>LN0[W)^EWI4V3B#VQI
M?FCH%FKJ:C-ST!F7-Z-S;]6F?/W '- ]"\)%C-Y11J*/&NQ-L,2RI(BF5%K#
M ,S<U@'[^]BH1=I^89]JOGY-KP]DIO0-IX]?JKK<S1?[YK"VZ@%13F>KFNV]
M-AIJ:>X["_4"5:ZS4(^W*!#P%",=(R%BR9:6'!.\CF3CG1,66Y9NG4E[C$7Y
ML=$WW"$]D#&1?2[LJS,G7<3S JS(5FX-VUQWIN3-J-M;-27/%.Q043*GG.AH
MP32Q0(DSQ1.K<J916!W+5IOBQR;D?@4%OKM=FL+DPE^W&2BWO[_Z2]67+MIY
MX7;J"K<?.U/U6-5;GCI?5 A<SGKU''%OL5"OW9C=/@.=N;N3N6,0;0E*):')
M&R)-@4A,FT2*\CQK[U(NC\KM[6')1APX4"3&^T8_\=[3#=+61#%4O!ES^("P
M[:T=<6A/.<VV#C+QSO2]0*^SB](.<,PATQ"T2,2&((B4RH.UD)+8I)*A6:H<
MMRH_5)8N6^Z)4T$3284DWC!!@BTL1\FY$?Y.QQQN*OVX_TD'\=36YL6(>!=/
M=;M'G3'IC,ES&Q/C<HA"9D(C@YB%,>Q,22DQ!@R&3XRYLD6-=A]VC*??/6*B
M;[L#<\\=AW1FI-L^ZFS)6[4ESY-/4]GQ9!4EV6FP33R G>&BD!QU$2$:Y=76
MR89[,S<]P_:1[O/NN%P7\)R:I>HVD+H-I&X#Z90,7M%99I$RR<EH(J4,&(P5
MDGCDG*6@I?2'-WB'W4#B-[3+Z3:0N@VDD]E $IWI.ZPJ\C..NIC&<RRC/Z+Q
M.TY1[5TFX\7;P7U=+JV/227"/"]-]:U-II"8K1'1TE3Y0A[.1?9<.U*"]O7S
MGG^X)B;'-&"/3SC"W^A*?+_=9[$2$9X$J<CS$+OLB[9.DDG0^)QY5)R8I+$D
MT3GB-/?$&!.Y9#YEOK6?_-1>Y_U8!/G9_O.YS[_X"Q;!RK1S<JMM!2*OH"2Q
MB+R1RA*7=2&:!IM5"H*+K=5^ZD-J]UWM_<5"1UQMY"L?+%I[(-UHR\/8]MR8
M+C$@^&$MK&_;(,9UWMK%=]/SC%[K'FKT!853OP>SNV0GV^ 0VPG!@-.')1>3
ME#L7F2#":8K5S!"&,"8)]593'Y)2=BM@O0^YV&+W\(=5_\1WH]30^'[,HSC(
MTS\/IG$XGLXG-U"*K;WS!CWXFIFI[7IV$H%/9WXR^ZY:% (B=#']%HD$AX-1
MWK(]*QE!LV;^<$=C]/24R>UP%B\_&.'P29V#&]X9S^@LA6IM#I<L5]?O>+3W
MNT9CL=9M$U5E0UZ62M*0(V]Z)L_MACS5S#27XJ-NZ^;TW_FCQVY8XY@S<K7?
MU"'W^*-]JV29?V]:QTSGX1\925G'2+\ZN&C$NZ%&;<2]3,873;]5[#Z$_]M:
MH=H&RD^ND-UUTO2+"L@\#+^L9*M-5Y<8 3![?HUA#(F%*YTFV.,9]ECZ?)[!
ME:C-F"XGXU M6J6-7?_5.5BNRI2\I-5>\%^VY*T19C @NZ&?CD=PCZL50S(,
M!Q\Q'B'?9F^R:,K9]$^"AP'83Q>_AQ_!CP=@+5/3K^D"FU0MQ]4^K)V"YE8P
M[N8UX4'O2V\T7ERU--EPQ>I2[)2(-*1KG7JPX>'HJNU<>OW'[6/:T0Q&@XOY
MQ:WCP/D'1ZDV^;T$Y+W"U<-G+/M)#:N:7J[4=)]O<")MZHX/%>\!#RY&*X+B
M)=U[AW"GB'#O;X6I96MHT()/@X3(MKG"<.TG^"FRH$[C^#(WF%.[S8$Z04"2
MQA.X"[()US\B>#[C"\0TO+!19]0^;+11VP6TSG6%V[:IW (%ERW'^\ONW,,!
M.!V5$[Y?,0H[:TT&E=Q]/*^-MS W#T@*?R'KL%\*Y+(YP052&5<(Q\3!< @/
MGS=J?YD1%0:C@B2O36NQU@(LFF0"_DS28OP ;0!2;2_N.G&5O+ZF'"OC.+S2
M]>F[/IZ+"BS3Q7##V$\JK7C3<6?<3MMB8MJK\I<<YY7>>%S@SOC[AFH<S<MF
M:_+%\Z^:-_<?/78N7-YP84P&"UIR7'J<T/JVC>%H>9<'N%OB9_/*!#W-DT_8
MVA,;]"U'"I\OQM/TI;KP7RHR7XY1_A!AM_JC+?FC%USI#2]ZV.S@5@G4ERW=
MI]M2N3:M@RGVJH>? +)'B"'@G_-1*S;5"-1%0EE:,YMK1J A2Z\-"T$TY\/9
MDNOZVD.GRX8$>+-ZJ]$,S>EG_ Q;18ZNM@;:R-,1@LAD@J0%0D<E<B0R14:\
MA8!0<&>YMC$8]RB&ZD40^?L,8L-S0&Z0@A]A!6=7V#NFBQ^?,GX4+S%^_/T<
MU*05E/_SORQGYKM>(S!=\+@5: -R5,4Z5;_EUEEZG*S\ D8O-M,PQ6FHH0\$
M%?",VF8@-OT)+B>#3P-PXMMVFX-I169 >+ -&*J</;;5X;X$G;*><>&Q.,PT
M.W,>\)'@'ILW.?J8MK*]#TW0C4=5$/XVQF3+;RAZTZ,LR?]M-'?ADFRL#MH_
M-/BS86.^#Y.=O^F%[IF=3\F7*&/#XR6Y-<11"@N@N??.44[CHQ*J-3L/(@*>
MW2]EWZ*MI^GABWRO'J7C4;Y/=OZ)9:'W"7LO8Q*CNM[3\]8!VE39/%P=VK_N
M\AQKY(V?>KZ2Y:;I5"/5,S"PHU0C'7RCZ=8KK1K;KPD[W"&#:]ZO.9S:HJ=B
M4<'E'<)M4G\1J13P:*=-T@'=QD]^,$24ZC?>)OBNYVLQ$UA!",?P!WY:O?20
MEW?<3DAUG3V/UMF3T:ZSYY%=RZZS9]?9\VDZ>QXT)%<RL&R3(-$@2[50EH1@
M)(DVI "*:D,.!VT:A5F;G&K@-=UP3+IF44OHV)WPK]F]X[DIYQZ;%#;+M\\9
M*6V#MF6KJ]V]IDY#2;=FXAWFWKIF4KNZ/)WIQ_:2TF?B?O<XJ5Y2IU)\=Z_
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M,ELFYC37^+ FAIT=C+.V,S'=*;CG.@7W:3P$Q4+ZLR[_^(8M=]0&C+<*1"6
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M+A7?:J!V'V#PZ7+V</OX&Y:_3F&Y?L^33X.8FS@).Y?N;%RZ/(-ZA-6?G4/
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MF>L)>,FGE<E^AM,+&QH0QYC+:)5J-MX\4]W?YPJCDM[%95XD0A $IW<]TX
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M,;$4B$L9]VXUGBV2&@\E)8!285G<XHY[DE7\D"<7>]9P1S"&^?1I'AT%5*8
MQ2."X> M =P1I :PZP+18C_"G0_B>0\ IA<RFIK\9FT#. W(_H!BV&\$?-M0
M5&. 4%VMP=Y)77UXX1/:>1AGR9/)<HMC4!,3)POE6FAI?)&$01!()-+Z> CJ
MB&8&#TES74RZ#@*1"A6-=B0%(0 )9"%>VT0,YR4K3VV16SGH7Q?34G/&?_/#
M^7[FG@V$)NJK[Z4Z38 &58(%A\@+EW8\G_0 YI *XR?"<,IJ6@8+I+=D8CJ=
M^U',N_5OO[+5F/>U!S0QHDV_UGGY#8'3!X :Q/+I#6 .X)UG]<LX&2!.86
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MM9?;GB-TF>M&,$EVTS3ERK.M;8+8G2[!]B3+G:EO<U:"YU/ #IA(Q#SP)VA
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MA]F-/O@1[*TJ*5-^B2]TB0KV3AT,+TI]RV0;T&X;7++J+N"2DEN1&Y 8//#
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M:/NEOA@RM0&=#"?TS$>%!<\$E*4L70_,G]IC5Y9$?<,'B03P?"^YWHJ'&V(
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MOO>RR3X6(A-BWWF(/3 A]I,(L6_&15M/\JR]GA@LPM3N?IO:W:^UW6V%IC^
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M*C_+F0>OL&-0Q*$WS R*L FV[0 3VD(1WK5#][9Q,4Y[N*IR_J?U9?@HYP$
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M,/:7QSCX+HJW[\B?W\&?8>33X_??'\/8K"<.L]VI["5[D(;OW^$O*0X3_S'
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M;HB4T+!-_$\=6_.'RM:P?F^[T6<W*IH4N8@P68ST-HO=)[*.9]L84QF.;=&
M]AW[5K6,<(I(D$2")I)$WS9UQ"=V$>UV/A/UR,-U$5&3! X;32)M[3LVM6H0
M48C1AZY [FT[Q]BX&OP1W<TZ-J]J)'GS,6C:,[9TUZ%+%H,0N V<L/[;JVW8
MOF^G5=L)HX(D&43IO.W<B)W[Y+MQE$2;]"(* N<Q8C[UTJLXL$_'?E:M*I(@
M*E!\>Q?'"SM)&F=NFL7D+:I*-NH?.S:K:EDI='_;F%&&+](6WSM?&@04]>\=
MVU.UH;#.B/9^VYT1N_,9IQ!=<HMC*AZ<\8P0YY&,%IUQLN>,;!@%T98(>A=1
MO.>7%@B$4:A*%K5[K'^4CI-2-="0*= X&D0FP40AI$X#I1$2$T&EF2!E*HC-
MI2!,O1V\47[ U&?^!!!G&MR!A28=6UZUZN3]J<CTMDVZ??#C??$]??*G57M0
MAT\>?2M^>HN%U;[?]W!3CMAMWJ]CKZLVI,Z]9H3?=GI"($;+GA9;=.Q>U5@D
M+(!ONZ0O.J-EM^I;=NQ:U4I4CM1XVS[M(1LMF]C6OGTKOZ\:CAK"-]YV5%,<
M1\L^5EMU[%[53*20>-LQ \$=+;O7WJ-C)ZLVI)9 C[>=-13QT;*[W;TZ=KAJ
MAFJ/_GC;9+UA("U[V]BX8TNK]J*:D)"W?9P>&]*R=X4&'?M5-?:PWF];9"A@
M1-VWP;TZ-K-JY.D1//*VTWK##MIL.TV-._:UQJ!3$X+PMI&Z8Q%:MK*E><=F
M5NT[]7$);]NIR5G:JEV66W5L7M7,HSI.W[9L41[4EHTW-5;[\?FA:EHRZ$U]
M.XW&_#=GGD=G[ 0*T-,E3AT_&.'5::76<:*JYJXN7P_1R.1X*DX5^I8/^79>
MM)\7P+OTL@ #V E]Y3D&S6JS]I-?R*</OW.V>/01&CI QZFJFMZZ3Y68 D-=
M42<!OX%IH'P>;X?-X&'+=CLG?EUM'A*\R8(;,D)REB2D"_;NHSJ3[/AC-WJH
MC@-8M0SV.(!L,G#:V'00G0\2$X*WM-Z"_'8:)UH[\NN'_,G9;F.\!<06_M?"
M\1K9M^.\5,V.PO)1O)@*0^2>V;?MGQ[_,%@FZM.O8]OK0M7$MK]).>:C* ;O
M^9#^'7M?-796(B[>#L'<A^!DZBDXZ3H&5=OH\&-P\G8.3)^#2U;S8/)Q$'2L
MG KT,Q_N_[R=C^GG0]%1GYQPBY/KL-1BP,O1GUC'2:F:XVM.2D&W9>,A/ZP)
M\7M[5W3'^$D5\TH4=V&Q($2I5"(*> _O+)5$5N$:NUD,Z6;G3N(G;8?+SL@=
M)['J6VB*.RSHNG)V(D@&5%LUV$+,$#FI2A%P%I&<**(S?3O ND(:\_OI[)DL
M*!CBKZ+XS@G41FU'<BRM]D/V^ZH'0@V/+-YT<K1C\C@>)V2\8BSEVUG1<U8&
M:U%]^W:<A?90V3?E2;>QK/:3_AA'2?(0QM@)_/_&WE^C (JQ@4L0PTLC'Y6$
M?/(*@>LP[T,]F5'B5X[-/$-WG+I6T+W2#41GB/+A$)\C8I.D3UW^I"6('-("
M-2*C*9V9GY7/]NT8FX@%SP_74#_#)((=1VX09&#I"+YY#.R=GL$/X1@Z'6>E
MZDEH/RMOCZ3=?(3!9V0LK8YS4G4]=.0NO!T5VT=%*O#5/SS^$[OI?72VB^*4
M5QT8>8;&#=)QN*J^C<[#I5@$JG_F<Z'19,ILWHZ>L:,GQ9:K+(5T&F75/WS9
MXS#!5*@N]AI[!"<-UG$4JY;T[J.HB$]L1L53Q^?$I?5*CM?;F=2:Y*58CRI_
M:SMPXRAUG*:JM;TN/:QDAJI+('L[)%H/R6"I:B")CF-1-7W7'XLW"<I8/N'@
M$]"C6_NN_Z%JBV8TW_;9X#Y+>765/N%86=TU#B H[C[B)3+#+>W0?03&4NPX
M'57KM#@=BJA+ARR<$3XHB+IR6-;S[?CH/#YK[$:AZP<X>0@]T@@"<LD4"SLM
MZ_X-.$2CZ'8<I:K)N>8HY0,C=>3**<KK#KX=*%-)TMV/D29:'0>G:CCNDU#]
M]GXM]0(Z-74#G7:=I*I96?,5A$[?#I7>2RA7=TLMA4[R"JX&EXQ+?AQY.8T:
MH^.H-0?%MU]:JLY=Z2'GP_P>8DIO5YIF](CAF:7#2'2<G1J8V#JDB;<7SM)Q
M4!ZE!,?/V*--H*0VRT!/(_>78:=C",6.P](3EJ3TQ+%165-6R)NGKL/(;P=(
M.XC)X!ME,)&.8](;\.3M5K%V*.0M(*/GV?>H!IA^C)WVD!TMA#L.3]4RW'AX
ME%M&B='G]XP<GWJ=Z S>CI6Y8T4O\]4>)BU$1:+1X/CT_?L_0\NST#M]?T)_
M''W"1HS1?MC^V+=D5/&PL8>+3207C.E4$,R%]J'.4I@.^]?;T3-V]&BA(=\E
M>C/=F <R_UHE33/-CJ-5M6;W.5KYN/R4P<AORM=DU;]ULS\DJ;\#'P)[I\A/
M>21TX=9): /L->C^9@;I.&=54W>?<R9GPU]&F$\AL+ITS26(S^KM"!HY@D0E
M@A 9RN=%E*2)=*6I)X,\<.LD(R*6&V0>L')!?AD%ON?0BXK\ET;!KS;<?DC^
M.N:H&I],QY&N&N'YD?9;14!EUHA.6W4-%@\SO,WKNX<[)&:/:)]\_BAG@'H=
M)0MOYU_K^9?64,C:<*-M"'D;5()_=,ADU3WE063DV-T_X37>.82_</LW[&^?
MR(8YSV2'MGC-B$#[6QS[T:"KVMID.LY_U770?*4K)EQUUDP+.CZ'>1>_#!&+
M!Y] ^H21G#P2LS\^8]-'ROP18^#M])LLHCK8<#.%7L<9K/H4.HNOOIES#'BL
ME!JJPWSD?3MVG(,ZA'&%]-N>F[DI%)QB%>EQMX]")E1!:N,Y)LL-*5'/?D(8
MH"'?LEM[.K$NZAVGI^HP** GES$DQ03@7S1WD\T!R4GP"'(5@/GMF.D^9@+D
MA/RZ#O]B\,'J2:_C*%6="BU'2>*TD#\VH62\G1Q-)V<$FD&_OATGH@.:_>UE
MLG=EB#@FG[*YVGS8;##8+*'=FBC2-)F[]AWQ2<LXN8JCW17VB-H1@.*=I5'\
M"OW83O6_:@S/H_U _JD.:J7QBBI.E=KDQ&3IK07#\G3TIK>/3QIMR*P1GS:2
M\V84^&%_.^OZI##J:F28&$+=)DW.<4B8$%EV \2N7N0Z3EX=L$NSG$5')"V*
M%@,X=&+4MV.SJ+H6(!EG*;_3 +?+)2+4I1]D*?9:!ZN2:GN7#V'>'1]"U1MB
MLM[&,5(XA$\+#&J43RIM<D[[3*&VFL>;G+*DCU"81[EU5(F> ^OLLQ. YOHW
M'.,/7YA/ 82)BWQ1 >Z\[N1;_2)-,]'Q>58].V8_SXI)NQ!ZJ+",7@C/2#"-
M@&NDL,V0Y!N_YK<O=1J<?.HSH$L:Q#,<5;YW]X[365=30-!F43R_=9T2_@.^
M,+H/0?A+946=V(6>:[Q!_$?UG'QYC(/OHGC[S@_3=YZ_>\?;O',"(C%_H12>
M8KPI'"S9Z?3]^]]3$EYZ##]_]R7Q_D7IF9+I_N6;Q-_M _S-.TTS(S_C$-2O
M8T\ 6H^:9R,=T[..P+TW?=(%,F;F3(<XWN'=(X['3KB.AI'9/A&BL9L]XF.Y
M2"/GW$*I?>9BVEINX\C-*+X>_U_ 5PM3ZB*7EUR1/\?; Q.,)&5D,"%[[,EH
M#C7&X]PA5[J+[YXP3I->S/4GLR36;HF($A+-)/7)LZ&)SUJ:,S-='W,TGN%V
M>@MB%I10(O7"W?&,0335PW,C62NL=TZOFNG4Q?8$DDO:;9&)K&F7R^0L/CI2
MU%[%6R?D:&%@(L*)&_M[;C?*$C_$/0_U.))SL-Q:9F\@K[UHS<$DSRH>R$ZI
MUQP3+Y46&<A 0^\Y&*DM=#&0G58:<S"E('X/9*6FYQP,-, 8#V2F@\H<C+6
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M,;.NE[^SJ=1FV\QZEX/RV9R_YDWX17'VXL0>=QJMLC1)G=!3/!)GPB/!/14
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MSO2_((A>P !2#JD3@3M$',L:[::#R<QG*LZ1ZVA,@@JKWG6=].L[&VL%N$?
M>CQ_O2?#U5AQ^O2P)*-=NYN8.[C.TI0H/'0N5X&SK1'66AKKUM/'&DFXZ9?I
MVG!-,_,Z')%:)=[$.+IEG4($>SXU!03A,:$W=:T8U+_WG%].Y:61TF2[QZA7
MUT-PC($]5)=O3*&EVY*^VQ/)E#FQUN!2H<BLD"?$\H=N(J(,@#6!V1"XW2!I
M%Q=U4E[H5K/";AD12>KARD"?NB=/],EIJ]->\R!671SW$*8"*$F>_^Q[F1/
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MKG&T-%^F]WA'A'^'&8O25Z;.&"A*;V2<Y48T-(DE MH!TBZI'$KETGNR$+5
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M8@DE)6^YB#X'L'$N_[6:NWH3F2\K)PJWD!\#TA/<3JW6KX;&BW-EYL+>7Z,
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M+E#^9'#_R,V20R$VUA%J%IB.Q*Z205D#XX^%C94H6&&%;1RLY80V>2<_')^
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MK*R#C29+TJ4=2Y*L"ZM6#)I21J)4[\A*MH0V)NP7/9(LC,T1%I82F8-*BU2
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M??[Z"3N08 P3N )\;QRZKQ/RWA1R2-*SE/YF@*M">%@=:^9!.+G=>HWW<(!
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M=)A9'YL%UH4>+%BF0AEGF6?JKXJX<(@.:,7N;&L1"F&-V6[GQ*],["XNA&6
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MK",_Y&CIGWM#=[<U>WGVQB["-,8/0#BYQ^]82JSI/3\55=)>+?SL2Q.JTRR
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MQ(_->1(./!#ZX3>02J18G@_H++HYN4(6MZ1_K7A !#P2%N? R%J.9JBN[?<
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MN%X;WE+5=>?(3Y0=&%$*RSU>)UE25CPT(O)J1TV D,T7OB%=T=3ZNJ\Z4=-
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M2.36D)#IF.9GO!)RL<C.0]Z'E!5ZWQO@=.W1]PBR-XYH2:?J\%50,KKS%FQ
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M[T!JD8"^OH<TM8+[.#%!!DD-;ME#64G/7PI*)RCX%:TK0)=EW3XSP%0'( $
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M'G:;J%;&K<NSOFR(%()8HHJ_T7(?K<'1EX\F)U3TS!9X0>(Z_@\<(K)'@#P
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M7OO4ICBTA%N5; OTKUO3\BMF0($9F2'1@6SC+4&BIXSL8O<U^EM>7()C?4R
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M1V=3W=._;Y,RJ=A$%V_)DHJRQ$:"K:LV@E@E2!3/3$*$P<(>HLESS;;+;)F
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MK77HCA,W_W#<TQ=(66#?N"H6%&IT6!G[7IC]:L!ZD_#$HSMFL1;<;JW++Q[
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M5M')+8U81!ZN_ 1.Z#+/<]2*Y),6ZFC$$JE97-G>)X%N^J_^^Z>KVF/JTB-
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M&E8/<Y;!/"ZTUN9,GW]0F%U,D;K[1?/U$4RL>( Q :!KR*D@IJ+2E!7!(VI
M[%Y 5CA>58)77'M6.#14 D>JEKQT^VH_](0$84NLBH,1I+(\M4;#Q2+7XG?_
M6E$308W$['X>'SH3K=3E+^/M/@]JA7^=EX6Z#,;-PV9X!2;H[34JP#&D:A3'
M@N,+0/3A[4#\'/IT%9[:06,6411W65(49Q=HK?4G_7]!RB'/I9$U4CO9.$IJ
M$X4_59.$/Z!<.VZZ2^H;?A4>'2]HS97=MN^4'?>4S0?Q%SPG])NOS^"/%#VK
M" Y/X ,$*;@'6>G8QI28376 ".6V#);-=Z^=CI3:3#]I0NX+;N$_:1E4"0TU
MYKW$F\SCQIUFNB=\ X4.4NSJ]??<"8X"4N#_N?2<O'U&TIEJ'D A#*4_NX+S
M]D.<ORN_&ZD+9/51S&)J7^#R&&I;?6<7X+ (B-2]$_T.:G('[0S3.^C/=EZ]
MK> )5[66^G(#@P#.QH=0;MRC%WB(PR"1F;T!O%X:!:PLM*:("\\@ILI7Q,;Z
M<M5F9G:L1&SW[8=.E$5P.FG?"38AM5LIYHNWQY/C19E"7$OZ$[A%)H,P..!7
M942(>PVALP3BWDL8?*?60*L6AR3N0J]DZ&Z-9MHF_ "2BDT/2*\K/XX92Q99
MCL;Z3/F+C<*L?.'$WHXR97);;5/_%2!F MG&![Q)#^ A13+8=M\QO[&6)#>&
M,;MTY?EI0@V]H+4V;:?R>8E&8\B.8H9!F6LX;%J1Z28Z*Z(O..:]9@1YTY2V
M:'R$3',(';:];-$8L6VL"!RZ;<XN8#H6ON9;SK9)S0IP:)9$ C1RQKM%H\>S
M=K=.'8EW+1J?7E( QUBZZ)!!N8N.;K5=-$C\FX[%\NV"AGG7,8ZE%2A)L266
MD\&N"%PQFJJ;@*Q(.RE%35RWB5UQR4R2HOEDK(!(BJIX#B"[8K:%B*I]X-1@
M\W.&30 .V,5C$#I"]-3/]V573#N3NNJ^-"MRA$C;>9M.O%&"^4W#2(QT>C@,
ME:)G+NOJ@=^4&5*,1X;B[+3K80,3(4F?ZG3O&HQ'CNJB+0P)RS9P#B(ONB.X
M &\",XSI+V<:Z:?K@24S>4 CD$(;GATO=.'O(Y3Q_@ID_\M[:3-\8+T%ZPES
M?PW@!'WT6/'?H8].PA?'"]""MD$MQT#DQ?!/5_#'X)"ML,I%+@75X,_I?[2P
MM,1A,XE%[)!201+]LOD15ZKZ*R;"-0X\LX5#?JF&B$'J;KE.BMI1K@DKG._]
M<UAT;%C+!FH<ZE5^2XSBFC76HB%)M"KVT [?]]3$+D7<:CS%YIHR)T=_RO(Y
M^DP)7"L"MK&T<KC/R8Q08XO\A.-TC8_15[\NJRTWA,R+% P:.F]A &=#S!'!
M;FM"(E#B&V]ZNTF32*"2OL4S"'+^B'8+7=.C)@CIMM%_N%K$&!.P%>NC?RD=
M4[O!B3I4U7N@+%3)X!.?GP^HEZ,HI4<DC62R3E[U'$[J&;E G,B-7T_H#M^X
MOZ4QKC1,9%D*!M3W9I]<?IK)FME]]!&YX$M&@U*N"Q0Y9>^$<']M2WP!D&]'
M3G3.V;@316<4QWQ$)Z/)&+(2*I2ERH^C,=U.LQX?<PLIC4W9+]%#Q>VF+QT
M\;IA[@FSB]Y+/$L'6C<GX[RT#^ ;_@M=&!'I:]K2,BKJN;9V9YU,GBP%7"-U
M/D8!TG<>5;H2[:TX\TPEH<0O(>7"OPW@;^'OTC??VVWW>X# Q\&5K;6H&-$T
MVL1'YS(,/J#4B^6^[-\)VI#*_=/C./+'- V*[*0IQD)T4 UT3YE4,^GZKU!
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M%(:.:@:K4$,HC3IF0]&VD.'<>W"_XG"?7(8^)+,P2UZR&A ,,R HT"G*[?T
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M$F%NBD;6*+LWZI>(2O#,3OK##42706ENC&=5;!V\7MJ6\P"^U8SD41C ?^Y
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MA?+H9K>+4E W1,WQZGITSGC6D([P@AR?9U-A]=#.GZ$&2]X6"7,);P S&(#
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MSMT+ ?-3L8UA==:_N/J]5YYYL9N%U57_PFKWWF?IF_*S[F54B5X?':@,,Q=
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ME&)^P@@OHK36-GTZO56(=]QIK47)C:'O24!K<BVR.H91@MX6789Q@ID=[:6
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MLS3/:KN0V849?]]IN"IJNLD.50?R@C1,8_))NP-QC'Q-GS[?PY;O-"P4?\0
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MYX/X-7!SB)")IDZ*ET[\?@,%Q7F6NYS]=4&T510"9B'>7Z6$ZN.,!?88SG@
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MBX=\CU*9W#:XAT2KVU+B?%Q943RL?I0:Z1;AW2?2?Y0BZE9B3GEX,$J==8L
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MU*,-XMM<S&AM'O[CE9. &\>+D,)$M0<9,[\%;M%#&'S@HT=4!:?__I(A-N\
M2$QM?AN3K[&(B2K/^4N8H& &R(J#V-N- KS,I_5YC*-P!X ;WT3AL1XC5LR:
MIB/P^ZG.%E[_($@2'V.?AW5F'R^_?8N\J&&4P4U.'MY_-%/$N*:R=>U$ 7!?
M Q<=;8 ;*!7-^%\; Y<^R@;<)QRB%.Q ?MY88JJZ+\R/-Y9\?1/'Z;$XOR>
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MBD<)M*![]!>Q'R,:Q:U(M6WTR6#KOF.D<UY%W#%,]E:D=#;O) VT]UN1Q]G
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M+"@82\C0AI@$A%6U,C:MA\ZDU%CU<Z9;!^" G#@FF5=$M*NZ?45*B5D-?@(
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M=@_%?2!PE/F=9N?.EE<3&DXY83E\IM9%BDA7VE&;LK'1B^37I6]+TV6]V#H
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M?4N70+6EG0=G$=:=XN:8$8E$:LDM2\R=#[%2H2(' C,Z$='BQ U89RPUGI8
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M%<?4>TYB9J%LPU6V[$6Z;!#ZX0M0QV5(CUD>X65X.(0!G_H:^G"F4>.-K&P
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M:U;BZ*52OQ).6;R7B"+8)H1&/P\)?[2B:@:\T9RS9$\FLZB9A%W,9B_'1;+
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M93UW7>0I3.5NBH;?B2P9Z 3,SX&O 7P16DX)&&^0;<A"*6=TJI!LEKH&2YE
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M#&];_CV/?_'&\>_! >(6#1\>6A[,1F#P2# D&34JIQA#J0&"XN()F4<UJUD
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MNOW]D^LW;L"]@#)7 #U,@0;69C$MS>I-L$B*.,"YZLF77:K4H  2PD@8EV9
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M=S354\X-N<]339H H$,JQW1B7*8ZVL'O3#G^Y6C'?=O*_P%02P,$%     @
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M"U6N( 9M<QKWPZM!NSS'^S]02P,$%     @ \H%=6-= ./;E&0  *<4   \
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M112;SK1@0(Q5&15Q1UHKH-DJ*S H'"*PH;PEVCK"#E0EU1D]DC3;5I3"2 [
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M2DQ,04:!T\!(41X.'E%9<5%1T7^X4^FX_.WGG\OQ0Z#_GQ]2#U 2$%?2#,"
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MX?37@75A:(O;+F9V>JYTC60.5M@Z_44;XS#[YQ,<9EQ_RC$A"3!ROE.SKXX
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MR%YLW22IQXA&1R_GFZJ/J41*ICZMS)D>P2@6[8"LW\[2%;WC[, D-JORX@(
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M%S*$S5O02W0G1@LN)K0PONAYWROX9KW=U2BME76"@9=L/UV;D<3B$QPQG=*
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MG!V03/BEA:/9MVU6S&F@A4Z&RI_[*21\\?H1%WOMA'/4FW&<:#8M"II(^+&
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MRQ:$^'10TAE&I,IW>,TZE_S<EW<[(CRO%3Y+6_;9";W&#Y"9(X_XV"?[V8-
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MBOFJ+%#CY?G^_-DDU?U/RE2.:<HOP@$72<9?Z%WK5H E<./9=*/X?K=F.\'
M_:P!I;#DV[RM[]RG?U*\PQ97+\M3PJ!?$3]"2CE9C,- <@07% \B%KW+O,V
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MIR<W+/%(P[55=#G^]B#C*T![,)OD.UU'54T8=NNU.GK!\WU_X!@F#6?@#2%
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M>1+*T-=H^&3&AY]6QVT>Z?ML8M?Y%OH#"2X6JEZ>:U&W8Q+=84)[@+1F5[K
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MZM<+]#IK7,>L,9P,# A.-6\4!CR<=9!C]%:!ZJ3J/C-)]+!;F=X)$2,^V@
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MZX6"ECQU:BI9O4SYB5F*<_\HLYC94AC?3-TM/ GCIA4*7X2XH)*-P_.IA=(
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M-CF "M/FVN^K8 =YOZ[F@,W&H_+(Q=U[E1<-W;WY<-W(DB)%VN5>V!R4%3=
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M)!NQF(% E9'PW4/Z!%YQ!(3"Z\:F@=2$@"DI+7(O5\&$>1'<RJ:B&K/ZX3$
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MR2<55LML\6['?F,J'C&;BX#!_56ZUO32/.<,%@H-1(FEJ]1X*M]Z58K?; #
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M8R/3,-IH?R%Y-W*9Z]J"S'\E VL"CEW]!E&.7F;6T\X80&"Q,"P;T==*@ 2
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M.QTTY@OT#47,;P4G/CH1(6>*O!"LD_H[7&3J6RSHC;V7N_BQX=V.Z%L-5)?
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M]\+T8R4X?8Z$K\_FC5\Z#$Y0*>+$-'C2<U!C0M\S'X;M<^[QMXT%EN*7T(^
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M5)5;2-0K-TH]K=\\)!Q?WHM&F=WW*@[:[ J>0C$8![_( #O%=%+DFBALT[A
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MA.V+:BZ<9?[D%515^K%$->Q/2AV=VREU-+&OU!$H&-)'V+!87>R)>+6K>G/
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ME_*J7F3KK'W=%:OR_:^(N@+OWE1DVOZKR"_)&W@J0,)^7T^-;3ME1L$VU+8
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M]";=*#.&!K\^Q'L,Z^6->\R:)(O"]K=R]Q2D:"UZ+EFM[=(@ V8.;0%W:$Y
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MJEJ[PJ\'6'G@:2%)%C>=N)]>LA I_>P19.%^$&(MXL)MRXG_CF=#QL5W>$!
M\2SK04]4Q8][C'X>I^WK2SWI+MRPW;C&@)"F[:(928VZA&@JN":]JB(-T,]_
MN&6$J4!SXL=RJ55XAPZ=A:=+:!#=#V]4+E>(XU;FQ(^Y#0_#N0*<0+Y:G1KW
M!BTPEN;4+><^L9.WDDYZ9N*#:#4(;KR!C.27QR'TK=/)3!ZC!-DMT+H- 1Y0
M#0)SU2#:CE]R"%YQ;<CO^@Y/5P0"&])T%Z^C; 7'^-0R J@'/8GS)>6DXEW"
M@.SZ""1@.EU,2U)Y1QD(H__LXC/L:0\3\@@#GME4/$DY2[E8=')%J']^'NZC
M,Z1!J/\7XU;/.AT_&O>@A# @9X<6K>7(UO HBY/*%LC!@_B4D1N)@6Q-XC2(
M.'#/<A </T-+5N2"LX-SA<[G! =H!T;*K-F6[(>G-J;CQ&2NX(,65.12RBCT
M* E&P<6.%.)-8V..^W26:5'>6/$4=4IRJ'F:R5&R F[)/#:,M#J$O,?D@:^O
M$H%RI]5]LD_3EQMQEZ),1;?05-N_W.&GY2^'?-5@^%:87 _\"RKP+T\K4OAT
M OXNE0=FL_B%'@K'\NJF?;@=>YS?!Q-TPHD9R?R!85EBT4F+]O1F6@$:&S1%
M>GQQ5[@@%8R>?_,4O5]II_*/'U-VQ9X>JG?GGPQ&_E=JZYG^D]OTEJ%PS0GW
M$QZ)?XRL4NX)%K#N0/Q$DE_N&O(%MYZTKL7N"CG\Q7OY]#<$CMRP!:7-81ZC
ME(ZNZD0D50N]_?4" P@B@]LM[337L0#5'E6^>GO]7]9>"],?.XIDF5-T3#[X
MZZ%>WR8Z7?O*]VP!55BR0<*$<^QQ3_AE5+\NE/S7Z*WY?$D+\>$[OV#YNWOD
M9NZB$^E4D/E@>]<9'"Z5OQ_PE;[63ZDH#L-O?QF.PJ\DK,S=AX0>A0YS+%AW
M$8LQ<=_]ZI9O^C/-N"B.4Z$_W5S)W+N-!>ZBLT[>?$W(>QQ44]CL#_^(FX_6
M;X3\;<C!K0OP@:S/#\C1(_]LJ6P_UAB'H__I:MZ;VG9&Z+&O^,='_A-:U[%H
MH@HJW_R3.\81NME!C!'Q*?_DGEKZB+B+AKE)!R!UW!V!/\_O]X-1HY<X\XL,
M9G[AJ%](^3OJ[-[37U6E5,!)WL^(HF;$UOX644.7[U"_3(2J)84,#/(/.%2C
MFWA3SN*?<.GMW2]#ESD:M,2#4K' &?5DGO_=@.^=[;Y&(>/"ORW#>'&R\&WZ
M-[LS:DON7.(>-7I3_*ZK>KD9M>1M[76!=)I7;;H?90105BJK0<]V46)8G]]/
M24Z+0=6Y@3SZ-J2]AD".06HENX95[$ A$4$V+R#K<DB/RMT8Y)"*MPT#N,IO
MS\J)AP%9;RN6BLI#Z:&:TK33U].451<\"RJ"\3:D:9ON;&FW4DZK&R9ETP*Z
MWF:;W-]H\10O5ESB^"DSC(Q$&2BA95A 9M?X#S\) TJ>I:Q]H]4@="V>0^;O
M2 WJ_QG9^)\&NJ1B.[8'#^"W?XQ+. ^E/4Z#H:[HJN@.Q&JIOFUF<:\+PC!G
MHF>'!Q:7C2<8GM I*!NG798-*Q]]6AG5HS8_X\4<>L(W,;CZS5/X2ICI[<,>
M/P5G%%-C#T_ D&"'X-YGF?!E0A=*$-615$:E))O9;L<ROJYV4.1\[S;:?'0;
MEHMTUK'I85P=AP4GS!<,%*T;.FSI'#SZ,8ZS9!;3[O\[""(#<=]7G'YF]43
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M*ERZ>A^X/^XE? HO>9"JY>M197XU3X])%I^T%T0A82P,2AC\^OG )<E@4B"
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M'9WV<>=5:;I*QR_@*4Q.WG"1O.HZ515*2.^+X]43;W1J_"^5ZWFZ$$,X&.N
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MIN[7\ON !6HA; H_THZANT*]Z] ?[[[71?_-]X*^7/N/__SZSZ__&WP]*F<
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MSRJ#YD$<C;! KS46V)K' F^-Q3#=F/M?3+*K68V<J %=)OP DA(9+1TGM2I
M_$*G#QUKI%I&5I[GEVS6C#"N/\S8BRVQZ\HN%F]O731=\VM,DYF,D)_YNJ?
M5\TA4<US(KI.DB/!TBLF5E H<XN_-.T=A]BZ'^D^$KG:QJ<GR$14*=^K.'32
MC7/4=M=\"0;IY?GJI#R^W*%^59QYM0!T^2@UR-&IBIM=-OYQ,QVO',ZJ[<19
MM9I-=+RN BOFOCQG_6D(_MTZ]$_XS\/?=CSABE$J3]/).DM0*^&RM3 ,8:I/
MK>0%=)0ZCX>S_";#WFZT^NH$F(<!AB4W8-E2<]M\" TYYCUI"@Z0C6X8LB"L
MSHN6GQ@A32TGM4FAJ@DC5;-5!IZ65.B:GM4V6-QU7E7=Q3R:1N(]N3S)545"
M$&D8\:/4&:%GC?_NO9\J\V.4D$>N!D%]ZYKM$ >K]FJL5+\T>0*<D2SP?94A
MM4BR;H5T,AF00RFNLV/L(21P>Y."SXS,5?JBEH0]0W;N;=-*0':)15N/=\8)
MK</#/*N>?4%X$)5^WHTFPAIW]= :K]R89B"#0XB=SQ&MF\XG31O?B2R@5FT,
M&DG="44H,1IQXJ%H/ZW/ND/;)^1MTZ]&@*P!*]Z1*$;==O@Y-39!G",?[F2K
M$M+4CLI<AXN=<AL"V3B$"KBQ/\JG!;9PDZP\UTZ+?MI;H4%PHQJ&GV[)._)2
M=9G._@('?@!74$2\I#[3VP===4$/#/"3^PCC(B;D;6S/O]N0OG 4.C3\QG-2
M*IX,5DVS>I^BXM0:?XI-N#_1L,CE2!293NC=Y3:KXV=K<'VJHP#$B9^HJ)_]
M<T-'9E;<'P/XCV^ >$:"7S)EQ=%5ZVX= F=8$4"^6#M $%;#^)CKJV4 CX)S
M!(7X7%FX]I<>@;2![)\;QIRUGJD19\G6.>O:AW=&O<$HJ;@U3ORKK_F:<N^_
M],Q0F'15N>7+ATP_;[:<R,UCV0[+5E032R=6$>Z1&/:,JC*\Y\F('GZ?\0.5
M3M; ?3^YQ$3.$*$I5,TAB,<JMA1BGRG8P%W9M0 ?"*!>YAT,U$3EF;WQO%F(
M3">SN682;\GE>6KM%71J<_8.!BC$D?U3CQ$4/^&,5^Y3.RST$3ZRZ<#=YYK-
M-T^%2L?'W6Z#',/-EOT_2N.SQ2]F(6"NP,.+2T4)U2T':<HQGYQRE7T>H ",
M_/'0NNJX=:N3 [3VJ/(ROTOEI/S<\D>#P/Y]\E+"PWTG\<$%^TPA#0H8<P4@
MD(!0I.1><'X)I4X$BIC:1(6LBN3VG9,Q\;P G9:2DN25,H$-.D/V:6?IBT8=
ML4%ZW.^FP,JUE-[I^ 4=SJOJU<_)?8:H%>K[")1Z#76?-'#/%T\3D0?6]A%J
MJM<%:>LXM] DQ@0PL"=Q?^HTC%&8=M6[%NK(403HYEUT^8)RR/!UFAX"%(^,
MPTIP:Z4/P&@K\%1P8X[$38%]S;_R+$]$FKQ*C!'=?^M8E,EF%\=!N<3P2$.
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MXX6XH^^4.\M/8>1_L?<><$UFV][_@Z"@(@B" @)!04%0FJ*T$!$!D9'>E*:
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M\*/=\?]3 GQ1P<I:NPD;9GZT[/[?PMYN_S^:NUL5#WG#:':>/9]T7?3'@LF
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M-E@8MWJ$8FE+H1$U@41'M*:11,:.5-$PYF-PSGR'MG7O(8&4SU?^*9NFI\G
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M0T(QJR*AMPT&:AT+ET5E,>U,G5P[F(CL[,-U^V9"[X_M7'D :2<%X1T$/.[
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MKK8(-IT3GOZF:Z2HTJ1N4#ZP/&FEJ<CJO_"CG8C_2%C5,/KP_NN%[OM4Y&;
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M\+IM![8N&Q_72]+3CNG?9X'CB5*A[AR16@R'XL\-GJ>8*9Y=82@%^VT"F+M
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M$U7B4Y@B,MJ,O)S;R(!)"0=6%)=XQ]HMOY4#&WNN:'BW*O7_\/3D'GOL\0?
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M.6Y+WPK#)J3NECOX^ A07X./0L:LR4 G(^$)&>C3MT<.$3_Q(=C6F0S96Z\
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M]J1=*QM=:%-(R9S]I,)WMTET!!,E [*?:K^3BTCPM.@U+Y?)"F;1U!)-@0L
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MX3ZQ^7.?B#WANFS2MZ;T<;-QH3;BYK49FQ9(E)I"1E&"7-*BQ*T,/3]RB("
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MWB?5Y.B#V/_>%>DLC6JC284-[_5(W.2C>1U\*[&?>*-X 3N4+7_5G\@4:/C
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M6+W<[>JC\5FWS!]_.0>Y1JL.:8_'E\8_9Q!-R0P9:5"Y\!).6]6?_6D]  "
M?X5:Q_3;X<_BV2@_U[*LUT7I&U:Y18:]"BV=F,B!J0ZY<1(DF[M70T6]A%[-
M4*W]WY4JAN*$R^OFA<LF>,>,]+U6>:*&O:HM.N=W?Z&0,<S2\GL;I=/VH^U@
MFGG#UBW2\K_[40H  ("_,@95C?R-<S8=+LAV=/1:^B--S:0TF>JI6B;1O"8E
M_Y:/)R23OHB++,(S9A(4:-K9^#%QXD+YDI3H!95C/O1JEQ[]SZ=19^DA2K@@
MVA]MV!=N+O\H[;V,PU%;M0NYRLIY&^+#FZ/#)$A&AR>^-#)<6(6*[YI+:%C8
M+3AIVNQ_@<L_    _ZH=8@,'CLFV= K;W;[5%3>-Q^CA+",_"FL^K4BI,\S<
MI"A89R/>ME2AI5)5M%\4?WEGY@)7G*'_63MEPR-=_].169KRI\9]#L)M,I0^
MYVB]7BZ=D"%G;*;NW3,[/;V)YAWGZVD8K^"W*^DA2 9)FH1&\&T]R5?"\>C/
MWT($  #@OZ*HQ.KRHAVUZ<B, OKJ-($895-ES'%.LGDXT.QBN/FEW069ZT6^
M@@NK'-B7*T2T2J&]FI&4X=MTY:?1T\RG7[!I7LJ/65,=T$X7R.RY4.S]\=4-
MAU3W1-UX_V,L _]CE[]O)Q'WK[7-<'\JF]2<2' 5*FVCFA"Z8/6^2@#Y+$=J
M$X-=Q"^/CF?.K3VX&"&PGJ"TQ*%WQC163=?U:,'H(!/B?5<TL;9O?=-U1J?E
M8C9SZZB"CUY JG(X/-?6>^KS%WCB'P  X)^G(Y(YZ7'[:@"AI&YV2@H;TY8E
M&O"CF<)30D@F%5TF'_O'9:P(?XV'X;#3"EM?\T0GK3_?6'IGN+F=8&^"O%!"
M@Y<_3\;['>%DQA#.U223ZD40!2=>1RO!K*+%!?,NIJUG$H<FFRT]3,.[\*HG
MG1\>*>1%W);D[W1;]J0XSG:R8M8WT=2=60_5L9>%W]E%[\"3H.42RPC_L?<K
MTMXO#%$(E8 /#]=9-%EP<O69>U+B_8?^Y@N>_[(<VLA5*@,W^V8[(MJHEOYZ
MT4))<]R$@?PSCX*'X4,L#$LD:-)5YP8Y0B6O.VR=J=,NF8$S3[1@ER)%RF1T
M7GC'I#A_,9NQ]=#R"AZ/+-NP_66KI'9CZP]Q?%)O! L0]P/->JTZ]LC1:^\>
M,#CZ('.]T%=VT9$;F[-*1!N^[65XC=S/2S=J)'3=\)ZE?.,2%1_BQX^$S[)'
MUHL/]'5MD"!4MD$#GHIA2$^R;BY=+?R8[<MX?SX-_K_ (@T  ."?4#%_,M:D
M:F_-0-C2!&8LA@097#=\E4!QQEP^+%V87N;;T8B57J>I,YOWPZAIB7R N4(X
M/&I=BMPES?A3U0\!82U:DU)4E[WKNJ4N8]JREU:S,*H?/E3=>9O#DH-#5Q+&
MA#_YEFFFS2QAEG/J[]=4A+[J",_;OE?7-([9JRMK%.=*.T98%;+XZ@_"M;V]
M^3U,+ OH(U-\Q?OO^]*Q-1TF07JY03Y[!I.;I;"9^PQ^_P'O/ALYAB$E%959
MNX]JBI=N7O8:<Z+(U,UHB-X;]98M_ Q_ND+:2;7SM"[T>4'6_SWE>,[F[%ZM
ML:*>LLF?(B>=]FI-=(TGRZ;OL-/0,\A/V+-O <4Q9<',F\!]R*&HV-^BV>1U
MV_*N4H-W[0ZLM>M3%DG?[&D@;.[X,8!3MHZ R<FJ5&T_N.YT2JW="3F6DVV*
MN.][DJW)#<YZ0GWV.>=+BY56D_(VMO(F$KK[%(SYS?.[+9CUC!#/?,E]6176
M2-!SXZ*>DAVZ F<_2^ED&ZE@FR?U10-V*:E,:@T[7JS52,EO?9JG_BI<5'+_
MI**^J:Z.8KREQ^TCP83>![-3[B0HIC-;1.Z67Y72O:*(]TPZ<<RMN5([_.OG
M5F([E;36CP6Y/1_+'OF8GSYNUJ%U)>FUJ;?VLV210V_@D3R/_<]?' ,  /QC
M>/>FTQ=#HDWB#LB4U/$7/*E\PO:B]=6]9HTD:(H254R",")KK7]\,J$E/A>?
MCQPQLA7"5QN-HMUX3OI0/9^>P"EN[DE7TTODYHW]^?,!9FF!S#:?N!:.:IF>
MZ$'S)_ZRN\OCW#LRME?N#ZTU]36R$+WIM5)2R^N7J"[:16+LHCJ$R>]L%'5+
MCTMA-]&;MSM4_/E&347$Q*0^+?%[W=/4KH.3&^J5;W^+L3?F])H,?L-="AX]
M P_+BY@V>NSS*.U3U5A#W$[5Y"GK1R@M68NRN:E<MC<@0?TLC)^MN(M8\:75
MEE%2W(PUE(P['>'UE#;7R$.]:%=3;X,31PX72M$X&5O33UKFP3E^.J:1S>.2
M$!:?/[.D3V@E*A#0S1]?&5"Q[/>>->2Z(ZQT\H.1X&L&#N'81VIRQKK_\LNY
M2O?U^ZEC+#I>M:+]53?&2% 6GP6C17A4?*D[9=3Y<HN+^:\LPWQ87*/#BVXE
M)Y(SUG/LC"9!FQ8O[^^[0HVP<'!SUM_)@UN.0"^(IG4^(H0T6(J?SI,VMO5;
M6L&[PLO $1V/!L8K"XA,VS=- ;<03Y[';4J51OO-21-$IQ!<8ZQOLOKF$ J[
M L=6N; *GQO@%5V31$6F>4%-?650%**M1"O^^=$!+JXW]/&)D6Z"V%\^O_3X
M%4'"84PN;UDVJ$@4ARISYU,OC0R44Z<R:(Y*O]#V#&,L=NNCU=O8H79R FZ/
M_9,7C#PHLH)EQG1[C7!19?LG">IJG_),2=!O'UG _-[*/OHPH+03".DS<IO&
MV8NHDI#+W2\**R!Q>[;HY!)E.89X13Z.,SU.5^7H-?;]!5ZL!@  ^*?I2 P6
MD?&4E'$OUJ!"LOR+T/3H3.0,8M3RH8!C+&'*802WW-E8"T?C<JF7F0;;QS<3
M^=; 3XO(>\CL@K9V(GE/FA85ORCYAQ(66HKHML>]A]!K%+M%#M?/*'ADO^3U
M860AFX #YS3;V:WS:NH<?&=]YB4)VJ_>JJ2FKNT:E]16Y..0('0GN1%E1,2N
M#^;6]93C^#)33/,4B7/-BX1JE_R%E'>Z$BY20?[.205B_GPJ8S_R-;!LL&%C
M5$<N?:@PEM"]LM$9<9E&_>%JQ#KKQ52FJ9I6.88'5__A6V/B/#\E6P3$6+06
MM'PJLL-<K2=!B+'+ZI7MZ7/I(>(AOE.-Y$[DJ9E[#9@21XAJ6]=FL<T,F;=N
MO"9!]G:37Y*S51'A\N+O^^I9.DY?&+]_*U.[ZZI"9WM[NYKA<^/XC/"0QI[;
M4_#,P9A*_F(E1;"[N5DLK<:EUL"XQ0./4,D%;2U$BC[>XI6?_\TR_*.]B=F=
MJA'$Q/32$NKNZKQ-%YMRDX2# ;:?K73OX>8990],4;@<O<YSIV<>!Q_Y79O2
M0874+F<]+D+O)4&9J!GD*%]*MML)=*%AQKS@KHVQ<2]_GJRVX#][D@<  /!?
MQ1<QK_#+AW/?^(]*JB<W:O28+APMS$7UHS0=K_?5&/H*6XQWGRZ6-IGS7H;7
M(#%E;LQG FXW/R&P;[J71B?/L?6JIZC=+6,+K[Y;MMAMVQ,_2X*@R9HA%ZFZ
MV8Z571<3R#VECIG%ER34?7>+S#+6QDM :J+]8D=9<V%KJ(K.B'0OBC?N9. /
M]N5LM<BF@O$LI2)WJLCNYKINT0>UC2.< ;65.Q"%U6?>5(A8NS*G'XTX/#Q=
M+OW<(XK/-TF-:ZX>I6$VV*EIEZ==%4F)<KC/-H0:T(KY,41>'O$2-;C+MIG,
M$&4Z(ZPU4?J"ZECG_L,F^6NBS6IJZ;LG]#\\?)C;&IFI50L/JYZ_%U!2[JY)
M]<M5MU7:AX>DY$2KZS]9E(]GG?$OC>0,$+"6>@!GU:+1E1+I\H"M$CEDP%^F
M$_%IHS'*U3(5HQ(DR$VU1[I2N$7A1<T3"5N%;%2RTJM?EGFXY$>*!'7EE@;=
M_%;&BV:SW-PC+ Z3Z^@@WB5Q7NXO[Y!U'C%#>D(ZMXZ_\9&.\+@A4*5B**NV
M@YKL[K1*O/^44LV1;P?=\[^L"D_0D_W#*T;B20GR>I?:V^D%!/+.<A.7S7JK
MUE7D 'HY>;.24.W \&[-:-.<!%F3H-,&<H[78\H,,X8;T8%;WU N#@*W"0$
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MD"#I_'O&(UP,Q6<>/=*PNN; S"*MR1?B98L6+"?D*&>6CYVK#+@;[5Z$2K+
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MB[[0/DM+<Q#13?-_EKSUO\?Y_^RK2P
M
M
M
M                      #P_RL4Z=/_ U!+ P04    " #R@5U8)_0UCFG.
M!  !H0D $0   &EM9S8S,C,W.3@X7S$N:G!G[+P'7%3-ENB[FR;G++E10)*
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M 1IBLO?T U#@# "A@>#1X&&; 1BNH@20/]*_>$D0/"@^ 2$1,0DI&>Z <FH
M#P*%XN%#"0CP<4X2Y [N=P"?AH#VM*@*(9V!#=$93WJQNPG9Q%P7RQH8#+^N
M<8O?] HG(64\Q<3,PG.6EX]?X(*$I)2TC*SJ)35UC<N:6D;&)J9F.._-UL[>
MP?&6D[.WCZ^??T!@4,2]^Y%1#QY&)R8EIZ0^?O(T+2?W15Y^P<O"HC=OWY57
M5+[_4-78U/RII;6MO>-;;U__P.#WH>&)2?34],SLW/S"^L;FUO;.S]V]_>-Z
M00 HY%_27]:+!E<O/'Q\*#[1<;T@>/['!]#@$YP6):15,2"R\:0[(W:7F/YB
M0G99 PF7N.$:PTVOKZ2,W!<F>-:/J_9'S?YC%0O_NVKVKQ7[6[V& 7(HKB(T
M>#2 $K!MP9<31@H" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" O+/0'V_O(M[@>B#5 ?\<&IHN!SM
M95BJ9SBE0'<TTJ)C6-,H$@ "T9YD"0@O\=;:0(8@:7)REP+^V^]DUAE&V1/F
M86MOA+! ->_11MVAR8E"8"W#V-%CU>[5\_O]JM^4)NRN80$_O8-I^&[1B<)F
M$!_F<_;LSZB!(HX$+$!V9OS@#7Q<$ M\,CA1,DO_JK%C1:54HUBNOQ6W>Y41
M"XPE8?:N8P1.%&I^1"N]F0L\FM@NBGH!;VRKQ"QE_>S  NO&OQ9,9K8,_K@Y
MJA)C!2X,HUK=3SLL\-$,"T3GGB@AI7+BEJHXX %WG+/_W<K2P^U[-@^:%DVH
M+F.!^PGN1T-*JRE88/+EB5+QE[G< ^&HK!\PBY=!&H?G'L%7VK% "!(+,)PL
M6;NKP89\Y#%KH/! X8'" X4'"@\4WG]MX94[[2."PO?*SMNW,S.SQ39S:*"W
MBR5FQJDDJ,YX$TFGZ"G+(CM)5GN5LJ;G):9LSV,:<^-TO@ZJ%[R+:8SF*_56
MSHGF WX#JF0ZF/TMTOX&I;3!9X[WZ'&F]OKNH.:3(GJT+C%B.=IAF50^I!Y,
M<!. S8X7OJK:F;/WR:!+&7&D7S>L+OOW'96"/ZJ:!38M."Y X8'" X4'"@\4
M'B@\4'B@\$#A@<(#A0<*#Q0>*#Q0>*#P0.&!P@.%!PH/%!XH/%!XH/! X8'"
M X4'"@\4WG\WX97-RV[)ONR\0M(J$&#3*Q_LR,S,O&K!@/[!FM'D3<;?(,9W
MR+2L].1L;61-C1^#S4QBD'C1?3,#9WH#-2^6^_0&R@3_0V&REL("<3)P%&R?
M93!YL#A@'",_C07"X',NUD;6*P:'IQ;WN:).K2.5<Z(%O\HT1O,]Q_MO L4X
M/KQUZOJ:TA&DN+^X(X0&"\ 2X/588(L0:8HDD\*(;1U=';NW"WMIH,8PRPY1
MH]?_':*8Q?'U=:DCWR0L<%'B(O)$Z6/IXP:8:D?J$E].=-D_NIU!0/Y9.;4%
MV]V-PE2U8H%LTAVM]5HBC.)I+%!:A@7F+M8FUEB.H^.RA^X-W:<WL+[:AU/I
MP/]4;$ZJ[Q(T?'?S,0:"DUM)H$[P!XVUZ\BY6+;K+;4X_8>\-/L/W]#P_R)2
MO^EO_C6-PU U+ #% CTLM18UY\9W/_=N._K1H4*SU>C-,GS^JJ=Q2"'AK<WC
MVP-Z1\3]I'6_%O:KKN/?H1*X]CHG6J#Y']W.("#_K%SO@:,G8?N+,,P]P2'!
MEM]TNS<\5C'*@<X!=V2@H[Z!&CWP/Q3(_1/*.Z@R!@N@NZ[O$F$BRZ<E5J9A
M#:%U.=*><)8MG/:KI<O .9G ?Q?&?M/=!0VP];U3AU180-EYVWGM+1PMHM?_
M[+O>W?UCD^_9\U?=+.!'+<X>T,$'KRIM<1D+8'XM"2[,A]!LR1>ZX:8SQ=3_
M!1H;!.2?$0A<!0O$/8 OOH+O4R/MD*PG=/NG+QCI??8G.D]P\^?I9RI_,7_^
MGP+AJ1/:>^''B:!+=3*<8!_S8.+3H4L/3OUMZ7K\Q>Z:?U:@_B>4]T;6KT&7
MQB]8 %&K9.IOHTBT<&SR6Y7_JI>A@WX>ANA@ 2L[G$&(T2_>/U%$%N>M:?1L
MY%7C#.&K_\F]# 3D/P/!T6^!%?>3VOV4U"YZSL]&T@8W?T[U_4='A?Z1_">C
MYA3N%'/71PR9_&\W,G:-C1$SM6B4^&2MO8+/5V)4L<#20E03?'?7?7]J?)]V
M\(597%R+:9Y9JG#'6,+@100/V3N/\;\=.X<%[MMB 9VZ#1@6<+3ZPM!^E/L0
MX]X 3T#VS^](N^^:*FV-8 %<L^[X:NOO>E^0;_[,68\ZC,G8P4]8;8?I75?/
M*9))/2WW PMP4U'H;,D;[K1HG]V8-GPE1[.*B#-H-?ADAK3K?V=>;C_$UR4>
M+FV3@(@XHM2 <D[6Y)I]&]%.>1ZR%L!MR_66LA:N^TPMZ+W\;4_2D<O3)2J]
M@]E:T7RE3=3_>3NR&,(SP5?^(,V)+)P-V:',!-'S52Q/<?Z:R^%TVYAS9BE6
M*WIU6PE0<:%/$M1,5K=)?-\1KK$V"#%2I2.=?[_%KN45.:'&X*Z9<>T+&\*C
M^ SMG0B\(--O?CKQE;*UK!/C&3G:D5P>^ +DY]N($IO"9?!MUU]A 9I=_G=Y
MXKF$#V@RUIIXH=]WF-F[E05[792:Q? KGB0"&QG>K3R7H>ORI&M.#A)C)J4Q
M2_Z?J2B-6G%F_&?7?T-S2E@9N26R7$@N5V%#YNBV<H_<EFN@2N_7/J8Z47<8
M(G7DY7Y$XO)-L+45+6A8_/F4O5O;8K8Z[?WA$QW2!]Z(4S7YXWNXVKPMG8F>
MPGQMQ@)2J+JVP86M S:I0T'8OBL6B,<"![*MM6OL_2]'\=XW\-JT,^UPTF76
M.]2J1[]W\)W<=MI';M U&85J1&DR(U)NJ!#A<Q!SO?PD61MGVF/3K\ZCKRMM
MTT3Y?G9$IJ&MVWE3R+_):VYVEOFB1ZDLQY$<S';.,U[<.O,4C'3?57A\RMLD
MF\^E2NQ63O2RZ/]U)++,UF[PS3G^GQEALAA'9I2O8K]U55Q4TH,5K:3/+?7!
M&9$8Y0&3!5F?:9XJ-:/HY$2)Y8\L^=T_+O^P83>F>([N063 /!.^FPE-4E&V
MY[PVXRR>=:'<56BU;=MF6],)6O:Z3LN-AV^)>*H"_8A7H:OP1DG46I>*W<(D
M^5J5HY4SM;ZKC_Q,-!_R]N2_N3/!NEYY"$&?0>>7LU8,L:3H<Q"EIJL?A=:2
M+>2U+]BW"Y^:X410M[Z)TYJ*5$R>;4/>B;$B>3DZ]1(W]L2$YUFT%]X0<[5<
MYN65!BA?A'G.;Y^IQK5[PE+KDQ^./U]+;F-6K;.6?6>'BT+$,P2U.4(=B)5W
M#''VH^>^?SG:=KW<QBQ1N#V4UX$#I\!J]5@'?)PN/)1_*IJ!1YH13C45%"X#
MR],O14_>#GMBQL4IP_61<I0M&(51?Q^T]3K%RL(@?2RC_T:V9#QN*O'A'VTG
M04#^'D#_ZO\G_XH2><((?<&P8H'6)OC@69PZ2JT]\Q%^ 2.WI1%Z:M=1"DU%
MJYFS%VIN5!?JCQ>Z,NK#-?"A;O?J*=A8'&;/'2. /-3% JE*.[U8P*Z4L?JU
MM(51-K-T_O;AT/V@MXCA*PM88,+.$NZG=#!=MUNT>"@W&;#]W$.RK58_8WV!
MBIFCQB-HA[?=)7N->T;NG7Z !^H@)J_N"?UZ (MUAZ[ %\'[+)LSFM6CVP)3
MBF?F;YJGSE&EB8<'')0LCDZ4Q5W)%$2^$CF^^8RZ-:HC"I?VAB\M-2PKCW_X
MFII%R.='"_:$"$VXN"S:I5WZ7+'TK%-6%!JF/"<X)\KTH"=._.-.#ZI I\]/
M(\O N@0+$*ME'6[BKC6.!:)+!9M"J9/,FDLVFC+UUME\1P[?!'#LGGF3]\0@
MPU[(T*HCE</3R=T[,Z?6[7.C7T4$GH3MW41TH/1JEW)W",3:MD2=*]-$'Z!]
M#W@ Y!ZB>A0QD6=TN+=(DZTNI/,;J/E:P,+R:IN3'"YT7U3T#I?C>#J+C[ED
MVN]R,;'FV8-[/%)V7N_,2JX&* [T)C#9(NPQMP]0ZUG/.49-D$NL\#TT[.C@
M^EHIL\/6:H[#(HGP;,Q7ZY27(?+AH3>%F.OG_$6L7T@I*+3NK@T/1 G'-LHH
M3]F);10,$D$+/(^(2U\I2J;XVVTO=189)$N)X^S7O#BI8'_=!/%;+) )WSTX
M7E&5,IE%=LU\1/YK/KL?:L6V/TR>5D/5DGY3RR@Q6L_,+6O&_=RY;^ZJW2]+
M6R_M!@T"FAY:_,S#=? ZR[7:V/-W*"G\J /<AJFI+SV!_=!OW;R=M/?UFGB>
MSI#+''63KM8!AX):T-CJO66W%G+G B("PD;Q<00T=HCPO3M=@,*[N!_9(C0*
MGAV;]4KH5H4HYE>*-EIOIX?VHO,Y],W&V);I#:SR3ZO)2G?>$PC7E :\-!4(
M!=]]_<C.3'B0*J ;:MRBD2W4MHVBT@TVE2BCGRMN3R'U2N^9O(6\7K'VJ>3]
M<-EIYNY.J:PO;^"D/AC6BB?THF>I?AKS'P[BA_I^.D+B.C1965T_S^CZ@F#M
M@"([/\'RDY6II=O4=P!YV_6N@'9VEP?5[US412^3OLF@AG=/!0_:DYO(+H[!
MA?/%\_C<5-48>G9YM>(,G^8^]>=#9-C%^O,M:918641GL&6V/?G4_L*[SZP8
MWDCCB 7D<<+^>;R4+'G]U/W6X<1O_:)5YUL3E?>>,'(GW:W'1)S]\'+F0E%'
MQV)I!180OSHQR^"=G%,KHK%&+_G\0E-G4KB7;KV&-!019S74)4L^6?;QC+F&
MT]3>K<(L<3EC8<]*=@+Z35)?@2+/NI?:5'RM3S-<@\R:GG2,B'*&?2MC7I%\
MV7:H KLOA6&HK?OY @M\?(P%'I:F?OOJ2J_&1%IT'L "2D]7+<T/?67[]KA&
MA^^37#2S=PW&*,S@U+0A?.YLC5MMQ<IW*ZZ+0TV%1K'O;2(L!P\%@^&KFEC@
MC@@6H#-Z/#G?@TBN*IODUW(UWPP2=/]4=>;6QBO15,[G[D_"O;0IZX-,>8(O
M+ @D&%X3CS7P]'/ /$9?BY&YI%S,!P"H#,AW:I7#300@:B*!I/E2C/["=4N&
M-)>44C3+:#<)D7&SE@Q#_4AI;Q:G#^NP ,-5:_ZU\O*8MU]8; ;=*&<4S*$-
MW#X2LX8M-O8F$J<Z?^Q8A3I>>MEOT#\7IXC3C7TRX=%C:UC@GGT_[M-+.-1+
M/,,/RID9O+78I2Y8V7M(X^+8]6V*KC/*WP!QPT9O4BG/<[#U6\YR]5*,T\2L
M0A"'F5HP[PY%W>%Z'.8(N6MJFHL2='F53"@I<U PW3Z_D;&F0*B@((H0=]99
M2!.:X*Z0;XP>& R1$HX-]4SF)45GK_:6[2A&,4,EDJS6,APY[%80/*=..>"Z
M>.S#M>U2(!&5;"A>'HH%0C],!+/=V&=C2>N?4+/6;;HOHS/$YLNP6/&1H;RB
MZWOR+"QX=AZSX[EK_"T@:*C!B#Z B^U,1/=[9IB!I8A4 ?Q^^I&A53=;3BVK
MZ6X@/?H\'2ND)[$C:'\*L=ZE2^0\*>'*:,53H26:@8HU1J$YL8!J1%L;<VD1
M4X?)EIYUM[= LCU%!V[.Y//T_M]IM%@_$N,:J:T.!=^'FA6;)>]R893.8(&[
M.&-/85UBS>A^:#^__[::9$U)']<R7;)_M2:-BG6P#CWIOK_(B[GG?/_ZKX4[
M5B+ABE$I0M]Q+O#-W[U[V;I(W$A;&]]NK]OB05Y&2NVZ8P$8!1:P3,<"%RVV
MHO<.>W=7O[+O7I_(&$?(:YY]-+UGHWNT-TIR4.W9$V<Q<\*,U:W+8<RQP(C>
M4>)[BY7Z"2?=>W:3Z8.;#@P+7>).XLB(R2L=*CX7:QM7C/82QSNJGE%]>KVP
MJY*2!/.M#>,ERCZBPD<S3&W-38G&=USFG*)IP/>1*1&T?^?PSC3T4A.==*VO
M0DNQLVS0 LT[6D>76 ^/ !FB-9RJD&U?@S^@+*,9CQ,3@]J^5V#-)_3P(LH/
MP"<=1U)Z/&,>FOLZQEC NN7X:*'*LS<OV&\ABGF;764A",'F5Y0R?JCQ[6>1
M%6):=Z">-R*19.E\P'S72JU@&#*GT6RG+[EJ>UM^X?54DHH:0V] < .MLWFJ
MY8M+>%2L3QQ?+[=Z+RF?>5=L09_[A=>.KZ%]B.T+PR(+/,+U=EV83 -STLQJ
M9M3TH3*LJQ1^ S=[[6;" JO#6."^A[94?N;#]%?<U9E2:D&FV6L;)'L/WCE"
MLT=K@^)'MW["T(W.P^>JM&\GV\HTL!4VM*A@HH@2XL6MS$/L!?9YD0[VAHCL
M#Q>C^;^VV)TVIM6LAR9JSHE:$=K>*EU4W_7]NI+>LZ17CZJ<(8;I]W\;";@Y
M,.IJ'H^8G6'MGAE2NN]A\H6O8<AJG[653&HJD(!A27S7;?B&?O,3I3']@DU+
MFKU!I>)#6<U0%X?O\*HAP9$Z;G^%C3LXG6DAYN>OFLKHXJJGF/-J@<4G+3C0
ML-"T7EI:G@,52S6Q5=3_(RVQZONL<X.:^9NRQ.V:]\EO.>J#T;P]WGWK5ET)
M:_-G]DJO!6(6ID1"#^F^[S1L,]P/,9$E^Q&TLV E:YC9BO,YFH@BE[,A^)IW
MCZ;)X9+M2L\D9YL8*Z$NE\(<E?B^PR4:#@63#JR?84[9NA=I?YBB-_-]=2B[
ML%.RX*<TZ<&Z < *G2>F$"U:KSDCPJGP:?IN5M^ZZ31@]DCTF8S*@F3TP%IY
M]'7+%V+DN6YM[>ST"6T-"X(]2B?,?"H7N^Z]#Q;!U_5VO0I[4M1\ G48ON\V
M-?'?[OGD'.63UP+AE1Z)J]$534K:&\B,6=N15G<+]9>9T"16D+V1M.^-\$S3
M.Y]36%B]^&:!C$J*EZ/U66]N?(LJ/V=$O 8^3<],]3AL/L&BOH3MUHL.0I.+
M&:YN8@1>/QC+M!>3(U6278>8N7(299@4U*S.&3L;^ KEU*'X#3W3'N81-<L]
MJ3>D>;#2X05?322:-V>)S#W[_,?M5U=?$^H205]#[^[><>F%GZA,1\#BI2CM
MC9J4D;K00-L,UU;#.R[I9 ^;M K.<3D</MY+,\DS4%\>XTK.B=Z"D058#.\/
MG4T06Z[F]:9$**.H94D7FV]R793O.AA1%? 9T[ +W&98&%^[=Q77FY4.[V"!
MW:))>274GN_=F2GNP)9),3WK" 1J35>CXO(??F$AL[;Q8[A87E2&Q;71^IQ:
M%]VUF/+X86H9A2MAHJL+YV5WH#\*LIK\>O$BN1LP"_>5TE!Q7:\#:^66EFZ]
M3JR8C3.PJGR@"-M3_G);LU7QZM3/KMYQMAL<>H72#,V#KN27!-77'>@*^.3.
MY[RKD<LOS9.]]N'T-3\_M#R_0L-6Z4KOQ%%Y-0F)W[!W>4>*DCZ]X_S>^M5)
MT7=SBE>M=SX8SW4XSPU]M15MH'W-^2">.H#S/C/3*]A#V/I*W78_?(NQM/3M
M=BV-Q#WJ-G.@X:,AI W?GVB@1H#!V(6_%NG]T<.-DF^]0_";TL0UW.@.TCN8
MA^^FH23D;%S.Q9=ZQ':(#Y)>9ECM^=1;.ARG&I['K^J9^MCU5J-YNZE1O,;>
M86O07-V$S>CRT+TNT6JGL5ZDI6/=E>";S]=T4SCRQ#7$5@R8I=O95@R^QUDL
MGVS4+XAF&[3BU9;E0)'-"[FZN3&32X%WQD:LRE(O7GTRE82!GQ[.+HUJ&38.
MNOV93;#\R@TT]^:'**\[@IFEP^((U(MW5UH\/9.N\!5H,,??U]?D!2@U>9]_
M\MWG;1IXCZ<=;G"YJ__@:'_V_I)GQ)R'DRE2-[KF63C]M)2=9Y]9Z?"NZ<"(
MW$VCC#NK604'0ZT31IH3BXX$5PQ0"(]H*D64W1TUCYH?SS",[MN:_O)>T5LZ
M1A-]AN$]HNI+5)W/9.$!=C_;6^7-*(J<O)P2F>R9;/9HOD>,PC!EL]&+V8_R
MKD\$[8@5JNN/%AY'7L,L==ANBY6<P5-X! 29;H04OKU0VI'\;QQ%HA9KYL@6
M[EO444XF >>:IZ28N'_BO2]T\"G24>-%%NRE?Z;@*Y[SV#(+S@Y1()7_7*IG
M9]2J.^6=L<_FV1=A=2&4HT*97HT#:.5[L;ZBKM?7U_^%7V7(ZI['6^=5U58^
MI$Z_/)3@QY7 F#>Z9BE36, GJPU/=-\L<R'-,LTNDEF=*?22'^=/(BSP*G"R
ML@G-/S@2VAF=;*_GE8?S6<[:_!<((X" _!5@>.F_7'B)=9VV4;N.][-Z2.#3
MX;RR9^_G!&,P#>]QZE\,/HZ;\)+N:/%/;/(;Y#]/]"-]8B\CY=WZ?&VLLYGS
MX0:\)D]CYCMTL_1G(P<CIHW#)VLQXT98@,&@^P=TTBZ5T3<#HP>=SJ9QPFT^
M:^L1'R<L*YL55-O"5%KL;?HX'FW2ROFVSN[Y^/N[W,J_2FQBD*BW=Q@5M!%'
MZU)@GMS>IM+(OR27*9=9@,R_C)=I%>4K4.ASL;G/(*;J[=G::PVP]=D_'C&I
M.F^D;;OCPULSCA\Q413726%(MX^8(^G0H9'+DM+--P3" ";  V GY.]O#.C]
MU(EPY>3QRWK:MZ%G]3SVR>JXO >D.R$J6W9S6L-**YIT:66Q97MU=S<=4]6.
M!;)9LHTLKK$6F)LQ^Y&*]Y[S$!QNO/'QU;2PR_SWR>)KPT/F2S70B7HL,/\M
M3!WNWQ6('_Y]1T&)+C:RNBJ6F*#J09^-,4#TFHG=N:*L,$;L['O.^# /N41E
M6.'L'LMZ<7_JV9*#N80A8@%/W@_5V@95ZB;XZ',7$?MV ZZ5CUS=*/M35%I"
M;S\__ [9-7N\D/8B+2/22=<<H^P'^$%QPRBP*&7>J(/K\ZH4G"O3O/(.8]2'
M?ATC[3@C1!-?1U8G1S-',WP[CLV,  6GE7CQZ-:L:)N'>%9*W)5@N@9V,>]6
MF:WHS3)ZWLA"E[U\'Z.T8KJ6[1*>=T\M"&?9(L(A1-FS&PJ!^':3+\W@ZP)M
M]+%H1*1 P%0D?NR=UP$_E>(@UCNTE14O7OQ<\#"-XAY6Z$I;CT*%J:O,9JJT
M*=V=,BHB6^Q_$Y,/KPI+ZMU@;N5]_A.9IEF1.+KUO5+*R5GJ<L?S#/L'!EE7
MTCHC6B23J,,-DHY0'4J2 %57S6?C_NE^IG9!NO9Z#$UFO=_\[L_V(I.E?ZEK
M[!]U?=_*&4]H2,S%&:M"E/V%5IV;P!R/N($H7F5!U-IF@HI6\IE \U)(JC1G
MYBD%)KLP&?D#QW!/ZUQK/T&*<_++O;FR_"8F#-V\ZVY11PF2?42?/5,60HL3
MY6!(?+N9,L'>4,ZK),N(&H>SAM+M3>PO'"OUX1!+6-06%E@F08>AR4>G$N+K
MQ"EEIJ#1.Z\#,D.4Y.;KVM E>JEYCXW*UT2B"(K(/@";;/:!7?2Q5&5*GZ&Q
M:K[O3/4>NN>_C?*M.I40^S7LFIN*W&M(E^A6.W.WZJ2N=W-_]1B&Z+9A >RB
MCD:SW[[GT+DPJ>>?:7HVZ-E\T0K!1CY8@.[: L7T)509/BK2$MWKP;QO]J0]
M9[1-^X)AHJXFWU1B4,9D^E&$)\Y?L<,"=:X8AKES%5$BK<B.\<'.V?W.U8JH
M-V9*:!A5C"[7F;AQ=;$7OIQ>9F'>X]#!7EZQ7:V-JQ-#'J7<JHBJ>',_&4['
MGFUYN^V2JLVD5([2]'P?)T/%@D@SL[5QC"(KYH,4YEYYRF0QSYL/B=P3*OB4
MTJ/0&[9LY.O+%G6XB3UZHFXQ"3ZG;;TBX!QP5=/73-I)T$2[<ROZ%@):#>4&
M]$+(48XCO)L7%EK7)3]>,*]$G;*]C_]S6V%-#OW=,V.PV^A> 0]#M0*)III5
M.D-3R"]A;LF=?>V!39Z;G<%)JQE4*MTJG\R0+F2I51)<4H(C>;$"[S,#WG__
M*2O8)#AT ;;[,PKS00,+/(]&M=P(1=*O!N_!&V3Y!G=BBLWKU/0'Z] _W/>G
M>3'A+BUS#:C0,L95ET!X VG_4;K6H&P=SD%?J]MNAV^=+36,%AS-UAXRTO_1
M2C[]Y6RW]XG(M]_K&G<LP.&%!>J5MB20&4UP%H[B3066.OQ:*OZ2<>)=^('U
M]?0CXP"1+I(N#X5 KJS;&Y2"I+6V#57P[R7ZGD\)-\/ACQ(&CS*@6X<NHYVB
ME#%"4D%<451ZF=:7AV)%F4B? X0 &T"D$AV]LR_'L\ESHT@N:3F#RJA5Y8N>
M];72H[?F29T!+T@5%^[=YCO\P/MA=:N>0Y*.LKA];$BH:[A<AO&143D6N/>C
M&Q,$1\=A@>:!42\2P)XS7(QXBCJ(;3 6"]P8A7<S*ZV.P._[A))(L?A\-$YH
M.Y-4:E 1N33NOZ9 )*,@6$SS^!N"+5O(3/UKBORE]+<:_OZW*IUOQA.:,G%B
M@:RV'237X+NDO"L];"BV0H6^+9GZ[NQ69L+:Z/?C#R6U;+7CT%25E9SA@:L-
M;'?T2AQ3S3R*V[]B[&_>R&/=UI!#E0CYLH:]N5'$?Y.X39H3LI?QL^N\AL1"
MRDP6%2_-: KOXYBPGS(4AW>1V@5IE<NO=BK"&_/:3/LDF+:V-^UO%,>+>04J
MA+%E-2U>+=O]]K7-@+-=>MJ2\DX'ZHZ.4G,HFY7KQ423^,-7,BV>\>KJWG&;
M;?+"A:C@]#-:R"<155Y!J)!:[U$T9U#?Q"V;HM8?288'4:9YEVL9HPH"%RN_
MM TA5MI&$(XR\PA_Y(5U>#2\O#L)MI\L@Q]KOC6V)(,*Y>VQ>;=QD64TU:2[
M\RFG71#R92M<"VD=>4HXAME;RK]GMOB!M^GWXS64Y/^4NT+9KY]8^)-^>.RG
M1.)LD0[.6@H%J85@G []YV(/1=:Z6"?]#W&.7D76 8]'^=BOPY>Q]DKUT;"2
MTI>,]W&3YW$>S.NVN1 2F=AE>@XV:46TD_L,05!*X/6[N4+^S$!\=GNKS6M$
M5O/=W<$BL_OIUT;^7%H?,6.W6S2X+/FFU//>6*^2]TPK&F&68/9Z-]&3XEUG
M*]#2M&[S+M0N>GUAH4-D:7IXQKSN81"[V=U#:0E&*=JPFZIA) NC;#2C@%>0
M8VSNF=JSA;>&X3LA_$3,:LP-W'8;K5E&249CG3?4$U1N%ETVZ(L7(PHMGYE<
MK-J^-O]&ULG(&+V7X"S[RL)C7)R *#\H\QDPM3T+C>Z.:TF-O?B04+-5 .6]
M8@9=< GK%W*7D"'_]NFT+1:X,@+X ;9A2ONS:<4GU/28GE#NYU7MZV<1/ ^?
M;5EPM)M(Z @KZ(J3YPK SP=3!^-:>4#>T[(R;#JS+_UJHO(]>VTN@,HS4;K;
M^C(S1WZUUF:QD8_ 586*6W/W4B[_:(V^?E4B.8;L:(J;H^Y)E[2"1KE/'=6%
M\JJ4V1 8GW"/AE\7ZUHKS'*;0:0YG2?V\@PL2+FARKN22<G:<POOQ:ZCM&FJ
M_&$G]=VE%Q%_;'P1-/,][^;B5W=-/);:H*3#OUS;:.!,+^#TA,_V;@,W!J#;
M/5)P7KX1\+A1NX0AR5/# ('VX$I"V/DKA'[H9EJ_5>3FI#,4R/[62UNG_?EZ
MS(MFSF1<S0/$XKZ$03=+Y*K+WQF=NR?PLIWW$*-:&^B6C1HI%D$)BQ':[E4[
M/M^KHR7:>)5?[6= XL!7<%I33F4V7M9?Z5F0R[D\PRZZJL6^F?U.=*Y%6BCO
M.LW "R*F&#%J_]E"Q5EH;$1!H8R^LAN3>NZY9D"AO7[18/#:VJS>9KY3ERCM
M>GO7=4Y8&TWWRT.Y!>F)EQ6I#V]Y?Y)-&BP<"@A6M>(XS00-!*I]V_=1'G)4
M"SK.!I:/8^6O#(<*W6SSMTS=PD]H_=!J/?9A*N3PM+S.-5_';'[UC)"$ZI<!
MX11*#^WT5:#0&9N$3!,O#?9UO=[M)[Y4V[JO/'0A33?8[ JG0L_4.#QCBQ1C
MUL1G"Y?FC(V2F*_)8:NCJYLX"NER+ZE>SEZ1F,$"U,+/T_3+$!TU<M"-]:]Z
MQ5368Y3P2*I=W8(-Q>[#._*=AR-WE'Y@ 9=2!8SSS#S*@RY/2D:AHM+ K)F_
MI>W?WZ@R\[^68[D<:XM>)EX_0F5.CEWIMNZ/1%/\_:H6_8\U'Q:X>=8S XE!
ME'#QP3!=2L$."1UK*P-$8IE\!M4$\Q*16U9<2-IGDKN97->&A/-,2@OG^U8P
MW/#6*BPP:(+[JQ8?]/ZFKT@K3Z@K$YNC2$:/VBUXPN=EF86"F3C3TE^TAK_$
MKT8?R2N,!0+CNC<<3;EV;T^X]-?@KL3A^<>5))'\2%-<30,__5G3X=ISX[N"
M@UN.BG_, S0V1I#VES@:E*$; &EB3?4G#+>KNNE#ICT!#T!>4K:L@7-#>J<5
MF*EY=9;%_.%&R2FCHA(3'<L57EP_Y<Y.MH/[B%-]42'"=5.7=U6LN?8W*,5>
MG._.5PM(L?JV'>A307NIV4M,Z1ZZC'T?P_[:Y6MALL;C,3>,H[RGVWX)E4,I
MV2115+-Y+<+6L_G)?-+7LECQGHP-S]&TY5?NICL23Q47PS3TVM#RL5$_T@NO
MDLUE0A&R"8GBX4%LP1QJ@=^=OV6;*"7)"J@8Q\2)_=:<8L@YI?5UJB-?G#F_
MR+!H^UIQV/)G^6/WZ^*)]T/5/KL5O#%0\\JB54*/P1>+<)-N(6LA4NN!G,A!
M.4=A\PI?W]\6VN74CG(0+6RX_:Q[?$@760Z_E5@>^^]/)6LZ_WAJ(WU](M-]
MG0NC> KS001SK[_#S.R7TJ.)(Z6#BP$HZ28I&6X[D<ZFV$!@LM:2.]GC:](0
M5VI1K7I-UV#]1S;&E\)3T$[/E%EI0VG%9BQPCE*&8>#K546>0:6R[,VPT>9E
M@Q%NNJ0ET1&DKFP<I7?FV9+]VMBYE[UQB<(_%@S,8[Y5O6S@\FR07KS;=T1@
M_&9=H7Q^A.U1QMW(CD0]92@DJ[$F;66Y]/OGT^<ZO32Q@%+\LOY@'EN.?%7[
M^)I,IM"X6O:*;WKIG,$BS9Y[$U554U'6 I7G^&*X3!PD("'C$3.E.F6C=Z;,
MR%;+Y>XKMCV4,S7#[PKN%[LLE%^9NY=KROMOE:[><YRXFI6V!Y2.B,W4UL^V
M:9SS1CBH<8;)Y<OPUI$335BNX/0KC!HW6,QQ'?FT];;LQT&J[C$VL2@>[<#,
M=IU;33?B28P2,EOQ[4+QXUJ>7=W?>77AI84WXNY]HFJ."&;F;>E98+#KHK"A
MIENWVKN4SU)FZ\.VG;Y79EF?"'L.%N8,8.1J]MR0"$<7PI8@'PFTE+^K7\M5
M$@?;/R;<SD+"PU_OE26^*N",V]R+W5[  K8'=8QU=S]O?_'KV1FN7\]/%%D>
M>C]&+4SU&G:^BV3*;QLJD9V]<'U8/Z_EO+GW-A$16Z88I4+146!"\LN^.N.N
MU&3T5#<YSJHOQ)W[1^_3 P'YWU'WZ]!\8Q;SJR9=2IG$F5ZV.Y2=9SMQQVYT
M/?\OL%'I'[9!BJP%"ZS/BASBK(ZJQ7&\[9=I;X?+6(=2^!'\DL<D1F*.WD M
MB%?Z]^7<_;_/$@+K3LPBNF>R6D,?K#9B ?+LPD6/^>"0F9$ZZ8E83\06T<!+
M+-#H[H@%%)366[' I O5K].*CW3">1;)#B/56ZMS:I:7LB53XHR36B6C22@U
MH<\UVG>F('L)5\WJ:..I1EN:XP.]Z*$C8;IW]F#7=?&B%R+-+HH4;V.!N[:\
MT>D7?%V#7(UG3+D=[[/Q+<8JO$5D9/B_6N K_=YXWE2K[5/%V'>SX@ NC/SD
MGPLF7(_?7H&*V]U\A"'"5:K<PP$+-%C7Y4HUAKCWC"&I,[T]6M1E'+B35G3U
MM';VUSJ:>*_#/F^+,.]</&&S+^:_^R!9^E98#,'DF&\\958B$5 ^Y?5I*'?$
M)7DW >?A+.*LLQD64'&>1V58\B7HFH1Q'M D#!2[L-SHFW3QNDQ)Q%6&3[,?
M"W^"?-KTQ;"863'.Z%LAQZT+<<PYKZR_M]O]L"PRB;JIL)ZP(+T@7;2]-9]?
M&B=:S+CU[(=/L&A=IT[UVTJY2/%8S\SR9889#-':B%5;I9LHFR.7S-X3G];7
M\DF]7&R;<9>15!+%S,8&5E)R'F7.0C_/GXAV\)?BFL9DCH2]COF<^68;*3%;
M\-3F$IP2K_K->^F>.G]X[Y;H)[G.G[*-ZW6'@9^Q (!S'P8JG<D6>6ICLN%5
MJ(C>3>9NKI<_D;2(/@%UO=PKRVDU%O*ZT95_\>2N\+H1,[]@29Q0_K/PVJZ:
MZD8.5E=UDY2^/0$O339)6;XVS@V9G6[.29Q;83G\RE[ZDQL2_G3DWB/-CS._
M[G)L"OAE^8M55#/95X*R1XB.#B)I::/W&?YS1)."$6N8[*,L>>\,FVL9X1ZL
MT[:M\GB>UV[8\-Y+6PV^,W"F)K$8)LCQ28TA:?(:,_+TB-LTM]'[&REC8>JC
MX:(91V*$GGV!U-')B6X_'"V?I7QQ%FRU&RBUY;&XJD*$?\I#A5U=7 ?SXSC8
M_@T^CAMC+%MU;W@/VV;VAY>">1BFJJSZ9PHX(_GMSL'G<V]03F6LX7J:N?>G
ML[EW_ O:>C3/I<=O/F2*55=9'/4^7("_&9<2$?NX QM(03K::D]>N%MJC$=B
MGLSF)_<$A<&'M3S^Q9%[DNGWGF<TU;:OC'O?5Z+WY/CT'RA8>AW+GG"/YXN)
MDO@WP2X,=Y>%79R20&N\PM #I7UBY"6DU''?A)%A <O'N%[LO"E6?K ]UY5A
MMM9E&,V'?"Z-5YMT_&PG +Z8#,>=P(JTZX&C?\#VIV&8<,'/78K$^\^D=;Z[
MC*^OXNXH"=>])="^RY5^C?,LC%WL6AF^3>0LZTXHR25;FTA#%0X4:JNP?>J#
M0U4<4_F56-P?,)]6Z#H1;RL9/M&S/EZG.+P5A.S<6CBDW9+/__UFS-?<LG=&
MC.4=1%^C8!,H7RS@B'\$)]WV#JC4%>F<;E0*S'6+%OSL.UYQ:R/0_=Q]O;$;
MRY&P+'Q_]H]/>#L;)VIK,MR29)W[=IQW%+2BU^N6%^/VEGF/#MW7<P^"T)A@
MG&\)9SUT>7MP!MZ)"*VHYF@WYY")%WH1%D]&#U7H6O-0 O0F+-UR*7:>T5IJ
M<]^U1'/8NA&]Q'=$W,W<78WX9&NYX#5&\>;R$J2+^1'Y/BKME:+5:HNSYHO]
M0-)\7@U6:HW3")Q<B#ACB;FROP2=BCH,9D.I>?FU]_HIJO;@>?[40ZZM9\1&
M="W>W&Q\S)@@U'1ZN#Z14)N/;3I2&IWEMBMOYB<0PU*H[M:=?9^_2^K6]I,I
M6J!#!=^.IHUS2Z; ##&_WSD,WR^P9^8%IKW4Q8S7X#16;G?1\[P)G,]4?IBH
MBA#Q(A)ZIM#YHMU$>8&^&U7Q.@6^N\_T/ZE;*%"^-?YVII^^52"BH0%S.A.U
M,[_[LPUY85TJ\IKZ;<2[*Z&F6&!(KVYS0>[N(D,,FDRD?+A-NB.F2:%BPW,5
M$=?*+BA/*>"3GPOWK8U&:FH);<NGXIH\1W[MGW-'$M&OX?)Y!IQ?\6MP/.&Z
M4AJ<?9^KCNQ0/'+W&6[2 U\NP+1;"@51-6N3"!]F"3&OSS@ZI[;XH9^72AT0
MHC$![5@@=.10\-OG!36;R70KN*3WS3-CZOHYY4(UHKX>?J]T*<4W*2(V;U,U
M5F51'2IM/$B;BH@-*6M;CFG]*-/&!C.4+BFVY3<T<PTZ8Z/N%4P7HO"5HJI\
M))Q%Y7[WSZ!9Y#J;+5>%!F$U*?^;RUP$3\* =MXP8,'[NH+UNV)C[SMZ%ZGU
M8V)M)SFRIY0YT6*O%ZC4]AZR5Z$W#VL&RFOTBK& <]>WN/>*QEC QW^.BI<W
M4]US^(W+>'W/S@7#X-JKLX-9\B,*7=%YN<ZP8>H7A_9]CL#=A";*.Y1J>OXD
MSU@D>+3Y(5'ZE^L5JLRZWF]\3ID+XA^S3(O>L#)<V+P2WW3N#2%LZ^MKC9N4
M@7\N@L!-;-TMX=U.2JMH>$R0:(<]CR^/[;/);WYE2\EFL:TEEFT77[U)U 4H
MIQ*#R!W>2:34?I,,?%.W2JC.8XOP)<K,Y1KI2=,3=-:2[UB]8?ZB?ZGK\>2E
M,.5'"4E\G/[UINVM%1HS@MW+)R9*6XO%>\+K,W**XC&=UY@7^_I$?UT=9YUY
MBFK)R4M!U[E<9MHGR/HA^J6[LN;EV"O>U?=X,R:J?59CW^,/ZEBK%0?<O'..
M*"'4$,(32#:"OR-_1'7364BIF6[^4(T+@# IB2$RUDKB95:C)PI3&XMF"H24
MH &3]NS<<3=?C3DVK2V@::G2$6(HZ=;;J/5VU/HX4N+^1!9K11YG10K@T,4L
M'DOHH<+;LYFE$KL]./C,\)GEA:4MQTOV+ D;\L%6/2^^3FV,IRCY1JG#>F+1
ME;WXVS!R^'3ET5O< %W4F&1X_,QU!N' 2\1;2M6AO)\HOK7#$+$VJ[_A<(M2
M5&"]H<N(FZHMJ?OYX1U-TU0N MY!9'O!'EL1Z3.[*HX8:R,T?/?PC]?#/!<*
M*O?$**QM6KM6/1 7"\LS=D0D$K,'\&;6>K=0>-J7V^I6U)K$E(EZ149E&ORV
MKGR.$O+.#*=0B<]A-(:5XI"/X]+=D0?C2]NM=9\MQ]1D>PI#S8(I]9/]_T_O
MU[K]Y_NUW.A0H05TZV)>Q?2!>^8?N,:4H<=A[P8SWU_7E&YY]6.Z85DS7;?U
MUIE,5\.5T!LBNS!,6/_]:[\LHC7]GH7J_HJY]&T7O1!4[C%.5S<==_0.)SS!
M#[\&L@*N^A]TAL*3Y#QA38YD)]S&X_?FX"[>=7SQR/[Y_^5$RJQEL6Y)N30)
MCBY^#K&=V,S7LC,X>$II'!N6J;5&*(<*"D*AT_D*F;H,@JNO33D]>N2DV*J@
MQN"O_8VGGTF#-JFM'4.3.873NSOMR)N&!F9!7#%GQ^(T?XV0X7PO5IXW,39Z
M56&0WDWI5M["G_D+9CDMO!EHXA>H#+O8",79N]=%# ZTWK@4]\YT&PJF"AS1
M3);_^CZ-(H83;]<H*%[3[MGDJE)(_*#WZ[JVU_+N!4=O^A]TV9YN(8;Y1V3L
M\_,>3GYT)^%A67/_,#=@%B%?BE/P!?*]Q;\O"MZ$GUPUG/5%*?:(9OP^AAFG
M1FF5T!/PQ42<^Z9C_&O;%X__\HOY1UB?TMO96&^$H'>\+C3D5<!LF*Y@;^ZI
M<^RI*^=FTLM=]C(_64HUK^[98@%7I1VM%1?8)UF1G7>$YW6GY1XS384I$RE^
M:+66/3"+B7A9.(#('/\F)ZC60<'5SE?(>[>D78/ W)><6+&60N.ZUK/N"T-K
M?JOEG]XRMQ\,M4@^&Y-#2_]L"4!:E++66[/:G=E7N1OQFFTV4^J.:+SXH,P6
M[P<DD7@Q\T!O3MGX_4<(B843P3I+R1.Q(:M3S>E?N<OJ19_T):JL[*)B1_F4
M8KRKJ Y#5'&6R/9X)V,0$Y_TA,1"NLRB7/_OS?!K"<E+<!@0] SG^$1V2^5$
M"\[K7?AU%87?ZU^#JR7#>R%ZZP4+6$"\]]C.K77PY7Q\OOGW/K\" ?G_&K+]
M7T=%,$_ CY-1UG9K8??UUIZEQMN-.,US;N$?_6[(?R2_S>21IK].I&KR:T=S
M=T4&MS0H1=#6=]7HS7*\?]]^\MLSX=1=7I,XG:<OGE84(A"H3'_^):H\O[JU
M]"$LT*UWZ(D%=M/6-EDD>*^6,_:GMBTWZ0JPO#T1U.G?7;P69;Q1DSKV-C3
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M)/U?G=;)D31VAGM-3]7(+Q)(?I'KY!>1<(QNWQJ\&Z858QY8+(2@QR'=1!=
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M)I85"5U$>+O<DH/TJRF&J*A31MM+;@H#.VB1UDMR-&W9X\D4M\'EVW0>]13
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MYVX+3\TQJ9DX7WFJA%A%;[,AQ"$-F 8F P02V@Y3*EXN1,TQ71/S*>=4Q>@
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M:J>;RUR?W]=IG>$/9R-DVXO9Y_B[+R*\[]:0MR1_&>*ZR/:3X=I\!\HB;].
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M. A.%B?I!#CY&>]630ZE4\ZXYS2,L?C.*% =HI&DX@Z6F-@D 4?&GS_D9&\
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M>'!$KS_-$T?):N@FQ@:I(,28PB2_=Z-\RNFJ/V56HXQ/:L[+3O9I(7"88EU
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MR488<^]!XN/[=96F!YE1.9&GUAX[WZVP1-0]"!,;5YOU.Z(8?'FXA2OW,6W
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MSNMM3QC&&KWKBMH#P)-E([QXTG]=,I&4#YM1W$)1/DSIG/M>0!;)0H'FA3O
M<H/N%M VJ1#Z8F]U.>]6'M_>/J)9E8YQ&"=T>U^GD6\?OO#< ?X%(&$O5B_N
MVEN?R%/*4US+V0'.*,ZD;S=JR<;^EZH5R'^]:U8V',<%EN6,Z]W4OL]:V5AJ
M&$5>7%<?EU[-&8"-G)B(>OVVMH;!ZO.D9\Q'K"4&U??:PKVL/GOV-?.F73,S
MXG@C+%?>P:>:HW?-J_::3 6=PPDHC %4Q2"#MD<L0\G4Q^R^GC0;X]V#TC^[
MOS(U?:",B/QD<_N#>0]!9=4(-[!&N&1$F9*]RR7D%OC^W-L&(DA#0^_#)>P!
MW7E74)Y./#'U)>?EV&VHAEEG #PXUK]Q7#(3OZFI:&!2'%EXJB ^]\#V)#)*
M3?>SVG6N)?AH1/=$:\"$IUGTD6=I D8/8C#BNG"J_@2M I$>1>=NV8!U'29U
M8,XS0DGQEJ=1AW?9]45&YA&N7L='EGHG!*C\ OP!0)R*&I!%_^RR3EG[VG=5
MEB-,&G'H%#O.WWPT".,.;7FOXC.WW385]9I.^I0D;*[Z8\ 2J"]L\<?AM=M+
M1^GKQ!&RUQFL($08/Z2E-;(.G'(D8^6F4/S<J>R-^/S[=,*<[&=T-/'4O$12
M*:)1^OR7J\_>T\]9?TIQG9% BGPF<(L33E5^KQ!<:"KLN20.7+(-9%)";$;0
MCKLCI#GT3E@A[>>E*:!80S0# #4U Q!N?0K6#*8LDDN*"Q36<MOXF-_#,V=)
M-]H48_$PLA]QN 66M'0>N2\_Z"7.P#Z?']!TD7XY?/CNMM8H*XX<;%:I:^;H
MU.09&9 J?N/B=8Q#;0P.E ^: X%ZLQ+ ]X?K.&D67A?]B)%5!BEZ=6S+D9)R
MI@Y1M[<JL_0^P3+$=& \X+BTD"7:M+C:3;VV':#S&V577")N]FB0IG ^HC(=
M"8>6+297;'Q_? ["A8:L %Q<J$9^W(#K7Z*%)TJ5,I<_.Y;T%<SU!0QQ93E(
M$ZFWY<NOO+_@*1O?4C>@30RP;7 2<L(W=%3#NC(-"$F;J&WH?07G<%?\R/'@
M(9(3* :'9>K?&G(?>2MGG^E3-JO2#).E48+T5$]L?]7X$;1F]'K-6'/[8['&
M=<:U3^94BU)P+BO$!&Y([^W!+/%M^ #$5I+!0I-#QX?&.+)>?=C,9[CICK-'
M\*=3"XG!G$5#.(E6,AKM17[OR5MG?*3L_4>GL1)'Z6: ;VFI63?_5(D]3:V]
M"Z*X]$J-<K!LV' Y0PBWIYLTGGLB)] XGGE3V'[C]@X0K?B3/B_#6\-XK1<<
M-.:@O#6TV7!E0292Q51]D^_:K44* >"-^=LMA'N>GWX9=ZK'\Y!1L8$+5Z.\
M.[BX'*X?4&1Q\,GJLXYOEQ.R^&EGKN1:9!A4"E5K\+#A46_]&3:>J=E_(MM=
M+>'^2J,^ ^FSBPD)T:_4C%C.<XD08Z%-! " RA\8%S,[N=\JR)']0(7X,*=V
M?"QS$\-#&H*S'1.3CXR3&?E/J7A0E?WJ4X[('/?<08UU2YNJU<//9CJ<N;@6
MU-0O=<[L+P/D'6L[]_UK^G4I[S8V;4E=B\\^+>!)KXC"ME)Q5UGCO+!'Z:P7
M/XMUOCC>TDJS[1?L=&P5G?:U544PD2IHUUF(V@TY9;J5X&\S4_!4Y"I9I(Z,
M7:!AWQ(+E/E>2HFP<\8]R2IL)XA-Y:.&X'O43F@>35)!]5):-K\7TYK!#B"\
M \PD;+>8!>QM<U8>>%HL*'O0:FKCUDHJF['500(XG2^P=&@^2F+F)KL^= 0'
M[8QX[A!C=2B*-U<2QQG0Q:U>PF7T]IOIH8OW7R%4[R*F@J'GQ\P4VBZ'?T)
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M[Z7 ,9IBF7!<.B*KXU7)2/;>%F\$2:=D;BUL0?+XG8OF4P0XC4#M!@^$82.
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MJ?P">B#2JK%]BJ""=J!JD:[F#I<=/]*Q]&9A!X"XGYR.RS7G3)*VH*'2\8!
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M'\YX>1QIOB;,]5!P%AZ+J GH"L(3E+LBG"8ZAU\^5.Q9K$!AY#(AIUN:%@J
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M7Z(^2K;2TK$[K5>>-)BQ?A@@D<_&A^2B I?(Q68JN@>$DV=_GWO!X),MY ,
MY,H 6;N9^-R7\*"+&UP/P]2@C"I-]2"04#$?IJ]^0L]X^;U-927?_GHE7DG.
MG%4&6\XT6N&S.9!G3F%GR+-Q1T%(67K$+.$5K/IXT?HPN']F7$KY1 :W&&,]
M+]B9#AAW LP*!9\$5O/^*>1<.[W%J:7V[*XF\[<2A08(;P3EO$J.!:H&_(]R
MGUL$8"Q#O>H[ZL@,O\/8L6*=$*QV-85C R_X+>ORQ2_O?Z]SF0NP<3ZY'IEP
MYOW,Y;?7VV$R7%1L@^4OG>8V1E:ZM(D_=4/UF=;]:!X3*<N,F7:,,J*53KQ-
M;;FUK_%,&A!=];!J<T(-WRAN6)/_9CG[/\HK%<C]$@07K><<Y^1SB2AUP<'%
M.'"PO;K=U]%W.Q[\8%827;SM<%QUG%R:8>[Z;D"!C%1YT9&K5CPR-&/@?.2J
M']F.1)YS,ZZ3Y9MWX;('F=?R G0O380/?DL0U>@NOY,Q^UI(*N.$U'%J!TD>
M],8X/8HV7I9?O=8R6#?%4[3#F?>GL*19O@/ECC(5;WXC+OV8^T9.WK;\_&&]
M/3EBH*IMU:MWSH_R+-L?!?-NY4/U<A7_F(J?R\MR?Q?-FI%RX86#?X2H"@]#
M;[A^C%CMGT/\N_!1T$<"D&"\O4>\.^TB._*!K#I_:A] :H3,MYO8@!40Y$=*
MTFG=ZS"^'IMD[RK#*%+B(3S7,U>-R\BSRW)_'LGZKO2\?)5CFV9G,@<:%\?U
MB/BJ1W\,>PK\L7H_YX(<9$ 2>L6'T96FF&LP$_[J?)'C7]^!C9]R@$,B@V.J
MF^UYS>=/IRJ<$]A]MYD2?+B\W+_4K"2\?^WU*9OAB[:Y=AN??;7L+BA1W5_R
M;!2[C/<78^ QW*Z$MFKAJ=TTHI@[QMR,8VVI &TFWJ*;Y2G3X5UO-T7OTNQP
M^'"OA4\JX'CV!1+J4C-30@6H_]UCIK]"\FB!Q?O'F&^SBBSA>:TR)!/TMJ3_
MX(ZNHB(#)[T(T]L V! 0ENJ*N<U*_>V'C)A=EO!S\\$J$\YF&$5"G7OW6V8R
MHYKJ*^OTOTFD3(&@&] $-;[,['^N=85(%07D;!@69%R-\'ZX8Q")'G?"PEKE
MLZ0L?2Z^9[M^5?K"G;<#R5J18<DHP_7<J% 7E@A=^.'LYHO?9S?'#V<WDU(B
MY@]3[DP'704Z1E_KA@N-1[D4-_+QI>I,$"^>^FM7&:=51M02&VT5ONEZ7%Q\
M+P=3=)=_PDY.%C\H]O.VS6.J;W8(#+J7VSCFPC[B/@LFD=-O1Y-?F]-G$ZN1
MB<L<_Q'*7_P^0E.)F4;PD$8EOOB_F@A'%HJZP*8!CN.@I)Q0?I#,(WI*I7=5
M#R U<7&6DCQ1JC()R,C^?-L*=OV;#J7M9BF%*CV3-"A#76TEZ="&MHYURBME
M._S,">E1@[BPNFB,E"5+LA)S((O1G@9FWS/SKFA"G8<9;_M:EX/ 5V:RIB%/
MB8*7$RY)]4K6X7G-; ?%.1?%:G3ZG:F53YRL%,.WQ$XKNQ.O[1)<P8!9JY3E
M\&(#=2LZ<97& MHTZ?E<O0WK,AL<H9.+<J?UF[[Z.H&WM0/!^^OO4?IS_"EC
M'RV\7R0IO)UJE$_;D'D^Q6$+C4-TPK)<N*@+BBUB<=\DH?&+HFJ-TS]*E$YQ
M$FV[67S"&92Z381 :](P0&\0( +*ZKP^9ON5 (2>3BD]EP1\]&QVA5KZE+1!
M9I7A7Y[TU)[D>R"+ SV7/L43'F,2)<V1(&6OFZ<_?D66UIC^NK;:W OG*<BB
ME]J\5/1"E&R01KX!93?%7@; "1=#.[@G:MV:?G_]QV#^K2@1?OXJHL=FB%"8
M%5%/2?MTO+9:HE#4*YE^G/ZN&&.6_"P9?J>5CI>E7(GYF-]_@T4%))! PO\_
M07=U.\1U\\7U[Y_.")/%/DAG'T"'XJ 1#3=$#O.9QZ/<XWKRYG[2!QD\?'ZM
M.L:,7[ZA5=F![F9"0MGF^[9M'8GAX>B#7>.#LYE7!#G@@>O@[K<,&=)DQP;>
MG9KS;YR7]?+E[3/[=565MI?TS?!;&@(LU"5\(+[HP>@H%->@8_;=-\50HH/[
MQ[*7_U/QE\H.ABD^O(<2@R$E0+.='Z!9:[\;\]_@.DD@@0022""!!!)((($$
M$D@@@0022""!!!)((($$$D@@@0022""!!!)((($$$D@@@83_=F!H'5 XF^7U
MMAP5JU\,N7-,:S4\&9]!-OS8SGA"I=^@9T?+,W4:)2!S> !<#D]H;C[?.+@[
MS+_+W11^>/#A_/W$[R:N-LD%K:8>'I+ OY_@/K1SZW>;),,DPR3#),/_9</D
M+>_?KB4^R=?.H<]%+N@\^E<[G)+'O*"A@BS=VKOA3@ $H.@H5UF-)W8Q7G03
M\K3_."?7\;.RZ<T$M^*.YN'A-JCB\$1X05'>ZKL=E?:#NVZ'!V#I\$3JPL4Y
M?&:%YCH\ENOP $@?GLCXAZ'?K:J03)-,DTR33)-,DTR33)-,DTR33)-,DTR3
M3)-,DTR33)-,DTQ/R#.JV-?Y)FPX9ZA *.S=,3^\_^U;'9%  @DDD$ ""220
M0 ()))!  @DDD$ ""2200 ()))! PK\7N4B=E<'3ACFVLQ/1$ %FC+QLKWL[
M6$7)H1O%<'%QR%0[^E)3ZAG$<QCWU_NW@,.B&,RZ9PC ":F!O2C4L" !^-I=
M&8378"VI;**1*2_Y">SU884UWDH?:PGES_4P6BD[K<BF:A%!]R45X" 759>:
M*D3,J-(&AM:W>VK1%A4K17S[80CT;K#Q\185>:=*,P.:2K_ <#('5WRE1'_H
MQ[?SHG<O</AX?-C(++C,5ILC&2AN?^WYCI^OC_Q\??<SLM+_!H4\_]?!$CY&
MQ_0U>7Y-D5O,60+P7A2+BYR39__S(_]^Y%/GIQ/Q7BP-J)K6PH/QQ*TF K#B
M>.3#O8#6BM"6]L]=W1$M;"8@EAT?, ^H-U&_(XU,246V9B SLE< \S88L,2\
M*[E! $*<E\=_RSG#5HW](2O6N!,('YI;:&$%Y:44TVWK5Z[7$H"SJ$V6S+>>
M2D5E9Z#'S\-_3HC%D15[N_&0M<GE-E]R<M0RBU %7:"@I^09IW?GZ,PDOLC/
M4W4W/%0>W3-O$KM09?A0G6[E+GSY4TYE"=_^:B7^OK1P2<]WPR"\T)S=HAH!
M\,PC *=TKPQSZP]+U-RT+'I-[M]3#*6-;]AL835%IJ:$7CC:3OXE''H2&2XN
M<"8_C.9O3B=#Q,+@7^4Y;_V^,DL''BRCP1KTJ87&LZ6WEVRON-5!)0>PUOS3
M5:@<^:1.O+UUW0O@NNQ[>A=HD[8>LG%O?6/:U=4X5C/('\DFFA"@RH/#I,3Z
M1/V^X;]U%&6UQ7\6?)P4OQQ<V/TTQ3;"Q^VVQ+BY&0*>06'V[A$H\^BC]5#?
M?D6!OYD#:1SWG$.[\(!Z,,S[7IPO<YVOW+4WO%@3PN!_8?JN'RUL5N"Z(K7@
MB?LK:"G!8'-=:(9=S 4V*&9>5O#J :M3T1:4 %3H$H!GZ29_?;IW%%8$NG6H
M%3-D^Y3!^ZMU!S'$9I(;BCD14*QY5OBA+'6$0CVGDIKJ__TJ!X*G=%><*F+&
M(&Q+4'/^UG:/Q.6)#PKD/A(9&=9+C"L4WR,::GG"UW8P2<M/G@#\N0;&*WA]
M@Y>:-S'ID]7]J;G*]FZ<6)&E""7M#F_HQ?EL4)VN&S6ER6 ^8$Y?ANQ)?$ML
M+'W?[^UB2UDC*LQ;T%. 0YUO'-F^.M#0"$E5Z7GPHZ<YX!/:G(N-4<P/GM$
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MBH=*D\"251MO<P*M-97,YQ+X_)7K7ZN/B;(HZZ%QLCYXU59:4:4SK[MTR0C
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MI$J(H1<H<.+-C^3@!]VO;,IR2K>0E;":YS,%[NX='UHK0L<_AP>WWXN/\+\
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MG3RM*GBOV8V'/)B,S&DUF/V(J0CN51S%DO>4B.S([Q^:?;/%,(U=:K]()=O
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MLG<F1K)&I=+330_M@$94ZLX[":?$8?F9 IK)S(=!Y.]Y^/R_U7+U_Y-K1X/
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MSIVE,U7">V+F'A6*&Q]J:JM20,M\UX''!A*2G-!*<0FB;T_"=6WRXS)%^W7
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M*9@H0_*=UI8CMN69M\W51+(\/:8+-5HXJM?5!B?^FBY2(92QYE#ZJSY=ZU_
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MV69._K5"J7%38W;K.J@<TB"2MT91@4#+J!G"Q<"E&_Y+XE74S1L<$4$VQ77
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M&<J\>?\!&L&-H#0;Y>\4-G3I@=]? W;\J%\:LC$<1@&-NHO"[6>$0>]YOVM
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M>:26"A:=X3]?Q;Y);9>2VP8KORU[AC&U6*FK8D5Q13&,DK-[_"1_<90_L"C
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MXG3L].W':WE0V16NJ8:HE<W+_*T<_G]_P8PT&<HO?&P56OU2];3KK /Q7MY
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MUO$]D<I?W8 2X(BDUCQM!!H(%ERBZ9!,VE%*N-9P^=E3J+UIKARIKQ:V2'I
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M6HY!S^\B\83Q%V^K0^$+??E^:<&*+)KTB<MS &Q*+D=A,>%1>>[+IH@?E_&
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MOEWHTV6.UQP]EG1,H,Q2.LB,1B](RH^R22GTJ1]#JYM:Q G?Q[AM%+XC1T]
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M!8!U&RE00FI;1]1&);&K[U(JPE6<@:O6]V6$*9N&M^:0>=S05:P=BT@T8QB
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M*&7MVD!%XJ4'0LZL%B;S4\MJ$S5DI-_2A-_[K-&2IR9FMSUN(H6W@%=W8KP
MB6;%#1=_QI2?8O!=<5=8YBA\).O'QSHC 9NA62] 4FN@!_.DAU>!P<^+2: 7
M:F, !F&2G%E-B+["FI_DX =G<SUH^IX';<O:FQ9V57K,J#,_2A&R'C[=1>;M
MI.G?R%>#&Q/\#CB0L>U9R(U&D.*-M0JOFZ7>^P;43P0['M<>'R[DNJ5$6Z 9
M*N^Q6$MKLS#&87)32B3[6."G8B<H#UIXGM_$4Z!S9M]NSSAU;L DN+_GN,=,
MI,2W(C0)#@$7N%(8V2\9M_[=:U/[I__*5]<Y-K;[@NP7YKS-N/ZJ5;U3><FQ
M'OYH(IF)$CSQT<-$&!7#8 H+NS?_C=W46+^$_:PH;AW.A9K53J**DV-VUM'X
MRZQQSB&%WWX!V?Y(JJ-J5W+^NKEBNV___1M*?8S];;9V_.+-6"BYWXX++VJT
M*\CQ5&_PSP&4:=E4E4&9C;RJ'G[U>?K7>[F,!VYS3434QPUM"EAG"49J%@P>
MREB\8LVE>+;AS/X@5"Z\%_YV"ZAN39ZKUOSRUO2I2I.$1AR$ELC;Y"-CN05H
M?O'#=A._O#*\.FY,X"$_Y8ZD\??H]IRM]N$M%BJ>'KM\^!G];;"QJI<U? "A
M&,;U4XE,Z,Q!3Q]Z(F8?UU3_:8XO@;5OR*T'SWI!J[U"1@N>E*OX2W[?P=#B
M=Y/YZO\.)O@OW7SOF[G@=H?T*#'.NHEOO(%_@]90(6CPVP,5NT%]693&K>,5
MELPA/"S]>F,W0(W[SP6IN2F,<+,6T19.X9V]X)&>CO4C]I/U)E>C7U"U'%(1
MJR]K-H<38C19>4X9*;N*4#@6OGQSR&_I@]^,:V+>,O[&;<5C!E=MV/3%!2*7
M#_ R\@01OE;+[O1^GGGI3Y^!,<:I3(HC\3:86F9G+<H^(E+;5>SC<?R--1A9
M[(AJ[G2-3%]<Z]*A'Z@_EMDDMT 3Y?G5]K>?'A;\WWKI'3FQK[*E5YKDUAO1
MA9="E;6"L_9ZW?Z_B)#9&;&V3T>9PB4I=ELQ:E2+NBQ'*ZQE-BY:@E& GA_!
MJ@O#^X"4$ZMO\(=5R52,WSS6>!D=".,+%8UBY95%X<"@#\46^\WNV*P\<HLD
MZ3S!.K$,="B$@C(XVB_89I24WLH2^#XC2190UW>6E"J>5AONZ*[ZT##BR#-L
M+S7L3T46+7/MUM3@([^#8T5/I 7VY7.IAE^/5$J*@;<JZ\<%N^B]E]TDL#Y;
M*IWKF"21QS;Q/ANP M6=Z8<WW@>(/SH8*Q*I+S 8$"=X\:H>"CA_34_BG1UA
M@T:U6MOLD;%U,.E<^[/QCB&LID&HK L2:3NY1$*3@S PII]Z=>TW3-6\Z,T*
M?<:PJE^MHL=J1PCR4ACN ]\IQLCCUA8@[S>#VP(&[SV<"7VL6 K6H3*.C6+5
MU7*F$D0%%?AZU)+3D-C+A0*!RK26@3)(_:\RWL\FAB^E/U^DZ0<K!&$R BYH
MT-5K%=U;.42[AE?B]9-"3LLD*IN3%EU[ANVY)4H=Z'NMN7!7K9%&,&(KHY_U
MF03(*IE+@(_#R6T- U/T7Y"7OV*M/K/?5L-'Q#"@CCBMCAT>KR^P* "A4DJ\
MP8/]X[=G*1&7+EDHH 5#/P7'"<[PA9;/& 7KF5U%BF4K&&X!W[1*1UD%RQ2L
M<Q&>/@*#MP1LJ4)%/$F)WK8@$*_*V<E3D49!#8MO,N&2%"_F$9C87*@V?/T(
MH4'X%$<NY&-LE#A+K1H8@HR\5HZ70?ZH*LDU'IFU*(UC?VK=Q>IML\KBB:'C
M22T?>\<U0SVFPPAE9^%5L^Z:ZUK@]9%4/Y<G=%/)P%\@D$%0(*CS9OD9>L2Y
M^:=KE_)"!;F-:"V)40VH<ES?_*ARH^O\\U:VKP^>M:?;\?"QTB(=S#_*+*Q.
M(T9%C>HVQ3;K;ZO1I?BJ\RKSU@JQ>/(EE)- U?^?OJ4F[I7?KA5-("@<YZVS
M![I9Q4CYK%88*IH:J#P'D@ R.MMW[,:UD@O!C\8H:ZR+ ./ <I]M#LN[UV\*
M1)I&?M+D\AF6U]\"M+WX-AO88%K_B)2+!U@9_&[>OLYPQ]AZ&-]6CJ>'HXGL
MZHN\S8V_=?_5<% (I3%?,Z<S7]-40NV\%?MXK^/=CH;_55BTVT'YQ3<[\T@F
MNR\R R/9"\RG^=<]5+8 2NS:UET5LJNK;Q;C@>4I%7O-?@ED,[@7 -^4$>=O
MI<D'L'#S*^9K9J"P3;ZW2-NW-*!<#QQLDV<&M2QD76I)6Y>""U4XJC*<:W0I
M)PF[?F@_$M"4[(GTE<"ZX$5U_1X=@I^T''XTGOE-<:F-9J'@)*8OKPL[:A!*
M8=A2K1=U/K<$NU1V^!Y_<VUM@?H0:9@V;FB@IGLL:+Z)5WF>88@=:%&FI6:
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MYA4#[NY"PJ]U4I?:!R+6AR-HAA+J.,YKZ:%MT7.4 %"#;U=URT+_ML]_J[B
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M?KUH+5NF:-/?7;ZZ&1@U>KZN'?7RX54T0P"-G,T;&U(_S2S'<3=V-V5(X[Y
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M%<1C=Y>87!;!86<9>DC0)# J[H(ZF?8TB<(#<BB$]@)Y+=JOG\)F&@G7!K:
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MP.;HJ?ABK1O:O>B*U)-.#EW''N#JT#Q);VB^ONDC-4W<N:?NN9)WTG'OR2H
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M;#?1^'9;!15R^<BQ9E<9XO[&.+= 09K:4/^MPA/EXG:NIPO% .2:5LU:'N?
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M1//>>?BRNZ(1N':Z_[3.<."4]FLW?_#\9)_29N8-;<C-R$LU:6(SI(Y4L*C
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MV^SL$Z-).Y3'?,VYBS5H6UZ9!B"ZZFK6^!B0?[SDJ:._:V?O\<P7N+L"C)V
M(J$&OBP_M>Z7V3FH(Y<BQ>^&L[W-B!C]FF/*#>T:_L=!*6:@Z #*BB45M/7
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MF*NKENTOX: 'JE42Q:(M=SPWNWKE\Y<ZN3%L2!6X"J!4GIMOVE?<.L/T9&W
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MR0G#^[WAY)))I>H?ZT)"?\_GI?^>VN+\N9? ,ZD5]#'@A^!$*ULK]N?:-O>
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MKS!NB?/\^;K5F(%N^O[UM4G73-?UG-^H75+K*$@_#RRIRYW3"G&M.H]8,UR
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M^+J6?3$'+8".=0)8L8A$H^SOD_(*EA'BVH;"RB/\P[U/A'"=+M]E6KOFEH4
MAD_!Y$H%_I5;D)G$ M,MT0@['XG+9;4_2GG;3O)L!.W._X:D"U#TLK2^AC0E
M<!XY *O#,"B7YBWC^NY$9HV,2@/HVHI@])$E=\F^?[ZW^=C!W;V%]M ];^0V
M>RK&I$M6(7U]3%*P=2CBU 7)Y]VL4!#<.Q@'82:1)2GQU)]>?J_Y9<TS)$"&
MF(Z,1-Z81)8C6<8AK+J(<\*O]QQ>J.=L?XJEY?/@,)[A2^LP'!K@MHCV;6TM
M5'Q399:08&EAP^+\"@>%1D9X4SLL+C;K9$RT*[2>[#:A6H;]NX=V&CT!T3#B
M;;9=CE.N2\)[.'2H<-5ZYD3Q:$\EA_D<(V:^DC5(9S?A2HYV+&V739W[G2J]
ML[0=I<CGOF&N7.G%8M&AN&Z*\:>1>46OYZA\%.>8 DT(;^\+9]I7U*CV/!Z4
M<3>SKO=>M7:K' 3D]T:$9E'_$JWJ!4W8,2!8F&*T/'KV^FKBUA9GBS/N"]7G
MIPN_M)&D[:+\_)8VABC:?W+90O@&J-%,;?[!ID@ZB_LQ@!3&4+_F@%&][WZ)
M%FKX= &AYVJP1,)IY!FZEF.T/& /7M"]8-/HD1C85/%"UEXJ<NB5VL$LJL:,
M8.N>'_6"T],_]RZ2SC:<@;2U<43ZD.+MQH ]&DN<.9Q7WLI<.LWPSYNP_<J@
MA'W_Z:;P2@\)".GT74 '>B&FCLUY070;UNDP>$1?E>1WYB'TL%W=?<>2Z&"H
MM%?C8]NL+'K84\ I9#;.'QHSQJZ&E_;2*Y/ [C*9L_)":*?.[,LL*U6AW$Q&
M7U9#[5FRZVP9DE^__^UOFS#&0HSLCR[</8D6:E1JGQQB_3-/"MV -H8*)7BH
MDKAM=@-%%YZL)O-0 A;"> @@^])?2U05U["GS"M%/NOM=!=LD!OF+3S2Y\6D
MIP?;J@LA@ASX\[(,M^*_FL/@W/W961^;6X,M5_HZB7E]LM,!X*V#Y(S-I\F5
MT_NE&53M8-#%V$"6"@Z6]QBEIE,WLW,X_PJ'!Y\5!EQ?4QP(J >*\PR+"];A
MA8?>_6U1@-/'@,!JNTLCH-"=ITJVPD7L6:*4_*%Q*.X/:8C[XT^TI_$F6,WW
M)DZ6)%LA;9^@T&L1=LGQ3.:1Z)TY&HD/[\S*U:-=L((?5X1V'HG(+:#1E Z3
M[U$(VN<SH0*?Q)CDB^?09X]T5Y \7?ASE7!A+)+%(]R/O(9]FC%?;$EH+O3I
M]96D5O=THCIC]X1M!,$!MR/<RR)9<B%^*B=)[6#X25*;R4_:K2Q_?6VF^_)5
M!<*C35>P3D W 1%V^UIO>F\[,R+,7^KLJZ[-KFKKG>/?.NN_90ENS'?^0+7.
MNNM!GHB&D)!ESU[9$<L3,6%S(D93C:I(A46IDLWC5; 5.^B/M1S#V&, N<GK
MZ=!&]O O/@1C#[^OM]'QY;3^R*;)57X?D\:%*> UE(COE\[S!$.HF951-R=N
M>X[Y0,G(M L:2]@5YJJ,%PV>P]_ FO:V)DM],.I!!N@5G &*[HBF6!+I2].J
MCV?DG12UT@7-V)#)%F2WC?VV;<N/L961D<T294FJ'T_S$?5079>>"%VGAP!Y
M\0>MW9);7AQ$*0V))MC<ZJX[CV1L[\7=\\!.%W<;/JLL-$G+C8]L1;*2[6O<
MO-G6>*]QWN9;E(?7"<]/_.%@=%CKAV/2[1C<T]8%49KI_9V*A1?[1G.K1@-*
MW0?^XRZ[;%2RO_SC5:R_5\A]IATKN21]TW4W$?NR^@N6DT_&](#7-SEH'B_!
M+A[BKA2(YV=YGJD<8]XR#U\7H6R,7'*;3>8V)MA0)JU?92VMZW6X.?^--D&8
M>,/P8H7)>NNL!Y9LD3-#L,!U;L^O8.6 -P92QSN]]<4W!L-<MS?_DO6T_J0]
M.Q>_GVF#R13H+,H#N-KIP4RG]S'YCOT1_3K?XUFEBU,\GV5N%V@1$R6[)RN5
M 0K2$%S6JIJ\GK+3VJ5UY'/ZDJ/+0Y^?R;AA0#W(A*W<8\ I_9'9E<E<E,G%
M$K2C 6-M5JVBQ=#GUTG/9^)QYY//55=U#<>9L'J3#GWRXM_7<I@.!;R.N[,5
MMID# ZZ!I5J)PY=<(5A3H+X3K1 O9X;)?E7]#OD#MF!KYS'?,&'AR#8V1SK,
MOBS!8S_K=^A@Z=<?$0G;D0'Z-.T(+-*JV)6ZV!: ,<F0B@'H Z/[[>R I'8A
M"@R!<DRJW'8F*3#9EZG?/M3&1EDY382'N5=3M7(X"A1+TP:ZF840K,!M)AK7
MD!$L/QD$X(&F:^7T2@NN<>29+2>SOM219'JU;@]Q-5KVDUP>=R2\DBZ!&T%#
MFL]75'X#**HCL>;[\EUVP^8]- 8ETJ3#3&JB.D,-L2[0IPU8WY0X2]9$0R]F
MB\+UH<9PRLO5]8:29RBULC;LNN%!3$Z&=OH#)P_[*@UQA?;$AFV]1-<[6W*$
M.\BL51B(UU1:S>"M.P61#8+@K%$,<;I%P0K2?V 8)<F>FH^X,JXY."U-J\KP
M=^D.HH;]V.G61'X=0UZ.*"CYIWU77#(&Y9[-4'![N2'6&6-Q>S8\)<J&-6&6
M,)_1QZ\SVNQD(Y_4@@L*6B?3;K(Q%4/J,>O^:%PQ)O6W]ZQ2ZW@=+H894&1$
M9P?KO3"08F/6C+RPNO)$2UJXDF:?R8 )CP)?UA:H&%3,^LTD3*Y0:. #DYYN
MY28@G!1VX%?$<E"'K\+!F E(F_IKCNY8!6[4LN>HOJC.6I%UU7U=FXER@D\.
M'N(N0'L0%T7%_+YJ[$V3/YD/0!A+Y#M8*?X+=VI1E)8I<C87[=VX2F(%[=P:
MLOX6=Q"UP%AR4K)3/+,,ZK]FZG>Q<LR:1.+SDA*';X]F,^T7 E5CL9EF/3/Q
M9$^E^ZJ'BHOIFM0  R60IG_(+?<)[U)QW"6(VH'_L/]PZ%%Q*X=&.Z<U-CJ4
M:^ #\_B#V>87RJ?L:VX!#S..)*@5Q<DZ2@E<HFVTJ(+-?)X1-#_\-RZQQ6O/
M_G(]U.<84#*L-XYMY=&0O:B4LV,T!@%F<V!1?0@NW8J^(@UF"_G[.I?+;868
MJ/E+JWD6/RVWXE)S^Y7Y6TO%3^D_.,\5>$>M\3(IV_8!?_5R/48TO%-XJB%V
MM ,4=NOUXC#2)#DD!B-J2!6Y4ZB;EAN7?,<-5;F^J_V >N!N-M+:N)WO0 A;
MA&%H$7&!7JZV^26SSYAH23?Y?X_9$W8#@@R+=YM.#%%UBJ$=3^,A'4\/^^@1
MOJP_]SU<GF5=]S4X!IPTGQ0_X@K=ERCT/M%)8SV1GZV5%C.[?L=-H+"QN@T%
MT2 1+O$32[F.^VI</46QKPHG5:1<9,P-1XD ^&SA;K,[*R1SM(F63Z^<IE61
M,Y*F52;2FT*(TK.4Q,?.)C*Q3ELZCO/NF]K#UT\[1BF?_?_@^>8)GJ]BV_+>
ME.@P(9XF6RCH#6V$1JY&<*?]5/>LF/9Z[I))%UYR?23J(,83]1F37-N@2,+C
M@=[HC]1KQ@2LO3(.I&\]6HIA>:_%=N2TZJAQA4^/:B[AEZ217K8WO8^F[?DY
M_L@(>2B 9A]7!GJ5VZ]JC5.1PVPX^2^=?RMY;GRU',CFZ 2-D/C,';H>^MSZ
MW6'V0@P\N_JMR\4E)(CHQ9)%'V<:=F"BH<;_Z!SWU,'<,2 4<PQHUBKL/8%D
M0;FF5^D 2>)S,I*@[&:WR??K SWQU\X\@J[Q-E*B2:"@6KUS( >#$ *H7JB<
M25E_.6&]B8_MLMM3'%]@]5C#3<&^H+6D"!PKB%IN>JU.'11-02[(B])B TZA
M-WK,!1;5U>:-9Z5,D'=.<9Y$^X8 80JU[),2*9MF%O+0!Q\[-N^CP.MEPM8,
M>#XAEOU3!/LF^;_H,?/SGSXP>?&A*S.3G=POG?@80#5NA\D2$G5LH\_.J5AQ
MLTY<_SJ_J3?N%RQ_M3DZ[JNOGYM8%@J_+9;*9,Q&)4&8,1! U&.<1'!%I-KS
MGA;3#U<SJ&5];QKB7HV+5RD=^8]Q+!3(*/EMYTY<N!\AXQF[!&QQ3N;9G]AG
M<F*I.%7=SEFAJXOV_J'J1PB; L;D8T25&L$W+"C?>'E_9,'5%@-0H;^^K"]0
M?&-&:/5N/;VS>)V>*05F:X$=#NK<#R/Q)KLY1:P_Y4TD&<$/;4-2;(O?FB&"
MX"V&'Z?'AX8S'#&N?W2GCK[]((4Q;J]N1812*6<APC6?N^-FC12%#Q]//0A_
M))LMBDA 1.2YR>2O[\YWAD:)]@-%8@&'(1D+XO<64'BRW:,+'P8$6]H/U0!N
M&6^R16T9BS BDI]ABX0-JL4K&KP%UYKN+Y*EKA-M$S.Y. XX8GY%PN[;#5=2
M0P&61'\9EA4(T"*]Z;7%4BTXJ,YVC=GR@615W3@H"0R*:-_LCSER+3=I>@+6
MO7'OK-:3O"K'U\WH(VP:S>:4&Z4*F3^B6@\93'%BVL24_G!^X"Y-JW8"=#=F
MOIPN*#G\7%1"89I2U3@%V!1A\F 9WEHN)-,?8\XGCY#Y1_*T\$E: #=I,W_[
MNY0@%_HXOAD.-J;R:ZU'G\7C.*A2&E+R74\Y1@>\,VTZM7KI$W0.(AKFOE#$
M@M;*49'EI[RCUIL_.GDFS2Y0KH=JB)@3E.DF&[QS>>-T+^\F*2G#8CB:\M6S
M&8?N>[A2=QN$8<+,Q$PYH#JD)DQ,K=%$U!&7C0NS!XAV-Q)01:":<:0_ER*X
MOI5=B*+96S+% 168L$8])/5F?3?\6_@IW=D($MT(&5Q;BYUOLC^P?Y- !52^
MR_C^.EQZ!;[<_X%57X>F^$XPD9 JOV_*-%0(8Y0B<=]\]$_!A,?][]O(]HAU
MW[JL<W[BW)P264T6GIR-IML:[?#/U.!_QD]=F;I[NK2"X 8"Z4)_30.(ZO?!
MC;<NZ*U>;2N]9PJL5+H4M0OM(^R9UQ--T:A?.3BEZ5U_P<CY@^5RKX^>[0XA
M(X<97Q$KG&E?M:_E-U2(L[B:X=23'@7<XD2><N&<Y6>9=1]R^PY=G?M_GF)Y
MX=6^#0H^0&LC,>O6 <NK3:ZG5_2<14MT]UW@Z>=]W,(W9<Y, A:([2(7RX4P
MDFA-JR#_@B^*Q/=>4?UX7,$]\OC-O.DF>[<3:U"GS=/BAK2[_K_%6OKZEE8P
M!F.IX6VSN\"[OYYWIMUF.FOS(#A;IXU8RJ%LG,*WMS]9'OBJ0+Q!C*KJTUIZ
MLO9NVEK;>- ;'B82:$ZAW$F$[4+6O*$51%))'QO&K*@2_.6S!W8/8PN&-5NI
MR)F'/-P77FO%-GTDA?&&8'&U'1'\8VRL@]7B03H<HX^C7]].DX3HA2??,O>Q
M%T91GG565[.OY!(T_U5R#+/.&FA]LW+T0>33N%:0??+=*RM*F2Y1*L] 5M;F
M^T%'\*QC0 &?]V>2FMSZP2=N3DR$E:RO!WUK.0:P[8#"#7)G6/=W4XXJVHX!
MKRYL_7Z3HG_P8[SURX2IQLI5AG? CZ$1/#+K(!@[,N5^99<PQ<Q;*\\K+O;.
M>=?/0 X"ZP_*0-.#[U\CA.(.J-KVU>IR,XHJHLOOW3)Y<D#BNDV,-B]DVL8)
M#*I(WW6YPLUB,_/ES,13>E4E6H_PW\\YM8RF&4&?5DW\5$J'G&4DEU9DV<)[
M!IMI"<'%&ET+_OZGIIYK+1*\@@ H!(STX6W#LKXRT=4ZNE[Z:;S^:J*^77AI
MM_*9V2O,9]WV0CPUOKV;@6U>1**=&$/W"+%[CP<6O5-'[4*;4*Q5GR#7OZ;"
M\(CFZH3PC7O^_>?KV'N.!%:<6O&PWDXTR?1;BMESXB-ZJS VIS9X/8/ D HT
M6_K!"6GY7W?XW^,.3T1$_S)-XO-A76,BY3)?(XQ$5.S9.M\PKH(%/U3<>U^A
MJ>+U7^0)7#[0K^NY"UZV2;:T]PYP&'J,F8YLVVVCZU.1BC11D>/NQ.M/,^;?
M7I*?";47'&=N%?[-O][0';&-X%2L&VAW%ZC6K:=5Y&F[<$H8&P#8SHTB;&G0
MKW*?BZ+LAE^?Y=DJ"%:MM;;"]8-GJ84O#*<E-5M92[F9Q08;A9'(,+"=Z.*>
M;$6'?+Q@#,F$Q58JAD+";KFM(?R Q0[%;Q!_@HWW-I3VI=?*W;SN$FA_EK5#
MZ/L]NR]HERYN%]E]"X'ZSGJJ;#@1Q4)6*INI.3H"O#[S7OA[.K/PSVWJ;VR
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M,># ?^N*?]#W:+>=BPX6\>G>N-!6Q]2GL/)$ALA" Y!X^71@GUWNW."68K_
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M%0V!N%_7%H^#:7;%M*O\4$ZKTC_53N<O>J'!0P38DU,&TFL( +5!U9% EM\
M ]_AE.VWX2]\-[Z@MA *C8:J?\NY>O*Z56T/X_,(D\/<PL8EQ47N?"U'>>=L
MM*S\II(,U7P*+>O7!YZR]%=PX0SN^0 6ZHBM<.(%,35!ON*>U&!4"?_@'+@U
M.1^RCL:+1R8VWIM[@;*\W.DJ>5WG:"(<98S.$Q6QDYA7$Y-K"W8@]7H;F-].
M:U9D78M/CGP;)+-8V%*GRH/ 72!"F9&LMIDY+YC?[PY;V&\)DX5>8ARTJFMS
M:;\>B5FWNDB$S/QLTUXL9'C&?P]@%6&[]?$H2^P%S#L;\^?Q<0?IM;C^/$TK
M:9%IJQ RFC?#KU9'_UK9"#XV[*XVHEY8W]A4\E %1=! PH.1+L :Y9Y\3YDI
M$WA;<1.:>PA*F;V9'KB07NT\<.=9$<>-RP_*5Z\#CW%(Q4Q;.O,UL6[;EO-<
M^G(1WO==M]6>QFOQ"YB\)+(RD9XZZT,-$S[1?0VLM?8$)OWS7#+CMHJWQ;U[
M:)9@M#M1+.#;5=#.V#7[\')7:?NQR5;*7AB1,EJY<-/Y>#XNFB!!BJ3(P)?;
MPC@7_C+>[BG51Z]F#NYO$[UJJ#82PP-W%>BEXWF<N/+;2J?[=>T7*23[B#HP
M8=)?C I81Q#K^^&FN3H,IR18:1\V?#9VPCH$[V\8 L%^N7;*WT?\)*PQ<&8*
M$[0H77"E,SC(SV%^5A# )\@S:.A5SD^D0^UHV;/-YI;/PV(UQ;,?2Z:;"PI+
M.8H $ZOTC. 3O3Y3"=7[\7DGT[@&RLZ B7GC(  9&I$^Z"Q='ZK\X)JF.>=Y
M](RTQ-*X?QL(:B-^(?SBY=5GDN?- $D'S4"@W#XBB [8.FLX72#8,7(0M6GD
MSB31+$EH_I0+AHF%<Z=3-E+:PV[21G\,V&I]%V0[KV"2W,/DT3.0@<<_<PJL
M^F@)OGGWK1X'04.0SSU$[O(>Q]%]NOGB(<WC-,XKC3WF8^^R'NDN!&<M$]I;
MAN%D'/TK,C9PHOC9=$%"BAA5Q(97H?_7Q*0AG,QV+QU>]7"?$Q,+OS9F9RVS
M2K?X7W5"D[O,D^MBP];. ;2A $=)*Y$GLPN0L0J-2+5'<^E,2RRDP#-8]@A?
M"0 '% < 77Y*6DJ\O\';;\H"7,EJX[..9]>\)Z@];?[:*N_*C]B1KUEWC&-L
MO6*.^W%C>C_1>Y)"YF&%4HV:X(/[XOE3(%&REN"FC7IT8!2.MWSZCI/&W9#<
M(HR*1+D$U(!CH@UV8@Y'\?UL/SGLM!;:_6NE_]?<<IMJ*)A8<NG"HV\3-2S=
M&9=+>22/9-I&WV^& :+6('[28.FC%;7Q%I0JWX$1TPIJY)542-!=C8T,HN5?
M17-9:D*58M_ G6\90V?+<Q&'8$WM=H2ZB=ZE)DO%LOM?5P]\.C7I4=(ZC#RB
MP]P2><K3H-%(PRY<C4)3+DF,>3? W9]RB*D#VQ2XCM4SA#<#PGB=(QD>J\-A
M6R9+/$8+F7),:@#B5YB(6DT[#3WQ*=9Z.M-Y:6JK,Z(?J.%U,1OZ;< _K)X^
MGKR&:A&O(N:+CX-N]@]@+XK_MXJULY/:A\"WMOX8TVV;%19?J1V'SJY,K=T'
M/3HB),TLH=4./OX3MD+8C#[7G5 II50O)AHF<.Z\0F\66 17-)C.%I@2U4SR
M@9/$9C1%?[YQD6T@;8ZUS0;1H\EE(DM? WX\'G5..''!N*9;&GKW<C/ #_2]
M,.Q34- ?FX>:?@-6GV:G'7MEM*,PS)/:\>C^*LL2BR\4 )]4\R.CTW-&&C^Z
M2:DDHC^Q=68\R9,NVIX#8DYI$>8:[EC+5G2E-*?5G]2N.P/!D*)90D7+)RR1
M7+\!_^2D.>E>8PY,3_!Y4W_;]_QA22F8HQELJ4Z9;Q.J,KS0)[^QFD&VFD-7
M'5(I4_PJ),%\JE;!QA.<Z*!9$K734J!NT,.&C1@7P?3GOGX$<%OPD-O:S(&M
M32-Z_J,5+O=79VR^! I+1&'4XA>0JV8KR.$'V^MAVX<KV[DG[K[N?UV<=%75
MOM!@[/XLJ(!',KO])#UAK;HR%>..-F;V"L^0%TN3P 5F-%9>!Q',L_<%Z#]M
M [JVY-8#M #"Y$G%D(^<FFHTE\>7#O4JCH4/5=G?M;(/I*GYM%^@8G2-?LR>
MMFT6>@]),D6CZ1FI$0 ZFHQX4W;&94G=LCV:7A61Z5F4LG",$M&\9CD/E"!C
M4>-!<NJGB[6Y;61E",#-;<<\C:<CBV'W-]KZLP!"*YEM(,,W*,VL)-3T_LHF
MBF#XI#8+,SN<12Q6^>18OMC973CW^4@8%S+.,DA!X*5QJ^>5<)A9DU0X8&H^
M$H8X5K.KKO(]^-B=$P629]NX;U8LA3W9SDF\DSU]_]PTPTU'W[B[M18VQ_"H
MHW+Q=&2,N+;[6UVIJ)+P1@]TI*('>HM]4VOYVJ]M2<NWI:ZM<)WH$ RIMCD!
M.M@X^E:?),ZODL^!N9 F23@>,'!(W:C+#H0(I& ]7O]GW%5X@'$S@VNW/-RV
M>.3.C[Z]QRXDS=)DT X^Y.XQD[+V]$3NC4'X77G#9PT]+/M;5%MG!\,)TN)Q
M +Z;!$H@#[Z^$J8'OMH66)P4FG'RV_JMJGY43_9WOP">LE"E^;PVI<0JOKP"
MOMTIS\7L<[<KR7PL/**L#4?2E&)XFED6X0!N7T9V;$5_26N_#E?A0=N\%PQH
M!QOSC0YXKR4RW&D5/:%[5,3>O:F>99_1MO0\0IMB.O17PIA;&A%BA*)K5FP]
M8,H %$F:0DA%ZX$ (Q<RF*7GD=-Z\/;1Y^$2381B)1PW-V_]. "(@0$\NO^]
MT6!><\#R31WT1?#7HQS+9BQAX_H+61\L#G7W>H=QS1"8TG7<%;6-E883<L33
MUG]H5M-^SD0\^OD@%]P['(;V)M3[P0B(F(N!9OLJTJQRZVBN]X\F S#FT)3G
M5<(7ED%+&F2$>DK;KL(M7@N/7"WX)W-/9^!2K^9?&7?/6;R_BNC=AN_%D?OD
MOYAR,QOY:):T;1YCO/LW8)F1"#CBM5[."EP3$W[3]P"5%>UU+[G+L5 X3GB\
MEI8_4ULKO[68L7G676RGTYS&N/ ?,M;!>+><HS*O\ZBA1VF0@]<K!S+A]OWA
MGPW&PJ<S?^1MRC-^\S'#OYU@ ([7OKO[FHE[1V'V$[JS AW^'R33'C=X3ORP
M?-4*-^C%%WW!S]N=\2T?RR\JSMZ4U\J8X.V?#^M.VL<['(!"YF3#FEU?TRK.
M_1K2$?%]S"+VO(O;+IVHV3UD<CXM,16"# ]6TDS_JI'U GY#/O$9Z%"B-8B6
MW#SU/.?7K,RK%#^6'<5FX/_<C'N#0#W6[1]_%8^-C)=YP>O76 -5.Z[;0GPF
M*>G5RUO0"0*+@"K:)02L U[X^]X04.<G +3][%(6Q%M3FA?)6+D;H_?N#1RV
M)YUA!Y.//),66Q5/*LP?F?GX^18Z\_%)RX%9N<V'9BYQ@XS4:\2B/RSTQL8$
M<C6>NE0;*W1-] >U54>+J ^&@:>UR-*)5@ .O/&KQTIRJ> :L4[Q"Q$2R2WO
M,=6Q&U(U()>%11%@!'TE_N"\WGO=N$R8B^.OFST(V&6"*"-'%%GBI!V#*F*G
M45 L"@Y-SSD]>NPVAOIIF,]\4KFB0IK:]R5>:RUPDYA1/7Y*:RZ=K9N!AA]8
M1L35ZVG!9#_'&%V(:3>RU:S!6>PI2F3NS9:*A4<=MU>TRQ>Q!U8 Y/DC5T(4
M^:J#3CX.56;'CGC$&KOSNAN99-C5K0B//GV4<S1KVSOK@ 2SSANJJ-('[JU
M,J9[<E=E.,] LN)OR;VW^$Z$8H#QJ>*P<0ZKW6EMC_9?(/<A(B)8>Y=(=OM>
MZ_46WX<D_T1.O6<\7[Z=,ALCD*Z%K8\.KQ\T+@7112T:U!><;IMYI5V]+$$&
MC"7V2+KKO]R4BZ%9AS]M[8<B97D^ZWG62]@A8J4TJ)U=@9BRUSSF!TIM36$0
MC+LVB\<29,-/U+FIY"(G6=?&_E(Y4@X_V"3-<FK<OPD$JF$5Z#U2W:Y;L^KC
MK#:#%NDO9KLU,Z  %[\@[F%(PT>FG#UJ(3G6S.D1GM\9,:E_N?\%&4KO<VPX
M_TQ#+OEP0FUP<*^H>STDPWQP:BI]I3Y=]H$5RU&S+IZFP=#,+D<T+42KZ>4@
MS]5GIB9G4?KJY!N"HOLEQ\A?DY(JID'F$U%H-'" FL2.U^C04)>/>QYG Y"H
M+&I>2_R%HJQ[- OCZ3HZK@**[H=9N.G8KRF)P7Q-%F:TY4';8CV3EL<G9OV$
MM\_)EIYQ_1*VRXUXK0_7WR_@G?+Z)2EAEXG&<2]+>*00"P$L/;F,>YCZ!3W,
MYY28K95D,/93W[I^*WD86!JPSLT42Z[E;,Z?>2IX7J+QDQ:+4)<C0-QJ"> G
M@O#QJH'2WUX[-O_.VLKQ-@R8<[E-$0YD62?QW[8H5[_2\JT&3.3G\3Q?8VB&
MXL!$X=@TJ_6S$<ZK.00!RX85E8T([<J;\.N9<W8:B]2\16 R^@'^OJH7]\D&
M^&1^RN+: [Y.9</Y.>.JRTIKG\&>!KQ%J40KP &1J=ZE-\5'&1Z2;!X4%.&,
MO60\X!C^1:ER7F0F7:G#(N_O1,#7)X@\B<P870'>K$AVB:A(]G&OZ^VQVX<>
MQ&WVO_KR]9L%(&+[AS9EW7>N'9CTK>#'J/\KC]0 ?H%.B7>@UT'/X>J<LE10
M?K#"671)L4*2)S"U;KD)".I(5X<X2CVA66?].&"22C'0.;7L"7HY[AY"QRQ-
M^XP\_?JQO_VXP:D\J7 U$IN$S^L#[MBB66_&T[ZYIZ96'5H51:RE;_S!HCM;
M8.IW-$A@U?$3UOFMNV]CM15ZH9<I.66J'8BW"=K-F\#[,Y]Z9)($.&Z%X\T)
M "/#@>-RKUZ6<LH2,?[//F%O7U#TTQN$<'L-"*1$3;1+Y;BKWXA-E]@(UOO9
M-,P.\ 8;1M7"Q@W5[DY>M*)OWIS.@C*;O@2+\M(4D<SZ'3T"M-GQ>O]<A?O"
M7=0.GH%0622GJL[/Y[4)P0;>5V(?)ZKHZ%#?B5IF\RJ>XO-*USI<SL?M[[-Y
M]MAQHFV2O:TGT=<?/&G()QW110WWWI8QN/CIJ"&+5D2ZXM7W'G,1:YR?OF]>
M]'B=%W^@+XN2\"9 @I>T?OF\MFK>>!YM]NOEF^;2(.I)/Z]AM+QH.;'0.9Z>
M>*_VW<_K'+<SPHV,]6VU@.F9.:&PYL2]F=SU\Y\MU+ !2C"')IA,5/( _XO$
M^C)1&534[9EMB'/VO-+MU5:)N_"U>&R0^"P-1F;AYMU(E^Y!%MDHD?9#9:-P
M^Y%&6APS.#N)IR.A>T@0'VK^C;R;]>.U]"PN.R.G?=2IEYD;S:4$)Q (TYKA
M !@Y'"1:]>](HS/TWU!)X?>83PKF&CW6JR[+A!:7SUW<TVZUC6HV-RMQ-F+U
M1S^VLXUCG?C9QVQ1\/XZTW:;L,MM2IT5ZEV7RKLN:3" I73\016U8'T@L%4*
M3GV><<$&Y].&T&ZEY418FIMXR-V]-]O8N8#S&-<"MUO[3[0Y'VC @D]F'T=I
M.F,,_;FUQ,-%Q+IG5):G7/,%N64!@*EP-M UMS/GNG'H#*Z9)DEK+7=WU"6E
M_H1,Y)/U'H'"VYZKH<9OC:PR\6"BQ[B^1Y>XB]",<NOFF1*AJ\6X7RIZ(DO2
M;L@H\<9[# Q[A>86ARRUX:8$Y/K6:B^Z  ="V+0)A+?#\>+TZ8REGV&+H+?(
MZ![NXF9^I)P^%M$=+KXNL#GE]=?H[GCIRZ &T@?18TL!K*\$@9 B2BXG7ZO6
M8C,0T::H='W@/X"YL$^Y=4HU;%IH(,;=S]YQ&#@O/&Z*FA0X1XSW3]2Y*V@'
M%*T'Y-N!0?W2D$@D=W<[S[BB_U/;[PI]Y8IPN)L6FU<S\3(!.,Z[NQ3=L0.;
M_CFEH77.K\/\1[W]?R@P<U5>/8U:AG <MM$6D9+BSLD@S&MFE@0E[!YX-;D)
M39Y<#QGN/XRB)RH(%^'([B P^4=%F/CJRP^?]W?@4!+0,KC9N,)L !4NLB21
ML*M^7N>_K;/RGAG%R<^='F4#$[\O/7G[O$G92^FH3?&MBC3[(S<O)SX^], .
M!FY32$))]?I)%8?%^KH\8WX'$X=Y56(VQP+F&A$*UB$W1Z<*$"P"J)(#L$/&
M2]#T<RE=W8E_1_>QGZTA:I ::Y0>6$^J[.5,\K!HG(:C\'@HJ,>P -2>0.?/
MP6$!(G;I 5L&TKT!V?FCQY:,]_MR[Z,$Q[&W6VN!:!.='1:6M)QM!MCL1VZE
MQ[X;74(PQ\OD'O\_OF_W_P<O%RQ[W:U_593FD4*K'R\ZQ.?)L9..!B[@2M72
MU;Q%*U/&ATX.+Z.J:JN+TS/\D,@;RUYS$U_]NTV-TX(,OTEWU79EGFH& [F2
ME"*) (])9[,J5J]]1AK/C/5$DBR/ZZ#I'P36DJ\C(ZK.NPE_[%>_YSWXG'I;
MH@C.[3_7"2?1,7?PZ"I/3,SWWI@A=C\BP%M6J4>S6J$32CE@$[ 5N+(S>O=E
MASX2TTU1GAH"_A- 'C*1T O;/8G9DQ/\MTE-V/31(+>=J;<^\9U>2:3,GLE$
M,8;1)MX.FT*'K;-G-HC39U2W/%)^ [256<6.6%>3D*OS?[1;7Y8$\.SY+RX)
MJDXU5&GO<*K#=BC54M;]UD=&&4CUV3\:W@</<T_5"(?],Y6[P?C1\K-_%/N?
M4C3_RP^,W"T9GUI$FQ^_>/N-TI.?7=2NYP.AW,B#\X$_:>WW,W0\OP"E(BI0
MC1XX?O<_Z@#LV870H",.J^D^D3]NV87;W5Q]UX=4/&L;]JFM=)N2L?+E-X#N
M\\6_N)&GT/;(]:)C3:!'TDD<BZ1%L9R4QB.2 U2YGBK0OWI0*GCIXN(@(G\C
MESH$@&S_%<C4C'?KG-$D"FKCUF[GX^S4M<"?X<P:U%&_S>"<+8\;6QQ32$(8
M?>./.5FM.QVKS_\BANH$MM/$_UEV[CB8H>V#"*PZSSCB!=4M7\81ZRC/E.R9
MH'PM4!PVDOAG+8)#KC._-51D5RC%5JL]+&,)X$M$_L,CAI>\I!'_)'W?2\T@
MM_\)BUZ<N!VLL"L5.&+!^&2U<KY_C< -]S#1+;:OA/4;;6%?NZIX:NZ8P).P
MJ0]AZ_P[4YRTWX#-X'J&S\YD?&ITT%W&%][S;W=O'G]NEAV7D1;)CWCX#KG.
M_^8W0/"T7N2-TL2*DTS43*8(XDN3N28X4;C%Z>F#B?<G&OP'8M%HC![[IC81
MGW-Z16<RZ+EPHS9=A\W86I5GX.0/\32YS3<Q9?3C7RI/F.;!U@:X$XT/)$\T
M:U9Y*ZO858R;911.<66=Z>%K@P$E!(VT&4^&Q.SN846,K')>QEVSRLAX!=^6
M/RN],12[^E'\V9SX/K\U$[LMZX7*G"%BRURG7QG^SHE<JY&EN[>NF[5BBS1P
M?"-6R\ R[=D@2O<#/L[!&SS?&GH)<!<9B46)(O"FTE7E:=^:4R7E1NJM9@!/
MD9%8L)3;Y55[(<+7RQT&"R&.GX1NTX_/I];SG^(XSL&RT @CVCH+?@P#KY9M
M.%0]^0WH>MD$]20F5_9Z$3:-7OR2T0J:<5S=-3'\0193 <8..1BC% P 0"@V
M!RC,*B;YM_OFJRE$_SYALO74X989-,_*WCZJ#"0Z[X5;0-L68!,O% )'\9OO
M?@-*,S:.>->(T76<7V^6V$AQM=@(6OK9&%T(7)D@:O1\OO'/6)Q:/D0$6O\Q
M<6FHE<B,/[=Z0^V#X!F^UO?VB;>,0=N1SD_H/^+Z?.K/;PH]<H WMYN+?A0B
M%D%2GK9U*!._.0B] *%/(;I(R>F#,,V:3(FR-_N))5U^0@6[]W)C$T=#*H",
M=(--BU,O:*'<<5[\'(%^ U-;DM1_YK4=U+Y45>64%J%)1).2KN;)_1-#/6+]
MG&'&_TAJ(U-_E=*4ZX\;*+9I ;-1,%'G/F\>^8V3+&5MYWB-K%$M=A&-*&()
MG)D1P?\UU_B6CW'WB*W(G=(&NSD#S?XUL;Q[V/=80737<E_['N=WVSPL#DGN
M<]OA2T3>X=0XMV?J??[@TAS33H-I!T/PO,F"NGT[*RSU?TS5H[UGL7;& %K:
MQH7A,]1F]:HC2SCV?9!YP;>OHT2O8W;_)?8^WX_SO&JG&O6E<D'EX EKHEVN
M?FB-RP6PD7M(<=1XP'B \)?58H*N\0DOM^BDR'._ 5SB5LO2\])@(I2&O3IX
M.ZM"\(RGA?O BPU7B%@:B416OJ:H?']&]0"7:[:^S1NU1Q),Z6I/6SJJ3'C?
MMR6G&]/X6!\G9HBE-2U!',&? TQ]_:Y]XV7!XJ('_$Z)]2<""P-@X*]^FGPT
M.:?"DU2W(?E!,SA05GO HYE:!A0U]#]H<.?B\]=>V_#OOP$?3MP L<D/\1D]
MA&!B5U'$&OAG[WVF#]LAM)PXWOC9K705 &1F@,TX26U>9;EQU%-6G,L)V5?&
MP04LAKLPAYI1HM!V"*7>IT6%_N;.3A2,S/,DA3X3T<=.%&XR#A@U]W0J]-!X
M@OU[(]E47TDM;UD"$U9;@\1P8)B5F;MIKPLPWRO$X];A5>%6)U'A6/V-$PE$
M@-@3T#O@T8^3+LGWM?4 C'P7'<EG$A_]\J[5_!S /]F[F5NP]/!C2'K\8*(5
M0)^%_*X-H#RIL'OIE//7S?.TF9D%Y<+KBH;MHR9H&FJM)B/HQ5J%\M>05U34
MUH\)V_:O92?3VL%$L2?M)6:%Y^Z*U><[FSC)V*>%DTAA0G;O1-<3;PXS)QPP
MOWCM2+D.'!+N55*9-]$YT41]B3]:1/OZX\U/]F%DJ[663A)QSA412$6G= &M
M4T:07#RL?*U7*5RU&Q56BV3$QM)4Q/<4%(]*XVZ"$G)7N?L#O:#2ZAKJX+%;
MZJ?V"1J*&FE;X>N?RSJ?CPFP\V8["K9W  ]4V<<[VX0)C'=G[.[7=[Q1F[YE
M&9"L#?TL >#&GL-Q,Q[=R;^QM:Z2"@X&!953_)^;NC7;V["9Q%Z2ZYI\77&J
MEP&[L(D*J\^RUX0*"(U'K /@ T]8UKUE88O(1.60O)+1LX>$XHQS6X0VSU!%
MRR5#XS6CNC:]LDI?NWP)+W[)_3*('+6TAB)Y&BJ,!V_HTM[V*!$A16HO;Y9_
M5"O\U@PF@H' 86&G<<<C>1.:@IW(XH),-%KAT+.Q/L\!4J+)2L#BS/>J2LL2
MM1/]6?YL<.!1.&$D9<Z'( 5OURR94:[;-.BPK[P]>UC/*_+M/M=&7HMPI39#
M(\/GZKG5Y[ =Y!.C=UTI\GKI%YZ_P+G"[="+D/1JT+7ERB"?,K/[;,( @ \!
M""P(F*MOYVW>-^.AJ!C7,S8$-OQ%EI( 1B2%9M(6[T _R5 W_YM8035?8^F,
MAQ/T]NLGTP1C%,P'P>HAQODMIZP2HW^_6V_SD1[ 0<3G</2[UQ\1AGO'_JX)
MZU]'M[@IRD"?9 &8L*C+$?'8GV.[.@7YG4M;\AN7.$X41Y*C.I.TK6C^3>!E
MO ;-/ %1/>"I8?A&E?+^%%"F/D]XTN?2P)-I_^SH-RJQ[N^3]#I+>I(\OL4H
MPD6U$(3V<\OJ_Z9/4&CQ.9WY8(3SL^#C]P0M5J^L4XN0R; VN/0];-O4V2--
M6"EL9<P8J-^=M-@. H$S]4[8!EW\O$?;Y?VB_#[=M\59C@\U@'4.9"HQVQ.A
M#V[TL#83??[C@VX$-$?23[055$HF3*4;LGE=;X_:Y.QS?E#1O_)@Q<Q0ZTN2
M'\0S8(9 O)S.ACV8XNAD+;F7A4F?\=,I?S3J>"5+HD621:^!_PJ)NN_,T2">
M'2+9'N)OYQYZEG4 ^?K!H <54(/G#Z?K3&UY!?2-Y;YYR[2:TS*9V>-/:8M(
M1(-%W@0=MJN4W]F7"V'\H;\&0T+!!H(3$1+[[X<W3_H=(VPR(;6M$_(G\O,^
M+7_]UJ@T'AA5!ZX#D&O/S?-8UJL>O*IY1S1SM<M! 0<L]VY_63?QV=2W2'"(
M6K)'*Z%\F+79(\QGWW>P*'^3JL(MLR-\8#A0(S2UW__'8.$):,*^8M$GG!S2
MO#DO7CLK#(TOM.^B."R-I?^[154;XLK871SW\';J"3?^Q+=G2P(QE>!'0_:[
M4 O5^C_893&':^+%JI(#MSM*W2>_>/1PGW+^7!OT8B 0Q;41[K$F^%8S#314
M75.1(>Q_3!D_+,EQ2M2CWL9]9WRIF2BB<?-L+[30Y3]MPLK'[MZ9YORY\/2#
M E%TM)AB1F,%89 X; UO4]LP#9M0(VXN/7/<F+?SHZ+)],^:)EYB^3G^[WET
M_$H2(F39>/WMVF9JRLE3S4"@])VJWX!/PWS6!RR?I7QX:6YZB>-+::A=$U&4
MS2L]4P2OE35]J=R<[]\)]F5O"G.RLU\?LFQ^7@BOJR-1Q GH]4 ZBB?]*NFB
MBMQ&4HI-]*4O6;16=K+H:C.Q3,/>HH H$L?RKU4N>$A7E;Q/EJ9O42\P(#E&
M5J'-#Z" ]JL3#;3I2I[T6^_EES(@ 7+<@#S$-CTEG(_=5/NUTD(=7_E-_1^L
ME-%!]S. R+ ^%U<PRR)!- XN_"UXIP&P0ZW_RO#01SR?XB./OL,<Y6R7FCTI
M<)ZU<3!30BP CE#G34,DUC]3_5!FGWJ5(Q4#/H>[:^WNA(BP'L/OHM,0_]8,
M2U<N<WZ DCI[G'B+.1)5GS<NE[KJ]?JBDWO[<=?PAOKCZ$SUQ^ADG5ZW4<3!
M\C]H@7]6J@H_5=R(^^'FYYHG6)PLBY-]!.L;(%VRQ%B"D9QA8[5;Q;\!/Z<Z
MY&)7G7):'*D!N<V5+8U+<CBW-D50@=^^\^X8XN/_J3]R%2GP(:]P5G@T88#]
MH8/)$T<OCR0YKY&OS_HLWY][>^\+D?NUH0H>=GJH 1_7LIJ1^?AG8(6D7N,R
M^(B1T25MZ)(LJRZ-W/" U\7!Q16>B% ,+/1J#(S H#0H$=>7QIY:2\9H@45L
MHK;#I+K$S@8\CM,4OVCC5Y=FMRP.HP)L0F:KM9::F._-OE5YZH<PK B#^&/5
M1:P'3BDV<<Y,A==CW?W7C,1R( )/%Q)GN)ZKKQP:2W2CN7HW!FQ4B+1Y73MH
M%#'KUNO [83;[X'V:^N,T1RP0Q!A<)>3SEA_$$JU1Y;B(+F6:)TY.Z\^2P7E
M@B:L,]_T/2NWC_9XG-#EF'W50/A&_?K!VT7L_"EM5]*GW3F(KC@^H\M8[SQ5
MWTOF^G&W#^8L6]$'R))\4G@6_EZ*5Z3'G'7_GMUI#/MO#&7U\ZTL92W#7E=J
M0ISG7FK/L5IL@D$>JAY0X5FV=[*SU6]ZW356E/C0+H78$Y]=>"XX)WNU__I%
M35 <J>J-J8P4S%UO5(UDLTRASVJTU _3%T!;OHD,$"W<L>I&>#_)1QV,,6TS
ML(OU2DD*P@2F1 ;Y-+5V?)"+*Y3TC==B*<)>< $PQ1AZZ+P7JD3$5.GN_@LS
M2^2^_=$>P@TGOQD 'BFB$L(!IYK;CIW)\T;$[-#4Z'S\._C_-V"ISVB+NZ>L
M)]'YHW!#F9#:9TFVJ^R'520BB2 8_N:;9(7)W6O%G1-6'23.9[.$7SL*E,X;
MR '26+98 U7PV84Y7/VJ^B+M+R?Y6!Q9@)@MN29E-^X!)_NU7-]$LLG#1G?>
MD4[-6%#./GUG3LN!Y8]R+<$'CGS>ZKIL8.^M*S'P.<WTH88]A9N^;I%WZ<YG
M:?="_5%-C)O$ 2ZL#31YN\7.@P#*9IH&-!=^? :U-38)EXADEY*(ZK+%=ARL
M&!L"T ]/8$6.N)P]"4<(5XJ5 S <Q)LX@'/7U-?@_RUH>=GBB$JB!5WZOM2W
MS%O'-0:"[W=AO2+UM/N3F\G9()CP6#KXNV&>>Q)9+NE&H0K&,KD3 :J =/T0
MVU_9G?A$X%V#X'SPBUFJK^6C):C]MFVU?+V8R$56SKSCLWJ_I,"-[H#F1J4E
M:1J@5SE%)7\/<[E:IXHZJI*J//BIRJ0R0A#]1HE[UE615686[N(]M'M%X5LD
MJV5)=9;'Q]2;M9(1+ Z]B\H5N@/.-F_%_[UC[F9VW>CBQ7,J92GJ5EY1475-
MR CPXM(H]I!&,>&IB\6*Y-$ZSM>IJ)$G HWJ])1$5_\FO"5&@9_]!</=,H4#
MQA6LX7G^UE,&P3-V[]@6I+A-[7"S #N1N4BUQ;H\J:ZYI7<2>LD$)L,AMD.)
M.+0C;)+8DUYRU^K>](W5Q+=<S9\_DN*86!AI2^^ (L=$N#J_I]RKO<7M,>4;
M+!=O0BX(I^L/6!U^Q)50J:>E,>\9Z"NJ&"0>J^+FY-HL^UY(#J*8"NNK(GT/
M8JYNL?[O#(,9#6?7GOU8O?BKF%96EI38RQT[8DOGGGX?2;\RR'0_YBI8ST\>
MS," PPV!RGLB]@?9?XO21Y1:JO;.ZS[RE]/[NQ;@DEJ>ZP65G>9(V3_K"M:K
M-R149M/ @EB]@#JS.F(-'\59M['FD%K7#CL ?,1K0"R_!P@3D2XG E*L;R)P
MZ^J1=:/N!O^+O3>/A[+O^\8/!H-D$#$92R%$98E&9HPE6V4M5):(DDJ,L<N>
MM6DP(C0&D:5"VA!"ED%E%(5LPPQCWW?BT7E=]W5RGIWW[WK][OM^/;_G^9U_
M?/ZA7J_#\?T>G\_[L[W?NYOF*?T1-A4:]9"*769V2"$R>ON@A_D[09+\7':2
MF@,WUQ>6E:#=#9*% NOR!LL/<C[XT%;TR,4?F^L.8\?K72&/=^D<?R*S?>@C
MWRAR5;^\>(_4!TU,GZK1[JIU-K(Z1.W5QCZGV<Z5WNL*MV9G*D[1!>>PP6/6
M=0<7F%XAXJO5#EKSZ%P 3PY^%\ ]Q5*H)32:Q^0)V]4S >*O8UGVZ(8P#+8)
M^T<Q^4.4&I<?]#<F?_SV4%T4?X>:MNA-4HL A)<IF+[I8)M-@'QT/0"U<8B(
M/37<-4/'BI4;%76E5J6E1O2L&+$KJ-! <200$XVZ9QMLNED9$J]5G#A*BT!#
MS=C5S!Q7M##8!7 Z"<Y$^:8;)';4#PK$9C16#2MSQR_'JF43$_<6(X]?VDJ2
M7XOBN^!'X$@5)CXR&!N<=GW68-<Y9\[^*Z+W<FX4BE(S.1S<3@3Y!1,3)CSJ
M_RK5SVK"CWJ8_TF,Q-3*ZO#;9*&0W-'S02S>HS?JLEZ^_:SO)AY)*^@OU5CL
MAB,5JZOKK^&:QR[NK\*?C2W##8&ZT!0/LB1()?.^%?W)L(U4Q 5'/;*4-SCD
M XD<<X;FBU/$#KR1N3L=&&QI@/92#9@)&,UK@)IR4G%&R!*!GX/;^O<+_L#,
M07K=PSY@&95Z.394]@ZW()>&?2C!XGEK;&:;S([-N_:?M[9=AS@PJ<\C>455
MSDP@](Y)&[M8B9%]RQ\V*70UL74N['*BD9D_V1)-XJ(K3$W9=]"E_L2_2I]S
M2LKP)Z,Z#3_RZ8CV\WHP/E&-1^+(6R?WCQ*0CI)-V[H62](([S.0GO>B2*]:
M*,*QO8/GT/*AGOP)L7MM3W>O<+"*'2%E% 36"S/A9[4\;GGQKS5\:O86D4;8
M"T4)D&"VS&U*15T()]\DVP(< XW%]$1HMXB)C<L,6*NX-;I<7*94!>LF3_ZT
M04;89XRS[,;T72O]$NCQ]OS+.></V9AZ-"E;<<(\'X'T>E;B7W ZR*LQ5KX*
MC/&@MDH*,9N:[_$Z41EV:U#B;&KP?1R\6Z.'W')4J&2A8/3E;51&]EVN8#;$
M8-0D"2!XCE3-+ZA(GGH\:6JN<<%IX(97\K.E&'ET&X7'4#FT)P(JO#S*>2S+
M2(Y/I9K)50^QAN5>@+4GWNB#T)]+]+/HS=7W6G'*)TRU+V-:Q=EY6+XCCVP"
MI^\:"U[51H>P].,5V\&YJ]A]LT?Y1EI&EG;S[B[5-6EWFDR>BFG-H.T+1YJ/
M'CC\35^#24I]DE4LJ RS;#^=;P19WNNO49UP$1Z\<I?CN !%FDY8J <C]:JS
MGIWV4MT$6,HJ" ?/T&^QZ*@9ZUU:]Q) DI3H-MMRM&\[-T-?#PG_^5#O>\$2
M(S)V,'!LN<@P:'0OKZT&MPZK&!-7IAB?;U;6OW4OO^HE+2C^)UMYBT*>BH?+
M&]+QEV,!%GT)0Q:9#\<.LP_(1%H_BF60=8@7! "[>(*)4-AA\MEV!WG+CZ-Z
M!Z1912DAO)2A\KLU>TWZK$@<)-IE3+-BM:AC-\5WCJ0TOK1WS#5_#_9I".M(
MK [DU*RS5[7BR%3DYRP=22=U*RJ"I4H 3KHIW#-]TDWW65=7_MO(SYJYP[P
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MQVL@./W+P^?Q5PTKJ%+NNEQ-!?K&?5*F<OI"';YFG\ V!LX<GUD ^4M)@!N
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M-H%6>*8>I+\2QJU\\AA6N)MR(X'F9!B-, #8AJ.ZR^YL']9!?N(IZ!/47=_
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M#>YS3#Z9_5*/J7< Z<\7K<E($A:*[#<I_^)4%T];'%Q,19Z0UL\NM 7UQPY
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M*:&KMC.;R76S6H\'_4HG%ZH;Q4YG:8IFV</KE M:5J0'V2=/O>ROOO>0I<\
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M5ZSQ\XN$"O9[Q&K+S.AC,PIS=CV5=K>0R#NV1PE:?6D>B9TP$*7>XZ;1Z Z
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M;21:#B):0!<3\>EW:M-;[F(//-=_Y SS62DE'Z\FD6++NM!^?F[7JP9-^G8
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M LVY9[M?7HNFTI\\-9,ZV ("Q0 :)S#\^B/6'D]+G[?<3@0XBPRJ<]N- ;R
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M\HZ-ZGH0-V QFQ[CYPRT\;XK+^9+L<XBO(U#4ABTVZ(D[]A6(B'(IZLCX*#
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MLV:S'ZF8+%/E\B;Y+_ND+:;C^:-\]D#OLTF-B^#I_,\P8C"29]-9?T'IP1;
M,32]L;@%D 6W@/#TAD\NG1EYJ%:_ _E68E\#TT%>@>R+-\IH2%L1,@(<8!$
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MDL=@(*7C ]S<D%:W_S@+=8B[QIL&GQLE6B]NFUZ[=+8_Q_7RS6R7!N?)4BG
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MDE-CO6P)"2A658)B+1Y:<$!#%" &+'R:8!;^EN'R9G3INK6!FOSP_G>*1 >
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MQYHX A5K#&7[,>>E0A=Z0K4DTL488$V:@N,X!Q;)._V!U.M;6;PQ.X!)2Z
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MI3*.C,F;#1Z#<P&&"E%&%?]K+4W85(1MFA^I;K@K<:AIW>P9';<235Z[K[;
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MZ525TY4B@#U"I+.2%J\A6(QTT%)SO&.:_$X]0S!.(LPD.#BZ;H:^BC?<3M8
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MM#\$$^.;Q[](?JZX4ZT4XLH6%5Z1437>B7/_>F/^>*1%OCZ6KE^8]M!+D93
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MLKB@9XP0-]??0_PT%5.]?G @&]T0VBP>=/+BSSVUU@VBB740:&![E'.0XV2
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M5Y4.']7Y,SANSZS$B+?UQ?[^%,#H[?NMPN[EY /A0#@0#H0#X4 X$ Z$ ^%
M^(\1,D_W#=+);OYX]7]5#_=?"4]&9Q(6^]+UX[G(;3Y)8XHB@*:WG_[U!_)
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M'9HZS7?.8*-&>&%WEA95(4#A5HMC.$GNPL6R:W,?E-E0OE*IX3+J0Y8;I5M
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MOLT[NC[V1E93C0\Z)8W"GV*,:*#Q[IH,TLGQNY97$GW7R?A#W2&B([N;^PJ
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M1Q8MLV_:0A0HN,/4YK@<]21(&H 'Y] 6J6F'8^[:7]JX\/C$3(9IRI*C(KT
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M19XH0LO=_%N'JQIXQB9!U8&,D7_(H$[>&LQ<%E?R.S_LV!ZCPMY*^WD!372
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MQ#>"U504@A[<*#S,NSC ?Y(5F^L(]CB"D:&LGI%+@\9V47,/U%Y11)NUJ2"
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M=9^9I, Y!0]-7@913[8X!:O&EU;*8^X,I; %*;79(.&,;VVN)1..GCP9.?:
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M'@\L5RMQ5>EW)$F2$FN\91)>0&2YH(C=E"(VD8R^5SJ&STC(KQ%Y2DEGQ<G
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M7&S:.#1]3,BR#*6!7$Y8<3.&5^Z$A;QY2^!^U4?@D!:]71<-^[+P)*[];PF
M.FD.R8*I@@I/ZG?WI^IQ&0!&\$M?M&."'Z^:\LS0FJ+'?N[]B6(A#=+0U3C
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M_J!'^P8PP0C&)38E^9$>5Z=U6#244Y06J@QM+V\7RO%7/)5PJ< .;^BEV,6
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M'QZ$F"Z'=81UQ&[D4<7,DT9Z>%U$/?I9#O"[S;+;869#ECWK7)7-,XPUO7;
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MPZJI)2OB%6&YYO='X3M*BTCG3="OJ/VP(=D=_,KYN'O,_9]KIG;'&;[Q5>\
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MI^Y]"6_S^ #?[>TPH?4%S L4:&M/8ZZ'34 .-CL67::L0"TK"QYQQ^L&:?6
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MU)H'<8GUF1E/2PF;4P#(/E6[P7I:[U'O_H/VLGQ=JNG!>L@V5S=J_:&2[^+
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M\G#7$=_NR&H&<G%&'$! L-^&+=L5+=#6,7XQDB=C3^$U=E7'-I+Z29OMER,
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M]-I1<JLGO"B+!SQI0)*HW+8E@$<FK.,YKZ700M2LY-*9=EQW]-KR]36%LO-
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MD7EVQ>2^\21"%S+T^"YKY&C0 4J*O!A=?X.+V]6)B+PWSZ7C=GFCY+H5YQI
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M#H*+<!;Z_;A\[?9/?,JA>A1^%,V/=:4IVEF%R"+U+Z7T\Q9Z%A4#7>,>=Q5
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MGN5U5V'*.M7A ;>O6EWY8%EAW>S74BT?&@#D,4<#YW/F;-!_9WX -IP^G-U
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MOF+(/]C.14C3MLFXRC5(X3Y-V' 6BE"*R^&1BM&&2!'3Q28]F&LH@IZ/[ E
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M)O#-WD*P/RCB.0(Z#J@=E<#3@B(P=E6\D/$.(8LUD=O/OUC'+=,TA[M(S,F
M;C\6?#;*5[%C G.1*9L6V?7:7"]!?[?1J9-31GI!VEW98\+@=8FS'+%6SE:]
M:7PC?\9A/57_W3#Z<+[$XW7S!>)F.K%WX6KZT#UNS,I4B9R+QH6$@H8!&V:*
MCE77Z:I=4SEG&5PSN:GC'J-SFND89MB0[O&#8WLB+EO)1EB<DJNUQ]K).#=
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MU$79\=,^#Y[)]O>WPO9."!>Y! ACA7=5+!HN^>R;;GH9K6!\E^+%B;OM(FW
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MAAAV>?_K!"@5!; 1<&LG&F \U/\[7,<=)1+WL:^[LF,[Y(B/(P$.Q">EMW\
M(D^<:XJ5[KZO:1>L#]>BYJ%D" 3W1HR+XJ^A_W%SH+A&[.X6OM35-VB[]M"Z
MD*XG!A(WUY>/28,,Q]U0'M 65QZLD",G6_BI+IBMWK]5 W8+23"'[R#$3Q(C
M@.W.XQ7\SL]$!>0 @-%@;O#9?HS>U"CM$KDMA.S_LH:.[O1S( !K6#&*>^4%
MDRMV\+L\^LNFR5=,*HRH'C53+:'G!/ON%"S +<,'T-+3 DRNCN%;JT9HO]4:
MZL9U#V]U^S!T@PDKM4G1U^P# U1($G<_Y!>K!T7PC#K>HPD0S)"X \!HXR0)
MK,_D^>,Z#I<2+TL3N(Y  &S!-H^,-SM9$.YMGO+RO;':JA6[4IL8<!ZF&QLY
M]CC2_8VGEC^_^Q0LYO;.CK^8F!H?RDN'V4EQ$(G[CDT^7QBW/B"NJ#I.Z;8C
ML#^>R$<NW>[?+;OOD<U1R2\V8<&9X1AVA7M"%PTY]$XGU1K6*:>_+3YA0%=_
M,OX&%H5F$3R?9_W3[->0 6WTJ;!*MD3^X7A!OCQC$;3)>LV:@5N:^=N:(:WP
MPM)DG<7.C-%]>TO_LME:JB>=M(CX5(;[O5JZ[ <VLRT5_NG(D%OU<KX'[N']
MH&>)+L40Y1GR68D^%JJK>T6:9%RW_["&9R+2YCGRWJNM!$9^S>( OFTA[_#W
MPQ,SQ8)+/<4(3Q4",U>%XM@P+PGJ.<TN#O Q*I+O280Y2;5^+>B*?-J27ZKQ
MQ;TE"7SINC7.->CNZKK%")VV4P=E3B_=>[2<5?SL$T8^J,P8G'<)Q;"?F!.[
MP[ 6>Q)?QGM+I+2;!]K94=L 1$H)I\'1,K[NL;<XS &A/%*$4&&3J-D?@"W^
M:A<U+V8BRI18>5/Q%*41-ZKI<9EO0(TAA>U]?T76WIV3TP;#/,3HCFOH,&.=
MK\J->R5ES1)8F$08GGB_D9F*EO#"W51(M;VYHV%M)%'RP8 DK7"N-V*'FN M
MO"AQ( *9IY4YVPCW?J_!7@R=?S+YNK2AHC^KKGE'(H9\3"J$1(HS0 %2J/!\
M+->I/Z &[YFPQ_9G]9]IP?MG"+W?K758U04KNVF--4VSM9*\M1OSP_]/>W?Z
MU-2Y!@ \&" L 0JH$ V!&I0*+8: $B A*)6 +5!Q 64W4*0@!8(A[)L3Q2(0
M:%T#VJH@E@M"+;NLE@34Q 599#=(V"1@4$$0+L[]4.W@3#_<N7?FWN?#[P\X
M9]YSSG/>]UD>"UA-C0G=)XN.?5Y0;_ SJD1/D[>[HPX[9+:)-K6$^";=?6\B
M0:H9[THES+4(*!;8F>?M5:20M<$3/LRL?%FL>ALV O^P)OSO30AG)VDG_%E"
M]O[._THG"[1$,\S-B^9"S^I7].$]W!!AKT';GA$=I]H/5USE"N.L'[J?.IOP
M9\4W_=U+<SYA:_P"QG=1,IU^*0(SR:H?W[>PXK_V^C9/-?R4]XGF'S9+39_9
M(X*9^,L1+<U.-A.,%H3K=;<Q]?[B"YKR>WIT@P?>X*)Q.\,^-B&;4S5U]7')
MD_N5)&&K><:]<*KJS1G?DM'HCA^>S_QNX?,"G7@R/)S4@+>*DTH2[?]P'+P5
MM_7:L9-V4XBCH^PW?E,QNLZA-M)>\\&WC[O6M]D=0Y[&DTB+GS"X3-*,ONO/
MK)@FSDAJ&?FTCWF)\*Y=3 "RH-GJJ+[4H5-E.<#,%&@^9?[HZ3)-ZYUSD]Y_
M45N/Y.1:Z#&Z3>NM#3RWGKK)4^=O5VE>4X6=QUD(Y"F*^$?Z:?9*-Y;C:UF_
M3Z+37+D?#9B_RQ[9%*WAI9\J-MK\M68%P2BI39RO/5SQ/8Y597&_:X?M9,.W
M*$."+4)AC#4THV,IQA;BM*MRDA6\#>9;]\8?2:1:C@9_-&S^K-3FT*S:(O70
MO^HT5;QN>3$&MRAZNGG2R"6#6DRG(<KNQ $3BF/TULVKR%^]G_<Y_GYWC6+*
M"A,]9X[\9;O?,9E8O,#XWI_:=9:+B"1A]OD^8+58SXZ$4IB3#:'E2OIVZ/R?
M711(HFM%^-L)JC7#@<_M,>([9+0T)[^,54]6C4*NJL3\91!M1&'R<$8&OBP]
MKJQ>'JDAA]##7T)$+KXBC?8?/;I\5]7;.[9P,=IY3O%>*-Q% CE:VE=YRF#P
MWNU)\A3>QB[>YRZMC$BU?I=W,_.KE=EOV]$^AI_5(Q<6 PK(YX\DD^O^1Z*
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MS0Z\W_U9K@V!E^/G^%'VX^E:^$PJ+R6=8"'\RM8G<_?.U>S_]F4#
M
M
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M>8B C(%_B?'H+]/^8=G_G&$!_UN6_5?#_LVN:> !-A;&>=A$ !BXN&+.^$S
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MA\W_1HI9?M-IR_B9:[ZUOLSGFD-$Z)EN3D_T>U::1YZS?@<T5Q._/-SVC]%
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M^SSU#?='Q-*5UJV>'+)4Z0CB#^VLA>V?SM:?FWC?$L$ARW^H5;IBCLR_07#
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MP77>3JEI-!!>VY*,*/BHR</X#*G;)"DT0'Q\%@O)_R.UJ$Q XQBL]Q4-I,;
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M8AVZJ'^7R&@8&;SUE1 ]@MB?"^LXOS57#1>/=-*E"FE#X%O7/+$='^;><TQ
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M4)T=L_--U/N-P1=%<PXQJ&>+R*'9NG-R-S]\K7=NU_X([>EQ@HYW&CE/#"_
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MX$+&6J(/RL3*LOYEF/N9I\[1!_"3D1_1]YF3_=[Q/P&\H@:]4@Q< *]H+,"
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M)Q8DO'%0/\<W!K[Q@HM]?P)02P,$%     @ \H%=6"9MM"16[0( K[$& !$
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MUWZ""RS7IEBWSK/V2\[^?1E[])_*V6\9^SU?HP 1)CHCY!CD !S8T^?(>$
M H% (! (! *!0" 0" 0"@4 @$ @$ H% (! (! *!0" 0" 0"@4 @$ @$ H%
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MZTN?"7;OSU( GV2P+,@[F':A)<R4(2GX=]?Z4]R7\\,6/:C4]2YA4ZE?!X%
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MVXTL]-M3J<OYLD._^PNB@/B)_3X48%T\7^44"M\>0WY# :M[XR.]5O -H:-
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MG?;9[CJ_LJ?26@Z8F'?3;JW=;EU"_'1XUN:<*L/8P\W9$WK%VQFY&7Q0P/T
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M_-Z#*;2=MG-4%9?>5_?UHNG@W('3Z'$R<J"\)._'HO&UQUK2!H'K:O+,N.P
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MS_!T2I[4L>WS135&S'1=3N"FJYCON_VP37RW7;.S*&/Q7;O4[7Y%( Z?E0;
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M;YRR"$-R3[$]:E5U/QL@;$[M==3MLN5.ZDHE]D2;WBON\OID8ETQ81]":L+
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MXLOGG82-URZSG$;C>E-QC&> >Y-K[EZ:\F/>C'*2VN&2]V9=2Z"R]HF_.F3
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M0NFU *+T4?,@.P,H1:XD&$3>C$,)QY 1JVS1N[+7&3:577R*N/A:[!%=,#N
M-!J+=&8?3L\K<OMBS% 6;LP)U3B51G#DRZC^^@G"@P</GC\U%^@^E9:H__:*
M*^MOO1]JW&V#JY7&.I\]-U;?+L!U_:\FV,EJGTIT2_F>$'*37O/IG??02IKT
ME(PUNY;:I1Q=O4^8Q?+C:U*-VR)CF"[7-1NUP[@17+G(%I<U:QG'H>BP._JJ
MC<OZCS4Y+8LU><]]!L<>.7Z03K8%7 ]N:DP=1.EM>L!ZP'X&R!6NSW$.$KJQ
MOJ+/S5;D9/%#^.?:]S?!?[XK$P\>/'CP_#NW/WW2E>5OE\X.B3I_1XN-T%AM
MW7):A,\2^DI6UZW3._?:B9*:L#*,?N4;8:N-:9Q&R;G)C)S.A5UFR10FS'0
M8U+=;/2?G01<(J/IE9I".ZZ!Y.S(K$93_3)((,ZB!9]PE]O4JC/$'N]5S%,
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M<*@[&/8Z:]I^%*YEG6EID85.B&]]PAQR399JLS@C9\CU4O>3<EE*V$6:A+)
MJL/?FLC#JT7W5U<'ZV80<\Y>UTO6'KIRVR--B%PV#KTE8K]./-PIU,ADEFOD
MO]0 3,W/%L8,*&:OF<YU]=R3W[(:.XE^/I@$KS@!SWNY'\Q1C<EPQ,L4W/9E
M67*G\G.>SDI_UMZB)1Y6^^'RO+=(WJK;Q:I<$U06(<B-.B,XEF8,.H515=.-
M.K^@7=J_7M0+#QX\_QHX2O!LF0^T1=XD;?:2#ICX<4S>O.7KE*&@:9K&T('$
M4GWI9UV93V'^.&='9&H6&3D.RE;8^B"I%==H6)+&<"32*U;< 1R1//6N'BD8
MG:![/RRG%E)/D8?U\$$RJ9)3U3X@VMQWK3*%YF;K=2<W/ASLLHEW:,M>G&<7
MF9!W\-@'M;KG)7#D6V!CUET]7IJCXAI^2</R3#!S>#14UDYOKE3PYE"' WBT
M2,DM8-MB5PW2(F@/:.'YN2C!;_&*^1,] 7:8+&V6X@S JD>V!L<Q)O<NR[QP
MYFI-P YBG:G7&V"20BGS9X"].MKFRA']-]L=)!))9P!#@^10S;*BJ-UO4B+B
MT8-3R6VK^D2TJA\-R" .8,+-DRRMN-="@@I5>=>])SNSBTDI"%BFZ+$QHU-N
MW:(!12^I=.P+7U.]2%BN-D;JOT_/#P2*#PS=K-65%?O!*(:CBG2=%8J8E8R!
M[TG.X. #[ZJZOKUY!?N4>"!D\9)_GGSQR#FWTE,I>U23S<LQO-WG.(>"@[7&
MAL!D(GE%9: T;Y=-N=;&P0Y"SJ2R=7J5S?VER?J*R@Q,;KO0*+)=H&/FAG]H
MN^1@0A3"3%=+3K8V^$;4$W&7CK:1$4$,)?>U1E]@88L,+@]7MW@TE(!A<^"4
MYENB,K"-#-!$!"T[U"G<KE0?3:C>F%7ZEOED9SO7G7#R?< 9( 6Q2SUN1US=
MU.88SSL)GKE L/8P"&<Z8J-%-[*K<A)B?^_ &PV2I=2JM0O\'0TX&)MF*IN'
M^SXB_6C#6^0&CZY9*1167S\#,-K[U)\!=A_FC1V]E/Z6([AP!GB S=R@.C]"
M\@]O-8H?]BD__&)7IQ.(>LGX\<E3GF$(*OYB0J.#Z _L+LR[1ZBF]%[\6(.J
MHF/A'!6(;XY\./]A;?KG_;['2,DS@$%Z=H'%,C0W]!933T$DZ,VBE9,!*C5L
M7I+AJK+JH&SF>TVSTU7K-:ZGZ:,/E,O"S7OSA)?RE4I=^#=.V*^.=*69F!S"
MG>:^+1^9"*:B+5;1*<&B%R 0?L=57XEDA5)9$4UDVN>O@1SIWS7JADP*VQ)&
M)Y%V*DIF*1(EA9:<#DDOS>QZ))F4&&5-#]\U=6=%"I@M:+:2 _RB[GLY>&Q]
MY^L5B%)&15UJW9HBLI^X9A]Y!EAEX,Z,H_WPA%O2HPBY,"BV:KZUPYB)SO<!
M;SGH&[$=T3& C\B F.6I@*.%*I+%'(A=;'JN'H_U!01'[F>6^,^D"%,AL4.0
MI?$#S86R[W6Q>B]W317CQ5#=5!=S*"Z!LN%QN6L:^D.-^+)\/+\/D\XR7R8E
M?C_5XKC,/J)6N&V2I2C'!17Q_L6$, 0@NE? ?2$-Y<NZT\WHGK64<EE\1QX_
M #_@3SI@(+=Y"ZJ&ACZZF?7+BS[_.XH$PV\V9;072H#9%\9[^N2)S@"O]1R7
MK@ZBN<+ZM8QC8C2_E!NHSQ:0=60\T8O:JF05F9_?"9+\>K"!=24<8HEX0LA)
M=#U"GCF@;^%UB"31!7YR\6TRJ1/R.V6-QAFO/QRH.,GJ**"$SP! -[&UT4\5
M3)(:,B>2ZTS[-4#; LAG!+?HWJ*.YP#7-568U'D$+?N'=^N2%9B5S!.%<5VF
M@G&0(I-B[1&3D2*@"$20R:GEF-P-/XCF>'U&!J<>RQ7XN?.AI@U5[;8O]AO^
M0)3TK&,/_7G=P3UV377D-\9UN=X9D*@9Z%0X&\9(S[Z0Z'?:Y[XZ<3Z=R_H7
MJ1[>T;C-Z<A7U,I"IP$ &M5GL B4J MR<VZ3B=$6JQI<RWX:=F$GH:UN!$'.
M*VX6GE@P,\BT.)RM+.A(HQ'*TWW,'5J"4$235OYVZ2A<N$T:?*SU7/5#FUQ!
MB?)8Z]V"#,&FC<EM7%JXBL_.0++9#!8:+V$L7\$TAX/#BC.W$$%#9P#?_>QO
MRGK))F0>I94"]F]:AP $HW9<8C$3$K&"E.PO7@X-O9F)=NL&:Z:>CK]<L^ M
MY5AWK R2-^I83DJ>>QP;SV4AMQ:U[-:; ::S!0Q?'0EVM:?%\> (3RS?6CYX
M(L/)$@'0FP/9ASF8+\"*0HKNJPVJYV>/A?9^23-KM1]'JX>OPBQH9$@9I=*=
MP \31+A#7X#=U#3EG[F?'(_<R.>S0":!V[:I5CE)TG:7A.?0 ]6#K6> K:-[
M)X1G@$<ZNQ\S+#=.)+.%N09C-,=KR^Z?/U4'I-*_H["'7/'0721J%"/.&@(L
MK+==4'ZIG$5I#* &UIT!\HMJZ5MA7X*)B&/?]-J7RLG/7CKA3DOH?SZ_MT>U
M'1]CNJH2.ZX^U%B1Q;W/5;,9\RS$4>M.K&&@H%1N.44V'/YS)\AEGC$)5$6&
M3JE 3&QW&@0Y;I&H 7OLFOMA9V^AU,1K6B@KST(K5#GX@Q !%BIK^4CM>A*G
M><JEP$*@( \5_<!+&G3.S<C'*C^&QT<U$[(+*:J=Q0<I9,B94G/L:R=)L97.
M7HHE&O9*K.AB:YJLXM%^@:'V?-/Z,=&$ M>T-G@B*TVKG3S1C26?]CVJWZXL
M4"QNY@CJ]=PLFV]QM'3?+YKI$)A*W)!OZQ)>7>&W/ZER3.*RIFM1,7DS?S0'
M(%@16?/8&OWQS$]_TO0,T'C/MJY[_ Q T-N)7!3&?> ;JYH+"9GIA.H9=*.=
MK*"R5(WF?]O:\VHN0<<J?P9!@*!S5=!!7?8=JLB@(!U2N'GG0>T'^7Y9*K;?
MXZ;_?H;M2J\HZ/C>Y;WYWBS+/.6RTF[2G_"-CQ^ '_"[!JAS]@K"<M%2NRG
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MSJL7FIPGK+X0B#N#6]O@5GX99L5EV:%6/;0^>=MMH:RI6QIEK1=_<I?7;[9
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MQ^]EOQJ#W:@:C4+XT]0%5F'W>+1O5*@_;70PC]PG'>)76D":^$B;B5E@RZ*
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MHR@FMUT(0]V0F='U!I4[JF;_B-?*HP.DBE6.?%XI[9)M8>ZPDA.@5/Y;)=C
M:_\9.QYMP[=I3E-33H!.9?U<M[J#-_"E^!-@_F8AA&8;5#Q'JR[K/O<WEQE<
M\:D;*#^VAQW0#$CH&5Z(SFCSZ?(CQC7 ?I*C:(J4#/V0\[BK'*DU@D9_0CK.
M].H$,;CO"#VG=[)SZ[=\I:>_G\!<U_$YAX&'<D%E[6G$\Q#._"DQ(9].G=^O
M\]K:7\GHUF=&G!MN"K=%02;=F>6%YL\BCJC.FKH$21^ZG0G"/IQD#A)M.=A
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M5Q5U;YA#904X[Z>(;]*?D0J,&677[=Q*"C0-+D5_047L]MR 9Z,\,&$>VJ"
MEZ]F10_]F<:3)I#PAP/:/;&BZBH/C,0DXYB$W$L>/Y_)J3(SD*H-7#/[NG8F
MF>F3BEM<-(5&GYB#'#F38=J-8"5RD6L^H'D+=*&1I;A&Y7[::S^4E0P*IJ^3
MJ@.;+N 8#8@ENE5S04QT91\B,S'\.:Y*PD8KFKUMY^7WT,$:V6B'9_O,F'6A
MYY^..,UN5(E\X*.?.</G>>[(Y:@.VI:^BN"6E;/D\25@L9=_-MA/IU'0I_3G
MH^'Y$Q?-E3/K=\F(7HR$#J%N@9Y#+4).@( PV^/!$V#MW0DPG9-A4SF/TTF
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MQF9\;0JL%ML@4&HG:3L=XU9!!>\,%S(CF+@GI]#K#X?\J10WUVYX%F212J/
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M)!05K[#@UI;MR%;%D?Y.16KK.Q55-7>EY=8!QP4_7.OD#JSWZL^-523O1Q'
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M--HN4LL<"[!(LOP;1?:&=NM59&)Z^MMP-^<=,1)G)OF[$CJ?=?@Q8XP&=ZV
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MW.,A(96>J:!IYX=85>\@6I4O<(+\<5 %1FSQ-K.MJT5:49HA[+FX"=:GM?7
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MB'W+<M$..W%W#%3"M,S-P*4Y)IM)_%&%8;9]F'HG,BB[!6V^P_V@K%K]EHG
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M/<5=]>]2AE$\L7>6+-3\-<95MVY4>GX>Y Q:\EO:7_PM APF49!VN$,<6XC
M5$_NMJF<$&)C%H3?]]\Q"+ATD<Y_+(;)-S-Q64KGJD6AROF5F@IZM;K&<JV5
MR0)V8085>U1GM[B^.E3=]7T.UX2/1J\6BW+,6P?ZURVD9B@<1DV45]^;MOE
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MN'/UE-QVXI-HI#NLI;O,&YO3'\X<L?\FB]94T:E/74&L-1"5T H2F]A].>5
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MF*T<CN.,+S>T@Z#EE'889ESTMF3-;NM>D:P'!5Q<XGD\W_CFOFG-MR[=5<,
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M9-N-,XRS3T:@=">J(.0Q\YV=;Y74=[-*WXEONNQ4BS7T:"0%W;IYVT-?A!3
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M2&0YC;"\B@?;NKIMBI1%DKZ,]""0%#!/92=H[=VZA&*JN,1C^ARE-\2\=36
MT1FJ*#S @*Q%,1DK1SC)*YQTEHFA3>ES(P"-E%W0UW2,C33Y:JF#W@36AQ--
MMTOO"%C1>S>C]P3LD/?'#)D']!5.!%%"WZ__Z'F_B=6&?O.N&_%>:%19GG C
M SW_@)\A9=JE^*-MO#%T_C-4#R63F0$J)"_/ND()U#U^P'\*J(2=/+:%;HQW
M9M(.BR?B!."!02=,/ A'OATFE#LP8"4)!U_"^WB6U).W53CN6096,FZ;LU'
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M^538_\W7C<'!4@)?+ZY ]1,^$,NQQ-Y<-<E?C2)3X3?8:?$Z  0W<[94N9/
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M%L G?TWJ$3W-CC;U*62!\;R85?BVUQI@7#BVR?$L)'9DP@WIR#?PQ[2MSR>
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M(VAO$V_9A-@GTGB >1D$V'O[@<<'',=Q1H)/W(>2, 7Y,@VAOE:\D+ER4;K
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ML;U$M',G/UI]_IG##3W6$O?,FM)O5FJPDZ**"/1UO_\'R+.WY(,Q=Q_S83:
M'26,<?9.\L:%?,5?+"!*&E"I:LN1[=(T(Q%T7NP'<TDR)FQ*QH 860S=#NF]
MD];N]@K+S+'DAPL5\B&"5T+J6.O%@$LQ0AHUM^K3,OX9&-!'7_G,<RK 4/"3
MA][6CM/.WM8I._!W7:E14-3DJ-K"Q_3!KW/G^MDT@('][(J5$(-B@SC/[KN'
MY[Z[1,,[D/X/7 8\@-"!5=/^X#)0^5 *03 \E.0:@BB*#A'PI3T]04[[S^^_
M#<7WV)OVS%RDK1&_:<+8<SX&E%(D?\I!ED#1)OB)U22ZMY*UPR6B<C5L\_XY
M&_202SI<PN5-'?)B+-82O( ;3.7HE%^+B'==LE)@=?\N:E;0S;'%8<ZXR(.[
M^6/<(-3*>E:NDJ>)#6.)C)1TB;RO525_M\E1"KI&]IYIU(H'\ QXKG^ODA#1
M@/,.$C2]^#M:]M7JI:$A*X>Q!@C'*/9 =/0(;<9W;6E*UR[RAHA]U8CLD;A]
MYX*&/C^= ]C3T#7QHWP2?PLE$WUW#\ [2L'/*4+C=LX:09__2_L'V?"E92$*
M^B_I#( 5%\-+X^'3O8S) WELA)X*2F@51?;6PGZ/%%54P8@Y$P40R-[TU1'-
M )K42*[&Y9CID4)XXE]"^&3^4T3_7W-8I:DB'E*GO."(4UYP-OT9BS_02Z_C
M.T\3$*0C-RJZ<Z_35-Q$0N?(BG2Y.OQUZA4AP>;I.:Q!TKP1\[M&G)%CVJK@
M?-I![(#'@57X3=BH5[^\4R0_B_=V9WL2T0?VW,V,[,.]I\_25E7NE1!*>($_
M+#?A?>%1]BT<)#5ASB/;Z&']).EP.O! ]U)HPY)/X(N/;/03;]BK0U!OJ)<Z
M[+)2XP:6/9O2K*]A?]D>Z6("G+,B7Q\K1A"0587!OP&L-:;THGA([AB=[GH+
M'0WDT'Q]=7_VSS89B7D-G9]+P>L:SZY55VY:[C<V6F'/5;*O$SGH069X.-NG
MUJ"= XFKFU?-<R5B?V%!.GB9=J[6_^.U7+B?:D.QK1I7@J@ :\<LQ K7Z-V?
MM#>L&GDWP?*Y>PZ&](F'P(I&AG?<[UT<VB^$#;Z.72@_)<!3^V3?,M*0QH"@
MI ^JOBM\)U1U=+IP=*_SNK<UN_)V[A^B0O<XPNM;=0+KI"Z31C$8R=?BEOC(
MU%FS$5IYQ\P)U_ O61(/,U3UQE,5@I1E[O9"Y'O4W@KJTJ2OF!_+LZ]>P0+2
M2K1D^Y^8Z,7=MCMX4H0+?QS#\)="J\]@(ZM9G[-+%-)PUB+FO@@;)?VASU).
M &>AXX<?T.-\)X!O6G^<:??<$NMDWI->@-5$\M,T*1^V^JU'@"SWH(/=>^@I
MBFCSO2;6E%5<AB=,)[8[2XPU27N]MVQ+@\Q08%%!Y7(]DEYT1S)LVA=Y635>
MB0MV&PAQO$>.8JS/JJ88R#X=H_8/0;RW*Q-:%M[Y5K\_^WC#"QZ[@9FX()5(
MY><)P=)NL=T$#,M^,KEHOWPO8C0H.G _R87T..>>!"C?0+28IT5(:]+,C7-&
M.GPOS1S@<A[*:MB#ZTQ3L 4X;3*E'\[!-Q:PFUV5K-=B5>(%II22HG&+CC+U
MT]!08+19YQ][FR88*?M'FXC6HGC0PGKIAK4MO:.0%X)B71(MWO9[8^X'_ZNF
M3R,03KO8<I>CGW\A6E 9PA!6[!_U9[9\5YH#T =X@Z11C;$]_0Z9OL@0!KI!
M#SPGUS62[./5-9".$@]]13X8<L58[J;17LQB^QB[38#)VOW@*>?"@"7//:X+
M>,8D'NH;Z:\,B[_];2_MJ[5\8]APFF6 !AV(BV*I;A&Y!['NR<W,RPI7@%?8
M1P@FR?5 TU+J\=[*SR.,ZZ"7-T,'TKD^!&G&B-/Y?OGLQN[9*7W&K:)/U8=-
M]@3@5@_,FA7&*6JMFLFGC/N%>,YVD%>V-/GK-#AU/O [$BNR2@F2?$"3WI5)
MAXB!3UM78QD<O8 I]=,&)?6(2JTKV#R S XG9X'77"-2='GS;(!GO'\V %EM
M"?T\6_$%:@OUI8(*GX<&;#G$GQ\N1-]LK]&K9[_KE16Y+>B!>*ZNSQ@Q,.)E
MKSA![\W@623;4R2/T1!K8E2N1[2P4_EUDG^.Z*+JS:)6YN?;D.X<$WM4AU=7
M7E#AZ#BLNV11&M#6<$ZPT_<7Y"9PG9-=!M*7]&([:?F%VL"9#^3!6"9_7#"\
MW FS:<0@S=^CD$:;#$ &U"V9P!KS"KH4Z:46+W2@/SMA?)X>/1X-P4L\?2I2
M(T)EI"C&M471<T!V#* /^K3T'V7.I/:9KPP5ACW=0$BL29>'3/%)# A>9'_&
M%;560K+:G^!'&[5$/5%'^2HBC0T'+T,.LG>8\_B RS]N[F#E^;5(^!MBSF&^
MN,#Q,P_V+_'PLA/ \TB'HT'4:MP)8"KOXC=_[F##%U?X0O6;K^=UIX#IE#K-
MCH ]M!/+KL>@=;*^*Q+KLPK23SR ::YU'?326YV 0./>N?OGIJ]XF&!97W*6
MR]V@1WY BV\9:3@JAO17&9 .G:B_ .YT>]W(LN[LGOM)Y;3H3?9C&P'^9:;*
MJ9JOIG0F/:X:--,R0;;H2?'#P'J==^F)4T/DYYF/22L82^AAK4K:VE"+58QR
MY!B&VPQKWZ'1C_&CR37B>_GNX'[#'H?67#!GE/ F0_*A)7!S";/>E=\YH:I,
MIOE<>:5P$+;[DW.K,"C,P+)D>HSC!]</DW.#!D [T&N<0!T&ZX9/ 2Z>N?L[
MOU2-Z+<WLBM]\HC6''.E#EH7?*8TI]3VK-'O _ZT/>Y\'/Q;;JU3W^F/#^*J
MU/Z&;VN+[U.T;3B?-75&A/BDPEVOU=_K53_Y&R-9 ^DS!/11M[H QNRC50C6
M[85OWFK^5*6:9+)*[*I?-&HI0<VTFR< AOFGZ2J6',M<K^VK8";TBDY'U 4%
ML"GF-W6*XJL4%(X(7P^X&)U3=Y:Z,OS60'1!/A$98?'>(;H)\4 %9E;%<8RU
MA,Q6W.*G14)1_&*6N_';ED> 90D_9[5+UJ\*RIA8C.V2)IU*M^O \\K+9-?*
M;21>*TI.C:IA''-IX -TN+CIZHZ/-ZJX'X!,KMQ$=%HL:KB,+P1(%)'\!9$,
MIR3!7N\M/,E?\("%.WZ!? G[:B%9'\_!=09 ''T)9!<_F&/^D=#_& TBA,N-
MDG<HCM+)1B3V4T:/8UW&P04:?[0Z:?XAH-E_G.787H+,A?ERN$:.X=\\(W =
MS4CMX8$E1-"3!2)JG:RYV->23G.W4_LS**=EH1N+T<CQ7!PZ@ ?DQ[MQ7F68
MP(6R'4+EG:6@41EM7$R@=\$1B.MDL!<3W:-DRWKU>UE?SYN:>)40IQX(J5.-
MT.\=,P"!19:QX:,S,CY^[#'[,<5Z["T['< <0O)LC.7_\7[%*W_1'BF\;9VU
M$$,P %;3TN&GRWCL8B+ZS/5A;];&--PVYP'0EQ0GC7H=)RJF+[USV'E]TP%[
M >(GT]P)Q$3XY;74^J1_'[V*.>8\8%"<4,R^Q1^(>_MGQU"^3V<H[4:>PK<'
M7"O -]!6ISV7[J+VKH0LH@H['#,'C._PZH3Q04ENW.,30*A.YE+4HN&&B2![
MU;EA+ 3BTI_!K_G8L+346)Y1@3P7 T!USOKT@AB74(,,"<5GK<X $5Q'2"J-
M)P3P;!E?Y_%54_L8DM73)%D] L9RV&%)MC<<^ZNL=&AK &P#F8[] =*9!^X!
MQ&E7\S]3/*7]Y6CZJ>2!A#NM G#6K]WYF'&=\I* >[1)\QQ8,_T,^P<E25Q-
M)<N/$\!7?,7Q<M)NZPE@77>T\97+'E.7M.YE;9^\<L6C+:4COL[M4=J[4 W^
M?9W=>ZX61]0K$GX"&G9_>##Z-\.(6E0?&>X8T!=$&1IDR0JQ1N-J#D#9+/4#
M"T38%$7^'0]"&R9@8 6DL!"(A00NX,C(*_(ZOOSM'!>W^5+<1%#8?V$0XW]J
M$*+A+IY_BR7%L +M>0QK+4U;!QOL*3U.#9L7DPWCT?. >/\0UKXZ!-C)^BGO
M5*,^G7^*_-#I@:7VBN.V/PQLP8Z\@ZIS\N0A<:;37\.X<X7Y;$53FT02JKF)
MG=(2VY(&"28FM[^#(3/Q&W?=_"6JO^*I\5PEVX3 /4A2:U7--?ROC70D!=0_
MP.I@,Q!?XQW/S:WCXH?FLA;UL$Q;BP@0N)$!F9L&9AV.3^X?,/;I:)$#DLW)
M H J;H[ZN8LM+>^N6I'NR.HOCV*B$4:4Y$=U79FDV7]-_VP7&G <FF5"/Y16
M66$<)UC96CQ]:>BYM8K!0H^V@6+\0G]FDWR"=PX1+RNQ#3'(:N!.D"NZ', Y
M[\4R\U: S?UQI]X#>G%')].BH"+)>353@N72SRK@9N>,:>6!K9:.*>H*3\T3
MUUM:\EXA@0;+]_DB55+T\]EBD+F\>8U=KTI?]6C)N[!;:)G>F$'-9:@J?:^T
M['OG_L!V(>U*&'?AQV>GD(RRK HN'S1OC>$._-PV2XK)MC]GX:M=V3#N_/;?
MY\#1._R=HH +>JU@!54#.]H:)][UEF?I5X7IOV9FR<=DR3)Y/'PJ=%J*YO_W
M4G1JV(S]KX^Z^9I]KH^W/8D)PI@@6BR#XJPXDQBLP%&T%K1BCOITEH-K(Y]Y
MPK7YB=L.?,GLO;RKQ7K98S[^3\+BKRV1G4(?]M N8D<3]^HXWYCC@87D<UE5
M,*/Y?X3*F,M++<RT-')6WZFXH^:XIH(GV<&O%97'6^C=;O3Z[?&%-TU]W)/_
M!JVP;6=)]#556>!QY4WD;K \_ZV:<XGQNF <)<(A/DJ @K[NX+3/B7:,</CS
M!#!.B@(;^].U]!39]3%>EG:TKIRB[OK=_.'Y6E\'6J_DX-6R ;WON L?K0S?
M5JDWK"Y_196SH4*U04\]60>Q@E:>J89@HJ/5^V]G_)P2KH1CN=E;.JA\7*=/
M ,+?O)YVU-QN'+>[?B=@35$:"=C:6>UPB36-OWY5I>*=;_G@?GQ? >O\MGB.
M%)A<?? %>(*Y!6_O07<LMV!TB>22\%-[T42'%M'T<_R"O:'AV/QF97,"8#($
M&$8)-G_G&7)J4A\QQQU)__IV*;3QC:,^,ZVS8YL'Q"6X@A58JRWA8BJ4%?FV
M>BQQBZ0DA;0;"E3&&1T^+_0Q.'.J*X@+.WNM1E<,K[>[5#\LKGZ#,$9XZ"&6
M0C@N!2G3/?O(I"S&M:&,5+<KV/-) Z<?6AQ&3]-[E[ NS)/MS+%VWA[ELW#<
M6:Z%[;FP>)<A->ZDAO'-=MZ9*>LDD_=)N-SH$!'@&PK881=N4B*^+#2;JS/0
MQ/+F8=ST 7Y23[.VBK12/_$\NIV39[;4UN3IJ:K3QN]+YB;B<4;-<E7$Y03@
MNW+D9"H2NW;,)O=%^R''&O5034F3.OI\$$AE\7%JH:59:MGRYR"$IV(;2? )
M(L)NH[3(!RC^/8O=>VXZ1S(K$D>.BC0^:\>S%(?%'\@U>/\MF>]?ME!JH YC
MTP_Z,/Q1*$=!N!=G^G2"+R<"K$<E_I%<*ND&X< @^Z?\=?4;GJ]<C-4;LE1N
MK9Z"$['_:7#BW#*1FW^&::4UIYG2!><4 [('U2:3_$<>KF@WWM:T3Q:&_B01
MC/0X 02<>HME?#<;:]=73@!KL"-J+?[X>3235';]6A!5?.P@/4H 5>"NA_>4
M.')!]PN?YBS<;]_:$<&C+TZS:.AW*R3CM!!BE-!*SF'.<GF3U()%%P5U_MM5
M":GS:6KG-NWY(P8@KH0DH^[4,*;B.5'1MEW:64F2G2%Y1Q/H0W[7[5=%\W M
MWGEIB_I1+&./:Z=&%MHV(2_-Y'H:;4Y-".FRJNA^DL^:7& O%+*D=^L5J%CA
MRD1TC!*[\@D 0>2=0<R_*+HJ'F-GAQ$('JKL9.ZLOL_MR !J"U ^EELK'/JP
M#0,I^H]9,M$#]AV%(XY M]1_W?M\?5(]2UBN])7ICQ3[3XKJ\;\.W';S[C_$
MRX6]X7XF?66-&2 5E*2;WB4VQ]IZ=Z!HNG@>+1XQ<X^G9:I05Q3M>@SKR!7J
M9>2^>N'13WF6+N=_;_.T\BPZ/IT)>KJL#\J6.+^AUW_!B< 3@!Q+ 6A*L9?6
M6/@O?'-JLO_) 9K_Y:/0!K8T10H+7IYV4V<9W(K<7D?WWSGU_]6.+\Z?=>DF
MW<[^IN/O;*,/PFQ%)D#960;@,996S_5FQAN>5SLDG"I@;?T&)F\C43-O3_N<
M'Q9P$Q_;.:\&F912GN^2!58 2#K'](S+&.EIM<>W22[(/)_I.=ZD\\!*79>1
M@LJ1969K\ / D:W*E*_C=%L>CM*<4''=A?B<>;)MF<;D5W9^$BT:7XI>NWE$
MW5>F%O=>EI8[>Z;JW@M]\[,0@!+E$=*&[.KI&GM%1!]7WSR83SI@*%(3(AOQ
M=YM-%<[JN'@&XTQ'9UX.@M;XN!7,/\%?B%1+31.EE>CRR_"S@^IK"*VH:N+=
M8TK"#57IILEI6"?6-<<T9CFO,+'F ;S-H^L[C:8D>4B!CN )H*YVZ[S!)8.[
M.Q"CZ'E7+?E'_TO?0X]W5/=_YH7^EP\^MB:&V]_R7P1\9(^GI4'Y:<A(7]I0
MXCP3'P!H@0< %EW,5*?\[A_JN[_VJ]_(.DRKE?82D]P0CNC5(BZE\G?L6#7K
M2L1CW,A\+"&1#K9+DE<GRA4N&@ *NVAO.GL'.75#$UWZ >:]^?P=[QLN*>[H
MGF4\G)M%[T;:ISL*("8(R"7]OS2L_==IB/^&3^//6?=Z2DK<IVFQ_\DN\/^O
M=:$SFHZ\TK4Q1LA?=^JG%;)KOGGS85_FR+AP%6U:,AA!*_S#Y4BYXZYW4QDX
MAD9/AJOQ=*AL3MTWK_NAM\FR3!0E_'H14O6!VI[ 3)>((][4:V[>Z(:'%*+T
M'MZ* 4"S97H?=];=@GN2-#:LM)HE[(/#\.-]#O^X*LHE1XH4NJP4;>JM13X)
MH_7KXMHEC^@(J>2B5AA,1,,7#0>= +T!B&@D1\38!)>,+G7_90!D)I+#HPE%
M9_#[_)BYW?X"'TZU$X!7"[QH6A@'E/EE%OC7[TO'ZBK$J]=K_DB$Q'S^G8$H
ME>.4=IM7P>(?\,R-_(//52V0G7I%C#@*^R81UH=<C"OT()6=Q<U(V/SXP]<F
MV?M7EP+K+/J3\9RX*KA3!H-URA]I/64SG\F;E_PP?N\FDJZ#XJJN.A'AD.B%
MA>XL]9VA7S="Y@?O46!RZ(07HN7TP?Q>28ULT;?[?F*;PK*DLOCQ$U^K"UR:
MH@9X-A*LHB+(L45BT]%X:$*G>L"T%W;S?8B0X'=!KB1G9V^=L/-(T._4[7]#
MY+Y[Z12?!<%';C5X !(4C,[C]H<\[8$3ZMX KT+TY&S&CE=X%40-I4L9<228
M9.9D%BI)/JGV1"B?FG,  XTCQ#9<BQ/4:8Q& =E[IAFCFY$*BE=R;/.ON=8R
MNFF(RY>93 F^F29<IT+LL.\?#FP7W PUNA_+9BHB?/GKFO!SN.0A;L1OY,"
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M77C5<JF^2.14Y6T.@7J3"6;+X-@F,L3HGH\5N9/1Q>K7^IRNA;D"2BWUB*7
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MGGPC8/1KBL5^3&UK[GU?<1PD?M"$SMRO3^HSE HUMK#ZS;QDS_U7FW&*%M_
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M9'D"64G> >(36Q#VY"1(A_VAQ ");BE\DQ0CC P2!WC#9?9YV5F_@B$#317
MI\F?!)X9"]RP\-5K4-:,7V%U-)[E,)/KHJ^1H*'9S>\^%!6*_BI.QA[$W4CV
M5'Q<.?SVRU9P=D6L[JL7D@]'!53GF#B4I<R=B4% Z\?2/L=1<Y&;U:7YD0A4
MW %-BIR!5KR-NJ@NO]''+@P?OU'\V,HA[,F-ZU;:*++KV'R?IFWVP8MKX_]
M51LUC_C^2#S3P5WC")0<0B/CN9*QV<A(Y/19*.T)&?Z_0;$UF'R3&=WC>P?E
MU'SZ,[)>$'A^E,000XZ JRN'L2JS%0#$MDQYRZ#>.C=!YB(!<Y/PK+]=SYK\
MBCQ'B.CX*HNF(G.?]8G;0 *#)QA&"^CQUKR;HX?/G4\S4YC&9RI,-['"R2Y/
MP]GQR=*N@S\J:?U(R9O#O3%2_N6;]%V#%'0^_79>;T3318@K_BK7;TGSGQL/
M^6ZG0$\ZN$F_@ IIHMLK3A'[1Y#X5 $!. AWD&$D(=M)6Q+%%*@H>>8FS*M#
MC/E7C5&%2S,O%VZ^E@;^-$Z)*$X$JD3'?XY5BQ6)B_SQ]LB^\&1W8#%L/3-M
M%N"F SAR@6U<+LOPLTB/LY&;-.EIX%"HOC;$&Q>!)SN2VYXJ/TR;@PITK%4Q
M?8I@B&397&F.^J9;='^\IC%3I)TC> -]]DOIA4I+WI^RE> 0G?,'@ZEZ*,](
MA'1SA.0=<:(-DD-S"]+6Z?B-5VX_EF_DY-SH@$EM@U8)BD9W%KQU) R90D2Y
MR90"@@=7PLL-/JVT(>Z_7/HZ;WPAI^ K$ZZ\E7()L!R@POX4&B4Z]W"&3B--
M"$MA &F;<'0R]C[0+0.O(EJ$EI!ZPV]ZHDIO9MU3A'_[TE[-X/O.5[#S]C!-
M!0-FP4K++^LY4AN]IK,+?@'<9 __618%K"TKN):EEM;)A)I^NB3!X4]C49YS
M.PZCJ0HV8=+4#[-'G?'-+\\Q^UQXK^N(5LY:(K'R\%JG&>MUXD2@"/QO[:.F
MEDBNH'M3T>E0O1G)LM6")%V$];JI;%\1EA]]S6Y#YAK@';AH'/6G*/P,UZ!E
M1<4=V\_5L<UN7 %W?M&);\_WBA/35>D;NU]T!]1_U@0[+P"N1R*"R]@Y)-SR
M+]1!R]]+OKPJM/OF1%O2PZ\2#;VW]K E/?T!LTZ G(N2W J C.#9*0<J$#F4
MPD1<(&>);,?R$@X ?F5+04M;]O9E56P95N9TPIFW<-F*]TQ%<Q88YQGW7\2[
M\9Q3GLGT1WDSF!:D+0H6-%^558:8>S-$1.PN-A*4P]7US]\69/5G,1PM>979
MQ,_UJKB/G>.ED2@>N7MXLE%A8GE"V$]ES";]&YY_$.J&_Z6/*"N=A;HAHGXM
M.LTG3I6?W3]4%VO// :X78Q.C98@&,"C&LQI*0E@XP]D;QNYTZQ;=R95#E_D
M6%Z4OAHNV"'U$'^A3S6$49<A)B;:K 3W2R:X7GN.40\T8KSW:6!LV58'9?/S
M:U2''.=SK?+UH\+A,0.AJ!H,[FBS>OL+8L0F^(8;@ <@<*O5!H*;$/9:@+1(
M;A7$^DA@'J@(Q0)E.^*6VP/W8S1:]6S2#,R4D766]T$P9]_2X#FO.:^\1:SF
M;)=5ZW?V (;6!0F/5F[NX%;\Y=J;31)[ Q;C 6 -%M+Q/H_&Y11$IXAJZOW!
M]/#I0Z>I8 N9#BH../W;X/;(<7G_6^(KM#PBWEJ#EWH1LQ M;Q>C>@@(@B]6
M:X6%W2D<I5L3]K.HOPG>NX)9Q@XR-]HFWAWIC6&YYII@+463G)F"PTA-L([^
M+G5B5_C<W2/1K^!"NMCGQH#%R(SB!UY@2.M,S>#I_K&@U?N8M<,@>>IXJ&"Q
M ')WOA48W"D1\= !KBV!*G)N.-/H KS_'$#PQ%744E&5]O@P' ,X$']HD]PI
M>C%[8<$2_OR!JDR#Y5:A/YD_%G6R]4*;OU-+?->F_R _=.N\ZHHF>52X0S%*
M@>WG*(1-_RE(*AHH9UC^T_2D;ZWUI&^-5"^_J_]94+Z=82;2[L55AWP-D2"O
M1NG K0*W]C_:$=V. >B"$QTO'A$;]74FUCB62=]O%(CR4!!I)4=YUF^--W-;
M(Q^X\I$AI70IA/)^#9)&\2?G(YZSIS3H0E\>:A]%2[T]!@Q"6GF<,[)77;&D
MZS*AN.4G-@/&2[3<Z[$:WH@$*3H@2.;SLV?#<XQ[A'X6KFL-^)FS&Q')^XWX
M8L O5T-#_[#E[?,?^4F<%.)Y\R9N@>8[)3S0@@3F+]C=#*+-O3\&O"@L,FLZ
M/V_<BH&M%@N.KK.C7"A@]WL_GBT=%,C.RE?.SHVU'LG$0WA1YX<XU:8/::=L
M'=F68E?\J.C[(EP\.&$*0Q-/N=F2KW=SZK^P(.9P32<Y'(L[<""^'-3I.=H<
M;:=Y[4$)O!ZQKP( *#M+S);KKMT@>I:9_8X*OV_.V.RE+>! Z78]U;V,U 3Y
M9Q?.;L1JJ/!61:F]E%\;2QQ8O98[7"'Y@M,;,D>?I9O L^7-R31J!@D1^_K)
M^<Z'.6$O+KJ@<OOPM=4@ZUZ;>Z&6 M6E99^\M"1SM]$#6:_#9I,<&CTNZ;A=
MD^5(4G?=-866A[+=DW'=U6,A#O\3X1V:TV3 <O J[HIK6!]=0#($M!_EAY%Z
M"M!%^=.A]<_<-X_I*K7T=L[TN]O[ >U^P?1F>?6$"A,>XO^&8UC*9@Y6P5QJ
MJEZXI^'+XQ5)R@NR%">5CI3E7HQPH7 UP05?XRT+/;H4U?$J=RP> ,^;3Y8Q
M'=KF(>NZ^H?<\',F/0;\D>-C^F$=YE=]5B5?W5J!TA*6YIQ[5--J$T_UZ@0^
M?72Z/LT6^H#DB6L$.'5BO;?HP7]V"H9BSV;[0]\&"+B&N 8@ALP9_2JQ9#:B
M:;Q-!?%DP2"NIS3#,F.YG.^8=>6KI:G;#R3[-R^;MWL'+Z,X%7 *'3!320?7
M.\%WE'3O0KBVN+L.@@ED'"&U9FI]%!F,QC>50=BT.66YKFF;VJN%5 ESZ36X
M+W77)=(V+K<^XTRSD$QQDMM+=@;$M[B+^0F7?VH5IA"0X+J>+!(@.WIPA- T
M\%P8F WZ0@5I0D/9(P)D,KW7C97B)GZ]4G%Z2)WIW&,E-Q]!P^A"#V39+>CY
M.S>6:F(G-(+="7WT,X!N,H'% B!E(]ZA7;*N7KX9!O>IMB&UIPOFC07,"7[+
MQ+S7,+AFQB7$]GJ'*XCR %\L+^UY>?7/%G&7Y[B'Z>%34OY%'22_!()*JB(^
MB3MB +,Y]R.(#H9$JET/U&VZES_25E,1[0B6)2_IO.4>'(S5*)<?Q.Z4VB L
M6V0V9J&[G:N#S%\>_SB?HLMA <CK!'628!\%J![@V1E0 \]2Z- ZC#26@5TB
MEK]<4OTL'QI0+VT)"LZMZGU[$<R_0O_)V9=>FEY4VG.Y_-L(S3#(X-Q$<%>4
MP@+]WCDDZ[:OX /6"%7G6G8;CM T,% A)GDK\<-5HT+;PT?VCBUWXF@R@^[4
M/W!&7G\R^&IQ?'U=[,@M[A@@?_N*\Y,=2MZ+U#S:\>:4,LV6;NFG*7L%T,%$
M'[=&]"5\1%_(H'3*XZE87I#A_U2'H'%Z\V3"X5&7Y88LF-RP3U2_;++.FIK^
M_K:T!$G;8B>0>;I*)OMIF^ZD[!4%<XYW K*'I2G^=IA'&<9[+T8>=<*^K3AC
ML+#Y  @^-?\G<^<@X?PO$X*ID=/NSF&M2.^JM^^/NK&!SI3\+[FOUCZ82^!S
M%_LXE#6$Q=$4L% ] 2H*8=DYT$=?S .HL"!PM^I^;8\^;@J:1N9'A@Q6C#;>
M00K>;$K$[=1<?@(8OA302<)IIAD\#FKQ+%*+B<%)C :MR.<NZ =(2R3.KM3X
MV]/=2?"974$+'0-\'8Y$C&6J"]O0ZLEJLPRY8!(I9Y%-CB,7SSE $>2O:W3^
M?Z>%V]HAQR1,Q\4_K79"X+V@.?HBYV3Q08M^&@M&?:XGJ',R3Q"=]$YJ\W\C
MOJ!'C]YS5+_H]%9G]?NKS)3JB&W2@<0/(JEKL+#4$RRP;Z$E+YO^>KFRN:]@
M?J^/(D5F"\3,E03E\*A%=@58Y#7P8I+?[9EPRP/ %S\+N5; CO:BB=FSFBLW
MH@3O79*G9MY7Y>7)6\GH"357_D.;+2=OD<$VX'9S+CS O02TU0KDC#+[G-$K
MNB<JK'N11L<RXAQB,8C"GR[EE?*4R<U?&L!G<'=A#&G^AA *+BTR*CI3Q]H/
M+>55C72?I0U"B@$AG8A!\+JZ8/ALL:8B4XB<KT\"GW7TY$40A#>O8<)R6U0)
M^^7.8.>E5QO+*-I""9ID%=)4M-.41M;N=6)R^B2E0X_]R!6;4\M)6S9>[P[[
M!?"[/XR?C_3US1N5,UZQRT[+_Y)#NWGK =(F;[Z+#F;J#,F54LA5S?G<>[?Z
M'6*4BV9#A8R=9'Y;RKKF$]_5@9^2<EYL/%O+*\Z )0FZ /<TKB=;5#[^=A'G
M+I@C-LGWE6 ^$^N# ;Z8HNO09O>#%\-, 15I[7%]:RPT6[-@R4'FDT[[/_GD
M!I1*)]O*(KQ2'7A)7O]4;4$L0,^)!$?\L6+FHK4;?O XW&7STC"]12GU\TV.
M##X2B3H(@NEIM9PFX]:=_;/^-<#Y]\_W2S_O6UC\GX:I/&C:Y$:RJ<F[X2Z%
M),"AB,CR*YI_B@D+='P?&>%/D&?6L8PC^%_Z$8UMXXJX8 $@Y4D&D.9UF/_8
M6Q@8#?C2"OE\PY\==4;FV2^$,1UF"N3F?FWZ&:X]X# #A.W;/"&9Z/JX1MO1
MOBJI+8V*_BZ" B"V(#+I^9\QP_I[ P.KI'XMXI,M8_#^NM7%@W7E4\H'+3_V
M*&:&/5X51[:J.K[KI 3]D4O/%WYUHDF@HQO@#IE(TR6&^=/(S<781A?<G[0P
M"W^)NWJBN0H+QIF-#,02-FB;<@&?Q%OHNIP]YP<PXYR+KK)^[:F%CAG7(XW0
MLN+SO=S$F=0 DUIY-2F^_6B&BQHUB9I@=V<A2T$+-8(ZJ,@[!_Z33Z^V\@4O
M[,?<LI)NW.FD3YM-FZG9^4_>B75DQH'B241AF+/<G'+:-O"04II6D@NS]%!9
M>V"R9^<DID$T<;S%R?K:'NBFBK+$3B(AG=+T\A)TH=S2BVQ_0]"HTFF/E5@R
M3(N0OT=&&Q<$[(@4;UR>U_,Y/\5W>\A0/,4>1-4R<(*+YU2;W1ZG;4M?WJ1.
M^E52%K>+2$Y%]E7Q/LL:./<5)$O*O/\"R$4Z#"LR)49))F+-#^SNPY_OW@*U
M#+!;TDT@!^)=_!C77E=)%5U[3LFG]Y,'%9M#C+(6!4!R!@>A85R]>PF*9.=N
MR5B#0#_U>!#CS)U[V!:H=4<19O] ,FJ2F#'[ER]X^R)=JF"ALP-M3Z<M5SRD
M+#<'8V%='!G2MIF"254^<N760QZ!<9O,^YZKC==QCC*51;YBQJ%:N-C)L.56
MQ[&)"7QRK6#([]&__7GMGJO=QE0DVJ@"_HF);3(_WS \ES;1GH9RT4:-=0*$
M'@JJMUX-L1!2Y\71B*C[=.*S<2;J*I_S[5@+#9W'1<B!V<CD),#T]BQI>/NZ
M_POH1^Y1$(?K%A!%OPK? BWX.BMZ]9<7CC2_UWL:RQ"KVM8 5N5=FSZ@MJ4J
M[>*<HLW_U%@3$?7VYE><GXJCY/I6A_U\U;1$@L\;&F5'!?=9()!]>]Y8[#<9
M3P-D3NB-V_"96Q MRJ<\ 9Z-.#(7ST[Q>8W6&QVP?U):17,;#!CI6L;*B@F0
M\W@T\D*6!U/FN]Q/*\TI#%V8U3MQR?]J*5_@A!^K2%<[]> !Z7\%KOG?=?#'
M;N7T7IF799[[7W62PB,;XY<JFCR9&\[,7O#%P)A>#"'SH0/]%^=%&GC$+2M0
M$T!8)+@K^1UGRL!+DE)%IF$>AJ!OL@#+N : FW@J4-/X:MXZ.#Y\-#^>[!"7
M[-M !J\WGHU,XK^=PMGA>ALAD3WHIEUV"RK4XJ*_A<OY.9#T%NWQ^J&#\@,3
MF3O)]Y?E.BE@O  _WJA9 U:;5\O;5&3<+J5/?P#(#BS/MRWONWT1I)G[YP/X
M6*.*/@98M%P=K;]QD>W3-MDL1.8U28&BJQ_;>NA.7PCG3>MSGSQ6YF1;[D09
MSO]K]+W_)QW_$M7P_7BQ(&E%F7"2!7BWUO>K+3*'?0^'DOH[+Q0N$=.F,^#S
M2Y=J!778!Q3-/KYQ'D&&MY<]Q=12&0P1;[XN4%9'[(%71F1&EKKB[:65JW&Z
M0G,%;Q*. 2U0SO5\MWX0OR#*]>7+#\3 I(VZM5]*B)9@Q&9\#& \V.Q[*I7L
MG6(XF(X^_QK<^T'4-:1Z[6ZW99H>*0OA C00OTV, _*. 919N%WH^O0Q@'5+
M33 +OI#5';?4/>N_%D[\%E=B9 U;+QBHHXC9CXE7DK2*])6D;TU<SDW7/RC^
M2&\=47NS*7H>BPPR2GD7J8++O@6]OSW+G*?(_%6\W7%Y+/.$-5F%'& =7FOK
M5#HC;:NAQE<IUS:42%F3%AX;+AA?79UD:Z!/G%H*K*L?+'<*LQVP,N6.!V83
MG*^TT>%"'S$=AGKNU'SI94+4#TVP'&7Q%E^$A[>R>*U<TC&)BMMLGDQEFL:A
MCW]#+X7H809#](KCCNK?++C 97#?%@@GE83_$,6MO5PS/EG_#]65'L'WMPF2
M6TIOS2:?NQ"$UG+[=,9:A(0C4/1U@/G 0]/0>H51,'$\2H5YZJJ.]A#^ I$F
MP>PUNKP=U<.X5Z4T[-'B(,$C6?#F5N'X^>&S@N\N&\/=E2@ -*0D44^F\FW?
M7![0GWDR"=;'HYF"[.<6KIB^7!H\%)I5K(1U)_<;4^3@]Y>M8IGUUR+;A=D@
M6K($@=7%ENW5O;WWA*JV8T :ZX9P^ZT"?G[!.;<I&[XL>,7:FY=6 U<>6U("
MY,?YN*:9P4,'@T:F3J<VZL<\@Q\0<$&J+2X%+0#(]8V\V4@J4"Y6\QY#&[/]
M4/YYQZ1AA6:.6R^5973/MD4L P%/%[Q:E+G,?TV<LR=.K.<QB*,AXE*6<**.
MD!"K<.E:<ZR&JE0L3#NQK^M0]$YI',>98MTGSW$Y@.G=G=4^FYX0(+W2Q>3:
M4?$D9%Q"2(T_(R^9HTHKCHL""-X?0^QS9KDA.5\^ZE\+%KPJL^@-T*!7.."@
M:A$,Z9-B<+/I[)H@^6;CH1UA/ADU 2V"3=ZD C_8WYB6I^\J 8=6Y!T"Q;D%
M]GQX\L2SXZN*-P22U-IU_5_,E_WF%G/T$CVQ7Y0UX0Z@9@%G9[]](%IY[8#N
M"&8N-7:#5?_%1E%5:7;10W7CX7["Y4RSZQ]7H3^>/%\>#?*.')))_^@_:6GL
M[P[]];-^+_]G1D2K?"Y/7 "0)Z[+XA-\S60TX+-(D,A7+JE?%UH/6'=D\IX3
M;;_N"7ZGW'KKD/;]S1<:]*L96E3L:0*RJXV\,F-1Q3E660OK=N$\+P(G+/W/
MX2PDGQYZ6^K%VDGH5"&&A>-YLY$<2903V[/ \-&U&^]N;U+AKVC2?_L>MO)V
M-:4W>!#4=#$H=;XJQM;O?D^\'6JL6+O7[E-:+C:G^+T@N7%@7%S;$F":P&GH
MMKTPK-0+_2ZK.K]/@X_K\AZ,7:Q:2FQ.AJ]EK.2>2!J-[1Z8T[%ST$Y=&1%T
M1?;'B\X\38QJ3N"],'?GH"T6IM&N)+DKOI.?LO;Q!K2:\VAC_/"A:X*NL&G%
M&\8$^!"]C^4!'3)94(]P[B7N#QVQG&, LVE!TR/^N:5:@];\APGYLW)9ARIT
M\F-7QW4UE,U6DF5)BWD.Z.P_!KE5DG2%:'?ED2'=F*>TE.!7],_)-0*#*!>$
MC.H8UT$]EB/3^S?\'D5,X$-(]P\BFP/U+39:(1CM[IT5VWN,J[;@V7 WU:>5
M/GM!L85BCG,D>"F&<=)U-)1P01&["S\&U!D= \*+Y>H^&@V-7/R%II2&"J$V
M)**0ZUX3=Y;@CT*TY#@F)K8*-T:>VC7F\8P<AC>W.]OFI"WZL0_4ET^>-Z=H
MHZ%PICPXB.#8ZQ3Y8J>7XB/6YX/A&$IF=S1.7NPC69!KVS'[VF7_$J0\-/!:
M]SMM+BZ9ZBV!?Z SBAZ5>N$:LXNPL)?X-$<  ?*7'Y4Q=35KY\7S2G9YJ!X@
M^4@H2L-UV7CEO:53E@J%RQ*%;"?) F))7'1^8NUI/#E_T?8^>W_!O>2VY)+)
MQ>&;:08S )'I "8TA;-$'&H;E\:I[;*R[,#T]1)UOK#J,0 :O7KW\:?'3(^T
M1+&\ 4S(%+FQP7C/]V82?=5K\GR?@[R1R</2ZTOB+?;!]"$'_7H.W$>/G;2*
M/X8O=$;I[D65+7]Z( M%WI_8GDL-GI/C05J4'@-.S?[9IT<2ZG(UN:]+S5$T
M=$ 7&.GZ@>[BH4S5PQ]WS@=NA.QCEEO/8OW\WA6K3ZX]=0 9$FR$\PR1!8D'
M9LT!T]<_.VQ;3KL1YJ<!$ANPU)EJOM/\>:;\4K2.:A"!IEQSN>TY>^_&Y$N$
M;V^^NOCD40*CS\0%L*6T;D!F423Z4QM#$$SO>(7+O(7),G>??>R_ R;AIP"3
M>D2?=ZJ&^.5-[RNU@=BJDD^7-6Y579M/AB8OZ$]:1=$MY)"4AG!Q3A7YG_.<
MD8:\A;--LW/XR7HM(&/IA(&]7!%Z[Y5/%Z0E*%DGGLD:1,FFQBUVZ>5)5;V,
MC2]\HQ!O<36^*CEP$LK<47@?'LWW\%4D$T,<1G8!=C\%-Z^SG<)N/+\IQ<;]
M6:A%X7QP>S);96/N(4GV/7O)VS%5P0P@*P$1C&<;LUASDMB*23"AD?/]#<C!
M; H,^?-!:HE/@G&1[8)]!]2JPU>QR\?[RMA7FO9 XPEF&DK>'/<%S^5!\:GJ
M\+6Y::'H=A6N:8:38F_QXUXGQ2U52 M8KD&\45K)-XJB]-M:=R:>K^"J+FM!
M?.^U0:K"/8*103)+_)T,YOW&3KW@[I)!R ZZVJ /6CKIM=?.WR+'S?N<'8FB
M7D_TLKX@ZI5UQ>V#A5WE,'?MVFZ$HZA!PIE<IND2:BR YAC@';'5MJ)L&C^J
M=W$-?V^HV-TU05*/*Y*"BKND#9_#AMQ&]V!*"!VZB/"/9N^RZ&S.UJ4I,NGQ
MG^[F(=%5I?2QB13HUZYB@6KJ-G88)X2%2>N7:2K*V9!FF4*2.!%?A8-4V[BB
M;[F:;'MU-/QB+SQW#"AP#?*"\N/W]3)TM!<\X#TUA@M!>8L,5)>B.=Y3'<JV
M'BD:YZY<.E^@A+S%A2_F9GZ"#RZ+@]33M-_]#)WTF49.JC(/'[WS%0SJ_BG4
M 0)[!.Z=#SY@W1)(='&7<*6V'^%UZ&9MR"BW\LP>OW6!W4% 0W(SP@]S*&B=
M:__!JTL%TW(1NHOK.!+('+T_F_:X[^6FTL5@1TKWEWMJL^MD](NX21,K9\+%
MUYD+0"4:^EZR8\ MP<K<["TQK%*_[P,],3Q$52?N X_W80/#84%FH1-SXXRL
M$13Q^L@_]* WX1ON[ W#$D%/89\,;%15P^S19-110I7 M \;/Z.P.W_<-AE\
M/W$Q-^0+G-ON&U_VF[-]O>J?([?=;41L01]?908NV)9?::1ICHP'NQ5%\CN>
M8&CE_D#QG@;H(']OIE'8B]F63_BV6<677MM[[J_HY.Y#$8;PD5O?G6$3S3$'
MK)WK?;+-46,RP*X@V 9SO8W3CJ5^:5(X!=*&%)0O<S7LJP.7:25P38OJB-RS
M;,'OZ%[U84?B+@R2'BXX\F_,*'-/_=E@.20,3>D3@.^RX&#Z110B,%(P.;TT
M3XV9.1,="H)49W0Y^%UI&=[DMII_E2DVB![S*Y??G;H?>V,H@Q*[]](1"PX!
M0HVC[/"/T9X_AYZN?MU/E%)4JKAF.JZ*_&%9:!#EXKL9."<^!RF0N(&Y$=FB
M$C9M7N"2T\O-G0,_HBI<$,SJ?1DE:.@NHF4[GC=>W%PVHOJB8C: A1D+-@*!
MCP'/CGR%,M?[2C7>T&586I6PHNC?,K=)30<@\7,4ZJZW=<\U/'B^#.X >]5E
MK[XXA!UA2J>'?ZX0K@]_CWHTKQPB!3L*K9\>GW$@7*\<38$OZNOHINCF+!TE
MU?X8?R'38SSV_=[!CYRC/!%CA]%Z=AO(Y\!!TAZB:=BRY'Y1?!+F4.%:,'#H
M=I1WUFC?R .?M-_"PO%>.<OEM::F4@0?-D&@-:]3V\-&/6UOP43T[HWTNYH;
MTY.A]VDV&Y:$]B8L/AE-&3J0W1W=;+UV!I_\*B)Y_+-,70TY<_Q]<JJO[[!:
M>%.$+J8"[?G)P8S/N61VI;B$QW(;FCK!;EV2$=VBP,\5'*U,QM U\U[1B=HY
MAT._@%M<M>U[4OR;YG?<)A];P*'K%*/)DA$<?F\Y^AUWIPPC+T4D2V!(@4?=
MJ*AF/[!]4#KFATFHXV']N_1FG7*T67]YGIOU.'^G2 !$,PY%<J0!(^69REG[
M47WT\M)[Q\,T8\?1OF#4Q(&N.G-U!I#NGNU0A_KX^[RB*76/7W9R=[Z_E:W\
M7IW&*]ZP79C(ET.IQ*!IQ/4:E32DJ<AL09TP0NK\E67A&P"GH2$@T+LV=L8[
MK&_GR3JA]1I44UO<Y4M=ZX793#URO J9!UOH>GK<0?$&\X_!*_A6__Y6X&X@
MY."<R#Y^O9B75/"AJ77IT/3C]/ =FJ#_!R3X!1<$$PZHBW6OLV=KB&A#G[^!
M32GB6:1#?ZK?XE^^?Q'^(_D&TR[:6Q4L]I+50:??OO:"9.%%D&"OM*3[:F^M
M"1U;6HXFCD=&/_JLRPF(/:4E6@E?OW^8_X7)]<.THG^2[V),_1I^S/C6@U&C
M:T:V#;PHT@:I ^0OUN7<_%?*#)F#6A@,=U+][$86\5PYF=RB8B;/;3VX+PK8
M=]ZVO"EE3D-8AW$TG]^GW@(KW?PNT[CYY(FY*XH=#EY\N?:J6M49#6P/F-X!
M:0%G_'',17=>6[8_7UKQV-)4-"=1A._E;XTTJ,6"WLD*."N++VY1E-30K!@,
M0JO/QDHZ\D9U<2Z.%&G7&(<ZT+6$\^4RL"]B5)C!^<QMHA;A/B/ZR28G[3R7
M@_YGZ(S\AU5Y_V4R-7:Q/S$:W];NA%2]+N()8 HC+=OES5829V>/RM%,[/V3
M\E67P.:P8<8R/N/:ZW[G%68U8I8SJE9/SDUB@2\]TX9[_:S2>>6=QEU\@]2V
M%J*W[_QRBVNRX/G)F;1IC4>SC'ESP(?[@=('-IN'U2GG6AE'+%1(VQ$X]G@N
M^N8UP<X:AF, 9\P?)7F*?".J%631_X!VOON<3=:>MC+K$VJA4&=0&\N39%EQ
MP@IB'W5&_4FWXLFVZ4%@><5&7X"5>0X*7,F#3TF5_H#X@8&1/0[6>N\=  ^S
M#&[E.>J..((A6N@-!_\<HW+3S7V'8\"38\ .$AVTX'&;F'5_@[+,C8\X@S.$
ME3=OLJ/<3)]M2-)E4D]*@7-]P^?I(=%+$-*]2K#_2",4]KG6M$:C&_1=5VKU
MVIF)B>ED\64<,O.JMTXL9:,U%T!8=0(@@1I\!;N=6/@E2ECMD&87'D ! SP%
M25%O)WD3I&>(UJ+E/W>U)N=W]G3]GMOEO9?US[/3J;"TK6"+S7ISY/2(E]WR
MXG^60I3,,V #F9*B,AABA:(EV+TC%;W53[<<E6N>ETSY>YB#SFED1,'([J%W
MQS' .)-HL>HW,J3PC9SK^Q=/1"AD[;9_[U)Y'!VMQ[_.29 >)%05$X+Z^P=/
M/>J[WO+MA,%Y;7R[K7[K2K%BK!S+M68 A:H4 *B=N%G\YTOH65/BL+WJ%U^G
M'%"EK?!XW=Y4S?^FO\E3W(!SAP LUX!R<0W%1G]S,4QAJ<< ;#-T>P!Z1*GW
M43N:*[N-)9K9G)*;C$,.F/M%(CSF]=.D"]?YF,/@")ZXMAW0%ABX%ZN^P)=*
MIST%/?0N/G(S.R+/CSHU 6I/#4AY\LU_X#*)4UXR,7QER(3[[G!3GG9DY:-@
MK6XMD2\9UKU69(%UO'->((7>X 5)UFU:SB_.=K*/@C -?%@@;\091/7:3BO9
M5/HZ,'AJ@/Y];"R<+:!56B)2)+!!G&,?0#WE]C? ]!/E]GQ-4VBV9[CO[:CK
MG=V'O*\78V\A;?K,MV=J.9LX+K/V6>(9KY)&CFUQ#^%S-'N[7O<'S70P::H\
M>F"JCT7>44M[?<Y9R0L,Q2&B/46E$1Q\ZU]EEYT< AY$=RIIR$T#//%I/.P[
M<U2,I!7Y<0M=H[%1EP7ITI*(N86ZEUMM_(_J7I] UZ]B[1*65I$BO9'E:0YK
M!PN/$H9"I4$?_>KY'AWT?D"+M0SN'#Q[*5IM%7:)H%4K5+9! >/QF* >V[-W
MJQ*_A/WN/(S;#1&*<J@O<C7E7FOK)O-&"47?D64!H$4ZO1;G!+W_O,)B']S$
M?.Q]=^[I-3;)G$.@5GXU$?9QQX!BYL^>4%76^,\%<#O:)7KG3',X&7NLL+2(
MB4VS_]ZNV<%"_<%97<X_A1&[/@$Q<T0'K-()F^*(Y0TSH7$,"_#MCQ3J13$*
M=5*HN_PX549RQ?OO;?XAI)I6Y'SJA8?7G^U*ZZ;6E$1N/8E7X..:B-B0\$_&
M<ZW9(:>D-/$)@2,_1@%IEU 1J.!6P#I67D5\N>L\/\WR0N9!V9WIC-;PIER;
M![[(\Z8F3E8>Z*UQ+N.-CHW(=R!XQ!:^Z+&1CTS56ZM/EW!*3U**VUG\RI8$
M7ZV7']6E7>YP'+:@]']=?-]!*C"N#;QWID*&];MCI IBU_B.Z]'D'ZIUQH-A
MA\)/Y3AF:2QIHRD @A&;R<@#ZA][5L> Z_7+*02<^A)88Z;&Z<2L7M0O%J8<
M,!1;%K,-UN.GG X6>0G/'H>)])=Q[NV&$C#*QX#4<-'5O=WW!(SJ"37:[7_R
M?$RR:O8PV[P6":J:)%HD (GRIE/WOI*5/L(7?HM9QYR$X"_RHZ;^-V>11T6.
MJ&=\\KKE#6<+IY.C'-GF>!#D(,5PJ> ONI?W$*7<DT5M!I8O(X0I9#!:)YCD
M5QX5[I_G6:]V@M50;DTTK)OCIYR),M%->)8]&7F2&BW6?$3/S8=T]E6&FZ9E
M[*%I56ANZ4'(62:FUP,TQ/PXA@$H'5.N-1_#QDT7K?MP9Q P1[/%&0+D'N<B
M,=9(FWA9(.,>"J"#2U:AX$ :?Y(CV[DF>#]?,6>OE*),HG+"[&/"^7:W-A9I
MD85;R$W3J,DH!EH[8<2+\R181R3#$J(W=WY.S:[1U;K2Z47]!I8PXK\4/S9(
MNRY&T#\&C,*.8I]7"N^>[F[\2Z_CV&.^]'!9YND?-WHIDESF,BB'K.:[JR;H
M M@#I,F1'2XIY[;&R^1OD,R</Q '["RBD(C$Q_=[UB*SW=@LW<7=VBM,"WIY
MMGG,XQ;L357)S$O/ 4 \:P"PACW.#VQGS6_8EY(@%RW^Z^O\D)5KBC&=??KZ
M0-Z.H,O+5SU)M4K.RM^<D>O83ZZ)K'TWO%8*/-U4?VC&6OJ_AL]@%5G ZX$$
MT476.RE'*=1R+9I*SJH@J9+9ONG!I+V+]WXY-+AW#H6LA(* /T%@\=EQEB_(
MY^)GJ(,Z6R0O?;Q"G1D7(-2V2/"F(6DH'#^_%_:X)#BB=9]2$M&7\B@Y"0;3
MDMJ9-:WJ?XN>O=+(QMW*,AU3CEQ?C(O,CI5S[4<[]O0YQL3+0;Z>RY!Y)]JQ
M5VQ85O5\PI:IQ.1KQ<Q^B/MAPSEA3ZG@X%'1KW(3]S"46H%R*YV5G+MMO%L%
M+H<RL2/B5V/ZO![KDY.7EC$J:8P]W<VQI-![[EC7X78>+NY;B]@E&!- '<B?
MGC^"B0$',4\>)-ZNK4NF;7<#.1#$)> _=D8PIR110O_^^3+IX+S^WP XHDOQ
MOQ?E&2B0GWX#W1CCFE_)IF.?9#YJLP9L/F\9B]CBE?:.E-!3/UG1:J#;[= C
M,CW:/T_8ES"Q<V7/._ULB'T%H-#F;,JJ&\YLDJ5%V2=2$<G\%^I]9SECY69U
M)G-3M&MT(0#//OF"\XVT)SL\^<>'0R?BSW Y!C1 MT33'.^<=GEZ)PH9IT0V
M3 ON/@N[>0U>RW;E03LEA%LJ,F6VLE6*-;DRBLGS9ZI[Q:<&/A4;;EZN#8 4
MHBN6SOLIV:;NCAYR57V#''=MG&\^)@&"TY#H-L<LB/QE?9E]5;R\377!WOWK
M.87#+"3<=IHF666U@6G1*710F^93L_A<1]SVO@+]0+YG5!/O7885YQ;988#Y
MF4J<^&QQ:G8LQ=-Z6L<*91[(+S2;.&&M16BY8AO=7ND48O;OW17;8SW>09 _
M+=+[S_Y?NU,@Y=I3=_$ J%V0GUB^.I06ZR@<UNPXCW*6=)-Z6-5TNE$BBV;3
M0:*MW"#A6FR/&,^&KP&&&P*2]BHV_UV#=#!B:*AV,PP.<N^DD)T3]H* R>W]
M/S-X'0.DC@'K6\> J?S$*QP%.MN^U]T@B4 L=Y"2L_>M^=[M^:[!][^_,?=W
M%CBM#RO60]_OO!?^&L0J!@()>$KE;>$43A3!3X159_\05NT]V=I]F,.E'+WW
MYH'8+J.*"I?0P\;6D1Q2]N1:3SQ/\O8<X6(W11QU&NDW\[/)^UN=L._S6/"O
MQ VU70$>2OZ/2CSD^F<H&X'1<@M"&L0P/VHO5)70_BX5)'!+)R8B2&0/GZWL
MC'R*'CPE>4/_]]W6=LF?C9),F#2U_F4YT@+^+E^!\A.Y)UFZ_S=KD]GW>E+N
MO\D"Z/U+'_R(KGEH[_"J)Z_3;Q77>S2&7R_0-2P3JU](TH]!4;"5K$A$ULZ=
M^7Z2A#%K2-M143Y,$%9M(.F+A<E%].?]I49MH&<J4/ZI95YG%NHQ.T],<O;Z
M%XWV5C9_5M4))16R@>:[NLBV_J-)3-=A-6RYL.[P9;2SK.1;3F<,=Y9$;_.%
M7<]A 48LX ))*0INVWB Z #\6>=[B';C*](8!C/%H$3((=N-HAJ#7W0KQ$<%
M(N"K/DG^/UK\J0']Z>_9@V1!*EP10>)D'*&W%P S-0Z3^Z)62B_),WA_0D"T
MD<]0B,ACP!$\9:*>1CWGF_4[]X!G]&_98Y6M>,X!5L?):"(ES[XO*V?+M'J@
M(=S,A\M65W;(4WSJWC+73#.I+X1%D^3XDEL0ES@&IYJW%\XY6_HI2>1O>"T'
M5XRO=3S=[/PT41V=+Y' 1:^170D->[/^?5_&J #_K7. -F(9JR _!GH_<0R@
M>V4A;TQ8D;I FM?I+!U*G.&AQI'#/A<=V'C"L@S ^N>:9VT[Z:8\CWP7W^]Y
M^(-SDF8DLGUJ',TQ+4O;HL/^3D;' -SC8\#JU#'@E9AWD(!GJ9)$&<7M7PL*
M?)TDW-R<8;Q@\18-P;@N*68$^SQ//H-FL&7\DV6N"7+>XOD#CO%?R'&"-S%<
M\K]X:+MFUS5V[L5E$8Y $]7M.5K!#]>[_V#;,O"0X2VO8$O4X8;L:VSNWX#A
M95E?/Y14MSY;0SFM=$T8\*@ZVV_5-$D)4G":D,+*Q#-_8)0M2QMU-)Z2\PN#
M)7ZL_"^X\J<7_CK-%E-^CZ[LG:TY3\N&#Z+^8-8/(7Z#^HG$)%*:<4R%[Z\Y
M@$&D'!=-YCDE.?8@>H5$!;"B]8^]R)&OJZT8(!DI)G#W;*S$P[G3&--4*KY\
M%_L'2FIE)4%TE#=2@R0BK-$G%?R_(C!T\ .IT<\-X#PH %B59XNEPSCU3+B
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M[.V4.A)##1W_<*0PFR)MB_V0%"$.X=.<?W/_X!7/BA+GG@C1WGL'6"T.Z1Z
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M5?+Y5GC\S;N8/_IV8.3-L) ZLR1"OOQ0&=T,1K"\VUO7I@GNWSC>#;#((/E
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MQA7'W+Y588'9%^Z*!_HM_B2J5P+^:M YN"/+$66[35(W8?2C2;1H0FJ]:78
M!YFF<84NGG%Y<_3Z;M2+/H@T4WU%#1KYJT!2.K\H'M9P%'X0VR-U9]#_XV!K
MQ/18P :1 6)1M/^SIYMTOK$9WH/<,N+5>:++S9206N9AZ4 H1S2 ^.4B]?F]
MWW!:;KB3.*ZNZ+%0OI7/>YZW_P9.O1"BW:!EU,"68YYJ>3';9*S@K%^<%VWB
M4L\FX.1=%0\#=R_BF*M-SI:;?*IAPY:2AKD10N_$>) Z=/S>4UA+(197LY
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MWE_&WAMB'+=<]N(V8;0SKB57%<F6GK\"2CLC\"8?3#/ PW9@= ZZ)>7<?ON
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MJ7537<'( "4_"Z._+W3TPY?7U-<(HHB@-^O@[!>)[/NB.YZN;6MS79.+$7*
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MX_"LZ_O\_1OQ\%]R3'ZHBCCS,!&H-BZI-I^[H,)&_/%;TANV(B(ZRV[:,YB
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MQIS5K6(6,UT--;M$WO:\,[=5*GWE3V6ZJMH;/,_;7'N? O+&0+GS[&OQZ:Y
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MB8G#)'U[L_#^^J[IC107 IKYV376 ]60FF9V7S=F7FQ6_K?;-#YRTCE)V^\
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MXV_-:1[S\)DDZCWG2U-#%<^]FN<U U;O8N?69LU&UY;1AODBBSH0(;W.%?L
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M9QLT5#\37C]3JVO1Z0B^ C6^\X'39O6M\8(+%CPVD^]!R48VD ?3<7GC*,?
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MBT28#RY5D@(7X9&<]I"A<(YL+O[&785'"GQ29*EDX'MB5&Y^9X!^\4W=P,E
MH-85>UX][=F[XAS+O85L83*]PB*8GW'/*V\;P?4H;.IXL/GD"CHNZ._PQ2S-
ML?;L*=Q]FY3":NCTW90F"G[6V3NKS<H>[V68H%!E#A?KIM:L:<XO8>$^ :MO
M=IKL_4:(MFR#RADWO_=%@E]'O0_*4ZVPSL;]I;7;GZZ?\S]!(C8C)A1/VQOY
M3)[@0&]F)#'#@U^]\A6*N2OERV4:O4GWP17/U-WU);&V><?:*Q^]7*TN)=A5
M3.[/=.TU0S-$5G^H9<RLS)>LF0J+C=W><\YV^69DRH7VU&V.3:CN;#M5$-QZ
MZTL)M/<+:O *$],;L$YU\1&\&UQY^"MM>Y>)OWGNZ'.#_GTH/$^&/L.\&T+;
MIL'XY2,P6^5JAVX:JR L[KG<U67<[XAR(N2N\'QZU+N49/E2>V^O= 5967F3
M)[&D'"F?/SPFGF5=/%[F=WN.#(&\;G/O'QE4Q5)Y7LG+[9J7S32! []:"B8K
MDLL7>QI@KKW3+V><SNG(P$>"?7(";T@-H)H$@;U.894"$?KW4XL%5M4"QTM!
M*KUXODN4;^!M2X$0F/VC#'%TP@(,0E,'K.GNO(7K0^775KL?P:7<PD&8T7@U
MZTMAS\=)CU".M-S:J0_DB8,3P*2!J<;X!+$SP.ZR\N(7WF7E.\. O7Q7O:F?
MJ:^[#>ZW0TRKK#L&)C!0"&VU85O8W:JJB'G<<]/7],W?@+SN5RG<G&@-+.Y'
MK(E@2^$W)5N5;(-U+5CVWL[VQ7+_>A#FS,X0EOAJ^Z#W=#2A-CEG-3VA>2?#
MRT0HZ\3K>_'>YW==WS2AV4ZF%!5,E >],\*$"T 6KK9@Z\P#7+)0%O/W*E;G
MR_:QF@J#KP20P9W!OU^2?['4+LH,GIP!Y')ERBLR!XN5P!,LT,UL?UJBY6W.
M,P#(3,86:\".JQ,G.XV\-$%W\&K@##" B%-$B.#/Q23I#2AD%ZQR2I<O;\#4
MUY]Q!JCLCA@^P;I[TM+%!].#8S#P4O@,X2;^$(=*=J$%([+V0W7[N8SN43_%
M:MNK[BH\?.7328K_BCS5C42BE@NQY[]<4  L*;V\]3"XEK#6>OL $5D38#.9
MXA/DS[B]YIIMHE.'LBRV8I%STLZPS:3[^5P>0J,LR*7PZRLEPESLW2AEZ<W5
M<DKSS)R7[])BV5)0V ':87&9\##^H/(S@/#YQ*@&V<TI?!3<&J8^;"&A(W+<
M.0J6:ZG<) LW>D3#H@B%OMJXE/RU>S9B+N+=&I1D2[R_,<J/8:I3:W!G>0%\
M(M/C[VINQX[(^/1<7TN]%6F7A$Z075S'SNSFQ\D6/I$M_, 6YK(XZ"57GD.C
M9W.9FRTP6[]/R&/P_"GJ^'YN7A*Q,_8Y5^V<F!4U==HJ-UK="._'<&#:1R+B
MH]ZBG,D2II->C3X18RB&==SZS#L>\6I4-2K!*$+U9H_I' @"E<WES70\7XS6
MCJ4+F;*$#+,[2:8&!-/-[!XIO1 +/@.H'R]J?^X+B ^_;4MOWRSGSD.$KY&'
MJ/&7^K<4V*2@@')_/CAZP047_*,@ KUU(%DJM?<!VDE,6BA\QZ$Y>6^2$>^'
M/AS=$*S@F,RE2/8A&4@NL,ZKL?@1LG2P+3E*3,CY@P ]TW5Z9X:=KD"&Y'.E
M[#/-YBV19?W#4JT89J*:BLIG)O-WX_.&'BDB32N#7$$') $4^<DE)5J0Z]*7
M<@( 8.R\6Z\@DZ3#P; K?RF),+TXFN @ 1QOATC\FC,*S]]YT7\M3+2H@S8X
MR266^S55C)H2'V9@"23M@ITGAKQ!V&<"[>;,V[-:974NT\"4>?ZT'OT7"(74
MN\)5")W)2,A$3RBSL.?+<4#L/+<XERWCISHE3/PA$1DCGKYUC\C#5J>#MN8A
M7,YV3LLU;#*N' 9!6(1ETDT7PM[8A4%B.;/O>$)$0_9)WWRLIMVE6>(PGS3$
MFG?M+BY#WY^D3FZ!CDX=<^%6#XG0!20[^;+ZZ20=)%M"<-624#8A^<>*W_PQ
M$FJ#_!HWM$IT9&:&\T:*%=Y)E&8PEV0^TN!^N2PI+?2R],WGV\$J*CT$*,T%
MJY5.8-OW&Z@"TL.TPLPQB>Y@37?9+P8)W;OWEQ]+MB6[T)3 E#44YHS$SS?/
M[&77)3#PB[19H-7M,P!&K>-6)?]<V-"G>2,K6J:<S43-1YZ08:#Z@-ZEJ&[F
MK1TFB*F"9UL#A?<,378.,KAE0*@_>[SIM GQ4-N]_68>G+92>:2U+E=6M/:9
MR#YF[$456WOJ5:XJZO/=D@QXS3YLXM5F]E)-TF0B,KWX_O&+PM^.-BD'&XF,
MQ-^N.J8):%,&?)AW4?641N[@<PD,(BL)7XLS(^D]_V@(X+5OB8&J0@^\KK'_
MCYT/F':4IL3(3[;=FY#X<CH;._VB]ZZDX2'E0&+/IU#@EZ"5@9R],P GE[K]
M0<S(&@>C\^R)&V5/D@+"U54[3#2D8OG X-W]'-ZH![<05:*5F=GFSQHN2<LN
MB#HL=VCG1!^9CWO?!C]^!EH02A3B^CI_&?N!+=KG'>/.,K;B]'/&H$"T<NZ6
M4VB8<!T6!"K>7=3Z\MI6*CB:S=G*2S$Q71=.RB-\*3(&RR@^N_Z FP;V<HDJ
M '<3K\]AWJA6<?N%+9S)X1[27#TEA''[990^2W^80L2P9IBJLC;149]3N>FD
M9\3!*G]_;BAW"]Y:3SZLF2FG3Y"*7<[Q9:P;+4W_OU2*RUE2>]#/?V^&E0EI
M]S1)V4DAL#KBJ508L8<B5V*?H%/5?<GOIC[+0?AC8-GZX[@JWC, 2Y?]#FU5
MQFLN*DIV[L4^F8/$WL,>.SOABDR-4J;K<1D+@8[;3^ NJZU'GDQG@'B'C>]W
M"6CT*'P3(5?5E]*E!?KCWIW?2]>?SO^^X((+_O'@"MG<"P=-JGUZ^*E?D''V
M#'"3Y!74*M77=J!;LRMOH4/!X8&-2F P19 4/5F:+X4D(Y6,5.Q.\&676 4U
M!SY?#6)G;\"=!']&PL6@)):7,>XRD^6[T'&9M^'H$ E$)U1X/7%Z]LBO24 <
ME)P?3!5 4.VM4SE[8B/,Y+_[H(9,ER\0*>8V$8J5"Y@"LRJC@!GQ.8U9@1M?
M]$1GLI9QS#**?"(%W)"2":F,A;+S%?0_G2'SOPL5MK>R_>=+["!#A6SRZTZ9
M141O"/^B8DJ.<@6O/P?L990DW2B2%',SA7$R *&<2U<2)Z!DJ7.+XR\5PL+X
M3(8IS,74]P*.>HTE+"Q7@'5T.<A[-XMV6"OL4"^6N$3%YA4/C_I+)05C?V*E
M5K7[LCL5-YV$,H7335"+#O?UFE&U&I@,(0.N9P*#EXY(<U2RN=DP!L979%3W
MF7Y[;%*T&JSX#S>/EV78R@QDB\PY4CZCMCPW?8_@J ++;>I=@QR=C_Z>L\I:
M#]&A2A*?*9_)+*MQAC,2[N2E2]] ID*485HQ*0WE;:<EO48S94M<<D,VI=RF
M*E<56D<DOU?CX$U-I-Z4VBJ/C'DY]95[^-Y/]F,DM.ZI],]K+I$)G^L4<$\\
M^1D@N@FL60S*\=9B/ ,DX'!?U B"%WN^J&Y>#PH3P*?-%9K==B'!J633.@50
MX$I[OO)QC(YSN:<6+@\GGF1\\]\Y S 8+GJC_7QVL+MIIS_/ !:_,P$'^!/8
M+5CA#%JCX;\4/"@73P6\S J23\!-J?_CDBZ!6J]S"5*@X@ZU;LE5?LQE1<^T
M=/O;+8E(OOQNG^$8&[Z,RAD/,?16:<Q3\X?5YWIXYJ7%/FCS -Z"N5XG?*(@
M]S6G6L_S_#Y$YR(95I=9'97C2Z12+"=9E#AW8#KRAC>BK"E^5KUN M<D@!^5
M&CR^5LC"#_!X[_6]DH%3@^XAMX!QX]1@R.SLKQNG=+G4&GG7MCCHFJ';'=H9
M+ZI\:&'=T2LIX46,F'+3_JCDTC<%/1G)N7S3:_DT,,C==S1PLS72^)383P81
M$?"?1#.Q%@1W&N'72VI/D,5DNNJ-*JA@'5EEN\6DGX@9ZW11>1N\(&-BI=Y8
MH$:*8N=R%D1'8X?APXUT413P+ZU&2:7U:LRKR]0G/1T9GAOC=W.5EMK'%-Z4
M/CJ?-3IQOV>!U<HXANN-5E].NH@] "QM:2DH JX_G4%QP047_./#6-MP+5O?
M^Z'>BJ&_'I*BS6WJX_*JWWXNUN%$6@%4/?@Y5R\@@)G2@))D\VB@1)8NA%;O
M"BL1LR1)5J.M)]L&53B_9O#G!)4[C\%CG;S+OK:+ 0"/E[6WY'CWE!&UNL&X
MN0;E</<6W 8VX);:2:]WF$^ON!!CZ"GCYNAV$*H"2G1@N,*U%Q--739&DI/-
M'/]Y?XV$T8XK-U]<,RVGE+P6$Y@M(IQO^1W%D6__]!_ 0?&O$.3[-%%*:?0N
M-HKHRBQK.B <7S=ES'U/#6H24"EA#V[+;\SRIV--[,E3L"K:90E&)DN@52)G
M/4L[DQ&?>N&#W6VTMTRTO[XD;\[.7DJ(IW]J=V6Q/U]-%2CZ*;:?UT;IMZF7
M_'MZR$.%?+^E%,T6&JTFIEO -.#)#''1I$'$0+EN!S:O1+EX1VH7X45-2JIP
M7WXX>XG24T:3HO?,>2R5IUN9"'+SCP_7:+_!!@[[<K*M]>>8ACI!.6/6"AVY
M/^W84DJT+DLZ#=+M"BJZ#9 ]%;_D1BKE_BJ*"02\B\KL,$W"/W.O9#"OD@9Q
MFE^S2 :_,<C$&-Z_[R#_*<@'0J-RG;S[^XG9I@.+)&PL <R0D'W,$;G)\V_<
MXT8UE%V]BW16TV\I#<2L*X&:OKV9,RJ]42N?W<^-Z!"T,H<FYWL]L5X)'.=6
MH0B; H1FB$#OJ3";#7)F/*0MT.;KVVAA%CRM\DQ#%OH.]Q'EY@D7UR]2Z[4S
MP,S/4T$G2K(;^X.."ZGB'HK@2.IP4X9XTQ0$</3 5]:%#H95K/Z5N(@2J/J8
M$6JC[BUM)TNWCM[\[=/HL-1:@$EU"K'L59R(>D9ZJ'+439(B@ ) (=<7FL\J
MTE-B<+^/M\B(6M,\_=4HJVI<J?6L'4E1?D*RK%JJ<)V];4TWR\JJ9]"XA06[
MM:RNYGG?=)JW;'3+ZY'?;MY@4MAN^>5@.Z]LL-RGSUB:KZ@J43=N_<<4C2T2
M@4&>Z-@:]2,)E&5P[!G [0M3D<BQ%W2Q4(&AQ]YVOXQUB]@>%8;BL)I+"_GM
MN_G31L4%%USP7P>N&XV>=QC$M4W;0Z@^K\@@1(AL0YL]X_FDQZ2<7Y>9&X00
M(^CNG $26_9RTSF:S%IUG![(EJQ6S#$(?33I9=LFO*DL:VQ@,[3D-7YN@A7D
M2TON>%QK"+4@G!6VX6M!!HVY!=LN\?O::IM^.*88MN'_+M^09,3R#00%7"+)
M6DSX3(3[=FGC%_1.M?O;EZMW0BLJG992T7OL0=(0Y&"Y_K*RHTKQJ[Y8$3/1
MD$3.A0@8Q*59[T_;__\>909-CDNA8[<.I]/D:V&'\-B/F+Z<P_ Q^BW9-ZT$
M6($2;X/WEJGLI9)))?#K.60[,\L(UBH-418LJE,PF3M&$1W]S+R I7/V2+5S
M1%*0-F?2M/^KYH/VN=P7"2B.; [#[RQ9Q$D>H-LX#\J#>0P,!K2-6DA_4!DJ
M^>;.XD1_>@HJJQ&B<?7K6!M#P,/9ZRW-YIE1GX*D/5.^+N0C/\,Y1=A-S!CZ
M$86?\&7VB04"9X R<,$"\/AGC?>J\FUC<3U/57ER&%O$=T&]D?T7>6LO)_%9
M.[D"N( [=729B T%"'LN?[C" D(H80+#\F;OQ%S%*K.4?2BZI[1:C%[3HSEU
MG3Y3&;@ZJ8SC?PZK^,;+JT3"7'K-_*7'Y5=A?48BK+&OBR0[P2K:Q>D:96:O
M+>E[Y0U%K.E=2%C>"8P6XMFW,=;%!4G'[T"JCR_Y^V>SY_G WR(^H+H_<;!C
M)%3'>:$IE085RCH!QIBV%"P.Y]M%&HLJ$^&#"R?]&]' >;594*< 1()7@!09
MWZ?NH'W!+]L+;LM_7",B74]O3_Z9.NTQN9_?^G %1\E'(\NX%_OBE-C:J=@5
MCBSS67A*CJ#G>^[,]Y$B(6M[C)38[!,N ^$&0W-OP(HPS1+G8)9*P!-)"(V2
M^I]^U"ZXX(+_LA!HP7"WH(&9X6)*]C[AK74L'V<.!RX;;U*HSW'?(;\A-%8W
MFII 0-<).IKY:J_3B4F3R<D,YV S927RI;A"LH%U#S;?YG;^7FQ&\E!(YF27
MA!!-=@9PV-G# V)WBA;TY]'&FQ)G@.2.#X[W>K684S.7>)>NS3?41[,9&=F)
M4;FR!/?G#40>/!HVLZ*=:B&5WAXQ$_?;;28<2. -78KL"/@!I!51J4AG"$JS
MUDM!<7W&_6EM\N_AO(*E*5&ZS"E0Y[G8W)_3:M0Z E:TT$7A$VZBJP,--5\T
M:)"Y>T9:#1_/<A(R">=BZ3R36##24:_][]A)E/(F(V[*:9+CWI9:*)MS9+$C
MP$Z5/15^3L]WX(\%PP<VSP#+N"Y%(V%!17)SN:RX0A"-"EN$-!]2]4E4^IH$
MZMVC[JK@YF \5$-JXPI82CGS5O'M3\]?N9[ZYL%=.K5/P-_S$&$+ST6/WM'
ME)7^X^P+HA^K/*5(21:2X]QL8UN$1GZ4!9%T0Z1LTBN5(@>%C.3:;V&>#\@!
M:4L>I&D]%>W3Y,IF[/4@OOUC$/Y!N[PUV>!JE\JB;/Z'K&SNP;<FG^_ .H%R
M0*LGX>?[G\^[?P"/T 477/!/P),7#=ZY $FZ.UM70-*<.*7+W/PRGUY>UE=*
M#H*RA1^$0:=V=W-+X-R&4-&W"@"#=W6WO;'T]'0M2\+B^SFUX@7LW]9M-7\^
MM\_>O/E8.%EE=H.V61L?)K/O(;;9BZ;X*D+DS1<B24]D=P5$8=&TJW!/ASO
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MJ1:I@N7C-6PU+ULVRVWWCD&2&[/5+PV8/4Z0YX.=]3%L(?)[H!:5R(#G53+
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M??;9YW\JET*QEW;.G(#2Y5OCI7/#-0P##FO(,1_^.8Z2.K-3_"BPK(AW >>
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ME/)*4/Y\=T?%*B=5I-E*K_MS 5R\GXG.=/%)'.I[+>KH&JM Y("UW%$1[$7
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MQSYZ$M!OQ+G9N,9-"_&<Q(TOG@+*-LG@")LVJ9YZ^??$%I6N)_=H0I\4G$]
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M-Y>EL]:<[C4U3+_<W,(R,IM;BU9*O^$59Z^'QLYDI)*(C__P1W<"
M
M
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MIY3</6YY.3M=]^'DMSO+*2(EA>14<_"_Z>#C<U[7QL[%QLN>4\G=U</&[18
M_+[/OVUT/X\M)^$@2XA(24B<%Q42^>5 _9<O_HW;SW/[>VE+[[=S!F'J^_-S
M?RG./0\ D#N$8Y/XY^=L,P"@-A( F"?^_!Q/#@# ">>M9N"7_6'Z65^N^_AX
M2%^XX._O+^3L8"?T\X#^^_9_#/@;ME]^GM#/C_OWP\-YV<'1QO>F#^?/XV;G
M?M/=UXO3V\/&SH'S_'^LQ/_M-_[E[W%.W\'1P<O!C? .8T(M<W9S(IQN-WMG
M'V=W-TYGM[]V$O^;;_L/V^_UFK#1%QP##%9" ,T  P!=[P.(Z4\ 4/,LPBN0
M?S]O6N3&P,^69\*Q^'N]_VV#_.=/)4KX^8^WL]-O[U/2-^2T\_7R^_VUG\T2
M( $H #C  "  =H ;X ?. Z* )" #* #*@ :@ Q@"5P%+P ZX#K@"7H _$ R$
M 5' ?2 12 4> =E  5 "E ,O@%J@"6@%NH WP"#P 9@$9H %8!78 ':!'Q (
M! :A@M!#$! .""]$$"(*04+D(,H0+8@^Y"K$&N($<8/X0H(A$9#[D&3((T@N
MI 12":F'M$)Z(.\@XY!9R#+D&^2 "$I$2<1 Q$9TAN@"$9)(D4B3R)#(@LB)
MR),HD.@.43Q1.E$>T3.B&J)6HC=$'XAFB%:)=J  ] 24"7H:>AZ*A"I!=:!F
M4$>H%S0$&@--@^9!RZ$-4"QT"#H#78-^)R8EIB?F)#Y/+$.L1FQ$;$?L21Q"
M'$O\B+B8N(:X@WB(>)9X@_B8A(J$E4201)I$G<24Q(G$GR2*)(VDD*2:I)/D
M \D"R2XI*2D3*1^I)*D:Z572&Z1!I+&DF:05I"VD[TAQI#LP& P!$X3)PG1@
M-C ?6!0L _8,]AKV'K8 VR<[0<9!)DJF0F9&YD863I9&]I3L%=E[LD6R'^0T
MY+SDTN0ZY/;DM\@3R O(&\@'R!?(?U#04O!1R%(84MR@"*-(IRBGZ*28HM@Z
M<>($UPFI$WHGG$^$GD@_\?Q$]XG9$]\IZ2@%*)4HS2E]*>,IBRA;*,<IMZBH
MJ,Y0*5"94?E0Q5.54+53?:+:IZ:G%J)6I[:G1E,_IJZA?D_]!4X.YX4KPBWA
M@? T>!5\ +Y&0TYSAD:)QH8FA.8Q33W-*,T.+3VM"*T.K2MM+.U3VA[:)3H8
MW1DZ93I[NCMT^73M=#AZ*#TWO1*]'7T$?0%])_T" RD#'X,ZPPV&^PQE#/T,
M&XQTC!<9C1D#&!\S-C/.,$&9SC"I,]UD2F!ZP33"='"2[:3B28>3]TZ6GWQ_
M<H_Y%+,"LP-S#',%\P?F P0G0AGA@DA"U"(^LA"S"+#HL?BS9+%TLJR=8C@E
M<\KN5,RI%Z<F6(E8!5CU68-8\UG[6'?8V-E4V3S8,MC:V=;8F=@5V&^P/V!_
MQ;[,0<\AQ^',\8#C-<<*)R.G(N=-SG3.#LZ-TZRGU4[[GLX]W7_Z!Q<?EQ%7
M.%<%UT=N"FXDMR/W ^XV[@T>#IXK/,$\I3P3O.2\2-[KO ]YL;Q[9_C.F)R)
M/E-[9HF/F4^=+Y"OE&^*GXI?GM^3/X]_^"SI6>19E[.99P<%B 3$!:X+/!88
M$"02E!!T%LP4?'>.Y)S4.;=S>>=&SU.>5SSO=[[T_*P0DY"64+A0K="7"SP7
MS"XD7<!>.!86%[XI7" \*4(GHB$2+M(@\DU40-1.]+'HL!B5F(H86JQ.;/.B
MX$6'BUD7Q\3IQ:^(1XNWB1])2$IX291++$OR2%I+8B1'D0Q(760LLEN*1.J2
M%%JJ2>J[M(2TC_0+Z:\RYV5<9)[*+*'X4 ZH A1.EDO61C97=D:.4\Y:+D=N
M1OZTO(U\GOR< K>"O4*APJ+B6<4;BL\4OUP2ON1UJ?K2GI*TTFVEELO0RZJ7
M8R[W*],I&RD_4OZDPJ7BI%*JLJ$JKAJDVJ)&HJ:IEJ0VJLZF;J=>HKZA(:EQ
M6Z-#DU+30/.1YIR6@):75L,5HBL:5U*N3&GS:KMIU^H .NHZ*3H?=?ET/74;
M]4CU=/4>ZWW6%]$/UL<:T!M8&3PUV#6\9)A@.&G$;^1KU&8,-S8W+C'>,[EL
MDFPR8WK!]+;IFZLL5YVOUIG!S(S-"LUVKBE?2[VV8"YN'F4^8L%G$6#18\EB
M>=.RV0IN96-594UB;6+]U/K01L<FSV;'5MT68[MAIV3WT&[57L'^@?VR@ZQ#
MLL.BHZQCLN.2DZQ3BM/R=?GK:=?7G)6<'SEOWE"[D7UCST7'I<@%?]/D9H4K
MF:NU:[T;G9N+6X<[NWN ^SL/08\HCQE/:<]4SPTO3:]";XBWA7>=#P,AF>KS
MY?>-])WUD_-[[+?O;^Q?%4 ;X!;0=TO@UKU;BX$J@4^"B(/L@MJ"3P>'!<_>
M5KR=&P()L0UI0W.C[Z 70E5#B\,HPES"WH8+AR>';T>81#3<8;L3>@<7J1I9
M&D4=Y14U&BT3G7V7^*[SW?Y[8O<R[AW'V,?TWA>^GW;_,-8NMC=.)"X]#A_O
M&-^?()&0E4B:Z)8XDB2?5)Q,FQR8C$NYDE+S@/-!S(/M5*O4GK2+:=D/*1[Z
M/IQ)UTJOR^#)2,PX?'3]T8?'EQY78%@Q]S![F?:9[[,4LLJSV;+O9Q_D..>,
MY:KFUN2=R4O+)\WWR_]<8%R ?8)\4E+(4GB_\*C(K6BF6+^XHT2RI.0IZ].$
M4J)2W]+E9^;/!LLNE]65GR_/K6"JN/\<>.[[?*72NG+DA>:+MBID5?E+WI>8
M:OKJF!I(S:V:C=KKM3-U5^O>U6O4MS7(-%0W"C46-9UN>MS,V)SPBN+5G5?X
MUX&O=UH\6M9:G5IQ;59MD^VF[<,=>AW]G9J=W5TJ7>U81>SK;MGNIA[IGOI>
M9&_M&XDW-7WB?=5OQ=]6]TOTUPQ(#M0-2@TVO$.]>_5>_GWKT.6AKF'UX3<?
MM#^\&S$:&1LU'YT9LQ];&K\YOCGA-_%C,G2*9"KF(\W'M$^LG_*FSTY7S$C,
M-,]>GNV;,YB;Q-GA5N>]YP\7[GRF^IRVR+%8LB2ZU+2LLCRX<FUE8=5C]<=:
MU#KM.N8+_Y>77Q6^]FV8;BQL>FWBO\5N(;:*MB]NM^WH[GS:==W]L1>SC]@O
M_H[\CCTP.5C\X7\(.TP_.GO4<*QY/(5WQ>/Q7P!J17MW6P? _K?\ 3\)* &4
M9&2G*$YQT9[D$>!A/<7)(\C/S\ESEI=7Y +O62$!04$I00&A"Q?%Q<4O7I#Y
M2]O/#X%0G3A!0TU#Z(%Y1/E/\XO*7!05%?U/D0H_M]___8_;SP\A^K_^D!:
MENQ$'<,(%. "(+00(EHB? ? 0=A1$LAOVY^R) @1E)B$%$9&3G&"$%!- Q!!
MH% B8B@)"3$A28+<)KP.$-.2T)T6422EU[.!<7DRB(8EY9)Q7ZIL9=1_M\$C
M9NL53D[!=)(9P<)[AH__K,!%<0E)I)2TTF5E%54U=0T#0R-C$T+V9F?OX.AT
MW?F&MX^OGW_ K<"(.Y%1T7?OQ22G/$A->YB>\2@OO^!)85%QR=,752^K:VKK
MZAO:VCLZN[#=/;WOAX8_C(R.C4_,SN'F%SXO+BVO;'[;VM[9W=O_?O!SOR
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M<:;68A#Y8$\?5359J Y[Y:6J+:9;R3 Y5>'$'967>4Z%2R^,LB"<K)78E]C
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M[,2/+['[74YR.O6 1L5S[R'&?H-:;:>54X]E(^6%]2R/]T4][1CNLV0Y:;8
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M;/8Y]I-?G0I/1G0%S)A4:'*9=IG.VMU3G_%@5+66!98$[^PKN?6F]*KV]L7
M&Z)X C>80WS'5Q^)KM*><G(TM!6K<M.F5O@>]C4"B_+MNB'8N[6P%'TEJ';%
MHR&[\X7V^3SF[N]/I+JQ\@))\4%?4'Z+<82<>?] UO<P/$I*6(TD@H@4"8O(
M*F)>(G]KB <B=5R.OJ._%N"!.8$@CBCC$2^>E6]N<:E15SU3I1#?84^DI,]?
M)5JL1W=EG6)9(X$=C'WK]A#5EONB+7QJ1:I55L3RO*O;J% EYQL9$FBA.A*:
M)3WZCG%!#CY$M!)?.<-#)4F<W4 >"QF5#_!=S[KQ?(<EMBE27_+Z]NT3*E?8
M&6MCX0^".RC=;GIA4T976UI8(:99I_>C29.U-#-X#<)+V\)%$J]E&PRRJU +
MHDT:)3S>2.-\/!LIMWM+N&5E!1>_.X@FKZD[\B1KJ_.5G"F,Y-6KP>J;-W /
MOWP=LS$E,3[8(2,L9_UU%*"=9(95(,L_G;V<(YUH%,H9D:BXI%B1*3@6@K@!
M]W>N[@\NLH=A9H!V*=E:ZT" !*5,UFE!@9GT<[S0!?_N3QC67__@O=49*/_K
M(_?H8Q:QDDWAL@M4:.PPQ\ZG"T>4QJ[. 2['<H3Y6_DF>LGV95I?:OU7WYGL
MC3@+]  Y^NL0X9@'?61LU:@J\B[T^(SR;L^&%PUC$*EY=SG2GT]@F6?.+F)V
MN*%9!=8_V!3];[.E3PL^/8M\\UPO6PL3:$*%@]]=9988L1>C:2V8)UF1TQ=)
MF1+&%8IEG?(N'TR.I<7NSZU96/:M8D@G!YX"T3NL029U)OU&VZ[.,<9ZE]_[
MW^P9%=]'R;)_1TYA*4+=;+5-PUI6O-1W=KA1KYYL:GP**(@73[5("L?PMW*&
M>G%PP][7)]R3I#J_6LIZQ]!HET3);LO6Y>'3)]'W8]R]'/0^8;TWL.VVWY1N
M\WV,?)X/A(^M> _TDG''%] $<#5+[.Z<TRM,#<^C3$8/S$NGM#S+ADZ<NL:O
M5YG<6+?M91X2G1V("SE_@]HA?E2>J_#0N\?6),NSQ1*)XQNI<OY0:CM:#U5Q
MOY\$@W!Y8>RK2&P&D'IU[/(3B&6LV<I+.&U[>6X:78A!E'&+S7(B^>I81$('
M#8JEYA!1+)LZ=2[Z:T,NZTST:6T/U7+5.EBUBP$5NX4DE[C%CNR).=6HKGSX
MQ,,C>PH=Q:T+QL08C@?V"1UV9YJR)CZ66]@JIOE1P+22/6 HWXH\P6XY]N7X
MVMEKD!PZ=^(#* **@*4=V*&&9U?$R6]1%]Q>^!P8%9E_)H%BL@O6*V=+*BDA
M9=>SNC-C30T\TZ$Y5(I0/\/;EUS2:C2KR-Q]?J!D"<X-8WQ=^O$QTB'3LP'Y
M,2K0P3 I*RMUZ_!%AKH?3Q6=.A]/RG"*WJ7DXDD'PX="=W?.7YAKDJ2J\1&A
M[H.GR^RT$/MU05;[!6MC]/BI"QBMR3CG:0)I7!8U=CFBS"(^3KAZ9Y\=ARPB
M >%^'=<Q]E"(#NTE$9-+11(?,^[_^:*T*F'8^1Y J,U6/V0YF.47IH\G\,#:
M@V!"GOLPX0>AUZKZ@.Z3WYFR^K;Q;K^2,)"5X &+43R@$/@M<"?A/L?F2O;.
M1_0VK(*O3'@:(A["_8?K?*ISV,/ HB-_JR/(JLR?\^N7(>?0V*?H45_"<,=>
M^? '=F>L^E L?",D\JC:ZWEVW6LQ/-!0U[T"YX/&JWA/-+?QWU'@"F54 ""A
MP!)0#IMES#7]G!U7WIL_RD\N?\",Q9EET_O"7KZ<B&9W>4K?[Z%H%\O^P^.V
M(E?,V_XB?J6/<;T3V$[^<V-8B@R-&O)N0[D"R3X=E$_K"K5()AR^?SQM*F<B
MTA,YVPVD=#$L9MT.DXTV#VAF+&UK&^&>Z%VL"<!IAW_[&-<NP$C<M>89U8I<
M4N^7TB7GSNEFWB)T[/M;Q[3[C^""(8OG,W\$1C)W#2V;?\XM42^N3W,4PC:R
M[O%!GR-D8=!JXR(*<M74%;H2?Y_;Y(6?;M?P+W:A.HR[O.-:6)T2S!915W$#
M^ZH+IJBR'XD2_NLKIG:G=)ZX$CH366M"9T*+7B)J6B0<TMM\1QY61U2KCQYP
M"Z0%L?1?45G(U)PKFK1-AG.SVXHN]O5+$HG%18S4L?"7CQG$2@A[N7ODQ0AT
M_",6CMW^F44F^_Y#LLC_"ZR__@9*!5V%ZQ^7$$W>V><HB72_2Y@4+8O]/1-Q
MV5^FF35R9\9Z;MV\1R?V/$.;5I/5-<1#;-44#\#PP +N>!R]MK/TH=78O/JQ
M9'C3N0"^0VX3JZTVJQ_;A-S#,F[C1VOR]87RHCD5_5P(,2312ZV;)U$DHF4U
MV4/&[.UPL*IKD;VFP%ES!^^'B\S?5:Z]+M(.U)/^5ERO3W)%59^#V>+^-:F/
M51&G+K!7?(,/;ZU;.F]LM;<;9P>',N<BK&\1ANP"^T#ZP7CAP&%VX<V4_;!P
M2 V/K:%W"H:R%CE@;E>HUK-J,=KVQB]FL(H2EIIQNX6B_G XYGU_*M_'%%^I
M3*'2DL*'].9O,N]*M?3,ST!V^-BS"BBV?@S<CS>_I4<5%N]?>:X=9<=,X7F\
MMSS@,G>!JK#I/L.S6:-:&XI8C#5]*E^HCI;O(LH.>LPH6[&W@ =>I>"!N\]*
MI-6#)A_*N4451:*<..XJ\>LG<Q*7<&ZH(V#AGET!S#P4N9O<[79ZT>N:QR](
M^'*^/RPETH;WBJK.B:087W2/KCFX7.I[2NVJ6&BGVCSC6LZV7/5[\\FRWHO:
MHN5/U)835<AP60\P^8A/,B2/XS)P\C^3PH/?DL*\B>8\TSLY^8!1&#%MHN(*
M6<7)?4(>P#&(!R9UCI@^K!L%O(X+I$AH\R9TH?&NVZHT/?79""YAZFFM^5BG
MYZOQ.GI98EVO4/>OA5YKXS%H8IH"B(& V?A;K8=B$W6-CZ/J_5+[KXY5RHJJ
M]Z \1_+*9J-C;QYD].8[O3B4J#5]EO3 NE%&LI[21#XYS CECLNXB&#ZQ*/?
MEULKQ6.=QCPALCPJ'QW8L^^-8UY/69.D9"#2$*,Y"4LNV(SW4N3#X&*!H'55
M]6C]4X[*GN&D,^2(U8CAVRI4WF^]#-TTED:DL4JQ&WB@D[?!-VKYDEOW%L-A
MQ@ "EB@RS9>E#=.6[#SFDS[\Y$C1%4%6L#MP3L4S99HME!7']WPDA+X@M+HT
M]69VFK9),I*25(4T\ M??- HYM.X[/V7HB4F2N'P[X<)EZ08FQFO-';TNJE?
MS7S8SD%UOX=J.]N/J2V6Z(1=R8 \/V>\=*+B3,SVY.1PI<HC8XJ[HNIX0#YQ
M18?H13#\NNO-7)4NC2^X=SV>!^RW5^/VJXNETF3,#V,>;P[PWK.\A84$X&*S
MS3J+C,OB3O[C<X:A7V_G?_6=9>%MO&;921\K:LZ5-$J,)/;$FF%0DQ$6T7HW
M,K[LA,VY(]IS@A/2'I1?XE_S@IP+@'*S#526'6RX,VC8-V(J>;Z_I]8.H%3@
M"&5F_Y!*<<-KN"'94S4_ #UG;X;)NEQLZRA GSR3[!G/8%?!UC ??Q1;2:ZH
M I02D7%S1@S36DF;#++PMIM/=@IBJCIB=;22<U*P;#<J&1Z<&RQY^\:[(UB9
MD._;FZN[8.ZXP0W"H4(!K#.QFZ-/ F'M<&H>/2K%%E$IZ^CR#S!G'"N=8L]B
MK!V"\QL'K3SNX+>+S7DCS6BUEQ(>G5 ['\\\C$]O,8Q-5F#U[0_D]Q1MN:UO
MG*,H1>J[6?;KL8O7H><Z*&?@*QZD*FIO/?' 1FU*""JERM\"YR<VZC;EQ%8;
MY-1L':PUS#ZWF6OWK>TI@W="AA)]+(X'XQD/;)=K9YY#F1O<5I:./V#?R]T/
M9W-%=9]"=LVH(-01K1S#]JRL]#$H34+G784'1LG1VU!+BXV1G=DFM=2[ZDJD
M;/'#CAQ)K.S-JI=<AH-_#3,=+NK1XU9[\X@OW.1=]5;J[5-F.+F!OAA9'<;]
M>X1F/?1S+&"J7L(#?Y@SXN;X#M'_]CMI9J/YAS)X(($9O5YT''M#$$TJ?Z'[
M]&859I^050GA@5U"HF3_3.<OY0?7T/^>;*4N,OI8/U$_HS5IX)2/!]H( T0A
MQ_>3>.!Y>5%;%O?M6RR.=[M"0PMJUC_ZVRU89C63=Z^Y]#6=G)4<Y:%NI^&F
MFE^$L:XQM_:P>>ZIRGK JX+32L;U3HX;DG D B%&<;[:TKPE3R3Y2@5=6#H"
M+SO.V46RP;R"^-EZ\, J!K@2X- 75SHEQG4XU*MFON<W8S_CBQQ@+,/I,,G5
MGU9&AC&O09%(W*U^:K7E[ ;D:K+#OJO;^T_Y_-W*?N[6AN5H":+J)SKCBCU?
M+B\,"+*7Y5[OR6^KV0S[EI >%O<VWO1;X%$ ,S14\.'FR8[AH8]ELY>^1#ZH
M8GO*[#E4:CW/T3@4[OUHW>'23#$/'9P;P8[CC)=M9?_0A6XKJCX^?+WW'KW)
M.'"EM6;>F6?=WG#PE<#]*--RW;-V<4LAYFDM/)(*,(.Z[>7ER16SP!LBS4T1
M BN*RUE!L>&B<.[!+?/L0X$@JZ]O\,!M/CQ :^$;EU,5QVF^'F>D$CA+Z*8"
M]8S:ECNXWPYON+IHN@HX5;MI2(BMP 4"^!#$K$[QJ2M6U"C4Q7V2-Y#/_6)9
ML_"/YO,[/[!%NO"/C&\.E8>(]S8[V:']E?/)GG65"CKF'C#%R4*7#Z5F.]?N
M!/<4G5)//\ #]SD'0^GIFV+OZ*5Q(P>LY>G$(F*3S,M>=\X[$JFI62Z8BQS&
M%*-^Q. .G8IEUZ?Z%K_(<++.$/.JB.H4ZM3S-=L:#;4K/;3H236Y#<]Y^=;X
MO!YJB5G4/C8V7M66FNPPR'I;/.'7Z\XI^YK%R#1-\\-80L=(HF8IA3U=C\/
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M@99H3<&(.%D;@):<P6R:]_907'SV1;'D!GF1RAX=J\!9OL* -5&%'A3<H#,
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M^Q>$Z6&(5%2H;RLBE_M%%=X&?$XM>?508*HS;BF@NWO>.F('QO[J#LMN!75
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M%T\N;M^MO=;OWL+&_RFY/IVF\%)9+8D#*7*G=E'R$WEYTE'4>U1YYE[_=XF
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MMJG5UM'FY2!.SY#/$33O)I@>(>6%@C(<%\)!*5J#. WR5Q6?G[[%4)3Q.T^
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MOFS&MH1Q+MA*2,>-H'G29/ZKH@*GE1?_]^#OL/+B$P/WNLV^57TT2G"K9.-
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M>_'?'\5>=.I1%')&\JV[=XO:Q;W&"4NS^YDP8U8$=^ ZCRZ!G1+]6KDMB%H
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M^1M/"]N[8ROFQBO ];EW.4R*AXR]KY=7W&<JW?P"L30VCIJ<L0 [#A3B3X1
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M3&IG[3;>MS];7_+:+U\LX7#O \$7LP%F?:@0S>B$G?6)0U+7L U&Y@^Z10I
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M;@,_X/UPWO;:@I[0V[ZR@5([O ..KUO,..^J=[ZMI.G:M07A51>;OO#X4KQ
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M8,@%\S'Q8J'LO@E3X@*Q-K."OY.I]E'YIU<'W*GYV0<<F(5H0M[[5ME'-(
M6CD5LF1U:H]A:[4")0YVS\5+^1$NM*HO+BLN]CEL;X@_ #?$U!2ISS[S0$#,
M@ODS /YB]><^6TJTX#/LC)M8+'/RB KMK4RWN$=Y??/'8V::2X5Q:NY&[AM9
M7'\AN2J8S0>]'J4^)9,@N_G,5WH* !2Y?:6#79#B:'&%K#,\3]VC,\3Z1*4F
MB+E?4NWT*HCJ\?EZ6 .%4CAW2 MT=MEPMI('H69I&0*8$V/H4U4934MZ]ZFC
MT&Y$I88_90CI0$I5++0U^U^_K@K82M"=[ &]"GEE1!E9J>H0]QI_S04Z'D\K
M)O5QKM4M7&+NU<JGQTZ(,PPOHE7)@0A^5W&1,(\AL,7SM#M2HE-VM]Y'%D<\
M?F>LXMP77YLZAV*,RL9]?\LT[A_5S0 U=!Z5,4>D^0,8:HT68+BKUF]?[5&Z
MOIC+[4EZ:8%+?'7)HB](+O>?]G4'Q9J#/]@9DJ[3+TU%S*(8YD>$? 76A)$V
M7[0?UI)%AON2>! PPVYW#?VZ1VW.&X%<ODBX5>2K*LQI6W4%PS(R>U1&]K:*
MDUZ-Y3,/WO,@\OZ0)AE'5DA,Y=QJ-ABV(?SFXZLW<17C-_C]P\(KR4Q!6+@O
M.1M:WN[-)B4P<C7^V>9+N[)(TL Q_?F]OA(LN6O]3)CTF/!>0GC,V6IQI=O,
MUF\35GW/-#[Q7$ P9;ZJ%"_$Z,''Q$E5JM\RBSZ_3:Z,*J%Y E];(SAD86 !
M7(C$BW1_^G/N$<5H^UB"[4H>/"=.*&AJDKZ2\P;DTU24V+4&*2Q]OPJTMSO*
MDQ!%2[WIVI1@8U@>\.[,S47;(R^K*#O@+8^]]C)/2,4(YYJWT\2.GF2HE\OB
M$6!F]SS?=:[6<#EHQ_#SFMC $5";QR!T!.3VX&<GO/X&_G\@MI\&:]_>#A7L
M^-A]XTG+]X9STK"D^KK:1@RI=_ G1F;R*BTEP\ M$=-$)O6A1CEC<.)GGZ(
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MG^XVK11^BS5[<@DOOP+J&.L.POY>RZ?B2?=11;<GL<-BQ&'B:O7"<Q$RM-0
MH%V2+9-UNB;^Y*WU"MN<R+IB88+=-7;E+G%3EQ+&BI8.1]QB?6_933)B^;03
M3;KTPJ9?N/>V^'"H.MU45(LND+VB.U,0N+"N0Z5?.$E/3-1_"6$6T-G?7#L
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M?2/:#.*?!@U2D,.[$%,UW6$-ZS0A1R.!LX.E67?UK+EP]&9RQ%:GO$X\U/-
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MK@U_(?"E?F0:(NJ"U1I1]*#<6*8,%D\RLJ2>'7TI#MLP4L^[MA,\XW 9>GM
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M)CTUG:O22[>.&K'O[^A^_T*S5XG#%_)_^K!'#R;L%,/V]+6+Q:T$&J&PS<(
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MD'@FZHR0/ABA-T^Q@Y@657JI^X?^&CCZ!!&,1G;J*;Q(E]45?<YHB<R),-%
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MK _RB4OP"W _3(S!^82G<&[ILG%5?[X?D)HP&Z+?Y/YSUK"3=/,)O8JT! :
M%/P&>":)8;[^-4SC^E<#"M(IH[O*>#QY5<DTP;!E6:J.U!F!R4+NQ*RQPY@0
MVQW$F?)GP%XWZ7<1&PP2$@[L&O'UEET+%T:\&=%YWFDW9Y)_,<#+)'\V0$56
MU$4R ,3UZ0'PIAH-.YUL- %/F9,"+@K%'ZIRH1SH(9#!!;AU3"^ZQ3G_-&7Z
MP;Q>U^/XE3LILFHE!>?\M5*Z5@N2]<ED)$C*G3EL,)CEDF8]3!S91T-+KEP,
MA@0-GAOH!REZSY=OJ28;E'VV%*,)V@CHK:-GH0CBKZ]T G-CL?<+T&?WSHC7
M?5A1X 1Y"G,538RY> K9<D-85"&>I!B*-+H[;TIW!3P$7#G=0-V56O[;*<O*
M5K+?B1R8.YZFSV\^&^]UR>^GJ^MX'SB>>ES=1!IPAHKO(UV;@++N96/JVTU,
MSQXRA5ED8N1ITE*_,:,ZD=P5H4^/+[$L^3?[L<>XH+"8O+9M9GO73(Q0K*='
M,P<][7HX7V^!OW#[];L?^9]<D$ZG5ZW&56Q\4P(ZN'%V(T" CP#3O([7F"'O
M?75!KDE=,#RX Q5/ \6BS_=7[TH9:!/Z6!5GW#F5NG0VE#0T1%K!@3$K3<V$
M/=* Q^4?#M3;&5:8F3VVR:CMKP[R4B"<4+VJ"W.L0I-96U'/UJ_;:CLZ?2X+
M/-1JXX2.JNB)0Z2%Z^ED4FP)UYA-#*7;NISVKTGRB4=Q0:ZZ*F30O2S976H'
MG@2[)I,'>MMYWQC<<:Z,Z_F28ETQT0OSUP<I,9YM)J;-5.R>4=WC89@Q'&5V
M_!JQ4V7Y#-:ITPE;FBRY3L>*MI^\\_;0V#=*9&$*M^J2ZOD [Y:2S0@:^J2W
M=T9!6D*T*@F##T*D[G1)GTZ?IOFZ9?-P Z.R%+,D!U-Y((GIU88U[$NSEIU4
M D>D5_.OQU6W\N_-4-$Z:F+Q@5K=U(2WOWX?<>KUC\:O)M:.@/MC?;MG4HJT
M@<RC5RFI<0 (44%))31.V&O:NUAEV,"Y;/1NQV$-\H*^PD1RX2''F@.><JV,
MY"L$M@A(BX9/'PEM\9OW\%_C$MV9EIN(ACU;"@%RI9@@XDLXHB=*CHRIY5J[
MUYN4F<G'7RHF[T-EYETCZ7GN9"3T^FQ%>I%BIPXTW8W;[9\_$>0$48Q']MQ\
MS$7SJGEENQ@,V^-@>Z6(.J8Y>%JSPJ(ZTEVM006?#H]Z!6LFI7?-1M N0%CU
M)@9&N>YPMBAEO23@R&#<OUP4;C#-+<PX'N>UE_TP_71U.M' 50TS'L^;%M_Q
MH:L/P(5_WFQLP]<G/?[1:209@F31*^D4Z&9/4A+JZY$H&2T#37[Z+<NU/GC5
MKN7E*G1]]JB#*A^SMA*@0O!$!$BX<]"?">?K:9R6'G)F*A)8;7I*RN4J*72F
M'ROL#"GNKJ.Q&UP_$)EA6"EPY#;GG4/RN(7PRCC8D=++=^.B)7%PP(-1[X[1
MCQ\RL*NHVNZ(*1C>(Q?92RL2I3:]=BRH?)U$^ZQ(72T#DU^/ETY5=!VX%K"(
M58*X M*TX=N'4M[YH[SC=QXT:'<Y*'-8Y/@['/7H1 8GLC9=K#6G/'A_C4%Q
M0;'U*CA=5CAUF<YZZ@L&()]@[/KCT>^/>[+/A4VK@VX'9O%UW5=R"%!!7'2+
M?"K$5405),>6:(;.0'?ZK!S7CQS*ZW6< @*L>]DCR[H3- ,!XKF!!!M7K\56
MJ+1*.]OY0:Y!]_SGSPRO.SMDGMT-W>9*AT1[2?5#,O^K*<I?\5?\%?_I 7KU
MMWVVY(T-]M9#W1LC=,%PG8.7NCK&!1-R2UAB<D+X):9+]XLPPBA/C9Z%V.8I
M#MJ7NZS>V??N_4P/C\-Z=-QH5"&7,(B'Q[ZP9?88T?W^<UA:W.[&I?,%<8LC
MFCWAPX/&6+J^QO([BDS+"F>SF1@+8N9[77&X5[66BHQZ](Q=%QG<LS^IN6"'
MDFMX3S]$R?-KKPHXZ^S-ZHH4/J7P[015557)^CU->X\3 .-1AW>\X13$]4RY
M*?N3HL^[IQ8O[KY'9G%S>U;IO:*K\T^=ULO[&#HIJ[F9I3-MG;UU\:?%Y(?Y
M:ND:NI8*)YOMP<JTGT\,9 WE61UXWH2_^>?:E4,L1:#'WYH7!^,,$]G$WU=:
M1?!T'B_>9ZO7I4=+7"5?8U*^/6(QB+>,,23@P"%-R"Z=$/CWJ(7?Y/W_Y[?L
M"^LES(4@E>P+FP5JGP80L]D5#U4?7/]EW9XD_Q]49@2=IB4RTDJBE4DWE8BD
M[#O-K/+PH,[Y @.RK>>&L=U#EE$N.[@06_:K_=D\QB4.6%J"H)0-_9E+6V^3
MTGE'$3DY^=O/@E32;$X !G)8'S<W=^Y*\O0QY\'RAS:MEUSW:$H:K%WS&'="
M9E^/&;IAP='52Z;XX,V!#^I:%VXDR%79O7 BC8OU8-!]8F%#*^S-S3Q3MO5@
M6*&;]-:/VT&\8666@CVM3N2N]&Z#[ X!M!]:SUT?3EB?37AP$1$7JRJGBMB[
M7%=I]BGQWLB=@E14LO"$-R55M1D%%X>U.%&\6',S]<A[##U2)_N=9 1T HBP
M'YX J4; 'L\?3FWP]3:(?.5'W?1/NI?Q@L>60 A!=2[P&O#UP63*EY@63H#?
M=W$"RS>*SUZ*?[7,(V_.Y\K 0EK%9J8,(8V6M)::J48_E>!.!#^ZRSHP7NK;
M-E>13^^JTGLO4* +0N43/F1Z[8>!BKI%;=(J<50$^P[+N,!U$+",6FFW]64=
MT9\?6;U5G 069;014I*L=!N9MT(NX7TP<M(D=?9M*2RFS 850E>_O$UFUF(,
MAO2 7K"]]G>@L1"$@IE6RV=31$:4TO-'Q]*[C3\RI+R<'+CB>[;O3EI0/T9H
M&;3R6/LW';-V8_:U,VJ38Y*^7V9N$Y$3?%@B%[*OT >?FMV1K52QF6/8;P$Z
M98ZYW+'>4B-)7C^.;XJBOVV< !FC]?H!R.+GR5:FAF6K,EXPM1CL40\]EHCD
M6 ## Y>,S1B'])?Q+ F^@50;G@C7(%I59P5:U>\+\&%T^[5#B.8)X' "[#[2
M-:<5T-]0"__5BYID:(,-B?G5C)I&R][4<+DB<M[10"N:$A<=9-\@YC<CH]\$
MIFH455@GM6::/ %:!CXW+E0>WTP\ 9X544]/!MH]0=2X[UJO"56/)<'MG&G3
M.*G48E(RHS60=^WK3X!@XVQT'_M1V+43@%F.[<G,!OV]5F_:W.P2.UHCK70B
MA-0GI]G%4%28[JZPQA/SYZ.MAO<.59JNKS-BIRL =6M25)/^LN 7:4493=#2
M6;6*B MAINJ\,-MQA3U9] DP$A15@](ARB1^>W6KFCH!(Q^'LS0/PGM_<%C5
MG$X&%NM8IPV/Q(%@N1THF,M]_,L"CNZ%6YF%A=M@K,?\'[0T"HHIO0+=?]C4
M0,>5X+2]2$LLCI;(+:G"7>CPZ\29V>"!]3T_:;"W3KXC:735V/R5YMZU*IM>
M/PV?\%U33_6@N\\Z//*LV(7&/0(K7X\%DKF(Q,7@Y0G).S_9ENJ4"\O'E1^?
MS^MF 4-'NP(^1'M*BES5Y$N]K1<5/B)L=L<^ZXI-Y#3^V]@V:V]>W:Q--J)(
M;D[3Q *<ECC#]BH[E>-V&@= \2D):&HB8RP"=J4>%XMMG0 1CN4G .\3V_BK
MG$[0I^:)Q9/Z O$65+M@@?&1MTMH.H?'<Z/O\F.!R]KSYR)/ %$Y[H9^T"[!
M@&DK=EL22?C,J:='VJEGX"211X2:,)AS%2EYK8-6F&9. /)=Z,9"[+(<R^JT
M*$9D1QSI5&_PL ,2%X,A>Z+X^[[Z &G]N@_:*KMW/+CO:COI7(4H##C+"69D
M2.2*]WW<.;>T5/Z/AV)_J;7Q'L!.@&OFWSI.@$<&>2/QOC0G0&+Q#^L3H)P'
M//0'C36S?#,] MTAS21ZK.,XR@@HV?+W:$P848L(>&B..(LW?!H1UDQ,7#J(
MC%\TTG^9;*)J3]^BE$:;A%S6 &#<L:@NQ C9EKVFO5+E\$4MHXE!44\V[ 6I
MP":MKZ2S\'?PK4BBPHC5R$5F07B^.V3CRGJF!]<)4"1,@2!I?.XK4_.S=!3G
MQ,6C:0?/[:6%6 >^S@P<KKH6F+J]=SJ9T-^R/!K$MB2\_"=F!2H,],\"(*LO
M!,)6,()!D[4: 6[__2\CR0[?\[JV9Y$8RU->W@&(8.1H='-HA4W6_"'=55*!
MIL5' @*2QT_0L^+H@_#IO4+>X0^&7AM:?BD$I[LVMB <B4F\>+-+*VF 2 HC
MU;KLM/[2U,[I';RH?KJB]$/8M[C:+CC50Y+.K5='L5 HWY6WK%:U!0(HN;B#
M/N="ZC=%<T:S7IQK\&0<594,XU$[C]AWK#[R22F/R?6B4_G,J"[U*/R>[OD$
M+>$.P.\$:/L.J#:1CNAE+:&6M O+J"NN]Y*KXE6Y8U67-7V [6NT#X16)-I;
M>D J62D*F3:BB%'0+"H!4H5LAMY8^^/YX#0ZX8/(F"7F;S[/+E'+(/@Z/K!<
MUNP65M7G]9F3@^ZM'+EE=!7<^V!/2X-E#- 0*1\J2=7!TFRE9-+:/_O]^>&W
MRQ>>^CQV1(F019"KRB[$^@#BW($? >_L '].X\7-,Q*KUS4I753ORG^(PP#\
M4 8EB@Y65Y39<]L;]3_\\LZQO&.A>:87*?/M8ZN4&\YN\LVPU W' AJ36T4N
MY#."!' T&"L(VY5I>%LW<K<_L>7"Z^(OXWGC$B$*8R_Y5,!7H#^>TC.+B]]U
MBSX#^*S]JN;:' 2IE]7I)>QI9?)#KX<^PJC 8^6:D=TI=#!(^'#QM:TZQQD!
M#5;6KP- ;11 XE&:8&Y&WJ3A\?H+JRMH8.)(Z_-:)9V8VV6O6VZQDN3XSRD=
MR/V.&\V/9'@JA_?XU&OE+ZK81MCP,[F*!<@L(6(S\VVVJUCY!@KJJ*UM:ADF
MA2G[>ALLCZ90':PBX3-2CKE\RPGZ0L&4C@@IWAC,>JCS6Y)@/ 3&]07P//X'
MO6!" ]6B4$U7SCMRN6,C&[]Q'G[Y/OUQR.T .J057_V6W9'W^.G:6C?U'6S
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M%_+VNWGEEZY9$_@":5Z)U/GQNEP.'(%U8E.5N_9-@%3W3FO-?.9[HP]2_O>
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MGP.])\#J.ZE*^2'#O'4G) )EEICVX,.;9M8WKEPF=BFJ<Z](<3:QJ!21P'9
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MD]\LOU-^7-664QC@:1'3O3"D(;_/2N;](N):VZN*,&/;B%(TW5U:.0=Z2CN
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MGNF=Q%8"2)4'*U8 [K ]5EDPOVL.2*?Y.12N& 59KJ<#6]JM-CBJU0 N3>,
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M8R^PFFMUDKLL[;V?7W$4D3\",(Q=C(V82+NOKLD,CI>SWD8:,Y8@(JST(*5
M< JHZ5; -@>9N^X+%KTC<]KD_J7)F6*AE]925N>560(9Y137VEF()Z'##2'[
M#NZ;.?/^2BJ)(6&FI:V=%]CO]\N;A;K@ /FF<Y=DR=:ES_RVQYG(DZNUS]O2
M!DFDC9J93KY/.:-\R5]]PGM,V5#G<(\:FY/@XF&UB^/YS"%17WRU(.:P<W'9
M#E0QVNQG88EEW#Z+KM56M"Q3?# ^\/&A245Y[,[()N^(RAX!S*8)D7X\E1="
MFB%":9Z\C",P 0VQPC)R"10*PP1$K8@[T4?EV<6H58#J<$X6=)2*###G .=!
MDCO:#G#:YV%KVS\,'*\_ O9O/N0^M<\J$899DHXI'[G,==MRR],&K7>XG.D[
M$I%OM[!I*DR)%)D@4!C("GL$ZP+7$[]Y1(:Z?/<T8R](:AU&.1(PS53W((15
MCU4YQ )1#<Z'3RH U?@A+.^[>=\7<TQV;AI?%"W+*!I#3SPVTP@HG&6=/!19
M_MH:Y790^"'X=OC:.;U6-ZQ&]U[SD*$_:00EW;U9Q>[P4C[^HMY.X\W("J^Z
MT[>\-KE[L,+[=[QZ&NA.6@I >/-=U3"1XI2<.[R1Y-3?Q@=CM^/'EK[V+&7<
M."WE&W!."WUW52!)DP\,=Z149G4KXRH<E=U>*SH"<KP"UT^DT(&KN5?AQX=$
M<=0!5^%LX40RPT/?1+85]P$E(1&:E;+[N@*N*59GY9O:H)B<%H.J48^!!VUQ
MEU\6+^Z_]K3\L/"3Z+O0BFZP [YM3R#CB^242><1-M%TU732='0RCW^4Y7 B
MHBR=S_%(/*_''W2T1#Z.?0D>W.!4>>8U;VK:^.59/VQ_M1;55S1AN!GYK)WS
MYP*^M BK'(#]SXTD!K4!I[O<U=WC?TPC;M_)U118X"$$IU-!#I;>0"L>!-:"
M,H^ MJG#&YI'0'W7)<Z1NONWW^J_(FIXD\#5<!X&W$DPJB[R)\S4/N=94?.[
MKRR9^Q8R]6;E$R&B'+[<<W+P35G:G,/.4Q/?FOCB$%;QL2H.:7NY$GR]8-1W
MN]^%8P66@JV[G"9\YP95F#]T/SZA*J#,?A^"#7@P/KY";"]Y_[OX; K=[P.T
M1MWXWZY_EAVPVA:4+VK\'+% >8[2"[($(7>1;*:E!1SN>>3WIGB_>&!%@:$+
MZFZ_6#UKQ=<;C)2;,2?9[%<$#G ??#(]4Q\(YF8D7GA,X154C6*OF;KO6!](
MIP%"<-CP_&)A:U'?KGQ@,+^+0PHU N=U*=Q:KXO>_ C#6''$ C"6EASNH>U/
MS^(3F,\5@:\? =Z*=.^RK_G#;(0TET=S^2D:B./1 [754?S7%>DF(A(??Y0#
MVR210P9DN,%V:_P/*TX84E"5_JV\_$RT_9?N?7'W 5'KAW7?^5^Z V-*8"$0
M.-BMTU$WAF@?VK%O[4;"'R2G$=N88GECO'?DIM_G<GK#QEF@T!0MX C8EKN:
MO+-_!#0].?[[5??R&6SV0_:$\M*'@4AQ2(:4Z#WW!XG-TG0:;J\^^:\\73!\
MK!DTK-\*>9KT G/\L,C21,FU[^Z5IPK*BK!/M^@%T7>"Z=JK.=]A*15M/LC!
M !( 2&3\OI9X=N[WKX&<Y5C#$4VY%X,Y/'ZT?@.?D2Y-?09)7M4+03][P[R4
M-Y=JM4]I6S(9:8AL\UAD2&9KG+Q%A2%]HH4.\W*Z]Q('K&_=C= /$.&^>]G,
MM>9%I'341@JEW[5XL;29:='))UK%' O(#ZTNC8T/:%?:<J2J?I-&-*R$+ ]]
M7>B<2YC[K-QX34 OB/A]P*N:6AS[DV^)JW[A#\-AN&D"QSFA!P7'7\TQ6:I]
MV<]>-N?=!V^9".<057&>1X'97_BXD]P;E):+#^7; P<T#]@VVK;;:MUF/!5-
M.GO=%EN(S'P(!P0__&S03MX:A3JX20 TX][J=\VK4[,$&6Q@ = OG0;1:U?[
M,<]+<CU.+-P>>-!,FW<]IU7A@?L<$?89WY![6(A/4_==@<?SDU<SXV\\=FD"
M6 ?59$5A=PI1D-$HY12ZMZ.KJKO7A1!"[R]0:<I]';F/X0)MRE[_OGW^89:#
M$,_^G/B8B(\DOTX2(4XVX4?9GKI>@5*8Z*-G"FE-*&H12DUIP6]7$RD#(::)
M^DV8%L^A"HJ#;EFQR\TR>K#F7)C)G9*]:JX,$UGBF6</G$GQR!0%*0D$OI%L
M<6<D%K4HH+CRN3WM,L>;7"2@ %H$"2.EEV6"/[_I=)+AT63]WG57$-7$PZ \
M@1"'GGU14CTL4@+)P3#05"*+O1^JPNE8>8N$D<H3?2QTDOO?/D(CQ;JHYS',
M#XOUQ1<?\R@\;8_4>G"G[0TD4%A04:^36??)@C5<C26DDU>:JI&79Y4.Q<.V
MNL=IM#3:\EK]T?T'+:<B46 7Q (?#Q/H E*%EP>K+@+-ZGUI4NXP!JNE@)VE
MT_18-0Q&8QX(2+G2<[847L8U"83/IWHDOE1XHNLPOLL;6[\.CBQM@Z$.N=HG
M?[C[!A;DBFG$7M]NH)T35N%@)FJ@FJH;X3Q<#?^6/?H-,Z)]NV#;(>\1T#!Y
M[&2;<^]AKDZS@";-N!*S"@>>)P9Y,P9;N'/SIBY#SUV=DFZXY;/KX'VL0,U/
M-#V<R[A]_+5Z*36ME/@^UTS4Q.,WK22  \M6D4#T>FN:X-R(OU@' 7"1]'3-
MNE.R%UNE;P*>1F1B_-J5Z@(%/F'HK3<:)#1'S*),(7'_5X$[6G9NM&J=:H[[
M]LJID2CY_+SPK$^"I>. ZSOF^"8M$,^"22E8^J31^C.PLNEIJ@7F&#8R9E53
MJ ]!1N!Q*P0Z?G#K?T7'L&'T-XM\[0CX336&^^_+5B8"?G7=$0(WEJMV(7'=
M7IJ'F(6JN6'N Y M6,-6WYJ?Q&HA#[%B\.()Z6);S0G;Q2Y/C.]BYN5L:L\T
M!S<[BWSD@;,$TWG7!A$B-B+(,CS[,ESG:3 W3C\$R=_U0(X3.,#!2%4>7ZZO
M<E*2@LU9,N?,MBT=LM^#Q44@+^L8T)9E<=%8%07T7@/B5?N7XVV5?D/[>AL1
M/*\TUVHHQMB0=U@ &OG/.>X/.0+XZUT8;X&#++;A'^)\]T\8KSK>#D<-RFDW
M@=$Z,YOQ&;9/:2U/LH5JQSJS6- F^6A!GWM):40< 0;E:C&F\B6_V@36GMM
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MNS6HMCB5 %=SZ+IU0?Z>UL0B#-^+Q6D;9$N.3X&SI:@7YUH..;UR;7T+[(^
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M=XH3J>Y#&Q!XF%[\*5LK^48@1K=XZ=2#N]J_Z$/7N#D'*X9^8F,>46?@@]:
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M+Z.!^<Y98]D?LIYKBTY+Y_P'%_;*'Q[8C3S:/V$]/F"V8UZQ.HKWV)'9['Y
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M.*M(G_>E^.E=Q02'7LT"!0N_^M?9G+C'ASM3R<7?WN=6&TWGO=0?EI!A>YK
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M23T?W;B25Y(4=_$B3-:E@CW"G@,4VQ^G1H3R)*SY*OGF.]7<9KU8/"&FZ4U
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MYDGX5<G-_Z=\P]=?9!\!K[[P@+*Z+XH)&_7G.N,=NV0=1V8<Q5O$OW#<+CT
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M0UVB8P2N_IA5A_( '$$H67-ZTPLC;T^HH5<OL8LW0(4Q\8&M1MVO+M$TOF
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MU&32\NX&;&5X<U^Z6[/*]FP)QJIEL@TR?2,&!+>H$$I9IEY\#R@MSZN8BK;
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MUF_O< R4'#9/[7W:S4O[K<Y<]X/SV8Q(09K_>=J$-SYIS,KW/;@2+WF5O+!
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MPO;1I0ESI<YT!E.%1A-LSIHL<^HO,AE%-S:^1(Y)U;EA%VXR()P8VL_X+P=
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MBCN?K9<=:O.@EAK Y";$M ET=1&((7$R?.(FA#8XP[+P^6="*)OI@&VN)C9
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M+IPIE*+O-HP+THI&\]?3M^0ZOQE[KC0I"P@G@5$-]Q[I^C 9K@B%N'H^?<[
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MR>C)5\;G\ UI0^:4*"P&M?Q:H6#&:*1D0J1%.:RI2W"\R0QEUP@HD&I/0,3
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MK*N+9NSC/TD)=9.D/1DRD+\;IJY&VUDIU<TK+\A42%\":H<W=J*!CQ)'%]%
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M$9Y=X_ ![RO_I)_]4V>(Z- 4]N&HU;?$NW6JKWE"20BK+:'4/9S>FQS;,>T
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MA]7UPCLY2M)B_+#X+I+>&$?@\ON-4:Y3 .T?[VM6AU-*,4<A@+E(%4D.7]O
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MMR1)]?.95N&IVNS+&@'2BC<\VG9),.PYWV<QR.])%X+8:^,]RK>N-IIQ9N2
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M$6)<2F[XBATJ>NID/U>S5C-R=I;C6"=T]YS#@)_B]VK(G!])$G3%FAO"WK=
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M:^Z@I( /$XQ\GV1Y>,.E."OK!MXVZ$=?J?:/8) FV>TE$-VYWT+4G$8!Y
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M_SM50 O6F&.?6I\D&?6I]YVT3'H8ST%J4/\3GY7A+8QY_E<E[E,=C,2GK]7
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M/=NRS]A%JAF76P\BW=INI[S> V:([0Y)9JNF<%QU[VV1?N@PQC<%F3$^BY^
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MY UCOH;9$BZ)L8,E?B:XS,U3P7\<_E9'[G^P]YYA4739VG U#31)0"2UI%9
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M)1#&K[.AI( 50CQ1JDZDAM'FL\VU!^\YJE0_Q7-Q?@ 3N#%/(]94A53O..(
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M%LNP,;T>:#R<L-Z:>]HV2,L1^@*U9D(RCA**(3DP[\AQ^^Q[EFIE]=J%TZU
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MP+HK%?SLBH:\G-R/Y,/PN&?2?C=R*\__0WZLV8?=GH4N+<+V[3]+)6K*5KX
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M=KN=\HL1P3DT+:C_54_9QIWNN&Q^Y+?7#S<^"&6RNS5,)4..37A%K"+4=C/
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MA#/T0+!M3^OQ*#QJ/"$#T_>952571"U&)42G/ +ZH@)4"A/F 3^*()8)*?4
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MGY[45H)(]&-41C)VL60BOTR<0CX4HSTEG]<&ERDXC&LIT#XEOBHM3J2BW4H
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MN491'(T&,>HJ2Y8.PRVE<4439>_-=6LD;8?G+".>)]Y8MSUG$HSQ.@.*"L^
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M);:@'IAFBE-F1H&.#W+\U3:O#RI(F_X2EFT2QF,7JS#V'2*7 !,L @+,>7J
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MI$&J7@S\6'XE]^@FJ@Q84Y]*K[.6+/WNWZML_T9CZ,S&A-(4[1?#;MJY"_'
MZJ68)#SV)*A^\B\>WAOOAZ@RCZ]\++&.O_NM+"AVCG!"T+T<U,[B^9P"#M_%
MJRLG&-(Z15:YR4#L>67(3 (?ZOHD@Z4S9CD8.$1[E#=NCXA<3-(.9Y0=87#M
M,[:E3!@$N?[Z@4<C0/_7<I(;NEMKF3J0(G'+3C9>-W5AUWC7 5>]_[+)G0''
M5S1/JHX>N!\TO+Z?OGS<\,9]\&?QO)%1VW-H*4N<2] @*V;.+/HIM1QDT<_*
MXWJQEBRS3P#IF!.A*O\$'/W!O0WJY0(19Q#OF+-,M3UE,.QTXDT4YM_ULC:O
M?ZV3TVDVX=^* 4 <@-6P,3Y6]./N-6OB+'NV8..]X^F"N4<U;8+Y)[-XI07%
MS,20?YE1":W[$IP?1D0"8:69N,DB:G#:JO$QT&:^KI&CJT]IK5;,!M'FNH;>
M*R3#@[(S8/JVX1D0X'RT)(.;9/G=*]831 +88RY,CK_0@B_%VL):_RN=DXE9
M!MW3S7S3*QNMS*QR])^Q3EXE"&MV2]8S0"%6!0:A+\2KSO Q%X_CP;;UUM[)
MSP2OU=W)*H9VQYI^\;7[@>%U0I#P@2].U9-1/>J&SQ@Z90;,"-2!7GN\\_A7
MOJ$H"0_#N@6"*TO%EJSBFOQ18CGCH\9 _!,5GK0F?2V.I^;V.16@&E.2XW+=
M,;;Q,(;Q*B0QHAF<35_U'Y-_+'%O/I?X1 M18(ZSN;M1*RO!<IA]0FJ_70"M
M 3WFKQK 7GJV)7)%4H&^#286ZU*7IMK1;AXM_%B"$YR^^2#X[:;,2^S'XA>U
MS(9:^Z4I\\9'[\[IM\D.H^)_MN[]BBW+Y&(K8J!V3=GNM?DGNJ))]$1!(T8K
MJG!!\VMU,^1X0UE3F75+O(AV'U-84/B)BUWV 3M3@=B^;@<AB[R:9;7H>25$
M=+HXO#*-Q5F"M9<#X0LU( !8 8#%Q"9>)"1RZ1$^IS\#R'RX62A\TQ0D?6O=
M%^AEO!%M](%U]AEX5[)0I[:Q-]A*B;T-LYH5@+50@P"\$JZ@-XA=A SV6(@=
M,&;?;L2;5749<,>ZES-EB,FV7PE3Z0,017N10&O)!EKLDD:.<C4R[ME>U#O!
M/&J CI/M*=/FFLGP[^7Q>H+J,R#R,N'A9)F"0^W$G0*E>5,"1)]!T% DD MI
M&=>@-AJ_RVF=L+IA/8NP(#0#\%ZF2*0)UO1%OPS'8W_!*4D5#ND VT75OR@A
MY1@*KEDE\@I@KK!7>W0EUGPV3-0\UD478&.+KG@K2STV=NW=LW>ZMV"?,\@R
M.3@ UQ\?\.\YO1OS5,Q[]9ORI^MF+M3!;Z+5O6)]L.NY6D%!T>6/S@ 2AU68
M58)'08:5..@F!7P-<&V?M&B!0*3LJ_'0*K/@4<D*S<$E$B9A*%2)9%&.D#H@
M_(.RO-TN'BB$8U(_8&[%KS5W=-D@S; V@'M<2$JTDOB/].G0E*293H6KO_0?
MZC&.OKB-3J)L[U$' %H7XKN>Y?C-ENATN*KFT6D0IW-AF R M8G/E![?PSP.
MI%T3(=97CX&!2D\&8^5@V&S(!V'W ;PGR7[:P-0RG7MYYJ:7E]Z#-TZ362%0
MH$\6N)#"K$[LPK=\2A:N6_-<,RY%E;CW[>U027AU![?&O7ZVR$6\*ZTIICV6
M*M\$^WX+,T1TM[FT K+X#.YP%@E*H= _KY[,OVPV-GCC4::"D99EU'%<+42I
M2K^G[S?CJ?V'MP9*__?2WO];_BW_EK\7^H6IZQO&HV)'GC91,8I$KS6RX7&+
M@> ^TIUD'G\Q;A_?^_Y?4V_??O=1V%_(G ]-3K>6Q 2YGUF&;9!1#T'Q&$7R
M</VID]U53X_LS^SM_P4!6SU!E:Z*F,Q[7/ISTWGU!59\MOKT3P]7_/Y)R^G^
M#GV<<27-JMRO?NP]OK#G='_'T;+;/N5PF(Z]3VG^0'F^9E_\>#GCNC[^2SK_
ME.H.?1T/8PJ3>7 &Z%I_/V$];GT<J'7;F-+)_O]))ONG;#9A)>FEOK<25Y"M
MP;3\R81[5./J+K9*LJ;7CR/\AOO[SZP/>=U4=PAWP>,'*6DBD4/O/FTRC.H]
M-;>*7[56CWR:4H5?)OTK.?^[AR/\6_XM_Y9_(CJ>W3]*JI*G!8TX4U%2PGDJ
M?4+M],\WMK_0XN(GBZZ3P:RY"0B("7+7C=.341*1_XKW@^?EIG/DM:_K?'RS
M9'K+]XL,:&4G0M T_><U#,]_\-.ZHG>UI;C%:E(KVUYU-B,Z 1>0E,J:]MA]
MOC'>KRGO(V'J)!UX$.N[)'M!RU"::SBPQ#%MW^D,$'#NKG7R%C2MEJY94@ZM
M^+FV8E4__K%G<FM],JI OPCRX9R5YY]=L*'_;!<@D+:O=5>XM>CJ)%:D:&=1
M)+4N*E5Z:[YO$"6^OO@?1^9X:,Z"B_S5<JH[Q%WLQ+B?Z2R-NMC9Y+#AM=%D
M%3NNH96]3+,L5-C*>_DFC# P#8]^YYBI;H L_MOG!__/"?&=VL20-KF%FK&I
MNB?/VL=9TNE#] FLZ/Z3>1/"+]*OCBN*KLE;Y'N_37<SY^3QT#^:RMO] ^A*
MP\F<.*\8O8C*D\:V9X /SP"CG/7K]_X2NKY];9^2T5@QK'C[7IJA.*=__@Q8
MR>(+JQ)]]"ZR)^._KR]BIL[^I! KL.=]6,QK<Z(Q-3%Z!ACVWWD<4 X:^VJJ
MZNTYP_CG3FAC.!&, YSV0O_6\&ZO(\6/WGHP/8?CIRT T0+XT<@R=ROZG@&A
MC94-W](=SX=6O D\C%E/;71?.!I9.LZO_H=C:8!215_K_E;[G]0= [9:U-4/
M4A,O0>)5V5\-P:G!-E+1*J#9ST:3+>1)GW3=R]>VX9RL4+*KOH&:($A:S1QX
MB+.8-[S=Z&78*TIMVLU2%@092;]9YQ8M0>F82WL1AN?;SHF\E))H=6B(TBQK
MS'8S$PDRI'D!Q:ME&KCYX,M-":JX/9O1!=_:!EV'M=&8.JK<)<,'FUIG0'K9
M "3OJZGNR=L92IG]+8Y7^=^]6D?[6;RNPC$IF[C-Y%4D^:SH)E*QM-)@@UTK
MM4:\!;SHXK,L%))&"N!SZS\7[$O7ZK3HOTPD&U NM 9%L#HTD_F(]P6XCGAG
M4/YK-\+R^93S>6L<XS,%(GUN!114%E+J)&TW@E?*>21Y\93=J?.X^5:EP^A1
MU1VLUZ\&==>@P0_V^7\[9YMY_ N-R?W.+-24@PI#/'$/=79("A;+%.X'C/P?
MT)#S;_FW_'<* 6-^>?D]WH*<$)C-%1TKC%6:Q _(,6^43& "MFAMW+UB#XLX
M.O*:/2F8A6/IVY0*-Z]N*=I8EU7!"9WKW)H9*;^^X76O"F740 [;G %D/S5&
MYP[(J[Q6UY^,MDF?KHV< 3:(?D0OX#PVF34686'M(=YRA2(; B%T_9$_M9*T
M1UEF:ZG$QBJ9E^+11PIW-;6W^^@O6:?F-EU0E!Z\2CPERQOXJ3,N8=_P"=7$
MFK_[--'F#6;-*]8*-0S1N&9MU]3"GTQ-"$0SL+B<M5<(38^1OA7CY;H@4>2*
MGF6W@=%_QC'.7&1-8IR9\GQ7*AD&>^%2?>U93U#T!)SV]JYDE-9&V&N!Y[^@
M-1Y9YO+(K G7&I(Q2%X1J84@^=Y1$^#G^'W,B"M)3T<._3$V3]A%6(/)KK#_
M&=_:NR/CVVE:?7!!;I4^V39O9BHP!]JB5)HKL$,B\ B_#IG:U0+A:3327++[
M=]K&1M:BZ%"D#Z=FHV7GK# 7XL(87669P^TWV30^F5_NRT@YV?4P)?:UT83,
M//DTK/BWC(!N^S+D.P<O;5Y4D<E:>U,(J_:S!\LA+T)*%H$B^^:76SCMG45]
M@4\<"]?9P'P=S1:"C+&RDT=]D$U:T)*^ONVC#X:&6L3"??(YG4V=2,^\*FG6
MJLKG:X[<OLH(EZ9<-G$P;,('29$F%-GZA\MGTP&,.$+[[KWN^EX":S9Y YMX
MU7X&38.3P6X;1#,%:/G3]4;BRC#[AU-!D0D5+V-!;0S@@4BOW,+F+/ZC"'IB
M4L97!%Z[3<OM(P1^?C\<2L9]N+\9FM\M_?# :4'<,A3,X<H8#<E863&Q>8ID
M19I "W.2 H5^6CA+BLUA4Y+(&&+SR&:=71Z!2\IP$=E3E:VI<F 9Q*/VA6DE
MWZ648663I-*-AJY3J0B&B,]$^G<VHY\6N;0/I;^*F>DC:<=Y%_1GJQ]23FL/
M%%DZCB(8KD#V@^[5^-$#P8*"&4PG?[>I]JGA,TZI/(07T*6 -;M6?RXWP#R'
M\2Y2FZG_.5;,YW%@[%@STB,WOC^1*<0Q?Z#CHC++45J4%QAZZ)\[3U)YLBI<
MNTZ$@G5R(-J!.7":N#BP?.7U0\U%.3T@&"H'B95CDLL[3,N_F!1F.ZD%\4+@
M02PX%P$!K-(^E]7!IHDV6I7HO;R\)EKG^/THKJO /9$)$Q@ H4%'/RSZON03
M(E@J#[#(2(KI:>?(+R5O(V4 IUP&U@H#V&WW[[ 9#EU(;RAZWM3/NPP<:U09
M+=G'#)W2CTRV640AJ\C_+_;>,RR*;=OW+FRD$9&<6J("@@0E"4U.2E+)020I
M04 D2TX-" JVC8 @2-,@04!RD)Q3DW.0')J,(#E#WW;M>\Y>:Y^][GOO^]SS
MK+W?EP^_#Z5=5,U9L^;\CQICCA'D\HR-(;KU8MXXDF$;@4='-[J!?CW<L,&;
M)"@\'O$(I3PW;1X$60)C(I19KCH_R,MP8^$*4.8 \%K94# ]<1?<(/UF1J^:
M O=I<C-6<#?7))W&#=*;N1,U[^Z0_G@S$CUZ9=):3M8VU<U"%:\!EMGP9/Z0
M@21I>.9+ OXS9C;AZ<1"05IQK^"6436?"MEEN*,,X\7H9.JCGT&# PP4<#K+
M'(%+BY_RC96SEPM.1)$FHXQ#A7RZ[^)J.)[^[&>GCQ"]DH!9EW#.NA.=P#M
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MKU9.W[2T3UADF'<C_7#!O18,6+(]@T$^>S\H&**3RVIE+1[4U\-'.K;P5.X
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M]OEZPN^\0\31(=P\65^-)=9,\2S&^1P\X8A2W)_^6V23/&/2W4ZNKZ\CZ6,
M2#&<&)4&^N*I/?#WA 37@TSIU(%6*(@AGRTA@RURQ2.M]W?NIP:B:!*9<3P
M\Y[D$F0'"CDB5?'Y6S>T/3<A2^J_K1 O5G!3Y[KNC, $].RGZ<B,/SYP64_V
M-)OTXUXNOT3NSY]&\:ZG/S"YC)Z;&C9B^%?[#MWX,_W[)?CF*''*$0JI@RRY
MY^"6B-2$?9S"KX[$ N]Z"#C>?)/%K'Y_>?S,[$6"8!YQS4\1EAUFKFB-;7Y&
MPER#K%-ZF<![)K=&[\AX8J(E(@30;!@." <CF/HSKLE[=Z<6UTP$[2:^TQ<O
MBKNY-'N@'PS\O<EX.O\DQU;^/< CK7[MX4[9LYX<529A,R;GP+!*@ED2PH;T
MRRT\S56W\EP2".HR#>]Y'[_*HV:UIA,W< H@E "A8B20J)C)1$+S(F5]"PO-
MS44;LLNW9@(#!\Q=?GN,('!S]74C@L%%MM=/="6(3WZDV1OS\4>B^,21H/"-
MY(:$$=T 5RR@[_Q:JAT+X$05XE6)V?:3G6P3<G<!7L]'=NR\Q\%=D^D-.7UI
M+.;^$6#N*.EZO<2_?%OP_RV(3XWE &.T=*J%+BI/:OD("ZAT9+/FWW9("KWY
MYN\31UIA8/>3JO*$5,#6 ,X5N"0=I7R/.OSW1B>!<'J<B50B\_(I5[S-2O3Q
ML/M*3?L)%GC<DGU]ASV(2N/!?R:_T#1HG^>SE\=9L^G+O5^VJ-QP]B$BE/./
MEO%?B40F>FH+4H@S//Q.F097OD6FNS\>4X^];?&PKZG$QN[INRQ]=WQ0@'-+
M]O._?$(_YYQS_O\#POUN;086D-H-<7S>XW*"5IE*^A3U:K#K>>B25$?"!//[
MY!^MI[V'1#F.3LA3ZAZ?6.ERZ6N*(Y''R5M4SJ]O=O<:4<AEM  ^%Z40#O-\
MO&N/?1-BEPV$A^K'G_C>^)*4VH91XOR'4K!$;>5];2>M+3OKTLW?K+[$^R?'
ML3)<55FVAL@[>##M&L[.BY9S)QX+^+WTE0LKY-A7G.-<I/UU)?#?+OL_[P'J
M%,.56LJ0\'P@+V^KVG7UN\X G ,P6U9-F7=,P<D=I?I_@?7PG'/..>><<\XY
MYYQSSCGGG'/..>><<\XYYYQSSCGGG'/..>?_.VSDDA\@5N@S>BT_<'6R $K3
M  ,, *=Z)C0<IY7GARK3%3(>/F,/:82#.5 ?\'K_\M(9YYSS;X9>W(G2ILO0
M.X>\L=9O#U0:;17F"HGG/Z!@>BEZ42?:O6E5Y8JA'"YDZ6VL?%W[T!8PRNK"
M8H,?K9&-R)4KC7$?[G80#!C+<W;IR"X]]+SG85)?==6+.\W#]*769>)R ?A/
M>?A[T=DJS;\\CNZ<ORA^,5?_0,_%2Z(PLY%&F3%8?SO85,'A-<JF<@.!.+J3
MY5I IB]BGL'FW=4A!O-D5D&9D(_6JPAM$FC*$MS%)Z_#IQS*,3!B[PMA?=+F
M*?"^=GIZ"[HJ0]'[+_#FG'/.OQ<>)DT/GWEQIRBEOM0B0K(6P'\Z(B^(SL(D
M-4.W:H(\._9+5"/:UI-HH&[/().!4+;M3L_4OSSGU3E_#=[;LV$'QZ58(&<+
M"RP]JPJ<*3D)G/EM^PW_2CP6J*\P&&%R]9!7^H$FCFFG4!5XC;!)[MEYV?O9
MX%$K5VR=Z:7#F/REW[;?G/X+) @^YYQ_*QQ\)388SECB+4/><S73+O*0R//_
M2$/85'YU^]1!HVA>D,0/:2C/0#^8#D=3X:$/2&N=#WQ=4;IRV1"3]_FB/&GE
M"&C.5L;(*I]Q?+@*HM:2< 7-* A38QAL^\OCQL_Y:\#8GW$]'E':$%!Y+&(!
MU6[6?N_XD<'1B.EUUHU"H@D%0KTN$$#:UJ0FIZBQ:DS^Y]/_$NA+TE]?T.R<
M<_ZMR&4^J,,"S-98P) 6"\A[[A$MG"A/0R5D65"Z#FW^OG*)3RB\,A8_ =-G
MI%@ /88%A@FP0$]?54!9S94#$E+2%LL09.$U$V0&'1M3F^ALN<I?/J.<\]?0
M];$ANI!B#?]>3(3RNTML6\IL+IG10QG/DZ #7(C01$Z(J 2)V'",C33UK:RT
MZ(M*H6C6]+9JARR9+@;G)C<4^1"S_C?$B@Q(ZD<0/FG4B**FFNRJ#/U?;7*<
M<\Z_&]2=!Y'H]^Z^LOA?YV-!WOY*=6QN3[NI^_3"3IY@@; BG("ZC 4^5P%N
M*/K-.2:6]W44I19R4U!U/D+&F.W.EU$8+ #& I@U++ :Z+=D;5SWUYL>Y_PE
M,%'/2I,8/701SZ*(LDYA>3,><#F"D.5EKM:!W_.]8G[%ZU%/:[AJ,R#A;Z:W
M^\JY_GI!\]]*9>3LU(E/VJF#R>F5U3<Y,4_+DN([4G6[AJ0BDJIM,X4]D<6B
M6^8O)^ _3,MP5C <(S1)V6$\UG)T(W235WR6<0T!CJW2DU "68JNC(LVNQ]6
ME3L:A\SDOE&W46RSG[C?3/W]R=ST13L!3T>8!P9ZHQ#%Y##LA-$0S$@*Y::H
M_U.?-/?"Z- [9FL?6U,.*:UE+N[.:A*_=O1I 1886>U[_EP^XB$UQ)D[B$HO
MSML,"WST.[;! @4:J@Q;2NRW=)S[K'+CK'+",@[/"'[=JTKH87&H5-KB ;AX
MZ[=VY2H?B&*!V\Q[[5C ,CTC>.ZM&]<=C_@PY:30MDUPR+4>]?O\TOSU7Z?S
M=VO9',0C9$Z4P/AQK@KOO@^FW_J97$ _[W*/ ^)*)+@<B7#/I1^6NC;QW'+>
MC )4WZB".FAWX0"C8!AQV1S3<K-7]J[FJ[=>]S!O1#[VZW:O^;GB]\Y:K_.;
ML^K@0K_J$N/[.<JB]R23L8R$>Z)4DY2%%%D^5^YY3 55<Q[^*-Z'W7*G0! X
M\)>^A(BV$^.A ?,PV5 -3I(4ZB>$+'-DGF0^W*B7\^!G-I";I$EEN6^F-F=$
M3@NQ0.];8_;'FI_7J-?OKCA5,"MKF CW/O91Z][@&//X=22NO^+T?;$UO-]5
M,#]TD5$P0! ^K)7H_;"TP,(@<*&I5A3D#IA="Q;PBA_I$H-':O'P1'=A=,)_
M4&G3Z&5XOY5X &$P)S_S/$(D;GADK,8,_"^55*[P 1H+W,(">\-8P#Q7."?4
MW<X]S5E49]X5]S1"9Z5X<3H\R6_8!2?#F?)?>:2$.[GJB7OBAL 1J$%Z<]D>
M)^6OX_[OHO7CL$+E\1BUF+X_#A[N12Q Z8>>0)^Z?<1)_CO95XU[OSE92FDM
M$7&W2E'X_4[DVWW)EE)^Q'K+PB$IE(OHG[O3L@Z]Y6W).?OO0I3Q(61DBNH*
MGOW*>66?[\E:^S N35%FID/;^)XF/(!O=ZHI70CMW!0Y\33T&[[DMP,RD1X:
ML#J^.]&"/%1+2<]AG>$X\90^=;,_Q>,NR5IDTA?2-AK$W7<&W5_OIO@G&+-O
MTI])+V"!8K\C7JL#9YP9M8$%QM1.:09[=^V=/YW>LESS664:NT>E)YKXE]_M
M7X".>.?5R_W5C\*_$UOT/L+D",AB/I49,H=)>$B_7GQT79NK-_BP@3*B0YP/
M$PK\X-FQXD$<)-TUY?]P3PM1V@)"<,T[^((VY\Y8XA.CU+F:#>:(2>0YU]$(
MF\I_@3"@<_X*2(DVF=^L?RZ/I_&0R^H#\!$ 7@L >.IEG$B7>V72I82_Y9^*
M-GV$5*IU\E@V]LCUEJXN+_UD_I9KJZ7-K5D $@*^6-A7Q5IW]<4G"Z3N]I6<
MBBT!4CU347Q$,$S$ZE_ B/[O8DOMK=_F7L)NG=^.2,[U"K_?'U5Q25\03=L4
M+,$"0<INIP<U/].PP.S-@I,;%3*/A.["W(E'I!JX"-3*0)-5KJ%S1QV=/A_4
M4+M&%+;LQ:I!EY91LM-,=.8,YI9@Q*Y"]:NAEU:[;SHK&[@\R0>8.DA-I8_0
M+.'&]+.\5W:4/XT<-A.^((.HR0D>,B62*:AR?WEGH:7ZQ?GUS24L0.+]S.7:
MGG@P@3;S-8X%QR[GE?959'@7E&W_SG9Q7+I4_'5#!8?>/-8<Z \'V3H&\G%'
M$SD#P^P^GG2GG,_^<^;D[ST64YU-K=/;5I]9J^CILB>5,3.[EYN0>A@KR2_8
M=VVH38S!G[[.=C+9*%[' F6TIUM8X,3H :>JRI)=DBHZN_>WI%T>OOF;<@MM
M'D^TWV0YB<$S%XD:B4\P*&Z3VDG1!)-_G(STY)Z+7--^^'W=*JF@4G96Z245
M18=:A\/74AX?ATL,)'/OI2GP.F],A-M^'TRJ?*M]D.GBY$CXZ",K'?U8&DLT
M7;/'C.QRMV'OV]F'6V3-,C*L 2&!/QP2IX_)?%8M@A+"$[Z%K+W4 \UTAX:X
MWA5187T&G:Q9.>Q65]5^"6EE[.HUVK6 JI!TE+9*!N"46DKFPNARW6EN>)3=
MZY03!IS6"SNVP *%PRG#<=Z_/QR"ALT*+)]P<H=O[K^RV"2-FOO 9'SRD\UG
MK;29ZDC/Z-Y=MMGUT.<KZ B_^I2*LQ.3_7XLL$D=-7L;I):HP!'U/A/ZRZ7#
M@EJ!SE;5EX;AQM-2PNZ$WPX8IU="VI0%1;64#;=4EBK%IZUW#SHV!2[J<6]'
M@UE (VH,P^+&)1N19Y+,9Q4E9["H*NM2A:4N\H??<4OIC*81%O"]?;R,!0Y"
M5[U!,Q!OR87#)M+80OI+TFZNSE%,WX8U#)US1;D%+1YR.(LT/IZU>O^M?1L.
ME &%3##+;4DE ,F@%[PJUO&I,7C6+%H26 );@/*83YTCE'-R9W-*[2QIY*]=
M Q)<GY!X3L-2S&"RO-^'KQA!GS_GK]&UT-1S92\N]OI"WIP:LT-TB0,D"9;D
M+NNO)N_DFY!X"V%YPGG+8X64"X^I,7!U=?  7-^>7%]0?G:FTTZ)A'E<:L%_
M8N9PMN\$H+7T!QLK1MGK(XK30&X;P6"Z4#W=;CTB#+,,98+W&76+>V"MB)B4
M"9.YO+28LW]K^VV-VE:)].7RJN+0+FALKD \9^'"Z)[?:S')YCC[MP$RSA_@
MN[)=SDL&.9-3FC*?NFN%AS[>V%7\K'UVT>X'>-Z_5U7IC+&*5\=SY7F+>EK;
MNK,)>0VFWO[8$@LDTU2J5)7,BIRX/_Q;4073X1#=4C7_HW"#6;';) =7?7P%
M)1[XZ[2=S/NW 'M:Z#N96( HXN?QIM_4KW($>LJ_>UAC ]J-J@+6U%>M,U&\
M62>BY7W)(E?R!WTWX/DL;B^H&4@.EH<3V9P&=Z*\]W,,>+,;>UGJ4PHX&9!
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M,HBD!O3Z(3RK0 ^G:!SK_E5:@BN<$B7-T=&KDOM%=MJ;JZ/00[LBMI1,RGS
M)LHKO0D(\TE$Q>8I5+@>;#@5.P-6F;A:]8ABM (*X7@F&%QO<%2IL'N]?!8E
M:0V-2_WS]5321@,^FK"DK<B_?5+!$O,C]0THO >NO.DL).KGRX->MR [=$TQ
M_ &41X.$:! J$(%##O;E@S MO-Q[&/#:V$T@B"Q40C%2-&AA\IX7GO)T6F&O
M"GUAF%68UX^-7UNP]/;+G=2+5X.H("IV'D3_)V[=(3$COGV@,1NW P[TFAE
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M%5+I#_-\]3T8/: Y[FFB!YZEUH598Z_IXE]J7V7=I;\2([7LX%J>DZ@L:_?
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M;F@%6*I(KW?>\D%&$!"*DR]*S/ABX[Z[(==KDQ@?A-@MG6JX(C6-WG7M]@?
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MWXNS,6@-&,*$F]9Z]722OD$<&U]0O9G)4I^=*:8<(CG(8(T*Q3&F ;"DZ--
MPS7*2C'1X1,%KA+-5/?0[D^U2Q$5TT/)C&>R"-2H#@3XC@1,#KQD;JK4.HX;
M737!B*[\T6J2?!U5*XEHDBZHI/(G\=(4%* 2,A&),'?1+>BR$[X5[+9/=\!2
MO"YY)#T]#ZC?$2-YQMFKY8?9!P\XI>%=?74DP(T@%Y"D!(T,WDF=S@ESL@O$
MH.85[>S # $OBG3NDJ8CO:X3$DJV-9EF:C-KFT#C^&>XN\@Z5^#6F*YWN0?W
MW2C'>IYF?3@01'O*WAKFWOTJPN9;"#]HO!CZ?JW;>>S1*]%DK>:VP$8M&XQ
MVJU&LADPE0O"=;6,\%4)AN!C2[V*A #%IH4Y8_IDFW8)&]T7?SI,*&.^$VKS
M,+L]>9D;5N^UB3CV.">,.S?LL.@)JZK7?;9W-(']RCC^@@;K;WS!>NU VM2H
MXO4F2HZT7I6;<A9=<G_554WL4J4O1N?ZPH7\TZC$@+):F+/=-$=[%,;#$'U%
M[\(6@,V; APAH>!,1E8H(#$].XC_7KP$1B!#O #WMTXC6L<6A-<6X_-]'1EM
M;ZE_L(QS+UHKM^=Q@586UDDEE5WR VNWJVXC.!;F(W(E-#U\F" ?5-&_$/'Q
MFQ$K;%7*F!8F)T6?2S^,RG$"-4&ZXU>R]"9$8V!HF%L!((%V)T,3,BI6? <F
MI>Q%HZW.O3^R" \TO8LT\2+W.ZL#Y9U+I]=>^GZ?6HM@8;5IZIOM O7COPM!
MI"V,#)LM8+]CN;HL:43C2X -30</UX0S30\-KY3;$\-[">-=X95*A.;/")+G
MB^K ]+T!<AG2O;NNFZDWEW%R=&7831C5 6>:584J#&)L6D-JZ8&M&ZTAN_:F
M)-@S[B8OZ#H[&+5\?%V1!-P\Y BH/*%8BRICC-)G*OD6&>/X(T[%Z)LU7')H
M2E7'7W%WO2ZRQ'K<&?MO]G'51EL;-S[Q2?%+]AO!DY=C^P@1(1VZ0&XM,)-)
M+$ZW5@W9/G&=;);_Y]"A&DRM\%?/X%_CN_;ZGB!>/:*Q$>HMN7Z$2:T!D628
MW:)MLMM<T%3B*N.5%1$WBL9O5VZS)CNTX%$Z+"1.^U<9)M3&?8E,81JOQ<DK
M>FM"KHLG#7V.4 9<"=Z"Q[@1I#/5>Z%'[)\L:(3N'DJ1C5=-!='[[7+S@*->
MC%('9WVF[O4I2;;$,%(')1.=B&-C(,-&'#0]AWG)'FD7'*%7G0%4R_G9&IU:
M,8QOANR^-$&"TKKVV]D^V0IM5NH9\_LT6.DL6*XZC%5P(RR^=9!O:%M63=\M
MJ]BF-Y_A$R93P5@ O)["4 &)-("?O:IH[X&*RD<VLV^"-S1.X)V"=O,U%7)O
M^%@V]NT.IFN+13[K:218O 7/"[& ^-3X2V:M!=_2 [9B;FME'T8S6OUP0TD(
MY  R$-Q597HA(SBGT-(EJ(V:F/]#B@ .49K23-8\U'J!/P?CF4V?5!\:I67,
MN_I\QC&Q\'7GKD:D8<PJ0#_2?TW+BUC_KL==&N\F[,YE3H;.77(,#Y$\0>(M
MM'[+ZS,8Z9C:>(:Y.PAK88'2,$.0YJ!J5F%=</R'H96">D(8R2=FL!!KQD+8
MGKX$K1-3TZK;U,%^<[^S>WM4*1NW?M,W*<#@12,(V!XIXEXT*Z@ZJ+',>V+3
M^>DKYQ<J#U$62K>;VQ8F&C'J4>-/;#O2J(#5-$<02O>V4APD=?EQ<R5/9V4>
MA9]W3D8&5,@0I=M4D&P_Y^[^45VY\+ $\LH=KV1/;DN/%=&I\KQJC^F@)=8W
MVPC,8*9^REEO/H<^YZ+LZ=3 Q"7Q=(A4N&.U-S8V#E^=,SV\EG(3#1$__/[E
M.SXBIO;S2!%MZD52=$_B-?,U!DIBQX9GK%]Y*)W(:6?+^#0.\@6FWTPI7C5J
MHHFW0=!R=8,I[3N7"6PBK/+E]CCV2DI6<!ALA6GBN+D%"-":=KAI3K"S1_R<
MO=J>FI92!-!5I'YGNK:]'1.#^-0GZ@ >(B:L?%&QDB/^&AM;@^0J&2G_3^HS
M0'$9AXR#P[3:T\]_*)+BWPWG"$*].HY_S<2*%5*C\IW37_E.QB@JXLPA>G98
M?@WM<%W*45^H6H4T_ 7+(R,6%]VHA49^\[+S&:,+7NA(CV1^MT4JR*QY(X+\
M8#2BV\,6273@'B04X.+A@5F\.*/NLT861P"&)E\5)> +BY"P&7?X.W+2O7N#
MX34$>:55@TL-^ \XR :FN8(+0K$/DZ "$5?#_)JH(DE-3DGI)O>GSX#ZU#,@
MN" 2SWG8BO X)#"X7)IYW1H'CP<, N5L^.G(7V!I7=OK6LK#[#+@NO39MY>_
MJ9C8>7Y&!XOSUFWZ]8?NQ.+R2EZWH@CZS?H%*0]REK<\X$I/^B-DKLK<I0>/
M0+U=]VAA+^14GE,L$BE8=CS7@-!L?KRYO);@^3R,%\G=M 0CI(032/"L^,EM
MT0=?$_$?E\19P'U;<U62?)6;-E5D'$E-4;'ET%;7HIL?M?XSP58:4JF$,R>,
MVJ((_"%FN.SO[JL&QB1J4ETOW82;XI@9$S\T,B@[%. YE .[%[G,9#E/B,K&
MR-F1="L&&9.MBTOHLW)#_49K:JS"'N1A1&%9SFGGK"RJ!,^,C_#-$))1$Y/P
MH=][_I[+DK:<K0],B8?GNKTT*/NE+O/CNM$#&5/C1=[!Q<'[O8;'V?/ C.U"
M'#^$L!^)C! N]BBOTLK44)C3$05U=D)IMA'2A\,,89FW?36"SQNLB\!N<?K'
M'J'W;53U=G,9139A:X )Y0QWP=8+TZ,X\:-XTXS06<Y_'=S=\6_1RLBW!^(C
MXG8<M6[JN4I.?-:2W"TL5,*%?/E&U>(![2I#^03BHGA$T0CI^+^!+>"OIO(]
MKCE]&S0^MCQ,**W@_MEZE#B8X<VXK&GNFFQAQ3P>'A86W>_+@P')>'\&_(E;
MJ S:?]WI'/Y.5':#FYP^E_:'E("LZG MAU7AVL]'5M]2&M@><!D(V4>*:-HK
M@-G^P&73\.[+-%UW30ZW87=+*8FIZQ &D,Q4F#>M?._M=%V?)MNK7@"[P=/\
MFO1Y;TZ@Q/ '$HA:@K'IWZ!P^2/__P>OROY>LZ$,0)')[V BEO'?:;(T]T7)
MLDU9;8LM)RNKQ"/LV:NNH65_ R;:R0X:#$*UG,6'M)&&\,R8+MI=CI>A0._?
M*5(C]4_0"/=OD4C5M?\\E*K[?P*V>JO>/S6L(&I=$\O\C+6G$\.$46115N\/
M7D7_Z-C]O'L,S#GIRK;6),_PX*[*'Q6P!$NF*'2,6D>(UI^EBXRO--+.X#8Z
MW,G[-]P @/1ON0'G=PP63XG*/B=_LH(,,RJG](T3$S#W2B@PZ8?^">]KNCX,
M+-R1G3213=JJF3?N&Y_9N+9L)A<*Y/^-(EO^A/?1U/Y&D5J:FU_J*RK6<!J,
M'8][*R?"3@8$,%]\%J;\'0+-\&8N>XBAL6S+T?IYW;%=;I\* 'DWVI.\J,<N
M':35"C8874FF6G?U)<0,7C1S# 68_F#*</R_#$?U?\?3:1 #%(;9N1UBKXX_
MF,,CP_OP XV\.\KUF@;UGV9PNZQ<2UE=X;GBHYQ9)$,C.?].P2>#9L[JGI B
MZ'C3([^J$6^I=E+O95GS<_ST[[DZ_\O(*J#V9V #L8FAI!Y2L[I4ZLGEWOMM
M+-ECVD-68^CCUUWNT>_/JRC(R:'I&+;8 F*:?]AC5=92R5)T82WTY0-K5GDE
MJ5F8:R+*:XW-=&]6#.^=I'.M]DTFO*8H2:V62"M _,ZRP7S^4A>[=&C6+.3M
M^%I8RCHO $;S7F1"Z:MYT)W()$NRXFI'V0@WW_@N!N0*4?_P&LD?@;G8]-]8
M+!"Z_,TR.MTFSH&Q)3JJ!</0;J!JX_<%D+![$%"1XW&NE,E<A]X;C\*R;85[
M*_Y=0"W^PP@7+2SBOUPG(5-6R./AQF7&DA=@U&0 4:MOAA=]F#8+WF=62%MW
M0!+;!#SCC5&Q\*3^.EK=&_T\VN_NY*VFIU'66E1F&:AHM&!93_UU@N_)EE'*
M*Y9)FBX#F#7%KSLL.U[8HXM]QA619J2,<@N6.& R8V@.:8G8O[7;_P*GZ/_W
MZ[]?_R=>A'P'(5-\*;I31CY<#,%W^:)LR2,$C<'II#U>S54-J&"@=T@L=,I8
M5Q[ZG3M!C"Z= &:Y$'+I5N2!&A<J?/>@PC>JOFE3*_\LOV+WXT9)R-R14S,Y
MV?RT"B[V-+-Z]&3\%;]%ZTDYGHV/0@0M&?2OT6>XQZ5Z6$#GIXL 4HWDA8Q,
M/%^2]XW$<3!)%#5B6=7]T]X"*CX81%$BR]@[Q0^VZ)N7].WHWA!20*Z^QZOJ
M<S%'?UO2Y]($QDA5SBA*D1)9?)*1Z4RB2UH3%7!5!B8\SPE*51(&W."8CM^)
M#_0-F&S<PGQM;F#8])=@^/*M44)870M=!4@SMUAAY:UY4A"A(F?<O>7I%TKW
M\GN@H'J6*/4H%_.=0D20Y[6J@0<W-09?O@GUJR*DBYV9TW<%Z8:(W=6GG>E)
M^\*>TES;T*:'9TA@4MK"5'5'*(YS 8Y#0]KGC/3Q0=RI>Q0:ZD 'MN<1D]QD
MJ&5RNH5+\YK6I]<<+)CI#>SSXZZX\VSFCH=88:N 3S232]J=[Q$ 2_TPD>4L
MU">'U7/+C-(981(1*]2$5K1PU5"BN03*+ @S9SR?-1<>GN.:UB3!,;U=IC9[
M:=87%E*P+43F;D=WZPY6'7%HPE_KDSDE_70&'/] !>CH,V!+9>VC\F#>TO>6
M6)((Z%1Q$/WGVHV/=R9.=2<3M/B<%M9CEIDJ,D(3/O6I&81^>*\H1@K%G:N_
M;5KZ<F^%Y$J5?WIP=P3Z>T2O\+*8 [N*N-Q]%@X'@]:&*>U)5!KP\#@$56"3
MZH9L;H@E25:89NL4&-W#4MY4$?=4DE PR\WXF*O[5-6P/?%5)>J+0YXKZ'ZC
M^\%.G&-HXTMXN++HZM<YGYWAS3^H>_!$Y(4%I0$/40,961]H=G;!)XI[>=SP
M!Y<G?NU'/DTP;=CQJUK/%Y4F8X5NGTAK;9YJ+1LOW7$_ \X [$^3QYNO3T^$
M#E3A*9L_]GZ">[X6P@UOV83MZFJ;4+K7G_ 46V3D3L]]U6VCS X2I!Q;PGAR
M&*_"@S?. .6^9>LRZT ?'1VZO)CQ/C8YY5N&%)DG^V#F4"%MA;^EXS>?*%[>
MF"X:>]*YR<TB*U0A\?KT<>09$(KZRJ(4EZ>JC[L38ZIZW/D^&P_<'[T[8D8N
M@Q;'3ZJ8&AL]='/9-"-#R=8B-BXN4.9J+,DSW/<TOJSGAP;$S6I.MIC%)K1]
M=$N?B.7KMW;IZ#T\=#7<;7<;>:^H(E>0NWI71')K@KZI.CZ.<;SMZO>@L%I#
M6V:1P^JKDKL[-"/%K7.-^MBT! 2LYZ>L0%HC73U(E/.6+8E\@U%R3A#1M@KU
MI.C(9]-^Y%ZE!6.)-?#K D5)M4LBB@:D.+XIJI!7UJ2S)TQ5!WEOF-L^$0M<
M!4&H!5R:Y[RYEX7WFW+N\U.X.#H6$&"3'XX\.YXT151H[B<R>15VCT&%]",Y
M-U%%E2=,ERO]1_\) 7D#\Z,34;6WO\\#,Y$/Q7[/B@X-P5R#Z4%%& ,ER&A0
M<:0^*(<_PNP3QX;_#]'M4<ZMDPX:H><MUME5"Y9@RL1=1H9L586O2J'1R->"
M1+45^N$8_I'KZ3:=B._:?@<W2[,/"/9^8CQ6MFQB?<XRF,Q)Y@-/HS9/W&=D
MLBKL*8&T44H$G=X0-0IY()\X Z:"@OT&\Y_YC?@2,NG4D:A>2\Y:_T2BQ!T9
MHDN9JO'#LR^IW"6IWDC;\EMDK41Z$?T?;J,:U2I-]*&$-2NI4NW^UC6Q)+4*
M]32=7CH\<65KTD!/?; 24VY&:5BRIM'?N$1#^AA'82T+=PNM8BXEY=4TH@ZJ
ME[ND#DS2&4.*OL%J2<XU4S&2\].=>%QW^ .:$)L+84Y-4+*9'-" :6Z E,@$
M@:(2/ZX>[D2[]!NZ3EH;"J*.=,!7H .KN@'?_3Y,=?NAIY@J-0U-/-EZM_5;
M[J6NA?5-LZ&<0J/0&-6O 5+0[N/G2+/\L>SX[S3ZM]"GHL5)2:W1GGNS1,1N
M8!X\V)"MB9@VW<O8Z/H>E,=,B46?6ZR4D;U"/#<W:$;X+7^<J6,7@:8[H2W+
M*!;G8OC,J9WU"C'A?7C<*LEY**D#,^1"G#8WFIUXQ5ID>"V>$BDXW9K]D.Q>
M("]L]IDA(TZJJJ:DG3^O WXP-M6C6Z.KB:R)TA2\09_^[!N(WE=DV=8N&7>*
M;K-PW##75]M7@JB$TO4J-G3<VFS2M/!62*Q*Q6WE&),84R_<["J^HN 0M$5L
M$P'>9W% V#9,A-H^E%]^<V]:)HCS?20]]@T"OPP&(1>?/I$N_IA/KI](/(R=
M*D]B+0QZW&\@:^HXU_E"WHZ^:J!WA>0T6I/!L^JD0YEXXZ@D'+G;Q-2W3NP:
MU2K4KDE'&^EJD%%MA?FV^O68O+,\YQ[U15L/]"4IMRI3=;K<RZ9FNM9_<T>:
M<2XX)O*!K_* $RY#1LF]\U_N8?+?*FXI7KO#I5JI02"3BV1IM^7#HB^R)E02
MZ1*8(%5(\JLFR4CD)UYHYHI?54R+BCX9>L!#_K,GR@ND0^]=2^]@9D<Z'DT:
M9M6ECT8NKE<MMU[__83IRV+AN]#8N()'F3%5$MKE9ODN&2+QSID*W.1TDB X
M[TC4[SMVJ,,[65/EM$S;28(=C8^O'$,=1MN5&HWD,95-YF@=L*H3&7)BDY,,
MI+L[B+:86F)6!.6_#3HBV)QZ\\/'6/:#=SA:44Y]^2L'R$(><:K>41[\Q\,B
MW24V"Q]T)7[Q-^_@HSC1XUX4[H[()H.^'V4*JMV478-S/5IP]$02V^]^U:*.
MU/VR/J2ZV=K':XF*T\X<V7Y6#_J^^#2!A'A7J9/6R/=6=(*"3J_MP+;J"..#
M%JT_'?K>6+Y9=R>4+B3I!Z;4[2M,M"5BOG2XP<SG1V%YR"NY\ ^KA;,O<3!)
MW9^B2"E_9D@0D?E#D@K34E$]EWU=2TV5__=M;UGPRF#FH 6TXHV%PV1TE&L-
M42>M/4>5V NEVCPF5@-9L?&[L%8Z3#+T FR:,%]"!8EW@J&=I9VUHIOM;M>J
MQU@[ @7\BO@,A%@Z9&MC4F-MDBFLL+]K,XOY"LOO1Z4A338X@6-9MPG2_A(E
MR4\#$BD'6E-.43TVSJ(&T5=G34 4D:)^R3F=_+;B(G._A88Q,;J01(OP@9!6
M=X[-V2.NE#W_L8:>L6TF$\OCDP$/,?OZ.Q?&_Z1+W2\@S,.6EG8U5(44U$(C
M:<Y<S38'H5WQCU1@+IP?]B9N.H!]6=$$""F)/KE<AGXL;\LQ5[-D%?51*&]B
MSL-=PJIG ?W#[6BXWWR'>126%UY'MC/DQ_$:$:NW^!._9^0;V\^B^)#7U@;J
M!D(7CL8+2[)+).XB-]#N^+H?8KL$KT3&V?)<@9]X6N)0/K.#%X4RD4MU3<3#
M)!GAQ=GXTN3WD\BBL;LHWDM.E2P30L=5N8+=':[[,50D:,^1^CR!O//!(*YL
MGW1?*.>9Y=?:NO?2AJ.PFC7?FSQYJ@2NC$GOUR[%[RO.]Z4Y;$SVVMTV2GP'
M(0)V@QR= G\CFL.O/[ DQF>=)OS\AD C[VR_K*;BVU.OCCUG\_@9QG(&.!V
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M_O[0+/W+?Y;)#T\2FO9'K6O3>Z7-GS!QK[!=L&'KI1_M^S^=L'$&
M
M                                        P!-.]+#E+U!+ P04
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M>ZTUY_S-M=;<?*1,BS<CEH#=H@K! ,'C9^[;<A,TDT<57(MB4F='F4XO27?
M+-]*07@NV._EFT?)/\9V_W)T('$L?7EC3_[4V.EV%,U-W%[-%QU:6.6U?<I\
M9R6(Z4\1] I[VM!_U'5D5PGFNV5'"6/A;FIKK&T*]HG[93E/.A@1W1%,>DV
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M^O.R1Q\6WC6^XXD(MT!M+"47EK![G71(YTE1U$\3(&(P7]\*<$NY=???^BY
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M]E3\&"2>T00P?FN >:QZ);= )PA)TF(IROT0@$?#C.3B$BG8S6[I:9KN7#U
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MI8Y\'F>?&^$$;;R+#FDC;FSD;/M6TOVGFR?X,X(DR<*2QY%I.N[^I:51>W-
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MO;"SMH60 R<O";3-FWR@$)L2.;NFJUF9'I8K<K$1?7O/C#\S76Z/T;1$Z0-
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MM_+4GVETY?6^DEXC?7D>@$93S#IRQYU;#$-3;9DP"] CU%U\J_2!HV+P@!\
M7\I2T\DW]W0-HR/SJ8_?;D]^N_13H]6Q&QH$\"@(=.%I/<E5F C6/!I^$V+F
M2+RE>./='F0#P]3^GOD#^F5:H>]U"<F6FGV^_4?T$4,V)ZU;U\""75XU-QZ>
MI3_J;9H,*;\8Q7F^\)^\*!MJ!\ LKRX6APJ*$E*=K&,3U._\'$0IA@.+YRT?
M ,2L%4PSK8TU]%$2R#8SZ%2SJ GM:R4P_V(+3<C%R>QLA)@919MZ$LG&>H7V
M[?FA3C<93I)5,4NVG7FL=IG(NRI\0/0HB\.MBIQ1)QE5*U]#>Q4N'\DY7A@[
M%>S/A&/'2,&.IEIW),:TN+Z&\:\.?.(N5U+AT[G:-GKMU^G3(;;&3_-XY6A0
M]OT4TGQ5IK1@LN]JK'CJ)^)XJEW=,9I-U-=IS\^=*9W&&RN^= E4!/W8O3J^
M3Z9'+DSJ(1/R9+3LO"6N>Z8AY9 (6NS3ONIQ>C1#!YOU)WE)^.43;H[CA7=9
M* A]Z-=,W!9VYMTF&W8W]@5%8_W'YG:F\*5DS(OB"N..XE(6)U%1]$/+(D#:
M;L<X@D"$0& KX6[%7X3KG*4-3Y^4<(XTI:3^QXX\5/$$YGJN)/!YSOWN/>A;
MC[$)UJ*C*!]$,))8OFD*4BL-N=:=?ZN>O]1ESG^ @_MI4@&-\91C^,.$M<N\
M07@ZQZH>Z" .=*7?GES2!FR0)X*_:X".OC KG*>U-[O[";H]OE7S\K! N4^#
M)BF&4B?+"%!QX(Z7[))1I6;-"[<E6U.'+GMA_^Q.,RK%]U) PSXE&YYQCW[7
M/KG&86$208Q&B[(M'.6)[XXXM(I^ZDXRCQEK9;>!E\E[6&73-^W+6-I273?)
MK#MW]&S;OY>4TA';R6BU/>A#F]F5DQ'_C%D\\)808&L.;7+)B'\J("5FB,3N
M8:O]7)HV0'J$=O+Z 7"&V_AHV^7@D2)S<^2"YH>':^K9D:XY]!V*2APA?TUI
M^\%TO*SL5NFDRPU"VR:W<:D_1;!"E*;+;;C!H4W/QO*DCZA-K)(-^,F1C0.Z
M H,6;]::Y&%J5"_H$&)Z_Y9BUB+3#<PW#QLJ5.^Q:PXV(344GCDS1XX[18,G
M9.(\&A'4!\#L'K;2*A=N.,]<T.[9P;%-2R6GSQ1?GUZ1WMU>L]7_5VM\NA1^
MTZ5>^WC3(VLPH^;; "I(4C]R'+J>%$1FH;OIY=P>D4>6^ZJXO6SU$U2T?,X.
M >\YNT"F5^DR,JOY#%ZHAI*[85I )'<K^2:M;\Y3',6#R<9F&+Z?8W5> SR6
M.YM+K>1QE^=&' B<Q-U_[ATA 4HBSH\*BO]!]DI-Y^_GO @AQ1:J CW9M9/,
M1@V?SVO[WN_A*OCT )Q>N--U0*$/ /.,N24^ATSV8V/,Z/+;7[!P"\K$T&Q=
M#?%49A%G)(6-IQWS#X L_TS/^9#5D:#L;S)<BS/\&.>"]'#.D74=6FC=^5QM
MV6COU4$SUA]9Q53?LC#>=POP3Z@I"$1^KV5L]HCQ5=_/M*T=@,LUAEUW)$XK
M\.R89;REL<9+8.BF !IICL$%3FK47AD4/!'KETB8!;_R@%N9?1KC.C3\86T'
M2915>9G(U@.@\8_,4T!I_O?*;^4TJV!XX&7TW3/0&>%BR6?1$K82-A3%\0L;
MD$24^<4=^+5IS!#UTJ]$X9LW?ORX07IG&%.@_9OV"[R/I[CP!'GLQ]:G0\CI
MV";D[-[2*O44:MV\90J6))^MZFNG'7/(M;C6A-05<K?M#^FKDO)^G\-QZN 3
MEE<4I?A8;)^"UI-J\^[BQM6M;DD]N6TOS:ABDO7^4@<8SGT/^GCR:[]VDNE<
M]+0S;"7)]"D6K@QT\B(5VW!RWI*H<D$\S6\]QD>,(O"BS.OO-;\HZ1+EQ-:$
M+Y$TP9Z26DV&4N%W_6[?;V6M3_Z<79O\R^S::X:_SJZ=]#G9T>*7[^0I137V
MBI&\*MU-T<F(-DQ4?7[#LR.MO*!%RB\4)P=PR@!,,[' Z<S0Y@RE#S\-)O+H
M8ZR<^'[6WZK*;PCOUB-BTOT!M;+A>&*:C*/F]JM#^,8$F.XL$.(OQ%N\R/VK
M-R7'C-\T=)87:/^,L#1_Y]8WW.;*1P JZ!XZ@#E@M"?]R#Z0MC.84^A@H<"Y
M6J(QWQ%SD5^>E41+W1<BN8E _TL(-NJ$5-LTY!+[?4^L%>\)O&ZL;B8@4Z%Q
MXQZ4_VFRO,S&EV9Q8&VF7L/CI?4?8Z0OD2-. T=T%\$8^6O%WJQE\S^,5KV>
M%4SIJLQ 7;?8 H42^9#A J>BY)EX[1N,JW:WB,>1'%?B+5%=1T4S6G')%Y&B
M883R8P#)8\0HXW,&J%DG[Y8P(Q\US46J;<S!I'9<[H"=&IDN@+/_6*V"Z; 6
M4ZVN.8!_Q2%84CM0E"+K1-(_\GLC41U"C/3<=_[-@H_;6NWA=-><7<CAH5'<
MN/ ;1Z,O0JFY,74?.;JWA:[+3D^6.W/T.._X*],.. >B[S'JRFN86:YEY#C6
M!NFJ1)]\0'VR7L#>+[+F)W37X\E=&&@4KGER>3<[?%9T1YWD*(.;M2<Y3;.K
MFX[<$B-Q]J;/!"5I=#U6&Y&^ L*Q2+)P0<W ZG>,9(I8E2]ZNLX]_I_JVVU(
M!-"Z:Y+SE3!MYR7_RIN)]<A7HK$Y.5%AN8!/1?^<ZMNYSS^\X7P6_XL&Y2IR
MYN*7]#]QJ_ZGUXE\"BU5M.8"U6D84K;4#4JC<A19]C)LUK[*2*__X4[N@8*P
M):(4#R7ZKR;I,PS1Q5SB3$X?JKKW:6TYRD.HHQ7,D2[^!_Z!&A%/@#R;9@<M
MXB3"[+ST43->WO,^FO[85\WW6RJ ^LGKXO_5JF-14J^^%2?2.H8P:(C-^8C_
M$UX;AU1N,H\L65/FJD&L7/ <IOV'YWW/A5VI]3:5QOZS[(O_SP(%W<4^ R,'
M#Q[O(AH+(%48!SA!7EV7"Q^(:KFDMW0G:+:[?/$+X#!'% KJ)H[7/GTZX1/]
MT[BV)K*N"+GXUO625G7/6VCB@%M0ZYYL:ZM3W43568VEZHVC\L9V;)]>)\1;
MR'R^H\DL:90Q0/BZ#JRYN_,D([]$?><J>%^A4=9=DCRU\0+@*/^]C%'O2P9)
M<Q/1?A');-24A:'))UBL/VRMTD7*:+J-2<MB.DO:S,AFJXSY6N/+"$V[RI]5
M9_-.32--BMU-;_GUPYT5!+OO1-FK B1P+0%S&6N,7A8LQM;B9*2D(7P*'/*;
MVH<CT7!!*R,KU^N( 4?T2%4.+:2P.$F#&$EA*U 7;]P2_*U;<G*&H/3:@E<0
M%MH&&PBC]*3KW?<'P&=K2Z6.>.T%SFP+ IZIIY&YPD@;F=JC:#H.:]@\TW>"
MPVD55^$H=3>X(VE&0@Z3+F6ET5]\2>I:>4:*CACLQR7).9 OD3.[N(-.>:#\
M1T*\%@&QTHZ&G0ZUTF)]A80SH!"N@C$M:2UZI=&"CFP)24JG:>%SJ!^700KC
M-WQS6HU7L>]ILOOUO0*U$87K[3B[O'(V#KYDSGS.H:17]U(D<,Z4=3ACZ:*&
M-R.4DO)SHJ.0_7<$]@]/'\P7L&G%DP> 9'7527K:+@;I4?ROQ'=(IL/N(UD4
MAGX\-3[@/Z:S+&KF:]*55Y-0-'RSSMZR>HL56-RF"?A,]8>MF:>H8!7:]CR-
MT\I:?7Q_+K]J-(E[6OEFBH(IWZ&^Z"'IH,,>%BDIW,-^ORXG0*FU)A%D9*_^
MGHG$I_"IGW8L;!T8"7"9HPNOB7ZN*V]5^/%,&N-(,)<!8YN4M$1M^3F<V\!>
MW^L!P#VYVO)MM@,NB7;RRYGGBB?10+RVC.U0+M 0I?/68:Y1"JZVFOXZ?^(B
M4L0KFQB?)=VJ5>Q:"/ERRT] CDYSXG((5&LQS<BET65$77Q!?<;HUP8+L11R
M,:(5B.@2CR+2^GHVC)4)LC8^KRHX0>E6@@UUOX'.:<E:/.EGWI2+"!&>KO]T
M,WE;H_@ Z-P:>S$D5S 02BZ!WCV)U.A5"@-W4SUO:6Y(7I:^BV>34'WZ7 *5
M<YJP.!OR61,[9D+Z#C<.ZW5U>F%:VKF&KI!X=$=33DX0.;$?.]Q*^Z@>S!W]
M8PCW=5C-R7MT@_MQ?G@'S6D6]EW[EPS2ZD8VGNPMCC3V,!X7X!<24+"5VQ]3
MUB[A8BZ%"_G==)%#D\!WN-1W9/FKA_A]?YS<0_)X3FW,OP[*!!@;(M'>GFM7
MA*S(O5C+@.3/82=^F@_]S'BMTO9IHHYC.1W@4@U+DJY[#(;HFM4+:T-&4MU?
MJO!M"X.^.!PK.Q]3N3LIMVL)6CT E@5MHG]&QO!?T8*%U-A%$BQ*X4:-P5>L
M//2'B7I,]]"7:J24??Q]M5JP0@/;#/+ZUC#:J+6EU2=284B P+XM)/B?FR>*
M5ARO3AOW!M'A)3+_QZMQ_J[\^7\#?ZX+;-:P*= 9DPFBE'>A>:I<HX"6;#'F
M'KUZV=.3YVG<U!9+DTQCSJ&!^]&/PB$BPFCT$A)N]P(6KM5:'R)_<@%573),
M/K(3(_D#_D,,.2.W?54'0H#4Y5XJ/64MI&BQEDXVLUACL:D]S[IDLF&, P=V
M^-E;MA6OZ5AU:SHWJ2:L_GJWI)7 +LL];BTU>;)P#[I7V>%20 /9Y8"-8$1R
MK["&7FGTM],/N.E+]TW&AT%.SL:WAG[4?=>9'WKZ8^,-OT(I5N6!1WE!&."\
M/8Q14!OF8:.ANK+(%IJ:95V #K>TJB!U]U-O]3OI.=O;E+'[P/Q,F#= T.WB
M&B)/8DX\-W45POTM(C]].I7EJF\H0<CS@GM* >UEEKO0K#N^#<YAP(AK^01'
MVF=7$I++#LP;59$0R+XO_L2TQ)00R,>9>4"=KN;=WMY'T9$;OL,>3V$"I,X=
M3]/2<O=V!+Z/[J\RPP :PO3JS#074H,'P!/;AHT[Y93-H(WE%S7D#8=F7N;9
M!K1#I/0AVWN>.#G-EO1/R/LUUP;=\:Z$8JL8P<ZQ$=-I[FK*D]XTA;*Y.C K
MQ90-F9_1-C@;\7Q[RR&Z[A5R.7Y\K&@:>Z>P$:W6*6NRV7(:"13E;V?VKL$[
M4A04;JC1)%K+NVT<XT+2%H6_O+#PN#CR,#2^>B^L>/'#2UL?[SZT/3ON!N/6
MTH7+M 2H=?;9T9K]M"?]Z!KE V8 =E5;@; .N9()LYJUU >9_(HU")"#T0H+
MUW4B"9"V;\W"72 T\B%RDW#VXE\>3[XD2M$P5:W[.=U+6!Y_=M:1OGP<9"^L
M%+ZPLA+0JJYL] $I?1 J0/\1S8.=+)PW<YVGOLQ+NK5E:V-EG65;G-_3Z,B;
MS (_P66JFMI/DH.'YZQ"O2\$7[X[C/+H*&\+ X0M$-:%2E%_!@1>%)O_"PR=
M_S_QG^'C1K_Q?PE_9>J6EW^E/Z-(?V7J4Y+_/?DI N2$T?_&?Q&4"%3 /2ON
MUF_(6O^:VN$"6.B=[BT?9VXP7"K^+;7S;X$0B1VSK4D*/8M!HI26=5$42:\/
M"4[(OO;V%V\;G.BB@B0S(Y[\8C:T_A"8V(;QRODRR:YV5"3$<HF@;?+XT@Y'
MEXDLJ"^3:6#D*\=' ?W[]<DPP*4G0UTN&">Y4%M/V_8L*Z+_AX0T\G@#&";G
M_<D+.%>SC"%E?5LJ(VU&E>5PBRQ*%2CN)()_&MD>1I-"@ZRY-/\ @/A'N>_&
M^+:ZKR6ORQ..K'ZQ;OMEFL2Q*-6/S XPHLK4!.R9EZ,A\"O('@"C^8]]G>S@
MHCF\M)5CR6O>KFJAR53**3UDW(]Y3-NT<MWK,W19?)2K=[(B9R3%S>!Y5.XR
MY0W%J0I$R*-(?>_$8HEN7*1C(DU2R.;KL,-QWT>Q-3_!P?_;YO\W_C5<*BY3
M<ZL(#BS;K=A200K*.Y8@W;EM+B@/?-= 4\XXYKQH)@=]=<YU-V-+3/J2?$NO
M: ]$EG$T/(=8A!P=KF40[<71&]Q.)\.F?T S**JHJ$?S$P?-:77&2M,<'1+H
M8@=V)PB0]O[XLVHX@SMU%#:S*<P7(?>IZXIX@AY_Y$FS'QNO49J7:2.8"!:V
MASA'X-GA^EXAK"$_!WW57S2,&.UY.>^Y T9.3!_'3*@(]>0A^Q4;A.IRYZ>V
M/D*09**-2:#;^2W%JI*;H4_PW($W;Y:6NYUD5.?"D<&Y[$L2#OX]<-858:Z#
MA8TK@?9\#]O[A//G/+A%OP!.=<MX0JQ.]!&6ACQTR+]")WV-]7VY1T<<8V>&
MG"/*PDECV/B?(J5!@:'>G+EZ.TG!6N3N&U(:X\81C"^1J3=PTIS+@"%*VGL@
MW&,;8Z9Y*O67=*-9?/"9T2?>="'#X[7,'_52MM8.2ALITNCMMK;*X*HUTBVT
M]2@2=UZ?36Q7* ) BC?*P&=;JB>+F^WPFJB#2LH.A@:$! 3^*=WPQ*CW(]9$
M;YBPO1OXH 9I?$>-U6OUD&=/8I$66MD<OQ@6 -8<+5O&F4_5P[:P9^N2M,#_
M?CW'>0M-^%M64H7?><<D(<_47GUC)?JDX %@(G9_ V)'$"!YAN7>)Z!=;\#[
M8(K_?J" LL<0?:4,7(X_!ZY*_ON!*'%1"6A6 >PK_Q,<!/SW X!N3M'?U(%_
MZ_VM][?>WWI_Z_VM][?>WWI_Z_W'>M7KZV1-](.^T(&X 7+_BVL4D+9%J/6(
MW94MR6K+*[![OYEP>/ "JB5;3PB,G<DK?\#I'P"?G;H1;,%0.;!2?:"<?C6F
ME\E-*@V-D"?5QOIX<Z2>= WT8I:)524%_1D385T&CB1(474M\F7H*['/XABY
MHQB GU-EY1-=G]1W3/0;U#^HPE>H22BH%LQ0&[!QNW3Y3LYDF%Y.!/YTHHUC
M,[.SSIC:JU%  ^8^ #K=[DO1KBIF1+KBMPYZ#_0O^MH81KYDG1I:*BZ9$Q.-
MV+Y"?YVW7OKDXXKO9YS<?.<+!;2,I1GWNVY[<LSUPMVZ..]J+KK721.EP*Y7
MS928XG6C7%^<[[2_1IBD7;H*J]];280!SH<R,6#A78B739-P5EK\'ZX]>77?
M5IY\=(A" L0'/*/ARZ<B/B4.X[:RJB 4KN%1_=5HO<*/ ^;\<21-=U[Q[E^
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M@^7K_@(@H"N#&ZWOW@GXYR9,G_>X\/9O8'-#<.H9WS%,U/ !D!7XZ+6S$5Q
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MY8>2_KKN,:14KH6;END)$^BX1U3G:!=,M<P')K/4#E4ROA9F1M#S,V]#$MJ
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MO1*G:XNWGMHT#ZNW]O;TF9[CL-E.*V$ /Y%=.B.JH"F-!3A4)6_(0\:VZ''
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MIBXITG%->#?7JNQ_-#@L#D.(@;>9,4 X^)K-R!7GY'B;3:J!'UWI3@#91F,
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M*'$H:[0.-SH- DW$HA_D88"-2PQP\!L+UK:Q%6O\MR*[0U6*]>/7GC\TE"0
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M_H H?=BXI?0NL;R:X/W]&UD^I2=5E7SIYKXI6#&42 %I3;WE,_TJMO2"-D1
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MEC :N.#=/NHHV.6:<K*"MM8.)7.T9#W0&*R:LO+3)JN*$+/2)FP'NH@PSHY
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M0>[=.3TN.F;\TW7*_.B5QW?*+J+MC"T9Z9522K*93&=N@6%OKI&$ ^AU5 '
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M";^M4]HH3FI[N]\Y$!]H/PVJ4"T .#C("3="=;9"[M>9L;Z E7)>FZ]=I^S
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MWFN+G>_A9YW*>3B7$7_G')P' !6&U&:TCD.>]":4R[A<JA3321?JYO IC-X
MK+JOC.QDZ*06T\;4.)MJFK1S-TS BI2G?_"GCTI4QW&1#Q']SE6RJTHIF8M\
M.GLMYV?&;KG0Y_::R -D@Y+(':HV!4;:7HR0!/PJJ'/:Q<W5Q?9H[;7D+SW\
MHYS!4S'W[V.+VU4[4K0+7A].KN+-AKNB$MI?XIT>[C>'2NR)0D$:[U8UF-66
M@])%GAN52F""?$K_TU/Y&*VYR!0[N%?_9L<YAN'#Q0W ,%Q(17JMPZWNU0V@
M-YL-(4;Y#>FDF[^\$FKX,FHLFH'63TMH[MRX:BIX?-^=M$Q![8'2VF]L1Q9
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MI;A,W=84M<G]]JZRGO//(#^%G8X1MD_Q9P4%L)XG:_-MW.UFY,;,I;JS=L
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M65[K_#*7/%U91!VMG,[2>%W>*XGGB5)$J"FAT1,)H6ZW;=AN[*/&MV@VG1O
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MZWF'D(PP@RC0MJ7A^.!B"AA<$V.M2B[:&LZ]85_]A'.)U;*=<@&U+;^2U1/
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M:523ZVL^:>EA5UQT]FA?EQO Y>D-X,J X;#&M?7\9/P&< "_ 2!=_#O 4S>
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MK^&CP;Z5];!)Y+O!0PCH?4#OHBME$*^*?1.028J@9=K'8'E&6W7*YG@@ ^A
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M-$;(-!9E&5L"4]5$]<;]Q$:?3D^J,L][:9:J*UT'!>2=(W_<UQEO<LZS>4X
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M2FWB>S6"+=;SMTEZINWQC#J(:*1VU,'AB/C[!03'>!8][-^YTZ-.V/KGT8-
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M2P$"% ,4    " #R@5U8!64DIV.J 0".9QD $0              @ %G100
M861P="TR,#(S,3(S,2YX<V102P$"% ,4    " #R@5U8HW[X+J(#  "H%@
M#P              @ 'Y[P4 861P="UE>#(S7S$N:'1M4$L! A0#%     @
M\H%=6("IV.G8"   -D    \              ( !R/,% &%D<'0M97@S,5\Q
M+FAT;5!+ 0(4 Q0    ( /*!75C<:#TE\ @  '1%   /              "
M <W\!0!A9'!T+65X,S%?,BYH=&U02P$"% ,4    " #R@5U8(2FG2PT&   V
M)P  #P              @ 'J!08 861P="UE>#,R7S$N:'1M4$L! A0#%
M  @ \H%=6$,?$O@O!@  SBL   \              ( !) P& &%D<'0M97@S
M,E\R+FAT;5!+ 0(4 Q0    ( /*!75C70#CVY1D  "G%   /
M  "  8 2!@!A9'!T+65X.3=?,2YH=&U02P$"% ,4    " #R@5U81>6R%AE5
M @#*@ 8 $0              @ &2+ 8 :6UG-C,R,S<Y.#A?,"YJ<&=02P$"
M% ,4    " #R@5U8)_0UCFG.!  !H0D $0              @ ':@0@ :6UG
M-C,R,S<Y.#A?,2YJ<&=02P$"% ,4    " #R@5U8R3A360M.  #T6   $0
M            @ %R4 T :6UG-C,R,S<Y.#A?,BYJ<&=02P$"% ,4    " #R
M@5U802X","D&  #R!@  $0              @ &LG@T :6UG-C,R,S<Y.#A?
M,RYJ<&=02P$"% ,4    " #R@5U8)FVT)%;M @"OL08 $0
M@ $$I0T :6UG-C,R,S<Y.#A?-"YJ<&=02P$"% ,4    " #R@5U8]PGD8T6N
M P"ULP< $0              @ &)DA  :6UG-C,R,S<Y.#A?-2YJ<&=02P$"
M% ,4    " #R@5U8B^=H8CNG 0!#3P( $0              @ ']0!0 :6UG
D-C,R,S<Y.#A?-BYJ<&=02P4&      \ #P"E P  9^@5

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>adpt-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:adpt="http://www.adaptivebiotech.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="adpt-20231231.xsd" xlink:type="simple"/>
    <context id="C_204a4f00-21f5-4dcb-a003-2209a2b96734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6ce95484-a0e7-43c5-830f-bb7a29b093db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1289e3d3-be6d-4b21-8182-0e0ea07d3d38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adpt:NonEmployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_546b97c7-d4df-492a-864d-7d19a8b5b897">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_dddab8cd-a34a-45e6-93ef-3d378391ba43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ee2c393f-edb6-49f1-8cc5-881b50f4a194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">adpt:MonteCarloValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5aa06285-f2dc-4040-87ff-e52ba00117cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d8710412-3f02-4dca-a349-7c6431efb35f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_80445f63-6e69-4b85-a4cc-f71cd5e32898">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_744c7609-f08e-4e56-a57b-92d4b5817a10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_83e9af4e-f8d0-4e18-894d-bef3e41d1fa4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_210fa5b6-4781-4834-bdb9-d0bc4fba918c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:RegulatoryMilestoneRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6d31f8e3-6174-4d62-813b-9a04cfbac43b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:CommonStockWarrantOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e97676e6-a32f-4929-a773-40c1fd1dd414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_321cee55-58fd-4472-9917-05fb1e50572d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_508f5dbc-ed11-4aeb-8235-78423618619e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c3ef0edc-d7e9-410c-9e8c-a9c962f71593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c0865de4-d48f-44cc-8042-17b502c84d61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6df997e0-9e1b-4ab7-9d87-d11884be8e4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_974e34a3-8a7b-44ac-b595-2e251f3f2e9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncAndRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c6893910-acd0-4028-a16a-e72e33a1a487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_eb640244-c177-44b5-8d08-c43654ceed7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4ec6bc83-92c5-47f4-97fb-4663a45fb872">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d207b5e8-b241-4c93-8d72-a110d70a2fa2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_38611b62-cabf-4f6e-b0a1-2efc9958f5fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fb89157d-97e5-40d0-828e-fcafd3b932a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_17868eb1-c4c5-48c6-b75e-f00ebc3afa5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a17c4258-455e-423a-b8b4-bc69663eb694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:ImmuneMedicineServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fbb4d461-a817-4980-9efc-c5c5e7bea481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f120f473-834e-48d7-9c3d-c58cb26bc159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c035e4ca-1c96-49e2-bf85-b7dc628cce3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fdc597b9-fce4-4adb-aca1-c9147dc51edc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_04747ad8-13d5-4de0-966f-56ff96064b6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3b24663a-22c4-43fd-8173-22c3ea3e4a68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a720e09d-5c96-4740-a504-9844af0c34ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e8a9a7fc-8e3b-4b0f-9703-17e3dba9a414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">adpt:MonteCarloValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b70f1afc-db7d-4741-a566-077b3ae24fae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7ca7acdb-a921-4bb3-90a1-1d13fd95b1fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b0f7c504-6f69-48ba-bdd7-d64ff949d238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1e722b79-1338-44ce-bc10-fb18fa0cad8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2ae500b5-b450-4303-939a-c1ade0ffffce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_dfa7b2ec-aa90-4f5c-b852-1f27ae360214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:SequencingRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_743fa22e-b9d5-4339-a15c-2d857ef34156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2253a734-72b4-4815-b0fe-904db241abd5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2c6f52ef-cda4-46f2-8c5e-0be3e165c699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ac72162c-f6d5-4828-ba60-f9c5be19f188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8b01e241-462b-4cbe-9903-9e86be9bdd64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:RegulatoryMilestoneRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_866da907-3204-49a4-a785-caa968f66943">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_233dab25-77c1-4413-89c5-c93d77ebf3f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f1d9df12-63b0-41e0-839c-848d1971a89b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_feb3a029-611b-49cd-afb7-35c3b0ac8813">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1b2a261c-6d6a-470b-b858-a470f3e89fa6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fa96d089-dfe6-4ac2-947d-35adf78b92c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncAndRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_39323104-bdda-4a5f-b4e0-aa2def94b95a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ab0a4bc0-c687-4b75-97a5-8e7d11a1a0be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_11c9cefe-d945-4687-baad-0cb3aed4a0b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c4af3728-9703-4193-8445-5f99fb79c576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1a866f0e-30b1-4ade-9e73-d9a9bba031bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8c236b85-61c5-4e71-b6c3-ced8a4945424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_13005d32-f646-429f-a0e2-4fd8c00bf69a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d77ee3a7-0648-4c68-ad86-6a36e26d4d2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="C_9af75d46-039e-4da0-97be-856b25cedf1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dd0b38a4-c17a-4584-ace9-9eb7a4dba7cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8432b103-20fe-4d39-a798-e24e82f7508a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f97d20b9-f753-4b1f-9310-f5374bf7a287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d8afb5c3-07c8-4db4-ac88-9ca5562689cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e3e3db77-5861-422c-a654-f78b40f8db36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">adpt:DigitalBiotechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3ebe0fdc-225c-4155-afc8-97ad3dc284b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_44860682-94f0-4904-9f2d-90b50cef0eaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDDevelopmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_241a14e0-c83c-46be-9595-a7086d9fdf64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8c9aa062-7dde-4480-8d81-ee9c2d275da3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_11a7257f-ddc9-4e22-ad34-a161c6bbbc38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e840ef1f-0c35-4d10-9610-9d3bd41786d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1e988e7e-5089-4aac-8a2c-022b8659ce3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a9f3e4a6-a161-4edd-ae17-b5c6c4d1afc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="C_c2513f06-b4d4-4816-bbc2-a3007d07bc1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bc38ff0f-2c7c-4c26-ba5a-4c9791880b39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b727e5f9-4a98-4fe3-92ea-13e9386f4879">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5b34e135-b44f-41a1-b917-b0dc0f2c4bf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7306e5e5-de3a-49c5-8ca6-d62df03366ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_590e8b43-3f28-4c61-98e6-73136a10b460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a78ff4ac-0c2c-49b3-b6c9-440cbe865835">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_aab74f81-a01f-4770-b79a-d5141418080d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-12</instant>
        </period>
    </context>
    <context id="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_041a7632-3fc1-4163-8570-83d81957490c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_41662c43-8800-4ae7-bc2d-55dfc7db0bb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a716e596-2c29-46d5-9c2b-dba9981ab3f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_58ce94ff-2264-4ea2-a84c-edf34c96332a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d63aae94-5743-4e75-a64b-3a0caabf8bd7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_96f09fd3-7634-4ea2-a021-1e8adb2f4bc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2023-12-29</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e47f789a-559d-43f2-a31d-acdeac94f7f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6f24c325-cbc5-4f36-913f-12d35e35dc7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ee1fde54-f065-4656-a66d-cb2acf02bfac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_adce8143-c708-4ab4-aad4-7932228c2737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2eb19fde-1742-44b2-a814-dd6adf82062d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5d4928f6-2311-4267-a962-fb87a6ccc8c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9b79125c-aadc-43ba-85de-4c5908f2bb4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_89c81479-2ca4-45be-bc13-7804c0d2f507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedMarketBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5d872d1b-6381-4a56-9eee-12e5744bc07e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a0652792-ebc5-4eac-b642-e4d6670801ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_af47b662-9bf3-44d8-8091-3006d4c6e691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d643066a-d834-4dbc-94f7-b192fb198f27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_225e2fb7-7901-40b4-90c2-b52ec6899530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_efab56ea-21ee-4b9f-a82c-12261558a450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_87dd786a-314b-49f8-baec-1edeb4120c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7982225b-427f-4a1e-8cd0-412895f4f7f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ef1ad520-2e19-4c3f-ad13-c493a883fa78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="C_7e26ca88-f723-4c17-a005-4eccedfed38e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2650e075-e451-49ad-955d-e9ad14d5bf33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b0dca8ac-f948-40e9-872d-4956561f7f9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_51e0ed6a-9fac-4c20-a4e8-435eb73af38d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_f834ab3e-f5d2-4656-891f-53272cd08ed4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedMarketBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_52090110-82a5-4e46-93f8-8226b4b52be6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_02b5636a-5e74-4e33-b07e-81d5098e6ddd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_919788e3-23fd-4409-b58e-83649ea5febe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_1a66f191-30ec-42f3-b59c-6f6b27af199f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3bce53c7-facd-4e2e-ad21-6441c070f91f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-12</instant>
        </period>
    </context>
    <context id="C_01aa24c7-60e3-49ec-b493-ede3c4266545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_82171477-fd8e-4a87-a38e-80b61f287043">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9a81b7d4-7c86-4a5a-9662-9fa8a4acafae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3e2c359c-7df3-4fd0-ade8-9c6156b3f9ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_99d18c69-4d22-43ef-8389-5fdf986876eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_097b7e33-8328-4df1-98a7-2fb97904b263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ff22cd37-5751-4b76-bb68-14093905829b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_27e427e6-2646-46ca-93cd-c733bfaf29eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_db4b7b1a-cb0e-4d01-8b52-9a8b1f192635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cd98abbe-6241-4fc8-af88-d9979790e940">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_682d1e35-b24e-473d-a5dc-2e2a8f3b17fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="C_879ff3e9-d994-4359-a193-fdc194e1100d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4bbcd131-d371-4bbb-964c-f9710f39d70f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e3bfaebb-d3c1-42af-942f-8e8d8be6dd92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3e2b380b-13d2-47a9-a0f7-95998f87ee50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_698d77cb-703e-4d5b-acbd-9c92d097b8bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_60b74489-28b2-4615-9786-6fdacef93898">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_95bf0290-eef6-4156-a6ce-f1dc2af43daa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_497af0a4-b8d1-426d-b46e-bab07be8dadd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="C_57eacb73-0b36-49e5-8d6b-de05bc131c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">adpt:MonteCarloValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5e49e82a-95b6-4034-a713-b8f1ec42273a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5345840c-9735-4c5d-b8ec-b10aa2abbce6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_90b18a98-b831-4016-b24b-b23fdc203a9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_46e84d5a-c9e4-4c07-ab2c-1b337f1e4935">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_905db261-8b17-447c-a833-556502ab34a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8a8f8700-656c-4aa0-a7b1-18a1188de95d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:CommonStockVestingOfOutstandingRestrictedStockUnitsAndMarketBasedRestrictedStockUnitsGrantedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_454dcbb2-775d-4dc6-8e99-ed83e128e3ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2b549b79-66c4-4298-ba5f-b1b62fef2585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="C_82f4bbd7-e097-4e32-bf62-da8405a3dbfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_623eef52-d53d-46c2-8e13-de37ddc266db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e77e6257-9358-42eb-8b65-6f87bb11fe8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ef915afd-ec97-428b-a6f3-a6066e32a6a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2a889da6-68e6-499f-9f09-345a151867c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b0c61c69-cbe1-4b8f-9a70-56d35c5b6efc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_67aee0e6-f162-469f-95d2-8cd5d55d1668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">adpt:DevelopmentMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_87feba55-a051-420f-828e-ec84f440b3a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a75aed5b-f247-4baf-af25-a000ba7211d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b2a6703f-315a-4dab-97f7-15768deba909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_091e55d9-10c4-4aba-84c0-5a9e97322c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a3dfafff-e989-4644-9b5f-c4c61d62483b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_26c20ab9-dfe4-46c3-b509-3bf6d6c00d37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_1ebf03ab-8700-457d-a330-2b6afbc9f9dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fab848dc-7a49-4318-bdad-9aa948d6f630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_9ea6d2a9-4933-428d-a214-8f22b0ee534e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="C_3787167f-f9fe-4167-8297-ba5c7cf2cf41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f352b237-e382-41ae-acc7-96078de3a980">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="C_a82a556c-1601-4580-ab77-910e118cd40c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:ImmuneMedicineRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f2870833-bf7c-4640-b2de-b1f3f45dc7ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-12</instant>
        </period>
    </context>
    <context id="C_1347ec09-38d8-439d-8a28-61beab707a2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_71aa9e96-4108-4a98-82b6-96eb9ed09cbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a21c196f-6dfe-415c-b90a-3c3da2b36e46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a850bcd3-da63-46d2-b9d7-bfe3de139a9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_18612828-7d58-4576-a6a2-b4505743ef18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_46c823cf-5ea5-4b9b-b0ea-af9c60b6fd51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2fd988f0-f2ea-429d-b4f6-17267c9ddedc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ff166e5f-74cd-481e-a4de-3d85ebc33d6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:ImmuneMedicineServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9b1f3710-0d39-453d-82f3-7b451fd927d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2024-02-23</instant>
        </period>
    </context>
    <context id="C_ea6a3074-5c90-4942-a6a0-917ee25491db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="C_8b6979c8-1fdd-4825-99b4-52c44d8a83f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7984164c-34fb-49f5-8c89-ae672ec9ae5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="C_c0b012e9-1d72-456e-818b-e7c99403c318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7763f050-ced0-429d-9db0-76d18214c5c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">adpt:MonteCarloValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ae994e8c-99db-42b9-978b-de43f2096cd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adpt:DevelopmentRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_79087f84-8200-4e59-be47-56564ec79f8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d3b1db82-a429-41f4-a3a7-519573159ff1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1bea693b-1342-45f0-bcda-ded1c10280e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_61d852e8-fe3d-43d3-9908-9744f1adec07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_52139d7b-c2be-477b-8367-d18a6a83b6e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c6dd27e3-1742-4ce3-b818-2cc2fe370e7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">adpt:AvailableForSaleSecuritiesDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7318b790-ee25-41a4-acff-80a6c93d4e3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_060ee2a5-56eb-46bd-b35a-e98de401cab1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fd3f7f0d-8716-4252-b061-74865b34ce51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_aef81851-9d40-4e26-b3cc-121716608ec6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_36aa5e03-ecb8-4303-b58a-1c55adb14e7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_27c4f267-cdd6-4003-8d32-93af9d170fbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c6428414-6c4a-46a9-aaa6-447acbd2d45a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:NonvestedMarketBasedRestrictedStockUnitsGrantedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6f19237c-a155-4029-b45f-b9fb5332f737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5b9b7218-2fe1-41c4-b97c-55fcf735df6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="C_461360c8-498f-4146-b38f-94ec6b8507ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ac662e7b-0f00-4834-864f-bfae853d3fae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncAndRocheGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7b1ddbb7-6337-4d2b-8237-82b13e821312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f60e9643-430c-4ac5-b6d2-f2549cc4ce16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5a86b9bb-1277-4e79-955e-d1edb50cca23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-12</startDate>
            <endDate>2022-09-12</endDate>
        </period>
    </context>
    <context id="C_155c8aa1-a117-426c-ae23-7248267399d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MedicareReimbursementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_18d7a278-e320-4faa-bd10-c3406fe899df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_f712f0be-9f2e-4186-a7b5-0091ce1762f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f7590b76-24a6-4b4b-aa70-3aa848e7a0e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_10ea6fb1-7d69-445d-8fcf-bcaaaf8ea019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:CommonStockExerciseOfOutstandingStockOptionsGrantedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_91cb6778-e1d1-4172-888b-784d43882ecc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_04434413-9490-4c62-8db8-4065a648f009">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_216614d0-45a0-4666-935c-4122d8cd59aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7e1886f0-fb32-4498-bc32-5c4175f816eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c4963ee4-2b06-4690-ba19-b7f24dff5cc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c035c769-db33-4f4f-a68d-722fe5a08f44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adpt:SeriesFOneConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MicrosoftCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_8026f205-9131-4390-94dd-4a04d3c584e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adpt:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bff5bd4a-2423-48c0-a5ec-9acfc6922d16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_43621f8b-6a5f-47d0-a30e-6bf513d24ad8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_be4b3886-95a1-499a-bdda-548e8b19d654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">adpt:NonvestedMarketBasedRestrictedStockUnitsGrantedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4c37a096-1a6a-45aa-8fc2-563181d9f721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d0727108-4458-4e50-b34a-e52b89840f12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_dfe2e57d-4fb2-4493-8bac-7c38728d7cb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MicrosoftCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_2bf1a599-2304-4abc-8e54-646171f11931">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:GenentechCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b809ccc7-b28c-4fe5-bb88-66507dc666e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_026378ef-7341-4384-9043-f55629b2679d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_5c8126e1-b6cc-428b-b0c0-8e108d6c872f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:NonvestedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2ba2e40d-74e7-4c45-8c1b-863af5547a3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0cf4be7f-ab3d-44bd-8576-4b5ab607235c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9d2cc705-f6fa-4bf8-a55b-b2a0844f2132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:MRDRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_701c755f-589d-411b-a770-4fbc3fc69793">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="C_3c608cb9-e9d3-4e98-b40b-a50be54d13e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d18ea8b5-6b95-48a5-8cf4-dca1eb7587d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cb59ede3-9e6b-4249-8eda-53f2caa6aa96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adpt:GenentechIncMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a8a04fa6-b5e0-4214-92b3-ab7f17428e2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adpt:OrbimedRoyaltyCreditOpportunitiesIvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adpt:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-12</instant>
        </period>
    </context>
    <context id="C_f45bf03e-7ed0-4ba6-8ffc-ba5f9e654d96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fdeb24a7-efd0-43c6-90cc-7c4a9389752a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adpt:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_55a33622-5845-472e-a76b-82768e6681b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">adpt:MarketBasedRestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_f1b230a8-3c3c-45c2-a49f-2549b9086405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1bac84b6-f743-48d7-8309-6858a505babc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="C_f90dae10-b7ce-472b-bbb0-33e4307f7344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_97bc012b-5315-4313-9c87-2f9e1fa58826">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6ea1b178-9b53-435d-bea7-af3f35409ca9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="U_Segment">
        <measure>adpt:Segment</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Employee">
        <measure>adpt:Employee</measure>
    </unit>
    <unit id="U_Performance_Obligation">
        <measure>adpt:Performance_Obligation</measure>
    </unit>
    <unit id="U_Vote">
        <measure>adpt:Vote</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_cd95f3fb-1b6e-4c7c-beef-668725e2a1e4">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_85eafb05-c8b6-4d46-b7c4-7d981967cf39">0001478320</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_ea9e46df-0042-4170-9204-7ef4ffd5aa19">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      id="F_55f8f7d6-632f-412e-bc01-7554244a9f4d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      id="F_d6a13563-c650-4666-8b43-b3a899701ff8"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      id="F_adfd113e-7a67-4aa1-b775-f1a7ae594c82"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      id="F_a75961d9-fdf4-4b72-9a99-3b20df2adb39"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="C_1e988e7e-5089-4aac-8a2c-022b8659ce3b"
      id="F_de9ea103-2ab7-4e3e-8c48-d7bbaf7c674a">http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_644ede94-23a3-4d5b-89f7-eb3175c3cb6c">http://www.adaptivebiotech.com/20231231#ImpairmentOfRightOfUseAndRelatedLongLivedAssets</us-gaap:ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <dei:DocumentType
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_37655dc6-7d30-4ccc-b20e-4cdc534576c4">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_700e129e-8e7b-47e2-915f-4f2c79342377">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_5f79e630-4fb5-498b-b23c-ad50683a7615">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_cf555f04-7046-4a9b-b336-2227057a8a4d">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_81134731-31df-47f0-aecd-db584d83e5ac">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_e080add7-d7ba-491b-877e-08991480ff6b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_ee57939e-66db-4c99-b7b1-f290d0f7084b">001-38957</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_7b498bb8-d218-4c9c-9807-c531c87339b3">ADAPTIVE BIOTECHNOLOGIES CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_62f46534-2118-40c4-874b-7aac3bcddb06">WA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_e1b86055-5b45-473d-adcf-535d692a6cf0">27-0907024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_0ced6460-ccdf-4752-8799-ebe364936e5c">1165 Eastlake Avenue East</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_87a4ab9e-f2f6-43b1-81aa-8ef9785ad088">Seattle</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_9ca7f2b9-beb7-4aa2-b3a4-e8e241f1998c">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_191c32d5-79c8-435b-baa5-bfed2d1bddfd">98109</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_ed95b0ec-4887-4e59-9ad5-b818bcfbacf4">(206)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_737f52ad-1e2a-48d1-a390-17258dc45a18">659-0067</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_121dd42b-d033-4609-9b10-f0893ea46c75">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_9aecc1aa-1031-4d4c-9de1-7b879dae6b69">ADPT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_ca684741-df6d-4fb0-9ac9-d5015a4aa7bf">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_d2079a94-993f-49ff-acda-dad2e5696497">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_93aecf34-1176-4535-8712-467c32f34416">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_79184b76-e536-4857-b3e2-7c9adb4e9a49">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_04aef337-c285-42d2-8bc2-cca0af009ba2">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_c4bae6aa-0a71-4990-9233-efa14c11b8cf">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_5ecbda32-7484-4af6-9277-f37152d6db30">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_f2e131f5-34e3-4510-96fb-9f26a31a72e9">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_b4e9990f-d472-4230-89d4-234d5ed7a906">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_5da85698-6a4a-44c2-80bc-fd5a10f9f60f">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_5ad394a2-984d-4dc1-846d-0dd64f994a0c">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_026378ef-7341-4384-9043-f55629b2679d"
      decimals="0"
      id="F_a2895f85-ef4a-4737-ade0-85565d2df610"
      unitRef="U_USD">756000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_9b1f3710-0d39-453d-82f3-7b451fd927d2"
      decimals="INF"
      id="F_a85bd9c9-f883-4c2d-a08b-f410f05d6b8f"
      unitRef="U_shares">145092271</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_3dff39db-a7b5-4787-9c8f-abacc75e58a5">&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;The information required by Part III of this Annual Report on Form 10-K, to the extent not set forth herein, is incorporated herein by reference from the Registrant&#x2019;s definitive proxy statement relating to the Annual Meeting of Shareholders to be held in 2024.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_e07eaef1-54ba-4af9-b39a-fdb60aeecce4">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_20042812-f0a2-4b34-a22f-d2aa54aef8f9">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_4a45e858-8abd-45e0-ae2b-3aa73f714c28">Seattle, Washington</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_88516f43-72a8-48c5-8693-04f293835149"
      unitRef="U_USD">65064000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_7d6e9ac2-4b92-45d9-acfb-c53d3fc28ab6"
      unitRef="U_USD">90030000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_30ee1585-f262-4ed3-8d39-7983a1941cce"
      unitRef="U_USD">281122000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_b7e47653-a781-4c03-b58b-b9393b4497c0"
      unitRef="U_USD">412282000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_229c92cf-309e-494d-918f-1d8417a6b584"
      unitRef="U_USD">281337000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_5f39e569-f5f8-41a0-86f2-47ce1adcc2f5"
      unitRef="U_USD">408166000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_683bc52e-989f-4587-aa5a-3bf5dd669c3d"
      unitRef="U_USD">37969000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_b6fb0b80-575d-433a-b234-9b593d80c76f"
      unitRef="U_USD">40057000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_d58186c3-7cc7-4b88-bb4f-2bf9ffa6e208"
      unitRef="U_USD">14448000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_d46ca4cb-f97b-4f62-97bc-8c108ee5610d"
      unitRef="U_USD">14453000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_736de2c5-2a6a-4d99-850f-7d6eaf4bef10"
      unitRef="U_USD">11370000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_76eeb1fa-82a0-4c3b-981f-0cc8475f77a6"
      unitRef="U_USD">9440000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_9aeaf490-ada8-4c96-8783-b0bc62b4b602"
      unitRef="U_USD">410188000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_6f174703-35e3-41c2-a5b3-c3b7c293a3a2"
      unitRef="U_USD">562146000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_48414404-65b1-44a4-8225-2114760e5d15"
      unitRef="U_USD">68227000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_667d8bb7-2cc8-493a-9236-2e7e6b4b47b8"
      unitRef="U_USD">83447000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_685b9adc-cd54-4182-a9be-e3589e54350a"
      unitRef="U_USD">52096000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_41954631-331a-4f31-a24b-cfe800e8b859"
      unitRef="U_USD">80763000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_306e602c-acba-491e-88fa-19d2c0faeb9c"
      unitRef="U_USD">2932000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_6e47c090-b01d-49d4-b3a3-9062a8134391"
      unitRef="U_USD">2398000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_58bff690-71a8-4938-af95-4ed3bfdbcc90"
      unitRef="U_USD">5128000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_1f437627-ef71-4918-b14c-6e1d2a17df7a"
      unitRef="U_USD">6827000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_8c4b5181-26a3-4842-9ce7-9a862eda7802"
      unitRef="U_USD">118972000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_67ed9a3a-aa29-4f92-b297-4968ad550c61"
      unitRef="U_USD">118972000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_d4a9f4b7-49a6-42da-865a-20511c86678c"
      unitRef="U_USD">3591000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_cf97e0bb-8aec-4a2a-a2fa-dd47db8c6a79"
      unitRef="U_USD">2064000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_759581a2-6590-4ecb-94ff-8b3d65c09136"
      unitRef="U_USD">661134000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_7c6d3b7e-ee9a-427b-8110-3c0be73c65b2"
      unitRef="U_USD">856617000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_316e7b30-fdf4-47b7-a412-e75b16193fb7"
      unitRef="U_USD">7719000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_91b5c1a2-e578-4645-b9ac-81c9f1bb223f"
      unitRef="U_USD">8084000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_0a698c57-3aeb-4531-aba9-0cd50e84e6bd"
      unitRef="U_USD">8597000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_10144f17-3d77-4d9d-976c-09792be14e79"
      unitRef="U_USD">12424000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_24303748-a497-4293-ac9c-97c09f0f8ebc"
      unitRef="U_USD">13685000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_2ce3e491-5f3e-4cf6-a80a-c80f4e4153d5"
      unitRef="U_USD">15935000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_6dd72c63-407b-452c-8bd5-4a0b5166beb6"
      unitRef="U_USD">9384000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_7b758265-c34a-4b12-a997-55290cca82a5"
      unitRef="U_USD">9230000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_8de45010-1d33-47db-803a-5d999bfa5311"
      unitRef="U_USD">48630000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_d046c84d-b59a-4b73-8570-a2035fcc49c4"
      unitRef="U_USD">64115000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_7ad62dc7-f948-4ee1-bd17-701e8fd0f17c"
      unitRef="U_USD">88015000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_9d2c579a-ba8f-42b1-9e84-faed7a46b321"
      unitRef="U_USD">109788000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_af05375d-deeb-4cf3-95a7-26bcd7cf8d7a"
      unitRef="U_USD">89388000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_23f6b6fc-be29-4f7e-81d0-0bcd838ef6dc"
      unitRef="U_USD">98772000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_3e138873-d971-444e-8d74-789ce7b42ebc"
      unitRef="U_USD">44793000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_09bc7ab5-67b8-4772-8d4c-adcb8e81df7a"
      unitRef="U_USD">58599000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_fc757deb-ef0d-47d9-bb70-9ca5329deff6"
      unitRef="U_USD">130660000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_6b290c78-2325-48ff-b430-dc3ed7b6e854"
      unitRef="U_USD">125360000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_429b1895-c0a8-4d1e-b454-5630a04ed154"
      unitRef="U_USD">352856000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_002965e2-00b2-4f24-92d6-f1ab32e23714"
      unitRef="U_USD">392519000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="4"
      id="F_137f8aee-6183-40d6-bac8-06dc15aa060b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="4"
      id="F_4ad5dc18-e1bb-483c-ba52-6269fd04e2b8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="INF"
      id="F_10ac623d-e827-4534-87b5-e0f6baa00ef7"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="INF"
      id="F_1178939a-98a9-460e-a862-cd46b3af735c"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="INF"
      id="F_3f16c2a2-6bc7-49e2-be2a-8f05c23659a4"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="INF"
      id="F_eef7452a-6a3f-4786-9788-2cf4c8042b22"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="INF"
      id="F_fcd83360-ee5c-42a6-996e-04acb28515f5"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="INF"
      id="F_9174f301-97bf-4bdb-aa67-6d7936e24ef8"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="4"
      id="F_df1e7f78-4f07-475e-9319-bf8323937a5d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="4"
      id="F_83310417-d669-4445-b71c-4f5a4fbcc89a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="INF"
      id="F_c60742e1-b589-4df2-910a-f4b5187b850f"
      unitRef="U_shares">340000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="INF"
      id="F_258739f7-407c-4532-8ffe-aa00700acd51"
      unitRef="U_shares">340000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="INF"
      id="F_aa2dd67d-e4cf-4d00-bca4-a4062a89df66"
      unitRef="U_shares">145082271</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="INF"
      id="F_7fea3b14-6c21-46ea-8eb5-e4dc419b9fc5"
      unitRef="U_shares">145082271</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="INF"
      id="F_edc9580a-7692-4673-bcfe-21335c1786c8"
      unitRef="U_shares">143105002</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="INF"
      id="F_38d4fe0a-03dd-4df1-aa23-ba3e6fca7659"
      unitRef="U_shares">143105002</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_343d615e-bcc7-4da9-a9f4-4cfa72f4b89e"
      unitRef="U_USD">14000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_8620b3f1-bbe6-4b28-8ac6-baacff3c37ed"
      unitRef="U_USD">14000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_7086aa9a-e38c-4284-ad0b-eaa4ddcf5c98"
      unitRef="U_USD">1452502000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_31423605-6d64-4f87-9b3d-7f6f7485d74f"
      unitRef="U_USD">1387349000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_4a365029-f41f-4466-bc22-d6a3a63fb3ab"
      unitRef="U_USD">215000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_37be76d8-9ea7-4300-9b50-b571e89d585d"
      unitRef="U_USD">-4116000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_b21216df-a418-4835-b6d4-3d4ef8b21ea6"
      unitRef="U_USD">-1144332000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_42a5b8de-166e-4252-a41c-5c8c02002d2a"
      unitRef="U_USD">-919082000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_0f5ad8cc-64b3-4c37-bc27-eab2b4fb6e96"
      unitRef="U_USD">308399000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_d82cab8b-00cd-49f1-960b-fa9189bb5e35"
      unitRef="U_USD">464165000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_b4b196e8-2ac5-42e1-be78-c820534f30c6"
      unitRef="U_USD">-121000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_ad08783d-5eb9-486d-ac4b-7f05d45e3497"
      unitRef="U_USD">-67000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_e265223a-7169-42fc-8eee-8e2f6464f7d6"
      unitRef="U_USD">308278000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_d1f11d03-f1a2-4fef-b480-429861d12da5"
      unitRef="U_USD">464098000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_d45c8dd0-af09-4661-bb9a-6135d96cf5d9"
      unitRef="U_USD">661134000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_c6ca085a-5c9b-4aec-bb4f-70627edf95a7"
      unitRef="U_USD">856617000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_0bc59ce1-406c-42ab-b995-baf08a820726"
      unitRef="U_USD">170276000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_9bd693ed-9bd7-448e-bbab-77c65cb91a74"
      unitRef="U_USD">185308000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_0e16e60b-2c01-46b8-bd7d-af29d6abbf1d"
      unitRef="U_USD">154344000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_ca31b980-1fac-40e2-85de-f798d9280749"
      unitRef="U_USD">75553000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_39e8f12e-6320-47f4-b537-0ec389cf6ffd"
      unitRef="U_USD">57909000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_a258af33-4213-4afa-b00f-b2c7ee490ac5"
      unitRef="U_USD">49301000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_4b8de064-7c8e-4d1a-9213-812c625e0f08"
      unitRef="U_USD">122117000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_e0004502-2a62-4b36-81d7-199ea2fe078d"
      unitRef="U_USD">141756000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_69e0d176-a6eb-4827-861c-edc7ef983dbe"
      unitRef="U_USD">142343000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_32fa4ce5-66ed-41e2-944d-244bf510f472"
      unitRef="U_USD">88579000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_f22fd15e-2cd6-457d-9f66-cecbe0eeba08"
      unitRef="U_USD">95603000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_493d29d4-2cb5-4621-b0f3-fd150155e89c"
      unitRef="U_USD">95465000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_dc0cfdba-6921-4f2f-8dca-2cbfd80fd7e7"
      unitRef="U_USD">83934000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_e6ba828d-6c44-4335-8191-19e44b15446e"
      unitRef="U_USD">88527000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_5836bbe0-bb57-4c65-bc25-537ee2e6a326"
      unitRef="U_USD">74502000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_29a9db24-848e-4fa8-adfc-00dee034c4c6"
      unitRef="U_USD">1699000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_43690e11-8c50-417c-b626-57905b785c25"
      unitRef="U_USD">1699000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_641883dd-3a0a-4ab8-bd86-cd44ced1769d"
      unitRef="U_USD">1699000</us-gaap:AmortizationOfIntangibleAssets>
    <adpt:ImpairmentOfRightOfUseAndRelatedLongLivedAssets
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_b06d36fc-79e6-4bc5-88df-203fc945aba9"
      unitRef="U_USD">25429000</adpt:ImpairmentOfRightOfUseAndRelatedLongLivedAssets>
    <us-gaap:CostsAndExpenses
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_ab5874c5-264e-4e18-8bb3-505567ab6ebe"
      unitRef="U_USD">397311000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_5ee6acab-2adf-4174-b78d-b8680aaaf301"
      unitRef="U_USD">385494000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_a0ea0d8b-7fae-4f1d-883d-ba571296b03c"
      unitRef="U_USD">363310000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_b7778a53-b24d-48dd-ba44-63343bdbd337"
      unitRef="U_USD">-227035000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_7eaa8da9-149c-47b9-9e94-890904bc406f"
      unitRef="U_USD">-200186000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_a069f064-756f-4617-806d-9425c0b197b5"
      unitRef="U_USD">-208966000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_925a22cd-d76e-451c-b9b6-a31f5889a2a4"
      unitRef="U_USD">15531000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_a40bdb6a-f035-487d-b02f-fcfeb2e8d530"
      unitRef="U_USD">4056000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_0917e310-4597-421b-9a9d-fbabaaedc444"
      unitRef="U_USD">1668000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestExpense
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_5594ea62-fa90-45fc-9a16-474bac70ff42"
      unitRef="U_USD">13800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_cc223ad8-41ac-4bbc-9e42-c30cbb4565c6"
      unitRef="U_USD">4238000</us-gaap:InterestExpense>
    <us-gaap:ProfitLoss
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_20551e3e-0fe9-4eb7-b6c2-b715955b56af"
      unitRef="U_USD">-225304000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_c98255b0-b401-43a5-be93-be9324592e6c"
      unitRef="U_USD">-200368000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_c6f4fc44-c4a0-4d49-9b92-43393d81eeda"
      unitRef="U_USD">-207298000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_1595f723-3181-4b43-bc2e-02ab4aed0659"
      unitRef="U_USD">-54000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_9a267627-8bba-4f79-8aa8-1e0723ba312b"
      unitRef="U_USD">-177000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_c5018b48-6c87-4a17-9fd8-5d08bd6f2f47"
      unitRef="U_USD">-19000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_df4be0f7-534f-4b4c-b9f8-a4ee6ecb597b"
      unitRef="U_USD">-225250000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_4a642927-dec3-422a-aa59-5157b6a270ff"
      unitRef="U_USD">-200191000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_60845696-c75b-4ebd-beba-de6ea4fffd4e"
      unitRef="U_USD">-207279000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="2"
      id="F_a5d9662c-9764-469d-a5f8-b4a2abe2fde3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="2"
      id="F_610ff099-e731-48b3-a360-a6aa424ff6d2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="2"
      id="F_eb1feef1-f78c-4933-b9cb-fed215d127b5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.4</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="2"
      id="F_61fddba3-39de-42a2-932c-5c44d511753d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.4</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="2"
      id="F_6ce31ab6-267a-429c-b099-bc0131da6221"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="2"
      id="F_0225bfb0-e7d6-42e7-943a-bbeb5ccc90b5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="0"
      id="F_c19ee979-82c6-40df-8a0e-ffa8a19e4c4a"
      unitRef="U_shares">144383294</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="0"
      id="F_8492cae6-fa1e-4b0d-9a15-92b5091d93a0"
      unitRef="U_shares">144383294</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="0"
      id="F_bdb19a74-6596-429d-85a5-a295fd9202d4"
      unitRef="U_shares">142515917</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="0"
      id="F_4c012577-000c-4fac-9f63-f15ec2e776fe"
      unitRef="U_shares">142515917</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="0"
      id="F_c7fb28d1-956f-49b5-a497-d266c7b84255"
      unitRef="U_shares">140354915</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="0"
      id="F_1ee3a202-48cb-418d-a916-2b52b05d2233"
      unitRef="U_shares">140354915</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_69e1de5f-79ee-4d39-ba6b-e69f68cd866b"
      unitRef="U_USD">-225304000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_ebdceb2d-bf3e-493c-bf7d-bcd53946ccc8"
      unitRef="U_USD">-200368000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_ec51f916-9a36-4567-805f-90109aa4cd6a"
      unitRef="U_USD">-207298000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_9265d431-3f16-4b02-bb7d-57c68bb0a6da"
      unitRef="U_USD">4331000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_f501de29-7560-45d5-b08b-635160a637e2"
      unitRef="U_USD">-2979000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_ffcb866b-accd-4590-b7a7-c45c239ecf9f"
      unitRef="U_USD">-2030000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_e7d35d16-5282-41ce-92d3-9c73e9d014cc"
      unitRef="U_USD">-220973000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_68207d55-ce44-48c1-aab2-a7cc7d85dcb4"
      unitRef="U_USD">-203347000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_2716d151-5f76-4e60-9ad7-fe9b607bce41"
      unitRef="U_USD">-209328000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_390059c1-5f34-481b-8c52-2063d9bf3509"
      unitRef="U_USD">-54000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_116f0d6a-9eed-47ba-b418-84824b00248a"
      unitRef="U_USD">-177000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_ae780d53-1bb3-4c13-a2f1-e07dabaa99ba"
      unitRef="U_USD">-19000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_191ba326-0629-42ae-b0ed-4b9f242ebd60"
      unitRef="U_USD">-220919000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_fd0fcdc1-3ef7-43e5-850e-4c5aef155ab2"
      unitRef="U_USD">-203170000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_644fd4ea-2077-4026-9a6b-42a30e65cde8"
      unitRef="U_USD">-209309000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_2ba2e40d-74e7-4c45-8c1b-863af5547a3d"
      decimals="INF"
      id="F_025c2450-6d6e-42b1-869c-92d3e8f462d4"
      unitRef="U_shares">137646896</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_2ba2e40d-74e7-4c45-8c1b-863af5547a3d"
      decimals="-3"
      id="F_8815c1cf-609b-493b-912a-1bcd8f072c95"
      unitRef="U_USD">14000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f90dae10-b7ce-472b-bbb0-33e4307f7344"
      decimals="-3"
      id="F_3bf9e773-04df-4072-8534-650f2326de49"
      unitRef="U_USD">1253971000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f120f473-834e-48d7-9c3d-c58cb26bc159"
      decimals="-3"
      id="F_0a54f696-5ce8-4b9c-92e3-648ae06f4353"
      unitRef="U_USD">893000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_919788e3-23fd-4409-b58e-83649ea5febe"
      decimals="-3"
      id="F_30bdc46e-35a5-400b-89d6-f029853ede47"
      unitRef="U_USD">-511612000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_cd98abbe-6241-4fc8-af88-d9979790e940"
      decimals="-3"
      id="F_04786e42-dd98-44ea-9a8f-550781c2b329"
      unitRef="U_USD">743266000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <adpt:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised
      contextRef="C_546b97c7-d4df-492a-864d-7d19a8b5b897"
      decimals="INF"
      id="F_a50cf9fb-7969-4fa1-9742-910e89a0d826"
      unitRef="U_shares">54162</adpt:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_546b97c7-d4df-492a-864d-7d19a8b5b897"
      decimals="INF"
      id="F_9b23fb0f-78bd-49ec-b57c-052d3358297c"
      unitRef="U_shares">3674057</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_6f24c325-cbc5-4f36-913f-12d35e35dc7d"
      decimals="-3"
      id="F_b8209fc5-1b7b-4580-804e-e9217979fc3d"
      unitRef="U_USD">26484000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_8f6df2e1-0159-415a-afa7-4160d9edd8c1"
      unitRef="U_USD">26484000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="C_546b97c7-d4df-492a-864d-7d19a8b5b897"
      decimals="INF"
      id="F_091a1a33-06ae-4258-9c27-70cd3978cc23"
      unitRef="U_shares">18750</adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6f24c325-cbc5-4f36-913f-12d35e35dc7d"
      decimals="-3"
      id="F_35e4e6bf-f41c-4a18-8907-5af85451dbe5"
      unitRef="U_USD">43251000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_111b8ebd-ab8d-4530-a539-4e6ca587c15a"
      unitRef="U_USD">43251000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <adpt:AdjustmentsToAdditionalPaidInCapitalCapitalContributions
      contextRef="C_6f24c325-cbc5-4f36-913f-12d35e35dc7d"
      decimals="-3"
      id="F_4c1e49c1-4afe-41b1-9ef9-2a8e42864206"
      unitRef="U_USD">300000</adpt:AdjustmentsToAdditionalPaidInCapitalCapitalContributions>
    <adpt:AdjustmentsToAdditionalPaidInCapitalCapitalContributions
      contextRef="C_623eef52-d53d-46c2-8e13-de37ddc266db"
      decimals="-3"
      id="F_ddbc5c6e-ff99-4c94-b822-3b17e4d69fc9"
      unitRef="U_USD">129000</adpt:AdjustmentsToAdditionalPaidInCapitalCapitalContributions>
    <adpt:AdjustmentsToAdditionalPaidInCapitalCapitalContributions
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_f78e7a8d-2188-4694-aa22-acda1aac386a"
      unitRef="U_USD">429000</adpt:AdjustmentsToAdditionalPaidInCapitalCapitalContributions>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_3e2c359c-7df3-4fd0-ade8-9c6156b3f9ae"
      decimals="-3"
      id="F_5068a297-d187-4e5e-bf8d-d65bf7ef7660"
      unitRef="U_USD">-2030000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_cd4affe0-cea2-42f9-a8b2-0b41d4f17032"
      unitRef="U_USD">-2030000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="C_5b34e135-b44f-41a1-b917-b0dc0f2c4bf4"
      decimals="-3"
      id="F_8d81aa81-4327-40b2-bf4a-b45d5149f18d"
      unitRef="U_USD">-207279000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_623eef52-d53d-46c2-8e13-de37ddc266db"
      decimals="-3"
      id="F_b38044da-2847-4058-a9d2-4bb1e44ebf45"
      unitRef="U_USD">-19000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_1f9af17c-9b34-461a-9b27-634eb13bad6f"
      unitRef="U_USD">-207298000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_99d18c69-4d22-43ef-8389-5fdf986876eb"
      decimals="INF"
      id="F_80c43238-7b83-4bfe-a4aa-4ee98402ff43"
      unitRef="U_shares">141393865</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_99d18c69-4d22-43ef-8389-5fdf986876eb"
      decimals="-3"
      id="F_61d3aec1-791d-4458-a6da-a1e2060e8e3c"
      unitRef="U_USD">14000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_a850bcd3-da63-46d2-b9d7-bfe3de139a9e"
      decimals="-3"
      id="F_204d10ca-16f8-431e-8c96-85793422b241"
      unitRef="U_USD">1324006000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_ac72162c-f6d5-4828-ba60-f9c5be19f188"
      decimals="-3"
      id="F_f924207d-9cd5-4cb0-aaf6-c4b842e1f030"
      unitRef="U_USD">-1137000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_d207b5e8-b241-4c93-8d72-a110d70a2fa2"
      decimals="-3"
      id="F_7f47e2e1-6cb5-4ba0-bf29-986d90b97d35"
      unitRef="U_USD">-718891000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_3e2b380b-13d2-47a9-a0f7-95998f87ee50"
      decimals="-3"
      id="F_50e3db37-51b6-4bc9-98ea-5d0371e5a871"
      unitRef="U_USD">110000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_6f19237c-a155-4029-b45f-b9fb5332f737"
      decimals="-3"
      id="F_96a1fe48-b178-4801-969b-0045178b1fe4"
      unitRef="U_USD">604102000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_698d77cb-703e-4d5b-acbd-9c92d097b8bd"
      decimals="INF"
      id="F_c14ab8ff-1fcc-489f-96f1-0689c4fc9cde"
      unitRef="U_shares">1406500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_e840ef1f-0c35-4d10-9610-9d3bd41786d6"
      decimals="-3"
      id="F_87bd2923-3d9a-4764-9d37-78f0fc98379e"
      unitRef="U_USD">7866000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_f2425b87-12c8-4673-b4eb-ebcbe4cc77c2"
      unitRef="U_USD">7866000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="C_698d77cb-703e-4d5b-acbd-9c92d097b8bd"
      decimals="INF"
      id="F_46a933e2-6c2b-4888-a00b-0ac1de6dad50"
      unitRef="U_shares">304637</adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_e840ef1f-0c35-4d10-9610-9d3bd41786d6"
      decimals="-3"
      id="F_a9723c1e-dc23-4f34-aaf0-09a6b1d47e4e"
      unitRef="U_USD">55477000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_5b2ebb94-a86a-41e8-ba80-9eb9d8a430b7"
      unitRef="U_USD">55477000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_7306e5e5-de3a-49c5-8ca6-d62df03366ee"
      decimals="-3"
      id="F_8f44cdb8-78bd-4bfe-88da-46658d833f42"
      unitRef="U_USD">-2979000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_d77538e1-dc8e-4483-8116-3815bcdd82da"
      unitRef="U_USD">-2979000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="C_0cf4be7f-ab3d-44bd-8576-4b5ab607235c"
      decimals="-3"
      id="F_7b584bdf-6e9d-490d-a1d3-8396c1957011"
      unitRef="U_USD">-200191000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_4c37a096-1a6a-45aa-8fc2-563181d9f721"
      decimals="-3"
      id="F_d9a2e09d-cd4c-48d3-9f39-80237f057f92"
      unitRef="U_USD">-177000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_46dc80ae-27db-41d0-8236-b323dc7ade2c"
      unitRef="U_USD">-200368000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_e47f789a-559d-43f2-a31d-acdeac94f7f7"
      decimals="INF"
      id="F_79bf8842-eb4e-4c24-8aab-a96fc107ddd6"
      unitRef="U_shares">143105002</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_e47f789a-559d-43f2-a31d-acdeac94f7f7"
      decimals="-3"
      id="F_50c5a8c7-4825-4697-959d-46069595bdd5"
      unitRef="U_USD">14000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_04747ad8-13d5-4de0-966f-56ff96064b6f"
      decimals="-3"
      id="F_5d5be5c2-7800-4261-bbd6-d455b63a8f06"
      unitRef="U_USD">1387349000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_27e427e6-2646-46ca-93cd-c733bfaf29eb"
      decimals="-3"
      id="F_eb826581-c2e8-4850-8d64-149f55aa9c70"
      unitRef="U_USD">-4116000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_2ae500b5-b450-4303-939a-c1ade0ffffce"
      decimals="-3"
      id="F_5e849397-81c1-4df2-897d-85056b5f76a8"
      unitRef="U_USD">-919082000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_11a7257f-ddc9-4e22-ad34-a161c6bbbc38"
      decimals="-3"
      id="F_fa956fc3-1321-41b8-9888-712ed8a2dd0a"
      unitRef="U_USD">-67000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_60a59376-eb09-4952-bd34-cdf093319ceb"
      unitRef="U_USD">464098000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_2650e075-e451-49ad-955d-e9ad14d5bf33"
      decimals="INF"
      id="F_23f3fd54-66e2-4f9f-9cf6-ab5ee11bd36e"
      unitRef="U_shares">470405</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_1b2a261c-6d6a-470b-b858-a470f3e89fa6"
      decimals="-3"
      id="F_c2433537-c133-4a4f-baf5-b55d9dbf0d28"
      unitRef="U_USD">2245000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_b0a77cb2-8bcd-436c-8220-f97ab835c5ce"
      unitRef="U_USD">2245000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="C_2650e075-e451-49ad-955d-e9ad14d5bf33"
      decimals="INF"
      id="F_d605dc1a-8635-48d6-80f9-33adcd5956e8"
      unitRef="U_shares">1506864</adpt:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_1b2a261c-6d6a-470b-b858-a470f3e89fa6"
      decimals="-3"
      id="F_21fba9be-2a40-41e1-91c4-498f9f8cc230"
      unitRef="U_USD">62908000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_2d6d9842-a7c1-4c62-9bd2-d457a8c35290"
      unitRef="U_USD">62908000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_71aa9e96-4108-4a98-82b6-96eb9ed09cbd"
      decimals="-3"
      id="F_5eb8d86c-e741-4148-81f0-237c967dfb79"
      unitRef="U_USD">4331000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_a27001ca-8873-40eb-a40d-7321bebe891d"
      unitRef="U_USD">4331000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="C_8c9aa062-7dde-4480-8d81-ee9c2d275da3"
      decimals="-3"
      id="F_6c6241a7-dd36-425b-8dbe-d33590a83efb"
      unitRef="U_USD">-225250000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_905db261-8b17-447c-a833-556502ab34a5"
      decimals="-3"
      id="F_d39f454a-6000-41ff-b784-d90158ce78de"
      unitRef="U_USD">-54000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_366e97fa-d248-4ca1-86e6-04e4ebc452f0"
      unitRef="U_USD">-225304000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_a720e09d-5c96-4740-a504-9844af0c34ea"
      decimals="INF"
      id="F_7014078c-3a83-4385-8b30-d4ff11a388f0"
      unitRef="U_shares">145082271</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_a720e09d-5c96-4740-a504-9844af0c34ea"
      decimals="-3"
      id="F_9506484d-7e4a-4496-a2e2-caf27241caa4"
      unitRef="U_USD">14000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_79087f84-8200-4e59-be47-56564ec79f8e"
      decimals="-3"
      id="F_52076652-504b-4ff0-b691-1d8cfce87b99"
      unitRef="U_USD">1452502000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_3c608cb9-e9d3-4e98-b40b-a50be54d13e1"
      decimals="-3"
      id="F_5bb8c686-6d0d-43f1-a2e8-5be49fa7575a"
      unitRef="U_USD">215000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f1d9df12-63b0-41e0-839c-848d1971a89b"
      decimals="-3"
      id="F_7d26dbfa-0675-4434-989e-79485fa493ec"
      unitRef="U_USD">-1144332000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_dddab8cd-a34a-45e6-93ef-3d378391ba43"
      decimals="-3"
      id="F_a2052a4f-d38f-4d24-9c56-b3467dde192f"
      unitRef="U_USD">-121000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_4d9403eb-3a0b-40b0-a3eb-7379728b86d3"
      unitRef="U_USD">308278000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_732fc02d-c483-420a-873d-082638d23fc7"
      unitRef="U_USD">-225304000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_c6b97dd3-96bd-4d1e-b368-67f798224049"
      unitRef="U_USD">-200368000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_2383a77b-d09a-4acd-9a89-3086a7e9ba35"
      unitRef="U_USD">-207298000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_fccfab3e-6e54-48f8-ba57-e6684753d602"
      unitRef="U_USD">20532000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_52231177-23b4-46e1-8279-b8df30b146a0"
      unitRef="U_USD">19221000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_5afe9a82-b3d1-4986-b165-dd96ef094a42"
      unitRef="U_USD">12254000</us-gaap:Depreciation>
    <adpt:NoncashLeaseExpense
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_6f357e68-50f5-409f-8cac-79d9b5d9859b"
      unitRef="U_USD">6920000</adpt:NoncashLeaseExpense>
    <adpt:NoncashLeaseExpense
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_0a2095d8-91b1-45b5-bf7b-43322a034a41"
      unitRef="U_USD">7227000</adpt:NoncashLeaseExpense>
    <adpt:NoncashLeaseExpense
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_bc747c73-476a-4a29-bb24-5e94f76dfc5a"
      unitRef="U_USD">7028000</adpt:NoncashLeaseExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_13fc3525-be4a-4292-bd62-eebf12a892d8"
      unitRef="U_USD">62908000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_013b6c6a-d2bc-4422-9171-e8a36282696f"
      unitRef="U_USD">55477000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_1d873eb1-13ea-41d3-ae69-f284e9ca7fa8"
      unitRef="U_USD">43251000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_728bf77c-4cd6-4153-b3f4-08a96a2e8040"
      unitRef="U_USD">1699000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_6a256a92-70e1-43e0-80f1-cd8e3570b765"
      unitRef="U_USD">1699000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_a2ab2d2c-cea2-49f1-ac95-f0fefffd15c0"
      unitRef="U_USD">1699000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_311f9322-a192-45ec-be93-6803f387c52d"
      unitRef="U_USD">9184000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_62218fca-be5b-4ba7-a6a4-02bddf2b58c8"
      unitRef="U_USD">-741000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_95c9762c-9907-4528-85b3-7efdd6124563"
      unitRef="U_USD">-7233000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <adpt:ImpairmentOfRightOfUseAndRelatedLongLivedAssets
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_d312624b-1d3c-473e-9ae2-fa2f0facafa1"
      unitRef="U_USD">25429000</adpt:ImpairmentOfRightOfUseAndRelatedLongLivedAssets>
    <adpt:InventoryReserve
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_4ddce295-fdb7-408d-b5f3-789a8ca83b05"
      unitRef="U_USD">1387000</adpt:InventoryReserve>
    <adpt:InventoryReserve
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_52e96cfd-4199-422c-8483-8ade50206de4"
      unitRef="U_USD">2638000</adpt:InventoryReserve>
    <adpt:NoncashInterestExpense
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_41d8703c-8a61-42e4-a7b9-50b3e8c2f032"
      unitRef="U_USD">5300000</adpt:NoncashInterestExpense>
    <adpt:NoncashInterestExpense
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_4b9eb0b3-1811-4c0e-aab7-bbfcc96ece82"
      unitRef="U_USD">985000</adpt:NoncashInterestExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_6efcddc7-47ad-4a39-a43d-7caff9cddf23"
      unitRef="U_USD">-172000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_fce68b43-304b-4056-bd3f-14f044f4a6f4"
      unitRef="U_USD">19000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_683e8434-25c2-4032-a401-fcc14a0851df"
      unitRef="U_USD">78000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_36323d47-1875-4dfc-b024-670323c50a9c"
      unitRef="U_USD">-2032000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_70123913-6c4c-4809-9d17-87ad77bcc05e"
      unitRef="U_USD">22648000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_d2e3bad5-1090-4055-8343-d4883412a8cc"
      unitRef="U_USD">7362000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_ddfda6f0-de18-4cd1-8f6a-4221113e5abe"
      unitRef="U_USD">2838000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_e921d1c3-dbcc-494c-b22f-f78f32856255"
      unitRef="U_USD">-817000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_e84ffda9-837b-4b0c-884a-ff6d6e99513f"
      unitRef="U_USD">5200000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_f4310959-c43c-415d-8743-125ac5e6d2c6"
      unitRef="U_USD">1930000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_6bbfc809-8ceb-48b4-875d-eed24336dee0"
      unitRef="U_USD">-3551000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_f4fbba50-95f4-4127-96b4-d30e94a21384"
      unitRef="U_USD">-1286000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_b7a3e0a0-b3a5-4c61-bd23-3a9ce9321f53"
      unitRef="U_USD">-5407000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_7131df47-9f54-41a6-bb15-5efd248f73ec"
      unitRef="U_USD">7111000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_aefdb342-7d84-419b-a831-2620afc37ee6"
      unitRef="U_USD">3940000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <adpt:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_5cb24daa-c8a2-406f-8cf4-ec9f762f171b"
      unitRef="U_USD">-8676000</adpt:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities>
    <adpt:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_c7caf1a6-9400-4515-bd60-b885efd0f0d1"
      unitRef="U_USD">-4050000</adpt:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities>
    <adpt:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_23db4054-cf54-4132-bde9-4b91e3fd1722"
      unitRef="U_USD">8522000</adpt:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_8a198b08-1136-45ee-b7d3-5d68c8578d37"
      unitRef="U_USD">-29291000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_4410a6d7-dc7b-40d6-b990-c0ddf39ea137"
      unitRef="U_USD">-56496000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_d946c4af-a544-460c-8505-3778ab18a8bf"
      unitRef="U_USD">-57727000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_75d36b2e-e4d7-42dc-a00d-ed2b6925475e"
      unitRef="U_USD">73000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_f5ac6aa9-e1e1-49ad-a939-ff3370cb1160"
      unitRef="U_USD">-169000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_d6441bce-303c-403f-992c-01701bd9163c"
      unitRef="U_USD">275000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_70867fd3-a4cf-43c2-87ac-4d24adcfbfda"
      unitRef="U_USD">-156324000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_c3c368a4-9f12-4c36-bbee-64965ff52370"
      unitRef="U_USD">-183945000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_e3e23ccc-7e68-4ac2-91f4-d742e9e4477f"
      unitRef="U_USD">-192727000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_bd03b041-427f-489a-b9ce-dbb2ec8e5b81"
      unitRef="U_USD">10697000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_029247f9-2203-4631-b11d-26dcf91d0d85"
      unitRef="U_USD">16349000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_dd1e930b-59ec-46c9-948d-bd96104a71f5"
      unitRef="U_USD">61746000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_a863b074-3ecd-4c30-b6e0-cb4444a0d937"
      unitRef="U_USD">429558000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_1bad0173-d08b-418b-af93-41de51b27bd1"
      unitRef="U_USD">278778000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_7e55c933-9b5e-4e57-9776-31007365e94f"
      unitRef="U_USD">316544000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_d0680763-7772-407f-ac32-b0634e2dbc9b"
      unitRef="U_USD">569902000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_25a20645-3e94-408a-b0a4-0050c1b7dd42"
      unitRef="U_USD">298032000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_b5598e1e-1fae-441b-b1c1-5bd0647e7f6e"
      unitRef="U_USD">559500000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_8541734e-dcca-46a4-9d57-9c23b5ac297a"
      unitRef="U_USD">129647000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_a5652cc9-b452-4f79-9c7b-cfd371760f38"
      unitRef="U_USD">2905000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_ef2947bb-de8e-43de-af1c-195017ccba5e"
      unitRef="U_USD">181210000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_5d3cd417-73bc-47bc-b638-ad396df80077"
      unitRef="U_USD">2245000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_d152ceaf-051c-4f7a-b878-e2550077174e"
      unitRef="U_USD">7890000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_87027ecc-bac2-4e13-86b7-b62af00a9978"
      unitRef="U_USD">26717000</us-gaap:ProceedsFromStockOptionsExercised>
    <adpt:ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_2d427ff2-efc3-4f96-8ef1-d68922b4c408"
      unitRef="U_USD">124375000</adpt:ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_b4fc2a30-ad73-45a8-bbd0-24fd9f8b1b00"
      unitRef="U_USD">429000</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_c8430bf6-d421-47e6-a579-3f545a5b1664"
      unitRef="U_USD">2245000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_12b262bb-23f9-47d2-b528-a0bb18aa2c80"
      unitRef="U_USD">132265000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_a6485092-22bc-4557-ba0d-88f992910287"
      unitRef="U_USD">27146000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_05ae7844-ef93-4ee8-9330-03f3f6e447f7"
      unitRef="U_USD">-24432000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_c210ee06-547b-443c-9539-f980e782f5d7"
      unitRef="U_USD">-48775000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_40668c41-0f99-43b6-aa01-ac38f975d25a"
      unitRef="U_USD">15629000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_74c388d1-b31b-4cfa-8e41-6c72adc99962"
      unitRef="U_USD">92428000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_6f19237c-a155-4029-b45f-b9fb5332f737"
      decimals="-3"
      id="F_03cc3090-e2d9-4f55-81a2-8daac6f32faf"
      unitRef="U_USD">141203000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_cd98abbe-6241-4fc8-af88-d9979790e940"
      decimals="-3"
      id="F_7b84cd71-7eab-4432-99e6-4fdb56a151cc"
      unitRef="U_USD">125574000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_80396357-36ba-4abf-90d7-6fea88cc7301"
      unitRef="U_USD">67996000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_6b0b0832-5583-47af-9143-c426071d4625"
      unitRef="U_USD">92428000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_6f19237c-a155-4029-b45f-b9fb5332f737"
      decimals="-3"
      id="F_94e192df-98fb-4f32-9ab7-157d4e3b4864"
      unitRef="U_USD">141203000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_d115348e-ef15-4a92-9fa9-0c3820361ba9"
      unitRef="U_USD">687000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_3c8adb99-6c98-402e-a8cc-09d5c0af069a"
      unitRef="U_USD">1719000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_993a5e12-c9df-4349-8a19-c1c47c8e7a35"
      unitRef="U_USD">682000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:InterestPaidNet
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_478e29d4-2ec1-47c1-90d8-287407d5c519"
      unitRef="U_USD">8985000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_b0f4feae-30f4-48e9-ad63-efcb29352fce"
      unitRef="U_USD">494000</us-gaap:InterestPaidNet>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_5b27f08c-0df7-427f-b7ce-c87b2e60ebff">&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;1.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Organization and Description of Business&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Adaptive Biotechnologies Corporation (&#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) is a commercial-stage company advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature&#x2019;s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our immune medicine platform applies our proprietary technologies to read the diverse genetic code of a patient&#x2019;s immune system and understand precisely how the immune system detects and treats disease in that patient. We capture these insights in our dynamic clinical immunomics database and related antigen annotations, which are underpinned by computational biology and machine learning, and use them to develop and commercialize clinical products and services that can be tailored to the needs of individual patients. We have commercial products and services and a robust pipeline of clinical products and services that we are designing to diagnose, monitor and enable the treatment of diseases, such as cancer and autoimmune disorders.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We were incorporated in the State of Washington on September 8, 2009 under the name Adaptive TCR Corporation. On December 21, 2011, we changed our name to Adaptive Biotechnologies Corporation. We are headquartered in Seattle, Washington.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_46e5faad-171b-4a81-97f8-98ad06e6336b">&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of Adaptive Biotechnologies Corporation, Adaptive Biotechnologies B.V., our wholly-owned subsidiary, and Digital Biotechnologies, Inc., a corporate subsidiary we have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% ownership interest in. The remaining interest in Digital Biotechnologies, Inc., held by certain of our related parties and their related family trusts, are shown in the consolidated financial statements as noncontrolling interest. All intercompany transactions and balances have been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, imputing interest for our revenue interest purchase agreement (the &#x201c;Purchase Agreement&#x201d;) that we entered into in September 2022, the provision for income taxes, including related reserves, the analysis of goodwill impairment and the recoverability and impairment of long-lived assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#x2019;s estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have determined that our chief executive officer is the chief operating decision maker (&#x201c;CODM&#x201d;). The CODM regularly reviews operating results and other financial information presented on a consolidated basis. While revenue is reviewed at levels lower than the consolidated entity, resource allocation decisions are made by the CODM based on the results presented at the consolidated entity level, which is determined to be a single reporting unit. The consolidated entity operates as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment and represents &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reportable segment. We present disaggregated revenue from contracts with customers by market opportunity and type of arrangement. See Note 3, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. We limit our credit risk associated with cash and cash equivalents by placing our investments with banks that we believe are highly creditworthy and with highly rated money market funds. Cash and cash equivalents primarily consist of bank deposits and investments in money market funds.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We had a restricted cash balance of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of December 31, 2023 and 2022, respectively. Our restricted cash primarily relates to certain balances we are required to maintain under lease arrangements for some of our property and facility leases.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Marketable securities are classified as available-for-sale, consist of United States (&#x201c;U.S.&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) government treasury and agency securities, corporate bonds and commercial paper and are reported at fair value. Unrealized holding gains and losses are reflected as a separate component of shareholders&#x2019; equity in accumulated other comprehensive gain (loss) until realized. Realized gains and losses on the sale of these securities are recognized in net income or loss. The cost of marketable securities sold is based on the specific identification method.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Financial Accounting Standards Board (&#x201c;FASB&#x201d;) has defined fair value as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. The FASB established a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The hierarchy defines three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A financial instrument categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. In certain cases, where there is limited activity or less transparency around valuation inputs, financial instruments are classified as Level 3 within the valuation hierarchy.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our financial instruments consist of Level 1 and Level 2 assets and have included Level 3 liabilities in the past. The carrying amounts of certain financial instruments approximate fair value due to their short maturities. We did not have any nonfinancial assets or liabilities that were measured or disclosed at fair value on a recurring basis as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentrations of Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We are subject to a concentration of risk from a limited number of suppliers, or in certain cases, single suppliers, for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, U.S. government treasury and agency securities, corporate bonds and commercial paper with high-quality accredited financial institutions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant customers are those that represent more than ten percent of our total revenue or accounts receivable, net balances for the periods and as of each consolidated balance sheet date presented, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:44.5%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.94%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.94%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.94%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.94%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.94%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Customer A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Customer B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Genentech, Inc. and Roche Group&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;* less than 10%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounts Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts receivable consists of amounts due from customers for services performed. We review our accounts receivable for credit impairment and regularly analyze the status of significant past due receivables to determine if any will potentially be uncollectible to estimate the amount of allowance necessary to reduce accounts receivable to its estimated net realizable value.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventory consists of laboratory materials and supplies used in lab analysis. We capitalize inventory when purchased and record expense upon order fulfillment for servicing revenue or utilization in our research and development laboratories. Inventory is valued at the lower of cost or market on a first-in, first-out basis. We periodically perform obsolescence assessments and write-off any inventory that is no longer usable. Long-term inventory of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was included within the other assets balance on the consolidated balance sheet as of December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment consists of computer equipment, computer software, laboratory equipment, leasehold improvements, furniture and office equipment and assets under construction. Property and equipment are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life. Maintenance and repairs are charged to expense as incurred and costs of improvements are capitalized.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Useful lives assigned to property and equipment are as follows:&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:84.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.14%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
          &lt;td style="width:49.14%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_de9ea103-2ab7-4e3e-8c48-d7bbaf7c674a;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shorter of estimated useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We review long-lived assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Gains and losses from asset disposals and impairment losses, if incurred, are classified within the consolidated statements of operations in accordance with the use of the asset, if not separately stated within its own financial statement line item. See Note 10, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for more information regarding the leasehold improvements impairment loss recognized during the year-ended December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date, which is regarded as their cost.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Intangible assets may also result from the purchase of assets and intellectual property in a transaction that does not qualify as a business combination. Intangible assets are amortized over their estimated useful lives on a straight-line basis which approximates their usage pattern. Intangible assets are reviewed for impairment at least annually or if indicators of potential impairment exist. We have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognized any impairment losses on intangible assets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October 1, or more frequently if events or changes in circumstances would more likely than not reduce the fair value of our single reporting unit below its carrying value. We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we so determine, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. If impairment exists, the carrying value of the goodwill is reduced to its fair value through an impairment charge recorded in the consolidated statements of operations. To date, we have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognized any impairment of goodwill.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory, office and warehouse facilities that we occupy. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of January 1, 2020 for commenced leases that existed as of our adoption of Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (Topic 842) (&#x201c;ASC 842&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Certain of our leases contain options to extend or terminate the lease; lease terms are adjusted for these options only when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory, office and warehouse facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on the consolidated balance sheets a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We review our right-of-use assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Impairment losses are classified within the consolidated statements of operations in accordance with the use of the asset, if not separately stated within its own financial statement line item. See Note 10, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for more information regarding the right-of-use asset impairment loss recognized during the year-ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Lease expense is recognized on a straight-line basis over the terms of the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the terms of the leases.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Interest Liability, Net and Related Imputed Interest&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The revenue interest liability balance associated with the Purchase Agreement that we entered into in September 2022 is presented net of unamortized issuance costs on the consolidated balance sheets. We impute our associated interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. The effective interest rate may vary during the term of the agreement depending on a number of factors, including changes in forecasted GAAP revenues. We evaluate the effective interest rate quarterly based on both achieved and forecasted revenues, utilizing the prospective method. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense and the time period for repayment.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1) identify the contract or contracts; (2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3) measure the transaction price, including the constraint on variable consideration; (4) allocate the transaction price to the performance obligations based on estimated selling prices; and (5) recognize revenue when (or as) we satisfy each performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We derive revenue by providing diagnostic and research services in our Immune Medicine and Minimal Residual Disease (&#x201c;MRD&#x201d;) business areas. Our Immune Medicine revenue consists of revenue generated from (1) providing sample testing services for our commercial research product, Adaptive Immunosequencing, to biopharmaceutical customers and academic institutions; (2) our collaboration agreements with Genentech, Inc. (&#x201c;Genentech&#x201d;) and other biopharmaceutical customers in areas of drug and target discovery; and (3) for prior years, providing our T-Detect COVID tests to clinical customers. Our MRD revenue consists of revenue generated from (1) providing our clonoSEQ report to clinical customers; (2) providing MRD sample testing services to biopharmaceutical customers and certain academic institutions, including investigator-led clinical trials; and (3) providing our clonoSEQ report or results to certain international laboratory sites through technology transfers.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For research customers who utilize either Adaptive Immunosequencing or our MRD services, contracts typically include an amount billed in advance of services (&#x201c;upfront&#x201d;) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; typical performance obligations under the terms of our research service contracts: (1) the delivery of our Adaptive Immunosequencing or MRD data for customer provided samples; and (2) related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the total samples expected to be delivered.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For agreements where we provide our clonoSEQ report to ordering physicians, we have identified one performance obligation: the delivery of a clonoSEQ report. We bill and receive payments for these transactions from commercial, government and medical institution payors. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted, as necessary, based on actual collection experience.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Regarding our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test report. This billing contemplates all necessary tests required during a patient&#x2019;s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test report is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient&#x2019;s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized either as we deliver our estimate of the remaining tests in a patient&#x2019;s treatment cycle or when the likelihood becomes remote that a patient will receive additional testing.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The contract transaction price for agreements we enter into with biopharmaceutical customers to further develop and commercialize their therapeutics may consist of a combination of non-refundable upfront fees, separately priced MRD testing fees and milestone fees earned upon our customers&#x2019; achievement of certain regulatory approvals. Depending on the contract, these agreements include single or multiple performance obligations. Such performance obligations include providing services to support our customers&#x2019; therapeutic development efforts, including regulatory support for our technology intended to be utilized as part of our customers&#x2019; registrational trials, developing analytical plans for our data, participating on joint research committees, assisting in completing a regulatory submission and providing MRD testing services related to customer-provided samples for our customers' regulatory submissions. Generally, the support services, excluding MRD testing services, are not distinct within the context of the contract and thus are accounted for as a single performance obligation. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated MRD testing services. When MRD sample testing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional MRD sample testing services is not considered part of the contract. We recognize revenue related to MRD testing services over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered, when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method using a cost-based model based on estimates of effort completed. Selecting the measure of progress and estimating progress to date requires significant judgment. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. At contract inception, we fully constrain any consideration related to regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers&#x2019; own submission decision-making. Variable consideration related to regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue will not occur. Milestone payments for regulatory approvals, which are not within our customers&#x2019; control, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2021, we executed an intellectual property license agreement that includes variable consideration related to sales-based royalties. Any consideration related to such royalties will be recognized as revenue at the later of when (i) the related sales occur or (ii) the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Contract Balances&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In certain circumstances, billing may occur prior to services being performed. Upfront payments are recorded as deferred revenue, or contract liabilities. We classify deferred revenue as current when we expect our performance obligations will be completed within the next twelve months; however, we do not control the timing of customer provided samples. For service and collaboration activities, excluding those related to our worldwide collaboration and license agreement with Genentech, we assess the performance obligations and recognize deferred revenue as current or non-current based upon forecasted delivery times, which are customer coordinated. In certain circumstances, a customer project may be cancelled or terminated prior to the delivery of all related services covered by a customer&#x2019;s upfront payment. In these circumstances, we recognize revenue when sufficient evidence is obtained that a reversal of revenue is not probable. We also recognize revenue when our estimate of total samples to be provided under certain of our agreements is reduced or, in the case of contract balances related to Medicare, when the likelihood becomes remote that a patient will receive additional testing. See Note 3, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for our deferred revenue policy related to our worldwide collaboration and license agreement with Genentech.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Share-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Share-based compensation includes compensation expense for stock option, restricted stock unit and market-based restricted stock unit grants made to employees and non-employees. It represents the grant date fair value of the grants and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of actual forfeitures. We estimate the grant date fair value of stock option and market-based restricted stock unit grants using the Black-Scholes option-pricing model and the Monte Carlo valuation model, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Advertising&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Advertising costs are expensed as incurred. Advertising expenses were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the year ended December 31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cost of Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cost of revenue includes the cost of materials, personnel-related expenses (including salaries, benefits and share-based compensation), shipping and handling expenses, equipment costs, allocated facility costs associated with processing samples and professional support costs related to our service revenue activities. Allocated facility costs include depreciation of laboratory equipment, as well as allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development expenses consist of laboratory materials costs, personnel-related expenses (including salaries, benefits and share-based compensation), equipment costs, allocated facility and information technology costs and contract service expenses. Research and development activities support further development and refinement of existing assays and products, discovery of new technologies and investments in our immune medicine platform. We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. Additionally, a component of our research and development expenses are costs supporting clinical and analytical validations to obtain regulatory approval for future clinical products and services. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Upfront payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized, then are recognized as an expense as the goods are consumed or the related services are performed. Costs to support our worldwide collaboration and license agreement with Genentech are also a component of our research and development expenses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sales and Marketing Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Sales and marketing expenses include personnel-related expenses (including salaries, benefits and share-based compensation) for commercial sales, product and account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility and information technology costs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of Right-of-Use and Related Long-Lived Assets Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Impairment of right-of-use and related long-lived assets expenses include our impairment charge for certain leased office and laboratory space, as well as impairment costs for related leasehold improvements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Interest Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Interest expense includes costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. We impute interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred tax assets and liabilities are measured at the consolidated balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in the period such tax rate changes are enacted. Our net deferred tax assets are fully offset by a valuation allowance, because of our history of losses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We recognize the effect of income tax positions only if those positions are more likely than not of being sustained upon examination.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We calculate basic net loss per share attributable to our common shareholders by dividing net loss attributable to us by our weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to our common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, outstanding common stock warrants, outstanding stock options, nonvested restricted stock units outstanding and the maximum nonvested market-based restricted stock units outstanding eligible to be earned are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to our common shareholders, as their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;New Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (Topic 280): &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which intends to enhance reportable segment disclosures about significant segment expenses. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the guidance is to be applied retrospectively. We are currently evaluating the impact of this guidance on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (Topic 740): &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which primarily intends to enhance the rate reconciliation and income taxes paid disclosures. This guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted and the guidance is to be applied prospectively; retrospective application is permitted. We are currently evaluating the impact of this guidance on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <adpt:BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_c7fdc308-b5e4-43c2-990e-d3f8ee89ad9a">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of Adaptive Biotechnologies Corporation, Adaptive Biotechnologies B.V., our wholly-owned subsidiary, and Digital Biotechnologies, Inc., a corporate subsidiary we have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% ownership interest in. The remaining interest in Digital Biotechnologies, Inc., held by certain of our related parties and their related family trusts, are shown in the consolidated financial statements as noncontrolling interest. All intercompany transactions and balances have been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;</adpt:BasisOfPresentationAndPrinciplesOfConsolidationPolicyPolicyTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="C_e3e3db77-5861-422c-a654-f78b40f8db36"
      decimals="2"
      id="F_7c352d2a-7dd7-4964-b707-054cfac9f479"
      unitRef="U_pure">0.70</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:UseOfEstimates
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_e4625e19-186c-4e80-a52b-df2f19dcdb6e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain performance obligations and the transaction price for certain contracts with customers, share-based compensation, imputing interest for our revenue interest purchase agreement (the &#x201c;Purchase Agreement&#x201d;) that we entered into in September 2022, the provision for income taxes, including related reserves, the analysis of goodwill impairment and the recoverability and impairment of long-lived assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management&#x2019;s estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_b65fc2a4-7b39-412b-92c0-ba335327ed7d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have determined that our chief executive officer is the chief operating decision maker (&#x201c;CODM&#x201d;). The CODM regularly reviews operating results and other financial information presented on a consolidated basis. While revenue is reviewed at levels lower than the consolidated entity, resource allocation decisions are made by the CODM based on the results presented at the consolidated entity level, which is determined to be a single reporting unit. The consolidated entity operates as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment and represents &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reportable segment. We present disaggregated revenue from contracts with customers by market opportunity and type of arrangement. See Note 3, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="INF"
      id="F_98f704d2-b7eb-4cee-8d42-3eeb9f3fd590"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="INF"
      id="F_a3ccc03e-8b32-401c-a5cc-ef2a5787c5d8"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_0b0c1eba-6f5d-43a8-ab89-765c16a181da">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. We limit our credit risk associated with cash and cash equivalents by placing our investments with banks that we believe are highly creditworthy and with highly rated money market funds. Cash and cash equivalents primarily consist of bank deposits and investments in money market funds.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_e0d864a8-bec7-408c-9847-233d57c3b029">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We had a restricted cash balance of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of December 31, 2023 and 2022, respectively. Our restricted cash primarily relates to certain balances we are required to maintain under lease arrangements for some of our property and facility leases.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-5"
      id="F_5e2fafcc-ad7e-499d-ae41-2479969fe192"
      unitRef="U_USD">2900000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-5"
      id="F_874d19ff-3c9d-4f09-a808-d718fbf36203"
      unitRef="U_USD">2400000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_c1181fd7-f2f0-45ae-9acc-796865a7345a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Marketable securities are classified as available-for-sale, consist of United States (&#x201c;U.S.&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) government treasury and agency securities, corporate bonds and commercial paper and are reported at fair value. Unrealized holding gains and losses are reflected as a separate component of shareholders&#x2019; equity in accumulated other comprehensive gain (loss) until realized. Realized gains and losses on the sale of these securities are recognized in net income or loss. The cost of marketable securities sold is based on the specific identification method.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_2d572830-5451-4435-85df-7eb8e5aff6b2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Financial Accounting Standards Board (&#x201c;FASB&#x201d;) has defined fair value as the exchange price that would be received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for that asset or liability in an orderly transaction between market participants on the measurement date. The FASB established a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The hierarchy defines three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A financial instrument categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. In certain cases, where there is limited activity or less transparency around valuation inputs, financial instruments are classified as Level 3 within the valuation hierarchy.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our financial instruments consist of Level 1 and Level 2 assets and have included Level 3 liabilities in the past. The carrying amounts of certain financial instruments approximate fair value due to their short maturities. We did not have any nonfinancial assets or liabilities that were measured or disclosed at fair value on a recurring basis as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_9a01ec45-6056-4554-affd-85a6963e29aa">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentrations of Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We are subject to a concentration of risk from a limited number of suppliers, or in certain cases, single suppliers, for some of our laboratory instruments and materials. This risk is managed by targeting a quantity of surplus stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash, cash equivalents and marketable securities are financial instruments that potentially subject us to concentrations of credit risk. We invest in money market funds, U.S. government treasury and agency securities, corporate bonds and commercial paper with high-quality accredited financial institutions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant customers are those that represent more than ten percent of our total revenue or accounts receivable, net balances for the periods and as of each consolidated balance sheet date presented, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:44.5%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.94%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.94%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.94%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.94%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.94%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Customer A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Customer B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Genentech, Inc. and Roche Group&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;* less than 10%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_896984de-5033-49a7-b65a-e696b7cdcec6">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For each significant customer, revenue as a percentage of total revenue for the periods presented and accounts receivable, net as a percentage of total accounts receivable, net as of the dates presented were as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:44.5%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.94%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.94%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.94%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.94%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:9.94%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Customer A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Customer B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Genentech, Inc. and Roche Group&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;* less than 10%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_5d4928f6-2311-4267-a962-fb87a6ccc8c3"
      decimals="3"
      id="F_14920464-2dcb-49f3-88e0-0c8526ef7e5f"
      unitRef="U_pure">0.158</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_9a81b7d4-7c86-4a5a-9662-9fa8a4acafae"
      decimals="3"
      id="F_538361c1-2d6c-4549-8f88-d8db6ed26eab"
      unitRef="U_pure">0.116</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_ff22cd37-5751-4b76-bb68-14093905829b"
      decimals="3"
      id="F_98a5c54b-ea46-47ec-89e3-bd1ba17b57c9"
      unitRef="U_pure">0.195</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_974e34a3-8a7b-44ac-b595-2e251f3f2e9d"
      decimals="3"
      id="F_4f1c3b74-fc3e-40a0-982d-ee79f1e5d1bc"
      unitRef="U_pure">0.278</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_ac662e7b-0f00-4834-864f-bfae853d3fae"
      decimals="3"
      id="F_1dec047d-3fc0-4353-b4b5-a182f8c0ae61"
      unitRef="U_pure">0.364</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_fa96d089-dfe6-4ac2-947d-35adf78b92c8"
      decimals="3"
      id="F_5f65a916-d2ed-4e14-bc55-5ab45de8515e"
      unitRef="U_pure">0.419</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_ff93d70c-0717-4d1a-93fb-633fac4d90eb">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounts Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accounts receivable consists of amounts due from customers for services performed. We review our accounts receivable for credit impairment and regularly analyze the status of significant past due receivables to determine if any will potentially be uncollectible to estimate the amount of allowance necessary to reduce accounts receivable to its estimated net realizable value.&lt;/span&gt;&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_0c15983a-78c3-4a55-89b9-4cbd9b4ad876">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Inventory consists of laboratory materials and supplies used in lab analysis. We capitalize inventory when purchased and record expense upon order fulfillment for servicing revenue or utilization in our research and development laboratories. Inventory is valued at the lower of cost or market on a first-in, first-out basis. We periodically perform obsolescence assessments and write-off any inventory that is no longer usable. Long-term inventory of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was included within the other assets balance on the consolidated balance sheet as of December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:OtherInventoryNoncurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-5"
      id="F_1ad8e597-632c-4b7c-8762-cd9595fa119f"
      unitRef="U_USD">2800000</us-gaap:OtherInventoryNoncurrent>
    <us-gaap:OtherInventoryNoncurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-5"
      id="F_d3d88578-5c94-43c5-bdcf-50521b2f793f"
      unitRef="U_USD">1400000</us-gaap:OtherInventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_9558a066-f73d-4b2d-a48c-e780938d4796">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment consists of computer equipment, computer software, laboratory equipment, leasehold improvements, furniture and office equipment and assets under construction. Property and equipment are recorded at cost and depreciation is recognized using the straight-line method based on estimated useful life. Maintenance and repairs are charged to expense as incurred and costs of improvements are capitalized.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Useful lives assigned to property and equipment are as follows:&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:84.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.14%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
          &lt;td style="width:49.14%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_de9ea103-2ab7-4e3e-8c48-d7bbaf7c674a;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shorter of estimated useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We review long-lived assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Gains and losses from asset disposals and impairment losses, if incurred, are classified within the consolidated statements of operations in accordance with the use of the asset, if not separately stated within its own financial statement line item. See Note 10, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for more information regarding the leasehold improvements impairment loss recognized during the year-ended December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <adpt:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_644b971d-da5b-4db2-bc1d-8d433e881c50">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Useful lives assigned to property and equipment are as follows:&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:84.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.14%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
          &lt;td style="width:49.14%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_de9ea103-2ab7-4e3e-8c48-d7bbaf7c674a;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shorter of estimated useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</adpt:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_36aa5e03-ecb8-4303-b58a-1c55adb14e7f"
      id="F_cda7e128-53bb-410d-9a92-2c556bf7fd58">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_91cb6778-e1d1-4172-888b-784d43882ecc"
      id="F_8cc82e98-732e-46e3-8b48-8389857a6eab">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_b0f7c504-6f69-48ba-bdd7-d64ff949d238"
      id="F_ac377e56-d6c8-42b3-b46f-3ee772712375">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_e77e6257-9358-42eb-8b65-6f87bb11fe8b"
      id="F_80bb8b89-f687-4860-b228-c9b345664057">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_c0865de4-d48f-44cc-8042-17b502c84d61"
      id="F_09e6d171-e34f-4d87-b391-99cc8c0eed43">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_bc38ff0f-2c7c-4c26-ba5a-4c9791880b39"
      id="F_c88de430-c81f-4c60-9fb0-7e902e50f49e">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_fca6b0d8-613a-4f83-bfd2-8d8e81d37053">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date, which is regarded as their cost.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Intangible assets may also result from the purchase of assets and intellectual property in a transaction that does not qualify as a business combination. Intangible assets are amortized over their estimated useful lives on a straight-line basis which approximates their usage pattern. Intangible assets are reviewed for impairment at least annually or if indicators of potential impairment exist. We have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognized any impairment losses on intangible assets.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="INF"
      id="F_014150b5-2237-4094-8e76-ae86c9de2dfc"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_6c1e4ae2-75be-4bb6-9b95-f68b24d5e7b3">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. We assess goodwill for impairment annually on October 1, or more frequently if events or changes in circumstances would more likely than not reduce the fair value of our single reporting unit below its carrying value. We evaluate goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value of our reporting unit is less than its carrying amount. If we so determine, or if we choose to bypass the qualitative assessment, we perform a quantitative goodwill impairment test. If impairment exists, the carrying value of the goodwill is reduced to its fair value through an impairment charge recorded in the consolidated statements of operations. To date, we have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognized any impairment of goodwill.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="INF"
      id="F_6d71f155-862e-412d-86f3-122b8f539a5a"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_a973cf30-ee28-4715-96db-d40b2a4d253e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We determine if an arrangement contains a lease at inception. We have operating lease agreements for the laboratory, office and warehouse facilities that we occupy. Operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities are recognized at the date the underlying asset becomes available for our use and are based on the present value of the future minimum lease payments over the lease term. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. As our leases generally do not provide an implicit interest rate, the present value of our future minimum lease payments is determined using our incremental borrowing rate. This rate is an estimate of the collateralized borrowing rate we would incur on our future lease payments over a similar term and is based on the information available to us at the lease commencement date, or as of January 1, 2020 for commenced leases that existed as of our adoption of Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (Topic 842) (&#x201c;ASC 842&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Certain of our leases contain options to extend or terminate the lease; lease terms are adjusted for these options only when it is reasonably certain we will exercise these options. Our lease agreements do not contain residual value guarantees or covenants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have made a policy election regarding our real estate leases not to separate nonlease components from lease components, to the extent they are fixed. Nonlease components that are not fixed are expensed as incurred as variable lease expense. Our leases for laboratory, office and warehouse facilities typically include variable nonlease components, such as common-area maintenance costs. We have also elected not to record on the consolidated balance sheets a lease that has a lease term of twelve months or less and does not contain a purchase option that we are reasonably certain to exercise.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We review our right-of-use assets for impairment annually or whenever events or circumstances indicate the carrying amount of an asset group may not be recoverable. Impairment losses are classified within the consolidated statements of operations in accordance with the use of the asset, if not separately stated within its own financial statement line item. See Note 10, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for more information regarding the right-of-use asset impairment loss recognized during the year-ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Lease expense is recognized on a straight-line basis over the terms of the leases. Incentives granted under our facilities leases, including rent holidays, are recognized as adjustments to lease expense on a straight-line basis over the terms of the leases.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <adpt:RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_58f3f580-da94-43b1-8b7f-bad3dfce69f5">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Interest Liability, Net and Related Imputed Interest&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The revenue interest liability balance associated with the Purchase Agreement that we entered into in September 2022 is presented net of unamortized issuance costs on the consolidated balance sheets. We impute our associated interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. The effective interest rate may vary during the term of the agreement depending on a number of factors, including changes in forecasted GAAP revenues. We evaluate the effective interest rate quarterly based on both achieved and forecasted revenues, utilizing the prospective method. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense and the time period for repayment.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</adpt:RevenueInterestLiabilityNetAndRelatedImputedInterestPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_8e39977e-287f-483a-a2d3-1338292d2bb0">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For all revenue-generating contracts, we perform the following steps to determine the amount of revenue to be recognized: (1) identify the contract or contracts; (2) determine whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (3) measure the transaction price, including the constraint on variable consideration; (4) allocate the transaction price to the performance obligations based on estimated selling prices; and (5) recognize revenue when (or as) we satisfy each performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We derive revenue by providing diagnostic and research services in our Immune Medicine and Minimal Residual Disease (&#x201c;MRD&#x201d;) business areas. Our Immune Medicine revenue consists of revenue generated from (1) providing sample testing services for our commercial research product, Adaptive Immunosequencing, to biopharmaceutical customers and academic institutions; (2) our collaboration agreements with Genentech, Inc. (&#x201c;Genentech&#x201d;) and other biopharmaceutical customers in areas of drug and target discovery; and (3) for prior years, providing our T-Detect COVID tests to clinical customers. Our MRD revenue consists of revenue generated from (1) providing our clonoSEQ report to clinical customers; (2) providing MRD sample testing services to biopharmaceutical customers and certain academic institutions, including investigator-led clinical trials; and (3) providing our clonoSEQ report or results to certain international laboratory sites through technology transfers.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For research customers who utilize either Adaptive Immunosequencing or our MRD services, contracts typically include an amount billed in advance of services (&#x201c;upfront&#x201d;) and subsequent billings as sample results are delivered to the customer. Upfront amounts received are recorded as deferred revenue, which we recognize as revenue upon satisfaction of performance obligations. We have identified &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; typical performance obligations under the terms of our research service contracts: (1) the delivery of our Adaptive Immunosequencing or MRD data for customer provided samples; and (2) related data analysis. We recognize revenue for both identified performance obligations as sample results are delivered to the customer. In periods where our sample estimates are reduced or a customer project is cancelled and, in either case, we have remaining related deferred revenue, we recognize revenue using a cumulative catch-up approach based on the proportion of samples delivered to date relative to the total samples expected to be delivered.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For agreements where we provide our clonoSEQ report to ordering physicians, we have identified one performance obligation: the delivery of a clonoSEQ report. We bill and receive payments for these transactions from commercial, government and medical institution payors. As payment from the respective payors may vary based on the various reimbursement rates and patient responsibilities, we consider the transaction price to be variable and record an estimate of the transaction price, subject to the constraint for variable consideration, as revenue at the time of delivery. The estimate of transaction price is based on historical and expected reimbursement rates with the various payors, which are monitored in subsequent periods and adjusted, as necessary, based on actual collection experience.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Regarding our clonoSEQ coverage under Medicare, we bill an episode of treatment when we deliver the first eligible test report. This billing contemplates all necessary tests required during a patient&#x2019;s treatment cycle, which is currently estimated at approximately four tests per patient, including the initial sequence identification test. Revenue recognition commences at the time the initial billable test report is delivered and is based upon cumulative tests delivered to date. We estimate the number of tests we expect to deliver over a patient&#x2019;s treatment cycle based on historical testing frequencies for patients by indication. These estimates are subject to change as we develop more information about utilization over time. Any unrecognized revenue from the initial billable test is recorded as deferred revenue and is recognized either as we deliver our estimate of the remaining tests in a patient&#x2019;s treatment cycle or when the likelihood becomes remote that a patient will receive additional testing.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The contract transaction price for agreements we enter into with biopharmaceutical customers to further develop and commercialize their therapeutics may consist of a combination of non-refundable upfront fees, separately priced MRD testing fees and milestone fees earned upon our customers&#x2019; achievement of certain regulatory approvals. Depending on the contract, these agreements include single or multiple performance obligations. Such performance obligations include providing services to support our customers&#x2019; therapeutic development efforts, including regulatory support for our technology intended to be utilized as part of our customers&#x2019; registrational trials, developing analytical plans for our data, participating on joint research committees, assisting in completing a regulatory submission and providing MRD testing services related to customer-provided samples for our customers' regulatory submissions. Generally, the support services, excluding MRD testing services, are not distinct within the context of the contract and thus are accounted for as a single performance obligation. The transaction price allocated to the respective performance obligations is estimated using an adjusted market assessment approach for the regulatory support services and a standalone selling price for the estimated MRD testing services. When MRD sample testing services are separately priced customer options, we assess if a material right exists and, if not, the customer option to purchase additional MRD sample testing services is not considered part of the contract. We recognize revenue related to MRD testing services over time using an output method based on the proportion of sample results delivered relative to the total amount of sample results expected to be delivered, when expected to be a faithful depiction of progress. We use the same method to recognize the regulatory support services. When an output method based on the proportion of sample results delivered is not expected to be a faithful depiction of progress, we utilize an input method using a cost-based model based on estimates of effort completed. Selecting the measure of progress and estimating progress to date requires significant judgment. Except for any non-refundable upfront fees, the other forms of compensation represent variable consideration. At contract inception, we fully constrain any consideration related to regulatory milestones, as the achievement of such milestones is subject to third-party regulatory approval and the customers&#x2019; own submission decision-making. Variable consideration related to regulatory milestones is estimated using the most likely amount method, where variable consideration is constrained until it is probable that a significant reversal of cumulative revenue will not occur. Milestone payments for regulatory approvals, which are not within our customers&#x2019; control, are not considered probable of being achieved until those approvals are received. Determining whether regulatory milestone payments are probable is an area that requires significant judgment. In making this assessment, we evaluate scientific, clinical, regulatory and other risks, as well as the level of effort and investment required to achieve the respective milestone.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2021, we executed an intellectual property license agreement that includes variable consideration related to sales-based royalties. Any consideration related to such royalties will be recognized as revenue at the later of when (i) the related sales occur or (ii) the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <adpt:NumberOfRevenuePerformanceObligation
      contextRef="C_dfa7b2ec-aa90-4f5c-b852-1f27ae360214"
      decimals="INF"
      id="F_85c8f9cd-f82d-4c9b-aeb3-52e7be83d0e1"
      unitRef="U_Performance_Obligation">2</adpt:NumberOfRevenuePerformanceObligation>
    <adpt:ContractBalancesPolicyTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_95ed821c-cc40-4e25-8b20-de6003f86cb3">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Contract Balances&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In certain circumstances, billing may occur prior to services being performed. Upfront payments are recorded as deferred revenue, or contract liabilities. We classify deferred revenue as current when we expect our performance obligations will be completed within the next twelve months; however, we do not control the timing of customer provided samples. For service and collaboration activities, excluding those related to our worldwide collaboration and license agreement with Genentech, we assess the performance obligations and recognize deferred revenue as current or non-current based upon forecasted delivery times, which are customer coordinated. In certain circumstances, a customer project may be cancelled or terminated prior to the delivery of all related services covered by a customer&#x2019;s upfront payment. In these circumstances, we recognize revenue when sufficient evidence is obtained that a reversal of revenue is not probable. We also recognize revenue when our estimate of total samples to be provided under certain of our agreements is reduced or, in the case of contract balances related to Medicare, when the likelihood becomes remote that a patient will receive additional testing. See Note 3, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for our deferred revenue policy related to our worldwide collaboration and license agreement with Genentech.&lt;/span&gt;&lt;/p&gt;</adpt:ContractBalancesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_b410e456-dde8-4eca-943c-55b26bf49404">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Share-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Share-based compensation includes compensation expense for stock option, restricted stock unit and market-based restricted stock unit grants made to employees and non-employees. It represents the grant date fair value of the grants and is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis, net of actual forfeitures. We estimate the grant date fair value of stock option and market-based restricted stock unit grants using the Black-Scholes option-pricing model and the Monte Carlo valuation model, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_82441e66-f247-47b2-906d-48a8349928c9">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Advertising&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Advertising costs are expensed as incurred. Advertising expenses were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the year ended December 31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-5"
      id="F_fe2695e1-2052-4b42-a43f-cdf867ffb9b0"
      unitRef="U_USD">8600000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-5"
      id="F_b9dca5f9-c85a-44f6-917b-070587d61975"
      unitRef="U_USD">13700000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-5"
      id="F_da0ee32a-5291-44f5-9e7f-60bdd92d9572"
      unitRef="U_USD">22400000</us-gaap:AdvertisingExpense>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_e94bca2f-b976-43a8-93e2-56ba7e8c5c6e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cost of Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cost of revenue includes the cost of materials, personnel-related expenses (including salaries, benefits and share-based compensation), shipping and handling expenses, equipment costs, allocated facility costs associated with processing samples and professional support costs related to our service revenue activities. Allocated facility costs include depreciation of laboratory equipment, as well as allocated facility occupancy and information technology costs. Costs associated with processing samples are recorded as expense, regardless of the timing of revenue recognition.&lt;/span&gt;&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_6f764179-c29c-40ff-941d-12007348ea99">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development expenses consist of laboratory materials costs, personnel-related expenses (including salaries, benefits and share-based compensation), equipment costs, allocated facility and information technology costs and contract service expenses. Research and development activities support further development and refinement of existing assays and products, discovery of new technologies and investments in our immune medicine platform. We also include in research and development expenses the costs associated with software development of applications to support future commercial opportunities, as well as development activities to support laboratory scaling and workflow. Additionally, a component of our research and development expenses are costs supporting clinical and analytical validations to obtain regulatory approval for future clinical products and services. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Upfront payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized, then are recognized as an expense as the goods are consumed or the related services are performed. Costs to support our worldwide collaboration and license agreement with Genentech are also a component of our research and development expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <adpt:SalesAndMarketingExpensePolicyTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_47dedc47-a448-44eb-afea-581e356720a7">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sales and Marketing Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Sales and marketing expenses include personnel-related expenses (including salaries, benefits and share-based compensation) for commercial sales, product and account management, marketing, reimbursement, medical education and business development personnel that support commercialization of our platform products. In addition, these expenses include external costs such as advertising expenses, customer education and promotional expenses, market analysis expenses, conference fees, travel expenses and allocated facility and information technology costs.&lt;/span&gt;&lt;/p&gt;</adpt:SalesAndMarketingExpensePolicyTextBlock>
    <adpt:ImpairmentOfRightOfUseAndRelatedLongLivedAssetsExpensesPolicyTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_c9cfd079-2361-4fa4-b182-bc196c952c1f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of Right-of-Use and Related Long-Lived Assets Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Impairment of right-of-use and related long-lived assets expenses include our impairment charge for certain leased office and laboratory space, as well as impairment costs for related leasehold improvements.&lt;/span&gt;&lt;/p&gt;</adpt:ImpairmentOfRightOfUseAndRelatedLongLivedAssetsExpensesPolicyTextBlock>
    <us-gaap:InterestExpensePolicyTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_a1672868-f43c-45a0-ac67-db71a0c32a8c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Interest Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Interest expense includes costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. We impute interest expense using the effective interest rate method. We calculate an effective interest rate which will amortize our related obligation to zero over the anticipated repayment period. A significant increase or decrease in or changes in timing of forecasted revenue will prospectively impact our interest expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:InterestExpensePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_cddc780c-df30-45aa-ae1c-dcbb3ab70217">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and the operating loss and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred tax assets and liabilities are measured at the consolidated balance sheet date using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities due to a change in tax rates is recognized in the period such tax rate changes are enacted. Our net deferred tax assets are fully offset by a valuation allowance, because of our history of losses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We recognize the effect of income tax positions only if those positions are more likely than not of being sustained upon examination.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_4aa0ce18-4916-4b35-8b1a-f3e7ec4caff8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We calculate basic net loss per share attributable to our common shareholders by dividing net loss attributable to us by our weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to our common shareholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, outstanding common stock warrants, outstanding stock options, nonvested restricted stock units outstanding and the maximum nonvested market-based restricted stock units outstanding eligible to be earned are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to our common shareholders, as their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_08c5767a-9e6d-4344-b7aa-8cd28941a43f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;New Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (Topic 280): &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which intends to enhance reportable segment disclosures about significant segment expenses. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the guidance is to be applied retrospectively. We are currently evaluating the impact of this guidance on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (Topic 740): &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which primarily intends to enhance the rate reconciliation and income taxes paid disclosures. This guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted and the guidance is to be applied prospectively; retrospective application is permitted. We are currently evaluating the impact of this guidance on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_6ac668d9-9efe-4cbb-aec6-7a4fc38e2d6a">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;3.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We disaggregate our revenue from contracts with customers by business area and type of arrangement, as we believe this best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents our disaggregated revenue for the periods presented (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Immune Medicine revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Service revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Collaboration revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total Immune Medicine revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;MRD revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Service revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Regulatory milestone revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total MRD revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;185,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;154,344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the year ended December 31, 2023, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in Immune Medicine service revenue related to cancelled customer contracts. Additionally, during the year ended December 31, 2023, we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in MRD service revenue related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote, cancelled customer contracts and changes in estimates of total samples to be provided under certain of our agreements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the year ended December 31, 2022, we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in Immune Medicine service revenue related to cancelled customer contracts. Additionally, during the year ended December 31, 2022, we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in MRD service revenue related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote, changes in estimates of total samples to be provided under certain of our agreements and cancelled customer contracts.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the year ended December 31, 2021, we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in MRD service revenue related to changes in estimates of total samples to be provided under certain of our agreements, Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote, a change in our estimate of expected cumulative tests per patient for one of our covered indications and cancelled customer contracts.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, we could receive up to an additional &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;440.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;milestone payments in future periods if certain regulatory approvals are obtained by our customers&#x2019; therapeutics in connection with MRD data generated from our MRD product.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Genentech Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2018, we entered into a worldwide collaboration and license agreement with Genentech (the &#x201c;Genentech Agreement&#x201d;) to leverage our capability to develop cellular therapies in oncology. Subsequent to receipt of regulatory approval in January 2019, we received a non-refundable, upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in February 2019 and may be eligible to receive more than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion over time, including payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upon the achievement of specified regulatory milestones ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of which was achieved in May 2023), up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upon the achievement of specified development milestones and up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;1,430.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upon the achievement of specified commercial milestones. In addition, we are separately able to receive tiered royalties at a rate ranging from the mid-single digits to the mid-teens on aggregate worldwide net sales of products arising from the strategic collaboration, subject to certain reductions, with aggregate minimum floors. Under the Genentech Agreement, we are pursuing two product development pathways for novel T cell therapeutic products in which Genentech intends to use T cell receptors (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x201c;TCRs&#x201d;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) screened by our immune medicine platform to engineer and manufacture cellular medicines:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Shared Products. The shared products will use &#x201c;off-the-shelf&#x201d; TCRs identified against cancer antigens shared among patients (&#x201c;Shared Products&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Personalized Product. The personalized product will use patient-specific TCRs identified by real-time screening of TCRs against cancer antigens in each patient (&#x201c;Personalized Product&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the terms of the Genentech Agreement, we granted Genentech exclusive worldwide licenses to develop and commercialize TCR-based cellular therapies in the field of oncology, including licenses to existing shared antigen data packages. Additionally, Genentech has the right to determine which product candidates to further develop for commercialization purposes. We determined that this arrangement meets the criteria set forth in Accounting Standards Codification (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x201c;ASC&#x201d;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) Topic 808, &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (&#x201c;ASC 808&#x201d;), because both parties are active participants in the activity and are exposed to significant risks and rewards depending on the activity&#x2019;s commercial failure or success. Because ASC 808 does not provide guidance on how to account for the activities under a collaborative arrangement, we applied the guidance in ASC Topic 606, &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x201c;ASC 606&#x201d;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) to account for the activities related to the Genentech Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In applying ASC 606, we identified the following performance obligations at the inception of the agreement:&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;"&gt;1.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;License to utilize on an exclusive basis all TCR-specific platform intellectual property to develop and commercialize any licensed products in the field of oncology. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;License to utilize all data and information within each shared antigen data package and any other know-how disclosed by us to Genentech in oncology. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;"&gt;3.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;License to utilize all private antigen TCR product data in connection with research and development activities in the field of use. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;"&gt;4.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;License to existing shared antigen data packages. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;"&gt;5.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development services for Shared Products development, including expansion of shared antigen data packages. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;"&gt;6.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development services for private product development. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:7.861%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:2.269%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:2.4625837050543202%;display:inline-flex;justify-content:flex-start;"&gt;7.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Obligations to participate on various joint research, development and project committees. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We determined that none of the licenses, research and development services or obligations to participate on various committees were distinct within the context of the contract, given such rights and activities were highly interrelated and there was substantial additional research and development to further develop the licenses. We considered factors such as the stage of development of the respective existing antigen data packages, the subsequent development that would be required to both identify and submit a potential target for investigational new drug acceptance under both product pathways and the variability in research and development pathways given Genentech&#x2019;s control of product commercialization. Specifically, under the Genentech Agreement, Genentech is not required to pursue development or commercialization activities pertaining to both product pathways and may choose to proceed with one or the other. Accordingly, we determined that all of the identified performance obligations were attributable to one general performance obligation, which is to further the development of our TCR-specific platform, including data packages, and continue to make our TCR identification process available to Genentech to pursue either product pathway.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Separately, we have a responsibility to Genentech to enter into a supply and manufacturing agreement for patient-specific TCRs as it pertains to any Personalized Product therapeutic. We determined this was an option right of Genentech should they pursue commercialization of a Personalized Product therapy. Because of the uncertainty resulting from the early stage of development, the novel approach of our collaboration with Genentech and our rights to future commercial milestones and royalty payments, we determined that this option right was not a material right that should be accounted for at inception. As such, we will account for the supply and manufacturing agreement when entered into between the parties.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We determined the initial transaction price shall be made up of only the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upfront, non-refundable payment, as all potential regulatory and development milestone payments were probable of significant revenue reversal given their achievement was highly dependent on factors outside our control. As a result, these payments were fully constrained and were not included in the initial transaction price. In May 2023, one of the regulatory milestones was achieved, resulting in a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million addition to the transaction price, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of which was recognized as revenue in the three months ended June 30, 2023, with the remainder included in deferred revenue to be recognized as revenue over the remaining research and development period. We continue to exclude the commercial milestones and potential royalties from the transaction price, as those items relate predominantly to the license rights granted to Genentech and will be assessed when and if such events occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As there are potential substantive developments necessary, which Genentech may be able to direct, we determined that we would apply a proportional performance model to recognize revenue for our performance obligation. We measure proportional performance using an input method based on costs incurred relative to the total estimated costs of research and development efforts to pursue both the Shared Products and Personalized Product pathways. When any of the potential regulatory and development milestones are no longer fully constrained and are included in the transaction price, such amounts will be recognized using the cumulative catch-up method based on proportional performance at such time. We currently expect to recognize revenue generated from the Genentech Agreement over a period of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;nine years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the effective date. This estimate of the research and development period considers pursuit options of development activities supporting both the Shared Products and Personalized Product, but may be reduced or increased based on the various activities as directed by the joint committees, decisions made by Genentech, regulatory feedback or other factors not currently known.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In total, we recognized &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;42.6&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;62.8&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;62.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in Immune Medicine collaboration revenue during the year ended December 31, 2023, 2022 and 2021, respectively, related to the Genentech Agreement. Costs related to the Genentech Agreement are included in research and development expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_cdad590d-5533-4ada-bdf0-f80a46495165">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents our disaggregated revenue for the periods presented (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Immune Medicine revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Service revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,777&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Collaboration revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total Immune Medicine revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;88,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;MRD revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Service revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Regulatory milestone revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total MRD revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;87,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;170,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;185,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;154,344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_c6893910-acd0-4028-a16a-e72e33a1a487"
      decimals="-3"
      id="F_2a68b682-973f-4cca-8211-ae0179fb447a"
      unitRef="U_USD">24959000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_c3ef0edc-d7e9-410c-9e8c-a9c962f71593"
      decimals="-3"
      id="F_0b37ef39-1948-4427-9df2-b465844d913e"
      unitRef="U_USD">31777000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_097b7e33-8328-4df1-98a7-2fb97904b263"
      decimals="-3"
      id="F_9827efac-3f93-431b-b548-03175dd9a70c"
      unitRef="U_USD">24482000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_204a4f00-21f5-4dcb-a003-2209a2b96734"
      decimals="-3"
      id="F_27eab2d8-e6a0-4543-9b6b-f1d263afade0"
      unitRef="U_USD">42578000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_46e84d5a-c9e4-4c07-ab2c-1b337f1e4935"
      decimals="-3"
      id="F_3b332988-1ad7-4dce-a8b0-71c010b96116"
      unitRef="U_USD">66387000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d8710412-3f02-4dca-a349-7c6431efb35f"
      decimals="-3"
      id="F_a8cfde20-62e0-428e-af3d-044985c53073"
      unitRef="U_USD">63651000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a82a556c-1601-4580-ab77-910e118cd40c"
      decimals="-3"
      id="F_67aeeadc-44a3-4022-a409-572a72f735b9"
      unitRef="U_USD">67537000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_f97d20b9-f753-4b1f-9310-f5374bf7a287"
      decimals="-3"
      id="F_2e7566c2-fff8-4b1d-8075-82eba78fcd63"
      unitRef="U_USD">98164000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_2253a734-72b4-4815-b0fe-904db241abd5"
      decimals="-3"
      id="F_8fd8ef46-32e3-4b4a-bc57-973132c8f434"
      unitRef="U_USD">88133000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d3b1db82-a429-41f4-a3a7-519573159ff1"
      decimals="-3"
      id="F_0f139a66-e7a1-484a-aba3-27510762e41e"
      unitRef="U_USD">102739000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_7e1886f0-fb32-4498-bc32-5c4175f816eb"
      decimals="-3"
      id="F_0a4a705e-f0aa-45b1-b767-eb48203508c7"
      unitRef="U_USD">81144000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b0dca8ac-f948-40e9-872d-4956561f7f9e"
      decimals="-3"
      id="F_6573212c-89fa-4eda-8429-9bdf88c71ec1"
      unitRef="U_USD">56211000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_210fa5b6-4781-4834-bdb9-d0bc4fba918c"
      decimals="-3"
      id="F_afbf5efc-c843-43d9-bcfa-3c1a952ccc05"
      unitRef="U_USD">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8b01e241-462b-4cbe-9903-9e86be9bdd64"
      decimals="-3"
      id="F_984d0ff0-4222-4dc3-a3a2-5c15100db809"
      unitRef="U_USD">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8b6979c8-1fdd-4825-99b4-52c44d8a83f2"
      decimals="-3"
      id="F_ab48b4e7-9d9c-483e-bb8c-196797b331d5"
      unitRef="U_USD">102739000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9d2cc705-f6fa-4bf8-a55b-b2a0844f2132"
      decimals="-3"
      id="F_897f32d0-31c5-44a1-8b14-2c428ac68284"
      unitRef="U_USD">87144000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_508f5dbc-ed11-4aeb-8235-78423618619e"
      decimals="-3"
      id="F_b830d6b3-6fc4-409f-831c-a4fe1fd1c691"
      unitRef="U_USD">66211000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_9181ed4f-4859-4413-8c13-a735d74dbdf9"
      unitRef="U_USD">170276000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_bb378aa2-1ec2-4ba3-bfd2-7d1bf9099358"
      unitRef="U_USD">185308000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_82ac82ed-7e6a-4e18-95b4-b27830795ed3"
      unitRef="U_USD">154344000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ff166e5f-74cd-481e-a4de-3d85ebc33d6f"
      decimals="-5"
      id="F_478820ea-4f10-433c-b304-e0172b4b1601"
      unitRef="U_USD">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_17868eb1-c4c5-48c6-b75e-f00ebc3afa5a"
      decimals="-5"
      id="F_dedb5792-6646-4a3d-a0b8-791db9446850"
      unitRef="U_USD">5600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a17c4258-455e-423a-b8b4-bc69663eb694"
      decimals="-5"
      id="F_7469994f-18fe-4f92-97df-a53826ce30bf"
      unitRef="U_USD">700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_879ff3e9-d994-4359-a193-fdc194e1100d"
      decimals="-5"
      id="F_caca7ab0-5e68-45b6-899e-b8b53e04759d"
      unitRef="U_USD">5200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_155c8aa1-a117-426c-ae23-7248267399d3"
      decimals="-5"
      id="F_9c9dc707-868c-4315-81fd-95793a7f65a4"
      unitRef="U_USD">5800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adpt:AdditionalMilestonePayment
      contextRef="C_44860682-94f0-4904-9f2d-90b50cef0eaa"
      decimals="INF"
      id="F_bff88cff-9bae-4da2-9594-c404a9b2f859"
      unitRef="U_USD">440000000</adpt:AdditionalMilestonePayment>
    <adpt:NonRefundableUpfrontPaymentsReceived
      contextRef="C_7984164c-34fb-49f5-8c89-ae672ec9ae5f"
      decimals="-5"
      id="F_e2dbd0b5-fd3e-41ca-8201-4392ebb609a6"
      unitRef="U_USD">300000000</adpt:NonRefundableUpfrontPaymentsReceived>
    <adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable
      contextRef="C_f7590b76-24a6-4b4b-aa70-3aa848e7a0e3"
      decimals="INF"
      id="F_bc2ec1d6-bc49-42f5-a8ff-4ff3c915b07d"
      unitRef="U_USD">1800000000</adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
    <adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable
      contextRef="C_11c9cefe-d945-4687-baad-0cb3aed4a0b3"
      decimals="INF"
      id="F_b08d28dc-9dda-4ccc-ac6d-8bbb4b919e20"
      unitRef="U_USD">75000000</adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
    <adpt:AdditionalTransactionPriceOfRegulatoryMilestone
      contextRef="C_8c236b85-61c5-4e71-b6c3-ced8a4945424"
      decimals="INF"
      id="F_711e5afe-6f74-4d1f-a202-51d57c8d029c"
      unitRef="U_USD">10000000</adpt:AdditionalTransactionPriceOfRegulatoryMilestone>
    <adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable
      contextRef="C_67aee0e6-f162-469f-95d2-8cd5d55d1668"
      decimals="INF"
      id="F_a7e41699-39ae-4076-a2f1-a659eaaa744c"
      unitRef="U_USD">300000000</adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
    <adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable
      contextRef="C_9af75d46-039e-4da0-97be-856b25cedf1f"
      decimals="INF"
      id="F_86f90ef5-4be0-4623-9c82-392dd464d11d"
      unitRef="U_USD">1430000000</adpt:RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable>
    <adpt:NonRefundableUpfrontPaymentsReceived
      contextRef="C_4bbcd131-d371-4bbb-964c-f9710f39d70f"
      decimals="-5"
      id="F_c7d1ddaf-733e-48a1-b3a3-1756a851eb15"
      unitRef="U_USD">300000000</adpt:NonRefundableUpfrontPaymentsReceived>
    <adpt:AdditionalTransactionPriceOfRegulatoryMilestone
      contextRef="C_a9f3e4a6-a161-4edd-ae17-b5c6c4d1afc8"
      decimals="-5"
      id="F_eee8f4f5-9581-4900-a8fd-2ccde0c98ff4"
      unitRef="U_USD">10000000</adpt:AdditionalTransactionPriceOfRegulatoryMilestone>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a9f3e4a6-a161-4edd-ae17-b5c6c4d1afc8"
      decimals="-5"
      id="F_acff17ee-24e6-42a8-b59d-b4f82ebdbd75"
      unitRef="U_USD">7700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adpt:RevenueRecognitionExpectedPeriod
      contextRef="C_2bf1a599-2304-4abc-8e54-646171f11931"
      id="F_ebd5cf90-0153-4894-ad6e-7e42de1196dc">P9Y</adpt:RevenueRecognitionExpectedPeriod>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4bbcd131-d371-4bbb-964c-f9710f39d70f"
      decimals="-5"
      id="F_4fb2b13f-b3f3-4f31-a8c2-5a6be1ac760d"
      unitRef="U_USD">42600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_90b18a98-b831-4016-b24b-b23fdc203a9b"
      decimals="-5"
      id="F_c2f68836-ab09-4e56-924f-003e7f74f2d7"
      unitRef="U_USD">62800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_aef81851-9d40-4e26-b3cc-121716608ec6"
      decimals="-5"
      id="F_af21d6d6-9828-43ac-b72c-6c4c4dd3b7b4"
      unitRef="U_USD">62000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adpt:DeferredRevenueTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_7eddde79-ec83-4758-8cd3-84e98a71b07a">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;4.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred revenue from the Genentech Agreement represents &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the current and non-current deferred revenue balances on the consolidated balance sheet, respectively, as of December 31, 2023 and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the current and non-current deferred revenue balances on the consolidated balance sheet, respectively, as of December 31, 2022. We expect our current deferred revenue to be recognized as revenue within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; months. We expect the majority of our non-current deferred revenue to be recognized as revenue over a period of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from December 31, 2023. This period of time represents an estimate of the research and development period to develop cellular therapies in oncology, which may be reduced or increased based on various research and development activities.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Changes in deferred revenue during the year ended December 31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred revenue balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions to deferred revenue during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue recognized during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred revenue balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was recognized as revenue that was included in the deferred revenue balance at December 31, 2022.&lt;/span&gt;&lt;/p&gt;</adpt:DeferredRevenueTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_590e8b43-3f28-4c61-98e6-73136a10b460"
      decimals="-5"
      id="F_12be69b9-2058-4018-8d31-fd16b41af384"
      unitRef="U_USD">13600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_590e8b43-3f28-4c61-98e6-73136a10b460"
      decimals="-5"
      id="F_751103ef-3338-48dc-95e9-50e960ce44cb"
      unitRef="U_USD">41100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_ae994e8c-99db-42b9-978b-de43f2096cd2"
      decimals="-5"
      id="F_80c78c14-2bca-4fa7-b965-ba8ac4e8a577"
      unitRef="U_USD">31800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_ae994e8c-99db-42b9-978b-de43f2096cd2"
      decimals="-5"
      id="F_6ad0a929-088e-49ea-b754-8d73def253ce"
      unitRef="U_USD">55500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_cb59ede3-9e6b-4249-8eda-53f2caa6aa96"
      id="F_9550d828-e285-4b26-acef-f8c2883a37d1">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_e97676e6-a32f-4929-a773-40c1fd1dd414"
      id="F_621636de-b55f-4140-bbca-9b2b602aba26">P4Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_6d46e323-436a-4344-8b82-b90d046e1bd0">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Changes in deferred revenue during the year ended December 31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred revenue balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions to deferred revenue during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue recognized during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred revenue balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_ea17f96b-4763-4571-9e8c-340a9176558c"
      unitRef="U_USD">122714000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_488c2540-57b2-46e9-a228-73e8add895c3"
      unitRef="U_USD">44471000</us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_f0775667-13a6-40d8-aa1d-156eb4478bbe"
      unitRef="U_USD">-73762000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_538c6c24-5816-4459-9cd9-d67144728dcb"
      unitRef="U_USD">93423000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_96f09fd3-7634-4ea2-a021-1e8adb2f4bc6"
      decimals="-5"
      id="F_10166144-c0af-47bf-a789-bab863cc2395"
      unitRef="U_USD">53200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_396f832e-b56b-4015-8264-e6dbb4e70713">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;5.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables set forth the fair values of financial assets as of December 31, 2023 and 2022 that were measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.07%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government treasury and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;264,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;264,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;281,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;326,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.07%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;385,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;385,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;408,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;446,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1 securities include highly liquid money market funds, for which we measure the fair value based on quoted prices in active markets for identical assets or liabilities. Level 2 securities consist of U.S. government treasury and agency securities, corporate bonds and commercial paper, and are valued based on recent trades of securities in inactive markets or on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_95ec8f23-80d8-4ee7-844f-56a76f01c933">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables set forth the fair values of financial assets as of December 31, 2023 and 2022 that were measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.07%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government treasury and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;264,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;264,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;281,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;326,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.07%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;385,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;385,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;408,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;446,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_38611b62-cabf-4f6e-b0a1-2efc9958f5fd"
      decimals="-3"
      id="F_1ef176e2-4dac-4c96-9a76-92b1773a23f1"
      unitRef="U_USD">45123000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_61d852e8-fe3d-43d3-9908-9744f1adec07"
      decimals="-3"
      id="F_f6abaa9b-d463-428f-b04b-5695de910886"
      unitRef="U_USD">45123000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_04434413-9490-4c62-8db8-4065a648f009"
      decimals="-3"
      id="F_5fbd026b-c977-4f37-88b6-4ba95d412e68"
      unitRef="U_USD">10630000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b727e5f9-4a98-4fe3-92ea-13e9386f4879"
      decimals="-3"
      id="F_a5f37173-14ac-4fa6-ac29-2409eed2a4c9"
      unitRef="U_USD">10630000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_743fa22e-b9d5-4339-a15c-2d857ef34156"
      decimals="-3"
      id="F_67a08f99-c7b8-4ac8-9e2f-cb7e9860987a"
      unitRef="U_USD">264426000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_01aa24c7-60e3-49ec-b493-ede3c4266545"
      decimals="-3"
      id="F_97140e3c-bb3e-41f0-8b68-adab7af4120e"
      unitRef="U_USD">264426000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c2513f06-b4d4-4816-bbc2-a3007d07bc1a"
      decimals="-3"
      id="F_c4629ec0-e230-4430-b4e2-0422b9dc1b97"
      unitRef="U_USD">6281000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7b1ddbb7-6337-4d2b-8237-82b13e821312"
      decimals="-3"
      id="F_767405a2-45d9-4581-a855-a3ede03d26c1"
      unitRef="U_USD">6281000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1bea693b-1342-45f0-bcda-ded1c10280e8"
      decimals="-3"
      id="F_7c6d8a36-a449-4a78-86fe-f9005a8aab65"
      unitRef="U_USD">45123000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b809ccc7-b28c-4fe5-bb88-66507dc666e2"
      decimals="-3"
      id="F_2a83d3d4-f00b-4e50-a3da-d08a0ba321ff"
      unitRef="U_USD">281337000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2a889da6-68e6-499f-9f09-345a151867c6"
      decimals="-3"
      id="F_2bbd43a5-25ba-4ab2-a2a1-83a158ea63e2"
      unitRef="U_USD">326460000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_233dab25-77c1-4413-89c5-c93d77ebf3f3"
      decimals="-3"
      id="F_fe3bc1c0-9a04-4425-9748-fad815331840"
      unitRef="U_USD">38502000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f1b230a8-3c3c-45c2-a49f-2549b9086405"
      decimals="-3"
      id="F_2828116e-3055-4343-b82e-44f809873afb"
      unitRef="U_USD">38502000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_461360c8-498f-4146-b38f-94ec6b8507ff"
      decimals="-3"
      id="F_7fa20fac-9c9c-430a-a407-e8fdbd3c5961"
      unitRef="U_USD">9969000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2c6f52ef-cda4-46f2-8c5e-0be3e165c699"
      decimals="-3"
      id="F_c66aa5e1-a7bb-4d7f-8c0d-c3133797b228"
      unitRef="U_USD">9969000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7318b790-ee25-41a4-acff-80a6c93d4e3a"
      decimals="-3"
      id="F_db0e1a45-39bd-4241-822d-0e66e622cdee"
      unitRef="U_USD">385848000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_744c7609-f08e-4e56-a57b-92d4b5817a10"
      decimals="-3"
      id="F_625c5a24-7084-49c2-b04f-baa9d594d2a3"
      unitRef="U_USD">385848000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_87feba55-a051-420f-828e-ec84f440b3a0"
      decimals="-3"
      id="F_949abe11-28e4-4a32-9ad2-f69f8c5c95ec"
      unitRef="U_USD">12349000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_db4b7b1a-cb0e-4d01-8b52-9a8b1f192635"
      decimals="-3"
      id="F_d257f311-4ae0-4279-b919-490ced5b2e6b"
      unitRef="U_USD">12349000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ee1fde54-f065-4656-a66d-cb2acf02bfac"
      decimals="-3"
      id="F_862e4e25-e5e5-4edd-9def-7715fd25d96e"
      unitRef="U_USD">38502000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6df997e0-9e1b-4ab7-9d87-d11884be8e4a"
      decimals="-3"
      id="F_c931a387-a9bf-431c-816b-525be9436ad3"
      unitRef="U_USD">408166000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_87dd786a-314b-49f8-baec-1edeb4120c74"
      decimals="-3"
      id="F_0467ed61-1aa4-4e7e-bbe8-548544295a1c"
      unitRef="U_USD">446668000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      id="F_2cf82994-c2f2-4696-bca9-7b450139d28b">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;6.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Available-for-sale investments consisted of the following as of December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.07%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government treasury and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;264,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;264,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;281,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;281,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.07%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;389,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;385,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;412,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;408,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All the U.S. government treasury and agency securities, corporate bonds and commercial paper designated as short-term marketable securities have an effective maturity date that is equal to or less than one year from the respective consolidated balance sheet date. Those that are designated as long-term marketable securities have an effective maturity date that is more than one year from the respective consolidated balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued interest receivable is excluded from the amortized cost and estimated fair value of our marketable securities. Accrued interest receivable of &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was presented separately within the prepaid expenses and other current assets balance on the consolidated balance sheet as of December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents the gross unrealized holding losses and fair values for investments in an unrealized loss position, and the length of time individual securities have been in a continuous loss position, as of December 31, 2023 (in thousands):&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.07%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Less Than 12 Months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;12 Months Or Greater&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government treasury and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We periodically review our available-for-sale securities to assess for credit impairment. Some of the factors considered in assessing impairment include the extent to which the fair value is less than the amortized cost basis, adverse conditions related to the security, an industry or geographic area, changes to security ratings or sector credit ratings and other relevant market data.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, we did not intend, nor were we more likely than not to be required, to sell our available-for-sale investments before the recovery of their amortized cost basis, which may be maturity. Based on our assessment, we concluded all impairment as of December 31, 2023 to be due to factors other than credit loss, such as changes in interest rates. A credit allowance was not recognized and the impairment of our available-for-sale securities was recorded in other comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_85979f03-5c13-4465-9844-c9f3a789c344">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Available-for-sale investments consisted of the following as of December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.07%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government treasury and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;264,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;264,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;281,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;281,337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.07%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Gain&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;389,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;385,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;412,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;408,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7ca7acdb-a921-4bb3-90a1-1d13fd95b1fd"
      decimals="-3"
      id="F_552ac076-480f-43ac-80e8-822de2c6afeb"
      unitRef="U_USD">10630000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7ca7acdb-a921-4bb3-90a1-1d13fd95b1fd"
      decimals="-3"
      id="F_2430d425-2b55-4ecf-87fe-d46e27786c10"
      unitRef="U_USD">10630000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_1ebf03ab-8700-457d-a330-2b6afbc9f9dc"
      decimals="-3"
      id="F_7eb17cd0-3ed4-4db7-9337-1ae260a1814c"
      unitRef="U_USD">264214000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_1ebf03ab-8700-457d-a330-2b6afbc9f9dc"
      decimals="-3"
      id="F_ce4e9da1-e691-434e-bed5-84fa93fd9b57"
      unitRef="U_USD">232000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_1ebf03ab-8700-457d-a330-2b6afbc9f9dc"
      decimals="-3"
      id="F_f4f543ef-5c08-4936-9569-45561be511c6"
      unitRef="U_USD">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1ebf03ab-8700-457d-a330-2b6afbc9f9dc"
      decimals="-3"
      id="F_75f081d7-5ff7-43e2-8608-8d4edf811888"
      unitRef="U_USD">264426000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_1a866f0e-30b1-4ade-9e73-d9a9bba031bb"
      decimals="-3"
      id="F_4a28e35e-cdd5-4fac-bfec-e1939d0b660c"
      unitRef="U_USD">6278000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_1a866f0e-30b1-4ade-9e73-d9a9bba031bb"
      decimals="-3"
      id="F_bcd8e0c8-282f-4a85-894d-047eda13ce6d"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1a866f0e-30b1-4ade-9e73-d9a9bba031bb"
      decimals="-3"
      id="F_fa647319-3d2f-4fec-ac9a-ab4da2f43cf2"
      unitRef="U_USD">6281000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c6dd27e3-1742-4ce3-b818-2cc2fe370e7b"
      decimals="-3"
      id="F_ff244f2c-5052-4851-874b-be90b2f9262d"
      unitRef="U_USD">281122000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_c6dd27e3-1742-4ce3-b818-2cc2fe370e7b"
      decimals="-3"
      id="F_f4403182-00ba-4d9a-8b0c-e5a61a78012a"
      unitRef="U_USD">235000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_c6dd27e3-1742-4ce3-b818-2cc2fe370e7b"
      decimals="-3"
      id="F_e0609286-8942-4f8c-9edf-5d5723f7b1d8"
      unitRef="U_USD">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c6dd27e3-1742-4ce3-b818-2cc2fe370e7b"
      decimals="-3"
      id="F_3b306d1d-59c6-499f-8426-66932558773e"
      unitRef="U_USD">281337000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a3dfafff-e989-4644-9b5f-c4c61d62483b"
      decimals="-3"
      id="F_575dc755-769c-40cc-bc3a-789ac3adaaa6"
      unitRef="U_USD">9969000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a3dfafff-e989-4644-9b5f-c4c61d62483b"
      decimals="-3"
      id="F_7b91ce7e-2e88-4941-aa8a-0eeb8c71ac6e"
      unitRef="U_USD">9969000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d8afb5c3-07c8-4db4-ac88-9ca5562689cf"
      decimals="-3"
      id="F_15f38cd9-dd39-44af-8d0d-50f6a33fed01"
      unitRef="U_USD">389898000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_d8afb5c3-07c8-4db4-ac88-9ca5562689cf"
      decimals="-3"
      id="F_b4cd95b9-4743-4e6a-aa47-07c330d93713"
      unitRef="U_USD">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d8afb5c3-07c8-4db4-ac88-9ca5562689cf"
      decimals="-3"
      id="F_fc29cf02-ab19-494a-9efa-ae16a5227699"
      unitRef="U_USD">4064000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d8afb5c3-07c8-4db4-ac88-9ca5562689cf"
      decimals="-3"
      id="F_e692ec6b-06f7-4b17-ba02-75ddc0b1e69a"
      unitRef="U_USD">385848000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_454dcbb2-775d-4dc6-8e99-ed83e128e3ca"
      decimals="-3"
      id="F_bbcc9595-7e3f-4e4a-8294-c01a405027ab"
      unitRef="U_USD">12415000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_454dcbb2-775d-4dc6-8e99-ed83e128e3ca"
      decimals="-3"
      id="F_3434aebe-9864-4026-9e04-df7c4badbbf2"
      unitRef="U_USD">66000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_454dcbb2-775d-4dc6-8e99-ed83e128e3ca"
      decimals="-3"
      id="F_4ee25851-0e80-499f-9cd9-db60cbd08af1"
      unitRef="U_USD">12349000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_321cee55-58fd-4472-9917-05fb1e50572d"
      decimals="-3"
      id="F_303a47ef-0744-4702-a8a4-291d0392ec0e"
      unitRef="U_USD">412282000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_321cee55-58fd-4472-9917-05fb1e50572d"
      decimals="-3"
      id="F_0a7ad4b4-af86-49f0-b796-36bf58f48f3a"
      unitRef="U_USD">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_321cee55-58fd-4472-9917-05fb1e50572d"
      decimals="-3"
      id="F_435c558f-b474-4633-b696-39cf4856bd8c"
      unitRef="U_USD">4130000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_321cee55-58fd-4472-9917-05fb1e50572d"
      decimals="-3"
      id="F_9c976733-1cd0-40c6-a5f1-51af0f9134fe"
      unitRef="U_USD">408166000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_adce8143-c708-4ab4-aad4-7932228c2737"
      decimals="-5"
      id="F_06e42ff6-7748-4eed-8a11-80558921eece"
      unitRef="U_USD">1000000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_060ee2a5-56eb-46bd-b35a-e98de401cab1"
      decimals="-5"
      id="F_a11a78b8-20a4-4c78-9bd0-49a38a815d5c"
      unitRef="U_USD">800000</us-gaap:InterestReceivableCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_e107cb54-cf91-4c63-8fbb-a01c1ddbaa11">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents the gross unrealized holding losses and fair values for investments in an unrealized loss position, and the length of time individual securities have been in a continuous loss position, as of December 31, 2023 (in thousands):&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.07%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Less Than 12 Months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;12 Months Or Greater&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government treasury and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_a21c196f-6dfe-415c-b90a-3c3da2b36e46"
      decimals="-3"
      id="F_56ea6851-7a4e-4c38-a24f-8764403fdfd0"
      unitRef="U_USD">48100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_a21c196f-6dfe-415c-b90a-3c3da2b36e46"
      decimals="-3"
      id="F_661e779b-d127-484e-94da-90556fddc410"
      unitRef="U_USD">20000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_01e48f74-541a-422a-8c65-d09d29ca21c0"
      unitRef="U_USD">48100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_c2b3fd4c-d43c-4fda-b5e1-eec572dd16e6"
      unitRef="U_USD">20000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_21b627dc-9742-4280-9359-56d2a0f5c72e">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;7.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net as of December 31, 2023 and 2022 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,069&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total property and equipment, at cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;141,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;137,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;54,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation expense was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;20.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the year ended December 31, 2023, 2022 and 2021, respectively. See Note 10, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for details regarding the impairment loss we recognized for certain leasehold improvements for the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_771a0c5d-53ee-4fe8-9124-afda212111a8">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net as of December 31, 2023 and 2022 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,965&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,069&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;74,734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total property and equipment, at cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;141,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;137,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;54,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;83,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_39323104-bdda-4a5f-b4e0-aa2def94b95a"
      decimals="-3"
      id="F_d9fadc12-19ce-4b3a-8848-843af54c29a3"
      unitRef="U_USD">49567000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1e722b79-1338-44ce-bc10-fb18fa0cad8d"
      decimals="-3"
      id="F_f5ff4e2b-618d-44f2-abfa-38095654d7b8"
      unitRef="U_USD">43592000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_80445f63-6e69-4b85-a4cc-f71cd5e32898"
      decimals="-3"
      id="F_db5df146-0985-4a94-b11a-0663aa187282"
      unitRef="U_USD">7970000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_58ce94ff-2264-4ea2-a84c-edf34c96332a"
      decimals="-3"
      id="F_dc79addb-5736-4edd-86ae-6dd402e38153"
      unitRef="U_USD">7766000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a75aed5b-f247-4baf-af25-a000ba7211d5"
      decimals="-3"
      id="F_3ed2de33-4eb1-4eb2-81c7-535a7b5f48b2"
      unitRef="U_USD">3820000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ab0a4bc0-c687-4b75-97a5-8e7d11a1a0be"
      decimals="-3"
      id="F_9bbad5a1-d40f-4537-a45a-2cf79cb1caea"
      unitRef="U_USD">5342000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_fb89157d-97e5-40d0-828e-fcafd3b932a1"
      decimals="-3"
      id="F_15bc841e-90bf-4e69-817b-b04ba2f6638c"
      unitRef="U_USD">1965000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8026f205-9131-4390-94dd-4a04d3c584e7"
      decimals="-3"
      id="F_e4b962be-230b-4a3a-b741-dc14ba297b19"
      unitRef="U_USD">1069000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3ebe0fdc-225c-4155-afc8-97ad3dc284b2"
      decimals="-3"
      id="F_16ec5c50-bfa1-4966-ad7f-27a4fe4a9e66"
      unitRef="U_USD">3405000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a716e596-2c29-46d5-9c2b-dba9981ab3f1"
      decimals="-3"
      id="F_c58df467-fdb8-45e5-90b7-3b7742c7897b"
      unitRef="U_USD">7625000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1e988e7e-5089-4aac-8a2c-022b8659ce3b"
      decimals="-3"
      id="F_630f4b07-6be9-4d08-b81a-e69d8ad4771a"
      unitRef="U_USD">74734000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_fbb4d461-a817-4980-9efc-c5c5e7bea481"
      decimals="-3"
      id="F_fd94ace4-38d2-419c-b577-0764a7b590c7"
      unitRef="U_USD">72403000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_f5d1549a-5a7d-4479-a2f9-646317af7d3f"
      unitRef="U_USD">141461000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_73c9a585-38c3-4cd6-b0ed-fa3b3a0002bc"
      unitRef="U_USD">137797000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_64957546-c164-46f9-814f-8116b547bb46"
      unitRef="U_USD">73234000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_236471ef-1bca-4567-9b5a-1d8133466c07"
      unitRef="U_USD">54350000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_6a466c19-ed03-4dcc-b8ce-df1e3f71628a"
      unitRef="U_USD">68227000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_3df61528-5f50-47b6-b74b-ae64342e54ae"
      unitRef="U_USD">83447000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-5"
      id="F_f485313e-3132-4f66-bad3-0a3286de9d49"
      unitRef="U_USD">20500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-5"
      id="F_e3159e61-33e6-4af6-854b-7f878087d98f"
      unitRef="U_USD">19200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-5"
      id="F_83264141-c01f-4a79-893e-d279c74818a9"
      unitRef="U_USD">12300000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_f684fb63-b4b3-407f-93c0-e25685aa4d47">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;8.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There have been &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; changes in the carrying amount of goodwill since its recognition in 2015.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Intangible assets subject to amortization as of December 31, 2023 and 2022 consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Accumulated Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Net Carrying Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Acquired developed technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Purchased intellectual property&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Accumulated Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Net Carrying Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Acquired developed technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Purchased intellectual property&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The developed technology was acquired in connection with our acquisition of Sequenta, Inc. in 2015. The remaining balance of the acquired developed technology and the purchased intellectual property is expected to be amortized over the next &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, expected future amortization expense for intangible assets was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total future amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="C_2fd988f0-f2ea-429d-b4f6-17267c9ddedc"
      decimals="INF"
      id="F_9049ddfb-4d1f-4c12-800a-4cff6ecf6f90"
      unitRef="U_USD">0</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_7f02e59c-0eec-4780-acc3-c21cb4866bb1">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Intangible assets subject to amortization as of December 31, 2023 and 2022 consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Accumulated Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Net Carrying Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Acquired developed technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Purchased intellectual property&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Accumulated Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Net Carrying Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Acquired developed technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Purchased intellectual property&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_a0652792-ebc5-4eac-b642-e4d6670801ba"
      decimals="-3"
      id="F_497a5121-746d-4c87-8bfd-584e431cb398"
      unitRef="U_USD">20000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_a0652792-ebc5-4eac-b642-e4d6670801ba"
      decimals="-3"
      id="F_11e1feb6-cd67-4607-8dff-a4cafd0b1b17"
      unitRef="U_USD">14970000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_a0652792-ebc5-4eac-b642-e4d6670801ba"
      decimals="-3"
      id="F_995b68db-53ec-4ef7-92b3-f1afdd4be1dc"
      unitRef="U_USD">5030000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_52090110-82a5-4e46-93f8-8226b4b52be6"
      decimals="-3"
      id="F_b947e920-a35a-43a1-8fc0-cec98a46643a"
      unitRef="U_USD">325000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_52090110-82a5-4e46-93f8-8226b4b52be6"
      decimals="-3"
      id="F_cbd3b05b-8381-48dc-82f0-1087bf4ff8ad"
      unitRef="U_USD">227000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_52090110-82a5-4e46-93f8-8226b4b52be6"
      decimals="-3"
      id="F_0e92e53c-95f2-4f2a-8a31-0498cad73c73"
      unitRef="U_USD">98000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_0448c5de-8fb0-4556-b0d5-ea304da001ab"
      unitRef="U_USD">20325000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_b0c41f8a-0305-4c82-bff1-cf8d3d04e63d"
      unitRef="U_USD">15197000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_2ce8c549-0c77-41e4-ae43-f3bf1074ea34"
      unitRef="U_USD">5128000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_216614d0-45a0-4666-935c-4122d8cd59aa"
      decimals="-3"
      id="F_156d52d3-30fd-4960-bc71-f7a39d2dddc1"
      unitRef="U_USD">20000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_216614d0-45a0-4666-935c-4122d8cd59aa"
      decimals="-3"
      id="F_8b91ad6c-2e4b-4fb0-918d-3cfd870a5929"
      unitRef="U_USD">13304000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_216614d0-45a0-4666-935c-4122d8cd59aa"
      decimals="-3"
      id="F_dce7f944-205e-4d5d-937d-6278f8d9b9b3"
      unitRef="U_USD">6696000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_7e26ca88-f723-4c17-a005-4eccedfed38e"
      decimals="-3"
      id="F_f4d26447-5418-44e7-9c38-a9aaa85109da"
      unitRef="U_USD">325000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_7e26ca88-f723-4c17-a005-4eccedfed38e"
      decimals="-3"
      id="F_432eb850-9fa9-4c75-bdd3-4a04de37de28"
      unitRef="U_USD">194000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_7e26ca88-f723-4c17-a005-4eccedfed38e"
      decimals="-3"
      id="F_83c70900-1da7-4eb4-a19b-bbfb4f0d5857"
      unitRef="U_USD">131000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_117fad7f-82ea-4740-91c0-7aab4adb358a"
      unitRef="U_USD">20325000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_c94880c9-243e-4144-aa8c-86d7c6171215"
      unitRef="U_USD">13498000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_67256c74-c8c4-4a9e-97b1-62951a2c3907"
      unitRef="U_USD">6827000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_52090110-82a5-4e46-93f8-8226b4b52be6"
      id="F_80a01ad7-8a4b-43cc-898d-62799553d884">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_1747c96d-ce03-48e0-b827-a62f39d77b94">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, expected future amortization expense for intangible assets was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:5pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total future amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_556291f7-5910-4ab8-846a-ebfdb27850e5"
      unitRef="U_USD">1703000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_2553016a-9a81-49b4-ba4f-f0555894e92f"
      unitRef="U_USD">1699000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_cd5918dc-becb-4b7f-8d9b-cf7db5439c42"
      unitRef="U_USD">1699000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_661aae4a-8fb9-4d0e-8a41-8189b2aec24e"
      unitRef="U_USD">27000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_0970a026-ff04-442c-b4e3-336a646a6f6d"
      unitRef="U_USD">5128000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_4f90a5a6-29f5-4cb5-a9b1-416c5cecf684">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;9.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued liabilities as of December 31, 2023 and 2022 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Clinical and contract research organization costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Travel and entertainment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Purchases of property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_ba37bb8a-3e84-4ea9-bd83-5e62ccd54e0c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued liabilities as of December 31, 2023 and 2022 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,920&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Clinical and contract research organization costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Travel and entertainment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Purchases of property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_d99cc2cf-2c9f-46c2-8a12-ef59b6a8cd1a"
      unitRef="U_USD">4920000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_6806453d-6d66-47f1-8f0f-4783f61b54bc"
      unitRef="U_USD">4744000</us-gaap:AccruedProfessionalFeesCurrent>
    <adpt:AccruedClinicalAndContractResearchOrganizationCostsCurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_7cb28899-0e3f-4755-8ca0-f96495c2f31b"
      unitRef="U_USD">863000</adpt:AccruedClinicalAndContractResearchOrganizationCostsCurrent>
    <adpt:AccruedClinicalAndContractResearchOrganizationCostsCurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_be7acfac-e706-4ea3-8fb8-53b72f90b64e"
      unitRef="U_USD">1533000</adpt:AccruedClinicalAndContractResearchOrganizationCostsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_a0b1766a-4328-4662-ba37-4ce207434a60"
      unitRef="U_USD">154000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_93af0e1a-250e-4ec5-9f4a-0bce7c7d41d3"
      unitRef="U_USD">233000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_6a542c15-b72a-4b02-a04f-9d9cf9bc9ebc"
      unitRef="U_USD">59000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_5eeccaa6-8fa5-47cd-986f-2bc8ed808aff"
      unitRef="U_USD">194000</us-gaap:AccruedIncomeTaxesCurrent>
    <adpt:AccruedPurchaseOfPropertyAndEquipmentCurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_a70cff50-29e5-4cf2-834d-2dc07c998c18"
      unitRef="U_USD">687000</adpt:AccruedPurchaseOfPropertyAndEquipmentCurrent>
    <adpt:AccruedPurchaseOfPropertyAndEquipmentCurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_34c5e693-912a-4f48-b05d-e6cc86144704"
      unitRef="U_USD">1680000</adpt:AccruedPurchaseOfPropertyAndEquipmentCurrent>
    <adpt:ComputerAndSoftware
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_7ac7ae1e-7a93-4e2d-a435-1b16a58fb9ce"
      unitRef="U_USD">1151000</adpt:ComputerAndSoftware>
    <adpt:ComputerAndSoftware
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_18d8d719-1eda-47c3-aaca-930142936078"
      unitRef="U_USD">2385000</adpt:ComputerAndSoftware>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_35ecbf7e-1094-4337-8f74-585174eec44c"
      unitRef="U_USD">763000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_60714ac8-2dc0-48de-b5fe-3081fdbe204d"
      unitRef="U_USD">1655000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_9d7e4e4e-d347-40ff-b8d4-545314a3f495"
      unitRef="U_USD">8597000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_7761e37a-c386-40cc-b7ff-72ab53653687"
      unitRef="U_USD">12424000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_3043d5aa-31ca-4587-8576-b38b27f4c2e9">&lt;div style="display:flex;margin-top:8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;10.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have operating lease agreements for laboratory, office and warehouse facilities that we occupy in various locations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In July 2011, we entered into a non-cancelable lease agreement with an, at the time, minority shareholder for office and laboratory space in Seattle, Washington. The lease terms were subsequently amended multiple times, most recently in August 2019, when we expanded the existing premises to approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash payment for rent of the expanded premises commenced &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, four months after the landlord delivered the expanded premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;October 2032&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, subject to our option to twice extend the lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The amended lease also requires us to pay additional amounts for operating and maintenance expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2023, we vacated this leased space. As such, we assessed the right-of-use asset and related leasehold improvements (together, the "asset group") for impairment by first comparing the carrying amount of the asset group to future net undiscounted cash flows projected to be generated over the remaining lease term. These projections include management's estimates of cash inflows from potential sublease income and outflows for operating and maintenance expenses. The carrying amount was found to be unrecoverable, thus we assessed the asset group's fair value. The extent to which the asset group's carrying amount exceeds its fair value represents the impairment cost to be recognized. Fair value was determined using the income approach, whereby we discounted estimated net cash flows using a rate commensurate with our estimated incremental borrowing rate. As a result of this assessment, which included unrecoverable operating and maintenance costs, we determined that the asset group was to be fully impaired. As such, an &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_644ede94-23a3-4d5b-89f7-eb3175c3cb6c;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;impairment charge&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was recognized during the year ended December 31, 2023, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million related to the right-of-use asset and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million related to the long-lived leasehold improvements, all of which were held for use.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2019, we entered into an agreement to rent approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet in what was a to-be-constructed, new headquarters building in Seattle, Washington. In connection with the lease, we entered into a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million letter of credit with one of our existing financial institutions. The lease commenced in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, when the landlord delivered the premises to us for construction of certain tenant improvements. We occupied the new building in 2021, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;cash payment for rent began in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;October 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and the lease term ends in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;August 2033&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;subject to our option to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;twice extend the lease&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. In connection with this lease, the landlord agreed to fund $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in improvements, which was subsequently reduced to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as a result of our change requests made during landlord construction of the building, net of an administration fee. As of December 31, 2022, we incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in certain tenant improvement costs, all of which had been reimbursed by the landlord. As of December 31, 2021, we incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in certain tenant improvement costs, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million had been reimbursed by the landlord. The remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million is presented as a reduction in the cash flows used to measure our ROU asset and lease liabilities on the consolidated balance sheet as of December 31, 2021. The lease also requires us to pay additional amounts for operating and maintenance expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In April 2018, we entered into a lease agreement to lease approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,400&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet in South San Francisco, California. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The lease term is through &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and provides for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; extension option&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; We are responsible for our share of allocable operating expenses, tax expenses and utilities costs during the duration of the lease term. In connection with the lease, the landlord funded agreed-upon improvements. The landlord was solely responsible for the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million cost of such improvements. The lease agreement was amended in February 2020 to lease approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,900&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; additional square feet and provides for a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million tenant improvement allowance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March 2021, we executed a lease to rent approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of a warehouse in Bothell, Washington, which we classified as an operating lease upon commencement during the year ended December 31, 2021. Rent obligations commenced in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;October 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and the lease expires &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;October 2031&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;subject to an early termination option after the seventh year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and an &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;option to twice extend the lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The lease requires us to pay certain operating expenses. Furthermore, the landlord agreed to fund $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in improvements in connection with this lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, we were not party to any finance leases. Our leases have remaining terms ranging from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years and include &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;options to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;extend certain of the leases&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and terminate certain of the leases after &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years of leasing. We adjust lease terms for these options only when it is reasonably certain we will exercise these options.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other information related to our operating leases as of December 31, 2023 and 2022 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.379999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.379999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.91&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.75&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities, less current portion balance on the consolidated balance sheet as of December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56,962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;121,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Imputed interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating lease expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the year ended December 31, 2023, 2022 and 2021, respectively. Variable lease expense for operating leases was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the year ended December 31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities for the year ended December 31, 2023 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Cash paid for amounts included in the measurement of lease liabilities for the year ended December 31, 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, net of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of cash received for tenant improvement allowances. Cash paid for amounts included in the measurement of lease liabilities was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and cash received for tenant improvement allowances was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the year ended December 31, 2021. For the year ended December 31, 2021, ROU assets obtained in exchange for operating lease liabilities was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfLand
      contextRef="C_497af0a4-b8d1-426d-b46e-bab07be8dadd"
      decimals="0"
      id="F_2ca18231-3722-479e-89a2-be56d002f94a"
      unitRef="U_sqft">65500</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_fab848dc-7a49-4318-bdad-9aa948d6f630"
      id="F_15680438-f300-4489-b5a5-c6c4fabe3dfd">Cash payment for rent of the expanded premises commenced January 2020, four months after the landlord delivered the expanded premises to us for construction of certain tenant improvements, and the lease term for both the existing premises and the expanded premises ends October 2032, subject to our option to twice extend the lease for five years.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <adpt:LesseeOperatingLeaseRentCommencementMonthAndYear
      contextRef="C_fab848dc-7a49-4318-bdad-9aa948d6f630"
      id="F_b0849427-f787-41ce-b7cc-56f71dd72586">2020-01</adpt:LesseeOperatingLeaseRentCommencementMonthAndYear>
    <adpt:LeaseExpirationMonthAndYear
      contextRef="C_fab848dc-7a49-4318-bdad-9aa948d6f630"
      id="F_20648bb9-4f8e-4399-8260-27a1dee35f1d">2032-10</adpt:LeaseExpirationMonthAndYear>
    <adpt:LesseeOperatingLeaseExtendedTermOfContract
      contextRef="C_fab848dc-7a49-4318-bdad-9aa948d6f630"
      id="F_c60dcffe-6cdb-4094-a892-8739b5350cb3">P5Y</adpt:LesseeOperatingLeaseExtendedTermOfContract>
    <adpt:ImpairmentOfRightOfUseAndRelatedLongLivedAssets
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-5"
      id="F_a58ae27a-7d98-4fc1-bbe8-f95bed9c2946"
      unitRef="U_USD">25400000</adpt:ImpairmentOfRightOfUseAndRelatedLongLivedAssets>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-5"
      id="F_b61b1fe9-005c-414f-8236-fb0495c22834"
      unitRef="U_USD">21200000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-5"
      id="F_10d2d195-ff19-46ec-bc32-8fb41958eeb3"
      unitRef="U_USD">4200000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:AreaOfLand
      contextRef="C_ea6a3074-5c90-4942-a6a0-917ee25491db"
      decimals="0"
      id="F_da0ccc47-3b04-41c3-9de4-32b7485ef34f"
      unitRef="U_sqft">100000</us-gaap:AreaOfLand>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_ea6a3074-5c90-4942-a6a0-917ee25491db"
      decimals="-5"
      id="F_45128b82-8615-4101-bfde-9cefc3da32f7"
      unitRef="U_USD">2100000</us-gaap:LettersOfCreditOutstandingAmount>
    <adpt:LeaseCommencementMonthAndYear
      contextRef="C_041a7632-3fc1-4163-8570-83d81957490c"
      id="F_8ed4f8c8-ccb5-4ee8-ad3f-044c3e29a5f3">2020-12</adpt:LeaseCommencementMonthAndYear>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_041a7632-3fc1-4163-8570-83d81957490c"
      id="F_953b6225-bf10-4194-9732-c437f7d1d972">cash payment for rent began in October 2021 and the lease term ends in August 2033, </us-gaap:LesseeOperatingLeaseOptionToExtend>
    <adpt:LesseeOperatingLeaseRentCommencementMonthAndYear
      contextRef="C_041a7632-3fc1-4163-8570-83d81957490c"
      id="F_480fc46e-7c44-40f9-8515-104344fce53a">2021-10</adpt:LesseeOperatingLeaseRentCommencementMonthAndYear>
    <adpt:LeaseExpirationMonthAndYear
      contextRef="C_041a7632-3fc1-4163-8570-83d81957490c"
      id="F_04d312a1-5c02-4672-ac52-be2b0d4201df">2033-08</adpt:LeaseExpirationMonthAndYear>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_041a7632-3fc1-4163-8570-83d81957490c"
      id="F_40214fbd-e101-4211-a8e6-b91d5dbcec24">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_fab848dc-7a49-4318-bdad-9aa948d6f630"
      id="F_a05ee39b-c5b3-4621-885c-6d253df99163">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <adpt:LesseeOperatingLeaseExtendedTermOfContract
      contextRef="C_041a7632-3fc1-4163-8570-83d81957490c"
      id="F_6c066913-6581-4c5c-bf7b-a6bbc17d080f">P5Y</adpt:LesseeOperatingLeaseExtendedTermOfContract>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="C_ea6a3074-5c90-4942-a6a0-917ee25491db"
      decimals="-5"
      id="F_bac1f965-1826-408a-b52a-9dd1b7362cf5"
      unitRef="U_USD">20000000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-5"
      id="F_699e1d9e-faee-4091-a225-98ddb39afef5"
      unitRef="U_USD">14800000</us-gaap:LeaseholdImprovementsGross>
    <adpt:TenantImprovementCostsIncurred
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-5"
      id="F_9ec4cbb2-c6d1-4082-85ea-d801f6e759c9"
      unitRef="U_USD">14900000</adpt:TenantImprovementCostsIncurred>
    <adpt:ProceedsFromLandlordReimbursements
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-5"
      id="F_25830b22-da6d-4868-b8c4-03947f2a811b"
      unitRef="U_USD">14900000</adpt:ProceedsFromLandlordReimbursements>
    <adpt:TenantImprovementCostsIncurred
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-5"
      id="F_83fc5479-6d21-4e82-806a-0e205a414812"
      unitRef="U_USD">14900000</adpt:TenantImprovementCostsIncurred>
    <adpt:ProceedsFromLandlordReimbursements
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-5"
      id="F_512eaa74-a4e1-492c-bcda-a388a2cf4d6b"
      unitRef="U_USD">10900000</adpt:ProceedsFromLandlordReimbursements>
    <adpt:TenantImprovementCostsReceivable
      contextRef="C_6f19237c-a155-4029-b45f-b9fb5332f737"
      decimals="-5"
      id="F_61235abf-8c17-4baf-90e0-7cce5a3db6d2"
      unitRef="U_USD">4000000</adpt:TenantImprovementCostsReceivable>
    <us-gaap:AreaOfLand
      contextRef="C_682d1e35-b24e-473d-a5dc-2e2a8f3b17fd"
      decimals="0"
      id="F_858ddca6-dedd-4268-bec4-0d01dbb05d3e"
      unitRef="U_sqft">13400</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_f352b237-e382-41ae-acc7-96078de3a980"
      id="F_0ba34557-7a73-4db7-9325-946ceb9eecdc">The lease term is through March 2026 and provides for one five-year extension option.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <adpt:LeaseExpirationMonthAndYear
      contextRef="C_f352b237-e382-41ae-acc7-96078de3a980"
      id="F_e48e473d-58b7-413c-b337-bef8be194ef9">2026-03</adpt:LeaseExpirationMonthAndYear>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_f352b237-e382-41ae-acc7-96078de3a980"
      id="F_13665d1f-19ae-4e10-afce-937ec2992e2f">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <adpt:LesseeOperatingLeaseExtendedTermOfContract
      contextRef="C_f352b237-e382-41ae-acc7-96078de3a980"
      id="F_d8358503-3217-4763-b0ce-db8b0d0bbd52">P5Y</adpt:LesseeOperatingLeaseExtendedTermOfContract>
    <us-gaap:TenantImprovements
      contextRef="C_682d1e35-b24e-473d-a5dc-2e2a8f3b17fd"
      decimals="-5"
      id="F_c5a20b6e-520b-4da0-89a3-be27196074fa"
      unitRef="U_USD">2400000</us-gaap:TenantImprovements>
    <us-gaap:AreaOfLand
      contextRef="C_2b549b79-66c4-4298-ba5f-b1b62fef2585"
      decimals="0"
      id="F_e86a7578-6502-4aa3-9ccd-4b7926de9a95"
      unitRef="U_sqft">19900</us-gaap:AreaOfLand>
    <adpt:TenantImprovementAllowanceAndCommenced
      contextRef="C_26c20ab9-dfe4-46c3-b509-3bf6d6c00d37"
      decimals="-5"
      id="F_4bbe5b66-a8ae-4ed8-8c6a-b03395967dad"
      unitRef="U_USD">600000</adpt:TenantImprovementAllowanceAndCommenced>
    <us-gaap:AreaOfLand
      contextRef="C_225e2fb7-7901-40b4-90c2-b52ec6899530"
      decimals="0"
      id="F_d1718418-57df-4336-9cf5-97e36fd4b75e"
      unitRef="U_sqft">27000</us-gaap:AreaOfLand>
    <adpt:LesseeOperatingLeaseRentObligationsCommencementMonthAndYear
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_2d0cc4cf-676f-488e-8e90-32a35287df7f">2021-10</adpt:LesseeOperatingLeaseRentObligationsCommencementMonthAndYear>
    <adpt:LeaseExpirationMonthAndYear
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_81b0efcf-d81d-4b28-81a9-288932e8c420">2031-10</adpt:LeaseExpirationMonthAndYear>
    <adpt:LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_7e2c4915-4316-4acf-ad37-64f857b0eb3c">subject to an early termination option after the seventh year</adpt:LesseeOperatingLeaseLeaseNotYetCommencedTerminationOptionDescription>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_333e4078-9b67-49ab-a786-78d20034ac2b">option to twice extend the lease for five years</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      id="F_3e48dd7d-3833-4375-ba19-c5aae5e2c92b">P5Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1>
    <adpt:LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-5"
      id="F_81bec065-a680-4c7f-8c32-e25d0396be1d"
      unitRef="U_USD">1200000</adpt:LesseeOperatingLeaseLeaseNotYetCommencedTenantImprovementReceivable>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_c035e4ca-1c96-49e2-bf85-b7dc628cce3a"
      id="F_63e3f037-97fe-46a8-adaa-7201c2d7f855">P2Y2M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_e3bfaebb-d3c1-42af-942f-8e8d8be6dd92"
      id="F_c8888885-61b9-4e80-9432-3da0728165cf">P9Y8M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_d622c0ba-72da-4204-b532-6e75a5c79b3e">options to extend certain of the leases up to 10.0 years</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_6fdff250-74fa-42eb-aa54-a98d2be6b456">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      id="F_0523c60b-8200-49fc-955c-d0617d3d95d4">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <adpt:LesseeOperatingLeaseTerminationPeriod
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_208e53c1-4075-4c18-b333-737216989bd6">P7Y</adpt:LesseeOperatingLeaseTerminationPeriod>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_72e86cd8-31bf-420c-82f7-068814b04d2c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other information related to our operating leases as of December 31, 2023 and 2022 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.379999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.379999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.91&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.75&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      id="F_99790eaf-52b5-4396-be92-4b4774b1911e">P8Y10M28D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      id="F_09d9cbeb-baab-4152-9b74-f4165fba463a">P9Y9M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="3"
      id="F_8810132a-0f98-4df6-b421-1227d469b5c4"
      unitRef="U_pure">0.046</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="3"
      id="F_0e1aa9e2-58e3-4282-a122-05aeff436051"
      unitRef="U_pure">0.046</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_d2d5b7c9-01da-4ac0-bfa6-ef1dccca15c3">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities, less current portion balance on the consolidated balance sheet as of December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56,962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;121,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Imputed interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_d3ecbc54-77e7-4f17-a75b-f4b87c8c1b1b"
      unitRef="U_USD">13692000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_a4c28e4e-a7ae-46a7-8baa-cc9ed81ce062"
      unitRef="U_USD">14098000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_131cc339-46a8-4446-9ff8-e8d17b870ebc"
      unitRef="U_USD">12330000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_85e377dd-6b9e-4322-89af-a1367943e66d"
      unitRef="U_USD">11944000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_9bc16dfe-e99f-4807-804c-85418a5ac9f8"
      unitRef="U_USD">12282000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_297df411-a421-46dc-880c-6c5c36a3f00c"
      unitRef="U_USD">56962000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_014da525-e8ef-4953-a82f-ef68e21aa579"
      unitRef="U_USD">121308000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_8f9f3e1d-2020-491b-8e31-3abd68169d98"
      unitRef="U_USD">22536000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_12241e46-2e80-449b-96be-acce5bfb255a"
      unitRef="U_USD">98772000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_7cd23fcc-0b6d-49d6-93e3-2427593ec3a0"
      unitRef="U_USD">9384000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_de581b1d-e458-425c-886a-6412cff1bea2"
      unitRef="U_USD">89388000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-5"
      id="F_fa85961b-8152-4ea1-a236-6420704419ef"
      unitRef="U_USD">11400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-5"
      id="F_1bc4c9f6-eeb0-440f-9bd0-59ac08012085"
      unitRef="U_USD">12400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-5"
      id="F_c6846f5f-cb6b-4869-921b-9e930cca4a3a"
      unitRef="U_USD">12400000</us-gaap:OperatingLeaseExpense>
    <adpt:OperatingLeaseVariableLeaseExpense
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-5"
      id="F_2a0d79cf-7d87-4db1-9c39-fe03f0bca93d"
      unitRef="U_USD">7100000</adpt:OperatingLeaseVariableLeaseExpense>
    <adpt:OperatingLeaseVariableLeaseExpense
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-5"
      id="F_f41877c1-75a0-4e21-8fcf-976f4a3a6005"
      unitRef="U_USD">7200000</adpt:OperatingLeaseVariableLeaseExpense>
    <adpt:OperatingLeaseVariableLeaseExpense
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-5"
      id="F_f34de189-ad52-46c9-861f-5ada2ace7e51"
      unitRef="U_USD">3500000</adpt:OperatingLeaseVariableLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-5"
      id="F_bf2af708-eed7-4a27-9764-c65fedeea50a"
      unitRef="U_USD">13400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-5"
      id="F_d0a16a35-1f6c-4ce7-bfb2-50e02f601a65"
      unitRef="U_USD">9200000</us-gaap:OperatingLeasePayments>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-5"
      id="F_5f4a2610-0b12-4294-9dac-8f068966d945"
      unitRef="U_USD">5200000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:OperatingLeasePayments
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-5"
      id="F_5c748f08-2d0c-4fdd-8265-421c7a0443c1"
      unitRef="U_USD">8300000</us-gaap:OperatingLeasePayments>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-5"
      id="F_6095e910-1254-41ee-984c-55f5b7061d4a"
      unitRef="U_USD">11500000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-5"
      id="F_67fb596d-d1e9-419d-b805-9d5082a00a5c"
      unitRef="U_USD">5400000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <adpt:RevenueInterestPurchaseAgreementTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_85b6c706-c2ad-4df6-9005-6cdd78b339ea">&lt;div style="font-size:0;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;"&gt;11.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue Interest Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Interest Purchase Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2022, we entered into the Purchase Agreement with OrbiMed Royalty &amp;amp; Credit Opportunities IV, LP (&#x201c;OrbiMed&#x201d;), an affiliate of OrbiMed Advisors LLC, as collateral agent and administrative agent for the purchasers party thereto (the &#x201c;Purchasers&#x201d;). Pursuant to the Purchase Agreement, we received $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million from the Purchasers at closing (the &#x201c;First Payment&#x201d;), less certain transaction expenses. We are also entitled to receive up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in subsequent installments as follows: (i) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upon our request occurring no later than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 12, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (the &#x201c;Second Payment&#x201d;) and (ii) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upon our request in connection with certain permitted acquisitions occurring no later than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 12, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (the &#x201c;Third Payment&#x201d;), in each case subject to certain funding conditions. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;To secure our obligations under the Purchase Agreement, we and our subsidiaries have granted OrbiMed a security interest in our core platform technology assets, subject to certain customary exclusions, as defined in the Purchase Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue Interest Payments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As consideration for such payments, the Purchasers have a right to receive certain revenue interests (the &#x201c;Revenue Interests&#x201d;) from us based on a percentage (the &#x201c;Applicable Payment Percentage&#x201d;) of all GAAP revenue (the &#x201c;Revenue Base&#x201d;). If only the First Payment has been made, the Applicable Payment Percentage shall be five percent of the quarterly Revenue Base. If both the First Payment and Second Payment have been made, the Applicable Payment Percentage shall be eight percent of the quarterly Revenue Base. If each of the First Payment, Second Payment and Third Payment have been made, the applicable payment percentage applied to the Revenue Interest shall be ten percent of the quarterly Revenue Base.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Payments in respect of the Revenue Interests shall be made quarterly within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; days following the end of each fiscal quarter (each, a &#x201c;Revenue Interest Payment&#x201d;). If OrbiMed has not received Revenue Interest Payments in the aggregate equal to or greater than the sum of its invested capital (the &#x201c;Cumulative Purchaser Payments&#x201d;) on or prior to September 12, 2028, the revenue interest rate shall be increased to a rate which, if applied retroactively to our cumulative Revenue Base, would have resulted in Revenue Interest Payments equal to the sum of all Cumulative Purchaser Payments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Return Cap&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;OrbiMed will be entitled to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the Revenue Interest Payments until it has received a total cumulative value of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;165&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the Cumulative Purchaser Payments (the &#x201c;Return Cap&#x201d;), unless full repayment of the amount of the Return Cap has not been made by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 12, 2032&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, in which case the Return Cap shall be increased to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;175&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the Cumulative Purchaser Payments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Put/Call Options&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Upon the occurrence of a Put Option Event (as defined in the Purchase Agreement), including material divestitures by us, a change in control, material judgments, or bankruptcy events, Purchasers representing at least a majority of the purchase commitments under the Purchase Agreement shall have the right but not the obligation ("the Put Option") to require us to repurchase all of the outstanding Revenue Interests at the applicable price (the &#x201c;Put/Call Price&#x201d;). Additionally, at any time following receipt of the First Payment, we may exercise a call option to repurchase all Revenue Interests at the applicable Put/Call Price.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For all Put Option Events other than a change of control or a material divestiture, the Put/Call Price shall be an amount equal to the applicable Return Cap. For a change of control or a material divestiture, prior to March 12, 2024, the Put/Call Price shall be an amount equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;120&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the Cumulative Purchaser Payments less the sum of all Revenue Interest Payments made by us to the Purchasers prior to such date, between March 12, 2024 and September 12, 2024, the Put/Call Price shall be an amount equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the Cumulative Purchaser Payments less the sum of all Revenue Interest Payments made by us to the Purchasers prior to such date, and after September 12, 2024, the Put/Call Price shall be equal to the applicable Return Cap.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounting Treatment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We evaluated the terms of the Purchase Agreement and concluded that the features of the Cumulative Purchaser Payments are similar to those of a debt instrument. Accordingly, we accounted for the transaction as debt recorded at amortized cost using the effective interest rate method. We further evaluated the terms of the debt and determined that the Put Option that is exercisable by the Purchasers upon certain contingent events requires bifurcation as a derivative. However, the value of the Put Option was determined to be immaterial due to the remote possibility of exercise. We assess the value of the Put Option periodically.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;To determine the amortization of the Purchase Agreement obligation, we are required to estimate the amount and timing of future Revenue Interest Payments based on our estimate of the timing and amount of future revenues and calculate an effective interest rate which will amortize the obligation to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; over the amortization period. The calculated effective interest rate as of December 31, 2023 was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the Purchase Agreement, we incurred debt issuance costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Debt issuance costs have been recorded to debt and are being amortized over the estimated term of the debt using the effective interest method, adjusted on a prospective basis for changes in the underlying assumptions and inputs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The assumptions used in determining the expected repayment term of the obligation and amortization period of the issuance costs requires that we make estimates that could impact the short- and long-term classification of these costs, as well as the period over which these costs will be amortized. We periodically assess the amount and timing of expected Revenue Interest Payments based on internal forecasts.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;To the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different than our original estimates, we will prospectively adjust the amortization of the revenue interest liability and the effective interest rate.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the revenue interest liability, net activity during the years ended December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue interest liability at inception&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue interest paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue interest payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue interest liability, net at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue interest paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue interest payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue interest liability, net at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue interest payable of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was included within the accounts payable balance on the consolidated balance sheet as of December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;</adpt:RevenueInterestPurchaseAgreementTextBlock>
    <adpt:UpfrontPaymentReceived
      contextRef="C_5a86b9bb-1277-4e79-955e-d1edb50cca23"
      decimals="-5"
      id="F_2c55ba6a-0dc9-4684-8bf8-9da31760be39"
      unitRef="U_USD">125000000</adpt:UpfrontPaymentReceived>
    <adpt:PotentialRevenueInterestPaymentToBeReceived
      contextRef="C_f2870833-bf7c-4640-b2de-b1f3f45dc7ae"
      decimals="-5"
      id="F_2b270710-87dc-4048-9d81-9829dd94d2b1"
      unitRef="U_USD">125000000</adpt:PotentialRevenueInterestPaymentToBeReceived>
    <adpt:PotentialRevenueInterestSecondPaymentToBeReceived
      contextRef="C_a8a04fa6-b5e0-4214-92b3-ab7f17428e2c"
      decimals="-5"
      id="F_c63b7ccf-42ef-4b0e-b3ec-6959254cb040"
      unitRef="U_USD">75000000</adpt:PotentialRevenueInterestSecondPaymentToBeReceived>
    <adpt:PurchaseAgreementSecondPaymentDate
      contextRef="C_5a86b9bb-1277-4e79-955e-d1edb50cca23"
      id="F_6740ac28-747e-4a40-b81a-126a3ef100ae">2025-09-12</adpt:PurchaseAgreementSecondPaymentDate>
    <adpt:PotentialRevenueInterestThirdPaymentToBeReceived
      contextRef="C_a8a04fa6-b5e0-4214-92b3-ab7f17428e2c"
      decimals="-5"
      id="F_2bc58829-9dce-400f-88d9-fdf3921bec90"
      unitRef="U_USD">50000000</adpt:PotentialRevenueInterestThirdPaymentToBeReceived>
    <adpt:PurchaseAgreementThirdPaymentDate
      contextRef="C_5a86b9bb-1277-4e79-955e-d1edb50cca23"
      id="F_d7d148cb-018e-4dc3-9393-8a8bfb9ca19d">2025-09-12</adpt:PurchaseAgreementThirdPaymentDate>
    <adpt:RevenueInterestPaymentTerm
      contextRef="C_5a86b9bb-1277-4e79-955e-d1edb50cca23"
      id="F_212ebf62-85cb-4cf0-9ba4-93a8fc580465">P45D</adpt:RevenueInterestPaymentTerm>
    <adpt:PercentageOfRevenueInterestPayments
      contextRef="C_a8a04fa6-b5e0-4214-92b3-ab7f17428e2c"
      decimals="2"
      id="F_32d1391f-cd06-4a3c-8277-32e2cf1d89dd"
      unitRef="U_pure">1</adpt:PercentageOfRevenueInterestPayments>
    <adpt:PercentageOfCumulativePurchaserPayments
      contextRef="C_a8a04fa6-b5e0-4214-92b3-ab7f17428e2c"
      decimals="2"
      id="F_2b184216-ec50-499e-88f1-8e96932bbda7"
      unitRef="U_pure">1.65</adpt:PercentageOfCumulativePurchaserPayments>
    <adpt:CumulativePurchaserPaymentsRepaymentDate
      contextRef="C_5a86b9bb-1277-4e79-955e-d1edb50cca23"
      id="F_b413ae3e-e0f6-4fb3-b9cd-b0b7471a3940">2032-09-12</adpt:CumulativePurchaserPaymentsRepaymentDate>
    <adpt:IncreaseInReturnCapPercentageOfCumulativePurchaserPayments
      contextRef="C_a8a04fa6-b5e0-4214-92b3-ab7f17428e2c"
      decimals="2"
      id="F_bc052111-08e7-486f-8498-f7afc55c507e"
      unitRef="U_pure">1.75</adpt:IncreaseInReturnCapPercentageOfCumulativePurchaserPayments>
    <adpt:PercentageOfCumulativePurchaserPayments
      contextRef="C_aab74f81-a01f-4770-b79a-d5141418080d"
      decimals="2"
      id="F_b48ddd42-337b-4cfb-a746-d5d90ddc09bf"
      unitRef="U_pure">1.20</adpt:PercentageOfCumulativePurchaserPayments>
    <adpt:PercentageOfCumulativePurchaserPayments
      contextRef="C_3bce53c7-facd-4e2e-ad21-6441c070f91f"
      decimals="2"
      id="F_794ecb55-0620-46c5-8865-03b646c88bc2"
      unitRef="U_pure">1.25</adpt:PercentageOfCumulativePurchaserPayments>
    <adpt:AmortizationOfPurchaseAgreementObligation
      contextRef="C_b0c61c69-cbe1-4b8f-9a70-56d35c5b6efc"
      decimals="INF"
      id="F_72c03825-7f27-442a-b502-57a511c0f6fe"
      unitRef="U_USD">0</adpt:AmortizationOfPurchaseAgreementObligation>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_c0b012e9-1d72-456e-818b-e7c99403c318"
      decimals="3"
      id="F_4c3ab7bd-6e55-4b9b-b99c-e9d94b678796"
      unitRef="U_pure">0.092</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="C_c0b012e9-1d72-456e-818b-e7c99403c318"
      decimals="-5"
      id="F_e8fdea54-80a8-4286-aebe-6492b64a4c83"
      unitRef="U_USD">600000</us-gaap:DeferredFinanceCostsNet>
    <adpt:ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_6bb82637-d51e-4283-9ada-0ad72fd83077">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the revenue interest liability, net activity during the years ended December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue interest liability at inception&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue interest paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue interest payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue interest liability, net at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue interest paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue interest payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Revenue interest liability, net at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</adpt:ScheduleOfRevenueInterestLiabilityNetActivityTableTextBlock>
    <adpt:RevenueInterestLiability
      contextRef="C_18612828-7d58-4576-a6a2-b4505743ef18"
      decimals="-3"
      id="F_965520f4-4ae5-401e-afd1-f3451716e0fd"
      unitRef="U_USD">125000000</adpt:RevenueInterestLiability>
    <us-gaap:InterestCostsCapitalized
      contextRef="C_18612828-7d58-4576-a6a2-b4505743ef18"
      decimals="-3"
      id="F_23cca901-cac6-45b8-81d5-6004871bac9f"
      unitRef="U_USD">625000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestExpenseDebt
      contextRef="C_18612828-7d58-4576-a6a2-b4505743ef18"
      decimals="-3"
      id="F_0f4f7491-bc7b-4642-9ad9-e7a993812546"
      unitRef="U_USD">4238000</us-gaap:InterestExpenseDebt>
    <adpt:RevenueInterestPaid
      contextRef="C_18612828-7d58-4576-a6a2-b4505743ef18"
      decimals="-3"
      id="F_203fe202-6c8b-41b0-97fa-85ee0c386cfc"
      unitRef="U_USD">-493000</adpt:RevenueInterestPaid>
    <adpt:RevenueInterestPayable
      contextRef="C_18612828-7d58-4576-a6a2-b4505743ef18"
      decimals="-3"
      id="F_13813004-0da7-47f2-967d-f5a2e6a9deff"
      unitRef="U_USD">2760000</adpt:RevenueInterestPayable>
    <adpt:RevenueInterestLiabilityNet
      contextRef="C_5e49e82a-95b6-4034-a713-b8f1ec42273a"
      decimals="-3"
      id="F_9e0bb63d-8bb3-445a-b444-8d5d70e45ec3"
      unitRef="U_USD">125360000</adpt:RevenueInterestLiabilityNet>
    <us-gaap:InterestExpenseDebt
      contextRef="C_b0c61c69-cbe1-4b8f-9a70-56d35c5b6efc"
      decimals="-3"
      id="F_79ebc34e-0c17-4113-9300-7749ead119f2"
      unitRef="U_USD">13800000</us-gaap:InterestExpenseDebt>
    <adpt:RevenueInterestPaid
      contextRef="C_b0c61c69-cbe1-4b8f-9a70-56d35c5b6efc"
      decimals="-3"
      id="F_5e92d850-e967-42bf-923f-ec6f3bc75a56"
      unitRef="U_USD">-6225000</adpt:RevenueInterestPaid>
    <adpt:RevenueInterestPayable
      contextRef="C_b0c61c69-cbe1-4b8f-9a70-56d35c5b6efc"
      decimals="-3"
      id="F_f6e4e3de-ed76-444b-930f-d2c221db644a"
      unitRef="U_USD">2275000</adpt:RevenueInterestPayable>
    <adpt:RevenueInterestLiabilityNet
      contextRef="C_c0b012e9-1d72-456e-818b-e7c99403c318"
      decimals="-3"
      id="F_2b8acd5d-1a2f-4ae5-8d7f-ce873c80d2ed"
      unitRef="U_USD">130660000</adpt:RevenueInterestLiabilityNet>
    <adpt:RevenueInterestPayable
      contextRef="C_b0c61c69-cbe1-4b8f-9a70-56d35c5b6efc"
      decimals="-5"
      id="F_7aee2c52-7d66-4599-962a-777c241ade23"
      unitRef="U_USD">2300000</adpt:RevenueInterestPayable>
    <adpt:RevenueInterestPayable
      contextRef="C_18612828-7d58-4576-a6a2-b4505743ef18"
      decimals="-5"
      id="F_83c0b030-d1c8-4258-9e6f-60b8e5db3233"
      unitRef="U_USD">2800000</adpt:RevenueInterestPayable>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_40299c13-3960-45bd-b114-0a860abd558a">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;12.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We are subject to claims and assessments from time to time in the ordinary course of business. We will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. We were not party to any material legal proceedings as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Indemnification Agreements&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the ordinary course of business, we may provide indemnification of varying scope and terms to vendors, lessors, customers and other parties with respect to certain matters including, but not limited to, losses arising out of breach of our agreements with them or from intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with members of our board of directors and certain of our executive officers that will require us to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments that we could be required to make under these indemnification agreements is, in many cases, unlimited. We have not incurred any material costs as a result of such indemnifications and are not currently aware of any indemnification claims.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_d7b40fbd-53ec-4dc1-a8b5-3298268cb797">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;13.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Shareholders&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our common stock has no preferences or privileges and is not redeemable. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Holders of our common stock are entitled to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; vote for each share of common stock held&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The holders of record of outstanding shares of common stock shall be entitled to receive, when, as and if declared, out of funds legally available, such cash and other dividends as may be declared from time to time.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, we &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;had reserved shares of common stock for the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares issuable upon the exercise of outstanding stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,875,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares issuable upon the vesting of outstanding restricted stock units granted and the maximum outstanding market-based restricted stock units eligible to be earned&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,582,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available for future grant under the 2019 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,299,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available for future grant under the Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,235,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total shares of common stock reserved for future issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,992,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) provides for annual increases in the number of shares that may be issued under the 2019 Plan on January 1, 2020 and on each subsequent January 1, thereafter, by a number of shares equal to the lesser of (a) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Furthermore, our Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) provides for annual increases in the number of shares available for issuance under our ESPP on January 1, 2020 and on each January 1, thereafter, by a number of shares equal to the smallest of (a) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by our board of directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective January 1, 2023, our 2019 Plan and ESPP reserves increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,155,250&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,431,050&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, respectively. Effective January 1, 2024, our 2019 Plan and ESPP reserves increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,254,113&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,450,822&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockVotingRights
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_458a123a-8d57-4ae5-a779-c994a7ecacd3">Holders of our common stock are entitled to one vote for each share of common stock held</us-gaap:CommonStockVotingRights>
    <adpt:NumberOfCommonStockVotingRights
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="INF"
      id="F_8ddafc4c-4642-4287-900d-b62aa99020ca"
      unitRef="U_Vote">1</adpt:NumberOfCommonStockVotingRights>
    <adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_54b1e8d3-c7c6-4358-bb74-c8bdb1878beb">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, we &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;had reserved shares of common stock for the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares issuable upon the exercise of outstanding stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,875,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares issuable upon the vesting of outstanding restricted stock units granted and the maximum outstanding market-based restricted stock units eligible to be earned&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,582,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available for future grant under the 2019 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,299,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available for future grant under the Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,235,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total shares of common stock reserved for future issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,992,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</adpt:ScheduleOfReservedSharesOfCommonStockTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_10ea6fb1-7d69-445d-8fcf-bcaaaf8ea019"
      decimals="0"
      id="F_bc0a969e-2519-42a3-a4bc-db235f4ba9eb"
      unitRef="U_shares">12875045</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_8a8f8700-656c-4aa0-a7b1-18a1188de95d"
      decimals="0"
      id="F_d989faff-ca32-4bb6-82fe-713184b141dc"
      unitRef="U_shares">11582134</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_5aa06285-f2dc-4040-87ff-e52ba00117cc"
      decimals="0"
      id="F_e26241fb-a21a-4f68-899d-b1879324d59c"
      unitRef="U_shares">15299763</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_d18ea8b5-6b95-48a5-8cf4-dca1eb7587d7"
      decimals="0"
      id="F_77a3a454-72cf-4231-962d-5fa1b6d3566d"
      unitRef="U_shares">4235348</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="0"
      id="F_ebbf0f2c-8505-4c7e-8f6a-48d693885327"
      unitRef="U_shares">43992290</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <adpt:PercentageOfAnnualIncreasesInNumberOfShares
      contextRef="C_d77ee3a7-0648-4c68-ad86-6a36e26d4d2f"
      decimals="INF"
      id="F_bab0cebd-17c4-4558-829e-2201f0bf6059"
      unitRef="U_pure">0.05</adpt:PercentageOfAnnualIncreasesInNumberOfShares>
    <adpt:PercentageOfAnnualIncreasesInNumberOfShares
      contextRef="C_1bac84b6-f743-48d7-8309-6858a505babc"
      decimals="2"
      id="F_8f31f0dd-5895-403b-90e4-faf12f857bdf"
      unitRef="U_pure">0.01</adpt:PercentageOfAnnualIncreasesInNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_ef1ad520-2e19-4c3f-ad13-c493a883fa78"
      decimals="INF"
      id="F_c7c5a479-abd1-4781-aa82-923e6cf33b24"
      unitRef="U_shares">7155250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_5b9b7218-2fe1-41c4-b97c-55fcf735df6e"
      decimals="INF"
      id="F_97b400bd-f68a-4058-a279-2c1d4a395dec"
      unitRef="U_shares">1431050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_9ea6d2a9-4933-428d-a214-8f22b0ee534e"
      decimals="INF"
      id="F_4eb1cb2e-a49d-4100-99f0-3af0819795d8"
      unitRef="U_shares">7254113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_701c755f-589d-411b-a770-4fbc3fc69793"
      decimals="INF"
      id="F_5ceeb3d7-febf-4b26-b522-95613549145a"
      unitRef="U_shares">1450822</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_79439f88-7df8-41a1-a4bd-bdf506d39dd6">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;14.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2009 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We adopted an equity incentive plan in 2009 (the &#x201c;2009 Plan&#x201d;) that provided for the issuance of incentive and nonqualified common stock options and other share-based awards for employees, directors and consultants. Under the 2009 Plan, the exercise price for incentive and nonqualified stock options were not to be less than the fair market value of our common stock at the date of grant. Stock options granted under this plan expire no later than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the grant date and vesting was established at the time of grant. Pursuant to the terms of the 2019 Plan, any shares subject to outstanding stock options originally granted under the 2009 Plan that terminate, expire or lapse for any reason without the delivery of shares to the holder thereof shall become available for issuance pursuant to awards granted under the 2019 Plan. While &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares are available for future grant under the 2009 Plan, it continues to govern outstanding equity awards granted thereunder.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2019 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2019 Plan became effective immediately prior to the closing of our initial public offering in July 2019. The 2019 Plan provides for the issuance of awards in the form of stock options and other share-based awards for employees, directors and consultants. Under the 2019 Plan, the stock option exercise price per share shall not be less than the fair market value of a share of stock on the effective date of grant, as defined by the 2019 Plan, unless explicitly qualified under the provisions of Section 409A or Section 424(a) of the Internal Revenue Code of 1986. Additionally, unless otherwise specified, stock options granted under this plan expire no later than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the grant date and vesting is established at the time of grant. Except for certain stock option and restricted stock unit grants made to non-employee directors, stock options and restricted stock units granted under the 2019 Plan generally vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; period, subject to continuous service through each applicable vesting date. As of December 31, 2023, we had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;34,853,581&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock authorized for issuance under the 2019 Plan.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Changes in shares available for grant during the year ended December 31, 2023 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares Available for Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available for grant at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,581,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2019 Equity Incentive Plan reserve increase effective January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,155,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,980,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options and restricted stock units forfeited or expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,542,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available for grant at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,299,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock option activity under the 2009 Plan and 2019 Plan during the year ended December 31, 2023 was as follows:&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.780000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.780000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares Subject to&lt;br/&gt;Outstanding Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Exercise&lt;br/&gt;Price per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,520,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,612,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,030,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;757,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;470,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,875,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options vested and exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,071,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted-average remaining contractual life for stock options outstanding as of December 31, 2023 was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years. The weighted-average remaining contractual life for vested and exercisable stock options as of December 31, 2023 was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The total intrinsic value of stock options exercised during the year ended December 31, 2023, 2022 and 2021 was &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;156.5&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Of the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;26.7&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million proceeds from exercise of stock options included on the consolidated statements of cash flows for the year ended December 31, 2021, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million related to stock options exercised during the year ended December 31, 2020 but settled during the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted stock unit activity under the 2019 Plan during the year ended December 31, 2023 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Restricted Stock Units&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Grant Date&lt;br/&gt;Fair Value per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonvested restricted stock units outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,981,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,949,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,755,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,506,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonvested restricted stock units outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,669,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The total fair value of restricted stock units vested during the year ended December 31, 2023, 2022 and 2021 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;12.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Market-Based Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition to the restricted stock units described above, our board of directors approved awards of market-based restricted stock units to our chief executive officer and chief scientific officer in March 2023. The shares of common stock that may be earned under the awards, each ranging from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;709,220&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, are calculated based upon our total shareholder return during a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; performance period as measured against that of the group of companies comprising the S&amp;amp;P Biotechnology Select Industry Index as of the grant date, subject to certain adjustments to such index group. Except as expressly provided in the terms of each award's agreement, vesting is subject to the respective grantee's continuous service through the end of the three-year performance period. These market-based restricted stock units, along with those granted to our chief executive officer in March 2022, under which &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;494,234&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares may be earned, remained outstanding as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Grant Date Fair Value of Stock Options, Restricted Stock Units and Market-Based Restricted Stock Units Granted&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The estimated grant date fair values of stock options granted during the years ended December 31, 2023, 2022 and 2021 were estimated using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.177%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.255%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.255%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.255%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fair value of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.86&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.27 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The determination of the grant date fair value of stock options granted using a Black-Scholes option-pricing model is affected by the fair value of our common stock, as well as assumptions regarding a number of variables that are subjective and generally require judgment to determine. The valuation assumptions were determined as follows:&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair value of common stock&#x2014;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of each share of common stock is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;The expected term of stock options granted to employees and non-employee directors is determined using the &#x201c;simplified&#x201d; method, as illustrated in ASC Topic 718, &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, as we do not have sufficient exercise history to determine a better estimate of expected term. Under this approach, the expected term is &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;based on the midpoint between the vesting date and the end of the contractual term of the stock option.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;We utilize a risk-free interest rate in the option valuation model based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected terms of the stock options.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;As we do not have sufficient trading history for our common stock, expected volatility is based on the historical volatility of our publicly traded industry peers utilizing a period of time consistent with our estimate of expected term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;We do not anticipate paying any cash dividends in the foreseeable future and, therefore, use an expected dividend yield of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in the option valuation model.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted-average grant date fair value per share of stock options granted during the year ended December 31, 2023, 2022 and 2021 was &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;5.61&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;7.36&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;24.22&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The grant date fair value of restricted stock units granted &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;is based on the closing price of our common stock on the date of grant, or other relevant determination date, as reported on The Nasdaq Global Select Market. &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted-average grant date fair value per share of restricted stock units granted during the year ended December 31, 2023, 2022 and 2021 was &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;8.29&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;11.43&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;37.98&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted-average grant date fair value per share of the market-based restricted stock units granted during the year ended December 31, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.89&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, and was determined using a Monte Carlo valuation model, which uses assumptions such as volatility, risk-free interest rate and dividend estimated for the respective performance periods. The weighted-average grant date fair value per share of the target payout level of the market-based restricted stock units outstanding as of December 31, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;956,337&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The aggregate share-based compensation expense of the market-based restricted stock units granted during the year ended December 31, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, and is recognized on a straight-line basis over the respective grants' &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; performance periods, which are also the requisite service periods. Attainment of each grant's respective market condition and the number of shares earned and vested does not impact the related share-based compensation expense recognized. Share-based compensation expense will be reversed only if the respective grantee does not provide continuous service through the respective performance period for reasons other than those expressly provided in the terms of the respective award.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The compensation cost related to stock options, restricted stock units and market-based restricted stock units for the years ended December 31, 2023, 2022 and 2021 are included on the consolidated statements of operations as follows (in thousands):&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost of revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,910&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sales and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, unrecognized share-based compensation expense and the remaining weighted-average recognition period were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrecognized Share-Based&lt;br/&gt;Compensation Expense&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Remaining Weighted-Average&lt;br/&gt;Recognition Period&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonvested stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.94&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.67&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonvested market-based restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.97&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_52139d7b-c2be-477b-8367-d18a6a83b6e7"
      id="F_cd322638-f5be-4c0a-9c78-cd6d43248691">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_feb3a029-611b-49cd-afb7-35c3b0ac8813"
      decimals="INF"
      id="F_224ffc8c-0785-4995-a147-4c195ca52767"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_b70f1afc-db7d-4741-a566-077b3ae24fae"
      id="F_f942f4e3-4d82-45d3-b01c-dabaa0c84ad2">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_1289e3d3-be6d-4b21-8182-0e0ea07d3d38"
      id="F_c7b05afe-d9e1-46aa-8566-ad8bcb525609">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_5aa06285-f2dc-4040-87ff-e52ba00117cc"
      decimals="INF"
      id="F_952a89fe-40ae-43b7-be6c-24598c9c94a6"
      unitRef="U_shares">34853581</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_7b5620c2-79d8-4a93-8bb7-0ee52de51f21">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Changes in shares available for grant during the year ended December 31, 2023 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares Available for Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available for grant at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,581,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2019 Equity Incentive Plan reserve increase effective January 1, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,155,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options and restricted stock units granted and the maximum market-based restricted stock units granted eligible to be earned&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,980,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options and restricted stock units forfeited or expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,542,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available for grant at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,299,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</adpt:ScheduleOfShareBasedCompensationSharesAvailableForGrantTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_f712f0be-9f2e-4186-a7b5-0091ce1762f6"
      decimals="INF"
      id="F_e956258c-a021-4911-8cf9-9d1c4825e05d"
      unitRef="U_shares">14581975</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <adpt:ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve
      contextRef="C_3b24663a-22c4-43fd-8173-22c3ea3e4a68"
      decimals="INF"
      id="F_bde0f595-bc0c-41dc-b496-5dc9a849b094"
      unitRef="U_shares">7155250</adpt:ShareBasedCompensationArrangementByShareBasedPayementEquityIncentivePlanReserve>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned
      contextRef="C_3b24663a-22c4-43fd-8173-22c3ea3e4a68"
      decimals="INF"
      id="F_a2903add-6866-4581-8df6-daff82811ab5"
      unitRef="U_shares">-9980059</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsRestrictedStockUnitsGrantedAndMaximumMarketBasedRestrictedStockUnitsGrantedEligibleToBeEarned>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired
      contextRef="C_3b24663a-22c4-43fd-8173-22c3ea3e4a68"
      decimals="INF"
      id="F_792448aa-4e94-4082-a792-2b30de74c3f8"
      unitRef="U_shares">3542597</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardsForfeitedCanceledOrExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_8432b103-20fe-4d39-a798-e24e82f7508a"
      decimals="INF"
      id="F_4424848f-83a0-40ec-837f-1d25ddc5c3a4"
      unitRef="U_shares">15299763</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_710a5a28-4560-4f3d-976b-aac4543e9633">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock option activity under the 2009 Plan and 2019 Plan during the year ended December 31, 2023 was as follows:&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.780000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.780000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares Subject to&lt;br/&gt;Outstanding Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Exercise&lt;br/&gt;Price per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,520,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,612,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,030,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;757,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;470,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,875,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options vested and exercisable at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,071,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="INF"
      id="F_2ee842cf-d9ef-432d-9396-704cfd13660a"
      unitRef="U_shares">13520997</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="2"
      id="F_9eb0b977-b95a-4654-a00c-0597995a70d2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="INF"
      id="F_fac99452-ac04-4d41-a12d-c9144c9520b3"
      unitRef="U_shares">1612032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="2"
      id="F_a97eee4b-6cff-4b81-893b-f69228a5a395"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="INF"
      id="F_a4b09401-93cb-4627-be4a-fee2853064e2"
      unitRef="U_shares">1030388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="2"
      id="F_9b16cb38-9f52-40f2-9ef5-9a6939d2034a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="INF"
      id="F_e86402cd-e9a0-4bc4-bb79-ae99ce763553"
      unitRef="U_shares">757191</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="2"
      id="F_cf99b9e7-632a-478c-a6ae-d7e6c59d44f9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="INF"
      id="F_28999fe6-2bac-412c-aeef-4888a72a2cb3"
      unitRef="U_shares">470405</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="2"
      id="F_f8e75347-1888-417c-baf8-643b5de5424b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="INF"
      id="F_e47bbb99-b5c8-4944-b325-b4b53d34ad77"
      unitRef="U_shares">12875045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="2"
      id="F_b46038d1-b75b-4463-af6a-eaa1b0736ff2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_5faa8923-6f53-42fc-8253-f1a715c1e254"
      unitRef="U_USD">506000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="INF"
      id="F_bbd29da0-8088-4742-ab86-3e7e08786da2"
      unitRef="U_shares">9071627</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisable>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="2"
      id="F_1e835718-e84f-447f-9b4d-8b516aedb4da"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.2</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_45ca8216-574f-431c-b6dd-6755b00220bf"
      unitRef="U_USD">506000</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_a2eb4b33-dae5-46a2-a13f-0d817e261783">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_7fdedcbb-0fdf-4910-ba8d-9c2fb7dc51af">P5Y3M18D</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExercisableOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-5"
      id="F_eb0dc546-1f1e-42cc-bce6-45aae70378a2"
      unitRef="U_USD">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-5"
      id="F_8517285c-3909-4d54-806c-9eb7298cb8aa"
      unitRef="U_USD">7600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-5"
      id="F_56840197-7061-45ef-8825-bc99b582ddb1"
      unitRef="U_USD">156500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-5"
      id="F_4b39a3cd-5194-4567-aadf-c9be05e2585a"
      unitRef="U_USD">26700000</us-gaap:ProceedsFromStockOptionsExercised>
    <adpt:ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-5"
      id="F_caa1b19c-b1b1-4d84-9719-1112429ee97a"
      unitRef="U_USD">300000</adpt:ProceedsFromSettlementOfStockOptionExercisedInPriorPeriods>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_c31ec8e8-ff18-40ec-8a77-7fab85bf6f3b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted stock unit activity under the 2019 Plan during the year ended December 31, 2023 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Restricted Stock Units&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average Grant Date&lt;br/&gt;Fair Value per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonvested restricted stock units outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,981,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,949,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,755,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,506,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonvested restricted stock units outstanding at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,669,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_fdeb24a7-efd0-43c6-90cc-7c4a9389752a"
      decimals="INF"
      id="F_12dba867-539b-4a83-bc89-3c3eda358d10"
      unitRef="U_shares">5981755</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_fdeb24a7-efd0-43c6-90cc-7c4a9389752a"
      decimals="2"
      id="F_46aa4f41-4ed4-4ab8-8127-1c27620cafe5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_43621f8b-6a5f-47d0-a30e-6bf513d24ad8"
      decimals="0"
      id="F_50c4a9c2-d3ed-41a8-a2a1-765e1c221fc6"
      unitRef="U_shares">6949587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_43621f8b-6a5f-47d0-a30e-6bf513d24ad8"
      decimals="2"
      id="F_da43bfd7-65c7-46eb-8497-2d4f627ff885"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_43621f8b-6a5f-47d0-a30e-6bf513d24ad8"
      decimals="0"
      id="F_49b749a9-379d-497e-8d84-2fca435e2357"
      unitRef="U_shares">1755018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_43621f8b-6a5f-47d0-a30e-6bf513d24ad8"
      decimals="2"
      id="F_9cc62e05-6b05-4767-a779-4144fadcb9b6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_43621f8b-6a5f-47d0-a30e-6bf513d24ad8"
      decimals="0"
      id="F_f594dd91-409f-44cf-9a28-1696d171fedf"
      unitRef="U_shares">1506864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_43621f8b-6a5f-47d0-a30e-6bf513d24ad8"
      decimals="2"
      id="F_560ffd0b-f035-4cab-82f1-63dad775b37a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_af47b662-9bf3-44d8-8091-3006d4c6e691"
      decimals="INF"
      id="F_824bad37-7950-477d-b0b0-d7f85cb212f4"
      unitRef="U_shares">9669460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_af47b662-9bf3-44d8-8091-3006d4c6e691"
      decimals="2"
      id="F_c5ab45dc-bdb1-4280-a795-cca51e9fdf1f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_efab56ea-21ee-4b9f-a82c-12261558a450"
      decimals="-5"
      id="F_e5701ff6-a6b7-4f25-b45d-ae779fea769a"
      unitRef="U_USD">12000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_9b79125c-aadc-43ba-85de-4c5908f2bb4d"
      decimals="-5"
      id="F_af8c34c6-6b91-4d3b-b63e-e7d42da40c25"
      unitRef="U_USD">3500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_d643066a-d834-4dbc-94f7-b192fb198f27"
      decimals="-5"
      id="F_8e4b1dce-7daf-4385-8c63-dd56e0e98a6d"
      unitRef="U_USD">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward
      contextRef="C_dd0b38a4-c17a-4584-ace9-9eb7a4dba7cd"
      decimals="INF"
      id="F_73373612-2a54-41ca-8366-6935b91b0e5e"
      unitRef="U_shares">0</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward
      contextRef="C_eb640244-c177-44b5-8d08-c43654ceed7c"
      decimals="INF"
      id="F_778a8666-c3a0-4e6d-9303-a702d70e3292"
      unitRef="U_shares">709220</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward>
    <adpt:SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm
      contextRef="C_866da907-3204-49a4-a785-caa968f66943"
      id="F_cb8f672e-1765-4a3a-a3fa-8020919ea41a">P3Y</adpt:SharebasedCompensationArrangementBySharebasedPaymentAwardPerformancePeriodTerm>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward
      contextRef="C_55a33622-5845-472e-a76b-82768e6681b9"
      decimals="INF"
      id="F_25e807cb-79f4-4226-acd6-523c63644688"
      unitRef="U_shares">0</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward
      contextRef="C_51e0ed6a-9fac-4c20-a4e8-435eb73af38d"
      decimals="INF"
      id="F_c26ff7f7-9eac-4aff-b607-629114418780"
      unitRef="U_shares">494234</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesEarnedUnderTheAward>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_5d6b83e7-5804-4811-816a-b6134d1d2296">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The estimated grant date fair values of stock options granted during the years ended December 31, 2023, 2022 and 2021 were estimated using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.177%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.255%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.255%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.255%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fair value of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.86&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.27 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="2"
      id="F_075181bf-eff3-42f5-95c9-3104ff2c4dc5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_6ce95484-a0e7-43c5-830f-bb7a29b093db"
      decimals="2"
      id="F_2d4ac9f7-8606-48cc-9fdc-563fccdedf75"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_d63aae94-5743-4e75-a64b-3a0caabf8bd7"
      decimals="2"
      id="F_3dfab32b-56ec-4202-806b-7e1cb228e053"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_82171477-fd8e-4a87-a38e-80b61f287043"
      decimals="2"
      id="F_43cbb2db-5741-486d-aed4-1dd10c482d34"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">30.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_2eb19fde-1742-44b2-a814-dd6adf82062d"
      decimals="2"
      id="F_46ef9338-929c-4db3-aac6-b2aac5862836"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">66.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_5345840c-9735-4c5d-b8ec-b10aa2abbce6"
      id="F_52a26aae-7280-4df1-8611-5a4f45565ee5">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_bff5bd4a-2423-48c0-a5ec-9acfc6922d16"
      id="F_e9cb006e-0c79-4e46-b874-ec0104d4b1eb">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_6ce95484-a0e7-43c5-830f-bb7a29b093db"
      id="F_fe9315f9-ce7d-4007-81f1-bdd3fe8237bd">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_d63aae94-5743-4e75-a64b-3a0caabf8bd7"
      id="F_d6da1930-ec2a-4aa6-90a1-811569df77a9">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_82171477-fd8e-4a87-a38e-80b61f287043"
      id="F_1a95c9e7-1f98-4611-abb5-d398e060ef46">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_2eb19fde-1742-44b2-a814-dd6adf82062d"
      id="F_c7b38114-5f69-420d-ae52-c34629d26eef">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="3"
      id="F_9b6a53ab-1d2c-43b4-8b29-1324bfb744d7"
      unitRef="U_pure">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="3"
      id="F_e3d3d7cb-bccc-4249-a6dd-cb07463b780c"
      unitRef="U_pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="3"
      id="F_e8073a10-16b3-4b4d-9519-93593aa1dcd1"
      unitRef="U_pure">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="3"
      id="F_569d92aa-c060-4cb4-b79d-a474fc6993f2"
      unitRef="U_pure">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="3"
      id="F_17fcc45e-c8c8-4e7c-9996-48e022d1edcd"
      unitRef="U_pure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="3"
      id="F_e8eb47c6-75e1-4bdd-9ba0-8da0f14e8572"
      unitRef="U_pure">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="3"
      id="F_c6717f5b-5dc6-4b5b-b252-cf05454fdf6b"
      unitRef="U_pure">0.712</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="3"
      id="F_1a1d518e-e98f-4d76-953e-830f67d745fb"
      unitRef="U_pure">0.716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="3"
      id="F_5d8e2ee8-96b7-4f01-b684-dcd9a214dfca"
      unitRef="U_pure">0.682</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="3"
      id="F_43ff65af-9a5a-4981-bfce-293393d401ab"
      unitRef="U_pure">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="3"
      id="F_352934d5-6e5c-4dc8-b774-8c0ccde2ed38"
      unitRef="U_pure">0.671</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="3"
      id="F_ebae85bb-ea61-4eb7-8f9e-b0b94c0ce2a4"
      unitRef="U_pure">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_13005d32-f646-429f-a0e2-4fd8c00bf69a"
      decimals="2"
      id="F_149c68c3-0274-40d4-ac24-4ade77616cef"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="2"
      id="F_6ab1b4fb-73cb-486c-a5b9-082a1eb62851"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="2"
      id="F_a0daeaa7-1c58-4fa8-b7e8-7cba66727e6d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="2"
      id="F_cc70e8d9-0898-49bd-affd-ed2c5db3d881"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">24.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_43621f8b-6a5f-47d0-a30e-6bf513d24ad8"
      decimals="2"
      id="F_8c96e4b8-4c6b-4d32-aaa4-77acbf088a57"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_1347ec09-38d8-439d-8a28-61beab707a2c"
      decimals="2"
      id="F_49177267-0d11-493c-9b9e-b9d4e9f28eba"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_f60e9643-430c-4ac5-b6d2-f2549cc4ce16"
      decimals="2"
      id="F_699b513a-221b-4730-8add-2422a0d5e6d9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">37.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_e8a9a7fc-8e3b-4b0f-9703-17e3dba9a414"
      decimals="2"
      id="F_d88c93db-676e-418b-961c-c1400d97b317"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_57eacb73-0b36-49e5-8d6b-de05bc131c61"
      decimals="2"
      id="F_b1846864-b9dc-4bd9-b864-0cbb0178883a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_b2a6703f-315a-4dab-97f7-15768deba909"
      decimals="INF"
      id="F_4bffa715-6bc2-48dd-b752-c8987b5f2e74"
      unitRef="U_shares">956337</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_b2a6703f-315a-4dab-97f7-15768deba909"
      decimals="2"
      id="F_2c60c982-7b87-4171-a685-cdcf94809b30"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ee2c393f-edb6-49f1-8cc5-881b50f4a194"
      decimals="-5"
      id="F_d1052254-525e-4d62-91ea-b531c7411b07"
      unitRef="U_USD">9800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7763f050-ced0-429d-9db0-76d18214c5c6"
      decimals="-5"
      id="F_a1752100-500c-4ab5-bbeb-6fba7149160f"
      unitRef="U_USD">4700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm
      contextRef="C_ee2c393f-edb6-49f1-8cc5-881b50f4a194"
      id="F_ef4615e8-1b04-41ae-8b4a-aa0dcf52452c">P3Y</adpt:ShareBasedCompensationArrangementByShareBasedPaymentAwardRequisiteServicePeriodTerm>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_0bec357f-bd7c-4e68-8a3d-df0959cd1986">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The compensation cost related to stock options, restricted stock units and market-based restricted stock units for the years ended December 31, 2023, 2022 and 2021 are included on the consolidated statements of operations as follows (in thousands):&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cost of revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,910&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sales and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5d872d1b-6381-4a56-9eee-12e5744bc07e"
      decimals="-3"
      id="F_bfa4b90f-7580-4ba4-851b-38056753cd8b"
      unitRef="U_USD">4186000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_41662c43-8800-4ae7-bc2d-55dfc7db0bb2"
      decimals="-3"
      id="F_8ef56f68-a3a9-474f-a27b-042cac0cb2b6"
      unitRef="U_USD">3910000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c4af3728-9703-4193-8445-5f99fb79c576"
      decimals="-3"
      id="F_117edbbc-c004-45fe-be79-a5cd1524f8b5"
      unitRef="U_USD">2100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f45bf03e-7ed0-4ba6-8ffc-ba5f9e654d96"
      decimals="-3"
      id="F_29163e01-5c4e-4424-ad86-8fba83a3f631"
      unitRef="U_USD">20465000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1a66f191-30ec-42f3-b59c-6f6b27af199f"
      decimals="-3"
      id="F_55941863-4a0b-45ec-a55d-65bfc24420de"
      unitRef="U_USD">17689000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_83e9af4e-f8d0-4e18-894d-bef3e41d1fa4"
      decimals="-3"
      id="F_d627af52-39dc-42ac-aa99-1d789b379a2b"
      unitRef="U_USD">14061000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_97bc012b-5315-4313-9c87-2f9e1fa58826"
      decimals="-3"
      id="F_8661de51-0941-4e74-a5cd-2c0ff61f5a61"
      unitRef="U_USD">14553000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_46c823cf-5ea5-4b9b-b0ea-af9c60b6fd51"
      decimals="-3"
      id="F_ff21e2ad-cdd9-40b2-a007-f90c36133e98"
      unitRef="U_USD">13597000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6ea1b178-9b53-435d-bea7-af3f35409ca9"
      decimals="-3"
      id="F_78f7dd47-d801-44e4-9547-7b2e9d2210f1"
      unitRef="U_USD">12312000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d0727108-4458-4e50-b34a-e52b89840f12"
      decimals="-3"
      id="F_e29019fd-bed1-4ce3-baad-82d4d173cb78"
      unitRef="U_USD">23704000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ef915afd-ec97-428b-a6f3-a6066e32a6a3"
      decimals="-3"
      id="F_df17342f-c940-40dd-874e-cd5ac206f604"
      unitRef="U_USD">20281000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4ec6bc83-92c5-47f4-97fb-4663a45fb872"
      decimals="-3"
      id="F_807e717b-4660-4c70-97e8-5dd79149c0f4"
      unitRef="U_USD">14778000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_95c5257b-2624-4e7d-b6e2-99cf62158f77"
      unitRef="U_USD">62908000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_5fcb168c-396f-4485-8171-97a1754f0632"
      unitRef="U_USD">55477000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_66723a4a-948c-4559-b40f-d0f4c2124a94"
      unitRef="U_USD">43251000</us-gaap:AllocatedShareBasedCompensationExpense>
    <adpt:ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_ad9bd927-2fe2-4988-b68b-1a507e73f876">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, unrecognized share-based compensation expense and the remaining weighted-average recognition period were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrecognized Share-Based&lt;br/&gt;Compensation Expense&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Remaining Weighted-Average&lt;br/&gt;Recognition Period&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonvested stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.94&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.67&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonvested market-based restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.97&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</adpt:ScheduleOfUnrecognizedShareBasedCompensationExpenseAndTheExpectedWeightedAverageRemainingRecognitionPeriodTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_5c8126e1-b6cc-428b-b0c0-8e108d6c872f"
      decimals="-3"
      id="F_3776433e-10ec-4e4c-9a6e-0a67926919f0"
      unitRef="U_USD">33892000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_02b5636a-5e74-4e33-b07e-81d5098e6ddd"
      id="F_702ddd97-8860-445e-ba2e-c2a629d5af0a">P1Y11M8D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_82f4bbd7-e097-4e32-bf62-da8405a3dbfa"
      decimals="-3"
      id="F_095c330b-4b23-4c0a-aa01-741c6f11fce5"
      unitRef="U_USD">76944000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_091e55d9-10c4-4aba-84c0-5a9e97322c47"
      id="F_6763c86a-8e0e-430f-b208-667a220c0958">P2Y8M1D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_f834ab3e-f5d2-4656-891f-53272cd08ed4"
      decimals="-3"
      id="F_402f18df-a1a9-48ce-865d-9c735e55a54e"
      unitRef="U_USD">8941000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_89c81479-2ca4-45be-bc13-7804c0d2f507"
      id="F_365752ba-0b90-40c5-997c-960f37d3cc89">P1Y11M19D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_6a9e11fc-4f22-4cf0-9283-a846591277d8">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;15.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Microsoft Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Summary of Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2017, we entered into a collaboration agreement with Microsoft Corporation ("Microsoft") (the &#x201c;Microsoft Agreement&#x201d;) to computationally derive a comprehensive T cell receptor antigen map for purposes of developing a universal diagnostic based on a single blood test.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Contemporaneously with the Microsoft Agreement, we entered into a separate agreement to use Microsoft&#x2019;s Azure cloud services at standard volume pricing with a minimum Azure purchase requirement of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;12.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million over the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;seven-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; term of the Microsoft Agreement, which has been met.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, contemporaneously with entering into the Microsoft Agreement, Microsoft made a preferred stock investment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;45.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as a part of our Series F-1 convertible preferred stock issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Summary of Accounting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The terms of the Microsoft Agreement meet the criteria under ASC 808, as both parties are active participants in the activity and are exposed to significant risks and rewards dependent on the commercial success of the activity. ASC 808 does not provide guidance on how to account for the activities under the collaboration and we determined that Microsoft did not meet the definition of a customer under ASC 606. Accordingly, we looked to other guidance to determine the accounting for the respective elements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We determined that the preferred stock issuance and commitment to use Microsoft&#x2019;s Azure cloud services were made at terms consistent with market rates. All consideration received as part of the Series F-1 convertible preferred stock issuance was accounted for as part of the Series F-1 preferred stock issuance. Since the commitment to purchase Microsoft&#x2019;s Azure cloud services was at market terms and we expected to meet the commitment in the ordinary course of business during the seven-year term, we recorded the expenses in the period in which the services were consumed. These costs are recorded in the consolidated statements of operations based on the underlying activities for which they support.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The remaining elements of the agreement were highly interrelated, so we evaluated them in the aggregate to determine the appropriate accounting application. Specifically, we determined that the transfer of license rights between the parties, our commitment to provide data and immunomics, diagnostic and bioinformatics expertise to Microsoft and Microsoft&#x2019;s commitment to provide machine learning software and related development services to us were highly interrelated because they were necessary for the parties to perform the activities under the Microsoft Agreement and, therefore, should be evaluated as one unit of account.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We accounted for these collaboration activities by analogy to ASC Topic 845, &lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Nonmonetary Transactions&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and determined that major uncertainties exist about the realizability of the value that would be assigned to an asset received from or provided to Microsoft under the collaboration and, therefore, fair value could not be reliably measured. As a result, we did not recognize any non-monetary assets or corresponding non-monetary income or expenses pertaining to the rights provided to us or to be received by us under the Microsoft Agreement.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <adpt:MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement
      contextRef="C_dfe2e57d-4fb2-4493-8bac-7c38728d7cb1"
      decimals="INF"
      id="F_5dae51d3-aa0d-48c8-9263-897d7973d751"
      unitRef="U_USD">12000000.0</adpt:MinimumServiceConsumptionRequirementAmountUnderLicenseAgreement>
    <adpt:MinimumServiceConsumptionRequirementTermUnderLicenseAgreement
      contextRef="C_dfe2e57d-4fb2-4493-8bac-7c38728d7cb1"
      id="F_4f9cd1db-9de7-4e6e-8146-c2ad201381c7">P7Y</adpt:MinimumServiceConsumptionRequirementTermUnderLicenseAgreement>
    <us-gaap:PreferredStockValue
      contextRef="C_c035c769-db33-4f4f-a68d-722fe5a08f44"
      decimals="-5"
      id="F_63647af4-1928-4a4a-aad6-61708d626f7d"
      unitRef="U_USD">45000000.0</us-gaap:PreferredStockValue>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_691e7ccc-3fee-4698-a467-93a42429f3c3">&lt;div style="font-size:0;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;"&gt;16.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restructuring&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March 2022, we implemented a restructuring plan to reduce operating costs and reduced our workforce by approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; employees. We incurred aggregate restructuring costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, all of which was recognized during the year ended December 31, 2022. These costs primarily related to one-time termination benefits and ongoing benefit arrangements, both of which included severance payments and extended benefits coverage support and were contingent upon the impacted employees&#x2019; execution and non-revocation of separation agreements. Our aggregate restructuring costs also included certain contract termination costs. The activities related to our reduction in workforce were primarily completed in March 2022 and the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million aggregate restructuring costs were paid as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="C_18d7a278-e320-4faa-bd10-c3406fe899df"
      decimals="INF"
      id="F_e2681911-3f90-4047-a3d0-9092fb50188b"
      unitRef="U_Employee">100</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-5"
      id="F_1df77413-101b-46d2-b014-a8933adc5af8"
      unitRef="U_USD">2000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:PaymentsForRestructuring
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-5"
      id="F_48f2d3e6-6ca1-4f0a-b77e-fb70b8b7fcfe"
      unitRef="U_USD">2000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_70005d32-0468-4892-b663-0a68d53f97f1">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;17.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of loss before provision for income taxes for the periods presented were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;225,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;207,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total loss before provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;225,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;207,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The significant components of our deferred tax assets and liabilities as of the dates presented were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;251,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credit carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonqualifying stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,859&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;416,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;371,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;402,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;346,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tangible and intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, requires that the tax benefit of net operating losses ("NOLs"), temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#x201c;more likely than not.&#x201d; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. The valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the year ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Federal tax laws impose substantial restrictions on the utilization of NOL and credit carryforwards in the event of an ownership change, as defined in Section 382 of the Internal Revenue Code of 1986. Accordingly, our ability to utilize these carryforwards may be limited due to such ownership changes. We have completed a Section 382 analysis for changes in ownership through June 30, 2023 and continue to monitor for changes that could trigger a limitation. Based on this analysis, we do not expect to have any permanent limitations on the utilization of our federal NOLs. Under the Tax Cuts and Jobs Act of 2017 federal income tax law, federal NOLs incurred in 2018 and future years may be carried forward indefinitely, but the deductibility of such federal NOLs is subject to an annual limitation. NOLs generated prior to 2018 are eligible to be carried forward up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years. As of December 31, 2023, we had U.S. federal NOLs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;192.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and U.S. federal tax credits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million that will begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. We also had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;768.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of NOLs as of December 31, 2023 that do not expire.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.4%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State tax, net of federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We account for global intangible low-taxed income as period costs when incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We recognize, in the consolidated financial statements, the effect of a tax position when it is more likely than not, based on the technical merits, that the position will be sustained upon examination. We had unrecognized tax benefits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the dates presented are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions in 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions in 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions in 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the year ended December 31, 2023, 2022 and 2021, we recognized uncertain tax positions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, related to a reduction of the research and development credit deferred tax asset. Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. We do not expect a material change to our unrecognized tax benefits over the next twelve months that would have an adverse effect on our operating results.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. We had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; accrued interest or penalties related to uncertain tax positions as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We file federal and certain state income tax returns, which provide varying statutes of limitations on assessments. However, because of NOL carryforwards, substantially all tax years since inception remain open to federal and state tax examination.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_9e6148c5-aa12-41dc-a843-6ea7d77bb029">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of loss before provision for income taxes for the periods presented were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;225,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;207,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total loss before provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;225,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;207,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_7d08b38c-eb5a-44cd-8b6b-afb9f4c47be5"
      unitRef="U_USD">-225335000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_d71fa123-1b25-42fa-bd1c-b79a14edbe27"
      unitRef="U_USD">-200427000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_dbc2f148-5bc7-4d96-aa30-aa78b0eb2408"
      unitRef="U_USD">-207314000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_8594ec18-8fc4-408c-ade4-7d063dd307fa"
      unitRef="U_USD">31000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_3f1b468f-da0a-4e23-b870-8f8ec2dc2067"
      unitRef="U_USD">59000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_bfe35784-7fa5-4f7a-84a1-92f4f1245cd8"
      unitRef="U_USD">16000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_e835a6fd-baf5-47f2-96b5-28d66c8bd40b"
      unitRef="U_USD">-225304000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_4754c82a-8b89-449d-85a2-d688570f231e"
      unitRef="U_USD">-200368000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_736020e7-a660-4df1-88bf-6783216a50e5"
      unitRef="U_USD">-207298000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_9f7f582f-e1cb-43b2-92d1-2ac116f74b42">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The significant components of our deferred tax assets and liabilities as of the dates presented were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;251,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credit carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonqualifying stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,859&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;416,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;371,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;402,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;346,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tangible and intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_36ca4ac3-f252-4dcb-92ae-27f6fce7ba78"
      unitRef="U_USD">251724000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_4d1ce108-27b1-4420-aa21-67d6eb6157ad"
      unitRef="U_USD">210609000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_53019306-a41a-4a49-befb-fb3c487ed4c8"
      unitRef="U_USD">43528000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_1aa697a1-2403-4995-ab17-d328a735f7c2"
      unitRef="U_USD">36848000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <adpt:DeferredTaxAssetsNonQualifiedStockOptions
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_498c501f-7cb7-489e-be3b-4cdd8aabe94a"
      unitRef="U_USD">29166000</adpt:DeferredTaxAssetsNonQualifiedStockOptions>
    <adpt:DeferredTaxAssetsNonQualifiedStockOptions
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_926bfa27-e5bd-4968-8ac6-73d7a7ac9103"
      unitRef="U_USD">23885000</adpt:DeferredTaxAssetsNonQualifiedStockOptions>
    <adpt:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_465e030a-2a4f-4c8b-ae7f-bf28ecf933d9"
      unitRef="U_USD">25357000</adpt:DeferredTaxAssetsOperatingLeaseLiabilities>
    <adpt:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_557dc104-79e2-4918-a272-f035ddd355ca"
      unitRef="U_USD">27199000</adpt:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_be894608-b14d-44f3-938e-50d91ec657b7"
      unitRef="U_USD">18874000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_a9802d6b-1bf3-496d-a69b-ddcfde642c5f"
      unitRef="U_USD">26170000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <adpt:Deferredtaxassetscapitalizedresearchanddevelopment
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_b1b61307-5ecc-4ec9-8b0a-10d4042b74e2"
      unitRef="U_USD">42134000</adpt:Deferredtaxassetscapitalizedresearchanddevelopment>
    <adpt:Deferredtaxassetscapitalizedresearchanddevelopment
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_3f68f437-5fde-400b-84cb-8baf71c4f326"
      unitRef="U_USD">40957000</adpt:Deferredtaxassetscapitalizedresearchanddevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_40ca8185-45da-4aed-9e7b-96b52c454ef9"
      unitRef="U_USD">6146000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_46ec8527-1aa9-40c1-a4f1-181e6b98023e"
      unitRef="U_USD">5859000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_636cd2d4-04b8-414e-a7fa-5525f3b2959f"
      unitRef="U_USD">416929000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_bfc3f21a-1ef3-4447-9651-32085dbc7f94"
      unitRef="U_USD">371527000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_65a37819-aad2-45b9-b563-0cc92c53ab56"
      unitRef="U_USD">402424000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_1ec19297-4729-4137-9d70-50cb051bae24"
      unitRef="U_USD">346578000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_e5469612-5f89-4cea-8c5c-e2fea34e18a6"
      unitRef="U_USD">14505000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_fa7396a3-458e-4f96-b1a6-d7f890e9981b"
      unitRef="U_USD">24949000</us-gaap:DeferredTaxAssetsNet>
    <adpt:DeferredTaxLiabilitiesTangibleAndIntangibleAssets
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_af85a1ea-52a9-41e3-994c-2816b79e33fe"
      unitRef="U_USD">1281000</adpt:DeferredTaxLiabilitiesTangibleAndIntangibleAssets>
    <adpt:DeferredTaxLiabilitiesTangibleAndIntangibleAssets
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_5f030a1a-3d94-495f-9e3f-50440cc1b469"
      unitRef="U_USD">4897000</adpt:DeferredTaxLiabilitiesTangibleAndIntangibleAssets>
    <adpt:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_11b58058-750e-4465-8da1-33d1422a44b2"
      unitRef="U_USD">13224000</adpt:DeferredTaxLiabilitiesRightOfUseAssets>
    <adpt:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_3a724ab2-fc5f-4509-be1c-a939c4dd193d"
      unitRef="U_USD">20052000</adpt:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_231f0df0-860c-4686-9ad0-7f297e8d8bd9"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_80f6a0e0-13df-42a0-bb46-8b82acc92e07"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-5"
      id="F_cf410d76-a67a-4911-a2d9-47a01196bf7c"
      unitRef="U_USD">55800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-5"
      id="F_63c3ce9e-2bde-49e2-bbc7-6c09b7513c0a"
      unitRef="U_USD">49600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <adpt:NetOperatingLossCarryforwardExpirationPeriod
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_e9c749b0-8d4e-4cac-b16f-540fe58b6d97">P20Y</adpt:NetOperatingLossCarryforwardExpirationPeriod>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_fd3f7f0d-8716-4252-b061-74865b34ce51"
      decimals="-5"
      id="F_0eaf3629-7195-4efa-b24e-25e65a555962"
      unitRef="U_USD">192500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_fd3f7f0d-8716-4252-b061-74865b34ce51"
      decimals="-5"
      id="F_f18db20e-ae28-4122-9270-ac49961a93d9"
      unitRef="U_USD">47200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse
      contextRef="C_95bf0290-eef6-4156-a6ce-f1dc2af43daa"
      id="F_4ff5b898-0e28-48bf-a904-4645772c8b24">2028</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <adpt:OperatingLossCarryforwardsExpirationYear
      contextRef="C_95bf0290-eef6-4156-a6ce-f1dc2af43daa"
      id="F_9e74ae51-390b-47ee-86be-1804796b4abb">2028</adpt:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-5"
      id="F_50aed942-cb86-478c-aeb8-4d6fe26e4908"
      unitRef="U_USD">768200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_2c88a319-36df-455f-9674-65f10472426c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The effective tax rate of our provision for income taxes differs from the federal statutory rate for the periods presented as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.4%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State tax, net of federal tax benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="INF"
      id="F_f224f4be-6aa8-47b2-95a1-7d72e2977719"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="INF"
      id="F_056e542c-4db6-4a9c-876e-4c23a66482f5"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="INF"
      id="F_419c3b21-8b81-46df-8167-215eb14498df"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="INF"
      id="F_66303bf4-27a7-4ad0-8248-e3e5885e3015"
      unitRef="U_pure">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="INF"
      id="F_10415ee5-e790-430f-814f-390ab4760298"
      unitRef="U_pure">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="INF"
      id="F_837bc6f1-ea2a-40cb-9cc8-0f80727c0ede"
      unitRef="U_pure">0.083</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="3"
      id="F_f50fe356-9d3f-4eee-a06c-0cac16d5d4f7"
      unitRef="U_pure">-0.029</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="3"
      id="F_90cbdc60-caf4-4280-b022-a632462eaf3f"
      unitRef="U_pure">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="3"
      id="F_4888909d-19dd-44a0-9796-07018563c16d"
      unitRef="U_pure">0.141</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <adpt:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="3"
      id="F_bd70bd55-59d5-4594-8cc3-d4e4fbf09ec1"
      unitRef="U_pure">-0.001</adpt:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <adpt:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="3"
      id="F_3f4d25c2-3f64-46ef-9e7b-4534ab1ff7d8"
      unitRef="U_pure">-0.002</adpt:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <adpt:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="3"
      id="F_56c0c0a4-b5ac-47fc-8cfb-f6952be92275"
      unitRef="U_pure">-0.001</adpt:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="3"
      id="F_ce082bd0-9520-49e4-8470-04588289d05c"
      unitRef="U_pure">0.023</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="3"
      id="F_11a4e189-1b1e-4fb1-a833-3d2397546698"
      unitRef="U_pure">0.03</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="3"
      id="F_e3a0a93e-e3d7-4989-9735-d672d640c1bf"
      unitRef="U_pure">0.047</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="3"
      id="F_c64a6c14-a9bd-4555-b225-eb7018e591d7"
      unitRef="U_pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="3"
      id="F_5eb6e4f0-e844-452a-8cc3-b370bd7bf6eb"
      unitRef="U_pure">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="3"
      id="F_dd4b0823-2697-46fe-8a86-aff9bdc2ec2f"
      unitRef="U_pure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="3"
      id="F_5d23bbb1-ab8d-44b1-bcae-4f7a87c97566"
      unitRef="U_pure">-0.253</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="3"
      id="F_c51f6764-723e-42c6-912d-e1aa208b2248"
      unitRef="U_pure">-0.244</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="3"
      id="F_4a6a557b-876b-4095-a275-936215c6d6d0"
      unitRef="U_pure">-0.477</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="3"
      id="F_31442bcd-1267-441b-9429-b41f6cb183e4"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="3"
      id="F_74fa712e-a685-4820-ad30-82151a80e1df"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="3"
      id="F_7ab01a8a-9a02-4454-959a-529d2e1ca222"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-5"
      id="F_87d74ad3-0fb5-44ff-988f-579779459d8b"
      unitRef="U_USD">9300000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_77683ddd-fc6f-4908-95b7-930026c374f0">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the dates presented are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions in 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions in 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions in 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_cd98abbe-6241-4fc8-af88-d9979790e940"
      decimals="-3"
      id="F_35edd9e5-ceb4-40b7-b83e-65b30c1936eb"
      unitRef="U_USD">3489000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_1f86f7ba-f42a-4cce-bd47-9e23ed964760"
      unitRef="U_USD">3426000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_6f19237c-a155-4029-b45f-b9fb5332f737"
      decimals="-3"
      id="F_44cedb13-be5b-4e36-9a47-349dbd24c695"
      unitRef="U_USD">6915000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_f1e05c3f-298f-4d1c-82b5-c56038ca2add"
      unitRef="U_USD">1202000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="-3"
      id="F_94fdbc8d-3dac-4ee5-b695-5ee5cbb1200d"
      unitRef="U_USD">8117000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_e3cd1f8d-b88f-4c1c-ad8f-1132423cae4e"
      unitRef="U_USD">1186000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="-3"
      id="F_cde14823-b191-4473-8366-a6eea46738b8"
      unitRef="U_USD">9303000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-5"
      id="F_ba9d5f7d-4439-4b53-9733-fc6c53c431ad"
      unitRef="U_USD">1200000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-5"
      id="F_f3e2cdd6-dc0f-4ffe-a894-9d8a51761c13"
      unitRef="U_USD">1200000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-5"
      id="F_ed53a66f-2989-4c4d-a5b9-af030c030fc6"
      unitRef="U_USD">3400000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_60b74489-28b2-4615-9786-6fdacef93898"
      decimals="INF"
      id="F_3a8a32e4-99ad-4208-bd11-8bb51bfaeaff"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_27c4f267-cdd6-4003-8d32-93af9d170fbe"
      decimals="INF"
      id="F_e35be707-dd68-467b-ae0f-7b64a61dbcf0"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_27cea654-11cb-4326-9922-cab2d79100ea">&lt;div style="display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;18.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the years ended December 31, 2023, 2022 and 2021 (in thousands, except share and per share amounts):&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss attributable to Adaptive Biotechnologies Corporation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;225,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;207,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;144,383,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,515,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;140,354,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Given the loss position for all periods presented, basic net loss per share attributable to our common shareholders is the same as diluted net loss per share attributable to our common shareholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the years ended December 31, 2023, 2022 and 2021, as they had an anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.177%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.255%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.255%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.255%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,839,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,892,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,097,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonvested restricted stock units outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,630,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,799,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;693,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Maximum nonvested market-based restricted stock units outstanding eligible to be earned&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,663,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;410,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock warrant outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,133,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,102,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,799,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_c6dca81f-0edb-4b64-8e76-32b4a7e492b4">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the years ended December 31, 2023, 2022 and 2021 (in thousands, except share and per share amounts):&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.211%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.782%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss attributable to Adaptive Biotechnologies Corporation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;225,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;207,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;144,383,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,515,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;140,354,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-3"
      id="F_a0a66565-df81-43de-98df-3174d32ceb08"
      unitRef="U_USD">-225250000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-3"
      id="F_cb69e71e-894e-4a26-9b0f-1e889c6449ce"
      unitRef="U_USD">-200191000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-3"
      id="F_b9bdab36-d95d-4363-8fb8-b291613d181e"
      unitRef="U_USD">-207279000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="0"
      id="F_98a4e6af-6315-48c6-8ef4-2840bae07cb8"
      unitRef="U_shares">144383294</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="0"
      id="F_5f119098-1d5a-481e-9429-7897fa5803dc"
      unitRef="U_shares">144383294</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="0"
      id="F_e20b355f-e0d2-4e18-92e2-11a558f51399"
      unitRef="U_shares">142515917</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="0"
      id="F_1dce62be-d62e-40d4-b873-642b1d756861"
      unitRef="U_shares">142515917</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="0"
      id="F_77d24013-c6a8-444c-956b-7bf6a6a60fa4"
      unitRef="U_shares">140354915</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="0"
      id="F_af8a4518-1971-4819-8b11-111bfa167bc9"
      unitRef="U_shares">140354915</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="2"
      id="F_fc07dd57-432f-46f5-8ba6-2f9cb01b926c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="2"
      id="F_3b582f5f-8017-42d7-b3a5-defe41ecba9a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="2"
      id="F_39755afd-753b-4c08-8a43-f8fe1248f501"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.4</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="2"
      id="F_3924ca9d-cde0-4a80-9c30-e37b5e2afec8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.4</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="2"
      id="F_f79799af-3526-4296-b0e3-8dfb9aa47b73"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="2"
      id="F_aee12fad-5f7c-4d5f-a010-31fe8071621a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_b5b953fd-b202-4c25-8a62-0f84473f3df4">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the years ended December 31, 2023, 2022 and 2021, as they had an anti-dilutive effect:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.177%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.255%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.255%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.255%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,839,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,892,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,097,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonvested restricted stock units outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,630,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,799,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;693,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Maximum nonvested market-based restricted stock units outstanding eligible to be earned&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,663,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;410,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock warrant outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,133,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,102,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,799,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c4963ee4-2b06-4690-ba19-b7f24dff5cc0"
      decimals="0"
      id="F_5899371e-cdd2-4467-a9fb-14f7106ba599"
      unitRef="U_shares">13839067</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3787167f-f9fe-4167-8297-ba5c7cf2cf41"
      decimals="0"
      id="F_c70d709f-b35e-4296-94a7-d7ceacf0604b"
      unitRef="U_shares">13892287</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_fdc597b9-fce4-4adb-aca1-c9147dc51edc"
      decimals="INF"
      id="F_b3b438a4-8079-45c5-af5b-ea6de27fe18b"
      unitRef="U_shares">13097374</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a78ff4ac-0c2c-49b3-b6c9-440cbe865835"
      decimals="0"
      id="F_2242dbef-b6d6-4c2c-a129-716eb8c520c8"
      unitRef="U_shares">9630579</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7982225b-427f-4a1e-8cd0-412895f4f7f9"
      decimals="0"
      id="F_bdcd7587-e4e9-4101-ad67-9f5fcef48968"
      unitRef="U_shares">4799850</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_241a14e0-c83c-46be-9595-a7086d9fdf64"
      decimals="INF"
      id="F_330fafba-311b-4c06-8af3-ac13ca67b34b"
      unitRef="U_shares">693173</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_be4b3886-95a1-499a-bdda-548e8b19d654"
      decimals="0"
      id="F_63d045ee-a237-4f2c-b875-52d2dd116518"
      unitRef="U_shares">1663961</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c6428414-6c4a-46a9-aaa6-447acbd2d45a"
      decimals="0"
      id="F_f71105a8-982e-4d7f-800a-4797352caba3"
      unitRef="U_shares">410282</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6d31f8e3-6174-4d62-813b-9a04cfbac43b"
      decimals="0"
      id="F_61f5d5bf-b0df-44fe-829d-cf7389c3ecae"
      unitRef="U_shares">8570</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="0"
      id="F_ef6bec21-f431-42e5-a2d8-827d5b7e5753"
      unitRef="U_shares">25133607</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="0"
      id="F_fecaab39-e3b2-425e-b2be-6e9dc785cac9"
      unitRef="U_shares">19102419</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="INF"
      id="F_5523a357-e11a-4a52-9bf8-16074cc5c543"
      unitRef="U_shares">13799117</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_055b5a7c-ef32-47bb-9ff9-6324a6bee76d">&lt;div style="display:flex;margin-top:9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;19.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Retirement Plan&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We maintain a salary deferral 401(k) plan (&#x201c;401(k) Plan&#x201d;) covering employees who have met certain eligibility requirements. Employees may defer up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of their compensation to the 401(k) Plan, subject to federal limits. We made $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#231f20;"&gt;2.3&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#231f20;white-space:pre-wrap;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in discretionary contributions during the year ended December 31, 2023, 2022 and 2021, respectively, which are fully vested after &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of employee service.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="2"
      id="F_f9913d5e-d313-4684-94f3-068a271ebab3"
      unitRef="U_pure">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      decimals="-5"
      id="F_ade3d766-2e8b-4a01-a196-c37aec7a8d28"
      unitRef="U_USD">2300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      decimals="-5"
      id="F_b09f4369-1682-44af-ab2d-c25867793031"
      unitRef="U_USD">2800000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      decimals="-5"
      id="F_cf6de775-cb6a-4542-8080-9047d3ad189d"
      unitRef="U_USD">2500000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <adpt:DefinedContributionPlanEmployeeServicePeriodForVesting
      contextRef="C_3ba98026-c119-4e6d-b9b5-2ad6779ef2ed"
      id="F_fb070278-c686-4609-b6ef-235854778d24">P1Y</adpt:DefinedContributionPlanEmployeeServicePeriodForVesting>
    <adpt:DefinedContributionPlanEmployeeServicePeriodForVesting
      contextRef="C_030867b4-3ba3-4e62-9885-bbfe6fa3e703"
      id="F_c0fa8850-5cd4-4b4b-80d4-f41d81ff1bc6">P1Y</adpt:DefinedContributionPlanEmployeeServicePeriodForVesting>
    <adpt:DefinedContributionPlanEmployeeServicePeriodForVesting
      contextRef="C_9e142887-9d0a-4e57-af9c-cfa731e1ff3d"
      id="F_fd9468b5-0eb7-455a-88dd-48d3bf2dc227">P1Y</adpt:DefinedContributionPlanEmployeeServicePeriodForVesting>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
